BindingDB Reactant_set_id,Ligand SMILES,Ligand InChI,Ligand InChI Key,BindingDB MonomerID,BindingDB Ligand Name,Target Name,Target Source Organism According to Curator or DataSource,IC50 (nM)
51075338,O=C(CCc1cccnc1)N(Cc1cccs1)Cc1nc2CCOCc2c(=O)[nH]1,"InChI=1S/C21H22N4O3S/c26-20(6-5-15-3-1-8-22-11-15)25(12-16-4-2-10-29-16)13-19-23-18-7-9-28-14-17(18)21(27)24-19/h1-4,8,10-11H,5-7,9,12-14H2,(H,23,24,27)",WEHBTALITPPXOG-UHFFFAOYSA-N,50439808,"CHEMBL2419717::US9227982, 12",Protein Wnt-3a,Homo sapiens, 41000
1138818,COc1cccc(OC)c1-c1noc(C2CC2)c1COc1ccc(c(Cl)c1)C1(O)CN(C1)c1ncc(cc1F)C(O)=O,"InChI=1S/C30H27ClFN3O7/c1-39-23-4-3-5-24(40-2)25(23)26-19(27(42-34-26)16-6-7-16)13-41-18-8-9-20(21(31)11-18)30(38)14-35(15-30)28-22(32)10-17(12-33-28)29(36)37/h3-5,8-12,16,38H,6-7,13-15H2,1-2H3,(H,36,37)",JJVVPLHMDOFRRR-UHFFFAOYSA-N,402336,"6-(3-(2-chloro-4-((5- cyclopropyl-3-(2,6- dimethoxyphenyl)isoxazol-4- yl)methoxy)phenyl)-3- hydroxyazetidin-1-yl)-5- fluoronicotinic acid::US10329286, Example 8::US11247986, Example 8",Bile acid receptor,Homo sapiens,
50666048,CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1,"InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+",RITAVMQDGBJQJZ-FMIVXFBMSA-N,25117,"AG-013736::AXITINIB::N-methyl-2-({3-[(E)-2-(pyridin-2-yl)ethenyl]-1H-indazol-6-yl}sulfanyl)benzamide::US10464902, Axitinib::US9205078, Axitinib ::US9617222, Compound A",Dual specificity protein kinase TTK,Homo sapiens,
50390373,CC(C)NCCN([C@@H]1CC[C@@]2(CC2C1)c1cccc(c1)C#N)C(=O)Nc1cc(Cl)nc(Cl)c1,"InChI=1S/C25H29Cl2N5O/c1-16(2)29-8-9-32(24(33)30-20-12-22(26)31-23(27)13-20)21-6-7-25(14-19(25)11-21)18-5-3-4-17(10-18)15-28/h3-5,10,12-13,16,19,21,29H,6-9,11,14H2,1-2H3,(H,30,31,33)/t19?,21-,25-/m1/s1",LCRYFIQZHFQDJZ-ZMFCXZKHSA-N,50215645,"1-((3R,6S)-6-(3-cyanophenyl)bicyclo[4.1.0]heptan-3-yl)-3-(2,6-dichloropyridin-4-yl)-1-(2-(isopropylamino)ethyl)urea::CHEMBL374844",Melanin-concentrating hormone receptor 1,Homo sapiens,
51338864,Clc1cccc2c(ccnc12)-n1cnc2c(cc(cc12)N1CCOCC1)-c1nnc[nH]1,"InChI=1S/C22H18ClN7O/c23-17-3-1-2-15-18(4-5-24-20(15)17)30-13-26-21-16(22-25-12-27-28-22)10-14(11-19(21)30)29-6-8-31-9-7-29/h1-5,10-13H,6-9H2,(H,25,27,28)",GDZNVPWDBYHIJL-UHFFFAOYSA-N,357385,"US10214519, Example 111","Phosphatidylinositol 3-kinase regulatory subunit alpha/4,5-bisphosphate 3-kinase catalytic subunit delta isoform",Homo sapiens, 12
51394416,Cc1cc(C)cc(c1)-c1ccc2c(NC(=O)c3ccccc3NC(=O)C=C)n[nH]c2c1,"InChI=1S/C25H22N4O2/c1-4-23(30)26-21-8-6-5-7-20(21)25(31)27-24-19-10-9-17(14-22(19)28-29-24)18-12-15(2)11-16(3)13-18/h4-14H,1H2,2-3H3,(H,26,30)(H2,27,28,29,31)",SBXDCZQCEQZTSA-UHFFFAOYSA-N,50563500,CHEMBL4765104,Fibroblast growth factor receptor 4,, 423
715859,CCCNC(=O)Nc1cccc(c1)-n1c(nc2cccc(Cl)c2c1=O)[C@H](C)Nc1ncnc(N)c1C#N,"InChI=1S/C25H24ClN9O2/c1-3-10-29-25(37)33-15-6-4-7-16(11-15)35-23(34-19-9-5-8-18(26)20(19)24(35)36)14(2)32-22-17(12-27)21(28)30-13-31-22/h4-9,11,13-14H,3,10H2,1-2H3,(H2,29,33,37)(H3,28,30,31,32)/t14-/m0/s1",YJGKKPWELJLAPJ-AWEZNQCLSA-N,362132,"(S)-1-(3-(2-(1-((6-amino-5-cyanopyrimidin-4-yl)amino)ethyl)-5-chloro-4-oxoquinazolin-3(4H)-yl)phenyl)-3-cyclopropylurea::US10221197, Compound 125","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform",Homo sapiens, 7000
51176088,CC(=O)N[C@@H]1[C@H](C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O)N=C(N)N,"InChI=1S/C12H20N4O7/c1-4(18)15-8-5(16-12(13)14)2-7(11(21)22)23-10(8)9(20)6(19)3-17/h2,5-6,8-10,17,19-20H,3H2,1H3,(H,15,18)(H,21,22)(H4,13,14,16)/t5-,6+,8+,9+,10+/m0/s1",ARAIBEBZBOPLMB-UFGQHTETSA-N,50330326,"(4S,5R,6R)-5-Acetylamino-4-guanidino-6-((1R,3R)-1,2,3-trihydroxy-propyl)-5,6-dihydro-4H-pyran-2-carboxylic acid::(4S,5R,6R)-5-Acetylamino-4-guanidino-6-((R)-1,2,3-trihydroxy-propyl)-5,6-dihydro-4H-pyran-2-carboxylic acid::(4S,5R,6R)-5-Acetylamino-4-guanidino-6-(1,2,3-trihydroxy-propyl)-5,6-dihydro-4H-pyran-2-carboxylic acid::(4S,5R,6R)-5-acetamido-4-(diaminomethyleneamino)-6-((1R,2R)-1,2,3-trihydroxypropyl)-5,6-dihydro-4H-pyran-2-carboxylic acid::(4S,5R,6R)-5-acetylamino-4-guanidino-6-((1R,2R)-1,2,3-trihydroxy-propy)-5,6-dihydro-4H-pyran-2-carboxylic acid::(4S,5R,6R)-5-acetylamino-4-guanidino-6-((1R,2R)-1,2,3-trihydroxy-propyl)-5,6-dihydro-4H-pyran-2-carboxylic acid::4-diaminomethylamino-3-methylcarboxamido-2-(1,2,3-trihydroxypropyl)-(3R)-3,4-dihydro-2H-6-pyrancarboxylic acid(Zanamivir)::5-Acetylamino-4-guanidino-6-(1,2,3-trihydroxy-propyl)-5,6-dihydro-4H-pyran-2-carboxylic acid::5-Acetylamino-4-guanidino-6-(1,2,3-trihydroxy-propyl)-5,6-dihydro-4H-pyran-2-carboxylic acid(zanamivir)::5-Formylamino-4-guanidino-6-(1,2,3-trihydroxy-propyl)-5,6-dihydro-4H-pyran-2-carboxylic acid::CHEMBL222813::GR-121167X::Relenza::Zanamivi",Neuraminidase,Influenza A virus, 8.6
497642,Nc1ccc(CN[C@H]2CCC(CC2)c2ccc(c(c2-c2nnn[nH]2)S(N)(=O)=O)C(F)(F)F)cn1,,,262829,"3-(4-{[(6-aminopyridin-3- yl)methyl]amino}cyclohex- yl)-2-(1H-tetrazol-5-yl)- 6- (trifluoromethyl)benzene sulfonamide::US9708336, 682",Metallo-beta-lactamase type 2,, 4.12
51247047,OC(CNCCCc1ccccc1)c1ccc(O)c2[nH]c(=O)ccc12,"InChI=1S/C20H22N2O3/c23-17-10-8-15(16-9-11-19(25)22-20(16)17)18(24)13-21-12-4-7-14-5-2-1-3-6-14/h1-3,5-6,8-11,18,21,23-24H,4,7,12-13H2,(H,22,25)",UTODCRACBJDRGN-UHFFFAOYSA-N,50510101,CHEMBL4536813,Beta-2 adrenergic receptor,Homo sapiens,
51020112,CC(C)(C)OC(=O)N1CCC2(CCN(C2)C(=O)c2cc(Cc3n[nH]c(=O)c4ccccc34)ccc2F)C1,"InChI=1S/C28H31FN4O4/c1-27(2,3)37-26(36)33-13-11-28(17-33)10-12-32(16-28)25(35)21-14-18(8-9-22(21)29)15-23-19-6-4-5-7-20(19)24(34)31-30-23/h4-9,14H,10-13,15-17H2,1-3H3,(H,31,34)",MOYOUBMGSIHZJF-UHFFFAOYSA-N,50288516,CHEMBL4159240,Poly [ADP-ribose] polymerase tankyrase-1,, 1000
860670,CC(C)n1nc(-c2cc3c(C)cccc3[nH]2)c2c(N)ncnc12,"InChI=1S/C17H18N6/c1-9(2)23-17-14(16(18)19-8-20-17)15(22-23)13-7-11-10(3)5-4-6-12(11)21-13/h4-9,21H,1-3H3,(H2,18,19,20)",HEDDQUIXAAICJH-UHFFFAOYSA-N,340899,"1-isopropyl-3-(4-methyl-1H-indol-2-yl)-1H- pyrazolo[3,4-d]pyrimidin-4-amine::US10544104, Compound 25::US11247972, Compound 25::US9765037, Compound 25",Proto-oncogene tyrosine-protein kinase Src,, 5020
51332154,Clc1nc(Nc2ccc(cc2)N2CCOCC2=O)nc(n1)N1CCCC1,"InChI=1S/C17H19ClN6O2/c18-15-20-16(22-17(21-15)23-7-1-2-8-23)19-12-3-5-13(6-4-12)24-9-10-26-11-14(24)25/h3-6H,1-2,7-11H2,(H,19,20,21,22)",XUCNQRWIELTSLI-UHFFFAOYSA-N,50369080,CHEMBL4167700,Prostaglandin G/H synthase 1,,>10000
493439,OC(c1ccc(CBr)cc1)(C(F)(F)F)C(F)(F)F,"InChI=1S/C10H7BrF6O/c11-5-6-1-3-7(4-2-6)8(18,9(12,13)14)10(15,16)17/h1-4,18H,5H2",LVLBRKWIJOFEHS-UHFFFAOYSA-N,261498,"2-(4-(bromomethyl)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol::US9708268, 1",Interleukin-17F,,<10000
864522,COc1cc(cn2ncnc12)-c1[nH]c2ccc(nc2c1C(C)C)N1CC(C1)NCC(=O)N(C)C,"InChI=1S/C24H30N8O2/c1-14(2)21-22(15-8-18(34-5)24-26-13-27-32(24)10-15)28-17-6-7-19(29-23(17)21)31-11-16(12-31)25-9-20(33)30(3)4/h6-8,10,13-14,16,25,28H,9,11-12H2,1-5H3",ICZMCTWORPHBMY-UHFFFAOYSA-N,427582,"US10544143, Example 18::US10544143, Example 27::US10730877, Example 27::US11053244, Example 27",Toll-like receptor 9,,>50000
51053015,O=C(NC1CCCCC1)Nc1ccc(Oc2ncnc3n[nH]cc23)cc1,"InChI=1S/C18H20N6O2/c25-18(22-12-4-2-1-3-5-12)23-13-6-8-14(9-7-13)26-17-15-10-21-24-16(15)19-11-20-17/h6-12H,1-5H2,(H2,22,23,25)(H,19,20,21,24)",CQEDTVBKKZWBLM-UHFFFAOYSA-N,50429488,CHEMBL2332863,Vascular endothelial growth factor receptor 2,Danio rerio,>100000
239964,COc1cc(ccn1)-c1cccnc1Oc1ccc(Nc2ccccn2)cc1,"InChI=1S/C22H18N4O2/c1-27-21-15-16(11-14-24-21)19-5-4-13-25-22(19)28-18-9-7-17(8-10-18)26-20-6-2-3-12-23-20/h2-15H,1H3,(H,23,26)",NNGQJZZBQQNMCU-UHFFFAOYSA-N,115311,"US8637500, 129","cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A",Rattus norvegicus, 7.393
50907562,COc1ccc2NC(=O)C(=Cc3cnc[nH]3)c2c1,"InChI=1S/C13H11N3O2/c1-18-9-2-3-12-10(5-9)11(13(17)16-12)4-8-6-14-7-15-8/h2-7H,1H3,(H,14,15)(H,16,17)",QNUKRWAIZMBVCU-UHFFFAOYSA-N,7238,"(3Z)-3-(1H-imidazol-5-ylmethylidene)-5-methoxy-2,3-dihydro-1H-indol-2-one::3-(3H-Imidazol-4-ylmethylene)-5-methoxy-1,3-dihydro-indol-2-one::SU9516::cid_5289419::imidazole indolinone driv.",Proto-oncogene tyrosine-protein kinase receptor Ret,Homo sapiens, 1600
50951706,CC(C)C(NC(=O)NC(C)(C)C)C(=O)c1ccc(Cl)cc1,"InChI=1S/C16H23ClN2O2/c1-10(2)13(18-15(21)19-16(3,4)5)14(20)11-6-8-12(17)9-7-11/h6-10,13H,1-5H3,(H2,18,19,21)",OPWGBOAEYGMIKX-UHFFFAOYSA-N,50390462,CHEMBL2071587,Transient receptor potential cation channel subfamily A member 1,, 2511.89
50253372,CC[C@@H]1N=C(N)O[C@H]1C,"InChI=1S/C6H12N2O/c1-3-5-4(2)9-6(7)8-5/h4-5H,3H2,1-2H3,(H2,7,8)/t4-,5-/m0/s1",KHXXSTHNMREFPM-WHFBIAKZSA-N,50138187,"(4S,5S)-4-Ethyl-5-methyl-oxazolidin-(2Z)-ylideneamine::CHEMBL105830","Nitric oxide synthase, inducible",Mus musculus, 170
634199,CC(C)(C)c1nc(-c2ccc(F)nc2)c2nnn(Cc3ccccc3Cl)c2n1,"InChI=1S/C20H18ClFN6/c1-20(2,3)19-24-16(12-8-9-15(22)23-10-12)17-18(25-19)28(27-26-17)11-13-6-4-5-7-14(13)21/h4-10H,11H2,1-3H3",JKBPPZMJKCLZOC-UHFFFAOYSA-N,322975,"5-tert-butyl-3-[(2-chlorophenyl)methyl]-7-(6-fluoropyridin-3-yl)triazolo[4,5-d]pyrimidine::US10183946, Example 6",Cannabinoid receptor 1,Homo sapiens,
50360735,Nc1c(Cl)cc(cc1Cl)C(=O)N(C1CC1)[C@H]1CC[C@H](CC1)C(=O)NCC(O)=O,"InChI=1S/C19H23Cl2N3O4/c20-14-7-11(8-15(21)17(14)22)19(28)24(13-5-6-13)12-3-1-10(2-4-12)18(27)23-9-16(25)26/h7-8,10,12-13H,1-6,9,22H2,(H,23,27)(H,25,26)/t10-,12+",PIVHVYCTSLIOPL-KLPPZKSPSA-N,50195490,"2-((1s,4s)-4-(4-amino-3,5-dichloro-N-cyclopropylbenzamido)cyclohexanecarboxamido)acetic acid::CHEMBL374318",11-beta-hydroxysteroid dehydrogenase 1,Homo sapiens,
231268,CCN(CCF)S(=O)(=O)NC(=O)[C@]1(C[C@H]1C=C)NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)[C@]21CCC1,"InChI=1S/C45H74FN7O7S/c1-10-31-26-45(31,40(58)50-61(59,60)51(11-2)25-23-46)49-37(55)33-27-44(42(8,9)43(44)21-17-22-43)28-53(33)39(57)35(41(5,6)7)48-38(56)34(30-18-13-12-14-19-30)47-36(54)32-20-15-16-24-52(32)29(3)4/h10,29-35H,1,11-28H2,2-9H3,(H,47,54)(H,48,56)(H,49,55)(H,50,58)/t31-,32+,33+,34+,35-,44-,45-/m1/s1",XFYOTNPRWVBFPP-LDFRYFKTSA-N,110382,"US8613914, 156::US9206232, 156",Genome polyprotein,Hepatitis C virus, 1.3
153714,CCCCC(C(=O)COc1c(F)c(F)cc(F)c1F)n1cc(nn1)C1(N)CCNCC1,"InChI=1S/C20H25F4N5O2/c1-2-3-4-14(29-10-16(27-28-29)20(25)5-7-26-8-6-20)15(30)11-31-19-17(23)12(21)9-13(22)18(19)24/h9-10,14,26H,2-8,11,25H2,1H3",QQEWYMAAWBFRBU-UHFFFAOYSA-N,81410,ML4162,Dipeptidyl peptidase 1,Mus musculus,>20000
620710,O=c1[nH]nc2CCCCc3[nH]c4cccc1c4c23,"InChI=1S/C14H13N3O/c18-14-8-4-3-7-9-12(8)13-10(15-9)5-1-2-6-11(13)16-17-14/h3-4,7,15H,1-2,5-6H2,(H,17,18)",FLCHMGRFSJQORK-UHFFFAOYSA-N,207557,"US9260440, 2::US9617273, Example 2",Poly [ADP-ribose] polymerase 2,, 1100
50276845,CC(C)(C)OC(=O)NCCCC(=O)NCCc1ccc(cc1)S(N)(=O)=O,"InChI=1S/C17H27N3O5S/c1-17(2,3)25-16(22)20-11-4-5-15(21)19-12-10-13-6-8-14(9-7-13)26(18,23)24/h6-9H,4-5,10-12H2,1-3H3,(H,19,21)(H,20,22)(H2,18,23,24)",CNVDNCXHNMHAIL-UHFFFAOYSA-N,50049519,CHEMBL3314168,Carbonic anhydrase 1,Homo sapiens,
50841735,COc1ccc(F)cc1C(C)(C)CC(O)(Cn1ccc(=O)c2ccccc12)C(F)(F)F,"InChI=1S/C23H23F4NO3/c1-21(2,17-12-15(24)8-9-20(17)31-3)13-22(30,23(25,26)27)14-28-11-10-19(29)16-6-4-5-7-18(16)28/h4-12,30H,13-14H2,1-3H3",PVYTWCNJUWKUOG-UHFFFAOYSA-N,50201109,1-[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentyl]-1H-quinolin-4-one::CHEMBL386465,Mineralocorticoid receptor,Homo sapiens, 120
499449,O=C(N[C@H]1CC[C@H](CCN2CCN(CC2)c2nsc3ccccc23)CC1)c1cc2ccccc2s1,"InChI=1S/C28H32N4OS2/c33-28(26-19-21-5-1-3-7-24(21)34-26)29-22-11-9-20(10-12-22)13-14-31-15-17-32(18-16-31)27-23-6-2-4-8-25(23)35-30-27/h1-8,19-20,22H,9-18H2,(H,29,33)/t20-,22-",PDADFIJOFSWDJB-AQYVVDRMSA-N,263372,"US9550741, I-6",D(2) dopamine receptor,Homo sapiens,
50905446,CCCc1ncc2Cc3c(ncn3-c3ccccc3-c2n1)C(=O)OCC,"InChI=1S/C20H20N4O2/c1-3-7-17-21-11-13-10-16-19(20(25)26-4-2)22-12-24(16)15-9-6-5-8-14(15)18(13)23-17/h5-6,8-9,11-12H,3-4,7,10H2,1-2H3",ISAMWRRMVCVCCO-UHFFFAOYSA-N,50378524,CHEMBL584546,Gamma-aminobutyric acid receptor subunit alpha-5/beta-3/gamma-2,Homo sapiens,
659605,OC(c1nccs1)c1ccc(F)c(c1)-c1ncnc2cc(sc12)N1CCOCC1,"InChI=1S/C20H17FN4O2S2/c21-14-2-1-12(18(26)20-22-3-8-28-20)9-13(14)17-19-15(23-11-24-17)10-16(29-19)25-4-6-27-7-5-25/h1-3,8-11,18,26H,4-7H2",AIDFNPQAXSJWSH-UHFFFAOYSA-N,315723,"US10172859, Example 144::US10172859, Example 145::US10172859, Example 146::US11065253, Example 146::US9732094, Example 146::[4-Fluoro-3-(6- morpholin-4-yl- thieno[3,2-d}- pyrimidin-4-yl)- phenyl]thiazol-2- yl-methanol1H NMR (500 MHz, DMSO-d6) ppm = 8.89 (s,1H), 7.76 (dd, J = 7.0, 2.3, 1H), 7.73 (d, J = 3.2,1H), 7.69-7.64 (m, 2H), 7.43-7.38 (m, 1H),6.96 (d, J = 4.6, 1H), 6.53 (s, 1H), 6.07 (d,J = 4.6, 1H), 3.77-3.71 (m, 4H), 3.44-3.38 (m,4H)",DNA-dependent protein kinase catalytic subunit,Homo sapiens,<3
696411,COc1ccc(F)cc1-c1c(cnc2[nH]c(cc12)C1CCN(CC(=O)N(C)C)CC1)C#N,"InChI=1S/C24H26FN5O2/c1-29(2)22(31)14-30-8-6-15(7-9-30)20-11-19-23(16(12-26)13-27-24(19)28-20)18-10-17(25)4-5-21(18)32-3/h4-5,10-11,13,15H,6-9,14H2,1-3H3,(H,27,28)",NDTXKBSFGOQMPJ-UHFFFAOYSA-N,167784,"US9073922, 275::US9796708, Example 275",Cyclin-T1/Cyclin-dependent kinase 9,Homo sapiens, 90.0
50255129,ClCCC(=O)N1CCN(CC1)c1ccc(\C=C2/C(=O)Nc3ccccc23)cc1,"InChI=1S/C22H22ClN3O2/c23-10-9-21(27)26-13-11-25(12-14-26)17-7-5-16(6-8-17)15-19-18-3-1-2-4-20(18)24-22(19)28/h1-8,15H,9-14H2,(H,24,28)/b19-15-",LSMZOIVOZFFQQJ-CYVLTUHYSA-N,50037258,CHEMBL3356290,Aurora kinase B,Homo sapiens, 587
505573,Cc1ccc(Cn2\c(=N\c3cccc(c3F)C(F)(F)F)[nH]c(=O)n(CCC(O)=O)c2=O)cc1,"InChI=1S/C21H18F4N4O4/c1-12-5-7-13(8-6-12)11-29-18(27-19(32)28(20(29)33)10-9-16(30)31)26-15-4-2-3-14(17(15)22)21(23,24)25/h2-8H,9-11H2,1H3,(H,30,31)(H,26,27,32)",UQDNDHAICJQXSJ-UHFFFAOYSA-N,266011,"US9718790, I-2086",P2X purinoceptor 3,Homo sapiens, 234
592198,Cn1cnc(c1)S(=O)(=O)N1C[C@@H](Nc2ccc(F)c(Cl)c2)[C@@H](C1)c1ccccc1,"InChI=1S/C20H20ClFN4O2S/c1-25-12-20(23-13-25)29(27,28)26-10-16(14-5-3-2-4-6-14)19(11-26)24-15-7-8-18(22)17(21)9-15/h2-9,12-13,16,19,24H,10-11H2,1H3/t16-,19+/m0/s1",OAGSQIPRTHVASO-QFBILLFUSA-N,308701,"US9656955, Example 215::trans-N-(3-chloro-4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine","Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase",Homo sapiens,
613912,CCOc1cc(-c2ccc(nc2)N2CCC(CN3CCN(CC)[C@H](C)C3)(CC2)C(=O)NCC(C)C)c2c(cnn2c1)C#N,"InChI=1S/C33H46N8O2/c1-6-39-15-14-38(21-25(39)5)23-33(32(42)36-18-24(3)4)10-12-40(13-11-33)30-9-8-26(19-35-30)29-16-28(43-7-2)22-41-31(29)27(17-34)20-37-41/h8-9,16,19-20,22,24-25H,6-7,10-15,18,21,23H2,1-5H3,(H,36,42)/t25-/m1/s1",QNAHRFJLRIRZMM-RUZDIDTESA-N,305636,"US10144734, Example 654::US10172845, Example 654::US10441581, Example 654::US10881652, Example 654",Proto-oncogene tyrosine-protein kinase receptor Ret [G810R],, 114
1176541,FC1CC(C1)n1cnc(c1-c1ccc2ncc(C#N)n2n1)-c1ccc(F)c(Cl)c1,"InChI=1S/C20H13ClF2N6/c21-15-5-11(1-2-16(15)23)19-20(28(10-26-19)13-6-12(22)7-13)17-3-4-18-25-9-14(8-24)29(18)27-17/h1-5,9-10,12-13H,6-7H2",QTSUEIBSKWPOLS-UHFFFAOYSA-N,282899,"6-(4-(3-chloro-4-fluorophenyl)-1-(3-fluorocyclobutyl)- 1H-imidazol-5-yl)imidazo[1,2-b]pyridazine-3- carbonitrile::US10287295, Example 104'::US11352360, Example 104'::US9884868, Example 104'",TGF-beta receptor type-1,, 0.500
50854004,CS(=O)(=O)NC(=O)CCCc1c([nH]c2ccc(cc12)C#N)-c1ccc(F)cc1,"InChI=1S/C20H18FN3O3S/c1-28(26,27)24-19(25)4-2-3-16-17-11-13(12-22)5-10-18(17)23-20(16)14-6-8-15(21)9-7-14/h5-11,23H,2-4H2,1H3,(H,24,25)",OVTPSSRHMPJRCX-UHFFFAOYSA-N,50236305,4-(5-cyano-2-(4-fluorophenyl)-1H-indol-3-yl)-N-(methylsulfonyl)butanamide::CHEMBL440405,C-X-C chemokine receptor type 2,Oryctolagus cuniculus, 2100
50153574,COc1cc(cc(OC)c1OC)-c1cc(=O)c2cc(O)ccc2o1,"InChI=1S/C18H16O6/c1-21-16-6-10(7-17(22-2)18(16)23-3)15-9-13(20)12-8-11(19)4-5-14(12)24-15/h4-9,19H,1-3H3",ZSGFQNBMEKWZEV-UHFFFAOYSA-N,50025558,CHEMBL519022,Tyrosine-protein kinase Lck,, 2
750716,CC(C)n1cc(C(=O)Nc2ccc(Oc3cc(cn4nccc34)N3CCS(=O)(=O)CC3)c(F)c2)c(=O)n(-c2ccc(F)cc2)c1=O,"InChI=1S/C31H28F2N6O6S/c1-19(2)37-18-24(30(41)39(31(37)42)22-6-3-20(32)4-7-22)29(40)35-21-5-8-27(25(33)15-21)45-28-16-23(17-38-26(28)9-10-34-38)36-11-13-46(43,44)14-12-36/h3-10,15-19H,11-14H2,1-2H3,(H,35,40)",JUEGXARGWCNIPG-UHFFFAOYSA-N,375853,"US9914731, Ex. No. 74",Tyrosine-protein kinase receptor UFO,, 55
50245168,O=C(NCCCCN1CCN(CC1)c1ccccc1)c1cc2ccccc2o1,"InChI=1S/C23H27N3O2/c27-23(22-18-19-8-4-5-11-21(19)28-22)24-12-6-7-13-25-14-16-26(17-15-25)20-9-2-1-3-10-20/h1-5,8-11,18H,6-7,12-17H2,(H,24,27)",CAWFRCMJYFIMLP-UHFFFAOYSA-N,50031448,CHEMBL3358494,D(2) dopamine receptor,Homo sapiens,
631094,Fc1ccccc1Cn1nc(cc1-c1ccon1)-c1nccc(NS(=O)(=O)CC(F)(F)F)n1,"InChI=1S/C19H14F4N6O3S/c20-13-4-2-1-3-12(13)10-29-16(14-6-8-32-27-14)9-15(26-29)18-24-7-5-17(25-18)28-33(30,31)11-19(21,22)23/h1-9H,10-11H2,(H,24,25,28)",AXCYEGAZZZCENL-UHFFFAOYSA-N,321763,"US10183021, Compound I-444",Guanylate cyclase soluble subunit alpha-1,,
50244503,Cc1noc(C)c1-c1ccc(cc1)-c1nc2cnccn2c1NC(C)(C)C,"InChI=1S/C21H23N5O/c1-13-18(14(2)27-25-13)15-6-8-16(9-7-15)19-20(24-21(3,4)5)26-11-10-22-12-17(26)23-19/h6-12,24H,1-5H3",YXPVTKHEWGXKEY-UHFFFAOYSA-N,50030894,CHEMBL3356559,Transcription initiation factor TFIID subunit 1,,
50426680,Nc1nc(N)c2c(CCCc3cc(cs3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)coc2n1,"InChI=1S/C19H21N5O6S/c20-15-14-9(7-30-17(14)24-19(21)23-15)2-1-3-11-6-10(8-31-11)16(27)22-12(18(28)29)4-5-13(25)26/h6-8,12H,1-5H2,(H,22,27)(H,25,26)(H,28,29)(H4,20,21,23,24)/t12-/m0/s1",YSCGOYFEYRSGDL-LBPRGKRZSA-N,50126175,CHEMBL3628347,Folate receptor alpha,Homo sapiens,>1000
727861,CN1CCc2cc(ccc2C(C1)NC(=O)c1cn(nn1)C(C)(C)C)-c1ccnc(Nc2cnn(C)c2)n1,"InChI=1S/C26H32N10O/c1-26(2,3)36-16-23(32-33-36)24(37)30-22-15-34(4)11-9-17-12-18(6-7-20(17)22)21-8-10-27-25(31-21)29-19-13-28-35(5)14-19/h6-8,10,12-14,16,22H,9,11,15H2,1-5H3,(H,30,37)(H,27,29,31)",UQBXNYTXHLBRME-UHFFFAOYSA-N,324360,"1-(tert-butyl)-N-(3- methyl-7-(2-((1- methyl-1H-pyrazol-4- yl)amino)pyrimidin-4- yl)-2,3,4,5-tetrahydro- 1H-benzo[d]azepin-1- yl)-1H-1,2,3-triazole-4- carboxamide::US10189829, Compound 52::US10227341, Compound 52::US10961237, Compound 52",Tyrosine-protein kinase BTK,Homo sapiens, 5.50
51043749,Cc1nn(C)c2n(Cc3ccccc3)cc(C(=O)NC3CCCCC3)c(=O)c12,"InChI=1S/C22H26N4O2/c1-15-19-20(27)18(21(28)23-17-11-7-4-8-12-17)14-26(22(19)25(2)24-15)13-16-9-5-3-6-10-16/h3,5-6,9-10,14,17H,4,7-8,11-13H2,1-2H3,(H,23,28)",JYEFPJKEFHNPMZ-UHFFFAOYSA-N,50426113,CHEMBL2316292,Cannabinoid receptor 1,Rattus norvegicus,
368555,Fc1ccc(nc1)-c1ccn(CC2OCCCN2C(=O)c2cc(F)ccc2-c2ncccn2)n1,"InChI=1S/C24H20F2N6O2/c25-16-3-5-18(23-27-8-1-9-28-23)19(13-16)24(33)32-10-2-12-34-22(32)15-31-11-7-21(30-31)20-6-4-17(26)14-29-20/h1,3-9,11,13-14,22H,2,10,12,15H2",YZRHBGIKWQSFJJ-UHFFFAOYSA-N,208518,"US9266870, 34",Orexin receptor type 2,Homo sapiens, 6.2
50924782,CC(C)Cn1c2ccc(Nc3ncccn3)cc2c2c3CNC(=O)c3c3-c4cn(C)nc4CCc3c12,"InChI=1S/C28H27N7O/c1-15(2)13-35-22-8-5-16(32-28-29-9-4-10-30-28)11-18(22)24-19-12-31-27(36)25(19)23-17(26(24)35)6-7-21-20(23)14-34(3)33-21/h4-5,8-11,14-15H,6-7,12-13H2,1-3H3,(H,31,36)(H,29,30,32)",AEULIVPVIDOLIN-UHFFFAOYSA-N,50379186,CEP-11981::CHEMBL2010872,Macrophage colony-stimulating factor 1 receptor,, 78
475460,CCS(=O)(=O)Nc1cccc(c1)-c1ccc(cn1)[C@H]1C[C@@H]1N,"InChI=1S/C16H19N3O2S/c1-2-22(20,21)19-13-5-3-4-11(8-13)16-7-6-12(10-18-16)14-9-15(14)17/h3-8,10,14-15,19H,2,9,17H2,1H3/t14-,15+/m1/s1",IXIZAMPTBONALH-CABCVRRESA-N,179864,"US9676701, 98 N-(3-(5-((trans)-2-aminocyclopropyl)pyridin-2-yl)phenyl)ethanesulfonamide hydrochloride",Lysine-specific histone demethylase 1A,Homo sapiens,
51171114,CCN(CC)C(=O)CC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCc1ccccc1)C(C)C)C(=O)c1nccs1,"InChI=1S/C31H45N5O6S/c1-7-36(8-2)25(37)15-14-23(27(38)30-32-16-17-43-30)33-28(39)24(18-20(3)4)34-29(40)26(21(5)6)35-31(41)42-19-22-12-10-9-11-13-22/h9-13,16-17,20-21,23-24,26H,7-8,14-15,18-19H2,1-6H3,(H,33,39)(H,34,40)(H,35,41)/t23-,24-,26-/m0/s1",HOSKYYVLDSUHCJ-GNKBHMEESA-N,50480496,CHEMBL555221,Replicase polyprotein 1ab,Human SARS coronavirus,
51254691,CC(=O)N1CCC(CC1)C(=O)N1N=CC[C@H]1c1ccccc1,"InChI=1S/C17H21N3O2/c1-13(21)19-11-8-15(9-12-19)17(22)20-16(7-10-18-20)14-5-3-2-4-6-14/h2-6,10,15-16H,7-9,11-12H2,1H3/t16-/m0/s1",RAZBNWZNUFECAN-INIZCTEOSA-N,50512989,CHEMBL4474320,Receptor-interacting serine/threonine-protein kinase 1,, 10.0
50432480,Cc1cc(COc2ccc(cc2)C(=O)NCC2(N3CCN(CC3)S(C)(=O)=O)C(=O)NC(=O)NC2=O)c2ccccc2n1,"InChI=1S/C28H30N6O7S/c1-18-15-20(22-5-3-4-6-23(22)30-18)16-41-21-9-7-19(8-10-21)24(35)29-17-28(25(36)31-27(38)32-26(28)37)33-11-13-34(14-12-33)42(2,39)40/h3-10,15H,11-14,16-17H2,1-2H3,(H,29,35)(H2,31,32,36,37,38)",FMMBVZGWJZFRLY-UHFFFAOYSA-N,50195898,"4-((2-methylquinolin-4-yl)methoxy)-N-((5-(4-(methylsulfonyl)piperazin-1-yl)-2,4,6-trioxo-hexahydropyrimidin-5-yl)methyl)benzamide::4-((2-methylquinolin-4-yl)methoxy)-N-((5-(4-(methylsulfonyl)piperazin-1-yl)-2,4,6-trioxohexahydropyrimidin-5-yl)methyl)benzamide::CHEMBL395880",Matrilysin,Homo sapiens,
50338308,CC(=O)c1c(O)c(OCc2ccccc2)c2occc2c1OCc1ccccc1,"InChI=1S/C24H20O5/c1-16(25)20-21(26)24(29-15-18-10-6-3-7-11-18)23-19(12-13-27-23)22(20)28-14-17-8-4-2-5-9-17/h2-13,26H,14-15H2,1H3",LLIUIMCUXHPION-UHFFFAOYSA-N,50182597,"5-acetyl-4,7-benzyloxy-6-hydroxybenzofuran::CHEMBL203909",Potassium voltage-gated channel subfamily A member 2,Homo sapiens,
50056733,COc1ccc(cc1O)-c1c2c(n3ccc4cc(OC)c(OC)cc4c13)c(=O)oc1cc(OS([O-])(=O)=O)c(OC)cc21,"InChI=1S/C29H23NO11S/c1-36-19-6-5-15(9-18(19)31)25-26-17-12-23(39-4)24(41-42(33,34)35)13-20(17)40-29(32)28(26)30-8-7-14-10-21(37-2)22(38-3)11-16(14)27(25)30/h5-13,31H,1-4H3,(H,33,34,35)/p-1",JMOHRMCZYHDLSW-UHFFFAOYSA-M,50077357,"14-(3-hydroxy-4-methoxyphenyl)-2,11,12-trimethoxy-6H-chromeno[4',3':4,5]pyrrolo[2,1-a]isoquinolin-6-one-2-sulphonyl sodium::CHEMBL430776",Integrase,Human immunodeficiency virus 1, 8000
73288,Cc1cccc2cc3CN(Cc4ccco4)\C(Sc3nc12)=N\CC1CCCO1,"InChI=1S/C22H23N3O2S/c1-15-5-2-6-16-11-17-13-25(14-19-8-4-10-27-19)22(28-21(17)24-20(15)16)23-12-18-7-3-9-26-18/h2,4-6,8,10-11,18H,3,7,9,12-14H2,1H3/b23-22-",NWBNUVKWUXHDII-FCQUAONHSA-N,39084,"3-(2-furanylmethyl)-9-methyl-N-(2-oxolanylmethyl)-4H-[1,3]thiazino[6,5-b]quinolin-2-imine::3-(furan-2-ylmethyl)-9-methyl-N-(oxolan-2-ylmethyl)-4H-[1,3]thiazino[6,5-b]quinolin-2-imine::MLS000032944::SMR000005542::[3-(2-furfuryl)-9-methyl-4H-[1,3]thiazino[6,5-b]quinolin-2-ylidene]-(tetrahydrofurfuryl)amine::[3-Furan-2-ylmethyl-8-methyl-3,4-dihydro-1-thia-3,9-diaza-anthracen-(2E)-ylidene]-(tetrahydro-furan-2-ylmethyl)-amine::cid_653192",Steroidogenic factor 1,Homo sapiens, 63660
50936164,C[C@H]1COCCN1c1cc(CS(C)(=O)=O)nc(n1)-c1ccc2[nH]ccc2c1,"InChI=1S/C19H22N4O3S/c1-13-11-26-8-7-23(13)18-10-16(12-27(2,24)25)21-19(22-18)15-3-4-17-14(9-15)5-6-20-17/h3-6,9-10,13,20H,7-8,11-12H2,1-2H3/t13-/m0/s1",XMHSFTLIAYTIQQ-ZDUSSCGKSA-N,50384251,CHEMBL2030446,Serine/threonine-protein kinase mTOR,Homo sapiens, 303
436402,COc1ccc(nc1)C(=O)Nc1ccc(cc1)C1CCNC1,"InChI=1S/C17H19N3O2/c1-22-15-6-7-16(19-11-15)17(21)20-14-4-2-12(3-5-14)13-8-9-18-10-13/h2-7,11,13,18H,8-10H2,1H3,(H,20,21)",NFRDYVXNBLCOIP-UHFFFAOYSA-N,250184,"US10501411, Example 94::US9452980, 94",Trace amine-associated receptor 1,Rattus norvegicus,
50508545,CN(C)c1ccc2nc3ccc(cc3sc2c1)=[N+](C)C,"InChI=1S/C16H18N3S/c1-18(2)11-5-7-13-15(9-11)20-16-10-12(19(3)4)6-8-14(16)17-13/h5-10H,1-4H3/q+1",RBTBFTRPCNLSDE-UHFFFAOYSA-N,50241461,"3,7-bis(dimethylamino)phenothiazin-5-ium chloride::Basic Blue 9::CHEMBL405110::Methylenblau::Methylene Blue anhydrous::Methylene blue::Methylene blue (10)::SAMPL5, CBC-G10::azul de metileno::bleu de methylene::cid_6099::methylthioninium chloride","Dihydrolipoyl dehydrogenase, mitochondrial",Sus scrofa,>1000000
50589101,CC(=O)NCCNc1cccc2ccccc12,"InChI=1S/C14H16N2O/c1-11(17)15-9-10-16-14-8-4-6-12-5-2-3-7-13(12)14/h2-8,16H,9-10H2,1H3,(H,15,17)",HZYHRPXUOHTHQR-UHFFFAOYSA-N,50323750,"2,2,2-Trifluoro-N-(2-(naphthalen-1-ylamino)-acetamide::CHEMBL1214323",Carbonic anhydrase 3,Homo sapiens,
684441,CCOC(=O)c1c(C)[nH]c2c1c(cn(C)c2=O)C#CC1(O)CCCCC1,"InChI=1S/C20H24N2O4/c1-4-26-19(24)15-13(2)21-17-16(15)14(12-22(3)18(17)23)8-11-20(25)9-6-5-7-10-20/h12,21,25H,4-7,9-10H2,1-3H3",WLTWGIAEBTYAAZ-UHFFFAOYSA-N,346468,"US10202378, Example 81::ethyl 4-[2-(1-hydroxycyclohexyl)ethynyl]-2,6-dimethyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-3-carboxylate",Transcription initiation factor TFIID subunit 1 [1504-1635],, 63.2
968709,CCn1cc(c(n1)C(F)(F)F)-c1cc(CNC(=N)C2CCOC2)cc(c1)C(=O)N[C@@H](C1CC1)c1ccc(F)c(C)c1,"InChI=1S/C30H33F4N5O2/c1-3-39-15-24(27(38-39)30(32,33)34)22-11-18(14-36-28(35)21-8-9-41-16-21)12-23(13-22)29(40)37-26(19-4-5-19)20-6-7-25(31)17(2)10-20/h6-7,10-13,15,19,21,26H,3-5,8-9,14,16H2,1-2H3,(H2,35,36)(H,37,40)/t21?,26-/m0/s1",XPEWSUMUZIKCHW-UQTORGHUSA-N,468838,"US10807959, Example 108",WD repeat-containing protein 5,,
95038,CC1CCCCC1NC(=O)CN1C(=O)c2cccc(N)c2C1=O,"InChI=1S/C17H21N3O3/c1-10-5-2-3-8-13(10)19-14(21)9-20-16(22)11-6-4-7-12(18)15(11)17(20)23/h4,6-7,10,13H,2-3,5,8-9,18H2,1H3,(H,19,21)",OOGAHNNWQMSGNQ-UHFFFAOYSA-N,51211,"2-(4-amino-1,3-diketo-isoindolin-2-yl)-N-(2-methylcyclohexyl)acetamide::2-(4-amino-1,3-dioxo-2-isoindolyl)-N-(2-methylcyclohexyl)acetamide::2-(4-amino-1,3-dioxoisoindol-2-yl)-N-(2-methylcyclohexyl)acetamide::2-[4-azanyl-1,3-bis(oxidanylidene)isoindol-2-yl]-N-(2-methylcyclohexyl)ethanamide::MLS001003307::SMR000344768::cid_3590153",Glycoprotein 42,Human herpesvirus 4 type 2,2020.0
51454501,CN(C)CCNC(=O)c1cncc(c1)-c1cccc(c1)C(=O)N[C@H]1CN[C@H](C1)C(=O)Nc1ccc(Cl)c(c1)C(F)(F)F,"InChI=1S/C29H30ClF3N6O3/c1-39(2)9-8-35-26(40)20-11-19(14-34-15-20)17-4-3-5-18(10-17)27(41)38-22-13-25(36-16-22)28(42)37-21-6-7-24(30)23(12-21)29(31,32)33/h3-7,10-12,14-15,22,25,36H,8-9,13,16H2,1-2H3,(H,35,40)(H,37,42)(H,38,41)/t22-,25-/m1/s1",OQXRMEANXAJBPJ-RCZVLFRGSA-N,50587248,CHEMBL5071546,Breakpoint cluster region protein/Tyrosine-protein kinase ABL1,Homo sapiens, 2410
231065,CCCNC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1CCC[C@H]1C(O)=O,"InChI=1S/C18H29N3O6/c1-4-8-19-15(22)13-14(27-13)16(23)20-12(10(3)5-2)17(24)21-9-6-7-11(21)18(25)26/h10-14H,4-9H2,1-3H3,(H,19,22)(H,20,23)(H,25,26)/t10-,11-,12-,13-,14-/m0/s1",ZEZGJKSEBRELAS-PEDHHIEDSA-N,16509,"(2S)-1-[(2S,3S)-3-methyl-2-{[(2S,3S)-3-(propylcarbamoyl)oxiran-2-yl]formamido}pentanoyl]pyrrolidine-2-carboxylic acid::CA074::CHEMBL490920::N-{[(2S,3S)-3-(propylcarbamoyl)oxiran-2-yl]carbonyl}-L-isoleucyl-L-proline::PrNH-tES-Ile-Pro-OH::epoxysuccinyl derivative CA074",Procathepsin L,Homo sapiens,>1.00e+5
1120085,NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1cccc(c1)C#N)C(F)(F)F,"InChI=1S/C30H27F3N6O/c31-30(32,33)27-15-26(39(38-27)25-9-2-5-21(13-25)17-35)29(40)37-24-8-3-7-23(14-24)28(36-18-19-10-11-19)22-6-1-4-20(12-22)16-34/h1-9,12-15,19,28,36H,10-11,17-18,35H2,(H,37,40)",VQJJJCIJWBDLSJ-UHFFFAOYSA-N,416879,"1-(3-(aminomethyl)phenyl)-N-(3-((3-cyanophenyl)(cyclopropylmethyl amino)methyl)phenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide::US10329260, Compound 152d::US10633345, Compound 152d::US10689346, Compound 152d::US11203574, Compound 152d::US11230530, Compound 152d",Plasma kallikrein,,
72376,CCCCOc1ncnc2c3cc(F)ccc3[nH]c12,"InChI=1S/C14H14FN3O/c1-2-3-6-19-14-13-12(16-8-17-14)10-7-9(15)4-5-11(10)18-13/h4-5,7-8,18H,2-3,6H2,1H3",RNRSUFSQCJVVCE-UHFFFAOYSA-N,36929,"4-butoxy-8-fluoranyl-5H-pyrimido[5,4-b]indole::4-butoxy-8-fluoro-5H-pyrimid[5,4-b]indole::4-butoxy-8-fluoro-5H-pyrimido[5,4-b]indole::MLS000041486::SMR000044810::cid_663916",Isoform 2 of Nuclear receptor ROR-alpha (Alpha-2),Homo sapiens, 13040
541930,COc1ncc(F)cc1CN1CCN(CC1)c1ccc(cn1)-c1cc(cn2ncc(C#N)c12)-c1cnn(C)c1,"InChI=1S/C28H26FN9O/c1-35-16-23(14-33-35)20-10-25(27-22(11-30)13-34-38(27)18-20)19-3-4-26(31-12-19)37-7-5-36(6-8-37)17-21-9-24(29)15-32-28(21)39-2/h3-4,9-10,12-16,18H,5-8,17H2,1-2H3",XKGRZWPYAYDGKY-UHFFFAOYSA-N,284447,"4-(6-(4-((5-fluoro-2- methoxypyridin-3- yl)methyl)piperazin-1- yl)pyridin-3-yl)-6-(1- methyl-1H-pyrazol-4- yl)pyrazolo[1,5-a]pyridine- 3-carbonitrile::US10023570, Example 457::US10174027, Example 457",Proto-oncogene tyrosine-protein kinase receptor Ret [658-1114],, 13.1
50090048,COc1cc2c(Oc3ccc(NS(=O)(=O)c4cccc(c4)-c4ccoc4)cc3F)ccnc2cc1OCCCN1CCOCC1,"InChI=1S/C33H32FN3O7S/c1-40-32-20-27-29(21-33(32)43-14-3-11-37-12-16-41-17-13-37)35-10-8-30(27)44-31-7-6-25(19-28(31)34)36-45(38,39)26-5-2-4-23(18-26)24-9-15-42-22-24/h2,4-10,15,18-22,36H,3,11-14,16-17H2,1H3",PDVPMUDAAPKQBR-UHFFFAOYSA-N,50010384,CHEMBL3263960,Insulin receptor,Homo sapiens,>12500
1149347,NC1CCCN(C1)C1CC(CC1n1cccn1)c1ccc(F)cc1,"InChI=1S/C19H25FN4/c20-16-6-4-14(5-7-16)15-11-18(23-9-1-3-17(21)13-23)19(12-15)24-10-2-8-22-24/h2,4-8,10,15,17-19H,1,3,9,11-13,21H2",MZAOLBDFKVMZHQ-UHFFFAOYSA-N,542437,"1-[4-(4-fluorophenyl)-2-pyrazol-1-yl-cyclopentyl] piperidin-3-amine::US11274091, Example 8",Short transient receptor potential channel 3,Homo sapiens, 7.97
1235910,CC(NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#CC3(O)CN4CCC3CC4)c2c(=O)n1-c1ccccc1,"InChI=1S/C33H31N7O3/c1-21(36-31(41)28-29(34)37-39-16-6-15-35-30(28)39)26-19-23-8-5-7-22(11-14-33(43)20-38-17-12-24(33)13-18-38)27(23)32(42)40(26)25-9-3-2-4-10-25/h2-10,15-16,19,21,24,43H,12-13,17-18,20H2,1H3,(H2,34,37)(H,36,41)",GBPGXWBBGSRQDS-UHFFFAOYSA-N,588125,"US11541059, Compound 62","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform",Homo sapiens, 2000
51421485,Clc1ccc(CNc2ncc(C(=O)NCCCN3CCCC3=O)c(NC3CCCC3)n2)c(Cl)c1,"InChI=1S/C24H30Cl2N6O2/c25-17-9-8-16(20(26)13-17)14-28-24-29-15-19(22(31-24)30-18-5-1-2-6-18)23(34)27-10-4-12-32-11-3-7-21(32)33/h8-9,13,15,18H,1-7,10-12,14H2,(H,27,34)(H2,28,29,30,31)",RUAVAAXWRAUNAC-UHFFFAOYSA-N,50574221,CHEMBL4847568,Peripheral plasma membrane protein CASK,Homo sapiens,
300700,FC(F)Oc1cccc(CNC(=O)Nc2ccc(cc2F)[C@H]2CNCCO2)c1,"InChI=1S/C19H20F3N3O3/c20-15-9-13(17-11-23-6-7-27-17)4-5-16(15)25-19(26)24-10-12-2-1-3-14(8-12)28-18(21)22/h1-5,8-9,17-18,23H,6-7,10-11H2,(H2,24,25,26)/t17-/m1/s1",QWRFRBFGFHDFNT-QGZVFWFLSA-N,158284,"US9029370, 78",Trace amine-associated receptor 1,Mus musculus,
582852,Cc1cccc(CNC(=O)c2nn(CCO)c3CCN(Cc4c[nH]c5ccccc45)Cc23)c1,"InChI=1S/C26H29N5O2/c1-18-5-4-6-19(13-18)14-28-26(33)25-22-17-30(10-9-24(22)31(29-25)11-12-32)16-20-15-27-23-8-3-2-7-21(20)23/h2-8,13,15,27,32H,9-12,14,16-17H2,1H3,(H,28,33)",URSCQDBITYKHCI-UHFFFAOYSA-N,303969,"US10138242, Compound 55",PEX5-related protein/Peroxisomal membrane protein PEX14,, 78570
1111002,C[C@H]1CN(Cc2ccc(F)c(c2)-c2ccc(N3CCN(C)CC3)c(NC(=O)c3c[nH]c(=O)cc3C(F)(F)F)c2)C[C@@H](C)O1,,,525583,"US11174250, Example 1",P61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534],, 764
1135199,C[C@@H]1COCCN1c1cc(nc(n1)-c1ccnc2[nH]ccc12)C(C)(C)O,"InChI=1S/C19H23N5O2/c1-12-11-26-9-8-24(12)16-10-15(19(2,3)25)22-18(23-16)14-5-7-21-17-13(14)4-6-20-17/h4-7,10,12,25H,8-9,11H2,1-3H3,(H,20,21)/t12-/m1/s1",LKROHSRCVLZJLI-GFCCVEGCSA-N,535718,"US11236089, Compound CY-212",Serine/threonine-protein kinase ATR,,<3.00
50932,CN1CCC(CC1)c1cc(C)c2nc([nH]c2c1)-c1c(NC[C@@H](O)c2cccc(Cl)c2)cc[nH]c1=O,"InChI=1S/C27H30ClN5O2/c1-16-12-19(17-7-10-33(2)11-8-17)14-22-25(16)32-26(31-22)24-21(6-9-29-27(24)35)30-15-23(34)18-4-3-5-20(28)13-18/h3-6,9,12-14,17,23,34H,7-8,10-11,15H2,1-2H3,(H,31,32)(H2,29,30,35)/t23-/m1/s1",RNSWXWFQTKBNOT-HSZRJFAPSA-N,27880,"4-{[(2S)-2-(3-chlorophenyl)-2-hydroxyethyl]amino}-3-[4-methyl-6-(1-methylpiperidin-4-yl)-1H-1,3-benzodiazol-2-yl]-1,2-dihydropyridin-2-one::benzimidazole scaffold, 2",Cytochrome P450 3A4,Homo sapiens, 14000
965561,C[C@@]1(O)CCC[C@H]1n1c2nc(NC3CCN(CC3)S(N)(=O)=O)ncc2cc(Cl)c1=O,"InChI=1S/C18H25ClN6O4S/c1-18(27)6-2-3-14(18)25-15-11(9-13(19)16(25)26)10-21-17(23-15)22-12-4-7-24(8-5-12)30(20,28)29/h9-10,12,14,27H,2-8H2,1H3,(H2,20,28,29)(H,21,22,23)/t14-,18-/m1/s1",AQSKGIKUFDLXKA-RDTXWAMCSA-N,370241,"US10233188, Example 128::US10800783, Example 128::US11396512, Example 128",Cyclin-dependent kinase 2/G1/S-specific cyclin-E1,Homo sapiens,
382358,CC(C)(O)C(=O)NCC1CCc2c(C1)sc1ncnc(Nc3ccc4[nH]c(=O)sc4c3)c21,,,218703,"US9296757, 25",Glutathione S-transferase A1/Isoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a) [T344D],, 42
50613192,OCCN1CCN(CC1)c1nc2CCN(CCc2c(Nc2ccc(cc2)C(F)(F)F)n1)c1ncccc1C(F)(F)F,"InChI=1S/C27H29F6N7O/c28-26(29,30)18-3-5-19(6-4-18)35-23-20-7-10-39(24-21(27(31,32)33)2-1-9-34-24)11-8-22(20)36-25(37-23)40-14-12-38(13-15-40)16-17-41/h1-6,9,41H,7-8,10-17H2,(H,35,36,37)",DGBYTQSMHNWONG-UHFFFAOYSA-N,50332852,"2-(4-(4-(4-(trifluoromethyl)phenylamino)-7-(3-(trifluoromethyl)pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[5,4-d]azepin-2-yl)piperazin-1-yl)ethanol::CHEMBL1630618",Transient receptor potential cation channel subfamily V member 1,Rattus norvegicus, 1161
50016233,N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O,"InChI=1S/C12H22N6O6/c13-6(2-1-3-16-12(14)15)10(22)17-5-8(19)18-7(11(23)24)4-9(20)21/h6-7H,1-5,13H2,(H,17,22)(H,18,19)(H,20,21)(H,23,24)(H4,14,15,16)/t6-,7-/m0/s1",IYMAXBFPHPZYIK-BQBZGAKWSA-N,50107402,(S)-2-[2-((S)-2-Amino-5-carbamimidoyl-pentanoylamino)-acetylamino]-succinic acid::(S)-2-[2-((S)-2-Amino-5-guanidino-pentanoylamino)-acetylamino]-succinic acid::2-[2-(2-Amino-5-guanidino-pentanoylamino)-acetylamino]-succinic acid(RGD)::CHEMBL313763,Integrin alpha-V/beta-3,Homo sapiens,>10000
109536,CC(C)OC(=O)c1cccnc1N1CCN(CC1)c1cccc(Cl)c1,"InChI=1S/C19H22ClN3O2/c1-14(2)25-19(24)17-7-4-8-21-18(17)23-11-9-22(10-12-23)16-6-3-5-15(20)13-16/h3-8,13-14H,9-12H2,1-2H3",AEBHMQALVKZIOJ-UHFFFAOYSA-N,57911,2-[4-(3-chlorophenyl)-1-piperazinyl]-3-pyridinecarboxylic acid propan-2-yl ester::2-[4-(3-chlorophenyl)piperazino]nicotinic acid isopropyl ester::MLS000763673::SMR000337259::cid_3783311::isopropyl 2-[4-(3-chlorophenyl)piperazino]nicotinate::propan-2-yl 2-[4-(3-chlorophenyl)piperazin-1-yl]pyridine-3-carboxylate,Streptokinase A,Streptococcus pyogenes M1 GAS,
51190178,CS(=O)(=O)CC[C@@H]1OCC[C@@]2([C@H]1COc1c(F)ccc(F)c21)S(=O)(=O)c1ccc(cc1)C#N,"InChI=1S/C22H21F2NO6S2/c1-32(26,27)11-8-19-16-13-31-21-18(24)7-6-17(23)20(21)22(16,9-10-30-19)33(28,29)15-4-2-14(12-25)3-5-15/h2-7,16,19H,8-11,13H2,1H3/t16-,19-,22-/m0/s1",MLWGZDGBSJDMEV-BPXKWBHBSA-N,50489350,CHEMBL2314616,Presenilin-1,, 66
51090868,Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)C1(CC1)S(=O)(=O)c1cccc(F)c1)C(F)(F)F,"InChI=1S/C23H21F4N5O3S/c24-14-2-1-3-15(10-14)36(33,34)22(4-5-22)19-12-18(30-21(31-19)32-6-8-35-9-7-32)16-13-29-20(28)11-17(16)23(25,26)27/h1-3,10-13H,4-9H2,(H2,28,29)",LESWEGHJBSSCQS-UHFFFAOYSA-N,50458751,CHEMBL4204166,"Phosphatidylinositol 3-kinase regulatory subunit alpha/4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",Homo sapiens, 14
147114,Cn1c2ccccc2n(CCOc2ccc(Cl)cc2Cl)c1=O,"InChI=1S/C16H14Cl2N2O2/c1-19-13-4-2-3-5-14(13)20(16(19)21)8-9-22-15-7-6-11(17)10-12(15)18/h2-7,10H,8-9H2,1H3",VAATXGICUHXDAV-UHFFFAOYSA-N,67822,"1-[2-(2,4-dichlorophenoxy)ethyl]-3-methyl-1,3-dihydro-2H-benzimidazol-2-one::1-[2-(2,4-dichlorophenoxy)ethyl]-3-methyl-2-benzimidazolone::1-[2-(2,4-dichlorophenoxy)ethyl]-3-methyl-benzimidazol-2-one::1-[2-(2,4-dichlorophenoxy)ethyl]-3-methylbenzimidazol-2-one::1-[2-[2,4-bis(chloranyl)phenoxy]ethyl]-3-methyl-benzimidazol-2-one::MLS000535113::SMR000142546::cid_748782",DNA damage-inducible transcript 3 protein,Mus musculus, 610
50949532,OC[C@H]1O[C@H](C[C@@H]1O)n1ccc(NCc2ccco2)nc1=O,"InChI=1S/C14H17N3O5/c18-8-11-10(19)6-13(22-11)17-4-3-12(16-14(17)20)15-7-9-2-1-5-21-9/h1-5,10-11,13,18-19H,6-8H2,(H,15,16,20)/t10-,11+,13+/m0/s1",IPAHXSYYUYRPBD-DMDPSCGWSA-N,50389505,CHEMBL2063041,Orphan methyltransferase M.SssI,,
50345212,CN1CCN(Cc2cnc(Nc3ncc(s3)-c3cc(C)nc(OC4CCCCC4)n3)cn2)CC1,"InChI=1S/C24H32N8OS/c1-17-12-20(29-23(28-17)33-19-6-4-3-5-7-19)21-14-27-24(34-21)30-22-15-25-18(13-26-22)16-32-10-8-31(2)9-11-32/h12-15,19H,3-11,16H2,1-2H3,(H,26,27,30)",DLIDUXYWQPLFEM-UHFFFAOYSA-N,50186375,CHEMBL210540::N-(5-(2-(cyclohexyloxy)-6-methylpyrimidin-4-yl)thiazol-2-yl)-5-((4-methylpiperazin-1-yl)methyl)pyrazin-2-amine,Cyclin-dependent kinase 5,Homo sapiens, 3000
1062032,COc1nc(ccc1Nc1ncc2ccnc(NCC(C)(C)OC)c2n1)-c1cnn(C)n1,"InChI=1S/C21H25N9O2/c1-21(2,32-5)12-24-18-17-13(8-9-22-18)10-23-20(28-17)27-15-7-6-14(26-19(15)31-4)16-11-25-30(3)29-16/h6-11H,12H2,1-5H3,(H,22,24)(H,23,27,28)",IBAASUCTOIZUSV-UHFFFAOYSA-N,241323,"US10479788, Example 167::US11046688, Example 167::US9409907, 167",Dual specificity protein kinase TTK,Homo sapiens, 23.0
1170988,CCN(CCN1CCC(CC1)c1c[nH]c2ccccc12)C(=O)[C@@H](C)O,,,555073,"US11339151, Example 49",Potassium voltage-gated channel subfamily H member 2,Homo sapiens,>10000
776728,CNC[C@@H]([C@@H](O)c1cc(F)cc(F)c1)c1ccc2ccccc2c1,"InChI=1S/C20H19F2NO/c1-23-12-19(20(24)16-9-17(21)11-18(22)10-16)15-7-6-13-4-2-3-5-14(13)8-15/h2-11,19-20,23-24H,12H2,1H3/t19-,20+/m1/s1",OKQCBRXAICHRKL-UXHICEINSA-N,388605,"US9944618, Compound ID No. 141",Sodium-dependent serotonin transporter,Homo sapiens,
832138,CCOc1cc(-c2ccc(nc2)N2CCC(CN3CCN(C)[C@@H](C)C3)(CC2)NC(=O)CC(C)C)c2c(cnn2c1)C#N,"InChI=1S/C32H44N8O2/c1-6-42-27-16-28(31-26(17-33)19-35-40(31)21-27)25-7-8-29(34-18-25)39-11-9-32(10-12-39,36-30(41)15-23(2)3)22-38-14-13-37(5)24(4)20-38/h7-8,16,18-19,21,23-24H,6,9-15,20,22H2,1-5H3,(H,36,41)/t24-/m0/s1",VZFTUFGJELBCMP-DEOSSOPVSA-N,305585,"US10144734, Example 603::US10172845, Example 603::US10441581, Example 603::US10881652, Example 603",Proto-oncogene tyrosine-protein kinase receptor Ret [V804M],, 158
312211,Cc1cc(=O)oc2cc(Oc3ccc(Nc4c5CCCCCc5nc5ccc(Cl)cc45)cc3)ccc12,"InChI=1S/C30H25ClN2O3/c1-18-15-29(34)36-28-17-22(12-13-23(18)28)35-21-10-8-20(9-11-21)32-30-24-5-3-2-4-6-26(24)33-27-14-7-19(31)16-25(27)30/h7-17H,2-6H2,1H3,(H,32,33)",RGNPGZWSRDIWQM-UHFFFAOYSA-N,192700,"7-(4-(2-Chloro-7,8,9,10-tetrahydro-6H-cyclohepta[b]quinolin-11-ylamino)phenoxy)-4-methyl-2H-chromen-2-one (8q)",Acetylcholinesterase,Electrophorus electricus, 54120
458759,Cc1ncc(NC(=O)c2ccnc(c2)C(C)(C)F)cc1-c1cc(N2CCOCC2)c(nn1)S(C)(=O)=O,"InChI=1S/C24H27FN6O4S/c1-15-18(19-13-20(31-7-9-35-10-8-31)23(30-29-19)36(4,33)34)12-17(14-27-15)28-22(32)16-5-6-26-21(11-16)24(2,3)25/h5-6,11-14H,7-10H2,1-4H3,(H,28,32)",JCCDDEBFSGDCSJ-UHFFFAOYSA-N,87897,"US10245267, Example 927::US10709712, Example 927::US9694016, 927",Serine/threonine-protein kinase B-raf [V600E],, 7.91
771923,CS(=O)(=O)N[C@H]1CCCN([C@H]1COC1CCN(CC1)c1ccccc1F)C(=O)[C@@H]1C[C@@H]1F,"InChI=1S/C22H31F2N3O4S/c1-32(29,30)25-19-6-4-10-27(22(28)16-13-18(16)24)21(19)14-31-15-8-11-26(12-9-15)20-7-3-2-5-17(20)23/h2-3,5,7,15-16,18-19,21,25H,4,6,8-14H2,1H3/t16-,18+,19+,21+/m1/s1",RZJOCKDDAFARFG-SAJDGTNDSA-N,386793,"N-(cis-1-(((1S,2S)-2- fluorocyclopropyl)carbonyl)-2-(((1- (2-fluorophenyl)piperidin-4- yl)oxy)methyl)piperidin-3- yl)methanesulfonamide::US10287305, Example 221::US10508083, Example 221::US11292766, Example 221",Orexin receptor type 2,Homo sapiens,
996146,COc1nc(ccc1CN1CC2(C1)CCNC2)-c1cccc(c1Cl)-c1cccc(c1Cl)-c1ccc(CN2CC3(C2)CCNC3)c(OC)n1,"InChI=1S/C38H42Cl2N6O2/c1-47-35-25(17-45-21-37(22-45)13-15-41-19-37)9-11-31(43-35)29-7-3-5-27(33(29)39)28-6-4-8-30(34(28)40)32-12-10-26(36(44-32)48-2)18-46-23-38(24-46)14-16-42-20-38/h3-12,41-42H,13-24H2,1-2H3",OMMPPLVCLXIUDL-UHFFFAOYSA-N,479799,"US10899735, No. 258",Programmed cell death 1 ligand 1/2,, 339
50278667,NCCOCCOc1ccc(Cl)c2NC(=O)NC3(CCCCC3)c12,"InChI=1S/C17H24ClN3O3/c18-12-4-5-13(24-11-10-23-9-8-19)14-15(12)20-16(22)21-17(14)6-2-1-3-7-17/h4-5H,1-3,6-11,19H2,(H2,20,21,22)",PHMHLMDLVDNVJG-UHFFFAOYSA-N,50151643,"5''-[2-(2-aminoethoxy)ethoxy]-8''-chlorospiro[cyclohexane-1,4''-(1'',2'',3'',4''-tetrahydroquinazoline)]-2''-one::CHEMBL184701","High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A",Homo sapiens, 1620
50465648,Nc1nc2cc(ccc2c(=O)n1CC1CC(CO1)c1ccccc1)-c1ccccc1,"InChI=1S/C25H23N3O2/c26-25-27-23-14-19(17-7-3-1-4-8-17)11-12-22(23)24(29)28(25)15-21-13-20(16-30-21)18-9-5-2-6-10-18/h1-12,14,20-21H,13,15-16H2,(H2,26,27)",RNOWCBRECJJYFL-UHFFFAOYSA-N,50145779,CHEMBL3765557,Cathepsin D,Homo sapiens,>200000
849913,COC(=O)N1CCC[C@H](NS(C)(=O)=O)[C@@H]1CO[C@H]1CC[C@H](CC1)c1ccccc1C(F)F,"InChI=1S/C22H32F2N2O5S/c1-30-22(27)26-13-5-8-19(25-32(2,28)29)20(26)14-31-16-11-9-15(10-12-16)17-6-3-4-7-18(17)21(23)24/h3-4,6-7,15-16,19-21,25H,5,8-14H2,1-2H3/t15-,16+,19-,20-/m0/s1",YHXIAOBZMFWYQX-JSJNYSNDSA-N,386874,"US10287305, Example 322::US10508083, Example 324::US11292766, Example 324::methyl cis-2-(((cis-4-(2- (difluoromethyl)phenyl)cyclohexyl)- oxy)methyl)-3- ((methylsulfonyl)amino)piperidine- 1-carboxylate",Orexin receptor type 2,Homo sapiens,
1119208,CN(C)CCn1nc2C[C@]3(CCc4cc(OCCCC(F)(F)F)ccc34)NC(=O)c2c1NC(=O)CS(C)(=O)=O,"InChI=1S/C25H32F3N5O5S/c1-32(2)10-11-33-22(29-20(34)15-39(3,36)37)21-19(31-33)14-24(30-23(21)35)9-7-16-13-17(5-6-18(16)24)38-12-4-8-25(26,27)28/h5-6,13H,4,7-12,14-15H2,1-3H3,(H,29,34)(H,30,35)/t24-/m0/s1",NAIHFZJRGJOTHE-DEOSSOPVSA-N,528834,"US11198695, Example I-46","Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase",, 440
51048551,CN1CCN(CC1)c1cc(CCc2cc(C)cc(N)n2)cc(CCc2cc(C)cc(N)n2)c1,"InChI=1S/C27H36N6/c1-19-12-23(30-26(28)14-19)6-4-21-16-22(5-7-24-13-20(2)15-27(29)31-24)18-25(17-21)33-10-8-32(3)9-11-33/h12-18H,4-11H2,1-3H3,(H2,28,30)(H2,29,31)",PRWXJDNYQGFJKM-UHFFFAOYSA-N,50427866,CHEMBL2326357,"Nitric oxide synthase, inducible",Mus musculus,
50405444,COC(CN1CCN(CCc2ccc(C#N)c(OC)c2)CC1)c1ccc2C(=O)OCc2c1C,"InChI=1S/C26H31N3O4/c1-18-21(6-7-22-23(18)17-33-26(22)30)25(32-3)16-29-12-10-28(11-13-29)9-8-19-4-5-20(15-27)24(14-19)31-2/h4-7,14,25H,8-13,16-17H2,1-3H3",YKMBLNOHJFYUHE-UHFFFAOYSA-N,50116825,CHEMBL3612800,Potassium voltage-gated channel subfamily H member 2,Homo sapiens, 9000
50027930,COc1cccc2OC(c3ccccc3)c3cc(ccc3-c12)N(C)S(C)(=O)=O,"InChI=1S/C22H21NO4S/c1-23(28(3,24)25)16-12-13-17-18(14-16)22(15-8-5-4-6-9-15)27-20-11-7-10-19(26-2)21(17)20/h4-14,22H,1-3H3",WWJZOFGIUZFPHR-UHFFFAOYSA-N,50144172,CHEMBL65074::N-(1-Methoxy-6-phenyl-6H-benzo[c]chromen-8-yl)-N-methyl-methanesulfonamide,Glucocorticoid receptor,, 210
1063242,COCc1ccc(NC(=O)c2c(-c3ccc(CO)cc3)n(c3ncnc(N)c23)C2(C)CC2)cc1,"InChI=1S/C26H27N5O3/c1-26(11-12-26)31-22(18-7-3-16(13-32)4-8-18)20(21-23(27)28-15-29-24(21)31)25(33)30-19-9-5-17(6-10-19)14-34-2/h3-10,15,32H,11-14H2,1-2H3,(H,30,33)(H2,27,28,29)",ZWRRUQKFMJNHNW-UHFFFAOYSA-N,311693,"Ex. Cpd. 145::US10807986, Example 145::US11046696, Compound 145",Proto-oncogene tyrosine-protein kinase receptor Ret,Homo sapiens, 1.000
51450013,CCc1cc(O)c(F)cc1-c1cc(N[C@H]2C[C@@H]3CC[C@H](C2)N3)c2nc(N)ncc2c1,"InChI=1S/C23H26FN5O/c1-2-12-7-21(30)19(24)10-18(12)13-5-14-11-26-23(25)29-22(14)20(6-13)28-17-8-15-3-4-16(9-17)27-15/h5-7,10-11,15-17,27-28,30H,2-4,8-9H2,1H3,(H2,25,26,29)/t15-,16+,17-",OOSFLRHKSBTYIX-BJWYYQGGSA-N,50585516,CHEMBL5075673,Tyrosine-protein kinase JAK3,Homo sapiens, 3.2
50181677,C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl,"InChI=1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1",KTEIFNKAUNYNJU-GFCCVEGCSA-N,50306682,"(R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine::3-(2,6-dichloro-3-fluorobenzyloxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine::3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-amine::CHEMBL601719::CRIZOTINIB::PF-2341066::US10370379, Crizotinib::US10543199, Compound Crizotinib::US10780082, Compound Crizotinib::US11059827, Compound Crizotinib::US11517561, Compound Crizotinib::US9126941, PF-2341066::US9199944, Crizotinib::US9226923, Crizotinib",Ribosomal protein S6 kinase alpha-5,Homo sapiens,
51370839,CC\C(=C(/c1cc2ccccc2[nH]1)c1ccc(\C=C\C(O)=O)cc1)c1ccc(Cl)cc1C(F)(F)F,"InChI=1S/C28H21ClF3NO2/c1-2-21(22-13-12-20(29)16-23(22)28(30,31)32)27(25-15-19-5-3-4-6-24(19)33-25)18-10-7-17(8-11-18)9-14-26(34)35/h3-16,33H,2H2,1H3,(H,34,35)/b14-9+,27-21+",RFWMQDCIHCMWHS-USYAYNFISA-N,50554250,CHEMBL4779838,Estrogen receptor,, 2.0
50871848,Nc1c2CCCCc2nc2ccccc12,"InChI=1S/C13H14N2/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13/h1,3,5,7H,2,4,6,8H2,(H2,14,15)",YLJREFDVOIBQDA-UHFFFAOYSA-N,8961,"1,2,3,4-tetrahydro-9-acridinamine::1,2,3,4-tetrahydroacridin-9-amine::9-THA::9-amino-1,2,3,4-tetrahydroacridine (THA)::CHEMBL1337960::CHEMBL95::Cognex::Tacrine::Tracine::US8999994, Tacrine::cid_1935::tacrine.HCl",Acetylcholinesterase,Homo sapiens, 205
50173750,Cc1cccnc1CCC1CCN(CC1)S(=O)(=O)CC1(CCOCC1)N(O)C=O,"InChI=1S/C20H31N3O5S/c1-17-3-2-10-21-19(17)5-4-18-6-11-22(12-7-18)29(26,27)15-20(23(25)16-24)8-13-28-14-9-20/h2-3,10,16,18,25H,4-9,11-15H2,1H3",IBSGSCYXBWXQDW-UHFFFAOYSA-N,50345508,"CHEMBL1784364::N-hydroxy-N-(4-((4-(2-(3-methylpyridin-2-yl)ethyl)piperidin-1-ylsulfonyl)methyl)tetrahydro-2H-pyran-4-yl)formamide::US10322143, Compound 13g",A disintegrin and metalloproteinase with thrombospondin motifs 5,Homo sapiens, 580
933181,OC(=O)COCc1ccc(\C=C\C23CCC(CC2)(CC3)OCc2c(onc2-c2c(Cl)cncc2Cl)C2CC2)cc1,"InChI=1S/C31H32Cl2N2O5/c32-24-15-34-16-25(33)27(24)28-23(29(40-35-28)22-5-6-22)18-39-31-12-9-30(10-13-31,11-14-31)8-7-20-1-3-21(4-2-20)17-38-19-26(36)37/h1-4,7-8,15-16,22H,5-6,9-14,17-19H2,(H,36,37)/b8-7+",ALUZIFDFSMWCNQ-BQYQJAHWSA-N,454152,"US10730863, Example 622",Bile acid receptor,Homo sapiens,
50208396,Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C,"InChI=1S/C31H37N5O3/c1-22-9-11-23(12-10-22)36-29(21-28(34-36)31(2,3)4)33-30(37)32-26-13-14-27(25-8-6-5-7-24(25)26)39-20-17-35-15-18-38-19-16-35/h5-14,21H,15-20H2,1-4H3,(H2,32,33,37)",MVCOAUNKQVWQHZ-UHFFFAOYSA-N,13533,"1-[2-(4-methylphenyl)-5-tert-butyl-pyrazol-3-yl]-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea::1-[5-tert-butyl-2-(4-methylphenyl)-3-pyrazolyl]-3-[4-[2-(4-morpholinyl)ethoxy]-1-naphthalenyl]urea::1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea::1-[5-tert-butyl-2-(p-tolyl)pyrazol-3-yl]-3-[4-(2-morpholinoethoxy)-1-naphthyl]urea::3-[2-(4-methylphenyl)-5-tert-butyl-pyrazol-3-yl]-1-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea::3-[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-1-{4-[2-(morpholin-4-yl)ethoxy]naphthalen-1-yl}urea::BIRB 796::BIRB-796::BIRB-796, 3::CHEMBL103667::D3RKN_73::Doramapimod::US11407771, Compound 43::US8933228, BIRB 796::US9187470, 43 (BIRB-796)::US9242960, BIRB 796::US9260410, BIRB796::cid_156422::diaryl urea compound 10",RAF proto-oncogene serine/threonine-protein kinase,Homo sapiens, 1400
51444534,CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C12CCC(CC1)(CC2)C(=O)NCCNC(=O)CCNC(=O)CCNC(=O)CCCCC[N+]1=C(\C=C\C=C\C=C2\N(C)c3ccc(cc3C2(C)C)S(O)(=O)=O)C(C)(C)c2cc(ccc12)S([O-])(=O)=O,"InChI=1S/C60H80N10O12S2/c1-8-35-69-52-51(53(74)70(36-9-2)56(69)76)65-54(66-52)59-25-28-60(29-26-59,30-27-59)55(75)64-34-33-63-50(73)24-32-62-49(72)23-31-61-48(71)18-14-11-15-37-68-45-22-20-41(84(80,81)82)39-43(45)58(5,6)47(68)17-13-10-12-16-46-57(3,4)42-38-40(83(77,78)79)19-21-44(42)67(46)7/h10,12-13,16-17,19-22,38-39H,8-9,11,14-15,18,23-37H2,1-7H3,(H6-,61,62,63,64,65,66,71,72,73,74,75,77,78,79,80,81,82)",RSQNWFQGKRBBTQ-UHFFFAOYSA-N,50583641,CHEMBL5086197,Adenosine receptor A1,Homo sapiens,
51047361,CC1=CC(=O)C(=O)c2c3CCCCc3ccc12,"InChI=1S/C15H14O2/c1-9-8-13(16)15(17)14-11(9)7-6-10-4-2-3-5-12(10)14/h6-8H,2-5H2,1H3",HLVLHKHCAQKXEK-UHFFFAOYSA-N,50458274,CHEMBL4206049,Liver carboxylesterase 1,,
235711,Oc1ccc(C[C@H]2CNC(=S)N2C[C@H]2CCCN2C[C@H](Cc2ccccc2)N2C[C@H](Cc3ccc(O)cc3)N(CCc3ccccc3)C2=S)cc1,"InChI=1S/C42H49N5O2S2/c48-39-17-13-33(14-18-39)24-36-27-43-41(50)46(36)29-35-12-7-22-44(35)28-37(25-32-10-5-2-6-11-32)47-30-38(26-34-15-19-40(49)20-16-34)45(42(47)51)23-21-31-8-3-1-4-9-31/h1-6,8-11,13-20,35-38,48-49H,7,12,21-30H2,(H,43,50)/t35-,36+,37+,38+/m1/s1",HJLIQEBRJUVETG-SPWOZAQASA-N,113969,(4S)-1-[(1S)-1-benzyl-2-[(2R)-2-[[(5S)-5-(4-hydroxybenzyl)-2-thioxo-imidazolidin-1-yl]methyl]pyrrolidino]ethyl]-4-(4-hydroxybenzyl)-3-phenethyl-imidazolidine-2-thione::(4S)-4-[(4-hydroxyphenyl)methyl]-1-[(2S)-1-[(2R)-2-[[(5S)-5-[(4-hydroxyphenyl)methyl]-2-sulfanylidene-1-imidazolidinyl]methyl]-1-pyrrolidinyl]-3-phenylpropan-2-yl]-3-(2-phenylethyl)-2-imidazolidinethione::(4S)-4-[(4-hydroxyphenyl)methyl]-1-[(2S)-1-[(2R)-2-[[(5S)-5-[(4-hydroxyphenyl)methyl]-2-sulfanylidene-imidazolidin-1-yl]methyl]pyrrolidin-1-yl]-3-phenyl-propan-2-yl]-3-(2-phenylethyl)imidazolidine-2-thione::(4S)-4-[(4-hydroxyphenyl)methyl]-1-[(2S)-1-[(2R)-2-[[(5S)-5-[(4-hydroxyphenyl)methyl]-2-sulfanylideneimidazolidin-1-yl]methyl]pyrrolidin-1-yl]-3-phenylpropan-2-yl]-3-(2-phenylethyl)imidazolidine-2-thione::MLS003177417::SMR001881196::cid_51359484,Disintegrin and metalloproteinase domain-containing protein 17,, 69489
50302986,CN(C)c1ccc(cc1)S(=O)(=O)c1sc2ncccc2c1-c1ccc(Cl)cc1,"InChI=1S/C21H17ClN2O2S2/c1-24(2)16-9-11-17(12-10-16)28(25,26)21-19(14-5-7-15(22)8-6-14)18-4-3-13-23-20(18)27-21/h3-13H,1-2H3",JDNNSFNYYPIQJR-UHFFFAOYSA-N,50066439,CHEMBL3401585,Metabotropic glutamate receptor 5,Rattus norvegicus,
50373125,N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,"InChI=1S/C32H37N5O5/c33-25(18-23-13-15-24(38)16-14-23)32(42)37-17-7-12-28(37)31(41)36-27(20-22-10-5-2-6-11-22)30(40)35-26(29(34)39)19-21-8-3-1-4-9-21/h1-6,8-11,13-16,25-28,38H,7,12,17-20,33H2,(H2,34,39)(H,35,40)(H,36,41)/t25-,26-,27-,28-/m0/s1",XIJHWXXXIMEHKW-LJWNLINESA-N,50139013,(S)-1-[(S)-2-Amino-3-(4-hydroxy-phenyl)-propionyl]-pyrrolidine-2-carboxylic acid [(S)-1-((S)-1-carbamoyl-2-phenyl-ethylcarbamoyl)-2-phenyl-ethyl]-amide::(S)-N-((S)-1-((S)-1-amino-1-oxo-3-phenylpropan-2-ylamino)-1-oxo-3-phenylpropan-2-yl)-1-((S)-2-amino-3-(4-hydroxyphenyl)propanoyl)pyrrolidine-2-carboxamide::1-[(S)-2-Amino-3-(4-hydroxy-phenyl)-propionyl]-pyrrolidine-2-carboxylicacid[1-((S)-(S)-1-carbamoyl-2-phenyl-ethylcarbamoyl)-2-phenyl-ethyl]-amide::CHEMBL333357::H-Tyr-Pro-Phe-Phe-NH2::Tyr-Pro-Phe-Phe-NH2::endomorphin-2,Mu-type opioid receptor,Homo sapiens,
51235651,CC(C)n1cc(cn1)-c1nc(Nc2ccc(N3CCC(CC3)N(C)CCO)c(F)c2)ncc1C,"InChI=1S/C25H34FN7O/c1-17(2)33-16-19(15-28-33)24-18(3)14-27-25(30-24)29-20-5-6-23(22(26)13-20)32-9-7-21(8-10-32)31(4)11-12-34/h5-6,13-17,21,34H,7-12H2,1-4H3,(H,27,29,30)",CVLXNRIQVFIVGY-UHFFFAOYSA-N,50505817,CHEMBL4447631,Tyrosine-protein kinase Lyn,Homo sapiens, 17
50775325,CC(C)=CCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1,"InChI=1S/C20H20N2O2/c1-15(2)13-14-18-19(23)21(16-9-5-3-6-10-16)22(20(18)24)17-11-7-4-8-12-17/h3-13,18H,14H2,1-2H3",RBBWCVQDXDFISW-UHFFFAOYSA-N,50248306,DA-2370::Feprazone,ATP-binding cassette sub-family C member 3,Homo sapiens, 133000
50083405,COc1ccc(cc1)[C@@H]1[C@H]([C@@H](CN1CC(=O)N(C)C1CCCCC1)c1ccc2OCOc2c1)C(O)=O,"InChI=1S/C28H34N2O6/c1-29(20-6-4-3-5-7-20)25(31)16-30-15-22(19-10-13-23-24(14-19)36-17-35-23)26(28(32)33)27(30)18-8-11-21(34-2)12-9-18/h8-14,20,22,26-27H,3-7,15-17H2,1-2H3,(H,32,33)/t22-,26-,27+/m0/s1",PJPSUSRDIRKFPW-WDDWZANVSA-N,50050972,"(2S,3S,4R)-4-Benzo[1,3]dioxol-5-yl-1-[(cyclohexyl-methyl-carbamoyl)-methyl]-2-(4-methoxy-phenyl)-pyrrolidine-3-carboxylic acid::CHEMBL8736",Endothelin-1 receptor,Rattus, 23.8
870962,C[C@H](N1C(=O)c2cc(ccc2[C@]1(OC1COC[C@@H]1O)c1ccc(Cl)cc1)C(C)(C)O)c1ccc(Cl)cc1,"InChI=1S/C29H29Cl2NO5/c1-17(18-4-9-21(30)10-5-18)32-27(34)23-14-20(28(2,3)35)8-13-24(23)29(32,19-6-11-22(31)12-7-19)37-26-16-36-15-25(26)33/h4-14,17,25-26,33,35H,15-16H2,1-3H3/t17-,25-,26?,29+/m0/s1",JLJRDOGQKDSPHW-QYEDSFCJSA-N,427091,"(3R)-3-(4-Chlorophenyl)-2-[(1S)-1-(4-chlorophenyl)ethyl]-3-{[(3S,4R)-4-hydroxyoxolan-3-yl]oxy}-6-(2-hydroxypropan-2-yl)-2,3-dihydro-1H-isoindol-1-one and (3R)-3-(4-chlorophenyl)-2-[(1S)-1-(4-chlorophenyl)ethyl]-3-{[(3R,4S)-4-hydroxyoxolan-3-yl]oxy}-6-(2-hydroxypropan-2-yl)-2,3-dihydro-1H-isoindol-1-one::US10544132, Example 46::US10981898, Example 46",E3 ubiquitin-protein ligase Mdm2,Homo sapiens, 10780
266262,Cc1onc(c1COc1ccc(cn1)C(=O)NCc1nc(no1)C1CC1)-c1ccccc1,"InChI=1S/C23H21N5O4/c1-14-18(21(27-31-14)15-5-3-2-4-6-15)13-30-19-10-9-17(11-24-19)23(29)25-12-20-26-22(28-32-20)16-7-8-16/h2-6,9-11,16H,7-8,12-13H2,1H3,(H,25,29)",ZJSBUMFNEAUGSZ-UHFFFAOYSA-N,133336,"US8846719, 19",Gamma-aminobutyric acid receptor subunit alpha-5,Homo sapiens,
50100015,Cc1ccc2c3CCN(Cc4ccccc4)Cc3c(=O)oc2c1,"InChI=1S/C20H19NO2/c1-14-7-8-17-16-9-10-21(12-15-5-3-2-4-6-15)13-18(16)20(22)23-19(17)11-14/h2-8,11H,9-10,12-13H2,1H3",JYTBEUORVGHEBI-UHFFFAOYSA-N,50059496,"3-Benzyl-8-methyl-1,2,3,4-tetrahydro-chromeno[3,4-c]pyridin-5-one::CHEMBL92489",5-hydroxytryptamine receptor 2A,Rattus norvegicus,
930423,Cn1cnc2ncn(Cc3nc(no3)[C@@H]3[C@H]4CN(C[C@@H]34)c3ccc(C#N)c(F)c3)c(=O)c12,"InChI=1S/C21H17FN8O2/c1-28-9-24-20-18(28)21(31)30(10-25-20)8-16-26-19(27-32-16)17-13-6-29(7-14(13)17)12-3-2-11(5-23)15(22)4-12/h2-4,9-10,13-14,17H,6-8H2,1H3/t13-,14+,17+",ZAGXFWMLCVBKQA-HALDLXJZSA-N,452757,"2-fluoro-4- ((1R,5S,6r)-6-(5-((7- methyl-6-oxo-6,7- dihydro-1H-purin-1- yl)methyl)-1,2,4- oxadiazol-3-yl)-3- azabicyclo[3.1.0]::US10711004, Example 79",Transient receptor potential cation channel subfamily A member 1,, 15.0
50088855,[O-]C(=O)C(F)(F)F.[O-]C(=O)C(F)(F)F.[O-]C(=O)C(F)(F)F.CCN(CC)c1ccc(cc1)C(=C1C=CC(C=C1)=[N+](CC)CC)c1ccc(cc1S([O-])(=O)=O)S(=O)(=O)NCCCC[C@H](NC(=O)Cc1csc(=[NH2+])n1C)C(=O)N[C@@H](Cc1cn(Cc2ccccc2)c[n+]1C)C(=O)NC1CC[NH+](C)CC1,"InChI=1S/C59H77N11O8S3.3C2HF3O2/c1-8-69(9-2)46-24-20-43(21-25-46)56(44-22-26-47(27-23-44)70(10-3)11-4)51-29-28-50(37-54(51)81(76,77)78)80(74,75)61-32-16-15-19-52(63-55(71)36-49-40-79-59(60)67(49)7)57(72)64-53(58(73)62-45-30-33-65(5)34-31-45)35-48-39-68(41-66(48)6)38-42-17-13-12-14-18-42;3*3-2(4,5)1(6)7/h12-14,17-18,20-29,37,39-41,45,52-53,60-61H,8-11,15-16,19,30-36,38H2,1-7H3,(H2-2,62,63,64,71,72,73,76,77,78);3*(H,6,7)/t52-,53-;;;/m0.../s1",XXAJFHKETAFVCS-GPPUWUEZSA-N,50009560,CHEMBL3234454,Type-1 angiotensin II receptor,Homo sapiens,
892836,CC(C)(O)[C@H](F)CNC(=O)c1cnc(cc1NCC1(O)CCC1)-c1cnn2cc(Cl)cnc12,"InChI=1S/C22H26ClFN6O3/c1-21(2,32)18(24)10-27-20(31)15-8-25-16(6-17(15)28-12-22(33)4-3-5-22)14-9-29-30-11-13(23)7-26-19(14)30/h6-9,11,18,32-33H,3-5,10,12H2,1-2H3,(H,25,28)(H,27,31)/t18-/m1/s1",LRBMKDOTRIPJPY-GOSISDBHSA-N,438423,"US10618903, Example 51",Interleukin-1 receptor-associated kinase 4,Homo sapiens, 10.00
402508,COc1cccc2CN(Cc3ccc(cc3)[C@H](C)NC(=O)c3cncs3)CCc12,"InChI=1S/C23H25N3O2S/c1-16(25-23(27)22-12-24-15-29-22)18-8-6-17(7-9-18)13-26-11-10-20-19(14-26)4-3-5-21(20)28-2/h3-9,12,15-16H,10-11,13-14H2,1-2H3,(H,25,27)/t16-/m0/s1",XIOSQPZGKNLCFC-INIZCTEOSA-N,230499,"US9340510, 2.001",Acetyl-CoA carboxylase 2,Homo sapiens, 135
836506,Cn1cc(nc1-c1ccc(Cn2c3nc(ncc3[nH]c2=O)-c2cccnc2N2CCOCC2)cc1)C(F)(F)F,"InChI=1S/C26H23F3N8O2/c1-35-15-20(26(27,28)29)33-22(35)17-6-4-16(5-7-17)14-37-24-19(32-25(37)38)13-31-21(34-24)18-3-2-8-30-23(18)36-9-11-39-12-10-36/h2-8,13,15H,9-12,14H2,1H3,(H,32,38)",CTJYCFRUKQMLFA-UHFFFAOYSA-N,325127,"9-(4-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2-::US10189841, Compound I-333::US10399980, Compound I-333",Ubiquitin carboxyl-terminal hydrolase 1,, 125
50382539,CC(C)OC(=O)N1CCC(CC1)O[C@H]1CC[C@@H](CC1)Oc1cnc(cn1)S(C)(=O)=O,"InChI=1S/C20H31N3O6S/c1-14(2)27-20(24)23-10-8-17(9-11-23)28-15-4-6-16(7-5-15)29-18-12-22-19(13-21-18)30(3,25)26/h12-17H,4-11H2,1-3H3/t15-,16-",OOZUGTUUVHOIQS-WKILWMFISA-N,50106163,CHEMBL3598094,Glucose-dependent insulinotropic receptor,Rattus norvegicus,
40784,CCCCOc1ccc(cc1)C(CC(O)=O)c1cccs1,"InChI=1S/C17H20O3S/c1-2-3-10-20-14-8-6-13(7-9-14)15(12-17(18)19)16-5-4-11-21-16/h4-9,11,15H,2-3,10,12H2,1H3,(H,18,19)",PNGSWCVAXCXVHE-UHFFFAOYSA-N,22492,"3-(4-butoxyphenyl)-3-(thiophen-2-yl)propanoic acid::3-Aryl-3-(4-phenoxy)-propionic Acid derivative, 46",Free fatty acid receptor 1,,
678258,Cc1cc(C)nc(c1)-c1cn[nH]c1C(=O)Nc1cc2nc(nn2cc1F)-c1ccccc1,"InChI=1S/C23H18FN7O/c1-13-8-14(2)26-18(9-13)16-11-25-29-21(16)23(32)27-19-10-20-28-22(15-6-4-3-5-7-15)30-31(20)12-17(19)24/h3-12H,1-2H3,(H,25,29)(H,27,32)",PEHBQLPLZWJRIY-UHFFFAOYSA-N,343318,"4-(4,6-dimethylpyridin-2-yl)-N-(6-fluoro-2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-1-methyl-1H-pyrazole-5-carboxamide::US9777000, Example 3.53","cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A",Homo sapiens,<5
971396,COCCCN1C(=O)N(CC(=O)NCCO)C[C@]11CC[C@@](CC1)(N(C)C)c1ccccc1,"InChI=1S/C24H38N4O4/c1-26(2)24(20-8-5-4-6-9-20)12-10-23(11-13-24)19-27(18-21(30)25-14-16-29)22(31)28(23)15-7-17-32-3/h4-6,8-9,29H,7,10-19H2,1-3H3,(H,25,30)/t23-,24+",ATGGPTGXYMYNHH-PSWAGMNNSA-N,469949,"CIS-2-[8-Dimethylamino-1-(3-methoxy-propyl)-2-oxo-8-phenyl-1,3- diazaspiro[4.5]decan-3-yl]-N-(2-hydroxy-ethyl)-acetamide::US10807989, Example SC_1180",Mu-type opioid receptor,Homo sapiens,
50179241,Cc1ccc(NC(=O)N(CCCCC2CCCCC2)CCc2ccc(SC(C)(C)C(O)=O)cc2)cc1[N+]([O-])=O,"InChI=1S/C30H41N3O5S/c1-22-12-15-25(21-27(22)33(37)38)31-29(36)32(19-8-7-11-23-9-5-4-6-10-23)20-18-24-13-16-26(17-14-24)39-30(2,3)28(34)35/h12-17,21,23H,4-11,18-20H2,1-3H3,(H,31,36)(H,34,35)",LRLDBAWAMQJEFB-UHFFFAOYSA-N,50099492,2-(4-{2-[1-(4-Cyclohexyl-butyl)-3-(4-methyl-3-nitro-phenyl)-ureido]-ethyl}-phenylsulfanyl)-2-methyl-propionic acid::CHEMBL281791,Peroxisome proliferator-activated receptor delta,,
840374,FC(F)(c1ccccc1)c1nc(N2CCC3(C2)N=N3)c2nnn(Cc3ccccc3Cl)c2n1,"InChI=1S/C22H17ClF2N8/c23-16-9-5-4-6-14(16)12-33-19-17(28-31-33)18(32-11-10-21(13-32)29-30-21)26-20(27-19)22(24,25)15-7-2-1-3-8-15/h1-9H,10-13H2",HHRNGZYZJQZLJO-UHFFFAOYSA-N,419262,"3-[(2-Chlorophenyl)methyl]-5-[difluoro(phenyl)methyl]-7-(1,2,5-triazaspiro[2.4]hept-1-en-5-yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine::US10457684, Example 6",Cannabinoid receptor 2,Homo sapiens,
1181822,CCn1nc(Cl)c2cnc(Nc3cn(nc3Cl)C3CCN(CC3)S(=O)(=O)C3CC3)nc12,"InChI=1S/C18H22Cl2N8O2S/c1-2-27-17-13(15(19)24-27)9-21-18(23-17)22-14-10-28(25-16(14)20)11-5-7-26(8-6-11)31(29,30)12-3-4-12/h9-12H,2-8H2,1H3,(H,21,22,23)",UFOROFMJWKVGFV-UHFFFAOYSA-N,559619,"US11370796, Compound 47",Leucine-rich repeat serine/threonine-protein kinase 2,Homo sapiens, 6.48
51309976,CN1CCC2(CC1)N[C@@H](CO)C(=O)N(C2=O)c1c(C)cccc1C,"InChI=1S/C18H25N3O3/c1-12-5-4-6-13(2)15(12)21-16(23)14(11-22)19-18(17(21)24)7-9-20(3)10-8-18/h4-6,14,19,22H,7-11H2,1-3H3/t14-/m0/s1",GEALIVCGHVSQSW-AWEZNQCLSA-N,50531605,CHEMBL4552298,Sigma non-opioid intracellular receptor 1,Cavia porcellus,
435251,CC(=O)N1CCc2c(C1)[nH]nc2C(=O)N1CCC(CC1)c1cccc(F)c1C(F)(F)F,"InChI=1S/C21H22F4N4O2/c1-12(30)29-10-7-15-17(11-29)26-27-19(15)20(31)28-8-5-13(6-9-28)14-3-2-4-16(22)18(14)21(23,24)25/h2-4,13H,5-11H2,1H3,(H,26,27)",VICXOPXLVAUSNR-UHFFFAOYSA-N,249464,"US10072016, Compound 63::US10407433, Compound 63::US10913746, Compound 63::US9434727, 63::US9777010, Compound 63",Retinol-binding protein 4,Homo sapiens, 4.456853
50421733,O[C@@H]1CN2CCC[C@@H](O)[C@@H]2[C@@H]1O,"InChI=1S/C8H15NO3/c10-5-2-1-3-9-4-6(11)8(12)7(5)9/h5-8,10-12H,1-4H2/t5-,6-,7-,8-/m1/s1",FXUAIOOAOAVCGD-WCTZXXKLSA-N,50168995,"(-)-swainsonine::(1S,2R,8R,8aR)-Octahydro-indolizine-1,2,8-triol::1S-8AB-OCTAHYDRO-INDOLIZIDINE-1A,2A,8B-TRIOL::CHEMBL371197::SWAINSONINE",Lysosomal alpha-mannosidase,Homo sapiens, 50
966539,O=C(N[C@@H]1CCCNC1)c1sc2nccc3n(-c4cccc(c4)-c4ccccc4)c(=O)[nH]c1c23,,,467768,"(R)-5-([1,1'-Biphenyl]-3-yl)-4-oxo-N-(piperidin-3-yl)-4,5-dihydro- 3H-1-thia-3,5,8-triazaacenaphthylene-2-carboxamide;::US10800792, Example 426::US10822348, Example 426",Tyrosine-protein kinase BTK,Homo sapiens, 126
51130191,O=C(Cc1cccc(OCCCC2CCNCC2)c1)Nc1nc(cs1)-c1c[nH]c2ncccc12,"InChI=1S/C26H29N5O2S/c32-24(31-26-30-23(17-34-26)22-16-29-25-21(22)7-2-10-28-25)15-19-4-1-6-20(14-19)33-13-3-5-18-8-11-27-12-9-18/h1-2,4,6-7,10,14,16-18,27H,3,5,8-9,11-13,15H2,(H,28,29)(H,30,31,32)",OKUPZBPYLVKVSU-UHFFFAOYSA-N,50463483,CHEMBL4245242,Serine/threonine-protein kinase PAK 3,,
50820144,CC(C)Cn1c2nc([nH]c2c(=O)n(CC(C)C)c1=O)-c1cc(OCC(=O)Nc2ccc(F)cc2)nn1C,"InChI=1S/C25H30FN7O4/c1-14(2)11-32-23-21(24(35)33(25(32)36)12-15(3)4)28-22(29-23)18-10-20(30-31(18)5)37-13-19(34)27-17-8-6-16(26)7-9-17/h6-10,14-15H,11-13H2,1-5H3,(H,27,34)(H,28,29)",ZASWTQRANFXXQJ-UHFFFAOYSA-N,50140979,"2-[5-(1,3-Diisobutyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)-1-methyl-1H-pyrazol-3-yloxy]-N-(4-fluoro-phenyl)-acetamide::CHEMBL32697",Adenosine receptor A2a,Homo sapiens,
327839,Cn1c(nc2c(N)nc(CCCCO)nc12)-n1nccn1,"InChI=1S/C12H16N8O/c1-19-11-9(18-12(19)20-14-5-6-15-20)10(13)16-8(17-11)4-2-3-7-21/h5-6,21H,2-4,7H2,1H3,(H2,13,16,17)",LXKQSSJIYWOEPP-UHFFFAOYSA-N,181010,"US9133197, 1",Adenosine receptor A2a,Homo sapiens,
50287315,CN1CCC(CC1)N1CNc2ccc(NC(=O)c3c(F)cc(F)cc3F)cc12,"InChI=1S/C20H21F3N4O/c1-26-6-4-14(5-7-26)27-11-24-17-3-2-13(10-18(17)27)25-20(28)19-15(22)8-12(21)9-16(19)23/h2-3,8-10,14,24H,4-7,11H2,1H3,(H,25,28)",BBYIBACYQLBDSC-UHFFFAOYSA-N,50156408,"2,4,6-Trifluoro-N-[3-(1-methyl-piperidin-4-yl)-2,3-dihydro-1H-benzoimidazol-5-yl]-benzamide::CHEMBL187581",5-hydroxytryptamine receptor 1F,Homo sapiens,
51227776,CCCCc1nc(Cl)c(CNC(=O)C(CS)Cc2ccc3ccccc3c2)n1Cc1ccc(cc1)-c1ccccc1C(O)=O,"InChI=1S/C36H36ClN3O3S/c1-2-3-12-33-39-34(37)32(21-38-35(41)29(23-44)20-25-15-16-26-8-4-5-9-28(26)19-25)40(33)22-24-13-17-27(18-14-24)30-10-6-7-11-31(30)36(42)43/h4-11,13-19,29,44H,2-3,12,20-23H2,1H3,(H,38,41)(H,42,43)",CHKOUVAKPRIMRS-UHFFFAOYSA-N,50503899,CHEMBL4471668,Neprilysin,, 398
50058703,CCOC(=O)C(=O)C1CCCN1C(=O)[C@@H]1CCCN1C(=O)CCCc1ccccc1,"InChI=1S/C23H30N2O5/c1-2-30-23(29)21(27)18-12-7-16-25(18)22(28)19-13-8-15-24(19)20(26)14-6-11-17-9-4-3-5-10-17/h3-5,9-10,18-19H,2,6-8,11-16H2,1H3/t18?,19-/m0/s1",LBLKMOXIRVMBGA-GGYWPGCISA-N,50037607,CHEMBL333638::Oxo-{1-[(S)-1-(4-phenyl-butyryl)-pyrrolidine-2-carbonyl]-pyrrolidin-2-yl}-acetic acid ethyl ester,Prolyl endopeptidase,, 10.3
50893588,Oc1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1,"InChI=1S/C20H14FN3O/c21-16-5-1-13(2-6-16)18-19(14-9-11-22-12-10-14)24-20(23-18)15-3-7-17(25)8-4-15/h1-12,25H,(H,23,24)",QHKYPYXTTXKZST-UHFFFAOYSA-N,13531,"4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole::4-[4-(4-Fluorophenyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]phenol::4-[4-(4-fluorophenyl)-5-(4-pyridyl)-4-imidazolin-2-ylidene]cyclohexa-2,5-dien-1-one::4-[5-(4-fluorophenyl)-4-(pyridin-4-yl)-1H-imidazol-2-yl]phenol::SB-202190::SB202190::biotinylated SB202190",Cyclin-dependent kinase 3,,
1039430,COCC1N(Cc2ccccc12)c1cn[nH]c(=O)c1Cl,,,431262,"US10550105, Example 207::US10870641, Example 207::US11014913, Example 207",Protein mono-ADP-ribosyltransferase TIPARP,,>1000
50314025,Cc1c[nH]c2ncnc(-c3ccc(NC(=O)N(CCO)c4ccc(F)cc4)cc3)c12,"InChI=1S/C22H20FN5O2/c1-14-12-24-21-19(14)20(25-13-26-21)15-2-6-17(7-3-15)27-22(30)28(10-11-29)18-8-4-16(23)5-9-18/h2-9,12-13,29H,10-11H2,1H3,(H,27,30)(H,24,25,26)",FCMRBYJIHLJQSI-UHFFFAOYSA-N,50072829,CHEMBL3410039,Mitogen-activated protein kinase 10,Homo sapiens,>10000
50594221,Cn1cc(Cc2cccc(n2)-c2cccc3OCOc23)c2cc(NC(=O)CC(C)(C)O)ccc12,"InChI=1S/C27H27N3O4/c1-27(2,32)14-25(31)29-19-10-11-23-21(13-19)17(15-30(23)3)12-18-6-4-8-22(28-18)20-7-5-9-24-26(20)34-16-33-24/h4-11,13,15,32H,12,14,16H2,1-3H3,(H,29,31)",VKKPZNVBRKYDRR-UHFFFAOYSA-N,50325894,"CHEMBL1224615::N-(3-((6-(benzo[d][1,3]dioxol-4-yl)pyridin-2-yl)methyl)-1-methyl-1H-indol-5-yl)-3-hydroxy-3-methylbutanamide",Cannabinoid receptor 1,Homo sapiens, 5
50547231,CC1(C)C(=O)N([C@H]2CCc3c2cccc3O)c2nc(Nc3ccccc3)ncc12,"InChI=1S/C23H22N4O2/c1-23(2)17-13-24-22(25-14-7-4-3-5-8-14)26-20(17)27(21(23)29)18-12-11-16-15(18)9-6-10-19(16)28/h3-10,13,18,28H,11-12H2,1-2H3,(H,24,25,26)/t18-/m0/s1",XLFNLJYGUOLEJS-SFHVURJKSA-N,50208911,CHEMBL3884319,Epidermal growth factor receptor,Homo sapiens, 10000
50253638,CCCCOC(=O)N1C[C@]2(C[C@H]1CNc1ncc[nH]1)CC(=NO2)C(=O)NC[C@H](NS(=O)(=O)c1c(C)cc(C)cc1C)C(O)=O,"InChI=1S/C28H39N7O8S/c1-5-6-9-42-27(39)35-16-28(12-20(35)14-32-26-29-7-8-30-26)13-21(33-43-28)24(36)31-15-22(25(37)38)34-44(40,41)23-18(3)10-17(2)11-19(23)4/h7-8,10-11,20,22,34H,5-6,9,12-16H2,1-4H3,(H,31,36)(H,37,38)(H2,29,30,32)/t20-,22-,28-/m0/s1",TZNXKIAIKROUOK-AHPZTNMXSA-N,50138306,"(5S,8S)-3-[(S)-2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-ethylcarbamoyl]-8-[(1H-imidazol-2-ylamino)-methyl]-1-oxa-2,7-diaza-spiro[4.4]non-2-ene-7-carboxylic acid butyl ester::CHEMBL126983",Integrin alpha-V/beta-1,Homo sapiens, 130
763450,COc1ccc(OCC2N(CCc3cc(OC)cc(OC)c23)C(=O)c2cccc(Cl)c2)cc1,"InChI=1S/C26H26ClNO5/c1-30-20-7-9-21(10-8-20)33-16-23-25-17(14-22(31-2)15-24(25)32-3)11-12-28(23)26(29)18-5-4-6-19(27)13-18/h4-10,13-15,23H,11-12,16H2,1-3H3",DGEWNXLNJIUWQA-UHFFFAOYSA-N,50436105,"CHEMBL2397253::US10273214, Example 1180-20","Glutamate receptor ionotropic, NMDA 2C",Homo sapiens, 11000
51151319,CC(=O)NCCc1c[nH]c2ccc(F)cc12,"InChI=1S/C12H13FN2O/c1-8(16)14-5-4-9-7-15-12-3-2-10(13)6-11(9)12/h2-3,6-7,15H,4-5H2,1H3,(H,14,16)",UDLASALUJLTGJV-UHFFFAOYSA-N,50471827,CHEMBL284521,Melatonin receptor type 1A/1B,Homo sapiens,
50355089,C[C@H](NC(=O)[C@@H]1COC(=O)[C@H](Cc2ccc(cc2)[N+]([O-])=O)N1)c1ccccc1,"InChI=1S/C20H21N3O5/c1-13(15-5-3-2-4-6-15)21-19(24)18-12-28-20(25)17(22-18)11-14-7-9-16(10-8-14)23(26)27/h2-10,13,17-18,22H,11-12H2,1H3,(H,21,24)/t13-,17-,18-/m0/s1",SFJZUUDKNPCJAG-KKXDTOCCSA-N,50192095,CHEMBL215930::cis-5-(4-nitrobenzyl)-6-oxo-N-((S)-1-phenylethyl)morpholine-3-carboxamide,Voltage-dependent T-type calcium channel subunit alpha-1G,Homo sapiens, 2130
50761678,COc1cc2[nH]c3nc(N)nc(NCc4ccccc4)c3c2cc1O,"InChI=1S/C18H17N5O2/c1-25-14-8-12-11(7-13(14)24)15-16(22-18(19)23-17(15)21-12)20-9-10-5-3-2-4-6-10/h2-8,24H,9H2,1H3,(H4,19,20,21,22,23)",WYUMYTHSGQZLIP-UHFFFAOYSA-N,50242541,CHEMBL4073523,Epidermal growth factor receptor,Homo sapiens,
50122111,CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)c1cc(O)ccc1O)C(=O)N[C@@H](CC)C(O)=O,"InChI=1S/C28H43N5O10/c1-4-15(3)23(27(41)30-18(5-2)28(42)43)33-26(40)20(10-12-22(36)37)32-25(39)19(8-6-7-13-29)31-24(38)17-14-16(34)9-11-21(17)35/h9,11,14-15,18-20,23,34-35H,4-8,10,12-13,29H2,1-3H3,(H,30,41)(H,31,38)(H,32,39)(H,33,40)(H,36,37)(H,42,43)/t15?,18?,19-,20-,23-/m0/s1",LNZLZVRFWYCKOF-MSMFUVKXSA-N,50070762,CHEMBL2372731::Nazumamide A (NAZA) analogue,Prothrombin,, 54000
51427462,CC(C)[C@H](Nc1ncnc2nc[nH]c12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,,,50576610,CHEMBL4847494,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform",Homo sapiens, 313
1035246,CO[C@H]1CC[C@@H](CC1)Nc1ncc(Cl)c(n1)-c1ccc2CN([C@H](C)C(=O)N[C@H](CO)c3cccc(C)c3)C(=O)c2c1,"InChI=1S/C31H36ClN5O4/c1-18-5-4-6-20(13-18)27(17-38)35-29(39)19(2)37-16-22-8-7-21(14-25(22)30(37)40)28-26(32)15-33-31(36-28)34-23-9-11-24(41-3)12-10-23/h4-8,13-15,19,23-24,27,38H,9-12,16-17H2,1-3H3,(H,35,39)(H,33,34,36)/t19-,23-,24-,27-/m1/s1",RESLBQNYLGHVCS-GVDONAMHSA-N,417964,"(2R)-2-[6-(5-chloro- 2-{[trans-4- methoxycyclohexyl] amino}pyrimidin-4-yl)- 1-oxo-2,3-dihydro- 1H-isoindol-2-yl]-N- [(1S)-2-hydroxy-1-(3- methylphenyl)ethyl] propanamide::US10457669, Example 629::US11001575, Example 629",Mitogen-activated protein kinase 1,Homo sapiens, 3.70
51019764,CCCCNCc1ccc(cc1)-c1nc(CN(C2CCCC2)S(=O)(=O)c2ccc(OC)c(OC)c2)cs1,"InChI=1S/C28H37N3O4S2/c1-4-5-16-29-18-21-10-12-22(13-11-21)28-30-23(20-36-28)19-31(24-8-6-7-9-24)37(32,33)25-14-15-26(34-2)27(17-25)35-3/h10-15,17,20,24,29H,4-9,16,18-19H2,1-3H3",YXZROCSVGRUEGS-UHFFFAOYSA-N,50417709,CHEMBL1643605,Vasopressin V1b receptor,,
50741388,OC(=O)CNC(=O)C1=CC2(CC1)CCN(C(=O)c1ccc(NC(=O)c3ccccc3-c3ccccc3)cc1)c1ccccc1C2,"InChI=1S/C37H33N3O5/c41-33(42)24-38-34(43)28-18-19-37(23-28)20-21-40(32-13-7-4-10-27(32)22-37)36(45)26-14-16-29(17-15-26)39-35(44)31-12-6-5-11-30(31)25-8-2-1-3-9-25/h1-17,23H,18-22,24H2,(H,38,43)(H,39,44)(H,41,42)",JYKTYQLAXRWNPF-UHFFFAOYSA-N,50147231,"2-[1-[4-(2-phenylphenylcarboxamido)benzoyl]spiro[2,3,4,5-tetrahydro-1H-benzo[b]azepine-4,1'-(2'-cyclopentene)]-3-ylcarboxamido]acetic acid::CHEMBL419183",Vasopressin V2 receptor,, 350
50888283,COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC,"InChI=1S/C14H18N4O3/c1-19-10-5-8(6-11(20-2)12(10)21-3)4-9-7-17-14(16)18-13(9)15/h5-7H,4H2,1-3H3,(H4,15,16,17,18)",IEDVJHCEMCRBQM-UHFFFAOYSA-N,18069,"5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine::CHEMBL22::TMP::Trimethoprim::Trimethoprim (TMP)::US10870625, Compound TMP",Dihydrofolate reductase,Pneumocystis carinii,
368730,COc1cc2nc([nH]c2cc1OC)-c1nc(sc1N1CCN([C@H](C)C1)C(=O)Cn1cnc2cccnc12)C(F)(F)F,"InChI=1S/C26H25F3N8O3S/c1-14-11-35(7-8-37(14)20(38)12-36-13-31-15-5-4-6-30-23(15)36)24-21(34-25(41-24)26(27,28)29)22-32-16-9-18(39-2)19(40-3)10-17(16)33-22/h4-6,9-10,13-14H,7-8,11-12H2,1-3H3,(H,32,33)/t14-/m1/s1",DQJDCGVYFWPJEV-CQSZACIVSA-N,208694,"US9266876, 161",C-X-C chemokine receptor type 3/Guanine nucleotide-binding protein subunit alpha-15,, 2
151536,CCOC(=O)c1c(NC(=S)NC(=O)N(C)C)scc1-c1ccc(C)o1,"InChI=1S/C16H19N3O4S2/c1-5-22-14(20)12-10(11-7-6-9(2)23-11)8-25-13(12)17-15(24)18-16(21)19(3)4/h6-8H,5H2,1-4H3,(H2,17,18,21,24)",YAHHFWGBZGKXKT-UHFFFAOYSA-N,65879,2-(dimethylcarbamoylthiocarbamoylamino)-4-(5-methyl-2-furyl)thiophene-3-carboxylic acid ethyl ester::2-[[[[dimethylamino(oxo)methyl]amino]-sulfanylidenemethyl]amino]-4-(5-methyl-2-furanyl)-3-thiophenecarboxylic acid ethyl ester::MLS000582162::SMR000200695::cid_1251205::ethyl 2-(dimethylcarbamoylcarbamothioylamino)-4-(5-methylfuran-2-yl)thiophene-3-carboxylate::ethyl 2-[({[(dimethylamino)carbonyl]amino}carbonothioyl)amino]-4-(5-methyl-2-furyl)-3-thiophenecarboxylate,C-C chemokine receptor type 6,, 47400
50496982,CCCCNC(=O)C1C(=O)N(O)C(=O)c2ccccc12,"InChI=1S/C14H16N2O4/c1-2-3-8-15-12(17)11-9-6-4-5-7-10(9)13(18)16(20)14(11)19/h4-7,11,20H,2-3,8H2,1H3,(H,15,17)",QQULFDYXVFUAMK-UHFFFAOYSA-N,50170912,CHEMBL3805930,Integrase,, 660
661572,CC(C)N(C)c1nc2CCN(CCc2c(Nc2ccc(nc2)C(F)(F)F)n1)c1ncccc1C(F)(F)F,"InChI=1S/C24H25F6N7/c1-14(2)36(3)22-34-18-9-12-37(21-17(23(25,26)27)5-4-10-31-21)11-8-16(18)20(35-22)33-15-6-7-19(32-13-15)24(28,29)30/h4-7,10,13-14H,8-9,11-12H2,1-3H3,(H,33,34,35)",QIKNKLZGIIGHNG-UHFFFAOYSA-N,245027,"US9422293, 266::US9738649, Example 266",Transient receptor potential cation channel subfamily V member 1,Homo sapiens, 120
865894,CC(C)c1c([nH]c2ccc(nc12)C1CCC(CC1)NCC(=O)N1CCOCC1)-c1cn2ncnc2c(C)c1C,"InChI=1S/C30H39N7O2/c1-18(2)27-28(23-16-37-30(32-17-33-37)20(4)19(23)3)35-25-10-9-24(34-29(25)27)21-5-7-22(8-6-21)31-15-26(38)36-11-13-39-14-12-36/h9-10,16-18,21-22,31,35H,5-8,11-15H2,1-4H3",ZCUIRECAFJFDEL-UHFFFAOYSA-N,428056,"US10544143, Example 490::US10730877, Example 490::US11053244, Example 490",Toll-like receptor 9,, 2127
50892144,CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl,"InChI=1S/C21H20ClNO5/c1-23-7-6-12(17(27)10-23)19-14(24)8-15(25)20-16(26)9-18(28-21(19)20)11-4-2-3-5-13(11)22/h2-5,8-9,12,17,24-25,27H,6-7,10H2,1H3/t12-,17+/m0/s1",BIIVYFLTOXDAOV-YVEFUNNKSA-N,5655,"2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]-4H-chromen-4-one::CHEMBL428690::Flavopiridol::US10294218, Example Flavopiridol::US9617225, Flavopiridol",Death-associated protein kinase 1,Homo sapiens,
51187123,FC(F)(F)C(=O)CSCCc1ccccc1,"InChI=1S/C11H11F3OS/c12-11(13,14)10(15)8-16-7-6-9-4-2-1-3-5-9/h1-5H,6-8H2",UJAGOKUXPHIFEB-UHFFFAOYSA-N,50412689,CHEMBL460809,Liver carboxylesterase B-1,, 162
172919,O=C1NCN(c2ccccc2)C11CCN(CC2COc3ccccc3O2)CC1,"InChI=1S/C22H25N3O3/c26-21-22(25(16-23-21)17-6-2-1-3-7-17)10-12-24(13-11-22)14-18-15-27-19-8-4-5-9-20(19)28-18/h1-9,18H,10-16H2,(H,23,26)",JVGBTTIJPBFLTE-UHFFFAOYSA-N,50020192,"8-(2,3-Dihydro-benzo[1,4]dioxin-2-ylmethyl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one::CHEMBL300555::Spiroxatrine",Alpha-2B adrenergic receptor,,
235817,Clc1ccc(cc1)-n1nc2c(cc1=O)[nH][nH]c2=O,"InChI=1S/C11H7ClN4O2/c12-6-1-3-7(4-2-6)16-9(17)5-8-10(15-16)11(18)14-13-8/h1-5,13H,(H,14,18)",BVWNEDJLGPEOJI-UHFFFAOYSA-N,52725,"5-(4-chlorophenyl)-1,2-dihydropyrazolo[4,3-c]pyridazine-3,6-dione::5-(4-chlorophenyl)-1,2-dihydropyrazolo[4,3-c]pyridazine-3,6-quinone::5-(4-chlorophenyl)-3-hydroxy-1,5-dihydro-6H-pyrazolo[4,3-c]pyridazin-6-one::MLS000755380::SMR000337771::cid_1475762",Disintegrin and metalloproteinase domain-containing protein 10,, 10075
51320165,Cn1c2nc3CN(CCn3c2c(=O)n(C)c1=O)[C@H]1CCc2ccccc12,"InChI=1S/C19H21N5O2/c1-21-17-16(18(25)22(2)19(21)26)24-10-9-23(11-15(24)20-17)14-8-7-12-5-3-4-6-13(12)14/h3-6,14H,7-11H2,1-2H3/t14-/m0/s1",RPKMNDYYVDIVKP-AWEZNQCLSA-N,50534194,CHEMBL4515367,Adenosine receptor A2b,Homo sapiens,
114065,CCOc1ccc(cc1)N1CSC2=C(C#N)C(CC(=O)N2C1)c1ccccc1Cl,"InChI=1S/C22H20ClN3O2S/c1-2-28-16-9-7-15(8-10-16)25-13-26-21(27)11-18(17-5-3-4-6-20(17)23)19(12-24)22(26)29-14-25/h3-10,18H,2,11,13-14H2,1H3",NHRWFZXWMCOFCE-UHFFFAOYSA-N,34523,"8-(2-chlorophenyl)-3-(4-ethoxyphenyl)-6-oxidanylidene-2,4,7,8-tetrahydropyrido[2,1-b][1,3,5]thiadiazine-9-carbonitrile::8-(2-chlorophenyl)-3-(4-ethoxyphenyl)-6-oxo-2,4,7,8-tetrahydropyrido[2,1-b][1,3,5]thiadiazine-9-carbonitrile::8-(2-chlorophenyl)-6-keto-3-p-phenetyl-2,4,7,8-tetrahydropyrido[2,1-b][1,3,5]thiadiazine-9-carbonitrile::MLS000117274::SMR000094225::cid_5309663",Large T antigen,Simian virus 40, 17380
1162365,CC(C)[C@H]1COC(=O)N1c1ccnc(N[C@@H](C)c2cc(C)c(cn2)-c2ccnc(c2)C(F)(F)F)n1,"InChI=1S/C24H25F3N6O2/c1-13(2)19-12-35-23(34)33(19)21-6-8-29-22(32-21)31-15(4)18-9-14(3)17(11-30-18)16-5-7-28-20(10-16)24(25,26)27/h5-11,13,15,19H,12H2,1-4H3,(H,29,31,32)/t15-,19+/m0/s1",ARCBKTZOKAIYLK-HNAYVOBHSA-N,50279396,"CHEMBL4172087::US11311527, Cpd ID IDH305::US11376246, Cpd ID IDH305",Isocitrate dehydrogenase [NADP] cytoplasmic [R132C],, 4150
50623970,FC(F)c1nc2oc(=O)cc(CCCC3(CC3)c3ccccc3)c2c(=O)[nH]1,"InChI=1S/C20H18F2N2O3/c21-16(22)17-23-18(26)15-12(11-14(25)27-19(15)24-17)5-4-8-20(9-10-20)13-6-2-1-3-7-13/h1-3,6-7,11,16H,4-5,8-10H2,(H,23,24,26)",DKYRUKZCEHDDCS-UHFFFAOYSA-N,50337019,"2-(difluoromethyl)-5-(3-(1-phenylcyclopropyl)propyl)-3H-pyrano[2,3-d]pyrimidine-4,7-dione::CHEMBL1672643",Hydroxycarboxylic acid receptor 2,Homo sapiens,
450358,C[C@]1(CC2(CCC2)OC(N)=N1)c1cc(NC(=O)c2ncc(Cl)cc2F)ccc1F,"InChI=1S/C20H19ClF2N4O2/c1-19(10-20(5-2-6-20)29-18(24)27-19)13-8-12(3-4-14(13)22)26-17(28)16-15(23)7-11(21)9-25-16/h3-4,7-9H,2,5-6,10H2,1H3,(H2,24,27)(H,26,28)/t19-/m0/s1",MYVNXXFZPZMOFC-IBGZPJMESA-N,258290,"US9493485, 9-131",Beta-secretase 1,Homo sapiens, 87
50244697,Cc1ncc(n1CCOc1cccc(\C=N\Nc2nc(cs2)-c2ccc(Br)cc2)c1)[N+]([O-])=O,"InChI=1S/C22H19BrN6O3S/c1-15-24-13-21(29(30)31)28(15)9-10-32-19-4-2-3-16(11-19)12-25-27-22-26-20(14-33-22)17-5-7-18(23)8-6-17/h2-8,11-14H,9-10H2,1H3,(H,26,27)/b25-12+",LTSZWLXXTSHDQH-BRJLIKDPSA-N,50031293,CHEMBL3357058,3-oxoacyl-[acyl-carrier-protein] synthase 3,Escherichia coli, 20800
51192147,Cc1ccc(OCCn2ccc(=O)n(Cc3ccccc3)c2=O)cc1,"InChI=1S/C20H20N2O3/c1-16-7-9-18(10-8-16)25-14-13-21-12-11-19(23)22(20(21)24)15-17-5-3-2-4-6-17/h2-12H,13-15H2,1H3",DVSAGIGYEYXAET-UHFFFAOYSA-N,50490654,CHEMBL2337201,Reverse transcriptase,Human immunodeficiency virus 1,
50427504,O=C(Nc1ccn[nH]1)N1CCN(CC1)c1nc(ns1)-c1ccccc1,"InChI=1S/C16H17N7OS/c24-15(18-13-6-7-17-20-13)22-8-10-23(11-9-22)16-19-14(21-25-16)12-4-2-1-3-5-12/h1-7H,8-11H2,(H2,17,18,20,24)",RZQJFUXCPKGHDT-UHFFFAOYSA-N,50245067,"4-(3-phenyl-1,2,4-thiadiazol-5-yl)-N-(1H-pyrazol-5-yl)piperazine-1-carboxamide::CHEMBL488686",Fatty-acid amide hydrolase 1 [30-579],, 125
50092757,N[C@@H]1C[C@@H](NC(=O)c2ccc(O)cc2)[C@@H](C1)OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(O)=O)c(O)c1,"InChI=1S/C27H24N2O10/c28-14-10-17(29-25(35)12-4-6-15(30)7-5-12)21(11-14)39-27(38)13-8-19(32)23(20(33)9-13)24(34)22-16(26(36)37)2-1-3-18(22)31/h1-9,14,17,21,30-33H,10-11,28H2,(H,29,35)(H,36,37)/t14-,17-,21-/m1/s1",FCVHMDURXUOCFY-SOIKWTOOSA-N,50055668,"4-(2-Carboxy-6-hydroxy-benzoyl)-3,5-dihydroxy-benzoic acid (1R,2R,4R)-4-amino-2-(4-hydroxy-benzoylamino)-cyclopentyl ester::CHEMBL432168",Protein kinase C zeta type,Homo sapiens, 1200
1135005,C[C@@H]1CN(CCO1)c1nc(C)cc(NC(=O)c2ccc(NS(=O)(=O)CF)cc2N2CCC3(CC3)CC2)n1,"InChI=1S/C25H33FN6O4S/c1-17-13-22(29-24(27-17)32-11-12-36-18(2)15-32)28-23(33)20-4-3-19(30-37(34,35)16-26)14-21(20)31-9-7-25(5-6-25)8-10-31/h3-4,13-14,18,30H,5-12,15-16H2,1-2H3,(H,27,28,29,33)/t18-/m1/s1",ZCQGLVASJYZJOU-GOSISDBHSA-N,535537,"(R)-4- ((Fluoromethyl)sulfonamido)- N-(6-methyl-2-(2- methylmorpholino)pyrimidin- 4-yl)-2-(6-azaspiro[2.5]octan- 6-yl)benzamide::US11236069, Example 6-3",Kinesin-like protein KIF18A [1-467],, 79.0
516365,CC(C)c1c([nH]c2ccc(cc12)C1CCN(CCC#N)CC1)-c1cc(c2ncnn2c1)C(C)(C)O,"InChI=1S/C28H34N6O/c1-18(2)25-22-14-20(19-8-12-33(13-9-19)11-5-10-29)6-7-24(22)32-26(25)21-15-23(28(3,4)35)27-30-17-31-34(27)16-21/h6-7,14-19,32,35H,5,8-9,11-13H2,1-4H3",GXECFFUJMBDDMR-UHFFFAOYSA-N,273428,"US10071079, Example 211::US10478424, Example 211",Toll-like receptor 8,, 212
1194977,OC(=O)[C@H](CCN(CCCCc1ccc2CCCNc2n1)CCC(F)F)Nc1ncc(cn1)C1CC1,"InChI=1S/C26H36F2N6O2/c27-23(28)11-15-34(13-2-1-5-21-9-8-19-4-3-12-29-24(19)32-21)14-10-22(25(35)36)33-26-30-16-20(17-31-26)18-6-7-18/h8-9,16-18,22-23H,1-7,10-15H2,(H,29,32)(H,35,36)(H,30,31,33)/t22-/m0/s1",WRAPGMNNYFJAFF-QFIPXVFZSA-N,465345,"US10793564, Compound 135::US11419869, Compound 135",Integrin alpha-V/beta-6,Homo sapiens, 150
431525,Cc1nc2c(OCc3c(F)cccc3F)cccn2c1C(=O)N[C@H]1[C@@H](Cc2ccccc12)C(O)=O,"InChI=1S/C26H21F2N3O4/c1-14-23(25(32)30-22-16-7-3-2-6-15(16)12-17(22)26(33)34)31-11-5-10-21(24(31)29-14)35-13-18-19(27)8-4-9-20(18)28/h2-11,17,22H,12-13H2,1H3,(H,30,32)(H,33,34)/t17-,22-/m1/s1",XMLVTBQYVNFTIZ-VGOFRKELSA-N,247306,"US9447090, 434",Guanylate cyclase soluble subunit alpha-1/beta-1,,
1004728,Nc1nccn2c(nc(-c3ccc(cc3)C(=O)Nc3cc(ccn3)C(F)(F)F)c12)[C@@H]1CCCCN1S(=O)(=O)C=C,"InChI=1S/C26H24F3N7O3S/c1-2-40(38,39)36-13-4-3-5-19(36)24-34-21(22-23(30)32-12-14-35(22)24)16-6-8-17(9-7-16)25(37)33-20-15-18(10-11-31-20)26(27,28)29/h2,6-12,14-15,19H,1,3-5,13H2,(H2,30,32)(H,31,33,37)/t19-/m0/s1",SSFQQODCTCCJNX-IBGZPJMESA-N,340131,"US10239883, Example 19::US10934296, Example 19::US9758524, Example 19",Tyrosine-protein kinase Lyn,Homo sapiens,
460048,Cn1ccc(COc2ccc3nc([C@@H]4[C@H](C(O)=O)C4(C)C)n(Cc4ccc(OC(F)(F)F)cc4)c3c2)n1,"InChI=1S/C26H25F3N4O4/c1-25(2)21(22(25)24(34)35)23-30-19-9-8-18(36-14-16-10-11-32(3)31-16)12-20(19)33(23)13-15-4-6-17(7-5-15)37-26(27,28)29/h4-12,21-22H,13-14H2,1-3H3,(H,34,35)/t21-,22+/m0/s1",HCBVSQDKTYZYKT-FCHUYYIVSA-N,145768,"US8952177, 122::US9089569, 122::US9695149, 122",Arachidonate 5-lipoxygenase-activating protein,Homo sapiens,
51203046,Oc1ccccc1\C=N\c1ccccc1\N=C\c1ccccc1O,"InChI=1S/C20H16N2O2/c23-19-11-5-1-7-15(19)13-21-17-9-3-4-10-18(17)22-14-16-8-2-6-12-20(16)24/h1-14,23-24H/b21-13+,22-14+",HXFYGSOGECBSOY-JFMUQQRKSA-N,50494678,CHEMBL1985188,Carbonic anhydrase 2,Homo sapiens,
50691026,CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3[nH]ncc23)CC1,"InChI=1S/C23H27N7O3S2/c1-35(31,32)30-7-5-28(6-8-30)15-16-13-20-21(34-16)23(29-9-11-33-12-10-29)26-22(25-20)17-3-2-4-19-18(17)14-24-27-19/h2-4,13-14H,5-12,15H2,1H3,(H,24,27)",LHNIIDJUOCFXAP-UHFFFAOYSA-N,25028,"4-[2-(1H-indazol-4-yl)-6-[(4-methanesulfonylpiperazin-1-yl)methyl]thieno[3,2-d]pyrimidin-4-yl]morpholine::GDC-0941::GDC0941::US10112932, pictilisib::US10851091, Compound pictilisib","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",Homo sapiens,
51297514,CO[C@H]1C[C@@]2(C)C([C@H](O)C[C@H]3[C@@]4(C)CCC(=O)C(C)(C)[C@@H]4CC[C@]23C)=C1[C@H](C)C[C@H](O)[C@@H](OC(C)=O)C(C)(C)O,"InChI=1S/C33H54O7/c1-18(15-21(36)28(30(5,6)38)40-19(2)34)26-22(39-10)17-33(9)27(26)20(35)16-24-31(7)13-12-25(37)29(3,4)23(31)11-14-32(24,33)8/h18,20-24,28,35-36,38H,11-17H2,1-10H3/t18-,20-,21+,22+,23+,24+,28-,31+,32+,33+/m1/s1",MMSCSHVTCNYOAT-VWDUMGLQSA-N,50528851,CHEMBL4475517,Bile acid receptor,Homo sapiens,
198845,COc1ccc(nc1-c1cc(C)ncc1F)C(=O)N[C@@H](CC(O)=O)c1ccccc1C,"InChI=1S/C23H22FN3O4/c1-13-6-4-5-7-15(13)19(11-21(28)29)27-23(30)18-8-9-20(31-3)22(26-18)16-10-14(2)25-12-17(16)24/h4-10,12,19H,11H2,1-3H3,(H,27,30)(H,28,29)/t19-/m0/s1",MTSWQBRGBADNCL-IBGZPJMESA-N,47345,"US9029559, 470",Lysosomal protective protein,, 118.2
615572,COc1ccc(CN2CCCN(CC2)c2ccc(cn2)-c2cc(OCC(C)(C)O)cn3ncc(C#N)c23)cn1,"InChI=1S/C29H33N7O3/c1-29(2,37)20-39-24-13-25(28-23(14-30)17-33-36(28)19-24)22-6-7-26(31-16-22)35-10-4-9-34(11-12-35)18-21-5-8-27(38-3)32-15-21/h5-8,13,15-17,19,37H,4,9-12,18,20H2,1-3H3",XHFMRGOUXQOXJZ-UHFFFAOYSA-N,296804,"US10112942, Example 539::US10137124, Example 539::US10172851, Example 539::US10555944, Example 539::US10953005, Example 539","Proto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M]",, 250
50575376,O=C([C@H]1C[C@H](CN1)Oc1ccc(cc1)C#N)N1CCCN(CC1)C1CCC1,"InChI=1S/C21H28N4O2/c22-14-16-5-7-18(8-6-16)27-19-13-20(23-15-19)21(26)25-10-2-9-24(11-12-25)17-3-1-4-17/h5-8,17,19-20,23H,1-4,9-13,15H2/t19-,20-/m1/s1",DCLRBWCBZZADCC-WOJBJXKFSA-N,50317682,"4-((3R,5R)-5-(4-cyclobutyl-1,4-diazepane-1-carbonyl)pyrrolidin-3-yloxy)benzonitrile::CHEMBL1095011",Histamine H3 receptor,Homo sapiens,
50425195,COc1ccc(CC[C@@H](OC(=O)[C@@H]2CCCCN2C(=O)[C@@H](C2CCCCC2)c2ccccc2)c2cccc(OCC(O)=O)c2)cc1OC,"InChI=1S/C39H47NO8/c1-45-34-22-20-27(24-35(34)46-2)19-21-33(30-16-11-17-31(25-30)47-26-36(41)42)48-39(44)32-18-9-10-23-40(32)38(43)37(28-12-5-3-6-13-28)29-14-7-4-8-15-29/h3,5-6,11-13,16-17,20,22,24-25,29,32-33,37H,4,7-10,14-15,18-19,21,23,26H2,1-2H3,(H,41,42)/t32-,33+,37+/m0/s1",POAFNNRQISTGEJ-QUBOUHRKSA-N,50125329,CHEMBL3623615,Peptidyl-prolyl cis-trans isomerase FKBP5,Homo sapiens,
677805,Cc1ccc(Oc2ccccn2)cc1-c1nccc2cc(ccc12)S(=O)(=O)Nc1ccncn1,"InChI=1S/C25H19N5O3S/c1-17-5-6-19(33-24-4-2-3-11-27-24)15-22(17)25-21-8-7-20(14-18(21)9-13-28-25)34(31,32)30-23-10-12-26-16-29-23/h2-16H,1H3,(H,26,29,30)",ANNMYRFWVOJSEY-UHFFFAOYSA-N,342948,"1-(2-methyl-5-(2-pyridinyloxy)phenyl)-N-4-pyrimidinyl-6-isoquinolinesulfonamide::US9776995, Example 40",Sodium channel protein type 9 subunit alpha,, 5690
349107,N=C1S\C(=C\c2ccco2)C(=O)N1c1nccs1,"InChI=1S/C11H7N3O2S2/c12-10-14(11-13-3-5-17-11)9(15)8(18-10)6-7-2-1-4-16-7/h1-6,12H/b8-6+,12-10?",RJHAJQSWEUEPCY-IIXGYHIASA-N,196158,"US9211296, Table 6, 12",DNA polymerase,, 32000
50777246,CCC1=C(OC(=O)N(C)C)c2cccn2-c2ccccc2O1,"InChI=1S/C17H18N2O3/c1-4-14-16(22-17(20)18(2)3)13-9-7-11-19(13)12-8-5-6-10-15(12)21-14/h5-11H,4H2,1-3H3",YGHGFQOXORJSOQ-UHFFFAOYSA-N,50052752,CHEMBL115704::Dimethyl-carbamic acid 5-ethyl-6-oxa-10b-aza-benzo[e]azulen-4-yl ester,Translocator protein,Rattus norvegicus,
945687,CC(C)(C)OC(=O)Nc1ccc2O[C@@H](CC(=O)NCCO)CN(c2c1)S(=O)(=O)c1cccc(c1)C(F)(F)F,"InChI=1S/C24H28F3N3O7S/c1-23(2,3)37-22(33)29-16-7-8-20-19(12-16)30(14-17(36-20)13-21(32)28-9-10-31)38(34,35)18-6-4-5-15(11-18)24(25,26)27/h4-8,11-12,17,31H,9-10,13-14H2,1-3H3,(H,28,32)(H,29,33)/t17-/m0/s1",MFGBKOWCPGDKEP-KRWDZBQOSA-N,352648,"(S)-tert-butyl (2-(2-((2- hydroxyethyl)amino)- 2-oxoethyl)-4-((3- (trifluoromethyl)phenyl) sulfonyl)-3,4- dihydro-2H- benzo[b][1,4]oxazin-6- yl)carbamate::US10745364, Example 37AJ::US9809561, 37AJ",Nuclear receptor ROR-gamma,, 5.73
50504723,Nc1ccc(cc1)-c1nc2ccccc2n2cccc12,"InChI=1S/C17H13N3/c18-13-9-7-12(8-10-13)17-16-6-3-11-20(16)15-5-2-1-4-14(15)19-17/h1-11H,18H2",DUTKRZVXBMKLQN-UHFFFAOYSA-N,50184319,CHEMBL3824080,DNA repair protein RAD51 homolog 1,Homo sapiens,>100000
454453,Nc1ncnc2n(cc(-c3ccc(Oc4c(F)c(F)cc(F)c4F)cc3F)c12)[C@@H]1CCN(C1)C#N,"InChI=1S/C23H15F5N6O/c24-15-5-12(35-21-19(27)16(25)6-17(26)20(21)28)1-2-13(15)14-8-34(11-3-4-33(7-11)9-29)23-18(14)22(30)31-10-32-23/h1-2,5-6,8,10-11H,3-4,7H2,(H2,30,31,32)/t11-/m1/s1",LDCONTUKJIBEOF-LLVKDONJSA-N,260644,"US10300066, Compound 118::US9532990, 118",Tyrosine-protein kinase BTK,Homo sapiens, 57
536761,CP(C)(=O)c1cc(cnc1F)-c1ccc2nc(oc2c1)-c1nc2ccccc2[nH]1,"InChI=1S/C21H16FN4O2P/c1-29(2,27)18-10-13(11-23-19(18)22)12-7-8-16-17(9-12)28-21(26-16)20-24-14-5-3-4-6-15(14)25-20/h3-11H,1-2H3,(H,24,25)",FGPOHRIUZZBAGW-UHFFFAOYSA-N,281546,"2-(1H-Benzo[d]imidazol-2-yl)-6-(5- (dimethylphosphoryl)pyridin-3- yl)benzo[d]oxazole bis(trifluoroacetate)::US10022387, Example 72","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform",Homo sapiens,<5000
484699,C[C@@H](Nc1nc(nc2nc(N(C)C3CCCC[C@@H]3O)n(C[C@H]3CC[C@H](C)CC3)c12)-c1noc(=O)[nH]1)C1CCC1,,,223706,"3-(6-{[(1r)-1- cyclobutylethyl]amino}- 8-{[(1r,2s)-2- hydroxycyclohexyl] (methyl)amino}-7- [(trans-4- methylcyclohexyl) methyl]-7h-purin-2- yl)-1,2,4-oxadiazol- 5(4h)-one::US9540377, 11.132::US9540377, 11.134",E3 ubiquitin-protein ligase Mdm2 [17-125],, 25.63
51211452,CC(=O)N[C@H](Cc1c[nH]c2ccc(Br)cc12)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(N)=O,"InChI=1S/C24H26BrN5O4/c1-14(31)29-21(10-16-12-27-19-8-7-17(25)11-18(16)19)24(34)30-20(23(33)28-13-22(26)32)9-15-5-3-2-4-6-15/h2-8,11-12,20-21,27H,9-10,13H2,1H3,(H2,26,32)(H,28,33)(H,29,31)(H,30,34)/t20-,21+/m0/s1",DXGRBXFKKUZQPR-LEWJYISDSA-N,50497851,CHEMBL3319087,Delta-type opioid receptor,Homo sapiens,
151695,Cc1ccc(c(C)c1)S(=O)(=O)N=C1C=C(Nc2cccc(c2)C(O)=O)C(=O)c2ccccc12,"InChI=1S/C25H20N2O5S/c1-15-10-11-23(16(2)12-15)33(31,32)27-21-14-22(24(28)20-9-4-3-8-19(20)21)26-18-7-5-6-17(13-18)25(29)30/h3-14,26H,1-2H3,(H,29,30)",RUWHEBZPTCVEMQ-UHFFFAOYSA-N,48039,"3-[[(4E)-4-(2,4-dimethylphenyl)sulfonylimino-1-keto-2-naphthyl]amino]benzoic acid::3-[[(4E)-4-(2,4-dimethylphenyl)sulfonylimino-1-oxidanylidene-naphthalen-2-yl]amino]benzoic acid::3-[[(4E)-4-(2,4-dimethylphenyl)sulfonylimino-1-oxo-2-naphthalenyl]amino]benzoic acid::3-[[(4E)-4-(2,4-dimethylphenyl)sulfonylimino-1-oxonaphthalen-2-yl]amino]benzoic acid::MLS000948061::SMR000620247::cid_5824726",C-C chemokine receptor type 6,, 39900
1164362,COc1cc2nc(N)n3nc(nc3c2cc1F)C1CCCN(c2cnn(CC(C)(C)O)c2)C1=O,"InChI=1S/C22H25FN8O3/c1-22(2,33)11-29-10-12(9-25-29)30-6-4-5-13(20(30)32)18-27-19-14-7-15(23)17(34-3)8-16(14)26-21(24)31(19)28-18/h7-10,13,33H,4-6,11H2,1-3H3,(H2,24,26)",XHUGNCIRTJIVJA-UHFFFAOYSA-N,551593,"US11312719, Example 139::rac-3-(5-amino-9-fluoro-8-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-2-yl)-1-(1-(2-hydroxy-2-methylpropyl)-1H-pyrazol-4-yl)piperidin-2-one",Adenosine receptor A2b,Homo sapiens, 2824
50320156,COc1ccc2c(c1)N(CC1CC1)C(=O)C21CCN(CC2CCCCCCC2)CC1,"InChI=1S/C26H38N2O2/c1-30-22-11-12-23-24(17-22)28(19-21-9-10-21)25(29)26(23)13-15-27(16-14-26)18-20-7-5-3-2-4-6-8-20/h11-12,17,20-21H,2-10,13-16,18-19H2,1H3",VPULAKGHRZPYSW-UHFFFAOYSA-N,50173258,"1'-cyclooctylmethyl-1-cyclopropylmethyl-6-methoxyspiro[2,3-dihydro-1H-indole-3,4'-(hexahydropyridine)]-2-one::CHEMBL197959",Mu-type opioid receptor,Homo sapiens, 10000
50694073,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1,"InChI=1S/C20H15ClN4/c21-15-5-7-16(8-6-15)23-20-18-4-2-1-3-17(18)19(24-25-20)13-14-9-11-22-12-10-14/h1-12H,13H2,(H,23,25)",YCOYDOIWSSHVCK-UHFFFAOYSA-N,4851,(4-chlorophenyl)-[4-(4-pyridylmethyl)phthalazin-1-yl]amine::(A) PTK787::CGP 79787::CHEMBL101253::CHEMBL75232::N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)-1-phthalazinamine::N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine::PTK-787::PTK787::ZK222584::cid_151194,Proto-oncogene tyrosine-protein kinase Src,,
50207165,Cc1cc(C(=O)Nc2ccc(cc2)-c2ccccc2S(N)(=O)=O)n(n1)-c1cc2ccccc2cc1O,"InChI=1S/C27H22N4O4S/c1-17-14-24(31(30-17)23-15-19-6-2-3-7-20(19)16-25(23)32)27(33)29-21-12-10-18(11-13-21)22-8-4-5-9-26(22)36(28,34)35/h2-16,32H,1H3,(H,29,33)(H2,28,34,35)",FRKLXQVPIVHUTQ-UHFFFAOYSA-N,50114442,2-(3-Hydroxy-naphthalen-2-yl)-5-methyl-2H-pyrazole-3-carboxylic acid (2'-sulfamoyl-biphenyl-4-yl)-amide::CHEMBL431127,Coagulation factor X,Homo sapiens,>11000
50805912,CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(N)=O,"InChI=1S/C31H41N13O5/c1-17(45)41-25(10-19-13-35-15-39-19)29(48)44-26(11-20-14-36-16-40-20)30(49)42-23(7-4-8-37-31(33)34)28(47)43-24(27(32)46)9-18-12-38-22-6-3-2-5-21(18)22/h2-3,5-6,12-16,23-26,38H,4,7-11H2,1H3,(H2,32,46)(H,35,39)(H,36,40)(H,41,45)(H,42,49)(H,43,47)(H,44,48)(H4,33,34,37)/t23-,24-,25-,26-/m0/s1",ZACRQOAPRSMDDR-CQJMVLFOSA-N,50115383,2-[2-[2-Acetylamino-3-(3H-imidazol-4-yl)-propionylamino]-3-(3H-imidazol-4-yl)-propionylamino]-5-guanidino-pentanoic acid [1-carbamoyl-2-(1H-indol-3-yl)-ethyl]-amide::CHEMBL104010,Melanocortin receptor 3,Mus musculus,
283273,CC(C)[C@H]1COC(=O)N1c1ccnc(NC(C)c2nc(c(C)s2)-c2ccc(Cl)cc2)n1,"InChI=1S/C22H24ClN5O2S/c1-12(2)17-11-30-22(29)28(17)18-9-10-24-21(26-18)25-13(3)20-27-19(14(4)31-20)15-5-7-16(23)8-6-15/h5-10,12-13,17H,11H2,1-4H3,(H,24,25,26)/t13?,17-/m1/s1",GIRJNOHFFVVNAL-LRHAYUFXSA-N,146309,"US8957068, 411::US8957068, 412",Isocitrate dehydrogenase [NADP] cytoplasmic,, 2907
468901,Clc1ccc(CNc2cc(nn2C(=O)c2cccc3OCCOc23)-c2cccnc2=O)s1,,,162628,"US9687479, 108 3-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2,3-dihydro-1,4-benzodioxin-5-yl)carbonyl]-1H-pyrazol-3-yl)-1,2-dihydropyridin-2-one",Prothrombin,,<100
51393823,Clc1cncc(-c2cnn(Cc3ccccc3)c2)c1N1CCC2(CCNC2=O)CC1,"InChI=1S/C23H24ClN5O/c24-20-14-25-13-19(18-12-27-29(16-18)15-17-4-2-1-3-5-17)21(20)28-10-7-23(8-11-28)6-9-26-22(23)30/h1-5,12-14,16H,6-11,15H2,(H,26,30)",NHLXKIYNBUVQKH-UHFFFAOYSA-N,50563297,CHEMBL4788142,Cyclin-C,,
50775821,CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,"InChI=1S/C13H24N4O3S/c1-13(2,3)14-8-10(18)9-20-12-11(15-21-16-12)17-4-6-19-7-5-17/h10,14,18H,4-9H2,1-3H3/t10-/m0/s1",BLJRIMJGRPQVNF-JTQLQIEISA-N,50292219,"(-)-3-morpholino-4-(3-tert-butylamino-2-hydroxypropoxy)-1,2,5-thiadiazole::(2S)-1-((1,1-dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol::(2S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol::(S)-1-(1,1-(dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol::(S)-1-(tert-butylamino)-3-((4-morpholino-1,2,5-thiadiazol-3-yl)oxy)propan-2-ol::(S)-timolol::CHEMBL499::S-(-)-3-(3-tert-butylamino-2-hydroxypropoxy)-4-morpholino-1,2,5-thiadiazole::TIMOLOL",ATP-binding cassette sub-family C member 4,Homo sapiens, 133000
232476,CCc1ncnc(N2CCN(CC2)C(C)=O)c1C#Cc1ccc(N)nc1,"InChI=1S/C19H22N6O/c1-3-17-16(6-4-15-5-7-18(20)21-12-15)19(23-13-22-17)25-10-8-24(9-11-25)14(2)26/h5,7,12-13H,3,8-11H2,1-2H3,(H2,20,21)",GKROGJIGFRYBLZ-UHFFFAOYSA-N,111653,"US8618111, B-40",Serine/threonine-protein kinase mTOR,Homo sapiens, 32
719914,CC(C)(C)OC(=O)N1C[C@H](N(C(=O)C1)c1cc(ccn1)C#N)C(=O)N([C@H](C(=O)NC1CC(F)(F)C1)c1ccccc1Cl)c1cc(F)cc(F)c1,"InChI=1S/C34H31ClF4N6O5/c1-33(2,3)50-32(49)43-17-26(45(28(46)18-43)27-10-19(16-40)8-9-41-27)31(48)44(23-12-20(36)11-21(37)13-23)29(24-6-4-5-7-25(24)35)30(47)42-22-14-34(38,39)15-22/h4-13,22,26,29H,14-15,17-18H2,1-3H3,(H,42,47)/t26-,29-/m0/s1",NBBOZZYCTJIARB-WNJJXGMVSA-N,363608,"US10640534, Compound 97::US10689414, Compound 97::US10717764, Compound 97::US11021515, Compound 97::US9850277, Compound 97",Isocitrate dehydrogenase [NADP] cytoplasmic [R132C],,<500
50562451,CCCc1ccc(cc1)-c1oc(COc2ccc(OCC(O)=O)c(C)c2)nc1-c1ccc(OC)cc1,"InChI=1S/C29H29NO6/c1-4-5-20-6-8-22(9-7-20)29-28(21-10-12-23(33-3)13-11-21)30-26(36-29)17-34-24-14-15-25(19(2)16-24)35-18-27(31)32/h6-16H,4-5,17-18H2,1-3H3,(H,31,32)",XXWKUDASTWQWDH-UHFFFAOYSA-N,50312397,2-(4-((4-(4-Methoxyphenyl)-5-(4-propylphenyl)oxazol-2-yl)-methoxy)-2-methylphenoxy)acetic Acid::CHEMBL1079910,Peroxisome proliferator-activated receptor delta,,
1097546,CN1C(N)=NC(C1=O)(c1ccc(OC(F)F)c(C)c1)c1cc(F)c(F)c(F)c1,"InChI=1S/C18H14F5N3O2/c1-8-5-9(3-4-13(8)28-16(22)23)18(15(27)26(2)17(24)25-18)10-6-11(19)14(21)12(20)7-10/h3-7,16H,1-2H3,(H2,24,25)",BTHSYBYBUVFNRA-UHFFFAOYSA-N,519492,"US11142505, FAH-19",Beta-secretase 1,Homo sapiens, 960
51450102,CCc1cc(O)c(F)cc1-c1cc(NC2CCN(C)CC2)c2nc(N)ncc2c1,"InChI=1S/C22H26FN5O/c1-3-13-10-20(29)18(23)11-17(13)14-8-15-12-25-22(24)27-21(15)19(9-14)26-16-4-6-28(2)7-5-16/h8-12,16,26,29H,3-7H2,1-2H3,(H2,24,25,27)",USBPOYIQCXNWQH-UHFFFAOYSA-N,50585511,CHEMBL5077126,Non-receptor tyrosine-protein kinase TYK2/Tyrosine-protein kinase JAK1/Tyrosine-protein kinase JAK2,Homo sapiens, 16
720659,Cc1oc2CCCCc2c1NC(=O)C[C@H]1C[C@@H]2CC[C@H](C1)N2CC(=O)NC(C)(C)C,"InChI=1S/C24H37N3O3/c1-15-23(19-7-5-6-8-20(19)30-15)25-21(28)13-16-11-17-9-10-18(12-16)27(17)14-22(29)26-24(2,3)4/h16-18H,5-14H2,1-4H3,(H,25,28)(H,26,29)/t16-,17-,18+",ZCUFTQMRCLHCBO-NNZMDNLPSA-N,363979,"US9856250, 19",Voltage-dependent T-type calcium channel subunit alpha-1H,, 48.0
51046198,COc1ccc(cc1OC)C(=O)OCCCCN[C@H]1CCCc2[nH]c(=O)ccc12,"InChI=1S/C22H28N2O5/c1-27-19-10-8-15(14-20(19)28-2)22(26)29-13-4-3-12-23-17-6-5-7-18-16(17)9-11-21(25)24-18/h8-11,14,17,23H,3-7,12-13H2,1-2H3,(H,24,25)/t17-/m0/s1",NYKBSLRJTXLUOV-KRWDZBQOSA-N,50426926,CHEMBL2323716,Acetylcholinesterase,Rattus norvegicus, 4100
51429825,CNC(=O)c1cc(cs1)-n1ncc2cc(Nc3c(F)cccc3Cl)cnc12,"InChI=1S/C18H13ClFN5OS/c1-21-18(26)15-6-12(9-27-15)25-17-10(7-23-25)5-11(8-22-17)24-16-13(19)3-2-4-14(16)20/h2-9,24H,1H3,(H,21,26)",JOWZBTCWJHFAQE-UHFFFAOYSA-N,50577640,CHEMBL4857979,Mitogen-activated protein kinase 8,Homo sapiens, 213
593704,C[C@@H]1[C@@H](CCCN1c1cnc(C(N)=O)c(Nc2ccc(cc2)C2(CCCC2)C#N)n1)NC(=O)N(C)C,"InChI=1S/C26H34N8O2/c1-17-20(31-25(36)33(2)3)7-6-14-34(17)21-15-29-22(23(28)35)24(32-21)30-19-10-8-18(9-11-19)26(16-27)12-4-5-13-26/h8-11,15,17,20H,4-7,12-14H2,1-3H3,(H2,28,35)(H,30,32)(H,31,36)/t17-,20-/m1/s1",FWMLVTFHWBYRMT-YLJYHZDGSA-N,309779,"3-(4-(1-cyanocyclopentyl)phenylamino)-5-((2R,3R)-3-(3,3-dimethylureido)-2-methylpiperidin-1-yl)pyrazine-2-carboxamide::US9656988, Example 248",Tyrosine-protein kinase BTK,Homo sapiens,<10
1107530,N[C@@H]1C[C@H](N(C1)C(=O)c1cn2cc(Cl)ccc2n1)c1nc(cs1)C(=O)NCc1ncn2ccc(Cl)cc12,"InChI=1S/C24H20Cl2N8O2S/c25-13-3-4-32-12-29-16(19(32)5-13)7-28-22(35)18-11-37-23(31-18)20-6-15(27)9-34(20)24(36)17-10-33-8-14(26)1-2-21(33)30-17/h1-5,8,10-12,15,20H,6-7,9,27H2,(H,28,35)/t15-,20+/m1/s1",FKQMDAAKAOWPEB-QRWLVFNGSA-N,524403,"2-((2S,4R)-4-amino-1-(6- chloroimidazo[1,2-a]pyridine-2- carbonyl)pyrrolidin-2-yl)-N-((7- chloroimidazo[1,5-a]pyridin-1- yl)methyl)thiazole-4-carboxamide::US11168083, Example 55",Coagulation factor X,Homo sapiens,>10000
853028,O=C(NCc1ccccc1)Nc1ccc(cc1)C1CCNC1,"InChI=1S/C18H21N3O/c22-18(20-12-14-4-2-1-3-5-14)21-17-8-6-15(7-9-17)16-10-11-19-13-16/h1-9,16,19H,10-13H2,(H2,20,21,22)",WGWIXBVIMOHDAY-UHFFFAOYSA-N,250099,"US10501411, Example 9::US9452980, 9",Trace amine-associated receptor 1,Rattus norvegicus,
51425892,OC(c1cnn(c1C1CC1)-c1cccc(NS(=O)(=O)c2ccccc2)c1)C(F)(F)F,"InChI=1S/C20H18F3N3O3S/c21-20(22,23)19(27)17-12-24-26(18(17)13-9-10-13)15-6-4-5-14(11-15)25-30(28,29)16-7-2-1-3-8-16/h1-8,11-13,19,25,27H,9-10H2",VYKCMXSYCRPJNC-UHFFFAOYSA-N,50575968,CHEMBL4872323,Nuclear factor erythroid 2-related factor 2,,
50378437,Cc1ccc(NC(=O)c2cccc(c2)C(F)(F)F)cc1Nc1ncccc1-c1ccncn1,"InChI=1S/C24H18F3N5O/c1-15-7-8-18(31-23(33)16-4-2-5-17(12-16)24(25,26)27)13-21(15)32-22-19(6-3-10-29-22)20-9-11-28-14-30-20/h2-14H,1H3,(H,29,32)(H,31,33)",NESXBRNDMQUVNG-UHFFFAOYSA-N,50207861,CHEMBL245549::N-(4-methyl-3-(3-(pyrimidin-4-yl)pyridin-2-ylamino)phenyl)-3-(trifluoromethyl)benzamide::N-{4-METHYL-3-[(3-PYRIMIDIN-4-YLPYRIDIN-2-YL)AMINO]PHENYL}-3-(TRIFLUOROMETHYL)BENZAMIDE,Vascular endothelial growth factor receptor 2,Homo sapiens, 61
876621,Cn1nc(c2cccc(Cl)c12)C(C)(C)NC(=O)C1CNCCOC1,"InChI=1S/C17H23ClN4O2/c1-17(2,20-16(23)11-9-19-7-8-24-10-11)15-12-5-4-6-13(18)14(12)22(3)21-15/h4-6,11,19H,7-10H2,1-3H3,(H,20,23)",RHSMUJZGIDLNEM-UHFFFAOYSA-N,275969,"US10071974, Example 80::US10071974, Example 81::US10071974, Example 82::US10577336, Example 82",Somatostatin receptor type 4,,
50501582,COc1ccc(NC(=O)CSc2nc3ccccc3c(=O)n2CCc2ccccn2)cc1,"InChI=1S/C24H22N4O3S/c1-31-19-11-9-18(10-12-19)26-22(29)16-32-24-27-21-8-3-2-7-20(21)23(30)28(24)15-13-17-6-4-5-14-25-17/h2-12,14H,13,15-16H2,1H3,(H,26,29)",IEFZMSHPGLWDFW-UHFFFAOYSA-N,50180631,CHEMBL3813973,Prostaglandin G/H synthase 2,Ovis aries, 800
51095443,CC(C)Cc1c([nH]c2c(cccc12)[N+]([O-])=O)C(O)=O,"InChI=1S/C13H14N2O4/c1-7(2)6-9-8-4-3-5-10(15(18)19)11(8)14-12(9)13(16)17/h3-5,7,14H,6H2,1-2H3,(H,16,17)",HCEBMPIOXCOVPW-UHFFFAOYSA-N,50449196,CHEMBL3127751,"Fructose-1,6-bisphosphatase 1",, 10300
889892,Cc1cccc(Nc2nc(Nc3cccc(NC(=O)C(=C)Cn4cccn4)c3)ncc2F)c1,"InChI=1S/C24H22FN7O/c1-16-6-3-7-18(12-16)28-22-21(25)14-26-24(31-22)30-20-9-4-8-19(13-20)29-23(33)17(2)15-32-11-5-10-27-32/h3-14H,2,15H2,1H3,(H,29,33)(H2,26,28,30,31)",IGGMIWAUQDAFGD-UHFFFAOYSA-N,397309,"US10596172, Compound I-98::US10828300, Compound I-98::US11351168, Compound I-98::US9987276, Compound I-98",Tyrosine-protein kinase BTK,Homo sapiens, 550
959952,COc1cccc(COc2ccccc2CN(CC[C@@H](N)C(O)=O)Cc2ccccc2OCc2cccc(OC)c2)c1,"InChI=1S/C34H38N2O6/c1-39-29-13-7-9-25(19-29)23-41-32-15-5-3-11-27(32)21-36(18-17-31(35)34(37)38)22-28-12-4-6-16-33(28)42-24-26-10-8-14-30(20-26)40-2/h3-16,19-20,31H,17-18,21-24,35H2,1-2H3,(H,37,38)/t31-/m1/s1",DVPGIFOQXACXCT-WJOKGBTCSA-N,464408,"US10793514, Compound 12",Neutral amino acid transporter B(0),, 5100
51441962,Cc1cc(Br)ccc1NC(=O)COc1ccc2cc(\C=C3\SC(=O)NC3=O)ccc2c1,"InChI=1S/C23H17BrN2O4S/c1-13-8-17(24)5-7-19(13)25-21(27)12-30-18-6-4-15-9-14(2-3-16(15)11-18)10-20-22(28)26-23(29)31-20/h2-11H,12H2,1H3,(H,25,27)(H,26,28,29)/b20-10+",OVYVATCIVXIUCL-KEBDBYFISA-N,50582535,CHEMBL5087514,Histone deacetylase 4,Homo sapiens, 550
50474794,[Na+].[Na+].[Na+].[Na+].CC(C)=CCC\C(C)=C\CC(Cc1cn(CCC=C(C)C)nn1)(P([O-])([O-])=O)P([O-])([O-])=O,"InChI=1S/C20H35N3O6P2.4Na/c1-16(2)8-6-10-18(5)11-12-20(30(24,25)26,31(27,28)29)14-19-15-23(22-21-19)13-7-9-17(3)4;;;;/h8-9,11,15H,6-7,10,12-14H2,1-5H3,(H2,24,25,26)(H2,27,28,29);;;;/q;4*+1/p-4/b18-11+;;;;",SPTJYBFALOMEBK-HSEBTKBPSA-J,50151852,CHEMBL3775694,Geranylgeranyl pyrophosphate synthase,Homo sapiens, 380
1078869,CC(C)N(C)C(=O)c1cn(CC2(O)CCN(CC2)C(=O)C[C@@H](C)c2ccccc2)c(=O)cc1-c1ccc(C)cc1,"InChI=1S/C33H41N3O4/c1-23(2)34(5)32(39)29-21-36(31(38)20-28(29)27-13-11-24(3)12-14-27)22-33(40)15-17-35(18-16-33)30(37)19-25(4)26-9-7-6-8-10-26/h6-14,20-21,23,25,40H,15-19,22H2,1-5H3/t25-/m1/s1",BOAGDSFECJZRPO-RUZDIDTESA-N,514353,"US11053213, Example 96",Ubiquitin carboxyl-terminal hydrolase 19,, 27500
50462731,Oc1ccc(CN=Nc2ccc(Br)cc2)c(O)c1,"InChI=1S/C13H11BrN2O2/c14-10-2-4-11(5-3-10)16-15-8-9-1-6-12(17)7-13(9)18/h1-7,17-18H,8H2",SGMBOFMCHLWMIY-UHFFFAOYSA-N,50279925,"4-[(4-Bromo-phenyl)-hydrazonomethyl]-benzene-1,3-diol::CHEMBL68327",Tyrosine-protein kinase Lck,, 521000
50980969,CNS(=O)(=O)c1ccc2c(c[nH]c(=O)c2c1)C(=O)NC[C@@H](O)CN1CCC(CC1)Oc1ccc(Cl)c(Cl)c1,"InChI=1S/C25H28Cl2N4O6S/c1-28-38(35,36)18-3-4-19-20(11-18)24(33)30-13-21(19)25(34)29-12-15(32)14-31-8-6-16(7-9-31)37-17-2-5-22(26)23(27)10-17/h2-5,10-11,13,15-16,28,32H,6-9,12,14H2,1H3,(H,29,34)(H,30,33)/t15-/m1/s1",AMEQLQYPRVOFMB-OAHLLOKOSA-N,50402117,CHEMBL2207284,C-C chemokine receptor type 3,Homo sapiens,
451567,CC(C)[C@]1(C)C(=N)N[C@@](C)(CS1(=O)=O)c1cc(N)ccc1F,"InChI=1S/C15H22FN3O2S/c1-9(2)15(4)13(18)19-14(3,8-22(15,20)21)11-7-10(17)5-6-12(11)16/h5-7,9H,8,17H2,1-4H3,(H2,18,19)/t14-,15+/m0/s1",ASLNFVWKKHRNQF-LSDHHAIUSA-N,259241,"US9499502, Table A: Entry 28",Beta-secretase 1,Homo sapiens,
50711806,COC[C@H]1CN(C(=O)O1)c1ccc(OCC[C@@H](O)C(F)(F)F)cc1,"InChI=1S/C15H18F3NO5/c1-22-9-12-8-19(14(21)24-12)10-2-4-11(5-3-10)23-7-6-13(20)15(16,17)18/h2-5,12-13,20H,6-9H2,1H3/t12-,13-/m1/s1",IALVDLPLCLFBCF-CHWSQXEVSA-N,50361617,BEFLOXATONE,Amine oxidase [flavin-containing] B,Bos taurus,
50049285,NC(N)=NCCCCN=C(N)N,"InChI=1S/C6H16N6/c7-5(8)11-3-1-2-4-12-6(9)10/h1-4H2,(H4,7,8,11)(H4,9,10,12)",HGMDNMBBCKDWTQ-UHFFFAOYSA-N,86165,Arcaine::CAS_2227::CHEMBL102740::NSC_2227,Deoxyhypusine synthase,Rattus norvegicus, 179000
956877,Nc1nn(Cc2ccc(cc2)C(=O)N2CCCC2)cc1C(=O)NCCOc1cccc(Cl)c1,"InChI=1S/C24H26ClN5O3/c25-19-4-3-5-20(14-19)33-13-10-27-23(31)21-16-30(28-22(21)26)15-17-6-8-18(9-7-17)24(32)29-11-1-2-12-29/h3-9,14,16H,1-2,10-13,15H2,(H2,26,28)(H,27,31)",SMHRRWCCPUBJDL-UHFFFAOYSA-N,463373,"3-amino-N-[2-(3-chlorophenoxy)ethyl]-1-({4-[(pyrrolidin-1-::US10781181, Example 51",Plasma kallikrein,, 427
50715279,CCCCC#Cc1nc(N)c2ncn([C@@H]3OC[C@@H](O)[C@H]3O)c2n1,"InChI=1S/C15H19N5O3/c1-2-3-4-5-6-10-18-13(16)11-14(19-10)20(8-17-11)15-12(22)9(21)7-23-15/h8-9,12,15,21-22H,2-4,7H2,1H3,(H2,16,18,19)/t9-,12-,15-/m1/s1",KVSBFXTVPHRJRK-DDHOLCJHSA-N,50363168,CHEMBL1945563,Adenosine receptor A2a,Homo sapiens,
50507304,O=C(NC1CCCCC1)c1ccc(nc1)C#Cc1ccccc1,"InChI=1S/C20H20N2O/c23-20(22-19-9-5-2-6-10-19)17-12-14-18(21-15-17)13-11-16-7-3-1-4-8-16/h1,3-4,7-8,12,14-15,19H,2,5-6,9-10H2,(H,22,23)",UVQBVTGQRSXVAW-UHFFFAOYSA-N,50293644,CHEMBL550624::N-cyclohexyl-6-(2-phenylethynyl)nicotinamide,Metabotropic glutamate receptor 5,Homo sapiens,
945898,CC(C[C@H]1CN(c2cc(NC(=O)OC(C)(C)C(F)(F)F)ccc2O1)S(=O)(=O)c1cccc(c1)C(F)(F)F)C(=O)NS(=O)(=O)C1CC1,"InChI=1S/C27H29F6N3O8S2/c1-15(23(37)35-45(39,40)19-8-9-19)11-18-14-36(46(41,42)20-6-4-5-16(12-20)26(28,29)30)21-13-17(7-10-22(21)43-18)34-24(38)44-25(2,3)27(31,32)33/h4-7,10,12-13,15,18-19H,8-9,11,14H2,1-3H3,(H,34,38)(H,35,37)/t15?,18-/m0/s1",VSGFMXADRZZHBV-PKHIMPSTSA-N,352868,"1,1,1-trifluoro-2-methylpropan-2-yl ((S)-2-((R and S)-3- (cyclopropanesulfonamido)-2-methyl- 3-oxopropyl)-4-((3- (trifluoromethyl)phenyl)sulfonyl)-3,4- dihydro-2H-benzo[b][1,4]oxazin-6- yl)carbamate::US10745364, Example 98D::US9809561, 98D",Nuclear receptor ROR-gamma,, 29.7
1260357,O=C(N1CCC2(C1)CCC(=O)NC2=O)c1ccc2ncsc2c1,"InChI=1S/C16H15N3O3S/c20-13-3-4-16(15(22)18-13)5-6-19(8-16)14(21)10-1-2-11-12(7-10)23-9-17-11/h1-2,7,9H,3-6,8H2,(H,18,20,22)",JWJJQVYGSHTVAA-UHFFFAOYSA-N,594658,"2-(Benzo[d]thiazole-6-carbonyl)-2,7-diazaspiro[4.5]decane-6,8-dione::US11584748, Example 25::US11584748, Example 56",Protein cereblon,,
50084600,C[C@H](c1ccccc1)n1c(C)c(C)c2c1nc([nH]c2=O)-c1ccc(Cl)cc1,"InChI=1S/C22H20ClN3O/c1-13-14(2)26(15(3)16-7-5-4-6-8-16)21-19(13)22(27)25-20(24-21)17-9-11-18(23)12-10-17/h4-12,15H,1-3H3,(H,24,25,27)/t15-/m1/s1",DYWXNZMNTJKRLH-OAHLLOKOSA-N,50051663,"2-(4-Chloro-phenyl)-5,6-dimethyl-7-((R)-1-phenyl-ethyl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one::CHEMBL84368",Adenosine receptor A1,Rattus norvegicus,
1726,CCN1c2nc(ccc2N(C)C(=O)c2cccnc12)-c1cccs1,"InChI=1S/C18H16N4OS/c1-3-22-16-12(6-4-10-19-16)18(23)21(2)14-9-8-13(20-17(14)22)15-7-5-11-24-15/h4-11H,3H2,1-2H3",YFEJBNCFMFTPFP-UHFFFAOYSA-N,1555,"2-ethyl-9-methyl-5-(thiophen-2-yl)-2,4,9,15-tetraazatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3,5,7,12,14-hexaen-10-one::Dipyridodiazepinone deriv. 44","Gag-Pol polyprotein [600-1027,Y780C]/[600-1155,Y780C]",Human immunodeficiency virus 1, 420
411264,Cc1nc(-c2cnc(C)cn2)n(n1)-c1cc(nc(C)n1)N1CC(C1)c1nc2ccccc2n1C,"InChI=1S/C24H24N10/c1-14-10-26-19(11-25-14)24-29-16(3)31-34(24)22-9-21(27-15(2)28-22)33-12-17(13-33)23-30-18-7-5-6-8-20(18)32(23)4/h5-11,17H,12-13H2,1-4H3",JOXPFBFNJLVXON-UHFFFAOYSA-N,236015,"US9365562, 53","Isoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)",,
51436495,Nc1nc2n(CCc3ccc(NC(=O)CCCCCCC(=O)NO)cc3)ncc2c2nc(nn12)-c1ccco1,"InChI=1S/C26H29N9O4/c27-26-31-24-19(25-30-23(32-35(25)26)20-6-5-15-39-20)16-28-34(24)14-13-17-9-11-18(12-10-17)29-21(36)7-3-1-2-4-8-22(37)33-38/h5-6,9-12,15-16,38H,1-4,7-8,13-14H2,(H2,27,31)(H,29,36)(H,33,37)",GDORGFVYOGNYSG-UHFFFAOYSA-N,50580296,CHEMBL5093149,Histone deacetylase 1,Homo sapiens, 8.0
195610,COc1ccc(OC)c(NC(=O)c2[nH]c(C)c(C(C)=O)c2C)c1,"InChI=1S/C17H20N2O4/c1-9-15(11(3)20)10(2)18-16(9)17(21)19-13-8-12(22-4)6-7-14(13)23-5/h6-8,18H,1-5H3,(H,19,21)",VMSBWVMXFXIZAZ-UHFFFAOYSA-N,89636,"4-acetyl-N-(2,5-dimethoxyphenyl)-3,5-dimethyl-1H-pyrrole-2-carboxamide::MLS000053898::N-(2,5-dimethoxyphenyl)-4-ethanoyl-3,5-dimethyl-1H-pyrrole-2-carboxamide::SMR000064307::cid_867000",Corticotropin-releasing factor-binding protein,Homo sapiens,
50329926,Cn1cc(cn1)[C@H]1C[C@H]2CSC(N)=N[C@]2(CO1)c1ccc(F)cc1F,"InChI=1S/C19H15F6N5O/c20-12-3-13(21)18(23)17(22)11(12)7-29-6-10(5-26-29)27-16(31)8-30-15(19(24)25)4-14(28-30)9-1-2-9/h3-6,9,19H,1-2,7-8H2,(H,27,31)",JBVZPXHGLQAXRZ-UHFFFAOYSA-N,41536,"US8865706, 15",Beta-secretase 1,Homo sapiens, 4.0
1148832,Cc1cccc(c1)-c1c(sc(c1-c1ccncc1)-c1ccc(F)cc1)C#CCCO,"InChI=1S/C26H20FNOS/c1-18-5-4-6-21(17-18)24-23(7-2-3-16-29)30-26(20-8-10-22(27)11-9-20)25(24)19-12-14-28-15-13-19/h4-6,8-15,17,29H,3,16H2,1H3",QFDJKEPSCQYTSU-UHFFFAOYSA-N,542044,"US11273153, Compound 3.48",Mitogen-activated protein kinase 14,Homo sapiens,
189680,Brc1ccc(Oc2ccc(C#N)c(c2)C#N)cc1,InChI=1S/C14H7BrN2O/c15-12-2-5-13(6-3-12)18-14-4-1-10(8-16)11(7-14)9-17/h1-7H,ZHWODKAGCZSVQP-UHFFFAOYSA-N,86778,"Phthalonitrile analogue, 4g",Amine oxidase [flavin-containing] A,, 1.92e+4
51406594,OC(=O)c1ccc(Cl)cc1-c1cccc2n(CCCOc3cccc4ccccc34)ccc12,"InChI=1S/C28H22ClNO3/c29-20-12-13-24(28(31)32)25(18-20)22-9-4-10-26-23(22)14-16-30(26)15-5-17-33-27-11-3-7-19-6-1-2-8-21(19)27/h1-4,6-14,16,18H,5,15,17H2,(H,31,32)",KGDQVKRMGYAUAI-UHFFFAOYSA-N,50568324,CHEMBL4860820,Bcl-2-like protein 1,Homo sapiens,
1066242,COc1ncc(cn1)-c1ccc(cc1Cl)C(=O)N1[C@@H](CC[C@@H]1c1ccccc1Cl)C(O)=O,"InChI=1S/C23H19Cl2N3O4/c1-32-23-26-11-14(12-27-23)15-7-6-13(10-18(15)25)21(29)28-19(8-9-20(28)22(30)31)16-4-2-3-5-17(16)24/h2-7,10-12,19-20H,8-9H2,1H3,(H,30,31)/t19-,20+/m1/s1",IUEWEZIMIOSGAE-UXHICEINSA-N,404159,"(2S,5R)-1-(3-chloro-4-(2-methoxypyrimidin-5-yl)benzoyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylic acid::US10017468, Compound 329::US10781171, Compound 329::US11072582, Compound 329",Free fatty acid receptor 2,Homo sapiens,
51449025,NS(=O)(=O)c1ccc(CNc2nc(Nc3cccc(NC(=O)N4CCCC4)c3)ncc2Br)cc1,"InChI=1S/C22H24BrN7O3S/c23-19-14-26-21(29-20(19)25-13-15-6-8-18(9-7-15)34(24,32)33)27-16-4-3-5-17(12-16)28-22(31)30-10-1-2-11-30/h3-9,12,14H,1-2,10-11,13H2,(H,28,31)(H2,24,32,33)(H2,25,26,27,29)",OEZHSZIDGUKBRK-UHFFFAOYSA-N,50585191,CHEMBL5079149,Non-receptor tyrosine-protein kinase TYK2,Homo sapiens, 48
665820,CCS(=O)(=O)Cc1ccccc1-c1ccc(c(F)c1)-c1cnc(N)cn1,"InChI=1S/C19H18FN3O2S/c1-2-26(24,25)12-14-5-3-4-6-15(14)13-7-8-16(17(20)9-13)18-10-23-19(21)11-22-18/h3-11H,2,12H2,1H3,(H2,21,23)",GOGOLDJIHLAMNI-UHFFFAOYSA-N,169344,"US9079866, 749::US9745328, Compound 749::US9884878, Compound 749",Flap endonuclease 1,Homo sapiens,
51089452,COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@]2([C@H]1c1cccc(Cl)c1F)C(=O)Nc1cc(Cl)sc21)C(O)=O,"InChI=1S/C29H28Cl2FN3O5S/c1-28(2,3)12-19-29(24-17(34-27(29)39)11-20(31)41-24)21(14-6-5-7-15(30)22(14)32)23(35-19)25(36)33-16-9-8-13(26(37)38)10-18(16)40-4/h5-11,19,21,23,35H,12H2,1-4H3,(H,33,36)(H,34,39)(H,37,38)/t19-,21-,23+,29+/m0/s1",YXQHJKFKRZDXHV-HNXAPSNLSA-N,50446196,CHEMBL3109041,E3 ubiquitin-protein ligase Mdm2,Homo sapiens, 7.0
50793987,CN1CCN(CC1)c1nc2ccccc2c2-c3ccsc3CCc12,"InChI=1S/C20H21N3S/c1-22-9-11-23(12-10-22)20-16-6-7-18-15(8-13-24-18)19(16)14-4-2-3-5-17(14)21-20/h2-5,8,13H,6-7,9-12H2,1H3",UQLASFOWQSFVMZ-UHFFFAOYSA-N,50076402,"6-(4-Methyl-piperazin-1-yl)-4,5-dihydro-3-thia-7-aza-cyclopenta[c]phenanthrene::CHEMBL288069",5-hydroxytryptamine receptor 2C,,
50124443,CCn1cc(C(=O)CC(=O)C(=O)OC)c2ccccc12,"InChI=1S/C15H15NO4/c1-3-16-9-11(10-6-4-5-7-12(10)16)13(17)8-14(18)15(19)20-2/h4-7,9H,3,8H2,1-2H3",CLULSGGUQBPYDX-UHFFFAOYSA-N,50154403,"4-(1-Ethyl-1H-indol-3-yl)-2,4-dioxo-butyric acid methyl ester::CHEMBL364097::Methyl 4-(1-Ethyl-1H-indol-3-yl)-2-hydroxy-4-oxo-but-2-enoate",Integrase,Human immunodeficiency virus 1,>100000
555420,C[C@@H]1C[C@H](N)CN(C1)c1ccncc1NC(=O)c1ccc2ccc(cc2n1)N1CC(C)(C)C1,"InChI=1S/C26H32N6O/c1-17-10-19(27)14-31(13-17)24-8-9-28-12-23(24)30-25(33)21-7-5-18-4-6-20(11-22(18)29-21)32-15-26(2,3)16-32/h4-9,11-12,17,19H,10,13-16,27H2,1-3H3,(H,30,33)/t17-,19+/m1/s1",UURNQJRXOUIRSZ-MJGOQNOKSA-N,291213,"N-{4-[(3S,5R)-3-Amino-5-methylpiperidin-1-yl]pyridin-3-yl}-7-(3,3-dimethylazetidin-1-yl)quinoline-2-carboxamide::US9580418, Example 33::US9890162, Example 33",Serine/threonine-protein kinase pim-1,,<10
50701907,Ic1ccc(CSc2nnc(o2)-c2ccc3OCCOc3c2)cc1,"InChI=1S/C17H13IN2O3S/c18-13-4-1-11(2-5-13)10-24-17-20-19-16(23-17)12-3-6-14-15(9-12)22-8-7-21-14/h1-6,9H,7-8,10H2",JEKRLGMLAOGKSA-UHFFFAOYSA-N,50357376,CHEMBL1917267,Telomerase reverse transcriptase,Homo sapiens, 3660
51121262,C1CC(C1)c1ccnc2N3CCNC[C@H]3CCc12,"InChI=1S/C15H21N3/c1-2-11(3-1)13-6-7-17-15-14(13)5-4-12-10-16-8-9-18(12)15/h6-7,11-12,16H,1-5,8-10H2/t12-/m1/s1",QRFXLVHUVBURRJ-GFCCVEGCSA-N,50459714,"CHEMBL4204710::US10836764, Compound 149",5-hydroxytryptamine receptor 2C,Homo sapiens,
51187013,Nc1n[nH]c2nccc(-c3ccc(NC(=O)Nc4cccc(c4)C(F)(F)F)cc3)c12,"InChI=1S/C20H15F3N6O/c21-20(22,23)12-2-1-3-14(10-12)27-19(30)26-13-6-4-11(5-7-13)15-8-9-25-18-16(15)17(24)28-29-18/h1-10H,(H2,26,27,30)(H3,24,25,28,29)",LYHXSDWIWVVZPB-UHFFFAOYSA-N,50372153,CHEMBL255955,Vascular endothelial growth factor receptor 2,Homo sapiens, 1.7
50480708,CSCC[C@H](NC(=O)[C@H](Cc1ccc(OS(O)(=O)=O)cc1)NC(=O)[C@@H](N)CC(O)=O)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,"InChI=1S/C49H62N10O16S3/c1-76-18-16-34(55-47(69)37(58-44(66)32(50)23-41(61)62)21-28-12-14-30(15-13-28)75-78(72,73)74)45(67)53-26-40(60)54-38(22-29-25-52-33-11-7-6-10-31(29)33)48(70)56-35(17-19-77-2)46(68)59-39(24-42(63)64)49(71)57-36(43(51)65)20-27-8-4-3-5-9-27/h3-15,25,32,34-39,52H,16-24,26,50H2,1-2H3,(H2,51,65)(H,53,67)(H,54,60)(H,55,69)(H,56,70)(H,57,71)(H,58,66)(H,59,68)(H,61,62)(H,63,64)(H,72,73,74)/t32-,34-,35-,36-,37-,38-,39-/m0/s1",IZTQOLKUZKXIRV-YRVFCXMDSA-N,21147,(3S)-3-[(2S)-2-[(2S)-2-{2-[(2S)-2-[(2S)-2-[(3S)-3-amino-3-formamidopropanoic acid]-3-[4-(sulfooxy)phenyl]propanamido]-4-(methylsulfanyl)butanamido]acetamido}-3-(1H-indol-3-yl)propanamido]-4-(methylsulfanyl)butanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid::CCK-8::CCK-8(SO3)::CHEMBL1121::H-Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2::SINCALIDE::Syncalide::[125I]CCK-8,Gastrin/cholecystokinin type B receptor,Homo sapiens, 1.2
213503,COc1ccc(\C=C(\C(=O)NCc2ccc(cc2)C(=O)Nc2ccccc2N)c2ccc(C)cc2)cc1OC,"InChI=1S/C32H31N3O4/c1-21-8-13-24(14-9-21)26(18-23-12-17-29(38-2)30(19-23)39-3)32(37)34-20-22-10-15-25(16-11-22)31(36)35-28-7-5-4-6-27(28)33/h4-19H,20,33H2,1-3H3,(H,34,37)(H,35,36)/b26-18+",KEAXYLKXZYDTTP-NLRVBDNBSA-N,97686,"US8476255, 29",Histone deacetylase 1,Mus musculus, 57
50478202,COc1ccc(\C=C2/CC(C)OC2=O)cc1,"InChI=1S/C13H14O3/c1-9-7-11(13(14)16-9)8-10-3-5-12(15-2)6-4-10/h3-6,8-9H,7H2,1-2H3/b11-8+",ONYWBNVSVNXDNV-DHZHZOJOSA-N,50154356,CHEMBL3775969,Dual specificity tyrosine-phosphorylation-regulated kinase 1B,, 10500
39448,CCCc1cc(ccc1OCCCOc1ccc2[C@H](CC(O)=O)CCc2c1)-c1nc2OCCCc2s1,"InChI=1S/C29H33NO5S/c1-2-5-21-16-22(29-30-28-26(36-29)6-3-13-35-28)9-12-25(21)34-15-4-14-33-23-10-11-24-19(17-23)7-8-20(24)18-27(31)32/h9-12,16-17,20H,2-8,13-15,18H2,1H3,(H,31,32)/t20-/m0/s1",DDAMWXQFEJPURM-FQEVSTJZSA-N,21803,"2-[(1S)-5-[3-(2-propyl-4-{5H,6H,7H-pyrano[2,3-d][1,3]thiazol-2-yl}phenoxy)propoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid::Indanylacetic Acid Analog, 34r",Peroxisome proliferator-activated receptor delta,,
787796,CC(C)(C)c1nc(cc(n1)C(F)(F)F)N1CCN(CCCCNC(=O)N2CCN(C(=O)C2)c2ccccc2)CC1,"InChI=1S/C28H38F3N7O2/c1-27(2,3)25-33-22(28(29,30)31)19-23(34-25)36-15-13-35(14-16-36)12-8-7-11-32-26(40)37-17-18-38(24(39)20-37)21-9-5-4-6-10-21/h4-6,9-10,19H,7-8,11-18,20H2,1-3H3,(H,32,40)",UGRUVQBETHORJS-UHFFFAOYSA-N,301917," N-(4-(4-(2-(tert-Butyl)-6-(trifluoromethyl)pyrimidin-4-yl)piperazin-1-yl)butyl)-3-oxo-4-phenylpiperazine-1-carboxamide ::US9598387, Compound 102::US9969743, 102",D(3) dopamine receptor,,
124777,Cc1ccc(cc1)C(=O)CNc1cccc(Cl)c1,"InChI=1S/C15H14ClNO/c1-11-5-7-12(8-6-11)15(18)10-17-14-4-2-3-13(16)9-14/h2-9,17H,10H2,1H3",VSOAYRFQTKQDCE-UHFFFAOYSA-N,67225,2-(3-Chloro-phenylamino)-1-p-tolyl-ethanone::2-(3-chloroanilino)-1-(4-methylphenyl)ethanone::2-(3-chloroanilino)-1-(p-tolyl)ethanone::2-[(3-chlorophenyl)amino]-1-(4-methylphenyl)ethanone::MLS000561352::SMR000177334::cid_788408,Apelin receptor,Homo sapiens, 4130
56742,CC(C)CNC(=O)c1ccc(c(c1)C(O)=O)-c1ccc(cc1C(=O)Nc1ccc(cc1)C(N)=N)-c1ccsc1CO,"InChI=1S/C31H30N4O5S/c1-17(2)15-34-29(37)20-6-10-24(26(14-20)31(39)40)23-9-5-19(22-11-12-41-27(22)16-36)13-25(23)30(38)35-21-7-3-18(4-8-21)28(32)33/h3-14,17,36H,15-16H2,1-2H3,(H3,32,33)(H,34,37)(H,35,38)(H,39,40)",REKBLSLNDZXMEV-UHFFFAOYSA-N,31495,"substituted biphenyl derivative, 36ai",Coagulation factor X,Homo sapiens, 450
808908,Cc1ccc(CC(=O)Nc2cn(CCCCn3cc(nn3)C(=O)NCc3cccnc3)nn2)cn1,"InChI=1S/C23H26N10O2/c1-17-6-7-18(13-25-17)11-22(34)27-21-16-33(31-29-21)10-3-2-9-32-15-20(28-30-32)23(35)26-14-19-5-4-8-24-12-19/h4-8,12-13,15-16H,2-3,9-11,14H2,1H3,(H,26,35)(H,27,34)",NZGOGFLFOHRLCQ-UHFFFAOYSA-N,404978,"1-(4-{4-[2-(6-methylpyridin-3- yl)acetamido]-1H-1,2,3-triazol-1- yl}butyl)-N-(pyridin-3-ylmethyl)- 1H-1,2,3-triazole-4-carboxamide::US10344025, Example 322::US11370786, Example 322","Glutaminase kidney isoform, mitochondrial",Homo sapiens, 300
50647120,CN(CCCNC(=O)c1ccc2c(c1)N(Cc1ccc(C)cc1C)C(=O)c1ccccc1S2=O)C1CCCCC1,"InChI=1S/C33H39N3O3S/c1-23-14-15-26(24(2)20-23)22-36-29-21-25(32(37)34-18-9-19-35(3)27-10-5-4-6-11-27)16-17-31(29)40(39)30-13-8-7-12-28(30)33(36)38/h7-8,12-17,20-21,27H,4-6,9-11,18-19,22H2,1-3H3,(H,34,37)",ZJRYVYSMLLTUKI-UHFFFAOYSA-N,50347282,CHEMBL1796130,L-cysteine:1D-myo-inositol 2-amino-2-deoxy-alpha-D-glucopyranoside ligase,Mycobacterium tuberculosis, 2000000
264644,COc1cc(ccn1)N1CCN(C1=O)c1cnccc1C,"InChI=1S/C15H16N4O2/c1-11-3-5-16-10-13(11)19-8-7-18(15(19)20)12-4-6-17-14(9-12)21-2/h3-6,9-10H,7-8H2,1-2H3",AOBJYZSGNJYOIH-UHFFFAOYSA-N,132138,"USRE45173, 72A","Steroid 17-alpha-hydroxylase/17,20 lyase",Homo sapiens, 9.4
808128,CN1CCC(CC1)Oc1ccc(nc1)-c1cnc2c(cnn2c1)-c1cccc2nc(C)ccc12,"InChI=1S/C27H26N6O/c1-18-6-8-23-22(4-3-5-26(23)31-18)24-16-30-33-17-19(14-29-27(24)33)25-9-7-21(15-28-25)34-20-10-12-32(2)13-11-20/h3-9,14-17,20H,10-13H2,1-2H3",ILUYOBAWAMCPBZ-UHFFFAOYSA-N,161928,"US10017516, Compound 60::US9682983, 60",Activin receptor type-1,Homo sapiens, 155
678355,Cc1cc2c(ccc3nnc(C)n23)n1Cc1ccccn1,"InChI=1S/C16H15N5/c1-11-9-15-14(6-7-16-19-18-12(2)21(15)16)20(11)10-13-5-3-4-8-17-13/h3-9H,10H2,1-2H3",ZFYQTIVFJMZMOL-UHFFFAOYSA-N,343408,"US10442803, Example 7::US11091484, Example 7::US9777003, Example 7",Bromodomain-containing protein 4 [42-168],, 550
1185753,COc1ccc(OCCN2CCNC(=O)C2)cc1Nc1ncc(Cl)c(Nc2ccc3ccccc3c2P(C)(C)=O)n1,"InChI=1S/C29H32ClN6O4P/c1-39-25-11-9-20(40-15-14-36-13-12-31-26(37)18-36)16-24(25)34-29-32-17-22(30)28(35-29)33-23-10-8-19-6-4-5-7-21(19)27(23)41(2,3)38/h4-11,16-17H,12-15,18H2,1-3H3,(H,31,37)(H2,32,33,34,35)",DRXIRBQDBFODMM-UHFFFAOYSA-N,561452,"US11390625, Compound 28::US11390625, Example 28","Epidermal growth factor receptor [1-18,20-1210,T790M,C797S]",, 185
50597191,CC(=O)OCc1cc(ccc1C\N=C(/S)NCc1ccc(NS(C)(=O)=O)cc1)C(C)(C)C,"InChI=1S/C23H31N3O4S2/c1-16(27)30-15-19-12-20(23(2,3)4)9-8-18(19)14-25-22(31)24-13-17-6-10-21(11-7-17)26-32(5,28)29/h6-12,26H,13-15H2,1-5H3,(H2,24,25,31)",KFHFJFSHOSPKIS-UHFFFAOYSA-N,50224194,CHEMBL47473,Transient receptor potential cation channel subfamily V member 1/2/4,Rattus norvegicus, 580
51434799,COc1ncc-2cc1NS(=O)(=O)c1cccc(c1)C(=O)NCc1cncc(c1)-c1ncnc3c(C)c-2sc13,"InChI=1S/C26H20N6O4S2/c1-14-21-24-22(31-13-30-21)17-6-15(9-27-11-17)10-28-25(33)16-4-3-5-19(7-16)38(34,35)32-20-8-18(23(14)37-24)12-29-26(20)36-2/h3-9,11-13,32H,10H2,1-2H3,(H,28,33)",CWLUZOJADRKJSM-UHFFFAOYSA-N,50579635,CHEMBL4868512,Serine/threonine-protein kinase pim-1,, 43
51002378,Cn1c2cc([nH]c2c(=O)n(C)c1=O)-c1ccc(OCC(=O)Nc2nc3ccccc3[nH]2)cc1,"InChI=1S/C23H20N6O4/c1-28-18-11-17(24-20(18)21(31)29(2)23(28)32)13-7-9-14(10-8-13)33-12-19(30)27-22-25-15-5-3-4-6-16(15)26-22/h3-11,24H,12H2,1-2H3,(H2,25,26,27,30)",RHXRPAQOUNYAHJ-UHFFFAOYSA-N,50410777,CHEMBL203043,Adenosine receptor A2b,Homo sapiens,
50084863,CC(C)(C)CC[C@@H](N1C(=O)C(=N[C@@]11CC[C@@H](CC1)C(C)(C)C)c1cc(F)cc(F)c1)c1ccc(cc1)C(=O)NCc1nn[nH]n1,"InChI=1S/C34H43F2N7O2/c1-32(2,3)14-13-27(21-7-9-22(10-8-21)30(44)37-20-28-39-41-42-40-28)43-31(45)29(23-17-25(35)19-26(36)18-23)38-34(43)15-11-24(12-16-34)33(4,5)6/h7-10,17-19,24,27H,11-16,20H2,1-6H3,(H,37,44)(H,39,40,41,42)/t24-,27-,34-/m1/s1",UMDCPMLQYQJRGI-OWWAFECUSA-N,50007225,CHEMBL3238217,Glucagon receptor,, 110
743165,CN([C@H]1CCN(Cc2nc(C)oc2C(F)(F)F)C1)c1cc(F)c(cc1C)S(=O)(=O)Nc1cscn1,"InChI=1S/C21H23F4N5O3S2/c1-12-6-18(35(31,32)28-19-10-34-11-26-19)15(22)7-17(12)29(3)14-4-5-30(8-14)9-16-20(21(23,24)25)33-13(2)27-16/h6-7,10-11,14,28H,4-5,8-9H2,1-3H3/t14-/m0/s1",ODMSQVRRGMVXCI-AWEZNQCLSA-N,373887,"(S)-2-fluoro-5-methyl-4-(methyl(1-((2-methyl-5-(trifluoromethyl)oxazol-4-yl)methyl)pyrrolidin-3-yl)amino)-N-(thiazol-4-yl)benzenesulfonamide::US10246453, Example 154",Sodium channel protein type 1 subunit alpha,, 16556
841333,CN1CCN(CC1)S(=O)(=O)N(Cc1ccc(cn1)-c1nnc(o1)C(F)F)c1ccccc1,"InChI=1S/C20H22F2N6O3S/c1-26-9-11-27(12-10-26)32(29,30)28(17-5-3-2-4-6-17)14-16-8-7-15(13-23-16)19-24-25-20(31-19)18(21)22/h2-8,13,18H,9-12,14H2,1H3",TZZYLOQLBZNTEZ-UHFFFAOYSA-N,419605,"US10464911, Example 33",Histone deacetylase 1,Homo sapiens, 15.0
259072,CN(C)CCNc1ccc(CO)c2oc3ccc(O)cc3c(=O)c12,"InChI=1S/C18H20N2O4/c1-20(2)8-7-19-14-5-3-11(10-21)18-16(14)17(23)13-9-12(22)4-6-15(13)24-18/h3-6,9,19,21-22H,7-8,10H2,1-2H3",BOTXZPXSICDQHE-UHFFFAOYSA-N,94854,"1-[2-(dimethylamino)ethylamino]-4-(hydroxymethyl)-7-oxidanyl-xanthen-9-one::1-[2-(dimethylamino)ethylamino]-7-hydroxy-4-(hydroxymethyl)-9-xanthenone::1-[2-(dimethylamino)ethylamino]-7-hydroxy-4-(hydroxymethyl)xanthen-9-one::1-[2-(dimethylamino)ethylamino]-7-hydroxy-4-methylol-xanthone::9H-Xanthen-9-one, 1-[[2-(dimethylamino)ethyl]amino]- 7-hydroxy-4-(hydroxymethyl)-::MLS002702888::SMR001566706::cid_337396",Transthyretin,,>55162
50971540,CC#CCO[C@@H]1C[C@H]2[C@@H]3CCC(=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)C=CC(=O)C=C12,"InChI=1S/C23H28O3/c1-4-5-12-26-20-14-16-17-6-7-21(25)23(17,3)11-9-18(16)22(2)10-8-15(24)13-19(20)22/h8,10,13,16-18,20H,6-7,9,11-12,14H2,1-3H3/t16-,17-,18-,20+,22+,23-/m0/s1",GNDYBZKXORBCFO-KVAKACLVSA-N,50398453,CHEMBL2179109,Aromatase,Homo sapiens, 112.3
50767796,CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1Cc2ccccc2CN1C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCN=C(N)N)C(N)=O,"InChI=1S/C64H98N18O13S/c1-37(2)32-46(57(89)75-42(54(69)86)26-31-96-3)74-53(85)35-73-55(87)47(33-38-14-5-4-6-15-38)79-60(92)50-34-39-16-7-8-17-40(39)36-82(50)63(95)45(23-25-52(68)84)77-56(88)43(22-24-51(67)83)76-58(90)49-21-13-30-81(49)62(94)44(19-9-10-27-65)78-59(91)48-20-12-29-80(48)61(93)41(66)18-11-28-72-64(70)71/h4-8,14-17,37,41-50H,9-13,18-36,65-66H2,1-3H3,(H2,67,83)(H2,68,84)(H2,69,86)(H,73,87)(H,74,85)(H,75,89)(H,76,90)(H,77,88)(H,78,91)(H,79,92)(H4,70,71,72)/t41-,42-,43-,44-,45-,46-,47-,48-,49-,50-/m0/s1",XIUBIMRSCFRWTN-SARDKLJWSA-N,50030165,Arg-Pro-Lys-Pro-Gln-Gln-Tic-Phe-Gly-Leu-Met::CHEMBL2372444,Substance-K receptor,, 520
6435,Cc1c(O)cccc1C(=O)N[C@@H](Cc1ccccc1)[C@H](O)C(=O)N1C[C@@H](Cl)C[C@H]1C(=O)NC(C)(C)C,"InChI=1S/C27H34ClN3O5/c1-16-19(11-8-12-22(16)32)24(34)29-20(13-17-9-6-5-7-10-17)23(33)26(36)31-15-18(28)14-21(31)25(35)30-27(2,3)4/h5-12,18,20-21,23,32-33H,13-15H2,1-4H3,(H,29,34)(H,30,35)/t18-,20-,21-,23-/m0/s1",SAFCQBPFQXDREG-ROQCDXFCSA-N,4124,"(2S,4S)-N-tert-butyl-4-chloro-1-[(2S,3S)-2-hydroxy-3-[(3-hydroxy-2-methylphenyl)formamido]-4-phenylbutanoyl]pyrrolidine-2-carboxamide::(3-Hydroxy-2-methylbenzoyl)-(2(S)-hydroxy-3(S)-amino-phenylbutanoyl)-4(S)-Cl-Pro-NH-t-Bu::AHPBA deriv. 9::CHEMBL113958",Dimer of Gag-Pol polyprotein [489-587],Human immunodeficiency virus 1, 0.8
50218577,CC(=O)CNc1nc(nc2nc(C)cn12)-c1ccccc1,"InChI=1S/C15H15N5O/c1-10-9-20-14(16-8-11(2)21)18-13(19-15(20)17-10)12-6-4-3-5-7-12/h3-7,9H,8H2,1-2H3,(H,16,17,18,19)",VGUQKUXXKQGMDW-UHFFFAOYSA-N,50120765,"1-(7-Methyl-2-phenyl-imidazo[1,2-a][1,3,5]triazin-4-ylamino)-propan-2-one::CHEMBL146234",Adenosine receptor A1,Bos taurus,
50745886,OC(=O)C(CCC\C=C(/c1ccccc1)c1cccnc1)Sc1ccccc1,"InChI=1S/C24H23NO2S/c26-24(27)23(28-21-13-5-2-6-14-21)16-8-7-15-22(19-10-3-1-4-11-19)20-12-9-17-25-18-20/h1-6,9-15,17-18,23H,7-8,16H2,(H,26,27)/b22-15+",NXOOOQXFKKSYNW-PXLXIMEGSA-N,50026528,7-Phenyl-2-phenylsulfanyl-7-pyridin-3-yl-hept-6-enoic acid::CHEMBL329064,Thromboxane-A synthase,Homo sapiens, 33
50078772,C[C@@H](N(C)C(=O)N1CC[C@@H](C[C@@H]1c1ccc(F)cc1C)NC1CC1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F,"InChI=1S/C27H30F7N3O/c1-15-10-20(28)4-7-23(15)24-14-22(35-21-5-6-21)8-9-37(24)25(38)36(3)16(2)17-11-18(26(29,30)31)13-19(12-17)27(32,33)34/h4,7,10-13,16,21-22,24,35H,5-6,8-9,14H2,1-3H3/t16-,22+,24-/m1/s1",VPSGABLRZGFPPI-CFJRQAHESA-N,50417975,CHEMBL1672057,Substance-P receptor,Homo sapiens,
947318,C[C@H](O)CNC(=O)c1cnn2ccc(nc12)N1CCCC1c1cncc(F)c1,"InChI=1S/C19H21FN6O2/c1-12(27)8-22-19(28)15-11-23-26-6-4-17(24-18(15)26)25-5-2-3-16(25)13-7-14(20)10-21-9-13/h4,6-7,9-12,16,27H,2-3,5,8H2,1H3,(H,22,28)/t12-,16?/m0/s1",CUAZXICLJJKGFD-HKALDPMFSA-N,127736,"US10251889, Example 109::US10758542, Example 109::US8791123, 109::US9782415, Example 109::US9796724, Example 109",Tyrosine-protein kinase JAK2 [808-1132],,>1000
803127,C[C@@H]1CC[C@H](CN1C(=O)c1ccccc1OC(F)(F)F)n1nc(C)c(n1)C(C)(C)O,"InChI=1S/C20H25F3N4O3/c1-12-9-10-14(27-24-13(2)17(25-27)19(3,4)29)11-26(12)18(28)15-7-5-6-8-16(15)30-20(21,22)23/h5-8,12,14,29H,9-11H2,1-4H3/t12-,14-/m1/s1",NSAJAKGXXXKIQN-TZMCWYRMSA-N,401851,"2-{5-Methyl-2-[(3R,6R)-6- methyl-1-{[2- (trifluoromethoxy)phenyl] carbonyl}piperidin-3-yl]-2H- 1,2,3-triazol-4-yl}propan-2-ol::US10010539, 67",Orexin/Hypocretin receptor type 1,Rattus norvegicus, 10.1
1089756,C[C@H](CO)Nc1n[nH]c2nccc(Oc3ccc(NC(=O)c4cc(nn(-c5ccc(F)cc5)c4=O)C(C)C)cc3F)c12,,,517036,"(R)-N-(3-fluoro-4-((3- ((1-hydroxypropan-2- yl)amino)-1H- pyrazolo[3,4-b]pyridin- 4-yl)oxy)phenyl)-2-(4- fluorophenyl)-6- isopropyl-3-oxo-2,3- dihydropyridazine-4- carboxamide::US11104676, Example 106",Hepatocyte growth factor receptor [Y1230H],, 6.40
1130067,CO[C@]1(CN2CCN3CCCC[C@@H]3C2)\C=C\C[C@H](C)[C@@H](CCO[Si](c2ccccc2)(c2ccccc2)C(C)(C)C)S(=O)(=O)NC(=O)c2ccc3OC[C@]4(CCCc5cc(Cl)ccc45)CN(C[C@@H]4CC[C@@H]14)c3c2,"InChI=1S/C59H77ClN4O6SSi/c1-43-16-14-31-59(68-5,41-62-33-34-63-32-13-12-18-48(63)39-62)52-26-23-46(52)38-64-40-58(30-15-17-44-36-47(60)25-27-51(44)58)42-69-54-28-24-45(37-53(54)64)56(65)61-71(66,67)55(43)29-35-70-72(57(2,3)4,49-19-8-6-9-20-49)50-21-10-7-11-22-50/h6-11,14,19-22,24-25,27-28,31,36-37,43,46,48,52,55H,12-13,15-18,23,26,29-30,32-35,38-42H2,1-5H3,(H,61,65)/b31-14+/t43-,46-,48+,52+,55+,58-,59-/m0/s1",SVKPJASVOYHCTB-BIYQAEMBSA-N,533904,"US11224601, Example 359",Bcl-2-like protein 11 [51-76]/Induced myeloid leukemia cell differentiation protein Mcl-1 [171-327],, 2.08
890766,OCC1CCc2c1c(ccc2Oc1cc(F)cc(F)c1)S(=O)(=O)C(F)F,"InChI=1S/C17H14F4O4S/c18-10-5-11(19)7-12(6-10)25-14-3-4-15(26(23,24)17(20)21)16-9(8-22)1-2-13(14)16/h3-7,9,17,22H,1-2,8H2",DGRCYAWGQLKYNI-UHFFFAOYSA-N,437736,"US10597366, Compound 24",Endothelial PAS domain-containing protein 1,Homo sapiens, 920
50663578,Cc1cn2c(cnc2c(Nc2ccc(C(=O)N3CCOCC3)c(Cl)c2)n1)-c1cn[nH]c1,"InChI=1S/C21H20ClN7O2/c1-13-12-29-18(14-9-24-25-10-14)11-23-20(29)19(26-13)27-15-2-3-16(17(22)8-15)21(30)28-4-6-31-7-5-28/h2-3,8-12H,4-7H2,1H3,(H,24,25)(H,26,27)",AXMMFQYWZDPEFR-UHFFFAOYSA-N,50354445,CHEMBL1836810,Tyrosine-protein kinase Lck,, 2000
50401956,OC[C@@H](N1CCCn2cc(cc2C1=O)-c1ccnc(NC2CC3(COC3)C2)n1)c1ccccc1,"InChI=1S/C26H29N5O3/c32-15-23(18-5-2-1-3-6-18)31-10-4-9-30-14-19(11-22(30)24(31)33)21-7-8-27-25(29-21)28-20-12-26(13-20)16-34-17-26/h1-3,5-8,11,14,20,23,32H,4,9-10,12-13,15-17H2,(H,27,28,29)/t23-/m1/s1",OWPUQESWKHKBDC-HSZRJFAPSA-N,50115396,CHEMBL3608463,Mitogen-activated protein kinase 1,Homo sapiens, 0.040000
737236,Cc1ccc(NC(=O)c2ccnc(c2)C(C)(F)F)cc1-c1cc(N2CCOCC2)c(=O)n(CCC#N)c1,"InChI=1S/C27H27F2N5O3/c1-18-4-5-21(32-25(35)19-6-8-31-24(15-19)27(2,28)29)16-22(18)20-14-23(33-10-12-37-13-11-33)26(36)34(17-20)9-3-7-30/h4-6,8,14-17H,3,9-13H2,1-2H3,(H,32,35)",KARKXYOHJUTQHZ-UHFFFAOYSA-N,77892,"US10245267, Example 334::US10709712, Example 334::US9694016, 334",Serine/threonine-protein kinase B-raf [V600E],, 2.30
50233817,COc1cc2CCN(Cc3cnc(N)nc3N)[C@H](C)c2c2OCOc12,"InChI=1S/C17H21N5O3/c1-9-13-10(5-12(23-2)14-15(13)25-8-24-14)3-4-22(9)7-11-6-20-17(19)21-16(11)18/h5-6,9H,3-4,7-8H2,1-2H3,(H4,18,19,20,21)/t9-/m1/s1",NTMLNTRPMUIDQA-SECBINFHSA-N,50128535,"5-(4-Methoxy-9-methyl-6,9-dihydro-7H-[1,3]dioxolo[4,5-h]isoquinolin-8-ylmethyl)-pyrimidine-2,4-diamine::CHEMBL310468",Dihydrofolate reductase,Homo sapiens, 9.8
51142303,C\C=C(\C)C(=O)OCC1(C)[C@@H]2C[C@@H](C)[C@@]34C=C(C)[C@H](OC(=O)C(\C)=C/C)[C@@]3(O)[C@H](O)C(C)=C[C@@H]([C@H]12)C4=O,"InChI=1S/C30H40O7/c1-9-15(3)26(33)36-14-28(8)21-12-19(7)29-13-18(6)25(37-27(34)16(4)10-2)30(29,35)23(31)17(5)11-20(22(21)28)24(29)32/h9-11,13,19-23,25,31,35H,12,14H2,1-8H3/b15-9-,16-10-/t19-,20+,21-,22+,23-,25+,28?,29-,30+/m1/s1",IMQVWZKEFSFWCH-FRTLHQRBSA-N,50468103,CHEMBL4295025,G protein-activated inward rectifier potassium channel 4,Homo sapiens, 1450
50512025,NCCCOc1ccccc1C(=O)Nc1nc2ccc(Oc3ccccc3)cc2s1,"InChI=1S/C23H21N3O3S/c24-13-6-14-28-20-10-5-4-9-18(20)22(27)26-23-25-19-12-11-17(15-21(19)30-23)29-16-7-2-1-3-8-16/h1-5,7-12,15H,6,13-14,24H2,(H,25,26,27)",GYBCZPSNDNTEHI-UHFFFAOYSA-N,50295698,2-(3-Amino-propoxy)-N-(6-phenoxy-benzothiazol-2-yl)-benzamide::CHEMBL563655,Voltage-dependent N-type calcium channel subunit alpha-1B,,
754826,C[C@@H]1C[C@H](N)CN(C1)c1c2CC[C@H](O)c2ncc1NC(=O)c1ccc(F)c(n1)-c1c(F)cc(cc1F)C(C)(C)O,"InChI=1S/C29H32F3N5O3/c1-14-8-16(33)13-37(12-14)27-17-4-7-23(38)25(17)34-11-22(27)36-28(39)21-6-5-18(30)26(35-21)24-19(31)9-15(10-20(24)32)29(2,3)40/h5-6,9-11,14,16,23,38,40H,4,7-8,12-13,33H2,1-3H3,(H,36,39)/t14-,16+,23+/m1/s1",AFSHCISYYIAZAH-WREIHNQOSA-N,377237,"N-{4-[(3S,5R)-3-Amino-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-[2,6-difluoro-4-(1-hydroxy-1-methylethyl)phenyl]-5-fluoropyridine-2-carboxamide::US10265307, Example 67-1::US10517858, Example 67 (Diastereoisomer 1)::US10828290, Example 67 (Diastereoisomer 1)::US11229631, Example 67 Diastereoisomer 1",Serine/threonine-protein kinase pim-2,Homo sapiens,<100
50404923,OP(O)(=O)C(F)(Cc1cccnc1)P(O)(O)=O,"InChI=1S/C7H10FNO6P2/c8-7(16(10,11)12,17(13,14)15)4-6-2-1-3-9-5-6/h1-3,5H,4H2,(H2,10,11,12)(H2,13,14,15)",HHDUHWLBPDOLIL-UHFFFAOYSA-N,50225999,"1-fluoro-2-(3-pyridinyl)-ethylidene-1,1-bisphosphonic acid::CHEMBL437758",Farnesyl pyrophosphate synthase,Homo sapiens, 16.4
50786350,CN(C)c1cc(Nc2nn(cc2C(N)=O)[C@H]2COCC[C@@H]2C#N)cc(F)n1,"InChI=1S/C17H20FN7O2/c1-24(2)15-6-11(5-14(18)22-15)21-17-12(16(20)26)8-25(23-17)13-9-27-4-3-10(13)7-19/h5-6,8,10,13H,3-4,9H2,1-2H3,(H2,20,26)(H,21,22,23)/t10-,13+/m1/s1",AHHGVSZRWGXENV-MFKMUULPSA-N,50250928,CHEMBL4092626,Tyrosine-protein kinase JAK1,Homo sapiens, 0.180000
872103,CCOc1cc(-c2ccc(nc2)N2CCN(CC2)C(=O)[C@@H](O)C(C)C)c2c(cnn2c1)C#N,"InChI=1S/C24H28N6O3/c1-4-33-19-11-20(22-18(12-25)14-27-30(22)15-19)17-5-6-21(26-13-17)28-7-9-29(10-8-28)24(32)23(31)16(2)3/h5-6,11,13-16,23,31H,4,7-10H2,1-3H3/t23-/m0/s1",MTEJEZLZCRERST-QHCPKHFHSA-N,296231,"US10112942, Example 38::US10137124, Example 38::US10172851, Example 38::US10555944, Example 38::US10953005, Example 38",Proto-oncogene tyrosine-protein kinase receptor Ret [658-1114],, 353
575570,CC(N1CC2CCC(C1)O2)C(=O)Nc1cc(ccc1OC(F)(F)F)C(=O)Nc1ccc(nc1)-c1cccc(F)c1,"InChI=1S/C28H26F4N4O4/c1-16(36-14-21-7-8-22(15-36)39-21)26(37)35-24-12-18(5-10-25(24)40-28(30,31)32)27(38)34-20-6-9-23(33-13-20)17-3-2-4-19(29)11-17/h2-6,9-13,16,21-22H,7-8,14-15H2,1H3,(H,34,38)(H,35,37)",XTYSNFAOAGFDBE-UHFFFAOYSA-N,300500,"N-[6-(3-fluorophenyl)pyridin-3-yl]-3-{[2-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)propanoyl]amino}-4-(trifluoromethoxy)benzamide::US10130633, Example 70",Protein Wnt-3a,Homo sapiens, 6300
1002000,O=C(N1CCCC1c1cnccn1)c1cc(on1)-c1ccc2OCOc2c1,"InChI=1S/C19H16N4O4/c24-19(23-7-1-2-15(23)14-10-20-5-6-21-14)13-9-17(27-22-13)12-3-4-16-18(8-12)26-11-25-16/h3-6,8-10,15H,1-2,7,11H2",QSINZVQQPUJCJD-UHFFFAOYSA-N,483269,"US10919885, Compound No. 418",Stearoyl-CoA desaturase,,>45000
475193,COc1cc2c(cc1-c1c(C)noc1C)[nH]c1nc(C)nc(-c3ccc(NC(=O)N4CCN(C)CC4)c4ccccc34)c21,"InChI=1S/C33H33N7O3/c1-18-29(19(2)43-38-18)25-16-27-24(17-28(25)42-5)30-31(34-20(3)35-32(30)36-27)23-10-11-26(22-9-7-6-8-21(22)23)37-33(41)40-14-12-39(4)13-15-40/h6-11,16-17H,12-15H2,1-5H3,(H,37,41)(H,34,35,36)",YPXANNJXRXDMDY-UHFFFAOYSA-N,179633,"US9675697, Cpd. No. 316",Bromodomain-containing protein 2 [364-436],,
50694298,CN(C)CC(=O)N1CCC(CC1)c1ccc(NC(=O)c2ncc([nH]2)C#N)c(c1)C1=CCCCC1,"InChI=1S/C26H32N6O2/c1-31(2)17-24(33)32-12-10-18(11-13-32)20-8-9-23(22(14-20)19-6-4-3-5-7-19)30-26(34)25-28-16-21(15-27)29-25/h6,8-9,14,16,18H,3-5,7,10-13,17H2,1-2H3,(H,28,29)(H,30,34)",GUBJNPWVIUFSTR-UHFFFAOYSA-N,50355499,CHEMBL1908395::CHEMBL1908842,Dual specificity tyrosine-phosphorylation-regulated kinase 1B,,
627970,Cn1cc(cn1)-c1cc(-c2ccc(nc2)N2[C@H]3CC[C@@H]2C[C@H](O)C3)c2c(cnn2c1)C#N,"InChI=1S/C24H23N7O/c1-29-13-18(12-27-29)16-6-22(24-17(9-25)11-28-30(24)14-16)15-2-5-23(26-10-15)31-19-3-4-20(31)8-21(32)7-19/h2,5-6,10-14,19-21,32H,3-4,7-8H2,1H3/t19-,20+,21+",DGXBVCAOSZHHAK-AERCQKQUSA-N,284189,"US10023570, Example 199::US10174028, Example 199",Proto-oncogene tyrosine-protein kinase receptor Ret [V804M],, 34.8
51177762,Br.OC(=O)CCCn1nc(ccc1=N)-c1ccc(OCc2cccc(c2)[N+]([O-])=O)cc1,"InChI=1S/C21H20N4O5/c22-20-11-10-19(23-24(20)12-2-5-21(26)27)16-6-8-18(9-7-16)30-14-15-3-1-4-17(13-15)25(28)29/h1,3-4,6-11,13,22H,2,5,12,14H2,(H,26,27)",LZTHAJBUMOQDLU-UHFFFAOYSA-N,50483961,CHEMBL1795561,Gamma-aminobutyric acid receptor subunit alpha-1/beta-2/gamma-2,Homo sapiens, 3.0
227146,O=C(CC#N)N[C@H]1CC[C@H](CCN2CCC(CC2)c2cccc3OCOc23)CC1,"InChI=1S/C23H31N3O3/c24-12-8-22(27)25-19-6-4-17(5-7-19)9-13-26-14-10-18(11-15-26)20-2-1-3-21-23(20)29-16-28-21/h1-3,17-19H,4-11,13-16H2,(H,25,27)/t17-,19-",ZJUQDFIINDCGDS-UAPYVXQJSA-N,107517,"US8598357, 20",D(2) dopamine receptor,Homo sapiens,
50349810,COc1cc2c(cc1-c1c(C)noc1C)[nH]c1ccnc(-c3c(C)noc3C)c21,"InChI=1S/C22H20N4O3/c1-10-19(12(3)28-25-10)15-8-17-14(9-18(15)27-5)21-16(24-17)6-7-23-22(21)20-11(2)26-29-13(20)4/h6-9,24H,1-5H3",ZBKQIKDKLUJFMK-UHFFFAOYSA-N,50092324,"CHEMBL3581655::US9675697, Cpd. No. 1",Bromodomain-containing protein 4,,
167870,CCOc1ccc(NC(=O)CN(C)C(=O)c2ccc(COc3ccccc3)cc2)cc1OCC,"InChI=1S/C27H30N2O5/c1-4-32-24-16-15-22(17-25(24)33-5-2)28-26(30)18-29(3)27(31)21-13-11-20(12-14-21)19-34-23-9-7-6-8-10-23/h6-17H,4-5,18-19H2,1-3H3,(H,28,30)",BFPKIYUTYPMKDV-UHFFFAOYSA-N,83977,"MLS002180496::N-[2-(3,4-diethoxyanilino)-2-keto-ethyl]-N-methyl-4-(phenoxymethyl)benzamide::N-[2-(3,4-diethoxyanilino)-2-oxoethyl]-N-methyl-4-(phenoxymethyl)benzamide::N-[2-[(3,4-diethoxyphenyl)amino]-2-oxidanylidene-ethyl]-N-methyl-4-(phenoxymethyl)benzamide::SMR001269526::cid_25161676",Apoptotic protease-activating factor 1,Homo sapiens,>100000
50517107,Cc1cc(C)c2nc(S)n(CCc3ccc(cc3)S(N)(=O)=O)c(=O)c2c1,"InChI=1S/C18H19N3O3S2/c1-11-9-12(2)16-15(10-11)17(22)21(18(25)20-16)8-7-13-3-5-14(6-4-13)26(19,23)24/h3-6,9-10H,7-8H2,1-2H3,(H,20,25)(H2,19,23,24)",HBHWKYQYGWPPBR-UHFFFAOYSA-N,50190138,CHEMBL3828605,Carbonic anhydrase 1,Homo sapiens,
51047878,Clc1ccc(cc1)N(C[C@@H]1CNC[C@H]1Cc1ccccc1)c1ccccc1,"InChI=1S/C24H25ClN2/c25-22-11-13-24(14-12-22)27(23-9-5-2-6-10-23)18-21-17-26-16-20(21)15-19-7-3-1-4-8-19/h1-14,20-21,26H,15-18H2/t20-,21+/m1/s1",FCWGSUKXROLTNW-RTWAWAEBSA-N,50427565,CHEMBL2322896,Renin,Homo sapiens, 14000
50477532,Cc1cccc(NC(=O)NC2N=C(c3ccccc3)c3ccccc3N(CC(=O)NCCSCc3csc(N=C(N)N)n3)C2=O)c1,"InChI=1S/C32H33N9O3S2/c1-20-8-7-11-22(16-20)36-31(44)39-28-29(43)41(25-13-6-5-12-24(25)27(38-28)21-9-3-2-4-10-21)17-26(42)35-14-15-45-18-23-19-46-32(37-23)40-30(33)34/h2-13,16,19,28H,14-15,17-18H2,1H3,(H,35,42)(H2,36,39,44)(H4,33,34,37,40)",TYYIQPKNUREZGD-UHFFFAOYSA-N,50287241,"CHEMBL285746::N-[2-(2-Guanidino-thiazol-4-ylmethylsulfanyl)-ethyl]-2-[2-oxo-5-phenyl-3-(3-m-tolyl-ureido)-2,3-dihydro-benzo[e][1,4]diazepin-1-yl]-acetamide",Gastrin/cholecystokinin type B receptor,Mus musculus, 35
50679149,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,"InChI=1S/C30H29ClN6O3/c1-4-39-28-16-25-23(15-26(28)36-29(38)9-7-13-37(2)3)30(20(17-32)18-34-25)35-21-10-11-27(24(31)14-21)40-19-22-8-5-6-12-33-22/h5-12,14-16,18H,4,13,19H2,1-3H3,(H,34,35)(H,36,38)/b9-7+",JWNPDZNEKVCWMY-VQHVLOKHSA-N,50161957,"4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(pyridin-2-ylmethoxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide::CHEMBL180022::HKI-272::N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide::N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)butanamide::NERATINIB::US10822334, Compound Neratinib",Maternal embryonic leucine zipper kinase,,
624480,Clc1ccccc1Cn1cnc(c1)-c1cc(ccn1)-c1c[nH]nn1,"InChI=1S/C17H13ClN6/c18-14-4-2-1-3-13(14)9-24-10-17(20-11-24)15-7-12(5-6-19-15)16-8-21-23-22-16/h1-8,10-11H,9H2,(H,21,22,23)",FEAWGCOCHKJAAI-UHFFFAOYSA-N,276040,"2-[1-[(2-chlorophenyl)methyl]imidazol-4-yl]-4-(1H-triazol-4-yl)pyridine::US10071984, Example 2::US10174003, Example 2::US9896436, Example 2",Lysine-specific demethylase 2B,,<100
51238264,CN(C)Cc1ccc(COc2ccc3c(CO)cc(=O)oc3c2)cc1,"InChI=1S/C20H21NO4/c1-21(2)11-14-3-5-15(6-4-14)13-24-17-7-8-18-16(12-22)9-20(23)25-19(18)10-17/h3-10,22H,11-13H2,1-2H3",PWCTXLAYYMUQLL-UHFFFAOYSA-N,50506795,CHEMBL4457458,Amine oxidase [flavin-containing] B,, 78
281734,CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCC(F)(F)CC4)c(c3)[N+]([O-])=O)c(Oc3cc4cc[nH]c4cc3F)c2)=C(C1)c1ccc(Cl)cc1,"InChI=1S/C47H50ClF3N6O6S/c1-46(2)15-13-33(38(27-46)31-3-5-34(48)6-4-31)29-55-19-21-56(22-20-55)35-7-9-37(43(24-35)63-44-23-32-14-18-52-41(32)26-39(44)49)45(58)54-64(61,62)36-8-10-40(42(25-36)57(59)60)53-28-30-11-16-47(50,51)17-12-30/h3-10,14,18,23-26,30,52-53H,11-13,15-17,19-22,27-29H2,1-2H3,(H,54,58)",MCEJBRBKHBZOAK-UHFFFAOYSA-N,145220,"US8952157, 411::US9303025, 411",Apoptosis regulator Bcl-2,,
50801547,NC(=O)c1ccc(N[C@H]2CCCNC2)c2cc([nH]c12)-c1cccc(F)c1,"InChI=1S/C20H21FN4O/c21-13-4-1-3-12(9-13)18-10-16-17(24-14-5-2-8-23-11-14)7-6-15(20(22)26)19(16)25-18/h1,3-4,6-7,9-10,14,23-25H,2,5,8,11H2,(H2,22,26)/t14-/m0/s1",KCXSHSRRSKFOQP-AWEZNQCLSA-N,50255163,CHEMBL4067770,Serine/threonine-protein kinase Chk1,Homo sapiens, 9
50662600,COc1ccc(CC(=O)NS(=O)(=O)c2ccc(Br)cc2)cc1,"InChI=1S/C15H14BrNO4S/c1-21-13-6-2-11(3-7-13)10-15(18)17-22(19,20)14-8-4-12(16)5-9-14/h2-9H,10H2,1H3,(H,17,18)",LOLCZXRSTYWMQO-UHFFFAOYSA-N,50353984,CHEMBL1828884,Epidermal growth factor receptor,Homo sapiens, 24150
864442,CC(C)c1c([nH]c2ccc(nc12)N1CC(C1)NC1CCOCC1)-c1cn2ncnc2c(C)c1C,"InChI=1S/C26H33N7O/c1-15(2)23-24(20-13-33-26(27-14-28-33)17(4)16(20)3)30-21-5-6-22(31-25(21)23)32-11-19(12-32)29-18-7-9-34-10-8-18/h5-6,13-15,18-19,29-30H,7-12H2,1-4H3",UNASQJNJFFQFCW-UHFFFAOYSA-N,427563,"1-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-N-(tetrahydro-2H-pyran-4-yl)azetidin-3-amine::US10544143, Example 1::US10730877, Example 1::US11053244, Example 1",Toll-like receptor 7,, 20.0
50573135,Cc1cn(Cc2ccc(cc2)C(N)=O)c2cc(ccc12)C(=O)Nc1c(Cl)cncc1Cl,"InChI=1S/C23H18Cl2N4O2/c1-13-11-29(12-14-2-4-15(5-3-14)22(26)30)20-8-16(6-7-17(13)20)23(31)28-21-18(24)9-27-10-19(21)25/h2-11H,12H2,1H3,(H2,26,30)(H,27,28,31)",LYQNYINZEXWAQG-UHFFFAOYSA-N,50215939,CHEMBL56406,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A/4B/4C/4D",,
175390,COCCCC\C(=N/OCCN)c1ccc(cc1)C(F)(F)F,"InChI=1S/C15H21F3N2O2/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18/h5-8H,2-4,9-11,19H2,1H3/b20-14+",CJOFXWAVKWHTFT-XSFVSMFZSA-N,50028091,(1E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one O-(2-aminoethyl)oxime::CHEMBL814::FLUVOXAMINE,Sodium-dependent noradrenaline transporter,Homo sapiens,
33492,CN(Cc1ccc2nc(C)[nH]c(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O,"InChI=1S/C21H22N4O6S/c1-11-22-14-4-3-12(9-13(14)19(28)23-11)10-25(2)17-7-6-16(32-17)20(29)24-15(21(30)31)5-8-18(26)27/h3-4,6-7,9,15H,5,8,10H2,1-2H3,(H,24,29)(H,26,27)(H,30,31)(H,22,23,28)/t15-/m0/s1",IVTVGDXNLFLDRM-HNNXBMFYSA-N,18795,"(2S)-2-[(5-{methyl[(2-methyl-4-oxo-1,4-dihydroquinazolin-6-yl)methyl]amino}thiophen-2-yl)formamido]pentanedioic acid::CHEMBL225071::RTX::Raltitrexed::Tomudex::ZD1694",Dihydrofolate reductase,Escherichia coli, 23000
831879,CCOc1cc(-c2ccc(nc2)N2CC[C@@H](NC(=O)OC(C)(C)C)[C@@H](O)C2)c2c(cnn2c1)C#N,"InChI=1S/C25H30N6O4/c1-5-34-18-10-19(23-17(11-26)13-28-31(23)14-18)16-6-7-22(27-12-16)30-9-8-20(21(32)15-30)29-24(33)35-25(2,3)4/h6-7,10,12-14,20-21,32H,5,8-9,15H2,1-4H3,(H,29,33)/t20-,21+/m1/s1",QIEZJVPZOIWZGE-RTWAWAEBSA-N,305498,"US10144734, Example 515::US10172845, Example 515::US10441581, Example 515::US10881652, Example 515::tert-butyl ((3S,4R)-1- (5-(3-cyano-6- ethoxypyrazolo[1,5- a]pyridin-4-yl)pyridin- 2-yl)-3- hydroxypiperidin-4- yl)carbamate",Proto-oncogene tyrosine-protein kinase receptor Ret [V804M],, 2392
50312882,Cc1ccc(C(=O)c2c(-c3ccccc3)n(C)n(-c3ccccc3)c2=O)c(N)c1-c1ccc2nc(sc2c1)C(F)(F)F,"InChI=1S/C32H23F3N4O2S/c1-18-13-15-22(27(36)25(18)20-14-16-23-24(17-20)42-31(37-23)32(33,34)35)29(40)26-28(19-9-5-3-6-10-19)38(2)39(30(26)41)21-11-7-4-8-12-21/h3-17H,36H2,1-2H3",DRQQNHJHIDNZOM-UHFFFAOYSA-N,50072035,CHEMBL3407861,Eukaryotic translation initiation factor 2-alpha kinase 3,, 88
50487791,OC(=O)[C@H](CNC(=O)c1ccc(OCCC2CCNCC2)cc1)NS(=O)(=O)c1ccccc1,"InChI=1S/C23H29N3O6S/c27-22(18-6-8-19(9-7-18)32-15-12-17-10-13-24-14-11-17)25-16-21(23(28)29)26-33(30,31)20-4-2-1-3-5-20/h1-9,17,21,24,26H,10-16H2,(H,25,27)(H,28,29)/t21-/m0/s1",UIJBJQDAZCEJGM-NRFANRHFSA-N,50091737,(S)-2-Benzenesulfonylamino-3-[4-(2-piperidin-4-yl-ethoxy)-benzoylamino]-propionic acid::2-((S)-Benzenesulfonylamino)-3-[4-(2-piperidin-4-yl-ethoxy)-benzoylamino]-propionic acid::2-Benzenesulfonylamino-3-[4-(2-piperidin-4-yl-ethoxy)-benzoylamino]-propionic acid::CHEMBL59562,Integrin alpha-IIb/beta-3,, 13
50827536,CN1CCC(C(CSCC(=O)N2CCCCC2)C1)c1ccc(Cl)cc1,"InChI=1S/C20H29ClN2OS/c1-22-12-9-19(16-5-7-18(21)8-6-16)17(13-22)14-25-15-20(24)23-10-3-2-4-11-23/h5-8,17,19H,2-4,9-15H2,1H3",VXDYZTDYUKVXNJ-UHFFFAOYSA-N,50156052,2-[4-(4-Chloro-phenyl)-1-methyl-piperidin-3-ylmethylsulfanyl]-1-piperidin-1-yl-ethanone::CHEMBL191330,Transporter,Rattus norvegicus,
50690790,Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F,"InChI=1S/C17H14ClF2IN2O2/c18-12-7-10(21)3-6-14(12)22-16-11(4-5-13(19)15(16)20)17(24)23-25-8-9-1-2-9/h3-7,9,22H,1-2,8H2,(H,23,24)",GFMMXOIFOQCCGU-UHFFFAOYSA-N,50132260,"2-(2-Chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide::2-(2-chloro-4-iodophenylamino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide::CHEMBL105442::CI-1040::PD-18435::PD-184352::US8575391, 341",Platelet-derived growth factor receptor alpha,Homo sapiens,
51416417,COc1ccc(cc1)-c1cc(=O)c2c(O)c(OC)c(OC)c(OC)c2o1,"InChI=1S/C19H18O7/c1-22-11-7-5-10(6-8-11)13-9-12(20)14-15(21)17(23-2)19(25-4)18(24-3)16(14)26-13/h5-9,21H,1-4H3",LXEVSYZNYDZSOB-UHFFFAOYSA-N,50060925,CHEBI:79628::GARDENIN B,Peroxisome proliferator-activated receptor gamma,Homo sapiens, 2500
50281823,CCOc1cccc(c1)-c1cc(ccc1C#CC(O)(c1cncn1C)c1ccc(cc1)C#N)C#N,"InChI=1S/C29H22N4O2/c1-3-35-26-6-4-5-24(16-26)27-15-22(18-31)7-10-23(27)13-14-29(34,28-19-32-20-33(28)2)25-11-8-21(17-30)9-12-25/h4-12,15-16,19-20,34H,3H2,1-2H3",QYLBZDCYGRTUQE-UHFFFAOYSA-N,50126036,6-[3-(4-Cyano-phenyl)-3-hydroxy-3-(3-methyl-3H-imidazol-4-yl)-prop-1-ynyl]-3''-ethoxy-biphenyl-3-carbonitrile::6-[3-(4-Cyano-phenyl)-3-hydroxy-3-(3-methyl-3H-imidazol-4-yl)-prop-1-ynyl]-3'-ethoxy-biphenyl-3-carbonitrile::CHEMBL24043,Geranylgeranyl transferase type-1 subunit beta/Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha,, 2400
127494,Fc1ccccc1NC(=O)CN1C(=O)c2ccccc2C1=O,"InChI=1S/C16H11FN2O3/c17-12-7-3-4-8-13(12)18-14(20)9-19-15(21)10-5-1-2-6-11(10)16(19)22/h1-8H,9H2,(H,18,20)",LXBMTSUDKRFZND-UHFFFAOYSA-N,68639,"2-(1,3-dioxo-2-isoindolyl)-N-(2-fluorophenyl)acetamide::2-(1,3-dioxoisoindol-2-yl)-N-(2-fluorophenyl)acetamide::2-[1,3-bis(oxidanylidene)isoindol-2-yl]-N-(2-fluorophenyl)ethanamide::MLS000109631::N-(2-fluorophenyl)-2-phthalimido-acetamide::SMR000105571::cid_723287",Glycogen synthase kinase-3 beta,Homo sapiens,
822024,FC(F)(F)Oc1cccc(c1)-c1cnc2ccc(N[C@H]3CC[C@@H](CC3)C#N)nn12,"InChI=1S/C20H18F3N5O/c21-20(22,23)29-16-3-1-2-14(10-16)17-12-25-19-9-8-18(27-28(17)19)26-15-6-4-13(11-24)5-7-15/h1-3,8-10,12-13,15H,4-7H2,(H,26,27)/t13-,15-",PKHSKJFGAUOKTM-CTYIDZIISA-N,242403,"US10392392, Example 8-86::US10875864, EX. 8-86::US9416132, 8-86",Serine/threonine-protein kinase pim-1,, 14.0
50252764,Cc1cccc(CNC(=O)c2cccc(c2)-c2ccc(cc2)S(=O)(=O)CC(O)=O)c1,"InChI=1S/C23H21NO5S/c1-16-4-2-5-17(12-16)14-24-23(27)20-7-3-6-19(13-20)18-8-10-21(11-9-18)30(28,29)15-22(25)26/h2-13H,14-15H2,1H3,(H,24,27)(H,25,26)",JZSGKCNSPZBKTO-UHFFFAOYSA-N,50137899,CHEMBL175280::[3'-(3-methyl-benzylcarbamoyl)-biphenyl-4-sulfonyl]-acetic acid,Replication protein E1,Human papillomavirus type 11, 27
50500521,COC(=O)[C@@H]1CCCN1C(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)C[C@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)N(C)C(=O)[C@@H](NC(=O)[C@H](C)O)C(C)C,"InChI=1S/C50H74N8O12/c1-29(2)25-36(45(64)52-31(5)47(66)57(8)39(27-34-19-14-11-15-20-34)48(67)58-24-16-21-38(58)50(69)70-9)53-42(62)28-40(60)35(26-33-17-12-10-13-18-33)54-46(65)37(22-23-41(51)61)56(7)49(68)43(30(3)4)55-44(63)32(6)59/h10-15,17-20,29-32,35-40,43,59-60H,16,21-28H2,1-9H3,(H2,51,61)(H,52,64)(H,53,62)(H,54,65)(H,55,63)/t31-,32-,35-,36-,37-,38-,39+,40-,43-/m0/s1",WFMVRFNXMBGKEW-HVGQEOIXSA-N,50400221,CHEMBL2181015,Cathepsin D,Homo sapiens, 50
567010,Clc1nccc(C(=O)N2CCc3c(C2)[nH]nc3-c2ccccc2)c1Cl,"InChI=1S/C18H14Cl2N4O/c19-15-13(6-8-21-17(15)20)18(25)24-9-7-12-14(10-24)22-23-16(12)11-4-2-1-3-5-11/h1-6,8H,7,9-10H2,(H,22,23)",UQHVENMLNXEZOV-UHFFFAOYSA-N,254219,"US10112937, Example 104::US10150765, Example 104::US10703749, Example 104::US9464084, 104",P2X purinoceptor 7,, 205
187165,COCc1cc(NC(=O)c2ccc(F)cc2)cc(c1)C1(C)CCSC(N)=N1,"InChI=1S/C20H22FN3O2S/c1-20(7-8-27-19(22)24-20)15-9-13(12-26-2)10-17(11-15)23-18(25)14-3-5-16(21)6-4-14/h3-6,9-11H,7-8,12H2,1-2H3,(H2,22,24)(H,23,25)",KCEVQICKCKDJAP-UHFFFAOYSA-N,35281,"US8546380, 896::US8633188, 896",Beta-secretase 1,Homo sapiens, 8497
910216,CCc1c([nH]c2ccc(cc12)C1CCN(CC(O)=O)CC1)-c1ccnc(C)c1,"InChI=1S/C23H27N3O2/c1-3-19-20-13-17(16-7-10-26(11-8-16)14-22(27)28)4-5-21(20)25-23(19)18-6-9-24-15(2)12-18/h4-6,9,12-13,16,25H,3,7-8,10-11,14H2,1-2H3,(H,27,28)",UPCMEHSVCKAHGV-UHFFFAOYSA-N,444286,"US10660877, Example 876",Toll-like receptor 7,, 958
51112516,CC1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O,"InChI=1S/C16H16ClN3O3S/c1-10-8-11-4-2-3-5-14(11)20(10)19-16(21)12-6-7-13(17)15(9-12)24(18,22)23/h2-7,9-10H,8H2,1H3,(H,19,21)(H2,18,22,23)",NDDAHWYSQHTHNT-UHFFFAOYSA-N,25901,"4-chloro-N-(2-methyl-2,3-dihydro-1H-indol-1-yl)-3-sulfamoylbenzamide::Indaflex::Indapamide::Indapamide (2)::Lozol::Noranat",Carbonic anhydrase 2,Homo sapiens,
598729,C[C@H](Nc1nn(C)c(=O)c2cccnc12)[C@@H](N(C)C)c1ccc(cc1)C(O)=O,"InChI=1S/C20H23N5O3/c1-12(17(24(2)3)13-7-9-14(10-8-13)20(27)28)22-18-16-15(6-5-11-21-16)19(26)25(4)23-18/h5-12,17H,1-4H3,(H,22,23)(H,27,28)/t12-,17+/m0/s1",BFQWSEXKEXWINT-YVEFUNNKSA-N,311506,"US10155764, Example 81",Histone acetyltransferase KAT2B [719-832],, 98.0
274656,CC(Nc1ncc(cn1)C(=O)NO)c1ccncc1,"InChI=1S/C12H13N5O2/c1-8(9-2-4-13-5-3-9)16-12-14-6-10(7-15-12)11(18)17-19/h2-8,19H,1H3,(H,17,18)(H,14,15,16)",UYQRPBKIKYLDGQ-UHFFFAOYSA-N,139307,"US8614223, 85",Histone deacetylase 6,Homo sapiens, 4
51259351,CN(C\C=C\c1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(cc2)C2CC2)c1C)C(=O)C=C,"InChI=1S/C28H28FN5O2/c1-4-25(35)34(3)13-5-6-22-26(31-16-32-27(22)30)23-14-21(29)15-24(17(23)2)33-28(36)20-11-9-19(10-12-20)18-7-8-18/h4-6,9-12,14-16,18H,1,7-8,13H2,2-3H3,(H,33,36)(H2,30,31,32)/b6-5+",QGWYFFMAGYSPLU-AATRIKPKSA-N,50514635,CHEMBL4559123,Tyrosine-protein kinase BTK,Homo sapiens, 3.8
385103,Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CC[C@@H](CC1)NC(=O)\C=C\CN1CCOCC1,"InChI=1S/C31H35N7O3/c32-30-28-29(22-8-14-26(15-9-22)41-25-5-2-1-3-6-25)36-38(31(28)34-21-33-30)24-12-10-23(11-13-24)35-27(39)7-4-16-37-17-19-40-20-18-37/h1-9,14-15,21,23-24H,10-13,16-20H2,(H,35,39)(H2,32,33,34)/b7-4+/t23-,24+",QWEKIGQOBHAQDZ-WWBGYUKBSA-N,191629,"US9181263, 25::US9278100, 25",Epidermal growth factor receptor,Homo sapiens, 272.9
51127955,CCCCCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)B(O)O,"InChI=1S/C20H33BN2O4/c1-4-5-7-12-19(24)22-17(14-16-10-8-6-9-11-16)20(25)23-18(21(26)27)13-15(2)3/h6,8-11,15,17-18,26-27H,4-5,7,12-14H2,1-3H3,(H,22,24)(H,23,25)/t17-,18-/m0/s1",UESZADMGJTUSQM-ROUUACIJSA-N,50462612,CHEMBL4246480,Proteasome subunit beta type-5,Homo sapiens, 2.3
51402534,Cc1cc(no1)[C@H](C1CCOCC1)n1c2cc(ccc2c2ncc(cc12)-c1c(C)nnn1C)C(C)(C)O,"InChI=1S/C28H32N6O3/c1-16-12-22(31-37-16)27(18-8-10-36-11-9-18)34-23-14-20(28(3,4)35)6-7-21(23)25-24(34)13-19(15-29-25)26-17(2)30-32-33(26)5/h6-7,12-15,18,27,35H,8-11H2,1-5H3/t27-/m0/s1",WFFRALIRWDMZPW-MHZLTWQESA-N,50566610,CHEMBL4857742,Bromodomain-containing protein 4,, 2.8
468741,CN(C)C(=O)c1cncc(Nc2snc(C)c2C(=O)Nc2ccc(F)c(F)c2)n1,"InChI=1S/C18H16F2N6O2S/c1-9-15(16(27)22-10-4-5-11(19)12(20)6-10)17(29-25-9)24-14-8-21-7-13(23-14)18(28)26(2)3/h4-8H,1-3H3,(H,22,27)(H,23,24)",HFGYZXREESJJSR-UHFFFAOYSA-N,162206,"US9682995, 104",Dual specificity protein kinase TTK,Homo sapiens,>20000
568049,CCOc1cc(-c2ccc(nc2)N2CCN(CC2)C(=O)Cc2ccc(F)cn2)c2c(cnn2c1)C#N,"InChI=1S/C26H24FN7O2/c1-2-36-22-12-23(26-19(13-28)15-31-34(26)17-22)18-3-6-24(30-14-18)32-7-9-33(10-8-32)25(35)11-21-5-4-20(27)16-29-21/h3-6,12,14-17H,2,7-11H2,1H3",BDOMYACNYFLEKA-UHFFFAOYSA-N,296224,"US10112942, Example 31::US10137124, Example 31::US10172851, Example 31::US10555944, Example 31::US10953005, Example 31",Proto-oncogene tyrosine-protein kinase receptor Ret,Homo sapiens, 13.5
51453242,C[C@]1(CO[C@](C)(C(N)=N1)C(F)(F)F)c1nc(NC(=O)c2ncc(cc2N)C(F)(F)F)ccc1F,"InChI=1S/C19H17F7N6O2/c1-16(7-34-17(2,15(28)32-16)19(24,25)26)13-9(20)3-4-11(30-13)31-14(33)12-10(27)5-8(6-29-12)18(21,22)23/h3-6H,7,27H2,1-2H3,(H2,28,32)(H,30,31,33)/t16-,17+/m0/s1",RNLNFTQJIYFRSH-DLBZAZTESA-N,50586755,CHEMBL5070669,Beta-secretase 2,, 182
528285,CC1(C)CN(C[C@H](F)[C@@H]1Oc1ccc(cc1C#N)-c1ncnc(Nc2ccc(cc2)N2CCN(CC2)C2COC2)n1)C(=O)CO,"InChI=1S/C32H37FN8O4/c1-32(2)19-41(28(43)16-42)15-26(33)29(32)45-27-8-3-21(13-22(27)14-34)30-35-20-36-31(38-30)37-23-4-6-24(7-5-23)39-9-11-40(12-10-39)25-17-44-18-25/h3-8,13,20,25-26,29,42H,9-12,15-19H2,1-2H3,(H,35,36,37,38)/t26-,29-/m0/s1",ZWIZDCQAFLVPFU-WNJJXGMVSA-N,277956,"2-(((4R,5S)-5-fluoro-1-(2- hydroxyacetyl)-3,3- dimethylpiperidin-4- yl)oxy)-5-(4-((4-(4-(oxetan- 3-yl)piperazin-1- yl)phenyl)amino)-1,3,5- triazin-2-yl)benzonitrile::US10040781, Example 178::US10253019, Example 178",Serine/threonine-protein kinase TBK1,, 2000
346950,C(Sc1ccccc1)c1ccc(CSc2ccccc2)cc1,"InChI=1S/C20H18S2/c1-3-7-19(8-4-1)21-15-17-11-13-18(14-12-17)16-22-20-9-5-2-6-10-20/h1-14H,15-16H2",TTWDUMRLHQJUFV-UHFFFAOYSA-N,194577,"US9205085, MSX- 211",C-X-C chemokine receptor type 4,, 1000
50475301,CCCN1c2ccccc2C(=N[C@H](NC(=O)Nc2cccc(C)c2)C1=O)N1CCN(C)CC1,"InChI=1S/C25H32N6O2/c1-4-12-31-21-11-6-5-10-20(21)23(30-15-13-29(3)14-16-30)27-22(24(31)32)28-25(33)26-19-9-7-8-18(2)17-19/h5-11,17,22H,4,12-16H2,1-3H3,(H2,26,28,33)/t22-/m1/s1",HIDXDIXMVZDVNO-JOCHJYFZSA-N,50286122,"1-[(S)-5-(4-Methyl-piperazin-1-yl)-2-oxo-1-propyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-3-m-tolyl-urea::CHEMBL319180",Cholecystokinin receptor type A,Rattus, 1900
462668,CS(=O)(=O)N1CCC(CC1)Nc1n[nH]c2ccc(cc12)C(c1ccc(Cl)cc1)c1ccc(Cl)cc1,"InChI=1S/C26H26Cl2N4O2S/c1-35(33,34)32-14-12-22(13-15-32)29-26-23-16-19(6-11-24(23)30-31-26)25(17-2-7-20(27)8-3-17)18-4-9-21(28)10-5-18/h2-11,16,22,25H,12-15H2,1H3,(H2,29,30,31)",QKENPAWWACETES-UHFFFAOYSA-N,115796,"US9682940, 125",Cannabinoid receptor 1,Homo sapiens,
198673,COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CCCO)c2ccccc12,"InChI=1S/C24H24N2O6/c1-30-18-11-14(12-19(31-2)22(18)32-3)20-21(24(29)25-23(20)28)16-13-26(9-6-10-27)17-8-5-4-7-15(16)17/h4-5,7-8,11-13,27H,6,9-10H2,1-3H3,(H,25,28,29)",IFUKBECSYNPLCY-UHFFFAOYSA-N,47165,"US8957103, C1::US9364459, I",Glycogen synthase kinase-3 beta,Homo sapiens, 3386
259364,NCC=CC(=N)c1ccn2c(cnc2c1)-c1cccc(NC(=O)NCC(F)(F)F)c1,"InChI=1S/C20H19F3N6O/c21-20(22,23)12-27-19(30)28-15-4-1-3-14(9-15)17-11-26-18-10-13(6-8-29(17)18)16(25)5-2-7-24/h1-6,8-11,25H,7,12,24H2,(H2,27,28,30)",HOVGKFRLRAHOTJ-UHFFFAOYSA-N,128430,"US8796244, 9",Fibroblast growth factor receptor 3,Homo sapiens, 4
50229929,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1,"InChI=1S/C35H30N4O4/c1-35-32(42-3)25(37(2)34(41)19-11-5-4-6-12-19)17-26(43-35)38-23-15-9-7-13-20(23)28-29-22(18-36-33(29)40)27-21-14-8-10-16-24(21)39(35)31(27)30(28)38/h4-16,25-26,32H,17-18H2,1-3H3,(H,36,40)/t25-,26-,32-,35+/m1/s1",BMGQWWVMWDBQGC-IIFHNQTCSA-N,50326053,CHEMBL608533::PKC-412,Calcium/calmodulin-dependent protein kinase type II subunit gamma,,
51090329,COc1cc2nc(C)oc2c(C[C@]2(C)[C@@H](C)CC[C@]3(C)[C@H]2CCC=C3C)c1O,"InChI=1S/C24H33NO3/c1-14-8-7-9-20-23(14,4)11-10-15(2)24(20,5)13-17-21(26)19(27-6)12-18-22(17)28-16(3)25-18/h8,12,15,20,26H,7,9-11,13H2,1-6H3/t15-,20+,23-,24+/m0/s1",ATQVAIUSAHRLDF-KSVBPBMVSA-N,50446565,CHEMBL3109402,Aurora kinase B,Homo sapiens,>100000
50853671,CC(C)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC(C)(C)C#N,"InChI=1S/C25H30F3N3O3S/c1-16(2)14-21(23(32)31-24(3,4)15-29)30-22(25(26,27)28)19-8-6-17(7-9-19)18-10-12-20(13-11-18)35(5,33)34/h6-13,16,21-22,30H,14H2,1-5H3,(H,31,32)/t21-,22-/m0/s1",MQLWDLYYNYALHH-VXKWHMMOSA-N,50233035,"(S)-4-methyl-2-[(S)-2,2,2-trifluoro-1-(4'-methanesulfonyl-biphenyl-4-yl)-ethylamino]-pentanoic acid (cyano-dimethyl-methyl)-amide::CHEMBL428417",Cathepsin B,Homo sapiens,>10000
1050348,CCOc1cccnc1Oc1cncc(c1)-c1ncc(cn1)C(=O)N[C@]1(CO)CCOC1,"InChI=1S/C22H23N5O5/c1-2-31-18-4-3-6-24-21(18)32-17-8-15(9-23-12-17)19-25-10-16(11-26-19)20(29)27-22(13-28)5-7-30-14-22/h3-4,6,8-12,28H,2,5,7,13-14H2,1H3,(H,27,29)/t22-/m0/s1",DFNKRIPGDXQUEM-QFIPXVFZSA-N,276761,"(S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(3-(hydroxymethyl)tetrahydrofuran-3-yl)pyrimidine-5-carboxamide::US10071992, Example 6b::US11034678, Example 6b::US11065249, WO2018033832-Ex.-6a::WO2018033832, Ex. 6a",Diacylglycerol O-acyltransferase 2,Homo sapiens, 23.2
51160230,CN1CC[C@@]23[C@H]4Oc5c2c(C[C@@H]1[C@]3(O)Cc1c4[nH]c2[C@@H]3Oc4c6c(C[C@H]7N(C)CC[C@@]36[C@@]7(O)Cc12)ccc4O)ccc5O,"InChI=1S/C34H35N3O6/c1-36-9-7-31-23-15-3-5-19(38)27(23)42-29(31)25-17(13-33(31,40)21(36)11-15)18-14-34(41)22-12-16-4-6-20(39)28-24(16)32(34,8-10-37(22)2)30(43-28)26(18)35-25/h3-6,21-22,29-30,35,38-41H,7-14H2,1-2H3/t21-,22-,29+,30+,31+,32+,33-,34-/m1/s1",ASOVJVGZJDVADR-UCDXVGGRSA-N,50475336,CHEMBL606959,Delta-type opioid receptor,Rattus norvegicus,
482341,Cc1nc2ccccc2n2c(nnc12)-c1cc(OCC(=O)c2ccccn2)ccc1Cl,"InChI=1S/C23H16ClN5O2/c1-14-22-27-28-23(29(22)20-8-3-2-6-18(20)26-14)16-12-15(9-10-17(16)24)31-13-21(30)19-7-4-5-11-25-19/h2-12H,13H2,1H3",AJCFLJFPXFEKEH-UHFFFAOYSA-N,204695,"2-[4-chloro-3-(4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-1-yl)-phenoxy]-1-pyridin-2-yl-ethanone::US9540379, 93","cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A",Homo sapiens,>1000
90480,CC(C)Nc1ncnc2n(ncc12)-c1ccc(Cl)cc1,"InChI=1S/C14H14ClN5/c1-9(2)19-13-12-7-18-20(14(12)17-8-16-13)11-5-3-10(15)4-6-11/h3-9H,1-2H3,(H,16,17,19)",DJYPPKXJBSHHDF-UHFFFAOYSA-N,48165,"1-(4-chlorophenyl)-N-propan-2-yl-4-pyrazolo[3,4-d]pyrimidinamine::1-(4-chlorophenyl)-N-propan-2-yl-pyrazolo[3,4-d]pyrimidin-4-amine::1-(4-chlorophenyl)-N-propan-2-ylpyrazolo[3,4-d]pyrimidin-4-amine::MLS000100781::SMR000017466::[1-(4-chlorophenyl)pyrazolo[3,4-d]pyrimidin-4-yl]-isopropyl-amine::cid_866407",Matrix metalloproteinase-14 [1-36],Homo sapiens,
50627808,COC(=O)CC(NCC1CN=C(c2ccccc2F)c2ccccc2N1C)c1ccccc1,"InChI=1S/C27H28FN3O2/c1-31-20(17-29-24(16-26(32)33-2)19-10-4-3-5-11-19)18-30-27(21-12-6-8-14-23(21)28)22-13-7-9-15-25(22)31/h3-15,20,24,29H,16-18H2,1-2H3",COAZJQLEWBNTGL-UHFFFAOYSA-N,50013191,"3-{[5-(2-Fluoro-phenyl)-1-methyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-2-ylmethyl]-amino}-3-phenyl-propionic acid methyl ester::CHEMBL141629",Delta-type opioid receptor/Kappa-type opioid receptor/Mu-type opioid receptor/Sigma non-opioid intracellular receptor 1,Rattus, 18
51030325,CC(C)N1CCN(CC1)C(=S)SCCOc1ccc2c(C)cc(=O)oc2c1,"InChI=1S/C20H26N2O3S2/c1-14(2)21-6-8-22(9-7-21)20(26)27-11-10-24-16-4-5-17-15(3)12-19(23)25-18(17)13-16/h4-5,12-14H,6-11H2,1-3H3",AYCMSQHGVRSOEG-UHFFFAOYSA-N,50295322,CHEMBL4167973,Acetylcholinesterase,Homo sapiens, 1990
50420751,CC(C)(C)c1ccc(CS(=O)(=O)CC(=O)N=c2scc(CC(O)=O)n2O)cc1,"InChI=1S/C18H22N2O6S2/c1-18(2,3)13-6-4-12(5-7-13)10-28(25,26)11-15(21)19-17-20(24)14(9-27-17)8-16(22)23/h4-7,9,24H,8,10-11H2,1-3H3,(H,22,23)",POIZOEYDEHXVML-UHFFFAOYSA-N,50251959,"2-(2-(2-(4-tert-butylbenzylsulfonyl)acetamido)-3-hydroxy-2,3-dihydrothiazol-4-yl)acetic acid::CHEMBL520935",Egl nine homolog 1,Homo sapiens, 3
50220032,COc1ccc(C[C@H](NC(C)=O)[C@H](O)CN[C@H]2CC3(CCC3)Oc3ncc(CC(C)(C)C)cc23)cc1OC,"InChI=1S/C30H43N3O5/c1-19(34)33-23(13-20-8-9-26(36-5)27(14-20)37-6)25(35)18-31-24-16-30(10-7-11-30)38-28-22(24)12-21(17-32-28)15-29(2,3)4/h8-9,12,14,17,23-25,31,35H,7,10-11,13,15-16,18H2,1-6H3,(H,33,34)/t23-,24-,25+/m0/s1",UVODFPUSJFFSKE-CCDWMCETSA-N,50397684,CHEMBL2181885,Beta-secretase 1,Homo sapiens, 18
355704,CCC(CC)(Cc1ccc(s1)C(=O)Oc1ccc(cc1F)C(N)=N)C(=O)N[C@@H](Cc1nn[nH]n1)C(O)=O,,,199976,"US9227949, 86",Serine protease 1,Homo sapiens,
51258255,OCC1OC2(CCN(CCc3ccccc3)CC2)CN(C1=O)c1ccccc1,"InChI=1S/C23H28N2O3/c26-17-21-22(27)25(20-9-5-2-6-10-20)18-23(28-21)12-15-24(16-13-23)14-11-19-7-3-1-4-8-19/h1-10,21,26H,11-18H2",QGQRUYNHBMRUGE-UHFFFAOYSA-N,50514266,CHEMBL4459117,Mu-type opioid receptor,Homo sapiens,
1002713,OC(=O)c1ccn(n1)C(=O)N1C[C@@H]2C[C@H](C[C@@H]2C1)OCc1ccccc1Cl,"InChI=1S/C19H20ClN3O4/c20-16-4-2-1-3-12(16)11-27-15-7-13-9-22(10-14(13)8-15)19(26)23-6-5-17(21-23)18(24)25/h1-6,13-15H,7-11H2,(H,24,25)/t13-,14+,15+",LFQHZMFSAFLVBM-FICVDOATSA-N,483642,"US10927105, Ex 15",Monoglyceride lipase,Homo sapiens, 550
50765691,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1,"InChI=1S/C21H31N5O2/c27-18-16-21(6-1-2-7-21)17-19(28)26(18)11-4-3-10-24-12-14-25(15-13-24)20-22-8-5-9-23-20/h5,8-9H,1-4,6-7,10-17H2",QWCRAEMEVRGPNT-UHFFFAOYSA-N,50001859,"(buspirone) 8-[4-(4-Pyrimidin-2-yl-piperazin-1-yl)-butyl]-8-aza-spiro[4.5]decane-7,9-dione::8-[4-(4-Pyrimidin-2-yl-piperazin-1-yl)-butyl]-8-aza-spiro[4.5]decane-7,9-dione : (Hydrochloride)::8-[4-(4-Pyrimidin-2-yl-piperazin-1-yl)-butyl]-8-aza-spiro[4.5]decane-7,9-dione; Hydrochloride(Buspirone)::8-[4-(4-pyrimidin-2-yl-piperazin-1-yl)-butyl]-8-aza-spiro[4.5]decane-7,9-dione::BUSPAR::BUSPIRONE::CHEMBL49::US10562853, Compound Buspirone",5-hydroxytryptamine receptor 1A,Rattus norvegicus,
75925,COc1ccc(CN2CCN(CC2)c2ccccc2F)c(OC)c1,"InChI=1S/C19H23FN2O2/c1-23-16-8-7-15(19(13-16)24-2)14-21-9-11-22(12-10-21)18-6-4-3-5-17(18)20/h3-8,13H,9-12,14H2,1-2H3",FTXHIWXQEQZCKC-UHFFFAOYSA-N,31037,"1-(2,4-dimethoxybenzyl)-4-(2-fluorophenyl)piperazine::1-[(2,4-dimethoxyphenyl)methyl]-4-(2-fluorophenyl)piperazine::MLS000105278::SMR000102159::cid_2173523",Sphingosine 1-phosphate receptor 3,Homo sapiens,
1187122,CNS(=O)(=O)N1CCC(CC1)Nc1ncc2ccc(=O)n(C3CCCC3)c2n1,"InChI=1S/C18H26N6O3S/c1-19-28(26,27)23-10-8-14(9-11-23)21-18-20-12-13-6-7-16(25)24(17(13)22-18)15-4-2-3-5-15/h6-7,12,14-15,19H,2-5,8-11H2,1H3,(H,20,21,22)",CGZPQEKNAAVWHA-UHFFFAOYSA-N,370122,"US10233188, Example 11::US10800783, Example 11::US11396512, Example 11",Cyclin-dependent kinase 2/G1/S-specific cyclin-E1,Homo sapiens,
617667,COc1cccc(n1)-c1nc(N[C@H](C)C2CC2)nc(N[C@H](C)C2CC2)n1,"InChI=1S/C19H26N6O/c1-11(13-7-8-13)20-18-23-17(15-5-4-6-16(22-15)26-3)24-19(25-18)21-12(2)14-9-10-14/h4-6,11-14H,7-10H2,1-3H3,(H2,20,21,23,24,25)/t11-,12-/m1/s1",WYXMPHFGDDGKSR-VXGBXAGGSA-N,280141,"US10028961, Compound 294::US10172864, Compound 294::US10946023, Compound 294",Isocitrate dehydrogenase [NADP] cytoplasmic [R132H],, 550
51062722,CC(C)n1ncnc1-c1nc-2c(CCOc3cc(ccc-23)-c2cnn(CC(C)(C)O)c2)s1,"InChI=1S/C23H26N6O2S/c1-14(2)29-21(24-13-26-29)22-27-20-17-6-5-15(9-18(17)31-8-7-19(20)32-22)16-10-25-28(11-16)12-23(3,4)30/h5-6,9-11,13-14,30H,7-8,12H2,1-4H3",XJCBJODXECFWKL-UHFFFAOYSA-N,50433535,CHEMBL2381374,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",Homo sapiens, 47
356868,Cc1c(NC(=O)c2ccc(cc2)C2CC2)cc(F)cc1-c1ncnc2[nH]c(cc12)C1=CCN(CC1)C(=O)N1CCCC1,"InChI=1S/C33H33FN6O2/c1-20-26(16-25(34)17-28(20)38-32(41)24-8-6-22(7-9-24)21-4-5-21)30-27-18-29(37-31(27)36-19-35-30)23-10-14-40(15-11-23)33(42)39-12-2-3-13-39/h6-10,16-19,21H,2-5,11-15H2,1H3,(H,38,41)(H,35,36,37)",UZQDYTBAPMZXKM-UHFFFAOYSA-N,200816,"US9233111, 30",Tyrosine-protein kinase BTK,Homo sapiens, 6
977083,N[C@H]1CCCN(C1)c1c(NC(=O)c2nc(c(F)cc2N)-c2c(F)cccc2F)cnc2NCCCc12,"InChI=1S/C25H26F3N7O/c26-15-6-1-7-16(27)20(15)21-17(28)10-18(30)22(34-21)25(36)33-19-11-32-24-14(5-2-8-31-24)23(19)35-9-3-4-13(29)12-35/h1,6-7,10-11,13H,2-5,8-9,12,29-30H2,(H,31,32)(H,33,36)/t13-/m0/s1",KCVZUSUTNUFEER-ZDUSSCGKSA-N,377182,"3-Amino-N-{4-[(3S)-3-aminopiperidin-1-yl]-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide::US10265307, Example 32::US10517858, Example 32::US10828290, Example 32::US11229631, Example 32",Serine/threonine-protein kinase pim-3,Homo sapiens,<100
50763914,CCOP(O)(=O)CCC(NC(=O)c1ccc(NCc2cnc3nc(N)[nH]c(=O)c3c2)cc1)C(O)=O,"InChI=1S/C21H25N6O7P/c1-2-34-35(32,33)8-7-16(20(30)31)25-18(28)13-3-5-14(6-4-13)23-10-12-9-15-17(24-11-12)26-21(22)27-19(15)29/h3-6,9,11,16,23H,2,7-8,10H2,1H3,(H,25,28)(H,30,31)(H,32,33)(H3,22,24,26,27,29)",FBRKPFQSNPGVGM-UHFFFAOYSA-N,50005866,"2-{4-[(2-Amino-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-6-ylmethyl)-amino]-benzoylamino}-4-(ethoxy-hydroxy-phosphoryl)-butyric acid::CHEMBL294973",Thymidylate synthase,Homo sapiens, 100000
50554037,CO[P@@]1(=O)CC[C@H]2COC(=O)C2=C(C)O1,"InChI=1S/C9H13O5P/c1-6-8-7(5-13-9(8)10)3-4-15(11,12-2)14-6/h7H,3-5H2,1-2H3/t7-,15-/m0/s1",JBANMOPKOHITOL-ZIDLFYJRSA-N,50308513,"(3R,8aR)-3-Methoxy-5-methyl-3-oxo-8,8a-dihydro-1H-3lambda*5*-furo[3,4-e][1,3,2]dioxaphosphepin-6-one::CHEMBL590031",Acetylcholinesterase,Homo sapiens, 30000
50437618,CN(Cc1ccccc1)C(=O)c1ccc(s1)C(=O)C(F)(F)F,"InChI=1S/C15H12F3NO2S/c1-19(9-10-5-3-2-4-6-10)14(21)12-8-7-11(22-12)13(20)15(16,17)18/h2-8H,9H2,1H3",CEBFXUYKCDHZEP-UHFFFAOYSA-N,25157,"CHEMBL462209::N-benzyl-N-methyl-5-(2,2,2-trifluoroacetyl)thiophene-2-carboxamide::thiophene derivative, 3c",Histone deacetylase 3,Homo sapiens, 560
50524383,C[C@@H](NC(=O)c1nn(c2c1CN(C\C2=C/c1ccc(F)cc1)C(=O)c1nc[nH]n1)-c1ccc(Cl)cc1Cl)c1ccccc1,"InChI=1S/C31H24Cl2FN7O2/c1-18(20-5-3-2-4-6-20)37-30(42)27-24-16-40(31(43)29-35-17-36-38-29)15-21(13-19-7-10-23(34)11-8-19)28(24)41(39-27)26-12-9-22(32)14-25(26)33/h2-14,17-18H,15-16H2,1H3,(H,37,42)(H,35,36,38)/b21-13+/t18-/m1/s1",MBEMYKYSBQQXMT-KOMLCTQHSA-N,50198735,CHEMBL3960011,Cannabinoid receptor 2,Homo sapiens,
1074466,FC1(F)CCC(CC1)NC(=O)C(N(C(=O)CCl)c1cccc2n(ccc12)C1CC1)c1cncnc1,"InChI=1S/C25H26ClF2N5O2/c26-12-22(34)33(21-3-1-2-20-19(21)8-11-32(20)18-4-5-18)23(16-13-29-15-30-14-16)24(35)31-17-6-9-25(27,28)10-7-17/h1-3,8,11,13-15,17-18,23H,4-7,9-10,12H2,(H,31,35)",PVKXIGIDEVPQHN-UHFFFAOYSA-N,512649,"WO2021219089, INSCoV-557A",Replicase polyprotein 1ab,,>25000
51065594,CC(C)COc1nc(ccc1CNC(=O)C(C)c1ccc(NS(C)(=O)=O)c(F)c1)C(F)(F)F,"InChI=1S/C21H25F4N3O4S/c1-12(2)11-32-20-15(6-8-18(27-20)21(23,24)25)10-26-19(29)13(3)14-5-7-17(16(22)9-14)28-33(4,30)31/h5-9,12-13,28H,10-11H2,1-4H3,(H,26,29)",YYYUBLPWJUJOSR-UHFFFAOYSA-N,50434932,CHEMBL2385408,Transient receptor potential cation channel subfamily V member 1,Homo sapiens, 68
50625051,CC[C@H]1COCC[C@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1CCN(CC1)c1cccc(c1)C(F)(F)F,"InChI=1S/C27H40F3N3O2/c1-4-20-18-35-15-9-24(20)31-22-8-10-26(17-22,19(2)3)25(34)33-13-11-32(12-14-33)23-7-5-6-21(16-23)27(28,29)30/h5-7,16,19-20,22,24,31H,4,8-15,17-18H2,1-3H3/t20-,22+,24+,26-/m0/s1",DNPRHSLKGYTIJX-RXDHMRHRSA-N,50337609,"CHEMBL1683064::cis-((1S,3R)-3-(3-ethyl-tetrahydro-2H-pyran-4-ylamino)-1-isopropylcyclopentyl)(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)methanone",C-C chemokine receptor type 5,, 312
992426,CCN1[C@H]2Cc3n(nc4cc(ccc34)C(=O)NCCN(C)C)[C@H]2[C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12,"InChI=1S/C32H31Cl2FN6O2/c1-4-40-26-16-25-19-10-8-17(30(42)36-12-13-39(2)3)14-23(19)38-41(25)29(26)27(20-6-5-7-22(34)28(20)35)32(40)21-11-9-18(33)15-24(21)37-31(32)43/h5-11,14-15,26-27,29H,4,12-13,16H2,1-3H3,(H,36,42)(H,37,43)/t26-,27-,29+,32+/m0/s1",GUZFCPUHQQRKAS-MRFOFCOLSA-N,454391,"US10717742, Example Ia-51::US10882866, Example Ia-51",E3 ubiquitin-protein ligase Mdm2 [23-117],, 7.00
50277333,N[C@@H](C1CC[C@@H](CC1)NS(=O)(=O)c1ccc(NS(=O)(=O)CC(F)(F)F)cc1)C(=O)N1CCCC1,"InChI=1S/C20H29F3N4O5S2/c21-20(22,23)13-33(29,30)25-15-7-9-17(10-8-15)34(31,32)26-16-5-3-14(4-6-16)18(24)19(28)27-11-1-2-12-27/h7-10,14,16,18,25-26H,1-6,11-13,24H2/t14?,16-,18-/m0/s1",ADSYCQHXJJBMGD-CMTKHDEESA-N,50137266,"CHEMBL140577::N-[4-((S)-1-Amino-2-oxo-2-pyrrolidin-1-yl-ethyl)-cyclohexyl]-4-(2,2,2-trifluoro-ethanesulfonylamino)-benzenesulfonamide::N-[4-(1-Amino-2-oxo-2-pyrrolidin-1-yl-ethyl)-cyclohexyl]-4-(2,2,2-trifluoro-ethanesulfonylamino)-benzenesulfonamide",Dipeptidyl peptidase 4,Homo sapiens, 2.6
51425671,COc1cccc(c1)-c1oc(CCC(O)=O)nc1-c1ccccc1,"InChI=1S/C19H17NO4/c1-23-15-9-5-8-14(12-15)19-18(13-6-3-2-4-7-13)20-16(24-19)10-11-17(21)22/h2-9,12H,10-11H2,1H3,(H,21,22)",JLLYLYAWTGEXCF-UHFFFAOYSA-N,50575857,CHEMBL4864263,Retinoic acid receptor RXR-beta,Homo sapiens,
50642757,CC(C)(C)C(=O)Nc1ccc(cc1)S(N)(=O)=O,"InChI=1S/C11H16N2O3S/c1-11(2,3)10(14)13-8-4-6-9(7-5-8)17(12,15)16/h4-7H,1-3H3,(H,13,14)(H2,12,15,16)",KGBTVIQRHXYTRQ-UHFFFAOYSA-N,16649,"2,2-dimethyl-N-(4-sulfamoylphenyl)propanamide::4-Pivaloylamido-benzenesulfonamide::CHEMBL23285::aromatic sulfonamide compound 14",Carbonic anhydrase 1,Homo sapiens,
50085536,CN1CCN2[C@H]3CCN(CCCC(=O)c4ccncc4)C[C@H]3c3cccc1c23,"InChI=1S/C23H28N4O/c1-25-14-15-27-20-9-13-26(12-3-6-22(28)17-7-10-24-11-8-17)16-19(20)18-4-2-5-21(25)23(18)27/h2,4-5,7-8,10-11,19-20H,3,6,9,12-16H2,1H3/t19-,20-/m0/s1",GCOQAARUFVDXHC-PMACEKPBSA-N,50007678,CHEMBL3233407,D(2) dopamine receptor,Rattus norvegicus,
629598,CC(c1ccc(C(F)F)c(F)c1)n1nc(CF)c2c1nc([nH]c2=O)N(C)C,,,320791,"(R)- or (S)-1-(1-(4-(Difluoromethyl)-3- fluorophenyl)ethyl)-6-(dimethylamino)-3- (fluoromethyl)-1H-pyrazolo[3,4- d]pyrimidin-4(5H)-one::US10174037, Example 196::US10174037, Example 197","cGMP-dependent 3',5'-cyclic phosphodiesterase",,
51040361,OC(=O)\C=C\C(O)=O,"InChI=1S/C4H4O4/c5-3(6)1-2-4(7)8/h1-2H,(H,5,6)(H,7,8)/b2-1+",VZCYOOQTPOCHFL-OWOJBTEDSA-N,26122,"(2E)-but-2-enedioic acid::FUMARIC ACID::Fumarate::fumarate, 10",Egl nine homolog 1,Homo sapiens,
50643282,O=C(NCc1ccccc1)c1cccnc1OC1CC2CCC1C2,"InChI=1S/C20H22N2O2/c23-19(22-13-14-5-2-1-3-6-14)17-7-4-10-21-20(17)24-18-12-15-8-9-16(18)11-15/h1-7,10,15-16,18H,8-9,11-13H2,(H,22,23)",YRADNWKOQRRDFI-UHFFFAOYSA-N,50228862,CHEMBL171141,"cAMP-specific 3',5'-cyclic phosphodiesterase 4C",, 220
87329,CCOC(=O)c1ccc(cc1)-n1sc2ccccc2c1=O,"InChI=1S/C16H13NO3S/c1-2-20-16(19)11-7-9-12(10-8-11)17-15(18)13-5-3-4-6-14(13)21-17/h3-10H,2H2,1H3",YICDSLBAVQXFOF-UHFFFAOYSA-N,46038,"4-(3-keto-1,2-benzothiazol-2-yl)benzoic acid ethyl ester::4-(3-oxo-1,2-benzothiazol-2-yl)benzoic acid ethyl ester::MLS-0315808.0001::cid_2467794::ethyl 4-(3-oxidanylidene-1,2-benzothiazol-2-yl)benzoate::ethyl 4-(3-oxo-1,2-benzothiazol-2-yl)benzoate",Mannose-6-phosphate isomerase,Homo sapiens, 23600
50391617,ONC(=O)\C=C\c1ccc2CN(Cc3ccc(cc3)-c3ccncc3)C(=O)c2c1,"InChI=1S/C23H19N3O3/c27-22(25-29)8-4-16-1-7-20-15-26(23(28)21(20)13-16)14-17-2-5-18(6-3-17)19-9-11-24-12-10-19/h1-13,29H,14-15H2,(H,25,27)/b8-4+",IFRRSKDLVRTGSJ-XBXARRHUSA-N,50216516,3-(2-(4-(pyridin-4-yl)benzyl)-3-oxoisoindolin-5-yl)-N-hydroxyacrylamide::CHEMBL246199,Histone deacetylase 4,Homo sapiens, 2100
50423057,CSc1ccccc1CN([C@H]1CCNC1)S(C)(=O)=O,"InChI=1S/C13H20N2O2S2/c1-18-13-6-4-3-5-11(13)10-15(19(2,16)17)12-7-8-14-9-12/h3-6,12,14H,7-10H2,1-2H3/t12-/m0/s1",BUJVJHVEEOZSIE-LBPRGKRZSA-N,50262682,CHEMBL477572::N-(2-Methylsulfanyl-benzyl)-N-(S)-pyrrolidin-3-yl-methanesulfonamide,Sodium-dependent dopamine transporter,Homo sapiens,
1116761,COCc1nnc(NS(=O)(=O)[C@@H](C)[C@H](C)c2cnc(C)cn2)n1-c1c(OC)ncnc1OC,"InChI=1S/C19H26N8O5S/c1-11-7-21-14(8-20-11)12(2)13(3)33(28,29)26-19-25-24-15(9-30-4)27(19)16-17(31-5)22-10-23-18(16)32-6/h7-8,10,12-13H,9H2,1-6H3,(H,25,26)/t12-,13-/m0/s1",YFWNWWXQUBQHPV-STQMWFEESA-N,528366,"US11191762, Example 9.0",Apelin receptor,Homo sapiens,
51125443,CCCCCCOc1c2CN(C(=O)c2c(OCCCCCC)c2ccccc12)c1ccc(CC(O)=O)cc1,"InChI=1S/C32H39NO5/c1-3-5-7-11-19-37-30-25-13-9-10-14-26(25)31(38-20-12-8-6-4-2)29-27(30)22-33(32(29)36)24-17-15-23(16-18-24)21-28(34)35/h9-10,13-18H,3-8,11-12,19-22H2,1-2H3,(H,34,35)",DKAJTTJQVGYKHG-UHFFFAOYSA-N,50461456,CHEMBL4228095,Prostaglandin E2 receptor EP4 subtype,Homo sapiens,
50402775,CC(C)[C@H](NC(=O)CCN(C)C)c1cc(C)ccc1N1CCN(CC1)C(=O)[C@H](C)Cc1ccc(Cl)cc1,"InChI=1S/C30H43ClN4O2/c1-21(2)29(32-28(36)13-14-33(5)6)26-19-22(3)7-12-27(26)34-15-17-35(18-16-34)30(37)23(4)20-24-8-10-25(31)11-9-24/h7-12,19,21,23,29H,13-18,20H2,1-6H3,(H,32,36)/t23-,29+/m1/s1",FRHBHVROLQSPMW-BTYSJIOQSA-N,50224181,1-{2-[(1S)-(3-dimethylaminopropionyl)amino-2-methylpropyl]-4-methylphenyl}-4-[(2R)-methyl-3-(4-chlorophenyl)propionyl]piperazine::CHEMBL427860::N-((S)-1-(2-(4-((R)-3-(4-chlorophenyl)-2-methylpropanoyl)piperazin-1-yl)-5-methylphenyl)-2-methylpropyl)-3-(dimethylamino)propanamide,Cytochrome P450 2C9,Homo sapiens,>10000
50525501,OC[C@@]12C[C@@H]1[C@H]([C@H](O)[C@@H]2O)n1cnc2c(NC(C3CC3)C3CC3)nc(Cl)nc12,"InChI=1S/C19H24ClN5O3/c20-18-23-16(22-11(8-1-2-8)9-3-4-9)12-17(24-18)25(7-21-12)13-10-5-19(10,6-26)15(28)14(13)27/h7-11,13-15,26-28H,1-6H2,(H,22,23,24)/t10-,13-,14+,15+,19+/m1/s1",HOGXFHNYQVRCAK-DRYZDSLUSA-N,50199464,CHEMBL3923870,Adenosine receptor A1,Homo sapiens,
1033647,ClCC(=O)N1CC2CC1CN2Cc1cccc(Cl)c1,"InChI=1S/C14H16Cl2N2O/c15-6-14(19)18-9-12-5-13(18)8-17(12)7-10-2-1-3-11(16)4-10/h1-4,12-13H,5-9H2",VSKDLORAYNFUSV-UHFFFAOYSA-N,496766,DAN-LON-a5fc619e-8,Replicase polyprotein 1ab,, 2170
1104992,Cc1ncc2nc3COP(S)(=O)O[C@@H]4[C@@H](F)[C@@H](COP(S)(=O)OCCn3c2n1)O[C@H]4n1cnc2c1nc(N)[nH]c2=O,,,523187,"US11161864, Example 11D",Stimulator of interferon genes protein [154-378],,<1000
50328983,COc1cc(OC2CCN(C)CC2)ccc1Nc1nccc(n1)-c1c[nH]c2cnccc12,"InChI=1S/C24H26N6O2/c1-30-11-7-16(8-12-30)32-17-3-4-21(23(13-17)31-2)29-24-26-10-6-20(28-24)19-14-27-22-15-25-9-5-18(19)22/h3-6,9-10,13-16,27H,7-8,11-12H2,1-2H3,(H,26,28,29)",FTZQWKAIKYEWPM-UHFFFAOYSA-N,50081173,CHEMBL3421972,Dual specificity protein kinase TTK,Homo sapiens, 20
51064023,Clc1ccc2[nH]c(=O)ccc2c1,"InChI=1S/C9H6ClNO/c10-7-2-3-8-6(5-7)1-4-9(12)11-8/h1-5H,(H,11,12)",OJEBWFGRUPIVSD-UHFFFAOYSA-N,50197522,CHEMBL3929492,Coagulation factor XI,Homo sapiens, 140000
748102,CS(=N)(=O)c1ccc(Nc2ncnc(n2)-c2ccc(O[C@H]3CCN(CC3(F)F)C=O)c(c2)C#N)cc1,"InChI=1S/C23H21F2N7O3S/c1-36(27,34)18-5-3-17(4-6-18)30-22-29-13-28-21(31-22)15-2-7-19(16(10-15)11-26)35-20-8-9-32(14-33)12-23(20,24)25/h2-7,10,13-14,20,27H,8-9,12H2,1H3,(H,28,29,30,31)/t20-,36?/m0/s1",VBVBCPLRKQJABM-PIPNLDLUSA-N,278260,"2-(((S)-3,3-difluoro-1-formylpiperidin-4-yl)oxy)-5-(4-((4-(S-methylsulfonimidoyl)phenyl)amino)-1,3,5-triazin-2-yl)benzonitrile::US10040781, Example 482::US10253019, Example 482",Tyrosine-protein kinase JAK2,Homo sapiens, 221
51400312,CC1CCCc2sc(NC(=S)Nc3ccccc3)c(C(N)=O)c12,"InChI=1S/C17H19N3OS2/c1-10-6-5-9-12-13(10)14(15(18)21)16(23-12)20-17(22)19-11-7-3-2-4-8-11/h2-4,7-8,10H,5-6,9H2,1H3,(H2,18,21)(H2,19,20,22)",XEWOCORPFIZSQN-UHFFFAOYSA-N,50565662,CHEMBL4777482,C-X-C chemokine receptor type 4,,>10000
51230631,NS(=O)(=O)c1cc(C(=O)NCCO)c(cc1Br)[S+]([O-])c1ccccc1,"InChI=1S/C15H15BrN2O5S2/c16-12-9-13(24(21)10-4-2-1-3-5-10)11(15(20)18-6-7-19)8-14(12)25(17,22)23/h1-5,8-9,19H,6-7H2,(H,18,20)(H2,17,22,23)",WMAKPMGOFNHAFL-UHFFFAOYSA-N,50504908,CHEMBL4566236,Carbonic anhydrase 14,Homo sapiens,
50966804,Fc1ccccc1\C=C1/Sc2ccc(cc2NC1=O)C(=O)NCCN1CCCC1,"InChI=1S/C22H22FN3O2S/c23-17-6-2-1-5-15(17)14-20-22(28)25-18-13-16(7-8-19(18)29-20)21(27)24-9-12-26-10-3-4-11-26/h1-2,5-8,13-14H,3-4,9-12H2,(H,24,27)(H,25,28)/b20-14-",WVZWNOATQPTBMX-ZHZULCJRSA-N,50396502,CHEMBL2170912,Glucose-6-phosphate dehydrogenase,Plasmodium falciparum, 11000
50573797,COc1ccc(Cn2c(nc3ccccc23)C2CCCN(C2)C2CCOCC2)cc1,"InChI=1S/C25H31N3O2/c1-29-22-10-8-19(9-11-22)17-28-24-7-3-2-6-23(24)26-25(28)20-5-4-14-27(18-20)21-12-15-30-16-13-21/h2-3,6-11,20-21H,4-5,12-18H2,1H3",WLXTZKAROJEVMI-UHFFFAOYSA-N,50316927,1-(4-methoxybenzyl)-2-(1-(tetrahydro-2H-pyran-4-yl)piperidin-3-yl)-1H-benzo[d]imidazole::CHEMBL1094852,Potassium voltage-gated channel subfamily H member 2,Homo sapiens,
50644887,C[C@@H]1NC(=N[C@@]1(c1ccc(F)cc1)c1ccc(F)nc1)c1ccc(=O)n(c1)C(F)F,"InChI=1S/C21H16F4N4O/c1-12-21(14-3-6-16(22)7-4-14,15-5-8-17(23)26-10-15)28-19(27-12)13-2-9-18(30)29(11-13)20(24)25/h2-12,20H,1H3,(H,27,28)/t12-,21-/m0/s1",MUTOQFPGGSSVLM-QKVFXAPYSA-N,50346228,"1-(Difluoromethyl)-5-[(4S,5S)-4-(4-fluorophenyl)-4-(6-fluoropyridin-3-yl)-5-methyl-4,5-dihydro-1H-imidazol-2-yl]pyridin-2(1H)-one::CHEMBL1784130",Potassium voltage-gated channel subfamily H member 2,Homo sapiens,>10
1092813,CCNc1nc(Nc2cc(nn2CC)C(C)(C)n2nccn2)ncc1C(F)(F)F,"InChI=1S/C17H22F3N9/c1-5-21-14-11(17(18,19)20)10-22-15(26-14)25-13-9-12(27-28(13)6-2)16(3,4)29-23-7-8-24-29/h7-10H,5-6H2,1-4H3,(H2,21,22,25,26)",BQJLGQQNMBGURT-UHFFFAOYSA-N,384402,"US10590114, No. 129::US11111235, No. 88::US9932325, Example 129::US9932325, Example 88",Leucine-rich repeat serine/threonine-protein kinase 2 [G2019S],,<30
50608950,CC(C)(C)[C@]1(O)CCN2C[C@H]3c4ccccc4CCc4cccc([C@@H]2C1)c34,"InChI=1S/C25H31NO/c1-24(2,3)25(27)13-14-26-16-21-19-9-5-4-7-17(19)11-12-18-8-6-10-20(23(18)21)22(26)15-25/h4-10,21-22,27H,11-16H2,1-3H3/t21-,22-,25-/m0/s1",ZZJYIKPMDIWRSN-HWBMXIPRSA-N,50008735,"(+)-3-(tert-butyl)-(3S,4aS,13bS)-2,3,4,4a,8,9,13b,14-octahydro-1H-benzo[4,5]cyclohepta[de]pyrido[2,1-a]isoquinolin-3-ol::(+)-butaclamol::(+/-)-3-(tert-butyl)-(3S,4aS,13bS)-2,3,4,4a,8,9,13b,14-octahydro-1H-benzo[4,5]cyclohepta[de]pyrido[2,1-a]isoquinolin-3-ol::(S)-(-)-3-(tert-butyl)-(3S,4aS,13bS)-2,3,4,4a,8,9,13b,14-octahydro-1H-benzo[6,7]cyclohepta[de]pyrido[2,1-a]isoquinolin-3-ol::3-(tert-butyl)-(3S,4aS,13bS)-2,3,4,4a,8,9,13b,14-octahydro-1H-benzo[4,5]cyclohepta[de]pyrido[2,1-a]isoquinolin-3-ol::3-(tert-butyl)-(3S,4aS,13bS)-2,3,4,4a,8,9,13b,14-octahydro-1H-benzo[4,5]cyclohepta[de]pyrido[2,1-a]isoquinolin-3-ol ((+)-butaclamol)::3-(tert-butyl)-(3S,4aS,13bS)-2,3,4,4a,8,9,13b,14-octahydro-1H-benzo[4,5]cyclohepta[de]pyrido[2,1-a]isoquinolin-3-ol((+)-butaclamol)::3-(tert-butyl)-(3S,4aS,13bS)-2,3,4,4a,8,9,13b,14-octahydro-1H-benzo[6,7]cyclohepta[de]pyrido[2,1-a]isoquinolin-3-ol(Butaclamol)::BUTACLAMOL::BUTACLAMOL, (-)::BUTACLAMOL,(+)::BUTACLAMOL,d-::CHEMBL8514::d-Butaclamol",Sodium channel protein type 1/2/3 subunit alpha,, 3600
51004805,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C,"InChI=1S/C29H35NO2/c1-5-15-29(32)16-14-26-24-12-8-20-17-22(31)11-13-23(20)27(24)25(18-28(26,29)2)19-6-9-21(10-7-19)30(3)4/h6-7,9-10,17,24-26,32H,8,11-14,16,18H2,1-4H3/t24-,25+,26-,28-,29-/m0/s1",VKHAHZOOUSRJNA-GCNJZUOMSA-N,18627,"(10S,11S,14S,15S,17R)-17-[4-(dimethylamino)phenyl]-14-hydroxy-15-methyl-14-(prop-1-yn-1-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-1,6-dien-5-one::Mifeprex::Mifepristone::RU-486::RU486 (tetramethyl-rhodamine conjugated)",Glucocorticoid receptor,,
397182,Cn1ncc(NC(=O)c2csc(n2)-c2cnc3cccnc3c2)c1[C@@H]1CC[C@@H](N)[C@H](F)CO1,"InChI=1S/C22H22FN7O2S/c1-30-20(19-5-4-14(24)13(23)10-32-19)17(9-27-30)28-21(31)18-11-33-22(29-18)12-7-16-15(26-8-12)3-2-6-25-16/h2-3,6-9,11,13-14,19H,4-5,10,24H2,1H3,(H,28,31)/t13-,14-,19+/m1/s1",KWXNSGZERGSWJP-LPMFXHHGSA-N,227446,"US9328106, 399",Serine/threonine-protein kinase pim-1,,
51352288,Cc1ccc(\C=C\c2cccc(c2)-c2nn(c(CC3CC3)c2Cc2ccc(c(F)c2)S(N)(=O)=O)-c2nc(cs2)C(O)=O)s1,"InChI=1S/C31H27FN4O4S3/c1-18-5-10-23(42-18)11-8-19-3-2-4-22(13-19)29-24(14-21-9-12-28(25(32)15-21)43(33,39)40)27(16-20-6-7-20)36(35-29)31-34-26(17-41-31)30(37)38/h2-5,8-13,15,17,20H,6-7,14,16H2,1H3,(H,37,38)(H2,33,39,40)/b11-8+",FBYATYKNYYAWRX-DHZHZOJOSA-N,50465091,CHEMBL4294999,L-lactate dehydrogenase A chain,Homo sapiens, 52
50877872,Clc1ccccc1[C@@H]1CC[C@@H](CC1)N1CCN(CC1)c1ccccn1,"InChI=1S/C21H26ClN3/c22-20-6-2-1-5-19(20)17-8-10-18(11-9-17)24-13-15-25(16-14-24)21-7-3-4-12-23-21/h1-7,12,17-18H,8-11,13-16H2/t17-,18+",QSUQNNQRYGZRHL-HDICACEKSA-N,50274944,CHEMBL458802::cis-4-[4-(2-Chlorophenyl)cyclohexyl]-1-(2-pyridinyl)piperazine,Sigma non-opioid intracellular receptor 1,Cavia porcellus,
482888,FC(F)Oc1ccccc1-n1nnnc1-c1ccccc1-c1ccccc1F,"InChI=1S/C20H13F3N4O/c21-16-10-4-3-8-14(16)13-7-1-2-9-15(13)19-24-25-26-27(19)17-11-5-6-12-18(17)28-20(22)23/h1-12,20H",SPCBWVUNUOIDHK-UHFFFAOYSA-N,205078,"US9556132, 58::process for preparing 1-[2-(difluoromethoxy)phenyl]-5-[2-(2-fluorophenyl)phenyl]-1h-1,2,3,4-tetrazole ",Intermediate conductance calcium-activated potassium channel protein 4,Homo sapiens, 1100
50925168,Cc1ccccc1NC(=O)Nc1cccc(c1)[N+]([O-])=O,"InChI=1S/C14H13N3O3/c1-10-5-2-3-8-13(10)16-14(18)15-11-6-4-7-12(9-11)17(19)20/h2-9H,1H3,(H2,15,16,18)",MSBVHIWAXMMCPU-UHFFFAOYSA-N,50379302,CHEMBL2011807,ATP-dependent RNA helicase DDX3X,Homo sapiens, 1000
810924,OC(=O)c1ccncc1Nc1nn(C2CCOCC2)c2ccc(F)cc12,"InChI=1S/C18H17FN4O3/c19-11-1-2-16-14(9-11)17(22-23(16)12-4-7-26-8-5-12)21-15-10-20-6-3-13(15)18(24)25/h1-3,6,9-10,12H,4-5,7-8H2,(H,21,22)(H,24,25)",YFWMMWXAAXINTP-UHFFFAOYSA-N,277765,"3-{[5-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazol-3-yl]amino}pyridine-4-carboxylic acid::US10040779, Example 62::US10336727, Example 62::US9617242, Example 62",Lysine-specific demethylase 4C,, 550
706368,CSc1c(-c2ccc(C)s2)c(nn1C[C@@H]1CC[C@H](COCC(O)=O)CC1)-c1ccccc1,"InChI=1S/C25H30N2O3S2/c1-17-8-13-21(32-17)23-24(20-6-4-3-5-7-20)26-27(25(23)31-2)14-18-9-11-19(12-10-18)15-30-16-22(28)29/h3-8,13,18-19H,9-12,14-16H2,1-2H3,(H,28,29)/t18-,19+",ZMROZIDRJCRQLR-KDURUIRLSA-N,357270,"2-(((1s,4s)-4-((5- (methylthio)-4-(5- methylthiophen-2-yl)-3- phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid::US10214518, Compound 111::US11098034, Compound 111",Major prion protein,Homo sapiens, 28.0
465772,OCCNC(=O)COc1nc(NCc2cccc(c2)C(F)(F)F)c2cc(ccc2n1)C(c1ccc(Cl)cc1)c1ccc(Cl)cc1,"InChI=1S/C33H27Cl2F3N4O3/c34-25-9-4-21(5-10-25)30(22-6-11-26(35)12-7-22)23-8-13-28-27(17-23)31(42-32(41-28)45-19-29(44)39-14-15-43)40-18-20-2-1-3-24(16-20)33(36,37)38/h1-13,16-17,30,43H,14-15,18-19H2,(H,39,44)(H,40,41,42)",YMRAMJXPOJXMAC-UHFFFAOYSA-N,143565,"US9682955, 40",Cannabinoid receptor 1,Homo sapiens,
50023995,CCCCN(CCCC)[C@H]1CCc2cccc(O)c2C1,"InChI=1S/C18H29NO/c1-3-5-12-19(13-6-4-2)16-11-10-15-8-7-9-18(20)17(15)14-16/h7-9,16,20H,3-6,10-14H2,1-2H3/t16-/m0/s1",SYSODJPJTHIXAV-INIZCTEOSA-N,50016775,"7-Dibutylamino-5,6,7,8-tetrahydro-naphthalen-1-ol::CHEMBL423987",5-hydroxytryptamine receptor 1A,Rattus norvegicus, 46
50884774,O=C(Oc1ccc2ccccc2c1)N1CCN2CCC1CC2,"InChI=1S/C18H20N2O2/c21-18(20-12-11-19-9-7-16(20)8-10-19)22-17-6-5-14-3-1-2-4-15(14)13-17/h1-6,13,16H,7-12H2",MQZFLDZRBIKMGM-UHFFFAOYSA-N,50296748,"CHEMBL564850::naphthalen-2-yl 1,4-diazabicyclo[3.2.2]nonane-4-carboxylate",Neuronal acetylcholine receptor subunit alpha-3,Homo sapiens, 4910
50878757,CC(C)Oc1ccccc1\C=C(/CC([O-])=O)c1nc2ccccc2s1,"InChI=1S/C20H19NO3S/c1-13(2)24-17-9-5-3-7-14(17)11-15(12-19(22)23)20-21-16-8-4-6-10-18(16)25-20/h3-11,13H,12H2,1-2H3,(H,22,23)/p-1/b15-11+",QIBUPJYJYNFVEA-RVDMUPIBSA-M,50266386,3-(benzo[d]thiazol-2-yl)-4-(2-isopropoxyphenyl)but-3-enoate,Trans-sialidase,Trypanosoma cruzi, 290000
716238,Cc1cc(C(=O)NCc2ccc(CN)cc2)c(C)n1Cc1csc(n1)-c1ccncc1,"InChI=1S/C24H25N5OS/c1-16-11-22(23(30)27-13-19-5-3-18(12-25)4-6-19)17(2)29(16)14-21-15-31-24(28-21)20-7-9-26-10-8-20/h3-11,15H,12-14,25H2,1-2H3,(H,27,30)",ROUDVONQVMIJDR-UHFFFAOYSA-N,186866,"US9670157, 32 2,5-Dimethyl-1-(2-pyridin-4-yl-thiazol-4-ylmethyl)-1H-pyrrole-3-carboxylic acid 4-aminomethyl-benzylamide::US9834513, 32",Kallikrein-1,, 10000
1198131,[O-][N+](=O)c1cc(ccc1NC[C@@H]1COCCO1)S(=O)(=O)NC(=O)c1ccc(cc1Oc1cnc2[nH]ccc2c1)N1CCC2(CC(C2)N2CCC[C@H]2c2ccccc2C2CC2)CC1,,,567671,"US11420968, Example F38",Bcl-2-like protein 1,Homo sapiens, 38.0
296936,Cc1cc(ccn1)-c1n[nH]c2ccc(cc12)C(=O)N[C@@H]1CCCN(Cc2ccncn2)C1,,,154704,"US8999957, Table 2, Compound 41",Mitogen-activated protein kinase 1,Mus musculus, 506.7
51188776,COc1cc2CC(Oc3cccc(CN4CCN(C)CC4)c3)C(=O)c2cc1OC,"InChI=1S/C23H28N2O4/c1-24-7-9-25(10-8-24)15-16-5-4-6-18(11-16)29-22-13-17-12-20(27-2)21(28-3)14-19(17)23(22)26/h4-6,11-12,14,22H,7-10,13,15H2,1-3H3",UNRGUOAZKUZHRW-UHFFFAOYSA-N,50169862,"5,6-Dimethoxy-2-[3-(4-methyl-piperazin-1-ylmethyl)-phenoxy]-indan-1-one::CHEMBL264242",Acetylcholinesterase,Rattus norvegicus, 6400
51096658,CNC(=O)c1nnc2ccc(cc2c1N[C@@H](C)C1CCOCC1)-c1ccc(OCCCN(C)C)nc1,"InChI=1S/C27H36N6O3/c1-18(19-10-14-35-15-11-19)30-25-22-16-20(6-8-23(22)31-32-26(25)27(34)28-2)21-7-9-24(29-17-21)36-13-5-12-33(3)4/h6-9,16-19H,5,10-15H2,1-4H3,(H,28,34)(H,30,31)/t18-/m0/s1",SJOFSBIUJPEXTG-SFHVURJKSA-N,50459003,CHEMBL4218854,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",Homo sapiens, 3800
51262924,Nc1ccc2n(CC(=O)c3ccc4ccccc4c3)c(=O)sc2c1,"InChI=1S/C19H14N2O2S/c20-15-7-8-16-18(10-15)24-19(23)21(16)11-17(22)14-6-5-12-3-1-2-4-13(12)9-14/h1-10H,11,20H2",SBCCWBKAQIYKKV-UHFFFAOYSA-N,50515889,CHEMBL4514325,Chromodomain Y-like protein 2,,
699322,COc1cc(OC)c(F)c(N2Cc3cnc(cc3C3(CC3)C2=O)-c2ccnc(NC(=O)C=C)c2)c1F,"InChI=1S/C26H22F2N4O4/c1-4-21(33)31-20-9-14(5-8-29-20)17-10-16-15(12-30-17)13-32(25(34)26(16)6-7-26)24-22(27)18(35-2)11-19(36-3)23(24)28/h4-5,8-12H,1,6-7,13H2,2-3H3,(H,29,31,33)",UGROMKOQSBRWOA-UHFFFAOYSA-N,291236,"N-(4-(2'-(2,6-difluoro-3,5-dimethoxyphenyl)-3'-oxo-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-[2,7]naphthyridine]-6'-yl)pyridin-2-yl)acrylamide::US10016438, Example 4::US9580423, Example 4::US9801889, Example 4",Fibroblast growth factor receptor 3,Homo sapiens, 20
51158266,CC(C)N(CCC1=C(C(C)c2ccccn2)c2ccccc2C1)C(C)C,"InChI=1S/C24H32N2/c1-17(2)26(18(3)4)15-13-21-16-20-10-6-7-11-22(20)24(21)19(5)23-12-8-9-14-25-23/h6-12,14,17-19H,13,15-16H2,1-5H3",HBRHULDGKNIFGB-UHFFFAOYSA-N,50474492,CHEMBL352375,Muscarinic acetylcholine receptor M1,,
891282,c1sc(nc1-c1cccc(c1)-c1ccccc1)-c1ccc2ccccc2c1,InChI=1S/C25H17NS/c1-2-7-18(8-3-1)21-11-6-12-22(15-21)24-17-27-25(26-24)23-14-13-19-9-4-5-10-20(19)16-23/h1-17H,RYZFPVXUVVKWOK-UHFFFAOYSA-N,393742,"US10597367, Example 32::US9969726, Example 32",Metabotropic glutamate receptor 5,Rattus norvegicus,
50426550,Nc1nccc(\C=C\c2c(nc3sccn23)-c2ccccc2)n1,"InChI=1S/C17H13N5S/c18-16-19-9-8-13(20-16)6-7-14-15(12-4-2-1-3-5-12)21-17-22(14)10-11-23-17/h1-11H,(H2,18,19,20)/b7-6+",GOJZHNWOESVAEU-VOTSOKGWSA-N,50272586,"(E/Z)-4-(2-(6-phenylimidazo[2,1-b]thiazol-5-yl)vinyl)pyrimidin-2-amine::CHEMBL497114",Vascular endothelial growth factor receptor 1,Homo sapiens, 30000
710241,COc1cccc(OC)c1-n1c(NS(=O)(=O)[C@H](C)[C@@H](OC(C)C)c2ncc(C)cn2)nnc1-c1cccnc1,"InChI=1S/C26H31N7O5S/c1-16(2)38-23(24-28-13-17(3)14-29-24)18(4)39(34,35)32-26-31-30-25(19-9-8-12-27-15-19)33(26)22-20(36-5)10-7-11-21(22)37-6/h7-16,18,23H,1-6H3,(H,31,32)/t18-,23-/m1/s1",TTWYRZCYYPCYSL-WZONZLPQSA-N,270058,"(1S,2R)-N-(4-(2,6-dimethoxyphenyl)-5-(3-pyridinyl)-4H-1,2,4-triazol-3-yl)-1-(1-methylethoxy)-1-(5-methyl-2-pyrimidinyl)-2-propanesulfonamide, (1R,2S)-N-(4-(2,6-dimethoxyphenyl)-5-(3-pyridinyl)-4H-1,2,4-triazol-3-yl)-1-(1-methylethoxy)-1-(5-methyl-2-pyrimidinyl)-2-propanesulfonamide::US10058550, Example 624.0::US10058550, Example 626.0::US10221162, Example 626.0::US9845310, Example 626.0",Apelin receptor,Homo sapiens,
733668,Cn1c(=O)n(Cc2nccs2)c2ccc(cc2c1=O)S(=O)(=O)NC1(C)CC1,"InChI=1S/C17H18N4O4S2/c1-17(5-6-17)19-27(24,25)11-3-4-13-12(9-11)15(22)20(2)16(23)21(13)10-14-18-7-8-26-14/h3-4,7-9,19H,5-6,10H2,1-2H3",FFQXXBIOWSDRGH-UHFFFAOYSA-N,371039,"US10239843, Example 146",Poly(ADP-ribose) glycohydrolase,, 671
50399415,CN1C(=O)c2ccc(OC(=O)CCc3ccc(N)nc3)cc2C1=O,"InChI=1S/C17H15N3O4/c1-20-16(22)12-5-4-11(8-13(12)17(20)23)24-15(21)7-3-10-2-6-14(18)19-9-10/h2,4-6,8-9H,3,7H2,1H3,(H2,18,19)",OSPQCZJJZMQHLM-UHFFFAOYSA-N,50322033,"2-Methylisoindole-1,3-dione-5-yl 3-(6-aminopyridin-3-yl)propionate::CHEMBL1171655",Tryptase beta-2/delta/gamma,Homo sapiens, 190
183137,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C(NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CC(N)=O)C(N)=O,"InChI=1S/C147H238N44O42S/c1-18-75(12)115(143(231)182-97(56-72(6)7)131(219)174-94(118(156)206)61-108(153)199)189-140(228)106(68-193)186-135(223)102(63-110(155)201)179-132(220)96(55-71(4)5)176-133(221)98(58-81-37-41-84(196)42-38-81)177-126(214)88(33-23-26-49-149)168-124(212)89(34-24-27-50-150)172-141(229)113(73(8)9)187-119(207)76(13)165-122(210)93(47-53-234-17)171-128(216)92(45-46-107(152)198)170-123(211)87(32-22-25-48-148)167-125(213)90(35-28-51-162-146(157)158)169-130(218)95(54-70(2)3)175-127(215)91(36-29-52-163-147(159)160)173-144(232)116(78(15)194)190-137(225)99(59-82-39-43-85(197)44-40-82)178-134(222)101(62-109(154)200)180-136(224)104(65-112(204)205)184-145(233)117(79(16)195)191-138(226)100(57-80-30-20-19-21-31-80)183-142(230)114(74(10)11)188-120(208)77(14)166-129(217)103(64-111(202)203)181-139(227)105(67-192)185-121(209)86(151)60-83-66-161-69-164-83/h19-21,30-31,37-44,66,69-79,86-106,113-117,192-197H,18,22-29,32-36,45-65,67-68,148-151H2,1-17H3,(H2,152,198)(H2,153,199)(H2,154,200)(H2,155,201)(H2,156,206)(H,161,164)(H,165,210)(H,166,217)(H,167,213)(H,168,212)(H,169,218)(H,170,211)(H,171,216)(H,172,229)(H,173,232)(H,174,219)(H,175,215)(H,176,221)(H,177,214)(H,178,222)(H,179,220)(H,180,224)(H,181,227)(H,182,231)(H,183,230)(H,184,233)(H,185,209)(H,186,223)(H,187,207)(H,188,208)(H,189,228)(H,190,225)(H,191,226)(H,202,203)(H,204,205)(H4,157,158,162)(H4,159,160,163)/t75-,76-,77-,78+,79+,86-,87-,88-,89-,90-,91-,92-,93-,94+,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,113-,114-,115-,116?,117-/m0/s1",HEOYHMUESMJFDC-CWQDQJDSSA-N,85877,VIP [D- Asn28]::VIP [D-Asn28],VIP peptides,Rattus,
277234,O=C(CC1COCCO1)N[C@H]1CC[C@H](CCN2CCC(CC2)c2coc3ccccc23)CC1,"InChI=1S/C27H38N2O4/c30-27(17-23-18-31-15-16-32-23)28-22-7-5-20(6-8-22)9-12-29-13-10-21(11-14-29)25-19-33-26-4-2-1-3-24(25)26/h1-4,19-23H,5-18H2,(H,28,30)/t20-,22-,23?",CQUFCEROSHHDTD-YEMPIKNUSA-N,141766,"US8921397, 8",D(3) dopamine receptor,,
928421,CCOCCOc1ccc(cn1)-c1cc(=O)[nH]c(n1)-c1c(F)ccc(CNC(=O)C(C)C)c1Cl,"InChI=1S/C24H26ClFN4O4/c1-4-33-9-10-34-20-8-6-15(12-27-20)18-11-19(31)30-23(29-18)21-17(26)7-5-16(22(21)25)13-28-24(32)14(2)3/h5-8,11-12,14H,4,9-10,13H2,1-3H3,(H,28,32)(H,29,30,31)",ZXMWDPUUYWCASI-UHFFFAOYSA-N,451585,"US10710967, Example 185",Prostaglandin E synthase,Homo sapiens, 52.0
50729383,CCCCCCCN1C(=O)NC(C1=O)(c1ccc(Br)cc1)c1ccc(Br)cc1,"InChI=1S/C22H24Br2N2O2/c1-2-3-4-5-6-15-26-20(27)22(25-21(26)28,16-7-11-18(23)12-8-16)17-9-13-19(24)14-10-17/h7-14H,2-6,15H2,1H3,(H,25,28)",DARDHNGWORIPGS-UHFFFAOYSA-N,50080104,"5,5-Bis-(4-bromo-phenyl)-3-heptyl-imidazolidine-2,4-dione::5,5-bis(4-bromophenyl)-3-heptylimidazolidine-2,4-dione::CHEMBL49407",Cannabinoid receptor 1,Homo sapiens,
50085841,CCC(=O)Nc1cc(OC)c(cc1Cl)C(=O)N[C@H]1CCN(Cc2ccccc2)C1,"InChI=1S/C22H26ClN3O3/c1-3-21(27)25-19-12-20(29-2)17(11-18(19)23)22(28)24-16-9-10-26(14-16)13-15-7-5-4-6-8-15/h4-8,11-12,16H,3,9-10,13-14H2,1-2H3,(H,24,28)(H,25,27)/t16-/m0/s1",APTCMKUWYITAOW-INIZCTEOSA-N,50052195,CHEMBL93198::N-((S)-1-Benzyl-pyrrolidin-3-yl)-5-chloro-2-methoxy-4-propionylamino-benzamide,D(2) dopamine receptor,Rattus norvegicus,
1147067,C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@@](O)(CF)CC[C@H]34)[C@@H]1CC[C@@H]2C(=O)Cn1nnc2cnccc12,"InChI=1S/C26H35FN4O2/c1-25-9-6-18-17-7-10-26(33,15-27)12-16(17)2-3-19(18)20(25)4-5-21(25)24(32)14-31-23-8-11-28-13-22(23)29-30-31/h8,11,13,16-21,33H,2-7,9-10,12,14-15H2,1H3/t16-,17-,18+,19+,20-,21+,25-,26+/m0/s1",FTZYVQGZJNKUFA-NMAPPNDSSA-N,540772,"US11261211, Compound SB-14",Gamma-aminobutyric acid receptor subunit alpha-1,,>500
50642832,CCCC(C)C(=O)Nc1ccc(cc1)S(N)(=O)=O,"InChI=1S/C12H18N2O3S/c1-3-4-9(2)12(15)14-10-5-7-11(8-6-10)18(13,16)17/h5-9H,3-4H2,1-2H3,(H,14,15)(H2,13,16,17)",QSFJQYWMTFBTCD-UHFFFAOYSA-N,50345210,2-methyl-N-(4-sulfamoylphenyl)pentanamide::CHEMBL1085095,Carbonic anhydrase 14,Homo sapiens,
1018336,CN([C@@H]1C[C@@H](C1)NS(=O)(=O)c1cnc(C)s1)c1ncnc2[nH]ccc12,,,159788,"US10966980, Example 38::US9035074, 38",Non-receptor tyrosine-protein kinase TYK2,Homo sapiens, 546
448064,NC(=O)CC(NC(=O)C1(N)CCN(CC1)c1ncnc2[nH]ccc12)c1ccc(Cl)cc1,,,256870,"US10654855, Example 66::US11236095, Example 66::US9492453, 66",RAC-alpha serine/threonine-protein kinase,, 6.6
738404,CC(C)Oc1ncc(cc1N1CCOCC1)-c1cc(NC(=O)c2cc(ccn2)C(C)(C)F)cnc1C,"InChI=1S/C27H32FN5O3/c1-17(2)36-26-24(33-8-10-35-11-9-33)12-19(15-31-26)22-14-21(16-30-18(22)3)32-25(34)23-13-20(6-7-29-23)27(4,5)28/h6-7,12-17H,8-11H2,1-5H3,(H,32,34)",NFDIQKBIDWDWPV-UHFFFAOYSA-N,87928,"US10245267, Example 957::US10709712, Example 957::US9694016, 957",Serine/threonine-protein kinase B-raf [V600E],, 6.23
1080633,COc1ccc(nc1)-c1nc2c(ccnc2[nH]1)-c1ccc(CN2CCOc3cc(cc(F)c3C2=O)C2CC2)c(F)c1,"InChI=1S/C31H25F2N5O3/c1-40-21-6-7-25(35-15-21)29-36-28-22(8-9-34-30(28)37-29)18-4-5-19(23(32)12-18)16-38-10-11-41-26-14-20(17-2-3-17)13-24(33)27(26)31(38)39/h4-9,12-15,17H,2-3,10-11,16H2,1H3,(H,34,36,37)",OSIUMCUMOLRQBT-UHFFFAOYSA-N,514816,"US11098041, Example 40",Tyrosine-protein kinase BTK [328-659],,<100
299114,COc1ccc(nc1-c1cccc(c1)-c1nnc(C)o1)C(=O)N[C@@H](CC(O)=O)c1ccc(C)cc1,"InChI=1S/C26H24N4O5/c1-15-7-9-17(10-8-15)21(14-23(31)32)28-25(33)20-11-12-22(34-3)24(27-20)18-5-4-6-19(13-18)26-30-29-16(2)35-26/h4-13,21H,14H2,1-3H3,(H,28,33)(H,31,32)/t21-/m0/s1",NBHBYESMGRRQLP-NRFANRHFSA-N,156817,"US9029559, 249",Lysosomal protective protein,, 8710
50463232,O[C@H]1C[C@@H](CP(O)(O)=O)C[C@](O)(C1)C(O)=O,"InChI=1S/C8H15O7P/c9-6-1-5(4-16(13,14)15)2-8(12,3-6)7(10)11/h5-6,9,12H,1-4H2,(H,10,11)(H2,13,14,15)/t5-,6+,8+/m1/s1",SWEXPEKCRDSBSH-CHKWXVPMSA-N,50028883,"(1S,3S,5R)-1,3-Dihydroxy-5-phosphonomethyl-cyclohexanecarboxylic acid::CHEMBL178075",3-dehydroquinate synthase,Escherichia coli,
621543,CN(C)S(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(cc2)C2(CC2)[N+]#[C-])c1F,"InChI=1S/C26H21F2N5O3S/c1-29-26(10-11-26)17-6-4-15(5-7-17)16-12-18-19(14-31-25(18)30-13-16)24(34)22-20(27)8-9-21(23(22)28)32-37(35,36)33(2)3/h4-9,12-14,32H,10-11H2,2-3H3,(H,30,31)",ZLMCSJGIOXHDRP-UHFFFAOYSA-N,317741,"US9624213, Compound P-0237",Serine/threonine-protein kinase B-raf [V600E],,<100.0
50327501,CNCc1csc(n1)-c1ccc(cc1)N1C[C@H](CNC(=O)c2ccc(Cl)s2)OC1=O,"InChI=1S/C20H19ClN4O3S2/c1-22-8-13-11-29-19(24-13)12-2-4-14(5-3-12)25-10-15(28-20(25)27)9-23-18(26)16-6-7-17(21)30-16/h2-7,11,15,22H,8-10H2,1H3,(H,23,26)/t15-/m0/s1",ITZHMNIHOLLIFO-HNNXBMFYSA-N,50080099,CHEMBL3415995,Coagulation factor X,Oryctolagus cuniculus, 1910
50737442,Cc1nc(Cn2cnc3c2C(=O)C=CC3=O)cs1,"InChI=1S/C12H9N3O2S/c1-7-14-8(5-18-7)4-15-6-13-11-9(16)2-3-10(17)12(11)15/h2-3,5-6H,4H2,1H3",VLDBWVXKOHLFNZ-UHFFFAOYSA-N,50112053,"1-(2-Methyl-thiazol-4-ylmethyl)-1H-benzoimidazole-4,7-dione::CHEMBL177325",Purine nucleoside phosphorylase,Homo sapiens,
441786,CNC(C)C(=O)Nc1ccc(-c2c(nc3cc(C)ccn23)-c2ccncc2)c(n1)C#Cc1ccc(cc1)-c1ccon1,"InChI=1S/C33H27N7O2/c1-21-14-18-40-30(20-21)38-31(25-12-16-35-17-13-25)32(40)26-9-11-29(37-33(41)22(2)34-3)36-28(26)10-6-23-4-7-24(8-5-23)27-15-19-42-39-27/h4-5,7-9,11-20,22,34H,1-3H3,(H,36,37,41)",FWYXNWZPJQXBSF-UHFFFAOYSA-N,253988,"US9481673, 82",Cytochrome P450 3A4,Homo sapiens, 2300
50490834,CC(C)(C)c1cc(=O)[nH]c(SCC(=O)c2ccc(cc2)S(N)(=O)=O)n1,"InChI=1S/C16H19N3O4S2/c1-16(2,3)13-8-14(21)19-15(18-13)24-9-12(20)10-4-6-11(7-5-10)25(17,22)23/h4-8H,9H2,1-3H3,(H2,17,22,23)(H,18,19,21)",OMYTZYUGUKDESE-UHFFFAOYSA-N,50380144,"CHEMBL2010994::carbonic anhydrase (CA) inhibitors, benzenesulphonamide ligand, 8",Carbonic anhydrase 9,Homo sapiens,
50834158,COc1ccc2c(CCCN3CCCCC3)cccc2c1,"InChI=1S/C19H25NO/c1-21-18-10-11-19-16(7-5-8-17(19)15-18)9-6-14-20-12-3-2-4-13-20/h5,7-8,10-11,15H,2-4,6,9,12-14H2,1H3",KUKSPSOQFDNBNK-UHFFFAOYSA-N,50179279,1-(3-(6-methoxynaphthalen-1-yl)propyl)piperidine hydrochloride::CHEMBL553091,Sigma non-opioid intracellular receptor 1,Cavia porcellus,
513944,CC(C)(C)n1c(=O)[nH]\c(=N/c2ccc(Oc3cccc(n3)C(N)=O)cc2)n(Cc2ccc(Cl)cc2)c1=O,"InChI=1S/C26H25ClN6O4/c1-26(2,3)33-24(35)31-23(32(25(33)36)15-16-7-9-17(27)10-8-16)29-18-11-13-19(14-12-18)37-21-6-4-5-20(30-21)22(28)34/h4-14H,15H2,1-3H3,(H2,28,34)(H,29,31,35)",PYPJFXASTVCJMD-UHFFFAOYSA-N,271917,"US10065941, Compound R-233::US9732060, Compound R-233",P2X purinoceptor 3,Homo sapiens, 318
50392361,Nc1ccc(Oc2cccc(c2)N(CC(O)C(F)(F)F)Cc2cccc(OC(F)(F)C(F)F)c2)cc1,"InChI=1S/C24H21F7N2O3/c25-22(26)24(30,31)36-20-6-1-3-15(11-20)13-33(14-21(34)23(27,28)29)17-4-2-5-19(12-17)35-18-9-7-16(32)8-10-18/h1-12,21-22,34H,13-14,32H2",OIJCKALHPUHDSY-UHFFFAOYSA-N,50128151,"3-((3-(1,1,2,2-tetrafluoroethoxy)benzyl)(3-(4-aminophenoxy)phenyl)amino)-1,1,1-trifluoropropan-2-ol::3-((3-(4-aminophenoxy)phenyl)(3-(1,1,2,2-tetrafluoroethoxy)benzyl)amino)-1,1,1-trifluoropropan-2-ol::3-{[3-(4-Amino-phenoxy)-phenyl]-[3-(1,1,2,2-tetrafluoro-ethoxy)-benzyl]-amino}-1,1,1-trifluoro-propan-2-ol::CHEMBL69170",Cholesteryl ester transfer protein,Homo sapiens, 700
259305,COC(=O)c1cccc(c1)-c1sc(NC(=O)c2c(F)cccc2F)cc1C,"InChI=1S/C20H15F2NO3S/c1-11-9-16(23-19(24)17-14(21)7-4-8-15(17)22)27-18(11)12-5-3-6-13(10-12)20(25)26-2/h3-10H,1-2H3,(H,23,24)",WQSDCURSTYANJT-UHFFFAOYSA-N,128391,"US8802721, 120",Interleukin-2,, 87
51154982,COc1ccc(cc1OC)-c1nnc(O)c2ccccc12,"InChI=1S/C16H14N2O3/c1-20-13-8-7-10(9-14(13)21-2)15-11-5-3-4-6-12(11)16(19)18-17-15/h3-9H,1-2H3,(H,18,19)",IIVDYPOZZPVJAU-UHFFFAOYSA-N,50473333,CHEMBL84860,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A/4B/4C/4D",, 1585
50055352,CC1=CC(C)(C)Nc2ccc3-c4cc(Cl)ccc4OC(c4ccc(F)c(C)c4)c3c12,"InChI=1S/C26H23ClFNO/c1-14-11-16(5-8-20(14)28)25-24-18(19-12-17(27)6-10-22(19)30-25)7-9-21-23(24)15(2)13-26(3,4)29-21/h5-13,25,29H,1-4H3",JSHHKDQSFNGJMA-UHFFFAOYSA-N,50062434,"9-Chloro-5-(4-fluoro-3-methyl-phenyl)-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene::CHEMBL104347",Progesterone receptor,,
459189,Cc1ccc(NC(=O)c2ccnc(c2)C(C)(C)O)cc1-c1cc(OC2CCOCC2)nc(c1)N1CCOCC1,"InChI=1S/C30H36N4O5/c1-20-4-5-23(32-29(35)21-6-9-31-26(16-21)30(2,3)36)19-25(20)22-17-27(34-10-14-38-15-11-34)33-28(18-22)39-24-7-12-37-13-8-24/h4-6,9,16-19,24,36H,7-8,10-15H2,1-3H3,(H,32,35)",BYXXBDVYEKKNKK-UHFFFAOYSA-N,88113,"US10245267, Example 1150::US10709712, Example 1150::US9694016, 1150",Serine/threonine-protein kinase B-raf [V600E],, 1.60
1083069,Cc1cccc2CN(CCc12)C(=O)c1cn(CC(=O)NC2CN(C2)C(=O)C=C)c2c(Cl)cc(Cl)cc12,"InChI=1S/C27H26Cl2N4O3/c1-3-25(35)32-12-19(13-32)30-24(34)15-33-14-22(21-9-18(28)10-23(29)26(21)33)27(36)31-8-7-20-16(2)5-4-6-17(20)11-31/h3-6,9-10,14,19H,1,7-8,11-13,15H2,2H3,(H,30,34)",FYQASLIOYJFNFY-UHFFFAOYSA-N,515984,"US11053226, Example 74","GTPase KRas [1-169,G12C,C118A]",, 170.00
50084067,Cc1c(-c2ccc(=O)n(CC(F)(F)F)c2)c2cc(F)ccc2n1CC(O)=O,"InChI=1S/C18H14F4N2O3/c1-10-17(11-2-5-15(25)23(7-11)9-18(20,21)22)13-6-12(19)3-4-14(13)24(10)8-16(26)27/h2-7H,8-9H2,1H3,(H,26,27)",SQRSFLBXXPFBHA-UHFFFAOYSA-N,50006833,CHEMBL3237236,Prostaglandin D2 receptor 2,Homo sapiens, 84
50724372,CC(C)[C@H](NCP(O)(O)=O)C(=O)N[C@@H](Cc1ccc(cc1)-c1ccccc1)C(=O)N1C[C@H](O)C[C@H]1C(O)=O,"InChI=1S/C26H34N3O8P/c1-16(2)23(27-15-38(35,36)37)24(31)28-21(25(32)29-14-20(30)13-22(29)26(33)34)12-17-8-10-19(11-9-17)18-6-4-3-5-7-18/h3-11,16,20-23,27,30H,12-15H2,1-2H3,(H,28,31)(H,33,34)(H2,35,36,37)/t20-,21+,22+,23+/m1/s1",HKDDPXBAKXLRGJ-LDVJMBRRSA-N,50283653,1-{(S)-3-Biphenyl-4-yl-2-[(S)-3-methyl-1-oxo-2-(phosphonomethyl-amino)-butylamino]-propionyl}-4-hydroxy-pyrrolidine-2-carboxylic acid::CHEMBL329372,Neprilysin,, 12
332598,CC(C)(CO)c1cc(NC(=O)c2ccc3cc4C(=O)NCCCn4c3c2)on1,"InChI=1S/C20H22N4O4/c1-20(2,11-25)16-10-17(28-23-16)22-18(26)13-5-4-12-8-15-19(27)21-6-3-7-24(15)14(12)9-13/h4-5,8-10,25H,3,6-7,11H2,1-2H3,(H,21,27)(H,22,26)",INAKAFWEISWUGV-UHFFFAOYSA-N,184327,"US9150577, 208",Ribosomal protein S6 kinase alpha-2,Homo sapiens, 96
50529399,CS(=O)(=O)c1ccc2n(nc(Oc3c(Cl)cccc3Cl)c2c1)-c1ccc(cc1)C(O)=O,"InChI=1S/C21H14Cl2N2O5S/c1-31(28,29)14-9-10-18-15(11-14)20(30-19-16(22)3-2-4-17(19)23)24-25(18)13-7-5-12(6-8-13)21(26)27/h2-11H,1H3,(H,26,27)",FVZXPOMEZHOAJF-UHFFFAOYSA-N,50203499,CHEMBL3947885,Retinoic acid receptor gamma,Homo sapiens, 4500
109531,NNc1nc(Nc2ccccc2)nc(Nc2ccccc2)n1,"InChI=1S/C15H15N7/c16-22-15-20-13(17-11-7-3-1-4-8-11)19-14(21-15)18-12-9-5-2-6-10-12/h1-10H,16H2,(H3,17,18,19,20,21,22)",LUFLTVHAAVPJCI-UHFFFAOYSA-N,57906,"(4-anilino-6-hydrazino-s-triazin-2-yl)-phenyl-amine::6-diazanyl-N2,N4-diphenyl-1,3,5-triazine-2,4-diamine::6-hydrazinyl-2-N,4-N-diphenyl-1,3,5-triazine-2,4-diamine::6-hydrazinyl-N2,N4-diphenyl-1,3,5-triazine-2,4-diamine::MLS000687381::SMR000285105::cid_253501",Streptokinase A,Streptococcus pyogenes M1 GAS,
122128,Fc1ccc(CSc2nnc(-c3ccccn3)n2Cc2cccs2)c(F)c1,"InChI=1S/C19H14F2N4S2/c20-14-7-6-13(16(21)10-14)12-27-19-24-23-18(17-5-1-2-8-22-17)25(19)11-15-4-3-9-26-15/h1-10H,11-12H2",FLFDFOZJEHKPGG-UHFFFAOYSA-N,65825,"2-[5-[(2,4-difluorobenzyl)thio]-4-(2-thenyl)-1,2,4-triazol-3-yl]pyridine::2-[5-[(2,4-difluorophenyl)methylsulfanyl]-4-(thiophen-2-ylmethyl)-1,2,4-triazol-3-yl]pyridine::2-[5-[(2,4-difluorophenyl)methylthio]-4-(thiophen-2-ylmethyl)-1,2,4-triazol-3-yl]pyridine::2-[5-[[2,4-bis(fluoranyl)phenyl]methylsulfanyl]-4-(thiophen-2-ylmethyl)-1,2,4-triazol-3-yl]pyridine::KSC-5-247E::KUC103901N::cid_44601468",Kappa-type opioid receptor,Homo sapiens,
477459,COCCOC(=O)N1C(C2=C(CCC2=O)N(C1=O)c1cccc(c1)C(F)(F)F)c1ccc(cc1)C#N,"InChI=1S/C25H20F3N3O5/c1-35-11-12-36-24(34)31-22(16-7-5-15(14-29)6-8-16)21-19(9-10-20(21)32)30(23(31)33)18-4-2-3-17(13-18)25(26,27)28/h2-8,13,22H,9-12H2,1H3",RXSNNPCNRZNENR-UHFFFAOYSA-N,211816,"US9290459, 31.2::US9670166, 31.2",Neutrophil elastase,Homo sapiens, 6.70
1013187,CC(C)C(=O)N1C2CC1CN(C2)c1ccc(cn1)-c1cc(OCC(C)(C)O)cn2ncc(C#N)c12,"InChI=1S/C26H30N6O3/c1-16(2)25(33)32-19-7-20(32)13-30(12-19)23-6-5-17(10-28-23)22-8-21(35-15-26(3,4)34)14-31-24(22)18(9-27)11-29-31/h5-6,8,10-11,14,16,19-20,34H,7,12-13,15H2,1-4H3",XGBWRVJYZBZAFX-UHFFFAOYSA-N,296621,"US10112942, Example 355::US10137124, Example 355::US10172851, Example 355::US10555944, Example 355::US10953005, Example 355","Proto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M]",, 5473
51081873,NCCN(CCNC(=O)CCC(=O)NCCOCCOCCNC(=O)NC(=N)NCCC[C@@H](NC(=O)C(c1ccccc1)c1ccccc1)C(=O)NCc1ccc(CNC(N)=O)cc1)CCNC(=O)CCC(=O)NCCOCCOCCNC(=O)NC(N)=NCCC[C@@H](NC(=O)C(c1ccccc1)c1ccccc1)C(=O)NCc1ccc(CNC(N)=O)cc1,"InChI=1S/C86H120N22O16/c87-37-46-108(47-40-92-71(109)33-35-73(111)94-42-49-121-53-55-123-51-44-98-85(119)106-81(88)96-38-13-23-69(77(113)100-57-61-25-29-63(30-26-61)59-102-83(90)117)104-79(115)75(65-15-5-1-6-16-65)66-17-7-2-8-18-66)48-41-93-72(110)34-36-74(112)95-43-50-122-54-56-124-52-45-99-86(120)107-82(89)97-39-14-24-70(78(114)101-58-62-27-31-64(32-28-62)60-103-84(91)118)105-80(116)76(67-19-9-3-10-20-67)68-21-11-4-12-22-68/h1-12,15-22,25-32,69-70,75-76H,13-14,23-24,33-60,87H2,(H,92,109)(H,93,110)(H,94,111)(H,95,112)(H,100,113)(H,101,114)(H,104,115)(H,105,116)(H3,90,102,117)(H3,91,103,118)(H4,88,96,98,106,119)(H4,89,97,99,107,120)/t69-,70-/m1/s1",IEUJAGBMWVPDJC-FAECOVEHSA-N,50442573,CHEMBL2440911,Neuropeptide Y receptor type 5,,
57440,COc1ccc(NC(=O)c2ccc(Nc3nc(Nc4ccc(O)cc4)ncc3F)cc2)cc1,"InChI=1S/C24H20FN5O3/c1-33-20-12-8-17(9-13-20)28-23(32)15-2-4-16(5-3-15)27-22-21(25)14-26-24(30-22)29-18-6-10-19(31)11-7-18/h2-14,31H,1H3,(H,28,32)(H2,26,27,29,30)",VLEHOZCAQJNQPI-UHFFFAOYSA-N,31876,"2,4-Bisanilinopyrimidine, 42",Aurora kinase A,Homo sapiens, 14
50880905,O=C(NCCc1nccs1)c1ccc2c(SSc3cccc4nc(ccc34)C(=O)NCCc3nccs3)cccc2n1,"InChI=1S/C30H24N6O2S4/c37-29(33-13-11-27-31-15-17-39-27)23-9-7-19-21(35-23)3-1-5-25(19)41-42-26-6-2-4-22-20(26)8-10-24(36-22)30(38)34-14-12-28-32-16-18-40-28/h1-10,15-18H,11-14H2,(H,33,37)(H,34,38)",ZZWWQLNFHHEYRR-UHFFFAOYSA-N,50264500,CHEMBL4103114,STAM-binding protein,,>100000
50102659,Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1,"InChI=1S/C30H23N5O/c1-30(2,18-31)22-9-11-23(12-10-22)35-28-24-15-19(21-14-20-6-4-5-7-25(20)32-16-21)8-13-26(24)33-17-27(28)34(3)29(35)36/h4-17H,1-3H3",JOGKUKXHTYWRGZ-UHFFFAOYSA-N,92862,"US9284315, BEZ-235::mTOR Inhibitor, BEZ235",Serine/threonine-protein kinase mTOR,Homo sapiens, 5.0
51275123,Cc1ccnc2N(C3CC3)c3ncccc3C(=O)Nc12,"InChI=1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20)",NQDJXKOVJZTUJA-UHFFFAOYSA-N,1434,"11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2 ,3 -e][1,4]diazepin-6-one::2-cyclopropyl-7-methyl-2,4,9,15-tetraazatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3,5,7,12,14-hexaen-10-one::BI-RG-587::CHEMBL57::Nevirapine::Nevirapine (NVP)::US11420959, Example NVP::Viramune",Reverse transcriptase,Human immunodeficiency virus 1, 181
50223676,Cc1cc(CN(c2ccc(cc2)-c2ccccc2S(N)(=O)=O)S(C)(=O)=O)n(n1)-c1cccc(c1)C(N)=N,"InChI=1S/C25H26N6O4S2/c1-17-14-22(31(29-17)21-7-5-6-19(15-21)25(26)27)16-30(36(2,32)33)20-12-10-18(11-13-20)23-8-3-4-9-24(23)37(28,34)35/h3-15H,16H2,1-2H3,(H3,26,27)(H2,28,34,35)",JXBHOVKAQIVYJP-UHFFFAOYSA-N,50123434,3-(5-{[Methanesulfonyl-(2'-sulfamoyl-biphenyl-4-yl)-amino]-methyl}-3-methyl-pyrazol-1-yl)-benzamidine::CHEMBL356416,Coagulation factor X,Homo sapiens, 500
50502413,CN1CCC(CC1)S(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2cccc(Cl)c2Cl)c1O,"InChI=1S/C19H20Cl3N3O4S/c1-25-9-7-11(8-10-25)30(28,29)18-13(21)5-6-15(17(18)26)24-19(27)23-14-4-2-3-12(20)16(14)22/h2-6,11,26H,7-10H2,1H3,(H2,23,24,27)",ITIUSBGOKOUQFX-UHFFFAOYSA-N,50182250,CHEMBL3819521,C-X-C chemokine receptor type 2,Homo sapiens, 1.6
50286794,CN([C@@H]1CCCC[C@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1,"InChI=1S/C19H26Cl2N2O/c1-22(19(24)13-14-8-9-15(20)16(21)12-14)17-6-2-3-7-18(17)23-10-4-5-11-23/h8-9,12,17-18H,2-7,10-11,13H2,1H3/t17-,18-/m1/s1",VQLPLYSROCPWFF-QZTJIDSGSA-N,50000296,"CHEMBL441765::CHEMBL482811::U-50488H::US11492374, ID 1",Kappa-type opioid receptor,Homo sapiens, 0.300000
867302,CC(C)c1c([nH]c2ccc(nc12)N1C[C@@H](C)N(C[C@@H]1C)C(=O)CCN1CCC(F)(F)C1)-c1cn2ncnc2c(C)c1C,,,428526,"US10544143, Example 962::US10730877, Example 962::US11053244, Example 962",Toll-like receptor 8,, 17.0
13449,CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](COCc1ccc(Br)cc1)NC(=O)c1c(F)cc(F)cc1F)C(N)=O,"InChI=1S/C28H34BrF3N4O6/c1-14(2)8-21(26(33)39)35-27(40)15(3)34-24(38)11-23(37)22(13-42-12-16-4-6-17(29)7-5-16)36-28(41)25-19(31)9-18(30)10-20(25)32/h4-7,9-10,14-15,21-23,37H,8,11-13H2,1-3H3,(H2,33,39)(H,34,38)(H,35,40)(H,36,41)/t15-,21-,22-,23-/m0/s1",BTVFEHHDPWMSER-OBAATPRFSA-N,7988,"(3S,4S)-5-[(4-bromophenyl)methoxy]-N-[(1S)-1-{[(1S)-1-carbamoyl-3-methylbutyl]carbamoyl}ethyl]-3-hydroxy-4-[(2,4,6-trifluorophenyl)formamido]pentanamide::CHEMBL113331::N-{(1S,2S)-1-(4-Bromobenzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethylcarbamoyl]-2-hydroxypropyl}-2,4,6-trifluorobenzamide::Statine-like inhibitor 27",Cathepsin D,Homo sapiens,
51213206,OC(=O)c1ccnc(c1)-c1cn(CCc2ccccc2)nn1,"InChI=1S/C16H14N4O2/c21-16(22)13-6-8-17-14(10-13)15-11-20(19-18-15)9-7-12-4-2-1-3-5-12/h1-6,8,10-11H,7,9H2,(H,21,22)",WJDRQPCTXDWIML-UHFFFAOYSA-N,50498689,CHEMBL3621857,Lysine-specific demethylase 5C,Homo sapiens, 7943
50895747,O[C@]1(Cc2cc(on2)-c2cn[nH]c2)CC[C@H](Cc2ccc(OC(F)(F)F)cc2)CC1,"InChI=1S/C21H22F3N3O3/c22-21(23,24)29-18-3-1-14(2-4-18)9-15-5-7-20(28,8-6-15)11-17-10-19(30-27-17)16-12-25-26-13-16/h1-4,10,12-13,15,28H,5-9,11H2,(H,25,26)/t15-,20+",ZAYUGTUDYGNQFR-GSXCWMCISA-N,50269760,CHEMBL4101281,"Glutamate receptor ionotropic, NMDA 2B",, 25
51023860,Cc1cc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)cc(NC(N)=O)c1,"InChI=1S/C27H41N3O5/c1-20-14-21(16-24(15-20)30-27(28)34)8-4-7-13-35-12-6-3-2-5-11-29-18-26(33)22-9-10-25(32)23(17-22)19-31/h9-10,14-17,26,29,31-33H,2-8,11-13,18-19H2,1H3,(H3,28,30,34)/t26-/m0/s1",DBESJEGRRAZRSW-SANMLTNESA-N,50419312,CHEMBL1835862,Beta-1 adrenergic receptor,Homo sapiens,
174280,CC(C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](N)Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](Cc1cccc2ccccc12)C(N)=O,"InChI=1S/C71H81N11O9/c1-44(2)63(71(91)81-61(39-47-23-10-5-11-24-47)67(87)77-58(64(74)84)41-50-27-18-26-49-25-12-13-28-53(49)50)82-66(86)57(31-16-17-36-72)76-70(90)62(42-51-43-75-56-30-15-14-29-54(51)56)80-69(89)60(40-48-32-34-52(83)35-33-48)79-68(88)59(38-46-21-8-4-9-22-46)78-65(85)55(73)37-45-19-6-3-7-20-45/h3-15,18-30,32-35,43-44,55,57-63,75,83H,16-17,31,36-42,72-73H2,1-2H3,(H2,74,84)(H,76,90)(H,77,87)(H,78,85)(H,79,88)(H,80,89)(H,81,91)(H,82,86)/t55-,57+,58-,59+,60+,61+,62-,63+/m1/s1",AWRMNKFDOAUSCG-OOSWLFMASA-N,84629,BIM 23056,Somatostatin receptor type 5,Rattus,
493162,COc1c(cc(Cl)c(C#N)c1C1CN(CC2CC2)C1)C(C)n1nc(C)c2c(N)ncnc12,"InChI=1S/C23H26ClN7O/c1-12-19-22(26)27-11-28-23(19)31(29-12)13(2)16-6-18(24)17(7-25)20(21(16)32-3)15-9-30(10-15)8-14-4-5-14/h6,11,13-15H,4-5,8-10H2,1-3H3,(H2,26,27,28)",DHMAUKKOJFKQKU-UHFFFAOYSA-N,261243,"US10092570, Example 266::US10376513, Example 266::US10646492, Example 266::US11433071, Example 266::US9707233, 266::US9730939, Example 266","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta/delta isoform",Homo sapiens,<10
854647,CNc1cc(Nc2cc(C)nc(c2)N2CCCC2)nc2c(cnn12)C(N)=O,"InChI=1S/C18H22N8O/c1-11-7-12(8-16(22-11)25-5-3-4-6-25)23-14-9-15(20-2)26-18(24-14)13(10-21-26)17(19)27/h7-10,20H,3-6H2,1-2H3,(H2,19,27)(H,22,23,24)",FNMUPMJVQYXXLO-UHFFFAOYSA-N,423572,"US10508120, Compound I-27::US10577373, Compound I-27::US11046698, Compound I-27",Non-receptor tyrosine-protein kinase TYK2 [556-888],,
50165383,CC(C)c1cccc(C(C)C)c1N1CCN(CCC2CCN(CC3COc4ccccc4O3)CC2)C1=O,"InChI=1S/C31H43N3O3/c1-22(2)26-8-7-9-27(23(3)4)30(26)34-19-18-33(31(34)35)17-14-24-12-15-32(16-13-24)20-25-21-36-28-10-5-6-11-29(28)37-25/h5-11,22-25H,12-21H2,1-4H3",PBTGVANSAJOWQK-UHFFFAOYSA-N,50092417,"1-{2-[1-(2,3-Dihydro-benzo[1,4]dioxin-2-ylmethyl)-piperidin-4-yl]-ethyl}-3-(2,6-diisopropyl-phenyl)-imidazolidin-2-one::CHEMBL124288",D(2) dopamine receptor,Rattus norvegicus, 480
51086626,CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)c1ccc(CN(CC)CC)o1)C(=O)N[C@@H](Cc1ccccc1)C(O)=O,"InChI=1S/C37H58N8O7/c1-7-24(6)31(35(49)43-29(36(50)51)21-25-14-11-10-12-15-25)44-33(47)28(20-23(4)5)42-32(46)27(16-13-19-40-37(38)39)41-34(48)30-18-17-26(52-30)22-45(8-2)9-3/h10-12,14-15,17-18,23-24,27-29,31H,7-9,13,16,19-22H2,1-6H3,(H,41,48)(H,42,46)(H,43,49)(H,44,47)(H,50,51)(H4,38,39,40)/t24-,27-,28-,29-,31-/m0/s1",VZVWPRUVQREUEM-LRLYEUBCSA-N,50444666,CHEMBL3098663,Cyclin-dependent kinase 4/G1/S-specific cyclin-D1,Homo sapiens, 41900
50137290,CC(=O)Nc1ccc(cc1)C#CCCCN1CCC(Cc2ccccc2)CC1,"InChI=1S/C25H30N2O/c1-21(28)26-25-13-11-22(12-14-25)8-6-3-7-17-27-18-15-24(16-19-27)20-23-9-4-2-5-10-23/h2,4-5,9-14,24H,3,7,15-20H2,1H3,(H,26,28)",SXHFOZMDNMIMRF-UHFFFAOYSA-N,50078484,CHEMBL81204::N-{4-[5-(4-Benzyl-piperidin-1-yl)-pent-1-ynyl]-phenyl}-acetamide,"Glutamate receptor ionotropic, NMDA 1/2B",Rattus, 1400
50390661,CC(C)CCN(CCC(C)C)C(=O)c1ccc2nc(Nc3ccc(cc3)C(C)=O)n(CCCNC(=O)OC(C)(C)C)c2c1,"InChI=1S/C34H49N5O4/c1-23(2)16-20-38(21-17-24(3)4)31(41)27-12-15-29-30(22-27)39(19-9-18-35-33(42)43-34(6,7)8)32(37-29)36-28-13-10-26(11-14-28)25(5)40/h10-15,22-24H,9,16-21H2,1-8H3,(H,35,42)(H,36,37)",RFFNBJUWAPQMDZ-UHFFFAOYSA-N,50215818,CHEMBL397140::tert-butyl 3-(2-(4-acetylphenylamino)-6-(diisopentylcarbamoyl)-1H-benzo[d]imidazol-1-yl)propylcarbamate,Melanocortin receptor 4,,
741383,C[C@@H]1CCCN([C@@H]1CNc1ccc(cn1)C(F)(F)F)C(=O)c1nc(C)ccc1-c1ccccn1,"InChI=1S/C25H26F3N5O/c1-16-6-5-13-33(21(16)15-31-22-11-9-18(14-30-22)25(26,27)28)24(34)23-19(10-8-17(2)32-23)20-7-3-4-12-29-20/h3-4,7-12,14,16,21H,5-6,13,15H2,1-2H3,(H,30,31)/t16-,21-/m1/s1",DLPSCLMVTPZXRV-IIBYNOLFSA-N,373455,"((2S,3R)-3-Methyl-2-(((5-(trifluoromethyl)pyridin-2-yl)amino)methyl)piperidin-1-yl)(6&#8242;-methyl-[2,3&#8242;-bipyridin]-2&#8242;-yl)methanone::US9896452, Ex. A217",Orexin/Hypocretin receptor type 1,Homo sapiens, 150
51250533,CCc1ccc(cc1-c1cccc(c1)-c1cnc2cnccn12)C(=O)Nc1ccc(cc1)C(F)(F)F,"InChI=1S/C28H21F3N4O/c1-2-18-6-7-21(27(36)34-23-10-8-22(9-11-23)28(29,30)31)15-24(18)19-4-3-5-20(14-19)25-16-33-26-17-32-12-13-35(25)26/h3-17H,2H2,1H3,(H,34,36)",KULCILVQAXSMEP-UHFFFAOYSA-N,50511480,CHEMBL4575992,Discoidin domain-containing receptor 2,Homo sapiens,>10000
51431805,CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1,"InChI=1S/C21H32Cl2N4O/c1-25(2)21(28)24-17-8-6-16(7-9-17)10-11-26-12-14-27(15-13-26)19-5-3-4-18(22)20(19)23/h3-5,16-17H,6-15H2,1-2H3,(H,24,28)/t16-,17-",KPWSJANDNDDRMB-QAQDUYKDSA-N,50443101,Cariprazine::RGH-188,5-hydroxytryptamine receptor 1A,,
450252,Cn1nccc1[C@H]1CCCC[C@@H]1Oc1cc(F)c(cc1Cl)S(=O)(=O)Nc1ccnc(=O)[nH]1,,,258245,"US9493448, 153::US9845313, Example 153",Sodium channel protein type 9 subunit alpha,,>100000
50418431,O=c1[nH]c(nc(NC2CCNCC2)c1-c1nc2ccccc2s1)N1CCOCC1,"InChI=1S/C20H24N6O2S/c27-18-16(19-23-14-3-1-2-4-15(14)29-19)17(22-13-5-7-21-8-6-13)24-20(25-18)26-9-11-28-12-10-26/h1-4,13,21H,5-12H2,(H2,22,24,25,27)",OKBLGUODEJGUAX-UHFFFAOYSA-N,203531,"US9221809, 88",Interleukin-1 receptor-associated kinase 4,Homo sapiens, 121
166663,COc1ccccc1\C=C1\SC(=S)N(CCC(=O)Nc2cccnc2)C1=O,"InChI=1S/C19H17N3O3S2/c1-25-15-7-3-2-5-13(15)11-16-18(24)22(19(26)27-16)10-8-17(23)21-14-6-4-9-20-12-14/h2-7,9,11-12H,8,10H2,1H3,(H,21,23)/b16-11+",TXSKTJXLPVVKOR-LFIBNONCSA-N,53300,"3-[(5E)-4-keto-5-o-anisylidene-2-thioxo-thiazolidin-3-yl]-N-(3-pyridyl)propionamide::3-[(5E)-5-[(2-methoxyphenyl)methylidene]-4-oxidanylidene-2-sulfanylidene-1,3-thiazolidin-3-yl]-N-pyridin-3-yl-propanamide::3-[(5E)-5-[(2-methoxyphenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]-N-pyridin-3-ylpropanamide::3-[(5E)-5-[(2-methoxyphenyl)methylidene]-4-oxo-2-sulfanylidene-3-thiazolidinyl]-N-(3-pyridinyl)propanamide::MLS001031537::SMR000664927::cid_2286451",Endoribonuclease toxin MazF,Escherichia coli str. K-12 substr. MG1655,
323775,COC(=O)c1nnc(Nc2ccccc2N2CC3(CCN(CC(C)(C)C)CC3)c3c2c(O)ccc3Cl)s1,"InChI=1S/C27H32ClN5O3S/c1-26(2,3)15-32-13-11-27(12-14-32)16-33(22-20(34)10-9-17(28)21(22)27)19-8-6-5-7-18(19)29-25-31-30-23(37-25)24(35)36-4/h5-10,34H,11-16H2,1-4H3,(H,29,31)",HBCBRIKFLXFWHF-UHFFFAOYSA-N,177977,"US9120798, 17",P2Y purinoceptor 1,, 48
51358682,Fc1cc2[nH]c3CCCc4n[nH]c(=O)c(c1)c2c34,"InChI=1S/C13H10FN3O/c14-6-4-7-11-10(5-6)15-8-2-1-3-9(12(8)11)16-17-13(7)18/h4-5,15H,1-3H2,(H,17,18)",YKIBUJVDRWECHV-UHFFFAOYSA-N,207562,"US10501467, Example 7::US9260440, 7::US9617273, Example 7",Poly [ADP-ribose] polymerase 1,, 6.0
50040175,CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12,"InChI=1S/C12H16N6O4/c1-2-14-11(21)8-6(19)7(20)12(22-8)18-4-17-5-9(13)15-3-16-10(5)18/h3-4,6-8,12,19-20H,2H2,1H3,(H,14,21)(H2,13,15,16)/t6-,7+,8-,12+/m0/s1",JADDQZYHOWSFJD-FLNNQWSLSA-N,21220,"(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-N-ethyl-3,4-dihydroxyoxolane-2-carboxamide::Adenosine analog, 3::Adenosine, N6-Ethyl-carboxamido::Adenosine-5-(N-ethylcarboxamide)::CHEMBL464859::N-Ethylcarboxamidoadenosine::NECA",Adenosine receptor A1,Rattus norvegicus,
50486833,Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1,"InChI=1S/C27H29N5O/c28-26-25-24(21-8-4-9-23(14-21)33-17-19-6-2-1-3-7-19)16-32(27(25)30-18-29-26)22-12-20(13-22)15-31-10-5-11-31/h1-4,6-9,14,16,18,20,22H,5,10-13,15,17H2,(H2,28,29,30)/t20-,22+",AECDBHGVIIRMOI-GRGXKFILSA-N,50157879,CHEMBL1614712,Mast/stem cell growth factor receptor Kit,, 6300
51403712,CN(C)c1nccc(n1)-c1cnc2ncccn12,"InChI=1S/C12H12N6/c1-17(2)12-14-6-4-9(16-12)10-8-15-11-13-5-3-7-18(10)11/h3-8H,1-2H3",UYXOVPJCCPREHU-UHFFFAOYSA-N,50567081,CHEMBL4872408,Dual specificity tyrosine-phosphorylation-regulated kinase 1A,Homo sapiens, 158
50818813,CN(C)c1cccc(CNCc2ccc3ccc(N)nc3c2)c1,"InChI=1S/C19H22N4/c1-23(2)17-5-3-4-14(10-17)12-21-13-15-6-7-16-8-9-19(20)22-18(16)11-15/h3-11,21H,12-13H2,1-2H3,(H2,20,22)",SOVIURHDFSQRNW-UHFFFAOYSA-N,50258724,CHEMBL4096369,"Nitric oxide synthase, endothelial",Bos taurus,
51067676,O=C(CN1CCN(CCCOc2ccc3c(cc(=O)oc3c2)-c2ccccc2)CC1)Nc1c2CCCCc2nc2ccccc12,"InChI=1S/C37H38N4O4/c42-35(39-37-29-11-4-6-13-32(29)38-33-14-7-5-12-30(33)37)25-41-20-18-40(19-21-41)17-8-22-44-27-15-16-28-31(26-9-2-1-3-10-26)24-36(43)45-34(28)23-27/h1-4,6,9-11,13,15-16,23-24H,5,7-8,12,14,17-22,25H2,(H,38,39,42)",LIGXGSONOCBWSR-UHFFFAOYSA-N,50435945,CHEMBL2391479,Cholinesterase,, 3160
50132891,COc1ccc(CCOc2ccc3c(c2)oc(cc3=O)N2CCOCC2)cc1,"InChI=1S/C22H23NO5/c1-25-17-4-2-16(3-5-17)8-11-27-18-6-7-19-20(24)15-22(28-21(19)14-18)23-9-12-26-13-10-23/h2-7,14-15H,8-13H2,1H3",GWRGBNRVPQOEAV-UHFFFAOYSA-N,50178112,7-(4-methoxyphenylethoxy)-2-morpholin-4-yl-chromen-4-one::CHEMBL197108,DNA-dependent protein kinase catalytic subunit,Homo sapiens, 3100
50945681,CCCCCCCCCCc1c(C)c(CCCCCCCCCC)c2CCCC[n+]2c1C,"InChI=1S/C31H56N/c1-5-7-9-11-13-15-17-19-23-29-27(3)30(24-20-18-16-14-12-10-8-6-2)31-25-21-22-26-32(31)28(29)4/h5-26H2,1-4H3/q+1",MNUFBGVKCOWOIH-UHFFFAOYSA-N,50351148,CHEMBL1817913::CHEMBL2057818,C-C chemokine receptor type 5,, 15200
212519,COC(=O)c1ccc2nc(cn2c1)-c1cccc(N)c1,"InChI=1S/C15H13N3O2/c1-20-15(19)11-5-6-14-17-13(9-18(14)8-11)10-3-2-4-12(16)7-10/h2-9H,16H2,1H3",NPXMRZXPVGXVFP-UHFFFAOYSA-N,97222,"2-(3-aminophenyl)-6-imidazo[1,2-a]pyridinecarboxylic acid methyl ester::2-(3-aminophenyl)imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester::MLS000696517::SMR000336620::cid_3845864::methyl 2-(3-aminophenyl)imidazo[1,2-a]pyridine-6-carboxylate",Nuclear receptor subfamily 0 group B member 1,Homo sapiens,>833.59
557792,NC[C@H]1CCCCN1C(=O)c1cc(ncc1Cl)-c1cnn2ccc(nc12)-c1ccccc1,"InChI=1S/C24H23ClN6O/c25-20-15-27-22(12-18(20)24(32)30-10-5-4-8-17(30)13-26)19-14-28-31-11-9-21(29-23(19)31)16-6-2-1-3-7-16/h1-3,6-7,9,11-12,14-15,17H,4-5,8,10,13,26H2/t17-/m1/s1",JJDCMRWUAYERPG-QGZVFWFLSA-N,292481,"(R)-(2-(aminomethyl)piperidin-1-yl)(5-chloro-2-(5-phenylpyrazolo[1,5-a]pyrimidin-3-yl)pyridin-4-yl)methanone::US10100058, Example 137",Calcium/calmodulin-dependent protein kinase type II subunit delta,, 1.82
51080455,CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2ccc(cc2)S(C)(=O)=O)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O,"InChI=1S/C33H33BrN4O6S/c1-20(35-2)31(39)36-27-19-38(32(40)21-9-13-24(14-10-21)45(4,42)43)29-8-6-5-7-28(29)37(33(27)41)18-26-25-15-12-23(34)17-22(25)11-16-30(26)44-3/h5-17,20,27,35H,18-19H2,1-4H3,(H,36,39)/t20-,27-/m0/s1",ODNRMXZHMWXBTG-DCFHFQCYSA-N,50441832,"CHEMBL2436205::US10053431, 90d",E3 ubiquitin-protein ligase XIAP,, 25700
1194155,CNc1ccc(-c2cc(NC)n3ncc(C(=O)N[C@@H]4CC[C@H]4OC)c3n2)n2ccnc12,"InChI=1S/C21H24N8O2/c1-22-14-4-6-16(28-9-8-24-20(14)28)15-10-18(23-2)29-19(26-15)12(11-25-29)21(30)27-13-5-7-17(13)31-3/h4,6,8-11,13,17,22-23H,5,7H2,1-3H3,(H,27,30)/t13-,17-/m1/s1",ADDCOWJHSHCQCP-CXAGYDPISA-N,565922,"US11414431, Compound I-490",Non-receptor tyrosine-protein kinase TYK2 [556-888],,
50613706,COc1cc2CCCO[C@@H](CCCCCC(=O)NO)C(=O)Nc3ccccc3OCc(c2)c1,"InChI=1S/C25H32N2O6/c1-31-20-15-18-8-7-13-32-23(11-3-2-4-12-24(28)27-30)25(29)26-21-9-5-6-10-22(21)33-17-19(14-18)16-20/h5-6,9-10,14-16,23,30H,2-4,7-8,11-13,17H2,1H3,(H,26,29)(H,27,28)/t23-/m0/s1",HIEFOIISQBSAEQ-QHCPKHFHSA-N,50333093,"(S)-6-(19-Methoxy-11-oxo-3,13-dioxa-10-azatricyclo[15.3.1.04,9]henicosa-1(21),4(9),5,7,17,19-hexaen-12-yl)hexanoic acid hydroxyamide::CHEMBL1631917",Histone deacetylase 3,Homo sapiens, 94
332131,C[C@@H]1CN([C@H](Cc2cccc(c2)-n2nccn2)CO1)C(=O)c1ccccc1-n1nccn1,"InChI=1S/C23H23N7O2/c1-17-15-28(23(31)21-7-2-3-8-22(21)30-26-11-12-27-30)20(16-32-17)14-18-5-4-6-19(13-18)29-24-9-10-25-29/h2-13,17,20H,14-16H2,1H3/t17-,20-/m1/s1",QWFXFQGJPGRBQR-YLJYHZDGSA-N,184062,"US9150566, 100",Orexin receptor type 2,Homo sapiens, 289
519521,Cc1nc(c(-c2ccc3nc(NC(=O)c4ccnc(F)c4)cn3n2)n1C1CCN(CCCF)CC1)-c1ccc(F)cc1,"InChI=1S/C30H29F3N8O/c1-19-35-28(20-3-5-22(32)6-4-20)29(41(19)23-10-15-39(16-11-23)14-2-12-31)24-7-8-27-36-26(18-40(27)38-24)37-30(42)21-9-13-34-25(33)17-21/h3-9,13,17-18,23H,2,10-12,14-16H2,1H3,(H,37,42)",UWFIHPBPGRXLEZ-UHFFFAOYSA-N,274568,"2-fluoro-N-(6-(4-(4-fluorophenyl)-1-(1-(3-fluoropropyl)piperidin-4-yl)-2-methyl-1H-imidazol-5-yl)imidazo[1,2-b]pyridazin-2-yl)isonicotinamide::US9556179, Compound 140",Casein kinase I isoform delta,, 2.29
50032983,Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2c(Br)cccc2c1C[C@@]35O,"InChI=1S/C26H25BrN2O3/c27-17-3-1-2-15-16-11-26(31)19-10-14-6-7-18(30)23-20(14)25(26,8-9-29(19)12-13-4-5-13)24(32-23)22(16)28-21(15)17/h1-3,6-7,13,19,24,28,30-31H,4-5,8-12H2/t19?,24-,25-,26+/m0/s1",KXQMACNKPIFADJ-VCCHHJRHSA-N,50013623,"9-bromo-22-cyclopropylmethyl-(2S,13R)-14-oxa-11,22-diazaheptacyclo[13.9.1.01,13.02,21.04,12.05,10.019,25]pentacosa-4(12),5(10),6,8,15(25),16,18-heptaene-2,16-diol",Mu-type opioid receptor,Cavia cutleri,
50978667,Cc1nc(N)nc(n1)-c1cccnc1Nc1cnc(Cl)c(NS(=O)(=O)c2ccc(F)cc2)c1,"InChI=1S/C20H16ClFN8O2S/c1-11-26-19(29-20(23)27-11)15-3-2-8-24-18(15)28-13-9-16(17(21)25-10-13)30-33(31,32)14-6-4-12(22)5-7-14/h2-10,30H,1H3,(H,24,28)(H2,23,26,27,29)",MUNMOKXVNKEMSH-UHFFFAOYSA-N,50401270,"CHEMBL2206912::US8772480, 264","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",Homo sapiens,
51302620,COc1cc(Cl)cc(c1)-c1nn(cc1-c1ccncc1)-c1cccc(NC(=O)Nc2cccc(c2)C(F)(F)F)c1,"InChI=1S/C29H21ClF3N5O2/c1-40-25-13-19(12-21(30)15-25)27-26(18-8-10-34-11-9-18)17-38(37-27)24-7-3-6-23(16-24)36-28(39)35-22-5-2-4-20(14-22)29(31,32)33/h2-17H,1H3,(H2,35,36,39)",DUJZSUKPBRZVOV-UHFFFAOYSA-N,50530157,CHEMBL4468905,Serine/threonine-protein kinase B-raf,Homo sapiens, 475
50853677,CC(C)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC(C)(C)C#N,"InChI=1S/C25H30F3N3O3S/c1-16(2)14-21(23(32)31-24(3,4)15-29)30-22(25(26,27)28)19-8-6-17(7-9-19)18-10-12-20(13-11-18)35(5,33)34/h6-13,16,21-22,30H,14H2,1-5H3,(H,31,32)/t21-,22-/m0/s1",MQLWDLYYNYALHH-VXKWHMMOSA-N,50233035,"(S)-4-methyl-2-[(S)-2,2,2-trifluoro-1-(4'-methanesulfonyl-biphenyl-4-yl)-ethylamino]-pentanoic acid (cyano-dimethyl-methyl)-amide::CHEMBL428417",Cathepsin K,Homo sapiens, 4
50821329,CN(C)C(=O)C1CN(C)CC[C@@H]1c1ccc(Cl)cc1,"InChI=1S/C15H21ClN2O/c1-17(2)15(19)14-10-18(3)9-8-13(14)11-4-6-12(16)7-5-11/h4-7,13-14H,8-10H2,1-3H3/t13-,14?/m1/s1",DMWLTIQYONJIPM-KWCCSABGSA-N,50147836,(S)-4-(4-Chloro-phenyl)-1-methyl-piperidine-3-carboxylic acid dimethylamide::CHEMBL102861,Sodium-dependent dopamine transporter,Rattus norvegicus,
51273363,CCOc1cccc2cc(-c3ccc(OC)c(OC)c3)c(=O)oc12,"InChI=1S/C19H18O5/c1-4-23-16-7-5-6-13-10-14(19(20)24-18(13)16)12-8-9-15(21-2)17(11-12)22-3/h5-11H,4H2,1-3H3",BSBXLVLZEWGUGJ-UHFFFAOYSA-N,50519749,CHEMBL4552685,Adenosine receptor A3,Homo sapiens,
347237,Fc1cc(OCCCN2CCN(CC2)c2cccc3sccc23)cc2CCC(=O)Nc12,"InChI=1S/C24H26FN3O2S/c25-20-16-18(15-17-5-6-23(29)26-24(17)20)30-13-2-8-27-9-11-28(12-10-27)21-3-1-4-22-19(21)7-14-31-22/h1,3-4,7,14-16H,2,5-6,8-13H2,(H,26,29)",VGMMKAWLAFTFHD-UHFFFAOYSA-N,194767,"US9206167, 116",5-hydroxytryptamine receptor 2A,Rattus norvegicus,
50572264,COc1cc2ncc3c(N)nc(cc3c2cc1OC)-c1cncc(OC[C@H](N)CC(C)C)c1,"InChI=1S/C25H29N5O3/c1-14(2)5-16(26)13-33-17-6-15(10-28-11-17)21-7-18-19-8-23(31-3)24(32-4)9-22(19)29-12-20(18)25(27)30-21/h6-12,14,16H,5,13,26H2,1-4H3,(H2,27,30)/t16-/m1/s1",YPVWKNICBVIRFI-MRXNPFEDSA-N,50316348,"2-(5-{[(2R)-2-Amino-4-methylpentyl]oxy}pyridin-3-yl)-8,9-dimethoxybenzo[c]-2,7-naphthyridin-4-amine::CHEMBL1094637",RAC-alpha serine/threonine-protein kinase,, 1395
50375273,O=C(Nc1ccc2nc(-c3ccccc3)c(nc2c1)-c1ccccc1)N1CCCC(C1)C(=O)N1CCCCC1,"InChI=1S/C32H33N5O2/c38-31(36-18-8-3-9-19-36)25-15-10-20-37(22-25)32(39)33-26-16-17-27-28(21-26)35-30(24-13-6-2-7-14-24)29(34-27)23-11-4-1-5-12-23/h1-2,4-7,11-14,16-17,21,25H,3,8-10,15,18-20,22H2,(H,33,39)",LNCQHPBMIVTJJH-UHFFFAOYSA-N,50205435,"CHEMBL389107::N-(2,3-diphenylquinoxalin-6-yl)-3-(piperidine-1-carbonyl)piperidine-1-carboxamide",Dual specificity protein phosphatase 22,Homo sapiens,>40000
573761,Clc1ccc(cc1)C(CNC(=O)c1cc(ccc1Cl)C#N)N1CCOCC1,"InChI=1S/C20H19Cl2N3O2/c21-16-4-2-15(3-5-16)19(25-7-9-27-10-8-25)13-24-20(26)17-11-14(12-23)1-6-18(17)22/h1-6,11,19H,7-10,13H2,(H,24,26)",JLJUTXSVZMZSOR-UHFFFAOYSA-N,242067,"US9415055, (+)2-chloro-N-[2-(4-chlorophenyl)-2-morpholino-ethyl]-5-cyano-benzamide::US9593105, 69",P2X purinoceptor 7,, 23
50516253,Cc1ccc2C(N=O)C(=O)N(Cc3cc(F)cc4COCOc34)c2c1,"InChI=1S/C18H15FN2O4/c1-10-2-3-14-15(4-10)21(18(22)16(14)20-23)7-11-5-13(19)6-12-8-24-9-25-17(11)12/h2-6,16H,7-9H2,1H3",CEFHLBGJHWUOBZ-UHFFFAOYSA-N,50297455,"1-((6-fluoro-4H-benzo[d][1,3]dioxin-8-yl)methyl)-3-(hydroxyimino)-6-methylindolin-2-one::CHEMBL551140",Mitogen-activated protein kinase 14,Homo sapiens,
126309,CC(C)(C)c1ccc(Oc2ccc(N)cc2)cc1,"InChI=1S/C16H19NO/c1-16(2,3)12-4-8-14(9-5-12)18-15-10-6-13(17)7-11-15/h4-11H,17H2,1-3H3",FHOZTGQNSUZCIN-UHFFFAOYSA-N,68082,4-(4-tert-butylphenoxy)aniline::MLS000686543::SMR000268191::[4-(4-tert-butylphenoxy)phenyl]amine::cid_82498,DNA damage-inducible transcript 3 protein,Mus musculus, 6900
489518,CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)CS(C)(=O)=O)c2cc(ccc2N(Cc2c(OC)ccc3c(Br)cccc23)C1=O)C#N,"InChI=1S/C29H30BrN5O6S/c1-17(32-2)28(37)33-23-15-34(27(36)16-42(4,39)40)25-12-18(13-31)8-10-24(25)35(29(23)38)14-21-19-6-5-7-22(30)20(19)9-11-26(21)41-3/h5-12,17,23,32H,14-16H2,1-4H3,(H,33,37)/t17-,23-/m0/s1",WEPCTAAUSDCYCZ-SBUREZEXSA-N,242675,"(S)-N-((S)-1-((5-bromo-2- methoxynaphthalen-1-yl)methyl)-7- cyano-5-(2-(methylsulfonyl)acetyl)-2- oxo-2,3,4,5-tetrahydro-1H- benzo[b][1,4]diazepin-3-yl)-2- (methylamino)propanamide hydrochloride::US10053431, 160",E3 ubiquitin-protein ligase XIAP [241-356],,>54800
50676283,Cn1nnc2c(ncn2c1=O)C(=O)NOS(N)(=O)=O,"InChI=1S/C6H7N7O5S/c1-12-6(15)13-2-8-3(4(13)9-11-12)5(14)10-18-19(7,16)17/h2H,1H3,(H,10,14)(H2,7,16,17)",UJNHBHKVLXJTPG-UHFFFAOYSA-N,50226856,CHEMBL4091278,Carbonic anhydrase 2,Homo sapiens,
50509192,Nc1nc(cc(n1)-c1ccco1)C(=O)NCc1ccccc1Cl,"InChI=1S/C16H13ClN4O2/c17-11-5-2-1-4-10(11)9-19-15(22)13-8-12(20-16(18)21-13)14-6-3-7-23-14/h1-8H,9H2,(H,19,22)(H2,18,20,21)",ZVWNHOGZGKJOCZ-UHFFFAOYSA-N,50294505,2-amino-N-(2-chlorobenzyl)-6-(furan-2-yl)pyrimidine-4-carboxamide::CHEMBL560904,Adenosine receptor A2a,Homo sapiens,
697506,CC[C@@H]1N(C[C@@H]2CC[C@H](OC2)C(F)(F)F)Cc2cc(cnc12)C(=O)N[C@@H](CO)c1ccc(cn1)S(=O)(=O)CC,"InChI=1S/C26H33F3N4O5S/c1-3-22-24-18(13-33(22)12-16-5-8-23(38-15-16)26(27,28)29)9-17(10-31-24)25(35)32-21(14-34)20-7-6-19(11-30-20)39(36,37)4-2/h6-7,9-11,16,21-23,34H,3-5,8,12-15H2,1-2H3,(H,32,35)/t16-,21-,22-,23-/m0/s1",ACAKRMFKIXEPKR-KKPKCPPISA-N,351604,"US9796710, Compound 6",Nuclear receptor ROR-gamma,,
1106697,CC(C)C(Cn1ccc2cnc(Nc3cnn(CC(=O)OCCO)c3)nc12)C(C)C,"InChI=1S/C21H30N6O3/c1-14(2)18(15(3)4)12-26-6-5-16-9-22-21(25-20(16)26)24-17-10-23-27(11-17)13-19(29)30-8-7-28/h5-6,9-11,14-15,18,28H,7-8,12-13H2,1-4H3,(H,22,24,25)",BHVQTTAUOBLHMV-UHFFFAOYSA-N,523977,"2-hydroxyethyl 2-(4-((7- (2-isopropyl-3- methylbutyl)-7H- pyrrolo[2,3-d]pyrimidin- 2-yl)amino)-1H-pyrazol- 1-yl)acetate::US11136329, Compound 88",Tyrosine-protein kinase JAK3,Homo sapiens,<100
51391813,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F,"InChI=1S/C19H22F3N5O2S/c1-10-14(11-6-7-24-13(9-11)18(2,3)19(20,21)22)30-16(25-10)26-17(29)27-8-4-5-12(27)15(23)28/h6-7,9,12H,4-5,8H2,1-3H3,(H2,23,28)(H,25,26,29)/t12-/m0/s1",STUWGJZDJHPWGZ-LBPRGKRZSA-N,50436459,CHEMBL2396661,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",Homo sapiens, 18
51185835,CCc1nc(Cl)c([nH]1)C1C(C(=O)OCC(C)C)=C(C)NC(C)=C1C(=O)OCC(C)C,"InChI=1S/C22H32ClN3O4/c1-8-15-25-19(20(23)26-15)18-16(21(27)29-9-11(2)3)13(6)24-14(7)17(18)22(28)30-10-12(4)5/h11-12,18,24H,8-10H2,1-7H3,(H,25,26)",LJILYATXUDXMDR-UHFFFAOYSA-N,50487602,CHEMBL2261185,Voltage-dependent L-type calcium channel subunit alpha-1C,, 2.6
18879,NS(=O)(=O)c1ccc(CCO)cc1,"InChI=1S/C8H11NO3S/c9-13(11,12)8-3-1-7(2-4-8)5-6-10/h1-4,10H,5-6H2,(H2,9,11,12)",RYKHXKKLCRPAJP-UHFFFAOYSA-N,10877,4-(2-hydroxyethyl)benzene-1-sulfonamide::CHEMBL6784::JMC522226 Compound 21::JMC523116 Compound 21::aromatic/heteroaromatic sulfonamide 22,"Carbonic anhydrase 5A, mitochondrial",Homo sapiens,
50712109,C(Cc1ccccc1)N1CCCCC1,"InChI=1S/C13H19N/c1-3-7-13(8-4-1)9-12-14-10-5-2-6-11-14/h1,3-4,7-8H,2,5-6,9-12H2",DBDVAKGHPZJLTH-UHFFFAOYSA-N,50109389,1-Phenethyl-piperidine::1-phenethylpiperidine::CHEMBL75228::N-(2-phenylethyl)piperidine::N-phenethylpiperidine,Amine oxidase [flavin-containing] A,, 757300
50324988,COC(=O)C1C2CCC(CC1c1ccc(cc1)-c1nccs1)N2C,"InChI=1S/C19H22N2O2S/c1-21-14-7-8-16(21)17(19(22)23-2)15(11-14)12-3-5-13(6-4-12)18-20-9-10-24-18/h3-6,9-10,14-17H,7-8,11H2,1-2H3",XUJAZHYZOMZFOS-UHFFFAOYSA-N,50175647,CHEMBL382943::methyl 8-methyl-3-(4-(thiazol-2-yl)phenyl)-8-aza-bicyclo[3.2.1]octane-2-carboxylate,Sodium-dependent dopamine transporter,Rattus norvegicus,
506687,CCNC(=O)c1noc(c1-c1ccc(CN2CCN(C)CC2)cc1)-c1cc(CC)c(O)cc1O,"InChI=1S/C26H32N4O4/c1-4-18-14-20(22(32)15-21(18)31)25-23(24(28-34-25)26(33)27-5-2)19-8-6-17(7-9-19)16-30-12-10-29(3)11-13-30/h6-9,14-15,31-32H,4-5,10-13,16H2,1-3H3,(H,27,33)",NAIOWGXKMUYTEJ-UHFFFAOYSA-N,265161,"US10413550, Example 57::US11234987, Example 57::US9718793, 57",Heat shock protein HSP 90-alpha,Homo sapiens,<10000
50253298,OC(=O)c1ccc(cc1)S(=O)(=O)N(Cc1ccc(cc1)C(F)(F)F)c1ncc(Cl)cc1Cl,"InChI=1S/C20H13Cl2F3N2O4S/c21-15-9-17(22)18(26-10-15)27(11-12-1-5-14(6-2-12)20(23,24)25)32(30,31)16-7-3-13(4-8-16)19(28)29/h1-10H,11H2,(H,28,29)",CMSUMMIXTLRWFY-UHFFFAOYSA-N,50036554,CHEMBL3353609,Transient receptor potential cation channel subfamily M member 8,, 11
50529098,C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N,"InChI=1S/C16H20N6O/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20)/t11-,13+/m1/s1",UJLAWZDWDVHWOW-YPMHNXCESA-N,50193995,"3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile::3-(4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile::3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile::CHEMBL221959::CP-690550::TOFACITINIB CITRATE::Tofacitinib::Tofacitinib citrate (1)::US10112907, Example 00035::US10399979, Compound Tofacitinib::US10766894, Compound TABLE 1.20::US10875847, Compound Tofacitinib::US11078206, Example Tofacitinib::US11203595, TABLE 1.20::US11339167, Example Tofacitinib",Tyrosine-protein kinase JAK3,Mus musculus, 156
50277308,CN(CCOc1ccc(Cc2sc(=O)[nH]c2O)cc1)c1ccccn1,"InChI=1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,22H,10-12H2,1H3,(H,20,23)",FLDPBMANMDLQTH-UHFFFAOYSA-N,28681,"5-[(4-{2-[methyl(pyridin-2-yl)amino]ethoxy}phenyl)methyl]-1,3-thiazolidine-2,4-dione::Avandia::BRL 49653::Brl-49653::CHEMBL121::ROSIGLITAZONE MALEATE::[3H]rosiglitazone::cid_5281055::rosiglitazone",Peroxisome proliferator-activated receptor gamma,Homo sapiens,
50075765,CCCc1nc(c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1)C(C)(C)O,"InChI=1S/C29H30N6O6/c1-5-8-23-30-25(29(3,4)38)24(27(36)39-16-22-17(2)40-28(37)41-22)35(23)15-18-11-13-19(14-12-18)20-9-6-7-10-21(20)26-31-33-34-32-26/h6-7,9-14,38H,5,8,15-16H2,1-4H3,(H,31,32,33,34)",UQGKUQLKSCSZGY-UHFFFAOYSA-N,50442892,Benicar::CS-866::OLMESARTAN MEDOXOMIL,Solute carrier organic anion transporter family member 1B3,, 977
665476,CC(C)S(=O)(=O)c1ncccc1-c1ccc(c(F)c1)-c1cnc(N)cn1,"InChI=1S/C18H17FN4O2S/c1-11(2)26(24,25)18-13(4-3-7-21-18)12-5-6-14(15(19)8-12)16-9-23-17(20)10-22-16/h3-11H,1-2H3,(H2,20,23)",AUZBYTWULTYYKP-UHFFFAOYSA-N,168994,"US9079866, 395::US9745328, Compound 395::US9884878, Compound 395",Flap endonuclease 1,Homo sapiens,
285913,NC(=O)c1cn(nc1Nc1ccc(F)cc1)C1CC[C@@H](C[C@@H]1C#N)OC(=O)NC1CCCCC1,"InChI=1S/C24H29FN6O3/c25-16-6-8-18(9-7-16)28-23-20(22(27)32)14-31(30-23)21-11-10-19(12-15(21)13-26)34-24(33)29-17-4-2-1-3-5-17/h6-9,14-15,17,19,21H,1-5,10-12H2,(H2,27,32)(H,28,30)(H,29,33)/t15-,19+,21?/m1/s1",JRXLXONTPFENPI-GAKLZJQJSA-N,147979,"US8962608, 34-2",Tyrosine-protein kinase JAK2,Homo sapiens, 164
50357559,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1CCN(C[C@@H]1F)c1ccc(cn1)C#N,"InChI=1S/C15H23N5O5/c1-2-4-24-5-3-9-18-13(16)10-14(19-9)20(7-17-10)15-12(23)11(22)8(6-21)25-15/h7-8,11-12,15,21-23H,2-6H2,1H3,(H2,16,18,19)/t8-,11+,12+,15?/m1/s1",QZIQXTJSJONATN-ZCUDWAKFSA-N,50095952,CHEMBL3593777,Potassium voltage-gated channel subfamily H member 2,Homo sapiens,>100000
844379,COc1cccc2[nH]c(cc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C[C@@H]1CCNC1=O)C(=O)CO,"InChI=1S/C24H32N4O6/c1-13(2)9-18(23(32)27-17(20(30)12-29)10-14-7-8-25-22(14)31)28-24(33)19-11-15-16(26-19)5-4-6-21(15)34-3/h4-6,11,13-14,17-18,26,29H,7-10,12H2,1-3H3,(H,25,31)(H,27,32)(H,28,33)/t14-,17-,18-/m0/s1",QDIMHKWNHMVDJB-WBAXXEDZSA-N,420298,"PF-00835231::PF-0835231::US11524940, Compound 741::WO2005113580-Ex-02::WO2021205298, Compound 1::cmdc.202100576, 6b",Replicase polyprotein 1ab,,
51202343,Cl.CCN1CCN(CC1)c1nc(C)nc2n(CC3CCOCC3)c(nc12)-c1ccccc1Cl,"InChI=1S/C24H31ClN6O/c1-3-29-10-12-30(13-11-29)23-21-24(27-17(2)26-23)31(16-18-8-14-32-15-9-18)22(28-21)19-6-4-5-7-20(19)25/h4-7,18H,3,8-16H2,1-2H3",PGBKYWIIHKALFL-UHFFFAOYSA-N,50494513,CHEMBL3092900,Cannabinoid receptor 2,,
50132761,CCCCCCC\C=C\CCCCCCCC[C@@H]1OC[C@@H](COP(O)([O-])=S)O1,"InChI=1S/C21H41O5PS/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21-24-18-20(26-21)19-25-27(22,23)28/h8-9,20-21H,2-7,10-19H2,1H3,(H2,22,23,28)/p-1/b9-8+/t20-,21+/m0/s1",GPCDCYBCUTWZFV-FIKIWUFISA-M,50177333,"CHEMBL200003::potassium O-((2R,4S)-2-(heptadec-9-enyl)-1,3-dioxolan-4-yl)methyl O-hydrogenphosphorothioate",Ectonucleotide pyrophosphatase/phosphodiesterase family member 2,, 363
340379,CC(C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCNCC1)C(=O)NCc1c(C)cc(C)[nH]c1=O,"InChI=1S/C30H36N6O2/c1-18(2)36-17-20(4)28-24(29(37)33-16-25-19(3)12-21(5)34-30(25)38)13-23(14-26(28)36)22-6-7-27(32-15-22)35-10-8-31-9-11-35/h6-7,12-15,17-18,31H,8-11,16H2,1-5H3,(H,33,37)(H,34,38)",OCWAKUTWRJNZGR-UHFFFAOYSA-N,190197,"EPZ008278::US9175331, 26",Histone-lysine N-methyltransferase EZH2 [A677G],, 9.3
51447500,CN(C)C(=O)[C@H]1CSCc2c(cccc2C(=O)OC[C@@H](NC(=O)[C@@H]2CCCN2C(C)=O)C(=O)N1)-c1ccc(cc1)C(O)=O,"InChI=1S/C30H34N4O8S/c1-17(35)34-13-5-8-25(34)27(37)31-23-14-42-30(41)21-7-4-6-20(18-9-11-19(12-10-18)29(39)40)22(21)15-43-16-24(32-26(23)36)28(38)33(2)3/h4,6-7,9-12,23-25H,5,8,13-16H2,1-3H3,(H,31,37)(H,32,36)(H,39,40)/t23-,24-,25+/m1/s1",RNGXYARCEQWNBD-SDHSZQHLSA-N,50584822,CHEMBL5092602,Kelch-like ECH-associated protein 1,,
50696736,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1,"InChI=1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H,3-5,8-11H2,1-2H3",XXJWYDDUDKYVKI-UHFFFAOYSA-N,50331096,"4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline::CHEMBL491473::Cediranib::US10464902, Cediranib::ZD-2171",Cyclin-dependent kinase 13,Homo sapiens,
50150899,COc1cccc(\C=C\c2nc3n(CCCO)c(=O)n(CC#C)c(=O)c3n2C)c1,"InChI=1S/C21H22N4O4/c1-4-11-25-20(27)18-19(24(21(25)28)12-6-13-26)22-17(23(18)2)10-9-15-7-5-8-16(14-15)29-3/h1,5,7-10,14,26H,6,11-13H2,2-3H3/b10-9+",FWLDDFYHEQMIGG-MDZDMXLPSA-N,50084860,"3-(3-Hydroxy-propyl)-8-[2-(3-methoxy-phenyl)-vinyl]-7-methyl-1-prop-2-ynyl-3,7-dihydro-purine-2,6-dione(MSX-2)::CHEMBL413079",Adenosine receptor A1,Rattus norvegicus,
42281,COc1cc(COc2cc(O)c3c(c2)oc(cc3=O)C(O)=O)ccc1NC(=O)C(O)=O,"InChI=1S/C20H15NO10/c1-29-14-4-9(2-3-11(14)21-18(24)20(27)28)8-30-10-5-12(22)17-13(23)7-16(19(25)26)31-15(17)6-10/h2-7,22H,8H2,1H3,(H,21,24)(H,25,26)(H,27,28)",VPQTWQRHEYLDMH-UHFFFAOYSA-N,23224,"7-{[4-(formamidoformic acid)-3-methoxyphenyl]methoxy}-5-hydroxy-4-oxo-4H-chromene-2-carboxylic acid::Oxamic acid derivative, 1",L-lactate dehydrogenase,Plasmodium falciparum, 48300
51103321,Cc1ccc(NC(=O)c2ccccc2NC(=O)C2CCCCC2)cc1,"InChI=1S/C21H24N2O2/c1-15-11-13-17(14-12-15)22-21(25)18-9-5-6-10-19(18)23-20(24)16-7-3-2-4-8-16/h5-6,9-14,16H,2-4,7-8H2,1H3,(H,22,25)(H,23,24)",RQHMBOSMNJPRFL-UHFFFAOYSA-N,50449866,CHEMBL3716352,Relaxin receptor 1,Homo sapiens,
50157991,COc1cc2CCN(CCc3ccc(NC(=O)c4ccccc4[N+]([O-])=O)cc3)Cc2cc1OC,"InChI=1S/C26H27N3O5/c1-33-24-15-19-12-14-28(17-20(19)16-25(24)34-2)13-11-18-7-9-21(10-8-18)27-26(30)22-5-3-4-6-23(22)29(31)32/h3-10,15-16H,11-14,17H2,1-2H3,(H,27,30)",OPEFHOQGDRRMFK-UHFFFAOYSA-N,50241472,"CHEMBL442464::N-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-2-nitrobenzamide::N-{4-[2-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl}-2-nitrobenzamide",Broad substrate specificity ATP-binding cassette transporter ABCG2,Homo sapiens, 40000
50456401,Cc1ccc2[nH]cc(CCN(CC=C)CC=C)c2c1,"InChI=1S/C17H22N2/c1-4-9-19(10-5-2)11-8-15-13-18-17-7-6-14(3)12-16(15)17/h4-7,12-13,18H,1-2,8-11H2,3H3",HTDIOUCPOHFDQH-UHFFFAOYSA-N,50140056,CHEMBL3753318,5-hydroxytryptamine receptor 2A,,
1142072,CNc1cc(nn1C)-c1cc2ncccc2c(n1)-c1ccn(n1)C1(CC#N)CC(C1)C#N,"InChI=1S/C23H21N9/c1-26-21-11-20(29-31(21)2)19-10-18-16(4-3-8-27-18)22(28-19)17-5-9-32(30-17)23(6-7-24)12-15(13-23)14-25/h3-5,8-11,15,26H,6,12-13H2,1-2H3",GKMFFKTVZSDFEU-UHFFFAOYSA-N,538729,"US11254668, Example 69::US11254668, Example 70",Tyrosine-protein kinase JAK3,Homo sapiens,>10000
1249938,CCn1c(c2CC(C)(C)COC(=O)[C@@H]3CCCN(N3)C(=O)[C@H](Cc3cc(O)cc(c3)-c3ccc1c2c3)NC(=O)[C@H](C(C)C)N(C)C(=O)[C@H]1CCN(C1)C(=O)C=C)-c1cnccc1COC,"InChI=1S/C50H63N7O8/c1-9-43(59)55-19-16-33(27-55)47(61)54(7)44(30(3)4)46(60)52-41-22-31-20-35(23-36(58)21-31)32-13-14-42-37(24-32)38(45(56(42)10-2)39-26-51-17-15-34(39)28-64-8)25-50(5,6)29-65-49(63)40-12-11-18-57(53-40)48(41)62/h9,13-15,17,20-21,23-24,26,30,33,40-41,44,53,58H,1,10-12,16,18-19,22,25,27-29H2,2-8H3,(H,52,60)/t33-,40-,41-,44-/m0/s1",KEDIJZKZFGWOMJ-MQSPAOBUSA-N,591350,"Synthesis of (2S)-N-[(8S,14S)-22-ethyl-4-hydroxy-21-[4-(methoxymethyl)pyridin-3-yl]-18,18-dimethyl-9,15-dioxo-16-oxa-10,22,28-triazapentacyclo[18.5.2.1{circumflex over (&#8195;)}[2,6].1{circumflex over (&#8195;)}[10,14].0{circumflex over (&#8195;)}[23,27]]nonacosa-1(26),2,4,6(29),20,23::US11566007, Example A28::US11566007, Example A91",GTPase KRas [G13C],, 550
909531,COc1cc(ccn1)-c1[nH]c2ccc(cc2c1C(C)C)C1CCN(C)CC1,"InChI=1S/C23H29N3O/c1-15(2)22-19-13-17(16-8-11-26(3)12-9-16)5-6-20(19)25-23(22)18-7-10-24-21(14-18)27-4/h5-7,10,13-16,25H,8-9,11-12H2,1-4H3",BSQLAHUSYWMOHV-UHFFFAOYSA-N,444049,"US10660877, Example 638",Toll-like receptor 8,, 55.1
51165880,CCC(=O)NCCC[C@@H](C)N(c1cc(Cl)ccc1CO)S(=O)(=O)c1ccc(Cl)cc1,"InChI=1S/C21H26Cl2N2O4S/c1-3-21(27)24-12-4-5-15(2)25(20-13-18(23)7-6-16(20)14-26)30(28,29)19-10-8-17(22)9-11-19/h6-11,13,15,26H,3-5,12,14H2,1-2H3,(H,24,27)/t15-/m1/s1",UUSHJHKKWMREIS-OAHLLOKOSA-N,50477941,CHEMBL403841,Presenilin-1,, 13
50115669,COc1ccc(cc1)C(=O)Nc1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl,"InChI=1S/C23H16ClNO6/c1-30-13-8-6-12(7-9-13)23(29)25-21-18(28)10-16(26)20-17(27)11-19(31-22(20)21)14-4-2-3-5-15(14)24/h2-11,26,28H,1H3,(H,25,29)",HDOFRSOUPSLNLW-UHFFFAOYSA-N,50199022,"CHEMBL224666::N-[2-(2-chlorophenyl)-5,7-dihydroxy-4-oxo-4Hchromen-8-yl]-4-methoxybenzamide",Cyclin-A1/Cyclin-A2/Cyclin-dependent kinase 2,Homo sapiens, 54000
50580049,COc1ccc(cc1OC1CCCC1)S(=O)(=O)C(CCCC(=O)N1CCCc2ccccc12)CC(=O)NO,"InChI=1S/C28H36N2O7S/c1-36-25-16-15-23(18-26(25)37-21-10-3-4-11-21)38(34,35)22(19-27(31)29-33)12-6-14-28(32)30-17-7-9-20-8-2-5-13-24(20)30/h2,5,8,13,15-16,18,21-22,33H,3-4,6-7,9-12,14,17,19H2,1H3,(H,29,31)",GSXKMMPZFVRZAU-UHFFFAOYSA-N,50090381,"3-(3-Cyclopentyloxy-4-methoxy-benzenesulfonyl)-7-(3,4-dihydro-2H-quinolin-1-yl)-7-oxo-heptanoic acid hydroxyamide::CHEMBL418443","cAMP-specific 3',5'-cyclic phosphodiesterase 4A/4B/4C/4D",, 36
50625394,CC1(C)C2CC[C@]1(CS(=O)(=O)Nc1ccc(cc1)S(N)(=O)=O)C(=O)C2,"InChI=1S/C16H22N2O5S2/c1-15(2)11-7-8-16(15,14(19)9-11)10-24(20,21)18-12-3-5-13(6-4-12)25(17,22)23/h3-6,11,18H,7-10H2,1-2H3,(H2,17,22,23)/t11?,16-/m0/s1",FSXHELJSQFRYHW-NBFOKTCDSA-N,50337746,"4-(((1R)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)methylsulfonamido)benzenesulfonamide::CHEMBL1683466","Carbonic anhydrase 5B, mitochondrial",Homo sapiens,
227955,OCC1OC(Oc2cc3c(cc(O)cc3=[OH+])oc2-c2ccc(O)cc2)C(O)C(O)C1O,"InChI=1S/C21H20O10/c22-8-16-17(26)18(27)19(28)21(31-16)30-15-7-12-13(25)5-11(24)6-14(12)29-20(15)9-1-3-10(23)4-2-9/h1-7,16-19,21-24,26-28H,8H2/p+1",NVBLGZSVOCZYSB-UHFFFAOYSA-O,108034,"5,7&#8208;dihydroxy&#8208;2&#8208;(4&#8208;hydroxyphenyl)&#8208;3&#8208; {[(2S,3R,4S,5S,6R)&#8208;3,4,5&#8208;trihydroxy&#8208;6&#8208; (hydroxymethyl)oxan&#8208;2&#8208;yl]oxy}&#8208;1&#955;&#8308;&#8208;chromen&#8208;1&#8208;ylium::Pelargonidin-3-glucoside (M9)",Alpha-glucosidase MAL12,Saccharomyces cerevisiae, 1.982e+5
918296,Fc1cc(cc(c1)-c1ccc(cc1F)C(=O)N1CCC(CC1)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12)C#N,"InChI=1S/C33H27F2N9O/c34-25-12-21(15-37)11-23(13-25)27-2-1-22(14-29(27)35)32(45)42-9-4-26(5-10-42)43-18-33(19-43,6-7-36)44-17-24(16-41-44)30-28-3-8-38-31(28)40-20-39-30/h1-3,8,11-14,16-17,20,26H,4-6,9-10,18-19H2,(H,38,39,40)",HPXDUENAACWXMF-UHFFFAOYSA-N,400374,"US10695337, Example 128::US11285140, Example 128::US9999619, Example 129",Tyrosine-protein kinase JAK2 [828-1132],, 30.0
51073637,COc1ccc2ccc(-c3cccnc3)c(F)c2c1,"InChI=1S/C16H12FNO/c1-19-13-6-4-11-5-7-14(16(17)15(11)9-13)12-3-2-8-18-10-12/h2-10H,1H3",NVRWXGKJXOBEQC-UHFFFAOYSA-N,50439002,CHEMBL2420675,"Steroid 17-alpha-hydroxylase/17,20 lyase",Homo sapiens, 106
51079143,CCOC(=O)c1c(O)coc1Nc1cnc2ccccc2c1,"InChI=1S/C16H14N2O4/c1-2-21-16(20)14-13(19)9-22-15(14)18-11-7-10-5-3-4-6-12(10)17-8-11/h3-9,18-19H,2H2,1H3",UKHMSTFAVQLBQF-UHFFFAOYSA-N,50441251,CHEMBL2431498,"Dihydroorotate dehydrogenase (quinone), mitochondrial",Homo sapiens,>50000
973127,CN([C@H]1CCN(Cc2csc(C)n2)C1)c1cc(F)c(cc1C)S(=O)(=O)Nc1cscn1,"InChI=1S/C20H24FN5O2S3/c1-13-6-19(31(27,28)24-20-11-29-12-22-20)17(21)7-18(13)25(3)16-4-5-26(9-16)8-15-10-30-14(2)23-15/h6-7,10-12,16,24H,4-5,8-9H2,1-3H3/t16-/m0/s1",GQMCCWCTLXZEJF-INIZCTEOSA-N,373843,"(S)-2-fluoro-5-methyl-4-(methyl(1-((2-methylthiazol-4-yl)methyl)pyrrolidin-3-yl)amino)-N-(thiazol-4-yl)benzenesulfonamide formate::US10246453, Example 110::US10815229, Example 110",Sodium channel protein type 1 subunit alpha,,>30000
51415433,O=Cc1ccc2c(c1)[nH]c1c(NC(=O)C3CC3)nccc21,"InChI=1S/C16H13N3O2/c20-8-9-1-4-11-12-5-6-17-15(14(12)18-13(11)7-9)19-16(21)10-2-3-10/h1,4-8,10,18H,2-3H2,(H,17,19,21)",PQSDMIBFNQMFIW-UHFFFAOYSA-N,50571743,CHEMBL4873680,Glycogen synthase kinase-3 beta,Homo sapiens, 400
182851,COc1ccc(c(OC)c1)S(=O)(=O)N1C(=O)[C@@](N2C[C@H](O)C[C@H]2C(=O)N(C)C)(c2cc(Cl)ccc12)c1ccccc1OC,"InChI=1S/C30H32ClN3O8S/c1-32(2)28(36)24-15-19(35)17-33(24)30(21-8-6-7-9-25(21)41-4)22-14-18(31)10-12-23(22)34(29(30)37)43(38,39)27-13-11-20(40-3)16-26(27)42-5/h6-14,16,19,24,35H,15,17H2,1-5H3/t19-,24+,30+/m1/s1",NJXZWIIMWNEOGJ-WEWKHQNJSA-N,50299343,"(2S,4R)-1-((R)-5-chloro-1-(2,4-dimethoxyphenylsulfonyl)-3-(2-methoxyphenyl)-2-oxoindolin-3-yl)-4-hydroxy-N,N-dimethylpyrrolidine-2-carboxamide::(2S,4R)-1-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,Ndimethyl-2-pyrrolidine carboxamide::CHEMBL582857::SR-149415::SSR149415",Vasopressin V1b receptor,,
50226482,Cc1cccnc1C1CCN(CC1)C(=O)Nc1ccc(cc1)C(F)(F)F,"InChI=1S/C19H20F3N3O/c1-13-3-2-10-23-17(13)14-8-11-25(12-9-14)18(26)24-16-6-4-15(5-7-16)19(20,21)22/h2-7,10,14H,8-9,11-12H2,1H3,(H,24,26)",DOUBDNJQWXEMSU-UHFFFAOYSA-N,50163220,"3-Methyl-3'',4'',5'',6''-tetrahydro-2''H-[2,4'']bipyridinyl-1''-carboxylic acid (4-trifluoromethyl-phenyl)-amide::CHEMBL175383",Transient receptor potential cation channel subfamily V member 1,Rattus norvegicus,
50472650,CN1C2=N[C@@H]3CCC[C@@H]3N2C2N(Cc3ccc(cc3)-c3ccc(F)cc3)NC(Nc3ccccc3)=C2C1=O,"InChI=1S/C30H29FN6O/c1-35-29(38)26-27(32-23-6-3-2-4-7-23)34-36(28(26)37-25-9-5-8-24(25)33-30(35)37)18-19-10-12-20(13-11-19)21-14-16-22(31)17-15-21/h2-4,6-7,10-17,24-25,28,32,34H,5,8-9,18H2,1H3/t24-,25+,28?/m1/s1",FLQCKSZQICZFTJ-CRWLQCRJSA-N,50150261,CHEMBL3771172,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A",Homo sapiens,
50299077,COc1cc(NCc2cnc3nc(N)nc(N)c3c2C)cc(OC)c1OC,"InChI=1S/C18H22N6O3/c1-9-10(8-22-17-14(9)16(19)23-18(20)24-17)7-21-11-5-12(25-2)15(27-4)13(6-11)26-3/h5-6,8,21H,7H2,1-4H3,(H4,19,20,22,23,24)",LRANACXXEDNIGR-UHFFFAOYSA-N,50029772,"5-Methyl-6-[(3,4,5-trimethoxy-phenylamino)-methyl]-pyrido[2,3-d]pyrimidine-2,4-diamine::CHEMBL23532",Dihydrofolate reductase,Rattus norvegicus, 2.1
50056014,Clc1ccc2nc(Nc3ccccc3I)oc(=O)c2c1,"InChI=1S/C14H8ClIN2O2/c15-8-5-6-11-9(7-8)13(19)20-14(17-11)18-12-4-2-1-3-10(12)16/h1-7H,(H,17,18)",BXNYJWKBNDSIMR-UHFFFAOYSA-N,50063714,"6-Chloro-2-(2-iodo-phenylamino)-benzo[d][1,3]oxazin-4-one::CHEMBL10246",Complement C1r subcomponent,Homo sapiens, 4000
50275471,Fc1cc2CCCOc2c(OCCNCCc2c[nH]c3ccccc23)c1,"InChI=1S/C21H23FN2O2/c22-17-12-15-4-3-10-26-21(15)20(13-17)25-11-9-23-8-7-16-14-24-19-6-2-1-5-18(16)19/h1-2,5-6,12-14,23-24H,3-4,7-11H2",ISBIUGFQLVFPNK-UHFFFAOYSA-N,50150106,CHEMBL124638::[2-(6-Fluoro-chroman-8-yloxy)-ethyl]-[2-(1H-indol-3-yl)-ethyl]-amine,Sodium-dependent serotonin transporter,Homo sapiens, 42.2
763575,Cn1cnc(c1-c1ccc2cc[nH]c2c1)-c1cc(ccn1)C(O)=O,"InChI=1S/C18H14N4O2/c1-22-10-21-16(15-9-13(18(23)24)5-7-20-15)17(22)12-3-2-11-4-6-19-14(11)8-12/h2-10,19H,1H3,(H,23,24)",YSKDANZJZJAOHN-UHFFFAOYSA-N,381950,"2-[5-(1H-indol-6-yl)-1-methyl- 1H-imidazol-4-yl]pyridine-4- carboxylic acid::US10273222, Example 22",Lysine-specific demethylase 5B,,<100
50553752,COc1cc2C\C(=C/c3ccc(cc3)N3CCN(CC3)c3ccccc3)C(=O)c2cc1OC,"InChI=1S/C28H28N2O3/c1-32-26-18-21-17-22(28(31)25(21)19-27(26)33-2)16-20-8-10-24(11-9-20)30-14-12-29(13-15-30)23-6-4-3-5-7-23/h3-11,16,18-19H,12-15,17H2,1-2H3/b22-16+",IFPARRBNOVWNHQ-CJLVFECKSA-N,50210839,CHEMBL3965447,Cholinesterase,, 5980
51304461,Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,50357312,"IBRUTINIB::PCI-32765::US10124003, Ref. Ex. Compound 1::US10711006, Compound Ibrutinib::US10793575, Example ibrutinib::US10835536, Ref. Ex. Comp 1::US10919899, Ibrutinib::US11078206, Example Ibrutinib::US11186578, Example Ibrutinib::US11339167, Example Ibrutinib::US11407754, Example Ibrutinib::US9108973, Ref 1::US9181263, 1::US9278100, 1",Tyrosine-protein kinase ITK/TSK,Homo sapiens, 77
50542425,O=C(C1CCCC1)c1cn(CCN2CCOCC2)c2ccccc12,"InChI=1S/C20H26N2O2/c23-20(16-5-1-2-6-16)18-15-22(19-8-4-3-7-17(18)19)10-9-21-11-13-24-14-12-21/h3-4,7-8,15-16H,1-2,5-6,9-14H2",HMSJDERPEWZRIU-UHFFFAOYSA-N,50303521,CHEMBL584534::Cyclopentyl(1-(2-morpholinoethyl)-1H-indol-3-yl)methanone,Cannabinoid receptor 2,Homo sapiens,
50644050,C[C@H](Cc1ccccc1)N(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C,"InChI=1S/C21H28N2O2/c1-16(14-18-10-7-6-8-11-18)23(5)21(24)25-20-13-9-12-19(15-20)17(2)22(3)4/h6-13,15-17H,14H2,1-5H3/t16-,17+/m1/s1",QGKSWUZOCNWHHA-SJORKVTESA-N,50345812,3-((S)-1-(dimethylamino)ethyl)phenylmethyl((R)-1-phenylpropan-2-yl)carbamate hydrochloride::CHEMBL1784958,Acetylcholinesterase,Homo sapiens, 302
50129705,CN1C[C@H]2CC[C@@H]1[C@@H](C2)C(=O)N[C@H](Cc1ccc(F)cc1)C(=O)N1CCC(CC1)(C1CCCCC1)C(=O)NC(C)(C)C,"InChI=1S/C34H51FN4O3/c1-33(2,3)37-32(42)34(25-8-6-5-7-9-25)16-18-39(19-17-34)31(41)28(21-23-10-13-26(35)14-11-23)36-30(40)27-20-24-12-15-29(27)38(4)22-24/h10-11,13-14,24-25,27-29H,5-9,12,15-22H2,1-4H3,(H,36,40)(H,37,42)/t24-,27+,28+,29+/m0/s1",ARFBDECCXOFCBN-HOLBEBDISA-N,50169442,"(1R,4S,6R)-2-Methyl-2-aza-bicyclo[2.2.2]octane-6-carboxylic acid [(R)-2-(4-tert-butylcarbamoyl-4-cyclohexyl-piperidin-1-yl)-1-(4-fluoro-benzyl)-2-oxo-ethyl]-amide::CHEMBL364346",Melanocortin receptor 4,,
50659598,CCN(CC)c1ccc2c(Oc3cc(ccc3C22N(CCc3ccc(cc3)S(N)(=O)=O)C(=O)c3ccccc23)N(CC)CC)c1,"InChI=1S/C36H40N4O4S/c1-5-38(6-2)26-15-19-31-33(23-26)44-34-24-27(39(7-3)8-4)16-20-32(34)36(31)30-12-10-9-11-29(30)35(41)40(36)22-21-25-13-17-28(18-14-25)45(37,42)43/h9-20,23-24H,5-8,21-22H2,1-4H3,(H2,37,42,43)",AXVQXDKRGPCGGE-UHFFFAOYSA-N,50352646,CHEMBL1822702,Carbonic anhydrase 9,Homo sapiens,
1022588,CC(C)(O)CNC(=O)c1nc(C(=O)N2CCC(F)CC2)c(s1)-c1cnc(NCCC(F)(F)F)cc1C(F)(F)F,"InChI=1S/C23H26F7N5O3S/c1-21(2,38)11-33-18(36)19-34-16(20(37)35-7-3-12(24)4-8-35)17(39-19)13-10-32-15(9-14(13)23(28,29)30)31-6-5-22(25,26)27/h9-10,12,38H,3-8,11H2,1-2H3,(H,31,32)(H,33,36)",QANVZUVYUBTVPS-UHFFFAOYSA-N,491870,"4-(4-Fluoropiperidine-1-carbonyl)-N-(2-hydroxy-2-methylpropyl)-5-(4-(trifluoromethyl)-6-((3,3,3-trifluoropropyl)amino)pyridin-3-yl)thiazole-2-carboxamide::US10975068, Example 8",Nuclear receptor ROR-gamma,,
981461,COc1cc(CNC(=O)c2cc(Cn3ccn(C)c3=N)cc(c2F)-c2ccc(F)cc2C(F)(F)F)cc(OC)c1,"InChI=1S/C28H25F5N4O3/c1-36-6-7-37(27(36)34)15-17-10-22(21-5-4-18(29)12-24(21)28(31,32)33)25(30)23(11-17)26(38)35-14-16-8-19(39-2)13-20(9-16)40-3/h4-13,34H,14-15H2,1-3H3,(H,35,38)",VWZAGEVGWUQNJL-UHFFFAOYSA-N,473256,"US10844044, Example 108",WD repeat-containing protein 5,,
77879,COc1ccc2c(C)n[nH]c3cccc1c23,"InChI=1S/C13H12N2O/c1-8-9-6-7-12(16-2)10-4-3-5-11(13(9)10)15-14-8/h3-7,15H,1-2H3",MXCNJRIUQVTTPS-UHFFFAOYSA-N,31997,6-Methoxy-3-methyl-1H-benzo[de]cinnoline::MLS000027089::SMR000010302::cid_644992,Serine/threonine-protein kinase PLK1,Homo sapiens,
395522,CCOC(=O)C1Cc2cc(C(=O)c3ccccc3F)c(O)c(O)c2O1,"InChI=1S/C18H15FO6/c1-2-24-18(23)13-8-9-7-11(15(21)16(22)17(9)25-13)14(20)10-5-3-4-6-12(10)19/h3-7,13,21-22H,2,8H2,1H3",HEDTVMHUBDAJRX-UHFFFAOYSA-N,225836,hsp90_127,Heat shock protein HSP 90-beta,Homo sapiens, 50000
51272703,Cc1nc(cs1)C(=O)Nc1cccc(NC(=O)COc2ccc3c(c2)occc3=O)c1,"InChI=1S/C22H17N3O5S/c1-13-23-18(12-31-13)22(28)25-15-4-2-3-14(9-15)24-21(27)11-30-16-5-6-17-19(26)7-8-29-20(17)10-16/h2-10,12H,11H2,1H3,(H,24,27)(H,25,28)",VGJUQZDOYBBMLP-UHFFFAOYSA-N,50519671,CHEMBL4470778,Rho-associated protein kinase 1,Homo sapiens, 473
805882,CCOC(=O)c1cnc(s1)N1CCCC(COc2cc(OC)cc3oc(cc23)-c2cn3nc(OC)sc3n2)C1,"InChI=1S/C26H27N5O6S2/c1-4-35-23(32)22-11-27-24(38-22)30-7-5-6-15(12-30)14-36-19-8-16(33-2)9-20-17(19)10-21(37-20)18-13-31-25(28-18)39-26(29-31)34-3/h8-11,13,15H,4-7,12,14H2,1-3H3",NGYWCXFVNBJHSX-UHFFFAOYSA-N,403314,"US10329307, Example 61",PRKC apoptosis WT1 regulator protein,, 1500
50605426,Cc1c(Cl)cccc1S(=O)(=O)Nc1nc(NCCc2ccccc2)nc2CCN(Cc3ccccc3)Cc12,"InChI=1S/C29H30ClN5O2S/c1-21-25(30)13-8-14-27(21)38(36,37)34-28-24-20-35(19-23-11-6-3-7-12-23)18-16-26(24)32-29(33-28)31-17-15-22-9-4-2-5-10-22/h2-14H,15-20H2,1H3,(H2,31,32,33,34)",LGUUETDTMQTHML-UHFFFAOYSA-N,50329499,"CHEMBL1270331::N-(6-benzyl-2-(phenethylamino)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)-3-chloro-2-methylbenzenesulfonamide",Calcium/calmodulin-dependent protein kinase type IV,Homo sapiens,>60000
51405561,Cc1ccc(cc1)-n1nc(nc1CNc1ccc(cc1)C(=O)NO)-c1ccccc1,"InChI=1S/C23H21N5O2/c1-16-7-13-20(14-8-16)28-21(25-22(26-28)17-5-3-2-4-6-17)15-24-19-11-9-18(10-12-19)23(29)27-30/h2-14,24,30H,15H2,1H3,(H,27,29)",FHXKGVZDSDZEEF-UHFFFAOYSA-N,50567888,CHEMBL4862349,Histone deacetylase 6,Homo sapiens, 310
51160199,C[C@@H](O)[C@H](NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)CNC(=O)CNC[C@@H](N)Cc1ccccc1)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(=O)N(N)N)C(=O)NN,"InChI=1S/C82H142FN35O20/c1-44(104-63(123)42-103-79(138)66(46(3)120)116-76(135)58(37-48-24-26-49(83)27-25-48)106-64(124)41-102-62(122)40-98-39-50(87)36-47-16-5-4-6-17-47)67(126)107-54(21-13-33-99-80(89)90)70(129)111-53(20-9-12-32-86)74(133)115-60(43-119)77(136)105-45(2)68(127)108-55(22-14-34-100-81(91)92)71(130)109-51(18-7-10-30-84)69(128)112-56(23-15-35-101-82(93)94)72(131)110-52(19-8-11-31-85)73(132)114-59(38-61(88)121)75(134)113-57(78(137)117-95)28-29-65(125)118(96)97/h4-6,16-17,24-27,44-46,50-60,66,98,119-120H,7-15,18-23,28-43,84-87,95-97H2,1-3H3,(H2,88,121)(H,102,122)(H,103,138)(H,104,123)(H,105,136)(H,106,124)(H,107,126)(H,108,127)(H,109,130)(H,110,131)(H,111,129)(H,112,128)(H,113,134)(H,114,132)(H,115,133)(H,116,135)(H,117,137)(H4,89,90,99)(H4,91,92,100)(H4,93,94,101)/t44-,45-,46+,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,66-/m0/s1",RONPEYBYZVADRG-OJQBRUKQSA-N,50475330,CHEMBL442297,Nociceptin receptor,Homo sapiens,
50456686,COc1ccc(CCN2CCC(CC2)C(O)c2cccc(OCCF)c2OC)cc1,"InChI=1S/C24H32FNO4/c1-28-20-8-6-18(7-9-20)10-14-26-15-11-19(12-16-26)23(27)21-4-3-5-22(24(21)29-2)30-17-13-25/h3-9,19,23,27H,10-17H2,1-2H3",YTQJBBJHLKKOLR-UHFFFAOYSA-N,50267555,(3-(2-Fluoroethoxy)-2-methoxyphenyl)-(1-(2-p-methoxyphenylethyl)-piperidine-4-yl)-methanol::CHEMBL490633,5-hydroxytryptamine receptor 2A,Rattus norvegicus,
798783,CN(C(C)=O)c1cnn(c1)C(=O)N1CC2CN(Cc3cc(cc(c3)C(F)(F)F)N3CCOCC3)CC2C1,"InChI=1S/C25H31F3N6O3/c1-17(35)30(2)23-10-29-34(16-23)24(36)33-14-19-12-31(13-20(19)15-33)11-18-7-21(25(26,27)28)9-22(8-18)32-3-5-37-6-4-32/h7-10,16,19-20H,3-6,11-15H2,1-2H3",VWEVJBUMBJLFAO-UHFFFAOYSA-N,399828,"N-methyl-N-(1-(5-(3-morpholino-5- (trifluoromethyl)benzyl)octahydropyrrolo [3,4-c]pyrrole-2-carbonyl)-1H-pyrazol- 4-yl)acetamide::US10323038, Example 114",Fatty-acid amide hydrolase 1,Mus musculus,<100
465664,Cc1cc(cnc1N)C(=O)NC1CCC(CC1)=Cc1cccc(Oc2ccc(Cl)c(C)n2)c1,"InChI=1S/C26H27ClN4O2/c1-16-12-20(15-29-25(16)28)26(32)31-21-8-6-18(7-9-21)13-19-4-3-5-22(14-19)33-24-11-10-23(27)17(2)30-24/h3-5,10-15,21H,6-9H2,1-2H3,(H2,28,29)(H,31,32)/b18-13-",FOEPYDRNMKOTOW-AQTBWJFISA-N,143288,"US9682953, 2.E-25",Fatty-acid amide hydrolase 1 [30-579],, 32
50626789,N[C@H](Cc1cc(F)ccc1F)C1CCN(CC1)c1ccc(F)nc1,"InChI=1S/C18H20F3N3/c19-14-1-3-16(20)13(9-14)10-17(22)12-5-7-24(8-6-12)15-2-4-18(21)23-11-15/h1-4,9,11-12,17H,5-8,10,22H2/t17-/m1/s1",QQVUXENLUIUCMJ-QGZVFWFLSA-N,50338430,"(R)-2-(2,5-difluorophenyl)-1-(1-(6-fluoropyridin-3-yl)piperidin-4-yl)ethanamine::CHEMBL1683136",Dipeptidyl peptidase 2,Homo sapiens, 52000
524944,CNc1nc(OCc2cn(nn2)-c2ccc(F)c(c2)C(C)(F)F)ncc1C,"InChI=1S/C17H17F3N6O/c1-10-7-22-16(23-15(10)21-3)27-9-11-8-26(25-24-11)12-4-5-14(18)13(6-12)17(2,19)20/h4-8H,9H2,1-3H3,(H,21,22,23)",VUOWLVQOWAMXQW-UHFFFAOYSA-N,276637,"2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,5-::US10071988, Example 577::US10233173, Example 577",Retinoic acid receptor RXR-alpha,Homo sapiens, 128
50206169,CC(C)NCC(O)c1ccc(O)c(O)c1,"InChI=1S/C11H17NO3/c1-7(2)12-6-11(15)8-3-4-9(13)10(14)5-8/h3-5,7,11-15H,6H2,1-2H3",JWZZKOKVBUJMES-UHFFFAOYSA-N,25392,"4-[1-hydroxy-2-(isopropylamino)ethyl]pyrocatechol;hydrochloride::4-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzene-1,2-diol::4-{1-hydroxy-2-[(propan-2-yl)amino]ethyl}benzene-1,2-diol, 2::CHEMBL434::ISOPROTERONOL::Isoprenaline::Isoproterenol::Isoproterenol (-)::Isoproterenol,(+)::Isoproterenol-l::Norisodrine::Novodrin",Beta-1 adrenergic receptor,Homo sapiens,
172462,COc1cc(N)c(Cl)cc1C(=O)NC1CCN2CCCC1C2,"InChI=1S/C16H22ClN3O2/c1-22-15-8-13(18)12(17)7-11(15)16(21)19-14-4-6-20-5-2-3-10(14)9-20/h7-8,10,14H,2-6,9,18H2,1H3,(H,19,21)",GZSKEXSLDPEFPT-UHFFFAOYSA-N,82422,CAS_109872-41-5::NSC_3035240::RENZAPRIDE,5-hydroxytryptamine receptor 4,,
50280686,Cc1ccc(cc1)C1=N[C@@H](Sc2ccccc2)[C@@H](O1)C=C,"InChI=1S/C18H17NOS/c1-3-16-18(21-15-7-5-4-6-8-15)19-17(20-16)14-11-9-13(2)10-12-14/h3-12,16,18H,1H2,2H3/t16-,18-/m0/s1",HMMHUOOBBQHGHE-WMZOPIPTSA-N,50152630,"(4S,5S)-4-Phenylsulfanyl-2-p-tolyl-5-vinyl-4,5-dihydro-oxazole::CHEMBL184472",Interstitial collagenase,,
51108174,Fc1ccc(Cn2ccc(NC(=O)Cc3ccc4[nH]ccc4c3)n2)cc1F,"InChI=1S/C20H16F2N4O/c21-16-3-1-14(10-17(16)22)12-26-8-6-19(25-26)24-20(27)11-13-2-4-18-15(9-13)5-7-23-18/h1-10,23H,11-12H2,(H,24,25,27)",SHDZUWIULZBHDM-UHFFFAOYSA-N,50452290,CHEMBL4207159,Voltage-dependent T-type calcium channel subunit alpha-1H,, 14
347922,COC1CCC2(Cc3ccc(CCC4CC4)cc3C22N=C(N)N(Cc3ccc(cc3)C#N)C2=O)CC1,"InChI=1S/C30H34N4O2/c1-36-25-12-14-29(15-13-25)17-24-11-10-21(5-4-20-2-3-20)16-26(24)30(29)27(35)34(28(32)33-30)19-23-8-6-22(18-31)7-9-23/h6-11,16,20,25H,2-5,12-15,17,19H2,1H3,(H2,32,33)",FEASUUSJHPORHM-UHFFFAOYSA-N,195477,"US9212153, 387,Ex. 329",Beta-secretase 1 [1-458],, 15.5
426974,CSc1ccc(Nc2nc(nc3CCN(CCc23)c2ncccc2C(F)(F)F)N2CCCCC2)cc1,"InChI=1S/C26H29F3N6S/c1-36-19-9-7-18(8-10-19)31-23-20-11-16-34(24-21(26(27,28)29)6-5-13-30-24)17-12-22(20)32-25(33-23)35-14-3-2-4-15-35/h5-10,13H,2-4,11-12,14-17H2,1H3,(H,31,32,33)",SRBRGADEBFLEFC-UHFFFAOYSA-N,244932,"US9422293, 160::US9738649, Example 160",Transient receptor potential cation channel subfamily V member 1,Rattus norvegicus, 100
846297,C[C@@H](O)CC(=O)N1CCC(CC1)c1ccc2[nH]c(c(CC(F)F)c2c1)-c1ccc2nc(C)nn2c1,,,273871,"US10071079, Example 657::US10478424, Example 657",Toll-like receptor 7,, 416
136454,[O-][N+](=O)c1cccc(c1)C(=O)COC(=O)CN1C(=O)C2C3CCC(C3)C2C1=O,"InChI=1S/C19H18N2O7/c22-14(10-2-1-3-13(7-10)21(26)27)9-28-15(23)8-20-18(24)16-11-4-5-12(6-11)17(16)19(20)25/h1-3,7,11-12,16-17H,4-6,8-9H2",TWJKYCDAQQTRKJ-UHFFFAOYSA-N,67222,"(3,5-Dioxo-4-aza-tricyclo[5.2.1.0*2,6*]dec-4-yl)-acetic acid 2-(3-nitro-phenyl)-2-oxo-ethyl ester::MLS000566901::SMR000175979::cid_3118009",Type-1 angiotensin II receptor,Homo sapiens, 26310
1152796,CC(C)c1nccc(C)c1-n1c2nc(c(F)cc2c(nc1=O)N1C[C@@H](C)N(C[C@@H]1C)C(=O)C=C)-c1ccccc1CO,"InChI=1S/C32H35FN6O3/c1-7-26(41)37-15-21(6)38(16-20(37)5)30-24-14-25(33)28(23-11-9-8-10-22(23)17-40)35-31(24)39(32(42)36-30)29-19(4)12-13-34-27(29)18(2)3/h7-14,18,20-21,40H,1,15-17H2,2-6H3/t20-,21+/m1/s1",XDAKAEMHDVNNBC-RTWAWAEBSA-N,544121,"(M)-4-[(2S,5R)- 2,5-dimethyl-4- prop-2-enoyl- piperazin-1-yl]- 6-fluoro-7-[2- (hydroxymethyl) phenyl]-1-(2- isopropyl-4- methyl-3- pyridyl)pyrido [2,3- d]pyrimidin-2- one::US11285156, Ex.# 94-2","GTPase KRas [1-169,G12C,C118A]",, 322
50485689,COc1ccc(cc1)N1CCN(CC1)C(=O)Nc1ccc(OC)c(c1)N1CCN(C)CC1,"InChI=1S/C24H33N5O3/c1-26-10-12-28(13-11-26)22-18-19(4-9-23(22)32-3)25-24(30)29-16-14-27(15-17-29)20-5-7-21(31-2)8-6-20/h4-9,18H,10-17H2,1-3H3,(H,25,30)",HCTBJYWMGCQPOS-UHFFFAOYSA-N,50290919,4-(4-Methoxy-phenyl)-piperazine-1-carboxylic acid [4-methoxy-3-(4-methyl-piperazin-1-yl)-phenyl]-amide; compound with (E)-but-2-enedioic acid::CHEMBL108645,5-hydroxytryptamine receptor 1D,Homo sapiens,
50354440,CCN1C(=S)N2CCCC2c2c1nc(-c1cccc(OC)c1)c(C#N)c2N1CCOCC1,"InChI=1S/C22H21N3O/c26-22-19-15-24(13-16-7-2-1-3-8-16)20-12-5-4-11-18(20)21(19)23-25(22)14-17-9-6-10-17/h1-5,7-8,11-12,15,17H,6,9-10,13-14H2",ZXIGHFLRSGWDLS-UHFFFAOYSA-N,50094947,CHEMBL3589376,Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta,Homo sapiens, 9760
51439068,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@H](NC1=O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@H](Cc1ccccc1)C(=O)N(C)[C@@H](CCCNC(N)=N)C(=O)N(C)[C@@H](Cc1c[nH]c3ccccc13)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N2)[C@@H](C)O)[C@@H](C)CC,,,50581301,CHEMBL5093939,Melanocortin receptor 4,,
50065221,O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12,"InChI=1S/C20H15N3O2/c24-19-15-11-17(21-13-7-3-1-4-8-13)18(12-16(15)20(25)23-19)22-14-9-5-2-6-10-14/h1-12,21-22H,(H,23,24,25)",AAALVYBICLMAMA-UHFFFAOYSA-N,50040929,"4,5-dianilinophthalimide::5,6-bis(phenylamino)-1H-isoindole-1,3(2H)-dione::CHEMBL268868::Cgp 52411",Proto-oncogene tyrosine-protein kinase Src,, 16000
50844159,COc1ccc(OC[C@@H]2CC[C@H]3CN(CCN3C2)c2nc(N)n3nc(nc3n2)-c2ccco2)cc1,"InChI=1S/C24H28N8O3/c1-33-18-6-8-19(9-7-18)35-15-16-4-5-17-14-31(11-10-30(17)13-16)23-27-22(25)32-24(28-23)26-21(29-32)20-3-2-12-34-20/h2-3,6-9,12,16-17H,4-5,10-11,13-15H2,1H3,(H2,25,26,27,28,29)/t16-,17+/m1/s1",DHWRYELCNPJLRF-SJORKVTESA-N,50156641,"(7RS,9aSR)-2-furan-2-yl-5-[7-(4-methoxy-phenoxymethyl)-octahydro-pyrido[1,2-a]pyrazin-2-yl]-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-ylamine::CHEMBL387327",Adenosine receptor A1,Rattus norvegicus,
50646512,CN1CCC(CC1)NC(=O)c1ccc(cc1)-c1ccc(cc1C)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1,"InChI=1S/C41H35N5O2/c1-26-21-34(13-14-35(26)27-7-9-28(10-8-27)41(48)44-33-17-19-45(2)20-18-33)46-39(47)16-12-31-24-43-38-15-11-29(23-36(38)40(31)46)32-22-30-5-3-4-6-37(30)42-25-32/h3-16,21-25,33H,17-20H2,1-2H3,(H,44,48)",OQNZFXCQVQSQDF-UHFFFAOYSA-N,50346970,CHEMBL1795884,Serine/threonine-protein kinase mTOR,,
50720262,CC(C)n1cc2OC3(CCN(CC3)C(=O)c3cc(C)c4[nH]nc(C)c4c3)CC(=O)c2n1,"InChI=1S/C23H27N5O3/c1-13(2)28-12-19-21(26-28)18(29)11-23(31-19)5-7-27(8-6-23)22(30)16-9-14(3)20-17(10-16)15(4)24-25-20/h9-10,12-13H,5-8,11H2,1-4H3,(H,24,25)",POQBAOOHSSEVOU-UHFFFAOYSA-N,50365290,CHEMBL1958371,Acetyl-CoA carboxylase 1,Rattus norvegicus, 12
51001776,Fc1ccc(C(=O)NC(=O)Nc2ccc3CCCNc3c2)c(Cl)c1,"InChI=1S/C17H15ClFN3O2/c18-14-8-11(19)4-6-13(14)16(23)22-17(24)21-12-5-3-10-2-1-7-20-15(10)9-12/h3-6,8-9,20H,1-2,7H2,(H2,21,22,23,24)",XGMNIMNOWWRWSJ-UHFFFAOYSA-N,50174402,"1-(2-Chloro-4-fluoro-benzoyl)-3-(1,2,3,4-tetrahydro-quinolin-7-yl)-urea::CHEMBL198770","Glycogen phosphorylase, liver form",Homo sapiens, 3467.37
50491806,COc1nc(nc(C)c1F)N1C[C@H]2C(=O)N(C)C(N)=N[C@]2(C1)c1c(F)ccc(F)c1F,"InChI=1S/C19H18F4N6O2/c1-8-13(22)15(31-3)26-18(25-8)29-6-9-16(30)28(2)17(24)27-19(9,7-29)12-10(20)4-5-11(21)14(12)23/h4-5,9H,6-7H2,1-3H3,(H2,24,27)/t9-,19-/m0/s1",VRRVVCOABSEJKG-UGZDLDLSSA-N,102969,"US8541427, 40",Cytochrome P450 3A4,Homo sapiens,>20000
50671587,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,"InChI=1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27)",UHTHHESEBZOYNR-UHFFFAOYSA-N,21,"6-[(4R,5S,6S,7R)-4,7-dibenzyl-3-(5-carboxypentyl)-5,6-dihydroxy-2-oxo-1,3-diazepan-1-yl]hexanoic acid::CHEMBL24828::DMPC Cyclic Urea 1::N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine::VANDETANIB::ZD-6474::ZD6474::cid_3081361",Serine/threonine-protein kinase 16,,
50484933,C(COc1nc(nc2CCCCc12)-c1ccccc1)CN1CCCCC1,"InChI=1S/C22H29N3O/c1-3-10-18(11-4-1)21-23-20-13-6-5-12-19(20)22(24-21)26-17-9-16-25-14-7-2-8-15-25/h1,3-4,10-11H,2,5-9,12-17H2",WYWPQLUAZPOYCP-UHFFFAOYSA-N,50034165,CHEMBL3359233,Sigma non-opioid intracellular receptor 1,Cavia porcellus,
51119657,O[C@@H]1CCN(C1)c1ncc(cc1-c1[nH]ncc1F)C(=O)Nc1ccc(OC(F)(F)Cl)cc1,"InChI=1S/C20H17ClF3N5O3/c21-20(23,24)32-14-3-1-12(2-4-14)27-19(31)11-7-15(17-16(22)9-26-28-17)18(25-8-11)29-6-5-13(30)10-29/h1-4,7-9,13,30H,5-6,10H2,(H,26,28)(H,27,31)/t13-/m1/s1",NAXNSUPRCUTVTP-CYBMUJFWSA-N,50459090,CHEMBL4213152,"1,3-beta-glucan synthase component GSC2",Saccharomyces cerevisiae,>30000
932029,CC(C)(C)CNC(=O)COc1cccc(c1)-c1nc2COCc2c(Nc2ccc(cc2)-c2cn[nH]c2)n1,"InChI=1S/C28H30N6O3/c1-28(2,3)17-29-25(35)16-37-22-6-4-5-19(11-22)26-33-24-15-36-14-23(24)27(34-26)32-21-9-7-18(8-10-21)20-12-30-31-13-20/h4-13H,14-17H2,1-3H3,(H,29,35)(H,30,31)(H,32,33,34)",XKSKWJHTUPYWCG-UHFFFAOYSA-N,453245,"2-(3-(4-((4-(1H-pyrazol-4-yl)phenyl)amino)-5,7-dihydrofuro[3,4-d]pyrimidin-2-yl)phenoxy)-N-neopentylacetamide::US10729691, Example 30",Putative sugar transporter,Plasmodium falciparum, 175
158701,CC(C)(C)[C@]1(O)CCN2C[C@H]3c4ccccc4CCc4cccc([C@@H]2C1)c34,"InChI=1S/C25H31NO/c1-24(2,3)25(27)13-14-26-16-21-19-9-5-4-7-17(19)11-12-18-8-6-10-20(23(18)21)22(26)15-25/h4-10,21-22,27H,11-16H2,1-3H3/t21-,22-,25-/m0/s1",ZZJYIKPMDIWRSN-HWBMXIPRSA-N,50008735,"(+)-3-(tert-butyl)-(3S,4aS,13bS)-2,3,4,4a,8,9,13b,14-octahydro-1H-benzo[4,5]cyclohepta[de]pyrido[2,1-a]isoquinolin-3-ol::(+)-butaclamol::(+/-)-3-(tert-butyl)-(3S,4aS,13bS)-2,3,4,4a,8,9,13b,14-octahydro-1H-benzo[4,5]cyclohepta[de]pyrido[2,1-a]isoquinolin-3-ol::(S)-(-)-3-(tert-butyl)-(3S,4aS,13bS)-2,3,4,4a,8,9,13b,14-octahydro-1H-benzo[6,7]cyclohepta[de]pyrido[2,1-a]isoquinolin-3-ol::3-(tert-butyl)-(3S,4aS,13bS)-2,3,4,4a,8,9,13b,14-octahydro-1H-benzo[4,5]cyclohepta[de]pyrido[2,1-a]isoquinolin-3-ol::3-(tert-butyl)-(3S,4aS,13bS)-2,3,4,4a,8,9,13b,14-octahydro-1H-benzo[4,5]cyclohepta[de]pyrido[2,1-a]isoquinolin-3-ol ((+)-butaclamol)::3-(tert-butyl)-(3S,4aS,13bS)-2,3,4,4a,8,9,13b,14-octahydro-1H-benzo[4,5]cyclohepta[de]pyrido[2,1-a]isoquinolin-3-ol((+)-butaclamol)::3-(tert-butyl)-(3S,4aS,13bS)-2,3,4,4a,8,9,13b,14-octahydro-1H-benzo[6,7]cyclohepta[de]pyrido[2,1-a]isoquinolin-3-ol(Butaclamol)::BUTACLAMOL::BUTACLAMOL, (-)::BUTACLAMOL,(+)::BUTACLAMOL,d-::CHEMBL8514::d-Butaclamol",Sigma non-opioid intracellular receptor 1,Rattus,
1022857,C[C@H]1CCCN1C(=O)c1nc(sc1-c1cnc(N[C@@H]2CCCC2(F)F)cc1C(F)(F)F)C(=O)NCC(C)(C)O,"InChI=1S/C25H30F5N5O3S/c1-13-6-5-9-35(13)22(37)18-19(39-21(34-18)20(36)32-12-23(2,3)38)14-11-31-17(10-15(14)25(28,29)30)33-16-7-4-8-24(16,26)27/h10-11,13,16,38H,4-9,12H2,1-3H3,(H,31,33)(H,32,36)/t13-,16+/m0/s1",UMEOAYCBDSHQBY-XJKSGUPXSA-N,492139,"5-(6-(((R*)-2,2-Difluorocyclopentyl)amino)-4-(trifluoromethyl)pyridin-3-yl)-N-(2-hydroxy-2-methylpropyl)-4-((S)-2-methylpyrrolidine-1-carbonyl)thiazole-2-carboxamide::US10975068, Example 280",Nuclear receptor ROR-gamma,,
1216210,CC(C)n1nc(-c2noc(C3CC3)c2-c2ccccn2)c2c(N)ncc(Cl)c12,"InChI=1S/C20H19ClN6O/c1-10(2)27-18-12(21)9-24-20(22)15(18)16(25-27)17-14(13-5-3-4-8-23-13)19(28-26-17)11-6-7-11/h3-5,8-11H,6-7H2,1-2H3,(H2,22,24)",GWDRQXMAYBMTEO-UHFFFAOYSA-N,576988,"US11472802, Example 8",Proto-oncogene tyrosine-protein kinase receptor Ret [V804M],, 0.017
51381513,OS(=O)(=O)C(C(=O)Nc1cnc2ccccc2c1)c1ccccc1,"InChI=1S/C17H14N2O4S/c20-17(16(24(21,22)23)12-6-2-1-3-7-12)19-14-10-13-8-4-5-9-15(13)18-11-14/h1-11,16H,(H,19,20)(H,21,22,23)",BDHSZYAVPQKKIY-UHFFFAOYSA-N,50558483,CHEMBL4778085,Tyrosine-protein phosphatase non-receptor type 2,Homo sapiens,>200000
50721323,NS(=O)(=O)c1ccc(cc1)-n1nnnc1-c1ccc(cc1)C(F)(F)F,"InChI=1S/C14H10F3N5O2S/c15-14(16,17)10-3-1-9(2-4-10)13-19-20-21-22(13)11-5-7-12(8-6-11)25(18,23)24/h1-8H,(H2,18,23,24)",HDGAMZKNYZRNRU-UHFFFAOYSA-N,50365758,CHEMBL1956386,Prostaglandin G/H synthase 2,Homo sapiens,>100000
50500071,COCCOc1nc(-c2cccc(c2)C(F)(F)F)n(n1)-c1ccc(NC(=O)CCl)cc1,"InChI=1S/C20H18ClF3N4O3/c1-30-9-10-31-19-26-18(13-3-2-4-14(11-13)20(22,23)24)28(27-19)16-7-5-15(6-8-16)25-17(29)12-21/h2-8,11H,9-10,12H2,1H3,(H,25,29)",YNPCFQRRZGAJJP-UHFFFAOYSA-N,50177227,CHEMBL3814547,Mucosa-associated lymphoid tissue lymphoma translocation protein 1,, 93000
78832,Cc1c(C)c(O)c(C=CCCC#CCCCC#CCO)c(C)c1O,"InChI=1S/C21H26O3/c1-16-17(2)21(24)19(18(3)20(16)23)14-12-10-8-6-4-5-7-9-11-13-15-22/h12,14,22-24H,5,7-10,15H2,1-3H3",YJJCOKZDOWPHHH-UHFFFAOYSA-N,50006811,"2-(12-Hydroxy-5,10-dodecadiynyl)-3,5,6-trimethyl-p-benzoquinone::2-(12-hydroxydodeca-5,10-diyn-1-yl)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione::2-(12-hydroxydodeca-5,10-diynyl)-3,5,6-trimethyl-1,4-benzoquinone::AA861::CHEMBL304818::cid_1967::docebenone",Tyrosine-protein phosphatase YopH,Yersinia enterocolitica,>50000
788924,O[C@@H](CNC(=O)c1ccnc(NC2CCCC2)c1)CN1CCc2ccccc2C1,"InChI=1S/C23H30N4O2/c28-21(16-27-12-10-17-5-1-2-6-19(17)15-27)14-25-23(29)18-9-11-24-22(13-18)26-20-7-3-4-8-20/h1-2,5-6,9,11,13,20-21,28H,3-4,7-8,10,12,14-16H2,(H,24,26)(H,25,29)/t21-/m0/s1",GDMQNDHVTFHNKD-NRFANRHFSA-N,179439,"US10307413, Compound 334::US10391089, Compound 334::US10980794, Cmpd No 334::US9675614, 334",Protein arginine N-methyltransferase 5,,<100
50488611,CCNCC(=O)N1N=C(CC1c1ccccc1)c1cc2ccccc2oc1=O,"InChI=1S/C22H21N3O3/c1-2-23-14-21(26)25-19(15-8-4-3-5-9-15)13-18(24-25)17-12-16-10-6-7-11-20(16)28-22(17)27/h3-12,19,23H,2,13-14H2,1H3",CAVZUUOEKYFUDX-UHFFFAOYSA-N,50160395,CHEMBL3786821,Telomerase reverse transcriptase,Homo sapiens, 6680
465190,CC1CN(CCO1)C1CN(C1)c1cnc2ccc(nc2n1)-c1ccc2oc(N)nc2c1,"InChI=1S/C22H23N7O2/c1-13-10-28(6-7-30-13)15-11-29(12-15)20-9-24-17-4-3-16(25-21(17)27-20)14-2-5-19-18(8-14)26-22(23)31-19/h2-5,8-9,13,15H,6-7,10-12H2,1H3,(H2,23,26)",IDOCBOMLGZNLKU-UHFFFAOYSA-N,141974,"US9682141, 547","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform",Homo sapiens,>10000
18244,CC(Cc1cccc(OC(=O)N(C)C2CCCCC2)c1)N(C)CC#C,"InChI=1S/C21H30N2O2/c1-5-14-22(3)17(2)15-18-10-9-13-20(16-18)25-21(24)23(4)19-11-7-6-8-12-19/h1,9-10,13,16-17,19H,6-8,11-12,14-15H2,2-4H3",FTMQGFFVKGHYEQ-UHFFFAOYSA-N,10829,"3-(N-Methyl,Ncyclohexylcarbamyloxy)-N-methyl-N-propargylphenylpropylamine Mesylate::3-{2-[methyl(prop-2-yn-1-yl)amino]propyl}phenyl N-cyclohexyl-N-methylcarbamate; methanesulfonic acid::Phenethylamine deriv. 53e",Acetylcholinesterase,Homo sapiens, 8670
452959,NC(=O)C(=C\c1ccc2cn[nH]c2c1)\C#N,"InChI=1S/C11H8N4O/c12-5-9(11(13)16)3-7-1-2-8-6-14-15-10(8)4-7/h1-4,6H,(H2,13,16)(H,14,15)/b9-3+",XLGYCNBBWHAJDG-YCRREMRBSA-N,259815,"US9505766, 15",Serine/threonine-protein kinase Nek2 [C22A],,>10000
50962415,CCCCCCCCCN[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@H]1OC,"InChI=1S/C16H33NO5/c1-3-4-5-6-7-8-9-10-17-11-12(18)13(19)14(20)15(21)16(11)22-2/h11-21H,3-10H2,1-2H3/t11-,12-,13+,14-,15+,16-/m0/s1",XIVQQGYSZPSBSE-KLOLGFOXSA-N,50394825,CHEMBL2164230,Lysosomal acid glucosylceramidase,Homo sapiens,
627972,CO[C@@H]1C[C@@H]2CC[C@H](C1)N2c1ccc(cn1)-c1cc(cn2ncc(C#N)c12)-c1cnn(C)c1,"InChI=1S/C25H25N7O/c1-30-14-19(13-28-30)17-7-23(25-18(10-26)12-29-31(25)15-17)16-3-6-24(27-11-16)32-20-4-5-21(32)9-22(8-20)33-2/h3,6-7,11-15,20-22H,4-5,8-9H2,1-2H3/t20-,21+,22+",DJCMPYFVTZZCKJ-ZBYYUNFXSA-N,284190,"US10023570, Example 200::US10174028, Example 200",Proto-oncogene tyrosine-protein kinase receptor Ret [V804M],, 50.7
50542741,CC(C)COC(=O)[C@@H](Cn1cncn1)NC(=O)c1ccc(cc1)-c1ccccc1F,"InChI=1S/C22H23FN4O3/c1-15(2)12-30-22(29)20(11-27-14-24-13-25-27)26-21(28)17-9-7-16(8-10-17)18-5-3-4-6-19(18)23/h3-10,13-15,20H,11-12H2,1-2H3,(H,26,28)/t20-/m1/s1",YIJUYZNEIGFWAF-HXUWFJFHSA-N,50207552,CHEMBL3892576,Cytochrome P450 2C19,Homo sapiens, 1890
50285629,CCCCCc1cc(O)cc(OCCCCCCCCCCCCNC2CC2)c1,"InChI=1S/C26H45NO2/c1-2-3-12-15-23-20-25(28)22-26(21-23)29-19-14-11-9-7-5-4-6-8-10-13-18-27-24-16-17-24/h20-22,24,27-28H,2-19H2,1H3",IRCVQHMAPOVLBT-UHFFFAOYSA-N,50055435,CHEMBL3321781,Cannabinoid receptor 1,Homo sapiens,
50930513,Nc1c2CCCCc2nc2cccc(N3CCN(CCCCc4c[nH]c5ccccc45)CC3)c12,"InChI=1S/C29H35N5/c30-29-23-10-2-4-12-25(23)32-26-13-7-14-27(28(26)29)34-18-16-33(17-19-34)15-6-5-8-21-20-31-24-11-3-1-9-22(21)24/h1,3,7,9,11,13-14,20,31H,2,4-6,8,10,12,15-19H2,(H2,30,32)",QJVGHNGLGSOMNC-UHFFFAOYSA-N,50272685,CHEMBL4126818,5-hydroxytryptamine receptor 1A,,
58525,CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CC[C@H](C)[C@H]1C(=O)Nc1cc(C)nn1-c1ccccc1,"InChI=1S/C28H40N6O3/c1-18-15-16-33(28(37)24(21-11-7-5-8-12-21)31-26(35)20(3)29-4)25(18)27(36)30-23-17-19(2)32-34(23)22-13-9-6-10-14-22/h6,9-10,13-14,17-18,20-21,24-25,29H,5,7-8,11-12,15-16H2,1-4H3,(H,30,36)(H,31,35)/t18-,20-,24-,25-/m0/s1",IBBHIZXRMBKKII-IYNDAXALSA-N,32578,CS-1,Baculoviral IAP repeat-containing protein 2 [269-336],Homo sapiens,
401508,CNC(=O)c1cccc(Nc2ncnc(n2)N2CC(C2)Oc2cc(Cl)ccc2Cl)c1,"InChI=1S/C20H18Cl2N6O2/c1-23-18(29)12-3-2-4-14(7-12)26-19-24-11-25-20(27-19)28-9-15(10-28)30-17-8-13(21)5-6-16(17)22/h2-8,11,15H,9-10H2,1H3,(H,23,29)(H,24,25,26,27)",CQGIHNRCGNJXCT-UHFFFAOYSA-N,229691,"US9334269, 18",Sodium channel protein type 9 subunit alpha,, 310
151938,OCCSC1=C(SCCO)C(=O)c2ccccc2C1=O,"InChI=1S/C14H14O4S2/c15-5-7-19-13-11(17)9-3-1-2-4-10(9)12(18)14(13)20-8-6-16/h1-4,15-16H,5-8H2",MAASHDQFQDDECQ-UHFFFAOYSA-N,50208827,"2,3-bis(2-hydroxyethylthio)naphthalene-1,4-dione::CHEMBL429095::N1786 (NSC95397)::NSC 9539::NSC 95397::NSC-95397::cid_262093",Hexokinase HKDC1 [W721R],Homo sapiens, 3150
544214,CC[C@H](NS(=O)(=O)c1ccc(-c2sc(nc2CC2CCCC2)-c2nnc(CC(C)(C)C(O)=O)o2)c(F)c1C(F)F)C(F)(F)F,"InChI=1S/C27H30F6N4O5S2/c1-4-17(27(31,32)33)37-44(40,41)16-10-9-14(20(28)19(16)22(29)30)21-15(11-13-7-5-6-8-13)34-24(43-21)23-36-35-18(42-23)12-26(2,3)25(38)39/h9-10,13,17,22,37H,4-8,11-12H2,1-3H3,(H,38,39)/t17-/m0/s1",BECOVIMMPUELIN-KRWDZBQOSA-N,285774,"US10080744, Example 3/41",Nuclear receptor ROR-gamma,,
239102,C(N=Nc1nc2ccccc2s1)c1ccc2OCOc2c1,"InChI=1S/C15H11N3O2S/c1-2-4-14-11(3-1)17-15(21-14)18-16-8-10-5-6-12-13(7-10)20-9-19-12/h1-7H,8-9H2",FLPXBDSAMCYBMJ-UHFFFAOYSA-N,114847,"1,3-benzodioxole-5-carbaldehyde 1,3-benzothiazol-2-ylhydrazone::1,3-benzothiazol-2-yl-[(E)-piperonylideneamino]amine::MLS000576981::N-[(E)-1,3-benzodioxol-5-ylmethylideneamino]-1,3-benzothiazol-2-amine::SMR000186009::cid_9561228",Oxysterols receptor LXR-beta,, 67521
50336609,FC(F)(F)c1cccc(Nc2ncnc3ccc(cc23)-c2cncs2)c1,"InChI=1S/C18H11F3N4S/c19-18(20,21)12-2-1-3-13(7-12)25-17-14-6-11(16-8-22-10-26-16)4-5-15(14)23-9-24-17/h1-10H,(H,23,24,25)",GDJPSUNLWNVYIH-UHFFFAOYSA-N,50086410,CHEMBL3426080,ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1,Homo sapiens, 2150
51096239,OC(=O)CCc1c([nH]c2cc(ccc12)-c1ccccc1)C(O)=O,"InChI=1S/C18H15NO4/c20-16(21)9-8-14-13-7-6-12(11-4-2-1-3-5-11)10-15(13)19-17(14)18(22)23/h1-7,10,19H,8-9H2,(H,20,21)(H,22,23)",GDRVFNVJBQRHAM-UHFFFAOYSA-N,50458867,CHEMBL3968577,Uracil nucleotide/cysteinyl leukotriene receptor,Homo sapiens,
1034804,CC(C)(C)OC(=O)CN1CCc2ccc(cc2C1=O)-c1nc(NC2CCOCC2)ncc1Cl,"InChI=1S/C24H29ClN4O4/c1-24(2,3)33-20(30)14-29-9-6-15-4-5-16(12-18(15)22(29)31)21-19(25)13-26-23(28-21)27-17-7-10-32-11-8-17/h4-5,12-13,17H,6-11,14H2,1-3H3,(H,26,27,28)",CJYOOBJKGKQVSI-UHFFFAOYSA-N,417526,"US10457669, Example 140::US11001575, Example 140",Mitogen-activated protein kinase 1,Homo sapiens, 120
50626442,CCO\N=C\c1c(cc(C)c2NC(C)(C)[C@H](O)[C@@H](C)c12)-c1cccc2cc[nH]c12,"InChI=1S/C24H29N3O2/c1-6-29-26-13-19-18(17-9-7-8-16-10-11-25-22(16)17)12-14(2)21-20(19)15(3)23(28)24(4,5)27-21/h7-13,15,23,25,27-28H,6H2,1-5H3/b26-13+/t15-,23+/m0/s1",RVNWJSHHOWQTNT-SYWQUHTRSA-N,50338317,"(+/-)-3-hydroxy-6-(1H-indol-7-yl)-2,2,4,8-tetramethyl-1,2,3,4-tetrahydroquinoline-5-carbaldehyde O-ethyl oxime::CHEMBL1682424",Glucocorticoid receptor,, 0.9
51048729,Cc1ccc(Cc2cc[n+](C)c(COc3ccc(C)cc3)c2)cc1,"InChI=1S/C22H24NO/c1-17-4-8-19(9-5-17)14-20-12-13-23(3)21(15-20)16-24-22-10-6-18(2)7-11-22/h4-13,15H,14,16H2,1-3H3/q+1",VDNDCWISAWQFKI-UHFFFAOYSA-N,50427980,CHEMBL2324261,Potassium voltage-gated channel subfamily H member 2,Homo sapiens, 346
50160965,Cc1ccc(cc1C)-c1ccc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2)cc1,"InChI=1S/C23H20N2O4S/c1-14-7-8-17(13-15(14)2)16-9-11-18(12-10-16)24-23(27)21-22(26)19-5-3-4-6-20(19)30(28,29)25-21/h3-13,25-26H,1-2H3,(H,24,27)",ATLCLKVCFGVILG-UHFFFAOYSA-N,50313223,"4-Hydroxy-1,1-dioxo-1,2-dihydro-1lambda*6*-benzo[e][1,2]thiazine-3-carboxylic acid(3',4'-dimethyl-biphenyl-4-yl)-amide::CHEMBL1086884",Prostaglandin E synthase,Homo sapiens,<26
50168722,CN1C(N)=N[C@](C1=O)(c1ccc(OC(F)F)cc1)c1cccc(c1)C#CCCF,"InChI=1S/C21H18F3N3O2/c1-27-18(28)21(26-20(27)25,15-8-10-17(11-9-15)29-19(23)24)16-7-4-6-14(13-16)5-2-3-12-22/h4,6-11,13,19H,3,12H2,1H3,(H2,25,26)/t21-/m1/s1",ONIZYHRXWWCZPM-OAQYLSRUSA-N,50329547,(R)-2-amino-4-(4-(difluoromethoxy)phenyl)-4-(3-(4-fluorobut-1-ynyl)phenyl)-1-methyl-1H-imidazol-5(4H)-one::CHEMBL1271141,Beta-secretase 1,Homo sapiens, 10
51347652,C[C@]1(CCC(F)(F)C(N)=N1)c1cc(NC(=O)c2cnc(OCF)cn2)ccc1F,"InChI=1S/C18H17F4N5O2/c1-17(4-5-18(21,22)16(23)27-17)11-6-10(2-3-12(11)20)26-15(28)13-7-25-14(8-24-13)29-9-19/h2-3,6-8H,4-5,9H2,1H3,(H2,23,27)(H,26,28)/t17-/m0/s1",HMMWZIDNPYYZHM-KRWDZBQOSA-N,50545174,CHEMBL4637181,Cytochrome P450 2D6,, 1000
208466,CSc1ccc(\C=C\c2ccc3cccc(O)c3n2)cc1,"InChI=1S/C18H15NOS/c1-21-16-11-6-13(7-12-16)5-9-15-10-8-14-3-2-4-17(20)18(14)19-15/h2-12,20H,1H3/b9-5+",ZTZFBDBMJQSZBB-WEVVVXLNSA-N,49979,2-[(E)-2-(4-methylsulfanylphenyl)ethenyl]quinolin-8-ol::2-[(E)-2-[4-(methylthio)phenyl]ethenyl]-8-quinolinol::2-[(E)-2-[4-(methylthio)phenyl]vinyl]quinolin-8-ol::MLS000760781::SMR000370890::cid_5731689,Tumor necrosis factor receptor superfamily member 10B,,
121634,CC1CCN(CC1)c1nc(C)nc2sc(C(=O)Nc3cc(F)ccc3C)c(C)c12,"InChI=1S/C22H25FN4OS/c1-12-7-9-27(10-8-12)20-18-14(3)19(29-22(18)25-15(4)24-20)21(28)26-17-11-16(23)6-5-13(17)2/h5-6,11-12H,7-10H2,1-4H3,(H,26,28)",MRWFWRKWPIFMJW-UHFFFAOYSA-N,59528,"MLS000682667::N-(5-fluoranyl-2-methyl-phenyl)-2,5-dimethyl-4-(4-methylpiperidin-1-yl)thieno[2,3-d]pyrimidine-6-carboxamide::N-(5-fluoro-2-methyl-phenyl)-2,5-dimethyl-4-(4-methylpiperidino)thieno[2,3-d]pyrimidine-6-carboxamide::N-(5-fluoro-2-methylphenyl)-2,5-dimethyl-4-(4-methyl-1-piperidinyl)-6-thieno[2,3-d]pyrimidinecarboxamide::N-(5-fluoro-2-methylphenyl)-2,5-dimethyl-4-(4-methylpiperidin-1-yl)thieno[2,3-d]pyrimidine-6-carboxamide::SMR000312024::cid_4137230",Tumor necrosis factor,Homo sapiens, 20000
51334795,CC(C)NCCCn1c(Sc2cc3OCOc3cc2I)nc2c(N)ncnc12,"InChI=1S/C18H21IN6O2S/c1-10(2)21-4-3-5-25-17-15(16(20)22-8-23-17)24-18(25)28-14-7-13-12(6-11(14)19)26-9-27-13/h6-8,10,21H,3-5,9H2,1-2H3,(H2,20,22,23)",SUPVGFZUWFMATN-UHFFFAOYSA-N,50180302,"8-(6-iodo-benzo[1,3]dioxol-5-ylsulfanyl)-9-(3-isopropylamino-propyl)adenine::8-(6-iodobenzo[d][1,3]dioxol-5-ylthio)-9-(3-(isopropylamino)propyl)-9H-purin-6-amine::8-[(6-IODO-1,3-BENZODIOXOL-5-YL)THIO]-9-[3-(ISOPROPYLAMINO)PROPYL]-9H-PURIN-6-AMINE::CHEMBL200102::US10336757, Compound PU-H71::US10676476, Example 9",Endoplasmin,, 301
51063480,CCOc1cc2c(n[nH]c2cc1-c1cnn(CC(C)C)c1)-c1cccc(c1)S(N)(=O)=O,"InChI=1S/C22H25N5O3S/c1-4-30-21-10-19-20(9-18(21)16-11-24-27(13-16)12-14(2)3)25-26-22(19)15-6-5-7-17(8-15)31(23,28)29/h5-11,13-14H,4,12H2,1-3H3,(H,25,26)(H2,23,28,29)",DCQJOTPFAGUJNC-UHFFFAOYSA-N,50433905,CHEMBL2380584,Dual specificity protein kinase TTK,Homo sapiens, 119
515173,CC(NC(=O)c1c(N)nn2cccnc12)c1cc(Cl)c2cncn2c1N1CCOCC1,"InChI=1S/C20H21ClN8O2/c1-12(25-19(30)16-17(22)26-29-4-2-3-24-18(16)29)13-9-14(21)15-10-23-11-28(15)20(13)27-5-7-31-8-6-27/h2-4,9-12H,5-8H2,1H3,(H2,22,26)(H,25,30)",XOYXKQWCTZWZQW-UHFFFAOYSA-N,272744,"2-Amino-N-[1-(8-chloro-5-morpholin-4- ylimidazo[1,5-a]pyridin-6-yl)ethyl]pyrazolo[1,5- a]pyrimidine-3-carboxamide trifluoroacetate salt (racemic mixture prepared)::US10065963, Example 145","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform",Homo sapiens,<100
50032593,Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1,"InChI=1S/C19H20FNO3/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18/h1-6,9,14,17,21H,7-8,10-12H2/t14-,17-/m0/s1",AHOUBRCZNHFOSL-YOEHRIQHSA-N,22416,"(3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine::(3S,4R)-3-[(2H-1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine::CHEMBL490::PAROXETINE::US09969700, Paroxetine::US9944618, Compound ID No. 182::[3H]Paroxetine",Sodium-dependent dopamine transporter,Mus musculus,
724061,CN(C1CCN(C)CC1)C(=O)c1ccc(Nc2nc3c(cccn3n2)N2CCC(C)(CC2)NC(C)=O)cc1,"InChI=1S/C28H38N8O2/c1-20(37)31-28(2)13-18-35(19-14-28)24-6-5-15-36-25(24)30-27(32-36)29-22-9-7-21(8-10-22)26(38)34(4)23-11-16-33(3)17-12-23/h5-10,15,23H,11-14,16-19H2,1-4H3,(H,29,32)(H,31,37)",CINFXIQWPMFKMW-UHFFFAOYSA-N,366663,"4-[[8-(4-acetamido-4- methyl-1-piperidyl)- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1- methyl-4- piperidyl)benzamide::US9873709, Example 1-260",Tyrosine-protein kinase JAK2,Homo sapiens,
50165621,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13,"InChI=1S/C26H21N3O4/c1-25-26(32,12-30)10-18(33-25)28-16-8-4-2-6-13(16)20-21-15(11-27-24(21)31)19-14-7-3-5-9-17(14)29(25)23(19)22(20)28/h2-9,18,30,32H,10-12H2,1H3,(H,27,31)/t18-,25+,26+/m1/s1",UIARLYUEJFELEN-LROUJFHJSA-N,50308060,"16-hydroxy-16-(hydroxymethyl)-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.1^{15,18}.0^{2,6}.0^{7,27}.0^{8,13}.0^{19,26}.0^{20,25}]octacosa-1(26),2(6),7(27),8(13),9,11,20(25),21,23-nonaen-3-one::CEP-701::CHEMBL603469::US11370779, Compound CEP-701","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform",Homo sapiens,
50861837,CC(C)[C@H](NC(=O)c1ccc(cc1)C(=O)NS(=O)(=O)c1ccc(Cl)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)c1nc2ccccc2o1,"InChI=1S/C36H38ClN5O8S/c1-20(2)29(31(43)35-38-26-8-5-6-10-28(26)50-35)39-34(46)27-9-7-19-42(27)36(47)30(21(3)4)40-32(44)22-11-13-23(14-12-22)33(45)41-51(48,49)25-17-15-24(37)16-18-25/h5-6,8,10-18,20-21,27,29-30H,7,9,19H2,1-4H3,(H,39,46)(H,40,44)(H,41,45)/t27-,29-,30-/m0/s1",AUBRXLUUCXRHAM-BKHJTQGXSA-N,50031209,(S)-1-{(S)-2-[4-(4-Chloro-benzenesulfonylaminocarbonyl)-benzoylamino]-3-methyl-butyryl}-pyrrolidine-2-carboxylic acid [(S)-1-(benzooxazole-2-carbonyl)-2-methyl-propyl]-amide::CHEMBL127714::N1-((S)-1-((S)-2-(((S)-1-(benzo[d]oxazol-2-yl)-3-methyl-1-oxobutan-2-yl)carbamoyl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)-N4-(4-chlorophenylsulfonyl)terephthalamide,Neutrophil elastase,Homo sapiens,
51090691,CCOc1cc(ccc1OC(C)C)C(Nc1ccc2c(N)nccc2c1)C(=O)NCc1cccc(c1)N(C)C(C)=O,"InChI=1S/C32H37N5O4/c1-6-40-29-18-24(10-13-28(29)41-20(2)3)30(36-25-11-12-27-23(17-25)14-15-34-31(27)33)32(39)35-19-22-8-7-9-26(16-22)37(5)21(4)38/h7-18,20,30,36H,6,19H2,1-5H3,(H2,33,34)(H,35,39)",LCUIJLFLRNXHCD-UHFFFAOYSA-N,50446796,CHEMBL3114839,Coagulation factor XI,Homo sapiens,
50304979,CC(C)C[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN1CCC=CC1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](C)N)[C@H](C)O)[C@H](C)O)[C@H](C)O)C(=O)N[C@@H](C)C(O)=O,"InChI=1S/C99H178N36O28/c1-51(2)47-68(89(155)119-55(6)96(162)163)129-86(152)66(33-35-71(104)140)125-81(147)60(26-12-16-38-101)123-84(150)64(30-22-41-113-98(108)109)127-91(157)70-32-24-46-135(70)95(161)54(5)118-80(146)59(25-11-15-37-100)120-74(143)49-115-73(142)48-116-92(158)75(56(7)137)131-90(156)69(50-136)130-85(151)61(28-14-20-45-134-43-18-10-19-44-134)124-83(149)63(29-21-40-112-97(106)107)122-79(145)53(4)117-93(159)76(57(8)138)132-88(154)67(34-36-72(105)141)126-82(148)62(27-13-17-39-102)128-94(160)77(58(9)139)133-87(153)65(121-78(144)52(3)103)31-23-42-114-99(110)111/h10,18,51-70,75-77,136-139H,11-17,19-50,100-103H2,1-9H3,(H2,104,140)(H2,105,141)(H,115,142)(H,116,158)(H,117,159)(H,118,146)(H,119,155)(H,120,143)(H,121,144)(H,122,145)(H,123,150)(H,124,149)(H,125,147)(H,126,148)(H,127,157)(H,128,160)(H,129,152)(H,130,151)(H,131,156)(H,132,154)(H,133,153)(H,162,163)(H4,106,107,112)(H4,108,109,113)(H4,110,111,114)/t52-,53+,54+,55+,56+,57+,58+,59+,60+,61+,62+,63+,64+,65+,66+,67+,68+,69+,70+,75+,76+,77+/m1/s1",PEBZIKCSRGTWSC-SDODRVGOSA-N,50067548,CHEMBL3402051,Amine oxidase [flavin-containing] B,,>100000
365012,ONC(=O)CCCCCCC(=O)Nc1ccccc1,"InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)",WAEXFXRVDQXREF-UHFFFAOYSA-N,19149,"CHEMBL98::N-hydroxy-N'-phenyloctanediamide::SAHA::US10011611, SAHA::US10188756, Compound SAHA::US11207431, SAHA::US11505523, Compound SAHA::US9115116, SAHA::US9353061, SAHA::US9428447, SAHA::US9695181, Vorinostat::Vorinostat::Zolinza::cid_5311::suberoylanilide hydroxamic acid",Histone deacetylase 1/11/4/6/8,Homo sapiens, 131
93899,CC(=O)Nc1ccc(cc1)C(=O)Nc1cccc(c1)-c1cnc2ccccc2n1,"InChI=1S/C23H18N4O2/c1-15(28)25-18-11-9-16(10-12-18)23(29)26-19-6-4-5-17(13-19)22-14-24-20-7-2-3-8-21(20)27-22/h2-14H,1H3,(H,25,28)(H,26,29)",MVAPFNCEPCNHIN-UHFFFAOYSA-N,48787,4-(acetylamino)-N-[3-(2-quinoxalinyl)phenyl]benzamide::4-acetamido-N-(3-quinoxalin-2-ylphenyl)benzamide::4-acetamido-N-[3-(2-quinoxalinyl)phenyl]benzamide::MLS000672627::SMR000295483::cid_2221462,Induced myeloid leukemia cell differentiation protein Mcl-1,Homo sapiens, 25477.02018
583656,CC(C)[C@@H]1CN(CCN1c1nc2ccccc2s1)c1ccc(F)c(c1)S(C)(=O)=O,"InChI=1S/C21H24FN3O2S2/c1-14(2)18-13-24(15-8-9-16(22)20(12-15)29(3,26)27)10-11-25(18)21-23-17-6-4-5-7-19(17)28-21/h4-9,12,14,18H,10-11,13H2,1-3H3/t18-/m0/s1",RGPYRFIDCPYCJL-SFHVURJKSA-N,304380,"(R)-2-(4-(4-fluoro-3-(methylsulfonyl)phenyl)-2-isopropylpiperazin-1-yl)benzo[d]thiazole::US10144715, Compound 7-56",Oxysterols receptor LXR-alpha,,
50045512,CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC(=O)Nc3ccc(F)cc3)ncnc12,"InChI=1S/C19H20FN7O5/c1-2-21-17(30)14-12(28)13(29)18(32-14)27-8-24-11-15(22-7-23-16(11)27)26-19(31)25-10-5-3-9(20)4-6-10/h3-8,12-14,18,28-29H,2H2,1H3,(H,21,30)(H2,22,23,25,26,31)/t12-,13+,14-,18+/m0/s1",CSPMYAVHHPHGTB-MOROJQBDSA-N,50454471,CHEMBL2113635,Adenosine receptor A3,Rattus norvegicus,
1003708,CN(C)C(=O)N1CCCC[C@H]1c1nc(-c2ccc(cc2)C(=O)Nc2ccccn2)c2c(nccn12)C(F)(F)F,"InChI=1S/C27H26F3N7O2/c1-35(2)26(39)36-15-6-4-7-19(36)24-34-21(22-23(27(28,29)30)32-14-16-37(22)24)17-9-11-18(12-10-17)25(38)33-20-8-3-5-13-31-20/h3,5,8-14,16,19H,4,6-7,15H2,1-2H3,(H,31,33,38)/t19-/m0/s1",FVQPPVMSCHMIKP-IBGZPJMESA-N,484416,"(S)-N,N-dimethyl-2- (1-(4-(pyridin-2- ylcarbamoyl)phenyl)-8- (trifluoromethyl)imidazo [1,5-a]pyrazin-3-yl) piperidine-1-carboxamide::US10933063, Compound 215",Tyrosine-protein kinase BTK,Homo sapiens,>100000
339780,CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@@H]4CCOC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1,"InChI=1S/C43H46ClN7O7S/c1-43(2)14-11-30(37(24-43)28-3-5-31(44)6-4-28)26-49-16-18-50(19-17-49)33-7-9-36(40(22-33)58-34-21-29-12-15-45-41(29)46-25-34)42(52)48-59(55,56)35-8-10-38(39(23-35)51(53)54)47-32-13-20-57-27-32/h3-10,12,15,21-23,25,32,47H,11,13-14,16-20,24,26-27H2,1-2H3,(H,45,46)(H,48,52)/t32-/m1/s1",LTQSONOIEBRYPY-JGCGQSQUSA-N,189669,"US10213433, Compound 238::US11369599, Compound 238::US9174982, 238",Apoptosis regulator Bcl-2,,
1110286,CC(C)CN1CCC(F)(CC1)C(=O)Nc1cc2cc(ccc2cn1)-n1nccn1,"InChI=1S/C21H25FN6O/c1-15(2)14-27-9-5-21(22,6-10-27)20(29)26-19-12-17-11-18(28-24-7-8-25-28)4-3-16(17)13-23-19/h3-4,7-8,11-13,15H,5-6,9-10,14H2,1-2H3,(H,23,26,29)",YNGWPBOHKOIIKD-UHFFFAOYSA-N,385363,"US10287267, Compound 1073::US10508099, Compound 1073::US10556885, Compound 1073::US11174244, Compound 1073",Dual specificity tyrosine-phosphorylation-regulated kinase 1A,Homo sapiens,
51446165,Cc1c(Nc2nc3ccccc3s2)cc(Cl)cc1OC1CCN(CC1)C(=O)CC(C(F)(F)F)C(F)(F)F,"InChI=1S/C24H22ClF6N3O2S/c1-13-17(33-22-32-16-4-2-3-5-19(16)37-22)10-14(25)11-18(13)36-15-6-8-34(9-7-15)21(35)12-20(23(26,27)28)24(29,30)31/h2-5,10-11,15,20H,6-9,12H2,1H3,(H,32,33)",IEMKKJCNFFIONU-UHFFFAOYSA-N,50584280,CHEMBL5082345,"Dihydroorotate dehydrogenase (quinone), mitochondrial",Homo sapiens, 794
51106292,CCS(=O)(=O)N1CCN(CC1)c1nc(nc(n1)-n1c(nc2c(OC)cccc12)C(F)F)N1CCOCC1,"InChI=1S/C22H28F2N8O4S/c1-3-37(33,34)31-9-7-29(8-10-31)20-26-21(30-11-13-36-14-12-30)28-22(27-20)32-15-5-4-6-16(35-2)17(15)25-19(32)18(23)24/h4-6,18H,3,7-14H2,1-2H3",GFAPOBFNHMOSKM-UHFFFAOYSA-N,50451233,CHEMBL4217752,"Phosphatidylinositol 3-kinase regulatory subunit alpha/4,5-bisphosphate 3-kinase catalytic subunit beta isoform",Homo sapiens,>1000
51242229,Clc1ccc(cc1)-c1ccc(o1)C(=O)N1CCN(Cc2ccc(OC3CCNCC3)c(Cl)c2)CC1,"InChI=1S/C27H29Cl2N3O3/c28-21-4-2-20(3-5-21)24-7-8-26(35-24)27(33)32-15-13-31(14-16-32)18-19-1-6-25(23(29)17-19)34-22-9-11-30-12-10-22/h1-8,17,22,30H,9-16,18H2",ILCKGRVWMQNEQC-UHFFFAOYSA-N,50508354,CHEMBL4524693,Urotensin-2 receptor,Homo sapiens, 370
50507945,Cc1cc(-c2cncs2)c2cccc(OCc3c(Cl)cncc3Cl)c2n1,"InChI=1S/C19H13Cl2N3OS/c1-11-5-13(18-8-23-10-26-18)12-3-2-4-17(19(12)24-11)25-9-14-15(20)6-22-7-16(14)21/h2-8,10H,9H2,1H3",BTMKNAFNOUAPOO-UHFFFAOYSA-N,50293873,"5-(8-((3,5-dichloropyridin-4-yl)methoxy)-2-methylquinolin-4-yl)thiazole::CHEMBL550142",B2 bradykinin receptor,Homo sapiens, 135
50273409,CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,"InChI=1S/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3/t17-/m0/s1",ZEUITGRIYCTCEM-KRWDZBQOSA-N,84745,"CAS_136434-34-9::DULOXETINE::LY-248686::LY248686::USRE49340, Rank 5",Cytochrome P450 2C19,Homo sapiens, 4100
50792590,Cc1ccc(cc1)C1CCN(Cc2ccc3OCC(=O)Nc3c2)CC1,"InChI=1S/C21H24N2O2/c1-15-2-5-17(6-3-15)18-8-10-23(11-9-18)13-16-4-7-20-19(12-16)22-21(24)14-25-20/h2-7,12,18H,8-11,13-14H2,1H3,(H,22,24)",BHPFUCZWSRDHAY-UHFFFAOYSA-N,50083350,"6-(4-p-Tolyl-piperidin-1-ylmethyl)-4H-benzo[1,4]oxazin-3-one::CHEMBL346398",D(4) dopamine receptor,Homo sapiens,
50817909,C(Oc1ccc(CN2CCCCC2)cc1)c1ccc(CN2CCCCC2)cc1,"InChI=1S/C25H34N2O/c1-3-15-26(16-4-1)19-22-7-9-24(10-8-22)21-28-25-13-11-23(12-14-25)20-27-17-5-2-6-18-27/h7-14H,1-6,15-21H2",IBFTUIVACGOPQU-UHFFFAOYSA-N,50126888,1-[4-(4-Piperidin-1-ylmethyl-benzyloxy)-benzyl]-piperazine; compound with oxalic acid::CHEMBL193978::CHEMBL416053,Histamine H3 receptor,Homo sapiens,
51425652,OC(=O)CCc1cc(-c2cc(cc(c2)C(F)(F)F)C(F)(F)F)n(n1)-c1ccc(Cl)cc1,"InChI=1S/C20H13ClF6N2O2/c21-14-1-4-16(5-2-14)29-17(10-15(28-29)3-6-18(30)31)11-7-12(19(22,23)24)9-13(8-11)20(25,26)27/h1-2,4-5,7-10H,3,6H2,(H,30,31)",BAANFZMNIGINLC-UHFFFAOYSA-N,50575880,CHEMBL4855407,Retinoic acid receptor RXR-alpha,Homo sapiens,
1170204,Cc1cc(Oc2ccccc2)cc2n(Cc3nc[nH]n3)c(CO)cc12,"InChI=1S/C19H18N4O2/c1-13-7-16(25-15-5-3-2-4-6-15)9-18-17(13)8-14(11-24)23(18)10-19-20-12-21-22-19/h2-9,12,24H,10-11H2,1H3,(H,20,21,22)",LJTYNXHTGIZXIH-UHFFFAOYSA-N,554785,"US11339144, Compound I-234",GTP-binding protein Rheb,Homo sapiens, 550000
50952525,OC(=O)c1ccn[nH]1,"InChI=1S/C4H4N2O2/c7-4(8)3-1-2-5-6-3/h1-2H,(H,5,6)(H,7,8)",KOPFEFZSAMLEHK-UHFFFAOYSA-N,50132132,1H-pyrazole-3-carboxylic acid::CHEMBL128679,Lysine-specific demethylase 4C,,>200000
1036375,COc1ccccc1Nc1ccc2c(c1)nc(CSC1CCOCC1)[nH]c2=O,"InChI=1S/C21H23N3O3S/c1-26-19-5-3-2-4-17(19)22-14-6-7-16-18(12-14)23-20(24-21(16)25)13-28-15-8-10-27-11-9-15/h2-7,12,15,22H,8-11,13H2,1H3,(H,23,24,25)",VKZPJNNPHSITQV-UHFFFAOYSA-N,434162,"US10562891, Example 84::US11008308, Example 84",Protein mono-ADP-ribosyltransferase PARP14,, 5500
1200761,Cc1n[nH]c(C#N)c1C(=O)Nc1ccc2[nH]nc(-c3ccoc3)c2c1,"InChI=1S/C17H12N6O2/c1-9-15(14(7-18)22-20-9)17(24)19-11-2-3-13-12(6-11)16(23-21-13)10-4-5-25-8-10/h2-6,8H,1H3,(H,19,24)(H,20,22)(H,21,23)",PSEMOUGZQJBMEN-UHFFFAOYSA-N,568990,"5-cyano-N-(3-(furan-3-yl)- 1H-indazol-5-yl)-3-methyl-  1H-pyrazole-4-carboxamide::US11427558, Example 137",Leucine-rich repeat serine/threonine-protein kinase 2,Homo sapiens,<100
1225728,Nc1nc(N)c(CC(=O)Nc2ccc(nc2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c(=O)[nH]1,,,581289,"(2S)-2-({5-[2-(2,4-diamino-6-oxo- 1,6-dihydropyrimidin-5- yl)acetamido]pyridin-2- yl}formamido)pentanedioic acid hydrochloride::US11504368, Example 7","Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrial",, 154
50192372,COC(=O)c1ccc2\C(=C(\Nc3ccc(cc3)N(C)C(=O)CN3CCN(C)CC3)c3ccccc3)C(=O)Nc2c1,"InChI=1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,32H,15-18,20H2,1-3H3,(H,33,38)/b29-28-",XZXHXSATPCNXJR-ZIADKAODSA-N,50026612,"BIBF-1120::Nintedanib::US10981896, Compound Nintedanib::US11046672, Nintedanib::US11208381, Nintedanib::Vargatef",Dual specificity protein kinase CLK1,Homo sapiens,
50608303,CC(C)n1nc(c2cc(ccc12)N1CCNCC1)S(=O)(=O)c1cccc2ccccc12,"InChI=1S/C24H26N4O2S/c1-17(2)28-22-11-10-19(27-14-12-25-13-15-27)16-21(22)24(26-28)31(29,30)23-9-5-7-18-6-3-4-8-20(18)23/h3-11,16-17,25H,12-15H2,1-2H3",YKEFFXDXDCCGLC-UHFFFAOYSA-N,50330522,1-isopropyl-3-(naphthalen-1-ylsulfonyl)-5-(piperazin-1-yl)-1H-indazole::CHEMBL1277837,5-hydroxytryptamine receptor 6,Homo sapiens,
50965364,Fc1ccc(nc1)-c1noc(n1)-c1cc(F)cc(c1)C#N,"InChI=1S/C14H6F2N4O/c15-10-1-2-12(18-7-10)13-19-14(21-20-13)9-3-8(6-17)4-11(16)5-9/h1-5,7H",RBSPCALDSNXWEP-UHFFFAOYSA-N,50395923,CHEMBL2164550,Potassium voltage-gated channel subfamily H member 2,Homo sapiens,>33000
50388901,CC(C)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)N[C@@H](C)C#N,"InChI=1S/C24H28F3N3O3S/c1-15(2)13-21(23(31)29-16(3)14-28)30-22(24(25,26)27)19-7-5-17(6-8-19)18-9-11-20(12-10-18)34(4,32)33/h5-12,15-16,21-22,30H,13H2,1-4H3,(H,29,31)/t16-,21-,22-/m0/s1",KNCKOELQLLGGIP-SSKFGXFMSA-N,50214540,"(S)-4-methyl-2-[(S)-2,2,2-trifluoro-1-(4'-methanesulfonyl-biphenyl-4-yl)-ethylamino]-pentanoic acid ((S)-cyano-methyl-methyl)-amide::CHEMBL250294",Cathepsin K,Homo sapiens, 0.9
213341,CC(=O)NCCCc1ccc(Oc2ccc(OC3CCCC3)cn2)cc1,"InChI=1S/C21H26N2O3/c1-16(24)22-14-4-5-17-8-10-19(11-9-17)26-21-13-12-20(15-23-21)25-18-6-2-3-7-18/h8-13,15,18H,2-7,14H2,1H3,(H,22,24)",ZLKMOUBQZRCJNB-UHFFFAOYSA-N,50332553,"CHEMBL1630707::N-(3-(4-(5-(cyclopentyloxy)pyridin-2-yloxy)phenyl)propyl)acetamide::US8470841, 7",Acetyl-CoA carboxylase 2 [151-2458],, 1.28e+3
59868,Cc1onc(c1C(=O)n1nnc2ccccc12)-c1ccccc1,"InChI=1S/C17H12N4O2/c1-11-15(16(19-23-11)12-7-3-2-4-8-12)17(22)21-14-10-6-5-9-13(14)18-20-21/h2-10H,1H3",XWEWIQCAIBLPHV-UHFFFAOYSA-N,33433,"1-[(5-methyl-3-phenyl-4-isoxazolyl)carbonyl]-1H-1,2,3-benzotriazole::1-benzotriazolyl-(5-methyl-3-phenyl-4-isoxazolyl)methanone::MLS000099557::SMR000071313::benzotriazol-1-yl-(5-methyl-3-phenyl-1,2-oxazol-4-yl)methanone::benzotriazol-1-yl-(5-methyl-3-phenyl-isoxazol-4-yl)methanone::cid_1121978",Coagulation factor XII,, 3973.366667
50718632,CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N[C@H]1CCCCN(Cc2ccccc2)C1,"InChI=1S/C25H40N4O2/c1-19(26-2)24(30)28-23(21-13-7-4-8-14-21)25(31)27-22-15-9-10-16-29(18-22)17-20-11-5-3-6-12-20/h3,5-6,11-12,19,21-23,26H,4,7-10,13-18H2,1-2H3,(H,27,31)(H,28,30)/t19-,22-,23-/m0/s1",OHZBEXNQDNVNLI-VJBMBRPKSA-N,50364510,CHEMBL1950732,Baculoviral IAP repeat-containing protein 2,, 270
640436,Cn1cc(cn1)-c1cc(nc2c(F)c(Cc3cnc(nc3)C3CC3)ccc12)C(N)=O,"InChI=1S/C22H19FN6O/c1-29-11-15(10-27-29)17-7-18(21(24)30)28-20-16(17)5-4-14(19(20)23)6-12-8-25-22(26-9-12)13-2-3-13/h4-5,7-11,13H,2-3,6H2,1H3,(H2,24,30)",HPXSKODGNCBYRZ-UHFFFAOYSA-N,213095,"US9278960, 7-33::US9636337, 7-33",Metabotropic glutamate receptor 2,, 36.0
178718,COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34,"InChI=1S/C37H38N2O6/c1-38-13-11-24-18-31(41-4)33-20-27(24)28(38)16-23-7-10-30(40-3)32(17-23)44-26-8-5-22(6-9-26)15-29-35-25(12-14-39(29)2)19-34-36(37(35)45-33)43-21-42-34/h5-10,17-20,28-29H,11-16,21H2,1-4H3/t28-,29-/m0/s1",YVPXVXANRNDGTA-VMPREFPWSA-N,50242977,CHEMBL500862::Cepharanthine::cepharantine,Trypanothione reductase,Crithidia fasciculata, 1.5e+4
1168137,CC(C)Oc1cc(C)c(cn1)-n1c2ccnc3sc(C(=O)N[C@@H]4CCC[C@@H]4N)c([nH]c1=O)c23,,,485591,"N-((1R,2S)-2-Aminocyclopentyl)-5-(*S)-(6-isopropoxy-4- methylpyridin-3-yl)-4-oxo-4,5-dihydro-3H-1-thia-3,5,8- triazaacenaphthylene-2-carboxamide::US10934310, Ex # 428::US11319329, Ex # 428",Tyrosine-protein kinase BTK,Homo sapiens, 214
51048615,CN(C)CCCn1c2-c3ccccc3C(=O)c2c2ccccc2c1=O,"InChI=1S/C21H20N2O2/c1-22(2)12-7-13-23-19-15-9-4-5-10-16(15)20(24)18(19)14-8-3-6-11-17(14)21(23)25/h3-6,8-11H,7,12-13H2,1-2H3",FYGFCQLVSPTQEJ-UHFFFAOYSA-N,50427894,CHEMBL425544,Retinoic acid receptor RXR-alpha,Homo sapiens,
50165828,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1,"InChI=1S/C35H30N4O4/c1-35-32(42-3)25(37(2)34(41)19-11-5-4-6-12-19)17-26(43-35)38-23-15-9-7-13-20(23)28-29-22(18-36-33(29)40)27-21-14-8-10-16-24(21)39(35)31(27)30(28)38/h4-16,25-26,32H,17-18H2,1-3H3,(H,36,40)/t25-,26-,32-,35+/m1/s1",BMGQWWVMWDBQGC-IIFHNQTCSA-N,50326053,CHEMBL608533::PKC-412,Interleukin-1 receptor-associated kinase 1,,
50679611,CN(C)C[C@@H]1CCn2cc(C3=C(C(=O)NC3=O)c3cn(CCO1)c1ccccc31)c1ccccc21,"InChI=1S/C28H28N4O3/c1-30(2)15-18-11-12-31-16-21(19-7-3-5-9-23(19)31)25-26(28(34)29-27(25)33)22-17-32(13-14-35-18)24-10-6-4-8-20(22)24/h3-10,16-18H,11-15H2,1-2H3,(H,29,33,34)/t18-/m0/s1",ZCBUQCWBWNUWSU-SFHVURJKSA-N,17055,"(18S)-18-[(dimethylamino)methyl]-17-oxa-4,14,21-triazahexacyclo[19.6.1.1^{7,14}.0^{2,6}.0^{8,13}.0^{22,27}]nonacosa-1(28),2(6),7(29),8(13),9,11,22(27),23,25-nonaene-3,5-dione::(9S)-9-[(dimethylamino)methyl]-6,7,10,11-tetrahydro-9H,18H-5,21:12,17-di(metheno)dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecine-18,20(19H)-dione::K00587a::LY 333531::LY-333531::LY333531::Ruboxistaurin::cid_153999",Mitogen-activated protein kinase 15,Homo sapiens,
51308350,Nc1ncnc2n([C@@H]3O[C@H](CCCOC(=O)C=C)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)cc3)nc12,"InChI=1S/C22H25ClN6O5/c1-2-15(30)33-9-3-4-14-17(31)18(32)21(34-14)29-20-16(19(24)26-11-27-20)28-22(29)25-10-12-5-7-13(23)8-6-12/h2,5-8,11,14,17-18,21,31-32H,1,3-4,9-10H2,(H,25,28)(H2,24,26,27)/t14-,17-,18-,21-/m1/s1",XOSUZIPWVSJZRF-HAXDFEGKSA-N,50531167,CHEMBL4583945,Heat shock-related 70 kDa protein 2,,
125258,Fc1ccc(NC(=O)CCC(=O)Nc2ccc(F)cc2)cc1,"InChI=1S/C16H14F2N2O2/c17-11-1-5-13(6-2-11)19-15(21)9-10-16(22)20-14-7-3-12(18)4-8-14/h1-8H,9-10H2,(H,19,21)(H,20,22)",NXRDDEZZRFPHAD-UHFFFAOYSA-N,67463,"N,N'-bis(4-fluorophenyl)butanediamide::N,N'-bis(4-fluorophenyl)succinamide::SR-01000483496-2::cid_479979",NADPH oxidase 1,Homo sapiens,>17000
51170827,COc1c(O)c(C(=O)\C=C\Nc2ccncc2)c(OC)c2ccoc12,"InChI=1S/C18H16N2O5/c1-23-16-12-6-10-25-17(12)18(24-2)15(22)14(16)13(21)5-9-20-11-3-7-19-8-4-11/h3-10,22H,1-2H3,(H,19,20)/b9-5+",UZYULOCSCOSJFD-WEVVVXLNSA-N,50480363,CHEMBL449897,Reverse transcriptase,Human immunodeficiency virus 1, 4800
50423660,CC(C)C(=O)Nc1ncc(s1)-c1ccncc1-c1ccccc1Cl,"InChI=1S/C18H16ClN3OS/c1-11(2)17(23)22-18-21-10-16(24-18)13-7-8-20-9-14(13)12-5-3-4-6-15(12)19/h3-11H,1-2H3,(H,21,22,23)",ROPKDJGJHNEEFN-UHFFFAOYSA-N,50124352,CHEMBL3623441,LIM domain kinase 1,Homo sapiens, 800
50690124,Cc1cc(C)nc(NC(=S)N2CCN(CC2)c2ccncc2)c1,"InChI=1S/C17H21N5S/c1-13-11-14(2)19-16(12-13)20-17(23)22-9-7-21(8-10-22)15-3-5-18-6-4-15/h3-6,11-12H,7-10H2,1-2H3,(H,19,20,23)",ITLPIAAGIQAGRA-UHFFFAOYSA-N,195607,"PHGDH-inactive::US11225469, Compound 71",D-3-phosphoglycerate dehydrogenase,,>57000
50099377,[Br-].[Br-].C(CCC[n+]1cc2ccccc2c2ccccc12)CC[n+]1cc2ccccc2c2ccccc12,"InChI=1S/C32H30N2.2BrH/c1(11-21-33-23-25-13-3-5-15-27(25)29-17-7-9-19-31(29)33)2-12-22-34-24-26-14-4-6-16-28(26)30-18-8-10-20-32(30)34;;/h3-10,13-20,23-24H,1-2,11-12,21-22H2;2*1H/q+2;;/p-2",GENORUDGXFJMHT-UHFFFAOYSA-L,50016849,CHEMBL3276410,Carboxylic ester hydrolase,,
51451400,COc1ccc(cc1)N1CCN(CCn2c3nc(N)nc(-c4ccc(C)o4)c3ncc2=O)[C@H](C)C1,"InChI=1S/C25H29N7O3/c1-16-15-31(18-5-7-19(34-3)8-6-18)11-10-30(16)12-13-32-21(33)14-27-23-22(20-9-4-17(2)35-20)28-25(26)29-24(23)32/h4-9,14,16H,10-13,15H2,1-3H3,(H2,26,28,29)/t16-/m1/s1",LKIIXSUVDSDCMG-MRXNPFEDSA-N,50585998,CHEMBL5091663,Adenosine receptor A2a,Homo sapiens, 296
51267339,CC(C)CN1CCc2c(ccc3[nH]ccc23)C1c1ccc(\C=C\C(O)=O)cc1,"InChI=1S/C24H26N2O2/c1-16(2)15-26-14-12-19-20-11-13-25-22(20)9-8-21(19)24(26)18-6-3-17(4-7-18)5-10-23(27)28/h3-11,13,16,24-25H,12,14-15H2,1-2H3,(H,27,28)/b10-5+",HRLHOAPGBLHTAI-BJMVGYQFSA-N,50517553,CHEMBL4451617,Estrogen receptor,, 316
51057031,CC(=O)NCCN1CCN(CC1)c1ncnc2cc(sc12)C(N)=O,"InChI=1S/C15H20N6O2S/c1-10(22)17-2-3-20-4-6-21(7-5-20)15-13-11(18-9-19-15)8-12(24-13)14(16)23/h8-9H,2-7H2,1H3,(H2,16,23)(H,17,22)",CYKFBJNULRRZFT-UHFFFAOYSA-N,50431108,CHEMBL2332051,"NAD-dependent protein deacetylase sirtuin-3, mitochondrial",, 770
51383362,Oc1cccc2ccc(nc12)C1SCC(=O)N1c1cccc(F)c1,"InChI=1S/C18H13FN2O2S/c19-12-4-2-5-13(9-12)21-16(23)10-24-18(21)14-8-7-11-3-1-6-15(22)17(11)20-14/h1-9,18,22H,10H2",MKNALTUFJWJGRJ-UHFFFAOYSA-N,50558959,CHEMBL4740594,Methionine aminopeptidase 1,Homo sapiens, 8900
196079,Cc1cccc(C)c1NC(=O)c1sccc1SCc1cccc(c1)C(F)(F)F,"InChI=1S/C21H18F3NOS2/c1-13-5-3-6-14(2)18(13)25-20(26)19-17(9-10-27-19)28-12-15-7-4-8-16(11-15)21(22,23)24/h3-11H,12H2,1-2H3,(H,25,26)",UMCWPYGKZKECIB-UHFFFAOYSA-N,89999,"MLS000325609::N-(2,6-dimethylphenyl)-3-[[3-(trifluoromethyl)benzyl]thio]thiophene-2-carboxamide::N-(2,6-dimethylphenyl)-3-[[3-(trifluoromethyl)phenyl]methylsulfanyl]thiophene-2-carboxamide::N-(2,6-dimethylphenyl)-3-[[3-(trifluoromethyl)phenyl]methylthio]-2-thiophenecarboxamide::N-(2,6-dimethylphenyl)-3-{[3-(trifluoromethyl)benzyl]sulfanyl}-2-thiophenecarboxamide::SMR000169988::cid_2765041",Corticotropin-releasing factor-binding protein,Homo sapiens,
625416,CC(NC(=O)c1cc(OC[C@H]2CCOC2)cc(c1)-c1ncc(C)s1)c1ncc(Cl)cc1F,"InChI=1S/C23H23ClFN3O3S/c1-13-9-27-23(32-13)17-5-16(6-19(7-17)31-12-15-3-4-30-11-15)22(29)28-14(2)21-20(25)8-18(24)10-26-21/h5-10,14-15H,3-4,11-12H2,1-2H3,(H,28,29)/t14?,15-/m0/s1",NHGFOVVSFOISFI-LOACHALJSA-N,319898,"N-[1-(5- Chloro-3- fluoropyridin- 2-yl)ethyl]-3- (5-methyL- 1,3-thiazol-2- yl)-5-[(3S)- tetrahydrofuran- 3-ylmethoxy] benzamide::US10174016, Example 65::US10202369, Example 65::US10472354, Example 65",P2X purinoceptor 3,Homo sapiens, 3.00
50471114,COc1ccccc1CN[C@H]1C2CCN(CC2)[C@H]1c1ccccc1,"InChI=1S/C21H26N2O/c1-24-19-10-6-5-9-18(19)15-22-20-16-11-13-23(14-12-16)21(20)17-7-3-2-4-8-17/h2-10,16,20-22H,11-15H2,1H3/t20-,21-/m0/s1",JUQHUETWINQXRD-SFTDATJTSA-N,50284131,"(2-Methoxy-benzyl)-((2S,3S)-2-phenyl-1-aza-bicyclo[2.2.2]oct-3-yl)-amine::CHEMBL166816",Substance-P receptor,Homo sapiens, 140
868677,CCC(C)c1ccc(cc1)N(C(C(=O)NC1CCCC1)c1cccnc1)C(=O)c1ccco1,"InChI=1S/C27H31N3O3/c1-3-19(2)20-12-14-23(15-13-20)30(27(32)24-11-7-17-33-24)25(21-8-6-16-28-18-21)26(31)29-22-9-4-5-10-22/h6-8,11-19,22,25H,3-5,9-10H2,1-2H3,(H,29,31)",KMPOAXYUGWTIIV-UHFFFAOYSA-N,47919,"Furan-2-carboxylic acid (4-sec-butyl-phenyl)-(cyclopentylcarbamoyl-pyridin-3-yl-methyl)-amide::MLS001222477::N-(4-butan-2-ylphenyl)-N-[2-(cyclopentylamino)-2-oxidanylidene-1-pyridin-3-yl-ethyl]furan-2-carboxamide::N-(4-butan-2-ylphenyl)-N-[2-(cyclopentylamino)-2-oxo-1-(3-pyridinyl)ethyl]-2-furancarboxamide::N-(4-butan-2-ylphenyl)-N-[2-(cyclopentylamino)-2-oxo-1-pyridin-3-ylethyl]furan-2-carboxamide::N-[2-(cyclopentylamino)-2-keto-1-(3-pyridyl)ethyl]-N-(4-sec-butylphenyl)-2-furamide::SMR000600355::acs.jmedchem.1c00409_ST.300::cid_3196508::med.21724, Compound 122",Replicase polyprotein 1a,, 34000
50983656,C[C@H](NC(=O)[C@@H](S)Cc1ccccc1)C(=O)N1CCC[C@H]1C(O)=O,"InChI=1S/C17H22N2O4S/c1-11(16(21)19-9-5-8-13(19)17(22)23)18-15(20)14(24)10-12-6-3-2-4-7-12/h2-4,6-7,11,13-14,24H,5,8-10H2,1H3,(H,18,20)(H,22,23)/t11-,13-,14-/m0/s1",YSFYVNRABGRTNY-UBHSHLNASA-N,50048514,(S)-1-[(S)-2-((S)-2-Mercapto-3-phenyl-propionylamino)-propionyl]-pyrrolidine-2-carboxylic acid::CHEMBL287896,Neprilysin,, 400
51057231,CCCCCCCC(=O)O[C@@H]1[C@@H](OC(=O)C(\C)=C/C)C(C)=C2[C@@H]3O[C@H]4N=C(C)O[C@@]4(C)[C@@]3(O)[C@H](C[C@](C)(OC(C)=O)[C@@H]12)OC(=O)CCC,"InChI=1S/C36H53NO11/c1-10-13-14-15-16-18-26(40)44-30-28-27(21(5)29(30)45-32(41)20(4)12-3)31-36(42,35(9)33(46-31)37-22(6)47-35)24(43-25(39)17-11-2)19-34(28,8)48-23(7)38/h12,24,28-31,33,42H,10-11,13-19H2,1-9H3/b20-12-/t24-,28+,29-,30-,31-,33+,34-,35+,36+/m0/s1",SQMJSIKUOUSKGN-HQNXNICLSA-N,50431169,CHEMBL2332551,Sarcoplasmic/endoplasmic reticulum calcium ATPase 1,Oryctolagus cuniculus,
50977781,CN(CC1=CC[C@H]2C[C@@H]1C2(C)C)Cc1ccc(cc1)-c1cccc(c1)C(F)(F)F,"InChI=1S/C25H28F3N/c1-24(2)21-12-11-20(23(24)14-21)16-29(3)15-17-7-9-18(10-8-17)19-5-4-6-22(13-19)25(26,27)28/h4-11,13,21,23H,12,14-16H2,1-3H3/t21-,23-/m0/s1",JQSSOYRLBSUNKQ-GMAHTHKFSA-N,50400945,CHEMBL2205084,C-X-C chemokine receptor type 3,,
958910,CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1,"InChI=1S/C31H28ClN7O2/c1-39(2)16-6-11-28(40)35-21-14-12-20(13-15-21)30(41)36-22-7-5-8-23(17-22)37-31-34-19-26(32)29(38-31)25-18-33-27-10-4-3-9-24(25)27/h3-15,17-19,33H,16H2,1-2H3,(H,35,40)(H,36,41)(H,34,37,38)/b11-6+",OBJNFLYHUXWUPF-IZZDOVSWSA-N,50110178,"CHEMBL3603847::US10787436, Compound I-23",Cyclin-dependent kinase 5 activator 1 [99-307],, 550
889140,Cn1c2ncc(cc2n(Cc2cncc(Cl)c2)c1=O)-c1cccc(F)c1F,"InChI=1S/C19H13ClF2N4O/c1-25-18-16(26(19(25)27)10-11-5-13(20)9-23-7-11)6-12(8-24-18)14-3-2-4-15(21)17(14)22/h2-9H,10H2,1H3",IFFCQSBYKDRCPL-UHFFFAOYSA-N,437039,"1-[(5-Chloro-3-pyridyl)methyl]-6-(2,3-difluorophenyl)-3-methyl-imidazo[4,5- b]pyridin-2-one::US10617676, Example 375::US11207298, Example 375","Glutamate receptor ionotropic, NMDA 2B",Homo sapiens, 1510
51028244,CC(C)(C)c1nnc2ccc(Sc3ccc(F)cc3F)cn12,"InChI=1S/C16H15F2N3S/c1-16(2,3)15-20-19-14-7-5-11(9-21(14)15)22-13-6-4-10(17)8-12(13)18/h4-9H,1-3H3",QBRGSYLNUUOUBB-UHFFFAOYSA-N,50305692,"3-tert-butyl-6-(2,4-difluorophenylthio)-[1,2,4]triazolo[4,3-a]pyridine hydrochloride::CHEMBL1198626::CHEMBL609275",Mitogen-activated protein kinase 13,Homo sapiens, 62
51230878,NS(=O)(=O)c1cc(C(=O)N2CCOCC2)c(Sc2ccccc2)cc1Cl,"InChI=1S/C17H17ClN2O4S2/c18-14-11-15(25-12-4-2-1-3-5-12)13(10-16(14)26(19,22)23)17(21)20-6-8-24-9-7-20/h1-5,10-11H,6-9H2,(H2,19,22,23)",KCHKZYKQHJUTFV-UHFFFAOYSA-N,50504945,CHEMBL4579206,Carbonic anhydrase 6,,
50577301,OC(COc1ccccc1)CN1CCC(CC1)c1ccc(Cc2ccc(F)cc2)cc1,"InChI=1S/C27H30FNO2/c28-25-12-8-22(9-13-25)18-21-6-10-23(11-7-21)24-14-16-29(17-15-24)19-26(30)20-31-27-4-2-1-3-5-27/h1-13,24,26,30H,14-20H2",VWQGDNWLMBJUHU-UHFFFAOYSA-N,50082322,1-{4-[4-(4-Fluoro-benzyl)-phenyl]-piperidin-1-yl}-3-phenoxy-propan-2-ol; hydrochloride::CHEMBL543622,Sodium channel protein type 1/2/3 subunit alpha,Rattus norvegicus, 360
50694593,CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12,"InChI=1S/C27H29FN8O3/c1-29-26(38)23-17(28)6-5-7-18(23)31-25-16-8-10-30-24(16)33-27(34-25)32-19-13-20-15(12-21(19)39-4)9-11-36(20)22(37)14-35(2)3/h5-8,10,12-13H,9,11,14H2,1-4H3,(H,29,38)(H3,30,31,32,33,34)",HZTYDQRUAWIZRE-UHFFFAOYSA-N,27817,"2-{[2-({1-[2-(dimethylamino)acetyl]-5-methoxy-2,3-dihydro-1H-indol-6-yl}amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino}-6-fluoro-N-methylbenzamide::pyrrolo[2,3-d]pyrimidine deriv., 40",Mitogen-activated protein kinase 10,Homo sapiens,
373009,CN1C(C(C(C)=O)=C(C)N(C1=O)c1cccc(c1)C(F)(F)F)c1ccc(cc1C(=O)N1CCC1)C#N,"InChI=1S/C26H23F3N4O3/c1-15-22(16(2)34)23(20-9-8-17(14-30)12-21(20)24(35)32-10-5-11-32)31(3)25(36)33(15)19-7-4-6-18(13-19)26(27,28)29/h4,6-9,12-13,23H,5,10-11H2,1-3H3",WMPDWROYDWUHHT-UHFFFAOYSA-N,211465,"US9290457, Example 1.7",Neutrophil elastase,Homo sapiens,<1
50193719,CCN(C1CCN(CCC(Cn2c(O)c(Cc3c[nH]c4ccccc34)[nH]c2=O)c2cccc(Cl)c2)CC1)C(=O)OCc1ccccc1,"InChI=1S/C37H42ClN5O4/c1-2-42(37(46)47-25-26-9-4-3-5-10-26)31-16-19-41(20-17-31)18-15-28(27-11-8-12-30(38)21-27)24-43-35(44)34(40-36(43)45)22-29-23-39-33-14-7-6-13-32(29)33/h3-14,21,23,28,31,39,44H,2,15-20,22,24-25H2,1H3,(H,40,45)",GPWGUUTTZSMWMP-UHFFFAOYSA-N,50106932,"(1-{3-(3-Chloro-phenyl)-4-[(R)-4-(1H-indol-3-ylmethyl)-2,5-dioxo-imidazolidin-1-yl]-butyl}-piperidin-4-yl)-ethyl-carbamic acid benzyl ester::CHEMBL105975",C-C chemokine receptor type 1,Homo sapiens,>1000
50738436,CN(C(=O)Cc1ccc(cc1)-c1ccccc1)c1nc(C)c(s1)S(N)(=O)=O,"InChI=1S/C19H19N3O3S2/c1-13-18(27(20,24)25)26-19(21-13)22(2)17(23)12-14-8-10-16(11-9-14)15-6-4-3-5-7-15/h3-11H,12H2,1-2H3,(H2,20,24,25)",WPXGIUPWYVACRH-UHFFFAOYSA-N,50237365,CHEMBL4090611,Carbonic anhydrase 9,Homo sapiens,
584053,CC(C)c1ccc(CN2CCN(CC2c2ccccc2)c2cccc(c2)S(C)(=O)=O)cn1,"InChI=1S/C26H31N3O2S/c1-20(2)25-13-12-21(17-27-25)18-29-15-14-28(19-26(29)22-8-5-4-6-9-22)23-10-7-11-24(16-23)32(3,30)31/h4-13,16-17,20,26H,14-15,18-19H2,1-3H3",CJVVVQGRSXIWNZ-UHFFFAOYSA-N,304576,"1-((6-isopropylpyridin-3-yl)methyl)-4-(3-(methylsulfonyl)phenyl)-2-phenylpiperazine::US10144715, Compound 46-42",Oxysterols receptor LXR-beta,,
50282490,CCN(CC)c1ccc(NC(=O)c2c(CCN3CCCCC3=O)onc2-c2c(Cl)cccc2Cl)cc1,"InChI=1S/C27H30Cl2N4O3/c1-3-32(4-2)19-13-11-18(12-14-19)30-27(35)25-22(15-17-33-16-6-5-10-23(33)34)36-31-26(25)24-20(28)8-7-9-21(24)29/h7-9,11-14H,3-6,10,15-17H2,1-2H3,(H,30,35)",RVQAINUYUARQMA-UHFFFAOYSA-N,50153547,"3-(2,6-Dichloro-phenyl)-5-[2-(2-oxo-piperidin-1-yl)-ethyl]-isoxazole-4-carboxylic acid (4-diethylamino-phenyl)-amide::CHEMBL363995",Growth hormone secretagogue receptor type 1,Homo sapiens, 9
51036733,Cc1ccnc(NCC2CCN(CC2)c2ccc(CC(NC(=O)c3c(C)cc(C)cc3C)C(O)=O)cc2)c1,"InChI=1S/C31H38N4O3/c1-20-9-12-32-28(17-20)33-19-25-10-13-35(14-11-25)26-7-5-24(6-8-26)18-27(31(37)38)34-30(36)29-22(3)15-21(2)16-23(29)4/h5-9,12,15-17,25,27H,10-11,13-14,18-19H2,1-4H3,(H,32,33)(H,34,36)(H,37,38)",RJFWKMUAMBANKC-UHFFFAOYSA-N,50423721,CHEMBL595105,Integrin alpha-5/beta-1,Homo sapiens, 2.3
20102,CC(C)C(N(Cc1ccccc1)S(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F)C(=O)NO,"InChI=1S/C16H17F9N2O4S/c1-9(2)11(12(28)26-29)27(8-10-6-4-3-5-7-10)32(30,31)16(24,25)14(19,20)13(17,18)15(21,22)23/h3-7,9,11,29H,8H2,1-2H3,(H,26,28)",VLTOUUSTKONGKC-UHFFFAOYSA-N,11342,"2-[benzyl(1,1,2,2,3,3,4,4,4-nonafluorobutane)sulfonamido]-N-hydroxy-3-methylbutanamide::Hydroxamate 22",Matrix metalloproteinase-9,Homo sapiens,
50794477,CC(C)c1noc(n1)-c1ncn-2c1[C@@H]1CCCN1C(=O)c1cc(ccc-21)C#C,"InChI=1S/C21H19N5O2/c1-4-13-7-8-15-14(10-13)21(27)25-9-5-6-16(25)18-17(22-11-26(15)18)20-23-19(12(2)3)24-28-20/h1,7-8,10-12,16H,5-6,9H2,2-3H3/t16-/m0/s1",KDGMRQJYYKGVCJ-INIZCTEOSA-N,50067436,"(S)-9-Ethynyl-3-(3-isopropyl-[1,2,4]oxadiazol-5-yl)-3b,4,5,6-tetrahydro-2,6a,11b-triaza-benzo[g]cyclopenta[e]azulen-7-one::9-Ethynyl-3-(3-isopropyl-[1,2,4]oxadiazol-5-yl)-3b,4,5,6-tetrahydro-2,6a,11b-triaza-benzo[g]cyclopenta[e]azulen-7-one::CHEMBL335888",Gamma-aminobutyric acid receptor subunit alpha-5/beta-3/gamma-2,Homo sapiens,
50882171,Clc1c(Cl)c(NS(=O)(=O)c2ccccc2)c(Cl)c(Cl)c1NS(=O)(=O)c1ccccc1,"InChI=1S/C18H12Cl4N2O4S2/c19-13-15(21)18(24-30(27,28)12-9-5-2-6-10-12)16(22)14(20)17(13)23-29(25,26)11-7-3-1-4-8-11/h1-10,23-24H",MGWQBOXYCUJGJI-UHFFFAOYSA-N,50268125,"CHEMBL483470::N,N'-(perchloro-1,4-phenylene)dibenzene sulfonamide",Liver carboxylesterase 1,,
536530,CN(c1ccccc1CNc1nc(cc2[nH]nc(C(N)=O)c12)-c1cc(F)c(O)cc1C1CC1)S(C)(=O)=O,"InChI=1S/C25H25FN6O4S/c1-32(37(2,35)36)20-6-4-3-5-14(20)12-28-25-22-19(30-31-23(22)24(27)34)11-18(29-25)16-9-17(26)21(33)10-15(16)13-7-8-13/h3-6,9-11,13,33H,7-8,12H2,1-2H3,(H2,27,34)(H,28,29)(H,30,31)",VFQLTBRWKTYVKQ-UHFFFAOYSA-N,281453,"6-(2-cyclopropyl-5-fluoro-4-hydroxyphenyl)-4-({2-[methyl(methylsul-fonyl)amino]benzyl}ami-no)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide::US10022376, Example 47",Tyrosine-protein kinase JAK2,Homo sapiens, 28.4
50894621,Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1,"InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)",ZBNZXTGUTAYRHI-UHFFFAOYSA-N,13216,"BMS-354825::CHEMBL1421::DASATINIB::N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide::N-(2-chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide::US10294227, Code Dasatinib::cid_3062316::med.21724, Compound Dasatinib",Hepatocyte growth factor receptor,Homo sapiens,
1212739,Cc1ncc(nc1CN1CC2(CC2)OC1=O)-c1cccc(c1)C(C)(F)F,"InChI=1S/C19H19F2N3O2/c1-12-16(10-24-11-19(6-7-19)26-17(24)25)23-15(9-22-12)13-4-3-5-14(8-13)18(2,20)21/h3-5,8-9H,6-7,10-11H2,1-2H3",VYWIDDWHSQWJIW-UHFFFAOYSA-N,575408,"5-[[6-[3-(1,1-Difluoroethyl)phenyl]-3-methyl-pyrazin-2- yl]methyl]-7-oxa-5-azaspiro[2.4]heptan-6-one::US11459336, Example 43","lutamate receptor ionotropic, NMDA 1/2B",Homo sapiens, 203
50131525,OC(=O)C(=O)CC(=O)c1cccc(NS(=O)(=O)c2cc(Cl)cc(Cl)c2)c1,"InChI=1S/C16H11Cl2NO6S/c17-10-5-11(18)7-13(6-10)26(24,25)19-12-3-1-2-9(4-12)14(20)8-15(21)16(22)23/h1-7,19H,8H2,(H,22,23)",WFKJNUAGCYJPSW-UHFFFAOYSA-N,50174476,"(Z)-4-[3-(3,5-Dichloro-benzenesulfonylamino)-phenyl]-2-hydroxy-4-oxo-but-2-enoic acid::CHEMBL198813",RNA-directed RNA polymerase,Hepatitis C virus, 140
50301946,C\C(CN1CCN(C[C@@H]2ON=C3[C@H]2COc2cc(OC(=O)C4CC4)ccc32)CC1)=C/c1ccccc1,"InChI=1S/C29H33N3O4/c1-20(15-21-5-3-2-4-6-21)17-31-11-13-32(14-12-31)18-27-25-19-34-26-16-23(35-29(33)22-7-8-22)9-10-24(26)28(25)30-36-27/h2-6,9-10,15-16,22,25,27H,7-8,11-14,17-19H2,1H3/b20-15+/t25-,27-/m0/s1",COPXFRMTXFPQKE-JZACSLLISA-N,50163483,"CHEMBL175911::Cyclopropanecarboxylic acid (3R,3aS)-3-[4-((E)-2-methyl-3-phenyl-allyl)-piperazin-1-ylmethyl]-3a,4-dihydro-3H-chromeno[4,3-c]isoxazol-7-yl ester",Alpha-2A adrenergic receptor,,
50636730,Cc1cc(N2CCc3cc(Br)ccc3C2)c2ccccc2n1,"InChI=1S/C19H17BrN2/c1-13-10-19(17-4-2-3-5-18(17)21-13)22-9-8-14-11-16(20)7-6-15(14)12-22/h2-7,10-11H,8-9,12H2,1H3",ZNVWUCYUAVERRR-UHFFFAOYSA-N,50342663,"4-(6-bromo-3,4-dihydroisoquinolin-2(1H)-yl)-2-methylquinoline::CHEMBL1770742",Acid-sensing ion channel 3,Homo sapiens, 27600
50541618,CCn1cnc(c1)-c1cc2nccc(Oc3ccc(NC(=O)CC(=O)Nc4ccccc4OC)cc3F)c2s1,"InChI=1S/C28H24FN5O4S/c1-3-34-15-21(31-16-34)25-13-20-28(39-25)24(10-11-30-20)38-22-9-8-17(12-18(22)29)32-26(35)14-27(36)33-19-6-4-5-7-23(19)37-2/h4-13,15-16H,3,14H2,1-2H3,(H,32,35)(H,33,36)",WCHXVWBCCCSTPJ-UHFFFAOYSA-N,50303273,"CHEMBL566844::N1-(4-(2-(1-ethyl-1H-imidazole-4-carbonyl)thieno[3,2-b]pyridin-7-yloxy)-3-fluorophenyl)-N3-(2-methoxyphenyl)malonamide",Hepatocyte growth factor receptor,Homo sapiens, 25
51166174,Cc1ccccc1CNC(=O)[C@H]1N(CSC1(C)C)C(=O)[C@@H](O)[C@H](Cc1ccccc1)NC(=O)c1cccc(N)c1Cl,"InChI=1S/C31H35ClN4O4S/c1-19-10-7-8-13-21(19)17-34-29(39)27-31(2,3)41-18-36(27)30(40)26(37)24(16-20-11-5-4-6-12-20)35-28(38)22-14-9-15-23(33)25(22)32/h4-15,24,26-27,37H,16-18,33H2,1-3H3,(H,34,39)(H,35,38)/t24-,26-,27+/m0/s1",XCMSKSMSGDIXRD-DOEKTCAHSA-N,50478140,CHEMBL404154,Protease,,
50219543,COc1ccc2oc3ncc(OCc4ccccc4)c(-c4ccccc4)c3c2c1,"InChI=1S/C25H19NO3/c1-27-19-12-13-21-20(14-19)24-23(18-10-6-3-7-11-18)22(15-26-25(24)29-21)28-16-17-8-4-2-5-9-17/h2-15H,16H2,1H3",DXUVNKBICOWQOQ-UHFFFAOYSA-N,50395890,CHEMBL2163774,Cyclin-dependent kinase 5 activator 1,Homo sapiens,
836577,CC(C)c1ccccc1-c1ncc2[nH]c(=O)n(Cc3ccc(cc3)C(=O)N3CCOC[C@H]3C)c2n1,,,325198,"(R)-2-(2-isopropylphenyl)-9-(4-(3-methylmorpholine-::US10189841, Compound I-404::US10399980, Compound I-404",Ubiquitin carboxyl-terminal hydrolase 1,, 1100
50617288,FC(F)(F)Oc1ccc(cc1)-n1cc(Cc2ccc(cc2)C(=O)Nc2nnn[nH]2)c(n1)C1CCCCC1,"InChI=1S/C25H24F3N7O2/c26-25(27,28)37-21-12-10-20(11-13-21)35-15-19(22(32-35)17-4-2-1-3-5-17)14-16-6-8-18(9-7-16)23(36)29-24-30-33-34-31-24/h6-13,15,17H,1-5,14H2,(H2,29,30,31,33,34,36)",GDZNQMSLCBZUND-UHFFFAOYSA-N,50334492,4-((3-cyclohexyl-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazol-4-yl)methyl)-N-(2H-tetrazol-5-yl)benzamide::CHEMBL1644174,Gastric inhibitory polypeptide receptor,Homo sapiens,>10000
51270345,Cn1nc(-c2ccccc2Cl)c2c1nnc1c(F)cc(F)cc21,"InChI=1S/C16H9ClF2N4/c1-23-16-13(15(22-23)9-4-2-3-5-11(9)17)10-6-8(18)7-12(19)14(10)20-21-16/h2-7H,1H3",JMVKQPJFAFIGHI-UHFFFAOYSA-N,50518779,CHEMBL4453495,"cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A",Homo sapiens, 1790
606195,Cc1cccc(Cl)c1C(=O)NCC(N1CCc2ccccc2C1)c1cncs1,"InChI=1S/C22H22ClN3OS/c1-15-5-4-8-18(23)21(15)22(27)25-11-19(20-12-24-14-28-20)26-10-9-16-6-2-3-7-17(16)13-26/h2-8,12,14,19H,9-11,13H2,1H3,(H,25,27)",OVCYWUVICQPSNM-UHFFFAOYSA-N,267131,"2-chloro-6-methyl-N-[2-(1,2,3,4-tetrahydroisoquinolin-2-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide::US10167281, Compound 19::US9718812, 19",P2X purinoceptor 7,, 104
1090561,Clc1ccc(Cn2nc(-c3ccccc3Cl)c3ccc(cc23)C(=O)NC2CCS(=O)(=O)C2)cc1,"InChI=1S/C25H21Cl2N3O3S/c26-18-8-5-16(6-9-18)14-30-23-13-17(25(31)28-19-11-12-34(32,33)15-19)7-10-21(23)24(29-30)20-3-1-2-4-22(20)27/h1-10,13,19H,11-12,14-15H2,(H,28,31)",AQVKVSUVKRZSTB-UHFFFAOYSA-N,517371,"1-(4-chlorobenzyl)-3-(2- chlorophenyl)-N-(1,1- dioxidotetrahydrothiophen-3-yl)- 1H-indazole-6-carboxamide::US11104690, Example 168",Diacylglycerol O-acyltransferase 2,Homo sapiens, 455
51282751,CNC(=O)c1c(oc2cc(N(c3ccc(B(O)O)c(Cl)c3)S(C)(=O)=O)c(cc12)C1CC1)-c1ccc(F)cc1,"InChI=1S/C26H23BClFN2O6S/c1-30-26(32)24-19-12-18(14-3-4-14)22(13-23(19)37-25(24)15-5-7-16(29)8-6-15)31(38(2,35)36)17-9-10-20(27(33)34)21(28)11-17/h5-14,33-34H,3-4H2,1-2H3,(H,30,32)",HRDHNBASQAPPRC-UHFFFAOYSA-N,50523184,CHEMBL4528447,Cytochrome P450 3A4,Homo sapiens,>33000
51073503,Clc1ccc2n(-c3ccccc3)c3nc(=O)[nH]c(=O)c3cc2c1,"InChI=1S/C17H10ClN3O2/c18-11-6-7-14-10(8-11)9-13-15(19-17(23)20-16(13)22)21(14)12-4-2-1-3-5-12/h1-9H,(H,20,22,23)",FXRJGHFGRXIXMM-UHFFFAOYSA-N,50438876,CHEMBL2420496,Tyrosyl-DNA phosphodiesterase 2,Homo sapiens,
67780,Cc1cc(no1)C(=O)Nc1cc(C)n(Cc2ccc(Cl)cc2)n1,"InChI=1S/C16H15ClN4O2/c1-10-7-15(18-16(22)14-8-11(2)23-20-14)19-21(10)9-12-3-5-13(17)6-4-12/h3-8H,9H2,1-2H3,(H,18,19,22)",YTQNANNNIWCWCA-UHFFFAOYSA-N,37292,"MLS000087314::N-[1-(4-chlorobenzyl)-5-methyl-1H-pyrazol-3-yl]-5-methylisoxazole-3-carboxamide::N-[1-(4-chlorobenzyl)-5-methyl-pyrazol-3-yl]-5-methyl-isoxazole-3-carboxamide::N-[1-[(4-chlorophenyl)methyl]-5-methyl-3-pyrazolyl]-5-methyl-3-isoxazolecarboxamide::N-[1-[(4-chlorophenyl)methyl]-5-methyl-pyrazol-3-yl]-5-methyl-1,2-oxazole-3-carboxamide::N-[1-[(4-chlorophenyl)methyl]-5-methylpyrazol-3-yl]-5-methyl-1,2-oxazole-3-carboxamide::SMR000023537::cid_3237514",Pantothenate synthetase,,>100000
219540,O=C1N(Cc2cccc(c2)-c2ccccc2)CCCC11CCN(CC1)c1cnc2ccccc2n1,"InChI=1S/C30H30N4O/c35-29-30(15-18-33(19-16-30)28-21-31-26-12-4-5-13-27(26)32-28)14-7-17-34(29)22-23-8-6-11-25(20-23)24-9-2-1-3-10-24/h1-6,8-13,20-21H,7,14-19,22H2",DHBHYLLJTLRILL-UHFFFAOYSA-N,102152,"US8530648, 49",Orexin receptor type 2,Homo sapiens,
238115,Cc1ccc(cc1)-c1nc2cc(C)ccc2o1,"InChI=1S/C15H13NO/c1-10-3-6-12(7-4-10)15-16-13-9-11(2)5-8-14(13)17-15/h3-9H,1-2H3",RETREZSKHMFVCD-UHFFFAOYSA-N,48186,"5-methyl-2-(4-methylphenyl)-1,3-benzoxazole::5-methyl-2-(p-tolyl)-1,3-benzoxazole::MLS000113249::SMR000109153::cid_85307",Nuclear hormone receptor family member daf-12,Caenorhabditis elegans,
50579931,CN(C)c1ccc(Nc2nccc(n2)-c2sc(C)nc2C)cc1,"InChI=1S/C17H19N5S/c1-11-16(23-12(2)19-11)15-9-10-18-17(21-15)20-13-5-7-14(8-6-13)22(3)4/h5-10H,1-4H3,(H,18,20,21)",FGGSNQOBRJVAKL-UHFFFAOYSA-N,8066,"2-Anilino-4-(thiazol-5-yl)pyrimidine deriv. 37::4-(dimethyl-1,3-thiazol-5-yl)pyrimidin-2-yl]-1-N,1-N-dimethylbenzene-1,4-diamine, 3::4-N-[4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-yl]-1-N,1-N-dimethylbenzene-1,4-diamine::N-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]N,N-dimethylbenzene-1,4-diamine",Cyclin-dependent kinase 9,Homo sapiens,
50884893,CSc1ccc(\C=C2/NC(=O)NC2=O)cc1,"InChI=1S/C11H10N2O2S/c1-16-8-4-2-7(3-5-8)6-9-10(14)13-11(15)12-9/h2-6H,1H3,(H2,12,13,14,15)/b9-6-",XTMVUGQFVUETDJ-TWGQIWQCSA-N,50297154,"(Z)-5-(4-(methylthio)benzylidene)imidazolidine-2,4-dione::CHEMBL569595",Glycogen synthase kinase-3 beta,Homo sapiens, 6900
50949472,C[C@H](N)C(=O)N1C[C@@H](Cl)C[C@H]1B(O)O,"InChI=1S/C7H14BClN2O3/c1-4(10)7(12)11-3-5(9)2-6(11)8(13)14/h4-6,13-14H,2-3,10H2,1H3/t4-,5-,6-/m0/s1",HPESIFUOBXUHNB-ZLUOBGJFSA-N,50389468,CHEMBL2063028,Dipeptidyl peptidase 8,Homo sapiens, 27000
53229,Cc1ncsc1C(=O)N(Cc1cc(=O)[nH]c2c(F)cccc12)c1ccccc1Cl,"InChI=1S/C21H15ClFN3O2S/c1-12-20(29-11-24-12)21(28)26(17-8-3-2-6-15(17)22)10-13-9-18(27)25-19-14(13)5-4-7-16(19)23/h2-9,11H,10H2,1H3,(H,25,27)",PBACZNNCRUWDOK-UHFFFAOYSA-N,29240,"quinolinone, 11","Nitric oxide synthase, inducible",Homo sapiens,
370739,Cc1ncc(c(OC[C@H]2C[C@@H]2c2ccc(OC(F)F)cn2)n1)-c1ccn(C)c(=O)c1,"InChI=1S/C21H20F2N4O3/c1-12-24-10-17(13-5-6-27(2)19(28)8-13)20(26-12)29-11-14-7-16(14)18-4-3-15(9-25-18)30-21(22)23/h3-6,8-10,14,16,21H,7,11H2,1-2H3/t14-,16+/m1/s1",DDTRNWDSNZFBCL-ZBFHGGJFSA-N,209790,"US9273033, 90","cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A",Homo sapiens,
233667,Cn1ccc2ncc(nc12)-c1cccnc1N[C@H]1CCCN(C1)S(C)(=O)=O,"InChI=1S/C18H22N6O2S/c1-23-10-7-15-18(23)22-16(11-20-15)14-6-3-8-19-17(14)21-13-5-4-9-24(12-13)27(2,25)26/h3,6-8,10-11,13H,4-5,9,12H2,1-2H3,(H,19,21)/t13-/m0/s1",RLYDDKYLBSDJBO-ZDUSSCGKSA-N,112547,"US8618103, I-43",Tyrosine-protein kinase JAK3,Homo sapiens, 3.254865
1217408,C[C@@](C(=O)NCC1(O)COC1)(c1ccccc1)n1ncc2c1nc(N)n1nc(nc21)-c1ccco1,"InChI=1S/C23H22N8O4/c1-22(14-6-3-2-4-7-14,20(32)25-11-23(33)12-34-13-23)31-19-15(10-26-31)18-27-17(16-8-5-9-35-16)29-30(18)21(24)28-19/h2-10,33H,11-13H2,1H3,(H2,24,28)(H,25,32)/t22-/m0/s1",AUQLMDIRDBZGIX-QFIPXVFZSA-N,577234,"(S)-2-(5-amino-2-(furan-2-yl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-7-yl)-N-((3-hydroxyoxetan-3-yl))methyl)-2-phenylpropanamide::US11472811, Example 31A",Adenosine deaminase,Homo sapiens, 28.0
681097,CC(C)CC(O)CN1CCCN(C1=O)c1cccc2n(ncc12)-c1ccccc1F,"InChI=1S/C23H27FN4O2/c1-16(2)13-17(29)15-26-11-6-12-27(23(26)30)20-9-5-10-21-18(20)14-25-28(21)22-8-4-3-7-19(22)24/h3-5,7-10,14,16-17,29H,6,11-13,15H2,1-2H3",CGMAREJKVSONFM-UHFFFAOYSA-N,344884,"1-[1-(2-fluorophenyl)-1H-::1-[1-(2-fluorophenyl)-1H-indazol-4-yl]-3-(2-hydroxy-4-methylpentyl)tetrahydropyrimidin-2(1H)-one::US9783527, Example 186",Sodium channel protein type 9 subunit alpha,, 1410
50123663,Clc1ccc(C[C@@H](NC(=O)C2Cc3ccccc3CN2)C(=O)N2CCN(CC2)C2CCCCC2)cc1,"InChI=1S/C29H37ClN4O2/c30-24-12-10-21(11-13-24)18-27(32-28(35)26-19-22-6-4-5-7-23(22)20-31-26)29(36)34-16-14-33(15-17-34)25-8-2-1-3-9-25/h4-7,10-13,25-27,31H,1-3,8-9,14-20H2,(H,32,35)/t26?,27-/m1/s1",YGHRPBJBMRFBDH-SSYAZFEXSA-N,50151504,"1,2,3,4-Tetrahydro-isoquinoline-3-carboxylic acid [(R)-1-(4-chloro-benzyl)-2-(4-cyclohexyl-piperazin-1-yl)-2-oxo-ethyl]-amide::CHEMBL361052",Melanocortin receptor 3,,
50298832,C1CC2CCC1c1c(Oc3cccnc3)nn3c(nnc3c21)-c1ccccc1,"InChI=1S/C22H19N5O/c1-2-5-16(6-3-1)20-24-25-21-18-14-8-10-15(11-9-14)19(18)22(26-27(20)21)28-17-7-4-12-23-13-17/h1-7,12-15H,8-11H2",ZTIASORFYBCQED-UHFFFAOYSA-N,50162224,"6-phenyl-4,5,7,8-tetraazatetracyclo[9.2.2.02,10.03,7]pentadeca-2(10),3,5,8-tetraen-9-yl 3-pyridyl ether::CHEMBL359638",Gamma-aminobutyric acid receptor subunit alpha-1/beta-3/gamma-2,Homo sapiens,
1178713,OC(=O)CCCCOc1ccc(nc1)-c1ccn[nH]1,"InChI=1S/C13H15N3O3/c17-13(18)3-1-2-8-19-10-4-5-11(14-9-10)12-6-7-15-16-12/h4-7,9H,1-3,8H2,(H,15,16)(H,17,18)",MZJLUDLXJNEHIX-UHFFFAOYSA-N,558212,"5-[[6-(1H-Pyrazol-5-yl)-3-pyridinyl]oxy]pentanoic Acid::US11365192, Example 10-1",Cytochrome P450 4F2,, 19000
871137,COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3ccc(cc3NC(=O)C=C)N3CCN(CC3)C(C)=O)ncn2)c1Cl,"InChI=1S/C29H32Cl2N8O5/c1-6-25(41)35-20-13-18(39-11-9-38(10-12-39)17(2)40)7-8-19(20)34-23-15-24(33-16-32-23)37(3)29(42)36-28-26(30)21(43-4)14-22(44-5)27(28)31/h6-8,13-16H,1,9-12H2,2-5H3,(H,35,41)(H,36,42)(H,32,33,34)",ZHZFVFGZCQNOAH-UHFFFAOYSA-N,249433,"US10537571, Compound 154::US10912774, Compound 154::US9434697, 154::US9730931, Compound 154",Fibroblast growth factor receptor 1,Homo sapiens, 777
155566,CCCCS(=O)(=O)N(C)[C@H]1CCN2CCc3ccccc3[C@H]2C1,"InChI=1S/C18H28N2O2S/c1-3-4-13-23(21,22)19(2)16-10-12-20-11-9-15-7-5-6-8-17(15)18(20)14-16/h5-8,16,18H,3-4,9-14H2,1-2H3/t16-,18+/m0/s1",LVHNKZNYJNTKDF-FUHWJXTLSA-N,81816,"AC1L33GU::AR-1K2981::CAS_82059-49-2::N-[(2S,11bR)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl]-N-methylbutane-1-sulfonamide hydrochloride::WY26703",Alpha-2A adrenergic receptor,,
51177261,Cc1cc(C)cc(c1)S(=O)(=O)c1c([nH]c2ccc(Cl)cc12)C(=O)NCCOc1ccccc1,"InChI=1S/C25H23ClN2O4S/c1-16-12-17(2)14-20(13-16)33(30,31)24-21-15-18(26)8-9-22(21)28-23(24)25(29)27-10-11-32-19-6-4-3-5-7-19/h3-9,12-15,28H,10-11H2,1-2H3,(H,27,29)",POFQMVBGPLUTLT-UHFFFAOYSA-N,50483703,CHEMBL1766241,Reverse transcriptase,Human immunodeficiency virus 1,>40000
307629,CCOc1ccc(C)nc1C(=O)N1C2CCC1C(COc1ccc(cn1)C(F)(F)F)C2,"InChI=1S/C22H24F3N3O3/c1-3-30-18-8-4-13(2)27-20(18)21(29)28-16-6-7-17(28)14(10-16)12-31-19-9-5-15(11-26-19)22(23,24)25/h4-5,8-9,11,14,16-17H,3,6-7,10,12H2,1-2H3",PDIIAZWKWPJDTA-UHFFFAOYSA-N,163917,"US9062078, 48::US9475819, 48::US9637496, 48::US9695183, 48",Orexin/Hypocretin receptor type 1,Rattus norvegicus,
50809394,COc1cccc(c1)C(=O)NCCCN1CCN(CC1)c1ccccc1OC,"InChI=1S/C22H29N3O3/c1-27-19-8-5-7-18(17-19)22(26)23-11-6-12-24-13-15-25(16-14-24)20-9-3-4-10-21(20)28-2/h3-5,7-10,17H,6,11-16H2,1-2H3,(H,23,26)",KTPQCLNOFMRFDQ-UHFFFAOYSA-N,50068374,3-Methoxy-N-{3-[4-(2-methoxy-phenyl)-piperazin-1-yl]-propyl}-benzamide::CHEMBL357448,5-hydroxytryptamine receptor 1A,Rattus norvegicus,
50119346,CC1(C)[C@H]2C[C@@H]1[C@]1(C)OB(O[C@@H]1C2)[C@H](CCCCN)NC(=O)Cn1nc(CC#N)nc1Cc1ccccc1[N+]([O-])=O,"InChI=1S/C28H38BN7O5/c1-27(2)19-15-21(27)28(3)22(16-19)40-29(41-28)23(10-6-7-12-30)32-26(37)17-35-25(33-24(34-35)11-13-31)14-18-8-4-5-9-20(18)36(38)39/h4-5,8-9,19,21-23H,6-7,10-12,14-17,30H2,1-3H3,(H,32,37)/t19-,21-,22+,23-,28-/m0/s1",YELLYQPFWRBWSX-NYQCOFSNSA-N,50069146,"CHEMBL2373405::N-[(R)-5-Amino-1-((1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxa-4-bora-tricyclo[6.1.1.0*2,6*]dec-4-yl)-pentyl]-2-[3-cyanomethyl-5-(2-nitro-benzyl)-[1,2,4]triazol-1-yl]-acetamide",Coagulation factor VII,Homo sapiens,
51183289,CCCCc1nn(CC(OCCC)c2ccccc2)c(=O)n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1,"InChI=1S/C31H35N7O2/c1-3-5-15-29-34-38(22-28(40-20-4-2)25-11-7-6-8-12-25)31(39)37(29)21-23-16-18-24(19-17-23)26-13-9-10-14-27(26)30-32-35-36-33-30/h6-14,16-19,28H,3-5,15,20-22H2,1-2H3,(H,32,33,35,36)",BDNZRTTUCHGDRE-UHFFFAOYSA-N,50044363,"5-Butyl-2-(2-phenyl-2-propoxy-ethyl)-4-[2'-(2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-2,4-dihydro-[1,2,4]triazol-3-one::CHEMBL308239",Type-1 angiotensin II receptor A/B,Rattus, 45
51012884,NC(N)=NN=Cc1ccc(Cl)c(c1)C(F)(F)F,"InChI=1S/C9H8ClF3N4/c10-7-2-1-5(4-16-17-8(14)15)3-6(7)9(11,12)13/h1-4H,(H4,14,15,17)",SYKKEBRXRXCNEC-UHFFFAOYSA-N,50394977,CHEMBL583068,Neuropeptide FF receptor 1,Homo sapiens,
50625220,CC(C)NC(=O)c1cccc(c1)-c1cc(n[nH]1)-c1ccc(CNC2CC2)cc1,"InChI=1S/C23H26N4O/c1-15(2)25-23(28)19-5-3-4-18(12-19)22-13-21(26-27-22)17-8-6-16(7-9-17)14-24-20-10-11-20/h3-9,12-13,15,20,24H,10-11,14H2,1-2H3,(H,25,28)(H,26,27)",XCCKQXYDJJDHMQ-UHFFFAOYSA-N,50337715,3-(5-(4-((cyclopropylamino)methyl)phenyl)-1H-pyrazol-3-yl)-N-isopropylbenzamide::CHEMBL1683312,Serine/threonine-protein kinase D1,Homo sapiens, 390
50505863,Fc1ccc(Cn2cccc(C(=O)NCC(=O)Nc3ccc4NC(=O)Cc4c3)c2=O)cc1F,"InChI=1S/C23H18F2N4O4/c24-17-5-3-13(8-18(17)25)12-29-7-1-2-16(23(29)33)22(32)26-11-21(31)27-15-4-6-19-14(9-15)10-20(30)28-19/h1-9H,10-12H2,(H,26,32)(H,27,31)(H,28,30)",JDUGSOODUPHJFA-UHFFFAOYSA-N,50185002,"CHEMBL3822974::US10351548, Compound IB32",3-phosphoinositide-dependent protein kinase 1,Homo sapiens, 6680
50790314,O=C1CCc2ccc(OCCCCCCN3CCCCC3)cc2N1,"InChI=1S/C20H30N2O2/c23-20-11-9-17-8-10-18(16-19(17)21-20)24-15-7-2-1-4-12-22-13-5-3-6-14-22/h8,10,16H,1-7,9,11-15H2,(H,21,23)",OPRPOGCTZWDVTJ-UHFFFAOYSA-N,50252563,CHEMBL4102298,Amine oxidase [flavin-containing] A,, 9400
51192846,CCN(CC)CCSC(=O)C(O)(c1ccccc1)c1ccccc1,"InChI=1S/C20H25NO2S/c1-3-21(4-2)15-16-24-19(22)20(23,17-11-7-5-8-12-17)18-13-9-6-10-14-18/h5-14,23H,3-4,15-16H2,1-2H3",BEJYISOPDBBZRK-UHFFFAOYSA-N,50491119,CHEMBL2377387,Muscarinic acetylcholine receptor M3,Homo sapiens,
456485,CC(N1CCN(Cc2cc(F)c(cc2C2CC2)C(N)=O)CC1)c1cc(Cl)cc(Cl)c1,"InChI=1S/C23H26Cl2FN3O/c1-14(16-8-18(24)11-19(25)9-16)29-6-4-28(5-7-29)13-17-10-22(26)21(23(27)30)12-20(17)15-2-3-15/h8-12,14-15H,2-7,13H2,1H3,(H2,27,30)",UHSPKNDHOJXKCW-UHFFFAOYSA-N,71525,"US9546164, 541::US9694002, 540::US9694002, 541",Sodium channel protein type 1/10/11/2/3/4/5/8/9 subunit alpha,Homo sapiens, 5.9
50910088,Cn1cc(C2=C(Sc3ccccc3)C(=O)NC2=O)c2ccccc12,"InChI=1S/C19H14N2O2S/c1-21-11-14(13-9-5-6-10-15(13)21)16-17(19(23)20-18(16)22)24-12-7-3-2-4-8-12/h2-11H,1H3,(H,20,22,23)",BLXHUSFCTBUDQK-UHFFFAOYSA-N,50312995,"3-(1-methyl-1H-indol-3-yl)-4-(phenylthio)-1H-pyrrole-2,5-dione::CHEMBL1086733",Glycogen synthase kinase-3 beta,Homo sapiens, 2000
51015226,COc1ccccc1CCCNCC1COC(O1)(c1ccccc1)c1ccccc1,"InChI=1S/C26H29NO3/c1-28-25-17-9-8-11-21(25)12-10-18-27-19-24-20-29-26(30-24,22-13-4-2-5-14-22)23-15-6-3-7-16-23/h2-9,11,13-17,24,27H,10,12,18-20H2,1H3",YKCXYNCLHSMBJV-UHFFFAOYSA-N,50415781,CHEMBL1088072,Alpha-1B adrenergic receptor,,
110063,CCCCCCCCCCCCN1[C@@H](CC(O)=O)c2cc(ccc2S1(=O)=O)C(F)(F)F,"InChI=1S/C22H32F3NO4S/c1-2-3-4-5-6-7-8-9-10-11-14-26-19(16-21(27)28)18-15-17(22(23,24)25)12-13-20(18)31(26,29)30/h12-13,15,19H,2-11,14,16H2,1H3,(H,27,28)/t19-/m0/s1",VIDDYFSFWDYDCF-IBGZPJMESA-N,58352,"2-[(3S)-1,1-diketo-2-lauryl-5-(trifluoromethyl)-3H-1,2-benzothiazol-3-yl]acetic acid::2-[(3S)-2-dodecyl-1,1-bis(oxidanylidene)-5-(trifluoromethyl)-3H-1,2-benzothiazol-3-yl]ethanoic acid::2-[(3S)-2-dodecyl-1,1-dioxo-5-(trifluoromethyl)-3H-1,2-benzothiazol-3-yl]acetic acid::MLS000881706::SMR000525337::cid_24747539",Streptokinase A,Streptococcus pyogenes M1 GAS,
50914673,NCCCn1nc(C(N)=O)c2CCc3cnc(Nc4ccccc4)nc3-c12,"InChI=1S/C19H21N7O/c20-9-4-10-26-17-14(16(25-26)18(21)27)8-7-12-11-22-19(24-15(12)17)23-13-5-2-1-3-6-13/h1-3,5-6,11H,4,7-10,20H2,(H2,21,27)(H,22,23,24)",OXICUMLYVMEXBW-UHFFFAOYSA-N,50321580,"1-(3-aminopropyl)-8-(phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide::CHEMBL1171950",Cyclin-dependent kinase 2,Homo sapiens, 1
51425372,OC(=O)C(F)(F)F.NCCCCCC1(CCCCCCCP1(O)=O)C(O)=O,"InChI=1S/C14H28NO4P.C2HF3O2/c15-11-7-4-6-10-14(13(16)17)9-5-2-1-3-8-12-20(14,18)19;3-2(4,5)1(6)7/h1-12,15H2,(H,16,17)(H,18,19);(H,6,7)",YKJIFLVZYLYOAK-UHFFFAOYSA-N,50575737,CHEMBL4861262,Carboxypeptidase B2,Homo sapiens, 1500
50702,COc1ccc(cc1)-c1ccc(C(=O)N[C@@H]([C@@H](C)OC(C)(C)C)C(O)=O)c(NC(=O)Nc2c(C)cc(C)cc2C)c1,"InChI=1S/C32H39N3O6/c1-18-15-19(2)27(20(3)16-18)35-31(39)33-26-17-23(22-9-12-24(40-8)13-10-22)11-14-25(26)29(36)34-28(30(37)38)21(4)41-32(5,6)7/h9-17,21,28H,1-8H3,(H,34,36)(H,37,38)(H2,33,35,39)/t21-,28+/m1/s1",ZYAQEXLNQYIHNU-PIKZIKFNSA-N,27730,"(2S,3R)-3-(tert-butoxy)-2-{[4-(4-methoxyphenyl)-2-{[(2,4,6-trimethylphenyl)carbamoyl]amino}phenyl]formamido}butanoic acid::anthranilimide based compound, 6","Glycogen phosphorylase, liver form",Homo sapiens, 3
80014,CC(C)OC(=O)CSc1nc2cc3OCOc3cc2cc1C#N,"InChI=1S/C16H14N2O4S/c1-9(2)22-15(19)7-23-16-11(6-17)3-10-4-13-14(21-8-20-13)5-12(10)18-16/h3-5,9H,7-8H2,1-2H3",JQGRFEXKKGQFJN-UHFFFAOYSA-N,42982,"(7-Cyano-[1,3]dioxolo[4,5-g]quinolin-6-ylsulfanyl)-acetic acid isopropyl ester::2-[(7-cyano-[1,3]dioxolo[4,5-g]quinolin-6-yl)thio]acetic acid isopropyl ester::2-[(7-cyano-[1,3]dioxolo[4,5-g]quinolin-6-yl)thio]acetic acid propan-2-yl ester::MLS000121901::SMR000119314::cid_1450739::propan-2-yl 2-[(7-cyano-[1,3]dioxolo[4,5-g]quinolin-6-yl)sulfanyl]acetate::propan-2-yl 2-[(7-cyano-[1,3]dioxolo[4,5-g]quinolin-6-yl)sulfanyl]ethanoate",Nuclear receptor coactivator 1,Homo sapiens,
1249255,CCn1c(c2CC(C)(C)COC(=O)[C@@H]3CCCN(N3)C(=O)[C@H](Cc3nc(cs3)-c3ccc1c2c3)NC(=O)[C@H](C(C)C)N(C)C(=O)[C@@H]1CCN(C1)S(=O)(=O)C=C)-c1cncnc1,"InChI=1S/C43H55N9O7S2/c1-8-51-35-13-12-27-17-30(35)31(38(51)29-20-44-25-45-21-29)19-43(5,6)24-59-42(56)32-11-10-15-52(48-32)41(55)33(18-36-46-34(27)23-60-36)47-39(53)37(26(3)4)49(7)40(54)28-14-16-50(22-28)61(57,58)9-2/h9,12-13,17,20-21,23,25-26,28,32-33,37,48H,2,8,10-11,14-16,18-19,22,24H2,1,3-7H3,(H,47,53)/t28-,32+,33+,37+/m1/s1",YCYZNUUCFHQODQ-PLUYPHSKSA-N,591492,"US11566007, Example A170",GTPase KRas [G12D],,>10000
50469118,CCCc1nc(CC)c(C(=O)OCCCC(=O)Nc2ccccc2)n1Cc1ccc(cc1F)-c1ccccc1S(=O)(=O)NC(=O)OCCC(C)C,"InChI=1S/C38H45FN4O7S/c1-5-13-34-41-32(6-2)36(37(45)49-22-12-18-35(44)40-29-14-8-7-9-15-29)43(34)25-28-20-19-27(24-31(28)39)30-16-10-11-17-33(30)51(47,48)42-38(46)50-23-21-26(3)4/h7-11,14-17,19-20,24,26H,5-6,12-13,18,21-23,25H2,1-4H3,(H,40,44)(H,42,46)",PBNKWFOVOSXATB-UHFFFAOYSA-N,50283228,Biphenylsulfonylcarbamate compound::CHEMBL430792,Type-1 angiotensin II receptor,Homo sapiens, 0.200000
976139,Cc1cc(Oc2ccccc2)ccc1-n1c2ccnc3sc(C(=O)N[C@@H]4CCCN(C4)C(=O)[C@H]4CCN4)c([nH]c1=O)c23,,,468174,"N-((R)-1-((R)-Azetidine-2-carbonyl)piperidin-3-yl)-5-(2-methyl-4- phenoxyphenyl)-4-oxo-4,5-dihydro-3H-1-thia-3,5,8- triazaacenaphthylene-2-carboxamide;::US10800792, Example 849::US10822348, Example 849",Tyrosine-protein kinase BTK [386-659],, 25.1
50815356,CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12,"InChI=1S/C12H16N6O4/c1-2-14-11(21)8-6(19)7(20)12(22-8)18-4-17-5-9(13)15-3-16-10(5)18/h3-4,6-8,12,19-20H,2H2,1H3,(H,14,21)(H2,13,15,16)/t6-,7+,8-,12+/m0/s1",JADDQZYHOWSFJD-FLNNQWSLSA-N,21220,"(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-N-ethyl-3,4-dihydroxyoxolane-2-carboxamide::Adenosine analog, 3::Adenosine, N6-Ethyl-carboxamido::Adenosine-5-(N-ethylcarboxamide)::CHEMBL464859::N-Ethylcarboxamidoadenosine::NECA",Adenosine receptor A2a,Homo sapiens,
51216520,Oc1cc(cc(O)c1O)-c1coc2cc(O)c(O)c(O)c2c1=O,"InChI=1S/C15H10O8/c16-7-1-5(2-8(17)13(7)20)6-4-23-10-3-9(18)14(21)15(22)11(10)12(6)19/h1-4,16-18,20-22H",DFURNQJNFBMYHM-UHFFFAOYSA-N,50456401,IRIGENOL,Receptor-type tyrosine-protein phosphatase S,, 500
50610235,Cn1ccnc1C(=O)NCC(C)(C)CN(C1=NS(=O)(=O)c2cc(F)ccc12)c1ccccc1,"InChI=1S/C23H24FN5O3S/c1-23(2,14-26-22(30)21-25-11-12-28(21)3)15-29(17-7-5-4-6-8-17)20-18-10-9-16(24)13-19(18)33(31,32)27-20/h4-13H,14-15H2,1-3H3,(H,26,30)",MRFUMRJHDPXIAR-UHFFFAOYSA-N,50331486,"1-Methyl-1H-imidazole-2-carboxylic acid{3-[(6-fluoro-1,1-dioxo-1H-1lambda*6*-benzo[d]isothiazol-3-yl)-phenyl-amino]-2,2-dimethyl-propyl}-amide::CHEMBL1289070",Potassium voltage-gated channel subfamily A member 3,Homo sapiens, 550
922653,C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#CC3CCN(CC3)S(C)(=O)=O)c2c(=O)n1-c1ccccc1,"InChI=1S/C32H29N7O4S/c1-21(35-31(40)28-29(33)36-38-17-7-16-34-30(28)38)26-20-24-9-6-8-23(13-12-22-14-18-37(19-15-22)44(2,42)43)27(24)32(41)39(26)25-10-4-3-5-11-25/h3-11,16-17,20-22H,14-15,18-19H2,1-2H3,(H,35,40)/t21-/m0/s1",CHXRHBPWUKCOBK-NRFANRHFSA-N,342532,"US10329299, Compound 83::US10675286, Compound 83::US9775844, Compound 83","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",Homo sapiens, 2000
51019827,COc1ccc(CCNc2cc(nc(OC)n2)-c2ccc(cc2)N(C)C)cc1,"InChI=1S/C22H26N4O2/c1-26(2)18-9-7-17(8-10-18)20-15-21(25-22(24-20)28-4)23-14-13-16-5-11-19(27-3)12-6-16/h5-12,15H,13-14H2,1-4H3,(H,23,24,25)",ICYPTMNUYMAVJH-UHFFFAOYSA-N,50417750,CHEMBL1644249,Prostaglandin D2 receptor,, 41.69
173243,Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12,"InChI=1S/C24H26ClFN4O/c25-18-1-6-23-21(15-18)22(16-30(23)20-4-2-19(26)3-5-20)17-7-10-28(11-8-17)13-14-29-12-9-27-24(29)31/h1-6,15-17H,7-14H2,(H,27,31)",GZKLJWGUPQBVJQ-UHFFFAOYSA-N,50001786,1-(2-{4-[5-chloro-1-(4-fluorophenyl)-1H-indol-3-yl]piperidin-1-yl}ethyl)imidazolidin-2-one::1-[2-[4-[5-chloro-1-(4-fluorophenyl)-indol-3-yl]-1-piperidyl]ethyl]imidazolidin-2-one::CHEMBL12713::Sertindole,Beta-arrestin-1,Oryctolagus cuniculus,
504090,Oc1ccc(CCC(=O)NCc2ccc(cc2)C(F)(F)F)cc1O,"InChI=1S/C17H16F3NO3/c18-17(19,20)13-5-1-12(2-6-13)10-21-16(24)8-4-11-3-7-14(22)15(23)9-11/h1-3,5-7,9,22-23H,4,8,10H2,(H,21,24)",XORVBPRQFULSIV-UHFFFAOYSA-N,264584,"US9718760, C345",Plasminogen activator inhibitor 1/Urokinase-type plasminogen activator,Homo sapiens, 539000
859389,CCc1nc2ccc(cn2c1N(C)c1nc(cs1)-c1ccc(F)cc1)C1CCN(CC(=O)N2CCC(CO)C2)CC1,"InChI=1S/C31H37FN6O2S/c1-3-26-30(35(2)31-34-27(20-41-31)23-4-7-25(32)8-5-23)38-17-24(6-9-28(38)33-26)22-11-13-36(14-12-22)18-29(40)37-15-10-21(16-37)19-39/h4-9,17,20-22,39H,3,10-16,18-19H2,1-2H3",FBHBZQSDEWXGTJ-UHFFFAOYSA-N,426481,"US10526329, Compound 117::US11072611, Compound 117",Ectonucleotide pyrophosphatase/phosphodiesterase family member 2,, 300
908850,CC(C)c1c([nH]c2ccc(cc12)C1CCN(CC1)C(=O)CN1CCC[C@@H]1CO)-c1cc(C)nc(C)c1,,,443824,"US10660877, Example 412",Toll-like receptor 8,, 34.0
50702144,Clc1ccc(cc1)C1CCN(CCCC(=O)c2ccc3CCN(CCc3c2)C(=O)c2ccccc2)CC1,"InChI=1S/C32H35ClN2O2/c33-30-12-10-24(11-13-30)26-14-19-34(20-15-26)18-4-7-31(36)29-9-8-25-16-21-35(22-17-28(25)23-29)32(37)27-5-2-1-3-6-27/h1-3,5-6,8-13,23,26H,4,7,14-22H2",ZIYJTXYUZSCVHR-UHFFFAOYSA-N,50357506,CHEMBL1914635,Melanin-concentrating hormone receptor 1,Rattus, 79
50506997,CCCCc1ccc(CN(CCCCOCC(O)=O)S(C)(=O)=O)cc1,"InChI=1S/C18H29NO5S/c1-3-4-7-16-8-10-17(11-9-16)14-19(25(2,22)23)12-5-6-13-24-15-18(20)21/h8-11H,3-7,12-15H2,1-2H3,(H,20,21)",LEMTUKURILRYMX-UHFFFAOYSA-N,50293505,2-(4-(N-(4-butylbenzyl)methylsulfonamido)butoxy)acetic acid::CHEMBL559561,Prostaglandin E2 receptor EP2 subtype,Rattus norvegicus, 701
50442614,Cc1cc(C)cc(C[C@H]2CCCCN2C(=O)CN2c3ccccc3-n3c(nnc3-c3ccccc3)[C@H](Cc3n[nH]c4ccccc34)C2=O)c1,"InChI=1S/C40H39N7O2/c1-26-20-27(2)22-28(21-26)23-30-14-10-11-19-45(30)37(48)25-46-35-17-8-9-18-36(35)47-38(29-12-4-3-5-13-29)43-44-39(47)32(40(46)49)24-34-31-15-6-7-16-33(31)41-42-34/h3-9,12-13,15-18,20-22,30,32H,10-11,14,19,23-25H2,1-2H3,(H,41,42)/t30-,32+/m1/s1",ZJGPYSQTJSMQNL-BHYZAODMSA-N,50380728,CHEMBL2017835,Gastrin/cholecystokinin type B receptor,Homo sapiens, 10.0
94317,OC(=O)c1ccc(cc1)-n1cccc1C=NNC(=O)c1cc2cc(Br)ccc2o1,"InChI=1S/C21H14BrN3O4/c22-15-5-8-18-14(10-15)11-19(29-18)20(26)24-23-12-17-2-1-9-25(17)16-6-3-13(4-7-16)21(27)28/h1-12H,(H,24,26)(H,27,28)",SIFPICQLVICEFD-UHFFFAOYSA-N,50726,4-[2-[[(5-bromanyl-1-benzofuran-2-yl)carbonylhydrazinylidene]methyl]pyrrol-1-yl]benzoic acid::4-[2-[[(5-bromo-1-benzofuran-2-carbonyl)hydrazinylidene]methyl]pyrrol-1-yl]benzoic acid::4-[2-[[(5-bromobenzofuran-2-carbonyl)hydrazono]methyl]pyrrol-1-yl]benzoic acid::4-[2-[[[(5-bromo-2-benzofuranyl)-oxomethyl]hydrazinylidene]methyl]-1-pyrrolyl]benzoic acid::4-{2-[(5-Bromo-benzofuran-2-carbonyl)-hydrazonomethyl]-pyrrol-1-yl}-benzoic acid::MLS001043301::SMR000414988::cid_1003204,Induced myeloid leukemia cell differentiation protein Mcl-1,Homo sapiens,1721.431107
1257951,Cc1nn(cc1Nc1ncc(Cl)c(OCC2COC2)n1)C(C)(C)C#N,"InChI=1S/C16H19ClN6O2/c1-10-13(5-23(22-10)16(2,3)9-18)20-15-19-4-12(17)14(21-15)25-8-11-6-24-7-11/h4-5,11H,6-8H2,1-3H3,(H,19,20,21)",XPGBSNMUIPRALK-UHFFFAOYSA-N,593180,"2-(4-((5-chloro-4-(oxetan-3- ylmethoxy)pyrimidin-2-yl)amino)- 3-methyl-1H-pyrazol-1-yl)-2- methylpropanenitrile::US11578061, Example 158",Leucine-rich repeat serine/threonine-protein kinase 2 [970-2527],, 125
50376960,Clc1cccc(c1)N1CCN(CCCCN2C(=O)C[C@H](NC(=O)C34CC5CC(CC(C5)C3)C4)C2=O)CC1,"InChI=1S/C29H39ClN4O3/c30-23-4-3-5-24(15-23)33-10-8-32(9-11-33)6-1-2-7-34-26(35)16-25(27(34)36)31-28(37)29-17-20-12-21(18-29)14-22(13-20)19-29/h3-5,15,20-22,25H,1-2,6-14,16-19H2,(H,31,37)/t20?,21?,22?,25-,29?/m0/s1",PWFKOTHBUIUXGW-FADFPCINSA-N,50206354,"CHEMBL231825::N-((S)-1-{4-[4-(3-chlorophenyl)piperazin-1-yl]butyl}pyrrolidin-2,5-dion-yl)-1-adamantanecarboxamide",5-hydroxytryptamine receptor 2A,Rattus norvegicus,
1165678,Oc1c2C(=O)N3CN([C@H]4c5ccccc5SCc5c(F)c(F)cc(OC\C=C/C33CC3)c45)n2ccc1=O,"InChI=1S/C27H21F2N3O4S/c28-17-12-19-21-16(22(17)29)13-37-20-5-2-1-4-15(20)23(21)32-14-30(27(8-9-27)7-3-11-36-19)26(35)24-25(34)18(33)6-10-31(24)32/h1-7,10,12,23,34H,8-9,11,13-14H2/b7-3-/t23-/m0/s1",QYYFWNWGMIOOMO-DFTTYVQVSA-N,552335,"US11312727, Compound 108C",Polymerase basic protein 2,, 2388
172594,C(Oc1cccnc1)[C@@H]1CCN1,"InChI=1S/C9H12N2O/c1-2-9(6-10-4-1)12-7-8-3-5-11-8/h1-2,4,6,8,11H,3,5,7H2/t8-/m0/s1",XKFMBGWHHBCWCD-QMMMGPOBSA-N,50049750,(S)-3-(azetidin-2-ylmethoxy)pyridine::3-((S)-1-Azetidin-2-ylmethoxy)-pyridine::A-159470::A-85380::CHEMBL59986,Acetylcholine receptor subunit alpha,Rattus,
51192413,CC(C)c1nc(SCc2ccc(cc2)-c2ccccc2C#N)c2ccccc2n1,"InChI=1S/C25H21N3S/c1-17(2)24-27-23-10-6-5-9-22(23)25(28-24)29-16-18-11-13-19(14-12-18)21-8-4-3-7-20(21)15-26/h3-14,17H,16H2,1-2H3",PMFZGFZEBDYMHD-UHFFFAOYSA-N,50490850,CHEMBL2349281,"High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A/cAMP-specific 3',5'-cyclic phosphodiesterase 7B",Homo sapiens,>100000
50511965,CCCCCCCCCCCCNC(=O)Oc1ccc(cc1)C1=NCCS1,"InChI=1S/C22H34N2O2S/c1-2-3-4-5-6-7-8-9-10-11-16-24-22(25)26-20-14-12-19(13-15-20)21-23-17-18-27-21/h12-15H,2-11,16-18H2,1H3,(H,24,25)",BNGJKAJIYBXVJX-UHFFFAOYSA-N,50295660,"CHEMBL557234::Dodecylcarbamic acid 4-(4,5-dihydrothiazol-2-yl)phenylester",Fatty-acid amide hydrolase 1 [30-579],, 6.3
786204,COc1ccc(CNC(=O)c2cnc(CNS(=O)(=O)c3ccc(F)c(Cl)c3)cn2)cn1,"InChI=1S/C19H17ClFN5O4S/c1-30-18-5-2-12(7-24-18)8-25-19(27)17-11-22-13(9-23-17)10-26-31(28,29)14-3-4-16(21)15(20)6-14/h2-7,9,11,26H,8,10H2,1H3,(H,25,27)",GIPLPUQPFVMLLX-UHFFFAOYSA-N,393190,"5-(3-chloro-4- fluorobenzenesulfon- amidomethyl)-N-[(6- methoxypyridin-3- yl)methyl]pyrazine-2- carboxamide::US9963434, Table 12.133","Glutamate receptor ionotropic, NMDA 2A",, 10000
50670651,CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1,"InChI=1S/C26H30FN7O3/c1-2-34(10-11-35)9-4-12-37-21-7-8-22-23(16-21)28-17-29-26(22)31-24-14-20(32-33-24)15-25(36)30-19-6-3-5-18(27)13-19/h3,5-8,13-14,16-17,35H,2,4,9-12,15H2,1H3,(H,30,36)(H2,28,29,31,32,33)",QYZOGCMHVIGURT-UHFFFAOYSA-N,26300,"2-{3-[(7-{3-[ethyl(2-hydroxyethyl)amino]propoxy}quinazolin-4-yl)amino]-1H-pyrazol-5-yl}-N-(3-fluorophenyl)acetamide::CHEMBL215152::cid_16007391::pyrazoloquinazoline deriv., 34",Serine/threonine-protein kinase 25,Homo sapiens,
51015754,Cc1ccc2cc(sc2c1)C(=O)NC1(CCCC1)C(=O)N[C@@H](CCCN1CCN(CC1)C(=O)c1cccn1C)Cc1ccccc1,"InChI=1S/C37H45N5O3S/c1-27-14-15-29-26-33(46-32(29)24-27)34(43)39-37(16-6-7-17-37)36(45)38-30(25-28-10-4-3-5-11-28)12-8-19-41-20-22-42(23-21-41)35(44)31-13-9-18-40(31)2/h3-5,9-11,13-15,18,24,26,30H,6-8,12,16-17,19-23,25H2,1-2H3,(H,38,45)(H,39,43)/t30-/m0/s1",GEIAIWAMZLASTE-PMERELPUSA-N,50415929,CHEMBL1083880,Substance-K receptor,Homo sapiens,
561207,Cc1cc(C)nc(n1)N1CC2CN(CC2C1)C(=O)c1ccccc1-c1nccn1C,"InChI=1S/C23H26N6O/c1-15-10-16(2)26-23(25-15)29-13-17-11-28(12-18(17)14-29)22(30)20-7-5-4-6-19(20)21-24-8-9-27(21)3/h4-10,17-18H,11-14H2,1-3H3",FSJYWJFWTBGKNF-UHFFFAOYSA-N,118386,"US11059828, Example 39::US8653263, 39::US9586962, Example 39::USRE48841, Example 39",Orexin receptor type 2,Homo sapiens,
802581,NC1CNc2c(C(N)=O)c(nn2C1)-c1ccc(Oc2ccccc2)cc1,"InChI=1S/C19H19N5O2/c20-13-10-22-19-16(18(21)25)17(23-24(19)11-13)12-6-8-15(9-7-12)26-14-4-2-1-3-5-14/h1-9,13,22H,10-11,20H2,(H2,21,25)",IOIPGNPFRJOTEC-UHFFFAOYSA-N,249955,"US10005782, Compound 84::US9447106, 84::US9556188, Compound 84",Tyrosine-protein kinase BTK,Homo sapiens, 2900
888057,CCNc1ncc2c(n1)N(C)CCN(c1cccc(OC(CCNC)c3ccccn3)c1)C2=O,"InChI=1S/C25H31N7O2/c1-4-27-25-29-17-20-23(30-25)31(3)14-15-32(24(20)33)18-8-7-9-19(16-18)34-22(11-13-26-2)21-10-5-6-12-28-21/h5-10,12,16-17,22,26H,4,11,13-15H2,1-3H3,(H,27,29,30)",AWBSENWJRYCHOK-UHFFFAOYSA-N,436418,"2-(ethylamino)-9- methyl-6-(3-(3- (methylamino)-1- (pyridin-2- yl)propoxy)phenyl)- 6,7,8,9-tetrahydro-5H- pyrimido[4,5- e][1,4]diazepin-5-one::US10590140, Example 193",Voltage-dependent calcium channel subunit alpha-2/delta-1 [25-1103],,
1124406,COC(=O)c1cc2NC(=O)\C(=C(/Nc3ccc(cc3)C(=O)N3CCN(CCO)CC3)c3ccccc3)c2cc1C,"InChI=1S/C31H32N4O5/c1-20-18-25-26(19-24(20)31(39)40-2)33-29(37)27(25)28(21-6-4-3-5-7-21)32-23-10-8-22(9-11-23)30(38)35-14-12-34(13-15-35)16-17-36/h3-11,18-19,32,36H,12-17H2,1-2H3,(H,33,37)/b28-27-",BLYDOULCQABGHT-DQSJHHFOSA-N,445228,"US10669235, Example 19::US11208381, Example 19",Platelet-derived growth factor receptor alpha,Homo sapiens,
1013308,CC(C)CNC(=O)N1C2CC1CN(C2)c1ccc(cn1)-c1cc(OCC(C)(C)O)cn2ncc(C#N)c12,"InChI=1S/C27H33N7O3/c1-17(2)10-30-26(35)34-20-7-21(34)14-32(13-20)24-6-5-18(11-29-24)23-8-22(37-16-27(3,4)36)15-33-25(23)19(9-28)12-31-33/h5-6,8,11-12,15,17,20-21,36H,7,10,13-14,16H2,1-4H3,(H,30,35)",NMVDCRRHAXXYDL-UHFFFAOYSA-N,296682,"US10112942, Example 417::US10137124, Example 417::US10172851, Example 417::US10555944, Example 417::US10953005, Example 417",Proto-oncogene tyrosine-protein kinase receptor Ret,Homo sapiens, 109
93254,Nc1ccc(cc1N1CCCCC1)N1CCCCC1,"InChI=1S/C16H25N3/c17-15-8-7-14(18-9-3-1-4-10-18)13-16(15)19-11-5-2-6-12-19/h7-8,13H,1-6,9-12,17H2",CHRDROHURUMVLJ-UHFFFAOYSA-N,34166,"(2,4-dipiperidinophenyl)amine::2,4-Di-piperidin-1-yl-phenylamine::2,4-bis(1-piperidinyl)aniline::2,4-di(piperidin-1-yl)aniline::MLS000033228::SMR000012925::cid_655480",Induced myeloid leukemia cell differentiation protein Mcl-1,Homo sapiens, 54000
51370517,CCn1nc2CCCCc2c1Nc1nc(cs1)-c1ccc(c(OC)n1)-n1cnc(C)c1,"InChI=1S/C22H25N7OS/c1-4-29-20(15-7-5-6-8-16(15)27-29)26-22-25-18(12-31-22)17-9-10-19(21(24-17)30-3)28-11-14(2)23-13-28/h9-13H,4-8H2,1-3H3,(H,25,26)",JPFIVLHIBZXRKR-UHFFFAOYSA-N,50534361,CHEMBL4445443,"1,3-beta-glucan synthase component GSC2",Saccharomyces cerevisiae, 8600
50319900,OC(=O)C1=C(CCC1)C(=O)Nc1ccc(cc1)-c1ccccc1,"InChI=1S/C19H17NO3/c21-18(16-7-4-8-17(16)19(22)23)20-15-11-9-14(10-12-15)13-5-2-1-3-6-13/h1-3,5-6,9-12H,4,7-8H2,(H,20,21)(H,22,23)",KKMNLDWJDASMGY-UHFFFAOYSA-N,16109,2-[(4-phenylphenyl)carbamoyl]cyclopent-1-ene-1-carboxylic acid::Biphenyl-4-ylcarbamoyl Cyclopentene Analog 1::CHEMBL348270,"Dihydroorotate dehydrogenase (quinone), mitochondrial",Rattus norvegicus, 1500
715417,FC(F)c1ccc(CCN2CCC(Nc3ncnc4[nH]ncc34)C(F)(F)C2)cc1,,,361999,"US10221182, Compound E1-1.6::US10221182, Compound E2-1.6","Glutamate receptor ionotropic, NMDA 2B",Homo sapiens, 21.2
281324,Oc1ccc(Nc2nc(NCCOCCOCCNC(=O)c3ccccc3)nc(Nc3ccc(cc3)C(=O)NCc3ccc(F)cc3)n2)cc1,"InChI=1S/C36H37FN8O5/c37-28-10-6-25(7-11-28)24-40-33(48)27-8-12-29(13-9-27)41-35-43-34(44-36(45-35)42-30-14-16-31(46)17-15-30)39-19-21-50-23-22-49-20-18-38-32(47)26-4-2-1-3-5-26/h1-17,46H,18-24H2,(H,38,47)(H,40,48)(H3,39,41,42,43,44,45)",KBZDTVRBFCWJHU-UHFFFAOYSA-N,144810,"US8952150, 99",Solute carrier organic anion transporter family member 2A1,, 23.7
50470691,CO[C@H]1[C@H](C[C@@H]2O[C@@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)[N+](C)(C)C,"InChI=1S/C30H30N4O3/c1-30-28(36-5)21(34(2,3)4)14-22(37-30)32-19-12-8-6-10-16(19)24-25-18(15-31-29(25)35)23-17-11-7-9-13-20(17)33(30)27(23)26(24)32/h6-13,21-22,28H,14-15H2,1-5H3/p+1/t21-,22-,28-,30+/m0/s1",MYOUXQLHWTWXON-VZYCLNPTSA-O,50283895,"3-methoxy-2-methyl-16-oxo-(2R,3S,4S,6S)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8(13),9,11,14,19,21(26),22,24,27-nonaen-4-yl(trimethyl)ammonium::CHEMBL335648",Epidermal growth factor receptor,Homo sapiens, 19
436249,Cc1ccc(cc1C)C(=O)Nc1ccc(cc1)[C@H]1CCCNC1,"InChI=1S/C20H24N2O/c1-14-5-6-17(12-15(14)2)20(23)22-19-9-7-16(8-10-19)18-4-3-11-21-13-18/h5-10,12,18,21H,3-4,11,13H2,1-2H3,(H,22,23)/t18-/m0/s1",GEPKFYJSXOSMME-SFHVURJKSA-N,250350,"US10501411, Example 260::US9452980, 260",Trace amine-associated receptor 1,Mus musculus,
69288,CCc1ccccc1NC(=O)C(Cc1cccnc1)C#N,"InChI=1S/C17H17N3O/c1-2-14-7-3-4-8-16(14)20-17(21)15(11-18)10-13-6-5-9-19-12-13/h3-9,12,15H,2,10H2,1H3,(H,20,21)",YICFJGNYIQOYJB-UHFFFAOYSA-N,37605,2-Cyano-N-(2-ethyl-phenyl)-2-pyridin-3-ylmethyl-acetamide::2-cyano-N-(2-ethylphenyl)-3-(3-pyridinyl)propanamide::2-cyano-N-(2-ethylphenyl)-3-(3-pyridyl)propionamide::2-cyano-N-(2-ethylphenyl)-3-pyridin-3-yl-propanamide::2-cyano-N-(2-ethylphenyl)-3-pyridin-3-ylpropanamide::MLS000035720::SMR000002073::cid_646700,fMet-Leu-Phe receptor,Homo sapiens,
50797899,NS(=O)(=O)c1ccc(Nc2ccnc(NC(=O)c3c(F)c(F)c(F)c(F)c3F)n2)cc1,"InChI=1S/C17H10F5N5O3S/c18-11-10(12(19)14(21)15(22)13(11)20)16(28)27-17-24-6-5-9(26-17)25-7-1-3-8(4-2-7)31(23,29)30/h1-6H,(H2,23,29,30)(H2,24,25,26,27,28)",BYXYWDVAUCLHPP-UHFFFAOYSA-N,50094368,"2,3,4,5,6-Pentafluoro-N-[4-(4-sulfamoyl-phenylamino)-pyrimidin-2-yl]-benzamide::CHEMBL140696",Carbonic anhydrase 1,Homo sapiens,
50717208,O[C@]1(CC[C@@H](CC1)N1CC[C@H](C1)NC(=O)CNC(=O)c1cccc(c1)C(F)(F)F)c1cccnn1,"InChI=1S/C24H28F3N5O3/c25-24(26,27)17-4-1-3-16(13-17)22(34)28-14-21(33)30-18-8-12-32(15-18)19-6-9-23(35,10-7-19)20-5-2-11-29-31-20/h1-5,11,13,18-19,35H,6-10,12,14-15H2,(H,28,34)(H,30,33)/t18-,19-,23-/m1/s1",CZBSLXMXLJXEBP-DNVFCKCGSA-N,50363949,CHEMBL1951774,C-C chemokine receptor type 2,, 7.3
51053615,Fc1cccc(NC(=O)\C=C\c2ccccc2)c1,"InChI=1S/C15H12FNO/c16-13-7-4-8-14(11-13)17-15(18)10-9-12-5-2-1-3-6-12/h1-11H,(H,17,18)/b10-9+",SQJXVMSLVGLGQR-MDZDMXLPSA-N,50429756,CHEMBL2336360::N-(3-Fluorophenyl)Cinnamamide,72 kDa type IV collagenase,, 1859
866084,COc1cc(cn2ncnc12)-c1[nH]c2ccc(nc2c1C(C)C)C1CCN(CC#N)CC1,"InChI=1S/C24H27N7O/c1-15(2)21-22(17-12-20(32-3)24-26-14-27-31(24)13-17)29-19-5-4-18(28-23(19)21)16-6-9-30(10-7-16)11-8-25/h4-5,12-16,29H,6-7,9-11H2,1-3H3",HGBATMHFIUZDDU-UHFFFAOYSA-N,428120,"US10544143, Example 555::US10730877, Example 555::US11053244, Example 555",Toll-like receptor 8,, 3.00
50300651,CCOC(=O)c1c(NC(=O)c2sc(Nc3ccc(C)cc3)nc2N(C)C)sc2CCCCc12,"InChI=1S/C24H28N4O3S2/c1-5-31-23(30)18-16-8-6-7-9-17(16)32-22(18)27-21(29)19-20(28(3)4)26-24(33-19)25-15-12-10-14(2)11-13-15/h10-13H,5-9H2,1-4H3,(H,25,26)(H,27,29)",UPSIRQTVGYTHEF-UHFFFAOYSA-N,50064621,CHEMBL3403729,Adenosine receptor A3,Homo sapiens,
51254727,CN1CCC(CC1)C(=O)N1N=CCC1c1ccccc1,"InChI=1S/C16H21N3O/c1-18-11-8-14(9-12-18)16(20)19-15(7-10-17-19)13-5-3-2-4-6-13/h2-6,10,14-15H,7-9,11-12H2,1H3",OKWCYSLFQVMVIB-UHFFFAOYSA-N,50513052,CHEMBL4527680,Receptor-interacting serine/threonine-protein kinase 1,,>10000
670697,Cc1ccc(cc1)-c1c(cc(OC[C@@H]2CCNC2)c2nn(CCOc3ccccc3)c(=O)n12)-c1ccc(cc1)C#N,"InChI=1S/C33H31N5O3/c1-23-7-11-27(12-8-23)31-29(26-13-9-24(20-34)10-14-26)19-30(41-22-25-15-16-35-21-25)32-36-37(33(39)38(31)32)17-18-40-28-5-3-2-4-6-28/h2-14,19,25,35H,15-18,21-22H2,1H3/t25-/m1/s1",AGVSWFFMFSYIIC-RUZDIDTESA-N,304057,"4-{5-(4-methylphenyl)-3-oxo-2-(2-phenoxyethyl)-8-[(3R)-pyrrolidin-3-ylmethoxy]-2,3-dihydro[1,2,4]triazolo[4,3-a]pyridin-6-yl}benzonitrile::US10138249, Example 14::US9758523, Example 14",Lysine-specific histone demethylase 1A,Homo sapiens,<50
50860661,CC(C)(C)Cn1cnc2ccc(nc12)-c1nc([nH]c1-c1ccc(F)cc1)-c1c(F)cccc1F,"InChI=1S/C26H22F3N5/c1-26(2,3)13-34-14-30-20-12-11-19(31-25(20)34)23-22(15-7-9-16(27)10-8-15)32-24(33-23)21-17(28)5-4-6-18(21)29/h4-12,14H,13H2,1-3H3,(H,32,33)",MRTSPTRJKFTETB-UHFFFAOYSA-N,50373948,CHEMBL404118,Mitogen-activated protein kinase 14,Homo sapiens, 7.2
754746,COc1ccc(F)c(-c2nc(C(=O)Nc3cnc4[C@H](O)CCc4c3N3CCC[C@H](N)C3)c(N)s2)c1F,"InChI=1S/C24H26F2N6O3S/c1-35-16-7-5-13(25)17(18(16)26)24-31-20(22(28)36-24)23(34)30-14-9-29-19-12(4-6-15(19)33)21(14)32-8-2-3-11(27)10-32/h5,7,9,11,15,33H,2-4,6,8,10,27-28H2,1H3,(H,30,34)/t11-,15+/m0/s1",FWNRHQYQQFAYQE-XHDPSFHLSA-N,377212,"US10265307, Example 53-2::US10517858, Example 53 (Diastereoisomer 2)::US10828290, Example 53 (Diastereoisomer 2)",Serine/threonine-protein kinase pim-3,Homo sapiens,<100
627677,CO[C@H](C(=O)N1CCN(CC1)c1ccc(cn1)-c1cc(cn2ncc(C#N)c12)-c1cnc(C)o1)c1ccccc1,"InChI=1S/C30H27N7O3/c1-20-32-18-26(40-20)23-14-25(28-24(15-31)17-34-37(28)19-23)22-8-9-27(33-16-22)35-10-12-36(13-11-35)30(38)29(39-2)21-6-4-3-5-7-21/h3-9,14,16-19,29H,10-13H2,1-2H3/t29-/m0/s1",HZAPGFUEDAAMHV-LJAQVGFWSA-N,284684,"US10023570, Example 719::US10174027, Example 719",Proto-oncogene tyrosine-protein kinase receptor Ret,Homo sapiens, 87.6
851342,Cn1cc(cn1)-c1ccc2cnc(NC(=O)C3CCN(CC(C)(F)F)CC3)cc2c1,"InChI=1S/C22H25F2N5O/c1-22(23,24)14-29-7-5-15(6-8-29)21(30)27-20-10-18-9-16(3-4-17(18)11-25-20)19-12-26-28(2)13-19/h3-4,9-13,15H,5-8,14H2,1-2H3,(H,25,27,30)",OBYONDURSTUMQK-UHFFFAOYSA-N,385083,"US10287267, Compound 83::US10508099, Compound 83::US10556885, Compound 83::US11174244, Compound 83",Glycogen synthase kinase-3 beta,Homo sapiens,
50031050,CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12,"InChI=1S/C19H23ClN2/c1-21(2)12-5-13-22-18-7-4-3-6-15(18)8-9-16-10-11-17(20)14-19(16)22/h3-4,6-7,10-11,14H,5,8-9,12-13H2,1-2H3",GDLIGKIOYRNHDA-UHFFFAOYSA-N,77970,"3-(2-chloranyl-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethyl-propan-1-amine;hydrochloride::3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethyl-1-propanamine;hydrochloride::3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine;hydrochloride::3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)propyl-dimethyl-amine;hydrochloride::CHLORIMIPRAMINE::CLOMIPRAMINE::CLOMIPRAMINE HYDROCHLORIDE::CLOMIPRIMINE::MLS000028511::SMR000058295::cid_68539::med.21724, Compound Clomipramine",Alpha-1A/Alpha-1B/Alpha-1D adrenergic receptor,,
1133934,Fc1ccc(cc1)S(=O)(NC(=O)Nc1c2CCCc2cc2CCCc12)=NC#N,"InChI=1S/C20H19FN4O2S/c21-15-7-9-16(10-8-15)28(27,23-12-22)25-20(26)24-19-17-5-1-3-13(17)11-14-4-2-6-18(14)19/h7-11H,1-6H2,(H2,23,24,25,26,27)",HUXGQLXQWZDOQV-UHFFFAOYSA-N,534822,"US11236045, Example 21",Uromodulin,, 62.0
50114222,Cc1noc(NS(=O)(=O)c2sccc2C(=O)Cc2cc3OCOc3cc2C)c1Cl,"InChI=1S/C18H15ClN2O6S2/c1-9-5-14-15(26-8-25-14)7-11(9)6-13(22)12-3-4-28-18(12)29(23,24)21-17-16(19)10(2)20-27-17/h3-5,7,21H,6,8H2,1-2H3",SWOBCLGSVXXLQF-UHFFFAOYSA-N,50066398,"3-[2-(6-Methyl-benzo[1,3]dioxol-5-yl)-acetyl]-thiophene-2-sulfonic acid (4-chloro-3-methyl-isoxazol-5-yl)-amide::CHEMBL326059",Endothelin receptor type B,Homo sapiens,
388179,CN1C2COCC1CC(C2)NC(=O)c1cn(-c2nccs2)c2ncc(F)cc12,"InChI=1S/C19H20FN5O2S/c1-24-13-5-12(6-14(24)10-27-9-13)23-18(26)16-8-25(19-21-2-3-28-19)17-15(16)4-11(20)7-22-17/h2-4,7-8,12-14H,5-6,9-10H2,1H3,(H,23,26)",VRBYIQKJZRNKLG-UHFFFAOYSA-N,221657,"US9303045, 162::US9695195, 162",5-hydroxytryptamine receptor 3A,Homo sapiens, 1.81
746524,C[C@H](Nc1nccc(NCCO)c1F)c1cc2cc(Cl)ccc2[nH]c1=O,,,375176,"6-chloro-3-[(1S)-1-({3-::US10253015, Compound I-36",Isocitrate dehydrogenase [NADP] cytoplasmic [R132C],,>1000
853229,Clc1ccc(NC(=O)Nc2ccc(CCC3CCNC3)cc2)cc1,"InChI=1S/C19H22ClN3O/c20-16-5-9-18(10-6-16)23-19(24)22-17-7-3-14(4-8-17)1-2-15-11-12-21-13-15/h3-10,15,21H,1-2,11-13H2,(H2,22,23,24)",FCHJTQQSYFFFBE-UHFFFAOYSA-N,250206,"US10501411, Example 116::US9452980, 116",Trace amine-associated receptor 1,Mus musculus,
131832,Oc1cc2ccccc2cc1C(=O)NN=Cc1ccncc1,"InChI=1S/C17H13N3O2/c21-16-10-14-4-2-1-3-13(14)9-15(16)17(22)20-19-11-12-5-7-18-8-6-12/h1-11,21H,(H,20,22)",LVOVRLMOYZZYDY-UHFFFAOYSA-N,65668,3-hydroxy-N-(4-pyridylmethyleneamino)-2-naphthamide::3-hydroxy-N-(pyridin-4-ylmethylideneamino)-2-naphthalenecarboxamide::3-hydroxy-N-(pyridin-4-ylmethylideneamino)naphthalene-2-carboxamide::3-oxidanyl-N-(pyridin-4-ylmethylideneamino)naphthalene-2-carboxamide::MLS001123699::SMR000658768::cid_795958,Heat shock factor protein 1,Mus musculus,
51379537,Cc1ccc(cc1)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)(F)F,"InChI=1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)",RZEKVGVHFLEQIL-UHFFFAOYSA-N,11639,"4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzene-1-sulfonamide::CHEMBL118::CLX::Celebrex::Celecoxib::US10322118, Urea-Based Scaffold Entry 9::US11478464, Compound Celecoxib::US8741944, Comparative Compound::US9388139, Celecoxib::cid_2662",Prostaglandin G/H synthase 2,Homo sapiens, 90
50097646,CSCC[C@H](NC(=O)c1cccc2cc(NC[C@@H](N)CS)ccc12)C(O)=O,"InChI=1S/C19H25N3O3S2/c1-27-8-7-17(19(24)25)22-18(23)16-4-2-3-12-9-14(5-6-15(12)16)21-10-13(20)11-26/h2-6,9,13,17,21,26H,7-8,10-11,20H2,1H3,(H,22,23)(H,24,25)/t13-,17+/m1/s1",YUXOGMIOPNYIQR-DYVFJYSZSA-N,50058204,(S)-2-{[6-((R)-2-Amino-3-mercapto-propylamino)-naphthalene-1-carbonyl]-amino}-4-methylsulfanyl-butyric acid::CHEMBL48866::RPR-113829,Dimer of Protein farnesyltransferase subunit beta,Homo sapiens, 1.8
981991,Nc1ncnc2n(nc(-c3cc4ccccc4[nH]3)c12)C1CC[C@@H](CC1)NC(=O)C1CC1,,,473662,"N-(trans-4-(4-Amino-3-(1H-indol-2-yl)-1H- pyrazolo[3,4-d]pyrimidin-1- yl)cyclohexyl)cyclopropanecarboxamide::US10844067, Example 5",Proto-oncogene tyrosine-protein kinase receptor Ret,Homo sapiens, 28.5
51451743,Cl.Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)[C@H](CC[C@@]35O)NC(=O)c1ccoc1,"InChI=1S/C25H28N2O5.ClH/c28-18-4-3-15-11-19-25(30)7-5-17(26-23(29)16-6-10-31-13-16)22-24(25,20(15)21(18)32-22)8-9-27(19)12-14-1-2-14;/h3-4,6,10,13-14,17,19,22,28,30H,1-2,5,7-9,11-12H2,(H,26,29);1H/t17-,19+,22-,24-,25+;/m0./s1",WBSVANNKUKFNOK-UQCSYHANSA-N,50586123,CHEMBL5073592,Delta-type opioid receptor,Homo sapiens,
50732830,NS(=O)(=O)c1ccc(cc1)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)NCC(O)=O,"InChI=1S/C15H17N5O6S/c16-27(25,26)11-3-1-9(2-4-11)14(23)20-12(5-10-6-17-8-19-10)15(24)18-7-13(21)22/h1-4,6,8,12H,5,7H2,(H,17,19)(H,18,24)(H,20,23)(H,21,22)(H2,16,25,26)/t12-/m0/s1",CWCWATFNQGYAKJ-LBPRGKRZSA-N,50101378,CHEMBL52227::[(S)-3-(3H-Imidazol-4-yl)-2-(4-sulfamoyl-benzoylamino)-propionylamino]-acetic acid,Carbonic anhydrase 1,Homo sapiens,
44298,OC(=O)CN1C(=O)C(Cc2ccccc12)NC(=O)c1cc2cc(Cl)ccc2[nH]1,"InChI=1S/C20H16ClN3O4/c21-13-5-6-14-12(7-13)9-15(22-14)19(27)23-16-8-11-3-1-2-4-17(11)24(20(16)28)10-18(25)26/h1-7,9,16,22H,8,10H2,(H,23,27)(H,25,26)",CCGBIWYBXDWOOH-UHFFFAOYSA-N,24371,"2-{3-[(5-chloro-1H-indole-2-)amido]-2-oxo-1,2,3,4-tetrahydroquinolin-1-yl}acetic acid::3,4-dihydro-2-quinolone (DHQ) derivative, 10","Glycogen phosphorylase, liver form",Homo sapiens, 237
51216538,Cc1ccc(C(O)=O)c(C)c1NC(=O)c1cc(cc2ccccc12)-c1cccc(Cl)c1,"InChI=1S/C26H20ClNO3/c1-15-10-11-21(26(30)31)16(2)24(15)28-25(29)23-14-19(17-7-5-8-20(27)13-17)12-18-6-3-4-9-22(18)23/h3-14H,1-2H3,(H,28,29)(H,30,31)",SIIGKILIYGRIJN-UHFFFAOYSA-N,50140258,CHEMBL3740325,Prostaglandin E2 receptor EP1 subtype,,
50664117,NC(=O)c1ccc(Nc2nnc(-c3ccc(O)cc3)c3ccccc23)cc1,"InChI=1S/C21H16N4O2/c22-20(27)14-5-9-15(10-6-14)23-21-18-4-2-1-3-17(18)19(24-25-21)13-7-11-16(26)12-8-13/h1-12,26H,(H2,22,27)(H,23,25)",LGCIFOOQZRHNIN-UHFFFAOYSA-N,50354686,CHEMBL1524400,Serine/threonine-protein kinase B-raf,Homo sapiens,
1100902,Oc1ccc2C(=C(CCc2c1)c1ccc(Cl)cc1Cl)c1ccc(O[C@H]2CCN(CCCF)C2)cc1,"InChI=1S/C29H28Cl2FNO2/c30-21-5-10-26(28(31)17-21)27-9-4-20-16-22(34)6-11-25(20)29(27)19-2-7-23(8-3-19)35-24-12-15-33(18-24)14-1-13-32/h2-3,5-8,10-11,16-17,24,34H,1,4,9,12-15,18H2/t24-/m0/s1",LINFCFKJWGTADI-DEOSSOPVSA-N,521190,"6-(2,4- dichlorophenyl)- 5-[4-[(3S)-1-(3- fluoropropyl)pyr- rolidin-3- yl]oxyphenyl]- 7,8- dihydronaphtha- len-2-ol::US11149031, Example 14","Estrogen receptor [298-554,D538G]",, 3310
51102404,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@@H]2CCCN2C(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@H](NC1=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N2)[C@@H](C)O,"InChI=1S/C63H96N20O18S2/c1-4-32(2)48-58(98)78-40-30-102-103-31-41(77-52(92)35(15-8-20-68-62(64)65)72-45(86)27-70-50(90)37(26-47(88)89)74-56(96)42-17-10-23-82(42)60(100)38(75-54(40)94)25-34-13-6-5-7-14-34)55(95)80-49(33(3)85)59(99)73-36(16-9-21-69-63(66)67)53(93)76-39(29-84)51(91)71-28-46(87)81-22-12-19-44(81)61(101)83-24-11-18-43(83)57(97)79-48/h5-7,13-14,32-33,35-44,48-49,84-85H,4,8-12,15-31H2,1-3H3,(H,70,90)(H,71,91)(H,72,86)(H,73,99)(H,74,96)(H,75,94)(H,76,93)(H,77,92)(H,78,98)(H,79,97)(H,80,95)(H,88,89)(H4,64,65,68)(H4,66,67,69)/t32-,33+,35-,36-,37-,38-,39-,40-,41-,42-,43-,44-,48-,49-/m0/s1",WPGYEGGDARHIAP-NEPSLTQLSA-N,50449675,CHEMBL4175285,Serine protease 1,Homo sapiens,
50704371,Cn1nc(nc1C1(CC1)c1ccccc1)-c1cnc(N)c(n1)-n1cnc2ccccc12,"InChI=1S/C23H20N8/c1-30-22(23(11-12-23)15-7-3-2-4-8-15)28-20(29-30)17-13-25-19(24)21(27-17)31-14-26-16-9-5-6-10-18(16)31/h2-10,13-14H,11-12H2,1H3,(H2,24,25)",YWIDMRZQZDODER-UHFFFAOYSA-N,50234172,CHEMBL4088819,"Phosphatidylinositol 3-kinase regulatory subunit alpha/4,5-bisphosphate 3-kinase catalytic subunit beta isoform",Homo sapiens,>31623
50339121,OC(=O)c1cccc(c1)-c1ncccc1-c1cc(Cl)ccc1OCc1ccccc1,"InChI=1S/C25H18ClNO3/c26-20-11-12-23(30-16-17-6-2-1-3-7-17)22(15-20)21-10-5-13-27-24(21)18-8-4-9-19(14-18)25(28)29/h1-15H,16H2,(H,28,29)",KDRGQJRCUVUELE-UHFFFAOYSA-N,50183183,3-(3-(2-(benzyloxy)-5-chlorophenyl)pyridin-2-yl)benzoic acid::CHEMBL206096,Cytochrome P450 1A2,Homo sapiens,>50000
51197814,OCCC(N1CCC(CC1)=C(c1ccccc1)c1ccccc1)C(=O)NCc1ccc(F)cc1,"InChI=1S/C29H31FN2O2/c30-26-13-11-22(12-14-26)21-31-29(34)27(17-20-33)32-18-15-25(16-19-32)28(23-7-3-1-4-8-23)24-9-5-2-6-10-24/h1-14,27,33H,15-21H2,(H,31,34)",GKPAFQFQYVEMJQ-UHFFFAOYSA-N,50492912,CHEMBL2414193,Sodium- and chloride-dependent GABA transporter 1,Rattus norvegicus, 9772
50850705,CCCCCCCCCCC#CC(O)c1ccccc1-c1ccc(Sc2ccc(OCCCCCC)cc2)c(c1)S([O-])(=O)=O,"InChI=1S/C37H48O5S2/c1-3-5-7-9-10-11-12-13-14-15-21-35(38)34-20-17-16-19-33(34)30-22-27-36(37(29-30)44(39,40)41)43-32-25-23-31(24-26-32)42-28-18-8-6-4-2/h16-17,19-20,22-27,29,35,38H,3-14,18,28H2,1-2H3,(H,39,40,41)/p-1",JEPABZVKYKGQIC-UHFFFAOYSA-M,50208894,CHEMBL277377::sodium 4-[(4-hexyloxyphenyl)thio]-20-(1-hydroxytridec-2-yl)biphenyl-3-sulfonate,Sphingosine 1-phosphate receptor 1,Homo sapiens, 520
50455328,Nc1nc(C(=O)NCc2cccc3cccnc23)c2cc(F)c(F)cc2n1,"InChI=1S/C19H13F2N5O/c20-13-7-12-15(8-14(13)21)25-19(22)26-17(12)18(27)24-9-11-4-1-3-10-5-2-6-23-16(10)11/h1-8H,9H2,(H,24,27)(H2,22,25,26)",RFBOIDHBCYJRIH-UHFFFAOYSA-N,50139777,CHEMBL3764260,Adenosine receptor A1,Homo sapiens,
322,COc1cccc2nc(oc12)C(=O)[C@H](CC(O)=O)NC(=O)c1ccc(CNS(=O)(=O)c2ccc(O)c(c2)C(O)=O)nc1,"InChI=1S/C26H22N4O11S/c1-40-20-4-2-3-17-23(20)41-25(30-17)22(34)18(10-21(32)33)29-24(35)13-5-6-14(27-11-13)12-28-42(38,39)15-7-8-19(31)16(9-15)26(36)37/h2-9,11,18,28,31H,10,12H2,1H3,(H,29,35)(H,32,33)(H,36,37)/t18-/m0/s1",SIRDBTDSADKLJV-SFHVURJKSA-N,279,"5-{[(5-{[(2S)-3-carboxy-1-(7-methoxy-1,3-benzoxazol-2-yl)-1-oxopropan-2-yl]carbamoyl}pyridin-2-yl)methyl]sulfamoyl}-2-hydroxybenzoic acid::6-[(4-Hydroxy-3-methyl-benzenesulfonylamino)methyl]-N-[1-(7-methoxy-benzooxazole-2-carbonyl)propyl]nicotinamide::Inhibitor 61::Pyridine Scaffold 61",Caspase-3,Homo sapiens,
50075335,Cc1cc2CSc3c(nn(c3-c2cc1F)-c1ccc(cc1)S(N)(=O)=O)C(F)(F)F,"InChI=1S/C18H13F4N3O2S2/c1-9-6-10-8-28-16-15(13(10)7-14(9)19)25(24-17(16)18(20,21)22)11-2-4-12(5-3-11)29(23,26)27/h2-7H,8H2,1H3,(H2,23,26,27)",DADHJCHABCTJSK-UHFFFAOYSA-N,50288333,"4-(8-Fluoro-7-methyl-3-trifluoromethyl-5H-isothiochromeno[4,3-c]pyrazol-1-yl)-benzenesulfonamide::CHEMBL94494",Prostaglandin G/H synthase 1,, 11099
50451050,CC[C@@]12C[C@H](O)[C@@](O)(C[C@H]1CCc1cc(O)ccc21)C#CC,"InChI=1S/C19H24O3/c1-3-9-19(22)11-14-6-5-13-10-15(20)7-8-16(13)18(14,4-2)12-17(19)21/h7-8,10,14,17,20-22H,4-6,11-12H2,1-2H3/t14-,17+,18-,19+/m1/s1",LENKTUVVULSELH-FDPIWHGQSA-N,50276471,"(2R,3S,4aR,10aR)-4a-Ethyl-2-prop-1-ynyl-1,2,3,4,4a,9,10,10aoctahydrophenanthrene-2,3,7-triol::CHEMBL457241",Glucocorticoid receptor,, 63
760052,O=C(Nc1ccc(cc1)-c1n[nH]c(=O)c2ccccc12)c1cnn2cc(OCCN3CCOCC3)ccc12,"InChI=1S/C28H26N6O4/c35-27(24-17-29-34-18-21(9-10-25(24)34)38-16-13-33-11-14-37-15-12-33)30-20-7-5-19(6-8-20)26-22-3-1-2-4-23(22)28(36)32-31-26/h1-10,17-18H,11-16H2,(H,30,35)(H,32,36)",NNZDJMDSGQADMM-UHFFFAOYSA-N,380193,"6-[2-(morpholin-4- yl)ethoxy]-N-[4-(4-oxo- 3,4-dihydrophthalazin-1- yl)phenyl]pyrazolo[1,5- a]pyridine-3- carboxamide::US9926282, Example 188",Rho-associated protein kinase 1,Homo sapiens,<100
1213469,CC1CN(CCN2CCC(CC2)c2noc3ccccc23)C(=O)c2ccn(C)c12,"InChI=1S/C23H28N4O2/c1-16-15-27(23(28)19-9-10-25(2)22(16)19)14-13-26-11-7-17(8-12-26)21-18-5-3-4-6-20(18)29-24-21/h3-6,9-10,16-17H,7-8,11-15H2,1-2H3",JLSHFCOIGLDZJK-UHFFFAOYSA-N,458608,"US10745401, Example 82::US11466007, Example 82",D(2) dopamine receptor,Homo sapiens,
50145888,COc1cc(NCc2ccc3nc(N)nc(N)c3c2C)cc(OC)c1OC,"InChI=1S/C19H23N5O3/c1-10-11(5-6-13-16(10)18(20)24-19(21)23-13)9-22-12-7-14(25-2)17(27-4)15(8-12)26-3/h5-8,22H,9H2,1-4H3,(H4,20,21,23,24)",NOYPYLRCIDNJJB-UHFFFAOYSA-N,18268,"5-methyl-6-{[(3,4,5-trimethoxyphenyl)amino]methyl}quinazoline-2,4-diamine::CHEMBL119::TMQ::Trimetrexate::US11111252, Compound TMQ::US11530198, Example Trimetrexate",Dihydrofolate reductase,Rattus norvegicus, 3
685700,OC(CC1c2cc(F)ccc2-c2cncn12)C12CC3CC(CC(C3)C1)C2,"InChI=1S/C22H25FN2O/c23-16-1-2-17-18(6-16)19(25-12-24-11-20(17)25)7-21(26)22-8-13-3-14(9-22)5-15(4-13)10-22/h1-2,6,11-15,19,21,26H,3-5,7-10H2",TVYSAKSWTQIQBL-UHFFFAOYSA-N,347004,"US10202388, Compound 7","Indoleamine 2,3-dioxygenase 1",Homo sapiens, 300
160484,CN1CCc2cc(Br)c(O)cc2C(C1)c1ccccc1,"InChI=1S/C17H18BrNO/c1-19-8-7-13-9-16(18)17(20)10-14(13)15(11-19)12-5-3-2-4-6-12/h2-6,9-10,15,20H,7-8,11H2,1H3",XFTVOHWWEQGXLS-UHFFFAOYSA-N,50010301,"8-Bromo-3-methyl-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol(SKF 83566)::CHEMBL324017::SKF 83566",5-hydroxytryptamine receptor 5B,Rattus,
1027976,Cc1cc(cc(C)n1)-c1nnc(N)nc1-c1ccccc1,"InChI=1S/C16H15N5/c1-10-8-13(9-11(2)18-10)15-14(19-16(17)21-20-15)12-6-4-3-5-7-12/h3-9H,1-2H3,(H2,17,19,21)",SORFNYWLKDSNNF-UHFFFAOYSA-N,50382492,"CHEMBL2024115::US10988455, Example 5(viii)",Adenosine receptor A1,Homo sapiens,
522025,FCCNC[C@H]1CC[C@@H](CC1)c1nnn2cnc3[nH]ccc3c12,,,198300,"US9216999, 107::US9556187, Example 107",Tyrosine-protein kinase JAK1,Homo sapiens, 310
192742,CCOC(=O)Cc1csc(NC(=O)c2sc3nc4cc(C)ccc4cc3c2N)n1,"InChI=1S/C20H18N4O3S2/c1-3-27-15(25)8-12-9-28-20(22-12)24-18(26)17-16(21)13-7-11-5-4-10(2)6-14(11)23-19(13)29-17/h4-7,9H,3,8,21H2,1-2H3,(H,22,24,26)",DGVJQCOKXOACNG-UHFFFAOYSA-N,52442,"2-[2-[(3-amino-7-methyl-thieno[2,3-b]quinoline-2-carbonyl)amino]thiazol-4-yl]acetic acid ethyl ester::2-[2-[[(3-amino-7-methyl-2-thieno[2,3-b]quinolinyl)-oxomethyl]amino]-4-thiazolyl]acetic acid ethyl ester::MLS000564527::SMR000172488::cid_3167478::ethyl 2-[2-[(3-amino-7-methylthieno[2,3-b]quinoline-2-carbonyl)amino]-1,3-thiazol-4-yl]acetate::ethyl 2-[2-[(3-azanyl-7-methyl-thieno[2,3-b]quinolin-2-yl)carbonylamino]-1,3-thiazol-4-yl]ethanoate::{2-[(3-Amino-7-methyl-thieno[2,3-b]quinoline-2-carbonyl)-amino]-thiazol-4-yl}-acetic acid ethyl ester",Delta-type opioid receptor,Homo sapiens,
51388483,COc1cccc(Nc2ccc([N+]([O-])=O)c3[nH]c(cc23)C(=O)NS(=O)(=O)c2cccc(OC)c2)c1,"InChI=1S/C23H20N4O7S/c1-33-15-6-3-5-14(11-15)24-19-9-10-21(27(29)30)22-18(19)13-20(25-22)23(28)26-35(31,32)17-8-4-7-16(12-17)34-2/h3-13,24-25H,1-2H3,(H,26,28)",PGYMTMDKJWTZNQ-UHFFFAOYSA-N,50560937,CHEMBL4740367,"Fructose-1,6-bisphosphatase 1",, 150
50134103,CCCCN(CC)c1nc(C)nc2n(-c3ccc(cc3Br)C(C)C)c(=S)sc12,"InChI=1S/C21H27BrN4S2/c1-6-8-11-25(7-2)19-18-20(24-14(5)23-19)26(21(27)28-18)17-10-9-15(13(3)4)12-16(17)22/h9-10,12-13H,6-8,11H2,1-5H3",LJRUUGDTTFDUCX-UHFFFAOYSA-N,50076896,"3-(2-Bromo-4-isopropyl-phenyl)-7-(butyl-ethyl-amino)-5-methyl-3H-thiazolo[4,5-d]pyrimidine-2-thione::CHEMBL18230",Corticotropin-releasing factor receptor 1,Homo sapiens,
50849589,O=C(Nc1nc2ccccc2n2n1nc(-c1ccccc1)c2=O)c1ccccc1,"InChI=1S/C22H15N5O2/c28-20(16-11-5-2-6-12-16)24-22-23-17-13-7-8-14-18(17)26-21(29)19(25-27(22)26)15-9-3-1-4-10-15/h1-14H,(H,23,24,28)",OFDQIHUVLITVFQ-UHFFFAOYSA-N,50224353,"CHEMBL235294::N-(1-oxo-2-phenyl-1H-3,3a,5,9b-tetraaza-cyclopenta[a]naphthalen-4-yl)-benzamide",Adenosine receptor A1,Homo sapiens,
51031745,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1,"InChI=1S/C21H31N5O2/c27-18-16-21(6-1-2-7-21)17-19(28)26(18)11-4-3-10-24-12-14-25(15-13-24)20-22-8-5-9-23-20/h5,8-9H,1-4,6-7,10-17H2",QWCRAEMEVRGPNT-UHFFFAOYSA-N,50001859,"(buspirone) 8-[4-(4-Pyrimidin-2-yl-piperazin-1-yl)-butyl]-8-aza-spiro[4.5]decane-7,9-dione::8-[4-(4-Pyrimidin-2-yl-piperazin-1-yl)-butyl]-8-aza-spiro[4.5]decane-7,9-dione : (Hydrochloride)::8-[4-(4-Pyrimidin-2-yl-piperazin-1-yl)-butyl]-8-aza-spiro[4.5]decane-7,9-dione; Hydrochloride(Buspirone)::8-[4-(4-pyrimidin-2-yl-piperazin-1-yl)-butyl]-8-aza-spiro[4.5]decane-7,9-dione::BUSPAR::BUSPIRONE::CHEMBL49::US10562853, Compound Buspirone",5-hydroxytryptamine receptor 1A,,
51263694,CS(=O)(=O)c1cccc(c1)-c1ccc(s1)C(=O)c1cc(F)c(F)c(O)c1F,"InChI=1S/C18H11F3O4S2/c1-27(24,25)10-4-2-3-9(7-10)13-5-6-14(26-13)17(22)11-8-12(19)16(21)18(23)15(11)20/h2-8,23H,1H3",ASDUNIRPFAQIPX-UHFFFAOYSA-N,50516201,CHEMBL4528459,17-beta-hydroxysteroid dehydrogenase type 2,Homo sapiens, 18
51263880,FC(F)Oc1ccc(NC(=O)NC2CCN(CC2)c2ncnc3n(c(nc23)-c2ccccc2Cl)-c2ccc(Cl)cc2)cn1,"InChI=1S/C29H24Cl2F2N8O2/c30-17-5-8-20(9-6-17)41-25(21-3-1-2-4-22(21)31)39-24-26(35-16-36-27(24)41)40-13-11-18(12-14-40)37-29(42)38-19-7-10-23(34-15-19)43-28(32)33/h1-10,15-16,18,28H,11-14H2,(H2,37,38,42)",LTNOPYMLPTUXSM-UHFFFAOYSA-N,50516235,CHEMBL4563408,Muscarinic acetylcholine receptor M2,,
528563,O=S1(=O)CCC(CC1)Oc1ccc(cc1C#N)-c1ncnc(Nc2ccc(cc2)N2CCN(CC2)C2COC2)n1,"InChI=1S/C28H31N7O4S/c29-16-21-15-20(1-6-26(21)39-25-7-13-40(36,37)14-8-25)27-30-19-31-28(33-27)32-22-2-4-23(5-3-22)34-9-11-35(12-10-34)24-17-38-18-24/h1-6,15,19,24-25H,7-14,17-18H2,(H,30,31,32,33)",LAHRVRATNQJNBP-UHFFFAOYSA-N,277795,"2-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)oxy)-5-(4-((4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)amino)-1,3,5-triazin-2-yl)benzonitrile::US10040781, Example 17::US10040781, Example 270::US10253019, Example 17",Tyrosine-protein kinase JAK2,Homo sapiens, 804000
50325650,COc1cc2CC[C@H](NC(=O)c3ccc(cc3)C(=O)Nc3cc(ccc3N)-c3cccs3)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC,"InChI=1S/C38H35N3O7S/c1-45-31-16-13-25-26(20-30(31)42)28(15-12-24-19-32(46-2)35(47-3)36(48-4)34(24)25)40-37(43)21-7-9-22(10-8-21)38(44)41-29-18-23(11-14-27(29)39)33-6-5-17-49-33/h5-11,13-14,16-20,28H,12,15,39H2,1-4H3,(H,40,43)(H,41,44)/t28-/m0/s1",ZJQWHJDXKHHLEP-NDEPHWFRSA-N,50079497,CHEMBL3417210,Histone deacetylase 1,Homo sapiens, 2240
51357265,CC1Cc2ccccc2N1CC(=O)N1CCCCC1,"InChI=1S/C16H22N2O/c1-13-11-14-7-3-4-8-15(14)18(13)12-16(19)17-9-5-2-6-10-17/h3-4,7-8,13H,2,5-6,9-12H2,1H3",GZJGEXMJBMQREH-UHFFFAOYSA-N,50548798,CHEMBL4793864,Muscarinic acetylcholine receptor M1,,
50752153,OCC(O)CO\N=C1\C(\Nc2ccccc\12)=C1\C(=O)Nc2ccccc12,"InChI=1S/C19H17N3O4/c23-9-11(24)10-26-22-17-13-6-2-4-8-15(13)20-18(17)16-12-5-1-3-7-14(12)21-19(16)25/h1-8,11,20,23-24H,9-10H2,(H,21,25)/b18-16-,22-17+",ZWXBEUSAAVHLFW-DLOIKSOESA-N,50005337,CHEMBL1276317,Cyclin-dependent kinase 6/G1/S-specific cyclin-D3,Homo sapiens, 75
50150725,COc1ccc(cc1)S(=O)(=O)N1CCN(CC1C(=O)NO)C(=O)NCCc1ccccc1,"InChI=1S/C21H26N4O6S/c1-31-17-7-9-18(10-8-17)32(29,30)25-14-13-24(15-19(25)20(26)23-28)21(27)22-12-11-16-5-3-2-4-6-16/h2-10,19,28H,11-15H2,1H3,(H,22,27)(H,23,26)",DYVJPNSKJGHBKT-UHFFFAOYSA-N,50084752,"4-(4-Methoxy-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-hydroxyamide 1-(phenethyl-amide)::CHEMBL125755",Stromelysin-1,, 27
51116288,C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12,"InChI=1S/C20H14NO4/c1-21-8-15-12(4-5-16-20(15)25-10-22-16)13-3-2-11-6-17-18(24-9-23-17)7-14(11)19(13)21/h2-8H,9-10H2,1H3/q+1",INVGWHRKADIJHF-UHFFFAOYSA-N,25525,"24-methyl-5,7,18,20-tetraoxa-24-azahexacyclo[11.11.0.0^{2,10}.0^{4,8}.0^{14,22}.0^{17,21}]tetracosa-1(13),2,4(8),9,11,14(22),15,17(21),23-nonaen-24-ium::CHEMBL490129::Pseudochelerythrine::Veadent::cid_5154::sanguinarine::sangvinarin",Regulator of G-protein signaling 17,, 12000
1215917,COc1cccc2[nH]c(cc12)C(=O)N[C@@H](CC1CC1)C(=O)N[C@@H](C[C@@H]1CCCNC1=O)C#N,,,509908,"US11124497, Compound 491::US11124497, Compound 491A (Isomer 1)::US11312704, Compound 491::US11472793, Compound 491::US11524940, Compound 491A (Isomer 1)",Replicase polyprotein 1ab,,>30000
50837878,CCCCCCCCCCCCCCCC(=O)c1c(O)oc(CO)c1O,"InChI=1S/C21H36O5/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-17(23)19-20(24)18(16-22)26-21(19)25/h22,24-25H,2-16H2,1H3",BKBKOAWPAIKUCJ-UHFFFAOYSA-N,50104694,(R)-4-hydroxy-5-(hydroxymethyl)-3-palmitoylfuran-2(5H)-one::(R)-5-Ethyl-3-hexadecanoyl-4-methyl-5H-furan-2-oneo::3-Hexadecanoyl-4-hydroxy-5-hydroxymethyl-5H-furan-2-one::CHEMBL108441::RK-682,Tyrosine-protein phosphatase non-receptor type 1,Homo sapiens, 4500
1102121,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@@](O)(CC[C@]4(C)[C@H]3CC[C@]12C)C(F)(F)F,"InChI=1S/C28H47F3O2/c1-18(7-6-13-24(2,3)32)21-10-11-22-20-9-8-19-17-27(33,28(29,30)31)16-15-25(19,4)23(20)12-14-26(21,22)5/h18-23,32-33H,6-17H2,1-5H3/t18-,19+,20+,21-,22+,23+,25+,26-,27+/m1/s1",PRAIWHBPXMVDTR-RYNHHEBDSA-N,521705,"US11149054, Compound 5116","Glutamate receptor ionotropic, NMDA 2A",,
99262,CN1C(=S)NC(=O)\C(=C/c2ccc(o2)N2CCCCCC2)C1=O,"InChI=1S/C16H19N3O3S/c1-18-15(21)12(14(20)17-16(18)23)10-11-6-7-13(22-11)19-8-4-2-3-5-9-19/h6-7,10H,2-5,8-9H2,1H3,(H,17,20,23)/b12-10+",HURVNUBCCDEKRW-ZRDIBKRKSA-N,52242,"(5E)-5-[[5-(1-azepanyl)-2-furanyl]methylidene]-1-methyl-2-sulfanylidene-1,3-diazinane-4,6-dione::(5E)-5-[[5-(azepan-1-yl)-2-furyl]methylene]-1-methyl-2-thioxo-hexahydropyrimidine-4,6-quinone::(5E)-5-[[5-(azepan-1-yl)furan-2-yl]methylidene]-1-methyl-2-sulfanylidene-1,3-diazinane-4,6-dione::5-{[5-(1-azepanyl)-2-furyl]methylene}-1-methyl-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione::MLS000594435::SMR000114505::cid_1740011",POsterior Segregation,Caenorhabditis elegans,
446333,CN1c2ccc(cc2N(C)S1(=O)=O)-n1cc(C(O)=O)c(=O)n(Cc2cccc(Cl)c2C(F)(F)F)c1=O,"InChI=1S/C21H16ClF3N4O6S/c1-26-15-7-6-12(8-16(15)27(2)36(26,34)35)28-10-13(19(31)32)18(30)29(20(28)33)9-11-4-3-5-14(22)17(11)21(23,24)25/h3-8,10H,9H2,1-2H3,(H,31,32)",SEJKURQMYZQGQO-UHFFFAOYSA-N,256000,"US9481672, 178",chymase,, 16
972794,Clc1cc(ccc1NC1CCN(Cc2ccccc2)C1)S(=O)(=O)Nc1ncns1,"InChI=1S/C19H20ClN5O2S2/c20-17-10-16(29(26,27)24-19-21-13-22-28-19)6-7-18(17)23-15-8-9-25(12-15)11-14-4-2-1-3-5-14/h1-7,10,13,15,23H,8-9,11-12H2,(H,21,22,24)",RGZJDZOTNRSBIE-UHFFFAOYSA-N,373759,"4-((1-benzylpyrrolidin-3-yl)amino)-3-chloro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide trifluoroacetate::US10246453, Example 26::US10662184, Example 26::US10815229, Example 26::US11299490, Example 26",Sodium channel protein type 1 subunit alpha,, 15014
51234655,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)NCCOCCOCCOCCNC(=O)CCC1=[N+]2C(C=C1)=Cc1c(C)cc(C)n1[B-]2(F)F,"InChI=1S/C49H54BF2N7O7/c1-29-25-30(2)58-39(29)26-32-14-13-31(59(32)50(58,51)52)15-16-40(60)54-18-20-64-22-24-65-23-21-63-19-17-53-36-27-41-56-37-11-7-5-9-33(37)43-44-35(28-55-48(44)61)42-34-10-6-8-12-38(34)57(46(42)45(43)56)49(3,66-41)47(36)62-4/h5-14,25-26,36,41,47,53H,15-24,27-28H2,1-4H3,(H,54,60)(H,55,61)/t36-,41-,47-,49+/m1/s1",NXSJMRCTGYTSTK-SQHKIPTKSA-N,50505541,CHEMBL4465866,Tyrosine-protein kinase Mer,Homo sapiens,
867768,CCn1c(nc2c(ncnc12)-c1ccc2NC(=O)C(C)(NCC3(F)COC3)c2c1)-c1cnc(C)nc1,"InChI=1S/C25H25FN8O2/c1-4-34-21(16-8-27-14(2)28-9-16)33-20-19(29-13-30-22(20)34)15-5-6-18-17(7-15)24(3,23(35)32-18)31-10-25(26)11-36-12-25/h5-9,13,31H,4,10-12H2,1-3H3,(H,32,35)",VQGRMRNBGZTLBM-UHFFFAOYSA-N,428755,"(R or S)-5-(9-ethyl-8-(2- methylpyrimidin-5-yl)-9H- purin-6-yl)-3-(((3- fluorooxetan-3- yl)methyl)amino)-3- methylindolin-2-one::US10544147, Compound 2-71::US10544147, Compound 2-72","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform",Homo sapiens, 3.00
50693929,Nc1nc(N)c2nc(-c3cccc(O)c3)c(nc2n1)-c1cccc(O)c1,"InChI=1S/C18H14N6O2/c19-16-15-17(24-18(20)23-16)22-14(10-4-2-6-12(26)8-10)13(21-15)9-3-1-5-11(25)7-9/h1-8,25-26H,(H4,19,20,22,23,24)",UJIAQDJKSXQLIT-UHFFFAOYSA-N,25084,"3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol::JMC504279 Compound 6::TG100-115",Serine/threonine-protein kinase ULK2,Homo sapiens,
944434,C=CC(=O)N1CC[C@@]2(C[C@@H](C2)n2c(NC(=O)c3ccc(s3)-c3cnco3)nc3ccccc23)C1,"InChI=1S/C25H23N5O3S/c1-2-22(31)29-10-9-25(14-29)11-16(12-25)30-18-6-4-3-5-17(18)27-24(30)28-23(32)21-8-7-20(34-21)19-13-26-15-33-19/h2-8,13,15-16H,1,9-12,14H2,(H,27,28,32)/t16-,25-",FINZRTUQZUBKBD-ODAJSGAPSA-N,50458592,"CHEMBL4211372::US10752615, Compound 16",Tyrosine-protein kinase ITK/TSK,Homo sapiens, 0.810
50782688,CCCCCCCCCCCCCCCC(=O)N[C@@H](COC1OC(COS([O-])(=O)=O)C(OS([O-])(=O)=O)C(OCc2ccccc2)C1OCc1ccccc1)[C@H](OCc1ccccc1)\C=C\CCCCCCCCCCCCC,"InChI=1S/C61H95NO14S2/c1-3-5-7-9-11-13-15-17-19-21-23-25-36-44-55(70-46-51-38-30-27-31-39-51)54(62-57(63)45-37-26-24-22-20-18-16-14-12-10-8-6-4-2)49-73-61-60(72-48-53-42-34-29-35-43-53)59(71-47-52-40-32-28-33-41-52)58(76-78(67,68)69)56(75-61)50-74-77(64,65)66/h27-36,38-44,54-56,58-61H,3-26,37,45-50H2,1-2H3,(H,62,63)(H,64,65,66)(H,67,68,69)/p-2/b44-36+/t54-,55+,56?,58?,59?,60?,61?/m0/s1",IABOBGKQJAGWNX-YYJCAEBZSA-L,50061136,"(2S,3R,4E)-3-(Benzoyloxy)-2-(hexadecanoylamino)-1-[[2,3-di-O-benzoyl-4,6-bis-O-(sodium oxysulfonyl)-beta-D-galactopyranosyl]oxy]-4-octadecene::CHEMBL215557",P-selectin,Homo sapiens, 100
249445,CC(C)CN(Cc1cc(Cl)c2OCC(F)(F)COc2c1)C(=O)C1CCN(Cc2cccc3cc[nH]c23)C1,"InChI=1S/C28H32ClF2N3O3/c1-18(2)12-34(13-19-10-23(29)26-24(11-19)36-16-28(30,31)17-37-26)27(35)22-7-9-33(15-22)14-21-5-3-4-20-6-8-32-25(20)21/h3-6,8,10-11,18,22,32H,7,9,12-17H2,1-2H3",NYZQNXXCSARADX-UHFFFAOYSA-N,121321,"US8722896, (-)-(3R)-1-(Indol-7-ylmethyl)- N-(9-chloro-3,3-difluoro- 3,4-dihydro-2H-1,5- benzodioxepin-7-ylmethyl)- N-isobutylpyrrolidine-3- carboxamide",Prokineticin receptor 2,,
250742,CO\N=C1\CCN(C1)c1nc(cc2ncn(C)c(=O)c12)-c1ccc(cc1)N1CCOCC1,"InChI=1S/C23H26N6O3/c1-27-15-24-20-13-19(16-3-5-18(6-4-16)28-9-11-32-12-10-28)25-22(21(20)23(27)30)29-8-7-17(14-29)26-31-2/h3-6,13,15H,7-12,14H2,1-2H3/b26-17-",BNNXOFKDIGLFSC-ONUIUJJFSA-N,122157,"US8722692, 597",Tyrosine-protein kinase SYK,Homo sapiens, 475
50428077,C[C@H](NC(=O)\C=C\c1ccccc1)C(=O)NCCc1c[nH]c2ccccc12,"InChI=1S/C22H23N3O2/c1-16(25-21(26)12-11-17-7-3-2-4-8-17)22(27)23-14-13-18-15-24-20-10-6-5-9-19(18)20/h2-12,15-16,24H,13-14H2,1H3,(H,23,27)(H,25,26)/b12-11+/t16-/m0/s1",IQLJMUHXUMZOMQ-PCUGXKRQSA-N,50244924,(S)-N-(1-(2-(1H-indol-3-yl)ethylamino)-1-oxopropan-2-yl)cinnamamide::CHEMBL472516,NAD-dependent protein deacetylase sirtuin-2,Homo sapiens, 109000
50450418,OC(=O)c1ccc(CN2\C(S\C(=C/c3ccc4ccccc4c3)C2=O)=N\c2ccccc2)cc1,"InChI=1S/C28H20N2O3S/c31-26-25(17-20-12-13-21-6-4-5-7-23(21)16-20)34-28(29-24-8-2-1-3-9-24)30(26)18-19-10-14-22(15-11-19)27(32)33/h1-17H,18H2,(H,32,33)/b25-17-,29-28-",YMCAFJIHSRLDLR-HZPABMAHSA-N,50267100,4-[(5-Naphthalen-2-ylmethylene-4-oxo-2-phenyliminothiazolidin-3-yl)methyl] benzoic acid::CHEMBL476666,Low molecular weight phosphotyrosine protein phosphatase,Saccharomyces cerevisiae, 27600
1029845,OCCNC(=O)CSc1nonc1\C(NC1Cc2cc(F)c(Cl)cc12)=N\O,"InChI=1S/C15H15ClFN5O4S/c16-9-5-8-7(3-10(9)17)4-11(8)19-14(20-25)13-15(22-26-21-13)27-6-12(24)18-1-2-23/h3,5,11,23,25H,1-2,4,6H2,(H,18,24)(H,19,20)",JCAJMOLQZWXAJA-UHFFFAOYSA-N,494819,"2-({4-[N-(4-chloro-3- fluorobicyclo[4.2.0]octa-1,3,5- trien-7-yl)-N'- hydroxycarbamimidoyl]-1,2,5- oxadiazo1-3-yl}sulfanyl)-N-(2- hydroxyethyl)acetamide::US10988487, Example 215","Indoleamine 2,3-dioxygenase 1",Homo sapiens, 261
1260137,CC[C@@H]1CN([C@@H](C)CN1C(C)c1ccc(CNC(=O)OC)cc1)c1nc(=O)n(C)c2ccc(nc12)C#N,"InChI=1S/C27H33N7O3/c1-6-22-16-33(25-24-23(32(4)26(35)31-25)12-11-21(13-28)30-24)17(2)15-34(22)18(3)20-9-7-19(8-10-20)14-29-27(36)37-5/h7-12,17-18,22H,6,14-16H2,1-5H3,(H,29,36)/t17-,18?,22+/m0/s1",ZEGCCFYQRNQFTI-UMJFLEMOSA-N,594548,"US11584747, Example 359::US11584747, Example 360",Diacylglycerol kinase alpha [9-727],, 150
51163837,CN1c2ccccc2C(=N[C@H](NC(=O)C2(CCC2)C(=O)N[C@H](O)C2CCCCC2)C1=O)c1ccc(cc1)C(F)(F)F,"InChI=1S/C30H33F3N4O4/c1-37-22-11-6-5-10-21(22)23(18-12-14-20(15-13-18)30(31,32)33)34-24(26(37)39)35-27(40)29(16-7-17-29)28(41)36-25(38)19-8-3-2-4-9-19/h5-6,10-15,19,24-25,38H,2-4,7-9,16-17H2,1H3,(H,35,40)(H,36,41)/t24-,25-/m1/s1",YXAAEFGOUNJTQF-JWQCQUIFSA-N,50476863,CHEMBL273493,Presenilin-1,, 280
51174976,Oc1c(nc2sc(cn2c1=O)N1CCOCC1)C(=O)NCc1ccc(F)cc1,"InChI=1S/C18H17FN4O4S/c19-12-3-1-11(2-4-12)9-20-16(25)14-15(24)17(26)23-10-13(28-18(23)21-14)22-5-7-27-8-6-22/h1-4,10,24H,5-9H2,(H,20,25)",OECRFKJOFOFEPR-UHFFFAOYSA-N,50482786,CHEMBL1257223,Integrase,, 1130
50672201,CCn1cc(C(O)=O)c(=O)c2cc(F)c(-c3cc(C)nc(C)c3)c(F)c12,"InChI=1S/C19H16F2N2O3/c1-4-23-8-13(19(25)26)18(24)12-7-14(20)15(16(21)17(12)23)11-5-9(2)22-10(3)6-11/h5-8H,4H2,1-3H3,(H,25,26)",ZQZJGSJCJYPTBV-UHFFFAOYSA-N,50231261,CHEMBL94671,DNA topoisomerase 2-alpha/2-beta,Homo sapiens,
1209861,CCNc1c(F)cccc1-c1ncc2c(nc(OCC34CCCN3CCC4)nc2c1F)N1CC2CCC(C1)N2,"InChI=1S/C29H35F2N7O/c1-2-32-24-20(6-3-7-22(24)30)25-23(31)26-21(14-33-25)27(37-15-18-8-9-19(16-37)34-18)36-28(35-26)39-17-29-10-4-12-38(29)13-5-11-29/h3,6-7,14,18-19,32,34H,2,4-5,8-13,15-17H2,1H3",OONFMMSTVBWDOG-UHFFFAOYSA-N,573411,"US11453683, Example 269",GTPase KRas [G12D],, 4038
50221878,Cc1ccc2c(OCCN3CCC(Cc4cccc(c4)N4CCCS4(=O)=O)CC3)cccc2n1,"InChI=1S/C27H33N3O3S/c1-21-9-10-25-26(28-21)7-3-8-27(25)33-17-16-29-14-11-22(12-15-29)19-23-5-2-6-24(20-23)30-13-4-18-34(30,31)32/h2-3,5-10,20,22H,4,11-19H2,1H3",WQRVLZPCOXHNAI-UHFFFAOYSA-N,50412131,CHEMBL522708,Beta-2 adrenergic receptor,Homo sapiens,
1210742,Nc1nc2n(cnc2c(=O)[nH]1)[C@@H]1S[C@@H]2COP(O)(=O)OC3[C@@H](COP(O)(=O)O[C@H]1C2O)O[C@H]([C@H]3O)n1cnc2c(N)ncnc12,,,573847,"(5R,7R,8R,12aR,14R,15R,15aS,16S)-7-(2-amino- 6-oxo-1,6-dihydro-9H-purin-9-yl)-14-(6-amino- 9H-purin-9-yl)-15,16-dihydroxyoctahydro-12H- 5,8-methanofuro[3,2-l][1,3,9,11,6,2,10] tetraoxathiadiphosphacyclotetradecine-2,10- diolate 2,10-dioxide::US11453697, Example 11","Stimulator of interferon genes protein [1-379,R71H,G230A,H232R,R293Q]",,
132563,CCOC(=O)NC1(N=C(NC1=O)c1ccccc1)C(F)(F)F,"InChI=1S/C13H12F3N3O3/c1-2-22-11(21)19-12(13(14,15)16)10(20)17-9(18-12)8-6-4-3-5-7-8/h3-7H,2H2,1H3,(H,19,21)(H,17,18,20)",UTBXQXDHJQPHJP-UHFFFAOYSA-N,73332,"MLS000052544::N-[5-keto-2-phenyl-4-(trifluoromethyl)-2-imidazolin-4-yl]carbamic acid ethyl ester::N-[5-oxo-2-phenyl-4-(trifluoromethyl)-1H-imidazol-4-yl]carbamic acid ethyl ester::SMR000082028::cid_2978721::ethyl N-[5-oxidanylidene-2-phenyl-4-(trifluoromethyl)-1H-imidazol-4-yl]carbamate::ethyl N-[5-oxo-2-phenyl-4-(trifluoromethyl)-1H-imidazol-4-yl]carbamate::ethyl [5-oxo-2-phenyl-4-(trifluoromethyl)-4,5-dihydro-1H-imidazol-4-yl]carbamate",Protein LANA1,Human herpesvirus 8,
51021800,COc1cc(C)c(c(C)c1C)S(=O)(=O)N[C@@H](Cc1ccc(Cl)cc1)C(=O)NCCCN1CCN(C)CC1,"InChI=1S/C27H39ClN4O4S/c1-19-17-25(36-5)20(2)21(3)26(19)37(34,35)30-24(18-22-7-9-23(28)10-8-22)27(33)29-11-6-12-32-15-13-31(4)14-16-32/h7-10,17,24,30H,6,11-16,18H2,1-5H3,(H,29,33)/t24-/m0/s1",UJNSLNJBUGNTIQ-DEOSSOPVSA-N,50418388,CHEMBL1773995,Vasopressin V1a receptor,,
666640,CN(C)S(=O)(=O)c1cc(cnc1N)-c1ccnc(NC(C)=O)c1,"InChI=1S/C14H17N5O3S/c1-9(20)18-13-7-10(4-5-16-13)11-6-12(14(15)17-8-11)23(21,22)19(2)3/h4-8H,1-3H3,(H2,15,17)(H,16,18,20)",CUSNPYAULLUKDQ-UHFFFAOYSA-N,337943,"US9751854, Compound I-119::US9802960, Compound I-119",Phosphatidylinositol 3-kinase catalytic subunit type 3,Homo sapiens,<10
196941,CC(C)Cc1ccc(cc1)C(C)C(=O)Nc1ccccc1O,"InChI=1S/C19H23NO2/c1-13(2)12-15-8-10-16(11-9-15)14(3)19(22)20-17-6-4-5-7-18(17)21/h4-11,13-14,21H,12H2,1-3H3,(H,20,22)",UMZHDHGUJFZBPU-UHFFFAOYSA-N,90667,MLS000778270::N-(2-Hydroxy-phenyl)-2-(4-isobutyl-phenyl)-propionamide::N-(2-hydroxyphenyl)-2-(4-isobutylphenyl)propionamide::N-(2-hydroxyphenyl)-2-[4-(2-methylpropyl)phenyl]propanamide::SMR000414944::cid_2849603,Corticotropin-releasing factor-binding protein,Homo sapiens,
359344,CCOCCCCNC(CC(C)C)C1(CCC1)c1ccc(SC)cc1,"InChI=1S/C22H37NOS/c1-5-24-16-7-6-15-23-21(17-18(2)3)22(13-8-14-22)19-9-11-20(25-4)12-10-19/h9-12,18,21,23H,5-8,13-17H2,1-4H3",OZMCXSBQOWTTBK-UHFFFAOYSA-N,202581,"US10035761, Compound 7g::US9238625, 7g",Sodium-dependent serotonin transporter,Homo sapiens,
51301509,CCOC(=O)N1CC2(C1)CC(C2)=CC#Cc1cccc(C)n1,"InChI=1S/C18H20N2O2/c1-3-22-17(21)20-12-18(13-20)10-15(11-18)7-5-9-16-8-4-6-14(2)19-16/h4,6-8H,3,10-13H2,1-2H3",YNPRRNZDLRQOKC-UHFFFAOYSA-N,50529956,CHEMBL4551238,Metabotropic glutamate receptor 5,Homo sapiens,
50653471,Cc1cccc2C(=O)N(C(=O)c12)c1ccnc(Cl)c1,"InChI=1S/C14H9ClN2O2/c1-8-3-2-4-10-12(8)14(19)17(13(10)18)9-5-6-16-11(15)7-9/h2-7H,1H3",YDJMWNHJNJVVMM-UHFFFAOYSA-N,50350123,CHEMBL1229651,Thymidylate synthase,Lactobacillus casei,
50880521,COc1ccc(C2=NC(C(N2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1,"InChI=1S/C25H24Cl2N2O2/c1-15(2)31-22-14-20(30-3)12-13-21(22)25-28-23(16-4-8-18(26)9-5-16)24(29-25)17-6-10-19(27)11-7-17/h4-15,23-24H,1-3H3,(H,28,29)",YRGSRFXZNYCJNK-UHFFFAOYSA-N,50266942,"4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole::CHEMBL515487",E3 ubiquitin-protein ligase Mdm2,Homo sapiens, 90
50169132,NC(=O)c1cnc(NC[C@@H]2CCCN2)c2cc(sc12)-c1ccc(Cl)cc1,"InChI=1S/C19H19ClN4OS/c20-12-5-3-11(4-6-12)16-8-14-17(26-16)15(18(21)25)10-24-19(14)23-9-13-2-1-7-22-13/h3-6,8,10,13,22H,1-2,7,9H2,(H2,21,25)(H,23,24)/t13-/m0/s1",DCMSFYRENMMFPF-ZDUSSCGKSA-N,50332123,"(S)-2-(4-chlorophenyl)-4-(pyrrolidin-2-ylmethylamino)thieno[3,2-c]pyridine-7-carboxamide::CHEMBL1288219",Serine/threonine-protein kinase Chk1,Homo sapiens, 197
50817294,CC(N)=NCCCC[C@H](N)C(O)=O,"InChI=1S/C8H17N3O2/c1-6(9)11-5-3-2-4-7(10)8(12)13/h7H,2-5,10H2,1H3,(H2,9,11)(H,12,13)/t7-/m0/s1",ONYFNWIHJBLQKE-ZETCQYMHSA-N,50063300,(L-N6-1-iminoethyl)lysine::(S)-6-Acetimidoylamino-2-amino-hexanoic acid::6-Acetimidoylamino-2-amino-hexanoic acid::CHEMBL1744034::CHEMBL7889::L-N6-(1-iminoethyl)lysine::N~6~-[(1Z)-ethanimidoyl]-L-lysine::l-NIL,"Nitric oxide synthase, endothelial",, 2600
50091434,COc1cc(cc(OC)c1OC)[C@@H]1[C@@H](C2CC2)[C@H]2[C@@H]1c1c(OC2(C)C)c2ccccc2[nH]c1=O,"InChI=1S/C28H31NO5/c1-28(2)24-21(14-10-11-14)20(15-12-18(31-3)26(33-5)19(13-15)32-4)22(24)23-25(34-28)16-8-6-7-9-17(16)29-27(23)30/h6-9,12-14,20-22,24H,10-11H2,1-5H3,(H,29,30)/t20-,21-,22+,24+/m1/s1",HWHNPTUQTILZGI-SVPADUAOSA-N,50011380,CHEMBL3261032,Toll-like receptor 4,Homo sapiens,
50876290,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@H](NC1=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c3ccccc13)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N2)[C@H](C)O)[C@@H](C)CC,"InChI=1S/C76H111N23O16S2/c1-7-39(3)58-71(112)94-54-36-116-117-37-55(69(110)97-60(42(6)101)72(113)86-41(5)61(102)92-53(35-100)67(108)96-59(40(4)8-2)74(115)99-29-17-25-57(99)73(114)98-28-16-24-56(98)70(111)95-58)93-63(104)49(23-15-27-83-76(79)80)88-65(106)51(31-44-33-84-47-21-13-12-20-46(44)47)90-62(103)48(22-14-26-82-75(77)78)87-64(105)50(30-43-18-10-9-11-19-43)89-66(107)52(91-68(54)109)32-45-34-81-38-85-45/h9-13,18-21,33-34,38-42,48-60,84,100-101H,7-8,14-17,22-32,35-37H2,1-6H3,(H,81,85)(H,86,113)(H,87,105)(H,88,106)(H,89,107)(H,90,103)(H,91,109)(H,92,102)(H,93,104)(H,94,112)(H,95,111)(H,96,108)(H,97,110)(H4,77,78,82)(H4,79,80,83)/t39-,40-,41-,42-,48-,49-,50+,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-/m0/s1",DBJGVYJTQHCOAH-KTIGORNTSA-N,50263804,CHEMBL4074074,Melanocyte-stimulating hormone receptor,,
50333246,OCc1ccccc1N1CC=C(NC1=O)c1cccc(c1)[N+]([O-])=O,"InChI=1S/C17H15N3O4/c21-11-13-4-1-2-7-16(13)19-9-8-15(18-17(19)22)12-5-3-6-14(10-12)20(23)24/h1-8,10,21H,9,11H2,(H,18,22)",BVJGNDZMKADVPL-UHFFFAOYSA-N,50083006,CHEMBL3422800,Transient receptor potential cation channel subfamily M member 8,,
50466813,OC(=O)CCc1ccccc1C[C@@H]1CCC[C@@H]1c1nc(co1)C(=O)NCCCCC1CCCCC1,"InChI=1S/C29H40N2O4/c32-27(33)17-16-22-12-4-5-13-23(22)19-24-14-8-15-25(24)29-31-26(20-35-29)28(34)30-18-7-6-11-21-9-2-1-3-10-21/h4-5,12-13,20-21,24-25H,1-3,6-11,14-19H2,(H,30,34)(H,32,33)/t24-,25-/m0/s1",REOJLAXLWPJOTB-DQEYMECFSA-N,50281918,3-(2-{2-[4-(4-Cyclohexyl-butylcarbamoyl)-oxazol-2-yl]-cyclopentylmethyl}-phenyl)-propionic acid::CHEMBL22244,Thromboxane A2 receptor,,
596328,ONC(=O)CCCCCCN(c1nccs1)c1ccccn1,"InChI=1S/C15H20N4O2S/c20-14(18-21)8-3-1-2-6-11-19(15-17-10-12-22-15)13-7-4-5-9-16-13/h4-5,7,9-10,12,21H,1-3,6,8,11H2,(H,18,20)",NSWXYHYGBYWCCU-UHFFFAOYSA-N,310737,"N-Hydroxy-7-(pyridin-2-yl(thiazol-2-yl)amino)heptanamide::US10150763, Example KK",Histone deacetylase 1,Homo sapiens, 5500
50103942,Clc1cccc(N2CCN(CCCCOc3cccc4c(C=O)cnn34)CC2)c1Cl,"InChI=1S/C22H24Cl2N4O2/c23-18-5-3-7-20(22(18)24)27-12-10-26(11-13-27)9-1-2-14-30-21-8-4-6-19-17(16-29)15-25-28(19)21/h3-8,15-16H,1-2,9-14H2",ZHLBCCKGUNFWNS-UHFFFAOYSA-N,50018951,CHEMBL3287400,D(3) dopamine receptor,,
354222,Oc1cc2CCN3CCc4c(CC3c2cc1O)ccc(O)c4O,"InChI=1S/C18H19NO4/c20-15-2-1-10-7-14-13-9-17(22)16(21)8-11(13)3-5-19(14)6-4-12(10)18(15)23/h1-2,8-9,14,20-23H,3-7H2",CTNWBZPXZUTRQV-UHFFFAOYSA-N,199161,"5,6,8,9,14,14a-hexahydrobenzo[4,5]azepino[2,1-a]isoquinoline-2,3,10,11-tetraol (18)",D(1A) dopamine receptor,, 1.1450e+5
789010,O[C@@H](CNC(=O)c1ncnc(NC2COC2)c1F)CN1CCc2ccccc2C1,"InChI=1S/C20H24FN5O3/c21-17-18(23-12-24-19(17)25-15-10-29-11-15)20(28)22-7-16(27)9-26-6-5-13-3-1-2-4-14(13)8-26/h1-4,12,15-16,27H,5-11H2,(H,22,28)(H,23,24,25)/t16-/m0/s1",NGRJZDNVHHKBIM-INIZCTEOSA-N,394777,"US10307413, Compound 422",Protein arginine N-methyltransferase 5,,<100
50424167,Fc1ccc(-c2noc(n2)C2CCN(CC2)c2cnc3ccc(Cl)cc3c2)c(Cl)c1,"InChI=1S/C22H17Cl2FN4O/c23-15-1-4-20-14(9-15)10-17(12-26-20)29-7-5-13(6-8-29)22-27-21(28-30-22)18-3-2-16(25)11-19(18)24/h1-4,9-13H,5-8H2",KZPYBMNBUZPMKP-UHFFFAOYSA-N,50261729,"6-chloro-3-(4-(3-(2-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)quinoline::CHEMBL468176",Muscarinic acetylcholine receptor M1,,
285203,CC1CN(C1)[C@@H]1CC[C@@H]([C@H](C1)C#N)n1cc(C(N)=O)c(Nc2ccc(cc2)S(=O)(=O)C(F)(F)F)n1,"InChI=1S/C22H25F3N6O3S/c1-13-10-30(11-13)16-4-7-19(14(8-16)9-26)31-12-18(20(27)32)21(29-31)28-15-2-5-17(6-3-15)35(33,34)22(23,24)25/h2-3,5-6,12-14,16,19H,4,7-8,10-11H2,1H3,(H2,27,32)(H,28,29)/t14-,16-,19+/m1/s1",CWIWGDKSABCMGA-OGWOLHLISA-N,147863,"US8962608, 28-187",Tyrosine-protein kinase JAK1,Homo sapiens, 0.2
50732138,NS(=O)(=O)c1cccc(NS(=O)(=O)c2ccc(NCc3cc(=O)oc4cc(Cl)ccc34)cc2)c1,"InChI=1S/C22H18ClN3O6S2/c23-15-4-9-20-14(10-22(27)32-21(20)11-15)13-25-16-5-7-18(8-6-16)34(30,31)26-17-2-1-3-19(12-17)33(24,28)29/h1-12,25-26H,13H2,(H2,24,28,29)",CWWNTMKCOPSSCO-UHFFFAOYSA-N,50087256,3-[4-(7-chloro-2-oxo-2H-4-chromenylmethylamino)phenylsulfonamido]-1-benzenesulfonamide::CHEMBL161658,Carbonic anhydrase 2,Homo sapiens,
50735057,CCCN(CCCCOc1ccn2nccc2c1)[C@@H]1CCc2c(O)cccc2C1,"InChI=1S/C24H31N3O2/c1-2-13-26(20-8-9-23-19(17-20)6-5-7-24(23)28)14-3-4-16-29-22-11-15-27-21(18-22)10-12-25-27/h5-7,10-12,15,18,20,28H,2-4,8-9,13-14,16-17H2,1H3/t20-/m1/s1",IWAHIMCMPBOXKG-HXUWFJFHSA-N,50236964,CHEMBL4094869,D(2) dopamine receptor,Homo sapiens,
261572,COc1ncc(-c2nc3C(=O)N(C(c3n2C(C)C)c2ccc(Cl)cc2)c2cc(Cl)cnc2O)c(OC)n1,"InChI=1S/C25H22Cl2N6O4/c1-12(2)32-20-18(30-21(32)16-11-29-25(37-4)31-23(16)36-3)24(35)33(17-9-15(27)10-28-22(17)34)19(20)13-5-7-14(26)8-6-13/h5-12,19H,1-4H3,(H,28,34)",CHOHEJZMEHHXSJ-UHFFFAOYSA-N,129843,"US8815926, 122",E3 ubiquitin-protein ligase Mdm2,Homo sapiens, 0.25
50342470,C(N1CCC(=CC1)c1ccccc1)c1cnn(c1)-c1ccccc1,"InChI=1S/C21H21N3/c1-3-7-19(8-4-1)20-11-13-23(14-12-20)16-18-15-22-24(17-18)21-9-5-2-6-10-21/h1-11,15,17H,12-14,16H2",UOKGFRGTMUWXQL-UHFFFAOYSA-N,50184792,"4-phenyl-1-((1-phenyl-1H-pyrazol-4-yl)methyl)-1,2,3,6-tetrahydropyridine::CHEMBL378455",D(2) dopamine receptor,Homo sapiens,
146267,CCOC(=O)c1c2ccc(OCC(=O)NN=Cc3ccc(C)cc3)cc2n2ccccc12,"InChI=1S/C25H23N3O4/c1-3-31-25(30)24-20-12-11-19(14-22(20)28-13-5-4-6-21(24)28)32-16-23(29)27-26-15-18-9-7-17(2)8-10-18/h4-15H,3,16H2,1-2H3,(H,27,29)",ULGZIELJJFJICI-UHFFFAOYSA-N,34724,"3-[2-[2-[(4-methylphenyl)methylidene]hydrazinyl]-2-oxoethoxy]-10-pyrido[1,2-a]indolecarboxylic acid ethyl ester::3-[2-keto-2-[N'-(4-methylbenzylidene)hydrazino]ethoxy]pyrid[1,2-a]indole-10-carboxylic acid ethyl ester::MLS000326532::SMR000179109::cid_1484858::ethyl 3-(2-{2-[(E)-(4-methylphenyl)methylidene]hydrazino}-2-oxoethoxy)pyrido[1,2-a]indole-10-carboxylate::ethyl 3-[2-[2-[(4-methylphenyl)methylidene]hydrazinyl]-2-oxidanylidene-ethoxy]pyrido[1,2-a]indole-10-carboxylate::ethyl 3-[2-[2-[(4-methylphenyl)methylidene]hydrazinyl]-2-oxoethoxy]pyrido[1,2-a]indole-10-carboxylate",X-box-binding protein 1,Homo sapiens, 9960
840520,CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)COC(=O)NS(=O)(=O)c4ccc(cc4)-c4ncccn4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12,"InChI=1S/C35H49N3O6S/c1-5-25-29-19-23(39)13-15-35(29,4)28-14-16-34(3)26(11-12-27(34)30(28)31(25)40)21(2)20-44-33(41)38-45(42,43)24-9-7-22(8-10-24)32-36-17-6-18-37-32/h6-10,17-18,21,23,25-31,39-40H,5,11-16,19-20H2,1-4H3,(H,38,41)/t21-,23-,25-,26-,27+,28+,29+,30+,31-,34-,35-/m1/s1",UPGSBBQNJFCRDC-VPWDKUPFSA-N,419353,"US10457703, Example 36",Bile acid receptor,Homo sapiens,
409249,COc1ccc(nc1)[C@H]1C[C@@H]1COc1cc(NCc2csc(C)n2)c(=O)n(C)n1,"InChI=1S/C20H23N5O3S/c1-12-23-14(11-29-12)8-21-18-7-19(24-25(2)20(18)26)28-10-13-6-16(13)17-5-4-15(27-3)9-22-17/h4-5,7,9,11,13,16,21H,6,8,10H2,1-3H3/t13-,16+/m1/s1",PJFTYDNWISQOJF-CJNGLKHVSA-N,234755,"US9353104, 49","Isoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)",,
50744371,OC(=O)C1CCCN1C(=O)CC(SC(=O)c1ccccc1)C(=O)c1ccc(Br)cc1,"InChI=1S/C22H20BrNO5S/c23-16-10-8-14(9-11-16)20(26)18(30-22(29)15-5-2-1-3-6-15)13-19(25)24-12-4-7-17(24)21(27)28/h1-3,5-6,8-11,17-18H,4,7,12-13H2,(H,27,28)",JQTULICRTAABED-UHFFFAOYSA-N,50027628,1-[3-Benzoylsulfanyl-4-(4-bromo-phenyl)-4-oxo-butyryl]-pyrrolidine-2-carboxylic acid::CHEMBL130584,Angiotensin-converting enzyme,Rattus norvegicus, 115
50695456,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1,"InChI=1S/C20H15ClN4/c21-15-5-7-16(8-6-15)23-20-18-4-2-1-3-17(18)19(24-25-20)13-14-9-11-22-12-10-14/h1-12H,13H2,(H,23,25)",YCOYDOIWSSHVCK-UHFFFAOYSA-N,4851,(4-chlorophenyl)-[4-(4-pyridylmethyl)phthalazin-1-yl]amine::(A) PTK787::CGP 79787::CHEMBL101253::CHEMBL75232::N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)-1-phthalazinamine::N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine::PTK-787::PTK787::ZK222584::cid_151194,NUAK family SNF1-like kinase 1,Homo sapiens,
50414201,CN(CCN1CCCCC1)CCc1ccc(OC(F)(F)F)cc1,"InChI=1S/C17H25F3N2O/c1-21(13-14-22-10-3-2-4-11-22)12-9-15-5-7-16(8-6-15)23-17(18,19)20/h5-8H,2-4,9-14H2,1H3",QTWYMQIZRRTWFB-UHFFFAOYSA-N,50261083,CHEMBL498564::N-Methyl-2-piperidin-1-yl-N-{2-[4-(trifluoromethoxy)phenyl]-ethyl}ethanamine,Sigma non-opioid intracellular receptor 1,Rattus,
1023983,CCCC[C@@H](C)Oc1ccnc(C[C@@](O)([C@@H](N)CSCC(C)C)C(O)=O)c1,"InChI=1S/C20H34N2O4S/c1-5-6-7-15(4)26-17-8-9-22-16(10-17)11-20(25,19(23)24)18(21)13-27-12-14(2)3/h8-10,14-15,18,25H,5-7,11-13,21H2,1-4H3,(H,23,24)/t15-,18+,20-/m1/s1",ULLYSVQFEAUMPV-MOXGXCLJSA-N,271289,"US10059720, Example 104::US10975091, Example 104",Leucyl-cystinyl aminopeptidase,Homo sapiens, 26.0
125989,Nc1c(sc2nc(ccc12)-c1cccs1)C(=O)Nc1nc2ccccc2s1,"InChI=1S/C19H12N4OS3/c20-15-10-7-8-12(13-6-3-9-25-13)21-18(10)27-16(15)17(24)23-19-22-11-4-1-2-5-14(11)26-19/h1-9H,20H2,(H,22,23,24)",WVHBEUUJHVJCPR-UHFFFAOYSA-N,41051,"3-Amino-6-thiophen-2-yl-thieno[2,3-b]pyridine-2-carboxylic acid benzothiazol-2-ylamide::3-amino-N-(1,3-benzothiazol-2-yl)-6-(2-thienyl)thieno[2,3-b]pyridine-2-carboxamide::3-amino-N-(1,3-benzothiazol-2-yl)-6-thiophen-2-yl-2-thieno[2,3-b]pyridinecarboxamide::3-amino-N-(1,3-benzothiazol-2-yl)-6-thiophen-2-ylthieno[2,3-b]pyridine-2-carboxamide::3-azanyl-N-(1,3-benzothiazol-2-yl)-6-thiophen-2-yl-thieno[2,3-b]pyridine-2-carboxamide::MLS000556593::SMR000147910::cid_1928929",DNA damage-inducible transcript 3 protein,Mus musculus,>10000
51020212,O=c1[nH]ccc2cc(O[C@H]3CCNC3)ccc12,"InChI=1S/C13H14N2O2/c16-13-12-2-1-10(7-9(12)3-6-15-13)17-11-4-5-14-8-11/h1-3,6-7,11,14H,4-5,8H2,(H,15,16)/t11-/m0/s1",MJHLFDZNTKULCZ-NSHDSACASA-N,50417856,CHEMBL1667972,Rho-associated protein kinase 1,Homo sapiens, 524.81
558118,CNC(=O)[C@@H]1CCN1c1cc(cc(n1)-c1cnn2ccc(nc12)-c1cccs1)C(=O)NC[C@H](C)N,"InChI=1S/C24H26N8O2S/c1-14(25)12-27-23(33)15-10-18(29-21(11-15)31-7-6-19(31)24(34)26-2)16-13-28-32-8-5-17(30-22(16)32)20-4-3-9-35-20/h3-5,8-11,13-14,19H,6-7,12,25H2,1-2H3,(H,26,34)(H,27,33)/t14-,19-/m0/s1",DBLNFPKHQWSNDD-LIRRHRJNSA-N,292649,"N-((S)-2-aminopropyl)-2-((S)-2-(methylcarbamoyl)azetidin-1-yl)-6-(5-(thiophen-2-yl)pyrazolo[1,5-a]pyrimidin-3-yl)isonicotinamide::US10100058, Example 305",Calcium/calmodulin-dependent protein kinase type II subunit delta,,
51436053,Cn1c(NC(=O)Nc2ccc(cc2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cc(=O)n(Cc2ccc(Cl)c(Cl)c2)c1=O,"InChI=1S/C25H23Cl2N5O8/c1-31-19(11-20(33)32(25(31)40)12-13-2-7-16(26)17(27)10-13)30-24(39)28-15-5-3-14(4-6-15)22(36)29-18(23(37)38)8-9-21(34)35/h2-7,10-11,18H,8-9,12H2,1H3,(H,29,36)(H,34,35)(H,37,38)(H2,28,30,39)/t18-/m0/s1",GSPWQHDZSQRWHV-SFHVURJKSA-N,50580121,CHEMBL5085594,"C-1-tetrahydrofolate synthase, cytoplasmic",,>10000
50745698,CNC1CC(c2ccccc12)c1ccc(Cl)cc1Cl,"InChI=1S/C16H15Cl2N/c1-19-16-9-14(11-4-2-3-5-13(11)16)12-7-6-10(17)8-15(12)18/h2-8,14,16,19H,9H2,1H3",FZVZQSNRXRBRNV-UHFFFAOYSA-N,50021221,"CHEMBL542117::[3-(2,4-Dichloro-phenyl)-indan-1-yl]-methyl-amine; hydrochloride",Sodium-dependent serotonin transporter,Rattus norvegicus, 21
673038,C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)\C=C\c1ccc(Cl)cc1Cc1nnn(C)n1,"InChI=1S/C24H26ClFN6O/c1-17-15-31(16-18-3-8-22(26)9-4-18)11-12-32(17)24(33)10-6-19-5-7-21(25)13-20(19)14-23-27-29-30(2)28-23/h3-10,13,17H,11-12,14-16H2,1-2H3/b10-6+/t17-/m1/s1",OLAMNGYDXFIKIV-DKISHCGFSA-N,322055,"(R,E)-3-(4-Chloro-2-((2-methyl-2H-tetrazol-5-yl)methyl)phenyl)-1-(4-(4-fluorobenzyl)-2-methylpiperazin-1-yl)prop-2-en-1-one::US10183025, Example 143::US9763957, Example 143",Ataxin-1,, 31.0
331630,COc1ccc(cc1-c1cccc(c1)C(CC(O)=O)c1nnc(C)o1)C(C)(C)C,"InChI=1S/C23H26N2O4/c1-14-24-25-22(29-14)19(13-21(26)27)16-8-6-7-15(11-16)18-12-17(23(2,3)4)9-10-20(18)28-5/h6-12,19H,13H2,1-5H3,(H,26,27)",DIAALKGBJIRCNN-UHFFFAOYSA-N,183760,"US9150526, 9",Lysosomal protective protein [29-480],, 61
51346848,Cc1cc(NS(=O)(=O)c2ccc(Nc3ccnc(SCC(=O)c4ccc(F)cc4)n3)cc2)no1,"InChI=1S/C22H18FN5O4S2/c1-14-12-21(27-32-14)28-34(30,31)18-8-6-17(7-9-18)25-20-10-11-24-22(26-20)33-13-19(29)15-2-4-16(23)5-3-15/h2-12H,13H2,1H3,(H,27,28)(H,24,25,26)",PGDLAIFDDVHUEY-UHFFFAOYSA-N,50544892,CHEMBL4633334,Carbonic anhydrase 9,Homo sapiens,
50190038,Cc1ccc(cc1)-c1c([N-]S(=O)(=O)c2ccc(cc2)C(C)(C)C)ncnc1OCCOc1ncc(Cl)cn1,"InChI=1S/C27H27ClN5O4S/c1-18-5-7-19(8-6-18)23-24(33-38(34,35)22-11-9-20(10-12-22)27(2,3)4)31-17-32-25(23)36-13-14-37-26-29-15-21(28)16-30-26/h5-12,15-17H,13-14H2,1-4H3/q-1",HLZRFVXMFALVBN-UHFFFAOYSA-N,50105027,CHEMBL176272::sodium salt of 4-tert-Butyl-N-{6-[2-(5-chloro-pyrimidin-2-yloxy)-ethoxy]-5-p-tolyl-pyrimidin-4-yl}-benzenesulfonamide,Endothelin-1 receptor,Rattus, 0.08
50548895,CCN(CC)C(=O)c1ccc(cc1)C1(CCN(CC=C)CC1)c1cccc(O)c1,"InChI=1S/C25H32N2O2/c1-4-16-26-17-14-25(15-18-26,22-8-7-9-23(28)19-22)21-12-10-20(11-13-21)24(29)27(5-2)6-3/h4,7-13,19,28H,1,5-6,14-18H2,2-3H3",GHGXXGRQBXBJPK-UHFFFAOYSA-N,50306297,"4-(1-allyl-4-(3-hydroxyphenyl)piperidin-4-yl)-N,N-diethylbenzamide::CHEMBL605931",Kappa-type opioid receptor,Homo sapiens,
222768,Cn1c2CC3CCC(N3)c2c2cc(ccc12)S(=O)(=O)c1cccc(OC(F)F)c1,"InChI=1S/C21H20F2N2O3S/c1-25-18-8-6-15(11-16(18)20-17-7-5-12(24-17)9-19(20)25)29(26,27)14-4-2-3-13(10-14)28-21(22)23/h2-4,6,8,10-12,17,21,24H,5,7,9H2,1H3",VMNCYKLGFBECRY-UHFFFAOYSA-N,104277,"US8575186, 40",5-hydroxytryptamine receptor 6,Homo sapiens,
51300223,Cc1cn(C[C@](C)(O)C(=O)Nc2ccc(C#N)c(c2)C(F)(F)F)c2ccc(F)cc12,"InChI=1S/C21H17F4N3O2/c1-12-10-28(18-6-4-14(22)7-16(12)18)11-20(2,30)19(29)27-15-5-3-13(9-26)17(8-15)21(23,24)25/h3-8,10,30H,11H2,1-2H3,(H,27,29)/t20-/m0/s1",DAXZYVGQYZDTFR-FQEVSTJZSA-N,50529663,CHEMBL4442857,Androgen receptor,Homo sapiens, 157
1013676,COc1cc(-c2ccc(nc2)N2CC3CC(C2)N3Cc2ccc(OC)nc2)c2c(CC#N)cnn2c1,"InChI=1S/C27H27N7O2/c1-35-23-10-24(27-20(7-8-28)13-31-34(27)17-23)19-4-5-25(29-12-19)32-15-21-9-22(16-32)33(21)14-18-3-6-26(36-2)30-11-18/h3-6,10-13,17,21-22H,7,9,14-16H2,1-2H3",DZBVCAIUXMOOKD-UHFFFAOYSA-N,296823,"US10112942, Example 558::US10137124, Example 558::US10172851, Example 558::US10555944, Example 558::US10953005, Example 558",Proto-oncogene tyrosine-protein kinase receptor Ret [G810R],, 3621
50419724,CNCc1cc(ccc1Cc1ccc(Cl)c(Cl)c1)S(N)(=O)=O,"InChI=1S/C15H16Cl2N2O2S/c1-19-9-12-8-13(22(18,20)21)4-3-11(12)6-10-2-5-14(16)15(17)7-10/h2-5,7-8,19H,6,9H2,1H3,(H2,18,20,21)",FFJCCOLDJHZNND-UHFFFAOYSA-N,50252069,"4-(3,4-dichlorobenzyl)-3-((methylamino)methyl)benzenesulfonamide::CHEMBL481306",Sodium-dependent serotonin transporter,Homo sapiens, 6
51192953,NS(=O)(=O)c1ccc(CN2C(=O)CCC2=O)cc1,"InChI=1S/C11H12N2O4S/c12-18(16,17)9-3-1-8(2-4-9)7-13-10(14)5-6-11(13)15/h1-4H,5-7H2,(H2,12,16,17)",AYNHSSHRIRNWEB-UHFFFAOYSA-N,50035688,CHEMBL2377780,Prostaglandin G/H synthase 2,Ovis aries,>100000
1069145,COc1nc(O[C@H]2C[C@@]3(C[C@@H](C3)NC(=O)c3cnn(c3C)-c3ccc(cn3)C(F)(F)F)C2)c(s1)C(N)=O,"InChI=1S/C23H23F3N6O4S/c1-11-15(10-29-32(11)16-4-3-12(9-28-16)23(24,25)26)19(34)30-13-5-22(6-13)7-14(8-22)36-20-17(18(27)33)37-21(31-20)35-2/h3-4,9-10,13-14H,5-8H2,1-2H3,(H2,27,33)(H,30,34)/t13-,14-,22-/m0/s1",QXKYZQBNLYXSQC-OKHZJLECSA-N,510935,"2-methoxy-4-{[(4s)-6-{5- methyl-1-[5- (trifluoromethyl)pyridin-2- yl]-1H-pyrazole-4- amido}spiro[3.3]heptan-2- yl]oxy}-1,3-thiazole-5- carboxamide::US11078197, Example 114",Rho-associated protein kinase 2,Homo sapiens, 115000
501519,COc1ccc2CN([C@@H](Cc2c1OCC#Cc1ccccc1)C(O)=O)C(=O)C(c1ccccc1)c1ccccc1,"InChI=1S/C34H29NO5/c1-39-30-20-19-27-23-35(33(36)31(25-15-7-3-8-16-25)26-17-9-4-10-18-26)29(34(37)38)22-28(27)32(30)40-21-11-14-24-12-5-2-6-13-24/h2-10,12-13,15-20,29,31H,21-23H2,1H3,(H,37,38)/t29-/m0/s1",YKXFIJFGQNQILE-LJAQVGFWSA-N,263930,"US9714224, 50",Type-2 angiotensin II receptor,, 96.2
51085177,CCCCNc1ncc(c(N[C@H]2CC[C@H](O)CC2)n1)-c1ccc(CNCCO)cn1,"InChI=1S/C22H34N6O2/c1-2-3-10-24-22-26-15-19(20-9-4-16(14-25-20)13-23-11-12-29)21(28-22)27-17-5-7-18(30)8-6-17/h4,9,14-15,17-18,23,29-30H,2-3,5-8,10-13H2,1H3,(H2,24,26,27,28)/t17-,18-",NLXWFBBYANWXPR-IYARVYRRSA-N,50444068,CHEMBL3092797,Tyrosine-protein kinase receptor UFO,, 70
51076166,CC(CNS(C)(=O)=O)[C@@H](c1ccccc1)c1ccc2n(ncc2c1)-c1ccc(F)cc1,"InChI=1S/C24H24FN3O2S/c1-17(15-27-31(2,29)30)24(18-6-4-3-5-7-18)19-8-13-23-20(14-19)16-26-28(23)22-11-9-21(25)10-12-22/h3-14,16-17,24,27H,15H2,1-2H3/t17?,24-/m0/s1",JWWHDSCWSHFYDM-UCSBTNPJSA-N,50440100,CHEMBL2426120,Glucocorticoid receptor,,
51244581,CN1CCN(CC1)c1ccc2c3CCN(Cc3c(=O)oc2c1C)C(=O)c1ccc(NS(C)(=O)=O)c(F)c1,"InChI=1S/C26H29FN4O5S/c1-16-23(30-12-10-29(2)11-13-30)7-5-19-18-8-9-31(15-20(18)26(33)36-24(16)19)25(32)17-4-6-22(21(27)14-17)28-37(3,34)35/h4-7,14,28H,8-13,15H2,1-3H3",YIENLOQGUANJTL-UHFFFAOYSA-N,50509360,CHEMBL4538356,"C-1-tetrahydrofolate synthase, cytoplasmic",Homo sapiens, 8000
874903,Fc1cc2CN(Cc2cc1OC1CCCNC1)c1cn[nH]c(=O)c1C(F)(F)F,,,431078,"5-[5-fluoro-6-(piperidin-3-yloxy)-2,3-dihydro-1H-isoindol-2-yl]-4-(trifluoromethyl)-2,3-dihydropyridazin-3-one::US10550105, Example 58::US10870641, Example 58::US11014913, Example 58",Protein mono-ADP-ribosyltransferase TIPARP,,<100
50321102,N#Cc1cnc2cnc(NCCN3CCOCC3)cc2c1Nc1ccc(Oc2ccccc2)cc1,"InChI=1S/C27H26N6O2/c28-17-20-18-30-25-19-31-26(29-10-11-33-12-14-34-15-13-33)16-24(25)27(20)32-21-6-8-23(9-7-21)35-22-4-2-1-3-5-22/h1-9,16,18-19H,10-15H2,(H,29,31)(H,30,32)",YUYWSKXPXLUJNA-UHFFFAOYSA-N,50173837,"6-(2-morpholinoethylamino)-4-(4-phenoxyphenylamino)-1,7-naphthyridine-3-carbonitrile::6-[(2-morpholin-4-ylethyl)amino]-4-[(4-phenoxyphenyl)amino]-[1,7]naphthyridine-3-carbonitrile::CHEMBL371095",Dual specificity mitogen-activated protein kinase kinase 1,Homo sapiens, 800
1249923,CCn1c(c2CC(C)(C)COC(=O)[C@@H]3CCCN(N3)C(=O)[C@H](Cc3cc(O)cc(c3)-c3ccc1c2c3)NC(=O)[C@H](C(C)C)N(C)C(=O)[C@H]1CCN(C1)C(=O)C=C)-c1cnccc1[C@H](C)OC,"InChI=1S/C51H65N7O8/c1-10-44(60)56-20-17-34(28-56)48(62)55(8)45(30(3)4)47(61)53-42-23-32-21-35(24-36(59)22-32)33-14-15-43-38(25-33)39(46(57(43)11-2)40-27-52-18-16-37(40)31(5)65-9)26-51(6,7)29-66-50(64)41-13-12-19-58(54-41)49(42)63/h10,14-16,18,21-22,24-25,27,30-31,34,41-42,45,54,59H,1,11-13,17,19-20,23,26,28-29H2,2-9H3,(H,53,61)/t31-,34-,41-,42-,45-/m0/s1",XVALWQLJSNYOAZ-PGZWVAKSSA-N,591398,"US11566007, Example A112::US11566007, Example A76",GTPase KRas [G13C],, 55.0
960812,CC1CN(CCC1n1cccn1)c1ccnc(n1)-c1cnc2ccc(cn12)C(F)(F)F,"InChI=1S/C21H20F3N7/c1-14-12-29(10-6-16(14)31-9-2-7-27-31)19-5-8-25-20(28-19)17-11-26-18-4-3-15(13-30(17)18)21(22,23)24/h2-5,7-9,11,13-14,16H,6,10,12H2,1H3",QRQDKCUJDSBNFH-UHFFFAOYSA-N,465046,"US10793563, Compound I-379",eIF-2-alpha kinase GCN2,Homo sapiens, 55
50779675,COC(=O)[C@H]([C@@H]1CCCCN1)c1cccc(F)c1,"InChI=1S/C14H18FNO2/c1-18-14(17)13(12-7-2-3-8-16-12)10-5-4-6-11(15)9-10/h4-6,9,12-13,16H,2-3,7-8H2,1H3/t12-,13-/m0/s1",GKVAYKZYNJEOFY-STQMWFEESA-N,50050123,(S)-(3-Fluoro-phenyl)-(S)-piperidin-2-yl-acetic acid methyl ester; hydrochloride::CHEMBL537930,Sodium-dependent dopamine transporter,Rattus norvegicus, 41
613357,CN1CC(COc2cc(-c3ccc(nc3)N3CCC(C)(CC3)NC(=O)c3ccccn3)c3c(cnn3c2)C#N)C1,"InChI=1S/C30H32N8O2/c1-30(35-29(39)26-5-3-4-10-32-26)8-11-37(12-9-30)27-7-6-22(15-33-27)25-13-24(40-20-21-17-36(2)18-21)19-38-28(25)23(14-31)16-34-38/h3-7,10,13,15-16,19,21H,8-9,11-12,17-18,20H2,1-2H3,(H,35,39)",JOHAMULTITXGOP-UHFFFAOYSA-N,305443,"US10144734, Example 460::US10172845, Example 460::US10441581, Example 460::US10881652, Example 460","Proto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M]",, 87.4
50608943,[Cl-].C[N+](C)(CC(=O)Nc1ccccc1)CC(=O)Nc1ccccc1,"InChI=1S/C18H21N3O2/c1-21(2,13-17(22)19-15-9-5-3-6-10-15)14-18(23)20-16-11-7-4-8-12-16/h3-12H,13-14H2,1-2H3,(H-,19,20,22,23)/p+1",MPOXTHSNJVUPKR-UHFFFAOYSA-O,50225700,Carcainium Chloride,Sodium channel protein type 1/2/3 subunit alpha,, 3900
50991145,CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3[nH]ncc23)CC1,"InChI=1S/C23H27N7O3S2/c1-35(31,32)30-7-5-28(6-8-30)15-16-13-20-21(34-16)23(29-9-11-33-12-10-29)26-22(25-20)17-3-2-4-19-18(17)14-24-27-19/h2-4,13-14H,5-12,15H2,1H3,(H,24,27)",LHNIIDJUOCFXAP-UHFFFAOYSA-N,25028,"4-[2-(1H-indazol-4-yl)-6-[(4-methanesulfonylpiperazin-1-yl)methyl]thieno[3,2-d]pyrimidin-4-yl]morpholine::GDC-0941::GDC0941::US10112932, pictilisib::US10851091, Compound pictilisib","Phosphatidylinositol 3-kinase regulatory subunit alpha/4,5-bisphosphate 3-kinase catalytic subunit beta isoform",Homo sapiens, 54
51115843,COCCCN1CC2C(CNC(=O)c3cccc4c(Cl)c(nn34)C(C)C)C2C1,"InChI=1S/C21H29ClN4O2/c1-13(2)20-19(22)17-6-4-7-18(26(17)24-20)21(27)23-10-14-15-11-25(12-16(14)15)8-5-9-28-3/h4,6-7,13-16H,5,8-12H2,1-3H3,(H,23,27)",KLECHXMLPPZMLD-UHFFFAOYSA-N,50456148,CHEMBL4214953,5-hydroxytryptamine receptor 4,,
699701,Cc1[nH]c2c(ccc(N3CCCC(C3)NC(=O)C=C)c2c1C)C(N)=O,,,165287,"US10604504, Example 83::US9688629, 83::US9802915, Example 83::US9920031, Example 83",Tyrosine-protein kinase BTK,Homo sapiens, 3.30
50445488,CCCCC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4C(=O)Cn4cncn4)[C@@H]3CC=C2C1,"InChI=1S/C28H39N3O3/c1-4-5-6-26(33)34-20-11-13-27(2)19(15-20)7-8-21-22-9-10-24(28(22,3)14-12-23(21)27)25(32)16-31-18-29-17-30-31/h7,10,17-18,20-23H,4-6,8-9,11-16H2,1-3H3/t20-,21-,22-,23-,27-,28-/m0/s1",UCAXUDRLNVTQLE-APJCQQALSA-N,50135090,CHEMBL3735678,3-oxo-5-alpha-steroid 4-dehydrogenase 1,Rattus norvegicus, 320000
1140838,CSc1cnc(N[C@H]2CC[C@@H](C2)Nc2nc3ccc(cc3s2)C(=O)N2CCC3(CCOC3)CC2)nc1,"InChI=1S/C26H32N6O2S2/c1-35-20-14-27-24(28-15-20)29-18-3-4-19(13-18)30-25-31-21-5-2-17(12-22(21)36-25)23(33)32-9-6-26(7-10-32)8-11-34-16-26/h2,5,12,14-15,18-19H,3-4,6-11,13,16H2,1H3,(H,30,31)(H,27,28,29)/t18-,19-/m0/s1",TTXQKOOPKSEEFT-OALUTQOASA-N,537846,"US11248001, Example 321",Proprotein convertase subtilisin/kexin type 9,,
50024595,Cc1nc2ccc(CN(CC#C)c3ccc(cc3)C(=O)NC(CCC(O)=O)C(O)=O)cc2c(=O)[nH]1,"InChI=1S/C25H24N4O6/c1-3-12-29(14-16-4-9-20-19(13-16)24(33)27-15(2)26-20)18-7-5-17(6-8-18)23(32)28-21(25(34)35)10-11-22(30)31/h1,4-9,13,21H,10-12,14H2,2H3,(H,28,32)(H,30,31)(H,34,35)(H,26,27,33)",PMTUUSDTAKQWQJ-UHFFFAOYSA-N,50012244,"2-{4-[(2-Methyl-4-oxo-3,4-dihydro-quinazolin-6-ylmethyl)-prop-2-ynyl-amino]-benzoylamino}-pentanedioic acid::2-{4-[(2-Methyl-4-oxo-3,4-dihydro-quinazolin-6-ylmethyl)-prop-2-ynyl-amino]-benzoylamino}-pentanedioic acid(DMPDDF)::CHEMBL25889",Dihydrofolate reductase,Lactobacillus casei, 35000
50965527,OC(=O)c1ccnc(c1)-c1cc(ccn1)C(=O)NCCc1ccccc1,"InChI=1S/C20H17N3O3/c24-19(23-9-6-14-4-2-1-3-5-14)15-7-10-21-17(12-15)18-13-16(20(25)26)8-11-22-18/h1-5,7-8,10-13H,6,9H2,(H,23,24)(H,25,26)",DSGOLESVOJUGOK-UHFFFAOYSA-N,50396019,"4&#39;-(phenethylcarbamoyl)-[2,2&#39;-bipyridine]-4-carboxylic acid (N3)::CHEMBL2169917",Lysine-specific demethylase 4E,Homo sapiens, 110
50822376,CCCCCCCCc1ccc2nc([nH]c2c1)[C@@H](N)CO,"InChI=1S/C17H27N3O/c1-2-3-4-5-6-7-8-13-9-10-15-16(11-13)20-17(19-15)14(18)12-21/h9-11,14,21H,2-8,12,18H2,1H3,(H,19,20)/t14-/m0/s1",XKKHMNGIHWTYAT-AWEZNQCLSA-N,50152541,(R)-2-Amino-2-(6-octyl-1H-benzoimidazol-2-yl)-ethanol; TFA::CHEMBL363076,Sphingosine 1-phosphate receptor 5,Homo sapiens,
1177491,CC(C)(C)NC(=O)c1cc(NC(=O)Cc2cc(Cl)cc(Cl)c2)ccn1,"InChI=1S/C18H19Cl2N3O2/c1-18(2,3)23-17(25)15-10-14(4-5-21-15)22-16(24)8-11-6-12(19)9-13(20)7-11/h4-7,9-10H,8H2,1-3H3,(H,23,25)(H,21,22,24)",IUBSSKSCLLEUOB-UHFFFAOYSA-N,509621,"US11364246, Example 5.19::US20200361871A1, Example 5.19",Anoctamin-1,Homo sapiens,
350135,CC(C)OC(=O)c1ccc(nc1)N1CCC(CC1)OC(=O)N1CCN(CC1)C(C)C,"InChI=1S/C22H34N4O4/c1-16(2)24-11-13-26(14-12-24)22(28)30-19-7-9-25(10-8-19)20-6-5-18(15-23-20)21(27)29-17(3)4/h5-6,15-17,19H,7-14H2,1-4H3",IIDWRCSIRLZSTB-UHFFFAOYSA-N,197067,"US9216182, 1.13",Histamine H3 receptor,Homo sapiens,
931679,OC(=O)c1ccc(CN2CC[C@@]3([C@H]2CCc2cc(ccc32)C(F)(C(F)(F)F)C(F)(F)F)S(=O)(=O)c2ccc(F)cc2)cc1Cl,"InChI=1S/C29H22ClF8NO4S/c30-23-13-16(1-8-21(23)25(40)41)15-39-12-11-26(44(42,43)20-6-4-19(31)5-7-20)22-9-3-18(14-17(22)2-10-24(26)39)27(32,28(33,34)35)29(36,37)38/h1,3-9,13-14,24H,2,10-12,15H2,(H,40,41)/t24-,26-/m1/s1",FJYXVQNSINUYKK-AOYPEHQESA-N,383058,"US10273259, Example 769::US10711020, Example 769",Nuclear receptor ROR-gamma [262-507],, 117
51238060,Nc1c(C(=O)N[C@H]2CC[C@H](CC2)c2ccccc2)n(-c2ccccc2)c(=O)[nH]c1=O,"InChI=1S/C23H24N4O3/c24-19-20(27(23(30)26-21(19)28)18-9-5-2-6-10-18)22(29)25-17-13-11-16(12-14-17)15-7-3-1-4-8-15/h1-10,16-17H,11-14,24H2,(H,25,29)(H,26,28,30)/t16-,17+",OZJCVDROTRKHCV-CALCHBBNSA-N,50506736,CHEMBL4584322,Endothelial lipase,Homo sapiens, 2350
50589181,NCCCCNCCCN,"InChI=1S/C7H19N3/c8-4-1-2-6-10-7-3-5-9/h10H,1-9H2",ATHGHQPFGPMSJY-UHFFFAOYSA-N,50009353,"1,5,10-triazadecane::4-azaoctamethylenediamine::4-azaoctane-1,8-diamine::CHEMBL19612::N-(3-aminopropyl)butane-1,4-diamine::spermidine","Carbonic anhydrase 5A, mitochondrial",Homo sapiens,
51379505,CC(=O)Oc1ccccc1C(O)=O,"InChI=1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)",BSYNRYMUTXBXSQ-UHFFFAOYSA-N,22360,2-(acetyloxy)benzoate::2-(acetyloxy)benzoic acid::Acetylsalicylic acid::Aspirin::Endosprin::Polopirin::Zorprin::acetylsalicylate::cid_2244,Prostaglandin G/H synthase 1,, 350
51406065,Fc1cccc(NS(=O)(=O)c2cc(F)c(O[C@H]3CCN(CC(F)(F)F)C[C@@H]3c3ccc(F)c(F)c3)c(F)c2)n1,"InChI=1S/C24H19F8N3O3S/c25-16-5-4-13(8-17(16)26)15-11-35(12-24(30,31)32)7-6-20(15)38-23-18(27)9-14(10-19(23)28)39(36,37)34-22-3-1-2-21(29)33-22/h1-5,8-10,15,20H,6-7,11-12H2,(H,33,34)/t15-,20+/m1/s1",ALYSSPGOUMAGSF-QRWLVFNGSA-N,50568138,CHEMBL4854735,Sodium channel protein type 5 subunit alpha,, 65
50567623,COc1ccc(cn1)N(C)C(=O)c1cnc(cn1)-c1ccc(cc1C)C#N,"InChI=1S/C20H17N5O2/c1-13-8-14(9-21)4-6-16(13)17-11-23-18(12-22-17)20(26)25(2)15-5-7-19(27-3)24-10-15/h4-8,10-12H,1-3H3",OJOXFOACQKDTBX-UHFFFAOYSA-N,50314508,5-(4-cyano-2-methylphenyl)-N-(6-methoxypyridin-3-yl)-N-methylpyrazine-2-carboxamide::CHEMBL1093367,Vasopressin V2 receptor,,
358103,CC(C)(O)[C@@H](NC(=O)Nc1cc2[nH]nc(N)c2cn1)c1ccc(F)cc1,,,202011,"US9233979, 443",Mitogen-activated protein kinase 1,Homo sapiens, 0.7
50481608,COc1cc(\C=N\NC(=O)Cn2c3ccccc3nc(C)c2=O)cc(OC)c1OC,"InChI=1S/C23H25ClFNO2/c24-18-7-5-17(6-8-18)23(28)14-20-11-12-21(15-23)26(20)13-1-2-22(27)16-3-9-19(25)10-4-16/h3-10,20-21,28H,1-2,11-15H2",CXQUOFVDYCOSEZ-UHFFFAOYSA-N,50155519,CHEMBL3775970,Aminopeptidase N,, 57550
501316,Oc1ccc2c(CCCC(c3ccncc3)=C2c2ccc(O[C@H]3CCN(CCCF)C3)cc2)c1,"InChI=1S/C29H31FN2O2/c30-14-2-17-32-18-13-26(20-32)34-25-8-5-22(6-9-25)29-27(21-11-15-31-16-12-21)4-1-3-23-19-24(33)7-10-28(23)29/h5-12,15-16,19,26,33H,1-4,13-14,17-18,20H2/t26-/m0/s1",VQJJJXIRLQIHGO-SANMLTNESA-N,263822,"5-[4-[(3S)- 1-(3- fluoropropyl)- pyrrolidin-3- yl]oxy- phenyl]-6-(4- pyridyl)- 8,9- dihydro- 7H- benzo[7]- annulen-2-ol::US9714221, Example 153",Estrogen receptor [D538G],, 74.0
50389057,CC(C)C[C@@H](N)c1cccc(c1N1CCN(CC1)C(=O)[C@@H](Cc1ccc(Cl)cc1Cl)NC(=O)CCN)C(F)(F)F,"InChI=1S/C28H36Cl2F3N5O2/c1-17(2)14-23(35)20-4-3-5-21(28(31,32)33)26(20)37-10-12-38(13-11-37)27(40)24(36-25(39)8-9-34)15-18-6-7-19(29)16-22(18)30/h3-7,16-17,23-24H,8-15,34-35H2,1-2H3,(H,36,39)/t23-,24-/m1/s1",QKOLGGSRJVIDED-DNQXCXABSA-N,50214683,"1-{4-[(1R)-2-(amino-3-methylbutyl)-6-trifluoromethylphenyl]-4-[(2R)-(3-aminopropionylamido)-3-(2,4-dichlorophenyl)propionyl]}-piperazine::CHEMBL391219",Melanocortin receptor 4,,
50154357,CCCN(CCC)C(=O)c1cc(cc(c1)S(=O)(=O)c1ccccc1)C(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNCc1cccc(OC)c1,"InChI=1S/C38H43F2N3O6S/c1-4-14-43(15-5-2)38(46)29-20-28(21-34(22-29)50(47,48)33-12-7-6-8-13-33)37(45)42-35(19-27-16-30(39)23-31(40)17-27)36(44)25-41-24-26-10-9-11-32(18-26)49-3/h6-13,16-18,20-23,35-36,41,44H,4-5,14-15,19,24-25H2,1-3H3,(H,42,45)/t35-,36+/m0/s1",SUHUZGDMCOOSBZ-MPQUPPDSSA-N,50294651,"CHEMBL555436::N1-((2S,3R)-1-(3,5-difluorophenyl)-3-hydroxy-4-(3-methoxybenzylamino)butan-2-yl)-5-(phenylsulfonyl)-N3,N3-dipropylisophthalamide",Beta-secretase 1,Homo sapiens, 11
50508971,Cc1ccc(NS(=O)(=O)c2cccs2)cc1Cl,"InChI=1S/C11H10ClNO2S2/c1-8-4-5-9(7-10(8)12)13-17(14,15)11-3-2-6-16-11/h2-7,13H,1H3",KOTPGHDHHVOARW-UHFFFAOYSA-N,50294367,CHEMBL558100::N-(3-Chloro-4-methylphenyl)thiophene-2-sulfonamide,Lethal factor,Bacillus anthracis,>100000
830001,CC(Nc1ncnc2[nH]cnc12)c1nc2cccc(C)n2c(=O)c1-c1ccc(cc1)C#N,,,394341,"US10428087, Example 61::US10829502, Example 61::US11401280, Example 61::US9975907, Example 61","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform",Homo sapiens,>500
848504,CC(C)(C)c1ccc(cc1)N(C(C(=O)NC1CCCC1)c1cccnc1)C(=O)c1c[nH]cn1,,,420993,"US9975885, Compound 47",Replicase polyprotein 1ab,Human SARS coronavirus, 1700
50029788,CC(Oc1ccccc1-c1ccccc1)C1=NCCN1,"InChI=1S/C17H18N2O/c1-13(17-18-11-12-19-17)20-16-10-6-5-9-15(16)14-7-3-2-4-8-14/h2-10,13H,11-12H2,1H3,(H,18,19)",OGOLMGZJNRNULQ-UHFFFAOYSA-N,50412250,CHEMBL128168,Alpha-2B adrenergic receptor,,
50180054,Fc1ccccc1N1CCN(Cc2c[nH]c3ncccc23)CC1,"InChI=1S/C18H19FN4/c19-16-5-1-2-6-17(16)23-10-8-22(9-11-23)13-14-12-21-18-15(14)4-3-7-20-18/h1-7,12H,8-11,13H2,(H,20,21)",OOKNJSVAHXTYKL-UHFFFAOYSA-N,50099887,"3-[4-(2-Fluoro-phenyl)-piperazin-1-ylmethyl]-1H-pyrrolo[2,3-b]pyridine::CHEMBL282424",5-hydroxytryptamine receptor 1E,Homo sapiens,
791715,Cc1nc2nonc2c(N)c1Cc1ccc(C#N)c(OCC(F)F)n1,"InChI=1S/C15H12F2N6O2/c1-7-10(12(19)13-14(20-7)23-25-22-13)4-9-3-2-8(5-18)15(21-9)24-6-11(16)17/h2-3,11H,4,6,19H2,1H3",IBUYTGADUJQKQO-UHFFFAOYSA-N,396206,"6-(7-Amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridin-6-ylmethyl)-2-(2,2-difluoro-ethoxy)-nicotinonitrile::US10308667, Example 109",Ghrelin O-acyltransferase,, 0.093
51144831,COc1ccc2c3CN(COc3ccc2c1)c1nc(cs1)-c1ccc(F)cc1,"InChI=1S/C22H17FN2O2S/c1-26-17-7-8-18-15(10-17)4-9-21-19(18)11-25(13-27-21)22-24-20(12-28-22)14-2-5-16(23)6-3-14/h2-10,12H,11,13H2,1H3",WQIGYQSUSNXXAB-UHFFFAOYSA-N,50469026,CHEMBL4283605,Reverse transcriptase,Human immunodeficiency virus 1,
50325186,O=S(=O)(Nc1ccccc1)N1CCC(CC1)(c1nccn1Cc1ccccc1)c1ccccc1,"InChI=1S/C27H28N4O2S/c32-34(33,29-25-14-8-3-9-15-25)31-19-16-27(17-20-31,24-12-6-2-7-13-24)26-28-18-21-30(26)22-23-10-4-1-5-11-23/h1-15,18,21,29H,16-17,19-20,22H2",FBLAYKAWVSYTGT-UHFFFAOYSA-N,50175717,"4-(1-benzyl-1H-imidazol-2-yl)-N,4-diphenylpiperidine-1-sulfonamide::CHEMBL199518",Mu-type opioid receptor,Homo sapiens,
51362655,Clc1ccc(cc1)-n1c(nc2ccccc2c1=O)-c1sc(NC(=O)c2ccco2)nc1-c1ccccc1,"InChI=1S/C28H17ClN4O3S/c29-18-12-14-19(15-13-18)33-25(30-21-10-5-4-9-20(21)27(33)35)24-23(17-7-2-1-3-8-17)31-28(37-24)32-26(34)22-11-6-16-36-22/h1-16H,(H,31,32,34)",OTAAAJWYDQOTRS-UHFFFAOYSA-N,50550814,CHEMBL4747947,Adenosine receptor A1,Rattus norvegicus,
612449,Cc1ccc(Cl)cc1C(=O)NC1(C)CCN(CC1)c1ccc(cn1)-c1cc(OCC(C)(C)O)cn2ncc(C#N)c12,"InChI=1S/C31H33ClN6O3/c1-20-5-7-23(32)13-25(20)29(39)36-31(4)9-11-37(12-10-31)27-8-6-21(16-34-27)26-14-24(41-19-30(2,3)40)18-38-28(26)22(15-33)17-35-38/h5-8,13-14,16-18,40H,9-12,19H2,1-4H3,(H,36,39)",IPFAVAPMBUVAOH-UHFFFAOYSA-N,305057,"5-chloro-N-(1-(5-(3- cyano-6-(2-hydroxy-2- methylpropoxy)pyrazolo [1,5-a]pyridin-4-yl) pyridin-2-yl)-4- methylpiperidin-4-yl)-2- methylbenzamide::US10144734, Example 73::US10172845, Example 73::US10441581, Example 73::US10881652, Example 73",Proto-oncogene tyrosine-protein kinase receptor Ret [658-1114],, 16.3
51346371,Oc1ccc(cc1)C(c1ccc(O)cc1)C(Cl)(Cl)Cl,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H",IUGDILGOLSSKNE-UHFFFAOYSA-N,50410509,CHEMBL196585::SJ000143975,Estrogen receptor,, 43
50600924,COC(=O)[C@@H]1C[C@H](I)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](C[C@]21C)c1ccoc1,"InChI=1S/C21H25IO6/c1-20-6-4-12-19(25)28-15(11-5-7-27-10-11)9-21(12,2)17(20)16(23)14(22)8-13(20)18(24)26-3/h5,7,10,12-15,17H,4,6,8-9H2,1-3H3/t12-,13-,14-,15-,17-,20-,21-/m0/s1",ZMMLDLJAIWFEMI-CEFSSPBYSA-N,50327507,"(3S,4aR,4bS,6S,8R,8aR,10aR)-3-Furan-3-yl-6-iodo-4a,8a-dimethyl-1,5-dioxo-dodecahydro-2-oxa-phenanthrene-8-carboxylic acid methyl ester::CHEMBL1257731",Kappa-type opioid receptor,Homo sapiens,
50461276,CO[C@@H]1CN(CCC(=O)N2CCOCC2)CC[C@@H]1NC(=O)c1cc(Cl)c(N)cc1OC,"InChI=1S/C21H31ClN4O5/c1-29-18-12-16(23)15(22)11-14(18)21(28)24-17-3-5-25(13-19(17)30-2)6-4-20(27)26-7-9-31-10-8-26/h11-12,17,19H,3-10,13,23H2,1-2H3,(H,24,28)/t17-,19+/m0/s1",OCVUHLRJDQASOP-PKOBYXMFSA-N,50142908,CHEMBL3758410,5-hydroxytryptamine receptor 4,, 954
51375109,Oc1ccc2C(=O)c3nnn(c3C(=O)c2c1)-c1ccc(F)c(Cl)c1,"InChI=1S/C16H7ClFN3O3/c17-11-5-7(1-4-12(11)18)21-14-13(19-20-21)15(23)9-3-2-8(22)6-10(9)16(14)24/h1-6,22H",KUSQYZAWKVNEKI-UHFFFAOYSA-N,50556075,CHEMBL4747007,"Indoleamine 2,3-dioxygenase 1",Homo sapiens, 355
50199925,CC(C)C1NC(=O)[C@@H](Cc2ccccc2)NC(=O)C(CC(O)=O)NC(=O)NNC(=O)C(CCCNC(N)=N)NC1=O,"InChI=1S/C25H37N9O7/c1-13(2)19-23(40)29-15(9-6-10-28-24(26)27)22(39)33-34-25(41)31-17(12-18(35)36)20(37)30-16(21(38)32-19)11-14-7-4-3-5-8-14/h3-5,7-8,13,15-17,19H,6,9-12H2,1-2H3,(H,29,40)(H,30,37)(H,32,38)(H,33,39)(H,35,36)(H4,26,27,28)(H2,31,34,41)/t15?,16-,17?,19?/m1/s1",DPVUQQDISRAKFA-DSICWQNTSA-N,50110233,"CHEMBL267155::[8-Benzyl-14-(3-guanidino-propyl)-11-isopropyl-3,6,9,12,15-pentaoxo-1,2,4,7,10,13hexaaza-cyclopentadec-5-yl]-acetic acid",Integrin alpha-V/beta-5,Homo sapiens, 2100
82435,CC1CCCN(C1)c1nc2ccccc2nc1C(C#N)C(=O)OC1CCCCC1,"InChI=1S/C23H28N4O2/c1-16-8-7-13-27(15-16)22-21(25-19-11-5-6-12-20(19)26-22)18(14-24)23(28)29-17-9-3-2-4-10-17/h5-6,11-12,16-18H,2-4,7-10,13,15H2,1H3",QXRWTYKHXFRJOY-UHFFFAOYSA-N,44435,2-cyano-2-[3-(3-methyl-1-piperidinyl)-2-quinoxalinyl]acetic acid cyclohexyl ester::2-cyano-2-[3-(3-methylpiperidino)quinoxalin-2-yl]acetic acid cyclohexyl ester::MLS000040157::SMR000043328::cid_662746::cyclohexyl 2-cyano-2-[3-(3-methylpiperidin-1-yl)quinoxalin-2-yl]acetate::cyclohexyl 2-cyano-2-[3-(3-methylpiperidin-1-yl)quinoxalin-2-yl]ethanoate,Ephrin type-A receptor 4,Mus musculus, 9810
587633,O=C(NCCCc1ncc[nH]1)c1ccc2nc(C3=CCOCC3)c(nc2c1)-c1cccs1,"InChI=1S/C24H23N5O2S/c30-24(27-9-1-4-21-25-10-11-26-21)17-5-6-18-19(15-17)29-23(20-3-2-14-32-20)22(28-18)16-7-12-31-13-8-16/h2-3,5-7,10-11,14-15H,1,4,8-9,12-13H2,(H,25,26)(H,27,30)",WHPNGTOQYUNLJS-UHFFFAOYSA-N,306138,"US10144742, Compound I-300",Nicotinamide phosphoribosyltransferase,Homo sapiens,<100
22101,N[C@@H](CC(=O)N1CCc2ccccc2C1)C(=O)N1CCC[C@H]1C#N,"InChI=1S/C18H22N4O2/c19-11-15-6-3-8-22(15)18(24)16(20)10-17(23)21-9-7-13-4-1-2-5-14(13)12-21/h1-2,4-5,15-16H,3,6-10,12,20H2/t15-,16-/m0/s1",XCUPYUKEECXEPG-HOTGVXAUSA-N,12182,"(2S)-1-[(2S)-2-amino-4-oxo-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)butanoyl]pyrrolidine-2-carbonitrile::CHEMBL179289::cyanopyrrolidine derivative 5",Dipeptidyl peptidase 2,Homo sapiens, 31259
51379910,Cc1cccc2n(Cc3cccc(c3C#N)C(F)(F)F)c(=O)n(C[C@H]3CC[C@@H](CC3)C(O)=O)c(=O)c12,"InChI=1S/C26H24F3N3O4/c1-15-4-2-7-21-22(15)23(33)32(13-16-8-10-17(11-9-16)24(34)35)25(36)31(21)14-18-5-3-6-20(19(18)12-30)26(27,28)29/h2-7,16-17H,8-11,13-14H2,1H3,(H,34,35)/t16-,17-",QDVBJHFEZRTDHU-QAQDUYKDSA-N,50557897,CHEMBL4761298,Cytochrome P450 2D6,,>100000
51132253,Cn1ccc(n1)-c1ccc(Cc2cc(nc3n(C)ccc23)C(=O)NC2CCOC(C)(C)C2)cn1,"InChI=1S/C26H30N6O2/c1-26(2)15-19(9-12-34-26)28-25(33)23-14-18(20-7-10-31(3)24(20)29-23)13-17-5-6-21(27-16-17)22-8-11-32(4)30-22/h5-8,10-11,14,16,19H,9,12-13,15H2,1-4H3,(H,28,33)",JPTMWXJBVKWMOU-UHFFFAOYSA-N,50464173,CHEMBL4238850,Muscarinic acetylcholine receptor M1,Rattus,
51414173,Cl.COc1ccc2nc3CC4CC(CC(C)=C4)c3c(N)c2c1,"InChI=1S/C18H20N2O.ClH/c1-10-5-11-7-12(6-10)17-16(8-11)20-15-4-3-13(21-2)9-14(15)18(17)19;/h3-5,9,11-12H,6-8H2,1-2H3,(H2,19,20);1H",KCMWKNABWVNMDK-UHFFFAOYSA-N,50571191,CHEMBL4850590,Cholinesterase,Homo sapiens, 3760
932712,C[C@@H]1CCCN1CCCOc1ccc(cc1)-n1c(C)nc2ccc(cc2c1=O)S(F)(F)(F)(F)F,"InChI=1S/C23H26F5N3O2S/c1-16-5-3-12-30(16)13-4-14-33-19-8-6-18(7-9-19)31-17(2)29-22-11-10-20(15-21(22)23(31)32)34(24,25,26,27)28/h6-11,15-16H,3-5,12-14H2,1-2H3/t16-/m1/s1",ZSYSMHSIJUGKDW-MRXNPFEDSA-N,438110,"US10618886, Compound IV::US10730853, Compound IV::US11420955, Compound IV",Histamine H3 receptor,Homo sapiens, 8.15
540042,CCN(C1CN(N=C1c1ccc(Cl)c(Cl)c1)C(\Nc1cc(F)cc(OC(F)F)c1)=N/C#N)C(=O)CO,"InChI=1S/C22H19Cl2F3N6O3/c1-2-32(19(35)10-34)18-9-33(31-20(18)12-3-4-16(23)17(24)5-12)22(29-11-28)30-14-6-13(25)7-15(8-14)36-21(26)27/h3-8,18,21,34H,2,9-10H2,1H3,(H,29,30)",GOXPTBFRMOWJPX-UHFFFAOYSA-N,283183,"Rac-N-[1-{N&#8242;-cyano-N-[3-(difluoromethoxy)-5-fluorophenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide::US10023539, Example 24",N-lysine methyltransferase SMYD2,, 63.1
318294,Cc1cnc(C)c2nc(CCc3nc(cn3C)-c3ccncc3)nn12,"InChI=1S/C18H19N7/c1-12-10-20-13(2)18-22-16(23-25(12)18)4-5-17-21-15(11-24(17)3)14-6-8-19-9-7-14/h6-11H,4-5H2,1-3H3",HQNLOVNPFMKKMR-UHFFFAOYSA-N,173194,"US9096589, 5,8-Dimethyl-2-[2-(1-methyl-4-pyridin-4-yl-1H-imidazol-2-yl)-ethyl]-[1,2,4]triazolo[1,5-a]pyrazine","cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A",Homo sapiens, 0.55
50378959,OC(C(=O)N1CCN(CC1)c1ccc2[nH]ncc2c1)c1ccc(Br)cc1,"InChI=1S/C19H19BrN4O2/c20-15-3-1-13(2-4-15)18(25)19(26)24-9-7-23(8-10-24)16-5-6-17-14(11-16)12-21-22-17/h1-6,11-12,18,25H,7-10H2,(H,21,22)",XWMMNGXDPDSMBN-UHFFFAOYSA-N,50208322,1-(4-(1H-indazol-5-yl)piperazin-1-yl)-2-(4-bromophenyl)-2-hydroxyethanone::CHEMBL239150::SR-899,Cytochrome P450 3A4,Homo sapiens, 4000
751831,CC#CCOc1cnc(cn1)C(=O)Nc1ccc2OCCC3(N=C(C)C(N)=N3)c2c1,"InChI=1S/C21H20N6O3/c1-3-4-8-30-18-12-23-16(11-24-18)20(28)25-14-5-6-17-15(10-14)21(7-9-29-17)26-13(2)19(22)27-21/h5-6,10-12H,7-9H2,1-2H3,(H2,22,27)(H,25,28)",LGQYIGQUEVQRCI-UHFFFAOYSA-N,136712,"US10231967, Example 13e::US8865911, 13e::US9918985, Example 13e",Beta-secretase 1 [1-460],, 22.0
355352,COc1n[nH]c2cc(NC(=O)N[C@H](COC(F)F)c3ccccc3)ncc12,,,199806,"US9226922, 442",Mitogen-activated protein kinase 1,Homo sapiens, 5.5
861391,COC(=O)Nc1cc(ccn1)-c1cnc(OC[C@](C)(N)CC(C)C)c(c1)C(F)F,"InChI=1S/C20H26F2N4O3/c1-12(2)9-20(3,23)11-29-18-15(17(21)22)7-14(10-25-18)13-5-6-24-16(8-13)26-19(27)28-4/h5-8,10,12,17H,9,11,23H2,1-4H3,(H,24,26,27)/t20-/m1/s1",LYPCNZGCERKJEG-HXUWFJFHSA-N,311388,"(R)-methyl (6-((2-amino-2,4-dimethylpentyl)oxy)-5-(difluoromethyl)-[3,4&#8242;-bipyridin]-2&#8242;-yl)carbamate::US10155760, Example 245::US10351563, Example 245::US10544120, Example 245::US10723734, Example 245::US10981910, Example 245::US9902722, Example 245",AP2-associated protein kinase 1,Homo sapiens, 11.0
611597,Fc1cccc(-c2ncccn2)c1C(=O)N1CC2CC(Nc3ccc(Br)cn3)C1C2,"InChI=1S/C22H19BrFN5O/c23-14-5-6-19(27-11-14)28-17-9-13-10-18(17)29(12-13)22(30)20-15(3-1-4-16(20)24)21-25-7-2-8-26-21/h1-8,11,13,17-18H,9-10,12H2,(H,27,28)",PGRFCBWNHDMEMV-UHFFFAOYSA-N,314987,"((1S,4S,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone::US10183953, Example 168::US9611277, Example 168",Orexin/Hypocretin receptor type 1,Rattus norvegicus,
351582,Cc1cc(N)ncc1-n1c(nc2c(Cl)ccc(Cl)c2c1=O)[C@@H](Nc1nc(N)nc(N)c1C#N)C1CC1,"InChI=1S/C23H20Cl2N10O/c1-9-6-15(27)30-8-14(9)35-21(32-18-13(25)5-4-12(24)16(18)22(35)36)17(10-2-3-10)31-20-11(7-26)19(28)33-23(29)34-20/h4-6,8,10,17H,2-3H2,1H3,(H2,27,30)(H5,28,29,31,33,34)/t17-/m0/s1",XPRIOGDYXUTIAO-KRWDZBQOSA-N,198102,"BDBM198103::US9221795, 98","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform",Homo sapiens, 640
50357011,CCO\N=C(/CCN1CCN(CC1)c1nccs1)c1ccccc1,"InChI=1S/C18H24N4OS/c1-2-23-20-17(16-6-4-3-5-7-16)8-10-21-11-13-22(14-12-21)18-19-9-15-24-18/h3-7,9,15H,2,8,10-14H2,1H3/b20-17+",JHVJCSPJYFYTJV-LVZFUZTISA-N,50193364,(E)-1-phenyl-3-(4-thiazol-2-ylpiperazin-1-yl)propanon-1-one O-ethyloxime::CHEMBL377388,D(4) dopamine receptor,Homo sapiens,
51052076,CN1CCc2cc(Cl)c(O)cc2[C@H](C1)c1ccccc1,"InChI=1S/C17H18ClNO/c1-19-8-7-13-9-16(18)17(20)10-14(13)15(11-19)12-5-3-2-4-6-12/h2-6,9-10,15,20H,7-8,11H2,1H3/t15-/m1/s1",GOTMKOSCLKVOGG-OAHLLOKOSA-N,82247,"8-Chloro-3-methyl-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol(SCH 23390)::CAS_87134-87-0::CHEMBL2158641::CHEMBL62::SCH 23388::SCH 23390::SCH 23390 (R-enantiomer)::SCH 23390,R(+)",D(1A) dopamine receptor,,
50205117,Cn1c2nc[nH]c2c(=O)n(Cc2ccccc2)c1=O,"InChI=1S/C13H12N4O2/c1-16-11-10(14-8-15-11)12(18)17(13(16)19)7-9-5-3-2-4-6-9/h2-6,8H,7H2,1H3,(H,14,15)",YAYRUHPCXIPTID-UHFFFAOYSA-N,50113235,"1-Benzyl-3-methyl-3,7-dihydro-purine-2,6-dione::CHEMBL63944",Adenosine receptor A2a,Rattus norvegicus,
620430,Cc1nn(C)cc1Nc1ncnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4ccccc4F)c3F)c12,"InChI=1S/C24H18F3N7O3S/c1-12-17(10-34(2)32-12)31-24-19-13(9-28-23(19)29-11-30-24)22(35)20-15(26)7-8-16(21(20)27)33-38(36,37)18-6-4-3-5-14(18)25/h3-11,33H,1-2H3,(H2,28,29,30,31)",MZNUIROSGLQZKD-UHFFFAOYSA-N,317049,"N-{3-[4-(1,3-Dimethyl-1H- pyrazol-4-ylamino)-7H- pyrrolo[2,3-d]pyrimidine-5- carbonyl]-2,4-difluoro- phenyl}-2-fluoro- benzenesulfonamide::US9617267, Compound P-1154",Cytochrome P450 3A4,Homo sapiens,>10000
1139150,CNc1cc2n(nc(-c3cncc(c3)C(F)(F)F)c2cn1)C1CC[C@@H](CC1)Oc1ccc(=O)n(C)n1,"InChI=1S/C24H24F3N7O2/c1-28-20-10-19-18(13-30-20)23(14-9-15(12-29-11-14)24(25,26)27)32-34(19)16-3-5-17(6-4-16)36-21-7-8-22(35)33(2)31-21/h7-13,16-17H,3-6H2,1-2H3,(H,28,30)/t16?,17-",ATBDIPDCACEXQS-FITNRVMRSA-N,537227,"2-methyl-6-(((1s,4s)-4-(6- (methylamino)-3-(5- (trifluoromethyl)pyridin-3- yl)-1H-pyrazolo[4,3- c]pyridin-1- yl)cyclohexyl)oxy)pyridazin- 3(2H)-one::US11247990, Example 52",Tyrosine-protein kinase Mer,Homo sapiens, 350
50001102,OC(=O)C(=O)CC(=O)c1cccnc1,"InChI=1S/C9H7NO4/c11-7(4-8(12)9(13)14)6-2-1-3-10-5-6/h1-3,5H,4H2,(H,13,14)",PISWNSJFMUGNKU-UHFFFAOYSA-N,50137869,"2,4-Dioxo-4-pyridin-3-yl-butyric acid::CHEMBL177968::CHEMBL2040556",RNA-directed RNA polymerase,Hepatitis C virus,>50000
51365739,COc1cccc(c1)-c1cnc2OS(=O)(=O)C=Cc2c1,"InChI=1S/C14H11NO4S/c1-18-13-4-2-3-10(8-13)12-7-11-5-6-20(16,17)19-14(11)15-9-12/h2-9H,1H3",KXASSMVTZKGURM-UHFFFAOYSA-N,50552044,CHEMBL4798084,Carbonic anhydrase 12,Homo sapiens,
50162960,COc1ccc(cc1)N1CCN(CC1)c1ccc(cc1)S(=O)(=O)C1(CCOCC1)C(=O)NO,"InChI=1S/C23H29N3O6S/c1-31-20-6-2-18(3-7-20)25-12-14-26(15-13-25)19-4-8-21(9-5-19)33(29,30)23(22(27)24-28)10-16-32-17-11-23/h2-9,28H,10-17H2,1H3,(H,24,27)",QQPOIMHFFPBDQM-UHFFFAOYSA-N,50320410,CHEMBL1084208::N-hydroxy-4-(4-(4-(4-methoxyphenyl)piperazin-1-yl)phenylsulfonyl)tetrahydro-2H-pyran-4-carboxamide,Matrix metalloproteinase-9,Homo sapiens, 722
1011768,Cc1cc(Nc2cc3ncccc3c(N[C@H]3C[C@@H]4CCC[C@H](C3)N4S(C)(=O)=O)n2)n[nH]1,,,277525,"US10072026, Example 4-16::US10947254, Example 4-16",Tyrosine-protein kinase JAK3,Homo sapiens,
50456984,NC(=O)[C@]1(Cc2ccc(F)cc2)C[C@@H]2CC[C@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl,"InChI=1S/C28H27Cl2FN2O/c29-24-7-3-1-5-22(24)26(23-6-2-4-8-25(23)30)33-20-13-14-21(33)17-28(16-20,27(32)34)15-18-9-11-19(31)12-10-18/h1-12,20-21,26H,13-17H2,(H2,32,34)/t20-,21-/m1/s1",SPEHUFZCQVFXFF-NHCUHLMSSA-N,50259098,CHEMBL3084526::endo-8-(bis(2-chlorophenyl)methyl)-3-(4-fluorobenzyl)-8-azabicyclo[3.2.1]octane-3-carboxamide,Nociceptin receptor,Homo sapiens,
50744047,C\C=C\c1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O,"InChI=1S/C12H16N2O5/c1-2-3-7-5-14(12(18)13-11(7)17)10-4-8(16)9(6-15)19-10/h2-3,5,8-10,15-16H,4,6H2,1H3,(H,13,17,18)",SMBMLBOPIUXCIM-UHFFFAOYSA-N,50028584,"1-(4-Hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-propenyl-1H-pyrimidine-2,4-dione::1-(4-Hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-propenyl-1H-pyrimidine-2,4-dione(BVDU)::4-Hydroxy-1-(4-hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-propenyl-1H-pyrimidin-2-one::CHEMBL2367811","Thymidine kinase, cytosolic",Rattus norvegicus,
343189,Cc1oc2n(C)c(=O)n(C)c(=O)c2c1CC(=O)Nc1nc(cs1)-c1ccc(F)c(OC(F)(F)F)c1,"InChI=1S/C21H16F4N4O5S/c1-9-11(16-17(31)28(2)20(32)29(3)18(16)33-9)7-15(30)27-19-26-13(8-35-19)10-4-5-12(22)14(6-10)34-21(23,24)25/h4-6,8H,7H2,1-3H3,(H,26,27,30)",YNQDIELZBNNYMX-UHFFFAOYSA-N,191719,"US9186360, 68",Transient receptor potential cation channel subfamily V member 4,,>10000
438594,COc1cc(-c2nc3N4CCOCC4CCOc3c(n2)C2(CCOCC2)S(C)(=O)=O)c2cc[nH]c2c1,,,251611,"US9453031, 34",DNA-dependent protein kinase catalytic subunit,Homo sapiens, 25000
743319,CN([C@H]1CCN(Cc2ccc(C)o2)C1)c1cc(F)c(cc1Cl)S(=O)(=O)Nc1cscn1,"InChI=1S/C20H22ClFN4O3S2/c1-13-3-4-15(29-13)10-26-6-5-14(9-26)25(2)18-8-17(22)19(7-16(18)21)31(27,28)24-20-11-30-12-23-20/h3-4,7-8,11-12,14,24H,5-6,9-10H2,1-2H3/t14-/m0/s1",CLPKNZQVQSGSCX-AWEZNQCLSA-N,373937,"(S)-5-chloro-2-fluoro-4-(methyl(1-((5-methylfuran-2-yl)methyl)pyrrolidin-3-yl)amino)-N-(thiazol-4-yl)benzenesulfonamide::US10246453, Example 204::US10815229, Example 204",Sodium channel protein type 5 subunit alpha,,>30000
51137327,CCS(=O)(=O)c1ccc(CC(=O)Nc2ccc(cc2)C(C)(C)C(=O)Nc2cc(ccn2)C(F)(F)F)cc1,"InChI=1S/C26H26F3N3O4S/c1-4-37(35,36)21-11-5-17(6-12-21)15-23(33)31-20-9-7-18(8-10-20)25(2,3)24(34)32-22-16-19(13-14-30-22)26(27,28)29/h5-14,16H,4,15H2,1-3H3,(H,31,33)(H,30,32,34)",JYILEEZLFMGOKQ-UHFFFAOYSA-N,50466368,CHEMBL4278291,Nuclear receptor ROR-gamma,Mus musculus, 78
50371875,COc1cc(ccc1NC(=O)c1cc2ccccc2n1C)-c1csc2c(cnc(N)c12)C(=O)N1CCN(C)CC1,"InChI=1S/C30H30N6O3S/c1-34-10-12-36(13-11-34)30(38)20-16-32-28(31)26-21(17-40-27(20)26)18-8-9-22(25(15-18)39-3)33-29(37)24-14-19-6-4-5-7-23(19)35(24)2/h4-9,14-17H,10-13H2,1-3H3,(H2,31,32)(H,33,37)",OLYJKDUGZAYMCA-UHFFFAOYSA-N,50202749,"CHEMBL232335::N-(4-(4-amino-7-(1-methylpiperazine-4-carbonyl)thieno[3,2-c]pyridin-3-yl)-2-methoxyphenyl)-1-methyl-1H-indole-2-carboxamide",Tyrosine-protein kinase Lck,, 17600
985863,CCOc1cc(COc2ccc(Sc3ccoc3C3NC(=O)NC3=O)cc2)ccn1,"InChI=1S/C21H19N3O5S/c1-2-27-17-11-13(7-9-22-17)12-29-14-3-5-15(6-4-14)30-16-8-10-28-19(16)18-20(25)24-21(26)23-18/h3-11,18H,2,12H2,1H3,(H2,23,24,25,26)",GCYJKRQDTKZQMM-UHFFFAOYSA-N,475584,"US10851089, Compound FC-14",Macrophage metalloelastase,Homo sapiens, 2750
817947,COc1nc(ccc1C#N)N(C)[C@@H]1CCN(C1)c1ncnc2[nH]ccc12,"InChI=1S/C18H19N7O/c1-24(15-4-3-12(9-19)18(23-15)26-2)13-6-8-25(10-13)17-14-5-7-20-16(14)21-11-22-17/h3-5,7,11,13H,6,8,10H2,1-2H3,(H,20,21,22)/t13-/m1/s1",SIZXITCJPWVYEC-CYBMUJFWSA-N,228668,"US10369153, Compound 42::US9346810, 42",Tyrosine-protein kinase JAK2,Homo sapiens,<100.0
50430660,CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(O)=O,"InChI=1S/C20H24O7S/c1-3-25-19(20(21)22)14-16-6-8-17(9-7-16)26-13-12-15-4-10-18(11-5-15)27-28(2,23)24/h4-11,19H,3,12-14H2,1-2H3,(H,21,22)/t19-/m0/s1",CXGTZJYQWSUFET-IBGZPJMESA-N,28798,(2S)-2-ethoxy-3-(4-{2-[4-(methanesulfonyloxy)phenyl]ethoxy}phenyl)propanoic acid::AZ 242::Galida::tesaglitazar,Peroxisome proliferator-activated receptor alpha,,
913235,COc1cc(ccc1OCC(=O)N1C[C@@H]2CN(C[C@H]2C1)C(=O)c1ccc2[nH]nnc2c1)C#N,,,446389,"US10669268, Example 15.93",Ataxin-1,, 921
50100811,Nc1nc(N)c2[nH]c(CSc3ccc4ccccc4c3)nc2n1,"InChI=1S/C16H14N6S/c17-14-13-15(22-16(18)21-14)20-12(19-13)8-23-11-6-5-9-3-1-2-4-10(9)7-11/h1-7H,8H2,(H5,17,18,19,20,21,22)",YFFHNJSASTWAQX-UHFFFAOYSA-N,50059927,"8-((naphthalen-2-ylthio)methyl)-9H-purine-2,6-diamine::8-(Naphthalen-2-ylsulfanylmethyl)-9H-purine-2,6-diamine::CHEMBL101908",Dihydrofolate reductase,Pneumocystis carinii, 105000
50112652,CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(O)=O,"InChI=1S/C22H36N2O5S/c1-2-3-16-30(27,28)24-21(22(25)26)17-19-7-9-20(10-8-19)29-15-5-4-6-18-11-13-23-14-12-18/h7-10,18,21,23-24H,2-6,11-17H2,1H3,(H,25,26)/t21-/m0/s1",COKMIXFXJJXBQG-NRFANRHFSA-N,50004058,(2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid::N-(Butylsulfonyl)-O-(4-(4-piperidyl)butyl)-L-tyrosine::N-(butylsulfonyl)-O-(4-piperidin-4-ylbutyl)-L-tyrosine::tirofiban,Integrin alpha-IIb/beta-3,, 600
51414493,COc1ccc(cc1)-c1n[nH]c2ncc(cc12)-c1ccc(NC(C)=O)cc1,"InChI=1S/C21H18N4O2/c1-13(26)23-17-7-3-14(4-8-17)16-11-19-20(24-25-21(19)22-12-16)15-5-9-18(27-2)10-6-15/h3-12H,1-2H3,(H,23,26)(H,22,24,25)",PVMYRLVGSWLCSL-UHFFFAOYSA-N,50571343,CHEMBL4872136,Dual specificity tyrosine-phosphorylation-regulated kinase 1A,Homo sapiens, 8.0
927987,Cc1ncc(NC(=O)c2ccnc(c2)C(C)(C)C#N)cc1-c1cc(nc(c1)N1CCOCC1)N1CC(O)C1,"InChI=1S/C28H31N7O3/c1-18-23(13-21(14-31-18)32-27(37)19-4-5-30-24(10-19)28(2,3)17-29)20-11-25(34-6-8-38-9-7-34)33-26(12-20)35-15-22(36)16-35/h4-5,10-14,22,36H,6-9,15-16H2,1-3H3,(H,32,37)",KOBZPEFNTFUTAU-UHFFFAOYSA-N,88049,"US10245267, Example 1083::US10709712, Example 1083::US9694016, 1083",Serine/threonine-protein kinase B-raf [V600E],, 35.2
926846,Cc1ccc(NC(=O)c2ccnc(c2)C(F)(F)F)cc1-c1cc(N2CCOCC2)n(C)c(=O)c1,"InChI=1S/C24H23F3N4O3/c1-15-3-4-18(29-23(33)16-5-6-28-20(11-16)24(25,26)27)14-19(15)17-12-21(30(2)22(32)13-17)31-7-9-34-10-8-31/h3-6,11-14H,7-10H2,1-2H3,(H,29,33)",CRNMRBXHDKNNKK-UHFFFAOYSA-N,81186,"US10245267, Example 485::US10709712, Example 485::US9694016, 485",RAF proto-oncogene serine/threonine-protein kinase,Homo sapiens, 0.400
892269,CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,"InChI=1S/C28H36ClN5O3S/c1-17(2)37-25-15-21(20-10-12-30-13-11-20)19(5)14-24(25)33-28-31-16-22(29)27(34-28)32-23-8-6-7-9-26(23)38(35,36)18(3)4/h6-9,14-18,20,30H,10-13H2,1-5H3,(H2,31,32,33,34)",VERWOWGGCGHDQE-UHFFFAOYSA-N,50436850,"CERITINIB::CHEMBL2403108::LDK378::US10053458, Comparative Example 2::US10618884, Example 16::US9809572, Example 16",ALK tyrosine kinase receptor,Homo sapiens,<5.00
150954,COc1ccc(CN2CCNCC2)c(OC)c1OC,"InChI=1S/C14H22N2O3/c1-17-12-5-4-11(13(18-2)14(12)19-3)10-16-8-6-15-7-9-16/h4-5,15H,6-10H2,1-3H3",UHWVSEOVJBQKBE-UHFFFAOYSA-N,80613,"1-(2,3,4-Trimethoxy-benzyl)-piperazine::1-(2,3,4-trimethoxybenzyl)piperazine;hydrochloride::1-[(2,3,4-trimethoxyphenyl)methyl]piperazine;hydrochloride::MLS001240268::SMR000674573::TRIMETAZIDINE::cid_9926449",DNA dC->dU-editing enzyme APOBEC-3G,Homo sapiens, 7190
50275242,O[C@H](CC[C@H]1CCCC(=O)N1CCSCCCC(O)=O)c1ccc(o1)C(F)(F)F,"InChI=1S/C19H26F3NO5S/c20-19(21,22)16-9-8-15(28-16)14(24)7-6-13-3-1-4-17(25)23(13)10-12-29-11-2-5-18(26)27/h8-9,13-14,24H,1-7,10-12H2,(H,26,27)/t13-,14-/m1/s1",SKOHCURJIZFDJS-ZIAGYGMSSA-N,50166463,(R)-4-(2-{(R)-2-[3-Hydroxy-3-(5-trifluoromethyl-furan-2-yl)-propyl]-6-oxo-piperidin-1-yl}-ethylsulfanyl)-butyric acid::CHEMBL191770,Prostaglandin E2 receptor EP4 subtype,Homo sapiens,
50521605,[O-][N+](=O)c1cc(ccc1NCCSc1ccccc1)S(=O)(=O)NC(=O)c1ccc(NC(=O)\C=C\c2ccccc2C(F)(F)F)cc1,"InChI=1S/C31H25F3N4O6S2/c32-31(33,34)26-9-5-4-6-21(26)12-17-29(39)36-23-13-10-22(11-14-23)30(40)37-46(43,44)25-15-16-27(28(20-25)38(41)42)35-18-19-45-24-7-2-1-3-8-24/h1-17,20,35H,18-19H2,(H,36,39)(H,37,40)/b17-12+",REDKMAYZALKKRQ-SFQUDFHCSA-N,50195322,CHEMBL3971723,Apoptosis regulator Bcl-2,,
1045078,CCOc1ncccc1-c1cc(NCc2c[nH]cn2)c(NC(C)CC)c(n1)C(C)=N,,,501500,"5-(2-ethoxy-3-pyridyl)-N-[1H-imidazol-4- ylmethyl)-3-methyl-1-[1- methylpropyl]pyrazolo[4,3-b]pyridin-7-amine, enantiomer 2::US11026923, Example 130","Dual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A",, 11.0
182285,COc1ccc2CC(CN(C)C)(c2c1)C1(O)CCCCC1,"InChI=1S/C18H27NO2/c1-19(2)13-17(18(20)9-5-4-6-10-18)12-14-7-8-15(21-3)11-16(14)17/h7-8,11,20H,4-6,9-10,12-13H2,1-3H3",UBIQMAFTTDZGEX-UHFFFAOYSA-N,85805,S33005,D(3) dopamine receptor,,
50940237,COc1ccc(cc1)S(=O)(=O)C(C)(Cc1ccc(cc1)-c1ccccc1)C(=O)NO,"InChI=1S/C23H23NO5S/c1-23(22(25)24-26,30(27,28)21-14-12-20(29-2)13-15-21)16-17-8-10-19(11-9-17)18-6-4-3-5-7-18/h3-15,26H,16H2,1-2H3,(H,24,25)",RKPWDSLUQARCLB-UHFFFAOYSA-N,50128594,3-biphenyl-4-yl-N-hydroxy-2-(4-methoxy-benzenesulfonyl)-2-methyl-propionamide::CHEMBL311966,Matrix metalloproteinase-9,Homo sapiens, 23
690465,C[C@@H]1CC(=O)Nc2cccc(C(=O)Nc3ccc(cc3)C#N)c2O1,"InChI=1S/C18H15N3O3/c1-11-9-16(22)21-15-4-2-3-14(17(15)24-11)18(23)20-13-7-5-12(10-19)6-8-13/h2-8,11H,9H2,1H3,(H,20,23)(H,21,22)/t11-/m1/s1",QAPGYFHGMNGXRD-LLVKDONJSA-N,349298,"N-(4-cyanophenyl)-2-methyl-4-oxo-3,5-dihydro-2H-1,5-benzoxazepine-9-carboxamide::US10206931, Example 105",CREB-binding protein,Homo sapiens,>19700
51351661,CC(C)c1cc(ccc1C(O)=O)-c1c(N)nn2ccc(nc12)-c1cc2CN([C@@H](C)C3CC3)C(=O)c2c(c1)C(F)(F)F,"InChI=1S/C30H28F3N5O3/c1-14(2)21-11-17(6-7-20(21)29(40)41)25-26(34)36-38-9-8-23(35-27(25)38)18-10-19-13-37(15(3)16-4-5-16)28(39)24(19)22(12-18)30(31,32)33/h6-12,14-16H,4-5,13H2,1-3H3,(H2,34,36)(H,40,41)/t15-/m0/s1",MYIWJCONSHUYIA-HNNXBMFYSA-N,50546764,CHEMBL4740423,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform",Homo sapiens, 76
284024,CS(=O)(=O)NC1CCN(C1)c1nccnc1C1CN(C1)c1ccc2ccccc2n1,"InChI=1S/C21H24N6O2S/c1-30(28,29)25-17-8-11-26(14-17)21-20(22-9-10-23-21)16-12-27(13-16)19-7-6-15-4-2-3-5-18(15)24-19/h2-7,9-10,16-17,25H,8,11-14H2,1H3",DZWMZPYNHWWJFR-UHFFFAOYSA-N,146816,"US8957073, 7.3::US9718803, 7.3","cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A",Homo sapiens, 11
51413326,CC(C)NC(=O)c1cc(cnc1N)-c1ccc(NC(=O)[C@H](N)c2ccccc2)cc1C,"InChI=1S/C24H27N5O2/c1-14(2)28-23(30)20-12-17(13-27-22(20)26)19-10-9-18(11-15(19)3)29-24(31)21(25)16-7-5-4-6-8-16/h4-14,21H,25H2,1-3H3,(H2,26,27)(H,28,30)(H,29,31)/t21-/m1/s1",XGBSJSCXJRRXAN-OAQYLSRUSA-N,50570950,CHEMBL4854154,Eukaryotic translation initiation factor 2-alpha kinase 3,, 1460
51364655,ONC(=O)c1ccc(Nc2c3CCCCc3nc3ccccc23)cc1,"InChI=1S/C20H19N3O2/c24-20(23-25)13-9-11-14(12-10-13)21-19-15-5-1-3-7-17(15)22-18-8-4-2-6-16(18)19/h1,3,5,7,9-12,25H,2,4,6,8H2,(H,21,22)(H,23,24)",CZOYPJGGAMPDBF-UHFFFAOYSA-N,50551534,CHEMBL4799871,Histone deacetylase 6,Homo sapiens, 3550
51192263,CC(C)S(=O)(=O)N1CCN(CC1)C(c1ccc(Cl)cc1)c1cccnc1,"InChI=1S/C19H24ClN3O2S/c1-15(2)26(24,25)23-12-10-22(11-13-23)19(17-4-3-9-21-14-17)16-5-7-18(20)8-6-16/h3-9,14-15,19H,10-13H2,1-2H3",QMPYVFGEBXUMLO-UHFFFAOYSA-N,50490748,CHEMBL1863056::DNDI1435775,Cytochrome P450 3A4/3A5,Homo sapiens, 810
1156454,COC(=O)N1[C@@H](C)CCc2c1ccc1n([C@H]3C[C@@H](C3)C(O)=O)c(Cc3ccccc3)nc21,"InChI=1S/C25H27N3O4/c1-15-8-9-19-20(27(15)25(31)32-2)10-11-21-23(19)26-22(12-16-6-4-3-5-7-16)28(21)18-13-17(14-18)24(29)30/h3-7,10-11,15,17-18H,8-9,12-14H2,1-2H3,(H,29,30)/t15-,17-,18-/m0/s1",OAMWXDBPABRCLA-SZMVWBNQSA-N,546747,"US11292791, Example 21",Bromodomain-containing protein 4,, 50500
211550,Oc1ccc(C=NCC2COc3ccccc3O2)cc1,"InChI=1S/C16H15NO3/c18-13-7-5-12(6-8-13)9-17-10-14-11-19-15-3-1-2-4-16(15)20-14/h1-9,14,18H,10-11H2",NEHSUEIZIBYGAB-UHFFFAOYSA-N,96584,"4-[(2,3-dihydro-1,4-benzodioxin-3-ylmethylamino)methylene]cyclohexa-2,5-dien-1-one::4-[(2,3-dihydro-1,4-benzodioxin-3-ylmethylamino)methylidene]-1-cyclohexa-2,5-dienone::4-[(2,3-dihydro-1,4-benzodioxin-3-ylmethylamino)methylidene]cyclohexa-2,5-dien-1-one::MLS000106702::SMR000111079::cid_5340822",Guanine nucleotide-binding protein subunit alpha-15,,>29913
51384256,CC(C)n1cc(cn1)-c1nc(Nc2ccc3CN(C\C=C\C(O)=O)CCc3c2)ncc1C,"InChI=1S/C24H28N6O2/c1-16(2)30-15-20(13-26-30)23-17(3)12-25-24(28-23)27-21-7-6-19-14-29(9-4-5-22(31)32)10-8-18(19)11-21/h4-7,11-13,15-16H,8-10,14H2,1-3H3,(H,31,32)(H,25,27,28)/b5-4+",SNRUIWMOAHSUGQ-SNAWJCMRSA-N,50559286,CHEMBL4760274,Tyrosine-protein kinase JAK2,, 128
588009,Cc1ccc(C#N)c(c1)-c1ccc2C3OC(c4cc(ccc34)C(=O)NCc3c(C)cc(N)nc3C)c2c1,"InChI=1S/C31H26N4O2/c1-16-4-5-21(14-32)24(10-16)19-6-8-22-25(12-19)30-26-13-20(7-9-23(26)29(22)37-30)31(36)34-15-27-17(2)11-28(33)35-18(27)3/h4-13,29-30H,15H2,1-3H3,(H2,33,35)(H,34,36)",LDXCGDUWYCAAIL-UHFFFAOYSA-N,306514,"(+-)-N-[(6-amino-2,4- dimethylpyridin-3-yl)-methyl]- 12-(2-cyano-5-methylphenyl)-15- oxatetracyclo[6.6.1.02,7.09,14] pentadeca-2,4,6,9,11,13- hexaene-4-carboxamide::US10144746, Compound 156",Plasma kallikrein,, 93.3
50388146,CCCC(Cc1ccc(OC)c(CNC(=O)c2ccc(cc2)C(F)(F)F)c1)C(O)=O,"InChI=1S/C22H24F3NO4/c1-3-4-16(21(28)29)11-14-5-10-19(30-2)17(12-14)13-26-20(27)15-6-8-18(9-7-15)22(23,24)25/h5-10,12,16H,3-4,11,13H2,1-2H3,(H,26,27)(H,28,29)",BEXZWJKLLDXOCX-UHFFFAOYSA-N,50214197,2-{4-methoxy-3-[(4-trifluoromethylbenzoylamino)-methyl]phenylmethyl}pentanoic acid::CHEMBL229786,Peroxisome proliferator-activated receptor delta,,
407235,Cn1nccc1-n1cc(C(=O)O[C@@H]2C[C@@H]3COC[C@H](C2)N3)c2ccccc12,"InChI=1S/C20H22N4O3/c1-23-19(6-7-21-23)24-10-17(16-4-2-3-5-18(16)24)20(25)27-15-8-13-11-26-12-14(9-15)22-13/h2-7,10,13-15,22H,8-9,11-12H2,1H3/t13-,14+,15-",MAMXENZGYWDRLN-QDMKHBRRSA-N,233384,"US9346829, 22",5-hydroxytryptamine receptor 3A,Homo sapiens, 0.65
527740,Fc1ccc2n(CCN3CCC(F)(F)CC3)nc(Nc3cnccc3C(=O)NC#N)c2c1,"InChI=1S/C21H20F3N7O/c22-14-1-2-18-16(11-14)19(28-17-12-26-6-3-15(17)20(32)27-13-25)29-31(18)10-9-30-7-4-21(23,24)5-8-30/h1-3,6,11-12H,4-5,7-10H2,(H,27,32)(H,28,29)",CRBLXBRTKXHMBY-UHFFFAOYSA-N,277777,"N-cyano-3-({1-[2-(4,4-difluoropiperidin-1yl)ethyl]-5-fluoro-1H-indazol-3-yl}amino)pyridine-4-carboxamide, TFA salt::US10040779, Example 74::US10336727, Example 74::US9617242, Example 74",Lysine-specific demethylase 4C,, 50
51454756,CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)O)C(=O)N[C@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O,"InChI=1S/C42H70N14O10/c1-22(2)20-30(36(61)50-23(3)33(58)53-29(40(65)66)15-10-18-49-42(46)47)54-34(59)24(4)51-38(63)32(25(5)57)55-37(62)31-16-11-19-56(31)39(64)28(14-9-17-48-41(44)45)52-35(60)27(43)21-26-12-7-6-8-13-26/h6-8,12-13,22-25,27-32,57H,9-11,14-21,43H2,1-5H3,(H,50,61)(H,51,63)(H,52,60)(H,53,58)(H,54,59)(H,55,62)(H,65,66)(H4,44,45,48)(H4,46,47,49)/t23-,24+,25-,27+,28+,29+,30+,31+,32+/m1/s1",KOUJJFLKINMWCU-RGLNHWONSA-N,50587350,CHEMBL5076900,C3a anaphylatoxin chemotactic receptor,Homo sapiens,
50454271,CC(C)Oc1cc(Cl)cc(C(=O)Nc2ccc(Cl)cn2)c1NC(=O)c1ccc(cc1)C(=N)N(C)C,"InChI=1S/C25H25Cl2N5O3/c1-14(2)35-20-12-18(27)11-19(25(34)30-21-10-9-17(26)13-29-21)22(20)31-24(33)16-7-5-15(6-8-16)23(28)32(3)4/h5-14,28H,1-4H3,(H,31,33)(H,29,30,34)",BCYFDAXBALEALQ-UHFFFAOYSA-N,50249117,"5-chloro-N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-3-isopropoxybenzamide::CHEMBL475551",Coagulation factor X,Homo sapiens, 0.5
366042,NC(=O)c1c2CN(CCn2c(Cl)c1-c1cccc(F)c1)C(=O)NCCC(F)(F)F,"InChI=1S/C18H17ClF4N4O2/c19-15-13(10-2-1-3-11(20)8-10)14(16(24)28)12-9-26(6-7-27(12)15)17(29)25-5-4-18(21,22)23/h1-3,8H,4-7,9H2,(H2,24,28)(H,25,29)",GUGMQEDMXDMAAH-UHFFFAOYSA-N,206999,"US9233965, 80",Casein kinase I isoform epsilon,, 9
907554,COc1cccc(Oc2ccc(cc2)-c2nn(C3CCCN(C3)C(=O)C=C)c3c(OCCN)cncc23)c1F,"InChI=1S/C29H30FN5O4/c1-3-26(36)34-14-5-6-20(18-34)35-29-22(16-32-17-25(29)38-15-13-31)28(33-35)19-9-11-21(12-10-19)39-24-8-4-7-23(37-2)27(24)30/h3-4,7-12,16-17,20H,1,5-6,13-15,18,31H2,2H3",OASYCZSTOXNJBS-UHFFFAOYSA-N,444717,"(R)-1-(3-(7-(2-aminoethoxy)-3-(4-(2-fluoro- 3-methoxyphenoxy)phenyl)- 1H-pyrazolo[4,3-c]pyridin-1-yl)piperidin-1- yl)prop-2-en-1-one::US10662187, Compound 87::US10793566, Compound 87",Tyrosine-protein kinase BTK,Homo sapiens, 55
50964263,CC(C)(C)OC(=O)N1CCC(CC1)N1C(C(=O)NCc2ccc(OC(F)(F)F)cc2)c2ccccc2C1=O,"InChI=1S/C27H30F3N3O5/c1-26(2,3)38-25(36)32-14-12-18(13-15-32)33-22(20-6-4-5-7-21(20)24(33)35)23(34)31-16-17-8-10-19(11-9-17)37-27(28,29)30/h4-11,18,22H,12-16H2,1-3H3,(H,31,34)",QGNZOANCXQXMOT-UHFFFAOYSA-N,50395364,CHEMBL2164374,Sodium channel protein type 5 subunit alpha,, 4500
50247495,CC1(CCN1C(=O)Cc1csc2ccccc12)C(=O)N(CCCC#N)Cc1ccc(Cl)cc1,"InChI=1S/C26H26ClN3O2S/c1-26(25(32)29(14-5-4-13-28)17-19-8-10-21(27)11-9-19)12-15-30(26)24(31)16-20-18-33-23-7-3-2-6-22(20)23/h2-3,6-11,18H,4-5,12,14-17H2,1H3",NHSOPVNCGWWJRH-UHFFFAOYSA-N,50032317,CHEMBL3353466,Free fatty acid receptor 2,Homo sapiens, 143
50721141,C1CCC(CC1)Nc1c(nc2sccn12)-c1ccc(cc1)N1CCOCC1,"InChI=1S/C21H26N4OS/c1-2-4-17(5-3-1)22-20-19(23-21-25(20)12-15-27-21)16-6-8-18(9-7-16)24-10-13-26-14-11-24/h6-9,12,15,17,22H,1-5,10-11,13-14H2",ULCHJALZVCDNEC-UHFFFAOYSA-N,50365641,CHEMBL1957980,Polyunsaturated fatty acid 5-lipoxygenase,Homo sapiens, 610
471981,C[C@@H](O)[C@H]1COC(=O)N1c1ccnc(N[C@H](C)c2cnc(cn2)-c2ccc(F)c(C)c2)n1,"InChI=1S/C22H23FN6O3/c1-12-8-15(4-5-16(12)23)18-10-25-17(9-26-18)13(2)27-21-24-7-6-20(28-21)29-19(14(3)30)11-32-22(29)31/h4-10,13-14,19,30H,11H2,1-3H3,(H,24,27,28)/t13-,14-,19-/m1/s1",HPYOOSCRXHFCAE-PJIJBLCYSA-N,247540,"US10112931, Example 79::US9434719, 79::US9688672, Example 79",Isocitrate dehydrogenase [NADP] cytoplasmic [R132H],, 5310
50625696,OC(CNCCCCCCCCCN1CCC(CC1)NC(=O)Nc1ccccc1-c1ccccc1)c1ccc(O)c2[nH]c(=O)ccc12,"InChI=1S/C38H49N5O4/c44-34-19-17-31(32-18-20-36(46)42-37(32)34)35(45)27-39-23-11-4-2-1-3-5-12-24-43-25-21-29(22-26-43)40-38(47)41-33-16-10-9-15-30(33)28-13-7-6-8-14-28/h6-10,13-20,29,35,39,44-45H,1-5,11-12,21-27H2,(H,42,46)(H2,40,41,47)",UPYWGAGJXOCCLN-UHFFFAOYSA-N,50337883,"1-(biphenyl-2-yl)-3-(1-(9-(2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino)nonyl)piperidin-4-yl)urea::CHEMBL1683940",Beta-2 adrenergic receptor,Homo sapiens,
50589723,NS(=O)(=O)Cc1noc2ccccc12,"InChI=1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12)",UBQNRHZMVUUOMG-UHFFFAOYSA-N,10888,"1,2-benzoxazol-3-ylmethanesulfonamide::CHEMBL750::SPR_2::US10172837, Zonisamide::Zonisamide::Zonisamide (ZNA)::Zonisamide (ZNS)::Zonisamide, 1::Zonisamide, ZNS",Carbonic anhydrase 2,Homo sapiens,
50779372,NC1=NCCCS1,"InChI=1S/C4H8N2S/c5-4-6-2-1-3-7-4/h1-3H2,(H2,5,6)",PQXQEOIFIUJLIE-UHFFFAOYSA-N,50049250,"CHEMBL306541::[1,3]Thiazinan-(2E)-ylideneamine::[1,3]Thiazinan-(2Z)-ylideneamine","Nitric oxide synthase, brain",Homo sapiens, 3200
51130400,O=c1n(cnc2ccc(cc12)-c1ccnc2ccccc12)-c1ccc(cc1)N1CCOCC1,"InChI=1S/C27H22N4O2/c32-27-24-17-19(22-11-12-28-25-4-2-1-3-23(22)25)5-10-26(24)29-18-31(27)21-8-6-20(7-9-21)30-13-15-33-16-14-30/h1-12,17-18H,13-16H2",MTDJGYWCNQTZLJ-UHFFFAOYSA-N,50463510,CHEMBL4244382,Mast/stem cell growth factor receptor Kit,,
50161090,NC(=N)NCCCC(NC(=O)C(c1ccccc1)c1ccc(Cl)cc1)C(=O)N[C@H]1CCc2ccccc12,"InChI=1S/C29H32ClN5O2/c30-22-15-12-21(13-16-22)26(20-8-2-1-3-9-20)28(37)35-25(11-6-18-33-29(31)32)27(36)34-24-17-14-19-7-4-5-10-23(19)24/h1-5,7-10,12-13,15-16,24-26H,6,11,14,17-18H2,(H,34,36)(H,35,37)(H4,31,32,33)/t24-,25?,26?/m0/s1",GUAYHTLGOSYHNP-IHSPPPAMSA-N,50090271,2-[2-(4-Chloro-phenyl)-2-phenyl-acetylamino]-5-guanidino-pentanoic acid (S)-indan-1-ylamide::CHEMBL41686,Neuropeptide Y receptor type 1,Homo sapiens, 3000
50264585,O=C(N(CCC#N)Cc1ccccc1)c1ccc(cc1)S(=O)(=O)Nc1ccccc1,"InChI=1S/C23H21N3O3S/c24-16-7-17-26(18-19-8-3-1-4-9-19)23(27)20-12-14-22(15-13-20)30(28,29)25-21-10-5-2-6-11-21/h1-6,8-15,25H,7,17-18H2",CJLCYOXEAFXEGB-UHFFFAOYSA-N,50043501,CHEMBL3355509,LIM domain kinase 2,Homo sapiens, 52
50341633,COc1ccccc1CN(C)CCCCOc1cccc(c1)-c1cc(=O)c2c(OC)c(OC)c(OC)cc2o1,"InChI=1S/C31H35NO7/c1-32(20-22-11-6-7-14-25(22)34-2)15-8-9-16-38-23-13-10-12-21(17-23)26-18-24(33)29-27(39-26)19-28(35-3)30(36-4)31(29)37-5/h6-7,10-14,17-19H,8-9,15-16,20H2,1-5H3",GDYOTQGQDLNPGL-UHFFFAOYSA-N,50088604,CHEMBL3577538,Acetylcholinesterase,Electrophorus electricus, 12230
561027,CN1CCN(CC1)c1nc2ccc(Cl)cc2n2cnnc12,"InChI=1S/C14H15ClN6/c1-19-4-6-20(7-5-19)13-14-18-16-9-21(14)12-8-10(15)2-3-11(12)17-13/h2-3,8-9H,4-7H2,1H3",OSPJDJMBSYTAAA-UHFFFAOYSA-N,294427,"US9586959, Compound disclosed in WO 2010030785, Example 55",Histamine H4 receptor,Homo sapiens, 22.0
50645616,CCCc1cc(ccc1OCCCOc1cccc(c1)-c1oc(=O)[nH]c1O)-c1ccccc1,"InChI=1S/C27H27NO5/c1-2-8-21-17-20(19-9-4-3-5-10-19)13-14-24(21)32-16-7-15-31-23-12-6-11-22(18-23)25-26(29)28-27(30)33-25/h3-6,9-14,17-18,29H,2,7-8,15-16H2,1H3,(H,28,30)",RAULXMKUQJNOKV-UHFFFAOYSA-N,50133652,"5-{3-[3-(3-Propyl-biphenyl-4-yloxy)-propoxy]-phenyl}-oxazolidine-2,4-dione::CHEMBL1783052::CHEMBL2037082::CHEMBL280293",Peroxisome proliferator-activated receptor gamma,Homo sapiens, 450
50671136,CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1,"InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)",KTUFNOKKBVMGRW-UHFFFAOYSA-N,13530,"4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide::CHEMBL941::Gleevec::Imatinib::Imatinib, 21::N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)-4-[(4-methylpiperazin-1-yl)methyl]benzamide::STI-571::STI571::US10906896, Cpd imatinib::US9255107, Imatinib::cid_5291::imatinib-CD3::med.21724, Compound 6",Ephrin type-A receptor 6,Homo sapiens,
1050478,Cc1cc(ccc1O)C(=O)N[C@@H](c1ccc(Cl)c(Cl)c1)c1ccc(Cl)cn1,"InChI=1S/C20H15Cl3N2O2/c1-11-8-13(3-7-18(11)26)20(27)25-19(17-6-4-14(21)10-24-17)12-2-5-15(22)16(23)9-12/h2-10,19,26H,1H3,(H,25,27)/t19-/m0/s1",WHIDMVZTEPZVKD-IBGZPJMESA-N,399230,"US10323029, Generic formula 52507 IB::US11034691, CYM generic formula 52507 IB",Sphingosine 1-phosphate receptor 1,Homo sapiens, 2200
50733265,Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCc3ccccc3)cc2)c(c1)C(=O)NO,"InChI=1S/C29H28N2O5S/c1-21-17-22(2)28(27(18-21)29(32)30-33)31(19-23-9-5-3-6-10-23)37(34,35)26-15-13-25(14-16-26)36-20-24-11-7-4-8-12-24/h3-18,33H,19-20H2,1-2H3,(H,30,32)",LSGQQGGAWBOKIB-UHFFFAOYSA-N,50103155,"2-[Benzyl-(4-benzyloxy-benzenesulfonyl)-amino]-N-hydroxy-3,5-dimethyl-benzamide::CHEMBL70207",Disintegrin and metalloproteinase domain-containing protein 17,, 429
666824,Cc1nccc(Nc2cc(ccn2)-c2cnc(C)c(c2)C(=O)N2CCC2)n1,"InChI=1S/C20H20N6O/c1-13-17(20(27)26-8-3-9-26)10-16(12-23-13)15-4-6-22-19(11-15)25-18-5-7-21-14(2)24-18/h4-7,10-12H,3,8-9H2,1-2H3,(H,21,22,24,25)",GQDPCLBRMGXZJR-UHFFFAOYSA-N,338128,"US9751854, Compound I-304::US9802960, Compound I-304",Phosphatidylinositol 3-kinase catalytic subunit type 3,Homo sapiens, 30
795608,C[C@@H]1CCC[C@](O)(CNC(=O)c2cn(CCC(F)F)c3cccc(Cl)c23)C1,"InChI=1S/C20H25ClF2N2O2/c1-13-4-3-8-20(27,10-13)12-24-19(26)14-11-25(9-7-17(22)23)16-6-2-5-15(21)18(14)16/h2,5-6,11,13,17,27H,3-4,7-10,12H2,1H3,(H,24,26)/t13-,20-/m1/s1",OUYQLHBHSMQZNU-ZUOKHONESA-N,398072,"4-Chloro-1-(3,3-difluoro-propyl)-1H-indole-3-carboxylic acid ((1R,3R)-1-hydroxy-3-methyl-cyclohexylmethyl)-amide::US10323000, Compound 8::US10676433, Compound 8",P2X purinoceptor 7,, 55
48537,CCc1[nH]c2ccccc2c1Cc1ccc(cc1)C(=O)N[C@@H]1CCOC[C@@H]1C(=O)NO,"InChI=1S/C24H27N3O4/c1-2-20-18(17-5-3-4-6-21(17)25-20)13-15-7-9-16(10-8-15)23(28)26-22-11-12-31-14-19(22)24(29)27-30/h3-10,19,22,25,30H,2,11-14H2,1H3,(H,26,28)(H,27,29)/t19-,22+/m0/s1",VCNCKDLZUXUYIX-SIKLNZKXSA-N,26563,"(3R,4R)-4-N-{4-[(2-ethyl-1H-indol-3-yl)methyl]benzene}-3-N-hydroxyoxane-3,4-dicarboxamide::2-ethyl indole, 19",72 kDa type IV collagenase,,
714538,COc1ncc(NCCNCCCF)cc1[C@H]1N(CC(F)(F)F)[C@H](C)Cc2c1[nH]c1ccccc21,,,361449,"N1-(3- fluoropropyl)- N2-(6- methoxy-5- ((1R,3R)-3- methyl-2- (2,2,2- trifluoroethyl)- 2,3,4,9- tetrahydro-1H- pyrido[3,4- b]indol-1- yl)pyridin-3- yl)ethane-1,2- diamine::US10221173, Example 41::US10590132, Example 41::US11046689, Example 41",Estrogen receptor,, 12.0
930252,Cc1nc2[nH]c(=O)n(C)c2c(=O)n1Cc1nc(no1)[C@@H]1CO[C@H](C1)c1ccc(Cl)cc1,,,452633,"1-((3-((3R,5R)-5-(4- chlorophenyl)tetrahydro- furan-3-yl)-1,2,4- oxadiazol-5-yl)methyl)- 2,7-dimethyl-7,9- dihydro-1H-purine-6,8- dione::US10710994, Example 111",Transient receptor potential cation channel subfamily A member 1,, 34.0
1202032,Clc1cncc2ccc(NC(=O)CCc3ccc(cc3)S(=O)(=O)Nc3ccccn3)cc12,"InChI=1S/C23H19ClN4O3S/c24-21-15-25-14-17-7-8-18(13-20(17)21)27-23(29)11-6-16-4-9-19(10-5-16)32(30,31)28-22-3-1-2-12-26-22/h1-5,7-10,12-15H,6,11H2,(H,26,28)(H,27,29)",CQFOGSLVBCLUPV-UHFFFAOYSA-N,569302,"US11427563, Compound 57",Rho-associated protein kinase 2,Homo sapiens, 370
51033769,ON(CCCP(O)(O)=O)C(=O)C(F)(F)F,"InChI=1S/C5H9F3NO5P/c6-5(7,8)4(10)9(11)2-1-3-15(12,13)14/h11H,1-3H2,(H2,12,13,14)",XSFPIPPKOYPIQE-UHFFFAOYSA-N,50422647,CHEMBL607356,1-deoxy-D-xylulose 5-phosphate reductoisomerase,Escherichia coli, 14125
50956273,O=C(Cc1nc(cc(=O)[nH]1)N1CCOCC1)Nc1ccccc1,"InChI=1S/C16H18N4O3/c21-15(17-12-4-2-1-3-5-12)10-13-18-14(11-16(22)19-13)20-6-8-23-9-7-20/h1-5,11H,6-10H2,(H,17,21)(H,18,19,22)",FPFCFOIMTFHSNY-UHFFFAOYSA-N,50389035,CHEMBL2064419,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform",Homo sapiens, 118
50589048,FC(F)(F)C(=O)NCCNCCCNCCNC(=O)C(F)(F)F,"InChI=1S/C11H18F6N4O2/c12-10(13,14)8(22)20-6-4-18-2-1-3-19-5-7-21-9(23)11(15,16)17/h18-19H,1-7H2,(H,20,22)(H,21,23)",OOCHSWKGVKRYIA-UHFFFAOYSA-N,50323746,"CHEMBL1214249::N1,N3-bis(2-(2,2,2-trifluoroacetamido)ethyl)-propane-1,3-diaminium trifluoroacetate","Carbonic anhydrase 5B, mitochondrial",Homo sapiens,
50140051,O=C(NCCCCc1ccccc1)\C=C\c1ccccc1,"InChI=1S/C19H21NO/c21-19(15-14-18-11-5-2-6-12-18)20-16-8-7-13-17-9-3-1-4-10-17/h1-6,9-12,14-15H,7-8,13,16H2,(H,20,21)/b15-14+",POGCSVZYJQGNCG-CCEZHUSRSA-N,50080013,(2E)-3-phenyl-N-(4-phenylbutyl)acrylamide::CHEMBL116684,"Glutamate receptor ionotropic, NMDA 1/2A",Rattus,>100000
1003331,CC(C)OCCN1CCC2(CC1)CN(C(C)C)C(=O)[C@H](C)O2,"InChI=1S/C17H32N2O3/c1-13(2)19-12-17(22-15(5)16(19)20)6-8-18(9-7-17)10-11-21-14(3)4/h13-15H,6-12H2,1-5H3/t15-/m0/s1",HJFPREHADYQNED-HNNXBMFYSA-N,484136,"(S)-9-(2-isopropoxyethyl)-4- isopropyl-2-methyl-1-oxa-4,9- diazaspiro[5.5]undecan-3- one::US10927128, Example 57",AP-4 complex subunit sigma-1,Homo sapiens,
50828297,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,"InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1",UREBDLICKHMUKA-CXSFZGCWSA-N,18207,"(1R,2S,10S,11S,13R,14R,15S,17S)-1-fluoro-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,13,15-trimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-5-one::US10869929, Compound Dexamethasone::dexamethasone::dexamethasone (tetramethyl-rhodamine conjugated )",Androgen receptor,Homo sapiens,<1000
15692,COc1ccc(cc1)S(=O)(=O)N(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OC(C)(C)C)OC1CCCC1,"InChI=1S/C27H38N2O7S/c1-27(2,3)35-26(31)28-24(18-20-10-6-5-7-11-20)25(30)19-29(36-22-12-8-9-13-22)37(32,33)23-16-14-21(34-4)15-17-23/h5-7,10-11,14-17,22,24-25,30H,8-9,12-13,18-19H2,1-4H3,(H,28,31)/t24-,25+/m0/s1",XBQGRVOIPHJWJN-LOSJGSFVSA-N,9165,"N-alkoxysulfonamide analog 5::N-alkoxysulfonamide analog entry e::tert-butyl N-[(2S,3R)-4-[(cyclopentyloxy)(4-methoxybenzene)sulfonamido]-3-hydroxy-1-phenylbutan-2-yl]carbamate","Dimer of Gag-Pol polyprotein [501-599,Q508K,L534I,L564I,C568A,C596A]",Human immunodeficiency virus 1,
50642513,COc1ccc2n(c(C)c(C(=O)N3CCCNCC3)c2c1)S(=O)(=O)c1ccc(OC)c(C)c1C,"InChI=1S/C25H31N3O5S/c1-16-17(2)23(10-9-22(16)33-5)34(30,31)28-18(3)24(20-15-19(32-4)7-8-21(20)28)25(29)27-13-6-11-26-12-14-27/h7-10,15,26H,6,11-14H2,1-5H3",PNQGELHLYTXMRZ-UHFFFAOYSA-N,50345068,"(1,4-diazepan-1-yl)(5-methoxy-1-(4-methoxy-2,3-dimethylphenylsulfonyl)-2-methyl-1H-indol-3-yl)methanone::CHEMBL1779234",Vasopressin V1a receptor,,
50895581,C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N,"InChI=1S/C16H20N6O/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20)/t11-,13+/m1/s1",UJLAWZDWDVHWOW-YPMHNXCESA-N,50193995,"3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile::3-(4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile::3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile::CHEMBL221959::CP-690550::TOFACITINIB CITRATE::Tofacitinib::Tofacitinib citrate (1)::US10112907, Example 00035::US10399979, Compound Tofacitinib::US10766894, Compound TABLE 1.20::US10875847, Compound Tofacitinib::US11078206, Example Tofacitinib::US11203595, TABLE 1.20::US11339167, Example Tofacitinib",5'-AMP-activated protein kinase catalytic subunit alpha-1,,
50916018,CSc1nc(NCc2cccnc2)c(C(O)=O)c(SCc2ccccc2)n1,"InChI=1S/C19H18N4O2S2/c1-26-19-22-16(21-11-14-8-5-9-20-10-14)15(18(24)25)17(23-19)27-12-13-6-3-2-4-7-13/h2-10H,11-12H2,1H3,(H,24,25)(H,21,22,23)",IAWJVKHNXLKFMR-UHFFFAOYSA-N,50322686,4-(Benzylthio)-2-(methylthio)-6-(3-pyridylmethylamino)pyrimidine-5-carboxylic Acid::CHEMBL1172961,Peroxisome proliferator-activated receptor gamma,Homo sapiens,
283967,CN(C)C1CCN(C1)c1nccnc1C1CN(C1)c1ccc2ccccc2n1,"InChI=1S/C22H26N6/c1-26(2)18-9-12-27(15-18)22-21(23-10-11-24-22)17-13-28(14-17)20-8-7-16-5-3-4-6-19(16)25-20/h3-8,10-11,17-18H,9,12-15H2,1-2H3",VMAQNBRTXIKONU-UHFFFAOYSA-N,146759,"US8957073, 6.6::US9718803, 6.6","cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A",Homo sapiens, 61
50243333,CC1=CC(C)(C)Nc2ccc3-c4cc(F)ccc4O\C(=C/c4ccccn4)c3c12,"InChI=1S/C25H21FN2O/c1-15-14-25(2,3)28-20-9-8-18-19-12-16(26)7-10-21(19)29-22(24(18)23(15)20)13-17-6-4-5-11-27-17/h4-14,28H,1-3H3/b22-13-",OOKFNRNSFDKPIG-XKZIYDEJSA-N,50133142,"9-Fluoro-2,2,4-trimethyl-5-[1-pyridin-2-yl-meth-(Z)-ylidene]-2,5-dihydro-1H-6-oxa-1-aza-chrysene::CHEMBL335879",Progesterone receptor,,
50450731,Nc1ccnc(c1)N1CCC(CC1)(C(=O)N1CCc2ccccc2C1)c1ccccc1,"InChI=1S/C26H28N4O/c27-23-10-14-28-24(18-23)29-16-12-26(13-17-29,22-8-2-1-3-9-22)25(31)30-15-11-20-6-4-5-7-21(20)19-30/h1-10,14,18H,11-13,15-17,19H2,(H2,27,28)",IWDSJHMQLGCBQF-UHFFFAOYSA-N,50257639,"(1-(4-aminopyridin-2-yl)-4-phenylpiperidin-4-yl)(3,4-dihydroisoquinolin-2(1H)-yl)methanone::CHEMBL493744",Potassium voltage-gated channel subfamily H member 2,Homo sapiens,
51045956,COc1ccc2n(c(C)nc2c1)-c1nc(nc(n1)N1CCOCC1)N1CCOCC1,"InChI=1S/C20H25N7O3/c1-14-21-16-13-15(28-2)3-4-17(16)27(14)20-23-18(25-5-9-29-10-6-25)22-19(24-20)26-7-11-30-12-8-26/h3-4,13H,5-12H2,1-2H3",PYOBCYYRODZSOR-UHFFFAOYSA-N,50426820,CHEMBL2323115,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform",Homo sapiens, 2770
767839,O=C(CC1CC1)N1CCN(CC1)[C@H]1CC[C@@H](CC1)Nc1ncnc2ccc(cc12)C#N,"InChI=1S/C24H30N6O/c25-15-18-3-8-22-21(13-18)24(27-16-26-22)28-19-4-6-20(7-5-19)29-9-11-30(12-10-29)23(31)14-17-1-2-17/h3,8,13,16-17,19-20H,1-2,4-7,9-12,14H2,(H,26,27,28)/t19-,20-",RRBKBOCPXMVBCQ-MXVIHJGJSA-N,384645,"4-({trans-4-[4- (cyclopropylacetyl) piperazin-1- yl]cyclohexyl}amino) quinazoline-6-carbonitrile::US9932350, 6-17",Interleukin-1 receptor-associated kinase 4,Homo sapiens, 9.00
51189035,CC(C)n1cnc2c(Nc3ccc(cc3)-c3cncnc3)nc(Cl)nc12,"InChI=1S/C18H16ClN7/c1-11(2)26-10-22-15-16(24-18(19)25-17(15)26)23-14-5-3-12(4-6-14)13-7-20-9-21-8-13/h3-11H,1-2H3,(H,23,24,25)",ZUVCFDIRJGFVPT-UHFFFAOYSA-N,50488802,CHEMBL2295951,Dual specificity tyrosine-phosphorylation-regulated kinase 1A,Homo sapiens, 3200
473032,C[C@H](NC(=O)C1(C)CN(C1)c1ncnn2cc(cc12)-c1ccc(cc1)S(C)(=O)=O)c1ccc(F)cc1,"InChI=1S/C26H26FN5O3S/c1-17(18-4-8-21(27)9-5-18)30-25(33)26(2)14-31(15-26)24-23-12-20(13-32(23)29-16-28-24)19-6-10-22(11-7-19)36(3,34)35/h4-13,16-17H,14-15H2,1-3H3,(H,30,33)/t17-/m0/s1",GGRNREPOXDDLTE-KRWDZBQOSA-N,175734,"US9688680, 279",Mast/stem cell growth factor receptor Kit [D816V],, 5.50
51071375,ON(CCC(c1ccc(Cl)c(Cl)c1)P(O)(O)=O)C(=O)c1ccccc1Cc1cccs1,"InChI=1S/C21H20Cl2NO5PS/c22-18-8-7-15(13-19(18)23)20(30(27,28)29)9-10-24(26)21(25)17-6-2-1-4-14(17)12-16-5-3-11-31-16/h1-8,11,13,20,26H,9-10,12H2,(H2,27,28,29)",RNHFOWGQTCFQEC-UHFFFAOYSA-N,50437801,CHEMBL2407188,1-deoxy-D-xylulose 5-phosphate reductoisomerase,Mycobacterium tuberculosis, 7000
50793282,NCC1C2CCC(CC2)C1c1ccc(Cl)c(Cl)c1,"InChI=1S/C15H19Cl2N/c16-13-6-5-11(7-14(13)17)15-10-3-1-9(2-4-10)12(15)8-18/h5-7,9-10,12,15H,1-4,8,18H2",UXZPRAPQLZIHRH-UHFFFAOYSA-N,50074608,"C-[3-(3,4-Dichloro-phenyl)-bicyclo[2.2.2]oct-2-yl]-methylamine::CHEMBL169814",Sodium-dependent dopamine transporter,Rattus norvegicus, 22
50913482,COc1c(F)cccc1CC(N1CCNCC1)c1ccccc1,"InChI=1S/C19H23FN2O/c1-23-19-16(8-5-9-17(19)20)14-18(15-6-3-2-4-7-15)22-12-10-21-11-13-22/h2-9,18,21H,10-14H2,1H3",RANMCMHHAKTCAZ-UHFFFAOYSA-N,50319819,1-(2-(3-fluoro-2-methoxyphenyl)-1-phenylethyl)piperazine::CHEMBL1086273,Potassium voltage-gated channel subfamily H member 2,Homo sapiens, 20800
50628123,C(Nc1ncccc1-c1nnc(Nc2ccc3OCCOc3c2)o1)c1ccc2[nH]ncc2c1,"InChI=1S/C23H19N7O3/c1-2-17(21(24-7-1)25-12-14-3-5-18-15(10-14)13-26-28-18)22-29-30-23(33-22)27-16-4-6-19-20(11-16)32-9-8-31-19/h1-7,10-11,13H,8-9,12H2,(H,24,25)(H,26,28)(H,27,30)",XSLTXDDPGLKZEV-UHFFFAOYSA-N,50339047,"5-(2-((1H-indazol-5-yl)methylamino)pyridin-3-yl)-N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1,3,4-oxadiazol-2-amine::CHEMBL1688351",Vascular endothelial growth factor receptor 2,Homo sapiens, 1400
234081,COc1cccc(c1)-c1nnc(o1)[C@H](Nc1ccc([N+]#[C-])c(Cl)c1C)[C@H](C)O,"InChI=1S/C20H19ClN4O3/c1-11-15(8-9-16(22-3)17(11)21)23-18(12(2)26)20-25-24-19(28-20)13-6-5-7-14(10-13)27-4/h5-10,12,18,23,26H,1-2,4H3/t12-,18+/m0/s1",SUEYNNNIDUVKDD-KPZWWZAWSA-N,112796,"US8629167, 6",Androgen receptor,Rattus norvegicus, 16
978850,CN(C)[C@]1(CC[C@]2(CN(CCc3ccncc3)C(=O)N2)CC1)c1ccccc1,"InChI=1S/C23H30N4O/c1-26(2)23(20-6-4-3-5-7-20)13-11-22(12-14-23)18-27(21(28)25-22)17-10-19-8-15-24-16-9-19/h3-9,15-16H,10-14,17-18H2,1-2H3,(H,25,28)/t22-,23+",DWJHZDSSTJTPDK-ZRZAMGCNSA-N,472127,"CIS-8-Dimethylamino-8-phenyl-3-(2-pyridin-4-yl-ethyl)-1,3-diazaspiro[4.5]decan-2- one::US10829480, Example SC_2166",Nociceptin receptor,Homo sapiens,
50556230,Fc1ccccc1Oc1ncccc1C1CCNCC1,"InChI=1S/C16H17FN2O/c17-14-5-1-2-6-15(14)20-16-13(4-3-9-19-16)12-7-10-18-11-8-12/h1-6,9,12,18H,7-8,10-11H2",OTTUCFBNHXCUBH-UHFFFAOYSA-N,50309507,2-(2-fluorophenoxy)-3-(piperidin-4-yl)pyridine::CHEMBL597530,Sodium-dependent noradrenaline transporter,Homo sapiens,
1084995,COc1cc(cn2ncnc12)-c1[nH]c2cc(C)c(nc2c1C(C)C)C1CCC(CC1)N(C)CC(C)(C)C,"InChI=1S/C30H42N6O/c1-18(2)25-27(21-14-24(37-8)29-31-17-32-36(29)15-21)33-23-13-19(3)26(34-28(23)25)20-9-11-22(12-10-20)35(7)16-30(4,5)6/h13-15,17-18,20,22,33H,9-12,16H2,1-8H3",DRNYAEVNOMCVCB-UHFFFAOYSA-N,427900,"US10544143, Example 334::US10544143, Example 336::US10730877, Example 336::US11053244, Example 336",Toll-like receptor 9,, 3439
51237089,COc1ncc(cc1NS(C)(=O)=O)-c1cc2COCc2c(OCCN2CCC(CC2)C(C)(C)O)c1,"InChI=1S/C25H35N3O6S/c1-25(2,29)20-5-7-28(8-6-20)9-10-34-23-13-17(11-19-15-33-16-21(19)23)18-12-22(27-35(4,30)31)24(32-3)26-14-18/h11-14,20,27,29H,5-10,15-16H2,1-4H3",YTBODSVQSOILIJ-UHFFFAOYSA-N,50506323,CHEMBL4556087,"Phosphatidylinositol 3-kinase regulatory subunit alpha/4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",Homo sapiens, 1995
895189,CCN1C(=O)N(Cc2cnc(cc12)-c1cn(CC(=O)N2CCOCC2)nc1C)c1c(F)c(OC)cc(OC)c1F,"InChI=1S/C27H30F2N6O5/c1-5-34-20-10-19(18-14-33(31-16(18)2)15-23(36)32-6-8-40-9-7-32)30-12-17(20)13-35(27(34)37)26-24(28)21(38-3)11-22(39-4)25(26)29/h10-12,14H,5-9,13,15H2,1-4H3",KNGYNRPKVJRSCS-UHFFFAOYSA-N,261950,"3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-7-(3-methyl-1-(2-morpholino-2-oxoethyl)-1H-pyrazol-4-yl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(1H)-one::US10251892, Example 51::US10632126, Example 51::US11173162, Example 51::US9708318, 51",Fibroblast growth factor receptor 2,Homo sapiens, 115
608297,C[C@H]1C(CCCN1C(=O)c1ncc(C)cc1-n1nccn1)N(C)c1nc2ccccc2o1,"InChI=1S/C23H25N7O2/c1-15-13-19(30-25-10-11-26-30)21(24-14-15)22(31)29-12-6-8-18(16(29)2)28(3)23-27-17-7-4-5-9-20(17)32-23/h4-5,7,9-11,13-14,16,18H,6,8,12H2,1-3H3/t16-,18?/m0/s1",WAVFTCZXODJVLZ-ATNAJCNCSA-N,314569,"((2S*,3R*)-3-(benzo[d]oxazol-2-yl(methyl)amino)-2-methylpiperidin-1-yl)(5-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone::US9611251, 187",Orexin/Hypocretin receptor type 1,Homo sapiens,
50264116,Cc1ccccc1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1,"InChI=1S/C22H31N3O2/c1-18-6-2-3-7-19(18)24-13-10-23(11-14-24)12-15-25-20(26)16-22(17-21(25)27)8-4-5-9-22/h2-3,6-7H,4-5,8-17H2,1H3",GUUIENZLFCYGEL-UHFFFAOYSA-N,50143715,"8-[2-(4-o-Tolyl-piperazin-1-yl)-ethyl]-8-aza-spiro[4.5]decane-7,9-dione::CHEMBL291908",Alpha-1B adrenergic receptor,,
476724,N[C@@H]1CCN(C1)C1CCC(CC1)N[C@H]1C[C@@H]1c1ccccc1,"InChI=1S/C19H29N3/c20-15-10-11-22(13-15)17-8-6-16(7-9-17)21-19-12-18(19)14-4-2-1-3-5-14/h1-5,15-19,21H,6-13,20H2/t15-,16?,17?,18-,19+/m1/s1",HEOKXBMRYSEMPZ-VVUWUOFOSA-N,254556,"US10214477, Example 15::US9469597, 15::US9670136, 15 (R)-1-(4-(((trans)-2-phenylcyclopropyl)amino)cyclohexyl)pyrrolidin-3-amine trihydrochloride",Amine oxidase [flavin-containing] B,,>100000
48338,CN(c1ccc2nc(C)n(C)c2c1)c1ccnc(Nc2cccc(c2)S(N)(=O)=O)n1,"InChI=1S/C20H21N7O2S/c1-13-23-17-8-7-15(12-18(17)26(13)2)27(3)19-9-10-22-20(25-19)24-14-5-4-6-16(11-14)30(21,28)29/h4-12H,1-3H3,(H2,21,28,29)(H,22,24,25)",BOSPJTDRCVFWMR-UHFFFAOYSA-N,26472,"3-({4-[(1,2-dimethyl-1H-1,3-benzodiazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)benzene-1-sulfonamide::3-aminobenzene sulfonamide, 12f",Cytochrome P450 2D6,, 25000
50662521,CNC[C@H](CCN1c2ccccc2N(c2ccccc2)S1(=O)=O)OC,"InChI=1S/C18H23N3O3S/c1-19-14-16(24-2)12-13-20-17-10-6-7-11-18(17)21(25(20,22)23)15-8-4-3-5-9-15/h3-11,16,19H,12-14H2,1-2H3/t16-/m0/s1",LFTRJEGVGRCFEP-INIZCTEOSA-N,50353931,CHEMBL1830875,Sodium-dependent noradrenaline transporter,Homo sapiens, 151
50172537,CNC(=O)C(CCCCCCC(=O)Nc1ccc(cc1)N(C)C)N=O,"InChI=1S/C18H28N4O3/c1-19-18(24)16(21-25)8-6-4-5-7-9-17(23)20-14-10-12-15(13-11-14)22(2)3/h10-13,16H,4-9H2,1-3H3,(H,19,24)(H,20,23)",TZBZCBUHLZQZST-UHFFFAOYSA-N,50341848,CHEMBL1767033::N9-(4-(Dimethylamino)phenyl)-2-(hydroxyimino)-N1-methylnonanediamide,Histone deacetylase 5,Homo sapiens,>100000
1167848,CC(=O)N[C@H]1CCCC[C@H]1NC(=O)c1sc2nccc3n(-c4ccc(Oc5ccccc5)cc4C)c(=O)[nH]c1c23,,,485201,"N-((1R,2S)-2-Acetamidocyclohexyl)-5-(2-methyl-4- phenoxyphenyl)-4-oxo-4,5-dihydro-3H-1-thia-3,5,8- triazaacenaphthylene-2-carboxamide::US10934310, Ex # 33::US11319329, Ex # 136",Tyrosine-protein kinase BTK,Homo sapiens, 30.2
51354606,Cn1cnc2c(ncnc12)-c1ccc2NC(=O)[C@@](C)(Cc3ccccc3)c2c1,"InChI=1S/C22H19N5O/c1-22(11-14-6-4-3-5-7-14)16-10-15(8-9-17(16)26-21(22)28)18-19-20(24-12-23-18)27(2)13-25-19/h3-10,12-13H,11H2,1-2H3,(H,26,28)/t22-/m0/s1",NQXCKWSIQSYSKN-QFIPXVFZSA-N,50547994,CHEMBL4791004,"Phosphatidylinositol 3-kinase regulatory subunit alpha/4,5-bisphosphate 3-kinase catalytic subunit delta isoform",Homo sapiens, 60
50895372,Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1,"InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)",ZBNZXTGUTAYRHI-UHFFFAOYSA-N,13216,"BMS-354825::CHEMBL1421::DASATINIB::N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide::N-(2-chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide::US10294227, Code Dasatinib::cid_3062316::med.21724, Compound Dasatinib",Casein kinase I isoform gamma-1,Homo sapiens,
135165,OC(=O)C1Nc2c(O)cccc2C2C=CCC12,"InChI=1S/C13H13NO3/c15-10-6-2-5-8-7-3-1-4-9(7)12(13(16)17)14-11(8)10/h1-3,5-7,9,12,14-15H,4H2,(H,16,17)",VQPJWSZWDZNVOJ-UHFFFAOYSA-N,31757,"6-hydroxy-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-4-carboxylic acid::6-oxidanyl-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-4-carboxylic acid::MLS-0015717.0001::cid_654089",Tyrosine-protein phosphatase non-receptor type 7,Homo sapiens, 11211
50073419,N[C@H]1CCSSC[C@@H](NC(=O)C[C@H](Cc2ccc(O)cc2)NC1=O)C(=O)NCc1ccccc1CC(O)=O,"InChI=1S/C26H32N4O6S2/c27-21-9-10-37-38-15-22(26(36)28-14-18-4-2-1-3-17(18)12-24(33)34)30-23(32)13-19(29-25(21)35)11-16-5-7-20(31)8-6-16/h1-8,19,21-22,31H,9-15,27H2,(H,28,36)(H,29,35)(H,30,32)(H,33,34)/t19-,21-,22+/m0/s1",VZYRMNZEFCZSER-ILWGZMRPSA-N,50331043,"2-(2-(((4S,8S,11S)-11-amino-8-(4-hydroxybenzyl)-6,10-dioxo-1,2-dithia-5,9-diazacyclotridecane-4-carboxamido)methyl)phenyl)acetic acid::CHEMBL1277717",Leucyl-cystinyl aminopeptidase,Homo sapiens,
279581,CCOC(=O)C1(N(C(=O)c2nn(c(C(C)C)c12)-c1ccccc1OC)c1ccc(F)c(Cl)c1)c1ccc(Cl)cc1,"InChI=1S/C30H26Cl2FN3O4/c1-5-40-29(38)30(18-10-12-19(31)13-11-18)25-26(28(37)35(30)20-14-15-22(33)21(32)16-20)34-36(27(25)17(2)3)23-8-6-7-9-24(23)39-4/h6-17H,5H2,1-4H3",WYNJGGKMGSZIJC-UHFFFAOYSA-N,143442,"US8969341, 90",E3 ubiquitin-protein ligase Mdm2,Homo sapiens, 5.2
997523,CCn1c(C)cn2c(ncc2c1=O)C1CCOCC1,"InChI=1S/C14H19N3O2/c1-3-16-10(2)9-17-12(14(16)18)8-15-13(17)11-4-6-19-7-5-11/h8-9,11H,3-7H2,1-2H3",WESIRYTURBTMCP-UHFFFAOYSA-N,474179,"7-ethyl-6-methyl-3-(tetrahydro- 2H-pyran-4-yl)imidazo[1,5- a]pyrazin-8(7H)-one::US10858362, Example 59::US10912773, Example 59::US11472810, Example 59","Dual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A",, 2333
444997,Cc1ccc(C(=O)N2C3CCC2C(COc2nccc(n2)C(F)(F)F)C3)c(n1)-n1ccnn1,"InChI=1S/C21H20F3N7O2/c1-12-2-4-15(18(27-12)30-9-8-26-29-30)19(32)31-14-3-5-16(31)13(10-14)11-33-20-25-7-6-17(28-20)21(22,23)24/h2,4,6-9,13-14,16H,3,5,10-11H2,1H3",GQBKJIDJCVECGP-UHFFFAOYSA-N,164001,"US9062078, 132::US9475819, 132::US9637496, 132::US9695183, 132",Orexin receptor type 2,Homo sapiens,
51278302,CC[C@H](C)[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCSC)C(=O)NCC(O)=O,"InChI=1S/C82H141N25O18S/c1-15-47(12)65(79(124)103-57(35-44(6)7)73(118)99-55(33-42(2)3)72(117)100-58(36-49-23-17-16-18-24-49)74(119)97-54(28-32-126-14)67(112)93-40-62(110)111)106-76(121)60(38-61(84)109)104-78(123)64(46(10)11)105-75(120)59(37-50-39-90-41-94-50)101-69(114)53(27-22-31-92-82(88)89)98-80(125)66(48(13)108)107-70(115)51(25-19-20-29-83)95-68(113)52(26-21-30-91-81(86)87)96-71(116)56(34-43(4)5)102-77(122)63(85)45(8)9/h16-18,23-24,39,41-48,51-60,63-66,108H,15,19-22,25-38,40,83,85H2,1-14H3,(H2,84,109)(H,90,94)(H,93,112)(H,95,113)(H,96,116)(H,97,119)(H,98,125)(H,99,118)(H,100,117)(H,101,114)(H,102,122)(H,103,124)(H,104,123)(H,105,120)(H,106,121)(H,107,115)(H,110,111)(H4,86,87,91)(H4,88,89,92)/t47-,48+,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,63-,64-,65-,66-/m0/s1",WQLAWDNFIOHQAT-VKXFQFOCSA-N,50521654,CHEMBL4541462,Serine/threonine-protein kinase B-raf,Homo sapiens,
1120406,CNC(=O)c1cc(Nc2nc(cc3ncn(C(C)C)c23)-c2ccc3c(c2)N([C@@H]2C[C@@H](C2)N2CC(C)(C)C2)C(=O)C3(C)C)ccc1C,"InChI=1S/C37H45N7O2/c1-21(2)43-20-39-30-17-29(41-33(32(30)43)40-24-11-9-22(3)27(14-24)34(45)38-8)23-10-12-28-31(13-23)44(35(46)37(28,6)7)26-15-25(16-26)42-18-36(4,5)19-42/h9-14,17,20-21,25-26H,15-16,18-19H2,1-8H3,(H,38,45)(H,40,41)/t25-,26+",VOMXBMNBIPSMMW-WMPKNSHKSA-N,529714,"US11203591, Example 122",Mitogen-activated protein kinase kinase kinase kinase 1,Homo sapiens, 0.100
1201217,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ncccc4C)cc3C(F)(F)F)c2cc1NC(=O)CCCN(C)C,"InChI=1S/C32H33F3N6O3/c1-5-43-29-16-26-23(15-27(29)39-30(42)9-7-13-41(3)4)31(21(17-36)18-38-26)40-25-11-10-22(14-24(25)32(33,34)35)44-19-28-20(2)8-6-12-37-28/h6,8,10-12,14-16,18H,5,7,9,13,19H2,1-4H3,(H,38,40)(H,39,42)",MPDAGVPGHCHPMC-UHFFFAOYSA-N,461324,"US10774068, Example 29::US11427560, Example 29",Serine/threonine-protein kinase 3,Homo sapiens, 550
51000319,Oc1ccc2C(N(CCc2c1)c1ccccc1)c1ccc(OCCN2CCCCC2)cc1,"InChI=1S/C28H32N2O2/c31-25-11-14-27-23(21-25)15-18-30(24-7-3-1-4-8-24)28(27)22-9-12-26(13-10-22)32-20-19-29-16-5-2-6-17-29/h1,3-4,7-14,21,28,31H,2,5-6,15-20H2",FMWVCTJKLAVRPB-UHFFFAOYSA-N,20586,"2-phenyl-1-{4-[2-(piperidin-1-yl)ethoxy]phenyl}-1,2,3,4-tetrahydroisoquinolin-6-ol::tetrahydroisoquinoline derivative, 18a",Estrogen receptor,, 19.01
51262220,OC(=O)CC1Cc2ccc(cc2N1S(=O)(=O)c1cccc(c1)C(F)(F)F)-c1cc(F)cc(Cl)c1,"InChI=1S/C23H16ClF4NO4S/c24-17-6-15(7-18(25)11-17)13-4-5-14-8-19(12-22(30)31)29(21(14)9-13)34(32,33)20-3-1-2-16(10-20)23(26,27)28/h1-7,9-11,19H,8,12H2,(H,30,31)",BMMYCRRAYKWVHI-UHFFFAOYSA-N,50515674,CHEMBL4583536,Nuclear receptor ROR-gamma,,
50966140,CCOc1[nH]nc(C(O)=O)c1Cc1cccc(c1)-c1ccc(F)cc1,"InChI=1S/C19H17FN2O3/c1-2-25-18-16(17(19(23)24)21-22-18)11-12-4-3-5-14(10-12)13-6-8-15(20)9-7-13/h3-10H,2,11H2,1H3,(H,21,22)(H,23,24)",PKOFXIKLSFCZSU-UHFFFAOYSA-N,50396190,CHEMBL2172053,2-Hydroxyacid oxidase 2,Rattus norvegicus, 1200
51001986,Clc1ccc(cc1)N(CC(=O)N\N=C1/C(=O)Nc2ccccc12)S(=O)(=O)c1ccc(NCCN2CCOCC2)cc1,"InChI=1S/C28H29ClN6O5S/c29-20-5-9-22(10-6-20)35(19-26(36)32-33-27-24-3-1-2-4-25(24)31-28(27)37)41(38,39)23-11-7-21(8-12-23)30-13-14-34-15-17-40-18-16-34/h1-12,30H,13-19H2,(H,32,36)(H,31,33,37)",SHUVSCHNMZHWMV-UHFFFAOYSA-N,50410621,CHEMBL2113177,Oxytocin receptor,Rattus,
50205802,CC(C)n1cnc2c(Nc3cccc(Cl)c3)nc(nc12)N(CCN(C)C)Cc1ccccc1,"InChI=1S/C25H30ClN7/c1-18(2)33-17-27-22-23(28-21-12-8-11-20(26)15-21)29-25(30-24(22)33)32(14-13-31(3)4)16-19-9-6-5-7-10-19/h5-12,15,17-18H,13-14,16H2,1-4H3,(H,28,29,30)",NZKHLCGGXIVSCV-UHFFFAOYSA-N,50113718,"CHEMBL80402::N*2*-Benzyl-N*6*-(3-chloro-phenyl)-N*2*-(2-dimethylamino-ethyl)-9-isopropyl-9H-purine-2,6-diamine",Cyclin-dependent kinase 1,Homo sapiens, 7000000
236601,CC1(C)Cc2c(CO1)nn(-c1ccccc1)c(=N)c2C#N,"InChI=1S/C16H16N4O/c1-16(2)8-12-13(9-17)15(18)20(19-14(12)10-21-16)11-6-4-3-5-7-11/h3-7,18H,8,10H2,1-2H3",LDXKPZVGFCDGPH-UHFFFAOYSA-N,64030,"3-Amino-6,6-dimethyl-2-phenyl-2,8-dihydro-6H-pyrano[3,4-c]pyridazine-4-carbonitrile::3-amino-6,6-dimethyl-2-phenyl-8H-pyrano[3,4-c]pyridazine-4-carbonitrile::3-azanyl-6,6-dimethyl-2-phenyl-8H-pyrano[3,4-c]pyridazine-4-carbonitrile::MLS001205950::SMR000513314::cid_738951",Tyrosyl-DNA phosphodiesterase 2,Homo sapiens, 1273
51108364,CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,"InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1",ULXXDDBFHOBEHA-CWDCEQMOSA-N,50322823,"(S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide::AFATINIB::CHEMBL1173655::US10085983, Compound BIBW2992::US10196365, Afatinib::US10435400, Compound BIBW2992::US9388170, Afatinib::US9890168, Compound BIBW2992::WO2022090481, Example afatinib",Epidermal growth factor receptor,Homo sapiens,<1.000000
51200982,CCc1cnc(SCC(=O)c2ccc(Cl)c(c2)S(N)(=O)=O)nc1,"InChI=1S/C14H14ClN3O3S2/c1-2-9-6-17-14(18-7-9)22-8-12(19)10-3-4-11(15)13(5-10)23(16,20)21/h3-7H,2,8H2,1H3,(H2,16,20,21)",SAVHXXXMJJLUJH-UHFFFAOYSA-N,50380152,CHEMBL2010999,Carbonic anhydrase 1,Homo sapiens,
50695447,COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1,"InChI=1S/C20H22N4O3/c1-25-16-6-3-13(4-7-16)12-27-17-8-5-14(10-18(17)26-2)9-15-11-23-20(22)24-19(15)21/h3-8,10-11H,9,12H2,1-2H3,(H4,21,22,23,24)",MYQAUKPBNJWPIE-UHFFFAOYSA-N,32362,"5-[[3-methoxy-4-[(4-methoxyphenyl)methoxy]phenyl]methyl]pyrimidine-2,4-diamine::GW-2580::[2-amino-5-(3-methoxy-4-p-anisyloxy-benzyl)pyrimidin-4-yl]amine::cid_11617559",Serine/threonine-protein kinase PknB,Mycobacterium tuberculosis,
1089455,CC[C@@H](CO)Nc1n[nH]c2nccc(Oc3ccc(NC(=O)c4cn(C(C)C)c(=O)n(-c5ccc(F)cc5)c4=O)cc3F)c12,,,516998,"(S)-N-(3-fluoro-4-((3- ((1-hydroxybutan-2- yl)amino)-1H- pyrazolo[3,4-b]pyridin- 4-yl)oxy)phenyl)-3-(4- fluorophenyl)-1- isopropyl-2,4-dioxo- 1,2,3,4- tetrahydropyrimidine- 5-carboxamide::US11104676, Example 68",Hepatocyte growth factor receptor,Homo sapiens, 2.70
50440979,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13,"InChI=1S/C28H26N4O3/c1-28-26(34-3)17(29-2)12-20(35-28)31-18-10-6-4-8-14(18)22-23-16(13-30-27(23)33)21-15-9-5-7-11-19(15)32(28)25(21)24(22)31/h4-11,17,20,26,29H,12-13H2,1-3H3,(H,30,33)/t17-,20-,26-,28+/m1/s1",HKSZLNNOFSGOKW-FYTWVXJKSA-N,2579,"(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1^{2,6}.0^{7,28}.0^{8,13}.0^{15,19}.0^{20,27}.0^{21,26}]nonacosa-8(13),9,11,14(28),15(19),20(27),21(26),22,24-nonaen-16-one::CHEMBL388978::Staurosporin, 4::Staurosporine::Staurosporine, 8::US9206188, Staurosporine::US9226923, Staurosporine",Dual specificity mitogen-activated protein kinase kinase 4,Homo sapiens,<1
50193840,COC(=O)c1ccc2\C(=C(\Nc3ccc(cc3)N(C)C(=O)CN3CCN(C)CC3)c3ccccc3)C(=O)Nc2c1,"InChI=1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,32H,15-18,20H2,1-3H3,(H,33,38)/b29-28-",XZXHXSATPCNXJR-ZIADKAODSA-N,50026612,"BIBF-1120::Nintedanib::US10981896, Compound Nintedanib::US11046672, Nintedanib::US11208381, Nintedanib::Vargatef",Mast/stem cell growth factor receptor Kit,,
51411948,COCCc1[nH]c(=O)c(-c2nnc(Cc3ccc(Cl)cc3)o2)c(O)c1-c1c(OC)cccc1OC,"InChI=1S/C25H24ClN3O6/c1-32-12-11-16-20(21-17(33-2)5-4-6-18(21)34-3)23(30)22(24(31)27-16)25-29-28-19(35-25)13-14-7-9-15(26)10-8-14/h4-10H,11-13H2,1-3H3,(H2,27,30,31)",TWDOKTIJAGQITI-UHFFFAOYSA-N,50570424,CHEMBL4860991,Apelin receptor,Homo sapiens,
907818,CC(C)c1c([nH]c2ccc(cc12)C1CCNCC1)-c1ccnc(C)c1F,"InChI=1S/C22H26FN3/c1-13(2)20-18-12-16(15-6-9-24-10-7-15)4-5-19(18)26-22(20)17-8-11-25-14(3)21(17)23/h4-5,8,11-13,15,24,26H,6-7,9-10H2,1-3H3",YWFHWWRZGWFBBT-UHFFFAOYSA-N,443454,"US10660877, Example 53",Toll-like receptor 7,, 2.90
50463932,Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NC1CCN(CC1)C(=O)C1CCCC1,"InChI=1S/C28H29Cl3N4O2/c1-17-25(27(36)32-22-12-14-34(15-13-22)28(37)19-4-2-3-5-19)33-35(24-11-10-21(30)16-23(24)31)26(17)18-6-8-20(29)9-7-18/h6-11,16,19,22H,2-5,12-15H2,1H3,(H,32,36)",BJLCJASKWHITMG-UHFFFAOYSA-N,50144615,CHEMBL3759255,Cannabinoid receptor 1,Homo sapiens,
278555,COc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCc2ccnc3[nH]c(=O)cnc23)c2ccccc12)C(C)(C)C,"InChI=1S/C33H31N7O4/c1-33(2,3)27-17-28(40(39-27)21-9-11-22(43-4)12-10-21)37-32(42)36-25-13-14-26(24-8-6-5-7-23(24)25)44-19-20-15-16-34-31-30(20)35-18-29(41)38-31/h5-18H,19H2,1-4H3,(H,34,38,41)(H2,36,37,42)",AUCMAJMDOAHHEL-UHFFFAOYSA-N,142631,"US8933228, 23",Tyrosine-protein kinase HCK,Homo sapiens, 22
16817,NCCNc1cc(-c2ccc[nH]2)c2C(=O)Nc3ccc(F)c1c23,"InChI=1S/C17H15FN4O/c18-10-3-4-12-16-14(17(23)22-12)9(11-2-1-6-20-11)8-13(15(10)16)21-7-5-19/h1-4,6,8,20-21H,5,7,19H2,(H,22,23)",CQCXWWWNUFQYJS-UHFFFAOYSA-N,10122,"7-[(2-aminoethyl)amino]-9-fluoro-5-(1H-pyrrol-2-yl)-2-azatricyclo[6.3.1.0^{4,12}]dodeca-1(11),4,6,8(12),9-pentaen-3-one::trisubstituted naphthostyril analogue 7b",Cyclin-dependent kinase 2/G1/S-specific cyclin-E1,Homo sapiens, 12
509994,Cc1n[nH]c2nc(nc(NCC(F)(F)F)c12)-c1ccc(NS(=O)(=O)c2cc(C)ccc2C#N)cc1,"InChI=1S/C22H18F3N7O2S/c1-12-3-4-15(10-26)17(9-12)35(33,34)32-16-7-5-14(6-8-16)19-28-20(27-11-22(23,24)25)18-13(2)30-31-21(18)29-19/h3-9,32H,11H2,1-2H3,(H2,27,28,29,30,31)",OZFYYYFLMGNVQT-UHFFFAOYSA-N,268950,"US9718825, Example 376",Serine/threonine-protein kinase Sgk1,Homo sapiens, 5.70
559772,OC(=O)c1ccncc1NCC1CCOc2cc(ccc12)-c1ccoc1,"InChI=1S/C20H18N2O4/c23-20(24)17-3-6-21-11-18(17)22-10-14-5-8-26-19-9-13(1-2-16(14)19)15-4-7-25-12-15/h1-4,6-7,9,11-12,14,22H,5,8,10H2,(H,23,24)",HRIGTZGZYXMXLS-UHFFFAOYSA-N,293686,"3-({[7-(furan-3-yl)-3,4-dihydro-2H-1-benzopyran-4-::US10106534, Example 28",Lysine-specific demethylase 4C,, 550
1164221,COc1cc2nc(N)n3nc(nc3c2cc1F)[C@@H]1CCCN(C1)c1ncn(n1)C(C)C(C)(C)O,"InChI=1S/C22H28FN9O2/c1-12(22(2,3)33)31-11-25-21(29-31)30-7-5-6-13(10-30)18-27-19-14-8-15(23)17(34-4)9-16(14)26-20(24)32(19)28-18/h8-9,11-13,33H,5-7,10H2,1-4H3,(H2,24,26)/t12?,13-/m1/s1",XXTWQFUSENGCGM-ZGTCLIOFSA-N,551519,"(R or S)-3-(3-((R)-3-(5-amino-9-fluoro-8-methoxy-[1,2,4] triazolo[1,5-c]quinazolin-2-yl)piperidin-1-yl)-1H- 1,2,4-triazolo-1-yl)-2-methylbutan-2-ol::US11312719, Example 64::US11312719, Example 65",Adenosine receptor A2a,Homo sapiens, 1.20
51313452,Cl.CN(CCOc1cc(COc2ccccc2)on1)C1CCCCC1,"InChI=1S/C19H26N2O3.ClH/c1-21(16-8-4-2-5-9-16)12-13-22-19-14-18(24-20-19)15-23-17-10-6-3-7-11-17;/h3,6-7,10-11,14,16H,2,4-5,8-9,12-13,15H2,1H3;1H",HINNLIOMVAVPKI-UHFFFAOYSA-N,50532486,CHEMBL4564992,Sodium-dependent serotonin transporter,Homo sapiens,
50649712,COc1ccc(cc1)-c1ncc2CCc3c([nH]c4CC5(CC5)NC(=O)c34)-c2n1,"InChI=1S/C22H20N4O2/c1-28-14-5-2-12(3-6-14)20-23-11-13-4-7-15-17-16(24-19(15)18(13)25-20)10-22(8-9-22)26-21(17)27/h2-3,5-6,11,24H,4,7-10H2,1H3,(H,26,27)",NGTDZYCIPFIDGW-UHFFFAOYSA-N,50348482,CHEMBL1801299,MAP kinase-activated protein kinase 2,Homo sapiens, 2500
51370160,CSCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)C1CCC(=O)N1)C(=O)N1CCCC1C(=O)N[C@@H](Cc1ccccc1)C(O)=O,,,50554010,CHEMBL4795982,Apelin receptor,Homo sapiens,
1214115,Cc1nc2ncc(cc2n1Cc1ccc(Cl)cc1)-c1cn(Cc2cccnc2)c(=O)c2[nH]ccc12,"InChI=1S/C27H21ClN6O/c1-17-32-26-24(34(17)15-18-4-6-21(28)7-5-18)11-20(13-31-26)23-16-33(14-19-3-2-9-29-12-19)27(35)25-22(23)8-10-30-25/h2-13,16,30H,14-15H2,1H3",OIHCXMYGSNISKR-UHFFFAOYSA-N,576062,"4-(1-(4-chlorobenzyl)-2-methyl- 1H-imidazo[4,5-b]pyridin- 6-yl)-6-(pyridin-3-ylmethyl)- 1,6-dihydro-7H-pyrrolo[2,3-c] pyridin-7-one::US11466034, Example 17",Bromodomain-containing protein 4 [349-460],,>300
51003236,CCCCCCCCCC[C@@H](O)[C@H]1CC[C@@H](O1)[C@H]1CC[C@@H](O1)[C@@H](C)O,"InChI=1S/C21H40O4/c1-3-4-5-6-7-8-9-10-11-17(23)19-13-15-21(25-19)20-14-12-18(24-20)16(2)22/h16-23H,3-15H2,1-2H3/t16-,17-,18-,19-,20-,21-/m1/s1",JJPMRTIXVDUCCW-UCGFNCKJSA-N,50411093,CHEMBL211884,"Acyl carrier protein, mitochondrial",Bos taurus, 280
300689,Clc1ccc(NC(=O)Nc2ccc(cc2Br)[C@@H]2CNCCO2)cn1,"InChI=1S/C16H16BrClN4O2/c17-12-7-10(14-9-19-5-6-24-14)1-3-13(12)22-16(23)21-11-2-4-15(18)20-8-11/h1-4,7-8,14,19H,5-6,9H2,(H2,21,22,23)/t14-/m0/s1",QQRAUORHUJEMBP-AWEZNQCLSA-N,158273,"US9029370, 67",Trace amine-associated receptor 1,Mus musculus,
51293446,COc1c(OCCCCCCC(O)=O)cc2oc3cc4OC(C)(C)C=Cc4c(O)c3c(=O)c2c1CC=C(C)C,"InChI=1S/C31H36O8/c1-18(2)11-12-20-26-22(17-24(30(20)36-5)37-15-9-7-6-8-10-25(32)33)38-23-16-21-19(13-14-31(3,4)39-21)28(34)27(23)29(26)35/h11,13-14,16-17,34H,6-10,12,15H2,1-5H3,(H,32,33)",QHLZYKWHQKCZMD-UHFFFAOYSA-N,50527193,CHEMBL4471352,Cytochrome P450 2C9,Homo sapiens,>10000
171351,C[N+](C)(C)CCOC(N)=O,"InChI=1S/C6H14N2O2/c1-8(2,3)4-5-10-6(7)9/h4-5H2,1-3H3,(H-,7,9)/p+1",VPJXQGSRWJZDOB-UHFFFAOYSA-O,50004656,"(2-Carbamoyloxy-ethyl)-trimethyl-ammonium::(2-Carbamoyloxyethyl)trimethylammonium chloride::(2-Hydroxyethyl)trimethyl ammonium chloride carbamate::(2-Hydroxyethyl)trimethylammonium chloride carbamate::(carbachol)(2-Carbamoyloxy-ethyl)-trimethyl-ammonium::2-((Aminocarbonyl)oxy)-N,N,N-trimethylethanaminium chloride::2-((Aminocarbonyl)oxy)-N,N,N-trimethylethanaminum chloride::2-(carbamoyloxy)-N,N,N-trimethylethanaminium::2-(carbamoyloxy)-N,N,N-trimethylethanaminium chloride::CARBACHOL::CARBASTAT::CHEMBL14::Carbachol chloride::Carbamylcholine::Choline carbamate chloride::Choline chloride, carbamate::Choline chlorine carbamate::Karbachol::Karbamoylcholin chlorid::MIOSTAT",Neuronal acetylcholine receptor subunit alpha-4,Homo sapiens,
478851,Cc1nccn1CC(=O)N1CCCN(CC1)c1nc2c(C)cccc2cc1CNC(=O)c1nccnc1N,"InChI=1S/C27H31N9O2/c1-18-5-3-6-20-15-21(16-32-27(38)24-25(28)31-8-7-30-24)26(33-23(18)20)35-11-4-10-34(13-14-35)22(37)17-36-12-9-29-19(36)2/h3,5-9,12,15H,4,10-11,13-14,16-17H2,1-2H3,(H2,28,31)(H,32,38)",YEBBWGWMJWUNSY-UHFFFAOYSA-N,195405,"US9670212, 55 3-amino-N-[(8-methyl-2-{4-[(2-methyl-1H-imidazol-1-yl)acetyl]-1,4-diazepan-1-yl}quinolin-3-yl)methyl]pyrazine-2-carboxamide","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform",Homo sapiens, 1000
467915,C1CN(CCN1)c1cnc(s1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12,"InChI=1S/C22H19N7S/c1-2-4-19-17(3-1)16(5-6-24-19)18-12-27-29-14-15(11-25-21(18)29)22-26-13-20(30-22)28-9-7-23-8-10-28/h1-6,11-14,23H,7-10H2",XJRNYUDHNXZYCF-UHFFFAOYSA-N,143207,"US10017516, Compound 7::US9682983, 7",Activin receptor type-1B,Homo sapiens, 3480
193133,Oc1ccc2oc(=O)c(cc2c1)-c1nn(cc1C=O)-c1ccccc1,"InChI=1S/C19H12N2O4/c22-11-13-10-21(14-4-2-1-3-5-14)20-18(13)16-9-12-8-15(23)6-7-17(12)25-19(16)24/h1-11,23H",PQAPIBDZDMDUOZ-UHFFFAOYSA-N,61162,3-(6-hydroxy-2-keto-chromen-3-yl)-1-phenyl-pyrazole-4-carbaldehyde::3-(6-hydroxy-2-oxo-1-benzopyran-3-yl)-1-phenyl-4-pyrazolecarboxaldehyde::3-(6-hydroxy-2-oxochromen-3-yl)-1-phenylpyrazole-4-carbaldehyde::3-(6-oxidanyl-2-oxidanylidene-chromen-3-yl)-1-phenyl-pyrazole-4-carbaldehyde::MLS000565419::SMR000152596::cid_2319222,Tyrosine-protein phosphatase non-receptor type 11,Homo sapiens, 1960
50574803,CC(C)=CCc1cc2[C@@H]3Oc4c(ccc5OC(C)(C)C(O)Cc45)[C@@H]3COc2cc1O,"InChI=1S/C25H28O5/c1-13(2)5-6-14-9-16-21(11-19(14)26)28-12-18-15-7-8-20-17(23(15)29-24(16)18)10-22(27)25(3,4)30-20/h5,7-9,11,18,22,24,26-27H,6,10,12H2,1-4H3/t18-,22?,24-/m0/s1",UNODSKHATHZQGW-HRKCMRQESA-N,50317439,CHEMBL1095422::erysubin D,Sialidase,Clostridium perfringens, 26390
50249921,CC1C(=O)c2nn(cc2OC11CCN(CC1)C(=O)c1ccc2[nH]ncc2c1)C(C)(C)C,,,50034499,CHEMBL3359259,Acetyl-CoA carboxylase 2,Homo sapiens, 63
664643,COc1cc(CCc2cnc3[nH]c(cc3n2)-c2ccc(CC#N)cc2)cc(OC)c1,"InChI=1S/C24H22N4O2/c1-29-20-11-17(12-21(13-20)30-2)5-8-19-15-26-24-23(27-19)14-22(28-24)18-6-3-16(4-7-18)9-10-25/h3-4,6-7,11-15H,5,8-9H2,1-2H3,(H,26,28)",XLIZHMBIMHCPTR-UHFFFAOYSA-N,337279,"(4-{2-[2-(3,5-dimethoxyphenyl)ethyl]-5H-pyrrolo[2,3-b]pyrazin-6-yl}phenyl)acetonitrile::US9745311, Example 14",Fibroblast growth factor receptor 2,Homo sapiens,<100
50479774,CN(CC(=O)N[C@@H](CCCCN)B(O)O)C(=O)CCc1ccccc1,"InChI=1S/C17H28BN3O4/c1-21(17(23)11-10-14-7-3-2-4-8-14)13-16(22)20-15(18(24)25)9-5-6-12-19/h2-4,7-8,15,24-25H,5-6,9-13,19H2,1H3,(H,20,22)/t15-/m0/s1",RIUCWNRPWWTWOU-HNNXBMFYSA-N,50069174,Boronate Ester analogue::CHEMBL317682::N-[(5-Amino-1-dihydroxyboranyl-pentylcarbamoyl)-methyl]-N-methyl-3-phenyl-propionamide,Prothrombin,,
50949008,CSc1ccccc1Nc1nc(nc2c(NCC3CC3)ncnc12)N1CCNCC1,"InChI=1S/C21H26N8S/c1-30-16-5-3-2-4-15(16)26-20-17-18(19(25-13-24-17)23-12-14-6-7-14)27-21(28-20)29-10-8-22-9-11-29/h2-5,13-14,22H,6-12H2,1H3,(H,23,24,25)(H,26,27,28)",HFLMLZKGLUEWBU-UHFFFAOYSA-N,50380246,CHEMBL2017214,Ketohexokinase,,<500
9201,CC(C)(C)c1cnc(CSc2cnc(NC(=O)Cc3cccnc3)s2)o1,"InChI=1S/C18H20N4O2S2/c1-18(2,3)13-9-20-15(24-13)11-25-16-10-21-17(26-16)22-14(23)7-12-5-4-6-19-8-12/h4-6,8-10H,7,11H2,1-3H3,(H,21,22,23)",VBDQMJNIWDFAKI-UHFFFAOYSA-N,5721,"2-aminothiazole 3::N-(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)-2-(pyridin-3-yl)acetamide",Cyclin-dependent kinase 2/G1/S-specific cyclin-E1,Homo sapiens, 5
295233,C[C@H]1CN(C[C@@H](C)N1)C(=O)N1Cc2c(NC(=O)c3ccccn3)n[nH]c2C1(C)C,,,153784,"US8999981, A29",Protein kinase C beta type,Homo sapiens,
50508517,OC(=O)CCc1c(c(c2CCCn12)-c1ccccc1)-c1ccc(Cl)cc1,"InChI=1S/C22H20ClNO2/c23-17-10-8-16(9-11-17)22-19(12-13-20(25)26)24-14-4-7-18(24)21(22)15-5-2-1-3-6-15/h1-3,5-6,8-11H,4,7,12-14H2,(H,25,26)",YPTJRGFJUSTGIA-UHFFFAOYSA-N,50294201,"3-(6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl)propanoic acid::CHEMBL550489",Prostaglandin E synthase,Homo sapiens, 1800
250367,Cn1cnc2cc(nc(NC3CC3)c2c1=O)-c1ccc(NCCO)nc1,"InChI=1S/C18H20N6O2/c1-24-10-21-14-8-13(11-2-5-15(20-9-11)19-6-7-25)23-17(16(14)18(24)26)22-12-3-4-12/h2,5,8-10,12,25H,3-4,6-7H2,1H3,(H,19,20)(H,22,23)",CVQAOAZCGUIKDX-UHFFFAOYSA-N,121781,"US8722692, 220",Tyrosine-protein kinase SYK,Homo sapiens, 135
50407234,O=C(COc1ccc(cc1)S(=O)(=O)NCCc1ccccc1)NCc1ccccc1,"InChI=1S/C23H24N2O4S/c26-23(24-17-20-9-5-2-6-10-20)18-29-21-11-13-22(14-12-21)30(27,28)25-16-15-19-7-3-1-4-8-19/h1-14,25H,15-18H2,(H,24,26)",NWKRQKGWRQQSMU-UHFFFAOYSA-N,50117839,CHEMBL3613982,Phosphatidylcholine:ceramide cholinephosphotransferase 1,, 23100
205716,O=CC1=C(Oc2ccccc2O1)c1ccccc1,InChI=1S/C15H10O3/c16-10-14-15(11-6-2-1-3-7-11)18-13-9-5-4-8-12(13)17-14/h1-10H,BQFFKKHQXOJXBD-UHFFFAOYSA-N,61115,"3-phenyl-1,4-benzodioxin-2-carbaldehyde::3-phenyl-1,4-benzodioxin-2-carboxaldehyde::3-phenyl-1,4-benzodioxine-2-carbaldehyde::MLS001008558::SMR000495839::cid_677881",Perilipin-1,Homo sapiens, 2568
51104507,CNC(=O)[C@@H](NC(=O)c1ccc(o1)-c1ccc(COc2nc3CCCc3c(=O)[nH]2)c(F)c1)C(C)C,"InChI=1S/C25H27FN4O5/c1-13(2)21(24(33)27-3)29-23(32)20-10-9-19(35-20)14-7-8-15(17(26)11-14)12-34-25-28-18-6-4-5-16(18)22(31)30-25/h7-11,13,21H,4-6,12H2,1-3H3,(H,27,33)(H,29,32)(H,28,30,31)/t21-/m0/s1",ABUATJUYOFRPHD-NRFANRHFSA-N,50450292,CHEMBL4175967,Collagenase 3,Homo sapiens, 697
50438596,C(Cc1ccccc1)[C@H]1CCC[C@@H](Cc2ccccc2)N1,"InChI=1S/C20H25N/c1-3-8-17(9-4-1)14-15-19-12-7-13-20(21-19)16-18-10-5-2-6-11-18/h1-6,8-11,19-21H,7,12-16H2/t19-,20+/m1/s1",SOVWMQSGUMWMAH-UXHICEINSA-N,50246394,"(2S,6R)-2-benzyl-6-phenethylpiperidine::CHEMBL455200",Synaptic vesicular amine transporter,,
50826455,O=c1cc(sc2ccc(cc12)C#N)C12CC3CC(CC(C3)C1)C2,"InChI=1S/C20H19NOS/c21-11-12-1-2-18-16(6-12)17(22)7-19(23-18)20-8-13-3-14(9-20)5-15(4-13)10-20/h1-2,6-7,13-15H,3-5,8-10H2",AYLZLUIAGWILQY-UHFFFAOYSA-N,50151136,2-Adamantan-1-yl-4-oxo-4H-thiochromene-6-carbonitrile::CHEMBL361700,Steryl-sulfatase,Homo sapiens,>30000
50633290,NC(N)=Nc1cc(Cl)nc(n1)-c1ccccc1,"InChI=1S/C11H10ClN5/c12-8-6-9(17-11(13)14)16-10(15-8)7-4-2-1-3-5-7/h1-6H,(H4,13,14,15,16,17)",DPTWAGJLIDIXLY-UHFFFAOYSA-N,50013316,CHEMBL422329::N-(6-Chloro-2-phenyl-pyrimidin-4-yl)-guanidine : (Hydrochloride),Potassium-transporting ATPase alpha chain 1/subunit beta,Homo sapiens, 6000
326010,C[C@@H](O)[C@H]1C[C@@H]2OC(=N[C@@H]2[C@@H](O)[C@@H]1O)N(C)C,"InChI=1S/C11H20N2O4/c1-5(14)6-4-7-8(10(16)9(6)15)12-11(17-7)13(2)3/h5-10,14-16H,4H2,1-3H3/t5-,6-,7+,8+,9-,10-/m1/s1",FZOKGSDDKBIICT-NRNPDCPVSA-N,179365,"US9126957, 1A",Protein O-GlcNAcase,Homo sapiens,
44600,CCNC(=O)Nc1nc2cc(c(OC)cc2[nH]1)-c1cnc(OC)nc1,"InChI=1S/C16H18N6O3/c1-4-17-15(23)22-14-20-11-5-10(13(24-2)6-12(11)21-14)9-7-18-16(25-3)19-8-9/h5-8H,4H2,1-3H3,(H3,17,20,21,22,23)",ADASGIIHCQJGMX-UHFFFAOYSA-N,24613,"3-ethyl-1-[6-methoxy-5-(2-methoxypyrimidin-5-yl)-1H-1,3-benzodiazol-2-yl]urea::Benzimidazole urea analogue, 17",DNA gyrase subunit A/B,Staphylococcus aureus,
50991021,Nc1c2CCCCc2nc2ccccc12,"InChI=1S/C13H14N2/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13/h1,3,5,7H,2,4,6,8H2,(H2,14,15)",YLJREFDVOIBQDA-UHFFFAOYSA-N,8961,"1,2,3,4-tetrahydro-9-acridinamine::1,2,3,4-tetrahydroacridin-9-amine::9-THA::9-amino-1,2,3,4-tetrahydroacridine (THA)::CHEMBL1337960::CHEMBL95::Cognex::Tacrine::Tracine::US8999994, Tacrine::cid_1935::tacrine.HCl",Cholinesterase,, 56
50598477,COc1cc(cc(OC)c1OC)-c1cc(ccc1OC)C(C)O,"InChI=1S/C18H22O5/c1-11(19)12-6-7-15(20-2)14(8-12)13-9-16(21-3)18(23-5)17(10-13)22-4/h6-11,19H,1-5H3",YRWZORVBMXAJEJ-UHFFFAOYSA-N,50326478,"1-(3',4',5',6-Tetramethoxybiphenyl-3-yl)ethanol::CHEMBL1243219",Polyphenol oxidase 2,Agaricus bisporus,>2000000
20101,CC(C)C(N(Cc1ccccc1)S(=O)(=O)c1c(F)c(F)c(F)c(F)c1F)C(=O)NO,"InChI=1S/C18H17F5N2O4S/c1-9(2)16(18(26)24-27)25(8-10-6-4-3-5-7-10)30(28,29)17-14(22)12(20)11(19)13(21)15(17)23/h3-7,9,16,27H,8H2,1-2H3,(H,24,26)",XFNJKSWXHKYCFN-UHFFFAOYSA-N,11341,"2-[benzyl(2,3,4,5,6-pentafluorobenzene)sulfonamido]-N-hydroxy-3-methylbutanamide::Hydroxamate 23",Matrix metalloproteinase-9,Homo sapiens,
50139706,CCCCS(=O)(=O)C[C@@H](NC(C)=O)C(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNCc1cccc(CC)c1,"InChI=1S/C28H39F2N3O5S/c1-4-6-10-39(37,38)18-26(32-19(3)34)28(36)33-25(14-22-12-23(29)15-24(30)13-22)27(35)17-31-16-21-9-7-8-20(5-2)11-21/h7-9,11-13,15,25-27,31,35H,4-6,10,14,16-18H2,1-3H3,(H,32,34)(H,33,36)/t25-,26+,27+/m0/s1",YTOZVAMWOLDKNH-OYUWMTPXSA-N,50196741,"(S)-N-((2S,3R)-4-(3-ethylbenzylamino)-1-(3,5-difluorophenyl)-3-hydroxybutan-2-yl)-2-acetamido-3-(butylsulfonyl)propanamide::CHEMBL232490",Beta-secretase 1,Homo sapiens,
50200725,CSc1sc(c2CC(C)(C)CC(=O)c12)-c1ccccn1,"InChI=1S/C16H17NOS2/c1-16(2)8-10-13(12(18)9-16)15(19-3)20-14(10)11-6-4-5-7-17-11/h4-7H,8-9H2,1-3H3",ZZTJJGWSKYVZIG-UHFFFAOYSA-N,50110706,"6,6-Dimethyl-3-methylsulfanyl-1-pyridin-2-yl-6,7-dihydro-5H-benzo[c]thiophen-4-one::CHEMBL17698",Gamma-aminobutyric acid receptor subunit alpha-1/beta-3/gamma-2,Homo sapiens,
50801106,CCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(=O)CCC,"InChI=1S/C28H40O8/c1-7-9-20(30)35-24-16(4)27(34)18(22-25(5,6)28(22,24)36-21(31)10-8-2)12-17(14-29)13-26(33)19(27)11-15(3)23(26)32/h11-12,16,18-19,22,24,29,33-34H,7-10,13-14H2,1-6H3/t16-,18+,19-,22?,24-,26-,27-,28-/m1/s1",BQJRUJTZSGYBEZ-AHNFSZCQSA-N,50057512,"(1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b-dihydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-5-oxo-1,1a,1b,4,4a,5,7a,7b,8,9-decahydro-9aH-cyclopropa[3,4]benzo[1,2-e]azulene-9,9a-diyl dibutanoate::CHEMBL27768::PDBu::phorbol 12,13-dibutanoate::phorbol 12,13-dibutyrate",Protein kinase C delta type,Mus musculus,
51105003,Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12,"InChI=1S/C21H26N6O2/c1-26-14-17(18-4-2-3-5-19(18)26)11-22-10-15-6-8-27(9-7-15)21-23-12-16(13-24-21)20(28)25-29/h2-5,12-15,22,29H,6-11H2,1H3,(H,25,28)",PAWIYAYFNXQGAP-UHFFFAOYSA-N,50105327,JNJ-26481585::Quisinostat,Histone deacetylase 8,Homo sapiens, 169
50597229,COc1ccc(Cn2cccc2C=CC(=O)CC(=O)C(O)=O)cc1,"InChI=1S/C18H17NO5/c1-24-16-8-4-13(5-9-16)12-19-10-2-3-14(19)6-7-15(20)11-17(21)18(22)23/h2-10H,11-12H2,1H3,(H,22,23)",WTMMMHOYGFOJHB-UHFFFAOYSA-N,50142743,"(E)-6-[1-(4-Methoxy-benzyl)-1H-pyrrol-2-yl]-2,4-dioxo-hex-5-enoic acid::CHEMBL198366::CHEMBL46032",Integrase,Human immunodeficiency virus 1, 41000
403259,CC1(C)OC(=O)N([C@H]1c1ccccc1)c1ccc(cc1)-c1cnc(N)c(c1)-c1ccc2nncn2n1,"InChI=1S/C27H23N7O2/c1-27(2)24(18-6-4-3-5-7-18)34(26(35)36-27)20-10-8-17(9-11-20)19-14-21(25(28)29-15-19)22-12-13-23-31-30-16-33(23)32-22/h3-16,24H,1-2H3,(H2,28,29)/t24-/m0/s1",LNBBOOMVYRTUHU-DEOSSOPVSA-N,230994,"US9340549, 12",Poly [ADP-ribose] polymerase tankyrase-2 [946-1162],, 49.3
50033434,OC(=O)c1ccc(OCCn2ccnc2)cc1,"InChI=1S/C12H12N2O3/c15-12(16)10-1-3-11(4-2-10)17-8-7-14-6-5-13-9-14/h1-6,9H,7-8H2,(H,15,16)",XQGZSYKGWHUSDH-UHFFFAOYSA-N,7962,4-(2-Imidazol-1-yl-ethoxy)-benzoic acid; hydrochloride::4-(2-imidazol-1-yl-ethoxy)-benzoic acid::4-[2-(1H-imidazol-1-yl)ethoxy]benzoic acid::CHEMBL267473::CHEMBL537708::Imidazole N-1 deriv. 13::dazoxiben,Thromboxane-A synthase,Homo sapiens, 3
297227,Brc1ccc(s1)S(=O)(=O)N1CCC[C@H]1C(=O)Nc1ccccc1,"InChI=1S/C15H15BrN2O3S2/c16-13-8-9-14(22-13)23(20,21)18-10-4-7-12(18)15(19)17-11-5-2-1-3-6-11/h1-3,5-6,8-9,12H,4,7,10H2,(H,17,19)/t12-/m0/s1",PSYHWFIOJGJPSO-LBPRGKRZSA-N,154936,"US9000029, 15",Orexin receptor type 2,Homo sapiens, 164
366692,CN1Cc2[nH]c3cccc4c3c2c(C1)n[nH]c4=O,"InChI=1S/C13H12N4O/c1-17-5-9-12-10(6-17)15-16-13(18)7-3-2-4-8(14-9)11(7)12/h2-4,14H,5-6H2,1H3,(H,16,18)",MOHNCACTMNLQPM-UHFFFAOYSA-N,207599,"US10501467, Example 44::US9260440, 44::US9617273, Example 44",Poly [ADP-ribose] polymerase 1,, 16
51272291,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC,"InChI=1S/C20H22N8O3/c1-21-20(30)16-14(9-15(25-26-16)24-19(29)11-7-8-11)23-13-6-4-5-12(17(13)31-3)18-22-10-28(2)27-18/h4-6,9-11H,7-8H2,1-3H3,(H,21,30)(H2,23,24,25,29)/i1D3",BZZKEPGENYLQSC-FIBGUPNXSA-N,50507816,Bms-986165::Deucravacitinib,Tyrosine-protein kinase JAK2,Homo sapiens,>10000
50602128,COc1ccc(Cc2cnc(N)nc2N)cc1,"InChI=1S/C12H14N4O/c1-17-10-4-2-8(3-5-10)6-9-7-15-12(14)16-11(9)13/h2-5,7H,6H2,1H3,(H4,13,14,15,16)",YMGUVTBVYOGUFZ-UHFFFAOYSA-N,50138707,"5-(4-Methoxy-benzyl)-pyrimidine-2,4-diamine::CHEMBL19023",Dihydrofolate reductase,Lactobacillus casei,
852628,CCO[C@@H]1CC[C@@H]2[C@H]1CC[C@@H]2C(=O)N1Cc2cccnc2Nc2ccc(cc12)N1C[C@@H]2C[C@H]1CO2,"InChI=1S/C28H34N4O3/c1-2-34-26-10-8-21-22(26)6-7-23(21)28(33)32-14-17-4-3-11-29-27(17)30-24-9-5-18(13-25(24)32)31-15-20-12-19(31)16-35-20/h3-5,9,11,13,19-23,26H,2,6-8,10,12,14-16H2,1H3,(H,29,30)/t19-,20-,21+,22+,23-,26+/m0/s1",RJKLTGMGINQZDR-PDXKIXJRSA-N,287867,"6-{[(1S,3aR,4R,6aR)-4- ethoxyoctahydropentalen- 1-yl]carbonyl}-8-[(1S,4S)- 2-oxa-5- azabicyclo[2.2.1]hept-5- yl]-6,11-dihydro-5H- pyrido[2,3-b] [1,5]benzodiazepine::US10086000, Example 84::US10508108, Example 84",Isocitrate dehydrogenase [NADP] cytoplasmic [R132H],, 56.0
50801234,NC(N)=Nc1ccc2c3C[C@@]4(O)C5Cc6ccc(O)c7O[C@@H](c3[nH]c2c1)[C@]4(CCN5CC1CC1)c67,"InChI=1S/C27H29N5O3/c28-25(29)30-15-4-5-16-17-11-27(34)20-9-14-3-6-19(33)23-21(14)26(27,7-8-32(20)12-13-1-2-13)24(35-23)22(17)31-18(16)10-15/h3-6,10,13,20,24,31,33-34H,1-2,7-9,11-12H2,(H4,28,29,30)/t20?,24-,26-,27+/m0/s1",XDKOGAAFSBGLBO-GZCZAXCTSA-N,50100462,"6`-guanidino-17-(cyclopropylmethyl)-6,7-didehydro-4,5alpha-epoxy-3,14-hydroxyindolo-[2`,3`:6,7]morphinian",Mu-type opioid receptor,Rattus norvegicus,
124227,BrCC(=O)Nc1c2CSCc2nn1-c1ccccc1,"InChI=1S/C13H12BrN3OS/c14-6-12(18)15-13-10-7-19-8-11(10)16-17(13)9-4-2-1-3-5-9/h1-5H,6-8H2,(H,15,18)",UVYKHQVJLYPQHW-UHFFFAOYSA-N,66817,"2-bromanyl-N-(2-phenyl-4,6-dihydrothieno[3,4-c]pyrazol-3-yl)ethanamide::2-bromo-N-(2-phenyl-4,6-dihydrothieno[3,4-c]pyrazol-3-yl)acetamide::MLS001066707::SMR000640753::cid_4162844",Bcl-2-like protein 11,Homo sapiens,
111125,O=C1NCCC(=NNc2ccccn2)c2c1[nH]c1ccccc21,"InChI=1S/C17H15N5O/c23-17-16-15(11-5-1-2-6-12(11)20-16)13(8-10-19-17)21-22-14-7-3-4-9-18-14/h1-7,9,20H,8,10H2,(H,18,22)(H,19,23)",MGYTXFGAXIKJRJ-UHFFFAOYSA-N,59129,"Hymenialdisine, 28f",Cyclin-dependent kinase 5 activator 1,Homo sapiens, 757
25773,CN1CCN(CC1)c1ccc(Nc2ncc3ccn(-c4cccnc4)c3n2)cc1,"InChI=1S/C22H23N7/c1-27-11-13-28(14-12-27)19-6-4-18(5-7-19)25-22-24-15-17-8-10-29(21(17)26-22)20-3-2-9-23-16-20/h2-10,15-16H,11-14H2,1H3,(H,24,25,26)",LIVPFCSSZNEUQL-UHFFFAOYSA-N,14196,"N-[4-(4-methylpiperazin-1-yl)phenyl]-7-(pyridin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine::pyrrolopyrimidine 19",Aurora kinase A,Mus musculus, 13
50091004,Clc1cccc(COc2ccc(Br)cc2OC2CNC2)c1,"InChI=1S/C16H15BrClNO2/c17-12-4-5-15(16(7-12)21-14-8-19-9-14)20-10-11-2-1-3-13(18)6-11/h1-7,14,19H,8-10H2",PESCSIDMHOYAPM-UHFFFAOYSA-N,50011237,"CHEMBL3260334::US9981909, Example 2",5-hydroxytryptamine receptor 2A,,
25645,NC(=[NH2+])c1cc2cc([nH]c2cc1Cl)-c1cc(Cl)cc(Cl)c1O,"InChI=1S/C15H10Cl3N3O/c16-7-3-9(14(22)11(18)4-7)13-2-6-1-8(15(19)20)10(17)5-12(6)21-13/h1-5,21-22H,(H3,19,20)/p+1",BWMVXULSVHMQIK-UHFFFAOYSA-O,14151,"APC-9850::{amino[6-chloro-2-(3,5-dichloro-2-hydroxyphenyl)-1H-indol-5-yl]methylidene}azanium",Prothrombin,,
51148072,CCNC(=O)[C@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1C(=O)CCc1ccc(F)cc1,"InChI=1S/C56H75FN12O10/c1-4-60-53(77)46-13-9-27-69(46)55(79)41(12-7-25-61-56(58)59)63-49(73)42(28-33(2)3)64-51(75)44(30-36-31-62-40-11-6-5-10-39(36)40)66-50(74)43(29-35-17-22-38(71)23-18-35)65-52(76)45(32-70)67-54(78)47-14-8-26-68(47)48(72)24-19-34-15-20-37(57)21-16-34/h5-6,10-11,15-18,20-23,31,33,41-47,62,70-71H,4,7-9,12-14,19,24-30,32H2,1-3H3,(H,60,77)(H,63,73)(H,64,75)(H,65,76)(H,66,74)(H,67,78)(H4,58,59,61)/t41-,42-,43-,44+,45-,46+,47-/m0/s1",YLAJGYGPVRSAJK-OOPKDDOGSA-N,50470117,CHEMBL264989,Gonadotropin-releasing hormone receptor,Rattus norvegicus,
1111348,CC(C)N1CCOc2c(F)cc(cc12)-c1nc(Nc2ccc(cn2)N2CCC(CC2)N(C)C)ncc1F,"InChI=1S/C27H33F2N7O/c1-17(2)36-11-12-37-26-21(28)13-18(14-23(26)36)25-22(29)16-31-27(33-25)32-24-6-5-20(15-30-24)35-9-7-19(8-10-35)34(3)4/h5-6,13-17,19H,7-12H2,1-4H3,(H,30,31,32,33)",HCEVZIBGQRWFCG-UHFFFAOYSA-N,525749,"US11174252, Compound 436",Cyclin-A2/Cyclin-dependent kinase 2,Homo sapiens, 8.00
1119268,Fc1cc(OCC(F)(F)F)cc2CC[C@]3(Cc4nn(c(-c5nnn[nH]5)c4C(=O)N3)-c3ccccn3)c12,,,528896,"US11198695, Example I-107","Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase",, 760
836326,CC(C)c1ccccc1-c1ncc2[nH]c(=O)n(Cc3ccc(CN4CCOCC4)cc3)c2n1,"InChI=1S/C26H29N5O2/c1-18(2)21-5-3-4-6-22(21)24-27-15-23-25(29-24)31(26(32)28-23)17-20-9-7-19(8-10-20)16-30-11-13-33-14-12-30/h3-10,15,18H,11-14,16-17H2,1-2H3,(H,28,32)",FDAPVBSMIMVKTB-UHFFFAOYSA-N,324947,"2-(2-isopropylphenyl)-9-(4-::US10189841, Compound I-153::US10399980, Compound I-153",Ubiquitin carboxyl-terminal hydrolase 1,,>2000
50683768,CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)-c1ccc(OCC2CN(C(=O)C2)c2cccc(F)c2)cc1,"InChI=1S/C28H30FN5O4/c1-3-12-32-26-24(27(36)33(13-4-2)28(32)37)30-25(31-26)19-8-10-22(11-9-19)38-17-18-14-23(35)34(16-18)21-7-5-6-20(29)15-21/h5-11,15,18H,3-4,12-14,16-17H2,1-2H3,(H,30,31)",ZRRQIBGDHZSYTH-UHFFFAOYSA-N,50232092,CHEMBL4090483,Adenosine receptor A2b,Homo sapiens,
128277,C(CNCC1COc2ccccc2O1)Cc1ccccc1,"InChI=1S/C18H21NO2/c1-2-7-15(8-3-1)9-6-12-19-13-16-14-20-17-10-4-5-11-18(17)21-16/h1-5,7-8,10-11,16,19H,6,9,12-14H2",CVAPBKKAWGUIRI-UHFFFAOYSA-N,69295,"2,3-dihydro-1,4-benzodioxin-3-ylmethyl(3-phenylpropyl)amine::MLS000755786::N-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-3-phenyl-1-propanamine::N-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-3-phenyl-1-propanamine::N-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-3-phenyl-propan-1-amine::N-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-3-phenylpropan-1-amine::SMR000337458::cid_3782462",Glycogen synthase kinase-3 beta,Homo sapiens,
51414679,Cn1cc(cn1)-c1cnccc1Oc1ccc(NC(=O)C2Cc3ccncc3N(C2=O)c2ccc(F)cc2)cc1,"InChI=1S/C30H23FN6O3/c1-36-18-20(15-34-36)26-16-32-13-11-28(26)40-24-8-4-22(5-9-24)35-29(38)25-14-19-10-12-33-17-27(19)37(30(25)39)23-6-2-21(31)3-7-23/h2-13,15-18,25H,14H2,1H3,(H,35,38)",QPMLGVWILAPGKR-UHFFFAOYSA-N,50571421,CHEMBL4866212,Tyrosine-protein kinase receptor UFO,, 150
228345,Cc1ncc(cc1NS(=O)(=O)c1ccccc1)C#Cc1c(C)ncnc1N1CCOCC1,"InChI=1S/C23H23N5O3S/c1-17-21(23(26-16-25-17)28-10-12-31-13-11-28)9-8-19-14-22(18(2)24-15-19)27-32(29,30)20-6-4-3-5-7-20/h3-7,14-16,27H,10-13H2,1-2H3",YORTWBNAICEBRY-UHFFFAOYSA-N,108163,"US8598157, I-40","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",Homo sapiens, 0.28
50470984,Cl.NCC1CC1c1cc(Cl)c(F)cc1OCC=C,"InChI=1S/C13H15ClFNO.ClH/c1-2-3-17-13-6-12(15)11(14)5-10(13)9-4-8(9)7-16;/h2,5-6,8-9H,1,3-4,7,16H2;1H",BFKVRYNWYCDLDI-UHFFFAOYSA-N,50148842,CHEMBL3770174,5-hydroxytryptamine receptor 2B,Homo sapiens,
51095973,COc1ccc(F)c(c1)-c1ccc(COc2cccc(c2)[C@@H](CC(O)=O)C2CC2)cc1C1=CCCC1(C)C,"InChI=1S/C33H35FO4/c1-33(2)15-5-8-30(33)28-16-21(9-13-26(28)29-18-24(37-3)12-14-31(29)34)20-38-25-7-4-6-23(17-25)27(19-32(35)36)22-10-11-22/h4,6-9,12-14,16-18,22,27H,5,10-11,15,19-20H2,1-3H3,(H,35,36)/t27-/m0/s1",CHEANNSDVJOIBS-MHZLTWQESA-N,50392861,CHEMBL2152070,Free fatty acid receptor 1,,
1201637,Cc1cncc2ccc(NC(=O)[C@@H]3C[C@H]3c3ccc(cc3)S(=O)(=O)Nc3cncc(n3)C3=CCNCC3)cc12,"InChI=1S/C29H28N6O3S/c1-18-14-31-15-21-2-5-22(12-24(18)21)33-29(36)26-13-25(26)19-3-6-23(7-4-19)39(37,38)35-28-17-32-16-27(34-28)20-8-10-30-11-9-20/h2-8,12,14-17,25-26,30H,9-11,13H2,1H3,(H,33,36)(H,34,35)/t25-,26+/m0/s1",PHMHQFXCZAIFKO-IZZNHLLZSA-N,569253,"US11427563, Compound 11::US11427563, Compound 144::US11427563, Compound 88",Tyrosine-protein kinase JAK2,Homo sapiens, 10.8
50933467,Cc1cc(F)c(Sc2nccn2C)cc1C(=O)Nc1cccc(N)c1,"InChI=1S/C18H17FN4OS/c1-11-8-15(19)16(25-18-21-6-7-23(18)2)10-14(11)17(24)22-13-5-3-4-12(20)9-13/h3-10H,20H2,1-2H3,(H,22,24)",FGZLRAIOKZQEDP-UHFFFAOYSA-N,50382965,CHEMBL2030483,"Glycogen phosphorylase, muscle form",Oryctolagus cuniculus, 2700
50040824,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CC3)cc(Cl)nc12,"InChI=1S/C14H17ClN4O4/c15-9-3-7(17-6-1-2-6)10-13(18-9)19(5-16-10)14-12(22)11(21)8(4-20)23-14/h3,5-6,8,11-12,14,20-22H,1-2,4H2,(H,17,18)/t8-,11-,12-,14-/m1/s1",NPHATOGXVQXFFX-LHNIVKCTSA-N,50407527,CHEMBL2113521,Adenosine deaminase,Bos taurus,
1209612,Cc1c2NCCOc2ncc1-c1cc2\C(=C\c3cc4ncccc4[nH]3)C(=O)Nc2cc1F,"InChI=1S/C24H18FN5O2/c1-12-17(11-28-24-22(12)27-5-6-32-24)14-9-15-16(23(31)30-20(15)10-18(14)25)7-13-8-21-19(29-13)3-2-4-26-21/h2-4,7-11,27,29H,5-6H2,1H3,(H,30,31)/b16-7-",VETQJCCLTCSMCF-APSNUPSMSA-N,50563731,"CHEMBL4799073::US11453681, Compound C44",Mitogen-activated protein kinase kinase kinase kinase 1,Homo sapiens, 0.050
348614,CN(C)C\C=C\C(=O)Nc1cccc(c1)-c1cnc2[nH]cc(Cl)c2c1,"InChI=1S/C19H19ClN4O/c1-24(2)8-4-7-18(25)23-15-6-3-5-13(9-15)14-10-16-17(20)12-22-19(16)21-11-14/h3-7,9-12H,8H2,1-2H3,(H,21,22)(H,23,25)/b7-4+",QLAKLVIXUIVHNO-QPJJXVBHSA-N,195908,"US9206188, 153::US9834551, Example 153",Tyrosine-protein kinase JAK2,Homo sapiens,>100000
630605,CC(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H]1CCC(=O)NCCC[C@H](NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CCN)NC1=O)C(O)=O,,,135702,"US10179804, Example 87::US10632171, Peptide No. 87::US8846601, 87::US9458201, 87",Melanocortin receptor 4,,
51240536,CC(C)[C@@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@H](Cc2ccccc2)NC(C)=O)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2NC(C)=O)C(=O)N1,"InChI=1S/C60H82N12O15S2/c1-32(2)45(28-73)69-59(86)47-31-89-88-30-46(70-54(81)41(63-33(3)75)23-35-15-7-5-8-16-35)58(85)66-42(24-36-17-9-6-10-18-36)55(82)67-43(25-37-27-62-39-20-12-11-19-38(37)39)56(83)65-40(21-13-14-22-61)53(80)68-44(57(84)71-47)26-49(77)72-60-50(64-34(4)76)52(79)51(78)48(29-74)87-60/h5-12,15-20,27,32,40-48,50-52,60,62,73-74,78-79H,13-14,21-26,28-31,61H2,1-4H3,(H,63,75)(H,64,76)(H,65,83)(H,66,85)(H,67,82)(H,68,80)(H,69,86)(H,70,81)(H,71,84)(H,72,77)/t40-,41-,42-,43-,44-,45+,46-,47-,48+,50+,51+,52+,60+/m0/s1",HGQBSADXQRPMQI-YHGOACRTSA-N,50507585,CHEMBL4549840,Somatostatin receptor type 5,Homo sapiens, 5.2
522488,C[C@@H]1CC[C@H](CN1C(=O)c1ccccc1-c1ncccn1)Oc1nccc2c1C(=O)OC2(C)C,"InChI=1S/C26H26N4O4/c1-16-9-10-17(33-23-21-20(11-14-29-23)26(2,3)34-25(21)32)15-30(16)24(31)19-8-5-4-7-18(19)22-27-12-6-13-28-22/h4-8,11-14,16-17H,9-10,15H2,1-3H3/t16-,17-/m1/s1",OXBQPGMMDFJVIP-IAGOWNOFSA-N,274932,"US9556190, Example 22",Orexin receptor type 2,Homo sapiens, 76.0
54717,CCOc1ccccc1-c1nnc2SCC(=Nn12)c1cccc(OC)c1,"InChI=1S/C19H18N4O2S/c1-3-25-17-10-5-4-9-15(17)18-20-21-19-23(18)22-16(12-26-19)13-7-6-8-14(11-13)24-2/h4-11H,3,12H2,1-2H3",WEDQPCYUYCLNPO-UHFFFAOYSA-N,30080,"triazolothiadiazine, 7J","cAMP-specific 3',5'-cyclic phosphodiesterase 4A",Homo sapiens, 11200
50519777,CC(NC(=O)c1ccccc1\N=C\c1c(O)ccc2ccccc12)c1ccccc1,"InChI=1S/C26H22N2O2/c1-18(19-9-3-2-4-10-19)28-26(30)22-13-7-8-14-24(22)27-17-23-21-12-6-5-11-20(21)15-16-25(23)29/h2-18,29H,1H3,(H,28,30)/b27-17+",UXJFDYIHRJGPFS-WPWMEQJKSA-N,50156760,(E)-2-((2-hydroxynaphthalen-1-yl)methyleneamino)-N-(1-phenylethyl)benzamide::2-((2-hydroxynaphthalen-1-yl)methyleneamino)-N-(1-phenylethyl)benzamide::2-{[(1-(2-hydroxy-naphthalen-1-yl)meth-(E)-ylidene]amino}-N-(1-phenylethyl)-benzamide::2-{[1-(2-hydroxynaphthalen-1-yl)meth-(E)-ylene]amino}-N-(1-phenylethyl)benzamide::CHEMBL380797::Sirtinol,NAD-dependent histone deacetylase SIR2,Saccharomyces cerevisiae, 68000
676347,COc1cccc(c1)-c1[nH]c(nc1C)C1(C)CCN(CC1)c1ncnc2[nH]c(cc12)-c1ccc(cc1)C(N)=O,"InChI=1S/C30H31N7O2/c1-18-25(21-5-4-6-22(15-21)39-3)36-29(34-18)30(2)11-13-37(14-12-30)28-23-16-24(35-27(23)32-17-33-28)19-7-9-20(10-8-19)26(31)38/h4-10,15-17H,11-14H2,1-3H3,(H2,31,38)(H,34,36)(H,32,33,35)",YVTMMPXIPJEWFJ-UHFFFAOYSA-N,342388,"4-[4-[4-[5-(3-methoxyphenyl)-4-methyl- 1H-imidazol-2-yl]-4-methyl-1- piperidyl]-7H-pyrrolo[2,3-d]pyrimidin- 6-yl]benzamide::US9771369, Compound P-3225",Mast/stem cell growth factor receptor Kit [D816V],,
639856,CCC(C1CC1)n1cc(cn1)-c1nc(cn2nccc12)-c1cnn(C[C@@H](O)CO)c1,"InChI=1S/C21H25N7O2/c1-2-19(14-3-4-14)27-10-16(8-24-27)21-20-5-6-22-28(20)12-18(25-21)15-7-23-26(9-15)11-17(30)13-29/h5-10,12,14,17,19,29-30H,2-4,11,13H2,1H3/t17-,19?/m1/s1",HGUMRBROBXBLAK-DUSLRRAJSA-N,325551,"US10189845, Example 213B::US10189845, Example 214A::US10730880, Example 214::US11028093, Example 214",Tyrosine-protein kinase JAK3,Homo sapiens, 5500
51234978,CCc1ccc(s1)S(=O)(=O)NC[C@H]1O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]1O,"InChI=1S/C13H21NO6S2/c1-3-8-4-5-10(21-8)22(18,19)14-6-9-12(16)13(17)11(15)7(2)20-9/h4-5,7,9,11-17H,3,6H2,1-2H3/t7-,9+,11+,12+,13+/m0/s1",NDNQDCVGROLIQH-OZNCUSTMSA-N,50505607,CHEMBL4442247,LecB,Pseudomonas aeruginosa, 4020
51015080,Cc1ncoc1-c1nnc(SCCCN2CC3CC3(C2)c2ccc(OC(F)(F)F)cc2)n1C,"InChI=1S/C22H24F3N5O2S/c1-14-18(31-13-26-14)19-27-28-20(29(19)2)33-9-3-8-30-11-16-10-21(16,12-30)15-4-6-17(7-5-15)32-22(23,24)25/h4-7,13,16H,3,8-12H2,1-2H3",SRVOWVHRVJSZKO-UHFFFAOYSA-N,50415734,CHEMBL1081966,Potassium voltage-gated channel subfamily H member 2,Homo sapiens, 316.23
120724,Cc1cc(no1)C(=O)Nc1sc2CCCCc2c1C#N,"InChI=1S/C14H13N3O2S/c1-8-6-11(17-19-8)13(18)16-14-10(7-15)9-4-2-3-5-12(9)20-14/h6H,2-5H2,1H3,(H,16,18)",ZSSNHLJWIDWUJU-UHFFFAOYSA-N,64548,"MLS000087310::N-(3-cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)-5-methylisoxazole-3-carboxamide::N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-5-methyl-1,2-oxazole-3-carboxamide::N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-5-methyl-3-isoxazolecarboxamide::N-(3-cyano-4,5,6,7-tetrahydrobenzothiophen-2-yl)-5-methyl-isoxazole-3-carboxamide::SMR000023533::cid_3239681",Serine/threonine-protein phosphatase,Candida dubliniensis (strain CD36 / ATCC MYA-646 / CBS 7987 / NCPF 3949 / NRRL Y-17841),
604481,COc1ccc(OC[C@@H]2CCc3cc(ccc3C2)[C@H]2CC[C@](N)(COP(O)(O)=O)C2)c(F)c1F,"InChI=1S/C24H30F2NO6P/c1-31-20-6-7-21(23(26)22(20)25)32-13-15-2-3-17-11-18(5-4-16(17)10-15)19-8-9-24(27,12-19)14-33-34(28,29)30/h4-7,11,15,19H,2-3,8-10,12-14,27H2,1H3,(H2,28,29,30)/t15-,19+,24-/m1/s1",UMGWWSCTACWGIW-YOQPTCTGSA-N,65136,"US10166249, Example 494::US9522888, 494",Sphingosine-1-phosphate lyase 1,,
21452,CCN(CC#N)C(=O)[C@@H](N)[C@@]12CC3CC(CC(O)(C3)C1)C2,"InChI=1S/C16H25N3O2/c1-2-19(4-3-17)14(20)13(18)15-6-11-5-12(7-15)9-16(21,8-11)10-15/h11-13,21H,2,4-10,18H2,1H3/t11?,12?,13-,15-,16?/m1/s1",CUWIFARYEDKKRP-UZAMWKIUSA-N,11911,(2S)-2-amino-N-(cyanomethyl)-N-ethyl-2-(3-hydroxyadamantan-1-yl)acetamide::seco-proline-based inhibitor 27,Dipeptidyl peptidase 4,Homo sapiens,
50977348,O=C(C1CCCCC1)N1CC2C3CC(C=C3)C2C1,"InChI=1S/C16H23NO/c18-16(11-4-2-1-3-5-11)17-9-14-12-6-7-13(8-12)15(14)10-17/h6-7,11-15H,1-5,8-10H2",DXMJULIKMLDOFU-UHFFFAOYSA-N,50277198,CHEMBL4163698,11-beta-hydroxysteroid dehydrogenase 1,Homo sapiens, 20
43848,O[C@@H](C1CC1)C(=O)N1CC(=C[C@H]1c1ccccc1)c1cc(F)ccc1F,"InChI=1S/C21H19F2NO2/c22-16-8-9-18(23)17(11-16)15-10-19(13-4-2-1-3-5-13)24(12-15)21(26)20(25)14-6-7-14/h1-5,8-11,14,19-20,25H,6-7,12H2/t19-,20-/m0/s1",FHIRATRLDJRXHH-PMACEKPBSA-N,24063,"(2S)-2-cyclopropyl-1-[(2S)-4-(2,5-difluorophenyl)-2-phenyl-2,5-dihydro-1H-pyrrol-1-yl]-2-hydroxyethan-1-one::CHEMBL382165::dihydropyrrole, 22",Potassium voltage-gated channel subfamily H member 2,Homo sapiens, 11000
790038,COc1cccc(CN2C=C(Oc3ccccc23)C(=O)N[C@H]2CCCC[C@@H]2O)c1,"InChI=1S/C23H26N2O4/c1-28-17-8-6-7-16(13-17)14-25-15-22(29-21-12-5-3-10-19(21)25)23(27)24-18-9-2-4-11-20(18)26/h3,5-8,10,12-13,15,18,20,26H,2,4,9,11,14H2,1H3,(H,24,27)/t18-,20-/m0/s1",KFVOGLASHAMYQY-ICSRJNTNSA-N,395163,"US10308620, Example 9",Muscarinic acetylcholine receptor M1,,
67152,CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C,"InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-",WINHZLLDWRZWRT-ATVHPVEESA-N,4814,"CHEMBL535::N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide::N-[2-(diethylamino)ethyl]-5-{[(3Z)-5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene]methyl}-2,4-dimethyl-1H-pyrrole-3-carboxamide::SU11248::SUNITINIB::SUNITINIB MALATE::US10464902, Sunitinib::US9163010, Sunitinib::US9914707, SU11248",Casein kinase I isoform gamma-1,Homo sapiens,
50456,Cc1n[nH]c2c(CO)ccc(Oc3cc(cc(c3)C#N)C#N)c12,"InChI=1S/C17H12N4O2/c1-10-16-15(3-2-13(9-22)17(16)21-20-10)23-14-5-11(7-18)4-12(6-14)8-19/h2-6,22H,9H2,1H3,(H,20,21)",GYIOHTJWSJFTCV-UHFFFAOYSA-N,27578,"5-{[7-(hydroxymethyl)-3-methyl-1H-indazol-4-yl]oxy}benzene-1,3-dicarbonitrile::Indazole Derivative, 8",Gag-Pol polyprotein [588-1027],Human immunodeficiency virus 1, 71
598621,Cc1cccc(n1)-c1nc2NCCn2c1-c1cc2cnccc2s1,"InChI=1S/C18H15N5S/c1-11-3-2-4-13(21-11)16-17(23-8-7-20-18(23)22-16)15-9-12-10-19-6-5-14(12)24-15/h2-6,9-10H,7-8H2,1H3,(H,20,22)",FPKHCAHBTFJUMY-UHFFFAOYSA-N,311398,"US10155763, Example 6",TGF-beta receptor type-1,, 6.10
50708602,CC(C)(C)OC(=O)NCCNc1nc(NCCNC(=O)OC(C)(C)C)n2nc(nc2n1)-c1ccco1,"InChI=1S/C22H33N9O5/c1-21(2,3)35-19(32)25-11-9-23-16-28-17(24-10-12-26-20(33)36-22(4,5)6)31-18(29-16)27-15(30-31)14-8-7-13-34-14/h7-8,13H,9-12H2,1-6H3,(H,25,32)(H,26,33)(H2,23,24,27,28,29,30)",WBPQESSCKHAZEZ-UHFFFAOYSA-N,50360195,CHEMBL1927425,Adenosine receptor A2b,Homo sapiens,>100000
407014,Fc1ccc2nccc(C(=O)NCC(=O)N3CCC[C@H]3C#N)c2c1,"InChI=1S/C17H15FN4O2/c18-11-3-4-15-14(8-11)13(5-6-20-15)17(24)21-10-16(23)22-7-1-2-12(22)9-19/h3-6,8,12H,1-2,7,10H2,(H,21,24)/t12-/m0/s1",CRWCYVOHVXAEMF-LBPRGKRZSA-N,50434166,"CHEMBL2385270::US9346814, Cmpd No 6 Example 9",Dipeptidyl peptidase 9,Homo sapiens,>100000
348062,CCCSc1ccc2CC3(CCC(CC3)OC)C3(N=C(N)N(CCOC)C3=O)c2c1,"InChI=1S/C23H33N3O3S/c1-4-13-30-18-6-5-16-15-22(9-7-17(29-3)8-10-22)23(19(16)14-18)20(27)26(11-12-28-2)21(24)25-23/h5-6,14,17H,4,7-13,15H2,1-3H3,(H2,24,25)",YAMDBYLOOGOYGR-UHFFFAOYSA-N,195397,"US10336717, Compound 533::US9212153, 533,Ex. 414",Beta-secretase 1 [1-458],, 8.9
1004,CC(C)(C)OC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@@H](Cc1ccc(OCC(O)=O)cc1)C(=O)N[C@@H]1[C@H](O)Cc2ccccc12,"InChI=1S/C35H42N2O8/c1-35(2,3)45-34(43)36-28(18-22-9-5-4-6-10-22)29(38)20-25(17-23-13-15-26(16-14-23)44-21-31(40)41)33(42)37-32-27-12-8-7-11-24(27)19-30(32)39/h4-16,25,28-30,32,38-39H,17-21H2,1-3H3,(H,36,43)(H,37,42)(H,40,41)/t25-,28+,29+,30-,32+/m1/s1",YDOBPQZYAZNHNJ-KNGUAOONSA-N,894,"2-{4-[(2R)-2-[(2S,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-4-phenylbutyl]-2-{[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]carbamoyl}ethyl]phenoxy}acetic acid::L-685,434 deriv. 43::N-(2(R)-Hydroxy-1(S)-indanyl)-5(S)-[(tert-butyloxycarbonyl)amino]-4(S)-hydroxy-6-phenyl-2(R)-[[4-(carboxymethyl)phenyl]methyl]hexanamide",Dimer of Gag-Pol polyprotein [489-587],Human immunodeficiency virus 1, 0.04
375242,Cc1ccc(cn1)-c1cc(ccc1N1C[C@H](O)[C@@H](O)C1)C(=O)Nc1ccc(OC(F)(F)F)cc1,"InChI=1S/C24H22F3N3O4/c1-14-2-3-16(11-28-14)19-10-15(4-9-20(19)30-12-21(31)22(32)13-30)23(33)29-17-5-7-18(8-6-17)34-24(25,26)27/h2-11,21-22,31-32H,12-13H2,1H3,(H,29,33)/t21-,22-/m0/s1",OJWQSGZBGYOEHG-VXKWHMMOSA-N,213417,"US9278981, 9",Tyrosine-protein kinase ABL1 [64-515],, 17
23532,CC1(C)O[C@@H]2CO[C@@]3(CNS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1,"InChI=1S/C12H22N2O7S/c1-10(2)18-7-5-17-12(6-14-22(13,15)16)9(8(7)19-10)20-11(3,4)21-12/h7-9,14H,5-6H2,1-4H3,(H2,13,15,16)/t7-,8-,9+,12+/m1/s1",NQRKKQKMTGLNOZ-XBWDGYHZSA-N,13055,"CHEMBL283695::Compound 8::Topiramate Sulfamide Analogue 8::amino-N-{[(1R,2S,6S,9R)-4,4,11,11-tetramethyl-3,5,7,10,12-pentaoxatricyclo[7.3.0.0^{2,6}]dodecan-6-yl]methyl}sulfonamide",Carbonic anhydrase 13,Mus musculus,
50461800,COC(=O)CCCOc1ccc(cc1)-c1ccc(s1)-c1noc(Cc2c[nH]c3ccccc23)n1,"InChI=1S/C26H23N3O4S/c1-31-25(30)7-4-14-32-19-10-8-17(9-11-19)22-12-13-23(34-22)26-28-24(33-29-26)15-18-16-27-21-6-3-2-5-20(18)21/h2-3,5-6,8-13,16,27H,4,7,14-15H2,1H3",MWKWEDWHENCBCE-UHFFFAOYSA-N,50143010,CHEMBL3758785,Tyrosine-protein phosphatase non-receptor type 1,Homo sapiens,>120000
50798142,NS(=O)(=O)c1nnc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)s1,"InChI=1S/C8H3F5N4O4S3/c9-1-2(10)4(12)6(5(13)3(1)11)24(20,21)17-7-15-16-8(22-7)23(14,18)19/h(H,15,17)(H2,14,18,19)",SNVIUSFXXHRDCP-UHFFFAOYSA-N,50094347,"5-(perfluorophenylsulfonamido)-1,3,4-thiadiazole-2-sulfonamide::5-Pentafluorobenzenesulfonylamino-[1,3,4]thiadiazole-2-sulfonic acid amide::CHEMBL94836",Carbonic anhydrase 4,Bos taurus,
51249981,CN1\C(=C\C=C\C=C\C2=[N+](CCCCCC(=O)NCC(=O)NCC(=O)NCCCNC(=N)Nc3ccc4[nH]c5[C@@H]6Oc7c8c(C[C@H]9N(CC%10CC%10)CC[C@@]68[C@@]9(O)Cc5c4c3)ccc7O)c3ccc(cc3C2(C)C)S([O-])(=O)=O)C(C)(C)c2cc(ccc12)S(O)(=O)=O,"InChI=1S/C66H78N10O12S2/c1-63(2)46-33-42(89(82,83)84)20-23-49(46)74(5)52(63)13-8-6-9-14-53-64(3,4)47-34-43(90(85,86)87)21-24-50(47)76(53)29-11-7-10-15-55(78)70-37-57(80)71-36-56(79)68-27-12-28-69-62(67)72-41-19-22-48-44(32-41)45-35-66(81)54-31-40-18-25-51(77)60-58(40)65(66,61(88-60)59(45)73-48)26-30-75(54)38-39-16-17-39/h6,8-9,13-14,18-25,32-34,39,54,61,73,81H,7,10-12,15-17,26-31,35-38H2,1-5H3,(H8-,67,68,69,70,71,72,77,78,79,80,82,83,84,85,86,87)/t54-,61+,65+,66-/m1/s1",JDGGWAITBYRVNA-UYKNXMGNSA-N,50511258,CHEMBL4438046,Kappa-type opioid receptor,Homo sapiens,
50484751,Cn1cnc2ncn(Cc3noc(CCc4ccc(Cl)cc4)n3)c(=O)c12,"InChI=1S/C17H15ClN6O2/c1-23-9-19-16-15(23)17(25)24(10-20-16)8-13-21-14(26-22-13)7-4-11-2-5-12(18)6-3-11/h2-3,5-6,9-10H,4,7-8H2,1H3",CQQRVWPXVJWBRU-UHFFFAOYSA-N,50157699,CHEMBL3785390,Transient receptor potential cation channel subfamily A member 1,, 211
364020,C1CN1c1nc(nc(n1)-c1cccn1-c1ccccc1)N1CC1,"InChI=1S/C17H16N6/c1-2-5-13(6-3-1)23-8-4-7-14(23)15-18-16(21-9-10-21)20-17(19-15)22-11-12-22/h1-8H,9-12H2",DAZONCQAIYYVKR-UHFFFAOYSA-N,205464,"PPiase inhibitor, 1",Inorganic pyrophosphatase,, 3.55e+5
853941,Oc1ccc(cc1F)C1CCN(CC1F)C1CCON(Cc2ccc(F)cc2)C1=O,"InChI=1S/C22H23F3N2O3/c23-16-4-1-14(2-5-16)12-27-22(29)20(8-10-30-27)26-9-7-17(19(25)13-26)15-3-6-21(28)18(24)11-15/h1-6,11,17,19-20,28H,7-10,12-13H2",JWFRNGYOYFWLSJ-UHFFFAOYSA-N,423289,"US10501451, Example 13, P-1::US10501451, Example 13, P-2::US10954225, Example 13,P-2","Glutamate receptor ionotropic, NMDA 2B",,
103837,COc1ccc(cc1Br)-c1c(C#N)c(N)n(c1C(=O)c1ccccc1)S(C)(=O)=O,"InChI=1S/C20H16BrN3O4S/c1-28-16-9-8-13(10-15(16)21)17-14(11-22)20(23)24(29(2,26)27)18(17)19(25)12-6-4-3-5-7-12/h3-10H,23H2,1-2H3",QHMSSSYIPMWCIK-UHFFFAOYSA-N,54686,2-amino-5-benzoyl-4-(3-bromo-4-methoxy-phenyl)-1-mesyl-pyrrole-3-carbonitrile::2-amino-5-benzoyl-4-(3-bromo-4-methoxyphenyl)-1-methylsulfonyl-3-pyrrolecarbonitrile::2-amino-5-benzoyl-4-(3-bromo-4-methoxyphenyl)-1-methylsulfonylpyrrole-3-carbonitrile::2-azanyl-4-(3-bromanyl-4-methoxy-phenyl)-1-methylsulfonyl-5-(phenylcarbonyl)pyrrole-3-carbonitrile::UNM-0000305776::cid_25220927,GTPase KRas [1-37],Homo sapiens,
50479235,O[B-](=[OH+])c1cccc(c1)[N+]([O-])=O,"InChI=1S/C6H6BNO4/c9-7(10)5-2-1-3-6(4-5)8(11)12/h1-4,9-10H",ZNRGSYUVFVNSAW-UHFFFAOYSA-N,50067887,3-NITROPHENYLBORONIC ACID::3-Nitro-phenyl-1-dihydroxyborane::3-Nitrophenyl boronic acid::Boronic acid derivative::CHEMBL20945::m-nitophenyl boronic acid,Subtilisin BL,Bacillus lentus,
50371072,CNCCCN1c2ccccc2CCc2ccccc12,"InChI=1S/C18H22N2/c1-19-13-6-14-20-17-9-4-2-7-15(17)11-12-16-8-3-5-10-18(16)20/h2-5,7-10,19H,6,11-14H2,1H3",HCYAFALTSJYZDH-UHFFFAOYSA-N,35229,"3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N-methylpropan-1-amine::5-(gamma-methylaminopropyl)iminodibenzyl::CHEMBL72::DESIPRAMINE HYDROCHLORIDE::DMI::Desipramin::Desipramine::Desmethylimipramine::N-(3-methylaminopropyl)iminobibenzyl::US9944618, Compound ID No. 174::demethylimipramine::monodemethylimipramine::norimipramine",Voltage-dependent L-type calcium channel subunit alpha-1C,, 1709
567670,CC1N(C=Cc2c1nnn2-c1ncc[nH]1)C(=O)c1cccc(c1Cl)C(F)(F)F,,,296292,"US10112937, Example 393",P2X purinoceptor 7,, 51.2
51156226,CCOC(=O)c1ccc(cc1)N1N=C(C2CC=CCC2C1=O)c1ccc(OCC)c(OCC)c1,"InChI=1S/C27H30N2O5/c1-4-32-23-16-13-19(17-24(23)33-5-2)25-21-9-7-8-10-22(21)26(30)29(28-25)20-14-11-18(12-15-20)27(31)34-6-3/h7-8,11-17,21-22H,4-6,9-10H2,1-3H3",OVLZKANHBRXYRB-UHFFFAOYSA-N,50473754,CHEMBL315934,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A/4B/4C/4D",, 10.0
37345,COc1ccc(Cn2c(C)cc3nc(N)[nH]c(=O)c23)cc1,"InChI=1S/C15H16N4O2/c1-9-7-12-13(14(20)18-15(16)17-12)19(9)8-10-3-5-11(21-2)6-4-10/h3-7H,8H2,1-2H3,(H3,16,17,18,20)",JRTRRGFUCMJTIT-UHFFFAOYSA-N,20683,"2-amino-5-[(4-methoxyphenyl)methyl]-6-methyl-3H,4H,5H-pyrrolo[3,2-d]pyrimidin-4-one::Pyrrolo[3,2-d]pyrimidine analogue, 11",Thymidylate synthase,Homo sapiens, 1500
50814210,CN1CCN(CC1)C(=O)c1cc2c(Br)cccc2[nH]1,"InChI=1S/C14H16BrN3O/c1-17-5-7-18(8-6-17)14(19)13-9-10-11(15)3-2-4-12(10)16-13/h2-4,9,16H,5-8H2,1H3",VYMYYMVDBIBNQD-UHFFFAOYSA-N,50133009,(4-Bromo-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone::(4-bromo-1H-indol-2-yl)(4-methylpiperazin-1-yl)methanone::CHEMBL128505,Histamine H4 receptor,Homo sapiens,
50866991,COc1ccc(OC(=O)N(CC(O)=O)Cc2ccc(OCCc3nc(oc3CO)-c3ccccc3)cc2)cc1,"InChI=1S/C29H28N2O8/c1-36-22-11-13-24(14-12-22)38-29(35)31(18-27(33)34)17-20-7-9-23(10-8-20)37-16-15-25-26(19-32)39-28(30-25)21-5-3-2-4-6-21/h2-14,32H,15-19H2,1H3,(H,33,34)",SZQYQVHETQTNHR-UHFFFAOYSA-N,50376415,CHEMBL429671,Peroxisome proliferator-activated receptor gamma,Homo sapiens,>15000
449863,CCOc1c(F)cccc1-c1nc(no1)[C@@H]1CCCN1C(=O)c1cc(OC)ccc1-n1nccn1,"InChI=1S/C24H23FN6O4/c1-3-34-21-16(6-4-7-18(21)25)23-28-22(29-35-23)20-8-5-13-30(20)24(32)17-14-15(33-2)9-10-19(17)31-26-11-12-27-31/h4,6-7,9-12,14,20H,3,5,8,13H2,1-2H3/t20-/m0/s1",FCJMMEVNQNVXGE-FQEVSTJZSA-N,257857,"US9493446, 326",Orexin receptor type 2,Homo sapiens, 3
50718018,CCCCCc1ccc(cc1)B(O)O,"InChI=1S/C11H17BO2/c1-2-3-4-5-10-6-8-11(9-7-10)12(13)14/h6-9,13-14H,2-5H2,1H3",UZRMPSOGFATLJE-UHFFFAOYSA-N,50364283,CHEMBL1952296,Lipoprotein lipase,Homo sapiens, 15000
50835768,Oc1ccc2C[C@@H]3C4CCCC[C@]4(CCN3CC3CC3)c2c1,"InChI=1S/C20H27NO/c22-16-7-6-15-11-19-17-3-1-2-8-20(17,18(15)12-16)9-10-21(19)13-14-4-5-14/h6-7,12,14,17,19,22H,1-5,8-11,13H2/t17?,19-,20-/m1/s1",NLBUEDSBXVNAPB-IPNZSQQUSA-N,50105483,"(-)-cyclorphan::17-cyclopropylmethyl-(1R,9R)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol::17-cyclopropylmethyl-(9R)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol::17-cyclopropylmethyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2,4,6-trien-4-ol::CHEMBL291468",Kappa-type opioid receptor,Homo sapiens,
50780495,NCCCCCCCCCCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)NCCCC1CCCCC1,"InChI=1S/C29H57N5O4/c30-20-12-6-4-2-1-3-5-10-19-27(36)33-26(23-35)29(38)34-25(18-11-13-21-31)28(37)32-22-14-17-24-15-8-7-9-16-24/h24-26,35H,1-23,30-31H2,(H,32,37)(H,33,36)(H,34,38)/t25-,26-/m0/s1",NPBHBDBZCHCPLI-UIOOFZCWSA-N,50057697,11-Amino-undecanoic acid {(S)-1-[(S)-5-amino-1-(3-cyclohexyl-propylcarbamoyl)-pentylcarbamoyl]-2-hydroxy-ethyl}-amide::CHEMBL33685,Glycylpeptide N-tetradecanoyltransferase,Candida albicans, 1300
50908829,CCOC(=O)Nc1nc(c(s1)C(=O)c1ccccc1)-c1ccccc1,"InChI=1S/C19H16N2O3S/c1-2-24-19(23)21-18-20-15(13-9-5-3-6-10-13)17(25-18)16(22)14-11-7-4-8-12-14/h3-12H,2H2,1H3,(H,20,21,23)",VMTZCTQCFMWSEO-UHFFFAOYSA-N,50308501,CHEMBL603129::Ethyl 5-benzoyl-4-phenylthiazol-2-ylcarbamate::cid_7315331,Adenosine receptor A2b,Homo sapiens,
51423468,Cc1cc(C)c(CNC(=O)c2cc(cc3N(CCc23)C(=O)C2CC2)-c2ccc(CN3CCOCC3)cc2)c(=O)[nH]1,"InChI=1S/C32H36N4O4/c1-20-15-21(2)34-31(38)28(20)18-33-30(37)27-16-25(17-29-26(27)9-10-36(29)32(39)24-7-8-24)23-5-3-22(4-6-23)19-35-11-13-40-14-12-35/h3-6,15-17,24H,7-14,18-19H2,1-2H3,(H,33,37)(H,34,38)",PSNNVJBDUZUMRC-UHFFFAOYSA-N,50575208,CHEMBL4851199,Histone-lysine N-methyltransferase EZH2,, 396
50841123,Fc1ccc2ncc(C#N)c(N3CCC(CC3)C(=O)Nc3ccccn3)c2c1,"InChI=1S/C21H18FN5O/c22-16-4-5-18-17(11-16)20(15(12-23)13-25-18)27-9-6-14(7-10-27)21(28)26-19-3-1-2-8-24-19/h1-5,8,11,13-14H,6-7,9-10H2,(H,24,26,28)",RIHYJBYHBURMFX-UHFFFAOYSA-N,50261453,CHEMBL4093138,Muscarinic acetylcholine receptor M4,,
51032593,OC[C@H]1O[C@H](Oc2ccccc2-c2cccc(CCc3ccc(O[C@H]4O[C@H](CO)[C@@H](O)[C@@H](O)[C@@H]4O)c(c3)-c3cccc(CC(O)=O)c3)c2)[C@@H](O)[C@H](O)[C@@H]1O,"InChI=1S/C40H44O14/c41-19-30-33(45)35(47)37(49)39(53-30)51-28-10-2-1-9-26(28)24-7-3-5-21(15-24)11-12-22-13-14-29(52-40-38(50)36(48)34(46)31(20-42)54-40)27(17-22)25-8-4-6-23(16-25)18-32(43)44/h1-10,13-17,30-31,33-42,45-50H,11-12,18-20H2,(H,43,44)/t30-,31-,33-,34-,35-,36-,37+,38+,39+,40+/m1/s1",KZAAFYHJWFQYPC-OHYNKQJXSA-N,50422280,CHEMBL2303893,E-selectin,Homo sapiens, 1000000
571813,CNC(=O)c1c(oc2cc(N(CC3CC3)S(C)(=O)=O)c(cc12)-c1cccc(c1)C(O)=O)-c1ccc(F)cc1,"InChI=1S/C28H25FN2O6S/c1-30-27(32)25-22-13-21(18-4-3-5-19(12-18)28(33)34)23(31(38(2,35)36)15-16-6-7-16)14-24(22)37-26(25)17-8-10-20(29)11-9-17/h3-5,8-14,16H,6-7,15H2,1-2H3,(H,30,32)(H,33,34)",DVGUOOBJCHXCRC-UHFFFAOYSA-N,298499,"US10125111, Compound 2002",Genome polyprotein,,
89930,O[C@H]1[C@H]2[C@H](CC(O)=O)C(=O)O[C@@H]3C(COC(=O)c4cc(O)c(O)c(O)c4)O[C@@H](OC(=O)c4cc(O)c(O)c(O)c4)[C@@H](OC(=O)c4cc(O)c(O)c(OC1=O)c24)[C@H]3OC(=O)c1cc(O)c(O)c(O)c1,"InChI=1S/C41H32O27/c42-15-1-10(2-16(43)26(15)51)35(56)62-9-22-31-33(66-36(57)11-3-17(44)27(52)18(45)4-11)34(41(63-22)68-37(58)12-5-19(46)28(53)20(47)6-12)67-38(59)13-7-21(48)29(54)32-25(13)24(30(55)40(61)65-32)14(8-23(49)50)39(60)64-31/h1-7,14,22,24,30-31,33-34,41-48,51-55H,8-9H2,(H,49,50)/t14-,22?,24-,30-,31+,33-,34-,41-/m0/s1",YGVHOSGNOYKRIH-AAYPSMFASA-N,47828,Chebulinic acid::MLS000697665::SMR000445569::cid_16745534,Regulator of G-protein signaling 16,Homo sapiens,
447417,COCCOCCOCCNC(=O)c1cc(Nc2cc(Oc3ccc(NC(=O)Nc4cc(cc(NS(C)(=O)=O)c4OC)C(C)(C)C)c4ccccc34)ccn2)cc(OC)c1,"InChI=1S/C43H52N6O10S/c1-43(2,3)29-24-36(40(56-6)37(25-29)49-60(7,52)53)48-42(51)47-35-12-13-38(34-11-9-8-10-33(34)35)59-31-14-15-44-39(27-31)46-30-22-28(23-32(26-30)55-5)41(50)45-16-17-57-20-21-58-19-18-54-4/h8-15,22-27,49H,16-21H2,1-7H3,(H,44,46)(H,45,50)(H2,47,48,51)",RAYAYIHOCMLVRR-UHFFFAOYSA-N,256505,"US9481648, 3",Potassium voltage-gated channel subfamily H member 2,Homo sapiens,>3000
50023450,CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CCC(O)=O)C(N)=O,"InChI=1S/C36H51N7O8S/c1-22(2)18-27(35(50)41-26(32(38)47)16-17-52-3)40-30(44)21-39-34(49)28(19-23-10-6-4-7-11-23)43-36(51)29(20-24-12-8-5-9-13-24)42-33(48)25(37)14-15-31(45)46/h4-13,22,25-29H,14-21,37H2,1-3H3,(H2,38,47)(H,39,49)(H,40,44)(H,41,50)(H,42,48)(H,43,51)(H,45,46)/t25-,26-,27-,28-,29-/m0/s1",QUPMCECAIWKMMD-ZIUUJSQJSA-N,50016358,4-Amino-4-{1-[1-({[1-(1-carbamoyl-3-methylsulfanyl-propylcarbamoyl)-3-methyl-butylcarbamoyl]-methyl}-carbamoyl)-2-phenyl-ethylcarbamoyl]-2-phenyl-ethylcarbamoyl}-butyric acid::CHEMBL428532,Substance-P receptor,Cavia cutleri,
50579385,Cc1ncnc(C)c1C(=O)N1CCC(C)(CC1)N1CCC(CC1)N1[C@H](CN(CC2CCOCC2)C1=O)c1ccccc1,"InChI=1S/C33H46N6O3/c1-24-30(25(2)35-23-34-24)31(40)36-17-13-33(3,14-18-36)38-15-9-28(10-16-38)39-29(27-7-5-4-6-8-27)22-37(32(39)41)21-26-11-19-42-20-12-26/h4-8,23,26,28-29H,9-22H2,1-3H3/t29-/m1/s1",LEIJVPCQIOHXMZ-GDLZYMKVSA-N,50319452,"(S)-3-(1'-(4,6-dimethylpyrimidine-5-carbonyl)-4'-methyl-1,4'-bipiperidin-4-yl)-4-phenyl-1-((tetrahydro-2H-pyran-4-yl)methyl)imidazolidin-2-one::CHEMBL1085230",C-C chemokine receptor type 5,,>500
50199776,COc1cccc(CNC(=O)c2ccc(Oc3ccc(cc3)C#C[C@]3(O)CN4CCC3CC4)cc2)c1,"InChI=1S/C30H30N2O4/c1-35-28-4-2-3-23(19-28)20-31-29(33)24-7-11-27(12-8-24)36-26-9-5-22(6-10-26)13-16-30(34)21-32-17-14-25(30)15-18-32/h2-12,19,25,34H,14-15,17-18,20-21H2,1H3,(H,31,33)/t30-/m0/s1",GQZCCXOGTHJTFK-PMERELPUSA-N,50026722,CHEMBL1940283,72 kDa type IV collagenase,,<10000
50271050,CC(C)CCC[C@@H](C)[C@H]1CCC2[C@]1(C)CCC[C@]2(C)C[C@H](O)C1=CC(=O)OC1O,"InChI=1S/C25H42O4/c1-16(2)8-6-9-17(3)19-10-11-21-24(4,12-7-13-25(19,21)5)15-20(26)18-14-22(27)29-23(18)28/h14,16-17,19-21,23,26,28H,6-13,15H2,1-5H3/t17-,19-,20+,21?,23?,24-,25-/m1/s1",JSDANYFQRXTLHP-DPUJRHHGSA-N,50147587,"(S)-4-{2-[(3R,7R)-1-((2R,3R)-1,5-Dimethyl-hexyl)-4,7a-dimethyl-octahydro-inden-4-yl]-1-hydroxy-ethyl}-5-hydroxy-5H-furan-2-one::CHEMBL110952",M-phase inducer phosphatase 2,Homo sapiens, 1620
1243730,Fc1ccc(cc1)C(c1ccc(F)cc1)S(=O)CCNCCN1CCN(CCCc2ccccc2)CC1,"InChI=1S/C30H37F2N3OS/c31-28-12-8-26(9-13-28)30(27-10-14-29(32)15-11-27)37(36)24-17-33-16-19-35-22-20-34(21-23-35)18-4-7-25-5-2-1-3-6-25/h1-3,5-6,8-15,30,33H,4,7,16-24H2",RUSNJUCHFQSTSM-UHFFFAOYSA-N,589785,"US11555013, Compound 8b",Sodium-dependent serotonin transporter,Rattus norvegicus,
282650,COC(=O)CCC(C(=O)\C=C\c1ccco1)C(=O)\C=C\c1ccc(O)c(OC(F)(F)F)c1,"InChI=1S/C22H19F3O7/c1-30-21(29)11-7-16(18(27)10-6-15-3-2-12-31-15)17(26)8-4-14-5-9-19(28)20(13-14)32-22(23,24)25/h2-6,8-10,12-13,16,28H,7,11H2,1H3/b8-4+,10-6+",GEWHBCNCXGBFPA-GZFKCFCKSA-N,145861,"US8956589, 30",Amyloid-beta precursor protein,Homo sapiens, 650
51169640,COc1ccc(cc1)S(=O)(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CN(C(=O)O1)c1cccc(c1)C(C)=O,"InChI=1S/C33H39N3O8S/c1-22(2)19-35(45(41,42)28-15-13-27(43-4)14-16-28)20-30(38)29(17-24-9-6-5-7-10-24)34-32(39)31-21-36(33(40)44-31)26-12-8-11-25(18-26)23(3)37/h5-16,18,22,29-31,38H,17,19-21H2,1-4H3,(H,34,39)/t29-,30+,31-/m0/s1",SLMZIXVIEWNEAM-YPKYBTACSA-N,12877,"(5S)-3-(3-Acetylphenyl)-N-[(1S,2R)-1-benzyl-2-hydroxy-3-[isobutyl[(4-methoxyphenyl)sulfonyl]amino]propyl]-2-oxooxazolidine-5-carboxamide::(5S)-3-(3-acetylphenyl)-N-[(2S,3R)-3-hydroxy-4-[(4-methoxybenzene)(2-methylpropyl)sulfonamido]-1-phenylbutan-2-yl]-2-oxo-1,3-oxazolidine-5-carboxamide::N-Aryl-oxazolidinone-5-carboxamide Analogue 21e",HIV-1 protease,,
511483,COc1cccc(OC)c1-n1c(NS(=O)(=O)[C@@H](C)[C@@H](OC(C)C)c2cnc(C)cn2)nnc1-c1cccc(C)n1,"InChI=1S/C27H33N7O5S/c1-16(2)39-25(21-15-28-18(4)14-29-21)19(5)40(35,36)33-27-32-31-26(20-11-8-10-17(3)30-20)34(27)24-22(37-6)12-9-13-23(24)38-7/h8-16,19,25H,1-7H3,(H,32,33)/t19-,25+/m0/s1",FMVCZUJFTVBQNZ-UQBPGWFLSA-N,270256,"(1S,2S)-N-(4-(2,6-dimethoxyphenyl)-5-(6-methyl-2-pyridinyl)-4H-1,2,4-triazol-3-yl)-1-(1-methylethoxy)-1-(5-methyl-2-pyrazinyl)-2-propanesulfonamide, (1R,2R)-N-(4-(2,6-dimethoxyphenyl)-5-(6-methyl-2-pyridinyl)-4H-1,2,4-triazol-3-yl)-1-(1-methylethoxy)-1-(5-methyl-2-pyrazinyl)-2-propanesulfonamide::US10058550, Example 824.0",Apelin receptor,Homo sapiens,
50693275,CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O,"InChI=1S/C28H39N7O3/c1-5-22-27(37)34(3)23-17-29-28(32-25(23)35(22)20-8-6-7-9-20)31-21-11-10-18(16-24(21)38-4)26(36)30-19-12-14-33(2)15-13-19/h10-11,16-17,19-20,22H,5-9,12-15H2,1-4H3,(H,30,36)(H,29,31,32)/t22-/m1/s1",XQVVPGYIWAGRNI-JOCHJYFZSA-N,25121,"4-{[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl]amino}-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide::BI 2536::CHEMBL513909::US10450297, Example 300::US8598172, 5",Cyclin-dependent kinase 9,Homo sapiens,
1245109,CC1(CCCCC1)[C@H](N)C(=O)N1Cc2ccc(F)cc2C1,"InChI=1S/C17H23FN2O/c1-17(7-3-2-4-8-17)15(19)16(21)20-10-12-5-6-14(18)9-13(12)11-20/h5-6,9,15H,2-4,7-8,10-11,19H2,1H3/t15-/m1/s1",HTMJAHPTKGPGQR-OAHLLOKOSA-N,514540,"US11096924, DASH-inhibitors 5320::US11583516, Cmpd ID 5320",Dipeptidyl peptidase 8,Homo sapiens, 1.90
797688,CC(C)(C)OC(=O)NC(C(=O)N[C@@H](c1ccc(Cl)cc1)c1ncc(Cl)cc1F)c1ccccc1,"InChI=1S/C25H24Cl2FN3O3/c1-25(2,3)34-24(33)31-21(15-7-5-4-6-8-15)23(32)30-20(16-9-11-17(26)12-10-16)22-19(28)13-18(27)14-29-22/h4-14,20-21H,1-3H3,(H,30,32)(H,31,33)/t20-,21?/m0/s1",HORDTCVRBHRZPF-BGERDNNASA-N,399413,"US10323029, Generic formula 52734 IB::US11034691, CYM generic formula 52734 IB",Sphingosine 1-phosphate receptor 3,Homo sapiens, 1500
698846,O[C@@H]1CCN(C1)C(=O)c1cnn2ccc(nc12)N1CCC[C@@H]1c1cc(F)ccc1F,"InChI=1S/C21H21F2N5O2/c22-13-3-4-17(23)15(10-13)18-2-1-7-27(18)19-6-9-28-20(25-19)16(11-24-28)21(30)26-8-5-14(29)12-26/h3-4,6,9-11,14,18,29H,1-2,5,7-8,12H2/t14-,18-/m1/s1",DSYTUISCOWQTPC-RDTXWAMCSA-N,127646,"US10251889, Example 19::US10758542, Example 19::US8791123, 19::US9782415, Example 19::US9796724, Example 19",Tyrosine-protein kinase JAK2 [808-1132],,>1000
943214,Cc1[nH]c2c(c(nn2c(=O)c1-c1nnc(o1)C1CCCCN1S(C)(=O)=O)C(F)(F)F)-c1ccccc1,,,457609,"US10738056, Compound D1056",Cyclic GMP-AMP synthase [155-522],,<20
738494,Cc1ccc(NC(=O)c2ccnc(c2)C(F)(F)F)cc1-c1cc(nc(NCCO)c1F)N1CCOCC1,"InChI=1S/C25H25F4N5O3/c1-15-2-3-17(32-24(36)16-4-5-30-20(12-16)25(27,28)29)13-18(15)19-14-21(34-7-10-37-11-8-34)33-23(22(19)26)31-6-9-35/h2-5,12-14,35H,6-11H2,1H3,(H,31,33)(H,32,36)",HEOYBSUVRGFOTO-UHFFFAOYSA-N,87975,"US10245267, Example 1006::US10709712, Example 1006::US9694016, 1006",Serine/threonine-protein kinase B-raf [V600E],, 3.97
50854151,CNCc1cc(ccc1Oc1ccc(Cl)c(Cl)c1)C(=O)N1CCN(CC1)C1CCC1,"InChI=1S/C23H27Cl2N3O2/c1-26-15-17-13-16(5-8-22(17)30-19-6-7-20(24)21(25)14-19)23(29)28-11-9-27(10-12-28)18-3-2-4-18/h5-8,13-14,18,26H,2-4,9-12,15H2,1H3",ODHBRFGOHMIIEN-UHFFFAOYSA-N,50371278,CHEMBL258153,Sodium-dependent serotonin transporter,Rattus norvegicus,
51144452,Cc1ccc(CN(c2ccc(cc2)C(O)=O)S(=O)(=O)c2ccc(cc2)-c2ccccc2)cc1,"InChI=1S/C27H23NO4S/c1-20-7-9-21(10-8-20)19-28(25-15-11-24(12-16-25)27(29)30)33(31,32)26-17-13-23(14-18-26)22-5-3-2-4-6-22/h2-18H,19H2,1H3,(H,29,30)",XSPJMOWUFDMTRC-UHFFFAOYSA-N,50468876,CHEMBL4290120,Polyunsaturated fatty acid 5-lipoxygenase,Homo sapiens, 1000
619499,CC[C@H](C)NC(=O)c1c[nH]c2ncc(NC3CCN(CC3)C(=O)C=C)nc12,,,316789,"2-[(1-acryloylpiperidin-4-yl)amino]-N-[(2S)-butan-2-yl]-5H-pyrrolo[2,3-b]pyrazine-7-carboxamide::US11111242, Example 285::US9617258, Example 285",Tyrosine-protein kinase JAK3,Homo sapiens, 0.300
50270303,CCC(C)Oc1cccc(c1)N(Cc1cccnc1)S(=O)(=O)CC(F)(F)F,"InChI=1S/C18H21F3N2O3S/c1-3-14(2)26-17-8-4-7-16(10-17)23(12-15-6-5-9-22-11-15)27(24,25)13-18(19,20)21/h4-11,14H,3,12-13H2,1-2H3",WZUXJHOWBDMZJG-UHFFFAOYSA-N,50147137,"2,2,2-Trifluoro-ethanesulfonic acid (3-sec-butoxy-phenyl)-pyridin-3-ylmethyl-amide::CHEMBL322588",Metabotropic glutamate receptor 2,,
50139064,C[C@@H]1CC[C@@]23CC[C@]4(C)[C@](OC2=O)(C=C[C@@H]2[C@@]5(C)C[C@@H](O)[C@H](O)C(=C)[C@@H]5CC[C@@]42C)[C@@H]3[C@H]1C,"InChI=1S/C29H42O4/c1-16-7-11-28-14-13-27(6)26(5)10-8-19-18(3)22(31)20(30)15-25(19,4)21(26)9-12-29(27,33-24(28)32)23(28)17(16)2/h9,12,16-17,19-23,30-31H,3,7-8,10-11,13-15H2,1-2,4-6H3/t16-,17+,19+,20-,21-,22-,23-,25+,26-,27+,28+,29+/m1/s1",ATPPQNYORHPCJE-OUZPOPPESA-N,50250330,"2alpha,3beta-dihydroxy-24-nor-urs-4(23),11-dien-28,13beta-olide::CHEMBL492155",Sterol O-acyltransferase 1,Rattus norvegicus, 154000
51145392,CC(C)c1cc2c(cn1)oc1nc(N)c(cc1c2=O)C(O)=O,"InChI=1S/C15H13N3O4/c1-6(2)10-4-7-11(5-17-10)22-14-8(12(7)19)3-9(15(20)21)13(16)18-14/h3-6H,1-2H3,(H2,16,18)(H,20,21)",HDNSOCZDMSVBGH-UHFFFAOYSA-N,357899,"US10214536, Compound 117",Inhibitor of nuclear factor kappa-B kinase subunit epsilon,Homo sapiens, 3090
51084465,Cc1csc(NC(=O)N2CCC(CC2)N2CCc3ccccc23)n1,"InChI=1S/C18H22N4OS/c1-13-12-24-17(19-13)20-18(23)21-9-7-15(8-10-21)22-11-6-14-4-2-3-5-16(14)22/h2-5,12,15H,6-11H2,1H3,(H,19,20,23)",RDYWYQCHUFFHQP-UHFFFAOYSA-N,50443724,"CHEMBL3093866::US9238658, 3",Acyl-CoA desaturase 1,, 153
51370060,OC(=O)c1ccc2c(n[nH]c2c1)N1CCC(F)(COCc2c(onc2-c2c(Cl)cccc2Cl)C2CC2)CC1,"InChI=1S/C27H25Cl2FN4O4/c28-19-2-1-3-20(29)22(19)23-18(24(38-33-23)15-4-5-15)13-37-14-27(30)8-10-34(11-9-27)25-17-7-6-16(26(35)36)12-21(17)31-32-25/h1-3,6-7,12,15H,4-5,8-11,13-14H2,(H,31,32)(H,35,36)",VRZWWESCFAYFJJ-UHFFFAOYSA-N,50553958,CHEMBL4777088,Bile acid receptor,Homo sapiens,
953162,CNC(=O)c1ccccc1Nc1nc(Nc2ccccc2C)ncc1Cl,"InChI=1S/C19H18ClN5O/c1-12-7-3-5-9-15(12)24-19-22-11-14(20)17(25-19)23-16-10-6-4-8-13(16)18(26)21-2/h3-11H,1-2H3,(H,21,26)(H2,22,23,24,25)",OYBLVJBZFCEUNG-UHFFFAOYSA-N,379152,"2-(5-Chloro-2-(o-tolylamino)pyrimidin-4-ylamino)-N-methylbenzamide::US10266549, Example 53::US10774092, Example 53",Serine/threonine-protein kinase ULK1,Homo sapiens,>2000
50851398,CC(C)Cn1c2CN(CCc2nc1C(F)(F)F)C(=O)C[C@H](N)Cc1cc(F)ccc1F,"InChI=1S/C21H25F5N4O/c1-12(2)10-30-18-11-29(6-5-17(18)28-20(30)21(24,25)26)19(31)9-15(27)8-13-7-14(22)3-4-16(13)23/h3-4,7,12,15H,5-6,8-11,27H2,1-2H3/t15-/m1/s1",IEVRTWAYWAATLW-OAHLLOKOSA-N,50222478,"(R)-3-amino-4-(2,5-difluorophenyl)-1-(3-isobutyl-2-(trifluoromethyl)-6,7-dihydro-3H-imidazo[4,5-c]pyridin-5(4H)-yl)butan-1-one::CHEMBL429829",Dipeptidyl peptidase 8,Homo sapiens,>100000
964397,Cc1c(Nc2nccc3cc(CNCCO)cnc23)cccc1-c1cccc(-c2nc3cc(CN4CCCC[C@H]4C(O)=O)cc(Cl)c3o2)c1C,"InChI=1S/C39H39ClN6O4/c1-23-28(29-8-6-10-32(24(29)2)44-37-35-27(12-13-42-37)17-26(21-43-35)20-41-14-16-47)7-5-9-30(23)38-45-33-19-25(18-31(40)36(33)50-38)22-46-15-4-3-11-34(46)39(48)49/h5-10,12-13,17-19,21,34,41,47H,3-4,11,14-16,20,22H2,1-2H3,(H,42,44)(H,48,49)/t34-/m0/s1",NNVJIZMTNRSGJB-UMSFTDKQSA-N,395390,"(S)-1-((7-chloro-2-(3&#8242;-((3-(((2-hydroxyethyl)amino)methyl)-1,7-naphthyridin-8-yl)amino)-2,2&#8242;-dimethyl-[1,1&#8242;-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-2-carboxylic acid::US10308644, Example 3::US10800768, Example 3::US11339149, Example 3",Programmed cell death 1 ligand 1 [19-238]/protein 1 [25-167],, 3000
51009551,C=COc1cncc(c1)N1CCCNCC1,"InChI=1S/C12H17N3O/c1-2-16-12-8-11(9-14-10-12)15-6-3-4-13-5-7-15/h2,8-10,13H,1,3-7H2",DWHQCXVYIKBENZ-UHFFFAOYSA-N,50088450,"1-(5-(vinyloxy)pyridin-3-yl)-1,4-diazepane::1-(5-Vinyloxy-pyridin-3-yl)-[1,4]diazepane::CHEMBL71228",Neuronal acetylcholine receptor subunit alpha-4,Homo sapiens, 5.01
688796,Nc1ncnc2n(Cc3cc4ccccc4nc3-c3ccccc3)nc(-c3cnn(CCO)c3)c12,"InChI=1S/C26H22N8O/c27-25-22-24(20-13-30-33(14-20)10-11-35)32-34(26(22)29-16-28-25)15-19-12-18-8-4-5-9-21(18)31-23(19)17-6-2-1-3-7-17/h1-9,12-14,16,35H,10-11,15H2,(H2,27,28,29)",ZRMYOWNHQGRHHE-UHFFFAOYSA-N,348260,"US9790228, Compound 179",Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta,Homo sapiens,>1000
50759508,Cn1cnc2c(N)nc(Cl)nc12,"InChI=1S/C6H6ClN5/c1-12-2-9-3-4(8)10-6(7)11-5(3)12/h2H,1H3,(H2,8,10,11)",XBMKMJLOOAHOKH-UHFFFAOYSA-N,50009702,2-Chloro-9-methyl-9H-purin-6-ylamine::CHEMBL317398,Heat shock protein HSP 90-alpha,Homo sapiens,>1250000
352857,C(Cc1ccccc1)N[C@H]1CC[C@H](CC1)c1nnn2cnc3[nH]ccc3c12,,,198329,"US9216999, 135a::US9556187, Example 135a",Tyrosine-protein kinase JAK3,Homo sapiens,>1000
1153587,CSc1cc(cc2nc(C)n(CCOc3ccc(Cl)cc3-c3ccnc4c(csc34)C(O)=O)c(=O)c12)C(F)(F)F,"InChI=1S/C27H19ClF3N3O4S2/c1-13-33-19-9-14(27(29,30)31)10-21(39-2)22(19)25(35)34(13)7-8-38-20-4-3-15(28)11-17(20)16-5-6-32-23-18(26(36)37)12-40-24(16)23/h3-6,9-12H,7-8H2,1-2H3,(H,36,37)",VCHXTNRHMDZRQD-UHFFFAOYSA-N,544738,"US11286268, Compound 222",Eukaryotic translation initiation factor 4E-binding protein 1,Homo sapiens, 67.4
580091,CC(C)(C)[C@H]1CN(Cc2c(C(N)=O)c(nn12)-c1ccc(F)c(Cl)c1)C(=O)Nc1ccc(cc1)C#N,"InChI=1S/C25H24ClFN6O2/c1-25(2,3)20-13-32(24(35)30-16-7-4-14(11-28)5-8-16)12-19-21(23(29)34)22(31-33(19)20)15-6-9-18(27)17(26)10-15/h4-10,20H,12-13H2,1-3H3,(H2,29,34)(H,30,35)/t20-/m1/s1",LFGXXJKDRCMQAG-HXUWFJFHSA-N,302850,"7-(tert-Butyl)-2-(3-chloro-4-fluorophenyl)-N-(4-cyanophenyl)-6,7-dihydropyrazolo[1,5-a]pyrazine-3,5(4H)-dicarboxamide::US9598423, Example A80",Casein kinase I isoform delta,,<10
50819607,OP(O)(=O)COCC(COCP(O)(O)=O)Cn1cnc2c1nc[nH]c2=O,"InChI=1S/C11H18N4O9P2/c16-11-9-10(12-4-13-11)15(5-14-9)1-8(2-23-6-25(17,18)19)3-24-7-26(20,21)22/h4-5,8H,1-3,6-7H2,(H,12,13,16)(H2,17,18,19)(H2,20,21,22)",UAIJWVVEDWVBMI-UHFFFAOYSA-N,50427809,CHEMBL2325753,Hypoxanthine-guanine phosphoribosyltransferase,Homo sapiens,
50971895,CN1CCOC(O)(C1)c1ccc(\C=C\c2ccccc2)cc1,"InChI=1S/C19H21NO2/c1-20-13-14-22-19(21,15-20)18-11-9-17(10-12-18)8-7-16-5-3-2-4-6-16/h2-12,21H,13-15H2,1H3/b8-7+",BNMKCGBRCPCKRC-BQYQJAHWSA-N,50276759,CHEMBL4161111,Squalene synthase,Rattus norvegicus, 7000
51344821,CNC(=O)c1cc(cn(Cc2cccnc2)c1=O)C(=O)NC1CCC1,"InChI=1S/C18H20N4O3/c1-19-17(24)15-8-13(16(23)21-14-5-2-6-14)11-22(18(15)25)10-12-4-3-7-20-9-12/h3-4,7-9,11,14H,2,5-6,10H2,1H3,(H,19,24)(H,21,23)",JPKQWGJWWWXQCQ-UHFFFAOYSA-N,50544317,CHEMBL4638058,Bromodomain-containing protein 4,, 1000
51396174,CN(CCC=C(c1sccc1C)c1sccc1C)[C@H](CO)C(=O)NCc1ccc(Cl)cc1,"InChI=1S/C25H29ClN2O2S2/c1-17-10-13-31-23(17)21(24-18(2)11-14-32-24)5-4-12-28(3)22(16-29)25(30)27-15-19-6-8-20(26)9-7-19/h5-11,13-14,22,29H,4,12,15-16H2,1-3H3,(H,27,30)/t22-/m1/s1",HABCOXFZLVZQIL-JOCHJYFZSA-N,50564007,CHEMBL4795631,Sodium- and chloride-dependent GABA transporter 1,Rattus norvegicus, 20417
1121118,C[C@@H]1Cc2cnc(NC3Cc4ccccc4C3)nc2CN1C(=O)[C@H]1CCN(C)C[C@@H]1c1ccccc1,"InChI=1S/C30H35N5O/c1-20-14-24-17-31-30(32-25-15-22-10-6-7-11-23(22)16-25)33-28(24)19-35(20)29(36)26-12-13-34(2)18-27(26)21-8-4-3-5-9-21/h3-11,17,20,25-27H,12-16,18-19H2,1-2H3,(H,31,32,33)/t20-,26+,27-/m1/s1",OOYQNSZDPNRUJS-JAMKYWPSSA-N,530280,"WO2022064009, Compound 29",CDK-activating kinase assembly factor MAT1/Cyclin-H/Cyclin-dependent kinase 7,Homo sapiens, 9.77
139345,Clc1cc2sc(=O)oc2cc1OC(=O)NC1CCCCC1,"InChI=1S/C14H14ClNO4S/c15-9-6-12-11(20-14(18)21-12)7-10(9)19-13(17)16-8-4-2-1-3-5-8/h6-8H,1-5H2,(H,16,17)",ZDMZAAOIAXENOR-UHFFFAOYSA-N,76189,"(5-chloranyl-2-oxidanylidene-1,3-benzoxathiol-6-yl) N-cyclohexylcarbamate::(5-chloro-2-oxo-1,3-benzoxathiol-6-yl) N-cyclohexylcarbamate::5-chloro-2-oxo-1,3-benzoxathiol-6-yl cyclohexylcarbamate::MLS000766725::N-cyclohexylcarbamic acid (5-chloro-2-keto-1,3-benzoxathiol-6-yl) ester::N-cyclohexylcarbamic acid (5-chloro-2-oxo-1,3-benzoxathiol-6-yl) ester::SMR000339621::cid_691373","Alkaline phosphatase, germ cell type",Homo sapiens, 5950
50625912,CN1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1,"InChI=1S/C19H21N5O2/c1-22-9-11-23(12-10-22)13-17(25)24-16-7-3-2-5-14(16)19(26)21-15-6-4-8-20-18(15)24/h2-8H,9-13H2,1H3,(H,21,26)",RMHMFHUVIITRHF-UHFFFAOYSA-N,39341,"11-[(4-methylpiperazin-1-yl)acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one::11-[2-(4-methyl-1-piperazinyl)-1-oxoethyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one;hydrochloride::11-[2-(4-methylpiperazin-1-yl)acetyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one;hydrochloride::11-[2-(4-methylpiperazin-1-yl)ethanoyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one;hydrochloride::11-[2-(4-methylpiperazino)acetyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one;hydrochloride::CHEMBL9967::MLS000069702::PIRENZEPINE::PIRENZEPINE DIHYDROCHLORIDE::SMR000058502::cid_185248",Muscarinic acetylcholine receptor M1/M2/M3/M4/M5,Rattus, 240
50270344,CC(C(=O)NCc1ccc(nc1C=C(C)C)C(F)(F)F)c1ccc(NS(C)(=O)=O)c(F)c1,"InChI=1S/C21H23F4N3O3S/c1-12(2)9-18-15(6-8-19(27-18)21(23,24)25)11-26-20(29)13(3)14-5-7-17(16(22)10-14)28-32(4,30)31/h5-10,13,28H,11H2,1-4H3,(H,26,29)",BNMYQTDYWXTYKD-UHFFFAOYSA-N,50046290,CHEMBL3314384,Transient receptor potential cation channel subfamily V member 1,Homo sapiens,
312037,CC(C)C1N(CCn2c1nc1ccc(cc21)S(C)(=O)=O)c1ncc(CO)c(n1)C(F)(F)F,"InChI=1S/C20H22F3N5O3S/c1-11(2)16-18-25-14-5-4-13(32(3,30)31)8-15(14)27(18)6-7-28(16)19-24-9-12(10-29)17(26-19)20(21,22)23/h4-5,8-9,11,16,29H,6-7,10H2,1-3H3",MWSOCMMZIFOCRI-UHFFFAOYSA-N,168075,"US9073931, E4",Oxysterols receptor LXR-beta,,
50561642,Oc1cccc(c1)-c1c(nn2c(ccnc12)-c1ccc(N[C@H]2CN3CCC2CC3)cc1)-c1ccncc1,"InChI=1S/C30H28N6O/c37-25-3-1-2-23(18-25)28-29(22-8-13-31-14-9-22)34-36-27(10-15-32-30(28)36)21-4-6-24(7-5-21)33-26-19-35-16-11-20(26)12-17-35/h1-10,13-15,18,20,26,33,37H,11-12,16-17,19H2/t26-/m0/s1",GMJUHMVIMKBELC-SANMLTNESA-N,50311983,"(R)-3-(2-(pyridin-4-yl)-7-(4-(quinuclidin-3-ylamino)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)phenol::CHEMBL1086871",Serine/threonine-protein kinase B-raf,Homo sapiens, 1
50040885,CC(C)(C(=O)OC1(C)C2CC3CC(C2)CC1C3)c1cccnc1,"InChI=1S/C20H27NO2/c1-19(2,15-5-4-6-21-12-15)18(22)23-20(3)16-8-13-7-14(10-16)11-17(20)9-13/h4-6,12-14,16-17H,7-11H2,1-3H3",NHPHHPFRHSBYCP-UHFFFAOYSA-N,50029230,2-Methyl-2-pyridin-3-yl-propionic acid 2-methyl-adamantan-2-yl ester::CHEMBL3084923,"Steroid 17-alpha-hydroxylase/17,20 lyase",Homo sapiens, 13
50998740,CS(=O)(=O)c1ccc(cc1)-n1cc(nc1-c1ccc(Cl)cc1)C#N,"InChI=1S/C17H12ClN3O2S/c1-24(22,23)16-8-6-15(7-9-16)21-11-14(10-19)20-17(21)12-2-4-13(18)5-3-12/h2-9,11H,1H3",UYBKGLYLRCILLW-UHFFFAOYSA-N,50057949,2-(4-Chloro-phenyl)-1-(4-methanesulfonyl-phenyl)-1H-imidazole-4-carbonitrile::CHEMBL415895,Prostaglandin G/H synthase 2,, 229
244294,C[C@@H](Nc1ncnc2CCN(Cc12)c1ccc(C)cn1)c1ccc(F)cc1,"InChI=1S/C21H22FN5/c1-14-3-8-20(23-11-14)27-10-9-19-18(12-27)21(25-13-24-19)26-15(2)16-4-6-17(22)7-5-16/h3-8,11,13,15H,9-10,12H2,1-2H3,(H,24,25,26)/t15-/m1/s1",DUPYPBQTFOKCSC-OAHLLOKOSA-N,118154,"US8653091, 49",P2X purinoceptor 3,Homo sapiens, 19
51037548,Nc1nc(N2CCN(CC2)C(=O)Nc2cccnc2)c2ncsc2n1,"InChI=1S/C15H16N8OS/c16-14-20-12(11-13(21-14)25-9-18-11)22-4-6-23(7-5-22)15(24)19-10-2-1-3-17-8-10/h1-3,8-9H,4-7H2,(H,19,24)(H2,16,20,21)",FLEPMDMQZVIRIZ-UHFFFAOYSA-N,50457858,CHEMBL4218639,Phosphatidylinositol 4-kinase beta,, 3387
290960,COc1cc(ccn1)-c1ccc2sc(nc2c1)C(C(=O)NCCS(N)(=O)=O)S(C)(=O)=O,"InChI=1S/C18H20N4O6S3/c1-28-15-10-12(5-6-20-15)11-3-4-14-13(9-11)22-18(29-14)16(30(2,24)25)17(23)21-7-8-31(19,26)27/h3-6,9-10,16H,7-8H2,1-2H3,(H,21,23)(H2,19,26,27)",XEINGMYRSNNYPB-UHFFFAOYSA-N,151292,"US8987314, B88",Endothelial lipase,Homo sapiens, 0.5
51333251,Cc1nccc2-c3ccc(Br)cc3NC(C)(C)c12,"InChI=1S/C15H15BrN2/c1-9-14-12(6-7-17-9)11-5-4-10(16)8-13(11)18-15(14,2)3/h4-8,18H,1-3H3",YBGLIPYAJPOYAD-UHFFFAOYSA-N,50539742,CHEMBL4642292,Delta-type opioid receptor,Homo sapiens,
50220027,CO[C@H](C)C(=O)N[C@@H](Cc1ccc2OCOc2c1)[C@H](O)CN[C@H]1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc12,"InChI=1S/C31H43N3O6/c1-19(37-5)28(36)34-23(12-20-7-8-26-27(13-20)39-18-38-26)25(35)17-32-24-15-31(9-6-10-31)40-29-22(24)11-21(16-33-29)14-30(2,3)4/h7-8,11,13,16,19,23-25,32,35H,6,9-10,12,14-15,17-18H2,1-5H3,(H,34,36)/t19-,23+,24+,25-/m1/s1",OMMVFRZSBCRMQD-LJYZBVLISA-N,50397678,CHEMBL2181880,Beta-secretase 1,Homo sapiens, 26
50345529,COC(=O)CCC[C@H]1CCC[C@](C1)(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1,"InChI=1S/C23H25ClF2O4S/c1-30-22(27)6-2-4-16-5-3-13-23(15-16,20-14-18(25)9-12-21(20)26)31(28,29)19-10-7-17(24)8-11-19/h7-12,14,16H,2-6,13,15H2,1H3/t16-,23-/m0/s1",AFKBLOZTLRRCHH-HJPURHCSSA-N,50186582,"CHEMBL425060::trans-methyl 4-(3-(4-chlorophenylsulfonyl)-3-(2,5-difluorophenyl)cyclohexyl)butanoate",Gamma-secretase subunit APH-1A/Gamma-secretase subunit APH-1B/Gamma-secretase subunit PEN-2/Nicastrin/Presenilin-1/Presenilin-2,Homo sapiens, 376
1225699,OC(=O)c1nn[nH]c1Sc1cccc(c1)C#CCC1CC1,"InChI=1S/C15H13N3O2S/c19-15(20)13-14(17-18-16-13)21-12-6-2-5-11(9-12)4-1-3-10-7-8-10/h2,5-6,9-10H,3,7-8H2,(H,19,20)(H,16,17,18)",DDVQEKIJCULHIT-UHFFFAOYSA-N,581260,"5-(3-(3-cyclopropylprop-1-  ynyl)phenylthio)-1H-1,2,3-  triazole-4-carboxylic acid::US11504367, Example 356",2-Hydroxyacid oxidase 1,Homo sapiens, 6.00
51000399,NC1=C(C#N)C(=N)CC2Oc3cc4OCCOc4cc3CC12,"InChI=1S/C16H15N3O3/c17-7-10-11(18)5-13-9(16(10)19)3-8-4-14-15(6-12(8)22-13)21-2-1-20-14/h4,6,9,13,18H,1-3,5,19H2",RJQQQHQJELURRA-UHFFFAOYSA-N,50162646,"8,10-Diamino-2,3,10a,11-tetrahydro-6aH-1,4,6-trioxa-naphthacene-9-carbonitrile::CHEMBL181069",MAP kinase-activated protein kinase 2,Homo sapiens, 55700
695715,Fc1ccc2N(CC(=O)Nc3scc(Br)c3-c3ncn[nH]3)C(=O)CCc2c1,"InChI=1S/C17H13BrFN5O2S/c18-11-7-27-17(15(11)16-20-8-21-23-16)22-13(25)6-24-12-3-2-10(19)5-9(12)1-4-14(24)26/h2-3,5,7-8H,1,4,6H2,(H,22,25)(H,20,21,23)",AHZNJVVIJQWSOW-UHFFFAOYSA-N,351597,"N-(4-bromo-3-(1H-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(6-fluoro-2-oxo-3,4-dihydroquinolin-1(2H)-yl)acetamide::US9796706, Compound 41",Mitogen-activated protein kinase 8,Homo sapiens,<100
843065,C[C@@H](NC(=O)c1cc(OC2CCN(CC(F)(F)F)CC2)cc(c1)-c1ncc(C)s1)c1cnc(C)cn1,"InChI=1S/C25H28F3N5O2S/c1-15-11-30-22(13-29-15)17(3)32-23(34)18-8-19(24-31-12-16(2)36-24)10-21(9-18)35-20-4-6-33(7-5-20)14-25(26,27)28/h8-13,17,20H,4-7,14H2,1-3H3,(H,32,34)/t17-/m1/s1",VOYLEHBGAUIAGN-QGZVFWFLSA-N,320146,"N-[(1R)-1-(5- methylpyrazin-2- yl)ethyl]-3-(5- methyl-1,3- thiazol-2-yl)-5-{[1- (2,2,2- trifluoroethyl) piperidin-4- yl]oxy}benzamide::US10174016, Example 313::US10202369, Example 313::US10472354, Example 313",P2X purinoceptor 2/3,Homo sapiens, 200
50166449,CCOC(=O)N1CCN(CC1)C(C)c1ccc(cc1)S(=O)(=O)c1ccccc1,"InChI=1S/C21H26N2O4S/c1-3-27-21(24)23-15-13-22(14-16-23)17(2)18-9-11-20(12-10-18)28(25,26)19-7-5-4-6-8-19/h4-12,17H,3,13-16H2,1-2H3",RRQQJDVDDCNRCT-UHFFFAOYSA-N,50092991,4-[1-(4-Benzenesulfonyl-phenyl)-ethyl]-piperazine-1-carboxylic acid ethyl ester::CHEMBL73145,Muscarinic acetylcholine receptor M2,,
50279218,N#Cc1cccc(c1)-c1ccn(c1)-c1ccccn1,"InChI=1S/C16H11N3/c17-11-13-4-3-5-14(10-13)15-7-9-19(12-15)16-6-1-2-8-18-16/h1-10,12H",GXXRNNGNWUNPKZ-UHFFFAOYSA-N,50151899,3-(1-Pyridin-2-yl-1H-pyrrol-3-yl)-benzonitrile::CHEMBL361120,Metabotropic glutamate receptor 5,Rattus norvegicus,
1098410,C[C@@H]1CN(Cc2cccc(c2C)C(F)(F)F)CCN1C(=O)Oc1cc(cnc1C)C#N,"InChI=1S/C22H23F3N4O2/c1-14-12-28(13-18-5-4-6-19(15(18)2)22(23,24)25)7-8-29(14)21(30)31-20-9-17(10-26)11-27-16(20)3/h4-6,9,11,14H,7-8,12-13H2,1-3H3/t14-/m1/s1",HOKZZMAVGNYNDS-CQSZACIVSA-N,520124,"US11129827, Example 21",Fatty-acid amide hydrolase 1,,<50000
848900,Cc1ccc(cc1-c1cnc2c(N)ncnn12)S(=O)(=O)NC12CCC(F)(CC1)CC2,"InChI=1S/C20H23FN6O2S/c1-13-2-3-14(10-15(13)16-11-23-18-17(22)24-12-25-27(16)18)30(28,29)26-20-7-4-19(21,5-8-20)6-9-20/h2-3,10-12,26H,4-9H2,1H3,(H2,22,24,25)",OOHBTUJHQXCDQM-UHFFFAOYSA-N,421145,"3-(4-aminoimidazo[2,1-f][1,2,4]triazin-7-yl)-N-(4- fluorobicyclo[2.2.2]octan-1-yl)-4- methylbenzenesulfonamide::US10479795, Example 188","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform",Homo sapiens,<100
50606946,Cc1cc2[C@H](CC3(CCN(CC3)C(=O)[C@@H]3CN(C[C@H]3c3ccc(F)cc3F)C3CCOCC3)c2cc1Cl)C(C)(C)c1ncnn1C,"InChI=1S/C36H44ClF2N5O2/c1-22-15-26-29(17-31(22)37)36(18-30(26)35(2,3)34-40-21-41-42(34)4)9-11-43(12-10-36)33(45)28-20-44(24-7-13-46-14-8-24)19-27(28)25-6-5-23(38)16-32(25)39/h5-6,15-17,21,24,27-28,30H,7-14,18-20H2,1-4H3/t27-,28+,30-/m0/s1",YOVYFFNNBORHTK-LXQNXJGFSA-N,50329958,"(6-chloro-5-methyl-3-(2-(1-methyl-1H-1,2,4-triazol-5-yl)propan-2-yl)-2,3-dihydrospiro[indene-1,4'-piperidine]-1'-yl)((3S,4R)-4-(2,4-difluorophenyl)-1-(tetrahydro-2H-pyran-4-yl)pyrrolidin-3-yl)methanone::CHEMBL1269575",Melanocortin receptor 4,, 0.84
727704,CNC1CCN(C1)c1cc(ccc1Nc1ccc(c(F)c1)S(=O)(=O)Nc1cscn1)C(F)(F)F,"InChI=1S/C21H21F4N5O2S2/c1-26-15-6-7-30(10-15)18-8-13(21(23,24)25)2-4-17(18)28-14-3-5-19(16(22)9-14)34(31,32)29-20-11-33-12-27-20/h2-5,8-9,11-12,15,26,28-29H,6-7,10H2,1H3",YZHSBAJGLZIGBN-UHFFFAOYSA-N,368255,"US10227338, Example 37",Sodium channel protein type 5 subunit alpha,,>10000
50672824,CCCN(CCC)C(=O)CCc1c([nH]c2ccc(Cl)cc12)-c1ccc(Cl)cc1,"InChI=1S/C23H26Cl2N2O/c1-3-13-27(14-4-2)22(28)12-10-19-20-15-18(25)9-11-21(20)26-23(19)16-5-7-17(24)8-6-16/h5-9,11,15,26H,3-4,10,12-14H2,1-2H3",CEQBAMJVNWVQBR-UHFFFAOYSA-N,50045873,"3-[5-Chloro-2-(4-chloro-phenyl)-1H-indol-3-yl]-N,N-dipropyl-propionamide::CHEMBL100377",Delta-type opioid receptor/Kappa-type opioid receptor/Mu-type opioid receptor/Sigma non-opioid intracellular receptor 1,Rattus,>1000
50919,Nc1c(N2CCc3ccc(CNC(=O)c4nc5sc6CS(=O)(=O)CCc6c5c(=O)[nH]4)cc3C2)c(=O)c1=O,"InChI=1S/C24H21N5O6S2/c25-17-18(20(31)19(17)30)29-5-3-12-2-1-11(7-13(12)9-29)8-26-23(33)21-27-22(32)16-14-4-6-37(34,35)10-15(14)36-24(16)28-21/h1-2,7H,3-6,8-10,25H2,(H,26,33)(H,27,28,32)",QHDIXGPUTSAIJX-UHFFFAOYSA-N,27877,"N-{[2-(2-amino-3,4-dioxocyclobut-1-en-1-yl)-1,2,3,4-tetrahydroisoquinolin-7-yl]methyl}-3,11,11-trioxo-8,1-dithia-4,6-diazatricyclo[7.4.0.0^{2,7}]trideca-1(9),2(7),5-triene-5-carboxamide::thiopyranothienopyrimidine, 1",Matrix metalloproteinase-14,,>10000
1183075,Cc1ccc(NC(=O)c2ccnc(c2)C(F)(F)F)cc1-c1cc(nc(c1)N1CCOCC1)C#CCN,"InChI=1S/C26H24F3N5O2/c1-17-4-5-21(33-25(35)18-6-8-31-23(14-18)26(27,28)29)16-22(17)19-13-20(3-2-7-30)32-24(15-19)34-9-11-36-12-10-34/h4-6,8,13-16H,7,9-12,30H2,1H3,(H,33,35)",NEPQIFKODBASIC-UHFFFAOYSA-N,559890,"(3S)-N-[3-[2-(2-ammopyrimidin-4-yl)-6- (morpholin-4-yl)pyridin-4-yl]-4- methylphenyl]-3-(2,2,2- trifluoroethyl)pyrrolidine-1-carboxamide::US11377431, Example 5",RAF proto-oncogene serine/threonine-protein kinase,Homo sapiens, 5.5
940179,CCN(C)CCCCC(=O)N1CCC2(CC2CNC(=O)c2cc3ccncc3o2)CC1,"InChI=1S/C24H34N4O3/c1-3-27(2)11-5-4-6-22(29)28-12-8-24(9-13-28)15-19(24)16-26-23(30)20-14-18-7-10-25-17-21(18)31-20/h7,10,14,17,19H,3-6,8-9,11-13,15-16H2,1-2H3,(H,26,30)",ZNXYDFLRRJOHQF-UHFFFAOYSA-N,455682,"N-([6-[2-(1,4-dimethylpiperidin-4-yl)acetyl]-6-azaspiro[2.5]octan-1-yl]methyl)furo[2,3-c]pyridine-2-carboxamide::US10730889, Example 275",Nicotinamide phosphoribosyltransferase,Homo sapiens, 121
438658,CNc1nc2ccccc2n1-c1nc2N3CCOC[C@H]3COc2c(n1)C(C)(C)S(C)(=O)=O,"InChI=1S/C21H26N6O4S/c1-21(2,32(4,28)29)17-16-18(26-9-10-30-11-13(26)12-31-16)25-20(24-17)27-15-8-6-5-7-14(15)23-19(27)22-3/h5-8,13H,9-12H2,1-4H3,(H,22,23)/t13-/m0/s1",JEWXHIMACGOZFL-ZDUSSCGKSA-N,251588,"US9453031, 11",Cytochrome P450 3A4,Homo sapiens, 39000
1212624,NCc1cccc(NC2CCC(=O)NC2=O)c1,"InChI=1S/C12H15N3O2/c13-7-8-2-1-3-9(6-8)14-10-4-5-11(16)15-12(10)17/h1-3,6,10,14H,4-5,7,13H2,(H,15,16,17)",RJRRDOKINQWNLU-UHFFFAOYSA-N,575294,"US11459335, Compound 91",DNA damage-binding protein 1/Protein cereblon,,
50634474,Cc1cccc(c1)-c1cnc(N)c(n1)C(=O)Nc1ccccc1,"InChI=1S/C18H16N4O/c1-12-6-5-7-13(10-12)15-11-20-17(19)16(22-15)18(23)21-14-8-3-2-4-9-14/h2-11H,1H3,(H2,19,20)(H,21,23)",JVLBMTZZNVPFEA-UHFFFAOYSA-N,50341731,3-amino-N-phenyl-6-(m-tolyl)pyrazine-2-carboxamide::CHEMBL1766777,Serine/threonine-protein kinase ATR,Homo sapiens, 560
50961184,CC(C)(C)OC(=O)c1ccc(NC(=O)CCNS(=O)(=O)c2ccc(cc2)C(N)=[NH2+])cc1,"InChI=1S/C21H26N4O5S/c1-21(2,3)30-20(27)15-4-8-16(9-5-15)25-18(26)12-13-24-31(28,29)17-10-6-14(7-11-17)19(22)23/h4-11,24H,12-13H2,1-3H3,(H3,22,23)(H,25,26)/p+1",UFIFBFHOQIHZMQ-UHFFFAOYSA-O,50394285,CHEMBL2159285,Prothrombin,,
25509,NC(=N)c1ccc2nc([nH]c2c1)-c1cccc(-c2ccccc2)c1O,"InChI=1S/C20H16N4O/c21-19(22)13-9-10-16-17(11-13)24-20(23-16)15-8-4-7-14(18(15)25)12-5-2-1-3-6-12/h1-11,25H,(H3,21,22)(H,23,24)",LMGQGPVCSYOMNS-UHFFFAOYSA-N,14143,"2-(2-HYDROXY-BIPHENYL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE::2-(2-hydroxy-3-phenylphenyl)-1H-1,3-benzodiazole-5-carboximidamide::APC-7806::CHEMBL327715",Urokinase-type plasminogen activator,Homo sapiens,
50419531,CCSC(=S)SCC(=O)c1ccn(c1)S(=O)(=O)c1ccccc1,"InChI=1S/C15H15NO3S4/c1-2-21-15(20)22-11-14(17)12-8-9-16(10-12)23(18,19)13-6-4-3-5-7-13/h3-10H,2,11H2,1H3",DDFYPRWDRDFLSI-UHFFFAOYSA-N,50252371,CHEMBL520279::Ethyl 2-oxo-2-[1-(phenyl-sulfonyl)-1H-pyrrol-3-yl]-ethyl trithiocarbonate,Histone deacetylase 6,Homo sapiens,
50979027,OC12C3C4C5C3C(C3C5CC4C13)N2CCc1ccccn1,"InChI=1S/C18H20N2O/c21-18-15-10-7-9-11-12(10)16(18)14(11)17(13(9)15)20(18)6-4-8-3-1-2-5-19-8/h1-3,5,9-17,21H,4,6-7H2",ABONQAUMSMWLEK-UHFFFAOYSA-N,50401359,CHEMBL2205816,5-hydroxytryptamine receptor 1B,Homo sapiens,
51304525,NC(=O)c1c2NCCC(CNC(=O)C=C)n2nc1-c1ccc(Oc2ccccc2)cc1,"InChI=1S/C23H23N5O3/c1-2-19(29)26-14-16-12-13-25-23-20(22(24)30)21(27-28(16)23)15-8-10-18(11-9-15)31-17-6-4-3-5-7-17/h2-11,16,25H,1,12-14H2,(H2,24,30)(H,26,29)",JTLIXOUWXJJHBC-UHFFFAOYSA-N,249906,"US10005782, Compound 33b::US9447106, 33::US9556188, Compound 33",Epidermal growth factor receptor,Homo sapiens, 0.720000
50180450,COC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1cccc2ccccc12,"InChI=1S/C21H18N2O5/c1-28-21(25)19(13-14-9-11-16(12-10-14)23(26)27)22-20(24)18-8-4-6-15-5-2-3-7-17(15)18/h2-12,19H,13H2,1H3,(H,22,24)/t19-/m0/s1",VMFGCGRAIBLAFY-IBGZPJMESA-N,50100021,(S)-2-[(Naphthalene-1-carbonyl)-amino]-3-(4-nitro-phenyl)-propionic acid methyl ester::CHEMBL33227,C-C chemokine receptor type 3,Homo sapiens, 25
50599660,Cc1ccc(cc1-c1cc2cnnc(-c3ccc(F)cc3F)c2n(C)c1=O)C(=O)NC1(C)CC1,"InChI=1S/C26H22F2N4O2/c1-14-4-5-15(24(33)30-26(2)8-9-26)10-19(14)20-11-16-13-29-31-22(23(16)32(3)25(20)34)18-7-6-17(27)12-21(18)28/h4-7,10-13H,8-9H2,1-3H3,(H,30,33)",XWJXKEARDJSUHS-UHFFFAOYSA-N,50326916,"3-(8-(2,4-Difluorophenyl)-1-methyl-2-oxo-1,2-dihydropyrido-[3,2-d]pyridazin-3-yl)-4-methyl-N-(1-methylcyclopropyl)benzamide::CHEMBL1254988",Mitogen-activated protein kinase 14,Homo sapiens, 3.1
51011310,CCCC(=O)Nc1cccc(c1)-c1cc(no1)C(O)=O,"InChI=1S/C14H14N2O4/c1-2-4-13(17)15-10-6-3-5-9(7-10)12-8-11(14(18)19)16-20-12/h3,5-8H,2,4H2,1H3,(H,15,17)(H,18,19)",CGVGVKRVKLCQOD-UHFFFAOYSA-N,50133279,5-(3-Butyrylamino-phenyl)-isoxazole-3-carboxylic acid::5-(3-butyramidophenyl)isoxazole-3-carboxylic acid::CHEMBL333158,Tyrosine-protein phosphatase non-receptor type 1,Homo sapiens,
51424356,COc1nc2ccc(OC)cc2n1CCNC(C)=O,"InChI=1S/C13H17N3O3/c1-9(17)14-6-7-16-12-8-10(18-2)4-5-11(12)15-13(16)19-3/h4-5,8H,6-7H2,1-3H3,(H,14,17)",OSKMTHQTYBZVLY-UHFFFAOYSA-N,50575512,CHEMBL4854625,Melatonin receptor type 1B,Homo sapiens,
64017,Cc1nc(C)c(s1)-c1ccnc(Nc2ccc(O)cc2)n1,"InChI=1S/C15H14N4OS/c1-9-14(21-10(2)17-9)13-7-8-16-15(19-13)18-11-3-5-12(20)6-4-11/h3-8,20H,1-2H3,(H,16,18,19)",GDZTURHUKDAJGD-UHFFFAOYSA-N,8053,"2-Anilino-4-(thiazol-5-yl)pyrimidine deriv. 24::4-[4-(2,4-Dimethyl-thiazol-5-yl)-pyrimidin-2-ylamino]-phenol::4-[4-(2,4-Dimethyl-thiazol-5-yl)-pyrimidin-2-ylamino]phenol, 5::4-{[4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-yl]amino}phenol::CHEMBL442957",Serine/threonine-protein kinase PLK1,Homo sapiens, 5e+3
415324,C(c1ccc(nc1)-c1cccnc1)n1ccnc1,"InChI=1S/C14H12N4/c1-2-13(9-15-5-1)14-4-3-12(8-17-14)10-18-7-6-16-11-18/h1-9,11H,10H2",AILVDOWAXGVJGR-UHFFFAOYSA-N,50378940,"CHEMBL2011256::US9394290, 26","Cytochrome P450 11B2, mitochondrial",, 3955
1256524,Nc1ccc(cc1NC(=O)C1CCCCC1)-c1cnccn1,"InChI=1S/C17H20N4O/c18-14-7-6-13(16-11-19-8-9-20-16)10-15(14)21-17(22)12-4-2-1-3-5-12/h6-12H,1-5,18H2,(H,21,22)",CMQDNICLNADMHV-UHFFFAOYSA-N,592346,"US11572368, Compound 27",Histone deacetylase 2,Homo sapiens, 3050
50488811,Clc1ccc(Nc2nnc(s2)-c2ccccc2Cl)cc1Cl,"InChI=1S/C14H8Cl3N3S/c15-10-4-2-1-3-9(10)13-19-20-14(21-13)18-8-5-6-11(16)12(17)7-8/h1-7H,(H,18,20)",GIJMTUACOHLGFT-UHFFFAOYSA-N,50160569,CHEMBL3785671,Beta-glucuronidase,, 2160
1218709,COc1cccc(C)c1-n1nc2CCN(Cc2c1-c1ccc(NC(N)=O)cc1)c1ncccc1C,"InChI=1S/C27H28N6O2/c1-17-6-4-8-23(35-3)24(17)33-25(19-9-11-20(12-10-19)30-27(28)34)21-16-32(15-13-22(21)31-33)26-18(2)7-5-14-29-26/h4-12,14H,13,15-16H2,1-3H3,(H3,28,30,34)",AUMPBYKINHRQES-UHFFFAOYSA-N,578068,"US11478460, Compound 1.408",C5a anaphylatoxin chemotactic receptor 1,, 275
120137,CCCCCn1c2ccccc2c(O)c(C(=O)Nc2ccccn2)c1=O,"InChI=1S/C20H21N3O3/c1-2-3-8-13-23-15-10-5-4-9-14(15)18(24)17(20(23)26)19(25)22-16-11-6-7-12-21-16/h4-7,9-12,24H,2-3,8,13H2,1H3,(H,21,22,25)",KDSLJSTWFGARIE-UHFFFAOYSA-N,64022,"1-amyl-2-hydroxy-4-keto-N-(2-pyridyl)quinoline-3-carboxamide::2-hydroxy-4-oxo-1-pentyl-N-(2-pyridinyl)-3-quinolinecarboxamide::2-hydroxy-4-oxo-1-pentyl-N-pyridin-2-ylquinoline-3-carboxamide::2-oxidanyl-4-oxidanylidene-1-pentyl-N-pyridin-2-yl-quinoline-3-carboxamide::4-Hydroxy-2-oxo-1-pentyl-1,2-dihydro-quinoline-3-carboxylic acid pyridin-2-ylamide::MLS001203014::SMR000505068::cid_1900370",Heat shock factor protein 1,Mus musculus,
1185950,COC(=O)c1sc(Br)cc1N1CCOCC1,"InChI=1S/C10H12BrNO3S/c1-14-10(13)9-7(6-8(11)16-9)12-2-4-15-5-3-12/h6H,2-5H2,1H3",PBWRIESVDDMFPC-UHFFFAOYSA-N,561645,"Step a::US11390631, Example 182",Gag-Pol polyprotein,,
50775433,N[C@@H](CCC(O)=O)C(O)=O,"InChI=1S/C5H9NO4/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H,7,8)(H,9,10)/t3-/m0/s1",WHUUTDBJXJRKMK-VKHMYHEASA-N,17657,(2S)-2-aminopentanedioic acid::(S)-Glu::D-Glutamate::Glutamate::L-Glu::L-Glutamate::L-Glutamic acid::L-[14C(U)]glutamate::L-gluatmate,Metabotropic glutamate receptor 3,,
50204121,COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)NC[C@@H](O)c3ccccc3)c2c1,"InChI=1S/C27H25ClN2O4/c1-17-22(15-26(32)29-16-25(31)18-6-4-3-5-7-18)23-14-21(34-2)12-13-24(23)30(17)27(33)19-8-10-20(28)11-9-19/h3-14,25,31H,15-16H2,1-2H3,(H,29,32)/t25-/m1/s1",AOIQKSHKQIJFMK-RUZDIDTESA-N,50112547,2-[1-(4-Chloro-benzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]-N-(2-hydroxy-2-phenyl-ethyl)-acetamide::CHEMBL441769,Prostaglandin G/H synthase 2,Homo sapiens, 47
704065,Cn1ccc(n1)-c1cc(ccc1C(F)(F)F)C(=O)Nc1cnc(CC(N)=O)nc1-c1ccccc1,"InChI=1S/C24H19F3N6O2/c1-33-10-9-18(32-33)16-11-15(7-8-17(16)24(25,26)27)23(35)30-19-13-29-21(12-20(28)34)31-22(19)14-5-3-2-4-6-14/h2-11,13H,12H2,1H3,(H2,28,34)(H,30,35)",BEDMMCGBBFILRB-UHFFFAOYSA-N,356116,"N-(2-(2-amino-2-oxoethyl)-4- phenylpyrimidin-5-yl)-3-(1- methyl-1H-pyrazol-3-yl)-4- (trifluoromethyl)benzamide::US9815846, Compound 116",High affinity nerve growth factor receptor,, 9.80
653097,O[C@@H]1CS[C@H]([C@@H]1O)c1cnc2c(NCCN3CCCCC3)nccn12,"InChI=1S/C17H25N5O2S/c23-13-11-25-15(14(13)24)12-10-20-17-16(19-5-9-22(12)17)18-4-8-21-6-2-1-3-7-21/h5,9-10,13-15,23-24H,1-4,6-8,11H2,(H,18,19)/t13-,14-,15+/m1/s1",QOXWNPKZQMOKSF-KFWWJZLASA-N,333343,"(2S,3R,4S)-2-(8-((2-(piperidin-1-yl)ethyl)amino)imidazo[1,2-a]pyrazin-3-yl)tetrahydrothiophene-3,4-diol::US10196396, Compound 154",Adenosine receptor A3,Homo sapiens, 55
511670,C[C@@H]([C@@H](C1CC1)c1cccc(OCC2CC(C2)Oc2ccc3C(=O)OCc3c2)c1)C(O)=O,"InChI=1S/C26H28O6/c1-15(25(27)28)24(17-5-6-17)18-3-2-4-20(11-18)30-13-16-9-22(10-16)32-21-7-8-23-19(12-21)14-31-26(23)29/h2-4,7-8,11-12,15-17,22,24H,5-6,9-10,13-14H2,1H3,(H,27,28)/t15-,16?,22?,24-/m0/s1",WJRSVHZHOISKJI-JPBIGIIBSA-N,270386,"US10059667, Example 107::US10059667, Example 108",Free fatty acid receptor 1,,
50878968,Cc1ccc(cc1-c1ccc2c(noc2c1)C1CCNCC1)C(=O)NC1CC1,"InChI=1S/C23H25N3O2/c1-14-2-3-17(23(27)25-18-5-6-18)12-20(14)16-4-7-19-21(13-16)28-26-22(19)15-8-10-24-11-9-15/h2-4,7,12-13,15,18,24H,5-6,8-11H2,1H3,(H,25,27)",UEWLDVUSFNQXKA-UHFFFAOYSA-N,50265371,CHEMBL497563::N-cyclopropyl-4-methyl-3-(3-(piperidin-4-yl)benzo[d]isoxazol-6-yl)benzamide,Cyclin-dependent kinase 2,Homo sapiens,>20000
50632129,CCOC(=O)c1ccc(NC(=O)c2nc3CCN(C)Cc3s2)c(NC(=O)c2cc3cc(Cl)ccc3[nH]2)c1,"InChI=1S/C26H24ClN5O4S/c1-3-36-26(35)14-4-6-18(29-24(34)25-31-19-8-9-32(2)13-22(19)37-25)20(11-14)30-23(33)21-12-15-10-16(27)5-7-17(15)28-21/h4-7,10-12,28H,3,8-9,13H2,1-2H3,(H,29,34)(H,30,33)",GRMSECMBYSJHNU-UHFFFAOYSA-N,50340859,"CHEMBL1761616::ethyl 3-(5-chloro-1H-indole-2-carboxamido)-4-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamido)benzoate",Coagulation factor X,Homo sapiens,>10000
995078,COc1nc(N[C@@H]2CCN(C2)C(=O)c2ccc(NC(=O)C=C)cc2)ncc1Cl,"InChI=1S/C19H20ClN5O3/c1-3-16(26)22-13-6-4-12(5-7-13)18(27)25-9-8-14(11-25)23-19-21-10-15(20)17(24-19)28-2/h3-7,10,14H,1,8-9,11H2,2H3,(H,22,26)(H,21,23,24)/t14-/m1/s1",AWDBOLXXOPJAAU-CQSZACIVSA-N,479007,"(R)-N-(4-(3-((5-chloro-4- methoxypyrimidin-2- yl)amino)pyrrolidine-1- carbonyl)phenyl)acrylamide::US10894788, Example 138::US10894788, Example 47::US10894788, Example 93::US11390618, Example 47",Cyclin-dependent kinase 12,,<100
929015,Nc1ncc(cc1C(=O)N[C@H]1CC[C@H](O)CC1)-c1ccc(cc1)[C@]12C[C@H]1CN(CCN1CCOCC1)C2,"InChI=1S/C29H39N5O3/c30-27-26(28(36)32-24-5-7-25(35)8-6-24)15-21(17-31-27)20-1-3-22(4-2-20)29-16-23(29)18-34(19-29)10-9-33-11-13-37-14-12-33/h1-4,15,17,23-25,35H,5-14,16,18-19H2,(H2,30,31)(H,32,36)/t23-,24-,25-,29+/m0/s1",JFDSOYMKCLUKEJ-VVEDBRRQSA-N,451781,"US10710980, Example 13::US10947218, Example 13",TGF-beta receptor type-1 [162-503],, 3100
50843043,CCCN1CCCN(CC1)c1ccc(O)c2NC(=O)COc12,"InChI=1S/C16H23N3O3/c1-2-6-18-7-3-8-19(10-9-18)12-4-5-13(20)15-16(12)22-11-14(21)17-15/h4-5,20H,2-3,6-11H2,1H3,(H,17,21)",QLRIUZVNMLEJEJ-UHFFFAOYSA-N,50261534,CHEMBL4065797,D(1B) dopamine receptor,,
661932,NCc1cccc2C(N(CCc12)C(=O)c1cn(nn1)-c1cccc(Cl)c1F)C(=O)Nc1ccc(cc1)C(O)=O,"InChI=1S/C27H22ClFN6O4/c28-20-5-2-6-22(23(20)29)35-14-21(32-33-35)26(37)34-12-11-18-16(13-30)3-1-4-19(18)24(34)25(36)31-17-9-7-15(8-10-17)27(38)39/h1-10,14,24H,11-13,30H2,(H,31,36)(H,38,39)",YTULCQGNUIGFGU-UHFFFAOYSA-N,335878,"4-(5-(Aminomethyl)-2-(1-(3-chloro-2-fluorophenyl)-1H-1,2,3-triazole-4-carbonyl)-1,2,3,4-tetrahydroisoquinoline-1-carboxamido)benzoic acid, TFA salt::US9738655, Example 109",Coagulation factor XI,Homo sapiens,
724516,CCOC(=O)N1CCC(=CC1)c1cccn2nc(Nc3ccc(cc3)C(=O)N3CCC4(CCCNC4)CC3)nc12,"InChI=1S/C30H37N7O3/c1-2-40-29(39)36-17-10-22(11-18-36)25-5-3-16-37-26(25)33-28(34-37)32-24-8-6-23(7-9-24)27(38)35-19-13-30(14-20-35)12-4-15-31-21-30/h3,5-10,16,31H,2,4,11-15,17-21H2,1H3,(H,32,34)",BLBZPISCWFDILX-UHFFFAOYSA-N,366956,"US9873709, Example 2-252::ethyl 4-[2-[4-(2,9- diazaspiro[5.5] undecane-9- carbonyl)anilino]- [1,2,4]triazolo[1,5- a]pyridin-8-yl]-3,6- dihydro-2H-pyridine- 1-carboxylate",Tyrosine-protein kinase JAK1,Homo sapiens,
50228726,CCCCC(=O)N[C@@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@H](Cc2ccccc2)NC(=O)C2(CCc3c(Br)cccc3C2)NC1=O)C(N)=O,"InChI=1S/C52H67BrN12O8/c1-2-3-21-43(66)60-42-28-44(67)57-24-10-9-19-38(45(54)68)61-48(71)41(27-33-30-59-37-18-8-7-16-35(33)37)63-46(69)39(20-12-25-58-51(55)56)62-47(70)40(26-31-13-5-4-6-14-31)64-50(73)52(65-49(42)72)23-22-34-32(29-52)15-11-17-36(34)53/h4-8,11,13-18,30,38-42,59H,2-3,9-10,12,19-29H2,1H3,(H2,54,68)(H,57,67)(H,60,66)(H,61,71)(H,62,70)(H,63,69)(H,64,73)(H,65,72)(H4,55,56,58)/t38-,39+,40-,41-,42+,52?/m0/s1",JQBRDWNKUJOZOW-MVZZTEKNSA-N,50126101,CHEMBL438286::MT-II cyclic peptide derivative,Melanocortin receptor 4,,
69366,O=S(=O)(Nc1cccc2ncccc12)c1cccs1,"InChI=1S/C13H10N2O2S2/c16-19(17,13-7-3-9-18-13)15-12-6-1-5-11-10(12)4-2-8-14-11/h1-9,15H",ANEULYGKZNTCEI-UHFFFAOYSA-N,37678,MLS000057468::N-(5-quinolinyl)-2-thiophenesulfonamide::N-(5-quinolyl)thiophene-2-sulfonamide::N-quinolin-5-ylthiophene-2-sulfonamide::SMR000064011::cid_2082094,fMet-Leu-Phe receptor,Homo sapiens,
126461,Fc1ccc(cc1F)-c1csc(NC(=O)CSc2ncnc3n[nH]cc23)n1,"InChI=1S/C16H10F2N6OS2/c17-10-2-1-8(3-11(10)18)12-5-27-16(22-12)23-13(25)6-26-15-9-4-21-24-14(9)19-7-20-15/h1-5,7H,6H2,(H,22,23,25)(H,19,20,21,24)",IVWLBDDQLIVONB-UHFFFAOYSA-N,68159,"MLS001006874::N-[4-(3,4-difluorophenyl)-1,3-thiazol-2-yl]-2-(1H-pyrazolo[3,4-d]pyrimidin-4-ylsulfanyl)acetamide::N-[4-(3,4-difluorophenyl)-2-thiazolyl]-2-(1H-pyrazolo[3,4-d]pyrimidin-4-ylthio)acetamide::N-[4-(3,4-difluorophenyl)thiazol-2-yl]-2-(1H-pyrazolo[3,4-d]pyrimidin-4-ylthio)acetamide::N-[4-[3,4-bis(fluoranyl)phenyl]-1,3-thiazol-2-yl]-2-(1H-pyrazolo[3,4-d]pyrimidin-4-ylsulfanyl)ethanamide::SMR000384380::cid_2473481",DNA damage-inducible transcript 3 protein,Mus musculus, 6690
51314143,CNc1nccc(n1)N1CC[C@@H](C1)NC(=O)Nc1ccc(OC(F)(F)F)cc1,"InChI=1S/C17H19F3N6O2/c1-21-15-22-8-6-14(25-15)26-9-7-12(10-26)24-16(27)23-11-2-4-13(5-3-11)28-17(18,19)20/h2-6,8,12H,7,9-10H2,1H3,(H,21,22,25)(H2,23,24,27)/t12-/m0/s1",YTLJCEWXUOBATL-LBPRGKRZSA-N,50532631,CHEMBL4586753,Cyclin-C,, 44
531220,CN(C(=O)[C@H](Cc1ccc(cc1)C#N)NC(=O)NS(=O)(=O)c1ccccc1C)c1ccc2OCOc2c1,"InChI=1S/C26H24N4O6S/c1-17-5-3-4-6-24(17)37(33,34)29-26(32)28-21(13-18-7-9-19(15-27)10-8-18)25(31)30(2)20-11-12-22-23(14-20)36-16-35-22/h3-12,14,21H,13,16H2,1-2H3,(H2,28,29,32)/t21-/m0/s1",WIZAEKPSRNAQGC-NRFANRHFSA-N,279238,"US10035760, Example 63",Envelope glycoprotein gp160,,
50027693,COc1cc(NCc2ccc3nc(N)nc(N)c3c2C)cc(OC)c1OC,"InChI=1S/C19H23N5O3/c1-10-11(5-6-13-16(10)18(20)24-19(21)23-13)9-22-12-7-14(25-2)17(27-4)15(8-12)26-3/h5-8,22H,9H2,1-4H3,(H4,20,21,23,24)",NOYPYLRCIDNJJB-UHFFFAOYSA-N,18268,"5-methyl-6-{[(3,4,5-trimethoxyphenyl)amino]methyl}quinazoline-2,4-diamine::CHEMBL119::TMQ::Trimetrexate::US11111252, Compound TMQ::US11530198, Example Trimetrexate",Bifunctional dihydrofolate reductase-thymidylate synthase,, 16
529913,COC1(CCC1)c1onc(c1C(=O)n1cc2CC\C(=C/C(O)=O)c3cccc1c23)-c1c(Cl)cc(Cl)cc1Cl,"InChI=1S/C28H21Cl3N2O5/c1-37-28(8-3-9-28)26-24(25(32-38-26)23-18(30)11-16(29)12-19(23)31)27(36)33-13-15-7-6-14(10-21(34)35)17-4-2-5-20(33)22(15)17/h2,4-5,10-13H,3,6-9H2,1H3,(H,34,35)/b14-10+",CAZZHNDDRFPVJL-GXDHUFHOSA-N,278550," (2E)-[1-{[5-(1-Methoxycyclobutyl)-3-(2,4,6-trichlorophenyl)-1,2-oxazol-4-yl]carbonyl}-3,4-dihydrobenzo[cd]indol-5(1H)-::US10040791, Example 12",Isocitrate dehydrogenase [NADP] cytoplasmic [R132C],, 144
1184667,O=C(Nc1ccncn1)c1cc2ccc(cc2[nH]1)-c1nccc(Nc2ccc3[nH]ncc3c2)n1,"InChI=1S/C24H17N9O/c34-24(32-21-5-7-25-13-27-21)20-10-14-1-2-15(11-19(14)30-20)23-26-8-6-22(31-23)29-17-3-4-18-16(9-17)12-28-33-18/h1-13,30H,(H,28,33)(H,26,29,31)(H,25,27,32,34)",HPOJEULFQYZBBP-UHFFFAOYSA-N,402325,"US10329282, Compound TDI01161::US11390609, Compound TDI01161",Rho-associated protein kinase 2,Homo sapiens, 210
1199356,NCC(=O)N[C@H]1CN[C@](CCCCB(O)O)(C1)C(O)=O,"InChI=1S/C11H21BN3O5/c13-6-9(16)15-8-5-11(10(17)18,14-7-8)3-1-2-4-12(19)20/h8,19-20H,1-7,13H2,(H,15,16)(H,17,18)/t8-,11-/m1/s1",WMUREZXCPOVACZ-LDYMZIIASA-N,568463,"US11420984, Example 13","Arginase-2, mitochondrial",Homo sapiens, 630
293339,Clc1ccc(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)Nc2ccc(Cl)cc2)cc1,"InChI=1S/C22H30Cl2N10/c23-15-5-9-17(10-6-15)31-21(27)33-19(25)29-13-3-1-2-4-14-30-20(26)34-22(28)32-18-11-7-16(24)8-12-18/h5-12H,1-4,13-14H2,(H5,25,27,29,31,33)(H5,26,28,30,32,34)",GHXZTYHSJHQHIJ-UHFFFAOYSA-N,152706,Chlorhexidine::Chlorhexidine (1),"Acetyltransferase, GNAT family",, 1.4e+4
51048828,C[C@H](CCC(=O)N[C@@H](CO)C(O)=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,"InChI=1S/C27H45NO5/c1-16(4-9-24(31)28-23(15-29)25(32)33)20-7-8-21-19-6-5-17-14-18(30)10-12-26(17,2)22(19)11-13-27(20,21)3/h16-23,29-30H,4-15H2,1-3H3,(H,28,31)(H,32,33)/t16-,17-,18-,19+,20-,21+,22+,23+,26+,27-/m1/s1",XIDPLSVCKATVQF-IOJOMAJISA-N,50428063,CHEMBL2322996,Ephrin type-A receptor 2,Homo sapiens, 33113
50146695,FC(F)(F)Oc1ccc(cc1)C(=O)NCCc1ccnc2ccccc12,"InChI=1S/C19H15F3N2O2/c20-19(21,22)26-15-7-5-14(6-8-15)18(25)24-12-10-13-9-11-23-17-4-2-1-3-16(13)17/h1-9,11H,10,12H2,(H,24,25)",JMLXBACNOOXDBB-UHFFFAOYSA-N,50231060,CHEMBL253198::N-(2-(quinolin-4-yl)ethyl)-4-(trifluoromethoxy)benzamide,Transient receptor potential cation channel subfamily V member 1,Homo sapiens,>10000
487569,CC1(C)C(N)=N[C@@](C)(CS1(=O)=O)c1cc(Nc2csc3cc(cnc23)C#N)ccc1F,"InChI=1S/C21H20FN5O2S2/c1-20(2)19(24)27-21(3,11-31(20,28)29)14-7-13(4-5-15(14)22)26-16-10-30-17-6-12(8-23)9-25-18(16)17/h4-7,9-10,26H,11H2,1-3H3,(H2,24,27)/t21-/m0/s1",YYLFRZJBVWKHIP-NRFANRHFSA-N,228430,"US9556135, 73",Cathepsin D,Homo sapiens, 27300
51263862,FC(F)Oc1ccc(NC(=O)NC2CCN(CC2)c2ncnc3n(c(nc23)-c2ccccc2Cl)-c2ccc(Cl)cc2)cn1,"InChI=1S/C29H24Cl2F2N8O2/c30-17-5-8-20(9-6-17)41-25(21-3-1-2-4-22(21)31)39-24-26(35-16-36-27(24)41)40-13-11-18(12-14-40)37-29(42)38-19-7-10-23(34-15-19)43-28(32)33/h1-10,15-16,18,28H,11-14H2,(H2,37,38,42)",LTNOPYMLPTUXSM-UHFFFAOYSA-N,50516235,CHEMBL4563408,Prostaglandin G/H synthase 1,,>10000
51114561,Cl[Se]c1ccccc1,InChI=1S/C6H5ClSe/c7-8-6-4-2-1-3-5-6/h1-5H,WJCXADMLESSGRI-UHFFFAOYSA-N,50028968,CHEMBL3335712,Histone-lysine N-methyltransferase EHMT1,Homo sapiens, 1100
439043,C[C@H]1N(CCn2c1nnc2-c1nc(C)cs1)C(=O)c1ccc(cc1)-c1cccs1,"InChI=1S/C21H19N5OS2/c1-13-12-29-20(22-13)19-24-23-18-14(2)25(9-10-26(18)19)21(27)16-7-5-15(6-8-16)17-4-3-11-28-17/h3-8,11-12,14H,9-10H2,1-2H3/t14-/m1/s1",WZHKQWSHHGMARO-CQSZACIVSA-N,50081399,"CHEMBL3422016::US10065961, Compound 19::US10683295, Compound 19::US10941151, Compound 19::US9475814, 19",Potassium voltage-gated channel subfamily H member 2,Homo sapiens, 17000
51098644,OC(=O)C[C@@H](C1CC1)c1ccc2CCC(Oc2c1)c1ccc(cc1)-c1cccc(OC(F)(F)F)c1,"InChI=1S/C28H25F3O4/c29-28(30,31)35-23-3-1-2-21(14-23)17-4-8-19(9-5-17)25-13-12-20-10-11-22(15-26(20)34-25)24(16-27(32)33)18-6-7-18/h1-5,8-11,14-15,18,24-25H,6-7,12-13,16H2,(H,32,33)/t24-,25?/m0/s1",HCBSOPSDBXRIII-SKCDSABHSA-N,50367224,CHEMBL4163496,Free fatty acid receptor 1,,
240053,CC(=O)N1CCC(CC1)c1cccnc1Oc1ccc(Nc2ccc(Cl)cn2)cc1,"InChI=1S/C23H23ClN4O2/c1-16(29)28-13-10-17(11-14-28)21-3-2-12-25-23(21)30-20-7-5-19(6-8-20)27-22-9-4-18(24)15-26-22/h2-9,12,15,17H,10-11,13-14H2,1H3,(H,26,27)",VIBAYRQTDLTCKX-UHFFFAOYSA-N,115414,"US8637500, 271","cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A",Rattus norvegicus, 1
50324951,CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)nc(NCCN3CCN(CCc4ccccc4)CC3)nc12,"InChI=1S/C26H37N9O4/c1-2-28-24(38)21-19(36)20(37)25(39-21)35-16-30-18-22(27)31-26(32-23(18)35)29-9-11-34-14-12-33(13-15-34)10-8-17-6-4-3-5-7-17/h3-7,16,19-21,25,36-37H,2,8-15H2,1H3,(H,28,38)(H3,27,29,31,32)/t19-,20+,21-,25+/m0/s1",GLQXBKNCFOACJO-UGCAPWQASA-N,50079341,CHEMBL3416778,Adenosine receptor A3,Homo sapiens,
803248,CC(C)Oc1cc(ccc1-c1cc(Nc2cnc(cn2)C#N)n[nH]1)C1CCN(C)CC1,"InChI=1S/C23H27N7O/c1-15(2)31-21-10-17(16-6-8-30(3)9-7-16)4-5-19(21)20-11-22(29-28-20)27-23-14-25-18(12-24)13-26-23/h4-5,10-11,13-16H,6-9H2,1-3H3,(H2,26,27,28,29)",OTUWWTDPEYSNSP-UHFFFAOYSA-N,401930,"5-[[5-[2-isopropoxy-4-(1-methyl-4-piperidyl)phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrilehydrochloride::US10010547, Example 38::US10973817, Example 38",Serine/threonine-protein kinase Chk1,Homo sapiens, 0.880
11479,Cn1c2ccccc2c2c3C(=O)NC(=O)c3c3c4ccc(F)cc4[nH]c3c12,"InChI=1S/C21H12FN3O2/c1-25-13-5-3-2-4-11(13)15-17-16(20(26)24-21(17)27)14-10-7-6-9(22)8-12(10)23-18(14)19(15)25/h2-8,23H,1H3,(H,24,26,27)",IYXMIIKETGSAHU-UHFFFAOYSA-N,6766,"20-fluoro-3-methyl-3,13,23-triazahexacyclo[14.7.0.0^{2,10}.0^{4,9}.0^{11,15}.0^{17,22}]tricosa-1(16),2(10),4(9),5,7,11(15),17(22),18,20-nonaene-12,14-dione::indolocarbazole deriv. 4(h)::indolocarbazole deriv. 4b",Calcium/calmodulin-dependent protein kinase type II subunit alpha,Rattus norvegicus,>2000
231240,CCN(CC)S(=O)(=O)NC(=O)[C@]1(C[C@H]1C=C)NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C(C)C)C(C)(C)C)C(C)(C)C21CCC1,"InChI=1S/C42H71N7O7S/c1-13-28-23-42(28,37(54)46-57(55,56)47(14-2)15-3)45-34(51)30-24-41(39(11,12)40(41)20-18-21-40)25-49(30)36(53)32(38(8,9)10)44-35(52)31(26(4)5)43-33(50)29-19-16-17-22-48(29)27(6)7/h13,26-32H,1,14-25H2,2-12H3,(H,43,50)(H,44,52)(H,45,51)(H,46,54)/t28-,29+,30+,31+,32-,41-,42-/m1/s1",VXDRIGYTIFAUHJ-UJSZJFJKSA-N,110354,"US8613914, 122::US9206232, 122",Genome polyprotein,Hepatitis C virus, 1.4
50281968,COc1ccc2cc(C(=O)\C=C\C=C\c3ccc(OC)c(OC)c3)c(=O)oc2c1,"InChI=1S/C23H20O6/c1-26-17-10-9-16-13-18(23(25)29-21(16)14-17)19(24)7-5-4-6-15-8-11-20(27-2)22(12-15)28-3/h4-14H,1-3H3/b6-4+,7-5+",LNIJVWFMIRFNER-YDFGWWAZSA-N,50052830,CHEMBL3318732,Polyamine deacetylase HDAC10,Homo sapiens, 85000
538140,CC[C@@H](NC(=O)c1cc(C(=O)N2CCC[C@@H]2C)n2CCOCc12)c1cccc(n1)C#N,"InChI=1S/C23H27N5O3/c1-3-18(19-8-4-7-16(13-24)25-19)26-22(29)17-12-20(28-10-11-31-14-21(17)28)23(30)27-9-5-6-15(27)2/h4,7-8,12,15,18H,3,5-6,9-11,14H2,1-2H3,(H,26,29)/t15-,18+/m0/s1",CTNKRCZLWSUART-MAUKXSAKSA-N,218291,"US9284333, 16ah::US9884860, Example 16ah",Potassium channel subfamily K member 3,, 3200
50813584,CS(=O)(=O)N[C@H](C(c1ccccc1)c1ccccc1)C(=O)N1CCC[C@H]1C(=O)NCc1ccc(s1)C(N)=N,"InChI=1S/C27H31N5O4S2/c1-38(35,36)31-24(23(18-9-4-2-5-10-18)19-11-6-3-7-12-19)27(34)32-16-8-13-21(32)26(33)30-17-20-14-15-22(37-20)25(28)29/h2-7,9-12,14-15,21,23-24,31H,8,13,16-17H2,1H3,(H3,28,29)(H,30,33)/t21-,24+/m0/s1",CRPPBRFZGAUWJM-XUZZJYLKSA-N,50111105,"(S)-1-((R)-2-Methanesulfonylamino-3,3-diphenyl-propionyl)-pyrrolidine-2-carboxylic acid (5-carbamimidoyl-thiophen-2-ylmethyl)-amide::1-(2-Methanesulfonylamino-3,3-diphenyl-propionyl)-pyrrolidine-2-carboxylic acid (5-carbamimidoyl-thiophen-2-ylmethyl)-amide; compound with benzamidine::CHEMBL1795037::CHEMBL7895",Prothrombin,,
860826,Fc1cc(Oc2ncccc2Cl)ccc1-c1cc(-c2cccc(NC(=O)C=C)c2)c2ncncc2c1,"InChI=1S/C28H18ClFN4O2/c1-2-26(35)34-20-6-3-5-17(12-20)23-13-18(11-19-15-31-16-33-27(19)23)22-9-8-21(14-25(22)30)36-28-24(29)7-4-10-32-28/h2-16H,1H2,(H,34,35)",FPKILVKKFMUZRD-UHFFFAOYSA-N,426708,"N-(3-(6-(4-((3-chloropyridin-2-yl)oxy)-2- fluorophenyl)quinazolin-8-yl)phenyl)acrylamide::US10544106, Compound C106::US11208388, Example 106",Tyrosine-protein kinase BTK,Homo sapiens,<100.0
50401096,O=C(COc1ccc(cc1)C12CC3CC(CC(C3)C1)C2)Nc1cncc(c1)C(=O)NCCc1ccncc1,"InChI=1S/C31H34N4O3/c36-29(35-27-14-25(18-33-19-27)30(37)34-10-7-21-5-8-32-9-6-21)20-38-28-3-1-26(2-4-28)31-15-22-11-23(16-31)13-24(12-22)17-31/h1-6,8-9,14,18-19,22-24H,7,10-13,15-17,20H2,(H,34,37)(H,35,36)",PBAQWBCTWPMCBU-UHFFFAOYSA-N,50222817,5-[2-(4-adamantan-1-yl-phenoxy)-acetylamino]-N-(2-pyridin-4-yl-ethyl)-nicotinamide::CHEMBL248836,Hypoxia-inducible factor 1-alpha,Homo sapiens,>30000
682755,CN(C)CCN(Cc1ncccc1C)C(=O)CNc1cccc2c1N(C)CCN(CC1CC1)C2=O,"InChI=1S/C27H38N6O2/c1-20-7-6-12-28-24(20)19-32(15-13-30(2)3)25(34)17-29-23-9-5-8-22-26(23)31(4)14-16-33(27(22)35)18-21-10-11-21/h5-9,12,21,29H,10-11,13-19H2,1-4H3",QLVVFBJSPRWUGD-UHFFFAOYSA-N,345969,"2-(4-Cyclopropylmethyl-1-methyl-5-oxo-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-9-ylamino)-N-(2-dimethylamino-ethyl)-N-(3-methyl-pyridin-2-ylmethyl)-acetamide::US10202368, Example 44",Atypical chemokine receptor 3,,
51052011,Oc1c(Br)cc(\C=N\NC(=O)c2ccc(cc2)-c2cccnc2)c(O)c1Br,"InChI=1S/C19H13Br2N3O3/c20-15-8-14(17(25)16(21)18(15)26)10-23-24-19(27)12-5-3-11(4-6-12)13-2-1-7-22-9-13/h1-10,25-26H,(H,24,27)/b23-10+",AJNNBLCBRLEXNQ-AUEPDCJTSA-N,50428998,CHEMBL2333655,NAD-dependent protein deacetylase sirtuin-1,Homo sapiens,
1167387,C[C@H]1CN(CCN1C)c1cc(F)c(cc1NC(=O)c1cn(C)c(=O)cc1C(F)F)-c1cnn(CCN2CCOCC2)c1,"InChI=1S/C29H36F3N7O3/c1-19-16-38(6-4-35(19)2)26-14-24(30)21(20-15-33-39(17-20)7-5-37-8-10-42-11-9-37)12-25(26)34-29(41)23-18-36(3)27(40)13-22(23)28(31)32/h12-15,17-19,28H,4-11,16H2,1-3H3,(H,34,41)/t19-/m0/s1",RVZIRFGDVGNDSW-IBGZPJMESA-N,553627,"4-(difluoromethyl)-N-[4- fluoro-5-[1-(2-morpholin- 4-ylethyl)pyrazol-4-yl]-2- [rac-(3R)-3,4- dimethylpiperazin-1- yl]phenyl]-1-methyl-6- oxopyridine-3-carboxamide::US11319299, Example 715",WD repeat-containing protein 5,,
167647,COc1ccc(CN=Nc2cc(nc(n2)N2CCCC2)N2CCCC2)cc1,"InChI=1S/C20H26N6O/c1-27-17-8-6-16(7-9-17)15-21-24-18-14-19(25-10-2-3-11-25)23-20(22-18)26-12-4-5-13-26/h6-9,14H,2-5,10-13,15H2,1H3",CHQMNGXFHWGOGE-UHFFFAOYSA-N,61197,"(2,6-dipyrrolidinopyrimidin-4-yl)-(p-anisylideneamino)amine::4-methoxybenzaldehyde (2,6-dipyrrolidin-1-ylpyrimidin-4-yl)hydrazone::MLS000720213::N-[(4-methoxyphenyl)methylideneamino]-2,6-bis(1-pyrrolidinyl)-4-pyrimidinamine::N-[(4-methoxyphenyl)methylideneamino]-2,6-dipyrrolidin-1-yl-pyrimidin-4-amine::N-[(4-methoxyphenyl)methylideneamino]-2,6-dipyrrolidin-1-ylpyrimidin-4-amine::SMR000304742::cid_2851352",Apoptotic protease-activating factor 1,Homo sapiens, 2630
288201,NC1(CCC1)c1ccc(cc1)-c1nc2c(cccn2c1-c1ccccc1)-c1ccc(F)cc1,"InChI=1S/C29H24FN3/c30-24-15-11-20(12-16-24)25-8-4-19-33-27(22-6-2-1-3-7-22)26(32-28(25)33)21-9-13-23(14-10-21)29(31)17-5-18-29/h1-4,6-16,19H,5,17-18,31H2",IAHBHCUTIPCVMP-UHFFFAOYSA-N,149570,"US8975265, 2-68",RAC-beta serine/threonine-protein kinase,, 521
50398596,COc1ccc2cc(ccc2c1)-c1[nH]c(nc1-c1ccncc1)-c1ccccc1Cl,"InChI=1S/C25H18ClN3O/c1-30-20-9-8-17-14-19(7-6-18(17)15-20)24-23(16-10-12-27-13-11-16)28-25(29-24)21-4-2-3-5-22(21)26/h2-15H,1H3,(H,28,29)",MXCQKVKYBUMFQZ-UHFFFAOYSA-N,50221342,4-(2-(2-chlorophenyl)-4-(6-methoxynaphthalen-2-yl)-1H-imidazol-5-yl)pyridine::CHEMBL236299,Angiopoietin-1 receptor,Homo sapiens, 157
428209,CC(C)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(cc2)C(F)(F)F)nc2NCCc12,"InChI=1S/C22H23F3N6O2S/c1-13(2)31-34(32,33)18-6-4-3-5-17(18)28-20-16-11-12-26-19(16)29-21(30-20)27-15-9-7-14(8-10-15)22(23,24)25/h3-10,13,31H,11-12H2,1-2H3,(H3,26,27,28,29,30)",GOWQKPFZFIKFOP-UHFFFAOYSA-N,245606,"US9428508, 61",Protein-tyrosine kinase 2-beta,,<500
51427929,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13,"InChI=1S/C28H26N4O3/c1-28-26(34-3)17(29-2)12-20(35-28)31-18-10-6-4-8-14(18)22-23-16(13-30-27(23)33)21-15-9-5-7-11-19(15)32(28)25(21)24(22)31/h4-11,17,20,26,29H,12-13H2,1-3H3,(H,30,33)/t17-,20-,26-,28+/m1/s1",HKSZLNNOFSGOKW-FYTWVXJKSA-N,2579,"(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1^{2,6}.0^{7,28}.0^{8,13}.0^{15,19}.0^{20,27}.0^{21,26}]nonacosa-8(13),9,11,14(28),15(19),20(27),21(26),22,24-nonaen-16-one::CHEMBL388978::Staurosporin, 4::Staurosporine::Staurosporine, 8::US9206188, Staurosporine::US9226923, Staurosporine",NADPH oxidase 4,Homo sapiens, 71
927480,Cc1ncc(NC(=O)c2cc(ccn2)C(F)(F)F)cc1-c1cc(N2CCOCC2)n2nccc2n1,"InChI=1S/C23H20F3N7O2/c1-14-17(18-12-21(32-6-8-35-9-7-32)33-20(31-18)3-5-29-33)11-16(13-28-14)30-22(34)19-10-15(2-4-27-19)23(24,25)26/h2-5,10-13H,6-9H2,1H3,(H,30,34)",BTYBKVCFADKILK-UHFFFAOYSA-N,87775,"US10245267, Example 810::US10709712, Example 810::US9694016, 810",RAF proto-oncogene serine/threonine-protein kinase,Homo sapiens, 0.300
157826,OCCN1CCN(CC\C=C2/c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1,"InChI=1S/C23H25F3N2OS/c24-23(25,26)17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)30-22)5-3-9-27-10-12-28(13-11-27)14-15-29/h1-2,4-8,16,29H,3,9-15H2/b18-5+",NJMYODHXAKYRHW-BLLMUTORSA-N,50026957,"(cis) 2-{4-[3-(2-Trifluoromethyl-thioxanthen-9-ylidene)-propyl]-piperazin-1-yl}-ethanol(Flupentixol)::(trans-flupenthixol)2-{4-[3-(2-Trifluoromethyl-thioxanthen-9-ylidene)-propyl]-piperazin-1-yl}-ethanol::2-(4-{3-[2-Trifluoromethyl-thioxanthen-(9E)-ylidene]-propyl}-piperazin-1-yl)-ethanol::2-{4-[3-(2-Trifluoromethyl-thioxanthen-9-ylidene)-propyl]-piperazin-1-yl}-ethanol::FLUPENTHIXOL, Alpha::FLUPENTHIXOL2-{4-[3-(2-Trifluoromethyl-thioxanthen-9-ylidene)-propyl]-piperazin-1-yl}-ethanol::Flupenthixol::Flupenthixol, Beta",Alpha-2C adrenergic receptor,Rattus,
614620,CC(C)[C@H](O)C(=O)N1CCN(CC1)c1ccc(cn1)-c1cc(OCCO)cn2ncc(C#N)c12,"InChI=1S/C24H28N6O4/c1-16(2)23(32)24(33)29-7-5-28(6-8-29)21-4-3-17(13-26-21)20-11-19(34-10-9-31)15-30-22(20)18(12-25)14-27-30/h3-4,11,13-16,23,31-32H,5-10H2,1-2H3/t23-/m0/s1",CUSSMNSNWTWXKU-QHCPKHFHSA-N,296371,"(S)-4-(6-(4-(2-hydroxy- 3- methylbutanoyl) piperazin-1-yl) pyridin-3-yl)-6- (2- hydroxyethoxy)pyrazolo [1,5-a]pyridine-3- carbonitrile 2,2,2- trifluoroacetate::US10112942, Example 104::US10137124, Example 104::US10172851, Example 104::US10555944, Example 104::US10953005, Example 104",Proto-oncogene tyrosine-protein kinase receptor Ret [658-1114],, 477
29375,NC(=O)c1[nH]cnc1-c1cccc(Cl)c1,"InChI=1S/C10H8ClN3O/c11-7-3-1-2-6(4-7)8-9(10(12)15)14-5-13-8/h1-5H,(H2,12,15)(H,13,14)",RFPHXAXVSFQOHJ-UHFFFAOYSA-N,16195,4-(3-Chlorophenyl)-1H-imidazole-5-carboxamide::Imidazole 8b,"Gag-Pol polyprotein [600-1029,C879S]/[600-1159,C879S]",Human immunodeficiency virus 1, 79800
50836966,OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1,"InChI=1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2",LNEPOXFFQSENCJ-UHFFFAOYSA-N,21398,"4-[4-(4-Chloro-phenyl)-4-hydroxy-piperidin-1-yl]-1-(4-fluoro-phenyl)-butan-1-one;propionate(HCl)::4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one::CHEMBL54::CHEMBL545608::Haloperidol::Haloperidol, 1",Sigma non-opioid intracellular receptor 1,Cavia porcellus,
50437705,CC1(C)SCN([C@@H]1C(=O)N[C@@H]1[C@H](O)Cc2ccccc12)C(=O)[C@@H](O)[C@H](Cc1ccccc1)NC(=O)COc1cccc(c1)[N+]([O-])=O,"InChI=1S/C33H36N4O8S/c1-33(2)30(31(41)35-28-24-14-7-6-11-21(24)16-26(28)38)36(19-46-33)32(42)29(40)25(15-20-9-4-3-5-10-20)34-27(39)18-45-23-13-8-12-22(17-23)37(43)44/h3-14,17,25-26,28-30,38,40H,15-16,18-19H2,1-2H3,(H,34,39)(H,35,41)/t25-,26+,28-,29-,30+/m0/s1",RFMOODWRTXUAKX-DOWNBTJOSA-N,50273735,"(R)-N-[(1S,2R)-2-Hydroxyindan-1-yl]-3-[(2S,3S)-3-(3-nitrophenoxyacetyl)amino-2-hydroxy-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide::CHEMBL508023::KNI-10255",Plasmepsin II,Plasmodium falciparum,
623044,COCCn1nc(C2CC2)c2C(=O)N(C(c12)c1ccc(Cl)cc1)c1cc(C)c2nnc(C)n2c1,"InChI=1S/C25H25ClN6O2/c1-14-12-19(13-30-15(2)27-28-24(14)30)32-22(17-6-8-18(26)9-7-17)23-20(25(32)33)21(16-4-5-16)29-31(23)10-11-34-3/h6-9,12-13,16,22H,4-5,10-11H2,1-3H3",SCOGYYPZUPWMLU-UHFFFAOYSA-N,318842,"6-(4-chlorophenyl)-3-cyclopropyl-5-(3-(difluoromethyl)-8-methyl-[1,2,4]triazolo[4,3-a]pyridin-6-yl)-1-methyl-5,6-dihydropyrrolo[3,4-c]pyrazol-4(1H)-one::US9624247, Example 4",Bromodomain-containing protein 4,,<11.0
51037966,COc1cc(c(OC)c(OCc2ccccc2)c1-c1ccc(O)cc1)-c1ccc(O)cc1,"InChI=1S/C27H24O5/c1-30-24-16-23(19-8-12-21(28)13-9-19)26(31-2)27(32-17-18-6-4-3-5-7-18)25(24)20-10-14-22(29)15-11-20/h3-16,28-29H,17H2,1-2H3",LCLKGYZABVMVLL-UHFFFAOYSA-N,50457915,CHEMBL4207664,Probable maltase-glucoamylase 2,, 19100
51092215,Fc1cc(cc(c1)[C@](Cc1ccccc1)(NC(=O)NC1CCCC1)c1ccc(Cl)cn1)C(F)(F)F,"InChI=1S/C26H24ClF4N3O/c27-20-10-11-23(32-16-20)25(15-17-6-2-1-3-7-17,34-24(35)33-22-8-4-5-9-22)18-12-19(26(29,30)31)14-21(28)13-18/h1-3,6-7,10-14,16,22H,4-5,8-9,15H2,(H2,33,34,35)/t25-/m0/s1",BLGKGVMDNWKDHK-VWLOTQADSA-N,50392499,CHEMBL2152152,Cholesteryl ester transfer protein,Homo sapiens, 2900
50706168,COc1cccc(c1)C(=O)Oc1ccc(COC(=O)Nc2ccncc2N)cc1,"InChI=1S/C21H19N3O5/c1-27-17-4-2-3-15(11-17)20(25)29-16-7-5-14(6-8-16)13-28-21(26)24-19-9-10-23-12-18(19)22/h2-12H,13,22H2,1H3,(H,23,24,26)",QCELNBLCEBFBCS-UHFFFAOYSA-N,50359296,CHEMBL1928386,Carboxylic ester hydrolase,, 61700
51343117,C[C@H](NS(=O)(=O)c1ccc(-c2sc(nc2Cc2ccc(F)cc2)-c2nnc(CC(C)(C)C(O)=O)o2)c(C(F)F)c1F)C(F)(F)F,"InChI=1S/C27H23F7N4O5S2/c1-12(27(32,33)34)38-45(41,42)17-9-8-15(19(20(17)29)22(30)31)21-16(10-13-4-6-14(28)7-5-13)35-24(44-21)23-37-36-18(43-23)11-26(2,3)25(39)40/h4-9,12,22,38H,10-11H2,1-3H3,(H,39,40)/t12-/m0/s1",LRJKAYGDKHTSDL-LBPRGKRZSA-N,50543673,CHEMBL4633899,Nuclear receptor ROR-gamma,, 430
851518,Cn1ncc(c1CN1CCCCC1)-c1ccc2cnc(NC(=O)C3CCN(CC3)C3COC3)cc2c1,"InChI=1S/C28H36N6O2/c1-32-26(17-33-9-3-2-4-10-33)25(16-30-32)21-5-6-22-15-29-27(14-23(22)13-21)31-28(35)20-7-11-34(12-8-20)24-18-36-19-24/h5-6,13-16,20,24H,2-4,7-12,17-19H2,1H3,(H,29,31,35)",XAWFNJPHSHLQEQ-UHFFFAOYSA-N,385259,"US10287267, Compound 826::US10508099, Compound 826::US10556885, Compound 826::US11174244, Compound 826",Glycogen synthase kinase-3 beta,Homo sapiens,
557868,CCN(CC)[C@@H](C)CNC(=O)c1cc(nc(c1)-c1cnn2ccc(nc12)-c1cccs1)N1CC(C1)NS(=O)(=O)Cc1ccon1,"InChI=1S/C30H35N9O4S2/c1-4-37(5-2)20(3)15-31-30(40)21-13-26(24-16-32-39-10-8-25(34-29(24)39)27-7-6-12-44-27)33-28(14-21)38-17-23(18-38)36-45(41,42)19-22-9-11-43-35-22/h6-14,16,20,23,36H,4-5,15,17-19H2,1-3H3,(H,31,40)/t20-/m0/s1",SSKHCSOGQGVIRO-FQEVSTJZSA-N,292519,"(S)-N-(2-(diethylamino)propyl)-2-(3-((isoxazol-3-ylmethyl)sulfonamido)azetidin-1-yl)-6-(5-(thiophen-2-yl)pyrazolo[1,5-a]pyrimidin-3-yl)isonicotinamide::US10100058, Example 175",Calcium/calmodulin-dependent protein kinase type II subunit delta,, 0.240
50460095,Fc1ccc2N(Cc3ccccc3C(F)(F)F)C(=O)C(=O)c2c1,"InChI=1S/C16H9F4NO2/c17-10-5-6-13-11(7-10)14(22)15(23)21(13)8-9-3-1-2-4-12(9)16(18,19)20/h1-7H,8H2",FHHVMNIPMGSCCR-UHFFFAOYSA-N,50258658,"5-fluoro-1-(2-(trifluoromethyl)benzyl)indoline-2,3-dione::CHEMBL467281",Muscarinic acetylcholine receptor M5,Homo sapiens,
657410,Cc1ccc(c(c1)C(=O)N1CCC[C@@]1(C)c1nc2cc(c(Cl)cc2[nH]1)C(F)(F)F)-c1ccccc1F,"InChI=1S/C27H22ClF4N3O/c1-15-8-9-16(17-6-3-4-7-21(17)29)18(12-15)24(36)35-11-5-10-26(35,2)25-33-22-13-19(27(30,31)32)20(28)14-23(22)34-25/h3-4,6-9,12-14H,5,10-11H2,1-2H3,(H,33,34)/t26-/m0/s1",XYCKHVGUGDRECK-SANMLTNESA-N,334885,"US11040966, Example 5.151::US9732075, Example 5.151::[(S)-2-(6-Chloro-5-trifluoromethyl-1H-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(2'-fluoro-4-methyl-biphenyl-2-yl)-methanone",Orexin receptor type 2,Homo sapiens, 40.0
830823,Cc1c(Cl)cccc1C(=O)NC1(C)CCN(CC1)c1ccc(cn1)-c1cc(OCC(C)(C)O)cn2ncc(C#N)c12,"InChI=1S/C31H33ClN6O3/c1-20-24(6-5-7-26(20)32)29(39)36-31(4)10-12-37(13-11-31)27-9-8-21(16-34-27)25-14-23(41-19-30(2,3)40)18-38-28(25)22(15-33)17-35-38/h5-9,14,16-18,40H,10-13,19H2,1-4H3,(H,36,39)",UKXCKYDNVFIPMS-UHFFFAOYSA-N,305056,"3-chloro-N-(1-(5-(3- cyano-6-(2-hydroxy-2- methylpropoxy)pyrazolo [1,5-a]pyridin-4-yl) pyridin-2-yl)-4- methylpiperidin-4-yl)-2- methylbenzamide::US10144734, Example 72::US10172845, Example 72::US10441581, Example 72::US10881652, Example 72","Proto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M]",, 14.7
429497,CCOC(C(=O)Nc1ccc(cc1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1C#N,"InChI=1S/C24H20ClN3O6/c1-3-34-23(22(30)27-17-8-5-14(6-9-17)24(31)32)28-13-20(33-2)19(11-21(28)29)18-10-16(25)7-4-15(18)12-26/h4-11,13,23H,3H2,1-2H3,(H,27,30)(H,31,32)",MUNUHSGUPNMRDO-UHFFFAOYSA-N,246213,"US10183932, Example 118::US9434690, 118::US9822102, Example 118",Plasma kallikrein,, 210
903224,COC[C@H](N1CCN(C)CC1)C(=O)Nc1cccc2c(c[nH]c12)-c1nc(Nc2cn(C)nc2OC)ncc1C,,,264226,"(2S)-3-methoxy-N- (3-{2-[(3-methoxy- 1-methyl-1H-pyrazol- 4-yl)amino]-5- methylpyrimidin-4-yl}- 1H-indol-7-yl)- 2-(4-methylpiperazin-1- yl)propanamide::US10167276, Example 46::US10654835, Example 46::US11247983, Example 46::US9714236, 46",Tyrosine-protein kinase JAK1 [866-1154],, 986
927589,Cc1ncc(NC(=O)c2cc(ccn2)C(F)(F)F)cc1-c1cc(N2CCOCC2)c2nccn2n1,"InChI=1S/C23H20F3N7O2/c1-14-17(18-12-20(32-6-8-35-9-7-32)21-28-4-5-33(21)31-18)11-16(13-29-14)30-22(34)19-10-15(2-3-27-19)23(24,25)26/h2-5,10-13H,6-9H2,1H3,(H,30,34)",AHSWXYMNZRQFGL-UHFFFAOYSA-N,87842,"US10245267, Example 868::US10709712, Example 868::US9694016, 868",Serine/threonine-protein kinase B-raf [V600E],, 1.30
804794,N[C@H]1CCCC[C@H]1Nc1ccn2ncc(C(=O)Nc3cn(CC(F)(F)F)nc3C(F)(F)F)c2n1,"InChI=1S/C19H20F6N8O/c20-18(21,22)9-32-8-13(15(31-32)19(23,24)25)29-17(34)10-7-27-33-6-5-14(30-16(10)33)28-12-4-2-1-3-11(12)26/h5-8,11-12H,1-4,9,26H2,(H,28,30)(H,29,34)/t11-,12+/m0/s1",RSUXKVHAOVSYNM-NWDGAFQWSA-N,402711,"5-{[(1R,2S)-2- aminocyclohexyl]amino}- N-[1-(2,2,2- trifluoroethyl)-3- (trifluoromethyl)-1H- pyrazol-4- yl]pyrazolo[1,5- a]pyrimidine-3- carboxamide trifluoroacetate::US10329294, Example 295",Interleukin-1 receptor-associated kinase 4,Homo sapiens, 1.000
50103667,C[C@H]1Oc2cc(cnc2N)-c2cc(ccc2CN(C)C(=O)c2ccc(F)cc12)S(C)(=O)=O,"InChI=1S/C23H22FN3O4S/c1-13-19-9-16(24)5-7-18(19)23(28)27(2)12-14-4-6-17(32(3,29)30)10-20(14)15-8-21(31-13)22(25)26-11-15/h4-11,13H,12H2,1-3H3,(H2,25,26)/t13-/m1/s1",OMIYERABHRFNAV-CYBMUJFWSA-N,50018837,CHEMBL3286827,ALK tyrosine kinase receptor,Homo sapiens,
371638,Cc1nc(no1)C(NC(=O)c1cccc(n1)-c1ccc(F)c(Cl)c1)C1CC1,"InChI=1S/C19H16ClFN4O2/c1-10-22-18(25-27-10)17(11-5-6-11)24-19(26)16-4-2-3-15(23-16)12-7-8-14(21)13(20)9-12/h2-4,7-9,11,17H,5-6H2,1H3,(H,24,26)",AMDKVUYZLMDDAS-UHFFFAOYSA-N,210524,"US9290451, 232",Cannabinoid receptor 2,Homo sapiens,
50805812,Cc1ccnc2CC(CC(=NN=C(N)N)c12)c1ccc(Cl)cc1Cl,"InChI=1S/C17H17Cl2N5/c1-9-4-5-22-14-6-10(12-3-2-11(18)8-13(12)19)7-15(16(9)14)23-24-17(20)21/h2-5,8,10H,6-7H2,1H3,(H4,20,21,24)",ZDKBVPUVPXHFJQ-UHFFFAOYSA-N,50115265,"CHEMBL545499::N-[7-(2,4-dichlorophenyl)-4-methyl-5,6,7,8-tetrahydro-5-quinolinyliden(imine)]iminomethanediamine. dihydrochloride",Sodium/hydrogen exchanger 1,Rattus norvegicus, 340
51334909,CO[C@H]1CCN(Cc2c(OC)cc(C)c3[nH]ccc23)[C@@H](C1)c1ccc(cc1)C(O)=O,,,160036,"US10093663, Example 21a::US9682968, Example-21a",Complement factor B,, 18
50196775,OC(CN(C(=O)c1ccc(Cl)cc1)c1ccccc1)Cn1c2ccccc2c2ccccc12,"InChI=1S/C28H23ClN2O2/c29-21-16-14-20(15-17-21)28(33)30(22-8-2-1-3-9-22)18-23(32)19-31-26-12-6-4-10-24(26)25-11-5-7-13-27(25)31/h1-17,23,32H,18-19H2",HGRCJSALWSEGCY-UHFFFAOYSA-N,50356523,CHEMBL1909684,Beta-secretase 1,Homo sapiens, 4700
676761,C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#Cc3cccnc3)c2c(=O)n1-c1ccccc1,"InChI=1S/C31H23N7O2/c1-20(35-30(39)27-28(32)36-37-17-7-16-34-29(27)37)25-18-23-10-5-9-22(14-13-21-8-6-15-33-19-21)26(23)31(40)38(25)24-11-3-2-4-12-24/h2-12,15-20H,1H3,(H2,32,36)(H,35,39)/t20-/m0/s1",DCKNZWBSTPZMQT-FQEVSTJZSA-N,50192895,"CHEMBL3928146::US10329299, Compound 17::US10675286, Compound 17::US9775844, Compound 17","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform",Homo sapiens, 2000
99612,COc1ccc(C(=O)\C=C\c2ccc(N3CCCCC3)c(c2)[N+]([O-])=O)c(OC)c1,"InChI=1S/C22H24N2O5/c1-28-17-8-9-18(22(15-17)29-2)21(25)11-7-16-6-10-19(20(14-16)24(26)27)23-12-4-3-5-13-23/h6-11,14-15H,3-5,12-13H2,1-2H3/b11-7+",SCWSCMBBZGPLLR-YRNVUSSQSA-N,52492,"(E)-1-(2,4-dimethoxyphenyl)-3-(3-nitro-4-piperidin-1-yl-phenyl)prop-2-en-1-one::(E)-1-(2,4-dimethoxyphenyl)-3-(3-nitro-4-piperidin-1-ylphenyl)prop-2-en-1-one::(E)-1-(2,4-dimethoxyphenyl)-3-(3-nitro-4-piperidino-phenyl)prop-2-en-1-one::(E)-1-(2,4-dimethoxyphenyl)-3-[3-nitro-4-(1-piperidinyl)phenyl]-2-propen-1-one::MLS000390406::SMR000255373::cid_15945163",POsterior Segregation,Caenorhabditis elegans,
51204500,Cc1cc(c(SCc2cc(=O)[nH]c3ccccc23)cc1Cl)S(=O)(=O)NC(=N)NCc1ccc(cc1)S(N)(=O)=O,"InChI=1S/C25H24ClN5O5S3/c1-15-10-23(39(35,36)31-25(27)29-13-16-6-8-18(9-7-16)38(28,33)34)22(12-20(15)26)37-14-17-11-24(32)30-21-5-3-2-4-19(17)21/h2-12H,13-14H2,1H3,(H,30,32)(H3,27,29,31)(H2,28,33,34)",YXCICDFDWQAFDO-UHFFFAOYSA-N,50495115,CHEMBL3104160,Carbonic anhydrase 12,Homo sapiens,
50266064,CC(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2cccc(NC(=O)CN3CCN(C)CC3)c2)ncc1Cl,"InChI=1S/C26H32ClN7O3S/c1-18(2)38(36,37)23-10-5-4-9-22(23)31-25-21(27)16-28-26(32-25)30-20-8-6-7-19(15-20)29-24(35)17-34-13-11-33(3)12-14-34/h4-10,15-16,18H,11-14,17H2,1-3H3,(H,29,35)(H2,28,30,31,32)",CSMSPOIEMWPZLD-UHFFFAOYSA-N,50044461,CHEMBL3357456,Hepatocyte growth factor receptor,Homo sapiens, 549
50520741,Oc1cccc(CCN(CCc2ccccc2)CCc2ccccc2)c1,"InChI=1S/C24H27NO/c26-24-13-7-12-23(20-24)16-19-25(17-14-21-8-3-1-4-9-21)18-15-22-10-5-2-6-11-22/h1-13,20,26H,14-19H2",OPLHBVXJMHVIQO-UHFFFAOYSA-N,50194197,CHEMBL3923010,Delta-type opioid receptor,Homo sapiens,
50415171,CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1,"InChI=1S/C33H39N5O5/c1-35-30(40)27(20-22-9-4-2-5-10-22)36-31(41)28(21-23-11-6-3-7-12-23)37-32(42)29-13-8-18-38(29)33(43)26(34)19-24-14-16-25(39)17-15-24/h2-7,9-12,14-17,26-29,39H,8,13,18-21,34H2,1H3,(H,35,40)(H,36,41)(H,37,42)/t26-,27-,28-,29-/m0/s1",WEITVBLLGNOHNQ-DZUOILHNSA-N,50271439,CHEMBL453689::Tyr-Pro-Phe-Phe-NHCH3,Delta-type opioid receptor,Rattus norvegicus,
51436922,Cc1ccc2c(NCCCCCCNc3nc(cc(=O)n3C)-c3ccncc3F)c3CCCCc3nc2c1,"InChI=1S/C30H35FN6O/c1-20-11-12-23-26(17-20)35-25-10-6-5-9-22(25)29(23)33-14-7-3-4-8-15-34-30-36-27(18-28(38)37(30)2)21-13-16-32-19-24(21)31/h11-13,16-19H,3-10,14-15H2,1-2H3,(H,33,35)(H,34,36)",RNWDPTGCROIQPR-UHFFFAOYSA-N,50580438,CHEMBL5083921,Acetylcholinesterase,Mus musculus, 298300
867246,CC(C)N(C)CC(=O)N1CCN(C[C@H]1C)c1ccc2[nH]c(c(C(C)C)c2n1)-c1cn2ncnc2c(C)c1C,,,428507,"US10544143, Example 943::US10730877, Example 943::US11053244, Example 943",Toll-like receptor 9,, 10046
587582,Fc1ccc(cc1)-c1nc2ccc(cc2nc1-c1ccc(F)cc1)C(=O)N1CC(C1)n1cccn1,"InChI=1S/C27H19F2N5O/c28-20-7-2-17(3-8-20)25-26(18-4-9-21(29)10-5-18)32-24-14-19(6-11-23(24)31-25)27(35)33-15-22(16-33)34-13-1-12-30-34/h1-14,22H,15-16H2",RRMXUTXSWZYNQU-UHFFFAOYSA-N,306087,"US10144742, Compound I-249",Nicotinamide phosphoribosyltransferase,Homo sapiens, 1500
566484,CC1N(CCc2c1nnn2-c1cc(C)ccn1)C(=O)c1cccc(Cl)c1Cl,"InChI=1S/C19H17Cl2N5O/c1-11-6-8-22-16(10-11)26-15-7-9-25(12(2)18(15)23-24-26)19(27)13-4-3-5-14(20)17(13)21/h3-6,8,10,12H,7,9H2,1-2H3",YMZRPAMOYRNYTO-UHFFFAOYSA-N,254334,"US10112937, Example 237::US10150765, Example 237::US10703749, Example 237::US9464084, 237",P2X purinoceptor 7,,
50624035,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(Cl)c(Cc2ncc(s2)-c2ccc(Cl)s2)c1,"InChI=1S/C20H19Cl2NO5S2/c21-11-2-1-9(20-19(27)18(26)17(25)12(8-24)28-20)5-10(11)6-16-23-7-14(30-16)13-3-4-15(22)29-13/h1-5,7,12,17-20,24-27H,6,8H2/t12-,17-,18+,19-,20+/m1/s1",LCPLNMQMXPLKAH-NMDLUNGESA-N,50337069,"(2S,3R,4R,5S,6R)-2-(4-Chloro-3-((5-(5-chlorothiophen-2-yl)thiazol-2-yl)methyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol::CHEMBL1672797",Sodium/glucose cotransporter 2,, 13.3
375555,OC[C@@H]1CCN(C1)c1ncc(cc1-c1cncnc1)C(=O)Nc1ccc(OC(F)(F)F)cc1,"InChI=1S/C22H20F3N5O3/c23-22(24,25)33-18-3-1-17(2-4-18)29-21(32)15-7-19(16-8-26-13-27-9-16)20(28-10-15)30-6-5-14(11-30)12-31/h1-4,7-10,13-14,31H,5-6,11-12H2,(H,29,32)/t14-/m1/s1",KSVMXLZKYBUCLY-CQSZACIVSA-N,213483,"US9278981, 75",Tyrosine-protein kinase ABL1 [64-515],, 0.6
816431,COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1ccc(C)cc1F,"InChI=1S/C27H27FN4O3/c1-19-6-11-22(24(28)13-19)14-29-27(34)23-17-32(30-25(23)18-35-2)16-21-9-7-20(8-10-21)15-31-12-4-3-5-26(31)33/h3-13,17H,14-16,18H2,1-2H3,(H,29,34)",XRBNFAVKAJTXOR-UHFFFAOYSA-N,408745," N-[(2-fluoro-4-methylphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 65::US11001578, Example 65::US11084809, Example 65::US11198691, Example 65",Plasma kallikrein,, 43.3
50099784,CCOC(=O)C1C(c2cc3ccccc3o2)C(C(=O)OCC)=C(N=C1C)c1ccccc1,"InChI=1S/C26H25NO5/c1-4-30-25(28)21-16(3)27-24(17-11-7-6-8-12-17)23(26(29)31-5-2)22(21)20-15-18-13-9-10-14-19(18)32-20/h6-15,21-22H,4-5H2,1-3H3",PFFBMDVBJJYFGS-UHFFFAOYSA-N,50059402,"4-Benzofuran-2-yl-2-methyl-6-phenyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid diethyl ester::CHEMBL90160",Adenosine receptor A3,Homo sapiens,
50096180,CC[C@H](C)[C@H](N)C(=O)NCC(=O)N[C@H]1C[C@H](N(C1)S(=O)(=O)c1ccc(C)cc1)C(=O)NO,"InChI=1S/C20H31N5O6S.ClH/c1-4-13(3)18(21)20(28)22-10-17(26)23-14-9-16(19(27)24-29)25(11-14)32(30,31)15-7-5-12(2)6-8-15;/h5-8,13-14,16,18,29H,4,9-11,21H2,1-3H3,(H,22,28)(H,23,26)(H,24,27);1H/t13-,14-,16-,18-;/m0./s1",QVRJGTLBQPBIAT-OYDMLLMWSA-N,50014604,CHEMBL3261751,72 kDa type IV collagenase,, 2050
98433,Cn1c2nc(N=NC=C(Br)Cc3ccccc3)n(CCO)c2c(=O)[nH]c1=O,"InChI=1S/C17H17BrN6O3/c1-23-14-13(15(26)21-17(23)27)24(7-8-25)16(20-14)22-19-10-12(18)9-11-5-3-2-4-6-11/h2-6,10,25H,7-9H2,1H3,(H,21,26,27)",WKENHJWIALXWRP-UHFFFAOYSA-N,52900,"8-[2-[(Z)-2-bromanyl-3-phenyl-prop-2-enylidene]hydrazinyl]-7-(2-hydroxyethyl)-3-methyl-purine-2,6-dione::8-[2-[(Z)-2-bromo-3-phenylprop-2-enylidene]hydrazinyl]-7-(2-hydroxyethyl)-3-methylpurine-2,6-dione::8-[N'-[(Z)-2-bromo-3-phenyl-prop-2-enylidene]hydrazino]-7-(2-hydroxyethyl)-3-methyl-xanthine::8-{N&#39;-[(Z)-2-Bromo-3-phenyl-prop-2-en-(E)-ylidene]-hydrazino}-7-(2-hydroxy-ethyl)-3-methyl-3,7-dihydro- purine-2,6-dione::MLS000333086::SMR000436442::cid_1398685",Zinc finger protein mex-5,Caenorhabditis elegans,
51003600,Clc1cc(cnc1Cl)N1CC[C@@H]2CN[C@@H]2C1,"InChI=1S/C11H13Cl2N3/c12-9-3-8(5-15-11(9)13)16-2-1-7-4-14-10(7)6-16/h3,5,7,10,14H,1-2,4,6H2/t7-,10-/m1/s1",PDNPYVGEHRTDKO-GMSGAONNSA-N,50411226,CHEMBL506353,Neuronal acetylcholine receptor subunit alpha-4/beta-2,,
51286353,CCn1c(SCc2ccc(\C=C\C(=O)Nc3ccccc3N)cc2)nc2cc(OC)ccc2c1=O,"InChI=1S/C27H26N4O3S/c1-3-31-26(33)21-14-13-20(34-2)16-24(21)30-27(31)35-17-19-10-8-18(9-11-19)12-15-25(32)29-23-7-5-4-6-22(23)28/h4-16H,3,17,28H2,1-2H3,(H,29,32)/b15-12+",MUTSCGGZWZWVHL-NTCAYCPXSA-N,50524396,CHEMBL4573943,Histone deacetylase 1,Homo sapiens, 100
474875,NC(=O)CNCCOc1cccc(c1)C(=O)NCC(O)CN1CCc2ccccc2C1,"InChI=1S/C23H30N4O4/c24-22(29)14-25-9-11-31-21-7-3-6-18(12-21)23(30)26-13-20(28)16-27-10-8-17-4-1-2-5-19(17)15-27/h1-7,12,20,25,28H,8-11,13-16H2,(H2,24,29)(H,26,30)",JPGWXFLHZMPPJL-UHFFFAOYSA-N,178897,"US10307413, Compound 222::US10391089, Compound 222::US10980794, Cmpd No 222::US9675614, 222",Protein arginine N-methyltransferase 5,,<100
784460,Cc1n[nH]c(C(=O)Nc2cnc3[nH]c(I)cc3c2)c1C,"InChI=1S/C13H12IN5O/c1-6-7(2)18-19-11(6)13(20)16-9-3-8-4-10(14)17-12(8)15-5-9/h3-5H,1-2H3,(H,15,17)(H,16,20)(H,18,19)",SRSVYCGELGRTME-UHFFFAOYSA-N,392482,"N-(2-iodo-1H-pyrrolo[2,3-b]pyridin- 5-yl)-3,4-dimethyl-1H-pyrazole-5- carboxamide::US10301280, Compound P-2188",Mast/stem cell growth factor receptor Kit [D816V],,
968674,Cc1nc(F)ccc1-c1cc(CNC2=NCCN2)cc(n1)C(=O)NCc1ccc(Cl)c(F)c1,"InChI=1S/C23H21ClF2N6O/c1-13-16(3-5-21(26)31-13)19-9-15(12-30-23-27-6-7-28-23)10-20(32-19)22(33)29-11-14-2-4-17(24)18(25)8-14/h2-5,8-10H,6-7,11-12H2,1H3,(H,29,33)(H2,27,28,30)",SMSOHNFGNDOORA-UHFFFAOYSA-N,468803,"US10807959, Example 73",WD repeat-containing protein 5,,
51277659,C[C@@H]1Cn2c(c(CCCOc3cc(C)c(Cl)c(C)c3)c3ccc(Cl)c(-c4c(C)nn(C)c4C)c23)C(=O)N1Cc1ccc(o1)C(O)=O,"InChI=1S/C35H36Cl2N4O5/c1-18-14-24(15-19(2)31(18)37)45-13-7-8-25-26-10-11-27(36)30(29-21(4)38-39(6)22(29)5)32(26)41-16-20(3)40(34(42)33(25)41)17-23-9-12-28(46-23)35(43)44/h9-12,14-15,20H,7-8,13,16-17H2,1-6H3,(H,43,44)/t20-/m1/s1",DBLYUECFQBVGCM-HXUWFJFHSA-N,429026,"US10533010, Example I-123::US11208415, Example I-123",Induced myeloid leukemia cell differentiation protein Mcl-1,Homo sapiens,
1040313,CN1CCN(CC1)c1ccc(cc1)-c1n[nH]c2cnc(nc12)-c1c(F)ccc2CNCCc12,"InChI=1S/C25H26FN7/c1-32-10-12-33(13-11-32)18-5-2-16(3-6-18)23-24-21(30-31-23)15-28-25(29-24)22-19-8-9-27-14-17(19)4-7-20(22)26/h2-7,15,27H,8-14H2,1H3,(H,30,31)",GHYNGNLPVAZBOD-UHFFFAOYSA-N,499018,"US11014929, Example 56",Mitogen-activated protein kinase kinase kinase kinase 1,Homo sapiens,
50514425,N[C@@H](CC(=O)N1CCC[C@H]1CNc1ncc(F)cn1)Cc1cc(F)c(F)cc1F,"InChI=1S/C19H21F4N5O/c20-12-8-25-19(26-9-12)27-10-14-2-1-3-28(14)18(29)6-13(24)4-11-5-16(22)17(23)7-15(11)21/h5,7-9,13-14H,1-4,6,10,24H2,(H,25,26,27)/t13-,14+/m1/s1",FYJPPDTZOPGILJ-KGLIPLIRSA-N,50296775,"(R)-3-amino-1-((S)-2-((5-fluoropyrimidin-2-ylamino)methyl)pyrrolidin-1-yl)-4-(2,4,5-trifluorophenyl)butan-1-one::CHEMBL549581",Dipeptidyl peptidase 4,Homo sapiens, 7.1
50979123,COc1ccc(CCN2C3C4C5C6C4C2(O)C2C6CC5C32)cc1,"InChI=1S/C20H23NO2/c1-23-10-4-2-9(3-5-10)6-7-21-19-15-11-8-12-14-13(11)16(19)18(14)20(21,22)17(12)15/h2-5,11-19,22H,6-8H2,1H3",TWMXGXSGGIIQDM-UHFFFAOYSA-N,50401376,CHEMBL2205812,Muscarinic acetylcholine receptor M3,Homo sapiens,
50461598,COc1ccc(cc1)C(=O)n1c(C)c(Cc2cccc(O[C@@H](C)C(O)=O)c2)c2cc(OC(F)(F)F)ccc12,"InChI=1S/C28H24F3NO6/c1-16-23(14-18-5-4-6-21(13-18)37-17(2)27(34)35)24-15-22(38-28(29,30)31)11-12-25(24)32(16)26(33)19-7-9-20(36-3)10-8-19/h4-13,15,17H,14H2,1-3H3,(H,34,35)/t17-/m0/s1",OFCWBJAYEIROGZ-KRWDZBQOSA-N,50157917,(2S)-2-(3-{[1-(4-METHOXYBENZOYL)-2-METHYL-5-(TRIFLUOROMETHOXY)-1H-INDOL-3-YL]METHYL}PHENOXY)PROPANOIC ACID::(S)-2-(3-((1-(4-methoxybenzoyl)-2-methyl-5-(trifluoromethoxy)-1H-indol-3-yl)methyl)phenoxy)propanoic acid::(S)-2-{3-[1-(4-Methoxy-benzoyl)-2-methyl-5-trifluoromethoxy-1H-indol-3-ylmethyl]-phenoxy}-propionic acid::CHEMBL179330,Peroxisome proliferator-activated receptor gamma,Homo sapiens, 1
993616,NC1=N[C@@](CF)([C@@H]2C[C@@]2(S1)\C=C\C(=O)N1CCOCC1)c1cc(ccc1F)C#Cc1ccc(cc1)C#N,"InChI=1S/C28H24F2N4O2S/c29-18-28(22-15-20(7-8-23(22)30)4-1-19-2-5-21(17-31)6-3-19)24-16-27(24,37-26(32)33-28)10-9-25(35)34-11-13-36-14-12-34/h2-3,5-10,15,24H,11-14,16,18H2,(H2,32,33)/b10-9+/t24-,27+,28-/m1/s1",HKMWURYHQXDLAG-NVAWJBEOSA-N,477919,"4-((3-((1R,5S,6S)-3-amino-5-(fluoromethyl)-1-((E)-3-morpholino-3-oxoprop-1-en-1-yl)-2-thia-4-azabicyclo[4.1.0]hept-3-en-5-yl)-4-fluorophenyl)ethynyl)benzonitrile::US10889581, Example 122",Cathepsin D,Homo sapiens, 84300
51277841,CN(CC1CCCCC1)[C@H]1CC[C@@]2(CC1)OC=Cc1ccccc21,"InChI=1S/C22H31NO/c1-23(17-18-7-3-2-4-8-18)20-11-14-22(15-12-20)21-10-6-5-9-19(21)13-16-24-22/h5-6,9-10,13,16,18,20H,2-4,7-8,11-12,14-15,17H2,1H3/t20-,22-",DFGZNCBJYISTLB-AQYVVDRMSA-N,50521528,CHEMBL4577975,Mu-type opioid receptor,Cavia cutleri,
1045073,CCOc1ncccc1-c1cc(NCc2noc(C)n2)c(NC(C)CC)c(n1)C(C)=N,"InChI=1S/C22H29N7O2/c1-6-13(3)26-21-18(25-12-19-27-15(5)31-29-19)11-17(28-20(21)14(4)23)16-9-8-10-24-22(16)30-7-2/h8-11,13,23,26H,6-7,12H2,1-5H3,(H,25,28)",DFUHIVBKOGIXKT-UHFFFAOYSA-N,501498,"5-(2-ethoxy-3-pyridyl)-3-methyl-N-[(5-methyl- 1,2,4-oxadiazol-3-yl)methyl]-1-[1- methylpropyl]pyrazolo[4,3-b]pyridin-7-amine, enantiomer 2::US11026923, Example 128","Dual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B",Homo sapiens, 0.260
50564344,COc1ccc2oc(=N)c(cc2c1)C(=O)Nc1ccc(O)cc1,"InChI=1S/C17H14N2O4/c1-22-13-6-7-15-10(8-13)9-14(16(18)23-15)17(21)19-11-2-4-12(20)5-3-11/h2-9,18,20H,1H3,(H,19,21)",SRNSNPQYFSKAGX-UHFFFAOYSA-N,50213367,CHEMBL310404,Tyrosine-protein kinase Lck,, 24100
50922796,Cn1cc(cn1)-c1cnc2ccc3ccc(NS(C)(=O)=O)cc3c(=O)c2c1,"InChI=1S/C19H16N4O3S/c1-23-11-14(10-21-23)13-7-17-18(20-9-13)6-4-12-3-5-15(22-27(2,25)26)8-16(12)19(17)24/h3-11,22H,1-2H3",HPFFXKLJHGEJTO-UHFFFAOYSA-N,50347686,CHEMBL1802602,Potassium voltage-gated channel subfamily H member 2,Homo sapiens, 10100
50956538,CCC[C@H]1COc2ccsc2C(N)=N1,"InChI=1S/C10H14N2OS/c1-2-3-7-6-13-8-4-5-14-9(8)10(11)12-7/h4-5,7H,2-3,6H2,1H3,(H2,11,12)/t7-/m0/s1",JIIBOYBTIWHZFJ-ZETCQYMHSA-N,50392587,CHEMBL1230023,"Nitric oxide synthase, inducible",Homo sapiens, 40
51440629,CCCCn1c(=O)n(CCCNC(=O)c2ccc(cc2)S(F)(=O)=O)c2[nH]c(nc2c1=O)C12CCC(CC1)(CC2)C(=O)NCCCCN=[N+]=[N-],"InChI=1S/C32H42FN9O6S/c1-2-3-20-42-27(44)24-25(41(30(42)46)21-6-18-35-26(43)22-7-9-23(10-8-22)49(33,47)48)39-28(38-24)31-11-14-32(15-12-31,16-13-31)29(45)36-17-4-5-19-37-40-34/h7-10H,2-6,11-21H2,1H3,(H,35,43)(H,36,45)(H,38,39)",PRYJQIVBGGDTIP-UHFFFAOYSA-N,50581958,CHEMBL5089483,Adenosine receptor A1,Homo sapiens,
50991047,FC(F)(F)c1cccc(Nc2nc(NC3CC3)nc(n2)N2CCNCC2)c1,"InChI=1S/C17H20F3N7/c18-17(19,20)11-2-1-3-13(10-11)23-15-24-14(22-12-4-5-12)25-16(26-15)27-8-6-21-7-9-27/h1-3,10,12,21H,4-9H2,(H2,22,23,24,25,26)",NCWADNOZGFPCTN-UHFFFAOYSA-N,50282183,CHEMBL4167322,Cholinesterase,, 3650
296662,CN1CCN(Cc2ccc(NC(=O)c3cccc4cc(Oc5cc(NC(C)=O)ncn5)ccc34)cc2C(F)(F)F)CC1,"InChI=1S/C30H29F3N6O3/c1-19(40)36-27-16-28(35-18-34-27)42-23-8-9-24-20(14-23)4-3-5-25(24)29(41)37-22-7-6-21(26(15-22)30(31,32)33)17-39-12-10-38(2)11-13-39/h3-9,14-16,18H,10-13,17H2,1-2H3,(H,37,41)(H,34,35,36,40)",MZZJNOOADWVFPD-UHFFFAOYSA-N,154577,K03859 (2),Cyclin-dependent kinase 2,Homo sapiens,>1.0e+4
393896,CN(C)c1ccc(Nc2nccc(n2)-c2sc(C)nc2C)cc1Cl,"InChI=1S/C17H18ClN5S/c1-10-16(24-11(2)20-10)14-7-8-19-17(22-14)21-12-5-6-15(23(3)4)13(18)9-12/h5-9H,1-4H3,(H,19,21,22)",FUDBRAFSKPGJJE-UHFFFAOYSA-N,8068,"2-Anilino-4-(thiazol-5-yl)pyrimidine deriv. 39::2-Chloro-N4-[4-(2,4-dimethylthiazol-5-yl)pyrimidin-2-yl]-N1,N1-dimethylbenzene-1,4-diamine::2-chloro-4-N-[4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-yl]-1-N,1-N-dimethylbenzene-1,4-diamine::CS20",Cyclin-dependent kinase 2,Homo sapiens,
200783,Brc1cccc(CN=Nc2nc(cs2)-c2cc3ccccc3oc2=O)c1,"InChI=1S/C19H12BrN3O2S/c20-14-6-3-4-12(8-14)10-21-23-19-22-16(11-26-19)15-9-13-5-1-2-7-17(13)25-18(15)24/h1-9,11H,10H2",WPAYSQMLGNYIAS-UHFFFAOYSA-N,92548,"Coumarin analogue, 3f",Cholinesterase,Homo sapiens,
51316177,CNC(=O)Nc1cc(Oc2cncc(OC)c2)c(cn1)[C@H]1CCCOC1,"InChI=1S/C18H22N4O4/c1-19-18(23)22-17-7-16(26-14-6-13(24-2)8-20-9-14)15(10-21-17)12-4-3-5-25-11-12/h6-10,12H,3-5,11H2,1-2H3,(H2,19,21,22,23)/t12-/m0/s1",APSOPISMEDAYTH-LBPRGKRZSA-N,50533114,CHEMBL4553907,Hexokinase-4,Homo sapiens,
1164178,COc1cc2nc(N)n3nc(nc3c2cc1F)C1CCC(C)N(C1)c1cnn(c1)C(C)(C)C(C)(C)O,"InChI=1S/C25H33FN8O2/c1-14-7-8-15(12-32(14)16-11-28-33(13-16)24(2,3)25(4,5)35)21-30-22-17-9-18(26)20(36-6)10-19(17)29-23(27)34(22)31-21/h9-11,13-15,35H,7-8,12H2,1-6H3,(H2,27,29)",RTTLGBAFQIOJQU-UHFFFAOYSA-N,551498,"3-(4-((2S,5R or 2R,5S)-5-(5-amino-9-fluoro-8-methoxy- [1,2,4]triazolo[1,5-c]quinazolin-2-yl)-2-methylpiperidin-1- yl)-1H-pyrazol-1-yl)-2,3-dimethylbutan-2-ol::US11312719, Example 43",Adenosine receptor A2b,Homo sapiens, 3.40
577005,CCC(c1cn(nn1)-c1ccc(F)c(F)c1)c1cc(-c2cnc(nc2)C(F)(F)F)c2c(N)ncnn12,"InChI=1S/C22H16F5N9/c1-2-13(17-9-35(34-33-17)12-3-4-15(23)16(24)5-12)18-6-14(19-20(28)31-10-32-36(18)19)11-7-29-21(30-8-11)22(25,26)27/h3-10,13H,2H2,1H3,(H2,28,31,32)",YJTGMSUQZMZDBE-UHFFFAOYSA-N,301455,"7-{1-[1-(3,4-difluorophenyl)-1H-1,2,3-triazol-4-yl]propyl}-5-[2-(trifluoromethyl)pyrimidin-5-yl]pyrrolo[2,1-f][1,2,4]triazin-4-amine,enantiomer 1::US10131670, Example 63::US10131670, Example 64",Cystic fibrosis transmembrane conductance regulator,,
50167920,CC1(C)CC[C@@H]2CC(=O)O[C@@H](CO)CC(=O)O[C@@H]3C[C@@H](CCCCc4cccc(O)c4)O[C@@]1(C3)O2,"InChI=1S/C27H38O8/c1-26(2)11-10-21-14-24(30)33-23(17-28)15-25(31)32-22-13-20(34-27(26,16-22)35-21)9-4-3-6-18-7-5-8-19(29)12-18/h5,7-8,12,20-23,28-29H,3-4,6,9-11,13-17H2,1-2H3/t20-,21-,22?,23-,27+/m1/s1",WQEXBJWFPAMSGJ-OMZVUVJISA-N,50327946,"1S,3R,5R,9R,13R)-9-Hydroxymethyl-3-[4-(3-hydroxy-phenyl)-butyl]-16,16-dimethyl-2,6,10,17-tetraoxa-tricyc lo[11.3.1.1'1,5']octadecane-7,11-dione::CHEMBL1258348",Protein kinase C delta type,Homo sapiens,
1001356,O=C(Nc1cnn(Cc2ccccc2)c1)c1cc(on1)-c1cccc2cn(nc12)C1COC1,"InChI=1S/C24H20N6O3/c31-24(26-18-10-25-29(13-18)11-16-5-2-1-3-6-16)21-9-22(33-28-21)20-8-4-7-17-12-30(27-23(17)20)19-14-32-15-19/h1-10,12-13,19H,11,14-15H2,(H,26,31)",WUGIFOITIPRCAR-UHFFFAOYSA-N,482947,"US10919885, Compound No. 95",Stearoyl-CoA desaturase,,>45000
50387354,C[C@H](CNCCc1ccncc1)c1c2CN(CCc2[nH]c1-c1cc(C)cc(C)c1)C(=O)C12CC3CC(CC(C3)C1)C2,"InChI=1S/C36H46N4O/c1-23-12-24(2)14-30(13-23)34-33(25(3)21-38-10-6-26-4-8-37-9-5-26)31-22-40(11-7-32(31)39-34)35(41)36-18-27-15-28(19-36)17-29(16-27)20-36/h4-5,8-9,12-14,25,27-29,38-39H,6-7,10-11,15-22H2,1-3H3/t25-,27?,28?,29?,36?/m1/s1",DBZQPMXYZLHNKR-RPFINBQBSA-N,50213650,"CHEMBL233341::adamantan-1-yl-{2-(3,5-dimethyl-phenyl)-3-[(S)-1-methyl-2-(2-pyridin-4-yl-ethylamino)-ethyl]-1,4,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-5-yl}-methanone",Gonadotropin-releasing hormone receptor,, 546
50783868,OC(=O)c1cccc(CN2CCC(CC2)NC(=O)c2ccc(Cl)nc2Cl)c1,"InChI=1S/C19H19Cl2N3O3/c20-16-5-4-15(17(21)23-16)18(25)22-14-6-8-24(9-7-14)11-12-2-1-3-13(10-12)19(26)27/h1-5,10,14H,6-9,11H2,(H,22,25)(H,26,27)",HSSZJQABPLNKAF-UHFFFAOYSA-N,50250260,CHEMBL4093112,Sodium- and chloride-dependent GABA transporter 1,Rattus norvegicus,>300000
964139,COc1cccc(F)c1-c1nccc(n1)C(=O)Nc1ccc(cc1N1C[C@@H]2C[C@H]1CN2)-c1cnccc1C#N,"InChI=1S/C29H24FN7O2/c1-39-26-4-2-3-22(30)27(26)28-33-10-8-24(35-28)29(38)36-23-6-5-17(21-15-32-9-7-18(21)13-31)11-25(23)37-16-19-12-20(37)14-34-19/h2-11,15,19-20,34H,12,14,16H2,1H3,(H,36,38)/t19-,20-/m0/s1",XRORCPXIZILXNC-PMACEKPBSA-N,466707,"US10800761, Example 26",Mitogen-activated protein kinase kinase kinase kinase 1,Homo sapiens,
50513529,Oc1ccc(\C=C\C(=O)\C=C\c2ccc(O)cc2)cc1,"InChI=1S/C17H14O3/c18-15-7-1-13(2-8-15)5-11-17(20)12-6-14-3-9-16(19)10-4-14/h1-12,18-19H/b11-5+,12-6+",FTEGUKWEUQPKIS-YDWXAUTNSA-N,50067044,"(1E,4E)-1,5-Bis-(4-hydroxy-phenyl)-penta-1,4-dien-3-one::(1E,4E)-1,5-bis(4-hydroxyphenyl)penta-1,4-dien-3-one::1,5-Bis(4-hydroxyphenyl)penta-1,4-dien-3-one::1,5-Bis-(4-hydroxy-phenyl)-penta-1,4-dien-3-one::CHEMBL129134",Tyrosinase,Homo sapiens, 79050
939992,CC(=O)N1CCC(CC1)C(=O)N1CCC2(CC2CNC(=O)c2cc3ccncc3o2)CC1,"InChI=1S/C24H30N4O4/c1-16(29)27-8-3-17(4-9-27)23(31)28-10-5-24(6-11-28)13-19(24)14-26-22(30)20-12-18-2-7-25-15-21(18)32-20/h2,7,12,15,17,19H,3-6,8-11,13-14H2,1H3,(H,26,30)",DQUAHOJYXGGKLZ-UHFFFAOYSA-N,455485,"N-[[6-(1-acetylpiperidine-4- carbonyl)-6-azaspiro[2.5]octan- 2-yl]methyl]furo[2,3-c]pyridine- 2-carboxamide::US10730889, Example 82::US11485745, Example 82",Nicotinamide phosphoribosyltransferase,Homo sapiens, 398
50013974,CN(C)c1ccc(cc1)-c1cc(-c2ccccc2)c2c(N)ncnc2n1,"InChI=1S/C21H19N5/c1-26(2)16-10-8-15(9-11-16)18-12-17(14-6-4-3-5-7-14)19-20(22)23-13-24-21(19)25-18/h3-13H,1-2H3,(H2,22,23,24,25)",VQHJJHAACJKZCA-UHFFFAOYSA-N,50095358,"7-(4-Dimethylamino-phenyl)-5-phenyl-pyrido[2,3-d]pyrimidin-4-ylamine::CHEMBL68492",Adenosine kinase,Rattus norvegicus, 470
50834233,C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)\C=C\c1ccc(Cl)cc1NC(C)=O,"InChI=1S/C23H25ClFN3O2/c1-16-14-27(15-18-3-8-21(25)9-4-18)11-12-28(16)23(30)10-6-19-5-7-20(24)13-22(19)26-17(2)29/h3-10,13,16H,11-12,14-15H2,1-2H3,(H,26,29)/b10-6+/t16-/m1/s1",DUFKTZBQJIHIAQ-VGZDNEPHSA-N,50174702,(R)-N-(2-(3-(4-(4-fluorobenzyl)-2-methylpiperazin-1-yl)-3-oxoprop-1-enyl)-5-chlorophenyl)acetamide::CHEMBL198949,C-C chemokine receptor type 3,Homo sapiens,>10000
50493703,CC(NC(=O)c1ccc2[nH]nc(-c3ccncc3)c2c1)c1cccc(Cl)c1,"InChI=1S/C21H17ClN4O/c1-13(15-3-2-4-17(22)11-15)24-21(27)16-5-6-19-18(12-16)20(26-25-19)14-7-9-23-10-8-14/h2-13H,1H3,(H,24,27)(H,25,26)",ZEKIJJKMJBIZDL-UHFFFAOYSA-N,50166350,CHEMBL3798631,Ephrin type-A receptor 2,Homo sapiens,>1000
51201807,CC(C(=O)NCCCNC1=CC(=O)C(NCCCNC(=O)C(C)c2ccc(c(F)c2)-c2ccccc2)=CC1=O)c1ccc(c(F)c1)-c1ccccc1,"InChI=1S/C42H42F2N4O4/c1-27(31-15-17-33(35(43)23-31)29-11-5-3-6-12-29)41(51)47-21-9-19-45-37-25-40(50)38(26-39(37)49)46-20-10-22-48-42(52)28(2)32-16-18-34(36(44)24-32)30-13-7-4-8-14-30/h3-8,11-18,23-28,45-46H,9-10,19-22H2,1-2H3,(H,47,51)(H,48,52)",ULYGZQJSGMQCKG-UHFFFAOYSA-N,50494339,CHEMBL3087682,Cholinesterase,Homo sapiens, 116000
168885,OC(=O)C1CC(=NO1)c1ccc(F)cc1,"InChI=1S/C10H8FNO3/c11-7-3-1-6(2-4-7)8-5-9(10(13)14)15-12-8/h1-4,9H,5H2,(H,13,14)",PBZBMHSUDXPYCP-UHFFFAOYSA-N,80137,"3-(4-Fluoro-phenyl)-4,5-dihydro-isoxazole-5-carboxylic acid::3-(4-fluorophenyl)-2-isoxazoline-5-carboxylic acid::3-(4-fluorophenyl)-4,5-dihydro-1,2-oxazole-5-carboxylic acid::3-(4-fluorophenyl)-4,5-dihydroisoxazole-5-carboxylic acid::MLS000067264::SMR000124761::cid_2981857",Apoptotic protease-activating factor 1,Homo sapiens,
51308264,O[C@@]1(CCN(C1=O)c1ccc2NC(=O)CCc2c1)C(=O)NCc1cc(F)cc(Cl)c1,"InChI=1S/C21H19ClFN3O4/c22-14-7-12(8-15(23)10-14)11-24-19(28)21(30)5-6-26(20(21)29)16-2-3-17-13(9-16)1-4-18(27)25-17/h2-3,7-10,30H,1,4-6,11H2,(H,24,28)(H,25,27)/t21-/m0/s1",RMWSKRBLJAUOOY-NRFANRHFSA-N,50524862,CHEMBL4475680,Methionine aminopeptidase 2,Homo sapiens, 75
54959,CC1CNC(=O)c2[nH]c3ccc(cc3c12)C(=O)Nc1cnccn1,"InChI=1S/C17H15N5O2/c1-9-7-20-17(24)15-14(9)11-6-10(2-3-12(11)21-15)16(23)22-13-8-18-4-5-19-13/h2-6,8-9,21H,7H2,1H3,(H,20,24)(H,19,22,23)",SCZSZUZHNGMDLI-UHFFFAOYSA-N,30228,"carboline analog, 40",MAP kinase-activated protein kinase 2 [41-364],Homo sapiens, 440
51258131,Cc1ccnc2N(C3CC3)c3ncccc3C(=O)Nc12,"InChI=1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20)",NQDJXKOVJZTUJA-UHFFFAOYSA-N,1434,"11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2 ,3 -e][1,4]diazepin-6-one::2-cyclopropyl-7-methyl-2,4,9,15-tetraazatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3,5,7,12,14-hexaen-10-one::BI-RG-587::CHEMBL57::Nevirapine::Nevirapine (NVP)::US11420959, Example NVP::Viramune",Reverse transcriptase,Human immunodeficiency virus 1, 404
51424917,COc1cc2c(NCc3ccc(cc3)C(=O)NO)cc(nc2cc1OCCCN1CCCC1)-c1ccc(C)o1,"InChI=1S/C30H34N4O5/c1-20-6-11-27(39-20)26-17-24(31-19-21-7-9-22(10-8-21)30(35)33-36)23-16-28(37-2)29(18-25(23)32-26)38-15-5-14-34-12-3-4-13-34/h6-11,16-18,36H,3-5,12-15,19H2,1-2H3,(H,31,32)(H,33,35)",QBKLIARRJUTMTQ-UHFFFAOYSA-N,50575610,CHEMBL4872188,Histone-lysine N-methyltransferase EHMT2,, 471
50885130,CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12,"InChI=1S/C19H19N5/c1-19(2,3)24-18-15(17(20)21-11-22-18)16(23-24)14-10-6-8-12-7-4-5-9-13(12)14/h4-11H,1-3H3,(H2,20,21,22)",XSHQBIXMLULFEV-UHFFFAOYSA-N,50229961,"1-(1,1-dimethylethyl)-3-(1-naphthalenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine::1-(tert-butyl)-3-(naphthalen-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (4)::1-NA-PP1::1-tert-butyl-3-(naphthalen-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (4)::1-tert-butyl-3-naphthalen-1-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine::4-Amino-1-tert-butyl-3-(1'-naphthyl)pyrazolo[3,4-d]pyrimidine::CHEMBL264406::US10544104, Compound 1::US11247972, Compound 1::US9765037, Compound 1",Casein kinase I isoform delta,, 150
291094,NS(=O)(=O)CCNC(=O)C(c1nc2ccc(cc2s1)-c1ccc(cc1)C(=O)NCCO)S(=O)(=O)CC1CC1,"InChI=1S/C24H28N4O7S3/c25-38(34,35)12-10-27-23(31)21(37(32,33)14-15-1-2-15)24-28-19-8-7-18(13-20(19)36-24)16-3-5-17(6-4-16)22(30)26-9-11-29/h3-8,13,15,21,29H,1-2,9-12,14H2,(H,26,30)(H,27,31)(H2,25,34,35)",FYUCHDVXIQUWSJ-UHFFFAOYSA-N,151263,"BDBM151426::US8987314, B59",Endothelial lipase,Homo sapiens, 3.7
51165702,Oc1ccc2CN(N(S(=O)(=O)c3ccc(F)cc3)S(=O)(=O)c3ccc(F)cc3)C(=O)c2c1O,"InChI=1S/C20H14F2N2O7S2/c21-13-2-6-15(7-3-13)32(28,29)24(33(30,31)16-8-4-14(22)5-9-16)23-11-12-1-10-17(25)19(26)18(12)20(23)27/h1-10,25-26H,11H2",IVUIJNADPLDCOE-UHFFFAOYSA-N,50477848,CHEMBL400246,Integrase,,>333000
817876,CN(C)C(=O)Cn1cc(C)c2ncc(cc12)-c1ccc(F)c(C)c1F,"InChI=1S/C19H19F2N3O/c1-11-9-24(10-17(25)23(3)4)16-7-13(8-22-19(11)16)14-5-6-15(20)12(2)18(14)21/h5-9H,10H2,1-4H3",RIZKGTBTXSJJCN-UHFFFAOYSA-N,409754,"2-[6-(2,4-Difluoro-3-methyl-phenyl)-3-methyl-pyrrolo[3,2-::US10377753, Example 622","Glutamate receptor ionotropic, NMDA 2B",Homo sapiens, 100
51124963,Cc1cc(Cl)ccc1COc1ccnn1-c1cc(ccn1)C(O)=O,"InChI=1S/C17H14ClN3O3/c1-11-8-14(18)3-2-13(11)10-24-16-5-7-20-21(16)15-9-12(17(22)23)4-6-19-15/h2-9H,10H2,1H3,(H,22,23)",PSOBPHXKKHPWMU-UHFFFAOYSA-N,191600,"2-(5-((4-chloro-2-methylbenzyl)oxy)-1Hpyrazol-1-yl)isonicotinic acid (N19)::US10173996, Example 89::US9604961, Example 89::US9714230, 89::US9908865, Example 89",Lysine-specific demethylase 4B,, 170
1004085,CC(c1ccc(nc1)C(F)(F)F)n1nc(C#N)c2c1nc([nH]c2=O)C1CCC1c1ncc(C)cn1,,,484509,"US10934294, Example 31::US10934294, Example 32::US10934294, Example 33::US11028092, Example 33","Isoform PDE9A2 of High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A (PDE9A2)",,
191573,COC(=O)c1cc(O)cc(OC)c1Oc1cc(C)cc(O)c1C(O)=O,"InChI=1S/C17H16O8/c1-8-4-11(19)14(16(20)21)12(5-8)25-15-10(17(22)24-3)6-9(18)7-13(15)23-2/h4-7,18-19H,1-3H3,(H,20,21)",XOKVHFNTYHPEHN-UHFFFAOYSA-N,50711,2-(2-carbomethoxy-4-hydroxy-6-methoxy-phenoxy)-6-hydroxy-4-methyl-benzoic acid::2-(2-methoxy-6-methoxycarbonyl-4-oxidanyl-phenoxy)-4-methyl-6-oxidanyl-benzoic acid::2-hydroxy-6-(4-hydroxy-2-methoxy-6-methoxycarbonylphenoxy)-4-methylbenzoic acid::CHEMBL469424::MLS000863583::SMR000440714::cid_3080568,Tyrosine-protein kinase ABL1,Homo sapiens, 20687
219830,CC1(C)CN(CC[C@]1(O)c1ccc(Cl)cc1)C(=O)[C@H]1CCC[C@H]1NC(=O)c1cccc(c1)C(N)=O,"InChI=1S/C27H32ClN3O4/c1-26(2)16-31(14-13-27(26,35)19-9-11-20(28)12-10-19)25(34)21-7-4-8-22(21)30-24(33)18-6-3-5-17(15-18)23(29)32/h3,5-6,9-12,15,21-22,35H,4,7-8,13-14,16H2,1-2H3,(H2,29,32)(H,30,33)/t21-,22+,27-/m0/s1",UCHRUAZFWFXKGC-XXAUWVGASA-N,102332,"US8536198, 89",C-C chemokine receptor type 1,Homo sapiens, 1.8
50368363,CN1CCC(CC1)c1ccc2nc(Nc3ccc(cn3)C(F)(F)F)[nH]c2c1,"InChI=1S/C19H20F3N5/c1-27-8-6-12(7-9-27)13-2-4-15-16(10-13)25-18(24-15)26-17-5-3-14(11-23-17)19(20,21)22/h2-5,10-12H,6-9H2,1H3,(H2,23,24,25,26)",FBFBLQCDCBRLRG-UHFFFAOYSA-N,50100083,CHEMBL3321972,Potassium voltage-gated channel subfamily H member 2,Homo sapiens, 4300
50329810,OC1C[C@@H]2CC[C@@H](C1)N2c1ccc(cc1)-c1n[nH]c2ccc(cc12)C(=O)N[C@@H](C1CC1)c1ccccn1,"InChI=1S/C30H31N5O2/c36-24-16-22-11-12-23(17-24)35(22)21-9-6-18(7-10-21)28-25-15-20(8-13-26(25)33-34-28)30(37)32-29(19-4-5-19)27-3-1-2-14-31-27/h1-3,6-10,13-15,19,22-24,29,36H,4-5,11-12,16-17H2,(H,32,37)(H,33,34)/t22-,23-,29-/m0/s1",DUKJABPGWUISRC-BOSRLCDASA-N,50081578,CHEMBL3422091,Dual specificity protein kinase TTK,Homo sapiens, 1.2
670477,Cc1c[nH]c(=O)cc1NC(=O)c1ccc(cc1Oc1ccc(F)cc1C)C(F)(F)F,"InChI=1S/C21H16F4N2O3/c1-11-7-14(22)4-6-17(11)30-18-8-13(21(23,24)25)3-5-15(18)20(29)27-16-9-19(28)26-10-12(16)2/h3-10H,1-2H3,(H2,26,27,28,29)",CCCHJFNYZTUPLI-UHFFFAOYSA-N,161301,"US10087143, Compound 86::US10738009, Compound 86::US9051270, 86::US9758483, Compound 86",Sodium channel protein type 10 subunit alpha,, 3550
50926675,CC[C@@H]1[C@@H](C)C[C@@H]2[C@@H]([C@@H](C)OC2=O)[C@H]1CCc1ccc(cn1)-c1cccc(c1)C(F)(F)F,"InChI=1S/C26H30F3NO2/c1-4-21-15(2)12-23-24(16(3)32-25(23)31)22(21)11-10-20-9-8-18(14-30-20)17-6-5-7-19(13-17)26(27,28)29/h5-9,13-16,21-24H,4,10-12H2,1-3H3/t15-,16+,21+,22-,23+,24-/m0/s1",UVOKOSOWWMCGFC-FYRYCRAESA-N,50380002,CHEMBL2012487,Proteinase-activated receptor 1,, 225
356805,CCC(CC)(NC(=O)C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCCc1ccccc1,"InChI=1S/C24H40N6O3/c1-5-24(6-2,30-20(31)17(3)4)22(33)29-19(13-10-15-28-23(25)26)21(32)27-16-14-18-11-8-7-9-12-18/h7-9,11-12,17,19H,5-6,10,13-16H2,1-4H3,(H,27,32)(H,29,33)(H,30,31)(H4,25,26,28)/t19-/m0/s1",YULOHHJNVBWZFQ-IBGZPJMESA-N,200737,"US9233086, 11L",WD repeat-containing protein 5 [24-334],,>10000
274663,CC(C)(Nc1ncc(cn1)C(=O)NO)c1cc(cc(c1)C(F)(F)F)C(F)(F)F,"InChI=1S/C16H14F6N4O2/c1-14(2,25-13-23-6-8(7-24-13)12(27)26-28)9-3-10(15(17,18)19)5-11(4-9)16(20,21)22/h3-7,28H,1-2H3,(H,26,27)(H,23,24,25)",ROUUBSJJXNNNTL-UHFFFAOYSA-N,139314,"US8614223, 92",Histone deacetylase 6,Homo sapiens, 33
986502,Brc1ccc2cc(ccc2c1)C(=O)N1C[C@H]2[C@@H]3CN(C[C@@H]3[C@H]2C1)C(=O)c1ccc2[nH]nnc2c1,,,474572,"US10849881, Example 1.004::[(3aS,3bS,6aR,6bR)-5-(1H-benzotriazole- 5-carbonyl)-octahydro-cyclobuta[1,2-c;3,4- c']dipyrrol-2-yl]-(6-bromo-naphthalen-2- yl)-methanone",Ataxin-1,, 17.0
50412873,NS(=O)(=O)Oc1ccc(CN(c2ccc(cc2)C#N)n2cnnc2)cc1,"InChI=1S/C16H14N6O3S/c17-9-13-1-5-15(6-2-13)22(21-11-19-20-12-21)10-14-3-7-16(8-4-14)25-26(18,23)24/h1-8,11-12H,10H2,(H2,18,23,24)",WEXGHQDVDVWOIU-UHFFFAOYSA-N,10017,"(4-{[(4-cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl) sulfamate::JMC503540 Compound 2::YM511 Analog 4::YM511-based dual aromatase-sulfatase inhibitor (DASI) 4::dual aromatase-sulfatase inhibitor 4",Aromatase,Homo sapiens, 100
51113509,CN(CC(=O)NCc1cnc2scc(-c3ccc(Br)cc3)n12)C(=O)Cc1ccccc1,"InChI=1S/C23H21BrN4O2S/c1-27(22(30)11-16-5-3-2-4-6-16)14-21(29)25-12-19-13-26-23-28(19)20(15-31-23)17-7-9-18(24)10-8-17/h2-10,13,15H,11-12,14H2,1H3,(H,25,29)",XSMPMIVUENKLMP-UHFFFAOYSA-N,50454815,CHEMBL4218468,"Indoleamine 2,3-dioxygenase 1",Homo sapiens, 690
51355018,Cc1onc(c1C(=O)NCCCCCNC(=O)CS)-c1ccccc1,"InChI=1S/C18H23N3O3S/c1-13-16(17(21-24-13)14-8-4-2-5-9-14)18(23)20-11-7-3-6-10-19-15(22)12-25/h2,4-5,8-9,25H,3,6-7,10-12H2,1H3,(H,19,22)(H,20,23)",WWLIISZAGFGMDE-UHFFFAOYSA-N,50439672,CHEMBL2417783,Histone deacetylase 1,Homo sapiens, 5700
768383,CN(C)c1nc(cc(=O)[nH]1)C(=O)NC(CO)c1ccc(cc1)C(F)(F)F,,,384986,"2-(dimethylamino)-N-{2- hydroxy-1-[4- (trifluoromethyl)phenyl]ethyl}-6- oxo-1,6-dihydropyrimidine-4- carboxamide::US10285989, Example 206","cGMP-dependent 3',5'-cyclic phosphodiesterase",,
50324803,CC(Nc1ncnc2sc(Br)cc12)c1ccccc1,"InChI=1S/C14H12BrN3S/c1-9(10-5-3-2-4-6-10)18-13-11-7-12(15)19-14(11)17-8-16-13/h2-9H,1H3,(H,16,17,18)",VRNQAFKWBFDABH-UHFFFAOYSA-N,50079107,CHEMBL3416602,Epidermal growth factor receptor,Homo sapiens, 156
630920,C[C@H]1CCCN([C@H]1C(=O)NS(=O)(=O)C1CC1)c1nc(ncc1F)-c1cc(-c2ccon2)n(Cc2ccccc2F)n1,"InChI=1S/C27H27F2N7O4S/c1-16-5-4-11-35(24(16)27(37)34-41(38,39)18-8-9-18)26-20(29)14-30-25(31-26)22-13-23(21-10-12-40-33-21)36(32-22)15-17-6-2-3-7-19(17)28/h2-3,6-7,10,12-14,16,18,24H,4-5,8-9,11,15H2,1H3,(H,34,37)/t16-,24+/m0/s1",CFOVXVSBIGGMAB-UPCLLVRISA-N,321597,"US10183021, Compound I-331",Guanylate cyclase soluble subunit alpha-1,,
898374,CC(NCc1cc(Cl)c(O[C@H]2CCc3c2cccc3-c2ccccc2F)cc1OCc1cncc(c1)C#N)c1ccn(C)n1,"InChI=1S/C35H31ClFN5O2/c1-22(32-12-13-42(2)41-32)40-20-25-15-30(36)35(16-34(25)43-21-24-14-23(17-38)18-39-19-24)44-33-11-10-27-26(7-5-8-29(27)33)28-6-3-4-9-31(28)37/h3-9,12-16,18-19,22,33,40H,10-11,20-21H2,1-2H3/t22?,33-/m0/s1",RHOQQLSZGOERJS-HUXBHJFZSA-N,440897,"US10639284, Compound 3.066::US11426364, Compound 3.066",Programmed cell death 1 ligand 1,, 300
50149832,COc1ccc2CCCC(CCCN3CCN(CC3)c3ccc(Cl)cc3)c2c1,"InChI=1S/C24H31ClN2O/c1-28-23-12-7-20-5-2-4-19(24(20)18-23)6-3-13-26-14-16-27(17-15-26)22-10-8-21(25)9-11-22/h7-12,18-19H,2-6,13-17H2,1H3",WZKDDXSAKSUASX-UHFFFAOYSA-N,50084491,"1-(4-Chloro-phenyl)-4-[3-(7-methoxy-1,2,3,4-tetrahydro-naphthalen-1-yl)-propyl]-piperazine (2HCL)::CHEMBL420067",5-hydroxytryptamine receptor 1A,Rattus norvegicus,
50960792,COc1ccccc1C[C@H](N1CCC(CN2CCC(CC2)Oc2ccc(Cl)c(Cl)c2)CC1)C(O)=O,"InChI=1S/C27H34Cl2N2O4/c1-34-26-5-3-2-4-20(26)16-25(27(32)33)31-14-8-19(9-15-31)18-30-12-10-21(11-13-30)35-22-6-7-23(28)24(29)17-22/h2-7,17,19,21,25H,8-16,18H2,1H3,(H,32,33)/t25-/m0/s1",VOPUEJLKUSXAOZ-VWLOTQADSA-N,50394125,CHEMBL2158775,Histamine H1 receptor,Homo sapiens,
51166537,COc1ccc(Oc2nc3ccccc3nc2N2CCN(C)CC2)cc1,"InChI=1S/C20H22N4O2/c1-23-11-13-24(14-12-23)19-20(22-18-6-4-3-5-17(18)21-19)26-16-9-7-15(25-2)8-10-16/h3-10H,11-14H2,1-2H3",KTVRQRNAKFZKNW-UHFFFAOYSA-N,50478277,CHEMBL260851,Histamine H4 receptor,Homo sapiens,
366058,NC(=O)c1c2CN(CCn2c(Cl)c1-c1cccc(c1)C(F)(F)F)C(=O)NC1CCOCC1,"InChI=1S/C21H22ClF3N4O3/c22-18-16(12-2-1-3-13(10-12)21(23,24)25)17(19(26)30)15-11-28(6-7-29(15)18)20(31)27-14-4-8-32-9-5-14/h1-3,10,14H,4-9,11H2,(H2,26,30)(H,27,31)",XDDNFRQRNABUFW-UHFFFAOYSA-N,207011,"US9233965, 96",Casein kinase I isoform epsilon,, 19
1261081,COc1ccc(CC[C@@H](N)C(=O)N[C@@H](C)C(=O)NCc2ccc(cc2)C(N)=N)c(OC)c1,"InChI=1S/C23H31N5O4/c1-14(22(29)27-13-15-4-6-17(7-5-15)21(25)26)28-23(30)19(24)11-9-16-8-10-18(31-2)12-20(16)32-3/h4-8,10,12,14,19H,9,11,13,24H2,1-3H3,(H3,25,26)(H,27,29)(H,28,30)/t14-,19+/m0/s1",VMNIMUYVNLHWHF-IFXJQAMLSA-N,595083,"US11584714, Compound 1111",Mannan-binding lectin serine protease 2,,
1116572,CC(C)COC(=O)NC(CCO[C@H]1C[C@H](CCc2ccc3CCCNc3n2)C1)C(O)=O,"InChI=1S/C23H35N3O5/c1-15(2)14-31-23(29)26-20(22(27)28)9-11-30-19-12-16(13-19)5-7-18-8-6-17-4-3-10-24-21(17)25-18/h6,8,15-16,19-20H,3-5,7,9-14H2,1-2H3,(H,24,25)(H,26,29)(H,27,28)/t16-,19-,20?",OJMCJIPSUJEOCM-QHARRCRTSA-N,528262,"US11180494, Example 132",Integrin alpha-V/beta-6,Homo sapiens, 150
1056985,Fc1cc(ccc1COc1ccccc1)-c1noc(n1)C(F)(F)F,"InChI=1S/C16H10F4N2O2/c17-13-8-10(14-21-15(24-22-14)16(18,19)20)6-7-11(13)9-23-12-4-2-1-3-5-12/h1-8H,9H2",GUKKYRKEKULSRK-UHFFFAOYSA-N,504749,"3-(3-Fluoro-4-(phenoxymethyl)phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole::US11066396, Example 168",Histone deacetylase 5,Homo sapiens, 1100
50780350,CCc1cc2OCOc2cc1Cn1c(C(O)=O)c(Cc2cccc(c2)-c2nnn[nH]2)c(=O)c2cc(OCCN)ccc12,"InChI=1S/C30H28N6O6/c1-2-18-12-25-26(42-16-41-25)13-20(18)15-36-24-7-6-21(40-9-8-31)14-22(24)28(37)23(27(36)30(38)39)11-17-4-3-5-19(10-17)29-32-34-35-33-29/h3-7,10,12-14H,2,8-9,11,15-16,31H2,1H3,(H,38,39)(H,32,33,34,35)",DKRMKDLKTIKQIE-UHFFFAOYSA-N,50249535,CHEMBL4096211,Endothelin receptor type B,Homo sapiens, 562
1039514,Fc1ccc(OC2CCNCC2)c2CN(Cc12)c1cn[nH]c(=O)c1C(F)(F)F,"InChI=1S/C18H18F4N4O2/c19-13-1-2-15(28-10-3-5-23-6-4-10)12-9-26(8-11(12)13)14-7-24-25-17(27)16(14)18(20,21)22/h1-2,7,10,23H,3-6,8-9H2,(H,25,27)",FNVHXBMAPHBJOD-UHFFFAOYSA-N,431346,"US10550105, Example 291::US10870641, Example 291::US11014913, Example 291",Protein mono-ADP-ribosyltransferase TIPARP,, 550
309426,Fc1ccc(NS(=O)(=O)c2ccc(Oc3ccc(nc3)C#N)c(c2)C#N)nc1,"InChI=1S/C18H10FN5O3S/c19-13-1-6-18(23-10-13)24-28(25,26)16-4-5-17(12(7-16)8-20)27-15-3-2-14(9-21)22-11-15/h1-7,10-11H,(H,23,24)",PQYCEXRLWIJBBP-UHFFFAOYSA-N,165866,"US9067922, 205",Solute carrier family 22 member 12,, 2628
82597,CCCSC1=N\C(=C/C=C/c2ccco2)C(=O)S1,"InChI=1S/C13H13NO2S2/c1-2-9-17-13-14-11(12(15)18-13)7-3-5-10-6-4-8-16-10/h3-8H,2,9H2,1H3/b5-3+,11-7-",NJAKAYNSGVTTFF-PGACXJNKSA-N,44455,"(4Z)-4-[(E)-3-(2-furanyl)prop-2-enylidene]-2-(propylthio)-5-thiazolone::(4Z)-4-[(E)-3-(2-furyl)prop-2-enylidene]-2-(propylthio)-2-thiazolin-5-one::(4Z)-4-[(E)-3-(furan-2-yl)prop-2-enylidene]-2-propylsulfanyl-1,3-thiazol-5-one::MLS000114057::SMR000109947::cid_2184820",Ephrin type-A receptor 4,Mus musculus,>50000
50435301,CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@@H]1CCC(=O)N1,"InChI=1S/C27H47NO5/c1-3-5-7-9-10-11-12-13-14-16-21(32-27(31)23-18-19-25(29)28-23)20-24-22(26(30)33-24)17-15-8-6-4-2/h21-24H,3-20H2,1-2H3,(H,28,29)/t21-,22-,23-,24-/m0/s1",HXMBYVLPFPHKTR-ZJZGAYNASA-N,50274183,"5-oxo-L-Proline-(1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl Ester::CHEMBL484393",Fatty-acid amide hydrolase 1 [30-579],,>50000
21773,NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3[nH]cnc3n2)cc1,"InChI=1S/C18H22N6O3S/c19-28(25,26)14-8-6-13(7-9-14)22-18-23-16-15(20-11-21-16)17(24-18)27-10-12-4-2-1-3-5-12/h6-9,11-12H,1-5,10H2,(H2,19,25,26)(H2,20,21,22,23,24)",OWXORKPNCHJYOF-UHFFFAOYSA-N,5544,4-{[6-(cyclohexylmethoxy)-9H-purin-2-yl]amino}benzene-1-sulfonamide::6-Cyclohexylmethoxy-2-(4 -sulfamoylanilino)purine::NU6102,Cyclin-A2 [171-432]/Cyclin-dependent kinase 2 [F82H],Homo sapiens, 33
50697250,Cc1cn(cn1)-c1cc(NC(=O)c2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)cc(c1)C(F)(F)F,"InChI=1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)",HHZIURLSWUIHRB-UHFFFAOYSA-N,50237710,4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide::AMN 107::AMN107::CHEMBL255863::NILOTINIB,Mitogen-activated protein kinase kinase kinase 5,,
51386769,Nc1nccn2c(nc(-c3ccc(cc3Oc3ccccc3)C(=O)Nc3cc(ccn3)C(F)(F)F)c12)[C@@H]1CC[C@H]2CCC(=O)N2C1,"InChI=1S/C33H28F3N7O3/c34-33(35,36)21-12-13-38-26(17-21)40-32(45)19-7-10-24(25(16-19)46-23-4-2-1-3-5-23)28-29-30(37)39-14-15-42(29)31(41-28)20-6-8-22-9-11-27(44)43(22)18-20/h1-5,7,10,12-17,20,22H,6,8-9,11,18H2,(H2,37,39)(H,38,40,45)/t20-,22+/m1/s1",PKPCBHYQAOQDGE-IRLDBZIGSA-N,50560330,CHEMBL4797320,Tyrosine-protein kinase BTK,Homo sapiens, 11
50465811,CCN(CC)CCCC1(C)OC=C(C1=O)c1ccccc1,"InChI=1S/C18H25NO2/c1-4-19(5-2)13-9-12-18(3)17(20)16(14-21-18)15-10-7-6-8-11-15/h6-8,10-11,14H,4-5,9,12-13H2,1-3H3",ILMOIGMXUROPNB-UHFFFAOYSA-N,50281408,2-(3-Diethylamino-propyl)-2-methyl-4-phenyl-furan-3-one; hydrochloride::CHEMBL543587,Sigma non-opioid intracellular receptor 1,Homo sapiens,
51111194,COc1cc2c(cc1-c1c(C)noc1C)[nH]c1nc(C)nc(-c3ccnc4ccccc34)c21,"InChI=1S/C26H21N5O2/c1-13-23(14(2)33-31-13)19-11-21-18(12-22(19)32-4)24-25(28-15(3)29-26(24)30-21)17-9-10-27-20-8-6-5-7-16(17)20/h5-12H,1-4H3,(H,28,29,30)",AEANZCXROGPSBY-UHFFFAOYSA-N,179481,"US9675697, Cpd. No. 73",Bromodomain-containing protein 1,,
733725,Cn1c2ccc(cc2c(=O)n(Cc2cnn(CC(N)=O)c2)c1=O)S(=O)(=O)NC1(C)CC1,"InChI=1S/C19H22N6O5S/c1-19(5-6-19)22-31(29,30)13-3-4-15-14(7-13)17(27)25(18(28)23(15)2)10-12-8-21-24(9-12)11-16(20)26/h3-4,7-9,22H,5-6,10-11H2,1-2H3,(H2,20,26)",MBRFBNICVWOBPK-UHFFFAOYSA-N,371096,"US10239843, Example 203",Poly(ADP-ribose) glycohydrolase,, 635
51169755,Cc1cc(ccc1C1CCCN1C(=O)c1cc(Cl)c(O)cc1O)C(=O)N1CC(F)(F)C1,"InChI=1S/C22H21ClF2N2O4/c1-12-7-13(20(30)26-10-22(24,25)11-26)4-5-14(12)17-3-2-6-27(17)21(31)15-8-16(23)19(29)9-18(15)28/h4-5,7-9,17,28-29H,2-3,6,10-11H2,1H3",QUODKSAJAYXMND-UHFFFAOYSA-N,50479787,CHEMBL471818,Heat shock protein HSP 90-alpha/90-beta,Homo sapiens, 30
51108650,CC(C)C1C(=S)Nc2ccc(Cl)cc2C(c2ccccc2)=[N+]1[O-],"InChI=1S/C18H17ClN2OS/c1-11(2)16-18(23)20-15-9-8-13(19)10-14(15)17(21(16)22)12-6-4-3-5-7-12/h3-11,16H,1-2H3,(H,20,23)",BWEJNCDFWWGOGA-UHFFFAOYSA-N,50452400,CHEMBL4213699,Muscarinic acetylcholine receptor M1,,
399128,COc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c3OCCc3c2Cl)cc1,"InChI=1S/C22H25ClO7/c1-28-13-4-2-11(3-5-13)8-12-9-15(21-14(17(12)23)6-7-29-21)22-20(27)19(26)18(25)16(10-24)30-22/h2-5,9,16,18-20,22,24-27H,6-8,10H2,1H3/t16-,18-,19+,20-,22+/m1/s1",APGNBALCJRLEHA-KQDNOMNESA-N,159404,"US9034921, E021::US9340521, E012",Sodium/glucose cotransporter 2,, 1.7
51253458,OC(=O)c1ccc(cc1)-n1cc(C(=O)c2c(Cl)cccc2Cl)c2ccccc12,"InChI=1S/C22H13Cl2NO3/c23-17-5-3-6-18(24)20(17)21(26)16-12-25(19-7-2-1-4-15(16)19)14-10-8-13(9-11-14)22(27)28/h1-12H,(H,27,28)",MYHNQIQWDRXLHS-UHFFFAOYSA-N,50512490,CHEMBL4454027,Nuclear receptor ROR-gamma,, 1.6
50325246,CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)nc(NCCN3CCN(CC3)c3ccc(cc3)[N+]([O-])=O)nc12,"InChI=1S/C24H32N10O6/c1-2-26-22(37)19-17(35)18(36)23(40-19)33-13-28-16-20(25)29-24(30-21(16)33)27-7-8-31-9-11-32(12-10-31)14-3-5-15(6-4-14)34(38)39/h3-6,13,17-19,23,35-36H,2,7-12H2,1H3,(H,26,37)(H3,25,27,29,30)/t17-,18+,19-,23+/m0/s1",LSZORRNSFRRABA-QPXQOZNCSA-N,50079339,CHEMBL3416784,Adenosine receptor A2a,Homo sapiens,
50627256,N[C@@H](CC(=O)N1CCn2nnc(-c3ccco3)c2C1)Cc1cc(F)c(F)cc1F,"InChI=1S/C19H18F3N5O2/c20-13-9-15(22)14(21)7-11(13)6-12(23)8-18(28)26-3-4-27-16(10-26)19(24-25-27)17-2-1-5-29-17/h1-2,5,7,9,12H,3-4,6,8,10,23H2/t12-/m1/s1",DOSNXUZYRBKPLV-GFCCVEGCSA-N,50338619,"(R)-3-amino-4-(2,4,5-trifluorophenyl)-1-(3-(furan-2-yl)-6,7-dihydro-[1,2,3]triazolo[1,5-a]pyrazin-5(4H)-yl)butan-1-one hydrochloride::CHEMBL1683996",Dipeptidyl peptidase 4,Homo sapiens, 15.8
50555028,CC[C@@]12CCN(CCc3ccccc3)C[C@@H]1Oc1ccc(O)cc21,"InChI=1S/C21H25NO2/c1-2-21-11-13-22(12-10-16-6-4-3-5-7-16)15-20(21)24-19-9-8-17(23)14-18(19)21/h3-9,14,20,23H,2,10-13,15H2,1H3/t20-,21-/m0/s1",GZBURIYLLVULIF-SFTDATJTSA-N,50017231,"(4aS,9aR)-4a-Ethyl-2-phenethyl-1,2,3,4,4a,9a-hexahydro-benzo[4,5]furo[2,3-c]pyridin-6-ol::4aS,9aR-(-)-cis-4a-Ethyl-2-(2-phenylethyl)-1,2,3,4,4a,9a-hexahydrobenzofuro[2,3-c]pyridin-6-ol::CHEMBL72180",Kappa-type opioid receptor,Homo sapiens,
1187152,CS(=O)(=O)N1CCC(CC1)Nc1ncc2cc(N)c(=O)n(C3CCCC3)c2n1,"InChI=1S/C18H26N6O3S/c1-28(26,27)23-8-6-13(7-9-23)21-18-20-11-12-10-15(19)17(25)24(16(12)22-18)14-4-2-3-5-14/h10-11,13-14H,2-9,19H2,1H3,(H,20,21,22)",LNKFDPXQGQIPDF-UHFFFAOYSA-N,370139,"US10233188, Example 28::US10800783, Example 28::US11396512, Example 28",Cyclin-dependent kinase 6/G1/S-specific cyclin-D1 [L188C],Homo sapiens,
882343,CNc1cc(nc2c(cnn12)C(=O)N[C@@H]1CC[C@H]1O)-c1cn(C(C)C)c2ncccc12,"InChI=1S/C22H25N7O2/c1-12(2)28-11-15(13-5-4-8-24-20(13)28)17-9-19(23-3)29-21(26-17)14(10-25-29)22(31)27-16-6-7-18(16)30/h4-5,8-12,16,18,23,30H,6-7H2,1-3H3,(H,27,31)/t16-,18-/m1/s1",FMPLCOQEHAJWLL-SJLPKXTDSA-N,424185,"US10508120, Compound I-640::US10577373, Compound I-640::US11046698, Compound I-640",Non-receptor tyrosine-protein kinase TYK2 [556-888],,
50831939,CC(O)[C@H](NC(=O)[C@@H]1CSSCC(NC(=O)C(Cc2ccccc2)NC(=O)CCS[C@@H]2OC(CO)[C@@H](O)[C@H](O)C2O)C(=O)N[C@@H](Cc2ccc(O)c(I)c2)C(=O)N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCC[NH3+])C(=O)N[C@@H](C(C)O)C(=O)N1)C(O)=O,"InChI=1S/C58H77IN10O18S3/c1-28(71)45-56(84)67-41(55(83)69-46(29(2)72)57(85)86)27-90-89-26-40(66-51(79)37(21-30-10-4-3-5-11-30)62-44(74)17-19-88-58-49(77)48(76)47(75)43(25-70)87-58)54(82)64-38(22-31-15-16-42(73)34(59)20-31)52(80)65-39(23-32-24-61-35-13-7-6-12-33(32)35)53(81)63-36(50(78)68-45)14-8-9-18-60/h3-7,10-13,15-16,20,24,28-29,36-41,43,45-49,58,61,70-73,75-77H,8-9,14,17-19,21-23,25-27,60H2,1-2H3,(H,62,74)(H,63,81)(H,64,82)(H,65,80)(H,66,79)(H,67,84)(H,68,78)(H,69,83)(H,85,86)/p+1/t28?,29?,36-,37?,38-,39+,40?,41-,43?,45-,46-,47+,48-,49?,58-/m0/s1",RTFUEKRNLLVDTB-GPYISCCDSA-O,50165163,"4-[(4R,7S,10S,13R,16S)-4-{[(1S)-1-carboxy-2-hydroxypropyl]carbamoyl}-16-[(4-hydroxy-3-iodophenyl)methyl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-19-[3-phenyl-2-(3-{[(2S,4S,5S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanyl}propanamido)propanamido]-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-10-yl]butan-1-aminium::Radiolabeled octreotide derivative",Somatostatin receptor type 1,,>1000
939667,CCC(CC)n1cc(cn1)-c1nc(cn2nccc12)-c1cnn(c1)C1CN(C1)C(=O)[C@H](C)O,"InChI=1S/C23H28N8O2/c1-4-18(5-2)29-11-17(9-26-29)22-21-6-7-24-31(21)14-20(27-22)16-8-25-30(10-16)19-12-28(13-19)23(33)15(3)32/h6-11,14-15,18-19,32H,4-5,12-13H2,1-3H3/t15-/m0/s1",VYIVPIOHJVLMDT-HNNXBMFYSA-N,325511,"(S)-2-hydroxy-1-(3-(4-(4-(1-(pentan-3-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl)-1H-pyrazol-1-yl)azetidin-1-yl)propan-1-one::US10189845, Example 173::US10730880, Example 173::US11028093, Example 173",Non-receptor tyrosine-protein kinase TYK2,Homo sapiens, 55
51428756,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1,"InChI=1S/C20H16ClN5O3/c1-22-19(27)16-10-12(6-8-23-16)11-29-20-17-15(7-9-28-17)18(25-26-20)24-14-4-2-13(21)3-5-14/h2-10H,11H2,1H3,(H,22,27)(H,24,25)",QFCXANHHBCGMAS-UHFFFAOYSA-N,50399538,BAY-579352::CHEMBL2079588,Platelet-derived growth factor receptor beta,Homo sapiens, 15
1242437,Clc1ccc(Oc2ccc(Oc3ncnc4ccc5N(CCOc5c34)C(=O)C=C)cc2)cc1,"InChI=1S/C25H18ClN3O4/c1-2-22(30)29-13-14-31-24-21(29)12-11-20-23(24)25(28-15-27-20)33-19-9-7-18(8-10-19)32-17-5-3-16(26)4-6-17/h2-12,15H,1,13-14H2",XYCNCHHDYVJDCA-UHFFFAOYSA-N,589058,"1-(10-(4-(4- chlorophenoxy) phenoxy)-2,3- dihydro-4H- [1,4]oxazino[2,3- f]quinazolin- 4-yl)prop-2-en- 1-one::US11548900, Example 36",Receptor tyrosine-protein kinase erbB-2,,<50
51326350,Cn1cc(cn1)-c1cnc2c(cnn2c1)-c1csc(c1)C(=O)N[C@@H]1CCCC[C@@H]1N,"InChI=1S/C21H23N7OS/c1-27-10-15(8-24-27)14-7-23-20-16(9-25-28(20)11-14)13-6-19(30-12-13)21(29)26-18-5-3-2-4-17(18)22/h6-12,17-18H,2-5,22H2,1H3,(H,26,29)/t17-,18+/m0/s1",LYADGAGFYYXXIO-ZWKOTPCHSA-N,50536679,CHEMBL4568087,Proto-oncogene tyrosine-protein kinase Src,, 3.0
50141983,CN(c1cc2COC[C@](C)(N)Cc3cccc(CC[C@@H](NC(=O)c(c2)c1)c1ccccc1)c3)S(C)(=O)=O,"InChI=1S/C29H35N3O4S/c1-29(30)18-22-9-7-8-21(14-22)12-13-27(24-10-5-4-6-11-24)31-28(33)25-15-23(19-36-20-29)16-26(17-25)32(2)37(3,34)35/h4-11,14-17,27H,12-13,18-20,30H2,1-3H3,(H,31,33)/t27-,29-/m1/s1",QQXBXYNIOWQZOP-XRKRLSELSA-N,50212186,"CHEMBL250120::N-((5R,14R)-5-amino-5-methyl-16-oxo-14-phenyl-3-oxa-15-aza-tricyclo[15.3.1.1*7,11*]docosa-1(21),7,9,11(22,17,19-hexaen-19-yl)-N-methyl-methanesulfonamide",Beta-secretase 1,Homo sapiens, 49
51222350,CCCCCCCCCCCCCC(=S)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(C)=O)[C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O,"InChI=1S/C49H87N13O7S/c1-5-7-8-9-10-11-12-13-14-15-16-24-41(70)55-29-18-17-21-38(60-47(69)42(33(3)6-2)62-46(68)37(58-34(4)63)22-19-30-56-48(51)52)44(66)59-39(23-20-31-57-49(53)54)45(67)61-40(43(50)65)32-35-25-27-36(64)28-26-35/h25-28,33,37-40,42,64H,5-24,29-32H2,1-4H3,(H2,50,65)(H,55,70)(H,58,63)(H,59,66)(H,60,69)(H,61,67)(H,62,68)(H4,51,52,56)(H4,53,54,57)/t33-,37-,38-,39-,40-,42-/m0/s1",HEMQTRCOHWZDFV-ZRBKABKMSA-N,50502278,CHEMBL4438193,NAD-dependent protein deacetylase sirtuin-1,Homo sapiens, 26
50250821,C[C@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CSSC[C@H](NC(=O)[C@H](Cc2ccccc2)NC1=O)C(O)=O)NC(=O)[C@H](N)Cc1ccc(O)cc1)[C@@H](C)c1c[nH]c2ccccc12,"InChI=1S/C64H77N11O12S2/c1-37(45-34-67-47-23-13-12-22-44(45)47)54-62(84)68-48(24-14-15-29-65)57(79)75-55(38(2)76)63(85)71-50(32-40-18-8-4-9-19-40)59(81)73-53(64(86)87)36-89-88-35-52(72-56(78)46(66)30-42-25-27-43(77)28-26-42)61(83)70-49(31-39-16-6-3-7-17-39)58(80)69-51(60(82)74-54)33-41-20-10-5-11-21-41/h3-13,16-23,25-28,34,37-38,46,48-55,67,76-77H,14-15,24,29-33,35-36,65-66H2,1-2H3,(H,68,84)(H,69,80)(H,70,83)(H,71,85)(H,72,78)(H,73,81)(H,74,82)(H,75,79)(H,86,87)/t37-,38-,46+,48-,49+,50-,51-,52+,53-,54+,55-/m0/s1",JBYIEFFUTRVYHS-AYOKHONPSA-N,50136822,CHEMBL406374::Somatostatin analogue,Somatostatin receptor type 3,Homo sapiens, 116
50531252,COc1cc(cc(OC)c1OC)C(C#Cc1c(C)nc(N)nc1N)C(C)C,"InChI=1S/C20H26N4O3/c1-11(2)14(7-8-15-12(3)23-20(22)24-19(15)21)13-9-16(25-4)18(27-6)17(10-13)26-5/h9-11,14H,1-6H3,(H4,21,22,23,24)",OHPJUBBWTNCBPF-UHFFFAOYSA-N,50298804,"(+/-)-6-methyl-5-(4-methyl-3-(3,4,5-trimethoxyphenyl)pent-1-ynyl)pyrimidine-2,4-diamine::CHEMBL582843",Dihydrofolate reductase,Homo sapiens, 290
89203,COC(=O)CCC(=O)Nc1sc(C)c(C)c1C(N)=O,"InChI=1S/C12H16N2O4S/c1-6-7(2)19-12(10(6)11(13)17)14-8(15)4-5-9(16)18-3/h4-5H2,1-3H3,(H2,13,17)(H,14,15)",BVBUTVDALUPISO-UHFFFAOYSA-N,47696,"4-[(3-carbamoyl-4,5-dimethyl-2-thienyl)amino]-4-keto-butyric acid methyl ester::4-[(3-carbamoyl-4,5-dimethyl-2-thiophenyl)amino]-4-oxobutanoic acid methyl ester::MLS000075656::N-(3-Carbamoyl-4,5-dimethyl-thiophen-2-yl)-succinamic acid methyl ester::SMR000012612::cid_649731::methyl 4-[(3-aminocarbonyl-4,5-dimethyl-thiophen-2-yl)amino]-4-oxidanylidene-butanoate::methyl 4-[(3-carbamoyl-4,5-dimethylthiophen-2-yl)amino]-4-oxobutanoate",Regulator of G-protein signaling 8,Homo sapiens,
50681399,CCCOc1ccc(C[C@H](NC(=O)c2cn(Cc3ccc(cc3)-c3ccc(Cl)cc3)c3ccccc23)C(=O)NS(=O)(=O)c2ccc(Cl)c(c2)[N+]([O-])=O)cc1,"InChI=1S/C40H34Cl2N4O7S/c1-2-21-53-31-17-9-26(10-18-31)22-36(40(48)44-54(51,52)32-19-20-35(42)38(23-32)46(49)50)43-39(47)34-25-45(37-6-4-3-5-33(34)37)24-27-7-11-28(12-8-27)29-13-15-30(41)16-14-29/h3-20,23,25,36H,2,21-22,24H2,1H3,(H,43,47)(H,44,48)/t36-/m0/s1",IODFXJPIHMAKHA-BHVANESWSA-N,50231468,CHEMBL4074232,Apoptosis regulator Bcl-2,,
50587966,COC1(CCOCC1)c1cc(F)cc(OCc2cc(-c3ccc(Cl)cc3)n(n2)S(N)(=O)=O)c1,"InChI=1S/C22H23ClFN3O5S/c1-30-22(6-8-31-9-7-22)16-10-18(24)12-20(11-16)32-14-19-13-21(27(26-19)33(25,28)29)15-2-4-17(23)5-3-15/h2-5,10-13H,6-9,14H2,1H3,(H2,25,28,29)",WYRUXQCDQBMXFY-UHFFFAOYSA-N,50110485,5-(4-Chloro-phenyl)-3-[3-fluoro-5-(4-methoxy-tetrahydro-pyran-4-yl)-phenoxymethyl]-pyrazole-1-sulfonic acid amide::CHEMBL349370,Prostaglandin G/H synthase 2,Homo sapiens,<100
1207418,CC(C[C@H]1NC(=O)N([C@H]2C[C@@]3(C[C@@H](C3)Oc3ncccc3C(N)=O)C2)C1=O)c1ccccc1,"InChI=1S/C25H28N4O4/c1-15(16-6-3-2-4-7-16)10-20-23(31)29(24(32)28-20)17-11-25(12-17)13-18(14-25)33-22-19(21(26)30)8-5-9-27-22/h2-9,15,17-18,20H,10-14H2,1H3,(H2,26,30)(H,28,32)/t15?,17-,18-,20-,25+/m1/s1",FNJGHIQWGOKVTA-XCEALFIJSA-N,572003,"2-(((alphaR)-6-((R)-2,5- dioxo-4-(2-phenyl- propyl)imidazolidin- 1- yl)spiro[3.3]heptan- 2- yl)oxy)nicotinamide::US11447487, Example 96",Rho-associated protein kinase 2,Homo sapiens, 264
566933,CC1N(CCc2c1nnn2-c1ncccn1)C(=O)c1cccc(c1Cl)C(F)(F)F,"InChI=1S/C18H14ClF3N6O/c1-10-15-13(28(26-25-15)17-23-7-3-8-24-17)6-9-27(10)16(29)11-4-2-5-12(14(11)19)18(20,21)22/h2-5,7-8,10H,6,9H2,1H3",JNGNNZPGWQOPGA-UHFFFAOYSA-N,254195,"US10112937, Example 80::US10150765, Example 80::US10703749, Example 80::US9464084, 80",P2X purinoceptor 7,,
1174331,CC(NC1CC1c1ccccc1)[C@H]1CC[C@@H](CC1)C(=O)NO,"InChI=1S/C18H26N2O2/c1-12(13-7-9-15(10-8-13)18(21)20-22)19-17-11-16(17)14-5-3-2-4-6-14/h2-6,12-13,15-17,19,22H,7-11H2,1H3,(H,20,21)/t12?,13-,15-,16?,17?",WMWWIWKSZDYTDT-XVYICHJISA-N,556373,"(1S,4R)?N-hydroxy-4-((1S)-1-((2-phenylcyclopropyl)amino)ethyl)cyclohexanecarboxamide TFA Salt::US11352322, Compound 34",Lysine-specific histone demethylase 1A,Homo sapiens, 31.0
50426491,C(=C/c1ccncn1)\c1c(nc2sccn12)-c1ccccc1,InChI=1S/C17H12N4S/c1-2-4-13(5-3-1)16-15(21-10-11-22-17(21)20-16)7-6-14-8-9-18-12-19-14/h1-12H/b7-6+,MRJKXXDKYLGLRQ-VOTSOKGWSA-N,50272101,"(E/Z)-6-phenyl-5-(2-(pyrimidin-4-yl)vinyl)imidazo[2,1-b]thiazole::CHEMBL505610",Vascular endothelial growth factor receptor 2,Homo sapiens, 77000
681283,Fc1ccccc1-n1ncc2c(cccc12)N1CCN(CC(=O)NC2CCCC2)C1=O,"InChI=1S/C23H24FN5O2/c24-18-8-3-4-9-21(18)29-20-11-5-10-19(17(20)14-25-29)28-13-12-27(23(28)31)15-22(30)26-16-6-1-2-7-16/h3-5,8-11,14,16H,1-2,6-7,12-13,15H2,(H,26,30)",ATYNQNPSJKCGAK-UHFFFAOYSA-N,345021,"N-cyclopentyl-2-{3-[1-(2-::N-cyclopentyl-2-{3-[1-(2-fluorophenyl)-1H-indazol-4-yl]-2-oxoimidazolidin-1-yl}acetamide::US9783527, Example 323",Sodium channel protein type 10 subunit alpha,, 695
1151067,CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(NS(=O)(=O)C(C)(C)C)c3)n2)cc1,"InChI=1S/C26H35N7O2S/c1-19-18-27-25(29-20-9-11-23(12-10-20)33-15-13-32(5)14-16-33)30-24(19)28-21-7-6-8-22(17-21)31-36(34,35)26(2,3)4/h6-12,17-18,31H,13-16H2,1-5H3,(H2,27,28,29,30)",ZFVWPEWZIRRFOU-UHFFFAOYSA-N,543516,"US11279703, TABLE 6.119::US11279703, TABLE 6.128::US11279703, TABLE 6.149::US11279703, TABLE 6.154::US11279703, TABLE 6.168::US11279703, TABLE 6.181::US11279703, TABLE 6.194::US11279703, TABLE 6.199::US11279703, TABLE 6.204::US11279703, TABLE 6.215::US11279703, TABLE 6.244::US11279703, TABLE 6.262::US11279703, TABLE 6.276::US11279703, TABLE 6.298::US11279703, TABLE 6.307::US11279703, TABLE 6.314::US11279703, TABLE 6.319::US11279703, TABLE 6.328::US11279703, TABLE 6.37",Bromodomain-containing protein 4 [75-147],, 133
50323445,Fc1cc-2c(CCc3nnc(-c4ccncc4)n-23)cc1-c1cccnc1,"InChI=1S/C20H14FN5/c21-17-11-18-14(10-16(17)15-2-1-7-23-12-15)3-4-19-24-25-20(26(18)19)13-5-8-22-9-6-13/h1-2,5-12H,3-4H2",MDQJCNKGZCAMKN-UHFFFAOYSA-N,50078609,CHEMBL3415164,"Cytochrome P450 11B2, mitochondrial",,>10000
50025875,COc1cc2CCN(C)[C@H]3CCc4ccccc4[C@H]3c2cc1O,"InChI=1S/C20H23NO2/c1-21-10-9-14-11-19(23-2)18(22)12-16(14)20-15-6-4-3-5-13(15)7-8-17(20)21/h3-6,11-12,17,20,22H,7-10H2,1-2H3/t17-,20-/m0/s1",JJXGGSUCGLJFTO-PXNSSMCTSA-N,50017823,"11-Methoxy-7-methyl-5,6a,7,8,9,13b-hexahydro-6H-7-aza-benzo[6,7]cyclohepta[1,2-a]naphthalen-12-ol::CHEMBL294186",D(1A) dopamine receptor,Rattus,
50438835,OC(=O)c1ccc(O)c2nc(ccc12)C(=O)Nc1ccc(OC(F)(F)F)cc1,"InChI=1S/C18H11F3N2O5/c19-18(20,21)28-10-3-1-9(2-4-10)22-16(25)13-7-5-11-12(17(26)27)6-8-14(24)15(11)23-13/h1-8,24H,(H,22,25)(H,26,27)",TVDCFKBHQOTKPR-UHFFFAOYSA-N,50133297,CHEMBL3634945,Lysine-specific demethylase 4A,,>100000
51334876,Cc1cc(C)c2[nH]ccc2c1CN1CCCCC1,"InChI=1S/C16H22N2/c1-12-10-13(2)16-14(6-7-17-16)15(12)11-18-8-4-3-5-9-18/h6-7,10,17H,3-5,8-9,11H2,1-2H3",RXZDXXAALUJXNK-UHFFFAOYSA-N,50540303,CHEMBL4636124,Complement factor B,, 50000
1198923,CC(C)c1c([nH]c2ccc(cc12)C(C)(C)C(=O)NCCC(C)(C)O)-c1ccnc(C)c1,"InChI=1S/C26H35N3O2/c1-16(2)22-20-15-19(26(6,7)24(30)28-13-11-25(4,5)31)8-9-21(20)29-23(22)18-10-12-27-17(3)14-18/h8-10,12,14-16,29,31H,11,13H2,1-7H3,(H,28,30)",HVLXWFYXQIZKAJ-UHFFFAOYSA-N,568257,"US11420973, Example 135",Toll-like receptor 8,, 551
1244112,COc1nc(cnc1CNC[C@@H]1CCC(=O)N1)-c1cccc(c1Cl)-c1cccc(c1Cl)-c1cnc(CN[C@@H]2CC[C@H](O)C2)c(OC)n1,"InChI=1S/C34H37Cl2N7O4/c1-46-33-28(15-37-14-20-10-12-30(45)41-20)39-16-26(42-33)24-7-3-5-22(31(24)35)23-6-4-8-25(32(23)36)27-17-40-29(34(43-27)47-2)18-38-19-9-11-21(44)13-19/h3-8,16-17,19-21,37-38,44H,9-15,18H2,1-2H3,(H,41,45)/t19-,20+,21+/m1/s1",ZLYDBKCVFRCIKM-HKBOAZHASA-N,452215,"US10710986, Example 353::US11555029, No. 353",Programmed cell death 1 ligand/protein 1,, 0.064
353721,Cc1ccc(CN2CC[C@@H](N3CC[C@@H]([C@@H](F)C3)c3ccc(O)cc3)C2=O)cc1F,"InChI=1S/C23H26F2N2O2/c1-15-2-3-16(12-20(15)24)13-27-11-9-22(23(27)29)26-10-8-19(21(25)14-26)17-4-6-18(28)7-5-17/h2-7,12,19,21-22,28H,8-11,13-14H2,1H3/t19-,21+,22-/m1/s1",LAKBGWVRKNIOGO-BAGYTPMASA-N,198732,"US9221796, 47, P-4","Glutamate receptor ionotropic, NMDA 2B",,
51050761,NS(=O)(=O)Oc1ccc(NC(=O)Nc2cccc(Oc3ccccc3)c2)cc1,"InChI=1S/C19H17N3O5S/c20-28(24,25)27-17-11-9-14(10-12-17)21-19(23)22-15-5-4-8-18(13-15)26-16-6-2-1-3-7-16/h1-13H,(H2,20,24,25)(H2,21,22,23)",DSXXTEFWYKBSEK-UHFFFAOYSA-N,50387143,CHEMBL2047823,Carbonic anhydrase 1,Homo sapiens,
50337473,COc1ccc(cc1)-n1nnc(n1)-c1ccccc1NC(=O)c1ccc(OC)c(OC)c1,"InChI=1S/C23H21N5O4/c1-30-17-11-9-16(10-12-17)28-26-22(25-27-28)18-6-4-5-7-19(18)24-23(29)15-8-13-20(31-2)21(14-15)32-3/h4-14H,1-3H3,(H,24,29)",WQDOCDOPVJZUQZ-UHFFFAOYSA-N,50086885,CHEMBL3426398,ATP-dependent translocase ABCB1,, 37200
51084330,Fc1cnc2[nH]cc(-c3nnc(N[C@H](C4CC4)c4cccnc4F)o3)c2c1,"InChI=1S/C18H14F2N6O/c19-10-6-12-13(8-23-16(12)22-7-10)17-25-26-18(27-17)24-14(9-3-4-9)11-2-1-5-21-15(11)20/h1-2,5-9,14H,3-4H2,(H,22,23)(H,24,26)/t14-/m1/s1",KSGGOJKIGSSSBJ-CQSZACIVSA-N,50443644,CHEMBL3093080,Cell division cycle 7-related protein kinase,Homo sapiens, 32
655105,CCn1c(nc2c(O[C@H]3CCN(C3)C(=O)C3CC3)ncnc12)-c1cnc(OC)c(c1)C(F)(F)F,"InChI=1S/C22H23F3N6O3/c1-3-31-17(13-8-15(22(23,24)25)19(33-2)26-9-13)29-16-18(31)27-11-28-20(16)34-14-6-7-30(10-14)21(32)12-4-5-12/h8-9,11-12,14H,3-7,10H2,1-2H3/t14-/m0/s1",ZNIDBLRZIIYCDZ-AWEZNQCLSA-N,334083,"5-{[(3S)-1- (cyclopropylcarbonyl)pyrrolidin- 3-yl]oxy}-9-ethyl-8-[6- methoxy-5- (trifluoromethyl)pyridin-3-yl]- 9H-purine::US9730940, Compound 3-26","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform",Homo sapiens,<1.000
1195647,CC(C)c1c([nH]c2ccc(cc12)-c1nnc(o1)C(=O)N1CCCN(C)CC1)-c1ccnc2[nH]ncc12,"InChI=1S/C26H28N8O2/c1-15(2)21-18-13-16(24-31-32-25(36-24)26(35)34-10-4-9-33(3)11-12-34)5-6-20(18)29-22(21)17-7-8-27-23-19(17)14-28-30-23/h5-8,13-15,29H,4,9-12H2,1-3H3,(H,27,28,30)",AVQWRYIEXLKDMK-UHFFFAOYSA-N,566756,"US11420958, Ex. No. 125",Toll-like receptor 8,, 40.0
50166222,CCCCN(O)C(=O)SC[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)NCC(O)=O,"InChI=1S/C15H26N4O8S/c1-2-3-6-19(27)15(26)28-8-10(13(23)17-7-12(21)22)18-11(20)5-4-9(16)14(24)25/h9-10,27H,2-8,16H2,1H3,(H,17,23)(H,18,20)(H,21,22)(H,24,25)/t9-,10-/m0/s1",JHOFGABPPOTPEX-UWVGGRQHSA-N,50092822,CHEMBL128447::S-(N-butyl-N-hydroxycarbamoyl)glutathione,Lactoylglutathione lyase,,
50066457,Clc1cnc(NCc2cnc[nH]2)c(c1)C(=O)NC1CCN(Cc2ccc3OCOc3c2)CC1,"InChI=1S/C23H25ClN6O3/c24-16-8-19(22(26-9-16)27-11-18-10-25-13-28-18)23(31)29-17-3-5-30(6-4-17)12-15-1-2-20-21(7-15)33-14-32-20/h1-2,7-10,13,17H,3-6,11-12,14H2,(H,25,28)(H,26,27)(H,29,31)",FHPVJZFHHRUENR-UHFFFAOYSA-N,50171600,"CHEMBL371700::N-(1-Benzo[1,3]dioxol-5-ylmethyl-piperidin-4-yl)-5-chloro-2-[(1H-imidazol-4-ylmethyl)-amino]-nicotinamide",Melanin-concentrating hormone receptor 1,Homo sapiens, 20
50563112,Clc1ccc(C(N2CCN(CC2)C(=O)C2CCCCC2)c2ccccc2)c(Cl)c1,"InChI=1S/C24H28Cl2N2O/c25-20-11-12-21(22(26)17-20)23(18-7-3-1-4-8-18)27-13-15-28(16-14-27)24(29)19-9-5-2-6-10-19/h1,3-4,7-8,11-12,17,19,23H,2,5-6,9-10,13-16H2",ZUPVKGBBKNFLPT-UHFFFAOYSA-N,50312591,"1-(Cyclohexylcarbonyl)-4-[(2,4-dichlorophenyl)(phenyl)methyl]piperazine::CHEMBL1087644",Cannabinoid receptor 1,Homo sapiens, 9.3
698619,CCc1nc2ccc(nn2c1N(C)c1nc(cs1)-c1ccc(F)cc1)N1CCC(CC1)c1ccccc1,"InChI=1S/C29H29FN6S/c1-3-24-28(34(2)29-32-25(19-37-29)22-9-11-23(30)12-10-22)36-26(31-24)13-14-27(33-36)35-17-15-21(16-18-35)20-7-5-4-6-8-20/h4-14,19,21H,3,15-18H2,1-2H3",UGTGJEKGZQWXKN-UHFFFAOYSA-N,354445,"N-(2-ethyl-6-(4- phenylpiperidin-1- yl)imidazo[1,2- b]pyridazin-3-yl)-4- (4-fluorophenyl)-N- methylthiazol-2- amine::US9796719, Compound 113",Ectonucleotide pyrophosphatase/phosphodiesterase family member 2,,>10000
264366,CCCn1c(C)nc(C(=O)NCC(O)CN2CCN(CC2)c2cccc(Cl)c2C)c1C,"InChI=1S/C23H34ClN5O2/c1-5-9-29-17(3)22(26-18(29)4)23(31)25-14-19(30)15-27-10-12-28(13-11-27)21-8-6-7-20(24)16(21)2/h6-8,19,30H,5,9-15H2,1-4H3,(H,25,31)",ULVJNAKJPCJFNL-UHFFFAOYSA-N,131890,"US8835436, Example 98",Sodium-dependent serotonin transporter,Homo sapiens, 12.1
50894116,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,5446,"CHEMBL553::ERLOTINIB HYDROCHLORIDE::Erlotinib::Erotinib::N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine Monohydrochloride::N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine::OSI-774::Tarceva::US10189853, erlotinib::US10507209, Compound Erlotinib::US11524945, Compound Erlotinib::US9409845, Table 1, Compound 22: erlotinib::US9730934, Erlotinib::WO2022090481, Example erlotinib::cid_176870",Tyrosine-protein kinase Fes/Fps,,
593521,NC(=O)c1nnc(N[C@@H]2CCCN(C2)C(=O)C=C)nc1Nc1ccc(cc1)C(=O)N1CCOCC1,"InChI=1S/C23H28N8O4/c1-2-18(32)31-9-3-4-17(14-31)26-23-27-21(19(20(24)33)28-29-23)25-16-7-5-15(6-8-16)22(34)30-10-12-35-13-11-30/h2,5-8,17H,1,3-4,9-14H2,(H2,24,33)(H2,25,26,27,29)/t17-/m1/s1",FDWZDHSRUXUKIR-QGZVFWFLSA-N,309594,"(R)-3-(1-acryloylpiperidin-3-ylamino)-5-(4-(morpholine-4-carbonyl)phenylamino)-1,2,4-triazine-6-carboxamide ::US9656988, Example 65",Tyrosine-protein kinase BTK,Homo sapiens,<10
898661,Nc1cc(c2C(CCc2n1)NC(=O)c1cnn(Cc2ccc(CN3CC4CC4C3=O)cc2)c1)C(F)(F)F,"InChI=1S/C26H25F3N6O2/c27-26(28,29)19-8-22(30)32-20-5-6-21(23(19)20)33-24(36)17-9-31-35(13-17)11-15-3-1-14(2-4-15)10-34-12-16-7-18(16)25(34)37/h1-4,8-9,13,16,18,21H,5-7,10-12H2,(H2,30,32)(H,33,36)",LWLSSQADCAKCMR-UHFFFAOYSA-N,440989,"US10640486, Example 24",Tyrosine-protein kinase BTK,Homo sapiens, 3300
1179858,CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NC[C@H]4CCCOC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1,"InChI=1S/C45H50ClN7O7S/c1-45(2)15-13-33(39(25-45)31-5-7-34(46)8-6-31)28-51-17-19-52(20-18-51)35-9-11-38(42(23-35)60-36-22-32-14-16-47-43(32)49-27-36)44(54)50-61(57,58)37-10-12-40(41(24-37)53(55)56)48-26-30-4-3-21-59-29-30/h5-12,14,16,22-24,27,30,48H,3-4,13,15,17-21,25-26,28-29H2,1-2H3,(H,47,49)(H,50,54)/t30-/m1/s1",KJTWZADQXPCUDA-SSEXGKCCSA-N,189467,"US10213433, Compound 13::US11369599, Compound 13::US9174982, 13",Apoptosis regulator Bcl-2,,
575289,CC(N1CCOCC1)C(=O)Nc1cc(NC(=O)c2ccc(nc2)-c2cccc(F)c2)ccc1OC(F)(F)F,"InChI=1S/C26H24F4N4O4/c1-16(34-9-11-37-12-10-34)24(35)33-22-14-20(6-8-23(22)38-26(28,29)30)32-25(36)18-5-7-21(31-15-18)17-3-2-4-19(27)13-17/h2-8,13-16H,9-12H2,1H3,(H,32,36)(H,33,35)",QPPPKBFFQKDCMX-UHFFFAOYSA-N,300619,"6-(3-fluorophenyl)-N-[3-{[2- (morpholin-4- yl)propanoyl]amino}-4- (trifluoromethoxy)phenyl] nicotinamide::US10130633, Example 189::US10130633, Example 190",Protein Wnt-3a,Homo sapiens, 138
50670657,CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1,"InChI=1S/C26H30FN7O3/c1-2-34(10-11-35)9-4-12-37-21-7-8-22-23(16-21)28-17-29-26(22)31-24-14-20(32-33-24)15-25(36)30-19-6-3-5-18(27)13-19/h3,5-8,13-14,16-17,35H,2,4,9-12,15H2,1H3,(H,30,36)(H2,28,29,31,32,33)",QYZOGCMHVIGURT-UHFFFAOYSA-N,26300,"2-{3-[(7-{3-[ethyl(2-hydroxyethyl)amino]propoxy}quinazolin-4-yl)amino]-1H-pyrazol-5-yl}-N-(3-fluorophenyl)acetamide::CHEMBL215152::cid_16007391::pyrazoloquinazoline deriv., 34",Citron Rho-interacting kinase,Homo sapiens,
51122982,CCc1cc(-c2ccc(F)cc2)n(Cc2ccc(cc2)C(=O)NO)n1,"InChI=1S/C19H18FN3O2/c1-2-17-11-18(14-7-9-16(20)10-8-14)23(21-17)12-13-3-5-15(6-4-13)19(24)22-25/h3-11,25H,2,12H2,1H3,(H,22,24)",JJVBDOLSGRETGE-UHFFFAOYSA-N,50460398,CHEMBL4226024,Histone deacetylase 8,Homo sapiens,>5000
328928,COc1ccccc1\C=C\S(=O)(=O)Nc1cccc(F)c1S(N)(=O)=O,"InChI=1S/C15H15FN2O5S2/c1-23-14-8-3-2-5-11(14)9-10-24(19,20)18-13-7-4-6-12(16)15(13)25(17,21)22/h2-10,18H,1H3,(H2,17,21,22)/b10-9+",SXOSYTOXUGKPMP-MDZDMXLPSA-N,181854,"US9145380, 57",Prostaglandin E synthase 2,, 620
50215691,CC(C)C[C@H](NC(=O)CCc1cccc2ccccc12)C(=O)N[C@H]1CC(=O)OC1O,"InChI=1S/C23H28N2O5/c1-14(2)12-18(22(28)25-19-13-21(27)30-23(19)29)24-20(26)11-10-16-8-5-7-15-6-3-4-9-17(15)16/h3-9,14,18-19,23,29H,10-13H2,1-2H3,(H,24,26)(H,25,28)/t18-,19-,23?/m0/s1",KYJHBJPEBQLNOM-GVLQVIKUSA-N,50119249,4-Methyl-2-(3-naphthalen-1-yl-propionylamino)-pentanoic acid (2-hydroxy-5-oxo-tetrahydro-furan-3-yl)-amide::CHEMBL101448,Caspase-1,Homo sapiens, 1860
50681295,CN(C)C[C@@H]1CCn2cc(C3=C(C(=O)NC3=O)c3cn(CCO1)c1ccccc31)c1ccccc21,"InChI=1S/C28H28N4O3/c1-30(2)15-18-11-12-31-16-21(19-7-3-5-9-23(19)31)25-26(28(34)29-27(25)33)22-17-32(13-14-35-18)24-10-6-4-8-20(22)24/h3-10,16-18H,11-15H2,1-2H3,(H,29,33,34)/t18-/m0/s1",ZCBUQCWBWNUWSU-SFHVURJKSA-N,17055,"(18S)-18-[(dimethylamino)methyl]-17-oxa-4,14,21-triazahexacyclo[19.6.1.1^{7,14}.0^{2,6}.0^{8,13}.0^{22,27}]nonacosa-1(28),2(6),7(29),8(13),9,11,22(27),23,25-nonaene-3,5-dione::(9S)-9-[(dimethylamino)methyl]-6,7,10,11-tetrahydro-9H,18H-5,21:12,17-di(metheno)dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecine-18,20(19H)-dione::K00587a::LY 333531::LY-333531::LY333531::Ruboxistaurin::cid_153999",Casein kinase I isoform gamma-2,Homo sapiens,
1026285,N#CC[C@H]1CC[C@@H](CC1)n1c(nc2cnc3[nH]ccc3c12)-c1cc[nH]n1,"InChI=1S/C19H17N7/c20-8-5-12-1-3-13(4-2-12)26-17-14-6-9-21-18(14)22-11-16(17)24-19(26)15-7-10-23-25-15/h6-7,9-13H,1-5H2/b19-15-/t12-,13-",SBCIUJCFNDKUQC-KHJRLVIRSA-N,493120,"2-((1r,4r)-4-(2-(1H-Pyrazol-3-yl)imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile::US10981911, Example 60",Tyrosine-protein kinase JAK3 [512-1124],, 72.0
50775179,Nc1nc(Cl)nc2n(cnc12)C1OC(CO)C(O)C1F,"InChI=1S/C10H11ClFN5O3/c11-10-15-7(13)5-8(16-10)17(2-14-5)9-4(12)6(19)3(1-18)20-9/h2-4,6,9,18-19H,1H2,(H2,13,15,16)",WDDPHFBMKLOVOX-UHFFFAOYSA-N,50008368,"(2R,3S)-5-(6-Amino-2-chloro-purin-9-yl)-4-fluoro-2-hydroxymethyl-tetrahydro-furan-3-ol::5-(6-Amino-2-chloro-purin-9-yl)-4-fluoro-2-hydroxymethyl-tetrahydro-furan-3-ol::CHEMBL277800",Adenosine receptor A1,Rattus norvegicus,
207737,Cc1ccc(\C=C\C(=O)Nc2nccs2)o1,"InChI=1S/C11H10N2O2S/c1-8-2-3-9(15-8)4-5-10(14)13-11-12-6-7-16-11/h2-7H,1H3,(H,12,13,14)/b5-4+",WXPPKRVWDCVHPH-SNAWJCMRSA-N,95378,"(E)-3-(5-methyl-2-furanyl)-N-(2-thiazolyl)-2-propenamide::(E)-3-(5-methyl-2-furyl)-N-thiazol-2-yl-acrylamide::(E)-3-(5-methylfuran-2-yl)-N-(1,3-thiazol-2-yl)prop-2-enamide::MLS000392762::SMR000261703::cid_2315023",Mitochondrial peptide methionine sulfoxide reductase,Bos taurus,>154980
352121,CC1(C)CC1NC[C@H]1CC[C@@H](CC1)c1nnn2cnc3[nH]ccc3c12,,,198493,"US9216999, 290::US9556187, Example 290",Tyrosine-protein kinase JAK1,Homo sapiens, 7.6
50097501,Cc1noc(NS(=O)(=O)c2ccsc2C(=O)N2CCN(Cc3ccc4OCOc4c3)CC2)c1Cl,"InChI=1S/C21H21ClN4O6S2/c1-13-18(22)20(32-23-13)24-34(28,29)17-4-9-33-19(17)21(27)26-7-5-25(6-8-26)11-14-2-3-15-16(10-14)31-12-30-15/h2-4,9-10,24H,5-8,11-12H2,1H3",NVIPEHOVDZROBC-UHFFFAOYSA-N,50058142,"2-(4-Benzo[1,3]dioxol-5-ylmethyl-piperazine-1-carbonyl)-thiophene-3-sulfonic acid (4-chloro-3-methyl-isoxazol-5-yl)-amide::CHEMBL296427",Endothelin receptor type B,Homo sapiens,>100000
50640292,CS(=O)(=O)Nc1ccc(Oc2ccc(OCCN3CCCC3)cc2)cc1,"InChI=1S/C19H24N2O4S/c1-26(22,23)20-16-4-6-18(7-5-16)25-19-10-8-17(9-11-19)24-15-14-21-12-2-3-13-21/h4-11,20H,2-3,12-15H2,1H3",UVBPJCVBBCXOGG-UHFFFAOYSA-N,50343923,CHEMBL1775110::N-(4-(4-(2-(Pyrrolidin-1-yl)ethoxy)phenoxy)phenyl)methanesulfonamide,Leukotriene A-4 hydrolase,Homo sapiens, 2100
51327535,CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N1Cc2ccccc2C[C@H]1C(N)=O,"InChI=1S/C33H41ClN10O5/c1-19(45)41-26(15-24-16-38-18-40-24)31(48)42-25(7-4-12-39-33(36)37)30(47)43-27(13-20-8-10-23(34)11-9-20)32(49)44-17-22-6-3-2-5-21(22)14-28(44)29(35)46/h2-3,5-6,8-11,16,18,25-28H,4,7,12-15,17H2,1H3,(H2,35,46)(H,38,40)(H,41,45)(H,42,48)(H,43,47)(H4,36,37,39)/t25-,26-,27+,28-/m0/s1",BEIFOQGYNJPYEP-BPXGVECKSA-N,50537095,CHEMBL4556149,Melanocyte-stimulating hormone receptor,Mus musculus,
1154804,Cc1cc2cnc(N3CCN(CC(C)(F)CF)CC3)c(C#N)c2c(=O)n1CC#Cc1ccc(Cl)cc1-c1ccnc2c(csc12)C(O)=O,"InChI=1S/C35H29ClF2N6O3S/c1-21-14-23-17-41-32(43-12-10-42(11-13-43)20-35(2,38)19-37)27(16-39)29(23)33(45)44(21)9-3-4-22-5-6-24(36)15-26(22)25-7-8-40-30-28(34(46)47)18-48-31(25)30/h5-8,14-15,17-18H,9-13,19-20H2,1-2H3,(H,46,47)",HUYAYKDIJLBBQU-UHFFFAOYSA-N,545955,"US11286268, Compound 1449",Eukaryotic translation initiation factor 4E-binding protein 1,Homo sapiens, 17.0
964596,C[C@H](CO)NCc1cnc2c(Nc3cccc(c3C)-c3cccc(-c4nc5cc(CN6CCC(CC6)C(O)=O)cc(C#N)c5o4)c3C)nccc2c1,"InChI=1S/C41H41N7O4/c1-24(23-49)44-20-28-17-30-10-13-43-39(37(30)45-21-28)46-35-9-5-7-33(26(35)3)32-6-4-8-34(25(32)2)40-47-36-18-27(16-31(19-42)38(36)52-40)22-48-14-11-29(12-15-48)41(50)51/h4-10,13,16-18,21,24,29,44,49H,11-12,14-15,20,22-23H2,1-3H3,(H,43,46)(H,50,51)/t24-/m1/s1",UBJOPTRCOPHEOU-XMMPIXPASA-N,395590,"(R)-1-((7-cyano-2- (3'-(3-((1-hydroxy- propan-2-ylamino)- methyl)-1,7- naphthyridin-8- ylamino)-2,2'- dimethyl biphenyl- 3-yl)benzo[d]oxazol- 5-yl)methyl)piperidine-::US10308644, Example 202::US10800768, Example 202::US11339149, Example 202",Programmed cell death 1 ligand 1 [19-238]/protein 1 [25-167],, 3000
1061874,COc1ccc(Nc2cc3c(cccc3cn2)-c2cnn(C)c2)c(OC)c1,"InChI=1S/C21H20N4O2/c1-25-13-15(12-23-25)17-6-4-5-14-11-22-21(10-18(14)17)24-19-8-7-16(26-2)9-20(19)27-3/h4-13H,1-3H3,(H,22,24)",SEROCBXXHACDIM-UHFFFAOYSA-N,241188,"US11046688, Example 30::US9409907, 30",Dual specificity protein kinase TTK,Homo sapiens, 74.0
1199527,C[C@H](O)[C@@H](NCc1cc(Cl)c(O[C@H]2CCc3c2cccc3-c2ccccc2F)cc1OCc1cncc(c1)C#N)C(O)=O,"InChI=1S/C33H29ClFN3O5/c1-19(39)32(33(40)41)38-17-22-12-27(34)31(13-30(22)42-18-21-11-20(14-36)15-37-16-21)43-29-10-9-24-23(6-4-7-26(24)29)25-5-2-3-8-28(25)35/h2-8,11-13,15-16,19,29,32,38-39H,9-10,17-18H2,1H3,(H,40,41)/t19-,29-,32+/m0/s1",DFZGINHKGOLUHQ-OESCGCGTSA-N,440775,"US10639284, Compound 2.122::US11426364, Compound 2.122",Programmed cell death 1 ligand 1,,<100
894137,Cc1[nH]c2c(cc(F)c(-c3cccc4CN(CC(F)(F)c34)C(=O)C=C)c2c1C)C(N)=O,"InChI=1S/C23H20F3N3O2/c1-4-17(30)29-9-13-6-5-7-14(20(13)23(25,26)10-29)19-16(24)8-15(22(27)31)21-18(19)11(2)12(3)28-21/h4-8,28H,1,9-10H2,2-3H3,(H2,27,31)",RWJOLNLBAJBYJS-UHFFFAOYSA-N,164793,"US10604504, Example 232::US9688629, 231::US9688629, 232::US9802915, Example 232::US9920031, Example 232",Tyrosine-protein kinase BTK,Homo sapiens, 0.100
51217099,CCNC(=O)NC(N)=NCCC[C@@H](NC(=O)C(c1ccccc1)c1ccccc1)C(=O)NCc1ccc(O)cc1,"InChI=1S/C30H36N6O4/c1-2-32-30(40)36-29(31)33-19-9-14-25(27(38)34-20-21-15-17-24(37)18-16-21)35-28(39)26(22-10-5-3-6-11-22)23-12-7-4-8-13-23/h3-8,10-13,15-18,25-26,37H,2,9,14,19-20H2,1H3,(H,34,38)(H,35,39)(H4,31,32,33,36,40)/t25-/m1/s1",SEADNQXXAGCERI-RUZDIDTESA-N,50246648,"(R)-1-((5-(4-hydroxybenzylamino)-4-(2,2-diphenylacetamido)-5-oxopentylamino)(amino)methylene)-3-ethylurea::CHEMBL511460",Neuropeptide Y receptor type 1,Homo sapiens,
50088504,O=C(CNC(=O)c1ncn[nH]1)N1CCC[C@H]1C#N,"InChI=1S/C10H12N6O2/c11-4-7-2-1-3-16(7)8(17)5-12-10(18)9-13-6-14-15-9/h6-7H,1-3,5H2,(H,12,18)(H,13,14,15)/t7-/m0/s1",LTHNMKNDEOGPBM-ZETCQYMHSA-N,50009347,CHEMBL3233566,Dipeptidyl peptidase 4,Homo sapiens,>100000
50425706,Cc1ccccc1O[C@@H]1[C@H](CN)COc2ccccc12,"InChI=1S/C17H19NO2/c1-12-6-2-4-8-15(12)20-17-13(10-18)11-19-16-9-5-3-7-14(16)17/h2-9,13,17H,10-11,18H2,1H3/t13-,17-/m1/s1",RQRGTZIPGLRQOJ-CXAGYDPISA-N,50272715,"((3R,4R)-4-(o-tolyloxy)-3,4-dihydro-2H-chromen-3-yl)methanamine::((3R,4R)-4-(o-tolyloxy)chroman-3-yl)methanamine::CHEMBL498509",Sodium-dependent serotonin transporter,Homo sapiens, 3800
567466,C[C@@H]1Cc2c(nnn2-c2ccc(F)cc2)[C@@H](C)N1C(=O)c1cccc(c1Cl)C(F)(F)F,"InChI=1S/C21H17ClF4N4O/c1-11-10-17-19(27-28-30(17)14-8-6-13(23)7-9-14)12(2)29(11)20(31)15-4-3-5-16(18(15)22)21(24,25)26/h3-9,11-12H,10H2,1-2H3/t11-,12-/m1/s1",OILNQGIYLDGWDH-VXGBXAGGSA-N,254377,"US10112937, Example 284::US10150765, Example 284::US10703749, Example 284::US9464084, 284",P2X purinoceptor 7,, 673
50395294,COc1ccccc1N1CCN(CC(O)CCNC(=O)c2ccc(cc2)-c2ccccn2)CC1,"InChI=1S/C27H32N4O3/c1-34-26-8-3-2-7-25(26)31-18-16-30(17-19-31)20-23(32)13-15-29-27(33)22-11-9-21(10-12-22)24-6-4-5-14-28-24/h2-12,14,23,32H,13,15-20H2,1H3,(H,29,33)",YPXXSRYKHFAWBF-UHFFFAOYSA-N,50219105,CHEMBL242644::N-(3-hydroxy-4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)-4-pyridin-2-ylbenzamide,D(3) dopamine receptor,, 12.8
50456114,O=C1Cc2ccccc2N1CCCN1CCc2ccccc2C1,"InChI=1S/C20H22N2O/c23-20-14-17-7-3-4-9-19(17)22(20)12-5-11-21-13-10-16-6-1-2-8-18(16)15-21/h1-4,6-9H,5,10-15H2",FMSOQNHSEFQTDJ-UHFFFAOYSA-N,50267833,"1-[3-(3,4-Dihydroisoquinolin-2(1H)-yl)propyl]-1,3-dihydro-2H-indol-2-one::CHEMBL455210",5-hydroxytryptamine receptor 1A,,
50078488,CCCN(c1ccncc1)n1ncc2ccccc12,"InChI=1S/C15H16N4/c1-2-11-18(14-7-9-16-10-8-14)19-15-6-4-3-5-13(15)12-17-19/h3-10,12H,2,11H2,1H3",WEMUITQZWVBMLV-UHFFFAOYSA-N,50048599,CHEMBL346142::Indazol-1-yl-propyl-pyridin-4-yl-amine; compound with (E)-but-2-enedioic acid,Acetylcholinesterase,Rattus norvegicus,>100000
50208263,O=C(Nc1ccccc1)Oc1ccc2CC3C4CCCCC4(CCN3CC3CC3)c2c1,"InChI=1S/C27H32N2O2/c30-26(28-21-6-2-1-3-7-21)31-22-12-11-20-16-25-23-8-4-5-13-27(23,24(20)17-22)14-15-29(25)18-19-9-10-19/h1-3,6-7,11-12,17,19,23,25H,4-5,8-10,13-16,18H2,(H,28,30)",PNQVNINMHSUQSR-UHFFFAOYSA-N,50204451,CHEMBL397035::MCL-429,Delta-type opioid receptor,Homo sapiens,
50058302,Nc1ccc(cc1)-c1cc(=O)c2cc(N)cc(N)c2o1,"InChI=1S/C15H13N3O2/c16-9-3-1-8(2-4-9)14-7-13(19)11-5-10(17)6-12(18)15(11)20-14/h1-7H,16-18H2",YDVZFTJSRVKMLJ-UHFFFAOYSA-N,50037394,"6,8-Diamino-2-(4-amino-phenyl)-chromen-4-one::CHEMBL112422",Tyrosine-protein kinase Lck,, 106000
50406963,CCCc1cc(NC(=O)c2ccc(Br)cc2)[nH]n1,"InChI=1S/C13H14BrN3O/c1-2-3-11-8-12(17-16-11)15-13(18)9-4-6-10(14)7-5-9/h4-8H,2-3H2,1H3,(H2,15,16,17,18)",LCTGDIGFDXPBRR-UHFFFAOYSA-N,7147,3-Benzamidoaminopyrazole deriv. 24::4-bromo-N-(5-propyl-1H-pyrazol-3-yl)benzamide::CHEMBL114432::N-(5-Propyl-1H-pyrazol-3-yl)-4-bromobenzamide,Cyclin-dependent kinase 2,Homo sapiens, 650
50109923,CCN(C=O)C1CCCCC1,"InChI=1S/C9H17NO/c1-2-10(8-11)9-6-4-3-5-7-9/h8-9H,2-7H2,1H3",BNTVUXYRPWLPFG-UHFFFAOYSA-N,50064276,CHEMBL45526::N-Cyclohexyl-N-ethyl-formamide,Alcohol dehydrogenase 1A,Homo sapiens,
532444,C[C@@H](Nc1nc(NC2(CC2)c2ccccc2)nc(n1)-c1cccc(n1)C(F)(F)F)C1CC1,"InChI=1S/C23H23F3N6/c1-14(15-10-11-15)27-20-29-19(17-8-5-9-18(28-17)23(24,25)26)30-21(31-20)32-22(12-13-22)16-6-3-2-4-7-16/h2-9,14-15H,10-13H2,1H3,(H2,27,29,30,31,32)/t14-/m1/s1",MMQKYUIBTNHALE-CQSZACIVSA-N,279883,"US10028961, Compound 30::US10028961, Compound 85::US10172864, Compound 85::US10946023, Compound 85",Isocitrate dehydrogenase [NADP] cytoplasmic [R132H],, 75
51437909,CCC(=O)N(CC1(CCOCC1)N1CCN(CC(C)C)CC1)c1cccc(n1)C(F)(F)F,"InChI=1S/C23H35F3N4O2/c1-4-21(31)30(20-7-5-6-19(27-20)23(24,25)26)17-22(8-14-32-15-9-22)29-12-10-28(11-13-29)16-18(2)3/h5-7,18H,4,8-17H2,1-3H3",PMOGZOJPMLRYGM-UHFFFAOYSA-N,50580843,CHEMBL5086571,Mu-type opioid receptor,Homo sapiens,
51374970,OC(=O)C[C@H](C(=O)N1CC[C@@H](CCc2ccc3CCCNc3n2)C1)c1ccc(Br)s1,"InChI=1S/C22H26BrN3O3S/c23-19-8-7-18(30-19)17(12-20(27)28)22(29)26-11-9-14(13-26)3-5-16-6-4-15-2-1-10-24-21(15)25-16/h4,6-8,14,17H,1-3,5,9-13H2,(H,24,25)(H,27,28)/t14-,17+/m1/s1",CGDCNLRQFMWABO-PBHICJAKSA-N,50556012,CHEMBL4750506,Integrin alpha-V/beta-5,Homo sapiens, 10.0
1013886,Oc1nn2c([nH]c(cc2=O)-c2ccc3occc3c2)c1-c1cccnc1,"InChI=1S/C19H12N4O3/c24-16-9-14(11-3-4-15-12(8-11)5-7-26-15)21-18-17(19(25)22-23(16)18)13-2-1-6-20-10-13/h1-10,21H,(H,22,25)",YMBMGMXPBPAXPX-UHFFFAOYSA-N,487270,"5-(Benzofuran-5-yl)-2-hydroxy-3-(pyridin-3-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one::US10953012, Example 147",PAS domain-containing serine/threonine-protein kinase [879-1323],,<10000
551946,Cc1cc(Oc2ncccc2Cl)ccc1-c1c(C)c(=O)[nH]c(=O)n1C,"InChI=1S/C18H16ClN3O3/c1-10-9-12(25-17-14(19)5-4-8-20-17)6-7-13(10)15-11(2)16(23)21-18(24)22(15)3/h4-9H,1-3H3,(H,21,23,24)",RAYDNTSRMZWXNU-UHFFFAOYSA-N,160884,"US10093655, Example 55::US11014909, Example 55::US9107923, 54::US9107923, 55",D(1A) dopamine receptor,,
1177688,CN[C@H]1CO[C@H](OC1)[C@H]1CCC[C@H](C)[C@@H](C)S(=O)(=O)NC(=O)c2ccc3OC[C@]4(CCCc5cc(Cl)ccc45)CN(C[C@@H]4CC[C@@H]14)c3c2,"InChI=1S/C37H50ClN3O6S/c1-23-6-4-8-31(36-45-19-29(39-3)20-46-36)30-12-9-27(30)18-41-21-37(15-5-7-25-16-28(38)11-13-32(25)37)22-47-34-14-10-26(17-33(34)41)35(42)40-48(43,44)24(23)2/h10-11,13-14,16-17,23-24,27,29-31,36,39H,4-9,12,15,18-22H2,1-3H3,(H,40,42)/t23-,24+,27-,29-,30+,31-,36+,37-/m0/s1",OIZZTPIMRRMBHN-SSCJHKLISA-N,557745,"US11364248, Example 41::US11364248, Example 42",Bcl-2-like protein 11 [51-76]/Induced myeloid leukemia cell differentiation protein Mcl-1 [171-327],, 7.99
407293,Cc1cc(ccn1)-c1n[nH]c2ccc(cc12)C(=O)NC1CCCC(O)(C1)C(O)c1ccccc1,,,233442,"US9351965, 49::US9351965, 50::US9351965, 51::US9351965, 52",Mitogen-activated protein kinase 1,Mus musculus, 25.0
50943777,Cc1cc(C)c(Nc2nc3cccc(N(CC4CC4)CC4CCOCC4)c3cc2C)c(C)c1,"InChI=1S/C29H37N3O/c1-19-14-20(2)28(21(3)15-19)31-29-22(4)16-25-26(30-29)6-5-7-27(25)32(17-23-8-9-23)18-24-10-12-33-13-11-24/h5-7,14-16,23-24H,8-13,17-18H2,1-4H3,(H,30,31)",AMPLHRZGGAECTP-UHFFFAOYSA-N,50387021,CHEMBL2049195,Corticotropin-releasing factor receptor 1,Homo sapiens, 742
50568719,NCCCCCN1c2ccccc2CN(C(Cc2c[nH]c3ccccc23)C1=O)C(=O)c1ccccc1,"InChI=1S/C30H32N4O2/c31-17-9-2-10-18-33-27-16-8-5-13-23(27)21-34(29(35)22-11-3-1-4-12-22)28(30(33)36)19-24-20-32-26-15-7-6-14-25(24)26/h1,3-8,11-16,20,28,32H,2,9-10,17-19,21,31H2",MYNLGMHVEFJZHC-UHFFFAOYSA-N,50214420,CHEMBL330352,Somatostatin receptor type 1/2/3/4/5,Rattus, 7000
50258101,Fc1ccc(NS(=O)(=O)c2ccoc2)c(F)c1Nc1ncccc1-c1ncnc2[nH]cnc12,"InChI=1S/C20H13F2N7O3S/c21-13-3-4-14(29-33(30,31)11-5-7-32-8-11)15(22)17(13)28-19-12(2-1-6-23-19)16-18-20(26-9-24-16)27-10-25-18/h1-10,29H,(H,23,28)(H,24,25,26,27)",ACIXGVIVJZJKNT-UHFFFAOYSA-N,50038473,"CHEMBL3354844::US9216981, 18",Serine/threonine-protein kinase B-raf,Homo sapiens, 1.000000
50596662,O=C(N1CCOCC1)c1ccc(nc1)-c1ccc2oc(CCN3CCCCCC3)cc2c1,"InChI=1S/C26H31N3O3/c30-26(29-13-15-31-16-14-29)21-5-7-24(27-19-21)20-6-8-25-22(17-20)18-23(32-25)9-12-28-10-3-1-2-4-11-28/h5-8,17-19H,1-4,9-16H2",RPBNYUHYVUUVSR-UHFFFAOYSA-N,50139406,CHEMBL159858::{6-[2-(2-Azepan-1-yl-ethyl)-benzofuran-5-yl]-pyridin-3-yl}-morpholin-4-yl-methanone,Histamine H3 receptor,Homo sapiens,
50720704,CC(C)n1cnc2c(Nc3cc(N)cc(Cl)c3)nc(N[C@H]3CCCNC3)nc12,"InChI=1S/C19H25ClN8/c1-11(2)28-10-23-16-17(24-15-7-12(20)6-13(21)8-15)26-19(27-18(16)28)25-14-4-3-5-22-9-14/h6-8,10-11,14,22H,3-5,9,21H2,1-2H3,(H2,24,25,26,27)/t14-/m0/s1",DLDXMINZRQNSDI-AWEZNQCLSA-N,50235031,CHEMBL4064123,Cyclin-dependent kinase/G2/mitotic-specific cyclin- 1,Homo sapiens,>1000
51101786,Cc1cnc(C)c2nc(nn12)-c1ccc2nc([nH]c2c1)-c1ccc(Cl)s1,"InChI=1S/C18H13ClN6S/c1-9-8-20-10(2)18-23-16(24-25(9)18)11-3-4-12-13(7-11)22-17(21-12)14-5-6-15(19)26-14/h3-8H,1-2H3,(H,21,22)",VUUCDKVXQXXASH-UHFFFAOYSA-N,50449434,CHEMBL4177028,"cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A",Homo sapiens, 161
597274,Fc1ccc(nc1)-n1cnc2CN(CCc12)C(=O)c1ccc(Cl)cc1Cl,"InChI=1S/C18H13Cl2FN4O/c19-11-1-3-13(14(20)7-11)18(26)24-6-5-16-15(9-24)23-10-25(16)17-4-2-12(21)8-22-17/h1-4,7-8,10H,5-6,9H2",DJIJTCUGJYMPTQ-UHFFFAOYSA-N,254405,"US10112937, Example 313::US10150765, Example 313::US10703749, Example 313::US9464084, 313",P2X purinoceptor 7,, 24717
51238626,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13,"InChI=1S/C28H26N4O3/c1-28-26(34-3)17(29-2)12-20(35-28)31-18-10-6-4-8-14(18)22-23-16(13-30-27(23)33)21-15-9-5-7-11-19(15)32(28)25(21)24(22)31/h4-11,17,20,26,29H,12-13H2,1-3H3,(H,30,33)/t17-,20-,26-,28+/m1/s1",HKSZLNNOFSGOKW-FYTWVXJKSA-N,2579,"(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1^{2,6}.0^{7,28}.0^{8,13}.0^{15,19}.0^{20,27}.0^{21,26}]nonacosa-8(13),9,11,14(28),15(19),20(27),21(26),22,24-nonaen-16-one::CHEMBL388978::Staurosporin, 4::Staurosporine::Staurosporine, 8::US9206188, Staurosporine::US9226923, Staurosporine",Homeodomain-interacting protein kinase 2,Homo sapiens, 5.9
51008343,CCOC(=O)c1cn(nn1)-c1nc(N)c2ncn(C3OC(COS(=O)(=O)NC(=O)c4ccccc4O)C(O)C3O)c2n1,"InChI=1S/C22H23N9O10S/c1-2-39-21(36)11-7-31(29-27-11)22-25-17(23)14-18(26-22)30(9-24-14)20-16(34)15(33)13(41-20)8-40-42(37,38)28-19(35)10-5-3-4-6-12(10)32/h3-7,9,13,15-16,20,32-34H,2,8H2,1H3,(H,28,35)(H2,23,25,26)",SKAWTNZJHSCDMM-UHFFFAOYSA-N,50412837,CHEMBL609103,Salicyl-AMP ligase / salicyl-S-ArCP synthetase,Mycobacterium tuberculosis,
841158,Cn1cc(Nc2nccc(n2)N2C[C@@H]3CC[C@H](C2)N3c2cc(ccn2)C#N)cn1,"InChI=1S/C20H21N9/c1-27-11-15(10-24-27)25-20-23-7-5-18(26-20)28-12-16-2-3-17(13-28)29(16)19-8-14(9-21)4-6-22-19/h4-8,10-11,16-17H,2-3,12-13H2,1H3,(H,23,25,26)/t16-,17+",GTXCSFLZRFJUBT-CALCHBBNSA-N,419649,"US10463675, Example 92::US10980815, Ex. No. 92::US11197867, Example 92",Tyrosine-protein kinase JAK2,Homo sapiens, 264
245278,Cc1cc(C)nc(n1)N1CC2CN(CC2C1)C(=O)c1cc(F)c(F)cc1-n1nccn1,"InChI=1S/C21H21F2N7O/c1-12-5-13(2)27-21(26-12)29-10-14-8-28(9-15(14)11-29)20(31)16-6-17(22)18(23)7-19(16)30-24-3-4-25-30/h3-7,14-15H,8-11H2,1-2H3",FSVYSEDKEGUOFP-UHFFFAOYSA-N,118613,"US11059828, Example 266::US8653263, 266::US9586962, Example 266::USRE48841, Example 266",Orexin/Hypocretin receptor type 1,Homo sapiens,
50097860,COC(=O)C1C2CCC(CC1c1ccc(F)cc1)N2CCCc1ccccc1,"InChI=1S/C24H28FNO2/c1-28-24(27)23-21(18-9-11-19(25)12-10-18)16-20-13-14-22(23)26(20)15-5-8-17-6-3-2-4-7-17/h2-4,6-7,9-12,20-23H,5,8,13-16H2,1H3",XFTMPSNNVZPRHJ-UHFFFAOYSA-N,50058293,3-(4-Fluoro-phenyl)-8-(3-phenyl-propyl)-8-aza-bicyclo[3.2.1]octane-2-carboxylic acid methyl ester::CHEMBL54628,Sodium-dependent serotonin transporter,Homo sapiens, 133
50456309,CC(C)(C)Nc1nc(nc2nc(-c3ccccc3Cl)c(cc12)-c1ccc(Cl)cc1)C(C)(C)C,"InChI=1S/C27H28Cl2N4/c1-26(2,3)25-31-23-20(24(32-25)33-27(4,5)6)15-19(16-11-13-17(28)14-12-16)22(30-23)18-9-7-8-10-21(18)29/h7-15H,1-6H3,(H,30,31,32,33)",FLTKRJYBXQQZTD-UHFFFAOYSA-N,50259225,"CHEMBL513648::N,2-di-tert-butyl-7-(2-chlorophenyl)-6-(4-chlorophenyl)pyrido[2,3-d]pyrimidin-4-amine",Cannabinoid receptor 1,Homo sapiens, 2.7
1171710,CCn1cc(Nc2ncc(C(N)=O)c(NCc3cc(F)ccc3Cl)n2)cn1,"InChI=1S/C17H17ClFN7O/c1-2-26-9-12(7-23-26)24-17-22-8-13(15(20)27)16(25-17)21-6-10-5-11(19)3-4-14(10)18/h3-5,7-9H,2,6H2,1H3,(H2,20,27)(H2,21,22,24,25)",RLAORTPAWWSRBL-UHFFFAOYSA-N,555403,"US11344549, Example 79",Tyrosine-protein kinase JAK1,Homo sapiens, 22.9
1008335,FC(F)(F)c1ccn(n1)-c1nc(NC2CCC(F)(F)CC2)nc(Nc2ccnc(c2)C2(CC2)C#N)n1,"InChI=1S/C22H20F5N9/c23-21(24)5-1-13(2-6-21)30-17-32-18(31-14-3-9-29-16(11-14)20(12-28)7-8-20)34-19(33-17)36-10-4-15(35-36)22(25,26)27/h3-4,9-11,13H,1-2,5-8H2,(H2,29,30,31,32,33,34)",POHHIURFWMYFGA-UHFFFAOYSA-N,486571,"US10946023, Compound 382",Isocitrate dehydrogenase [NADP] cytoplasmic [R132H],, 550
723110,Cc1cc(CN2CCC[C@H](C2)C(O)=O)ccc1OCc1cccc(c1C)-c1ccccc1,"InChI=1S/C28H31NO3/c1-20-16-22(17-29-15-7-11-24(18-29)28(30)31)13-14-27(20)32-19-25-10-6-12-26(21(25)2)23-8-4-3-5-9-23/h3-6,8-10,12-14,16,24H,7,11,15,17-19H2,1-2H3,(H,30,31)/t24-/m1/s1",CSGXVUMLNZXMMP-XMMPIXPASA-N,365803,"(3R)-1-({3-methyl-4-[(2-methyl- 3-phenylphenyl)methoxy] phenyl[methyl)piperidine-3- carboxylic acid::US9872852, Example 55",Programmed cell death 1 ligand 1,, 555
51220441,Cc1nn(C)c(C)c1CNC1CCc2c(C1)sc1ncn(Cc3ccc4ccccc4c3)c(=O)c21,"InChI=1S/C28H29N5OS/c1-17-24(18(2)32(3)31-17)14-29-22-10-11-23-25(13-22)35-27-26(23)28(34)33(16-30-27)15-19-8-9-20-6-4-5-7-21(20)12-19/h4-9,12,16,22,29H,10-11,13-15H2,1-3H3",SSXGNOHJKHXTAA-UHFFFAOYSA-N,50501464,CHEMBL4085575,NAD-dependent protein deacetylase sirtuin-2,Homo sapiens, 7430
50843963,Nc1nc(OCCCCc2ccccc2)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,"InChI=1S/C20H25N5O5/c21-17-14-18(25(11-22-14)19-16(28)15(27)13(10-26)30-19)24-20(23-17)29-9-5-4-8-12-6-2-1-3-7-12/h1-3,6-7,11,13,15-16,19,26-28H,4-5,8-10H2,(H2,21,23,24)/t13-,15-,16-,19-/m1/s1",VZCKGCMWUBEJIH-NVQRDWNXSA-N,50208792,"(2R,3R,4S,5R)-2-(6-amino-2-(4-phenylbutoxy)-9H-purin-9-yl)-5-(hydroxymethyl)-tetrahydrofuran-3,4-diol::CHEMBL387324",Adenosine receptor A3,Homo sapiens,
51436898,Cn1c(NCCNc2c3CCCCc3nc3ccc(Cl)cc23)nc(cc1=O)-c1ccncn1,"InChI=1S/C24H24ClN7O/c1-32-22(33)13-21(20-8-9-26-14-29-20)31-24(32)28-11-10-27-23-16-4-2-3-5-18(16)30-19-7-6-15(25)12-17(19)23/h6-9,12-14H,2-5,10-11H2,1H3,(H,27,30)(H,28,31)",MWSYVZTUNLPXHY-UHFFFAOYSA-N,50580417,CHEMBL5092653,Acetylcholinesterase,Mus musculus, 18800
51046410,CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(CN)cc1)NC(=O)[C@H](Cc1ccccc1)N=[N+]=[N-])C(=O)N[C@@H](Cc1ccc(N)cc1)\C=C\S(C)(=O)=O,"InChI=1S/C36H46N8O5S/c1-24(2)19-31(34(45)40-30(17-18-50(3,48)49)20-26-13-15-29(38)16-14-26)41-35(46)32(21-27-9-11-28(23-37)12-10-27)42-36(47)33(43-44-39)22-25-7-5-4-6-8-25/h4-18,24,30-33H,19-23,37-38H2,1-3H3,(H,40,45)(H,41,46)(H,42,47)/b18-17+/t30-,31+,32+,33+/m1/s1",KVWGALLOHHTTDN-BQYZZHICSA-N,50427003,CHEMBL2326262,Proteasome subunit beta type-2,Homo sapiens, 100
50417152,C[C@@H]1CN(C(=O)c2cc(COc3ccc(Cl)cn3)nn12)c1cccc(F)c1,"InChI=1S/C19H16ClFN4O2/c1-12-10-24(16-4-2-3-14(21)7-16)19(26)17-8-15(23-25(12)17)11-27-18-6-5-13(20)9-22-18/h2-9,12H,10-11H2,1H3/t12-/m1/s1",XDRWUVOKDOFEAT-GFCCVEGCSA-N,50122261,CHEMBL3617631,Metabotropic glutamate receptor 3,, 206
429052,F[C@H]1CCN(C1)c1ncc(cc1C#N)-c1ccnc(Nc2ccc(NC(=O)CN3CCCC3)nc2)n1,"InChI=1S/C25H26FN9O/c26-19-6-10-35(15-19)24-17(12-27)11-18(13-30-24)21-5-7-28-25(32-21)31-20-3-4-22(29-14-20)33-23(36)16-34-8-1-2-9-34/h3-5,7,11,13-14,19H,1-2,6,8-10,15-16H2,(H,28,31,32)(H,29,33,36)/t19-/m0/s1",JMPORDHLIUIPQP-IBGZPJMESA-N,245969,"US9433622, DMX- 66",Serine/threonine-protein kinase TBK1,,<30
50584909,COc1ccc(C(Cc2ccncc2)c2ccc(Cl)cc2)c(F)c1OC1CCCC1,"InChI=1S/C25H25ClFNO2/c1-29-23-11-10-21(24(27)25(23)30-20-4-2-3-5-20)22(16-17-12-14-28-15-13-17)18-6-8-19(26)9-7-18/h6-15,20,22H,2-5,16H2,1H3",IZHRHJLGDDERDG-UHFFFAOYSA-N,50113413,4-[2-(4-Chloro-phenyl)-2-(3-cyclopentyloxy-2-fluoro-4-methoxy-phenyl)-ethyl]-pyridine::CHEMBL284479,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A",Homo sapiens, 110
50092893,Cc1oc(cc1COc1ccc(cc1)-c1csnn1)C(O)=O,"InChI=1S/C15H12N2O4S/c1-9-11(6-14(21-9)15(18)19)7-20-12-4-2-10(3-5-12)13-8-22-17-16-13/h2-6,8H,7H2,1H3,(H,18,19)",KXTISFZVPDQPAL-UHFFFAOYSA-N,50012494,CHEMBL3260450,Prostaglandin E2 receptor EP4 subtype,Homo sapiens,
694501,COc1cc2c(Nc3ccc(Br)c(Cl)c3Cl)ncnc2cc1OC[C@@H]1CN2CCOCC2CO1,"InChI=1S/C23H23BrCl2N4O4/c1-31-19-6-15-18(27-12-28-23(15)29-17-3-2-16(24)21(25)22(17)26)7-20(19)34-11-14-8-30-4-5-32-9-13(30)10-33-14/h2-3,6-7,12-14H,4-5,8-11H2,1H3,(H,27,28,29)/t13?,14-/m0/s1",QPNYAXXXUXFKDG-KZUDCZAMSA-N,351301,"N-(4-bromo-2,3-dichlorophenyl)-7-{[(3S,9aS)- hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin- 3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4- amine::US9796704, Entry 27",Vascular endothelial growth factor receptor 2,Homo sapiens, 10500
1241074,Cn1cc2ncc(-c3ccc(Nc4ccc(cn4)N4CCC(O)CC4)c4C(=O)NCc34)c2cn1,"InChI=1S/C25H25N7O2/c1-31-14-22-19(13-29-31)18(11-26-22)17-3-4-21(24-20(17)12-28-25(24)34)30-23-5-2-15(10-27-23)32-8-6-16(33)7-9-32/h2-5,10-11,13-14,16,33H,6-9,12H2,1H3,(H,27,30)(H,28,34)",BDXWXGRIICMAOV-UHFFFAOYSA-N,500784,"7-((5-(4- hydroxy- piperidin-1- yl)pyridin-2- yl)amino)-4- (6-methyl-6H- pyrrolo[2,3- d]pyridazin-3- yl)isoindolin- 1-one::US11021481, Compound I-448::US11078201, Compound I-448::US11548890, Compound I-448",Mitogen-activated protein kinase kinase kinase kinase 1,Homo sapiens, 550
144208,CC(Oc1ccccc1)C(=O)Nc1nnc(o1)-c1ccc(C)c(C)c1,"InChI=1S/C19H19N3O3/c1-12-9-10-15(11-13(12)2)18-21-22-19(25-18)20-17(23)14(3)24-16-7-5-4-6-8-16/h4-11,14H,1-3H3,(H,20,22,23)",GUTPDQJXUCPAHD-UHFFFAOYSA-N,78455,"N-[5-(3,4-dimethylphenyl)-1,3,4-oxadiazol-2-yl]-2-phenoxy-propanamide::N-[5-(3,4-dimethylphenyl)-1,3,4-oxadiazol-2-yl]-2-phenoxy-propionamide::N-[5-(3,4-dimethylphenyl)-1,3,4-oxadiazol-2-yl]-2-phenoxypropanamide::VU0405176-1::cid_44251489",Voltage-dependent T-type calcium channel subunit alpha-1H,,
1121500,COc1cc(F)c(c(F)c1)-n1cc(nc1NC(=O)c1ccc(OC(F)F)cc1)C(=O)NCc1ccncc1,"InChI=1S/C25H19F4N5O4/c1-37-17-10-18(26)21(19(27)11-17)34-13-20(23(36)31-12-14-6-8-30-9-7-14)32-25(34)33-22(35)15-2-4-16(5-3-15)38-24(28)29/h2-11,13,24H,12H2,1H3,(H,31,36)(H,32,33,35)",MMUOPMXNXUYSPD-UHFFFAOYSA-N,530519,"WO2022076764, Example 48",fMet-Leu-Phe receptor,Homo sapiens,
51352791,NC(=O)c1[nH]c2ccc(Cl)cc2c1-c1ccc(cc1)C(=O)N1CCCC1,"InChI=1S/C20H18ClN3O2/c21-14-7-8-16-15(11-14)17(18(23-16)19(22)25)12-3-5-13(6-4-12)20(26)24-9-1-2-10-24/h3-8,11,23H,1-2,9-10H2,(H2,22,25)",DHRBOVAUJOFFCM-UHFFFAOYSA-N,50547185,CHEMBL4752469,Microtubule-associated protein 2,Homo sapiens, 251
857119,Fc1ccc(cc1)[C@@H]1C[C@H]1NCCC[C@H](NC(=O)c1ccc(cc1)-n1ccnn1)C(=O)N1CC2(COC2)C1,"InChI=1S/C28H31FN6O3/c29-21-7-3-19(4-8-21)23-14-25(23)30-11-1-2-24(27(37)34-15-28(16-34)17-38-18-28)32-26(36)20-5-9-22(10-6-20)35-13-12-31-33-35/h3-10,12-13,23-25,30H,1-2,11,14-18H2,(H,32,36)/t23-,24-,25+/m0/s1",PQPFZYRWWCGPDZ-CCDWMCETSA-N,424991,"N-((2S)-5-((1R,2S)-2-(4- fluorophenyl)cyclopropylamino)-1-oxo-1- (2-oxa-6-azaspiro[3.3]heptan-6-yl)pentan-2- yl)-4-(1H-1,2,3-triazol-1-yl)benzamide::US10519118, Example 59::US11230534, Example 59",Lysine-specific histone demethylase 1A,Homo sapiens, 17000
51173970,CC(=O)N1CCC(CC1)C(=O)N1CCC(CC1)N1CCN(CC1)C(=O)c1cc(nc(c1)-c1ccc2[nH]c(C)c(C)c2c1)-c1ccccc1,"InChI=1S/C39H46N6O3/c1-26-27(2)40-35-10-9-31(23-34(26)35)37-25-32(24-36(41-37)29-7-5-4-6-8-29)39(48)45-21-19-43(20-22-45)33-13-17-44(18-14-33)38(47)30-11-15-42(16-12-30)28(3)46/h4-10,23-25,30,33,40H,11-22H2,1-3H3",LPALQJQUDYNDOK-UHFFFAOYSA-N,50482273,CHEMBL1170490,Acetyl-CoA carboxylase 1/2,Homo sapiens, 33
50403275,CC[C@H](C)[C@@H]1NC(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](Cc4cnc[nH]4)NC(=O)[C@H](CCCCN)NC3=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N2)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)O)C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N,"InChI=1S/C169H274N54O47S7/c1-14-84(5)126-159(263)207-112(70-125(234)235)150(254)221-131(91(12)230)163(267)219-127(85(6)15-2)164(268)223-63-34-47-122(223)158(262)201-100(42-24-28-57-172)140(244)208-113(73-224)151(255)196-104(46-33-62-188-169(182)183)141(245)213-120-80-275-274-78-118-155(259)198-102(44-31-60-186-167(178)179)136(240)194-101(43-25-29-58-173)144(248)220-130(90(11)229)162(266)215-116(135(239)189-72-124(233)217-128(88(9)227)161(265)216-121(165(269)270)81-277-276-79-119(156(260)218-126)211-133(237)86(7)191-134(238)97(174)39-30-59-185-166(176)177)76-272-273-77-117(212-142(246)105(52-53-123(175)232)199-146(250)108(66-92-35-18-16-19-36-92)202-132(236)87(8)192-160(264)129(89(10)228)222-157(120)261)154(258)197-99(41-23-27-56-171)138(242)206-111(69-95-71-184-82-190-95)149(253)210-114(74-225)152(256)200-106(54-64-271-13)143(247)193-98(40-22-26-55-170)137(241)204-110(68-94-48-50-96(231)51-49-94)147(251)195-103(45-32-61-187-168(180)181)139(243)203-107(65-83(3)4)145(249)209-115(75-226)153(257)205-109(148(252)214-118)67-93-37-20-17-21-38-93/h16-21,35-38,48-51,71,82-91,97-122,126-131,224-231H,14-15,22-34,39-47,52-70,72-81,170-174H2,1-13H3,(H2,175,232)(H,184,190)(H,189,239)(H,191,238)(H,192,264)(H,193,247)(H,194,240)(H,195,251)(H,196,255)(H,197,258)(H,198,259)(H,199,250)(H,200,256)(H,201,262)(H,202,236)(H,203,243)(H,204,241)(H,205,257)(H,206,242)(H,207,263)(H,208,244)(H,209,249)(H,210,253)(H,211,237)(H,212,246)(H,213,245)(H,214,252)(H,215,266)(H,216,265)(H,217,233)(H,218,260)(H,219,267)(H,220,248)(H,221,254)(H,222,261)(H,234,235)(H,269,270)(H4,176,177,185)(H4,178,179,186)(H4,180,181,187)(H4,182,183,188)/t84-,85-,86-,87-,88+,89+,90+,91+,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,126-,127-,128-,129-,130-,131-/m0/s1",FGIIXYFGJJQSRB-KSIGKOHTSA-N,50115494,CHEMBL3608993,Potassium voltage-gated channel subfamily A member 3,Homo sapiens, 156
50372090,CC(C)N1CCN(CC1)C(CN1CCN(CCCc2c(C)cccc2-c2ccccc2)CC1)c1ccc(F)cc1,"InChI=1S/C35H47FN4/c1-28(2)39-23-25-40(26-24-39)35(31-14-16-32(36)17-15-31)27-38-21-19-37(20-22-38)18-8-13-33-29(3)9-7-12-34(33)30-10-5-4-6-11-30/h4-7,9-12,14-17,28,35H,8,13,18-27H2,1-3H3",JBXYADWMJLOTTL-UHFFFAOYSA-N,50202933,(+/-)-1-[2-(4-fluorophenyl)-2-(4-isopropylpiperazin-1-yl)ethyl]-4-[3-(3-methylbiphenyl-2-yl)propyl]piperazine::CHEMBL226227,Delta-type opioid receptor,Rattus norvegicus,>10000
626020,C[C@@H](NC(=O)c1cc(OC[C@H]2CN(C)CCO2)cc(c1)-c1ncc(Cl)s1)c1cnc(nc1)C(F)(F)F,"InChI=1S/C23H23ClF3N5O3S/c1-13(16-8-29-22(30-9-16)23(25,26)27)31-20(33)14-5-15(21-28-10-19(24)36-21)7-17(6-14)35-12-18-11-32(2)3-4-34-18/h5-10,13,18H,3-4,11-12H2,1-2H3,(H,31,33)/t13-,18-/m1/s1",AJIHXKQJGQMCEX-FZKQIMNGSA-N,320200,"3-(5-chloro- 1,3-thiazol-2- yl)-5-{[(2R)-4- methylmorpholin- 2-yl]methoxy}-N- {(1R)-1-[2- (trifluoromethyl) pyrimidin-5-yl] ethyl}benzamide::US10174016, Example 367::US10202369, Example 367::US10472354, Example 367",P2X purinoceptor 3,Homo sapiens, 13.0
50800959,COc1ccc(cc1)S(=O)(=O)N1CC(C)(C)CN(C1C(=O)NO)S(=O)(=O)c1ccc(OC)cc1,"InChI=1S/C21H27N3O8S2/c1-21(2)13-23(33(27,28)17-9-5-15(31-3)6-10-17)20(19(25)22-26)24(14-21)34(29,30)18-11-7-16(32-4)8-12-18/h5-12,20,26H,13-14H2,1-4H3,(H,22,25)",MCSWSPNUKWMZHM-UHFFFAOYSA-N,50066659,"1,3-BIS-(4-METHOXY-BENZENESULFONYL)-5,5-DIMETHYL-HEXAHYDRO-PYRIMIDINE-2-CARBOXYLIC ACID HYDROXYAMIDE::CHEMBL115727::MMP inhibitor II",Interstitial collagenase,, 24
50821323,CN(C)C(=O)C[C@H]1CN(C)CC[C@@H]1c1ccc(Cl)cc1,"InChI=1S/C16H23ClN2O/c1-18(2)16(20)10-13-11-19(3)9-8-15(13)12-4-6-14(17)7-5-12/h4-7,13,15H,8-11H2,1-3H3/t13-,15+/m0/s1",IGOIMDYNTJNYKK-DZGCQCFKSA-N,50147831,"2-[(3R,4S)-4-(4-Chloro-phenyl)-1-methyl-piperidin-3-yl]-N,N-dimethyl-acetamide::CHEMBL103297",Sodium-dependent dopamine transporter,Rattus norvegicus,
947658,FC(F)(F)c1cccc(NC(=O)Nc2cccc(c2)C(=O)c2ccc3nccnc3c2)c1,"InChI=1S/C23H15F3N4O2/c24-23(25,26)16-4-2-6-18(13-16)30-22(32)29-17-5-1-3-14(11-17)21(31)15-7-8-19-20(12-15)28-10-9-27-19/h1-13H,(H2,29,30,32)",BSBAWIINPIJMCN-UHFFFAOYSA-N,458751,"US10759766, Compound C009",Vascular endothelial growth factor receptor 2,Homo sapiens,<100.0
443774,NC(=O)\C=C\c1c[nH]c2ncnc(OCC(F)(F)F)c12,"InChI=1S/C11H9F3N4O2/c12-11(13,14)4-20-10-8-6(1-2-7(15)19)3-16-9(8)17-5-18-10/h1-3,5H,4H2,(H2,15,19)(H,16,17,18)/b2-1+",BKXGJUGZEFIAJO-OWOJBTEDSA-N,254967,"US9505765, 191",Mitogen-activated protein kinase kinase kinase 7/TGF-beta-activated kinase 1 and MAP3K7-binding protein 1,, 33
51332215,CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(c2)-c2ccccn2)c(Cl)c1,"InChI=1S/C19H14Cl2N2O3S/c1-27(25,26)13-6-7-14(17(21)11-13)19(24)23-12-5-8-16(20)15(10-12)18-4-2-3-9-22-18/h2-11H,1H3,(H,23,24)",BPQMGSKTAYIVFO-UHFFFAOYSA-N,50249522,2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide::CHEMBL473417::VISMODEGIB,Cytochrome P450 3A4,Homo sapiens,>20000
787899,C1CN(CCO1)[C@H]1CC[C@@H](CC1)Nc1ncnc2ccc(cc12)-c1cccnc1,"InChI=1S/C23H27N5O/c1-2-18(15-24-9-1)17-3-8-22-21(14-17)23(26-16-25-22)27-19-4-6-20(7-5-19)28-10-12-29-13-11-28/h1-3,8-9,14-16,19-20H,4-7,10-13H2,(H,25,26,27)/t19-,20-",YGWQQKKAMHPAFS-MXVIHJGJSA-N,393953,"N-[trans-4-(morpholin- 4-yl)cyclohexyl]-6- (pyridin-3- yl)quinazolin-4-amine::US9969749, Example 1-46",Interleukin-1 receptor-associated kinase 4,Homo sapiens, 19.0
50798729,Cn1cc(cc(Nc2ccc(cn2)N2CCN(CC2)C2COC2)c1=O)-c1cccc(N2CCn3c4CCCCc4cc3C2=O)c1CO,"InChI=1S/C36H41N7O4/c1-39-20-25(17-30(35(39)45)38-34-10-9-26(19-37-34)40-11-13-41(14-12-40)27-22-47-23-27)28-6-4-8-32(29(28)21-44)43-16-15-42-31-7-3-2-5-24(31)18-33(42)36(43)46/h4,6,8-10,17-20,27,44H,2-3,5,7,11-16,21-23H2,1H3,(H,37,38)",FGAHWCREJZNLBB-UHFFFAOYSA-N,50254279,CHEMBL4060453,Tyrosine-protein kinase BTK,Homo sapiens, 8.0
51329998,OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.CC1(C)\C(=C/C=C/C=C/C2=[N+](CCCCS([O-])(=O)=O)c3ccccc3C2(C)C)N(CCCCCC(=O)NCCN2CCN(CCCCC3CCN(CC(=O)N4c5ccccc5NC(=O)c5ccccc45)CC3)CC2)c2ccccc12,"InChI=1S/C65H84N8O6S.3C2HF3O2/c1-64(2)52-25-11-15-29-56(52)71(59(64)32-7-5-8-33-60-65(3,4)53-26-12-16-30-57(53)72(60)40-21-22-48-80(77,78)79)39-19-6-9-34-61(74)66-37-43-69-46-44-68(45-47-69)38-20-18-23-50-35-41-70(42-36-50)49-62(75)73-55-28-14-10-24-51(55)63(76)67-54-27-13-17-31-58(54)73;3*3-2(4,5)1(6)7/h5,7-8,10-17,24-33,50H,6,9,18-23,34-49H2,1-4H3,(H2-,66,67,74,76,77,78,79);3*(H,6,7)",KGOBQPRGWBIPOA-UHFFFAOYSA-N,50538311,CHEMBL4641714,Muscarinic acetylcholine receptor M5,Homo sapiens,
51332877,CCn1nnc2c(C)c(ccc12)[C@@H](CC(O)=O)c1cc(C)c2CCN(Cc2c1)C(=O)c1ccccc1,"InChI=1S/C29H30N4O3/c1-4-33-26-11-10-24(19(3)28(26)30-31-33)25(16-27(34)35)21-14-18(2)23-12-13-32(17-22(23)15-21)29(36)20-8-6-5-7-9-20/h5-11,14-15,25H,4,12-13,16-17H2,1-3H3,(H,34,35)/t25-/m0/s1",QQOWDADZZIZEDA-VWLOTQADSA-N,50539569,CHEMBL4635041,Kelch-like ECH-associated protein 1,,
51441219,CNC(=O)c1c(oc2ccc(O)c(CN3CCC4(COC4)C3)c12)-c1ccc(O)c(C)c1,"InChI=1S/C24H26N2O5/c1-14-9-15(3-4-17(14)27)22-21(23(29)25-2)20-16(18(28)5-6-19(20)31-22)10-26-8-7-24(11-26)12-30-13-24/h3-6,9,27-28H,7-8,10-13H2,1-2H3,(H,25,29)",YDBMSYAQKBJBQZ-UHFFFAOYSA-N,50582194,CHEMBL5085116,Potassium voltage-gated channel subfamily H member 2,Homo sapiens, 16600
171906,CC(=O)Nc1ccc(\C=C\c2ccc(O)c(O)c2)cc1,"InChI=1S/C16H15NO3/c1-11(18)17-14-7-4-12(5-8-14)2-3-13-6-9-15(19)16(20)10-13/h2-10,19-20H,1H3,(H,17,18)/b3-2+",GGXBCSFQFOQXSS-NSCUHMNNSA-N,84961,"Stilbene derivative, 5",Alpha-glucosidase MAL12,Saccharomyces cerevisiae,>2.00e+5
989882,CC(C)(O)COc1cc(-c2ccc(nc2)N2CCC(C)(CC2)NC(=O)c2ccccc2)c2c(cnn2c1)C#N,"InChI=1S/C30H32N6O3/c1-29(2,38)20-39-24-15-25(27-23(16-31)18-33-36(27)19-24)22-9-10-26(32-17-22)35-13-11-30(3,12-14-35)34-28(37)21-7-5-4-6-8-21/h4-10,15,17-19,38H,11-14,20H2,1-3H3,(H,34,37)",HRYAKWCGTCQHHS-UHFFFAOYSA-N,305013,"US10144734, Example 29::US10172845, Example 29::US10441581, Example 29::US10881652, Example 29",Proto-oncogene tyrosine-protein kinase receptor Ret [V804M],, 54.6
50004395,CCCCN(CCCCCSc1nc(c([nH]1)-c1ccc(OC)cc1)-c1ccc(OC)cc1)c1nc2cc(ccc2o1)C(C)(C)C,"InChI=1S/C37H46N4O3S/c1-7-8-22-41(36-38-31-25-28(37(2,3)4)16-21-32(31)44-36)23-10-9-11-24-45-35-39-33(26-12-17-29(42-5)18-13-26)34(40-35)27-14-19-30(43-6)20-15-27/h12-21,25H,7-11,22-24H2,1-6H3,(H,39,40)",ROYQJKVQYGXCIA-UHFFFAOYSA-N,50285447,"CHEMBL53397::{5-[4,5-Bis-(4-methoxy-phenyl)-1H-imidazol-2-ylsulfanyl]-pentyl}-butyl-(5-tert-butyl-benzooxazol-2-yl)-amine",Sterol O-acyltransferase 1,Rattus norvegicus, 80
50694453,CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O,"InChI=1S/C28H39N7O3/c1-5-22-27(37)34(3)23-17-29-28(32-25(23)35(22)20-8-6-7-9-20)31-21-11-10-18(16-24(21)38-4)26(36)30-19-12-14-33(2)15-13-19/h10-11,16-17,19-20,22H,5-9,12-15H2,1-4H3,(H,30,36)(H,29,31,32)/t22-/m1/s1",XQVVPGYIWAGRNI-JOCHJYFZSA-N,25121,"4-{[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl]amino}-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide::BI 2536::CHEMBL513909::US10450297, Example 300::US8598172, 5",Serine/threonine-protein kinase PAK 3,,
101840,Oc1ccc(cc1C(=O)OCC(=O)Nc1nc2ccccc2s1)S(=O)(=O)Nc1ccccc1Cl,"InChI=1S/C22H16ClN3O6S2/c23-15-5-1-2-6-16(15)26-34(30,31)13-9-10-18(27)14(11-13)21(29)32-12-20(28)25-22-24-17-7-3-4-8-19(17)33-22/h1-11,26-27H,12H2,(H,24,25,28)",JBTOYBYOWRSEKP-UHFFFAOYSA-N,54063,"5-[(2-chlorophenyl)sulfamoyl]-2-hydroxy-benzoic acid [2-(1,3-benzothiazol-2-ylamino)-2-keto-ethyl] ester::5-[(2-chlorophenyl)sulfamoyl]-2-hydroxybenzoic acid [2-(1,3-benzothiazol-2-ylamino)-2-oxoethyl] ester::MLS000774737::SMR000372493::[2-(1,3-benzothiazol-2-ylamino)-2-oxidanylidene-ethyl] 5-[(2-chlorophenyl)sulfamoyl]-2-oxidanyl-benzoate::[2-(1,3-benzothiazol-2-ylamino)-2-oxoethyl] 5-[(2-chlorophenyl)sulfamoyl]-2-hydroxybenzoate::cid_2404664",M1 family aminopeptidase,Plasmodium falciparum (isolate FcB1 / Columbia), 44360
50419582,CC(C)C1(CC[C@@H](C)[C@H]2CC[C@@]3(C)[C@@H]4C[C@H](OS([O-])(=O)=O)[C@H]5[C@@H](O)[C@H](OS([O-])(=O)=O)[C@H](C[C@]5(C)C4=CC[C@]23C)OS([O-])(=O)=O)CC1C,"InChI=1S/C31H52O13S3/c1-17(2)31(15-19(31)4)13-8-18(3)20-9-11-30(7)22-14-23(42-45(33,34)35)25-26(32)27(44-47(39,40)41)24(43-46(36,37)38)16-28(25,5)21(22)10-12-29(20,30)6/h10,17-20,22-27,32H,8-9,11-16H2,1-7H3,(H,33,34,35)(H,36,37,38)(H,39,40,41)/p-3/t18-,19?,20-,22-,23+,24+,25+,26-,27-,28-,29-,30+,31?/m1/s1",NKLGRJLCGSYVNU-ALGPKGRHSA-K,50252376,CHEMBL455091::Topsentiasterol sulfate E,Transcription factor p65,,
51407985,CCCCCCNC(=O)\N=C(/N)NCCCc1sc(N)nc1C,"InChI=1S/C15H28N6OS/c1-3-4-5-6-9-19-15(22)21-13(16)18-10-7-8-12-11(2)20-14(17)23-12/h3-10H2,1-2H3,(H2,17,20)(H4,16,18,19,21,22)",CKIPXVNSJRXNTQ-UHFFFAOYSA-N,50568744,CHEMBL4853668,D(3) dopamine receptor,,
51072942,Brc1ccccc1OCCCCn1ccnc1,"InChI=1S/C13H15BrN2O/c14-12-5-1-2-6-13(12)17-10-4-3-8-16-9-7-15-11-16/h1-2,5-7,9,11H,3-4,8,10H2",ITQSGIJZBMXRMD-UHFFFAOYSA-N,50271548,1-(4-(2-bromophenoxy)butyl)-1H-imidazole::CHEMBL504297,Heme oxygenase 1,Rattus norvegicus, 53000
50832972,CCCCCCC[C@H]1O[C@@H]1C(OC(=O)c1ccc(I)cc1)C(=O)NC1CCCCC1,"InChI=1S/C24H34INO4/c1-2-3-4-5-9-12-20-21(29-20)22(23(27)26-19-10-7-6-8-11-19)30-24(28)17-13-15-18(25)16-14-17/h13-16,19-22H,2-12H2,1H3,(H,26,27)/t20-,21+,22?/m1/s1",JGYPSIUZIQZSFE-LKXRKSRJSA-N,50260364,CHEMBL4065603,Procathepsin L,Homo sapiens, 16860
1056917,Cc1noc(n1)[C@@H]1CCCCN1c1ccc(cn1)-c1noc(n1)C(F)(F)F,"InChI=1S/C16H15F3N6O2/c1-9-21-14(26-23-9)11-4-2-3-7-25(11)12-6-5-10(8-20-12)13-22-15(27-24-13)16(17,18)19/h5-6,8,11H,2-4,7H2,1H3/t11-/m0/s1",LYXFZOVHSVAQQN-NSHDSACASA-N,504714,"(S)-3-methyl-5-(1- (5-(5- (trifluoromethyl)- 1,2,4-oxadiazol-3- yl)pyridin-2-yl) piperidin-2-yl)- 1,2,4-oxadiazole::US11066396, Example 140",Histone deacetylase 6,Homo sapiens, 26.0
192425,Cc1cc(C)c2cc3n(ccc3cc2n1)C1OC[C@H](O)[C@H](O)[C@H]1O,"InChI=1S/C18H20N2O4/c1-9-5-10(2)19-13-6-11-3-4-20(14(11)7-12(9)13)18-17(23)16(22)15(21)8-24-18/h3-7,15-18,21-23H,8H2,1-2H3/t15-,16-,17+,18?/m0/s1",XGGWXDRQNGFDSY-XNHLSEOASA-N,40632,"(3R,4S,5S)-2-(6,8-dimethyl-1-pyrrolo[2,3-g]quinolinyl)oxane-3,4,5-triol;hydrochloride::(3R,4S,5S)-2-(6,8-dimethylpyrrolo[2,3-g]quinolin-1-yl)oxane-3,4,5-triol;hydrochloride::(3R,4S,5S)-2-(6,8-dimethylpyrrolo[2,3-g]quinolin-1-yl)tetrahydropyran-3,4,5-triol;hydrochloride::MLS000047960::SMR000033958::Structure contains non-supported carbohydrate derivative!::cid_6602841",Polyadenylate-binding protein 1,Homo sapiens,>66000
50594846,Clc1ccc(s1)C(=O)N1CCN(CC1)c1ccc(cc1)N(Cc1cnc[nH]1)S(=O)(=O)c1ccccc1,"InChI=1S/C25H24ClN5O3S2/c26-24-11-10-23(35-24)25(32)30-14-12-29(13-15-30)20-6-8-21(9-7-20)31(17-19-16-27-18-28-19)36(33,34)22-4-2-1-3-5-22/h1-11,16,18H,12-15,17H2,(H,27,28)",DLJAGEPCQCBENN-UHFFFAOYSA-N,50126557,CHEMBL284508::N-{4-[4-(5-Chloro-thiophene-2-carbonyl)-piperazin-1-yl]-phenyl}-N-(3H-imidazol-4-ylmethyl)-benzenesulfonamide,Protein farnesyltransferase subunit beta/geranylgeranyltransferase type-1 subunit alpha,Bos taurus, 600
326178,CCCCN(CCCC)C(=O)c1cc(C)n(n1)-c1ccc(NS(=O)c2c(C)onc2-c2ccccc2)cc1C(=O)N1Cc2ccccc2C[C@H]1CO,"InChI=1S/C40H46N6O5S/c1-5-7-20-44(21-8-6-2)40(49)35-22-27(3)46(41-35)36-19-18-32(43-52(50)38-28(4)51-42-37(38)29-14-10-9-11-15-29)24-34(36)39(48)45-25-31-17-13-12-16-30(31)23-33(45)26-47/h9-19,22,24,33,43,47H,5-8,20-21,23,25-26H2,1-4H3/t33-,52?/m0/s1",CUKVCPXQZDATEX-UPHSDLEZSA-N,179563,"US9126980, 8",Apoptosis regulator Bcl-2,, 835.86
100706,CN1CCN(CC1)C1Cc2ccc(Cl)cc2Sc2ccc(F)cc12,"InChI=1S/C19H20ClFN2S/c1-22-6-8-23(9-7-22)17-10-13-2-3-14(20)11-19(13)24-18-5-4-15(21)12-16(17)18/h2-5,11-12,17H,6-10H2,1H3",GPRZDPJGSSBXME-UHFFFAOYSA-N,53439,"1-(3-chloro-8-fluoro-10,11-dihydrodibenzo[b,f]thiepin-10-yl)-4-methylpiperazine::1-(9-chloranyl-3-fluoranyl-5,6-dihydrobenzo[b][1]benzothiepin-5-yl)-4-methyl-piperazine;methanesulfonic acid::1-(9-chloro-3-fluoro-5,6-dihydrobenzo[b][1]benzothiepin-5-yl)-4-methyl-piperazine;mesylic acid::1-(9-chloro-3-fluoro-5,6-dihydrobenzo[b][1]benzothiepin-5-yl)-4-methylpiperazine;methanesulfonic acid::MLS001179382::Nonacylated oxime, 28::SMR000475923::cid_21151824",Ubiquitin carboxyl-terminal hydrolase isozyme L1,Mus musculus, 3.21e+5
1240194,Clc1ccccc1CNC(=O)CSc1nnc(-c2c[nH]c3ccccc23)n1Cc1ccco1,"InChI=1S/C24H20ClN5O2S/c25-20-9-3-1-6-16(20)12-27-22(31)15-33-24-29-28-23(30(24)14-17-7-5-11-32-17)19-13-26-21-10-4-2-8-18(19)21/h1-11,13,26H,12,14-15H2,(H,27,31)",HZQRXURGPHBDGR-UHFFFAOYSA-N,582646,"US11548860, Compound 2::Z92489215",Cytochrome P450 2C9,Homo sapiens, 1800
50523157,CCOC(=O)C1=C(C[Se]C(=O)c2ccc(C)cc2)NC(=O)NC1c1ccc(O)c(OC)c1,"InChI=1S/C23H24N2O6Se/c1-4-31-21(27)19-16(12-32-22(28)14-7-5-13(2)6-8-14)24-23(29)25-20(19)15-9-10-17(26)18(11-15)30-3/h5-11,20,26H,4,12H2,1-3H3,(H2,24,25,29)",FFOGUYPWPVLUBD-UHFFFAOYSA-N,50197169,CHEMBL3949042,Acetylcholinesterase,Electrophorus electricus, 13570
51389563,Fc1ccc(Br)c(F)c1Nc1ncnc2cc3OCCOc3cc12,"InChI=1S/C16H10BrF2N3O2/c17-9-1-2-10(18)15(14(9)19)22-16-8-5-12-13(24-4-3-23-12)6-11(8)20-7-21-16/h1-2,5-7H,3-4H2,(H,20,21,22)",NVCSIFNUNPPUFH-UHFFFAOYSA-N,50561525,CHEMBL4786961,Epidermal growth factor receptor,Homo sapiens, 16
51429789,CC(C)N1CC[C@H](C1)NC(=O)c1cc(cs1)-n1ncc2cc(Nc3ccccc3Cl)ccc12,"InChI=1S/C25H26ClN5OS/c1-16(2)30-10-9-19(14-30)29-25(32)24-12-20(15-33-24)31-23-8-7-18(11-17(23)13-27-31)28-22-6-4-3-5-21(22)26/h3-8,11-13,15-16,19,28H,9-10,14H2,1-2H3,(H,29,32)/t19-/m1/s1",WXTIZLXTOMJFTP-LJQANCHMSA-N,50577633,CHEMBL4869300,Mitogen-activated protein kinase 10,Homo sapiens, 31
732677,CN(C)CCCN1C(=O)Cc2ccc(cc12)-c1ccc(C[C@H](NC(=O)[C@H]2N[C@@H]3CC[C@H]2C3)C#N)c(F)c1,"InChI=1S/C29H34FN5O2/c1-34(2)10-3-11-35-26-15-19(5-7-21(26)16-27(35)36)18-4-6-20(25(30)14-18)12-24(17-31)33-29(37)28-22-8-9-23(13-22)32-28/h4-7,14-15,22-24,28,32H,3,8-13,16H2,1-2H3,(H,33,37)/t22-,23+,24-,28-/m0/s1",XVWGIESADAKPIF-IMBSWCNGSA-N,150603,"US10238633, Example 277::US8987249, 277::US9713606, 277",Dipeptidyl peptidase 1,, 3.00
50081995,CCCc1cc(=O)oc2c3[C@@H](O)C(C)[C@H](C)Oc3c3C=CC(C)(C)Oc3c12,"InChI=1S/C22H26O5/c1-6-7-13-10-15(23)26-21-16(13)20-14(8-9-22(4,5)27-20)19-17(21)18(24)11(2)12(3)25-19/h8-12,18,24H,6-7H2,1-5H3/t11?,12-,18-/m0/s1",NIDRYBLTWYFCFV-KESLLWIESA-N,50050430,"(10S,12S)-12-Hydroxy-6,6,10,11-tetramethyl-4-propyl-11,12-dihydro-6H,10H-dipyrano[2,3-f;2',3'-h]chromen-2-one::CHEMBL282382",Gag-Pol polyprotein [489-587],Human immunodeficiency virus 1, 700
368550,Cc1ccc(-c2ncccn2)c(n1)C(=O)N1CCCOC1Cn1ccc(n1)-c1ccc(F)cc1,"InChI=1S/C25H23FN6O2/c1-17-4-9-20(24-27-11-2-12-28-24)23(29-17)25(33)32-13-3-15-34-22(32)16-31-14-10-21(30-31)18-5-7-19(26)8-6-18/h2,4-12,14,22H,3,13,15-16H2,1H3",XMTCRKRHFLBROW-UHFFFAOYSA-N,208513,"US9266870, 29",Orexin receptor type 2,Homo sapiens, 1.2
51438229,COc1cc(C)c2[nH]cc(\C=N\NC(=N)NCCc3ccc(I)cc3)c2c1,"InChI=1S/C20H22IN5O/c1-13-9-17(27-2)10-18-15(11-24-19(13)18)12-25-26-20(22)23-8-7-14-3-5-16(21)6-4-14/h3-6,9-12,24H,7-8H2,1-2H3,(H3,22,23,26)/b25-12+",SSHLGCTYVIDPHR-BRJLIKDPSA-N,50581004,CHEMBL5075697,Relaxin-3 receptor 1,Homo sapiens,
451470,C[C@]1(CS(=O)(=O)C(C)(C)C(=N)N1)c1cc(cs1)-c1cncc(c1)-c1cnco1,"InChI=1S/C19H20N4O3S2/c1-18(2)17(20)23-19(3,10-28(18,24)25)16-5-14(9-27-16)12-4-13(7-21-6-12)15-8-22-11-26-15/h4-9,11H,10H2,1-3H3,(H2,20,23)/t19-/m0/s1",NHMWXOQJSMLEEZ-IBGZPJMESA-N,259143,"US9499502, 27al",Beta-secretase 1,Homo sapiens,
98299,Cc1n[nH]c(NNC(=O)c2ccccc2)c1[N+]([O-])=O,"InChI=1S/C11H11N5O3/c1-7-9(16(18)19)10(13-12-7)14-15-11(17)8-5-3-2-4-6-8/h2-6H,1H3,(H,15,17)(H2,12,13,14)",WPALKMIPBZCECL-UHFFFAOYSA-N,52796,Benzoic acid N&#39;-(5-methyl-4-nitro-2H-pyrazol-3-yl)-hydrazide::MLS001044430::N'-(5-methyl-4-nitro-1H-pyrazol-3-yl)benzohydrazide::SMR000424797::cid_3401729,Zinc finger protein mex-5,Caenorhabditis elegans,
550237,Nc1nccn2c(nc(-c3ccc(cc3)C(=O)Nc3cc(ccn3)C(F)(F)F)c12)-c1ccc(nc1)C(O)=O,"InChI=1S/C25H16F3N7O3/c26-25(27,28)16-7-8-30-18(11-16)33-23(36)14-3-1-13(2-4-14)19-20-21(29)31-9-10-35(20)22(34-19)15-5-6-17(24(37)38)32-12-15/h1-12H,(H2,29,31)(H,37,38)(H,30,33,36)",SZGXJESHWMTTRR-UHFFFAOYSA-N,288424,"5-[8-amino-1-(4- {[4- (trifluoromethyl) pyridin-2- yl]carbamoyl} phenyl)imidazo[1,5- a]pyrazin-3- yl]pyridine-2- carboxylic acid::US10087188, Example 29",Tyrosine-protein kinase BTK,Homo sapiens, 11.3
215079,OS(=O)(=O)ON1[C@H]2CN([C@@H](CC2)C(=O)N[C@H]2CCNC[C@@H]2F)C1=O,"InChI=1S/C12H19FN4O6S/c13-8-5-14-4-3-9(8)15-11(18)10-2-1-7-6-16(10)12(19)17(7)23-24(20,21)22/h7-10,14H,1-6H2,(H,15,18)(H,20,21,22)/t7-,8+,9+,10+/m1/s1",BFXWSEXOZZPNPH-KATARQTJSA-N,98738,"US8487093, 84",Beta-lactamase,Pseudomonas aeruginosa, 110
889884,CN1CCC(COc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)CC1,"InChI=1S/C26H29FN6O2/c1-3-24(34)29-20-5-4-6-21(15-20)30-25-23(27)16-28-26(32-25)31-19-7-9-22(10-8-19)35-17-18-11-13-33(2)14-12-18/h3-10,15-16,18H,1,11-14,17H2,2H3,(H,29,34)(H2,28,30,31,32)",AYPVIBZTYJYHQB-UHFFFAOYSA-N,397169,"US10596172, Compound I-90::US10828300, Compound I-90::US11351168, Compound I-90::US9987276, Compound I-90",Tyrosine-protein kinase BTK,Homo sapiens,<10
896023,NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(Oc2ccccc2)c1F)C(F)(F)F,"InChI=1S/C24H18F4N4O2/c25-22-18(10-5-11-20(22)34-17-8-2-1-3-9-17)30-23(33)19-13-21(24(26,27)28)31-32(19)16-7-4-6-15(12-16)14-29/h1-13H,14,29H2,(H,30,33)",VUYMCUFLTORTFW-UHFFFAOYSA-N,416746,"1-(3-(aminomethyl)phenyl)-N-(2-fluoro-3-phenoxyphenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide::US10329260, Compound 23c::US10633345, Compound 23c::US10689346, Compound 23c::US11203574, Compound 23c::US11230530, Compound 23c",Plasma kallikrein,,
50182037,CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl,"InChI=1S/C21H20ClNO5/c1-23-7-6-12(17(27)10-23)19-14(24)8-15(25)20-16(26)9-18(28-21(19)20)11-4-2-3-5-13(11)22/h2-5,8-9,12,17,24-25,27H,6-7,10H2,1H3/t12-,17+/m0/s1",BIIVYFLTOXDAOV-YVEFUNNKSA-N,5655,"2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]-4H-chromen-4-one::CHEMBL428690::Flavopiridol::US10294218, Example Flavopiridol::US9617225, Flavopiridol","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",Homo sapiens,
833553,Cc1cc2c(cc(NC3CN(C3)C(=O)OC(C)(C)C)c3nnc(C)n23)n1Cc1ccccc1,"InChI=1S/C25H30N6O2/c1-16-11-22-21(30(16)13-18-9-7-6-8-10-18)12-20(23-28-27-17(2)31(22)23)26-19-14-29(15-19)24(32)33-25(3,4)5/h6-12,19,26H,13-15H2,1-5H3",RVXZEDZYQCJSEO-UHFFFAOYSA-N,343645,"US10442803, Example 244::US11091484, Example 244::US9777003, Example 244::tert-Butyl 3-(6-benzyl-1,7-dimethyl-6H- pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyridin- 4-ylamino)azetidine-1-carboxylate",Bromodomain-containing protein 4 [342-460],,<1000
50058792,CN1CCc2cccc-3c2[C@H]1Cc1ccc(O)c(O)c-31,"InChI=1S/C17H17NO2/c1-18-8-7-10-3-2-4-12-15(10)13(18)9-11-5-6-14(19)17(20)16(11)12/h2-6,13,19-20H,7-9H2,1H3/t13-/m1/s1",VMWNQDUVQKEIOC-CYBMUJFWSA-N,50001955,"(-)6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol(APO)::(Apomorphine) 6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol::(R)-6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol ((R)-apomorphine)::(R)-6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol (apomorphine)::(R)-6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol(apomorphine)::(apomorphine)6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol::6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol::6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol ((R)-apomorphine)::6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol((R)-apomorphine)::APOKYN::APOMORPHINE::APOMORPHINE HYDROCHLORIDE::APOMORPHINE6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol::CHEMBL53",D(3) dopamine receptor,,
51286560,CC(C)(C)N1C(=O)C=C(Cl)S1(=O)=O,"InChI=1S/C7H10ClNO3S/c1-7(2,3)9-6(10)4-5(8)13(9,11)12/h4H,1-3H3",HVIHMBJTRYBOCP-UHFFFAOYSA-N,50524462,CHEMBL4463777,Carbonic anhydrase 1,Homo sapiens,
50054895,COC(=O)[C@@H]1[C@H]2CC[C@@H](C[C@@H]1c1ccccc1)N2C,"InChI=1S/C16H21NO2/c1-17-12-8-9-14(17)15(16(18)19-2)13(10-12)11-6-4-3-5-7-11/h3-7,12-15H,8-10H2,1-2H3/t12-,13+,14+,15-/m0/s1",OMBOXYLBBHNWHL-YJNKXOJESA-N,22396,"(1R,2S,3S,5S)-3-(4-chlorophenyl)-2-[5-(4-fluorophenyl)-1,3-thiazol-2-yl]-8-methyl-8-azabicyclo[3.2.1]octane::WIN 35,065-2::WIN35,065-2::Win 35,065::methyl (1R,2S,3S,5S)-8-methyl-3-phenyl-8-azabicyclo[3.2.1]octane-2-carboxylate::troparil, 1R-(exo,exo)-isomer",Sodium-dependent dopamine transporter,Rattus norvegicus,
50610379,Oc1c(Br)cc2c(-c3ccccc3S(O)(=O)=O)c3cc(Br)c(=O)c(O)c3oc2c1O,"InChI=1S/C19H10Br2O8S/c20-10-5-8-13(7-3-1-2-4-12(7)30(26,27)28)9-6-11(21)15(23)17(25)19(9)29-18(8)16(24)14(10)22/h1-6,22,24-25H,(H,26,27,28)",NZBIQVXBGVBMFU-UHFFFAOYSA-N,50331547,CHEMBL210287::bromopyrogallol red,Nuclear factor NF-kappa-B p105 subunit,, 30000
1039694,FC(F)(F)c1c(cn[nH]c1=O)N1CC[C@H](COCCOc2cccc(c2)C(=O)N2CCN(CC2)c2ccc(cn2)C#N)C1,,,431526,"US10550105, Example 471::US10870641, Example 471::US11014913, Example 471",Protein mono-ADP-ribosyltransferase TIPARP,,<100
624500,CCOc1ccccc1CCn1cnc(c1)-c1cc(ccn1)-c1c[nH]nn1,"InChI=1S/C20H20N6O/c1-2-27-20-6-4-3-5-15(20)8-10-26-13-19(22-14-26)17-11-16(7-9-21-17)18-12-23-25-24-18/h3-7,9,11-14H,2,8,10H2,1H3,(H,23,24,25)",YIGRHNBSMBEKHZ-UHFFFAOYSA-N,276047,"2-[1-[2-(2-ethoxyphenyl)ethyl]imidazol-4-yl]-4-(1H-triazol-4-yl)pyridine::US10071984, Example 9::US10174003, Example 9::US9896436, Example 9",Lysine-specific demethylase 2B,,<100
860807,C=CC(=O)N1CCC(C1)c1cc(cc2cncnc12)-c1ccc(Oc2ccccc2)cc1,"InChI=1S/C27H23N3O2/c1-2-26(31)30-13-12-20(17-30)25-15-21(14-22-16-28-18-29-27(22)25)19-8-10-24(11-9-19)32-23-6-4-3-5-7-23/h2-11,14-16,18,20H,1,12-13,17H2",SKOPZWHKGHSJQP-UHFFFAOYSA-N,426689,"1-(3-(6-(4-phenoxyphenyl)quinazolin-8- yl)pyrrolidin-1-yl)prop-2-en-1-one::US10544106, Compound C048",Tyrosine-protein kinase BTK,Homo sapiens,<100.0
51320299,Cn1c2nc3CN(CCc4c(Cl)cccc4Cl)CCn3c2c(=O)n(C)c1=O,"InChI=1S/C18H19Cl2N5O2/c1-22-16-15(17(26)23(2)18(22)27)25-9-8-24(10-14(25)21-16)7-6-11-12(19)4-3-5-13(11)20/h3-5H,6-10H2,1-2H3",KDWCRIXUNJSKKH-UHFFFAOYSA-N,50534215,CHEMBL4463864,Adenosine receptor A2a,Rattus norvegicus,
50266067,CC(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2cccc(NC(=O)CN3CCN(CC3)C(=O)CO)c2)ncc1Cl,"InChI=1S/C27H32ClN7O5S/c1-18(2)41(39,40)23-9-4-3-8-22(23)32-26-21(28)15-29-27(33-26)31-20-7-5-6-19(14-20)30-24(37)16-34-10-12-35(13-11-34)25(38)17-36/h3-9,14-15,18,36H,10-13,16-17H2,1-2H3,(H,30,37)(H2,29,31,32,33)",YRQIZIMDOXXDDC-UHFFFAOYSA-N,50044464,CHEMBL3357459,Hepatocyte growth factor receptor,Homo sapiens, 338
1077028,Cc1cc(C)nc(n1)N1CC2CN(CC2C1)C(=O)c1sccc1-n1cccc1,"InChI=1S/C21H23N5OS/c1-14-9-15(2)23-21(22-14)26-12-16-10-25(11-17(16)13-26)20(27)19-18(5-8-28-19)24-6-3-4-7-24/h3-9,16-17H,10-13H2,1-2H3",DVFNTCCOGHJMNT-UHFFFAOYSA-N,118355,"US11059828, Example 8::US8653263, 8::US9586962, Example 8::USRE48841, Example 8",Orexin/Hypocretin receptor type 1,Homo sapiens,
51150808,CC(C)c1ccc2N(CCc2c1)C(=O)Nc1cccnc1,"InChI=1S/C17H19N3O/c1-12(2)13-5-6-16-14(10-13)7-9-20(16)17(21)19-15-4-3-8-18-11-15/h3-6,8,10-12H,7,9H2,1-2H3,(H,19,21)",RPWNUVPNNDNAAT-UHFFFAOYSA-N,50471643,CHEMBL40698,5-hydroxytryptamine receptor 2C,Homo sapiens,
15908,Cc1cccc(CNc2c3C(O)CCCc3nc3ccccc23)c1,"InChI=1S/C21H22N2O/c1-14-6-4-7-15(12-14)13-22-21-16-8-2-3-9-17(16)23-18-10-5-11-19(24)20(18)21/h2-4,6-9,12,19,24H,5,10-11,13H2,1H3,(H,22,23)",VQTIDCIBXATCPW-UHFFFAOYSA-N,9373,"9-Amino-1 ,2,3,4-tetrahydroacridin-1-ol deriv. 1aa::9-{[(3-methylphenyl)methyl]amino}-1,2,3,4-tetrahydroacridin-1-ol",Acetylcholinesterase,Rattus norvegicus, 24500
51213958,CC(C)n1c(C)nc2cnc(Nc3ccnc(n3)N3CC[C@H](O)C(F)(F)C3)cc12,"InChI=1S/C19H23F2N7O/c1-11(2)28-12(3)24-13-9-23-17(8-14(13)28)25-16-4-6-22-18(26-16)27-7-5-15(29)19(20,21)10-27/h4,6,8-9,11,15,29H,5,7,10H2,1-3H3,(H,22,23,25,26)/t15-/m0/s1",SXBQBMPZTKSXKA-HNNXBMFYSA-N,50498985,CHEMBL3734786,Epidermal growth factor receptor/Receptor tyrosine-protein kinase erbB-2/Receptor tyrosine-protein kinase erbB-3/Receptor tyrosine-protein kinase erbB-4,,
51031274,COc1c(cc(Cc2cnc(N)nc2N)cc1C(C)C)C(C)C,"InChI=1S/C18H26N4O/c1-10(2)14-7-12(8-15(11(3)4)16(14)23-5)6-13-9-21-18(20)22-17(13)19/h7-11H,6H2,1-5H3,(H4,19,20,21,22)",SMLJPKAFENVMOT-UHFFFAOYSA-N,50421818,CHEMBL280374,Dihydrofolate reductase,Rattus norvegicus, 13000
270465,CC(C)(C)NC(=O)Nc1cnn2ccc(nc12)N1CCC[C@@H]1c1cc(F)ccc1F,"InChI=1S/C21H24F2N6O/c1-21(2,3)27-20(30)25-16-12-24-29-10-8-18(26-19(16)29)28-9-4-5-17(28)14-11-13(22)6-7-15(14)23/h6-8,10-12,17H,4-5,9H2,1-3H3,(H2,25,27,30)/t17-/m1/s1",KGXJJZLPOKXQBF-QGZVFWFLSA-N,136586,"US10005783, 3::US10047097, 3::US10774085, Example 3::US11267818, Example 3::US8865698, 3::US9676783, 3",High affinity nerve growth factor receptor,, 22.2
766453,CN(C)C(=O)c1ccc2cc(ccc2c1)C(=O)C1CCCN(C1)C1CCCC1,"InChI=1S/C24H30N2O2/c1-25(2)24(28)20-12-10-17-14-19(11-9-18(17)15-20)23(27)21-6-5-13-26(16-21)22-7-3-4-8-22/h9-12,14-15,21-22H,3-8,13,16H2,1-2H3",MPYNRUWMJJTULK-UHFFFAOYSA-N,383687,"6-(1-cyclobutylpiperidine-3-carbonyl)-N,N-dimethyl-2-naphthamide::US10280149, Example 178",Lysine-specific demethylase 2B,, 188
383690,Cc1ccc(F)c(CNc2cc(NC3CC3)n3ncc(\C=C4/NC(=O)NC4=O)c3n2)c1Cl,"InChI=1S/C21H19ClFN7O2/c1-10-2-5-14(23)13(18(10)22)9-24-16-7-17(26-12-3-4-12)30-19(28-16)11(8-25-30)6-15-20(31)29-21(32)27-15/h2,5-8,12,26H,3-4,9H2,1H3,(H,24,28)(H2,27,29,31,32)/b15-6-",AQYUSIJQYVUMQG-UUASQNMZSA-N,219973,"US9303033, X44, Table 50A, Compound 55",Casein kinase II subunit alpha/beta,Homo sapiens,<10
50307026,O=C(NCCc1ccccc1)Nc1ccc(cc1)-c1cn[nH]c1,"InChI=1S/C18H18N4O/c23-18(19-11-10-14-4-2-1-3-5-14)22-17-8-6-15(7-9-17)16-12-20-21-13-16/h1-9,12-13H,10-11H2,(H,20,21)(H2,19,22,23)",DWGJNYSMPHRXBP-UHFFFAOYSA-N,50431163,CHEMBL2332078,Rho-associated protein kinase 2,Homo sapiens, 88
694993,COc1cc2c(Nc3ccc(Cl)c(Cl)c3)ncnc2cc1OCc1noc(n1)C1CCCCN1,"InChI=1S/C23H22Cl2N6O3/c1-32-19-9-14-18(27-12-28-22(14)29-13-5-6-15(24)16(25)8-13)10-20(19)33-11-21-30-23(34-31-21)17-4-2-3-7-26-17/h5-6,8-10,12,17,26H,2-4,7,11H2,1H3,(H,27,28,29)",PCRLTROAULDNDE-UHFFFAOYSA-N,351425,"N-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[(5- piperidin-2-yl-1,2,4-oxadiazol-3- yl)methyl]oxy}quinazolin-4-amine::US9796704, Entry 145",Ephrin type-A receptor 2,Homo sapiens, 10500
1255250,CCn1c(c2CC(C)(C)COC(=O)[C@@H]3CCCN(N3)C(=O)[C@H](Cc3nc(cs3)-c3ccc1c2c3)NC(=O)[C@H](C(C)C)N(C)C(=O)N1C[C@H]2[C@@H]1CCN2C(=O)C=C)-c1cccnc1[C@H](C)OC,"InChI=1S/C49H63N9O7S/c1-10-41(59)56-21-18-38-39(56)25-57(38)48(63)54(8)43(28(3)4)45(60)52-35-23-40-51-36(26-66-40)30-16-17-37-32(22-30)33(44(55(37)11-2)31-14-12-19-50-42(31)29(5)64-9)24-49(6,7)27-65-47(62)34-15-13-20-58(53-34)46(35)61/h10,12,14,16-17,19,22,26,28-29,34-35,38-39,43,53H,1,11,13,15,18,20-21,23-25,27H2,2-9H3,(H,52,60)/t29-,34-,35-,38-,39-,43-/m0/s1",UOHBHQMPDKUQHL-CRUQLWCQSA-N,591867,"US11566007, Example A547",GTPase NRas [Q61R],, 550
50290430,COC(=O)C12O[C@@H]1C(=C)C[C@@]1(O)C3CC[C@@]4(C)C5C=CC(=O)OC[C@]5([C@@H](C)OC(C)=O)[C@@H](OC(C)=O)[C@@H](OC(C)=O)C4[C@@]3(C)[C@H](OC(C)=O)[C@H](OC(C)=O)[C@@]21C,"InChI=1S/C40H52O16/c1-18-16-39(48)26-14-15-35(8)25-12-13-27(46)50-17-38(25,19(2)51-20(3)41)31(53-22(5)43)28(52-21(4)42)29(35)36(26,9)32(54-23(6)44)33(55-24(7)45)37(39,10)40(30(18)56-40)34(47)49-11/h12-13,19,25-26,28-33,48H,1,14-17H2,2-11H3/t19-,25?,26?,28+,29?,30-,31+,32-,33+,35+,36+,37-,38-,39-,40?/m1/s1",VKDXHXWBOARFPD-MDAQDJAWSA-N,50158201,CHEMBL362198::Correloid,Potassium voltage-gated channel subfamily A member 3,Homo sapiens, 100
1103824,CC1(C)CC(CCO1)n1c(nc2cnc3ccc(cc3c12)C#N)C1CCC(F)C1,"InChI=1S/C23H25FN4O/c1-23(2)11-17(7-8-29-23)28-21-18-9-14(12-25)3-6-19(18)26-13-20(21)27-22(28)15-4-5-16(24)10-15/h3,6,9,13,15-17H,4-5,7-8,10-11H2,1-2H3",YZPHYZVOZXGFQJ-UHFFFAOYSA-N,522423,"1-(2,2-dimethyltetrahydro- 2H-pyran-4-yl)-2-(3- fluorocyclopentyl)-1H- imidazo[-c]quinoline-8- carbonitrile, DIAST A::US11161844, Example 39::US11161844, Example 40::US11161844, Example 41::US11161844, Example 42::US11161844, Example 53::US11161844, Example 54::US11161844, Example 55::US11161844, Example 56",Leucine-rich repeat serine/threonine-protein kinase 2,Homo sapiens,>3000
1011177,Cc1ccc(cc1CN1C[C@H]2CCCN2c2ncc(cc2S1(=O)=O)C#N)[C@H](CC(O)=O)c1ccn2c(nnc2c1C)C(F)F,"InChI=1S/C30H29F2N7O4S/c1-17-5-6-20(24(12-26(40)41)23-7-9-39-28(18(23)2)35-36-30(39)27(31)32)11-21(17)15-37-16-22-4-3-8-38(22)29-25(44(37,42)43)10-19(13-33)14-34-29/h5-7,9-11,14,22,24,27H,3-4,8,12,15-16H2,1-2H3,(H,40,41)/t22-,24+/m1/s1",DFMNXBRGOVUFCJ-VWNXMTODSA-N,487039,"US10947252, Example 540::US11427601, Example 540",Kelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2,,
50408141,CC(C)(C)c1cc(NC(=O)c2c(Cl)cc(N)cc2Cl)ccc1O,"InChI=1S/C17H18Cl2N2O2/c1-17(2,3)11-8-10(4-5-14(11)22)21-16(23)15-12(18)6-9(20)7-13(15)19/h4-8,22H,20H2,1-3H3,(H,21,23)",VWLDZXITCJEFAM-UHFFFAOYSA-N,50118081,CHEMBL3613426,Bile acid receptor,Homo sapiens, 5200
1140121,CCNc1cc2n(nc(-c3cnn(C)c3)c2cn1)C1CC[C@@H](CC1)Oc1ccccc1S(C)(=O)=O,"InChI=1S/C25H30N6O3S/c1-4-26-24-13-21-20(15-27-24)25(17-14-28-30(2)16-17)29-31(21)18-9-11-19(12-10-18)34-22-7-5-6-8-23(22)35(3,32)33/h5-8,13-16,18-19H,4,9-12H2,1-3H3,(H,26,27)/t18?,19-",XJWVUJVVTSKKFL-HSNGWXBGSA-N,537551,"N-ethyl-3-(1-methyl-1H-pyrazol-4- yl)-1-((ls,4s)-4-(2- (methylsulfonyl)phenoxy)cyclohexyl)- 1H-pyrazolo[4,3-c]pyridin-6- amine::US11247990, Example 376",Tyrosine-protein kinase receptor UFO,, 110
50759166,OC(=O)CCC(NC(=O)c1cccc(Cl)c1)C(=O)NN1CCC2(CCCCC2)CC1,"InChI=1S/C22H30ClN3O4/c23-17-6-4-5-16(15-17)20(29)24-18(7-8-19(27)28)21(30)25-26-13-11-22(12-14-26)9-2-1-3-10-22/h4-6,15,18H,1-3,7-14H2,(H,24,29)(H,25,30)(H,27,28)",YARSCZBHMLSKFA-UHFFFAOYSA-N,50008219,4-(3-Aza-spiro[5.5]undec-3-ylcarbamoyl)-4-(3-chloro-benzoylamino)-butyric acid::CHEMBL123684,Gastrin/cholecystokinin type B receptor,Rattus, 800
50967054,CN1c2ccc(cc2C(=C)c2ccccc2C1=O)C(C)=O,"InChI=1S/C18H15NO2/c1-11-14-6-4-5-7-15(14)18(21)19(3)17-9-8-13(12(2)20)10-16(11)17/h4-10H,1H2,2-3H3",XLPHZTCBPKMHIB-UHFFFAOYSA-N,50396604,CHEMBL2171905,Oxysterols receptor LXR-alpha,, 4900
50754921,CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(NC(=O)c4cccc(c4)-c4cccnc4)c3)cc2C(F)(F)F)CC1,"InChI=1S/C33H32F3N5O2/c1-22-8-9-25(18-30(22)39-32(43)24-6-3-5-23(17-24)26-7-4-12-37-20-26)31(42)38-28-11-10-27(29(19-28)33(34,35)36)21-41-15-13-40(2)14-16-41/h3-12,17-20H,13-16,21H2,1-2H3,(H,38,42)(H,39,43)",KBCISYCUHRRWQT-UHFFFAOYSA-N,50240228,CHEMBL4060882,Macrophage colony-stimulating factor 1 receptor,, 20
50603989,CN1CCC(CC1)=C1c2cccn2CCc2ccc(cc12)C#N,"InChI=1S/C20H21N3/c1-22-10-6-17(7-11-22)20-18-13-15(14-21)4-5-16(18)8-12-23-9-2-3-19(20)23/h2-5,9,13H,6-8,10-12H2,1H3",BUQZDJWQOJESIN-UHFFFAOYSA-N,50026963,"11-(1-Methyl-piperidin-4-ylidene)-6,11-dihydro-5H-benzo[d]pyrrolo[1,2-a]azepine-9-carbonitrile::CHEMBL176365",D(1A)/D(1B)/D(2)/D(3)/D(4) dopamine receptor,Rattus,
839567,CN(c1ncccc1CNc1nc(Nc2ccc(cc2)C(=O)NCCNC(C)=O)ncc1C(F)(F)F)S(C)(=O)=O,"InChI=1S/C24H27F3N8O4S/c1-15(36)28-11-12-30-22(37)16-6-8-18(9-7-16)33-23-32-14-19(24(25,26)27)20(34-23)31-13-17-5-4-10-29-21(17)35(2)40(3,38)39/h4-10,14H,11-13H2,1-3H3,(H,28,36)(H,30,37)(H2,31,32,33,34)",JDPWVQNFNVIVRO-UHFFFAOYSA-N,418747,"N-[2-(acetylamino)ethyl]-4-({4-[({2- [methyl(methylsulfonyl)amino]pyridin-3- yl}methyl)amino]-5- (trifluoromethyl)pyrimidin-2- yl}amino)benzamide (245)::US10450297, Example 245",Focal adhesion kinase 1 [410-689],, 2.62
915988,COc1ccc(COc2ccc(Nc3ccc4ncc(OC(C)C)nc4c3C#N)cc2OC)cn1,"InChI=1S/C26H25N5O4/c1-16(2)35-25-14-28-21-8-7-20(19(12-27)26(21)31-25)30-18-6-9-22(23(11-18)32-3)34-15-17-5-10-24(33-4)29-13-17/h5-11,13-14,16,30H,15H2,1-4H3",WEFHAQSYFXFUGJ-UHFFFAOYSA-N,447640,"3-isopropoxy-6-((3-methoxy-4-((6-methoxypyridin-3-yl)methoxy)phenyl)amino)quinoxaline-5-carbonitrile::US10689362, Example 119",Mast/stem cell growth factor receptor Kit,,
51311643,CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,"InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1",ULXXDDBFHOBEHA-CWDCEQMOSA-N,50322823,"(S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide::AFATINIB::CHEMBL1173655::US10085983, Compound BIBW2992::US10196365, Afatinib::US10435400, Compound BIBW2992::US9388170, Afatinib::US9890168, Compound BIBW2992::WO2022090481, Example afatinib",Epidermal growth factor receptor,Homo sapiens, 0.500000
124398,CC1CC(C)CN(C1)C(=O)c1ccc(o1)-c1ccc(cc1)[N+]([O-])=O,"InChI=1S/C18H20N2O4/c1-12-9-13(2)11-19(10-12)18(21)17-8-7-16(24-17)14-3-5-15(6-4-14)20(22)23/h3-8,12-13H,9-11H2,1-2H3",QTLSKAASRCRKSN-UHFFFAOYSA-N,66961,"(3,5-dimethyl-1-piperidinyl)-[5-(4-nitrophenyl)-2-furanyl]methanone::(3,5-dimethylpiperidin-1-yl)-[5-(4-nitrophenyl)furan-2-yl]methanone::(3,5-dimethylpiperidino)-[5-(4-nitrophenyl)-2-furyl]methanone::MLS001138960::SMR000708702::cid_24980426",Bcl-2-like protein 11,Homo sapiens,
50399952,C[C@H](Nc1cc(ccn1)-c1c(nc(C2CCNCC2)n1C)-c1cccc(c1)C(F)(F)F)c1ccccc1,"InChI=1S/C29H30F3N5/c1-19(20-7-4-3-5-8-20)35-25-18-23(13-16-34-25)27-26(22-9-6-10-24(17-22)29(30,31)32)36-28(37(27)2)21-11-14-33-15-12-21/h3-10,13,16-19,21,33H,11-12,14-15H2,1-2H3,(H,34,35)/t19-/m0/s1",ZLQKJFNLHHGAQF-IBGZPJMESA-N,15459,4-[1-methyl-2-(piperidin-4-yl)-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-5-yl]-N-[(1S)-1-phenylethyl]pyridin-2-amine::4-{1-methyl-2-piperidin-4-yl-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-5-yl}-N-[(1S)-1-phenylethyl]pyridin-2-amine::CHEMBL303144::L-790070,Mitogen-activated protein kinase 11,Homo sapiens, 0.1
114012,CC(C)c1ccc(cc1)S(=O)(=O)N1CCN(CCC(=O)Nc2ccc(cc2)N(C)C)CC1,"InChI=1S/C24H34N4O3S/c1-19(2)20-5-11-23(12-6-20)32(30,31)28-17-15-27(16-18-28)14-13-24(29)25-21-7-9-22(10-8-21)26(3)4/h5-12,19H,13-18H2,1-4H3,(H,25,29)",KQDNHVGNLRRMDQ-UHFFFAOYSA-N,60378,MLS000047489::N-[4-(dimethylamino)phenyl]-3-(4-p-cumenylsulfonylpiperazino)propionamide::N-[4-(dimethylamino)phenyl]-3-[4-(4-propan-2-ylphenyl)sulfonyl-1-piperazinyl]propanamide::N-[4-(dimethylamino)phenyl]-3-[4-(4-propan-2-ylphenyl)sulfonylpiperazin-1-yl]propanamide::N-[4-(dimethylamino)phenyl]-3-{4-[(4-isopropylphenyl)sulfonyl]piperazin-1-yl}propanamide::SMR000033500::cid_3241036,Large T antigen,Simian virus 40, 15130
50433374,Clc1ccc(cc1)C(NC(=O)CNC(=O)CCc1ccccc1)c1ccccc1,"InChI=1S/C24H23ClN2O2/c25-21-14-12-20(13-15-21)24(19-9-5-2-6-10-19)27-23(29)17-26-22(28)16-11-18-7-3-1-4-8-18/h1-10,12-15,24H,11,16-17H2,(H,26,28)(H,27,29)",ZBWMUFAKPSHRGZ-UHFFFAOYSA-N,50263361,CHEMBL514681::N-(2-((4-chlorophenyl)(phenyl)methylamino)-2-oxoethyl)-3-phenylpropanamide,Cytochrome P450 2C9,Homo sapiens,>50000
480889,Cc1cc(C)n2nc(\C=C\c3cccc(n3)N3CCCC3)nc2n1,"InChI=1S/C18H20N6/c1-13-12-14(2)24-18(19-13)21-16(22-24)9-8-15-6-5-7-17(20-15)23-10-3-4-11-23/h5-9,12H,3-4,10-11H2,1-2H3/b9-8+",KNLVRLGTQKVGIW-CMDGGOBGSA-N,202252,"(e)-5,7-dimethyl-2-(2-(6-(pyrrolidin-1-yl)pyridin-2-yl)vinyl)[1,2,4]triazolo[1,5-a]pyrimidine::US9540384, 47","cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A",Homo sapiens, 31.0
122270,Brc1cccc2C(=O)N(CSc12)c1ccccc1,"InChI=1S/C14H10BrNOS/c15-12-8-4-7-11-13(12)18-9-16(14(11)17)10-5-2-1-3-6-10/h1-8H,9H2",ULNACOSQVDBHCL-UHFFFAOYSA-N,61973,"8-bromanyl-3-phenyl-2H-1,3-benzothiazin-4-one::8-bromo-3-phenyl-2H-1,3-benzothiazin-4-one::KSC-6-211::KUC105622N::cid_45479203",Glucose-6-phosphate 1-dehydrogenase,Leuconostoc mesenteroides,>25000
798685,CS(=O)(=O)Nc1cnn(c1)C(=O)N1CC2CN(Cc3ccccc3Cl)CC2C1,"InChI=1S/C18H22ClN5O3S/c1-28(26,27)21-16-6-20-24(12-16)18(25)23-10-14-8-22(9-15(14)11-23)7-13-4-2-3-5-17(13)19/h2-6,12,14-15,21H,7-11H2,1H3",WJQNJURFKGPYHF-UHFFFAOYSA-N,399779,"1-(5-(2- chlorobenzyl)octahydropyrrolo[3,4- c]pyrrole-2-carbonyl)-N- (methylsulfonyl)-1H-pyrazole-4- carboxamide::US10323038, Example 6",Fatty-acid amide hydrolase 1,Mus musculus, 550
519897,Cc1nc(c(-c2ccc3nc(NC(=O)C4=CCc5ccncc45)cn3n2)n1C)-c1ccc(F)cc1,"InChI=1S/C26H20FN7O/c1-15-29-24(17-3-6-18(27)7-4-17)25(33(15)2)21-9-10-23-30-22(14-34(23)32-21)31-26(35)19-8-5-16-11-12-28-13-20(16)19/h3-4,6-14H,5H2,1-2H3,(H,31,35)",KMVXBTIOSWQJNE-UHFFFAOYSA-N,274758,"N-(6-(4-(4-fluorophenyl)-1,2- dimethyl-1H-imidazol-5-yl) imidazo[1,2-b]pyridazin-2- yl)-1H-pyrrolo[3,2-c] pyridine-3-carboxamide::US9556179, Compound 334",Casein kinase I isoform epsilon,, 0.966
51101441,Cc1c(Br)cn(Cc2ccc(F)cc2)c(=O)c1C(=O)NC1CCCCCC1,"InChI=1S/C21H24BrFN2O2/c1-14-18(22)13-25(12-15-8-10-16(23)11-9-15)21(27)19(14)20(26)24-17-6-4-2-3-5-7-17/h8-11,13,17H,2-7,12H2,1H3,(H,24,26)",GBQCNXBVFXUOFL-UHFFFAOYSA-N,50408224,CHEMBL4164954,Lysophosphatidylserine lipase ABHD12,Homo sapiens, 2100
50959825,N[C@@H](Cc1ccc(O)cc1)C(=O)N1Cc2ccccc2C[C@H]1c1nc(c[nH]1)-c1ccccc1,"InChI=1S/C27H26N4O2/c28-23(14-18-10-12-22(32)13-11-18)27(33)31-17-21-9-5-4-8-20(21)15-25(31)26-29-16-24(30-26)19-6-2-1-3-7-19/h1-13,16,23,25,32H,14-15,17,28H2,(H,29,30)/t23-,25-/m0/s1",SWZLGDBFWBZXTL-ZCYQVOJMSA-N,50154036,"(S)-2-amino-3-(4-hydroxyphenyl)-1-((S)-3-(4-phenyl-1H-imidazol-2-yl)-3,4-dihydroisoquinolin-2(1H)-yl)propan-1-one::2-Amino-3-(4-hydroxy-phenyl)-1-[3-(4-phenyl-1H-imidazol-2-yl)-3,4-dihydro-1H-isoquinolin-2-yl]-propan-1-one::CHEMBL361274",Delta-type opioid receptor,Rattus norvegicus,
50603264,CC(C)C(=O)NCc1ccc2Sc3ccccc3C[C@H](N3CCN(C)CC3)c2c1,"InChI=1S/C24H31N3OS/c1-17(2)24(28)25-16-18-8-9-23-20(14-18)21(27-12-10-26(3)11-13-27)15-19-6-4-5-7-22(19)29-23/h4-9,14,17,21H,10-13,15-16H2,1-3H3,(H,25,28)/t21-/m0/s1",SHVCHMGRIYXVAY-NRFANRHFSA-N,50328506,"(S)-N-((11-(4-methylpiperazin-1-yl)-10,11-dihydrodibenzo[b,f]thiepin-2-yl)methyl)isobutyramide::CHEMBL1259190",Alpha-1B adrenergic receptor,Cricetulus griseus,
50952212,CCOC(=O)c1ccc(cc1)N1CC(C(=O)c2ccc(OC)cc2)=C(O)C1=O,"InChI=1S/C21H19NO6/c1-3-28-21(26)14-4-8-15(9-5-14)22-12-17(19(24)20(22)25)18(23)13-6-10-16(27-2)11-7-13/h4-11,24H,3,12H2,1-2H3",FWYZKWKOUCUIDN-UHFFFAOYSA-N,50274398,CHEMBL4125741,P2X purinoceptor 3,Homo sapiens,>10000
50741633,CN(C)C\C=C\C(=O)Nc1ccc2ncc(C#N)c(Nc3cccc(Br)c3)c2c1,"InChI=1S/C22H20BrN5O/c1-28(2)10-4-7-21(29)26-18-8-9-20-19(12-18)22(15(13-24)14-25-20)27-17-6-3-5-16(23)11-17/h3-9,11-12,14H,10H2,1-2H3,(H,25,27)(H,26,29)/b7-4+",ABDIOQXDBJMGHB-QPJJXVBHSA-N,50122567,(E)-4-Dimethylamino-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-quinolin-6-yl]-amide::4-Dimethylamino-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-quinolin-6-yl]-amide::CHEMBL30973,Epidermal growth factor receptor,Homo sapiens, 310
600340,Oc1cc(O)c2c(c1)c(C=C)cn(-c1ccc(O)c(F)c1)c2=O,"InChI=1S/C17H12FNO4/c1-2-9-8-19(10-3-4-14(21)13(18)5-10)17(23)16-12(9)6-11(20)7-15(16)22/h2-8,20-22H,1H2",UZCGSEMPWJYIKG-UHFFFAOYSA-N,312139,"2-(3-fluoro-4-hydroxyphenyl)-6,8-dihydroxy-4-vinylisoquinolin-1(2H)-one::US9604931, 15c::US9623021, Compound 15c",Steroid hormone receptor ERR1,Homo sapiens,
491061,C[C@H]([C@H](C)n1c(=O)cc(Nc2ccc(Oc3ccc(F)cn3)cc2)n(Cc2ccc(Cl)cc2)c1=O)C(O)=O,"InChI=1S/C27H24ClFN4O5/c1-16(26(35)36)17(2)33-25(34)13-23(32(27(33)37)15-18-3-5-19(28)6-4-18)31-21-8-10-22(11-9-21)38-24-12-7-20(29)14-30-24/h3-14,16-17,31H,15H2,1-2H3,(H,35,36)/t16-,17+/m1/s1",TYYGTJWQWWOPLO-SJORKVTESA-N,246672,"US9550763, Compound I-325",P2X purinoceptor 3,Homo sapiens, 11.0
50434376,C[N+](C)(CC=C)c1ccc(CCC(=O)CCc2ccc(cc2)[N+](C)(C)CC=C)cc1,"InChI=1S/C27H38N2O/c1-7-21-28(3,4)25-15-9-23(10-16-25)13-19-27(30)20-14-24-11-17-26(18-12-24)29(5,6)22-8-2/h7-12,15-18H,1-2,13-14,19-22H2,3-6H3/q+2",ZAEXMNKDGJNLTA-UHFFFAOYSA-N,10624,"1,5-bis(4-allyldimethylammoniumphenyl)-pentan-3-one dibromide::4-(5-{4-[dimethyl(prop-2-en-1-yl)aminiumyl]phenyl}-3-oxopentyl)-N,N-dimethyl-N-(prop-2-en-1-yl)anilinium dibromide::BW284c51::CHEMBL140020::CHEMBL464538",Acetylcholinesterase,Electrophorus electricus, 63
487542,COc1cnc(cn1)C(=O)Nc1ccc(F)c(c1)[C@@]1(CS(=O)(=O)C(C)(C)C(N)=N1)C(F)F,"InChI=1S/C19H20F3N5O4S/c1-18(2)17(23)27-19(16(21)22,9-32(18,29)30)11-6-10(4-5-12(11)20)26-15(28)13-7-25-14(31-3)8-24-13/h4-8,16H,9H2,1-3H3,(H2,23,27)(H,26,28)/t19-/m0/s1",XCNQMVNUQKTPJS-IBGZPJMESA-N,228417,"US9556135, 36",Beta-secretase 1,Homo sapiens, 20.2
50772205,CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1,"InChI=1S/C13H18ClNO/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10/h5-9,15H,1-4H3",SNPPWIUOZRMYNY-UHFFFAOYSA-N,50048392,"2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one::BUPROPION::BUPROPION HYDROCHLORIDE::CHEMBL894::US9944618, Compound ID No. 176",Bile salt export pump,, 133000
151625,CN(C)CCCNC(=O)C(\NC(=O)c1ccc(C)cc1)=C\c1ccc(o1)-c1ccc(Br)cc1,"InChI=1S/C26H28BrN3O3/c1-18-5-7-20(8-6-18)25(31)29-23(26(32)28-15-4-16-30(2)3)17-22-13-14-24(33-22)19-9-11-21(27)12-10-19/h5-14,17H,4,15-16H2,1-3H3,(H,28,32)(H,29,31)/b23-17-",IFTAUFOEDCOUKF-QJOMJCCJSA-N,63623,MLS000709318::N-[(Z)-1-[5-(4-bromophenyl)-2-furanyl]-3-[3-(dimethylamino)propylamino]-3-oxoprop-1-en-2-yl]-4-methylbenzamide::N-[(Z)-1-[5-(4-bromophenyl)furan-2-yl]-3-[3-(dimethylamino)propylamino]-3-oxidanylidene-prop-1-en-2-yl]-4-methyl-benzamide::N-[(Z)-1-[5-(4-bromophenyl)furan-2-yl]-3-[3-(dimethylamino)propylamino]-3-oxoprop-1-en-2-yl]-4-methylbenzamide::N-[(Z)-2-[5-(4-bromophenyl)-2-furyl]-1-[3-(dimethylamino)propylcarbamoyl]vinyl]-4-methyl-benzamide::SMR000289985::cid_2131984,C-C chemokine receptor type 6,, 24600
425418,Cc1cncc(c1)C(=O)Nc1cccc(CN2CCC(F)(CC2)C(=O)NC2CCCCC2)c1,"InChI=1S/C26H33FN4O2/c1-19-14-21(17-28-16-19)24(32)29-23-9-5-6-20(15-23)18-31-12-10-26(27,11-13-31)25(33)30-22-7-3-2-4-8-22/h5-6,9,14-17,22H,2-4,7-8,10-13,18H2,1H3,(H,29,32)(H,30,33)",PAURUYBABKHNHH-UHFFFAOYSA-N,243841,"US9428456, 4.001",Atypical chemokine receptor 3,,
167245,CCc1ccc(cc1)C(=O)Cn1ncc(Cl)c(Cl)c1=O,"InChI=1S/C14H12Cl2N2O2/c1-2-9-3-5-10(6-4-9)12(19)8-18-14(20)13(16)11(15)7-17-18/h3-7H,2,8H2,1H3",BQQGDSBHPFKTNO-UHFFFAOYSA-N,48505,"4,5-bis(chloranyl)-2-[2-(4-ethylphenyl)-2-oxidanylidene-ethyl]pyridazin-3-one::4,5-dichloro-2-[2-(4-ethylphenyl)-2-keto-ethyl]pyridazin-3-one::4,5-dichloro-2-[2-(4-ethylphenyl)-2-oxoethyl]-3-pyridazinone::4,5-dichloro-2-[2-(4-ethylphenyl)-2-oxoethyl]pyridazin-3-one::MLS000566342::SMR000153517::cid_2471413",Orotidine 5'-phosphate decarboxylase,,
543242,Cc1cc(cn(C)c1=O)-c1cc(ccc1OC1CCCC1)S(C)(=O)=O,"InChI=1S/C19H23NO4S/c1-13-10-14(12-20(2)19(13)21)17-11-16(25(3,22)23)8-9-18(17)24-15-6-4-5-7-15/h8-12,15H,4-7H2,1-3H3",BBZJVFYLQXGXFH-UHFFFAOYSA-N,285365,"5-(2-cyclopentyloxy-5-methylsulfonylphenyl)- 1,3-dimethylpyridin-2-one::BDBM486209::US10023592, Example 419",Bromodomain-containing protein 4,,<500
50265465,CNC(=O)[C@H](CC(C)C)C[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1nccc2ccccc12,"InChI=1S/C27H33N3O3/c1-18(2)15-21(26(32)28-3)17-24(31)23(16-19-9-5-4-6-10-19)30-27(33)25-22-12-8-7-11-20(22)13-14-29-25/h4-14,18,21,23-24,31H,15-17H2,1-3H3,(H,28,32)(H,30,33)/t21-,23+,24+/m1/s1",FUYWVLJIKTYOLC-NHTMILBNSA-N,50144402,"CHEMBL302328::Isoquinoline-1-carboxylic acid ((1S,2S,4R)-1-benzyl-2-hydroxy-6-methyl-4-methylcarbamoyl-heptyl)-amide",C-C chemokine receptor type 1,Homo sapiens, 580
50602650,Clc1ccc2Nc3[nH]ncc3N=C(c3ccccc3Cl)c2c1,"InChI=1S/C16H10Cl2N4/c17-9-5-6-13-11(7-9)15(10-3-1-2-4-12(10)18)20-14-8-19-22-16(14)21-13/h1-8H,(H2,19,21,22)",DSOFZQOBDBYXJD-UHFFFAOYSA-N,50328276,"7-chloro-5-(2-chlorophenyl)-2,10-dihydrobenzo[e]pyrazolo[4,3-b][1,4]diazepine::CHEMBL1257793",Cyclin-dependent kinase 2/G1/S-specific cyclin-E1/G1/S-specific cyclin-E2,Homo sapiens, 440
51094343,CCCCC(=O)C=C(C)C=CCCC(=O)N1CCCC1=O,"InChI=1S/C17H25NO3/c1-3-4-9-15(19)13-14(2)8-5-6-10-16(20)18-12-7-11-17(18)21/h5,8,13H,3-4,6-7,9-12H2,1-2H3",SHWIXYZQCHEFEH-UHFFFAOYSA-N,50448690,CHEMBL3127728,Inosine-5'-monophosphate dehydrogenase 2,Mus musculus,>200000
50331302,CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC(=O)c3ccc(OC)cc3)ncnc12,"InChI=1S/C20H22N6O6/c1-3-21-19(30)15-13(27)14(28)20(32-15)26-9-24-12-16(22-8-23-17(12)26)25-18(29)10-4-6-11(31-2)7-5-10/h4-9,13-15,20,27-28H,3H2,1-2H3,(H,21,30)(H,22,23,25,29)/t13-,14+,15-,20+/m0/s1",VPFWEOMLKRXUAC-LDNFRZNASA-N,50179024,"(2S,3S,4R,5R)-N-ethyl-3,4-dihydroxy-5-(6-(4-methoxybenzamido)-9H-purin-9-yl)-tetrahydrofuran-2-carboxamide::CHEMBL205058",Adenosine receptor A3,Rattus norvegicus,
51368379,OC(=O)C(F)(F)F.NC(=N)NCCC[C@@H]1NC[C@H](Cc2cn(CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCNC(=O)[C@@H](NC(=O)[C@H](CC3CCCCC3)NC(=O)c3ccno3)C3CCCCC3)nn2)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC1=O,"InChI=1S/C95H163N15O33.C2HF3O2/c96-95(97)99-19-10-17-81-89(114)101-74-86(111)104-84(72-87(112)113)91(116)105-82(69-76-11-4-1-5-12-76)90(115)103-79(73-100-81)71-80-75-110(109-108-80)22-24-121-26-28-123-30-32-125-34-36-127-38-40-129-42-44-131-46-48-133-50-52-135-54-56-137-58-60-139-62-64-141-66-68-142-67-65-140-63-61-138-59-57-136-55-53-134-51-49-132-47-45-130-43-41-128-39-37-126-35-33-124-31-29-122-27-25-120-23-21-98-94(119)88(78-15-8-3-9-16-78)107-92(117)83(70-77-13-6-2-7-14-77)106-93(118)85-18-20-102-143-85;3-2(4,5)1(6)7/h1,4-5,11-12,18,20,75,77-79,81-84,88,100H,2-3,6-10,13-17,19,21-74H2,(H,98,119)(H,101,114)(H,103,115)(H,104,111)(H,105,116)(H,106,118)(H,107,117)(H,112,113)(H4,96,97,99);(H,6,7)/t79-,81-,82+,83-,84-,88-;/m0./s1",XRLWIGUUSSYUSI-ZDXCBNKRSA-N,50553227,CHEMBL4763124,Proteinase-activated receptor 2,Homo sapiens,
492127,NCC1(Cc2ccc(cc2C1)N1CCC(O)C1)c1cccc(c1)-c1ncnc2[nH]ccc12,,,246917,"1-{2-(Aminomethyl)-2-[3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl]-2,3-dihydro-1H-inden-5-yl}pyrrolidin-3-ol::US10053465, 54::US10519163, Example 54::US11136326, Example 54",Tyrosine-protein kinase receptor UFO,, 2000
51046747,CCCS(=O)(=O)N1CCN(CC1)C1(CNC(=O)c2c(N)cccc2Cl)CCCCC1,"InChI=1S/C21H33ClN4O3S/c1-2-15-30(28,29)26-13-11-25(12-14-26)21(9-4-3-5-10-21)16-24-20(27)19-17(22)7-6-8-18(19)23/h6-8H,2-5,9-16,23H2,1H3,(H,24,27)",JNLBIGAUODXCNF-UHFFFAOYSA-N,50427198,CHEMBL2324158,Sodium- and chloride-dependent glycine transporter 1,, 15
956994,Nc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)N[C@@H]1CCN(Cc2cccc(Cl)c2)C1,"InChI=1S/C28H29ClN6O2/c29-23-5-3-4-22(14-23)15-33-13-11-24(18-33)31-28(37)25-19-35(32-27(25)30)17-21-9-7-20(8-10-21)16-34-12-2-1-6-26(34)36/h1-10,12,14,19,24H,11,13,15-18H2,(H2,30,32)(H,31,37)/t24-/m1/s1",AZEWSURGSXDQEJ-XMMPIXPASA-N,463432,"3-amino-N-[(3R)-1-[(3-chlorophenyl)methyl]pyrrolidin-3-yl]-1-({4-[(2-oxopyridin-1-::US10781181, Example 108",Kallikrein-1,,>40000
50405274,CCOC(=N)c1nc2ccc3ncn(CC)c(=O)c3c2s1,"InChI=1S/C14H14N4O2S/c1-3-18-7-16-8-5-6-9-11(10(8)14(18)19)21-13(17-9)12(15)20-4-2/h5-7,15H,3-4H2,1-2H3",KXPLADSXXPSEQO-UHFFFAOYSA-N,50247372,"8-Ethyl-9-oxo-8,9-dihydro-6-thiazolo[5,4-f]quinazoline-2-carboximidic acid ethyl ester::CHEMBL506669",Cyclin-dependent kinase 1,Homo sapiens, 50000
50640167,CN1C2CCCC1CC(C2)NC(=O)n1c2ccccc2[nH]c1=O,"InChI=1S/C17H22N4O2/c1-20-12-5-4-6-13(20)10-11(9-12)18-16(22)21-15-8-3-2-7-14(15)19-17(21)23/h2-3,7-8,11-13H,4-6,9-10H2,1H3,(H,18,22)(H,19,23)",KQXMAPPEQLLSJE-UHFFFAOYSA-N,50007897,"2-Oxo-2,3-dihydro-benzoimidazole-1-carboxylic acid (9-methyl-9-aza-bicyclo[3.3.1]non-3-yl)-amide::CHEMBL65226",5-hydroxytryptamine receptor 3A/3B,Rattus,
912835,COC(=O)c1cnc(N)c(c1)-c1cc2cc(NC(=O)c3cc(C)ccc3F)ccc2s1,"InChI=1S/C23H18FN3O3S/c1-12-3-5-18(24)16(7-12)22(28)27-15-4-6-19-13(8-15)10-20(31-19)17-9-14(23(29)30-2)11-26-21(17)25/h3-11H,1-2H3,(H2,25,26)(H,27,28)",GFRAHBVAUJIIKH-UHFFFAOYSA-N,365336,"US10633373, Example 41::US10669265, Example 41::US9868726, Example 41::methyl 6-amino-5-{5-[(2- fluoro-5- methylbenzoyl)amino]-1- benzothien-2-yl}nicotinate",Platelet-derived growth factor receptor beta,Homo sapiens, 38.0
122796,Clc1ccc(CC(=N)NOC(=O)c2cccs2)cc1Cl,"InChI=1S/C13H10Cl2N2O2S/c14-9-4-3-8(6-10(9)15)7-12(16)17-19-13(18)11-2-1-5-20-11/h1-6H,7H2,(H2,16,17)",MXWMURAWIXCINV-UHFFFAOYSA-N,64608,"2-(3,4-dichlorophenyl)-N&#39;-[(2-thienylcarbonyl)oxy]ethanimidamide::2-thiophenecarboxylic acid [(Z)-[1-amino-2-(3,4-dichlorophenyl)ethylidene]amino] ester::MLS000576354::SMR000197995::[(Z)-[1-amino-2-(3,4-dichlorophenyl)ethylidene]amino] thiophene-2-carboxylate::[(Z)-[1-azanyl-2-(3,4-dichlorophenyl)ethylidene]amino] thiophene-2-carboxylate::cid_9587374::thiophene-2-carboxylic acid [(Z)-[1-amino-2-(3,4-dichlorophenyl)ethylidene]amino] ester",Vacuolar aminopeptidase 1,Saccharomyces cerevisiae,
1180663,CC(=O)Nc1ccc(CC(O)=O)c(OCc2cc(-c3cccc(CN)c3)c3occc3c2)c1,"InChI=1S/C26H24N2O5/c1-16(29)28-22-6-5-20(12-25(30)31)24(13-22)33-15-18-10-21-7-8-32-26(21)23(11-18)19-4-2-3-17(9-19)14-27/h2-11,13H,12,14-15,27H2,1H3,(H,28,29)(H,30,31)",WQHZPSDATWAEJZ-UHFFFAOYSA-N,559101,"US11370774, Compound 224c",Complement factor D,,<1000
42127,O=C(CCCCCCc1cccnc1)c1ncc(o1)-c1ccccn1,"InChI=1S/C20H21N3O2/c24-18(11-4-2-1-3-8-16-9-7-12-21-14-16)20-23-15-19(25-20)17-10-5-6-13-22-17/h5-7,9-10,12-15H,1-4,8,11H2",MLNUKPVTGKVHLU-UHFFFAOYSA-N,23033,"1-[5-(pyridin-2-yl)-1,3-oxazol-2-yl]-7-(pyridin-3-yl)heptan-1-one::alpha-ketooxazole, 5f",Carboxylic ester hydrolase,Homo sapiens, 1000
473276,Cc1ccc(CNC(=O)C2(C)CN(C2)c2ncnn3cc(cc23)-c2ccc(cc2)C(C)(C)O)cc1,"InChI=1S/C28H31N5O2/c1-19-5-7-20(8-6-19)14-29-26(34)28(4)16-32(17-28)25-24-13-22(15-33(24)31-18-30-25)21-9-11-23(12-10-21)27(2,3)35/h5-13,15,18,35H,14,16-17H2,1-4H3,(H,29,34)",NQRXCIGOTFGGFQ-UHFFFAOYSA-N,175619,"US9688680, 168","Mast/stem cell growth factor receptor Kit [V560G,D816V]",, 55
50161759,COC(=O)[C@@H](Cc1cnc[nH]1)NC(=O)CN1CCN(CC1=O)S(=O)(=O)c1cc2ccc(Cl)cc2s1,"InChI=1S/C21H22ClN5O6S2/c1-33-21(30)16(8-15-9-23-12-24-15)25-18(28)10-26-4-5-27(11-19(26)29)35(31,32)20-6-13-2-3-14(22)7-17(13)34-20/h2-3,6-7,9,12,16H,4-5,8,10-11H2,1H3,(H,23,24)(H,25,28)/t16-/m1/s1",ANSKJRGBKVMOGK-MRXNPFEDSA-N,50090602,(R)-2-{2-[4-(6-Chloro-benzo[b]thiophene-2-sulfonyl)-2-oxo-piperazin-1-yl]-acetylamino}-3-(3H-imidazol-4-yl)-propionic acid methyl ester::CHEMBL46147,Coagulation factor X,Homo sapiens,
128851,Fc1cccc(Cl)c1CSc1nnc(o1)-c1ccncc1,"InChI=1S/C14H9ClFN3OS/c15-11-2-1-3-12(16)10(11)8-21-14-19-18-13(20-14)9-4-6-17-7-5-9/h1-7H,8H2",LYGRNBTYIUNQHN-UHFFFAOYSA-N,69780,"2-[(2-chloranyl-6-fluoranyl-phenyl)methylsulfanyl]-5-pyridin-4-yl-1,3,4-oxadiazole::2-[(2-chloro-6-fluoro-benzyl)thio]-5-(4-pyridyl)-1,3,4-oxadiazole::2-[(2-chloro-6-fluorophenyl)methylsulfanyl]-5-pyridin-4-yl-1,3,4-oxadiazole::2-[(2-chloro-6-fluorophenyl)methylthio]-5-pyridin-4-yl-1,3,4-oxadiazole::4-{5-[(2-chloro-6-fluorobenzyl)sulfanyl]-1,3,4-oxadiazol-2-yl}pyridine::MLS001166181::SMR000550049::cid_2382787",Glycogen synthase kinase-3 beta,Homo sapiens,
51309995,ONC(=O)CCCCCCC(=O)Nc1ccccc1,"InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)",WAEXFXRVDQXREF-UHFFFAOYSA-N,19149,"CHEMBL98::N-hydroxy-N'-phenyloctanediamide::SAHA::US10011611, SAHA::US10188756, Compound SAHA::US11207431, SAHA::US11505523, Compound SAHA::US9115116, SAHA::US9353061, SAHA::US9428447, SAHA::US9695181, Vorinostat::Vorinostat::Zolinza::cid_5311::suberoylanilide hydroxamic acid",Histone deacetylase 5,Homo sapiens, 18440
1012028,Cc1cc(Nc2cc3ncc(C)cc3c(N[C@H]3C[C@@H]4CCC[C@H](C3)N4S(=O)(=O)N3CC(C3)C#N)n2)n[nH]1,,,277590,"US10072026, Example 6-9::US10947254, Example 6-9",Tyrosine-protein kinase JAK3,Homo sapiens,
1047162,COc1cc2nc(NCCCCNC(=O)OC3CCCC3)c3nnc(C)n3c2cc1OC,"InChI=1S/C22H30N6O4/c1-14-26-27-21-20(23-10-6-7-11-24-22(29)32-15-8-4-5-9-15)25-16-12-18(30-2)19(31-3)13-17(16)28(14)21/h12-13,15H,4-11H2,1-3H3,(H,23,25)(H,24,29)",QZUWXMIBNOOEFG-UHFFFAOYSA-N,502200,"US11028090, Example 66::[4-(7,8- dimethoxy- 1-methyl-[1,2,4] triazolo[4,3-a] quinoxaline-4- ylamino)-butyl]- carbamic acid cyclopentyl- ester",Bromodomain-containing protein 4,, 13.0
1248316,CCn1c(c2CC(C)(C)COC(=O)[C@@H]3CCCN(N3)C(=O)[C@H](Cc3cc(O)cc(c3)-c3ccc1c2c3)NC(=O)[C@H](C(C)C)N(C)C(=O)[C@H]1CCN(C1)C(=O)C=C)-c1ccccc1N1CCOCC1,"InChI=1S/C53H67N7O8/c1-8-46(62)58-20-18-36(31-58)50(64)56(7)47(33(3)4)49(63)54-43-27-34-25-37(28-38(61)26-34)35-16-17-45-40(29-35)41(30-53(5,6)32-68-52(66)42-14-12-19-60(55-42)51(43)65)48(59(45)9-2)39-13-10-11-15-44(39)57-21-23-67-24-22-57/h8,10-11,13,15-17,25-26,28-29,33,36,42-43,47,55,61H,1,9,12,14,18-24,27,30-32H2,2-7H3,(H,54,63)/t36-,42-,43-,47-/m0/s1",KZRNBZUQGYINKI-BBRXYTKESA-N,591348,"US11566007, Example A26",GTPase KRas [G12S],,>10000
1218062,CCc1nn(CCN2CCOCC2)c2CN(C)C\C=C/Cn3c(C(O)=O)c(CCCOc4cccc5ccccc45)c4ccc(Cl)c(-c12)c34,"InChI=1S/C39H44ClN5O4/c1-3-32-36-33(45(41-32)20-19-43-21-24-48-25-22-43)26-42(2)17-6-7-18-44-37-30(15-16-31(40)35(36)37)29(38(44)39(46)47)13-9-23-49-34-14-8-11-27-10-4-5-12-28(27)34/h4-8,10-12,14-16H,3,9,13,17-26H2,1-2H3,(H,46,47)/b7-6-",SJXJNUGYXIGETG-SREVYHEPSA-N,572189,"(rac)-(11Z)-4-chloro-3-ethyl-14-methyl-1-[2-(morpholin-4-yl)ethyl]-7-{3-[(naphthalen-1-yl)oxy]-propyl}-10,13,14,15-tetrahydro-1H-pyrazolo[3&#8242;,4&#8242;:8,9][1,6]diazacycloundecino[10,11,1-hi]indole-8-carboxylic Acid::US11447504, Example 42::US11447504, Example 43::US11447504, Example 44::US11478451, Example 44","Apoptosis regulator Bcl-2/Bcl2-associated agonist of cell death [103-127,M117N]",,>20000
51397971,CC(=O)c1c(N2CCOCC2)c2ccc(Nc3nccc(n3)-c3ccccc3C)cc2oc1=O,"InChI=1S/C26H24N4O4/c1-16-5-3-4-6-19(16)21-9-10-27-26(29-21)28-18-7-8-20-22(15-18)34-25(32)23(17(2)31)24(20)30-11-13-33-14-12-30/h3-10,15H,11-14H2,1-2H3,(H,27,28,29)",BHISNYJXWAVZHJ-UHFFFAOYSA-N,50564805,CHEMBL4800337,Cyclin-T1/Cyclin-dependent kinase 9,Homo sapiens, 489
784312,Cc1[nH]nc(C(=O)Nc2cnc3[nH]c(cc3c2)C2=CCN(CC2)C(=O)C2CC2)c1Cl,"InChI=1S/C21H21ClN6O2/c1-11-17(22)18(27-26-11)20(29)24-15-8-14-9-16(25-19(14)23-10-15)12-4-6-28(7-5-12)21(30)13-2-3-13/h4,8-10,13H,2-3,5-7H2,1H3,(H,23,25)(H,24,29)(H,26,27)",AZOWRBNFRSYRIS-UHFFFAOYSA-N,392390,"4-chloro-N-[2-[1- (cyclopropanecarbonyl)-3,6-dihydro- 2H-pyridin-4-yl]-1H-pyrrolo[2,3- b]pyridin-5-yl]-5-methyl-1H- pyrazole-3-carboxamide::US10301280, Compound P-2039",Mast/stem cell growth factor receptor Kit [D816V],,
473192,COc1ccc(cc1)-c1cc2c(ncnn2c1)N1CC(C1)C(=O)NC(CO)c1ccccc1,"InChI=1S/C25H25N5O3/c1-33-21-9-7-17(8-10-21)19-11-23-24(26-16-27-30(23)14-19)29-12-20(13-29)25(32)28-22(15-31)18-5-3-2-4-6-18/h2-11,14,16,20,22,31H,12-13,15H2,1H3,(H,28,32)",HBVBEZQEXNHAAX-UHFFFAOYSA-N,175483,"US9688680, 83","Mast/stem cell growth factor receptor Kit [V560G,D816V]",, 550
707856,CC(=O)N1CCN(C(=O)C1(C)C)c1cccc(-c2cc(Cl)c3c(N)ncnn23)c1F,"InChI=1S/C20H20ClFN6O2/c1-11(29)27-8-7-26(19(30)20(27,2)3)14-6-4-5-12(16(14)22)15-9-13(21)17-18(23)24-10-25-28(15)17/h4-6,9-10H,7-8H2,1-3H3,(H2,23,24,25)",HYTRLCCDZKAIIM-UHFFFAOYSA-N,358505,"4-acetyl-1-(3-{4-amino-5-chloropyrrolo [2,1-f][1,2,4]triazin-7-yl}-2- fluorophenyl)-3,3-dimethylpiperazin-2- one::US10214537, Example 582","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform",Homo sapiens, 5.00
314840,COC(=O)COc1ccc2c(NC(=O)N3[C@@H]4C[C@@H]4C[C@H]3C(=O)Nc3cccc(OC(F)(F)F)c3)cn(C(N)=O)c2c1,"InChI=1S/C26H24F3N5O7/c1-39-22(35)12-40-15-5-6-17-18(11-33(24(30)37)20(17)10-15)32-25(38)34-19-7-13(19)8-21(34)23(36)31-14-3-2-4-16(9-14)41-26(27,28)29/h2-6,9-11,13,19,21H,7-8,12H2,1H3,(H2,30,37)(H,31,36)(H,32,38)/t13-,19-,21+/m1/s1",FSIAISCQJVHFJH-DYHNYNMBSA-N,170848,"US9085555, 276",Complement factor D,, 1310
50092851,CCCCCCn1c2ccc(cc2c2ccccc2c1=O)C(O)(C(F)(F)F)C(F)(F)F,"InChI=1S/C22H21F6NO2/c1-2-3-4-7-12-29-18-11-10-14(20(31,21(23,24)25)22(26,27)28)13-17(18)15-8-5-6-9-16(15)19(29)30/h5-6,8-11,13,31H,2-4,7,12H2,1H3",WPXRSSQLGMFIPI-UHFFFAOYSA-N,50012279,CHEMBL1091940,Nuclear receptor ROR-alpha,Homo sapiens, 7600
54071,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,16673,"4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide::4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-picolinamide;tosylic acid::BAY 43-9006::BAY 439006::BAY439006::CHEMBL1336::Hit compound, 8::Nexavar::Sorafenib::Sorafenib, 4::US10183928, Sorafenib::US10202365, Compound Sorafenib::US10227329, Compound Sorafenib::US10584114, Compound Sorafenib::US10774070, Compound Sorafenib::US10980809, Example Sorafenib::US11279688, Compound Sorafenib::US11505527, Compound Sorafenib::US9029401, Sorafenib::US9469639, Sorafenib::US9902709, Comparative example 1::Xarelto::cid_216239",Serine/threonine-protein kinase B-raf [V600E],, 43
664877,Cc1cc(Oc2nccc3NCCc23)ccc1-c1c(C)n[nH]c(=O)c1C,"InChI=1S/C20H20N4O2/c1-11-10-14(26-20-16-6-8-21-17(16)7-9-22-20)4-5-15(11)18-12(2)19(25)24-23-13(18)3/h4-5,7,9-10,21H,6,8H2,1-3H3,(H,24,25)",DQHDWDLSIPXMEI-UHFFFAOYSA-N,337370,"5-[4-(2,3-dihydro-1H-pyrrolo[3,2-c]pyridin-4-yloxy)-2- methylphenyl]-4,6-dimethylpyridazin-3(2H)-one::US9745317, 10::US9745317, 8::US9745317, 9",D(1A) dopamine receptor,,
50033009,N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H]1CCSSCC[C@H](NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(O)=O,"InChI=1S/C47H63N13O12S2/c48-30(23-38(62)63)39(64)54-31(8-4-16-52-47(49)50)40(65)55-32-14-18-73-74-19-15-33(56-43(68)34(57-41(32)66)20-27-10-12-29(61)13-11-27)42(67)58-35(22-28-24-51-25-53-28)45(70)60-17-5-9-37(60)44(69)59-36(46(71)72)21-26-6-2-1-3-7-26/h1-3,6-7,10-13,24-25,30-37,61H,4-5,8-9,14-23,48H2,(H,51,53)(H,54,64)(H,55,65)(H,56,68)(H,57,66)(H,58,67)(H,59,69)(H,62,63)(H,71,72)(H4,49,50,52)/t30-,31-,32-,33-,34-,35-,36-,37-/m0/s1",FULUKRVDSYUNQA-MDKUUQCZSA-N,50228272,CHEMBL411997,Type-1 angiotensin II receptor A/B,Rattus, 2.1
285779,NC(=O)c1cn(nc1Nc1ccc(cc1)S(=O)(=O)C(F)(F)F)[C@H]1CC[C@H](C[C@@H]1C#N)N1CCC1,"InChI=1S/C21H23F3N6O3S/c22-21(23,24)34(32,33)16-5-2-14(3-6-16)27-20-17(19(26)31)12-30(28-20)18-7-4-15(10-13(18)11-25)29-8-1-9-29/h2-3,5-6,12-13,15,18H,1,4,7-10H2,(H2,26,31)(H,27,28)/t13-,15-,18+/m1/s1",DVVWSGQIUQPLJA-SIIHOXLZSA-N,147845,"US8962608, 28-169",Tyrosine-protein kinase JAK2,Homo sapiens, 5
647457,Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(Oc2ccnc(Nc3ccccc3C)n2)c2ccccc12)C(C)(C)C,"InChI=1S/C36H35N7O2/c1-23-14-16-25(17-15-23)43-32(22-31(42-43)36(3,4)5)40-35(44)39-29-18-19-30(27-12-8-7-11-26(27)29)45-33-20-21-37-34(41-33)38-28-13-9-6-10-24(28)2/h6-22H,1-5H3,(H,37,38,41)(H2,39,40,44)",IHAAICCNNPXTHZ-UHFFFAOYSA-N,330279,"1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)- 3-(4-((2-(o-tolylamino)pyrimidin-4-yl)oxy) naphthalen-1-yl)urea::US10238658, Example 21::US10813932, Example 21::US9724347, Example 21::US9993478, Example 21",Glycogen synthase kinase-3 alpha,Homo sapiens,>1670
50126275,Fc1ccc(cc1)N1CCN(CCCN2C(=O)CC(C2=O)=C2c3ccccc3-c3ccccc23)CC1,"InChI=1S/C30H28FN3O2/c31-21-10-12-22(13-11-21)33-18-16-32(17-19-33)14-5-15-34-28(35)20-27(30(34)36)29-25-8-3-1-6-23(25)24-7-2-4-9-26(24)29/h1-4,6-13H,5,14-20H2",SXQSGPCTXZOSBC-UHFFFAOYSA-N,50072892,"3-Fluoren-9-ylidene-1-{3-[4-(4-fluoro-phenyl)-piperazin-1-yl]-propyl}-pyrrolidine-2,5-dione::CHEMBL341663",D(2) dopamine receptor,Rattus norvegicus,
51274646,COc1ccc(CN2Cc3c(C2)n(CCN)nc3C(=O)NCc2cccc3ccccc23)c2ccccc12,"InChI=1S/C31H31N5O2/c1-38-29-14-13-23(25-11-4-5-12-26(25)29)18-35-19-27-28(20-35)36(16-15-32)34-30(27)31(37)33-17-22-9-6-8-21-7-2-3-10-24(21)22/h2-14H,15-20,32H2,1H3,(H,33,37)",ULKWQMAYOHHZRF-UHFFFAOYSA-N,50520194,CHEMBL4579832,Peroxisomal membrane protein PEX14,,
50799965,CCCN(CCC)C1CCC(=CC1)C#C,"InChI=1S/C14H23N/c1-4-11-15(12-5-2)14-9-7-13(6-3)8-10-14/h3,7,14H,4-5,8-12H2,1-2H3",IOUKEEFTYOZOKJ-UHFFFAOYSA-N,50085331,"(4-Ethynyl-cyclohex-3-enyl)-dipropyl-amine::4-ethynyl-N,N-dipropylcyclohex-3-enamine::CHEMBL162762",D(2) dopamine receptor,Homo sapiens,
51008759,Cn1c(cc2cc(CCC(O)=O)ccc12)-c1ccc(Cl)cc1,"InChI=1S/C18H16ClNO2/c1-20-16-8-2-12(3-9-18(21)22)10-14(16)11-17(20)13-4-6-15(19)7-5-13/h2,4-8,10-11H,3,9H2,1H3,(H,21,22)",SPEOIBQTTZVEEF-UHFFFAOYSA-N,50286282,CHEMBL4164361,Free fatty acid receptor 1,,
50450234,CNC(=O)N1CCN(Cc2ccc(cc2)-c2cc3nccc(Oc4ccc(NC(=O)N5CCN(C5=O)c5ccccc5)cc4F)c3s2)CC1,"InChI=1S/C36H34FN7O4S/c1-38-34(45)42-17-15-41(16-18-42)23-24-7-9-25(10-8-24)32-22-29-33(49-32)31(13-14-39-29)48-30-12-11-26(21-28(30)37)40-35(46)44-20-19-43(36(44)47)27-5-3-2-4-6-27/h2-14,21-22H,15-20,23H2,1H3,(H,38,45)(H,40,46)",WOBLFEIWTSKVMT-UHFFFAOYSA-N,50248053,"4-(4-(7-(2-fluoro-4-(2-oxo-3-phenylimidazolidine-1-carboxamido)phenoxy)thieno[3,2-b]pyridin-2-yl)benzyl)-N-methylpiperazine-1-carboxamide::CHEMBL503016",Hepatocyte growth factor receptor,Homo sapiens, 80
650350,COc1cc2ncc(nc2cc1OC)-c1cc(F)c(CC(=O)Nc2cc(on2)C(C)(C)C(F)(F)F)cc1F,"InChI=1S/C25H21F5N4O4/c1-24(2,25(28,29)30)21-10-22(34-38-21)33-23(35)6-12-5-15(27)13(7-14(12)26)18-11-31-16-8-19(36-3)20(37-4)9-17(16)32-18/h5,7-11H,6H2,1-4H3,(H,33,34,35)",JWGMDMMYKGLQEQ-UHFFFAOYSA-N,331798,"US9725465, Example 219",Mast/stem cell growth factor receptor Kit,,
51090846,Cc1cccnc1CN1CCC2(CC1)N(C(=O)N(C2=O)c1ccc(cc1)-c1ccc(cc1C)C(O)=O)c1ccncn1,"InChI=1S/C32H30N6O4/c1-21-4-3-14-34-27(21)19-36-16-12-32(13-17-36)30(41)37(31(42)38(32)28-11-15-33-20-35-28)25-8-5-23(6-9-25)26-10-7-24(29(39)40)18-22(26)2/h3-11,14-15,18,20H,12-13,16-17,19H2,1-2H3,(H,39,40)",PHOCCMVBRLGOKP-UHFFFAOYSA-N,50385806,CHEMBL2041193,Egl nine homolog 1,Homo sapiens, 0.200000
51165312,Cc1noc(C)c1CNC(=O)[C@H]1N(COC11CCCC1)C(=O)[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H]1[C@H](O)COc2ccccc12,"InChI=1S/C35H42N4O8/c1-21-26(22(2)47-38-21)18-36-33(43)31-35(14-8-9-15-35)46-20-39(31)34(44)27(40)17-24(16-23-10-4-3-5-11-23)32(42)37-30-25-12-6-7-13-29(25)45-19-28(30)41/h3-7,10-13,24,27-28,30-31,40-41H,8-9,14-20H2,1-2H3,(H,36,43)(H,37,42)/t24-,27+,28-,30+,31-/m1/s1",WLSFSMDYWCPRCG-WGHHUXKWSA-N,50477634,CHEMBL395207,Protease,, 0.200000
51247514,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1-c1cc2CN(CCc2o1)S(C)(=O)=O,"InChI=1S/C25H31N5O4S/c1-18-16-26-25(27-20-5-7-21(8-6-20)33-14-13-29-10-3-4-11-29)28-24(18)23-15-19-17-30(35(2,31)32)12-9-22(19)34-23/h5-8,15-16H,3-4,9-14,17H2,1-2H3,(H,26,27,28)",NTEHSFLLEWTQSH-UHFFFAOYSA-N,50510266,CHEMBL4521339,Tyrosine-protein kinase JAK3,Homo sapiens, 57
864452,CC(C)c1c([nH]c2ccc(nc12)C1CCC(CC1)NCC1(CC1)S(C)(=O)=O)-c1cn2ncnc2c(C)c1C,"InChI=1S/C29H38N6O2S/c1-17(2)25-26(22-14-35-28(31-16-32-35)19(4)18(22)3)34-24-11-10-23(33-27(24)25)20-6-8-21(9-7-20)30-15-29(12-13-29)38(5,36)37/h10-11,14,16-17,20-21,30,34H,6-9,12-13,15H2,1-5H3",HODZQOPSHRDZFY-UHFFFAOYSA-N,427566,"4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-N-((1-(methylsulfonyl)cyclopropyl)methyl)cyclohexan-1-amine::US10544143, Example 4::US10730877, Example 419::US11053244, Example 419",Toll-like receptor 8,, 0.710
51057487,CC(C)n1cnc2c(NCc3ccccc3N)nc(NCC(C)(C)O)nc12,"InChI=1S/C19H27N7O/c1-12(2)26-11-23-15-16(21-9-13-7-5-6-8-14(13)20)24-18(25-17(15)26)22-10-19(3,4)27/h5-8,11-12,27H,9-10,20H2,1-4H3,(H2,21,22,24,25)",DCHDOYXSTZNERE-UHFFFAOYSA-N,50431292,CHEMBL2347580,Cyclin-H/Cyclin-dependent kinase 7,Homo sapiens, 1200
50524719,CC(=O)c1ccc(OCc2cccc(F)c2)cc1O,"InChI=1S/C15H13FO3/c1-10(17)14-6-5-13(8-15(14)18)19-9-11-3-2-4-12(16)7-11/h2-8,18H,9H2,1H3",UFWGBYKUPYCCBE-UHFFFAOYSA-N,50199101,CHEMBL3920226,Amine oxidase [flavin-containing] B,, 2.8
460984,Cn1cc2cc(c(F)cc2n1)C(F)(F)c1nnc2ccc(nn12)-c1cncc(F)c1,"InChI=1S/C19H11F4N7/c1-29-9-11-5-13(14(21)6-16(11)27-29)19(22,23)18-26-25-17-3-2-15(28-30(17)18)10-4-12(20)8-24-7-10/h2-9H,1H3",FLPSCXZHVOJZAS-UHFFFAOYSA-N,106389,"US9695175, 33",Hepatocyte growth factor receptor [1038-1346],, 242
75417,CSc1nc(NCc2ccco2)c2ccccc2n1,"InChI=1S/C14H13N3OS/c1-19-14-16-12-7-3-2-6-11(12)13(17-14)15-9-10-5-4-8-18-10/h2-8H,9H2,1H3,(H,15,16,17)",CIGMTZDJSAFWMN-UHFFFAOYSA-N,40172,2-furfuryl-[2-(methylthio)quinazolin-4-yl]amine::MLS000541384::N-(2-furanylmethyl)-2-(methylthio)-4-quinazolinamine::N-(2-furylmethyl)-2-(methylsulfanyl)-4-quinazolinamine::N-(furan-2-ylmethyl)-2-methylsulfanyl-quinazolin-4-amine::N-(furan-2-ylmethyl)-2-methylsulfanylquinazolin-4-amine::SMR000126242::cid_3720072,Estrogen receptor,,>50000
70404,CCc1cc2c(nc[nH]c2=O)s1,"InChI=1S/C8H8N2OS/c1-2-5-3-6-7(11)9-4-10-8(6)12-5/h3-4H,2H2,1H3,(H,9,10,11)",GXZAQJCUXCKYKB-UHFFFAOYSA-N,37871,"6-Ethyl-thieno[2,3-d]pyrimidin-4-ol::6-ethyl-3H-thieno[2,3-d]pyrimidin-4-one::CHEMBL6215::MLS000029626::SMR000009585::cid_645569",cAMP-dependent protein kinase catalytic subunit alpha,Homo sapiens,>59640
1209910,Oc1cc(-c2ncc3c(nc(OCCc4ccccc4F)nc3c2F)N2CC3CCC(C2)N3)c2c(Cl)cccc2c1,"InChI=1S/C31H26ClF2N5O2/c32-24-6-3-5-18-12-21(40)13-22(26(18)24)28-27(34)29-23(14-35-28)30(39-15-19-8-9-20(16-39)36-19)38-31(37-29)41-11-10-17-4-1-2-7-25(17)33/h1-7,12-14,19-20,36,40H,8-11,15-16H2",SGTLBEMOGHWVIE-UHFFFAOYSA-N,573339,"US11453683, Example 67",GTPase KRas [G12D],, 1246
51335209,[I-].C[N+](C)(C)C[C@@H]1COC[C@H](O1)c1ccc(cc1)S(=O)(=O)c1ccccc1,"InChI=1S/C20H26NO4S.HI/c1-21(2,3)13-17-14-24-15-20(25-17)16-9-11-19(12-10-16)26(22,23)18-7-5-4-6-8-18;/h4-12,17,20H,13-15H2,1-3H3;1H/q+1;/p-1/t17-,20+;/m1./s1",FPYOERQVOVHGLH-XLCHORMMSA-M,50540466,CHEMBL4633895,Muscarinic acetylcholine receptor M1,,
1219812,Cn1ncc(c1-c1ccc(Cl)cc1)-c1ccc2c(c1)c(CN)n[nH]c2=O,"InChI=1S/C19H16ClN5O/c1-25-18(11-2-5-13(20)6-3-11)16(10-22-25)12-4-7-14-15(8-12)17(9-21)23-24-19(14)26/h2-8,10H,9,21H2,1H3,(H,24,26)",JMOXLIADPBCTPR-UHFFFAOYSA-N,578935,"4-(aminomethyl)-6-(5-(4-chlorophenyl)-1- methyl-1H-pyrazol-4-yl)phthalazin-1(2H)- one::US11479551, Example 4-96::US11492351, Example 4-96",Methylosome protein 50/Protein arginine N-methyltransferase 5,, 116
50657642,Nc1nc2ccc(cc2s1)-c1cnc(Cl)c(NS(=O)(=O)c2ccc(F)cc2)c1,"InChI=1S/C18H12ClFN4O2S2/c19-17-15(24-28(25,26)13-4-2-12(20)3-5-13)7-11(9-22-17)10-1-6-14-16(8-10)27-18(21)23-14/h1-9,24H,(H2,21,23)",NCRYSHBHDZWERB-UHFFFAOYSA-N,50351947,CHEMBL1822052,RAC-alpha serine/threonine-protein kinase,, 44
597361,Cc1nc2[C@H]3CCC[C@@H](Cc2c(n1)-c1cnn(C)c1)N3C(=O)c1ccc(F)c(Cl)c1Cl,"InChI=1S/C22H20Cl2FN5O/c1-11-27-20(12-9-26-29(2)10-12)15-8-13-4-3-5-17(21(15)28-11)30(13)22(31)14-6-7-16(25)19(24)18(14)23/h6-7,9-10,13,17H,3-5,8H2,1-2H3/t13-,17+/m0/s1",IZPHVYHHIQJFSX-SUMWQHHRSA-N,310841,"US10150766, Example 33",P2X purinoceptor 7,,>10000
50327953,N[C@@H]1C[C@H]1c1ccc(NC(=O)[C@H](Cc2ccccc2)NC(=O)OCc2ccccc2)cc1,"InChI=1S/C26H27N3O3/c27-23-16-22(23)20-11-13-21(14-12-20)28-25(30)24(15-18-7-3-1-4-8-18)29-26(31)32-17-19-9-5-2-6-10-19/h1-14,22-24H,15-17,27H2,(H,28,30)(H,29,31)/t22-,23+,24-/m0/s1",HDVDLEPVLVTECB-VXNXHJTFSA-N,50080870,CHEMBL3421673,Amine oxidase [flavin-containing] B,, 32020
111323,NCCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12,"InChI=1S/C12H17N7O4/c13-1-2-15-11(22)8-6(20)7(21)12(23-8)19-4-18-5-9(14)16-3-17-10(5)19/h3-4,6-8,12,20-21H,1-2,13H2,(H,15,22)(H2,14,16,17)/t6-,7+,8-,12+/m0/s1",XZUQLQNOMFGRFJ-FLNNQWSLSA-N,50106539,"(2S,3S,4R,5R)-5-(6-Amino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2-carboxylic acid (2-amino-ethyl)-amide::(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-N-(2-aminoethyl)-3,4-dihydroxy-tetrahydrofuran-2-carboxamide::5'-N-[(2-AMINO)ETHYL CARBOXAMIDO] ADENOSINE::5-(6-Amino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2-carboxylic acid (2-amino-ethyl)-amide::Adenosine analog, 1::CHEMBL129903",Adenosine receptor A1,Homo sapiens,
50381599,COCCOCc1c2CCOc2c(C[C@@H](C)N)c2CCOc12,"InChI=1S/C17H25NO4/c1-11(18)9-14-12-3-5-22-17(12)15(10-20-8-7-19-2)13-4-6-21-16(13)14/h11H,3-10,18H2,1-2H3/t11-/m1/s1",LSJOUYHVPXKFHU-LLVKDONJSA-N,50210079,"(R)-2-[8-(2-methoxy-ethoxymethyl)-2,3,6,7-tetrahydro-benzo[1,2-b;4,5-b']difuran-4-yl]-1-methyl-ethylamine::CHEMBL397321",5-hydroxytryptamine receptor 2A,Rattus norvegicus, 0.88
1122401,Cc1cc(Cn2c3cc(cnc3[nH]c2=O)-c2cc(F)cc(F)c2)no1,"InChI=1S/C17H12F2N4O2/c1-9-2-14(22-25-9)8-23-15-5-11(7-20-16(15)21-17(23)24)10-3-12(18)6-13(19)4-10/h2-7H,8H2,1H3,(H,20,21,24)",AXXJWYXKURHIPG-UHFFFAOYSA-N,437186,"6-(3,5-Difluorophenyl)-1-[(5-methylisoxazol-3-yl)methyl]-3H-imidazo[4,5- b]pyridin-2-one::US10617676, Example 523::US11207298, Example 523","Glutamate receptor ionotropic, NMDA 1/2B",Homo sapiens, 133
217908,CCO\N=C(/C)c1ccc2nnc(Cc3ccc4ncccc4c3)n2n1,"InChI=1S/C19H18N6O/c1-3-26-24-13(2)16-8-9-18-21-22-19(25(18)23-16)12-14-6-7-17-15(11-14)5-4-10-20-17/h4-11H,3,12H2,1-2H3/b24-13+",JLJSJVGAIRCSCT-ZMOGYAJESA-N,100695,"US8507676, 42",Hepatocyte growth factor receptor,Homo sapiens, 7
50949734,C1Cc2c[nH]nc2-c2[nH]c3ccccc3c2C1,"InChI=1S/C14H13N3/c1-2-7-12-10(5-1)11-6-3-4-9-8-15-17-13(9)14(11)16-12/h1-2,5,7-8,16H,3-4,6H2,(H,15,17)",HBWXPQZQCDQNND-UHFFFAOYSA-N,50389604,CHEMBL1929485,Vascular endothelial growth factor receptor 2,Homo sapiens, 620
50365580,CSc1nn(CC(=O)Nc2nc3ccc(cc3s2)S(N)(=O)=O)c(NC(=S)Nc2ccccc2)c1C#N,"InChI=1S/C21H18N8O3S4/c1-34-19-14(10-22)18(27-20(33)24-12-5-3-2-4-6-12)29(28-19)11-17(30)26-21-25-15-8-7-13(36(23,31)32)9-16(15)35-21/h2-9H,11H2,1H3,(H2,23,31,32)(H2,24,27,33)(H,25,26,30)",CINWICXFRLTDDQ-UHFFFAOYSA-N,50098354,CHEMBL3594418,Carbonic anhydrase 1,Homo sapiens,
1262730,CCc1cc2ncc(CN3CCN(CC3)c3ccc(nc3)C(=O)N[C@@H]3CCCOC3)cc2[nH]c1=O,,,595732,"US11591331, Example 54",Poly [ADP-ribose] polymerase 2,, 8000
50723794,CCCN(CCC)[C@H]1CCn2cccc2C1,"InChI=1S/C14H24N2/c1-3-8-15(9-4-2)14-7-11-16-10-5-6-13(16)12-14/h5-6,10,14H,3-4,7-9,11-12H2,1-2H3/t14-/m0/s1",BCXCDTKLXHURCX-AWEZNQCLSA-N,50366327,CHEMBL192037,D(1A) dopamine receptor,Rattus, 14500
50677352,Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2cc(Oc3ccnc(c3)-c3ncc([nH]3)C(F)(F)F)ccc12,"InChI=1S/C24H16F6N6O/c1-36-19-7-6-15(10-17(19)34-22(36)33-14-4-2-13(3-5-14)23(25,26)27)37-16-8-9-31-18(11-16)21-32-12-20(35-21)24(28,29)30/h2-12H,1H3,(H,32,35)(H,33,34)",YABJJWZLRMPFSI-UHFFFAOYSA-N,31088,1-methyl-5-[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]pyridin-4-yl]oxy-N-[4-(trifluoromethyl)phenyl]benzimidazol-2-amine::1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-2-benzimidazolamine::CHIR-265::[1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridyl]oxy]benzimidazol-2-yl]-[4-(trifluoromethyl)phenyl]amine::cid_11656518,Uncharacterized serine/threonine-protein kinase SBK3,Homo sapiens,
50798200,CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(cc12)S(N)(=O)=O,"InChI=1S/C10H16N2O4S3/c1-3-12-8-4-6(2)18(13,14)10-7(8)5-9(17-10)19(11,15)16/h5-6,8,12H,3-4H2,1-2H3,(H2,11,15,16)/t6-,8-/m0/s1",IAVUPMFITXYVAF-XPUUQOCRSA-N,10884,"(2S,4S)-4-(ethylamino)-2-methyl-1,1-dioxo-2H,3H,4H-1,7-thieno[2,3-b]thiopyran-6-sulfonamide::Dorzolamide (DRZ)::Dorzolamide (DZA)",Carbonic anhydrase 1,Homo sapiens,
953984,COCCN1CCC(CC1)n1cc(cn1)-c1cnc(N)c(n1)-c1cc(C)c(=O)n(n1)-c1c(Cl)c(OC)cc(OC)c1Cl,"InChI=1S/C28H32Cl2N8O4/c1-16-11-19(35-38(28(16)39)26-23(29)21(41-3)12-22(42-4)24(26)30)25-27(31)32-14-20(34-25)17-13-33-37(15-17)18-5-7-36(8-6-18)9-10-40-2/h11-15,18H,5-10H2,1-4H3,(H2,31,32)",ULZYEHHPVPISAH-UHFFFAOYSA-N,350067,"US10208024, Example 66::US10766881, Example 66",Fibroblast growth factor receptor 2 [403-822],, 7.80
1139833,CCNc1cc2n(nc(-c3cnn(c3)C(C)(C)C#N)c2cn1)C1CC[C@@H](CC1)Oc1cn(C)nc1C(F)(F)F,"InChI=1S/C26H30F3N9O/c1-5-31-22-10-20-19(12-32-22)23(16-11-33-37(13-16)25(2,3)15-30)34-38(20)17-6-8-18(9-7-17)39-21-14-36(4)35-24(21)26(27,28)29/h10-14,17-18H,5-9H2,1-4H3,(H,31,32)/t17?,18-",MHTGAJNCTSTOEM-WEBLMRDCSA-N,537455,"2-(4-(6-(ethylamino)-1- ((1s,4s)-4-((1-methyl-3- (trifluoromethyl)-1H- pyrazol-4- yl)oxy)cyclohexyl)-1H- pyrazolo[4,3-c]pyridin-3- yl)-1H-pyrazol-1-yl)-2- methylpropanenitrile::US11247990, Example 280",Tyrosine-protein kinase receptor UFO,,<20
50380238,COc1cccc(CCN2CCC(CC2)N(C)C(=O)[C@@H]2CCCN2S(=O)(=O)c2ccc3c(Cl)cccc3c2)c1,"InChI=1S/C30H36ClN3O4S/c1-32(24-14-18-33(19-15-24)17-13-22-6-3-8-25(20-22)38-2)30(35)29-10-5-16-34(29)39(36,37)26-11-12-27-23(21-26)7-4-9-28(27)31/h3-4,6-9,11-12,20-21,24,29H,5,10,13-19H2,1-2H3/t29-/m0/s1",MLLRKHUYNKZGBH-LJAQVGFWSA-N,50209265,(S)-N-(1-(3-methoxyphenethyl)piperidin-4-yl)-1-(5-chloronaphthalen-2-ylsulfonyl)-N-methylpyrrolidine-2-carboxamide::CHEMBL245531,C-C chemokine receptor type 4,,
51243410,OC(=O)c1cccc(c1)-c1ccc(\C=C2\NC(=S)NC2=O)o1,"InChI=1S/C15H10N2O4S/c18-13-11(16-15(22)17-13)7-10-4-5-12(21-10)8-2-1-3-9(6-8)14(19)20/h1-7H,(H,19,20)(H2,16,17,18,22)/b11-7+",LTMSPBMJBBAVBQ-YRNVUSSQSA-N,50508904,CHEMBL4526685,Glycogen synthase kinase-3 alpha,Homo sapiens, 145
166738,COC(=O)CSc1nc2cc(C)cc(C)c2cc1C#N,"InChI=1S/C15H14N2O2S/c1-9-4-10(2)12-6-11(7-16)15(17-13(12)5-9)20-8-14(18)19-3/h4-6H,8H2,1-3H3",ZKPARJRYOCRTBT-UHFFFAOYSA-N,83467,"(3-Cyano-5,7-dimethyl-quinolin-2-ylsulfanyl)-acetic acid methyl ester::2-[(3-cyano-5,7-dimethyl-2-quinolinyl)thio]acetic acid methyl ester::2-[(3-cyano-5,7-dimethyl-2-quinolyl)thio]acetic acid methyl ester::MLS000031388::SMR000005252::cid_648917::methyl 2-(3-cyano-5,7-dimethyl-quinolin-2-yl)sulfanylethanoate::methyl 2-(3-cyano-5,7-dimethylquinolin-2-yl)sulfanylacetate",Endoribonuclease toxin MazF,Escherichia coli str. K-12 substr. MG1655,
50687497,CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12,"InChI=1S/C27H29FN8O3/c1-29-26(38)23-17(28)6-5-7-18(23)31-25-16-8-10-30-24(16)33-27(34-25)32-19-13-20-15(12-21(19)39-4)9-11-36(20)22(37)14-35(2)3/h5-8,10,12-13H,9,11,14H2,1-4H3,(H,29,38)(H3,30,31,32,33,34)",HZTYDQRUAWIZRE-UHFFFAOYSA-N,27817,"2-{[2-({1-[2-(dimethylamino)acetyl]-5-methoxy-2,3-dihydro-1H-indol-6-yl}amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino}-6-fluoro-N-methylbenzamide::pyrrolo[2,3-d]pyrimidine deriv., 40",Mast/stem cell growth factor receptor Kit,,
382827,CCN(CC)CCNC(=O)c1ccc(s1)-c1cc(NC2CC2)n2ncc(\C=C3/NC(=O)NC3=O)c2n1,"InChI=1S/C24H28N8O3S/c1-3-31(4-2)10-9-25-23(34)19-8-7-18(36-19)16-12-20(27-15-5-6-15)32-21(28-16)14(13-26-32)11-17-22(33)30-24(35)29-17/h7-8,11-13,15,27H,3-6,9-10H2,1-2H3,(H,25,34)(H2,29,30,33,35)/b17-11-",LMQINQAKAQXUCU-BOPFTXTBSA-N,219113,"US9303033, J11, Table 23A, Compound 70",Casein kinase II subunit alpha/beta,Homo sapiens,<10
433153,COc1cc(C)ccc1C(C)C,"InChI=1S/C11H16O/c1-8(2)10-6-5-9(3)7-11(10)12-4/h5-8H,1-4H3",LSQXNMXDFRRDSJ-UHFFFAOYSA-N,248170,"Thymol derivative, 21",Secreted chorismate mutase,, 2.158e+4
157864,CC(C)NCC(O)COc1cccc2ccccc12,"InChI=1S/C16H21NO2/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16/h3-9,12,14,17-18H,10-11H2,1-2H3",AQHHHDLHHXJYJD-UHFFFAOYSA-N,25761,"Anapriline::Avlocardyl::CHEMBL27::PROPANOLOL(-)::PROPRANOLOL, d::PROPRANOLOL, l-::PROPRANOLOL,(+)::PROPRANOLOL,(-)::Propanolol::Propanolol,(+/-)::Propranolol::[2-hydroxy-3-(naphthalen-1-yloxy)propyl](propan-2-yl)amine",Alpha-2C adrenergic receptor,Rattus,
50222213,Oc1ccc(cc1)-c1ccc2Nc3ccsc3C(=O)Nc2c1,"InChI=1S/C17H12N2O2S/c20-12-4-1-10(2-5-12)11-3-6-13-15(9-11)19-17(21)16-14(18-13)7-8-22-16/h1-9,18,20H,(H,19,21)",SCRAWZGLWQRYOB-UHFFFAOYSA-N,50414210,CHEMBL553642,Serine/threonine-protein kinase Chk1,Homo sapiens,
51299751,Cn1cc(Nc2nccc(n2)N2C[C@@H]3CC[C@H](C2)N3C(=O)[C@@H]2CC2(F)F)cn1,"InChI=1S/C18H21F2N7O/c1-25-8-11(7-22-25)23-17-21-5-4-15(24-17)26-9-12-2-3-13(10-26)27(12)16(28)14-6-18(14,19)20/h4-5,7-8,12-14H,2-3,6,9-10H2,1H3,(H,21,23,24)/t12-,13+,14-/m0/s1",BUWBRTXGQRBBHG-MJBXVCDLSA-N,329924,"US10463675, Example 7::US10980815, Ex. No. 7::US11197867, Example 7::US9663526, Example 7",Tyrosine-protein kinase JAK2,Homo sapiens, 77
50066196,Oc1ccc2CC3N(CC4CC4)CCC45[C@@H](Oc1c24)c1ncccc1C[C@@]35O,"InChI=1S/C23H24N2O3/c26-16-6-5-14-10-17-23(27)11-15-2-1-8-24-19(15)21-22(23,18(14)20(16)28-21)7-9-25(17)12-13-3-4-13/h1-2,5-6,8,13,17,21,26-27H,3-4,7,9-12H2/t17?,21-,22?,23+/m0/s1",UUKFYSADJMUSTK-KNKPGDGXSA-N,50002041,CHEMBL195784,Kappa-type opioid receptor,Cavia porcellus,
50478350,COC(=O)[C@H](CC(C)C)NC(=O)C1(CS)CCc2ccccc2C1,"InChI=1S/C19H27NO3S/c1-13(2)10-16(17(21)23-3)20-18(22)19(12-24)9-8-14-6-4-5-7-15(14)11-19/h4-7,13,16,24H,8-12H2,1-3H3,(H,20,22)/t16-,19?/m0/s1",LPSDUDIJENZOJR-UCFFOFKASA-N,50287693,"(S)-2-[(2-Mercaptomethyl-1,2,3,4-tetrahydro-naphthalene-2-carbonyl)-amino]-4-methyl-pentanoic acid methyl ester::CHEMBL64661",Neprilysin,Rattus norvegicus,
508635,Nc1ncnc2n(nc(-c3ccc(cc3)C(=O)Nc3cc(ccn3)C(F)(F)F)c12)[C@@H]1CCCN(C1)C(=O)C1CCC1,"InChI=1S/C28H27F3N8O2/c29-28(30,31)19-10-11-33-21(13-19)36-26(40)17-8-6-16(7-9-17)23-22-24(32)34-15-35-25(22)39(37-23)20-5-2-12-38(14-20)27(41)18-3-1-4-18/h6-11,13,15,18,20H,1-5,12,14H2,(H2,32,34,35)(H,33,36,40)/t20-/m1/s1",WUKZFVCBDVZJHM-HXUWFJFHSA-N,267678,"(R)-4-(4-amino-1-(1-(3-(methylthio)propanoyl)piperidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide::US9718828, Example, 277",Tyrosine-protein kinase BTK,Homo sapiens,
416362,Cc1nc2cccc(-c3cc4c(CCNC4=O)[nH]3)c2nc1NC1CCCOC1,,,238552,"US9394297, 198::US9394297, 208::US9394297, 209",Serine/threonine-protein kinase pim-1,, 3.83
1124032,OCc1ncccc1-c1cnc(NCc2c3C(O)COc3ccc2F)n2cnnc12,"InChI=1S/C20H17FN6O3/c21-14-3-4-17-18(16(29)9-30-17)13(14)7-24-20-23-6-12(19-26-25-10-27(19)20)11-2-1-5-22-15(11)8-28/h1-6,10,16,28-29H,7-9H2,(H,23,24)",BDGYMZHPAPDHFB-UHFFFAOYSA-N,291928,"5-fluoro-4-(((8-(2-(hydroxymethyl)pyridin-3-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-yl)amino)methyl)-2,3-dihydrobenzofuran-3-ol::US11207325, Example 243::US9580437, Example 243",Polycomb protein EED,, 15.4
51067267,Cn1c(nnc1C12CCC(CC1)(CC2)c1noc(n1)C(C)(F)F)-c1ccccc1C(F)(F)F,"InChI=1S/C22H22F5N5O/c1-19(23,24)18-28-16(31-33-18)20-7-10-21(11-8-20,12-9-20)17-30-29-15(32(17)2)13-5-3-4-6-14(13)22(25,26)27/h3-6H,7-12H2,1-2H3",AHAIJYTWSYJSSZ-UHFFFAOYSA-N,50435691,CHEMBL2391968,11-beta-hydroxysteroid dehydrogenase 1,Homo sapiens, 3100
834046,CC(C)C(=O)N1CCC(CC1)c1cc(-c2ccc(NC(=O)c3cc(C)c(-c4cccnc4)n(-c4ccccc4)c3=O)cc2)c2c(N)ncnn12,"InChI=1S/C39H38N8O3/c1-24(2)38(49)45-18-15-27(16-19-45)33-21-31(35-36(40)42-23-43-47(33)35)26-11-13-29(14-12-26)44-37(48)32-20-25(3)34(28-8-7-17-41-22-28)46(39(32)50)30-9-5-4-6-10-30/h4-14,17,20-24,27H,15-16,18-19H2,1-3H3,(H,44,48)(H2,40,42,43)",XVMKDIBPZRMTGI-UHFFFAOYSA-N,397042,"US10442810, Example 106::US10844069, Example 106::US9981975, Example 106",Tyrosine-protein kinase receptor TYRO3,Homo sapiens,>100
601157,Cc1noc(n1)-c1c(NC(=O)C2=C(C3CCC2CC3)C(O)=O)sc2COCCc12,"InChI=1S/C20H21N3O5S/c1-9-21-18(28-23-9)16-12-6-7-27-8-13(12)29-19(16)22-17(24)14-10-2-4-11(5-3-10)15(14)20(25)26/h10-11H,2-8H2,1H3,(H,22,24)(H,25,26)",FWUAAOWNUVYRNR-UHFFFAOYSA-N,312358,"3-[3-(3-Methyl-[1,2,4]oxadiazol-5-yl)-4,7-dihydro-5H-thieno[2,3-c]pyran-2-ylcarbamoyl]-bicyclo[2.2.2]oct-2-ene-2-carboxylic acid::US9604977, Example 104","Fatty acid-binding protein, adipocyte",, 610
50785227,N[C@]1(CC[C@H](C1)C(O)=O)C(O)=O,"InChI=1S/C7H11NO4/c8-7(6(11)12)2-1-4(3-7)5(9)10/h4H,1-3,8H2,(H,9,10)(H,11,12)/t4-,7+/m1/s1",YFYNOWXBIBKGHB-FBCQKBJTSA-N,66976,"(1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid;hydrate::(1S,3R)-1-azanylcyclopentane-1,3-dicarboxylic acid;hydrate::CHEMBL34453::MLS002153209::SMR001230688::cid_16218853::trans-( )-ACPD monohydrate",Metabotropic glutamate receptor 1,,
989110,C[C@@H](COCCC(=O)N1CCN(CC1)c1ncc(Cl)cn1)Oc1cn[nH]c(=O)c1C(F)(F)F,,,431613,"US10550105, Example 543A::US10550105, Example 715::US10870641, Example 715::US11014913, Example 715",Protein mono-ADP-ribosyltransferase TIPARP,,<100
51440283,CC(C)(C)C(=O)OCO[P@]1(=O)OC[C@H]2O[C@H]([C@H](F)[C@@H]2O[P@](=O)(OCOC(=O)C(C)(C)C)OC[C@H]2O[C@H]([C@H](F)[C@@H]2O1)n1cnc2c(N)ncnc12)n1cnc2c(N)ncnc12,"InChI=1S/C32H42F2N10O14P2/c1-31(2,3)29(45)49-13-53-59(47)51-7-15-22(18(34)28(55-15)44-12-42-20-24(36)38-10-40-26(20)44)58-60(48,54-14-50-30(46)32(4,5)6)52-8-16-21(57-59)17(33)27(56-16)43-11-41-19-23(35)37-9-39-25(19)43/h9-12,15-18,21-22,27-28H,7-8,13-14H2,1-6H3,(H2,35,37,39)(H2,36,38,40)/t15-,16-,17-,18-,21-,22-,27-,28-,59+,60+/m1/s1",MZDMDFWEUYOXDZ-GVDXARJFSA-N,50581800,CHEMBL5073386,Stimulator of interferon genes protein,,
51162158,COc1ccc(\C=C2/c3sccc3C(=O)c3ccccc23)cc1,"InChI=1S/C20H14O2S/c1-22-14-8-6-13(7-9-14)12-18-15-4-2-3-5-16(15)19(21)17-10-11-23-20(17)18/h2-12H,1H3/b18-12-",QHIJXJMXXXLFLW-PDGQHHTCSA-N,50476055,CHEMBL376853,Tubulin beta chain,, 3300
1017987,CCn1cc(Nc2nc(N[C@H]3CN(CC[C@H]3C)C(=O)C=C)c3c(SC)n[nH]c3n2)cn1,,,489524,"US10961247, Ex. No. 132",Tyrosine-protein kinase JAK3,Homo sapiens, 25.5
723716,Fc1ccc(Cn2cccc(C(=O)NCc3cccc(c3)-c3ccc4cn[nH]c4c3)c2=O)cc1F,"InChI=1S/C27H20F2N4O2/c28-23-9-6-18(12-24(23)29)16-33-10-2-5-22(27(33)35)26(34)30-14-17-3-1-4-19(11-17)20-7-8-21-15-31-32-25(21)13-20/h1-13,15H,14,16H2,(H,30,34)(H,31,32)",FOGWWFMUPDFHLK-UHFFFAOYSA-N,366398,"US9873693, Compound 328",3-phosphoinositide-dependent protein kinase 1 [51-360],,<500
50550456,COc1ccc(Oc2cccc(CN3CCN(CC3)C(=O)Oc3ccc(cc3)[N+]([O-])=O)c2)cc1,"InChI=1S/C25H25N3O6/c1-32-21-9-11-22(12-10-21)33-24-4-2-3-19(17-24)18-26-13-15-27(16-14-26)25(29)34-23-7-5-20(6-8-23)28(30)31/h2-12,17H,13-16,18H2,1H3",SSRDUXSVIZJVGA-UHFFFAOYSA-N,50307059,4-Nitrophenyl 4-(3-(4-Methoxyphenoxy)benzyl)piperazine-1-carboxylate::CHEMBL603111,Monoglyceride lipase,Mus musculus, 130
1190367,COc1nc(Nc2ccc(CN3CCC(C)CC3)cc2)nc2[nH]cc(-c3ccc(F)cc3F)c12,"InChI=1S/C26H27F2N5O/c1-16-9-11-33(12-10-16)15-17-3-6-19(7-4-17)30-26-31-24-23(25(32-26)34-2)21(14-29-24)20-8-5-18(27)13-22(20)28/h3-8,13-14,16H,9-12,15H2,1-2H3,(H2,29,30,31,32)",USOBXZYMQTZFQG-UHFFFAOYSA-N,563367,"5-(2,4- difluorophenyl)-4- methoxy- N-(4-((4-methyl piperidin-1-yl) methyl)phenyl)-7H- pyrrolo[2,3- d]pyrimidin-2-amine::US11407757, Cpd 30",Tyrosine-protein kinase Mer,Homo sapiens, 65
66322,CN[C@H]1C[C@@H]2O[C@](C)([C@H]1OC)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13,"InChI=1S/C28H26N4O3/c1-28-26(34-3)17(29-2)12-20(35-28)31-18-10-6-4-8-14(18)22-23-16(13-30-27(23)33)21-15-9-5-7-11-19(15)32(28)25(21)24(22)31/h4-11,17,20,26,29H,12-13H2,1-3H3,(H,30,33)/t17-,20-,26-,28+/m0/s1",HKSZLNNOFSGOKW-HMWZOHBLSA-N,31096,CHEMBL290084::Staurosporine::cid_451705,Dual specificity testis-specific protein kinase 1,Homo sapiens,
1259942,CC[C@@H]1CN([C@@H](CC)CN1C(C)c1ccc2oc(nc2c1)C1CC1)c1nc(=O)n(C)c2ccc(nc12)C#N,"InChI=1S/C29H33N7O2/c1-5-21-16-36(27-26-24(34(4)29(37)33-27)11-10-20(14-30)31-26)22(6-2)15-35(21)17(3)19-9-12-25-23(13-19)32-28(38-25)18-7-8-18/h9-13,17-18,21-22H,5-8,15-16H2,1-4H3/t17?,21-,22+/m1/s1",ZHHWVSYIYZAETJ-RRNUJPESSA-N,594449,"US11584747, Example 253::US11584747, Example 254",Diacylglycerol kinase alpha [9-727],, 2850
51171790,CON(C)C(=O)c1cc2ccn(Cc3ccc(F)cc3F)c2cn1,"InChI=1S/C17H15F2N3O2/c1-21(24-2)17(23)15-7-11-5-6-22(16(11)9-20-15)10-12-3-4-13(18)8-14(12)19/h3-9H,10H2,1-2H3",YUWXRZDVTDQFQW-UHFFFAOYSA-N,50480890,CHEMBL576852,Integrase,,>50000
460647,CN(C)C1CCN(CC1)c1nc(-c2ccc(cc2)C#N)c(-c2cnc3N(C)C(=O)COc3c2)n2cncc12,"InChI=1S/C28H28N8O2/c1-33(2)21-8-10-35(11-9-21)27-22-15-30-17-36(22)26(25(32-27)19-6-4-18(13-29)5-7-19)20-12-23-28(31-14-20)34(3)24(37)16-38-23/h4-7,12,14-15,17,21H,8-11,16H2,1-3H3",FKIBBIRJDQPQLK-UHFFFAOYSA-N,105586,"US10047086, 105::US9695168, 105",Lysine-specific histone demethylase 1A [151-852],,<50
50534277,NC(=O)c1cccc2[nH]c(nc12)-c1ccc(cc1)-c1ccccc1,"InChI=1S/C20H15N3O/c21-19(24)16-7-4-8-17-18(16)23-20(22-17)15-11-9-14(10-12-15)13-5-2-1-3-6-13/h1-12H,(H2,21,24)(H,22,23)",YTKLAAYEYWFEIM-UHFFFAOYSA-N,50300017,2-(biphenyl-4-yl)-1H-benzo[d]imidazole-4-carboxamide::CHEMBL578185,Poly [ADP-ribose] polymerase 1,,
50143078,Fc1ccccc1N1CCN(CC1)C(=O)CNS(=O)(=O)c1cccc2ncccc12,"InChI=1S/C21H21FN4O3S/c22-17-6-1-2-8-19(17)25-11-13-26(14-12-25)21(27)15-24-30(28,29)20-9-3-7-18-16(20)5-4-10-23-18/h1-10,24H,11-15H2",VVGDALNRAPAUGX-UHFFFAOYSA-N,50216393,CHEMBL231242::N-(2-(4-(2-fluorophenyl)piperazin-1-yl)-2-oxoethyl)quinoline-5-sulfonamide::quinolinesulfon-5-yl-{2-[4-(2-fluorophenyl)piperazin-1-yl]-2-oxoethyl}amide,P2X purinoceptor 7,,>1000
677898,COc1ccc(c(F)n1)-c1ccc(c(OC)c1)-c1nccc2cc(ccc12)S(=O)(=O)Nc1nncs1,"InChI=1S/C24H18FN5O4S2/c1-33-20-12-14(18-7-8-21(34-2)28-23(18)25)3-5-19(20)22-17-6-4-16(11-15(17)9-10-26-22)36(31,32)30-24-29-27-13-35-24/h3-13H,1-2H3,(H,29,30)",VGEHAKYGIJOZPB-UHFFFAOYSA-N,343003,"1-(4-(2-fluoro-6-methoxy-3-pyridinyl)-2-methoxyphenyl)-N-1,3,4-thiadiazol-2-yl-6-isoquinolinesulfonamide::US9776995, Example 196",Sodium channel protein type 9 subunit alpha,, 1050
87141,COc1ccc(cc1)\N=N\c1n(C)c2ccccc2[n+]1C,"InChI=1S/C16H17N4O/c1-19-14-6-4-5-7-15(14)20(2)16(19)18-17-12-8-10-13(21-3)11-9-12/h4-11H,1-3H3/q+1",BGYSMPFKYLADNT-UHFFFAOYSA-N,46511,"(1,3-dimethylbenzimidazol-3-ium-2-yl)-(4-methoxyphenyl)diazene;besylate::2-(4-Methoxy-phenylazo)-1,3-dimethyl-3H-benzoimidazol-1-ium::MLS001012295::SMR000425125::benzenesulfonate;(1,3-dimethyl-2-benzimidazol-3-iumyl)-(4-methoxyphenyl)diazene::benzenesulfonate;(1,3-dimethylbenzimidazol-3-ium-2-yl)-(4-methoxyphenyl)diazene::cid_12425557",Eukaryotic translation initiation factor 2-alpha kinase 3,,
50543545,OC(=O)CC1CCC2(CC1)CCN(CC2)c1cc(SC(F)(F)F)cc(c1)C#N,"InChI=1S/C20H23F3N2O2S/c21-20(22,23)28-17-10-15(13-24)9-16(12-17)25-7-5-19(6-8-25)3-1-14(2-4-19)11-18(26)27/h9-10,12,14H,1-8,11H2,(H,26,27)",DXIACLRPBPXBLP-UHFFFAOYSA-N,50208093,"CHEMBL3953289::US9708270, 25",Free fatty acid receptor 4,Mus musculus,
50212229,O=C(NC1CCN(Cc2ccccc2)CC1)Nc1ccccc1CN1CCC(Cc2ccccc2)CC1,"InChI=1S/C32H40N4O/c37-32(33-30-17-21-35(22-18-30)24-28-11-5-2-6-12-28)34-31-14-8-7-13-29(31)25-36-19-15-27(16-20-36)23-26-9-3-1-4-10-26/h1-14,27,30H,15-25H2,(H2,33,34,37)",WQBJUUITOQERMR-UHFFFAOYSA-N,50117441,1-(1-Benzyl-piperidin-4-yl)-3-[2-(4-benzyl-piperidin-1-ylmethyl)-phenyl]-urea::CHEMBL125108,C-C chemokine receptor type 3,Homo sapiens, 3900
376897,O=C(N1CCN(CC1)c1ccccn1)c1cccc(Cc2n[nH]c(=O)c3CCCCc23)c1,"InChI=1S/C25H27N5O2/c31-24-21-9-2-1-8-20(21)22(27-28-24)17-18-6-5-7-19(16-18)25(32)30-14-12-29(13-15-30)23-10-3-4-11-26-23/h3-7,10-11,16H,1-2,8-9,12-15,17H2,(H,28,31)",VTGAOVFIBGQVQP-UHFFFAOYSA-N,213916,"BDBM214371::US9283222, Table 3, Compound 23",Poly [ADP-ribose] polymerase 1,,
1185181,CC(C)NC(=O)c1cc2ccc(cc2[nH]1)-c1nc(Cc2ccccc2)cc(Nc2ccc3[nH]ncc3c2)n1,"InChI=1S/C30H27N7O/c1-18(2)32-30(38)27-14-20-8-9-21(15-26(20)35-27)29-34-24(12-19-6-4-3-5-7-19)16-28(36-29)33-23-10-11-25-22(13-23)17-31-37-25/h3-11,13-18,35H,12H2,1-2H3,(H,31,37)(H,32,38)(H,33,34,36)",CDGWMWYGUBSHEK-UHFFFAOYSA-N,561246,"6-(4-((1H-indazol- 5-yl)amino)-6- benzylpyrimidin-2- yl)-N-isopropyl-1H- indole-2- carboxamide::US11390609, Compound TDI01898",Rho-associated protein kinase 1,Homo sapiens,>10000
51320204,Cn1c2nc3CN(CC#Cc4cccc(Cl)c4)CCn3c2c(=O)n(C)c1=O,"InChI=1S/C19H18ClN5O2/c1-22-17-16(18(26)23(2)19(22)27)25-10-9-24(12-15(25)21-17)8-4-6-13-5-3-7-14(20)11-13/h3,5,7,11H,8-10,12H2,1-2H3",IQFMIXXYUGSEJM-UHFFFAOYSA-N,50534192,CHEMBL4463900,Adenosine receptor A1,Rattus norvegicus,
51052892,Clc1cccc(c1)C(=O)NC1CCCC(C1)NC(=O)c1cccc(Cl)c1,"InChI=1S/C20H20Cl2N2O2/c21-15-6-1-4-13(10-15)19(25)23-17-8-3-9-18(12-17)24-20(26)14-5-2-7-16(22)11-14/h1-2,4-7,10-11,17-18H,3,8-9,12H2,(H,23,25)(H,24,26)",HWGZRRMCVQFHPS-UHFFFAOYSA-N,50429441,CHEMBL2338595,Metabotropic glutamate receptor 5,Homo sapiens, 139
51182518,CCCC1COCCC1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)NCc1cc(cc(c1)C(F)(F)F)C(F)(F)F,"InChI=1S/C26H36F6N2O2/c1-4-5-18-15-36-9-7-22(18)34-21-6-8-24(13-21,16(2)3)23(35)33-14-17-10-19(25(27,28)29)12-20(11-17)26(30,31)32/h10-12,16,18,21-22,34H,4-9,13-15H2,1-3H3,(H,33,35)/t18?,21-,22?,24+/m1/s1",GAWLGGFBSVEUMN-FRYXHQTHSA-N,50258043,"(1S,3R)-N-(3,5-bis(trifluoromethyl)benzyl)-1-isopropyl-3-(3-propyltetrahydro-2H-pyran-4-ylamino)cyclopentanecarboxamide::CHEMBL494540",C-C chemokine receptor type 2,, 3.0
372253,Oc1cc(CCc2ccc(cc2C(F)(F)F)C(F)(F)F)n[nH]c1=O,"InChI=1S/C14H10F6N2O2/c15-13(16,17)8-3-1-7(10(5-8)14(18,19)20)2-4-9-6-11(23)12(24)22-21-9/h1,3,5-6H,2,4H2,(H,21,23)(H,22,24)",SLHOHUJHXJOCDY-UHFFFAOYSA-N,210822,"US10463663, Example 62::US11129828, Example 62::US9290456, 62::US9931340, Example 62",D-amino-acid oxidase,Homo sapiens, 29
169785,NCCCCC1NC(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(CSSCC(NC(=O)C(CO)NC1=O)C(=O)NCc1cccc2ccccc12)NC(=O)C(N)Cc1ccccc1,"InChI=1S/C55H64N10O9S2/c56-24-9-8-19-43-51(70)63-46(30-66)54(73)65-47(50(69)59-28-36-15-10-14-35-13-4-5-16-39(35)36)31-75-76-32-48(64-49(68)41(57)25-33-11-2-1-3-12-33)55(74)61-44(26-34-20-22-38(67)23-21-34)52(71)62-45(53(72)60-43)27-37-29-58-42-18-7-6-17-40(37)42/h1-7,10-18,20-23,29,41,43-48,58,66-67H,8-9,19,24-28,30-32,56-57H2,(H,59,69)(H,60,72)(H,61,74)(H,62,71)(H,63,70)(H,64,68)(H,65,73)",GWJANPFAIFAIBQ-UHFFFAOYSA-N,84623,NC4-28B,Somatostatin receptor type 3,Homo sapiens,
50237059,COc1cc2CC3CCCNC3c2cc1OC,"InChI=1S/C14H19NO2/c1-16-12-7-10-6-9-4-3-5-15-14(9)11(10)8-13(12)17-2/h7-9,14-15H,3-6H2,1-2H3",QNEFWYSQFKTFTK-UHFFFAOYSA-N,50027387,CHEMBL3329366,Melatonin receptor type 1A,Homo sapiens,
50292847,CC(C)NCc1ccc(C[C@@H]2NC(=O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@@H](Cc3ccccc3)NC(=O)[C@@H](CCCCN)NC(=O)[C@H](N)CSSC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](NC2=O)[C@@H](C)O)[C@@H](C)O)C(N)=O)cc1,"InChI=1S/C74H97N15O15S2/c1-41(2)78-36-48-24-22-46(23-25-48)33-57-70(100)88-62(42(3)91)73(103)85-58(34-47-26-28-50(93)29-27-47)71(101)89-63(43(4)92)74(104)86-60(38-90)72(102)87-61(64(77)94)40-106-105-39-52(76)65(95)80-54(21-13-14-30-75)66(96)81-55(31-44-15-7-5-8-16-44)67(97)82-56(32-45-17-9-6-10-18-45)68(98)84-59(69(99)83-57)35-49-37-79-53-20-12-11-19-51(49)53/h5-12,15-20,22-29,37,41-43,52,54-63,78-79,90-93H,13-14,21,30-36,38-40,75-76H2,1-4H3,(H2,77,94)(H,80,95)(H,81,96)(H,82,97)(H,83,99)(H,84,98)(H,85,103)(H,86,104)(H,87,102)(H,88,100)(H,89,101)/t42-,43-,52-,54-,55-,56+,57+,58+,59+,60+,61+,62-,63-/m1/s1",CLYXKNIFFVWQGI-HXVVHKOFSA-N,50159415,"CHEMBL414717::Des-AA1,2,5-[D-Trp8,IAmp9,Tyr11]Cbm-SRIF",Somatostatin receptor type 3,Homo sapiens,>1000
50982806,Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1cc(n[nH]1)-c1ccc(=O)n(C)c1)C(C)(C)C,"InChI=1S/C24H27N7O2/c1-15-6-9-17(10-7-15)31-21(13-19(29-31)24(2,3)4)26-23(33)25-20-12-18(27-28-20)16-8-11-22(32)30(5)14-16/h6-14H,1-5H3,(H3,25,26,27,28,33)",RBUCXKUZGLHBPG-UHFFFAOYSA-N,50403000,CHEMBL2207437,Protein-tyrosine kinase 2-beta,Mus musculus, 2500
50262618,CCn1c(Nc2ccccc2C#N)nc2ccsc2c1=O,"InChI=1S/C15H12N4OS/c1-2-19-14(20)13-12(7-8-21-13)18-15(19)17-11-6-4-3-5-10(11)9-16/h3-8H,2H2,1H3,(H,17,18)",FSHLSXKQTBBNKX-UHFFFAOYSA-N,50042047,CHEMBL3360159,"High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A",Homo sapiens, 2300
50546218,CS(=O)(=O)N1CC[C@@H](C1)N(Cc1ccccc1F)c1ccc(C#N)c(Cl)c1,"InChI=1S/C19H19ClFN3O2S/c1-27(25,26)23-9-8-17(13-23)24(12-15-4-2-3-5-19(15)21)16-7-6-14(11-22)18(20)10-16/h2-7,10,17H,8-9,12-13H2,1H3/t17-/m0/s1",WWMZDVNNRCLYSM-KRWDZBQOSA-N,50304971,(S)-2-chloro-4-((2-fluorobenzyl)(1-(methylsulfonyl)pyrrolidin-3-yl)amino)benzonitrile::CHEMBL584422,Cytochrome P450 2D6,, 18000
1044855,CCOc1ncccc1-c1cc(NCc2cc(C)n(C)n2)c2n(nc(C)c2n1)C(C)C,"InChI=1S/C23H29N7O/c1-7-31-23-18(9-8-10-24-23)19-12-20(25-13-17-11-15(4)29(6)28-17)22-21(26-19)16(5)27-30(22)14(2)3/h8-12,14H,7,13H2,1-6H3,(H,25,26)",LOSBPLVFUGTAOA-UHFFFAOYSA-N,279024,"N-[(1,5-dimethylpyrazol-3-yl)methyl]-5-(2-ethoxy-3-pyridyl)-1-isopropyl-3-methyl-pyrazolo[4,3-b]pyridin-7-amine::US10034861, Example 54::US10512632, Example 54::US10806718, Example 54::US11026923, Example 54::US11491140, Example 54","Dual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C",, 4.60
50593622,CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1,"InChI=1S/C17H14O4S/c1-22(19,20)14-9-7-12(8-10-14)15-11-21-17(18)16(15)13-5-3-2-4-6-13/h2-10H,11H2,1H3",RZJQGNCSTQAWON-UHFFFAOYSA-N,22369,"4-(4-methanesulfonylphenyl)-3-phenyl-2,5-dihydrofuran-2-one::CHEMBL122::MK 0966::Rofecoxib::US11478464, Compound Rofecoxib",Prostaglandin G/H synthase 1,,>100000
50191291,O=S(=O)(N1C[C@H](CN2CCC(CC2)c2ccccc2)[C@H](C1)c1ccccc1)c1ccccc1,"InChI=1S/C28H32N2O2S/c31-33(32,27-14-8-3-9-15-27)30-21-26(28(22-30)25-12-6-2-7-13-25)20-29-18-16-24(17-19-29)23-10-4-1-5-11-23/h1-15,24,26,28H,16-22H2/t26-,28+/m0/s1",WNJMESXYCKJYEA-XTEPFMGCSA-N,50105523,"1-((3S,4S)-1-Benzenesulfonyl-4-phenyl-pyrrolidin-3-ylmethyl)-4-phenyl-piperidine::CHEMBL329131",C-C chemokine receptor type 5,, 152
1189762,CN1c2cc(ccc2OCC(NC(=O)c2n[nH]c(Cc3ccccc3)n2)C1=O)C#CCCOc1ccc2ncccc2c1,,,562863,"US11407736, Compound I-38::US11472782, Compound I-38",Receptor-interacting serine/threonine-protein kinase 1,, 68.0
405948,CN(Cc1ccc(cc1)C(C)(C)C)C1CCN(CC1)C(=O)Cn1cc(NC(=O)c2cnn3cccnc23)c(n1)-c1cc(Cl)ccc1OC(F)F,"InChI=1S/C36H39ClF2N8O3/c1-36(2,3)24-8-6-23(7-9-24)20-44(4)26-12-16-45(17-13-26)31(48)22-46-21-29(42-34(49)28-19-41-47-15-5-14-40-33(28)47)32(43-46)27-18-25(37)10-11-30(27)50-35(38)39/h5-11,14-15,18-19,21,26,35H,12-13,16-17,20,22H2,1-4H3,(H,42,49)",BELWFPKGSPJUOP-UHFFFAOYSA-N,232574,"US9346815, 120::US9604984, Example 120",Tyrosine-protein kinase JAK2,Homo sapiens,
790640,CN1CCc2c(C1)nc(C(=O)Nc1cccc(c1C)-c1cccc(-c3nc4cc(CN5CC[C@@H](C5)C(O)=O)cc(C#N)c4o3)c1C)n2C,"InChI=1S/C37H37N7O4/c1-21-26(27-8-6-10-29(22(27)2)40-35(45)34-39-31-20-42(3)13-12-32(31)43(34)4)7-5-9-28(21)36-41-30-16-23(15-25(17-38)33(30)48-36)18-44-14-11-24(19-44)37(46)47/h5-10,15-16,24H,11-14,18-20H2,1-4H3,(H,40,45)(H,46,47)/t24-/m0/s1",FMGLSVOXFKOWOZ-DEOSSOPVSA-N,395423,"(S)-1-((7-cyano-2-(3&#8242;-(1,5-dimethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2&#8242;-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid::US10308644, Example 36::US10800768, Example 36::US11339149, Example 36",Programmed cell death 1 ligand 1 [19-238]/protein 1 [25-167],,<10
694021,CN1C(=O)CCc2c(F)c(ccc12)-c1n[nH]cc1CC1CCN(CC1)C(=O)c1ccnn1C,"InChI=1S/C24H27FN6O2/c1-29-19-5-3-18(22(25)17(19)4-6-21(29)32)23-16(14-26-28-23)13-15-8-11-31(12-9-15)24(33)20-7-10-27-30(20)2/h3,5,7,10,14-15H,4,6,8-9,11-13H2,1-2H3,(H,26,28)",GDMNMAUIOFQMQC-UHFFFAOYSA-N,351263,"CHEM-US-00074::US9796702, 24::US9796702, 26","Cytochrome P450 11B2, mitochondrial",,
213258,O=C(Nc1nnc(s1)-c1ccccc1)c1nc(ccc1Nc1cncnc1)C1CC1,"InChI=1S/C21H17N7OS/c29-19(26-21-28-27-20(30-21)14-4-2-1-3-5-14)18-17(24-15-10-22-12-23-11-15)9-8-16(25-18)13-6-7-13/h1-5,8-13,24H,6-7H2,(H,26,28,29)",LWTLVZYRCFDRCS-UHFFFAOYSA-N,97537,"Roche-Dataset for PDE10A, Compound 670::US8470820, 48","cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A",Homo sapiens, 435
337472,CC(C)(O)[C@H](F)CNC(=O)c1cnc(cc1NC1CCC1)-n1cnc2cc(cnc12)C#N,"InChI=1S/C22H24FN7O2/c1-22(2,32)18(23)11-27-21(31)15-10-25-19(7-16(15)29-14-4-3-5-14)30-12-28-17-6-13(8-24)9-26-20(17)30/h6-7,9-10,12,14,18,32H,3-5,11H2,1-2H3,(H,25,29)(H,27,31)/t18-/m1/s1",NBPPZDZNZRNBFM-GOSISDBHSA-N,187790,"US9169252, 338",Interleukin-1 receptor-associated kinase 4,Homo sapiens, 4.5
873002,COc1ccc(CN2C3CC2CN(C3)c2ccc(cn2)-c2cc(OCc3cncn3C)cn3ncc(C#N)c23)cn1,"InChI=1S/C30H29N9O2/c1-36-19-32-13-25(36)18-41-26-8-27(30-22(9-31)12-35-39(30)17-26)21-4-5-28(33-11-21)37-15-23-7-24(16-37)38(23)14-20-3-6-29(40-2)34-10-20/h3-6,8,10-13,17,19,23-24H,7,14-16,18H2,1-2H3",UHVDBJPXGVMWQI-UHFFFAOYSA-N,296731,"US10112942, Example 466::US10137124, Example 466::US10172851, Example 466::US10555944, Example 466::US10953005, Example 466","Proto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M]",, 46.4
680975,FC1CCN(CC1)C(=O)CN1CCN(C1=O)c1cccc2n(ncc12)-c1ccccc1F,"InChI=1S/C23H23F2N5O2/c24-16-8-10-27(11-9-16)22(31)15-28-12-13-29(23(28)32)19-6-3-7-20-17(19)14-26-30(20)21-5-2-1-4-18(21)25/h1-7,14,16H,8-13,15H2",QZTAOLNUGHNMJR-UHFFFAOYSA-N,344767,"1-[1-(2-fluorophenyl)-1H-::1-[1-(2-fluorophenyl)-1H-indazol-4-yl]-3-[2-(4-fluoropiperidin-1-yl)-2-oxoethyl]imidazolidin-2-one::US9783527, Example 69",Sodium channel protein type 10 subunit alpha,, 4800
50201596,C(Cc1c[nH]c2ccccc12)NCc1c[nH]c2ccccc12,"InChI=1S/C19H19N3/c1-3-7-18-16(5-1)14(12-21-18)9-10-20-11-15-13-22-19-8-4-2-6-17(15)19/h1-8,12-13,20-22H,9-11H2",RNQKFVUQTYKTMI-UHFFFAOYSA-N,50111161,CHEMBL269653::[2-(1H-Indol-3-yl)-ethyl]-(1H-indol-3-ylmethyl)-amine,Melanocyte-stimulating hormone receptor,,
50688118,COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC,"InChI=1S/C22H23FN6O5/c1-22(2)20(30)28-19-13(34-22)6-7-16(27-19)26-18-12(23)10-24-21(29-18)25-11-8-14(31-3)17(33-5)15(9-11)32-4/h6-10H,1-5H3,(H3,24,25,26,27,28,29,30)",NHHQJBCNYHBUSI-UHFFFAOYSA-N,60665,"BDBM50249542::US9145414, R406::US9212178, R406",Cytoplasmic tyrosine-protein kinase BMX,Homo sapiens,
50740834,Nc1ccc(cc1)S(N)(=O)=O,"InChI=1S/C6H8N2O2S/c7-5-1-3-6(4-2-5)11(8,9)10/h1-4H,7H2,(H2,8,9,10)",FDDDEECHVMSUSB-UHFFFAOYSA-N,10857,4-aminobenzene-1-sulfonamide::CHEMBL21::Sulfanilamide::aromatic sulfonamide compound 5::aromatic/heteroaromatic sulfonamide 2::halogenosulfanilamide deriv. 5a,Carbonic anhydrase 1,Homo sapiens,
593350,NC(=O)C1CNCCN1c1cc(nc(n1)-c1ccc(Oc2ccc(F)cc2)cc1)C(N)=O,"InChI=1S/C22H21FN6O3/c23-14-3-7-16(8-4-14)32-15-5-1-13(2-6-15)22-27-17(20(24)30)11-19(28-22)29-10-9-26-12-18(29)21(25)31/h1-8,11,18,26H,9-10,12H2,(H2,24,30)(H2,25,31)",HXLNLMXKKIOHJX-UHFFFAOYSA-N,185938,"US9163008, 27::US9656968, Compound 27",Sodium channel protein type 9 subunit alpha,, 260
50073455,C[C@](O)(c1ccc(cc1)C(=O)N(C1CC1)[C@H]1CC[C@@](O)(CC1)C1CC1)C(F)(F)F,"InChI=1S/C22H28F3NO3/c1-20(28,22(23,24)25)15-4-2-14(3-5-15)19(27)26(17-8-9-17)18-10-12-21(29,13-11-18)16-6-7-16/h2-5,16-18,28-29H,6-13H2,1H3/t18-,20-,21+/m0/s1",SWXZIRVTPISJMP-SESVDKBCSA-N,50248211,"CHEMBL526305::N-cyclopropyl-N-((1s,4R)-4-cyclopropyl-4-hydroxycyclohexyl)-4-((S)-1,1,1-trifluoro-2-hydroxypropan-2-yl)benzamide::N-cyclopropyl-N-(cis-4-cyclopropyl-4-hydroxycyclohexyl)-4-[(1S)-2,2,2-trifluoro-1-hydroxy-1-methylethyl]benzamide",11-beta-hydroxysteroid dehydrogenase 1,Homo sapiens, 52
50970655,O=Cc1ccc(cc1)N1CCN(CC1)S(=O)(=O)c1ccc2NC(=O)Cc2c1,"InChI=1S/C19H19N3O4S/c23-13-14-1-3-16(4-2-14)21-7-9-22(10-8-21)27(25,26)17-5-6-18-15(11-17)12-19(24)20-18/h1-6,11,13H,7-10,12H2,(H,20,24)",SSVMEIZADFTJPV-UHFFFAOYSA-N,50398024,CHEMBL2181095,Lysosomal alpha-glucosidase,Homo sapiens, 4110
51267334,CC(C)CN1CCc2cccc3[nH]cc(C1c1ccc(\C=C\C(O)=O)cc1)c23,"InChI=1S/C24H26N2O2/c1-16(2)15-26-13-12-18-4-3-5-21-23(18)20(14-25-21)24(26)19-9-6-17(7-10-19)8-11-22(27)28/h3-11,14,16,24-25H,12-13,15H2,1-2H3,(H,27,28)/b11-8+",FJOTVKIMZYPXQE-DHZHZOJOSA-N,50517549,CHEMBL4554684,Estrogen receptor,, 39811
50695286,C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N,"InChI=1S/C16H20N6O/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20)/t11-,13+/m1/s1",UJLAWZDWDVHWOW-YPMHNXCESA-N,50193995,"3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile::3-(4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile::3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile::CHEMBL221959::CP-690550::TOFACITINIB CITRATE::Tofacitinib::Tofacitinib citrate (1)::US10112907, Example 00035::US10399979, Compound Tofacitinib::US10766894, Compound TABLE 1.20::US10875847, Compound Tofacitinib::US11078206, Example Tofacitinib::US11203595, TABLE 1.20::US11339167, Example Tofacitinib",Ephrin type-B receptor 6,Homo sapiens,
51373429,Nc1ncc(cn1)-c1nc(N2CCOCC2)c2ccn(CCCCCCC(=O)NO)c2n1,"InChI=1S/C21H28N8O3/c22-21-23-13-15(14-24-21)18-25-19-16(20(26-18)29-9-11-32-12-10-29)6-8-28(19)7-4-2-1-3-5-17(30)27-31/h6,8,13-14,31H,1-5,7,9-12H2,(H,27,30)(H2,22,23,24)",YLDAIYDYJXZDGW-UHFFFAOYSA-N,50555464,CHEMBL4744689,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform",Homo sapiens, 92
737387,Cn1cc(cc(N2CCOCC2)c1=O)-c1cc(NC(=O)c2cccc(c2)C(F)F)ccc1F,"InChI=1S/C24H22F3N3O3/c1-29-14-17(12-21(24(29)32)30-7-9-33-10-8-30)19-13-18(5-6-20(19)25)28-23(31)16-4-2-3-15(11-16)22(26)27/h2-6,11-14,22H,7-10H2,1H3,(H,28,31)",GWUWXAPVCNAQLC-UHFFFAOYSA-N,81124,"US10245267, Example 417::US10709712, Example 417::US9694016, 417",RAF proto-oncogene serine/threonine-protein kinase,Homo sapiens, 0.600
654533,COc1c(cc(Cl)c(C)c1-c1ccnc(c1)C(=O)NCCO)C(C)n1nc(C)c2c(N)ncnc12,"InChI=1S/C24H26ClN7O3/c1-12-17(25)10-16(14(3)32-23-20(13(2)31-32)22(26)29-11-30-23)21(35-4)19(12)15-5-6-27-18(9-15)24(34)28-7-8-33/h5-6,9-11,14,33H,7-8H2,1-4H3,(H,28,34)(H2,26,29,30)",SMTNSBXQKKGWLV-UHFFFAOYSA-N,255807,"4-{3-[1-(4-Amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl}-N-(2-hydroxyethyl)pyridine-2-carboxamide::US10092570, Example 18::US10376513, Example 18::US10646492, Example 18::US11433071, Example 18::US9707233, 18::US9730939, Example 18::US9932341, Example 18","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform",Homo sapiens,<10
51373319,ONC(=O)CCCCCCn1cnc2c(nc(nc12)N1CCOCC1)N1CCOCC1,"InChI=1S/C20H31N7O4/c28-16(24-29)5-3-1-2-4-6-27-15-21-17-18(25-7-11-30-12-8-25)22-20(23-19(17)27)26-9-13-31-14-10-26/h15,29H,1-14H2,(H,24,28)",NUVDAMNLGKTMIT-UHFFFAOYSA-N,50555469,CHEMBL4752658,"Phosphatidylinositol 3-kinase regulatory subunit alpha/4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",Homo sapiens,>10000
51234985,C[C@@H]1O[C@H](CNC(=O)c2ccccc2)[C@@H](O)[C@H](O)[C@@H]1O,"InChI=1S/C14H19NO5/c1-8-11(16)13(18)12(17)10(20-8)7-15-14(19)9-5-3-2-4-6-9/h2-6,8,10-13,16-18H,7H2,1H3,(H,15,19)/t8-,10+,11+,12+,13+/m0/s1",JQQZRLRIXNBNGH-VECUTGAWSA-N,50505623,CHEMBL4548491,LecB,Pseudomonas aeruginosa, 8730
294247,COc1ccc(O)c(c1)C(=O)\C=C\c1cccc(OC)c1OC,"InChI=1S/C18H18O5/c1-21-13-8-10-16(20)14(11-13)15(19)9-7-12-5-4-6-17(22-2)18(12)23-3/h4-11,20H,1-3H3/b9-7+",NRAAGHLLAJEOAZ-VQHVLOKHSA-N,153274,"(E)-3-(2,3-Dimethoxyphenyl)-1-(2-hydroxy-5-methoxyphenyl)prop-2-en-1-one (3g)",Amine oxidase [flavin-containing] A,Rattus norvegicus,>1.00e+5
51263180,C[C@@H]1[C@H](O)CC[C@@]2(C)[C@H]1CC[C@@]1(C)[C@H]2[C@H](O)C[C@H]2\C([C@H](C[C@]12C)OC(C)=O)=C(/CCC=C(C)C)C(=O)OCc1ccccc1,"InChI=1S/C38H54O6/c1-23(2)12-11-15-27(35(42)43-22-26-13-9-8-10-14-26)33-29-20-31(41)34-36(5)18-17-30(40)24(3)28(36)16-19-37(34,6)38(29,7)21-32(33)44-25(4)39/h8-10,12-14,24,28-32,34,40-41H,11,15-22H2,1-7H3/b33-27-/t24-,28-,29-,30+,31+,32-,34-,36-,37-,38-/m0/s1",REWCIBDKWWPGMH-ASKGCPBJSA-N,50515967,CHEMBL4439071,ATP-dependent translocase ABCB1,, 17
50700610,Clc1ccccc1-c1csc2nc([nH]c(=O)c12)C(=O)NCc1cccc(OCCOc2nc[nH]n2)c1,"InChI=1S/C24H19ClN6O4S/c25-18-7-2-1-6-16(18)17-12-36-23-19(17)21(32)29-20(30-23)22(33)26-11-14-4-3-5-15(10-14)34-8-9-35-24-27-13-28-31-24/h1-7,10,12-13H,8-9,11H2,(H,26,33)(H,27,28,31)(H,29,30,32)",HYPFCLOTXYNWMW-UHFFFAOYSA-N,50233880,CHEMBL4090287,Collagenase 3,Homo sapiens, 0.054000
443603,C[C@]12CC[C@H]3[C@@H](CCc4cc(ccc34)C(=O)NCCCC(O)=O)[C@@H]1CC=C2c1cncnc1,"InChI=1S/C27H31N3O3/c1-27-11-10-21-20-6-5-18(26(33)30-12-2-3-25(31)32)13-17(20)4-7-22(21)24(27)9-8-23(27)19-14-28-16-29-15-19/h5-6,8,13-16,21-22,24H,2-4,7,9-12H2,1H3,(H,30,33)(H,31,32)/t21-,22-,24+,27-/m1/s1",VFSCYKJFNFHIRS-FQUWXVCBSA-N,254831,"US9487554, 18",Aldo-keto reductase family 1 member C3/Glutathione S-transferase P,Homo sapiens, 31.8
589074,CCOc1ccc2nc(O[C@H]3CC[C@@H](CC3)OC[C@H](C)NC(C)=O)n(C)c2c1C1CC1,"InChI=1S/C24H35N3O4/c1-5-29-21-13-12-20-23(22(21)17-6-7-17)27(4)24(26-20)31-19-10-8-18(9-11-19)30-14-15(2)25-16(3)28/h12-13,15,17-19H,5-11,14H2,1-4H3,(H,25,28)/t15-,18-,19-/m0/s1",WXEONIALLBUAQB-SNRMKQJTSA-N,307492,"US10150728, Example I-735",Acetyl-CoA carboxylase 2,Homo sapiens, 677
1223491,C[C@H]1[C@H](CCN1C(=O)C(=O)NC1(CC(F)(F)C1)c1c[nH]nn1)C(=O)Nc1ccc(Cl)c(Cl)c1,,,580402,"US11491148, Compound C15",Capsid protein,,
913685,COc1ccc(cc1F)-c1c(nc2cccnn12)C(=O)N1CCC1,"InChI=1S/C17H15FN4O2/c1-24-13-6-5-11(10-12(13)18)16-15(17(23)21-8-3-9-21)20-14-4-2-7-19-22(14)16/h2,4-7,10H,3,8-9H2,1H3",GGBSVVWNJGUOLN-UHFFFAOYSA-N,285582,"US10077269, Example 55::US10669279, Example 55::US9598421, Example 55::azetidin-1-yl[3-(3-fluoro-4-methoxyphenyl)imidazo[1,2-b]pyridazin-2-yl]methanone","cAMP-specific 3',5'-cyclic phosphodiesterase 4D",,>20900
50889472,COc1cccc(NC(=O)c2ccccc2OCc2cn(CCN3CCc4cc(OC)c(OC)cc4C3)nn2)c1,"InChI=1S/C30H33N5O5/c1-37-25-8-6-7-23(17-25)31-30(36)26-9-4-5-10-27(26)40-20-24-19-35(33-32-24)14-13-34-12-11-21-15-28(38-2)29(39-3)16-22(21)18-34/h4-10,15-17,19H,11-14,18,20H2,1-3H3,(H,31,36)",GQQAPGUMHVTVGJ-UHFFFAOYSA-N,50268576,CHEMBL4071352,ATP-dependent translocase ABCB1,, 8.7
50968373,COc1cc(ccc1-c1nc2c(C)nn(C3CCCCC3)c(=O)c2[nH]1)N1CC[C@H](N)C1,"InChI=1S/C23H30N6O2/c1-14-20-21(23(30)29(27-14)16-6-4-3-5-7-16)26-22(25-20)18-9-8-17(12-19(18)31-2)28-11-10-15(24)13-28/h8-9,12,15-16H,3-7,10-11,13,24H2,1-2H3,(H,25,26)/t15-/m0/s1",LHZWBPTXJAFTCG-HNNXBMFYSA-N,50397071,CHEMBL2171425,"High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A",Homo sapiens, 80
51211922,CC1(C)CC1C(=O)N1CC2CC(C1)N2,"InChI=1S/C11H18N2O/c1-11(2)4-9(11)10(14)13-5-7-3-8(6-13)12-7/h7-9,12H,3-6H2,1-2H3",LJEPPQATHWQMBV-UHFFFAOYSA-N,50498053,CHEMBL3329545,Neuronal acetylcholine receptor subunit alpha-4/beta-2,,
50615148,Nc1cc(c(cc1S(N)(=O)=O)S(N)(=O)=O)C(F)(F)F,"InChI=1S/C7H8F3N3O4S2/c8-7(9,10)3-1-4(11)6(19(13,16)17)2-5(3)18(12,14)15/h1-2H,11H2,(H2,12,14,15)(H2,13,16,17)",KRVABEGPNKGLOT-UHFFFAOYSA-N,10866,"4-amino-6-(trifluoromethyl)benzene-1,3-disulfonamide::CHEMBL418::aromatic/heteroaromatic sulfonamide 11",Carbonic anhydrase,Stylophora pistillata,
50133979,Nc1ccc(cc1)[C@H](NS(=O)(=O)c1cnccc1N[C@H](CO)Cc1ccccc1)C(=O)N1CCC(CCF)CC1,"InChI=1S/C29H36FN5O4S/c30-14-10-21-12-16-35(17-13-21)29(37)28(23-6-8-24(31)9-7-23)34-40(38,39)27-19-32-15-11-26(27)33-25(20-36)18-22-4-2-1-3-5-22/h1-9,11,15,19,21,25,28,34,36H,10,12-14,16-18,20,31H2,(H,32,33)/t25-,28-/m0/s1",PYACADUHDHRESY-LSYYVWMOSA-N,50076819,4-((S)-1-Hydroxymethyl-2-phenyl-ethylamino)-pyridine-3-sulfonic acid {(S)-1-(4-amino-phenyl)-2-[4-(2-fluoro-ethyl)-piperidin-1-yl]-2-oxo-ethyl}-amide::CHEMBL12506,Prothrombin,,
633875,O=c1[nH]ncc2nc(nc(Nc3ccc(OCCC4CCNCC4)cc3)c12)N1CCCCCC1,"InChI=1S/C25H33N7O2/c33-24-22-21(17-27-31-24)29-25(32-14-3-1-2-4-15-32)30-23(22)28-19-5-7-20(8-6-19)34-16-11-18-9-12-26-13-10-18/h5-8,17-18,26H,1-4,9-16H2,(H,31,33)(H,28,29,30)",LGYDROLDDQMUTM-UHFFFAOYSA-N,322798,"2-(azepan-1-yl)-4-((4-(2-(piperidin-4- yl)ethoxy)phenyl)amino)pyrimido[4,5- d]pyridazin-5(6H)-one::US10183944, Example 168::US10647720, Ex. # 168",Tyrosine-protein kinase SYK,Homo sapiens,<50
51061876,COc1ccc2c(nn(C)c2c1)-c1cnc2[nH]cc(C(=O)N[C@H](C)C(=O)N3CC(C3)C#N)c2n1,"InChI=1S/C23H22N8O3/c1-12(23(33)31-10-13(7-24)11-31)27-22(32)16-8-25-21-20(16)28-17(9-26-21)19-15-5-4-14(34-3)6-18(15)30(2)29-19/h4-6,8-9,12-13H,10-11H2,1-3H3,(H,25,26)(H,27,32)/t12-/m1/s1",MJJPFIFLAMTXHQ-GFCCVEGCSA-N,50433247,CHEMBL2376149,Tyrosine-protein kinase JAK1/JAK2,Homo sapiens, 2610
873650,CCN1CCC(F)(CC1)C(=O)Nc1cc2cc(ccc2cn1)-c1cn(C)nn1,"InChI=1S/C20H23FN6O/c1-3-27-8-6-20(21,7-9-27)19(28)23-18-11-16-10-14(4-5-15(16)12-22-18)17-13-26(2)25-24-17/h4-5,10-13H,3,6-9H2,1-2H3,(H,22,23,28)",PWQZTCCNTXEHBA-UHFFFAOYSA-N,385126,"US10287267, Compound 282::US10508099, Compound 282::US10556885, Compound 282::US11174244, Compound 282",Glycogen synthase kinase-3 beta,Homo sapiens,
314178,Cn1cc(-c2cc3ccccc3o2)c2ccc(cc12)S(=O)(=O)Nc1ncns1,"InChI=1S/C19H14N4O3S2/c1-23-10-15(18-8-12-4-2-3-5-17(12)26-18)14-7-6-13(9-16(14)23)28(24,25)22-19-20-11-21-27-19/h2-11H,1H3,(H,20,21,22)",NBCPHYCWWCIAEM-UHFFFAOYSA-N,170228,"US9079902, 59",Sodium channel protein type 5 subunit alpha,,>10000
1219371,COC1(CC(C)(C)C(=O)C(=C1)C#N)c1ncc(Cl)cc1C(F)(F)F,"InChI=1S/C16H14ClF3N2O2/c1-14(2)8-15(24-3,5-9(6-21)13(14)23)12-11(16(18,19)20)4-10(17)7-22-12/h4-5,7H,8H2,1-3H3",ABAGHOROPCKUEJ-UHFFFAOYSA-N,578673,"3-[5-chloro-3- (trifluoromethyl)pyridin- 2-yl]-3-methoxy-5,5- dimethyl-6- oxocyclohex-1-ene-1- carbonitrile (Enantiomer A)::US11479539, Compound 208",hek293 luciferase,,
597161,C[C@H]1N(CCc2c1nnn2-c1ncccn1)C(=O)c1cccc(c1F)C(F)(F)F,"InChI=1S/C18H14F4N6O/c1-10-15-13(28(26-25-15)17-23-7-3-8-24-17)6-9-27(10)16(29)11-4-2-5-12(14(11)19)18(20,21)22/h2-5,7-8,10H,6,9H2,1H3/t10-/m1/s1",IWJSYJVLWVVIIM-SNVBAGLBSA-N,254364,"US10112937, Example 271::US10150765, Example 271::US10703749, Example 271::US9464084, 271",P2X purinoceptor 7,, 3.30
50249510,ONC(=O)[C@H]1CCCOC(=O)NCCCC[C@H](NC(=O)[C@@H]1Cc1ccc(cc1)-c1ccccc1C(F)(F)F)C(=O)NCC(=O)N1CCOCC1,"InChI=1S/C34H42F3N5O8/c35-34(36,37)27-8-2-1-6-24(27)23-12-10-22(11-13-23)20-26-25(31(45)41-48)7-5-17-50-33(47)38-14-4-3-9-28(40-30(26)44)32(46)39-21-29(43)42-15-18-49-19-16-42/h1-2,6,8,10-13,25-26,28,48H,3-5,7,9,14-21H2,(H,38,47)(H,39,46)(H,40,44)(H,41,45)/t25-,26+,28-/m0/s1",RWKJBOMUESGCBO-REUBFRLUSA-N,50104975,"(8S,11R,12S)-2,10-Dioxo-11-(2'-trifluoromethyl-biphenyl-4-ylmethyl)-1-oxa-3,9-diaza-cyclopentadecane-8,12-dicarboxylic acid 12-hydroxyamide 8-[(2-morpholin-4-yl-2-oxo-ethyl)-amide]::(8S,11R,12S)-N12-hydroxy-N8-(2-morpholino-2-oxoethyl)-2,10-dioxo-11-((2'-(trifluoromethyl)biphenyl-4-yl)methyl)-1-oxa-3,9-diazacyclopentadecane-8,12-dicarboxamide::2,10-Dioxo-11-(2'-trifluoromethyl-biphenyl-4-ylmethyl)-1-oxa-3,9-diaza-cyclopentadecane-8,12-dicarboxylic acid 12-hydroxyamide 8-[(2-morpholin-4-yl-2-oxo-ethyl)-amide]::CHEMBL325163",72 kDa type IV collagenase,,
622945,OC(=O)[C@@H]1C[C@@H](CN1C(=O)C(c1ccccc1)c1ccccc1)NC(=O)N(c1ccccc1)c1ccccc1,"InChI=1S/C32H29N3O4/c36-30(29(23-13-5-1-6-14-23)24-15-7-2-8-16-24)34-22-25(21-28(34)31(37)38)33-32(39)35(26-17-9-3-10-18-26)27-19-11-4-12-20-27/h1-20,25,28-29H,21-22H2,(H,33,39)(H,37,38)/t25-,28-/m0/s1",ZRVCPEWFXXPDLS-LSYYVWMOSA-N,318770,"(2S,4S)-1-(2,2-diphenylacetyl)-4-(3,3-diphenyluriedo)-pyrrolidine-2-carboxylic acid::US9624243, 64",Type-2 angiotensin II receptor,, 3358
1184411,Clc1cnccc1-c1ccc(cc1)C(=O)N[C@@H]1CCN(C1)C#N,"InChI=1S/C17H15ClN4O/c18-16-9-20-7-5-15(16)12-1-3-13(4-2-12)17(23)21-14-6-8-22(10-14)11-19/h1-5,7,9,14H,6,8,10H2,(H,21,23)/t14-/m1/s1",SFYBOLDZCPBPKD-CQSZACIVSA-N,404385,"(R)-4-(3-chloropyridin-4-yl)-N- (1-cyanopyrrolidin-3- yl)benzamide::US10343992, Example 38::US10689345, Example 38::US11066365, Example 38::US11390584, Example 49",Ubiquitin carboxyl-terminal hydrolase 30,, 550
50029917,CS(=O)(=O)\C=C\C(Cc1ccccc1)NC(=O)CN,"InChI=1S/C13H18N2O3S/c1-19(17,18)8-7-12(15-13(16)10-14)9-11-5-3-2-4-6-11/h2-8,12H,9-10,14H2,1H3,(H,15,16)/b8-7+",DLBCEDMSCPLRMY-BQYQJAHWSA-N,50026018,2-Amino-N-(1-benzyl-3-methanesulfonyl-allyl)-acetamide::CHEMBL13279,Dipeptidyl peptidase 1,,
975319,Cc1cc(Oc2ccccc2)ccc1-n1c2ccnc3sc(C(=O)N[C@@H]4CCN(C4)C(=O)C=C)c([nH]c1=O)c23,,,467354,"(R)-N-(1-Acryloylpyrrolidin-3-yl)-5-(*S)-(2-methyl-4- phenoxyphenyl)-4-oxo-4,5-dihydro-3H-1-thia-3,5,8- triazaacenaphthylene-2-carboxamide;::US10800792, Example 5::US10822348, Example 5",Tyrosine-protein kinase BTK [386-659],, 7.94
224445,COCCOc1ncccc1C1C(C(=O)CC(C)C)C(=O)C(=O)N1c1ccc(cc1)-c1ccc(C)o1,"InChI=1S/C28H30N2O6/c1-17(2)16-22(31)24-25(21-6-5-13-29-27(21)35-15-14-34-4)30(28(33)26(24)32)20-10-8-19(9-11-20)23-12-7-18(3)36-23/h5-13,17,24-25H,14-16H2,1-4H3",PNQPHJREMQOXLL-UHFFFAOYSA-N,105850,"US8575197, I-360",P2X purinoceptor 3,Homo sapiens, 21
354936,COc1ccc2C[C@H]3N(CCC(O)=O)CC[C@@]45[C@@H](Oc1c24)[C@]1(CC[C@@]35C[C@@H]1COCc1ccccc1)OC,"InChI=1S/C31H37NO6/c1-35-23-9-8-21-16-24-29-11-12-31(36-2,22(17-29)19-37-18-20-6-4-3-5-7-20)28-30(29,26(21)27(23)38-28)13-15-32(24)14-10-25(33)34/h3-9,22,24,28H,10-19H2,1-2H3,(H,33,34)/t22-,24-,28-,29-,30+,31-/m1/s1",JIKNKSSGOZQLQU-NPBSHTHCSA-N,199391,"US9221831, 56",Kappa-type opioid receptor,Homo sapiens,
51020615,Brc1ccc(Br)c(c1)S(=O)(=O)N[C@@H]1CCN(C1)C#N,"InChI=1S/C11H11Br2N3O2S/c12-8-1-2-10(13)11(5-8)19(17,18)15-9-3-4-16(6-9)7-14/h1-2,5,9,15H,3-4,6H2/t9-/m1/s1",MPJZWOZVGUFRSZ-SECBINFHSA-N,50418002,CHEMBL1672427,Cathepsin S,Homo sapiens, 125.89
50718854,CC(C)NC(=O)c1cccc(NC(=O)Nc2ccc(cc2)-c2ncnc3n(C)ccc23)c1,"InChI=1S/C24H24N6O2/c1-15(2)27-23(31)17-5-4-6-19(13-17)29-24(32)28-18-9-7-16(8-10-18)21-20-11-12-30(3)22(20)26-14-25-21/h4-15H,1-3H3,(H,27,31)(H2,28,29,32)",HENQQNHTKQZKIP-UHFFFAOYSA-N,50364648,CHEMBL1951345,Cytochrome P450 3A4,Homo sapiens, 2900
50621587,Cn1cc(CN2CCN(CC2C(O)=O)c2cc(C(=O)Nc3ccc4CCc5c(nn(c5-c4c3)-c3ccc(F)cc3)C(N)=O)c(Cl)cn2)cn1,"InChI=1S/C34H31ClFN9O4/c1-42-16-19(14-39-42)17-43-10-11-44(18-28(43)34(48)49)29-13-26(27(35)15-38-29)33(47)40-22-6-2-20-3-9-24-30(32(37)46)41-45(31(24)25(20)12-22)23-7-4-21(36)5-8-23/h2,4-8,12-16,28H,3,9-11,17-18H2,1H3,(H2,37,46)(H,40,47)(H,48,49)",YZGWZCOIRRVTDL-UHFFFAOYSA-N,50336182,"4-(4-{[3-Carbamoyl-1-(4-fluorophenyl)-4,5-dihydro-1H-benzo[g]indazol-8-yl]carbamoyl}-5-chloropyridin-2-yl)-1-[(1-methyl-1H-pyrazol-4-yl)methyl]piperazine-2-carboxylicacid::CHEMBL1669570",Inhibitor of nuclear factor kappa-B kinase subunit beta,Homo sapiens, 3.9
50023402,CN(CC(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O)C(=O)[C@@H]1CSSC[C@@H](N)C(=O)N[C@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1,"InChI=1S/C44H63N15O12S2/c1-59(20-36(64)53-27(8-5-15-51-44(49)50)38(66)52-19-35(48)63)43(71)32-22-73-72-21-26(45)37(65)55-29(17-24-9-11-25(60)12-10-24)41(69)56-30(16-23-6-3-2-4-7-23)40(68)54-28(13-14-33(46)61)39(67)57-31(18-34(47)62)42(70)58-32/h2-4,6-7,9-12,26-32,60H,5,8,13-22,45H2,1H3,(H2,46,61)(H2,47,62)(H2,48,63)(H,52,66)(H,53,64)(H,54,68)(H,55,65)(H,56,69)(H,57,67)(H,58,70)(H4,49,50,51)/t26-,27-,28-,29-,30+,31+,32+/m1/s1",XZTXFSDOTYOJEJ-XMMWIWGISA-N,50016312,CHEMBL265119::[Sar7D-Arg8]VP (Vasopressin ),Vasopressin V1a/V1b receptor,Rattus,
795443,Cc1cccc2N(C(=O)\C(=C/c3c(Cl)cccc3C(F)(F)F)c12)c1ccc(C(O)=O)c(O)c1,"InChI=1S/C24H15ClF3NO4/c1-12-4-2-7-19-21(12)16(11-15-17(24(26,27)28)5-3-6-18(15)25)22(31)29(19)13-8-9-14(23(32)33)20(30)10-13/h2-11,30H,1H3,(H,32,33)/b16-11-",JEHVMJNOGKLITL-WJDWOHSUSA-N,398002,"US10322108, Example 6",Nuclear receptor ROR-gamma,,<100
51051056,Oc1c(O)c(cc(C(=O)c2ccc(Oc3ccccc3)cc2)c1O)C(=O)c1nc2ccccc2s1,"InChI=1S/C27H17NO6S/c29-22(15-10-12-17(13-11-15)34-16-6-2-1-3-7-16)18-14-19(24(31)26(33)23(18)30)25(32)27-28-20-8-4-5-9-21(20)35-27/h1-14,30-31,33H",CYBLECRKSFPWGB-UHFFFAOYSA-N,50371611,CHEMBL258819,Induced myeloid leukemia cell differentiation protein Mcl-1,Homo sapiens,
51183144,Cc1ccc(OCCCOc2ccc3[C@H](CC(O)=O)CCc3c2)c(C)c1,"InChI=1S/C22H26O4/c1-15-4-9-21(16(2)12-15)26-11-3-10-25-19-7-8-20-17(13-19)5-6-18(20)14-22(23)24/h4,7-9,12-13,18H,3,5-6,10-11,14H2,1-2H3,(H,23,24)/t18-/m0/s1",XNQKRHGPWPVZTM-SFHVURJKSA-N,21765,"2-[(1S)-5-[3-(2,4-dimethylphenoxy)propoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid::Indanylacetic Acid Analog, 17l",Peroxisome proliferator-activated receptor gamma,Homo sapiens,
50331468,C\C(\C=C\[C@H]1CCCN1c1ccc2c(c1)C(C)(C)CCC2(C)C)=C/C(O)=O,"InChI=1S/C24H33NO2/c1-17(15-22(26)27)8-9-18-7-6-14-25(18)19-10-11-20-21(16-19)24(4,5)13-12-23(20,2)3/h8-11,15-16,18H,6-7,12-14H2,1-5H3,(H,26,27)/b9-8+,17-15+/t18-/m1/s1",MNVPYFNLMYKEKF-JFCAQSKFSA-N,50179124,"(R,2E,4E)-3-methyl-5-(1-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)pyrrolidin-2-yl)penta-2,4-dienoic acid::CHEMBL208503",Retinoic acid receptor RXR-alpha,Homo sapiens,
50670229,CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N,"InChI=1S/C21H27N7O3/c1-4-28-18-15(30-12-13-6-5-9-23-10-13)11-24-14(7-8-21(2,3)29)16(18)25-20(28)17-19(22)27-31-26-17/h11,13,23,29H,4-6,9-10,12H2,1-3H3,(H2,22,27)/t13-/m0/s1",KGPGFQWBCSZGEL-ZDUSSCGKSA-N,25013,"4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[(3S)-piperidin-3-ylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methylbut-3-yn-2-ol::GSK-690693::GSK690693::US10550114, Compound GSK690693",Ephrin type-A receptor 4,Homo sapiens,
50949126,C[C@H](Nc1ncnc2cc3oc(=O)n(CCCN4CCOCC4)c3cc12)c1ccccc1,"InChI=1S/C24H27N5O3/c1-17(18-6-3-2-4-7-18)27-23-19-14-21-22(15-20(19)25-16-26-23)32-24(30)29(21)9-5-8-28-10-12-31-13-11-28/h2-4,6-7,14-17H,5,8-13H2,1H3,(H,25,26,27)/t17-/m0/s1",MYTTUHJKUWGZNX-KRWDZBQOSA-N,50389375,CHEMBL2064399,Epidermal growth factor receptor,Homo sapiens, 3700
50246253,Nc1nc(I)nc2n(cnc12)C1CC(OP(O)(O)=O)[C@]2(COP(O)(O)=O)C[C@H]12,"InChI=1S/C12H16IN5O8P2/c13-11-16-9(14)8-10(17-11)18(4-15-8)6-1-7(26-28(22,23)24)12(2-5(6)12)3-25-27(19,20)21/h4-7H,1-3H2,(H2,14,16,17)(H2,19,20,21)(H2,22,23,24)/t5-,6?,7?,12+/m1/s1",FOLHZLOARGJPNX-KCNSGJITSA-N,50134966,"CHEMBL343651::Phosphoric acid mono-[(1R,5S)-4-(6-amino-2-iodo-purin-9-yl)-1-phosphonooxymethyl-bicyclo[3.1.0]hex-2-yl] ester",P2Y purinoceptor 1,,
1014004,COc1ccc(cc1)-c1cc(=O)n2ncc(-c3ccc(F)cc3)c2[nH]1,"InChI=1S/C19H14FN3O2/c1-25-15-8-4-13(5-9-15)17-10-18(24)23-19(22-17)16(11-21-23)12-2-6-14(20)7-3-12/h2-11,22H,1H3",RDTDBZZRDSVAHM-UHFFFAOYSA-N,487440,"3-(4-Fluorophenyl)-5-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-7(4H)-one::US10953012, Example 53",Casein kinase II subunit alpha',Homo sapiens,<10000
702846,CC[C@@H](NC(=O)c1cc(=O)[nH]c(n1)-c1ccccc1)c1ccc(SC(F)(F)F)c(F)c1,,,355294,"N-[(1R)-1-{3-fluoro-4- [(trifluoromethyl)sulfanyl]phenyl}pro- pyl]-6-oxo-2-phenyl-1,6- dihydropyrimidine-4-carboxamide::US9815796, Example 385","cGMP-dependent 3',5'-cyclic phosphodiesterase",,
50017502,Cc1nnc2CN=C(c3cc(sc3-n12)C#CCO)c1ccccc1Cl,"InChI=1S/C18H13ClN4OS/c1-11-21-22-16-10-20-17(13-6-2-3-7-15(13)19)14-9-12(5-4-8-24)25-18(14)23(11)16/h2-3,6-7,9,24H,8,10H2,1H3",SAICKZLDVXOFFG-UHFFFAOYSA-N,50011858,"3-[4-(2-Chloro-phenyl)-9-methyl-6H-1-thia-5,7,8,9a-tetraaza-cyclopenta[e]azulen-2-yl]-prop-2-yn-1-ol::CHEMBL32327",Platelet-activating factor receptor,Homo sapiens, 180
51088139,Cc1c2COC(=O)c2c(O)c(O)c1O,"InChI=1S/C9H8O5/c1-3-4-2-14-9(13)5(4)7(11)8(12)6(3)10/h10-12H,2H2,1H3",IREYRQPUBOQACQ-UHFFFAOYSA-N,50445475,CHEMBL3104854,ALK tyrosine kinase receptor,Homo sapiens, 5020
939172,Cn1cc(cn1)-c1cn2nccc2c(n1)-c1cnn(c1)C1(C)CCCC1,"InChI=1S/C19H21N7/c1-19(6-3-4-7-19)26-12-15(10-22-26)18-17-5-8-20-25(17)13-16(23-18)14-9-21-24(2)11-14/h5,8-13H,3-4,6-7H2,1-2H3",KRTPHJWJOAAJKP-UHFFFAOYSA-N,325387,"6-(1-methyl-1H-pyrazol-4-yl)-4-(1-(1-methylcyclopentyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine::US10189845, Example 49::US10730880, Example 49::US11028093, Example 49",Non-receptor tyrosine-protein kinase TYK2,Homo sapiens, 550
50954489,CN1CCC[C@@H]1Cn1nc(Cc2ccc(Cl)cc2)c2nccnc2c1=O,"InChI=1S/C19H20ClN5O/c1-24-10-2-3-15(24)12-25-19(26)18-17(21-8-9-22-18)16(23-25)11-13-4-6-14(20)7-5-13/h4-9,15H,2-3,10-12H2,1H3/t15-/m1/s1",DGZLHXBKGBELTQ-OAHLLOKOSA-N,50391705,CHEMBL2146812,Histamine H3 receptor,Homo sapiens,
51198259,CCCCCNC1C=CN(Cc2ccccc2)c2cc([125I])ccc12,"InChI=1S/C21H25IN2/c1-2-3-7-13-23-20-12-14-24(16-17-8-5-4-6-9-17)21-15-18(22)10-11-19(20)21/h4-6,8-12,14-15,20,23H,2-3,7,13,16H2,1H3/i22-2",PXVNBCAIUMPGJP-ONBQKKEBSA-N,50493060,CHEMBL2419774,Sodium channel protein type 2 subunit alpha,, 1500
50606030,Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F,"InChI=1S/C13H9F3N4/c1-8-17-18-12-6-5-11(19-20(8)12)9-3-2-4-10(7-9)13(14,15)16/h2-7H,1H3",GUOQUXNJZHGPQF-UHFFFAOYSA-N,50026756,"3-Methyl-6-(3-trifluoromethyl-phenyl)-[1,2,4]triazolo[4,3-b]pyridazine::CHEMBL13662::CI-218872::CL 218872::CL218,872::v3-Methyl-6-(3-trifluoromethyl-phenyl)-[1,2,4]triazolo[4,3-b]pyridazine",Gamma-aminobutyric acid receptor subunit alpha-1/beta-3/gamma-2,Homo sapiens,
50647908,Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,"InChI=1S/C10H13N5O4/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10/h2-4,6-7,10,16-18H,1H2,(H2,11,12,13)/t4-,6-,7-,10-/m1/s1",OIRDTQYFTABQOQ-KQYNXXCUSA-N,14487,"(2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol::Adenine-beta-D-arabinofuranoside::Adenosine::CHEMBL477::N6-Methylado::[U-14C]adenosine::cid_191::cid_60961",Adenosine receptor A2a/A2b,Homo sapiens,
247821,NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CCC(O)=O)NC(=O)CCc1ccc(cc1)-c1ccccc1,"InChI=1S/C26H29N5O5/c27-25(35)22(14-20-15-28-16-29-20)31-26(36)21(11-13-24(33)34)30-23(32)12-8-17-6-9-19(10-7-17)18-4-2-1-3-5-18/h1-7,9-10,15-16,21-22H,8,11-14H2,(H2,27,35)(H,28,29)(H,30,32)(H,31,36)(H,33,34)/t21-,22-/m0/s1",OTOPPWBRBAVQCM-VXKWHMMOSA-N,120199,"US8691753, 48",Stromelysin-2,Homo sapiens,
1250682,CCn1c(c2CC(C)(C)COC(=O)[C@@H]3CCCN(N3)C(=O)[C@H](Cc3cc(O)cc(c3)-c3ccc1c2c3)NC(=O)[C@H](C(C)C)N(C)C(=O)[C@H]1CCN(C1)C(=O)C=C)-c1ccncc1CCOC,"InChI=1S/C51H65N7O8/c1-9-44(60)56-20-16-35(29-56)48(62)55(7)45(31(3)4)47(61)53-42-24-32-22-36(25-37(59)23-32)33-13-14-43-39(26-33)40(46(57(43)10-2)38-15-18-52-28-34(38)17-21-65-8)27-51(5,6)30-66-50(64)41-12-11-19-58(54-41)49(42)63/h9,13-15,18,22-23,25-26,28,31,35,41-42,45,54,59H,1,10-12,16-17,19-21,24,27,29-30H2,2-8H3,(H,53,61)/t35-,41-,42-,45-/m0/s1",ZQGWQIBTLVYCQP-ZAILGRLISA-N,591370,"US11566007, Example A48",GTPase KRas [G12V],, 550
151279,CCn1c(SCC(=O)N2CCN(CC2)c2ccc(Cl)cc2)nc2ccccc2c1=O,"InChI=1S/C22H23ClN4O2S/c1-2-27-21(29)18-5-3-4-6-19(18)24-22(27)30-15-20(28)26-13-11-25(12-14-26)17-9-7-16(23)8-10-17/h3-10H,2,11-15H2,1H3",UOHJTTYUBKMUAQ-UHFFFAOYSA-N,80525,2-({2-[4-(4-chlorophenyl)-1-piperazinyl]-2-oxoethyl}thio)-3-ethyl-4(3H)-quinazolinone::2-[2-[4-(4-chlorophenyl)piperazin-1-yl]-2-oxidanylidene-ethyl]sulfanyl-3-ethyl-quinazolin-4-one::2-[2-[4-(4-chlorophenyl)piperazin-1-yl]-2-oxoethyl]sulfanyl-3-ethylquinazolin-4-one::2-[[2-[4-(4-chlorophenyl)-1-piperazinyl]-2-oxoethyl]thio]-3-ethyl-4-quinazolinone::2-[[2-[4-(4-chlorophenyl)piperazino]-2-keto-ethyl]thio]-3-ethyl-quinazolin-4-one::MLS000862116::SMR000076043::cid_980267,DNA dC->dU-editing enzyme APOBEC-3A,Homo sapiens, 2830
50502182,Nc1nc2[nH]c(SCc3ccc(F)cc3F)nc2c(=O)[nH]1,"InChI=1S/C12H9F2N5OS/c13-6-2-1-5(7(14)3-6)4-21-12-16-8-9(18-12)17-11(15)19-10(8)20/h1-3H,4H2,(H4,15,16,17,18,19,20)",UPSXUROZOKKJQV-UHFFFAOYSA-N,50181525,CHEMBL3818521,2-amino-4-hydroxy-6-hydroxymethyldihydropteridine diphosphokinase,,
51134913,Nc1ccccc1NC(=O)c1ccc(cc1)C(=O)NCCNc1nonc1\C(Nc1ccc(F)c(Br)c1)=N\O,"InChI=1S/C25H22BrFN8O4/c26-17-13-16(9-10-18(17)27)31-23(33-38)21-22(35-39-34-21)29-11-12-30-24(36)14-5-7-15(8-6-14)25(37)32-20-4-2-1-3-19(20)28/h1-10,13,38H,11-12,28H2,(H,29,35)(H,30,36)(H,31,33)(H,32,37)",SVRNWBRVAJUUOX-UHFFFAOYSA-N,50465399,CHEMBL4291940,"Indoleamine 2,3-dioxygenase 1",Homo sapiens,
325148,CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3cnc(OC[C@@H]4CCN(CC(F)F)C4)c(Cl)c3)c(Oc3cccc4[nH]ncc34)c2)=C(C1)c1ccc(Cl)cc1,"InChI=1S/C45H49Cl2F2N7O5S/c1-45(2)14-12-31(36(22-45)30-6-8-32(46)9-7-30)26-54-16-18-56(19-17-54)33-10-11-35(41(20-33)61-40-5-3-4-39-37(40)24-51-52-39)43(57)53-62(58,59)34-21-38(47)44(50-23-34)60-28-29-13-15-55(25-29)27-42(48)49/h3-11,20-21,23-24,29,42H,12-19,22,25-28H2,1-2H3,(H,51,52)(H,53,57)/t29-/m1/s1",XZUYDUXXQGLVOW-GDLZYMKVSA-N,178873,"US9125913, 445",Apoptosis regulator Bcl-2,,
831893,CCOc1cc(-c2ccc(nc2)N2CCC(NC(=O)CC(C)C)[C@H](O)C2)c2c(cnn2c1)C#N,"InChI=1S/C25H30N6O3/c1-4-34-19-10-20(25-18(11-26)13-28-31(25)14-19)17-5-6-23(27-12-17)30-8-7-21(22(32)15-30)29-24(33)9-16(2)3/h5-6,10,12-14,16,21-22,32H,4,7-9,15H2,1-3H3,(H,29,33)/t21?,22-/m1/s1",BUNUYDOXNGBTCX-FOIFJWKZSA-N,416209,"US10441581, Example 520",Proto-oncogene tyrosine-protein kinase receptor Ret [G810R],, 31.1
347013,CC(C)[C@H](Cc1ccc(cc1)C(F)(F)F)C(=O)NC[C@]1(NC(=O)NC1=O)C1CC1,"InChI=1S/C20H24F3N3O3/c1-11(2)15(9-12-3-5-14(6-4-12)20(21,22)23)16(27)24-10-19(13-7-8-13)17(28)25-18(29)26-19/h3-6,11,13,15H,7-10H2,1-2H3,(H,24,27)(H2,25,26,28,29)/t15-,19-/m0/s1",VXXYNKXMRXANKX-KXBFYZLASA-N,194645,"US9206139, 4",A disintegrin and metalloproteinase with thrombospondin motifs 4,Homo sapiens, 14
51365652,NS(=O)(=O)c1ccc(NC(=O)CSC(=S)N2CCN(Cc3ccc(F)cc3)CC2)cc1,"InChI=1S/C20H23FN4O3S3/c21-16-3-1-15(2-4-16)13-24-9-11-25(12-10-24)20(29)30-14-19(26)23-17-5-7-18(8-6-17)31(22,27)28/h1-8H,9-14H2,(H,23,26)(H2,22,27,28)",ABZBORHAEWIHGS-UHFFFAOYSA-N,50552015,CHEMBL4783836,Carbonic anhydrase 1,Homo sapiens,
50797642,Fc1ccc(Nc2nc(SCC#C)nc(-c3ccccc3)c2C#N)cc1,"InChI=1S/C20H13FN4S/c1-2-12-26-20-24-18(14-6-4-3-5-7-14)17(13-22)19(25-20)23-16-10-8-15(21)9-11-16/h1,3-11H,12H2,(H,23,24,25)",AHCYKMOPOMVXJE-UHFFFAOYSA-N,50075498,CHEMBL3415531,Lysine-specific histone demethylase 1A,Homo sapiens, 125000
720383,NC(=O)c1ccc(Oc2ccc3ncnc(N)c3n2)cc1,"InChI=1S/C14H11N5O2/c15-13-12-10(17-7-18-13)5-6-11(19-12)21-9-3-1-8(2-4-9)14(16)20/h1-7H,(H2,16,20)(H2,15,17,18)",ZEHWHWAIQZGFTH-UHFFFAOYSA-N,299577,"4-(4-aminopyrido [3,2-d]pyrimidin- 6-yl)oxybenzamide::US9592235, Example 346::US9855269, Compound 243",Mitogen-activated protein kinase kinase kinase kinase 4,Homo sapiens, 5000
50372022,FC(F)(F)c1ccccc1CNC(=O)[C@H](CCC(=O)N1CCN(CC1)C1CCCCC1)N1[C@H](\C=C\c2ccccc2)[C@H](N2[C@H](COC2=O)c2ccccc2)C1=O,"InChI=1S/C43H48F3N5O5/c44-43(45,46)34-19-11-10-16-32(34)28-47-40(53)36(22-23-38(52)49-26-24-48(25-27-49)33-17-8-3-9-18-33)50-35(21-20-30-12-4-1-5-13-30)39(41(50)54)51-37(29-56-42(51)55)31-14-6-2-7-15-31/h1-2,4-7,10-16,19-21,33,35-37,39H,3,8-9,17-18,22-29H2,(H,47,53)/b21-20+/t35-,36+,37-,39+/m1/s1",KFDDKHKLWGIBTA-FNCFBVQQSA-N,50202869,"(S)-N-(2-(trifluoromethyl)benzyl)-5-(4-cyclohexylpiperazin-1-yl)-5-oxo-2-((3S,4R)-2-oxo-3-((S)-2-oxo-4-phenyloxazolidin-3-yl)-4-((E)-styryl)azetidin-1-yl)pentanamide::CHEMBL394867",Vasopressin V1a receptor,,
1007392,FC(F)(F)c1cccc(n1)-c1nc(NC2CCC(F)(F)C2)nc(NC2CCC(F)(F)C2)n1,"InChI=1S/C19H19F7N6/c20-17(21)6-4-10(8-17)27-15-30-14(12-2-1-3-13(29-12)19(24,25)26)31-16(32-15)28-11-5-7-18(22,23)9-11/h1-3,10-11H,4-9H2,(H2,27,28,30,31,32)",JWMKUJAOIPXYIG-UHFFFAOYSA-N,279884,"US10028961, Compound 31::US10172864, Compound 31::US10946023, Compound 31",Isocitrate dehydrogenase [NADP] cytoplasmic [R132C],,<50
537046,Nc1ncnc2ccc(cc12)-c1ccc(CNc2ncccc2C(=O)NCc2cc(F)c(F)cc2F)s1,"InChI=1S/C26H19F3N6OS/c27-19-10-21(29)20(28)9-15(19)11-33-26(36)17-2-1-7-31-25(17)32-12-16-4-6-23(37-16)14-3-5-22-18(8-14)24(30)35-13-34-22/h1-10,13H,11-12H2,(H,31,32)(H,33,36)(H2,30,34,35)",BZKHSYKOMZCBKX-UHFFFAOYSA-N,281823,"2-({[5-(4-aminoquinazolin-6- yl)thiophen-2-yl]methyl}amino)- N-(2,4,5-trifluorobenzyl)pyridine- 3-carboxamide (TFA salt)::US10030016, Example 3.11",3-phosphoinositide-dependent protein kinase 1 [51-359],,<100
75221,CCC1(CC)NC(=O)N(CC(=O)Nc2sc3CCCc3c2C(N)=O)C1=O,"InChI=1S/C17H22N4O4S/c1-3-17(4-2)15(24)21(16(25)20-17)8-11(22)19-14-12(13(18)23)9-6-5-7-10(9)26-14/h3-8H2,1-2H3,(H2,18,23)(H,19,22)(H,20,25)",FECCIQFGKNBYBM-UHFFFAOYSA-N,40005,"2-[2-[4,4-diethyl-2,5-bis(oxidanylidene)imidazolidin-1-yl]ethanoylamino]-5,6-dihydro-4H-cyclopenta[b]thiophene-3-carboxamide::2-[[2-(4,4-diethyl-2,5-diketo-imidazolidin-1-yl)acetyl]amino]-5,6-dihydro-4H-cyclopenta[b]thiophene-3-carboxamide::2-[[2-(4,4-diethyl-2,5-dioxo-1-imidazolidinyl)-1-oxoethyl]amino]-5,6-dihydro-4H-cyclopenta[b]thiophene-3-carboxamide::2-[[2-(4,4-diethyl-2,5-dioxoimidazolidin-1-yl)acetyl]amino]-5,6-dihydro-4H-cyclopenta[b]thiophene-3-carboxamide::MLS000053183::SMR000067296::cid_2081875",Estrogen receptor,,<1562.5
50292587,COc1ccc(\C=C(/C)C(=O)c2cc(OC)c(OC)c(OC)c2)cc1F,"InChI=1S/C20H21FO5/c1-12(8-13-6-7-16(23-2)15(21)9-13)19(22)14-10-17(24-3)20(26-5)18(11-14)25-4/h6-11H,1-5H3/b12-8+",HOTCJDIFBMQISC-XYOKQWHBSA-N,50159300,"(E)-3-(3''-Fluoro-4''-methoxyphenyl)-2-methyl-1-(3',4',5'-trimethoxyphenyl)prop-2-en-1-one::(E)-3-(3-Fluoro-4-methoxy-phenyl)-2-methyl-1-(3,4,5-trimethoxy-phenyl)-propenone::CHEMBL426644",Tubulin beta-1 chain,Homo sapiens, 650
50161729,[O-][N+](=O)c1cc2c(OCCC3CCCCN3)c(-c3ccc(Cl)s3)c(=[OH+])[n-]c2cc1Cl,"InChI=1S/C20H19Cl2N3O4S/c21-13-10-14-12(9-15(13)25(27)28)19(29-8-6-11-3-1-2-7-23-11)18(20(26)24-14)16-4-5-17(22)30-16/h4-5,9-11,23H,1-3,6-8H2,(H,24,26)",NOQHMKNICUECRI-UHFFFAOYSA-N,50090580,7-Chloro-3-(5-chloro-thiophen-2-yl)-6-nitro-4-(2-piperidin-2-yl-ethoxy)-1H-quinolin-2-one::CHEMBL416459,Gonadotropin-releasing hormone receptor,Rattus norvegicus, 23
1237711,CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1,"InChI=1S/C25H34FN3O2/c1-19(2)18-31-24-10-6-20(7-11-24)16-27-25(30)29(23-12-14-28(3)15-13-23)17-21-4-8-22(26)9-5-21/h4-11,19,23H,12-18H2,1-3H3,(H,27,30)",RKEWSXXUOLRFBX-UHFFFAOYSA-N,139370,"ACP-103::Nuplazid::Pimavanserin::Pimavanserin hydrochloride::Pimavanserin tartrate::WO2023288027, Cmpd PIMA::bis(1-(4-fluorobenzyl)-1-(1-methylpiperidin-4-yl)-3-(4-(2-methylpropoxy)benzyl)urea) (2R,3R)-2,3-dihydroxybutanedioate",BDBP50000595,,
51017369,CO[C@H]1CC[C@@](C)(CC1)N1CCC(CC1)N1C(=O)Cc2ccc(C)cc12,"InChI=1S/C22H32N2O2/c1-16-4-5-17-15-21(25)24(20(17)14-16)18-8-12-23(13-9-18)22(2)10-6-19(26-3)7-11-22/h4-5,14,18-19H,6-13,15H2,1-3H3/t19-,22-",ZCMNJNNUKNOUAH-XYWHTSSQSA-N,50416735,CHEMBL1223805,Muscarinic acetylcholine receptor M5,Homo sapiens,
834650,FC(F)(F)C1(CC1)N[C@@H]1CC[C@H](C1)C(=O)N1Cc2cccnc2Nc2ccc(cc12)N1CCOCC1,"InChI=1S/C26H30F3N5O2/c27-26(28,29)25(7-8-25)32-19-4-3-17(14-19)24(35)34-16-18-2-1-9-30-23(18)31-21-6-5-20(15-22(21)34)33-10-12-36-13-11-33/h1-2,5-6,9,15,17,19,32H,3-4,7-8,10-14,16H2,(H,30,31)/t17-,19-/m1/s1",WVEWIQHICOTLQU-IEBWSBKVSA-N,416334,"(1S,3S)-3-[(8-morpholin-4-yl- 5,11-dihydro-6H-pyrido[2,3- b][1,5]benzodiazepin-6- yl)carbonyl]-N-[1- (trifluoromethyl)cyclopropyl]- cyclopentanamine::US10442819, Example 478",Isocitrate dehydrogenase [NADP] cytoplasmic [R132H],, 185
50717896,Cc1ccccc1C(OC1CN(C1)C(=O)N1CCCCC1)c1cccnc1Cl,"InChI=1S/C22H26ClN3O2/c1-16-8-3-4-9-18(16)20(19-10-7-11-24-21(19)23)28-17-14-26(15-17)22(27)25-12-5-2-6-13-25/h3-4,7-11,17,20H,2,5-6,12-15H2,1H3",OGJPXBQFYXPTNO-UHFFFAOYSA-N,50364242,CHEMBL1952074,Fatty-acid amide hydrolase 1,, 206000
50952777,CC(C)N(C)[C@@H]1CC[C@H](NC(=O)Cc2nc3cccc(c3[nH]2)C(F)(F)F)[C@H](CS(=O)(=O)c2ccccc2)C1,"InChI=1S/C27H33F3N4O3S/c1-17(2)34(3)19-12-13-22(18(14-19)16-38(36,37)20-8-5-4-6-9-20)32-25(35)15-24-31-23-11-7-10-21(26(23)33-24)27(28,29)30/h4-11,17-19,22H,12-16H2,1-3H3,(H,31,33)(H,32,35)/t18-,19+,22-/m0/s1",MGFMKXDGFJBKMH-JQVVWYNYSA-N,50391011,CHEMBL2088211,C-C chemokine receptor type 2,, 51
51245639,COc1cccc(c1)-c1ccc(C[C@H](CC(O)=O)NC(=O)CCC(O)=O)cc1,"InChI=1S/C21H23NO6/c1-28-18-4-2-3-16(12-18)15-7-5-14(6-8-15)11-17(13-21(26)27)22-19(23)9-10-20(24)25/h2-8,12,17H,9-11,13H2,1H3,(H,22,23)(H,24,25)(H,26,27)/t17-/m1/s1",CYUXFAHRLNDKQJ-QGZVFWFLSA-N,50509653,CHEMBL4518025,Neprilysin,, 60
241541,C[C@]1(CO[C@](C)(C(N)=N1)C(F)(F)F)c1cccc(NC(=O)c2ncc(cc2Cl)C#N)n1,"InChI=1S/C19H16ClF3N6O2/c1-17(9-31-18(2,16(25)29-17)19(21,22)23)12-4-3-5-13(27-12)28-15(30)14-11(20)6-10(7-24)8-26-14/h3-6,8H,9H2,1-2H3,(H2,25,29)(H,27,28,30)/t17-,18+/m0/s1",DPIDWDAWIQYLLV-ZWKOTPCHSA-N,116244,"US10035794, Example 20::US10683287, Example 20::US8637508, 20",Beta-secretase 2,, 41
51417149,CN(c1cccc2cccnc12)S(=O)(=O)c1cnc2ccsc2c1,"InChI=1S/C17H13N3O2S2/c1-20(15-6-2-4-12-5-3-8-18-17(12)15)24(21,22)13-10-16-14(19-11-13)7-9-23-16/h2-11H,1H3",LQTUYMXYSMGJHQ-UHFFFAOYSA-N,50572430,CHEMBL4855759,ATP-dependent translocase ABCB1,, 29100
50975007,C[C@@H](O)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O,"InChI=1S/C37H74N18O9/c1-20(40)28(57)50-22(10-3-5-15-38)29(58)51-24(12-7-17-47-35(41)42)30(59)52-25(13-8-18-48-36(43)44)32(61)55-27(21(2)56)33(62)53-23(11-4-6-16-39)31(60)54-26(34(63)64)14-9-19-49-37(45)46/h20-27,56H,3-19,38-40H2,1-2H3,(H,50,57)(H,51,58)(H,52,59)(H,53,62)(H,54,60)(H,55,61)(H,63,64)(H4,41,42,47)(H4,43,44,48)(H4,45,46,49)/t20-,21+,22-,23-,24-,25-,26-,27-/m0/s1",QKXIYITZZUBQFY-XTZJLTRESA-N,50399753,CHEMBL2179835,Furin,Homo sapiens,
50391363,N#Cc1ccc(cc1)C1CCCc2cncn12,"InChI=1S/C14H13N3/c15-8-11-4-6-12(7-5-11)14-3-1-2-13-9-16-10-17(13)14/h4-7,9-10,14H,1-3H2",CLPFFLWZZBQMAO-UHFFFAOYSA-N,8611,"4-{5H,6H,7H,8H-imidazo[1,5-a]pyridin-5-yl}benzonitrile::CHEMBL468419::CHEMBL9298::Fadrozole::US9271963, Fadrozole",Aromatase,Homo sapiens, 52
50534346,COCCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3F)c2cc1NC(=O)[C@@H]1CCCN1C(=O)C=C,"InChI=1S/C25H24ClF2N5O4/c1-3-21(34)33-8-4-5-19(33)25(35)32-18-11-14-17(12-20(18)37-10-9-36-2)29-13-30-24(14)31-16-7-6-15(27)22(26)23(16)28/h3,6-7,11-13,19H,1,4-5,8-10H2,2H3,(H,32,35)(H,29,30,31)/t19-/m0/s1",JTLHPKSZESHKCP-IBGZPJMESA-N,50300027,"(S)-1-Acryloyl-N-[4-(3-chloro-2,4-difluorophenylamino)-7-(2-methoxyethoxy)quinazolin-6-yl]pyrrolidine-2-carboxamide::CHEMBL569880",Fibroblast growth factor receptor 1,Homo sapiens,>10
50654241,CCC(=O)NC(c1ccc(Br)o1)c1cc(Cl)c2cccnc2c1O,"InChI=1S/C17H14BrClN2O3/c1-2-14(22)21-15(12-5-6-13(18)24-12)10-8-11(19)9-4-3-7-20-16(9)17(10)23/h3-8,15,23H,2H2,1H3,(H,21,22)",RRKCLBNDKRYVRP-UHFFFAOYSA-N,50350412,CHEMBL1410433,Polyunsaturated fatty acid lipoxygenase ALOX12,Homo sapiens,>75000
384893,CC(C)(C)c1ccc(Nc2cccc(c2)C(O)=O)cc1,"InChI=1S/C17H19NO2/c1-17(2,3)13-7-9-14(10-8-13)18-15-6-4-5-12(11-15)16(19)20/h4-11,18H,1-3H3,(H,19,20)",KMYHPILDAZPTQP-UHFFFAOYSA-N,50337286,"3-[N-(4-tert-butylphenyl)amino]benzoic acid::CHEMBL1682205::US9271961, 10",Prostaglandin G/H synthase 2,Homo sapiens,>100000
488445,Cc1ccc(SCCNC(=O)c2ccc(Oc3cc4OCCC(C(O)=O)c4cc3Cl)cc2)cc1,"InChI=1S/C26H24ClNO5S/c1-16-2-8-19(9-3-16)34-13-11-28-25(29)17-4-6-18(7-5-17)33-24-15-23-21(14-22(24)27)20(26(30)31)10-12-32-23/h2-9,14-15,20H,10-13H2,1H3,(H,28,29)(H,30,31)",IAZGYHIMCGXVMM-UHFFFAOYSA-N,231205,"Sodium 6-chloro-7-(4-(2-(p-tolylthio)ethylcarbamoyl)phenoxy)chroman-4-carboxylate::US9556139, 112",Prostaglandin D2 receptor 2,Homo sapiens,
50813477,CC(C)C[C@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1ccc(cc1)N=C(N)N)NC(=O)C1CCCN1C(=O)[C@@H](CCCCN)NC(=O)CN(CCN(CCN(CC(O)=O)CC(O)=O)CC(O)=O)CC(O)=O)C(C)(C)C)C(O)=O,"InChI=1S/C67H104N18O19/c1-39(2)31-48(64(103)104)79-61(100)56(67(3,4)5)80-58(97)47(33-41-17-21-43(86)22-18-41)78-60(99)50-14-10-26-85(50)63(102)45(12-8-24-73-65(69)70)76-57(96)46(32-40-15-19-42(20-16-40)74-66(71)72)77-59(98)49-13-9-25-84(49)62(101)44(11-6-7-23-68)75-51(87)34-82(36-53(90)91)29-27-81(35-52(88)89)28-30-83(37-54(92)93)38-55(94)95/h15-22,39,44-50,56,86H,6-14,23-38,68H2,1-5H3,(H,75,87)(H,76,96)(H,77,98)(H,78,99)(H,79,100)(H,80,97)(H,88,89)(H,90,91)(H,92,93)(H,94,95)(H,103,104)(H4,69,70,73)(H4,71,72,74)/t44-,45+,46+,47+,48+,49?,50+,56-/m1/s1",NGHVUEJSKRCXOE-KMSSUWJSSA-N,50130889,CHEMBL408387::DTPA-DLys-Pro-Arg-Phe(4-Gu)-Arg-Pro-Tyr-tBuGly-Leu-OH,Neurotensin receptor type 1,Homo sapiens, 24.6
51332901,Nc1c2CCCCc2nc2ccccc12,"InChI=1S/C13H14N2/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13/h1,3,5,7H,2,4,6,8H2,(H2,14,15)",YLJREFDVOIBQDA-UHFFFAOYSA-N,8961,"1,2,3,4-tetrahydro-9-acridinamine::1,2,3,4-tetrahydroacridin-9-amine::9-THA::9-amino-1,2,3,4-tetrahydroacridine (THA)::CHEMBL1337960::CHEMBL95::Cognex::Tacrine::Tracine::US8999994, Tacrine::cid_1935::tacrine.HCl",Cholinesterase,, 45
902332,CC(C)(C)CN1CCCC(CC1)C(=O)Nc1cc2cc(ccc2cn1)-c1cnccn1,"InChI=1S/C25H31N5O/c1-25(2,3)17-30-11-4-5-18(8-12-30)24(31)29-23-14-21-13-19(6-7-20(21)15-28-23)22-16-26-9-10-27-22/h6-7,9-10,13-16,18H,4-5,8,11-12,17H2,1-3H3,(H,28,29,31)",AYSRTXGJMRWTBE-UHFFFAOYSA-N,442901,"US10653688, Compound 82",Dual specificity tyrosine-phosphorylation-regulated kinase 1A,Homo sapiens,
502039,O=C1COCCN1c1ccc(cc1)N1CCN(CCCc2c[nH]c3ccc(cc23)C#N)CC1,"InChI=1S/C26H29N5O2/c27-17-20-3-8-25-24(16-20)21(18-28-25)2-1-9-29-10-12-30(13-11-29)22-4-6-23(7-5-22)31-14-15-33-19-26(31)32/h3-8,16,18,28H,1-2,9-15,19H2",PRQJLVOEUIWDMJ-UHFFFAOYSA-N,264095,"3-(3-(4-(4-(3-oxomorpholino)phenyl)piperazin-1-yl)propyl)-1H-indole-5-carbonitrile::US9714232, 8",5-hydroxytryptamine receptor 1A,Rattus norvegicus, 10.00
358835,Oc1c(C=O)cc(cc1N(=O)=O)-c1cccc2ncccc12,"InChI=1S/C16H10N2O4/c19-9-11-7-10(8-15(16(11)20)18(21)22)12-3-1-5-14-13(12)4-2-6-17-14/h1-9,20H",LFFOXNMZCQIGTC-UHFFFAOYSA-N,111226,"US8614253, 26-13::US9241942, 26-13",Serine/threonine-protein kinase/endoribonuclease IRE1,Homo sapiens, 333
50267038,CCCCN(CC(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)C(=O)[C@@H]1CCSCCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1,"InChI=1S/C45H71N11O11S/c1-6-8-18-56(25-38(61)51-31(21-26(3)4)40(62)49-24-36(48)59)45(67)30-16-19-68-20-17-37(60)50-32(22-28-12-10-9-11-13-28)43(65)55-39(27(5)7-2)44(66)52-29(14-15-34(46)57)41(63)54-33(23-35(47)58)42(64)53-30/h9-13,26-27,29-33,39H,6-8,14-25H2,1-5H3,(H2,46,57)(H2,47,58)(H2,48,59)(H,49,62)(H,50,60)(H,51,61)(H,52,66)(H,53,64)(H,54,63)(H,55,65)/t27-,29-,30-,31-,32-,33-,39-/m0/s1",DSODNURHHWNVSF-UNGLXHEOSA-N,50044735,CHEMBL3354584,Vasopressin V2 receptor,,
50897214,O=C1C[C@H](C(=O)N1)c1c[nH]c2ccccc12,,,312065,"US9603836, Compound 4a::US9949951, 4a","Indoleamine 2,3-dioxygenase 1",Homo sapiens, 83000
926664,Cc1cc(C(=O)Nc2ccc(C)c(c2)-c2cc(N3CCOCC3)c(=O)n(C)c2)n(C)n1,"InChI=1S/C23H27N5O3/c1-15-5-6-18(24-22(29)20-11-16(2)25-27(20)4)13-19(15)17-12-21(23(30)26(3)14-17)28-7-9-31-10-8-28/h5-6,11-14H,7-10H2,1-4H3,(H,24,29)",MVCSKNRBGKDLBT-UHFFFAOYSA-N,77944,"US10245267, Example 381::US10709712, Example 381::US9694016, 381",RAF proto-oncogene serine/threonine-protein kinase,Homo sapiens, 25.5
413397,Cc1ccc(NS(=O)(=O)c2ccc(C)cc2)cc1,"InChI=1S/C14H15NO2S/c1-11-3-7-13(8-4-11)15-18(16,17)14-9-5-12(2)6-10-14/h3-10,15H,1-2H3",GPLXRIVINNIQFY-UHFFFAOYSA-N,237281,"Carbonic anhydrase inhibitors (CAIs), 1",Carbonic anhydrase 1,Homo sapiens,
51185496,CCOC(=O)C1=C(C)NC(=S)NC1c1ccccc1,"InChI=1S/C14H16N2O2S/c1-3-18-13(17)11-9(2)15-14(19)16-12(11)10-7-5-4-6-8-10/h4-8,12H,3H2,1-2H3,(H2,15,16,19)",QMFBVGUFEGVPNG-UHFFFAOYSA-N,175352,"Ethyl 6-methyl-4-phenyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (7)",Dihydrofolate reductase,Homo sapiens, 580
50563735,C[C@H]1CN(CCN1C(=O)c1ccc2cc[nH]c2c1)C(=O)c1ccc(cc1)-c1ccccc1C(F)(F)F,"InChI=1S/C28H24F3N3O2/c1-18-17-33(14-15-34(18)27(36)22-11-8-20-12-13-32-25(20)16-22)26(35)21-9-6-19(7-10-21)23-4-2-3-5-24(23)28(29,30)31/h2-13,16,18,32H,14-15,17H2,1H3/t18-/m0/s1",CZUGKEKGXKWONC-SFHVURJKSA-N,50312780,(S)-(4-(1H-indole-6-carbonyl)-3-methylpiperazin-1-yl)(2'-(trifluoromethyl)biphenyl-4-yl)methanone::CHEMBL1080735,D(3) dopamine receptor,,
866134,CC(C)c1c([nH]c2cc(C)c(nc12)C1CCN(CC(C)(C)O)CC1)-c1cc(C)c2ncnn2c1,"InChI=1S/C27H36N6O/c1-16(2)22-24(20-11-18(4)26-28-15-29-33(26)13-20)30-21-12-17(3)23(31-25(21)22)19-7-9-32(10-8-19)14-27(5,6)34/h11-13,15-16,19,30,34H,7-10,14H2,1-6H3",PVBXOQLQMLQDEG-UHFFFAOYSA-N,428137,"US10544143, Example 572::US10730877, Example 572::US11053244, Example 572",Toll-like receptor 7,, 4.60
50319732,COc1ccccc1N1CCC(CC1)C(=O)Nc1ccc(OC)c(c1)N1CCN(C)CC1,"InChI=1S/C25H34N4O3/c1-27-14-16-29(17-15-27)22-18-20(8-9-24(22)32-3)26-25(30)19-10-12-28(13-11-19)21-6-4-5-7-23(21)31-2/h4-9,18-19H,10-17H2,1-3H3,(H,26,30)",SYERHDJULLPKRY-UHFFFAOYSA-N,50173093,1-(2-Methoxy-phenyl)-piperidine-4-carboxylic acid [4-methoxy-3-(4-methyl-piperazin-1-yl)-phenyl]-amide::CHEMBL195927,D(1B) dopamine receptor,,
1214578,FC(F)(F)c1ccc(o1)C(=O)NC1CC2(C1)CC(C2)c1nc2cc(Cl)ccc2o1,"InChI=1S/C20H16ClF3N2O3/c21-11-1-2-14-13(5-11)26-18(29-14)10-6-19(7-10)8-12(9-19)25-17(27)15-3-4-16(28-15)20(22,23)24/h1-5,10,12H,6-9H2,(H,25,27)",CBPJFNVRDKJMNZ-UHFFFAOYSA-N,576370,"N-[6-(5-chloro-1,3-benzoxazol-2-yl)spiro[3.3]heptan-2-yl]-5-(trifluoromethyl)furan-2-carboxamide::WO2022112207, Example 1",External core antigen,, 2291
51194400,NCCCC(O)=O,"InChI=1S/C4H9NO2/c5-3-1-2-4(6)7/h1-3,5H2,(H,6,7)",BTCSSZJGUNDROE-UHFFFAOYSA-N,24183,"4-amino-n-[2,3-3H]butyric acid::4-aminobutanoic acid::Aminalon::CHEMBL96::GABA::Gamma-Aminobutyric acid::[3H]GABA::cid_119",Sodium- and chloride-dependent GABA transporter 3,Mus musculus, 11482
290680,COc1ncc(cn1)-c1cc2c(N[C@@H]3CN(C[C@@H]3CF)C(=O)C3(CC3)C#N)c(cnn2c1)C(N)=O,"InChI=1S/C23H23FN8O3/c1-35-22-27-6-15(7-28-22)13-4-18-19(16(20(26)33)8-29-32(18)10-13)30-17-11-31(9-14(17)5-24)21(34)23(12-25)2-3-23/h4,6-8,10,14,17,30H,2-3,5,9,11H2,1H3,(H2,26,33)/t14-,17+/m0/s1",GVCOQGZPNLFXGH-WMLDXEAASA-N,151073,"US8987268, 280",Tyrosine-protein kinase JAK1,Homo sapiens, 0.9
50469685,CC(=O)c1cc(-c2ccccc2CO)c2cc(C)ccn12,"InChI=1S/C18H17NO2/c1-12-7-8-19-17(13(2)21)10-16(18(19)9-12)15-6-4-3-5-14(15)11-20/h3-10,20H,11H2,1-2H3",ROFXVCWNRLBADO-UHFFFAOYSA-N,50148282,CHEMBL3771216,Bromodomain adjacent to zinc finger domain protein 2A,, 1000
50858866,N[C@@H]([C@H]1CC(O)=NO1)C(O)=O,"InChI=1S/C5H8N2O4/c6-4(5(9)10)2-1-3(8)7-11-2/h2,4H,1,6H2,(H,7,8)(H,9,10)/t2-,4+/m1/s1",NTHMUJMQOXQYBR-FONMRSAGSA-N,50373182,CHEMBL260122,Metabotropic glutamate receptor 2,,
323584,C[C@H]1COCCN1C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2OCOc2cc1-c1cc(C(=O)N(c2ccc(O)cc2)c2ccc3n(C)ccc3c2)c2CCCCn12,"InChI=1S/C47H47N5O6/c1-30-28-56-20-19-49(30)27-36-21-31-7-3-4-8-33(31)26-51(36)46(54)39-25-45-44(57-29-58-45)24-38(39)43-23-40(42-9-5-6-17-50(42)43)47(55)52(34-10-13-37(53)14-11-34)35-12-15-41-32(22-35)16-18-48(41)2/h3-4,7-8,10-16,18,22-25,30,36,53H,5-6,9,17,19-21,26-29H2,1-2H3/t30-,36-/m0/s1",DXOJGKZHDBGBOL-ARPOTICCSA-N,177798,"US9120791, Example 16::US9603854, 16",Apoptosis regulator Bcl-2,, 18
50781973,COc1cccc(c1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1ccc(cc1)C(=O)N(C(C)C)C(C)C,"InChI=1S/C30H43N3O2/c1-9-17-31-19-24(7)32(20-23(31)6)29(27-11-10-12-28(18-27)35-8)25-13-15-26(16-14-25)30(34)33(21(2)3)22(4)5/h9-16,18,21-24,29H,1,17,19-20H2,2-8H3/t23-,24+,29+/m1/s1",CYICNDXWTYTFMA-UQARTHHBSA-N,50059823,"4-[(S)-((2S,5R)-4-Allyl-2,5-dimethyl-piperazin-1-yl)-(3-methoxy-phenyl)-methyl]-N,N-diisopropyl-benzamide::CHEMBL102059",Delta-type opioid receptor,Rattus norvegicus, 344
1027652,CCS(=O)(=O)c1ccc2C(N(Cc2c1)C(=O)C1(CC1)C#N)C(=O)Nc1ccc(cc1)C(O)(C(F)(F)F)C(F)(F)F,"InChI=1S/C25H21F6N3O5S/c1-2-40(38,39)17-7-8-18-14(11-17)12-34(21(36)22(13-32)9-10-22)19(18)20(35)33-16-5-3-15(4-6-16)23(37,24(26,27)28)25(29,30)31/h3-8,11,19,37H,2,9-10,12H2,1H3,(H,33,35)",ZGKQACVUJQAEHT-UHFFFAOYSA-N,493588,"US10988445, Example 105",Nuclear receptor ROR-gamma,, 398
201561,COc1ccc(C(=O)N2CCC3(CC2)N(CN(CC(=O)NCCc2ccc(Cl)cc2Cl)C3=O)c2ccccc2)c(OC)c1,"InChI=1S/C32H34Cl2N4O5/c1-42-25-10-11-26(28(19-25)43-2)30(40)36-16-13-32(14-17-36)31(41)37(21-38(32)24-6-4-3-5-7-24)20-29(39)35-15-12-22-8-9-23(33)18-27(22)34/h3-11,18-19H,12-17,20-21H2,1-2H3,(H,35,39)",TWOVSEVREOPZGM-UHFFFAOYSA-N,92887,"Triazaspirobenzyl, 5",Dihydrolipoyl dehydrogenase,Mycobacterium tuberculosis, 2e+3
51310897,COC(=O)N[C@H](CN1CCC[C@H]1c1ncc([nH]1)-c1ccc2c3[C@@H](C)c4ccc(cc4Oc3ccc2c1)-c1cnc([nH]1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C1CCOCC1)C1CCOCC1,"InChI=1S/C50H60N8O8/c1-29-35-11-8-34(38-27-52-47(54-38)41-7-5-19-58(41)48(59)45(56-50(61)63-3)31-16-22-65-23-17-31)25-43(35)66-42-13-10-32-24-33(9-12-36(32)44(29)42)37-26-51-46(53-37)40-6-4-18-57(40)28-39(55-49(60)62-2)30-14-20-64-21-15-30/h8-13,24-27,29-31,39-41,45H,4-7,14-23,28H2,1-3H3,(H,51,53)(H,52,54)(H,55,60)(H,56,61)/t29-,39+,40-,41-,45-/m0/s1",XYYNLRWFHZDVKB-PWCZPXJNSA-N,50531958,CHEMBL4575633,Nonstructural protein 5A,,
380383,CC(C)(CN1CCOCC1)NC(=O)c1ccc(NC(=O)N2Cc3ccc(F)cc3C2)cc1,"InChI=1S/C24H29FN4O3/c1-24(2,16-28-9-11-32-12-10-28)27-22(30)17-4-7-21(8-5-17)26-23(31)29-14-18-3-6-20(25)13-19(18)15-29/h3-8,13H,9-12,14-16H2,1-2H3,(H,26,31)(H,27,30)",TVASYQRZUCEKCD-UHFFFAOYSA-N,216213,"US9302989, 1094",Nicotinamide phosphoribosyltransferase,Homo sapiens, 44
50423265,CC1(C)Cc2nc(sc2C(=O)C1)-c1ccncc1,"InChI=1S/C14H14N2OS/c1-14(2)7-10-12(11(17)8-14)18-13(16-10)9-3-5-15-6-4-9/h3-6H,7-8H2,1-2H3",ZXTHGVQPYUJWIX-UHFFFAOYSA-N,50262357,"5,5-dimethyl-2-(pyridin-4-yl)-5,6-dihydrobenzo[d]thiazol-7(4H)-one::CHEMBL469057","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform",Homo sapiens, 35730
50226650,COC(=O)C[C@@H]1N(CCN(CC(=O)N[C@@H](CCCN=C(N)N)C(=O)c2nccs2)C1=O)S(=O)(=O)Cc1ccccc1,"InChI=1S/C25H33N7O7S2/c1-39-21(34)14-19-24(36)31(11-12-32(19)41(37,38)16-17-6-3-2-4-7-17)15-20(33)30-18(8-5-9-29-25(26)27)22(35)23-28-10-13-40-23/h2-4,6-7,10,13,18-19H,5,8-9,11-12,14-16H2,1H3,(H,30,33)(H4,26,27,29)/t18-,19-/m0/s1",OVBHVFLKMRIMFI-OALUTQOASA-N,50228755,((S)-4-{[(S)-4-Guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-methyl}-3-oxo-1-phenylmethanesulfonyl-piperazin-2-yl)-acetic acid methyl ester::CHEMBL272961::methyl 2-((S)-1-(benzylsulfonyl)-4-(2-((S)-5-guanidino-1-oxo-1-(thiazol-2-yl)pentan-2-ylamino)-2-oxoethyl)-3-oxopiperazin-2-yl)acetate,Coagulation factor X,Homo sapiens, 85.0
50595806,CCCCc1nc2n[nH]cc2c2nc(nn12)-c1cccc(Cl)c1,"InChI=1S/C16H15ClN6/c1-2-3-7-13-19-15-12(9-18-21-15)16-20-14(22-23(13)16)10-5-4-6-11(17)8-10/h4-6,8-9H,2-3,7H2,1H3,(H,18,21)",GJFLKCHEPONTBP-UHFFFAOYSA-N,50149117,"5-Butyl-2-(3-chloro-phenyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine::CHEMBL124900",Adenosine receptor A3,Homo sapiens,<10
122156,COc1cc(ccc1O)-c1nc(c([nH]1)-c1ccccc1)-c1ccccc1,"InChI=1S/C22H18N2O2/c1-26-19-14-17(12-13-18(19)25)22-23-20(15-8-4-2-5-9-15)21(24-22)16-10-6-3-7-11-16/h2-14,25H,1H3,(H,23,24)",GVVMEVSFLBMIMJ-UHFFFAOYSA-N,65837,"4-(4,5-diphenyl-1,3-dihydroimidazol-2-ylidene)-2-methoxy-1-cyclohexa-2,5-dienone::4-(4,5-diphenyl-1,3-dihydroimidazol-2-ylidene)-2-methoxy-cyclohexa-2,5-dien-1-one::4-(4,5-diphenyl-1,3-dihydroimidazol-2-ylidene)-2-methoxycyclohexa-2,5-dien-1-one::4-(4,5-diphenyl-4-imidazolin-2-ylidene)-2-methoxy-cyclohexa-2,5-dien-1-one::SR-01000442018-2::cid_5337430",NADPH oxidase 1,Homo sapiens, 1810
50068749,CC1(C)[C@@H]2CC[C@@]1(CS(=O)(=O)N1CCC3(CCc4ccccc34)CC1)[C@H](C2)NC(=O)Cc1ccccc1,"InChI=1S/C31H40N2O3S/c1-29(2)25-13-15-31(29,27(21-25)32-28(34)20-23-8-4-3-5-9-23)22-37(35,36)33-18-16-30(17-19-33)14-12-24-10-6-7-11-26(24)30/h3-11,25,27H,12-22H2,1-2H3,(H,32,34)/t25-,27+,31-/m1/s1",SOFJTVINDOUOCN-YHZWXPKMSA-N,50043132,"1N-[7,7-dimethyl-1-spiro[2,3-dihydro-1H-indene-1,4'-(hexahydropyridine)]-1-ylsulfonylmethyl-(1S,2S,4R)-bicyclo[2.2.1]hept-2-yl]-2-phenylacetamide::CHEMBL435815",Oxytocin receptor,Rattus, 250
51318886,CCCS(=O)(=O)N1CCN(CC1)C1(CNC(=O)c2ccc(Cl)cc2Cl)CCCCC1,"InChI=1S/C21H31Cl2N3O3S/c1-2-14-30(28,29)26-12-10-25(11-13-26)21(8-4-3-5-9-21)16-24-20(27)18-7-6-17(22)15-19(18)23/h6-7,15H,2-5,8-14,16H2,1H3,(H,24,27)",UOVNJWABMVOCSX-UHFFFAOYSA-N,50427189,CHEMBL2324167,Sodium- and chloride-dependent glycine transporter 2,Homo sapiens,>75000
927937,CCC(F)(F)c1cc(ccn1)C(=O)Nc1cnc(C)c(c1)-c1cc(NCCO)nc(c1)N1CCOCC1,"InChI=1S/C26H30F2N6O3/c1-3-26(27,28)22-12-18(4-5-29-22)25(36)32-20-15-21(17(2)31-16-20)19-13-23(30-6-9-35)33-24(14-19)34-7-10-37-11-8-34/h4-5,12-16,35H,3,6-11H2,1-2H3,(H,30,33)(H,32,36)",KLZDAZKIRBISQK-UHFFFAOYSA-N,88024,"US10245267, Example 1058::US10709712, Example 1058::US9694016, 1058",Serine/threonine-protein kinase B-raf [V600E],, 10.8
1158844,Cc1nocc1C(=O)N[C@@H](Cc1ccccc1)C(=O)Nc1ccc(cc1)-c1c(C)cc[n+]([O-])c1C,"InChI=1S/C27H26N4O4/c1-17-13-14-31(34)19(3)25(17)21-9-11-22(12-10-21)28-27(33)24(15-20-7-5-4-6-8-20)29-26(32)23-16-35-30-18(23)2/h4-14,16,24H,15H2,1-3H3,(H,28,33)(H,29,32)/t24-/m0/s1",PRYVRJJHWPJKLA-DEOSSOPVSA-N,548083,"WO2022091056, Example 74",Interleukin-17 receptor A/,, 1530
50174582,CC(C)(C)[C@H](NC(=O)[C@H](CCCc1ccccc1)CC(=O)NO)C(=O)NC(C)(c1ccccc1)c1ccccc1,"InChI=1S/C33H41N3O4/c1-32(2,3)29(31(39)35-33(4,26-19-10-6-11-20-26)27-21-12-7-13-22-27)34-30(38)25(23-28(37)36-40)18-14-17-24-15-8-5-9-16-24/h5-13,15-16,19-22,25,29,40H,14,17-18,23H2,1-4H3,(H,34,38)(H,35,39)(H,36,37)/t25-,29-/m1/s1",DJWZYQPRHLAHAP-VAVYLYDRSA-N,50097229,"(R)-N*1*-[(S)-1-(1,1-Diphenyl-ethylcarbamoyl)-2,2-dimethyl-propyl]-N*4*-hydroxy-2-(3-phenyl-propyl)-succinamide::(R)-N1-((S)-1-(1,1-diphenylethylamino)-3,3-dimethyl-1-oxobutan-2-yl)-N4-hydroxy-2-(3-phenylpropyl)succinamide::CHEMBL152267",72 kDa type IV collagenase,, 26
51234515,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)CCOCCOCCOCCNC(=O)CCC1=[N+]2C(C=C1)=Cc1c(C)cc(C)n1[B-]2(F)F,"InChI=1S/C50H56BF2N7O7/c1-30-26-31(2)59-39(30)27-33-15-14-32(60(33)51(59,52)53)16-17-41(61)54-18-20-64-22-24-66-25-23-65-21-19-56(4)40-28-42-57-37-12-8-6-10-34(37)44-45-36(29-55-49(45)62)43-35-11-7-9-13-38(35)58(47(43)46(44)57)50(3,67-42)48(40)63-5/h6-15,26-27,40,42,48H,16-25,28-29H2,1-5H3,(H,54,61)(H,55,62)/t40-,42-,48-,50+/m1/s1",OSVUGUHRKMMBSE-INMRTLOZSA-N,50505542,CHEMBL4576489,Tyrosine-protein kinase ITK/TSK,Homo sapiens,
1031559,Cc1ccnc(NC(=O)C2CCOc3ccc(Cl)cc23)c1N,"InChI=1S/C16H16ClN3O2/c1-9-4-6-19-15(14(9)18)20-16(21)11-5-7-22-13-3-2-10(17)8-12(11)13/h2-4,6,8,11H,5,7,18H2,1H3,(H,19,20,21)",LBYWTRXCIGSDSO-UHFFFAOYSA-N,495303,MAT-POS-500f4700-1,Replicase polyprotein 1ab,, 71600
606035,Cc1ccc(NC(=O)c2cccc(c2)C(F)(F)F)cc1-c1cc(NCCO)nc(c1)C1(O)CCOCC1,"InChI=1S/C27H28F3N3O4/c1-17-5-6-21(32-25(35)18-3-2-4-20(13-18)27(28,29)30)16-22(17)19-14-23(26(36)7-11-37-12-8-26)33-24(15-19)31-9-10-34/h2-6,13-16,34,36H,7-12H2,1H3,(H,31,33)(H,32,35)",DKCVTJBBGDEEMG-UHFFFAOYSA-N,313678,"N-(3-(2-((2- hydroxyethyl) amino)-6-(4- hydroxytetrahydro- 2H-pyran-4- yl)pyridin-4-yl)-4- methylphenyl)-3- (trifluoromethyl) benzamide::US10167279, Example 304",RAF proto-oncogene serine/threonine-protein kinase,Homo sapiens, 383
258360,CC(C)(C)NC(=O)c1cnn2ccc(nc12)N1CC(F)(F)C[C@@H]1c1cccc(F)c1,"InChI=1S/C21H22F3N5O/c1-20(2,3)27-19(30)15-11-25-29-8-7-17(26-18(15)29)28-12-21(23,24)10-16(28)13-5-4-6-14(22)9-13/h4-9,11,16H,10,12H2,1-3H3,(H,27,30)/t16-/m1/s1",FNUKQFDNWARLGZ-MRXNPFEDSA-N,127686,"US10251889, Example 59::US10758542, Example 59::US8791123, 59::US9782415, Example 59::US9796724, Example 59",Tyrosine-protein kinase JAK2,Homo sapiens,>1000
50680503,CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,"InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1",ULXXDDBFHOBEHA-CWDCEQMOSA-N,50322823,"(S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide::AFATINIB::CHEMBL1173655::US10085983, Compound BIBW2992::US10196365, Afatinib::US10435400, Compound BIBW2992::US9388170, Afatinib::US9890168, Compound BIBW2992::WO2022090481, Example afatinib",Phosphatidylinositol 5-phosphate 4-kinase type-2 beta,Homo sapiens,
50983978,OC(=O)COCCCCC1=CCC[C@@H]1CNS(=O)(=O)c1ccc(F)cc1,"InChI=1S/C18H24FNO5S/c19-16-7-9-17(10-8-16)26(23,24)20-12-15-6-3-5-14(15)4-1-2-11-25-13-18(21)22/h5,7-10,15,20H,1-4,6,11-13H2,(H,21,22)/t15-/m1/s1",BLXVKGGCYLNORA-OAHLLOKOSA-N,50403458,CHEMBL21204,Thromboxane A2 receptor,, 200
332660,COCCN1CCN(CCn2ccc(Nc3ncc4CCc5nn(C)c(Cc6cccc(c6)-c6cnn(C)c6)c5-c4n3)n2)CC1,"InChI=1S/C33H41N11O/c1-40-23-27(22-35-40)25-6-4-5-24(19-25)20-29-31-28(38-41(29)2)8-7-26-21-34-33(37-32(26)31)36-30-9-10-44(39-30)16-15-42-11-13-43(14-12-42)17-18-45-3/h4-6,9-10,19,21-23H,7-8,11-18,20H2,1-3H3,(H,34,36,37,39)",DUJYZAINCFXLIR-UHFFFAOYSA-N,184385,"US9150578, I-033",Insulin receptor [964-1370],, 0.24
50368102,COc1ccc(C[C@H](NC(=O)[C@H](C)NC(=O)CN2CCOCC2)C(=O)N[C@@H](CC2CCCCC2)C(=O)[C@@]2(C)CO2)cc1,"InChI=1S/C22H16ClF2N3O/c1-27(20-9-5-3-7-17(20)25)13-21-26-18-11-10-14(24)12-15(18)22(29)28(21)19-8-4-2-6-16(19)23/h2-12H,13H2,1H3",YXEYBIQZOWYSHS-UHFFFAOYSA-N,50099662,CHEMBL3319481,Proteasome subunit beta type-8,Homo sapiens, 6.6
120489,CC(C)c1nnc(NC(=O)C2CCN(CC2)C(=O)c2ccco2)s1,"InChI=1S/C16H20N4O3S/c1-10(2)14-18-19-16(24-14)17-13(21)11-5-7-20(8-6-11)15(22)12-4-3-9-23-12/h3-4,9-11H,5-8H2,1-2H3,(H,17,19,21)",BIBGFWBTLNIJNO-UHFFFAOYSA-N,64354,"1-(2-furoyl)-N-(5-isopropyl-1,3,4-thiadiazol-2-yl)isonipecotamide::1-(Furan-2-carbonyl)-piperidine-4-carboxylic acid (5-isopropyl-[1,3,4]thiadiazol-2-yl)-amide::1-(furan-2-carbonyl)-N-(5-propan-2-yl-1,3,4-thiadiazol-2-yl)piperidine-4-carboxamide::1-(furan-2-ylcarbonyl)-N-(5-propan-2-yl-1,3,4-thiadiazol-2-yl)piperidine-4-carboxamide::1-[2-furanyl(oxo)methyl]-N-(5-propan-2-yl-1,3,4-thiadiazol-2-yl)-4-piperidinecarboxamide::MLS001218605::SMR000606324::cid_6497483",Heat shock factor protein 1,Mus musculus,
1254396,CCn1c(c2CC(C)(C)COC(=O)[C@@H]3CCCN(N3)C(=O)[C@H](Cc3nc(cs3)-c3ccc1c2c3)NC(=O)[C@H](C(C)C)N(C)C(=O)N1CCN([C@H](C)C1)C(=O)C=C)-c1cccnc1[C@H](C)OC,"InChI=1S/C49H65N9O7S/c1-11-41(59)57-22-21-55(26-30(57)5)48(63)54(9)43(29(3)4)45(60)52-37-24-40-51-38(27-66-40)32-17-18-39-34(23-32)35(44(56(39)12-2)33-15-13-19-50-42(33)31(6)64-10)25-49(7,8)28-65-47(62)36-16-14-20-58(53-36)46(37)61/h11,13,15,17-19,23,27,29-31,36-37,43,53H,1,12,14,16,20-22,24-26,28H2,2-10H3,(H,52,60)/t30-,31+,36+,37+,43+/m1/s1",XOCDWAKEQSWREH-NMNBTQAZSA-N,591753,"US11566007, Example A432",GTPase NRas [G12C],, 55.0
50300473,CN1CCN(CC1)C1=Cn2cccc2Sc2ccccc12,"InChI=1S/C17H19N3S/c1-18-9-11-19(12-10-18)15-13-20-8-4-7-17(20)21-16-6-3-2-5-14(15)16/h2-8,13H,9-12H2,1H3",JFLBTRDHDHTNGX-UHFFFAOYSA-N,50137976,9-(4-Methyl-piperazin-1-yl)-4-thia-10a-aza-benzo[f]azulene::CHEMBL367045,5-hydroxytryptamine receptor 2A,Rattus norvegicus,
50281884,CCOc1cc(NC(=O)Nc2ccc(Oc3ccccc3)cc2)ccc1C(=O)NCCN(CC)CC,"InChI=1S/C28H34N4O4/c1-4-32(5-2)19-18-29-27(33)25-17-14-22(20-26(25)35-6-3)31-28(34)30-21-12-15-24(16-13-21)36-23-10-8-7-9-11-23/h7-17,20H,4-6,18-19H2,1-3H3,(H,29,33)(H2,30,31,34)",YHJKXFOFXSGYAS-UHFFFAOYSA-N,50153213,CHEMBL188179::N-(2-Diethylamino-ethyl)-2-ethoxy-4-[3-(4-phenoxy-phenyl)-ureido]-benzamide,Melanin-concentrating hormone receptor 1,Homo sapiens, 240
50389545,C[C@@H]1CN(CC(=O)N2CC(C)(C)c3ccc(Cl)cc23)CCN1,"InChI=1S/C17H24ClN3O/c1-12-9-20(7-6-19-12)10-16(22)21-11-17(2,3)14-5-4-13(18)8-15(14)21/h4-5,8,12,19H,6-7,9-11H2,1-3H3/t12-/m1/s1",NUUUULZSGGTOOQ-GFCCVEGCSA-N,155969,"US9018214, 20",Baculoviral IAP repeat-containing protein 2,, 3700
1112489,Fc1cccc(CN2CCC2)c1CNc1cc(F)c(c(F)c1)S(=O)(=O)Nc1ccsn1,"InChI=1S/C20H19F3N4O2S2/c21-16-4-1-3-13(12-27-6-2-7-27)15(16)11-24-14-9-17(22)20(18(23)10-14)31(28,29)26-19-5-8-30-25-19/h1,3-5,8-10,24H,2,6-7,11-12H2,(H,25,26)",WBNDVYTWLBQVRX-UHFFFAOYSA-N,526081,"4-((2-(azetidin-1-ylmethyl)-6-fluorobenzyl)amino)-2,6-difluoro-N-(isothiazol-3-yl)benzenesulfonamide 2,2,2-trifluoroacetate::US11174268, Example 188",Sodium channel protein type 8 subunit alpha,Homo sapiens, 12.0
50223736,C[C@H](CNc1cccc(CCS(=O)(=O)NS(=O)(=O)c2ccccc2)c1)NC[C@H](O)c1cccc(Cl)c1,"InChI=1S/C25H30ClN3O5S2/c1-19(27-18-25(30)21-8-6-9-22(26)16-21)17-28-23-10-5-7-20(15-23)13-14-35(31,32)29-36(33,34)24-11-3-2-4-12-24/h2-12,15-16,19,25,27-30H,13-14,17-18H2,1H3/t19-,25+/m1/s1",IABOTPGCAUXJSC-CLOONOSVSA-N,50027818,CHEMBL347400,Beta-1 adrenergic receptor,Homo sapiens,
1047756,CCC(CC)n1cc(cn1)-c1nc(cn2nccc12)-c1cnn(CC2CCOCC2)c1,"InChI=1S/C23H29N7O/c1-3-20(4-2)29-15-19(12-26-29)23-22-5-8-24-30(22)16-21(27-23)18-11-25-28(14-18)13-17-6-9-31-10-7-17/h5,8,11-12,14-17,20H,3-4,6-7,9-10,13H2,1-2H3",AOFUXVYOOMKRGG-UHFFFAOYSA-N,325342,"4-(1-(pentan-3-yl)-1H- pyrazol-4-yl)-6-(1- ((tetrahydro-2H-pyran-4- yl)methyl)-1H-pyrazol-4- yl)pyrazolo[1,5-a]pyrazine::US10189845, Example 4::US10730880, Example 4::US11028093, Example 4",Tyrosine-protein kinase JAK2,Homo sapiens, 55
1125891,CCCOc1ccc(F)cc1C(=O)Nc1cccc(c1)-c1nnc(o1)-c1ccco1,"InChI=1S/C22H18FN3O4/c1-2-10-28-18-9-8-15(23)13-17(18)20(27)24-16-6-3-5-14(12-16)21-25-26-22(30-21)19-7-4-11-29-19/h3-9,11-13H,2,10H2,1H3,(H,24,27)",VLDNHSHMPWHLBE-UHFFFAOYSA-N,532120,"US11208404, Compound 126",Lysocardiolipin acyltransferase 1,, 110
528070,N#Cc1cc(ccc1OC1CCOCC1)-c1ncnc(Nc2ccc(Cn3ccnc3)cc2)n1,"InChI=1S/C25H23N7O2/c26-14-20-13-19(3-6-23(20)34-22-7-11-33-12-8-22)24-28-16-29-25(31-24)30-21-4-1-18(2-5-21)15-32-10-9-27-17-32/h1-6,9-10,13,16-17,22H,7-8,11-12,15H2,(H,28,29,30,31)",CMQXQMALEDSQQH-UHFFFAOYSA-N,277884,"5-(4-((4-((1H-imidazol-1-yl)methyl)phenyl)amino)-1,3,5-triazin-2-yl)-2-((tetrahydro-2H-pyran-4-yl)oxy)benzonitrile::US10040781, Example 106::US10253019, Example 106",Inhibitor of nuclear factor kappa-B kinase subunit epsilon,Homo sapiens, 4000
349658,Cc1cccc(CCc2cc(O)c(=O)[nH]n2)c1,"InChI=1S/C13H14N2O2/c1-9-3-2-4-10(7-9)5-6-11-8-12(16)13(17)15-14-11/h2-4,7-8H,5-6H2,1H3,(H,14,16)(H,15,17)",CGJFENTXONCNNT-UHFFFAOYSA-N,196660,"US10202399, Example 20::US9212147, 20",D-amino-acid oxidase,Homo sapiens, 4.6
853613,C[C@H](O)CNC(=O)c1cncnc1Nc1cc(ncc1C(C)=C)-c1cc(Cl)ccc1F,"InChI=1S/C22H21ClFN5O2/c1-12(2)16-10-26-19(15-6-14(23)4-5-18(15)24)7-20(16)29-21-17(9-25-11-28-21)22(31)27-8-13(3)30/h4-7,9-11,13,30H,1,8H2,2-3H3,(H,27,31)(H,25,26,28,29)/t13-/m0/s1",GVDHTILDVBEBLW-ZDUSSCGKSA-N,280339,"(S)-4-(2-(5-chloro-2-fluorophenyl)-5-(prop-1-en-2-yl)pyridin-4-ylamino)-N-(2-hydroxypropyl)pyrimidine-5-carboxamide::US10030004, Compound 4a::US10501436, Compound 4a::US11053216, Compound 4a",TGF-beta receptor type-1,, 28.1
50896607,Cn1cc(cn1)-c1cc2CCCN(c3nn(C4CCOCC4)c4CCN(Cc34)C(N)=O)c2cc1C(F)F,"InChI=1S/C26H31F2N7O2/c1-32-14-17(13-30-32)19-11-16-3-2-7-34(23(16)12-20(19)24(27)28)25-21-15-33(26(29)36)8-4-22(21)35(31-25)18-5-9-37-10-6-18/h11-14,18,24H,2-10,15H2,1H3,(H2,29,36)",UZNAWORAPXOQDJ-UHFFFAOYSA-N,50269848,CHEMBL4069831,Bromodomain-containing protein 4,, 9600
50597083,COc1ccc(cc1)N(C)c1ccc(NC2=NCCN2)cc1,"InChI=1S/C17H20N4O/c1-21(15-7-9-16(22-2)10-8-15)14-5-3-13(4-6-14)20-17-18-11-12-19-17/h3-10H,11-12H2,1-2H3,(H2,18,19,20)",RQTFZZMYMVELQT-UHFFFAOYSA-N,50223866,CHEMBL10044,Prostacyclin receptor,Homo sapiens,
51172820,CCn1c2ccccc2c2nnc(nc12)S(=O)(=O)CCCn1c2ccccc2[nH]c1=O,"InChI=1S/C21H20N6O3S/c1-2-26-16-10-5-3-8-14(16)18-19(26)23-20(25-24-18)31(29,30)13-7-12-27-17-11-6-4-9-15(17)22-21(27)28/h3-6,8-11H,2,7,12-13H2,1H3,(H,22,28)",XRSSSUGIVBGONB-UHFFFAOYSA-N,50481567,CHEMBL600648,"dTDP-4-dehydrorhamnose 3,5-epimerase",Mycobacterium tuberculosis H37Rv, 800
51348125,Cc1ccc(cc1)C1=CC(=O)C=CC1=O,"InChI=1S/C13H10O2/c1-9-2-4-10(5-3-9)12-8-11(14)6-7-13(12)15/h2-8H,1H3",RGVRHOACBLJGAW-UHFFFAOYSA-N,50545367,CHEMBL2252839,Histone-lysine N-methyltransferase SETD7,,>200000
51019907,CC(C)(C)n1cc2c(n1)nc(NC(=O)Nc1cccc(Cl)c1)n1nc(nc21)-c1ccco1,"InChI=1S/C21H19ClN8O2/c1-21(2,3)29-11-14-16(27-29)25-19(26-20(31)23-13-7-4-6-12(22)10-13)30-18(14)24-17(28-30)15-8-5-9-32-15/h4-11H,1-3H3,(H2,23,25,26,27,31)",BKGNWAOTMICOMA-UHFFFAOYSA-N,50094689,"1-(8-tert-Butyl-2-furan-2-yl-8H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-yl)-3-(3-chloro-phenyl)-urea::1-(8-tert-butyl-2-(furan-2-yl)-8H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-yl)-3-(3-chlorophenyl)urea::CHEMBL344724",Adenosine receptor A3,Homo sapiens,
51423560,Cc1cccc(N2CCN(CC2)C(=O)Cn2nc(C(=O)N3CCC(=O)CC3)c3[C@@H]4C[C@@H]4Cc23)c1C,"InChI=1S/C27H33N5O3/c1-17-4-3-5-22(18(17)2)29-10-12-30(13-11-29)24(34)16-32-23-15-19-14-21(19)25(23)26(28-32)27(35)31-8-6-20(33)7-9-31/h3-5,19,21H,6-16H2,1-2H3/t19-,21-/m1/s1",DSGIWTHAFBUADH-TZIWHRDSSA-N,50575243,CHEMBL4851825,"Indoleamine 2,3-dioxygenase 1",Homo sapiens,<0.510000
50993264,NCCCC[C@H](N)C(=O)NCC(O)=O,"InChI=1S/C8H17N3O3/c9-4-2-1-3-6(10)8(14)11-5-7(12)13/h6H,1-5,9-10H2,(H,11,14)(H,12,13)/t6-/m0/s1",HGNRJCINZYHNOU-LURJTMIESA-N,50188483,"((S)-2,6-Diamino-hexanoylamino)-acetic acid::CHEMBL91561::Lys-Gly",Angiotensin-converting enzyme,Homo sapiens, 3235936.57
50918590,COc1ccc(CN=Nc2nc3ccccc3nc2Cc2ccccc2)cc1OC,"InChI=1S/C24H22N4O2/c1-29-22-13-12-18(15-23(22)30-2)16-25-28-24-21(14-17-8-4-3-5-9-17)26-19-10-6-7-11-20(19)27-24/h3-13,15H,14,16H2,1-2H3",JEFVJDDRTJSEPX-UHFFFAOYSA-N,50378850,CHEMBL1257220,Amine oxidase [flavin-containing] B,, 460000
1112990,Cc1cc(c(F)cc1NCc1ccccc1CN1CCC1)S(=O)(=O)Nc1cccc(F)n1,"InChI=1S/C23H24F2N4O2S/c1-16-12-21(32(30,31)28-23-9-4-8-22(25)27-23)19(24)13-20(16)26-14-17-6-2-3-7-18(17)15-29-10-5-11-29/h2-4,6-9,12-13,26H,5,10-11,14-15H2,1H3,(H,27,28)",XQZCAXYSJIJVEC-UHFFFAOYSA-N,526222,"4-((2-(azetidin-1-ylmethyl)benzyl)amino)-2-fluoro-N-(6-fluoropyridin-2-yl)-5-methylbenzenesulfonamide::US11174268, Example 329",Sodium channel protein type 8 subunit alpha,Homo sapiens, 214
691204,COc1ccc(cc1F)-c1c(nc(N2CCCNCC2)n(C)c1=O)-c1ccc(C#N)c(F)c1,"InChI=1S/C24H23F2N5O2/c1-30-23(32)21(15-6-7-20(33-2)19(26)12-15)22(16-4-5-17(14-27)18(25)13-16)29-24(30)31-10-3-8-28-9-11-31/h4-7,12-13,28H,3,8-11H2,1-2H3",KOUNYOOFGLDXQE-UHFFFAOYSA-N,283263,"4-[2-[1,4]diazepan-1-yl-5-(3-fluoro- 4-methoxy-phenyl)-1-methyl-6- oxo-1,6-dihydro-pyrimidin-4-yl]- 2-fluoro-benzonitrile::US10023543, Example 46::US10207999, Example 46::US10328077, Example 46::US10548896, Example 46::US10849898, Example 46::US10960005, Example 46::US11084793, Example 46::US9573930, Example 46::US9771329, Example 46::US9776974, Example 46",Lysine-specific histone demethylase 1A,Homo sapiens,<100
50718340,CNC(=O)[C@H]1CC[C@@H](CC1)Nc1ncc2nc(Nc3c(F)cc(F)cc3F)n([C@H]3CCOC3)c2n1,"InChI=1S/C23H26F3N7O2/c1-27-21(34)12-2-4-14(5-3-12)29-22-28-10-18-20(32-22)33(15-6-7-35-11-15)23(30-18)31-19-16(25)8-13(24)9-17(19)26/h8-10,12,14-15H,2-7,11H2,1H3,(H,27,34)(H,30,31)(H,28,29,32)/t12-,14-,15-/m0/s1",YEBFCGFMUQJOCV-QEJZJMRPSA-N,50364377,CHEMBL1950304,Mitogen-activated protein kinase 14,Homo sapiens, 4200
7247,Brc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1,"InChI=1S/C17H13BrN4O/c1-2-16(23)21-13-6-7-15-14(9-13)17(20-10-19-15)22-12-5-3-4-11(18)8-12/h2-10H,1H2,(H,21,23)(H,19,20,22)",HTUBKQUPEREOGA-UHFFFAOYSA-N,4567,"4-anilinoquinazoline deriv. 2::BMC163482 Compound 1::CHEMBL285063::N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}prop-2-enamide::US9422297, PD168393",Epidermal growth factor receptor,Homo sapiens, 0.70
50933334,CN(CCOc1ccc(Cc2sc(=O)[nH]c2O)cc1)c1ccccn1,"InChI=1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,22H,10-12H2,1H3,(H,20,23)",FLDPBMANMDLQTH-UHFFFAOYSA-N,28681,"5-[(4-{2-[methyl(pyridin-2-yl)amino]ethoxy}phenyl)methyl]-1,3-thiazolidine-2,4-dione::Avandia::BRL 49653::Brl-49653::CHEMBL121::ROSIGLITAZONE MALEATE::[3H]rosiglitazone::cid_5281055::rosiglitazone",Amine oxidase [flavin-containing] A,Rattus norvegicus,
565399,CS(=O)(=O)Nc1cncc(c1)-c1nnc(Nc2ccc3[nH]ncc3c2)s1,"InChI=1S/C15H13N7O2S2/c1-26(23,24)22-12-5-10(6-16-8-12)14-20-21-15(25-14)18-11-2-3-13-9(4-11)7-17-19-13/h2-8,22H,1H3,(H,17,19)(H,18,21)",YXHRAZYQDMASPK-UHFFFAOYSA-N,295718,"US10112935, Compound A-18",Rho-associated protein kinase 1,Homo sapiens, 8000
51031055,Cc1nn(-c2ccccc2)c2c1c(=O)oc1ccc(NCc3ccccc3)cc21,"InChI=1S/C24H19N3O2/c1-16-22-23(27(26-16)19-10-6-3-7-11-19)20-14-18(12-13-21(20)29-24(22)28)25-15-17-8-4-2-5-9-17/h2-14,25H,15H2,1H3",GWXADKMHWFINJE-UHFFFAOYSA-N,50300242,CHEMBL4163924,Carbonic anhydrase 12,Homo sapiens,
51149722,CCC(=O)NCCCn1c(cc2ccc(OC)cc12)C(=O)OC,"InChI=1S/C17H22N2O4/c1-4-16(20)18-8-5-9-19-14-11-13(22-2)7-6-12(14)10-15(19)17(21)23-3/h6-7,10-11H,4-5,8-9H2,1-3H3,(H,18,20)",WIJVDXLQIUBDDL-UHFFFAOYSA-N,50471139,CHEMBL59826,Melatonin receptor type 1A/1B,Homo sapiens, 4.8
50684612,CCN(CC)CCCCCCCCOc1ccc(\C=C\C(O)=O)cc1OC,"InChI=1S/C22H35NO4/c1-4-23(5-2)16-10-8-6-7-9-11-17-27-20-14-12-19(13-15-22(24)25)18-21(20)26-3/h12-15,18H,4-11,16-17H2,1-3H3,(H,24,25)/b15-13+",MTLAAHSBOUTZHH-FYWRMAATSA-N,50232234,CHEMBL4059684,Acetylcholinesterase,Homo sapiens, 3.2
50732827,CSCC[C@H](NC(=O)c1ccc(cc1)S(N)(=O)=O)C(O)=O,"InChI=1S/C12H16N2O5S2/c1-20-7-6-10(12(16)17)14-11(15)8-2-4-9(5-3-8)21(13,18)19/h2-5,10H,6-7H2,1H3,(H,14,15)(H,16,17)(H2,13,18,19)/t10-/m0/s1",WUOPUVMWZOMQOQ-JTQLQIEISA-N,50101355,(S)-4-Methylsulfanyl-2-(4-sulfamoyl-benzoylamino)-butyric acid::CHEMBL300436,Carbonic anhydrase 2,Homo sapiens,
50391738,C[C@H]1Cn2c(CN1C(=O)c1cccc(Cl)c1Cl)nnc2-c1ccc(F)cc1,"InChI=1S/C19H15Cl2FN4O/c1-11-9-26-16(23-24-18(26)12-5-7-13(22)8-6-12)10-25(11)19(27)14-3-2-4-15(20)17(14)21/h2-8,11H,9-10H2,1H3/t11-/m0/s1",LEKYBEUSNCUHQO-NSHDSACASA-N,50110108,CHEMBL3604333,P2X purinoceptor 7,, 7.7
50399878,CCNC(=O)N1CC[C@@H]2[C@H](C[C@@H]3[C@@H]([C@@H](C)OC3=O)[C@H]2C=Cc2ccc(cn2)-c2cccc(F)c2)C1,"InChI=1S/C28H32FN3O3/c1-3-30-28(34)32-12-11-23-20(16-32)14-25-26(17(2)35-27(25)33)24(23)10-9-22-8-7-19(15-31-22)18-5-4-6-21(29)13-18/h4-10,13,15,17,20,23-26H,3,11-12,14,16H2,1-2H3,(H,30,34)/t17-,20-,23-,24+,25-,26+/m1/s1",XHORWCJGETUHBJ-JTORJZGBSA-N,50222034,"(1R,3aR,4aS,8aS,9S,9aS)-N-ethyl-dodecahydro-1-methyl-3-oxo-9-[(e)-2-[5-(3-fluorophenyl)-2-pyridinyl]ethenyl]furo[3,4-g]-isoquinoline-6-carboxamide::CHEMBL397480",Proteinase-activated receptor 1,, 18.5
51256851,CCN(CCCOc1ccc(C(C)=O)c(O)c1)Cc1ccccc1,"InChI=1S/C20H25NO3/c1-3-21(15-17-8-5-4-6-9-17)12-7-13-24-18-10-11-19(16(2)22)20(23)14-18/h4-6,8-11,14,23H,3,7,12-13,15H2,1-2H3",NEOMFPFEJLOQMR-UHFFFAOYSA-N,50513761,CHEMBL4450361,Cholinesterase,, 18700
886401,C[C@@H]1N([C@@H](CO)Cc2c1cccc2-c1cnn(c1)C1CC1)C(=O)Cc1c(Cl)cccc1Cl,"InChI=1S/C25H25Cl2N3O2/c1-15-19-4-2-5-20(16-12-28-29(13-16)17-8-9-17)21(19)10-18(14-31)30(15)25(32)11-22-23(26)6-3-7-24(22)27/h2-7,12-13,15,17-18,31H,8-11,14H2,1H3/t15-,18+/m0/s1",HGQHLJRFATXYPS-MAUKXSAKSA-N,435774,"1-((1S,3R)-5-(1-cyclopropyl- 1H-pyrazol-4-yl)-3- (hydroxymethyl)-1-methyl- 3,4-dihydroisoquinolin-2(1H)- yl)-2-(2,6- dichlorophenyl)ethan-1-one::US10611751, Example 3",D(1A) dopamine receptor,,
50774753,CN1CCC(CC1)C1=Cc2ccccc2Oc2ccccc12,"InChI=1S/C20H21NO/c1-21-12-10-15(11-13-21)18-14-16-6-2-4-8-19(16)22-20-9-5-3-7-17(18)20/h2-9,14-15H,10-13H2,1H3",QROVFOKADCFWLB-UHFFFAOYSA-N,50036437,"4-Dibenzo[b,f]oxepin-10-yl-1-methyl-piperidine; hydrochloride::CHEMBL539057",D(4) dopamine receptor,Homo sapiens,
50479379,Cc1c2CNCCc2sc1C(=O)NCC(=O)c1ccc(OCC(O)=O)c(OCC(O)=O)c1,"InChI=1S/C21H22N2O8S/c1-11-13-7-22-5-4-17(13)32-20(11)21(29)23-8-14(24)12-2-3-15(30-9-18(25)26)16(6-12)31-10-19(27)28/h2-3,6,22H,4-5,7-10H2,1H3,(H,23,29)(H,25,26)(H,27,28)",RWFZWACTJSUZOO-UHFFFAOYSA-N,50288229,"(2-Carboxymethoxy-5-{2-[(3-methyl-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine-2-carbonyl)-amino]-acetyl}-phenoxy)-acetic acid::CHEMBL89016",Integrin alpha-IIb/beta-3,, 18
50183175,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13,"InChI=1S/C26H21N3O4/c1-25-26(32,12-30)10-18(33-25)28-16-8-4-2-6-13(16)20-21-15(11-27-24(21)31)19-14-7-3-5-9-17(14)29(25)23(19)22(20)28/h2-9,18,30,32H,10-12H2,1H3,(H,27,31)/t18-,25+,26+/m1/s1",UIARLYUEJFELEN-LROUJFHJSA-N,50308060,"16-hydroxy-16-(hydroxymethyl)-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.1^{15,18}.0^{2,6}.0^{7,27}.0^{8,13}.0^{19,26}.0^{20,25}]octacosa-1(26),2(6),7(27),8(13),9,11,20(25),21,23-nonaen-3-one::CEP-701::CHEMBL603469::US11370779, Compound CEP-701",Death-associated protein kinase 3,Homo sapiens,
50526330,NC(Cc1cc(Cl)cc(c1)-c1cccc(c1)C(O)=O)C(O)=O,"InChI=1S/C16H14ClNO4/c17-13-5-9(6-14(18)16(21)22)4-12(8-13)10-2-1-3-11(7-10)15(19)20/h1-5,7-8,14H,6,18H2,(H,19,20)(H,21,22)",DEPCDIKTLCGBCH-UHFFFAOYSA-N,50200521,CHEMBL3894202,"Glutamate receptor ionotropic, kainate 1",Rattus,
51099430,Clc1nc(Nc2ccc(cc2)N2CCOCC2=O)nc(n1)N1CCN(CC1)c1ccccc1,"InChI=1S/C23H24ClN7O2/c24-21-26-22(25-17-6-8-19(9-7-17)31-14-15-33-16-20(31)32)28-23(27-21)30-12-10-29(11-13-30)18-4-2-1-3-5-18/h1-9H,10-16H2,(H,25,26,27,28)",SSIAPPPVWSHIRZ-UHFFFAOYSA-N,50369121,CHEMBL4160466,Prostaglandin G/H synthase 1,,>10000
50466226,CC(C)C[C@H](O)[C@H](O)[C@H](CC1CCCCC1)NC(=O)[C@H](Cc1csc(N)n1)NC(=O)[C@H](Cc1ccccc1)NS(=O)(=O)N1CCOCC1,"InChI=1S/C33H52N6O7S2/c1-22(2)17-29(40)30(41)26(18-23-9-5-3-6-10-23)36-31(42)27(20-25-21-47-33(34)35-25)37-32(43)28(19-24-11-7-4-8-12-24)38-48(44,45)39-13-15-46-16-14-39/h4,7-8,11-12,21-23,26-30,38,40-41H,3,5-6,9-10,13-20H2,1-2H3,(H2,34,35)(H,36,42)(H,37,43)/t26-,27-,28-,29-,30+/m0/s1",QGJKHQRFJGLJLV-VFFRCKCKSA-N,50006844,"(S)-N-[(S)-2-(2-Amino-thiazol-4-yl)-1-((1S,2R,3S)-1-cyclohexylmethyl-2,3-dihydroxy-5-methyl-hexylcarbamoyl)-ethyl]-2-(morpholine-4-sulfonylamino)-3-phenyl-propionamide::(S)-N-{(1S,2S)-2-(2-Amino-thiazol-4-yl)-1-[1-((S)-cyclohexylmethyl)-2,3-dihydroxy-5-methyl-hexylcarbamoyl]-ethyl}-2-((R)-morpholine-4-sulfonylamino)-3-phenyl-propionamide::CHEMBL34894::CI-992::N-[2-(2-Amino-thiazol-4-yl)-1-(1-cyclohexylmethyl-2,3-dihydroxy-5-methyl-hexylcarbamoyl)-ethyl]-2-(morpholine-4-sulfonylamino)-3-phenyl-propionamide",Renin,Rattus norvegicus, 0.320000
412815,C[C@H](Nc1ncnc(N)c1-c1cc(O)cc(c1)C(F)(F)F)c1nn2ccc(C)c2c(=O)n1-c1ccccc1,"InChI=1S/C26H22F3N7O2/c1-14-8-9-35-21(14)25(38)36(18-6-4-3-5-7-18)24(34-35)15(2)33-23-20(22(30)31-13-32-23)16-10-17(26(27,28)29)12-19(37)11-16/h3-13,15,37H,1-2H3,(H3,30,31,32,33)/t15-/m0/s1",YOURQHZNTIANMX-HNNXBMFYSA-N,236932,"US9388189, 28","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform",Homo sapiens, 5
50299175,COc1ccc(NCc2ccc3nc(N)nc(N)c3n2)cc1OC,"InChI=1S/C16H18N6O2/c1-23-12-6-4-9(7-13(12)24-2)19-8-10-3-5-11-14(20-10)15(17)22-16(18)21-11/h3-7,19H,8H2,1-2H3,(H4,17,18,21,22)",ONOFLDOKBQQVPB-UHFFFAOYSA-N,50049597,"6-[(3,4-Dimethoxy-phenylamino)-methyl]-pyrido[3,2-d]pyrimidine-2,4-diamine::CHEMBL55928",Dihydrofolate reductase,Rattus norvegicus, 60
51199301,COc1cccc2c(C(=O)Nc3c(Cl)cncc3Cl)c(nn12)C(F)(F)F,"InChI=1S/C15H9Cl2F3N4O2/c1-26-10-4-2-3-9-11(13(15(18,19)20)23-24(9)10)14(25)22-12-7(16)5-21-6-8(12)17/h2-6H,1H3,(H,21,22,25)",IGHLODVHSRZSQA-UHFFFAOYSA-N,50493421,CHEMBL2425776,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B",, 6130
51076331,COc1cc(OCCF)ccc1-c1nc(CSc2nc(N)cc(N)n2)cs1,"InChI=1S/C17H18FN5O2S2/c1-24-13-6-11(25-5-4-18)2-3-12(13)16-21-10(8-26-16)9-27-17-22-14(19)7-15(20)23-17/h2-3,6-8H,4-5,9H2,1H3,(H4,19,20,22,23)",GHZGXBQKFQIGOX-UHFFFAOYSA-N,50440141,CHEMBL2426587,Deoxycytidine kinase,Mus musculus, 5469
50791641,O=C1CCc2ccc(OCCCCCN3CCN(CC3)c3ccccn3)cc2N1,"InChI=1S/C23H30N4O2/c28-23-10-8-19-7-9-20(18-21(19)25-23)29-17-5-1-4-12-26-13-15-27(16-14-26)22-6-2-3-11-24-22/h2-3,6-7,9,11,18H,1,4-5,8,10,12-17H2,(H,25,28)",BCSQVUXITOSZGN-UHFFFAOYSA-N,50252575,CHEMBL4086828,Acetylcholinesterase,Electrophorus electricus, 15600
668697,CC(C)(C)c1c(Cl)nc2ccc(cc2c1Cl)C(O)(c1cccnc1)c1cccc(Cl)c1,"InChI=1S/C25H21Cl3N2O/c1-24(2,3)21-22(27)19-13-16(9-10-20(19)30-23(21)28)25(31,17-7-5-11-29-14-17)15-6-4-8-18(26)12-15/h4-14,31H,1-3H3",DKGHINYMIQEBSY-UHFFFAOYSA-N,339071,"US10201546, Example 26",Nuclear receptor ROR-gamma,, 1000
51445621,[O-][N+](=O)c1ccc(CCNC(=O)Nc2ccc(Cl)cc2)cc1,"InChI=1S/C15H14ClN3O3/c16-12-3-5-13(6-4-12)18-15(20)17-10-9-11-1-7-14(8-2-11)19(21)22/h1-8H,9-10H2,(H2,17,18,20)",KMOBTPOOIVNICU-UHFFFAOYSA-N,50584049,CHEMBL5087480,Cannabinoid receptor 1,, 776
282589,Cn1cc(Cl)c(COc2ccc3nc([C@@H]4CCCC[C@@H]4C(O)=O)n(Cc4ccc(cc4)-c4ccc(cc4)C(F)(F)F)c3c2)n1,"InChI=1S/C33H30ClF3N4O3/c1-40-18-27(34)29(39-40)19-44-24-14-15-28-30(16-24)41(31(38-28)25-4-2-3-5-26(25)32(42)43)17-20-6-8-21(9-7-20)22-10-12-23(13-11-22)33(35,36)37/h6-16,18,25-26H,2-5,17,19H2,1H3,(H,42,43)/t25-,26+/m1/s1",QDTGFSDRCIWRKE-FTJBHMTQSA-N,145795,"US8952177, 151::US9089569, 151::US9695149, 151",Arachidonate 5-lipoxygenase-activating protein,,
49389,CC(C)N(CCN1CN(c2ccccc2)C2(CCN(CC2)C2CCC(C)(C)c3ccccc23)C1=O)C(C)C,"InChI=1S/C33H48N4O/c1-25(2)36(26(3)4)23-22-35-24-37(27-12-8-7-9-13-27)33(31(35)38)18-20-34(21-19-33)30-16-17-32(5,6)29-15-11-10-14-28(29)30/h7-15,25-26,30H,16-24H2,1-6H3",OYYKUZKRRODNKD-UHFFFAOYSA-N,26943,"3-{2-[bis(propan-2-yl)amino]ethyl}-8-(4,4-dimethyl-1,2,3,4-tetrahydronaphthalen-1-yl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one::spiropiperidine analogue, 64",Mu-type opioid receptor,Homo sapiens,
85439,Cc1cccn2c1nc1n(CCc3ccccc3)c(=N)c(cc1c2=O)C(=O)NCCN1CCOCC1,"InChI=1S/C27H30N6O3/c1-19-6-5-11-33-24(19)30-25-22(27(33)35)18-21(26(34)29-10-13-31-14-16-36-17-15-31)23(28)32(25)12-9-20-7-3-2-4-8-20/h2-8,11,18,28H,9-10,12-17H2,1H3,(H,29,34)",SDINGFXVXNJCRR-UHFFFAOYSA-N,42970,"2-azanylidene-10-methyl-N-(2-morpholin-4-ylethyl)-5-oxidanylidene-1-(2-phenylethyl)dipyrido[3,4-c:1',2'-f]pyrimidine-3-carboxamide::2-imino-10-methyl-N-(2-morpholin-4-ylethyl)-5-oxo-1-(2-phenylethyl)dipyrido[3,4-c:1',2'-f]pyrimidine-3-carboxamide::2-imino-10-methyl-N-[2-(4-morpholinyl)ethyl]-5-oxo-1-(2-phenylethyl)-3-dipyrido[3,4-c:1',2'-f]pyrimidinecarboxamide::2-imino-5-keto-10-methyl-N-(2-morpholinoethyl)-1-phenethyl-dipyrido[3,4-c:1',2'-f]pyrimidine-3-carboxamide::MLS000113803::SMR000109695::cid_1311835",Nuclear receptor coactivator 2,Homo sapiens,
1141450,COc1cc(ccn1)-c1cccc(c1)N(CC12CCC(CC1)(CC2)c1nnc(C)s1)C(=O)C1CCC(F)(F)C1,"InChI=1S/C30H34F2N4O2S/c1-20-34-35-27(39-20)29-12-9-28(10-13-29,11-14-29)19-36(26(37)23-6-8-30(31,32)18-23)24-5-3-4-21(16-24)22-7-15-33-25(17-22)38-2/h3-5,7,15-17,23H,6,8-14,18-19H2,1-2H3",RJCLGNCDERHCRK-UHFFFAOYSA-N,538334,"US11254663, Example 235",Bile acid receptor,Homo sapiens,
50627142,COc1c(C)c2COC(=O)c2c(O)c1CCOP(O)(=O)CCSC[C@@H]1O[C@@H]([C@@H](O)[C@H]1O)n1cnc2c(N)ncnc12,"InChI=1S/C24H30N5O10PS/c1-11-13-7-37-24(33)15(13)17(30)12(20(11)36-2)3-4-38-40(34,35)5-6-41-8-14-18(31)19(32)23(39-14)29-10-28-16-21(25)26-9-27-22(16)29/h9-10,14,18-19,23,30-32H,3-8H2,1-2H3,(H,34,35)(H2,25,26,27)/t14-,18-,19-,23-/m0/s1",ZXNCBGGEQHAKGR-BCJZVPSXSA-N,50338550,CHEMBL1683752::Mycophenolic ethylenephosphonate-5'-thioadenosine,Inosine-5'-monophosphate dehydrogenase 2,Homo sapiens,
50554645,CCn1nnc2c(nc(nc12)-c1ccc(NC(=O)Nc2ccc(cc2)C(=O)N2CCN(C)CC2)cc1)N1CCOCC1,"InChI=1S/C29H34N10O3/c1-3-39-27-24(34-35-39)26(37-16-18-42-19-17-37)32-25(33-27)20-4-8-22(9-5-20)30-29(41)31-23-10-6-21(7-11-23)28(40)38-14-12-36(2)13-15-38/h4-11H,3,12-19H2,1-2H3,(H2,30,31,41)",ZAXFYGBKZSQBIV-UHFFFAOYSA-N,50308767,"1-[4-(3-Ethyl-7-morpholin-4-yl-3H-[1,2,3]triazolo-[4,5-d]pyrimidin-5-yl)phenyl]-3-{4-[(4-methylpiperazin-1-yl)carbonyl]-phenyl}urea::CHEMBL589258::PKI-402",Serine/threonine-protein kinase mTOR,Homo sapiens, 1.7
51017716,CN1C(=O)COc2ccc(CCN3CCN(CC3)c3cccc4nc(C)ccc34)cc12,"InChI=1S/C25H28N4O2/c1-18-6-8-20-21(26-18)4-3-5-22(20)29-14-12-28(13-15-29)11-10-19-7-9-24-23(16-19)27(2)25(30)17-31-24/h3-9,16H,10-15,17H2,1-2H3",JAELRPUWEUXJPW-UHFFFAOYSA-N,50413077,CHEMBL522257,Potassium voltage-gated channel subfamily H member 2,Homo sapiens,
1130332,C[C@H]1C\C=C\[C@](O)(Cc2nccs2)[C@@H]2CC[C@H]2CN2C[C@@]3(CCCc4cc(Cl)ccc34)COc3ccc(cc23)C(=O)NS(=O)(=O)[C@@H]1C,"InChI=1S/C36H42ClN3O5S2/c1-23-5-3-14-36(42,19-33-38-15-16-46-33)30-10-7-27(30)20-40-21-35(13-4-6-25-17-28(37)9-11-29(25)35)22-45-32-12-8-26(18-31(32)40)34(41)39-47(43,44)24(23)2/h3,8-9,11-12,14-18,23-24,27,30,42H,4-7,10,13,19-22H2,1-2H3,(H,39,41)/b14-3+/t23-,24+,27-,30+,35-,36-/m0/s1",FKNKHVYBFAJRER-SCABIXNYSA-N,471231,"US10821115, Example 100245::US10821115, Example 100246::US11224601, Example 100246",Bcl-2-like protein 11 [51-76]/Induced myeloid leukemia cell differentiation protein Mcl-1 [171-327],, 1.71
51110405,Cl.OC(=O)CCN1CCC2(COc3cc(ccc23)C#Cc2ccccc2Cl)CC1,"InChI=1S/C23H22ClNO3/c24-20-4-2-1-3-18(20)7-5-17-6-8-19-21(15-17)28-16-23(19)10-13-25(14-11-23)12-9-22(26)27/h1-4,6,8,15H,9-14,16H2,(H,26,27)",BTDBUAJVBJBIIX-UHFFFAOYSA-N,50453334,CHEMBL4213894,Sphingosine 1-phosphate receptor 5,Homo sapiens,
203430,Cc1cc(=O)n([nH]1)-c1ccc2ccccc2n1,"InChI=1S/C13H11N3O/c1-9-8-13(17)16(15-9)12-7-6-10-4-2-3-5-11(10)14-12/h2-8,15H,1H3",JWOSTXNRDXXHPH-UHFFFAOYSA-N,39217,5-methyl-2-(2-quinolinyl)-1H-pyrazol-3-one::5-methyl-2-(2-quinolyl)-3-pyrazolin-3-one::5-methyl-2-quinolin-2-yl-1H-pyrazol-3-one::MLS000038963::SMR000035962::cid_459731,Sentrin-specific protease 8,Homo sapiens, 30400
50610323,CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1,"InChI=1S/C17H18F3NO/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20/h2-10,16,21H,11-12H2,1H3",RTHCYVBBDHJXIQ-UHFFFAOYSA-N,30130,"CHEMBL1201082::CHEMBL41::Fluoxetin::Fluoxetine::Prozac::US9120771, Fluoxetine::cid_62857",Sodium-dependent dopamine transporter,Rattus norvegicus,
713639,C[N+]1(CCN)CC[C@@H](C1)NS(=O)(=O)c1ccc(-c2cccc3[nH]c(N)nc23)c(-c2nn[nH]n2)c1S(N)(=O)=O,"InChI=1S/C21H26N11O4S2/c1-32(10-8-22)9-7-12(11-32)29-38(35,36)16-6-5-13(14-3-2-4-15-18(14)26-21(23)25-15)17(19(16)37(24,33)34)20-27-30-31-28-20/h2-6,12,29H,7-11,22H2,1H3,(H2,23,25)(H2,24,33,34)/q+1/b14-13+/t12-,32?/m0/s1",IJLHELHLLCLSEM-WRWAFURQSA-N,361092,"(3S)-3-{[4-(2-amino-1H-1,3-benzodiazol-4-yl)-2-sulfamoyl-3-(2H-1,2,3,4-tetrazol-5-yl)benzene]sulfonamido}-1-(2-aminoethyl)-1-methylpyrrolidin-1-ium methaneperoxoate::US10221163, Example 249",Metallo-beta-lactamase type 2,, 0.015
50586885,CCN(CC)C(=O)c1ccccc1NCc1c[nH]cn1,"InChI=1S/C15H20N4O/c1-3-19(4-2)15(20)13-7-5-6-8-14(13)17-10-12-9-16-11-18-12/h5-9,11,17H,3-4,10H2,1-2H3,(H,16,18)",DJYTZDSAQZPKOG-UHFFFAOYSA-N,50218598,CHEMBL117482,Alpha-1A adrenergic receptor,Homo sapiens,
50825221,Nc1cc(Cl)c(cc1S(N)(=O)=O)S(N)(=O)=O,"InChI=1S/C6H8ClN3O4S2/c7-3-1-4(8)6(16(10,13)14)2-5(3)15(9,11)12/h1-2H,8H2,(H2,9,11,12)(H2,10,13,14)",IHJCXVZDYSXXFT-UHFFFAOYSA-N,10867,"4-amino-6-chlorobenzene-1,3-disulfonamide::CHEMBL266240::aromatic/heteroaromatic sulfonamide 12",Carbonic anhydrase 1,Homo sapiens,
50051080,CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@]1(CCc2ccccc2C1)NC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)[C@@H](C)CC)C(=O)NCC(N)=O,"InChI=1S/C42H60N8O10/c1-6-23(3)34(39(58)45-22-32(44)52)49-40(59)35(24(4)7-2)48-38(57)31(16-17-33(53)54)47-41(60)42(19-18-27-10-8-9-11-28(27)21-42)50-36(55)25(5)46-37(56)30(43)20-26-12-14-29(51)15-13-26/h8-15,23-25,30-31,34-35,51H,6-7,16-22,43H2,1-5H3,(H2,44,52)(H,45,58)(H,46,56)(H,47,60)(H,48,57)(H,49,59)(H,50,55)(H,53,54)/t23-,24-,25+,30-,31-,34-,35-,42-/m0/s1",SCAQEXMVOPQFKF-IDNAVRPDSA-N,50057007,"4-[(2-{2-[2-Amino-3-(4-hydroxy-phenyl)-propionylamino]-propionylamino}-1,2,3,4-tetrahydro-naphthalene-2-carbonyl)-amino]-4-{1-[1-(carbamoylmethyl-carbamoyl)-2-methyl-butylcarbamoyl]-2-methyl-butylcarbamoyl}-butyric acid::CHEMBL369499",Delta-type opioid receptor,Rattus norvegicus,
51036046,Cc1nc2c3CCN(CCCSc4nnc(-c5cccc6nc(C)ccc56)n4C)CCc3c(Cl)cc2o1,"InChI=1S/C28H29ClN6OS/c1-17-8-9-20-22(6-4-7-24(20)30-17)27-32-33-28(34(27)3)37-15-5-12-35-13-10-19-21(11-14-35)26-25(16-23(19)29)36-18(2)31-26/h4,6-9,16H,5,10-15H2,1-3H3",HULQLOOBDVQQSC-UHFFFAOYSA-N,50423593,CHEMBL403815,Potassium voltage-gated channel subfamily H member 2,Homo sapiens, 1585
19747,ONS(=O)(=O)c1ccccc1,"InChI=1S/C6H7NO3S/c8-7-11(9,10)6-4-2-1-3-5-6/h1-5,7-8H",BRMDATNYMUMZLN-UHFFFAOYSA-N,11372,CHEMBL55310::Hydroxysulfonamide 53::N-hydroxybenzenesulfonamide,Carbonic anhydrase 4,Bos taurus,
959967,N[C@H](CCN(Cc1ccccc1OCc1ccccc1F)Cc1ccccc1OCc1ccccc1F)C(O)=O,"InChI=1S/C32H32F2N2O4/c33-27-13-5-1-11-25(27)21-39-30-15-7-3-9-23(30)19-36(18-17-29(35)32(37)38)20-24-10-4-8-16-31(24)40-22-26-12-2-6-14-28(26)34/h1-16,29H,17-22,35H2,(H,37,38)/t29-/m1/s1",KQUJLMQZLYSIQA-GDLZYMKVSA-N,464426,"US10793514, Compound 19",Amino acid transporter,, 7900
50107323,Nc1nc(N)c(c(OCc2ccccn2)n1)[N+]([O-])=O,"InChI=1S/C10H10N6O3/c11-8-7(16(17)18)9(15-10(12)14-8)19-5-6-3-1-2-4-13-6/h1-4H,5H2,(H4,11,12,14,15)",QBTJCYMBEOZPEL-UHFFFAOYSA-N,50062814,"5-Nitro-6-(pyridin-2-ylmethoxy)-pyrimidine-2,4-diamine::CHEMBL358146",Methylated-DNA--protein-cysteine methyltransferase,Homo sapiens, 18000
795916,O[C@@]1(CNC(=O)c2cn(CCN3CCCC3=O)c3cccc(Cl)c23)CCCC(F)(F)C1,"InChI=1S/C22H26ClF2N3O3/c23-16-4-1-5-17-19(16)15(12-28(17)11-10-27-9-2-6-18(27)29)20(30)26-14-21(31)7-3-8-22(24,25)13-21/h1,4-5,12,31H,2-3,6-11,13-14H2,(H,26,30)/t21-/m0/s1",DZPFVUSVHAVVJR-NRFANRHFSA-N,398247,"(S)-4-chloro-N-((3, 3-difluoro-1-hydroxycyclohexyl)methyl)-1-(2-(2-oxopyrrolidin-1-yl)ethyl)-1H-indole-3-carboxamide::US10323000, Compound 187::US10676433, Compound 187",P2X purinoceptor 7,, 55
706872,COc1cc(OC)c(F)c(N2Cc3cnc(CNC(=O)C=C)cc3N(C3CC(F)(F)C3)C2=O)c1F,"InChI=1S/C23H22F4N4O4/c1-4-18(32)29-10-13-5-15-12(9-28-13)11-30(22(33)31(15)14-7-23(26,27)8-14)21-19(24)16(34-2)6-17(35-3)20(21)25/h4-6,9,14H,1,7-8,10-11H2,2-3H3,(H,29,32)",QIUUMEUBLDQMON-UHFFFAOYSA-N,357705,"N-((3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(3,3-difluorocyclobutyl)-2-oxo-1,2,3,4-tetrahydropyrido[4,3-d]pyrimidin-7-yl)methyl)acrylamide::US10214528, Example 9::US10738048, Example 9::US11014923, Example 9::US9890156, Example 9",Fibroblast growth factor receptor 2,Homo sapiens,>200
50470148,ONC(=O)C[C@@H](CCCc1ccc(Cl)cc1)C(=O)N[C@@H](CC1CCCCC1)C(=O)NCCCCN1CCOCC1,"InChI=1S/C30H47ClN4O5/c31-26-13-11-23(12-14-26)9-6-10-25(22-28(36)34-39)29(37)33-27(21-24-7-2-1-3-8-24)30(38)32-15-4-5-16-35-17-19-40-20-18-35/h11-14,24-25,27,39H,1-10,15-22H2,(H,32,38)(H,33,37)(H,34,36)/t25-,27+/m1/s1",MWWSEQIBKWJTDA-VPUSJEBWSA-N,50283707,(R)-2-[3-(4-Chloro-phenyl)-propyl]-N*1*-[(S)-2-cyclohexyl-1-(4-morpholin-4-yl-butylcarbamoyl)-ethyl]-N*4*-hydroxy-succinamide::CHEMBL93695,72 kDa type IV collagenase,,
50581368,CC(C)COC(=O)Nc1ccc(cc1)-c1cnc2c(cnn2c1N)-c1cccc(c1)N1CCN(C)CC1,"InChI=1S/C28H33N7O2/c1-19(2)18-37-28(36)32-22-9-7-20(8-10-22)24-16-30-27-25(17-31-35(27)26(24)29)21-5-4-6-23(15-21)34-13-11-33(3)12-14-34/h4-10,15-17,19H,11-14,18,29H2,1-3H3,(H,32,36)",FLOXVEVSESQZRQ-UHFFFAOYSA-N,50320221,"CHEMBL1085317::isobutyl4-(7-amino-3-(3-(4-methylpiperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-6-yl)phenylcarbamate",Vascular endothelial growth factor receptor 2,Homo sapiens, 5350
50934222,COc1cc2nccc(Oc3ccc(NC(=O)c4c(C)n(C)n(-c5ccccc5)c4=O)cc3F)c2cc1OC,"InChI=1S/C29H25FN4O5/c1-17-27(29(36)34(33(17)2)19-8-6-5-7-9-19)28(35)32-18-10-11-24(21(30)14-18)39-23-12-13-31-22-16-26(38-4)25(37-3)15-20(22)23/h5-16H,1-4H3,(H,32,35)",SBLMCLDRWJNEJK-UHFFFAOYSA-N,50383191,CHEMBL2031893,Mitogen-activated protein kinase 14,Homo sapiens, 1000
10237,CCc1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O,"InChI=1S/C23H29N7O/c1-2-16-13-17-14-26-23(28-21(17)30(22(16)31)18-5-3-4-6-18)27-20-8-7-19(15-25-20)29-11-9-24-10-12-29/h7-8,13-15,18,24H,2-6,9-12H2,1H3,(H,25,26,27,28)",UCQQUALXTHNJFW-UHFFFAOYSA-N,6291,"8-Cyclopentyl-6-ethyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one Hydrochloride::8-cyclopentyl-6-ethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H,8H-pyrido[2,3-d]pyrimidin-7-one::Pyrido-[2,3-d]-pyrimidin-7-one 25",Cyclin-A2/Cyclin-dependent kinase 2,Homo sapiens,>5000
51230931,CCCCNC(=O)c1cc(c(Cl)cc1Sc1ccccc1)S(N)(=O)=O,"InChI=1S/C17H19ClN2O3S2/c1-2-3-9-20-17(21)13-10-16(25(19,22)23)14(18)11-15(13)24-12-7-5-4-6-8-12/h4-8,10-11H,2-3,9H2,1H3,(H,20,21)(H2,19,22,23)",LHVJYOYHQKRYSI-UHFFFAOYSA-N,50504900,CHEMBL4574321,Carbonic anhydrase 12,Homo sapiens,
51198552,CN(C(=O)c1ccncc1)c1ccc(OCc2cn3ccccc3n2)cc1,"InChI=1S/C21H18N4O2/c1-24(21(26)16-9-11-22-12-10-16)18-5-7-19(8-6-18)27-15-17-14-25-13-3-2-4-20(25)23-17/h2-14H,15H2,1H3",HZIZHNHVCNGYCV-UHFFFAOYSA-N,50493163,CHEMBL2419370,"cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A",Homo sapiens, 1600
50935133,Cc1cc2oc3c(nc(CN4CC[C@H](O)C4)[nH]c3=O)c2cc1Br,"InChI=1S/C16H16BrN3O3/c1-8-4-12-10(5-11(8)17)14-15(23-12)16(22)19-13(18-14)7-20-3-2-9(21)6-20/h4-5,9,21H,2-3,6-7H2,1H3,(H,18,19,22)/t9-/m0/s1",CGLCQOJIDHILHH-VIFPVBQESA-N,50383741,CHEMBL2030384,Cell division cycle 7-related protein kinase,Homo sapiens, 104000
51242657,CC(C)COc1ccc(cc1[N+]([O-])=O)-c1nc(C)c(s1)C(O)=O,"InChI=1S/C15H16N2O5S/c1-8(2)7-22-12-5-4-10(6-11(12)17(20)21)14-16-9(3)13(23-14)15(18)19/h4-6,8H,7H2,1-3H3,(H,18,19)",HXPJAFTXHCOOJC-UHFFFAOYSA-N,50508633,CHEMBL4455012,Xanthine dehydrogenase/oxidase,Bos taurus, 33
1078790,C[C@H](CC(=O)N1CCC(O)(Cn2cnc(cc2=O)-c2cccc3cnn(C)c23)CC1)c1ccccc1,"InChI=1S/C28H31N5O3/c1-20(21-7-4-3-5-8-21)15-25(34)32-13-11-28(36,12-14-32)18-33-19-29-24(16-26(33)35)23-10-6-9-22-17-30-31(2)27(22)23/h3-10,16-17,19-20,36H,11-15,18H2,1-2H3/t20-/m1/s1",LMBBGTNHFCLGPB-HXUWFJFHSA-N,514272,"US11053213, Example 16",Ubiquitin carboxyl-terminal hydrolase 19,, 27500
51317720,Cn1c(Oc2ccc(cc2)-c2ccc(cc2)C#N)cc(=O)n(O)c1=O,"InChI=1S/C18H13N3O4/c1-20-17(10-16(22)21(24)18(20)23)25-15-8-6-14(7-9-15)13-4-2-12(11-19)3-5-13/h2-10,24H,1H3",VHLRLNURMITXFK-UHFFFAOYSA-N,50533388,CHEMBL4454421,Reverse transcriptase/RNaseH,Human immunodeficiency virus 1, 11000
50870603,CCN1C[C@]2(COC(=O)c3ccccc3-n3c(O)ccc3O)CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@@H]5[C@](O)(C[C@@H]6OC)[C@@](O)([C@@H](OC)[C@H]23)C14,"InChI=1S/C36H48N2O10/c1-6-37-17-33(18-48-31(41)19-9-7-8-10-22(19)38-25(39)11-12-26(38)40)14-13-24(45-3)35-21-15-20-23(44-2)16-34(42,27(21)28(20)46-4)36(43,32(35)37)30(47-5)29(33)35/h7-12,20-21,23-24,27-30,32,39-40,42-43H,6,13-18H2,1-5H3/t20-,21-,23+,24+,27-,28+,29-,30+,32?,33+,34-,35+,36-/m1/s1",WQBUWBGUTJAIJF-CPIHIRBUSA-N,50292360,CHEMBL451640::lycaconitine,Neuronal acetylcholine receptor subunit alpha-7,Rattus norvegicus,
197677,CC1CCCC(C)N1C(=O)COC(=O)c1cccs1,"InChI=1S/C14H19NO3S/c1-10-5-3-6-11(2)15(10)13(16)9-18-14(17)12-7-4-8-19-12/h4,7-8,10-11H,3,5-6,9H2,1-2H3",CURXROMGEKAKIX-UHFFFAOYSA-N,91319,"2-thiophenecarboxylic acid [2-(2,6-dimethyl-1-piperidinyl)-2-oxoethyl] ester::MLS002248126::SMR001315606::[2-(2,6-dimethylpiperidin-1-yl)-2-oxidanylidene-ethyl] thiophene-2-carboxylate::[2-(2,6-dimethylpiperidin-1-yl)-2-oxoethyl] thiophene-2-carboxylate::cid_3338624::thiophene-2-carboxylic acid [2-(2,6-dimethylpiperidino)-2-keto-ethyl] ester",Corticotropin-releasing factor-binding protein,Homo sapiens,
50001410,Cn1c2cc3cc(OCCCCC(O)=O)ccc3nc2[nH]c1=O,"InChI=1S/C16H17N3O4/c1-19-13-9-10-8-11(23-7-3-2-4-14(20)21)5-6-12(10)17-15(13)18-16(19)22/h5-6,8-9H,2-4,7H2,1H3,(H,20,21)(H,17,18,22)",VUHFMTBOSKAVGD-UHFFFAOYSA-N,50000904,"5-(1-Methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]quinolin-7-yloxy)-pentanoic acid::CHEMBL90601",P2Y purinoceptor 12,Homo sapiens,
50619143,CCOC(=O)CN1c2ccccc2C(=NC(NC(=O)c2ccc(Cl)cc2)C1=O)c1ccccc1F,"InChI=1S/C26H21ClFN3O4/c1-2-35-22(32)15-31-21-10-6-4-8-19(21)23(18-7-3-5-9-20(18)28)29-24(26(31)34)30-25(33)16-11-13-17(27)14-12-16/h3-14,24H,2,15H2,1H3,(H,30,33)",BMWKQHPGKPJLPG-UHFFFAOYSA-N,50019206,"(RS)-[3-(4-Chloro-benzoylamino)-5-(2-fluoro-phenyl)-2-oxo-2,3-dihydro-benzo[e][1,4]diazepin-1-yl]-acetic acid ethyl ester::CHEMBL40668::[3-(4-Chloro-benzoylamino)-5-(2-fluoro-phenyl)-2-oxo-2,3-dihydro-benzo[e][1,4]diazepin-1-yl]-acetic acid ethyl ester::[3-(4-Chloro-benzoylamino)-5-(2-fluoro-phenyl)-2-oxo-2,3-dihydro-benzo[e][1,4]diazepin-1-yl]-acetic acid ethyl ester: 0.1C4H8O2",Cholecystokinin receptor type A/Gastrin/cholecystokinin type B receptor,Homo sapiens, 1900
877923,O=C(N[C@@H]1C[C@@H]2CC[C@H](C1)N2S(=O)(=O)CCNCCN1CCOCC1)c1cc(on1)C1CC1,"InChI=1S/C22H35N5O5S/c28-22(20-15-21(32-25-20)16-1-2-16)24-17-13-18-3-4-19(14-17)27(18)33(29,30)12-6-23-5-7-26-8-10-31-11-9-26/h15-19,23H,1-14H2,(H,24,28)/t17-,18+,19-",MZXRNOFEYOIBLW-REPLKXPHSA-N,433040,"5-cyclopropyl-N-((1R,3r,5S)-8-((2-((2- morpholinoethyl)amino)ethyl)sulfonyl)-8- azabicyclo[3.2.1]octan-3-yl)isoxazole-3- carboxamide::US10577363, Compound 743",Histone-lysine N-methyltransferase SMYD3,, 514
51130045,CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(cs2)-c2c[nH]c3ncccc23)c1,"InChI=1S/C19H17N5O3S2/c1-29(26,27)24-13-5-2-4-12(8-13)9-17(25)23-19-22-16(11-28-19)15-10-21-18-14(15)6-3-7-20-18/h2-8,10-11,24H,9H2,1H3,(H,20,21)(H,22,23,25)",HIUHVDROHDSKTC-UHFFFAOYSA-N,50463479,CHEMBL4249925,Mitogen-activated protein kinase 10,Homo sapiens,
50058611,CCn1cc(C2=NCC3(CN4CCC3CC4)O2)c2ccccc12,"InChI=1S/C19H23N3O/c1-2-22-11-16(15-5-3-4-6-17(15)22)18-20-12-19(23-18)13-21-9-7-14(19)8-10-21/h3-6,11,14H,2,7-10,12-13H2,1H3",HQSDGCAZUNCTGQ-UHFFFAOYSA-N,50455923,CHEMBL429401,5-hydroxytryptamine receptor 3A/3B,Rattus, 13
50740139,CC1(C)O[C@@H]2CO[C@]3(OC(C)(C)O[C@H]3[C@@H]2O1)C(=O)NNS(N)(=O)=O,"InChI=1S/C12H21N3O8S/c1-10(2)20-6-5-19-12(9(16)14-15-24(13,17)18)8(7(6)21-10)22-11(3,4)23-12/h6-8,15H,5H2,1-4H3,(H,14,16)(H2,13,17,18)/t6-,7-,8+,12-/m1/s1",SWRLPUGZUYBDEP-HZLHGAJGSA-N,50124182,"2-{[(3aR,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis[1,3]dioxolo[4,5-b:4',5'-d]pyran-3a-yl]carbonyl}hydrazinesulfonamide::CHEMBL352471",Carbonic anhydrase 2,Homo sapiens,
50952139,CCCCC(CC)OC(=O)CCCNC(=O)NC12CC3CC(CC(C3)C1)C2,"InChI=1S/C22H38N2O3/c1-3-5-7-19(4-2)27-20(25)8-6-9-23-21(26)24-22-13-16-10-17(14-22)12-18(11-16)15-22/h16-19H,3-15H2,1-2H3,(H2,23,24,26)",AARCKJCHDVEVDV-UHFFFAOYSA-N,50390715,CHEMBL2070328,Bifunctional epoxide hydrolase 2,, 4
50116448,CCOC(=O)C(Cc1cccc(c1)C(N)=N)NC(=O)CNS(=O)(=O)c1ccc(C)cc1,"InChI=1S/C21H26N4O5S/c1-3-30-21(27)18(12-15-5-4-6-16(11-15)20(22)23)25-19(26)13-24-31(28,29)17-9-7-14(2)8-10-17/h4-11,18,24H,3,12-13H2,1-2H3,(H3,22,23)(H,25,26)",DXPBRYSUDXIFKV-UHFFFAOYSA-N,50067525,3-(3-Carbamimidoyl-phenyl)-2-[2-(toluene-4-sulfonylamino)-acetylamino]-propionic acid ethyl ester::CHEMBL135041,Prothrombin,,
50457700,CO[C@@H](Cc1ccc(OCCc2nc(oc2C)-c2ccccc2)c2ccsc12)C(O)=O,"InChI=1S/C24H23NO5S/c1-15-19(25-23(30-15)16-6-4-3-5-7-16)10-12-29-20-9-8-17(14-21(28-2)24(26)27)22-18(20)11-13-31-22/h3-9,11,13,21H,10,12,14H2,1-2H3,(H,26,27)/t21-/m0/s1",DAYKLWSKQJBGCS-NRFANRHFSA-N,50277897,"(2S)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1-benzothiophen-7-yl}propanoic acid::Aleglitazar::CHEMBL519504",Peroxisome proliferator-activated receptor alpha,,
50407892,ONC(=O)C1(CS(=O)(=O)N2CCC(CC2)c2ccc(cc2)C#N)CCN(CC1)C(=O)O[C@H]1CCOC1,"InChI=1S/C24H32N4O7S/c25-15-18-1-3-19(4-2-18)20-5-10-28(11-6-20)36(32,33)17-24(22(29)26-31)8-12-27(13-9-24)23(30)35-21-7-14-34-16-21/h1-4,20-21,31H,5-14,16-17H2,(H,26,29)/t21-/m0/s1",BTZCYRDTCBYYDO-NRFANRHFSA-N,50229634,(S)-tetrahydrofuran-3-yl 4-((4-(4-cyanophenyl)piperidin-1-ylsulfonyl)methyl)-4-(hydroxycarbamoyl)piperidine-1-carboxylate::CHEMBL253890,Disintegrin and metalloproteinase domain-containing protein 10,, 39
50976782,CCCN(CCC)[C@H]1CCc2c(O)cccc2C1,"InChI=1S/C16H25NO/c1-3-10-17(11-4-2)14-8-9-15-13(12-14)6-5-7-16(15)18/h5-7,14,18H,3-4,8-12H2,1-2H3/t14-/m0/s1",MDBWEQVKJDMEMK-AWEZNQCLSA-N,50115277,"(2R,3R)-6-Dipropylamino-5,6,7,8-tetrahydro-naphthalen-1-ol::(2R,3S)-6-Dipropylamino-5,6,7,8-tetrahydro-naphthalen-1-ol::(2S)-6-Dipropylamino-5,6,7,8-tetrahydro-naphthalen-1-ol::(2S,3R)-6-Dipropylamino-5,6,7,8-tetrahydro-naphthalen-1-ol::(S)-(-)-5-hydroxy-2-(N,N-di-n-propylamino)tetralin::(S)-6-Dipropylamino-5,6,7,8-tetrahydro-naphthalen-1-ol::(S)-6-Dipropylamino-5,6,7,8-tetrahydro-naphthalen-1-ol.HCl::6-Dipropylamino-5,6,7,8-tetrahydro-naphthalen-1-ol::CHEMBL269004",D(3) dopamine receptor,,
50998532,O=C(NC(C1CC1)c1ccccc1)OCCCc1cnc[nH]1,"InChI=1S/C17H21N3O2/c21-17(22-10-4-7-15-11-18-12-19-15)20-16(14-8-9-14)13-5-2-1-3-6-13/h1-3,5-6,11-12,14,16H,4,7-10H2,(H,18,19)(H,20,21)",AISUIUPQHGHDCK-UHFFFAOYSA-N,50118162,(Cyclopropyl-phenyl-methyl)-carbamic acid 3-(1H-imidazol-4-yl)-propyl ester;0.8C2H2O4::CHEMBL128585,Histamine H1 receptor,Cavia porcellus,
50787388,NC(=O)CC[C@H](NC(=O)c1ccc(COc2cccnc2)cc1-c1ccccc1)C(O)=O,"InChI=1S/C24H23N3O5/c25-22(28)11-10-21(24(30)31)27-23(29)19-9-8-16(15-32-18-7-4-12-26-14-18)13-20(19)17-5-2-1-3-6-17/h1-9,12-14,21H,10-11,15H2,(H2,25,28)(H,27,29)(H,30,31)/t21-/m0/s1",YOCZOOZCVZXRAC-NRFANRHFSA-N,50067583,(S)-4-Carbamoyl-2-{[5-(pyridin-3-yloxymethyl)-biphenyl-2-carbonyl]-amino}-butyric acid::CHEMBL337847,Protein farnesyltransferase subunit beta/geranylgeranyltransferase type-1 subunit alpha,Bos taurus, 48
50282182,CC(C)[C@@H](Oc1ccc(CNC(=O)[C@@H]2CCCN2C(=O)CC([NH3+])Cc2cc(ccc2F)C(F)(F)F)cc1)C(O)=O,"InChI=1S/C28H33F4N3O5/c1-16(2)25(27(38)39)40-21-8-5-17(6-9-21)15-34-26(37)23-4-3-11-35(23)24(36)14-20(33)13-18-12-19(28(30,31)32)7-10-22(18)29/h5-10,12,16,20,23,25H,3-4,11,13-15,33H2,1-2H3,(H,34,37)(H,38,39)/p+1/t20?,23-,25+/m0/s1",ADAJAZUUPSIOFM-RYORKLGYSA-O,50153402,CHEMBL184630::Trifluoro-acetate3-{(S)-2-[4-((R)-1-carboxy-2-methyl-propoxy)-benzylcarbamoyl]-pyrrolidin-1-yl}-1-(2-fluoro-5-trifluoromethyl-benzyl)-3-oxo-propyl-ammonium;,Dipeptidyl peptidase 4,Homo sapiens, 12
50458763,CCc1ccc(cc1)S(=O)(=O)N[C@H]1[C@H](O)Cc2ccc(NC(=O)c3cccc(OC)c3)cc12,"InChI=1S/C25H26N2O5S/c1-3-16-7-11-21(12-8-16)33(30,31)27-24-22-15-19(10-9-17(22)14-23(24)28)26-25(29)18-5-4-6-20(13-18)32-2/h4-13,15,23-24,27-28H,3,14H2,1-2H3,(H,26,29)/t23-,24-/m1/s1",KCRNOVULDSNKBZ-DNQXCXABSA-N,50099581,"CHEMBL288131::N-((2R,3R)-3-(4-ethylphenylsulfonamido)-2-hydroxy-2,3-dihydro-1H-inden-5-yl)-3-methoxybenzamide::N-[3-(4-Ethyl-benzenesulfonylamino)-2-hydroxy-indan-5-yl]-3-methoxy-benzamide",Potassium voltage-gated channel subfamily A member 5,, 160
995720,O=C(Cn1nnc2ccccc12)N(Cc1ccsc1)c1ccc(NC(=O)C2CC2)cc1,"InChI=1S/C23H21N5O2S/c29-22(14-28-21-4-2-1-3-20(21)25-26-28)27(13-16-11-12-31-15-16)19-9-7-18(8-10-19)24-23(30)17-5-6-17/h1-4,7-12,15,17H,5-6,13-14H2,(H,24,30)",OCKMJWOFMCSMEX-UHFFFAOYSA-N,479369,ALP-POS-c59291d4-3::ML300-based SC inhibitor 1::acs.jmedchem.1c00409_ST.352,Replicase polyprotein 1ab,,
369243,C[C@H](Nc1ncnc(N)c1C#Cc1ncccn1)c1nc2cccc(Cl)c2c(=O)n1-c1ccccc1,"InChI=1S/C26H19ClN8O/c1-16(33-24-18(23(28)31-15-32-24)11-12-21-29-13-6-14-30-21)25-34-20-10-5-9-19(27)22(20)26(36)35(25)17-7-3-2-4-8-17/h2-10,13-16H,1H3,(H3,28,31,32,33)/t16-/m0/s1",XZZYHVABMXORNM-INIZCTEOSA-N,208876,"US9266878, 102a","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform",Homo sapiens,<100
434754,CN[C@@H](C)C(=O)N[C@H](C(=O)N1C[C@H](CC1C(=O)N[C@@H]1CCCc2ccccc12)NC(=O)c1ccc(COc2ccc(CN(NC(=O)[C@H](C)NC)C(=O)[C@@H]3CCCC[C@H]3C(=O)NC3CCCc4ccccc34)cc2)cc1)C(C)(C)C,"InChI=1S/C62H81N9O8/c1-38(63-6)55(72)68-54(62(3,4)5)61(78)70-36-45(34-53(70)59(76)67-52-25-15-19-43-17-9-11-21-48(43)52)65-57(74)44-30-26-41(27-31-44)37-79-46-32-28-40(29-33-46)35-71(69-56(73)39(2)64-7)60(77)50-23-13-12-22-49(50)58(75)66-51-24-14-18-42-16-8-10-20-47(42)51/h8-11,16-17,20-21,26-33,38-39,45,49-54,63-64H,12-15,18-19,22-25,34-37H2,1-7H3,(H,65,74)(H,66,75)(H,67,76)(H,68,72)(H,69,73)/t38-,39-,45-,49+,50+,51?,52+,53?,54+/m0/s1",ZNXRDQOMLFCSOT-PQRBCLMOSA-N,249175,"US9453048, 17",E3 ubiquitin-protein ligase XIAP [241-356],Homo sapiens, 0.27
50208651,COc1cc2ncnc(N3CCN(CC3)C(=S)Nc3ccc(Br)c(Cl)c3)c2cc1OC,"InChI=1S/C21H21BrClN5O2S/c1-29-18-10-14-17(11-19(18)30-2)24-12-25-20(14)27-5-7-28(8-6-27)21(31)26-13-3-4-15(22)16(23)9-13/h3-4,9-12H,5-8H2,1-2H3,(H,26,31)",SEEORMPQTKDNNU-UHFFFAOYSA-N,50115354,"4-(6,7-Dimethoxy-quinazolin-4-yl)-piperazine-1-carbothioic acid (4-bromo-3-chloro-phenyl)-amide::CHEMBL102908",Platelet-derived growth factor receptor beta,Homo sapiens, 100
50261310,CN(C)CCN(C)Cc1ccc(cc1)C(=O)Nc1ccc(Cl)cc1C(=O)Nc1ccc(Cl)cn1,"InChI=1S/C25H27Cl2N5O2/c1-31(2)12-13-32(3)16-17-4-6-18(7-5-17)24(33)29-22-10-8-19(26)14-21(22)25(34)30-23-11-9-20(27)15-28-23/h4-11,14-15H,12-13,16H2,1-3H3,(H,29,33)(H,28,30,34)",XUUKJPBPIUZXMS-UHFFFAOYSA-N,50142156,5-Chloro-N-(5-chloro-pyridin-2-yl)-2-(4-{[(2-dimethylamino-ethyl)-methyl-amino]-methyl}-benzoylamino)-benzamide::CHEMBL172256,Vitamin K-dependent protein C,Homo sapiens,>11000
998424,CCc1nn(C[C@@H](C)COC(=O)c2ccc(C)cc2OC)c2CC3(CCOCC3)CNC(=O)c12,"InChI=1S/C26H35N3O5/c1-5-20-23-21(13-26(16-27-24(23)30)8-10-33-11-9-26)29(28-20)14-18(3)15-34-25(31)19-7-6-17(2)12-22(19)32-4/h6-7,12,18H,5,8-11,13-16H2,1-4H3,(H,27,30)/t18-/m1/s1",GBLYLBWIWFXFJW-GOSISDBHSA-N,481392,"US10906915, Ex. 187::[(2R)-3-(3-ethyl-4-oxo- spiro[6,8-dihydro-5H- pyrazolo[4,3-c]azepine- 7,4'-tetrahydropyran]-1-yl)- 2-methyl-propyl] 2- methoxy-4-methyl- benzoate","cAMP-specific 3',5'-cyclic phosphodiesterase 4D",,<100
1196304,CNc1nnc(o1)-c1ccc2[nH]c(c(C(C)C)c2c1)-c1ccnc(C)c1,"InChI=1S/C20H21N5O/c1-11(2)17-15-10-14(19-24-25-20(21-4)26-19)5-6-16(15)23-18(17)13-7-8-22-12(3)9-13/h5-11,23H,1-4H3,(H,21,25)",WKMXILZIUGQKSN-UHFFFAOYSA-N,566977,"US11420958, Ex. No. 346",Toll-like receptor 7,, 158
44395,COc1ccc2c(OCc3nnc4ccc(nn34)-c3cccs3)ccnc2c1,"InChI=1S/C20H15N5O2S/c1-26-13-4-5-14-16(11-13)21-9-8-17(14)27-12-20-23-22-19-7-6-15(24-25(19)20)18-3-2-10-28-18/h2-11H,12H2,1H3",RCSQEQJYZYUSFU-UHFFFAOYSA-N,24480,"7-methoxy-4-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-a]pyridazin-3-yl]methoxy}quinoline::Triazolopyridazine, 10j",Hepatocyte growth factor receptor,Homo sapiens, 2
842003,CC(C)NC(=O)N1CCCCC1C1COc2c(ccc3[nH]c(=O)n1c23)-c1c(C)noc1C,,,318534,"2-[7-(3,5-dimethylisoxazol-4- yl)-2-oxo-1,2,4,5- tetrahydroimidazo[1,5,4- de][1,4]benzoxazin-4-yl]-N- isopropylpiperidine-1- carboxamide::US10464947, Example 80::US11498926, Example 80::US9624241, Example 80",Bromodomain-containing protein 4 [42-168],, 5500
50939784,CC(C)Cc1ccc(cc1)C(C)c1nc2cc(OCc3ccccn3)ccc2n1Cc1ccccc1Cl,"InChI=1S/C32H32ClN3O/c1-22(2)18-24-11-13-25(14-12-24)23(3)32-35-30-19-28(37-21-27-9-6-7-17-34-27)15-16-31(30)36(32)20-26-8-4-5-10-29(26)33/h4-17,19,22-23H,18,20-21H2,1-3H3",VTROTSTZAVOQTL-UHFFFAOYSA-N,50385378,CHEMBL2036379,Arachidonate 5-lipoxygenase-activating protein,Homo sapiens, 180
935581,Cc1ncc(s1)-c1cc(cn2cc(Cn3cc(nn3)C(=O)NCc3ncn4ccc(Cl)c(F)c34)nc12)C1CC1,"InChI=1S/C26H21ClFN9OS/c1-14-29-8-22(39-14)18-6-16(15-2-3-15)9-36-10-17(32-25(18)36)11-37-12-21(33-34-37)26(38)30-7-20-24-23(28)19(27)4-5-35(24)13-31-20/h4-6,8-10,12-13,15H,2-3,7,11H2,1H3,(H,30,38)",WTMMADILQWOTEV-UHFFFAOYSA-N,455247,"US10730874, Compound I-257::US11352356, Compound I-257",Plasma kallikrein,,
508658,CC1(COC1)C(=O)N1CCC[C@H](C1)c1nc(-c2ccc(cc2)C(=O)Nc2cc(ccn2)C(F)(F)F)c2c(N)ncc(C=C)n12,"InChI=1S/C31H30F3N7O3/c1-3-22-14-37-26(35)25-24(39-27(41(22)25)20-5-4-12-40(15-20)29(43)30(2)16-44-17-30)18-6-8-19(9-7-18)28(42)38-23-13-21(10-11-36-23)31(32,33)34/h3,6-11,13-14,20H,1,4-5,12,15-17H2,2H3,(H2,35,37)(H,36,38,42)/t20-/m1/s1",OLOPXDCWDGTSHS-HXUWFJFHSA-N,267701,"(R)-4-(8-amino-5-chloro-3-(1-(3-methyloxetane-3-carbonyl)piperidin-3-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide::US9718828, Example, 302",Tyrosine-protein kinase BTK,Homo sapiens,
50642638,COc1ccc(c(OC)c1)S(=O)(=O)N1C(=O)[C@@](N2C[C@H](O)C[C@H]2C(=O)N(C)C)(c2cc(Cl)ccc12)c1nccnc1OC,"InChI=1S/C28H30ClN5O8S/c1-32(2)26(36)21-13-17(35)15-33(21)28(24-25(42-5)31-11-10-30-24)19-12-16(29)6-8-20(19)34(27(28)37)43(38,39)23-9-7-18(40-3)14-22(23)41-4/h6-12,14,17,21,35H,13,15H2,1-5H3/t17-,21+,28-/m1/s1",XSVCEDLKELNLBS-SSVXIMEWSA-N,50345146,"(2S,4R)-1-((R)-5-chloro-1-(2,4-dimethoxyphenylsulfonyl)-3-(3-methoxypyrazin-2-yl)-2-oxoindolin-3-yl)-4-hydroxy-N,N-dimethylpyrrolidine-2-carboxamide::CHEMBL1779403",Vasopressin V2 receptor,,
123821,Clc1ccccc1Cn1ncc(Cl)c(Cl)c1=O,"InChI=1S/C11H7Cl3N2O/c12-8-4-2-1-3-7(8)6-16-11(17)10(14)9(13)5-15-16/h1-5H,6H2",OCSOJUHXYHYEKJ-UHFFFAOYSA-N,61616,"4,5-bis(chloranyl)-2-[(2-chlorophenyl)methyl]pyridazin-3-one::4,5-dichloro-2-(2-chlorobenzyl)-3(2H)-pyridazinone::4,5-dichloro-2-(2-chlorobenzyl)pyridazin-3-one::4,5-dichloro-2-[(2-chlorophenyl)methyl]-3-pyridazinone::4,5-dichloro-2-[(2-chlorophenyl)methyl]pyridazin-3-one::MLS000680249::SMR000268404::cid_720233",Bcl-2-like protein 11,Homo sapiens,
50304502,Oc1cc(on1)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(ncc1F)-c1c[nH]c2ncc(F)cc12,"InChI=1S/C22H20F2N6O2/c23-12-5-13-14(8-26-20(13)25-7-12)21-27-9-15(24)22(29-21)28-19-11-3-1-10(2-4-11)18(19)16-6-17(31)30-32-16/h5-11,18-19H,1-4H2,(H,25,26)(H,30,31)(H,27,28,29)/t10?,11?,18-,19+/m1/s1",JYDWJFDOWRSYSW-DJZCKWSOSA-N,50067518,CHEMBL3401981,cAMP-dependent protein kinase catalytic subunit alpha,Homo sapiens,
51022538,COc1ccccc1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1,"InChI=1S/C22H31N3O3/c1-28-19-7-3-2-6-18(19)24-13-10-23(11-14-24)12-15-25-20(26)16-22(17-21(25)27)8-4-5-9-22/h2-3,6-7H,4-5,8-17H2,1H3",AYYCFGDXLUPJAQ-UHFFFAOYSA-N,50026917,"8-(2-(4-(2-methoxyphenyl)piperazin-1-yl)ethyl)-8-azaspiro[4.5]decane-7,9-dione::8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione::8-{2-[4-(2-Methoxy-phenyl)-piperazin-1-yl]-ethyl}-8-aza-spiro[4.5]decane-7,9-dione::8-{2-[4-(2-Methoxy-phenyl)-piperazin-1-yl]-ethyl}-8-aza-spiro[4.5]decane-7,9-dione(BMY-7378)::BMY 7378::BMY-7378::CHEMBL1256934::CHEMBL13647::CHEMBL543741",Alpha-1D adrenergic receptor,Homo sapiens,
396842,FC1CNCCC1NC(=O)c1cc(NC(=O)c2cc(c(F)cc2Cl)-c2ncccc2F)n(n1)-c1ccccc1,"InChI=1S/C27H22ClF3N6O2/c28-18-12-20(30)17(25-19(29)7-4-9-33-25)11-16(18)26(38)35-24-13-23(36-37(24)15-5-2-1-3-6-15)27(39)34-22-8-10-32-14-21(22)31/h1-7,9,11-13,21-22,32H,8,10,14H2,(H,34,39)(H,35,38)",GUWKIZWXKYPMEJ-UHFFFAOYSA-N,227106,"US9328096, 794",High affinity nerve growth factor receptor [441-796],, 25.7
738526,CO[C@@H](C)COc1ncc(cc1N1CCOCC1)-c1cc(NC(=O)c2cccc(c2)C(F)(F)F)cnc1C,"InChI=1S/C27H29F3N4O4/c1-17(36-3)16-38-26-24(34-7-9-37-10-8-34)12-20(14-32-26)23-13-22(15-31-18(23)2)33-25(35)19-5-4-6-21(11-19)27(28,29)30/h4-6,11-15,17H,7-10,16H2,1-3H3,(H,33,35)/t17-/m0/s1",OWLWCBXQZLBGRU-KRWDZBQOSA-N,87991,"US10245267, Example 1022::US10709712, Example 1022::US9694016, 1022",Serine/threonine-protein kinase B-raf [V600E],, 1.49
832707,COc1cc(-c2cnc(cn2)N2CCC(C)(CC2)NC(=O)c2cc(F)ccc2Cl)c2c(cnn2c1)C#N,"InChI=1S/C26H23ClFN7O2/c1-26(33-25(36)19-9-17(28)3-4-21(19)27)5-7-34(8-6-26)23-14-30-22(13-31-23)20-10-18(37-2)15-35-24(20)16(11-29)12-32-35/h3-4,9-10,12-15H,5-8H2,1-2H3,(H,33,36)",HWWURLDGKVDHGA-UHFFFAOYSA-N,305776,"2-chloro-N-(1-(5-(3- cyano-6- methoxypyrazolo[1,5- a]pyridin-4-yl)pyrazin-2- yl)-4-methylpiperidin-4- yl)-5-fluorobenzamide::US10144734, Example 794::US10172845, Example 794::US10441581, Example 794::US10881652, Example 794",Proto-oncogene tyrosine-protein kinase receptor Ret [G810R],, 32.0
51271755,COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1,"InChI=1S/C25H25ClN6O4S/c1-25(2,27)24(33)28-15-7-6-8-17(13-15)37(34,35)32-23-22(29-19-9-4-5-10-20(19)30-23)31-21-14-16(36-3)11-12-18(21)26/h4-14H,27H2,1-3H3,(H,28,33)(H,29,31)(H,30,32)",QINPEPAQOBZPOF-UHFFFAOYSA-N,50197062,Pilaralisib::SAR-245408::XL-147,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",Homo sapiens, 39
535380,CC1(C(=O)Nc2nc(nc(N)c12)-c1nn(CCC(F)(F)C(F)(F)F)c2cc(Cl)ccc12)c1ccc(CCC(O)=O)c(Br)c1,"InChI=1S/C27H21BrClF5N6O3/c1-25(13-4-2-12(16(28)10-13)3-7-18(41)42)19-21(35)36-23(37-22(19)38-24(25)43)20-15-6-5-14(29)11-17(15)40(39-20)9-8-26(30,31)27(32,33)34/h2,4-6,10-11H,3,7-9H2,1H3,(H,41,42)(H3,35,36,37,38,43)",WLWFREMAMWVCEL-UHFFFAOYSA-N,280743,"3-(4-{4-amino- 2-[6-chloro-1- (3,3,4,4,4- pentafluoro- butyl)-1H- indazol-3-yl]- 5-methyl-6- oxo-6,7- dihydro-5H- pyrrolo[2,3-d] pyrimidin-5-yl}- 2-bromophenyl) propanoic acid::US10030027, Example 4B::US10428076, Example 4B",Guanylate cyclase soluble subunit alpha-1,,
600010,Oc1ccc(cc1)N(C(=O)c1cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n2CCCCc12)c1ccccc1C#N,"InChI=1S/C43H40ClN5O4/c44-32-12-17-36(42(51)48-27-31-9-2-1-7-29(31)23-34(48)28-46-19-21-53-22-20-46)37(24-32)41-25-38(40-11-5-6-18-47(40)41)43(52)49(33-13-15-35(50)16-14-33)39-10-4-3-8-30(39)26-45/h1-4,7-10,12-17,24-25,34,50H,5-6,11,18-23,27-28H2/t34-/m0/s1",VIGQNABWJZHITO-UMSFTDKQSA-N,177901,"US9120791, Example 134::US9603854, 134",Apoptosis regulator Bcl-2,, 37
50530205,OC(=O)c1ccc2nc(-c3ccccc3)c(nc2c1)-c1ccc(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)cc1,"InChI=1S/C34H29N5O3/c40-33(41)25-14-15-27-29(20-25)36-32(31(35-27)23-6-2-1-3-7-23)24-12-10-22(11-13-24)21-38-18-16-26(17-19-38)39-30-9-5-4-8-28(30)37-34(39)42/h1-15,20,26H,16-19,21H2,(H,37,42)(H,40,41)",DNNVPDHNAOWAES-UHFFFAOYSA-N,15163,"3-(4-{[4-(2-oxo-2,3-dihydro-1H-1,3-benzodiazol-1-yl)piperidin-1-yl]methyl}phenyl)-2-phenylquinoxaline-6-carboxylic acid::quinoxaline 16b",RAC-alpha serine/threonine-protein kinase,, 166
457291,Cc1ccc(NC(=O)c2cccc(c2)C(F)(F)F)cc1-c1cc(N2CCOCC2)c(=O)n(C)c1,"InChI=1S/C25H24F3N3O3/c1-16-6-7-20(29-23(32)17-4-3-5-19(12-17)25(26,27)28)14-21(16)18-13-22(24(33)30(2)15-18)31-8-10-34-11-9-31/h3-7,12-15H,8-11H2,1-2H3,(H,29,32)",IINLTCRAWJXNKT-UHFFFAOYSA-N,202770,"US10245267, Example 117::US10709712, Example 117::US9242969, 117::US9694016, 117",Serine/threonine-protein kinase B-raf [V600E],, 2.30
792412,CC1(CNC1)Oc1cc(Br)ccc1OCc1ccc(o1)C(F)(F)F,"InChI=1S/C16H15BrF3NO3/c1-15(8-21-9-15)24-13-6-10(17)2-4-12(13)22-7-11-3-5-14(23-11)16(18,19)20/h2-6,21H,7-9H2,1H3",VWHNHXHPMRDLRJ-UHFFFAOYSA-N,396591,"3-[5-Bromo-2-(5-trifluoromethyl-furan-2-ylmethoxy)-phenoxy]-azetidine::US9981909, Example 216",5-hydroxytryptamine receptor 7,Rattus norvegicus,
50330064,Cl.COc1ccc(OC)c2c3oc(-c4cccc(F)c4)c(OCCOC(=O)[C@H](C)N)c(=O)c3cc(OC)c12,"InChI=1S/C27H26FNO8.ClH/c1-14(29)27(31)36-11-10-35-26-23(30)17-13-20(34-4)21-18(32-2)8-9-19(33-3)22(21)25(17)37-24(26)15-6-5-7-16(28)12-15;/h5-9,12-14H,10-11,29H2,1-4H3;1H/t14-;/m0./s1",KXSRHQSMQOIIRG-UQKRIMTDSA-N,50081937,CHEMBL3422355,Cytochrome P450 1A2,Homo sapiens, 86
766052,CC1(C)[C@@H]2CC[C@@]1(NC(=O)OCc1ccccc1)c1nnc(cc21)-c1c(F)cccc1F,"InChI=1S/C25H23F2N3O2/c1-24(2)17-11-12-25(24,28-23(31)32-14-15-7-4-3-5-8-15)22-16(17)13-20(29-30-22)21-18(26)9-6-10-19(21)27/h3-10,13,17H,11-12,14H2,1-2H3,(H,28,31)/t17-,25-/m1/s1",ACDOPZMPMIOPBT-CRICUBBOSA-N,383199,"US10280144, Compound 2::benzyl ((5S,8S)-3-(2,6- difluorophenyl)-9,9-dimethyl- 5,6,7,8-tetrahydro-5,8- methanocinnolin-8-yl)carbamate",Nuclear receptor ROR-gamma,, 222
50296070,CCCC\C(=C/c1cc(ccc1OCc1ccc(cc1)C(F)(F)F)-c1ccccc1)C(O)=O,"InChI=1S/C27H25F3O3/c1-2-3-7-22(26(31)32)17-23-16-21(20-8-5-4-6-9-20)12-15-25(23)33-18-19-10-13-24(14-11-19)27(28,29)30/h4-6,8-17H,2-3,7,18H2,1H3,(H,31,32)/b22-17+",PBIVKAAJQBKJKW-OQKWZONESA-N,50062720,CHEMBL3397708,Presenilin-1,,
50748672,ONC(=O)c1cccc(c1)-c1ccccc1,"InChI=1S/C13H11NO2/c15-13(14-16)12-8-4-7-11(9-12)10-5-2-1-3-6-10/h1-9,16H,(H,14,15)",SEPGPMDDTZHYJV-UHFFFAOYSA-N,50015109,CHEMBL154517::biphenyl-3-carboxylic acid hydroxyamide,Polyunsaturated fatty acid 5-lipoxygenase,Rattus norvegicus, 6000
50502249,Nc1nc2[nH]c(SCc3ccc(Br)cc3)nc2c(=O)[nH]1,"InChI=1S/C12H10BrN5OS/c13-7-3-1-6(2-4-7)5-20-12-15-8-9(17-12)16-11(14)18-10(8)19/h1-4H,5H2,(H4,14,15,16,17,18,19)",CQTLYQRZHQFOAJ-UHFFFAOYSA-N,50181545,CHEMBL3818002,2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase,,
51111922,O[C@@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]([C@@H]1O)n1ccc(=O)[nH]c1=O,"InChI=1S/C9H15N2O15P3/c12-5-1-2-11(9(15)10-5)8-7(14)6(13)4(24-8)3-23-28(19,20)26-29(21,22)25-27(16,17)18/h1-2,4,6-8,13-14H,3H2,(H,19,20)(H,21,22)(H,10,12,15)(H2,16,17,18)/t4-,6-,7-,8-/m1/s1",PGAVKCOVUIYSFO-XVFCMESISA-N,50118213,5'-UTP::CHEMBL336296::H4utp::UTP::uridine 5'-(tetrahydrogen triphosphate)::uridine 5'-triphosphoric acid,P2Y purinoceptor 2,Homo sapiens,
154142,CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12,"InChI=1S/C17H19ClN2S/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20/h3-4,6-9,12H,5,10-11H2,1-2H3",ZPEIMTDSQAKGNT-UHFFFAOYSA-N,50001888,"(chloropromazine) [3-(2-Chloro-phenothiazin-10-yl)-propyl]-dimethyl-amine::(chlorpromazine)[3-(2-Chloro-phenothiazin-10-yl)-propyl]-dimethyl-amine::1-(2-Allyl-phenoxy)-3-isopropylamino-propan-2-ol::1N,1N-dimethyl-3-(2-chloro-10H-10-phenothiazinyl)-1-propanamine::3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethylpropan-1-amine::CHEMBL71::CHLORPROMAZINE::CHLORPROMAZINE HIBENZATE::CHLORPROMAZINE HYDROCHLORIDE::CHLORPROMAZINE PHENOLPHTHALINATE::CHLORPROMAZINE TANNATE::Chlorpromazine;[3-(2-Chloro-phenothiazin-10-yl)-propyl]-dimethyl-amine::PROMAPAR::SONAZINE::THORAZINE::[3-(2-Chloro-phenothiazin-10-yl)-propyl]-dimethyl-amine (chlor-promazine)::[3-(2-Chloro-phenothiazin-10-yl)-propyl]-dimethyl-amine( Chlorpromazine)::[3-(2-Chloro-phenothiazin-10-yl)-propyl]-dimethyl-amine(clorpromazine)::chloropromazine::med.21724, Compound 15",Histamine H1 receptor,Rattus,
17604,COc1ccc(Br)cc1[C@H](CC=C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)CSCc1ccccc1,"InChI=1S/C29H35BrN2O6S/c1-5-9-21(22-14-20(30)12-13-25(22)38-4)28(36)32-27(18(2)3)29(37)31-23(15-26(34)35)24(33)17-39-16-19-10-7-6-8-11-19/h5-8,10-14,18,21,23,27H,1,9,15-17H2,2-4H3,(H,31,37)(H,32,36)(H,34,35)/t21-,23-,27-/m0/s1",XGWZYQWSQQWRDR-MYIHVTGJSA-N,10533,(3S)-5-(benzylsulfanyl)-3-[(2S)-2-[(2S)-2-(5-bromo-2-methoxyphenyl)pent-4-enamido]-3-methylbutanamido]-4-oxopentanoic acid::valine aspartyl ketone 12,Caspase-7,Homo sapiens, 2215
1084690,CC(C)c1c([nH]c2ccc(nc12)C1CCC(CC1)NC1COC1)-c1cn2cnnc2c(C)c1C,"InChI=1S/C27H34N6O/c1-15(2)24-25(21-11-33-14-28-32-27(33)17(4)16(21)3)31-23-10-9-22(30-26(23)24)18-5-7-19(8-6-18)29-20-12-34-13-20/h9-11,14-15,18-20,29,31H,5-8,12-13H2,1-4H3",DAFVWYIPVOQCBO-UHFFFAOYSA-N,427800,"US10544143, Example 233::US10544143, Example 234::US10730877, Example 234::US11053244, Example 234",Toll-like receptor 8,, 24.0
50000353,O=c1oc(nc2ccccc12)N1CCCCC1,"InChI=1S/C13H14N2O2/c16-12-10-6-2-3-7-11(10)14-13(17-12)15-8-4-1-5-9-15/h2-3,6-7H,1,4-5,8-9H2",SWRDBJRQOWWFLS-UHFFFAOYSA-N,50406308,CHEMBL145581,Neutrophil elastase,Homo sapiens,
51302595,CC(C)C[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H]2CCCN2C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O,"InChI=1S/C39H67N11O10/c1-20(2)15-25-34(56)46-24(11-9-13-42-39(40)41)33(55)43-19-30(51)45-26(18-31(52)53)35(57)48-27(16-21(3)4)37(59)50-14-10-12-28(50)38(60)49(8)29(17-22(5)6)36(58)44-23(7)32(54)47-25/h20-29H,9-19H2,1-8H3,(H,43,55)(H,44,58)(H,45,51)(H,46,56)(H,47,54)(H,48,57)(H,52,53)(H4,40,41,42)/t23-,24-,25-,26-,27-,28+,29-/m0/s1",XJFNXAGFIMODFB-VVYSMVTKSA-N,50530128,CHEMBL4470879,Integrin alpha-V/beta-6,Homo sapiens, 180
50011174,O[C@@H](CNCCc1ccc(NS(=O)(=O)c2ccc(cc2)N2CCN(Cc3ccc(F)c(F)c3)C2=O)cc1)c1cccnc1,"InChI=1S/C31H31F2N5O4S/c32-28-12-5-23(18-29(28)33)21-37-16-17-38(31(37)40)26-8-10-27(11-9-26)43(41,42)36-25-6-3-22(4-7-25)13-15-35-20-30(39)24-2-1-14-34-19-24/h1-12,14,18-19,30,35-36,39H,13,15-17,20-21H2/t30-/m0/s1",VYGFYOQPAGZNSF-PMERELPUSA-N,50075903,"4-[3-(3,4-Difluoro-benzyl)-2-oxo-imidazolidin-1-yl]-N-{4-[2-((R)-2-hydroxy-2-pyridin-3-yl-ethylamino)-ethyl]-phenyl}-benzenesulfonamide::CHEMBL350931",Beta-2 adrenergic receptor,Homo sapiens, 3500
51050170,Oc1ccc(cc1F)-c1ccc(O)c(CN=O)c1,"InChI=1S/C13H10FNO3/c14-11-6-9(2-4-13(11)17)8-1-3-12(16)10(5-8)7-15-18/h1-6,16-17H,7H2",ZVGFVUVGHWNAPE-UHFFFAOYSA-N,50428450,CHEMBL475278,Carbonic anhydrase 1,Homo sapiens,
51398672,CCCCCCCCCOCC(=O)NS(=O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12,"InChI=1S/C21H34N6O8S/c1-2-3-4-5-6-7-8-9-33-11-15(28)26-36(31,32)34-10-14-17(29)18(30)21(35-14)27-13-25-16-19(22)23-12-24-20(16)27/h12-14,17-18,21,29-30H,2-11H2,1H3,(H,26,28)(H2,22,23,24)/t14-,17-,18-,21-/m1/s1",DMXVUOGFRWKZBY-HAXDFEGKSA-N,50565079,CHEMBL4795362,Medium/long-chain-fatty-acid--CoA/3-oxocholest-4-en-26-oate--CoA ligase,,
626060,CCc1cnc(s1)-c1cc(OCC2(F)CN(C)C2)cc(c1)C(=O)N[C@H](C)c1ccc(nc1)C(F)(F)F,"InChI=1S/C25H26F4N4O2S/c1-4-20-11-31-23(36-20)18-7-17(8-19(9-18)35-14-24(26)12-33(3)13-24)22(34)32-15(2)16-5-6-21(30-10-16)25(27,28)29/h5-11,15H,4,12-14H2,1-3H3,(H,32,34)/t15-/m1/s1",HCTVCZSENAWJEB-OAHLLOKOSA-N,320220,"3-(5-ethyl-1,3- thiazol-2-yl)-5-[(3- fluoro-1- methylazetidin-3- yl)methoxy]-N- {(1R)-1-[6- (trifluoromethyl) pyridin-3-yl] ethyl}benzamide::US10174016, Example 387::US10202369, Example 387::US10472354, Example 387",P2X purinoceptor 3,Homo sapiens, 19.0
1025188,Cc1ncn(C)c1CSc1cc(N)nc2[nH]nnc12,"InChI=1S/C11H13N7S/c1-6-7(18(2)5-13-6)4-19-8-3-9(12)14-11-10(8)15-17-16-11/h3,5H,4H2,1-2H3,(H3,12,14,15,16,17)",MLJYJARGDKJZJV-UHFFFAOYSA-N,492843,"7-(((1,4-dimethyl-1H- imidazol-5-yl)methyl)thio)- 3H-[1,2,3]triazolo[4,5-b] pyridin-5-amine::US10981879, Example 77",Myeloperoxidase,Homo sapiens, 610
351866,FC(F)(F)c1ccc(CCN2CCC(CC2)c2nnn3cnc4[nH]ccc4c23)cc1,"InChI=1S/C21H21F3N6/c22-21(23,24)16-3-1-14(2-4-16)6-10-29-11-7-15(8-12-29)18-19-17-5-9-25-20(17)26-13-30(19)28-27-18/h1-5,9,13,15,25H,6-8,10-12H2",NIGMZMFZEBEOSJ-UHFFFAOYSA-N,198234,"US9216999, 42::US9556187, Example 42",Tyrosine-protein kinase JAK1,Homo sapiens, 82
50762964,CC(=O)Nc1ccc(NC(=O)Nc2ccc(cc2)-c2nc(N3CCOCC3)c3cccnc3n2)cc1,"InChI=1S/C26H25N7O3/c1-17(34)28-19-8-10-21(11-9-19)30-26(35)29-20-6-4-18(5-7-20)23-31-24-22(3-2-12-27-24)25(32-23)33-13-15-36-16-14-33/h2-12H,13-16H2,1H3,(H,28,34)(H2,29,30,35)",DKZPTDGOVHBSJY-UHFFFAOYSA-N,50243313,CHEMBL4103534,"Phosphatidylinositol 3-kinase regulatory subunit alpha/4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",Homo sapiens, 2.5
606531,Cc1nnn2CCN(c3ccc(Cl)cc3)c3cc(CO)ccc3-c12,"InChI=1S/C18H17ClN4O/c1-12-18-16-7-2-13(11-24)10-17(16)22(8-9-23(18)21-20-12)15-5-3-14(19)4-6-15/h2-7,10,24H,8-9,11H2,1H3",ORTRBMKXQWFMTN-UHFFFAOYSA-N,313790,"US10167292, Example 34",Bromodomain-containing protein 3 [51-123],,<100
402676,C[C@H]1OC(=O)C2CC(F)(F)[C@@H](C)[C@H](\C=C\c3ccc(cn3)-c3cccc(F)c3)C12,"InChI=1S/C23H22F3NO2/c1-13-19(21-14(2)29-22(28)20(21)11-23(13,25)26)9-8-18-7-6-16(12-27-18)15-4-3-5-17(24)10-15/h3-10,12-14,19-21H,11H2,1-2H3/b9-8+/t13-,14+,19-,20?,21?/m0/s1",MCFWIZMCCHEXBK-PZNXONMCSA-N,230664,"US9340530, 2",Proteinase-activated receptor 1,,
50945348,FC(F)(F)Oc1ccccc1S(=O)(=O)N1CC(C1)C(=O)N1CCN(CC1)c1ccncc1,"InChI=1S/C20H21F3N4O4S/c21-20(22,23)31-17-3-1-2-4-18(17)32(29,30)27-13-15(14-27)19(28)26-11-9-25(10-12-26)16-5-7-24-8-6-16/h1-8,15H,9-14H2",ABCISIOUDAPUAB-UHFFFAOYSA-N,50387788,CHEMBL2058899,Muscarinic acetylcholine receptor M1,, 2500
50860936,Oc1ccc(cc1NC(=O)c1ccccc1)-c1ccccc1,"InChI=1S/C19H15NO2/c21-18-12-11-16(14-7-3-1-4-8-14)13-17(18)20-19(22)15-9-5-2-6-10-15/h1-13,21H,(H,20,22)",INXWGOLWSBWSOQ-UHFFFAOYSA-N,50232005,CHEMBL269935::N-(4-hydroxy-biphenyl-3-yl)-benzamide::N-(4-hydroxybiphenyl-3-yl)benzamide,Histone deacetylase 6,Homo sapiens,>50000
158786,CNC(=S)NCCSCc1[nH]cnc1C,"InChI=1S/C9H16N4S2/c1-7-8(13-6-12-7)5-15-4-3-11-9(14)10-2/h6H,3-5H2,1-2H3,(H,12,13)(H2,10,11,14)",FPBPLBWLMYGIQR-UHFFFAOYSA-N,81468,CAS_34839-70-8::Metiamide::NSC_1548992,Histamine H2 receptor,Cavia porcellus,
50972989,CN1C[C@@H]([C@H](C1)c1ccc(\C=C\C(=O)Nc2ccccc2N)cc1F)C(=O)Nc1ccc(Cl)cc1,"InChI=1S/C27H26ClFN4O2/c1-33-15-21(22(16-33)27(35)31-19-10-8-18(28)9-11-19)20-12-6-17(14-23(20)29)7-13-26(34)32-25-5-3-2-4-24(25)30/h2-14,21-22H,15-16,30H2,1H3,(H,31,35)(H,32,34)/b13-7+/t21-,22+/m1/s1",PZYNOSYZPXJRNG-NAHVQIJJSA-N,50399004,CHEMBL2177582,Histone deacetylase 7,Homo sapiens,>30000
50157044,CCN(CC)C(=O)c1ccc(cc1)N(C1CCN(CC(C)c2ccccc2)CC1)c1cccc(O)c1,"InChI=1S/C31H39N3O2/c1-4-33(5-2)31(36)26-14-16-27(17-15-26)34(29-12-9-13-30(35)22-29)28-18-20-32(21-19-28)23-24(3)25-10-7-6-8-11-25/h6-17,22,24,28,35H,4-5,18-21,23H2,1-3H3",UJJLKLKIVAJGRK-UHFFFAOYSA-N,50302764,"CHEMBL568865::N,N-diethyl-4-((3-hydroxyphenyl)(1-(2-phenylpropyl)piperidin-4-yl)amino)benzamide",Delta-type opioid receptor,Homo sapiens,
50257760,N[C@@H]([C@H]1CC[C@@H](CC1)NS(=O)(=O)c1ccc(OC(F)(F)F)cc1)C(=O)N1CCCC1,"InChI=1S/C19H26F3N3O4S/c20-19(21,22)29-15-7-9-16(10-8-15)30(27,28)24-14-5-3-13(4-6-14)17(23)18(26)25-11-1-2-12-25/h7-10,13-14,17,24H,1-6,11-12,23H2/t13-,14-,17-/m0/s1",WJMXEGCIFZKOOF-ZQIUZPCESA-N,50140538,CHEMBL23979::N-[4-((S)-1-Amino-2-oxo-2-pyrrolidin-1-yl-ethyl)-cyclohexyl]-4-trifluoromethoxy-benzenesulfonamide,Dipeptidyl peptidase 4,Homo sapiens, 89
50684315,Clc1cccc(Cl)c1C(=O)Nc1cn[nH]c1C(=O)NC1CCNCC1,"InChI=1S/C16H17Cl2N5O2/c17-10-2-1-3-11(18)13(10)15(24)22-12-8-20-23-14(12)16(25)21-9-4-6-19-7-5-9/h1-3,8-9,19H,4-7H2,(H,20,23)(H,21,25)(H,22,24)",OVPNQJVDAFNBDN-UHFFFAOYSA-N,24654,"4-N-(2,6-dichlorobenzene)-3-N-(piperidin-4-yl)-1H-pyrazole-3,4-diamido::AT7519::JMC514986 Compound 33::pyrazole diamide, 33",Ephrin type-A receptor 6,Homo sapiens,
1049294,C[C@@H]1CN(CCN1C(=O)NCCC1CCN(Cc2ccccc2)CC1)c1ccc(cn1)C(F)(F)F,"InChI=1S/C26H34F3N5O/c1-20-18-33(24-8-7-23(17-31-24)26(27,28)29)15-16-34(20)25(35)30-12-9-21-10-13-32(14-11-21)19-22-5-3-2-4-6-22/h2-8,17,20-21H,9-16,18-19H2,1H3,(H,30,35)/t20-/m1/s1",UGMRMSCESDAAEU-HXUWFJFHSA-N,502705,"(2R)-N-[2-(1-benzylpiperidin-4-yl)ethyl]-2-methyl-4-[5- (trifluoromethyl)pyridin-2-yl]piperazine-1-carboxamide::US11033539, Cpd. No. 3-14",Muscarinic acetylcholine receptor M2,,
50346949,COc1ccc2[nH]c(cc2c1)C(=O)c1cc2c(Cl)cccc2[nH]1,"InChI=1S/C18H13ClN2O2/c1-23-11-5-6-14-10(7-11)8-16(20-14)18(22)17-9-12-13(19)3-2-4-15(12)21-17/h2-9,20-21H,1H3",JARCTNGBOAVXHD-UHFFFAOYSA-N,50187372,(4-Chloro-1H-indol-2-yl)-(5-methoxy-1H-indol-2-yl)-methanone::CHEMBL383276,Platelet-derived growth factor receptor alpha/beta,Mus musculus,>30000
214983,OS(=O)(=O)ON1[C@H]2CN([C@@H](CC2)C(=O)N[C@@H]2CNC[C@@H]2F)C1=O,"InChI=1S/C11H17FN4O6S/c12-7-3-13-4-8(7)14-10(17)9-2-1-6-5-15(9)11(18)16(6)22-23(19,20)21/h6-9,13H,1-5H2,(H,14,17)(H,19,20,21)/t6-,7+,8-,9+/m1/s1",CEAGXQKBRTYLPI-XAVMHZPKSA-N,98746,"US8487093, 98",Beta-lactamase,Klebsiella pneumoniae, 190
1102769,FC(F)Oc1cc2NC(=O)COc2cc1-c1n[nH]cc1NC(=O)c1cnn2cccnc12,"InChI=1S/C19H13F2N7O4/c20-19(21)32-13-5-11-14(31-8-15(29)25-11)4-9(13)16-12(7-23-27-16)26-18(30)10-6-24-28-3-1-2-22-17(10)28/h1-7,19H,8H2,(H,23,27)(H,25,29)(H,26,30)",FIWZXYWXBGFQSA-UHFFFAOYSA-N,521950,"N-[3-[6-(difluoromethoxy)-3- oxo-4H-1,4-benzoxazin-7-yl]- 1H-pyrazol-4-yl]pyrazolo[1,5- a]pyrimidine-3-carboxamide::US11155557, Example 40",Tyrosine-protein kinase JAK1,Homo sapiens,
51240255,CC[C@H](C)[C@@H]1NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]4CCCN4C(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccc(O)cc5)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC1=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N4)NC(=O)[C@@H](NC3=O)[C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N2,"InChI=1S/C142H224N50O46S6/c1-8-68(5)110-136(236)182-81(44-67(3)4)124(224)176-75(24-13-15-37-143)118(218)173-76(25-14-16-38-144)121(221)186-92-62-240-242-64-94-133(233)172-74(26-17-39-155-139(147)148)113(213)161-54-104(203)169-84(47-99(146)198)114(214)162-55-103(202)168-83(46-72-31-33-73(196)34-32-72)125(225)185-91-61-239-244-66-96(189-128(228)87(50-109(210)211)181-130(230)90(60-195)183-127(227)86(49-108(208)209)180-120(220)78(28-19-41-157-141(151)152)174-119(219)77(177-131(92)231)27-18-40-156-140(149)150)138(238)192-43-21-30-97(192)135(235)165-53-101(200)166-70(7)112(212)184-95(134(234)191-111(69(6)9-2)137(237)188-94)65-243-241-63-93(132(232)178-80(35-36-98(145)197)122(222)175-79(123(223)190-110)29-20-42-158-142(153)154)187-126(226)82(45-71-22-11-10-12-23-71)167-102(201)52-159-100(199)51-160-115(215)85(48-107(206)207)179-129(229)89(59-194)171-106(205)56-163-116(216)88(58-193)170-105(204)57-164-117(91)217/h10-12,22-23,31-34,67-70,74-97,110-111,193-196H,8-9,13-21,24-30,35-66,143-144H2,1-7H3,(H2,145,197)(H2,146,198)(H,159,199)(H,160,215)(H,161,213)(H,162,214)(H,163,216)(H,164,217)(H,165,235)(H,166,200)(H,167,201)(H,168,202)(H,169,203)(H,170,204)(H,171,205)(H,172,233)(H,173,218)(H,174,219)(H,175,222)(H,176,224)(H,177,231)(H,178,232)(H,179,229)(H,180,220)(H,181,230)(H,182,236)(H,183,227)(H,184,212)(H,185,225)(H,186,221)(H,187,226)(H,188,237)(H,189,228)(H,190,223)(H,191,234)(H,206,207)(H,208,209)(H,210,211)(H4,147,148,155)(H4,149,150,156)(H4,151,152,157)(H4,153,154,158)/t68-,69-,70-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,110-,111-/m0/s1",WONGRAWCJSVHOJ-GYRZNHFHSA-N,50507481,CHEMBL4564063,Prothrombin,,
50183103,COC(=O)c1ccc2\C(=C(\Nc3ccc(cc3)N(C)C(=O)CN3CCN(C)CC3)c3ccccc3)C(=O)Nc2c1,"InChI=1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,32H,15-18,20H2,1-3H3,(H,33,38)/b29-28-",XZXHXSATPCNXJR-ZIADKAODSA-N,50026612,"BIBF-1120::Nintedanib::US10981896, Compound Nintedanib::US11046672, Nintedanib::US11208381, Nintedanib::Vargatef",Serine/threonine-protein kinase 3,Homo sapiens,
197822,CC(C)c1ccc(cc1)C(c1c(O)c2ccccc2oc1=O)c1c(O)c2ccccc2oc1=O,"InChI=1S/C28H22O6/c1-15(2)16-11-13-17(14-12-16)22(23-25(29)18-7-3-5-9-20(18)33-27(23)31)24-26(30)19-8-4-6-10-21(19)34-28(24)32/h3-15,22,29-30H,1-2H3",HJFQCLUSKVFGHQ-UHFFFAOYSA-N,50226830,"4-hydroxy-3-((4-hydroxy-2-oxo-2H-chromen-3-yl)(4-isopropylphenyl)methyl)-2H-chromen-2-one::CHEMBL237188::Dicoumarol derivative, 5::cid_54677783",Corticotropin-releasing factor-binding protein,Homo sapiens,
1168714,CNC(=O)c1ccc(cn1)N1CCN(Cc2ccc3nc(CCF)c(=O)[nH]c3c2)CC1,"InChI=1S/C22H25FN6O2/c1-24-21(30)18-5-3-16(13-25-18)29-10-8-28(9-11-29)14-15-2-4-17-20(12-15)27-22(31)19(26-17)6-7-23/h2-5,12-13H,6-11,14H2,1H3,(H,24,30)(H,27,31)",IJAODHMIIARWJQ-UHFFFAOYSA-N,553962,"US11325906, Example 25",Potassium voltage-gated channel subfamily H member 2,Homo sapiens,>40000
50654797,O=C(N1CCN(CC1)C1(C(=O)NC(=O)NC1=O)c1ccc(Oc2ccccc2)cc1)c1cccs1,"InChI=1S/C25H22N4O5S/c30-21(20-7-4-16-35-20)28-12-14-29(15-13-28)25(22(31)26-24(33)27-23(25)32)17-8-10-19(11-9-17)34-18-5-2-1-3-6-18/h1-11,16H,12-15H2,(H2,26,27,31,32,33)",QEINCUZDRZTOOF-UHFFFAOYSA-N,50350608,CHEMBL1812926,72 kDa type IV collagenase,, 73
647603,COc1cc2CCN(CCCCn3c4ccccc4oc3=O)Cc2cc1OC,"InChI=1S/C22H26N2O4/c1-26-20-13-16-9-12-23(15-17(16)14-21(20)27-2)10-5-6-11-24-18-7-3-4-8-19(18)28-22(24)25/h3-4,7-8,13-14H,5-6,9-12,15H2,1-2H3",RJOLCJAZFJGNAH-UHFFFAOYSA-N,312183,"US9604926, Compound CM-295::US9724435, Compound CM-295",Sigma non-opioid intracellular receptor 1,Rattus,
557834,CCN(CC)[C@@H](C)CNC(=O)c1cc(NCCN(C)C)nc(c1)-c1cnn2ccc(nc12)-c1ccccc1,"InChI=1S/C29H38N8O/c1-6-36(7-2)21(3)19-31-29(38)23-17-26(33-27(18-23)30-14-16-35(4)5)24-20-32-37-15-13-25(34-28(24)37)22-11-9-8-10-12-22/h8-13,15,17-18,20-21H,6-7,14,16,19H2,1-5H3,(H,30,33)(H,31,38)/t21-/m0/s1",IMRGQEBDPCOREI-NRFANRHFSA-N,292502,"(S)-N-(2-(diethylamino)propyl)-2-((2-(dimethylamino)ethyl)amino)-6-(5-phenylpyrazolo[1,5-a]pyrimidin-3-yl)isonicotinamide::US10100058, Example 158",Calcium/calmodulin-dependent protein kinase type II subunit delta,, 0.560
51347461,NC(=O)c1cc(Br)cc2[nH]c(nc12)-c1ccncc1,"InChI=1S/C13H9BrN4O/c14-8-5-9(12(15)19)11-10(6-8)17-13(18-11)7-1-3-16-4-2-7/h1-6H,(H2,15,19)(H,17,18)",MFMOSBDEOQIGBY-UHFFFAOYSA-N,50545113,CHEMBL4647033,Serine/threonine-protein kinase N2,Homo sapiens, 170
689861,O=C(Nc1nc2cccc(-c3ccc(COc4ccccc4)cc3)n2n1)C1CC1,"InChI=1S/C23H20N4O2/c28-22(18-13-14-18)25-23-24-21-8-4-7-20(27(21)26-23)17-11-9-16(10-12-17)15-29-19-5-2-1-3-6-19/h1-12,18H,13-15H2,(H,25,26,28)",XJJLVTDOHXWXFW-UHFFFAOYSA-N,349119,"Cyclopropanecarboxylic acid [5-(4-phenoxymethyl-phenyl)- [1,2,4]triazolo[1,5-a]pyridin-2- yl]-amide::US10206907, Compound 238",Tyrosine-protein kinase JAK1 [850-1154],,<100
480883,CN(C)c1cccc(\C=C\c2nc(N(C)C)c3cc(Cl)ccc3n2)n1,"InChI=1S/C19H20ClN5/c1-24(2)18-7-5-6-14(21-18)9-11-17-22-16-10-8-13(20)12-15(16)19(23-17)25(3)4/h5-12H,1-4H3/b11-9+",LOFOCPNPVGOLFG-PKNBQFBNSA-N,202234,"(e)-6-chloro-2-(2-(6-(dimethylamino)pyridin-2-yl)vinyl)-n,n-dimethylquinazolin-4-amine::US9540384, 41","cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A",Homo sapiens, 750
389073,CC(C)(C)c1cc(no1)N1C(C(C(=O)c2ccc(Cl)cc2)=C(O)C1=O)c1cccc(F)c1,"InChI=1S/C24H20ClFN2O4/c1-24(2,3)17-12-18(27-32-17)28-20(14-5-4-6-16(26)11-14)19(22(30)23(28)31)21(29)13-7-9-15(25)10-8-13/h4-12,20,30H,1-3H3",SGVWWAFILPHYJW-UHFFFAOYSA-N,222365,IPR-1196 (18),Urokinase plasminogen activator surface receptor,, 47300
51154606,C1CN=C(N1)C1c2ccccc2Oc2ccccc12,"InChI=1S/C16H14N2O/c1-3-7-13-11(5-1)15(16-17-9-10-18-16)12-6-2-4-8-14(12)19-13/h1-8,15H,9-10H2,(H,17,18)",OOZRSNQXSFEXBA-UHFFFAOYSA-N,50473183,CHEMBL275564,Nischarin,,
50229609,COc1ccc(cc1)S(=O)(=O)N(Cc1ccccc1)c1c(cnc2c(C)cccc12)C(=O)NO,"InChI=1S/C25H23N3O5S/c1-17-7-6-10-21-23(17)26-15-22(25(29)27-30)24(21)28(16-18-8-4-3-5-9-18)34(31,32)20-13-11-19(33-2)12-14-20/h3-15,30H,16H2,1-2H3,(H,27,29)",JFQFSHSHMHJPSW-UHFFFAOYSA-N,50126633,4-(N-benzyl-4-methoxyphenylsulfonamido)-N-hydroxy-8-methylquinoline-3-carboxamide::4-[Benzyl-(4-methoxy-benzenesulfonyl)-amino]-8-methyl-quinoline-3-carboxylic acid hydroxyamide::CHEMBL289411,Interstitial collagenase,, 152
50393141,CCCCCOc1ccc(NS(=O)(=O)c2ccc3CN(Cc3c2)C(=O)Nc2ccc(cc2)C(C)(C)C)c(F)c1,"InChI=1S/C30H36FN3O4S/c1-5-6-7-16-38-25-13-15-28(27(31)18-25)33-39(36,37)26-14-8-21-19-34(20-22(21)17-26)29(35)32-24-11-9-23(10-12-24)30(2,3)4/h8-15,17-18,33H,5-7,16,19-20H2,1-4H3,(H,32,35)",HCLVCLSUVTYAOF-UHFFFAOYSA-N,159695,"US9035059, 14-18",2-acylglycerol O-acyltransferase 2,, 147
761143,CC(C)n1c(nc2C(=O)N(C(c12)c1ccc(Cl)cc1)c1ccc(=O)n(C)c1)-c1ccccn1,"InChI=1S/C25H22ClN5O2/c1-15(2)30-23-21(28-24(30)19-6-4-5-13-27-19)25(33)31(18-11-12-20(32)29(3)14-18)22(23)16-7-9-17(26)10-8-16/h4-15,22H,1-3H3",OOPLGRXMPNAWKN-UHFFFAOYSA-N,380634,"6-(4-chlorophenyl)-1-isopropyl-5-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-(Pyridin-2-yl)-5,6-dihydropyrrolo[3,4-d]imidazol-4(1H)-one::US9890166, Example 20",Bromodomain-containing protein 3,, 610
51125084,CC1=C(C(NC(=O)N1)c1ccc(F)c(CC(=O)NCc2cc(C)ccc2C)c1)C(=O)Nc1ccc2[nH]ncc2c1,"InChI=1S/C30H29FN6O3/c1-16-4-5-17(2)21(10-16)14-32-26(38)13-20-11-19(6-8-24(20)31)28-27(18(3)34-30(40)36-28)29(39)35-23-7-9-25-22(12-23)15-33-37-25/h4-12,15,28H,13-14H2,1-3H3,(H,32,38)(H,33,37)(H,35,39)(H2,34,36,40)",WVYPJRPGGXFBPN-UHFFFAOYSA-N,50461328,CHEMBL4224914,Beta-adrenergic receptor kinase 1,Homo sapiens, 1900
50165657,CCCCCCC(C)(C)c1ccc-2c(OC(C)(C)c3ccc(CO)cc-23)c1,"InChI=1S/C25H34O2/c1-6-7-8-9-14-24(2,3)19-11-12-20-21-15-18(17-26)10-13-22(21)25(4,5)27-23(20)16-19/h10-13,15-16,26H,6-9,14,17H2,1-5H3",CFQBPYBPMFYBLY-UHFFFAOYSA-N,50092584,"CHEMBL331838::[3-(1,1-Dimethyl-heptyl)-6,6-dimethyl-6H-benzo[c]chromen-9-yl]-methanol",Cannabinoid receptor 1,Homo sapiens,
50660365,CC(C)[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(cc2)[N+]([O-])=O)NC(=O)C(C)(C)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O,"InChI=1S/C55H74N12O13S2/c1-31(2)45-52(76)62-41(28-44(57)69)49(73)63-42(53(77)66-24-10-14-43(66)51(75)59-37(13-8-9-23-56)47(71)60-38(46(58)70)25-34-17-21-36(68)22-18-34)29-81-82-30-55(3,4)54(78)64-40(27-33-15-19-35(20-16-33)67(79)80)48(72)61-39(50(74)65-45)26-32-11-6-5-7-12-32/h5-7,11-12,15-22,31,37-43,45,68H,8-10,13-14,23-30,56H2,1-4H3,(H2,57,69)(H2,58,70)(H,59,75)(H,60,71)(H,61,72)(H,62,76)(H,63,73)(H,64,78)(H,65,74)/t37-,38-,39-,40-,41-,42-,43-,45-/m0/s1",JJKDJJIRIJTKGT-HSLJZQCHSA-N,50453149,CHEMBL2115368,Vasopressin V1a receptor,Rattus,
51134551,C[C@H](CC(=O)N1CCC(O)(Cn2cnc3c(-c4cccc(c4)C(N)=O)n(C)nc3c2=O)CC1)c1ccccc1,"InChI=1S/C29H32N6O4/c1-19(20-7-4-3-5-8-20)15-23(36)34-13-11-29(39,12-14-34)17-35-18-31-24-25(28(35)38)32-33(2)26(24)21-9-6-10-22(16-21)27(30)37/h3-10,16,18-19,39H,11-15,17H2,1-2H3,(H2,30,37)/t19-/m1/s1",JDLLYACWFFLZNR-LJQANCHMSA-N,50465203,"CHEMBL4281720::US10766903, Example 28",Ubiquitin carboxyl-terminal hydrolase 7,Homo sapiens, 30
691748,COCC1(Cn2c(CN3CCC(CC3)c3cccc(OCc4ccc(Cl)cc4F)n3)nc3ccc(cc23)C(O)=O)CCC1,"InChI=1S/C33H36ClFN4O4/c1-42-21-33(12-3-13-33)20-39-29-16-23(32(40)41)7-9-28(29)36-30(39)18-38-14-10-22(11-15-38)27-4-2-5-31(37-27)43-19-24-6-8-25(34)17-26(24)35/h2,4-9,16-17,22H,3,10-15,18-21H2,1H3,(H,40,41)",JDZHYTGFLAYCAJ-UHFFFAOYSA-N,349883,"2-[(4-{6-[(4-chloro-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-{[1-(methoxymethyl)cyclobutyl]methyl}-1H-benzimidazole-6-carboxylic acid::US10208019, Example 11A-74",Glucagon-like peptide 1 receptor,,
1198850,CC(C)N1CC2CN(CC2C1)C(=O)c1ccc2[nH]c(c(C(C)C)c2c1)-c1cc(C)nc(C)c1,,,568232,"US11420973, Example 110",Toll-like receptor 9,, 410
50426634,O=C1NCCc2ccccc12,"InChI=1S/C9H9NO/c11-9-8-4-2-1-3-7(8)5-6-10-9/h1-4H,5-6H2,(H,10,11)",YWPMKTWUFVOFPL-UHFFFAOYSA-N,50339016,"3,4-dihydroisoquinolin-1(2H)-one::CHEMBL1688212",Protein mono-ADP-ribosyltransferase PARP10,, 30000
50995488,COc1c(Cl)cc(Cl)c(O)c1C(=O)NCCN1CCN(CC1)c1cccc(Cl)c1Cl,"InChI=1S/C20H21Cl4N3O3/c1-30-19-14(23)11-13(22)18(28)16(19)20(29)25-5-6-26-7-9-27(10-8-26)15-4-2-3-12(21)17(15)24/h2-4,11,28H,5-10H2,1H3,(H,25,29)",MGAAQQVYULJSPC-UHFFFAOYSA-N,50408400,CHEMBL168245,D(3) dopamine receptor,,
803783,CCN(CCN(C)c1nc(C)cc(C)n1)C(=O)c1ccc(OC)nc1C1CC1,"InChI=1S/C21H29N5O2/c1-6-26(12-11-25(4)21-22-14(2)13-15(3)23-21)20(27)17-9-10-18(28-5)24-19(17)16-7-8-16/h9-10,13,16H,6-8,11-12H2,1-5H3",VLLVBCCTOIMVGZ-UHFFFAOYSA-N,402061,"2-cyclopropyl-N-{2-[(4,6- dimethylpyrimidin-2- yl)(methyl)amino]ethyl}-N-ethyl-6- methoxypyridine-3-carboxamide::US10011595, B-19",Orexin/Hypocretin receptor type 1,Homo sapiens, 9682
535800,CC(C)c1cc([nH]n1)C(=O)N1CCC(C1)c1nc(C)cc(n1)-c1cnn(C)c1,"InChI=1S/C20H25N7O/c1-12(2)16-8-18(25-24-16)20(28)27-6-5-14(11-27)19-22-13(3)7-17(23-19)15-9-21-26(4)10-15/h7-10,12,14H,5-6,11H2,1-4H3,(H,24,25)",KZMBBRVEMMYESC-UHFFFAOYSA-N,281162,"US10022354, Example 102",Lysine-specific demethylase 5A,Homo sapiens, 0.760
50409627,COc1ccccc1N1CCN(CCCCNC(=O)c2nnn(Cc3ccccc3Br)c2C)CC1,"InChI=1S/C26H33BrN6O2/c1-20-25(29-30-33(20)19-21-9-3-4-10-22(21)27)26(34)28-13-7-8-14-31-15-17-32(18-16-31)23-11-5-6-12-24(23)35-2/h3-6,9-12H,7-8,13-19H2,1-2H3,(H,28,34)",YFSQZKVPESKTJY-UHFFFAOYSA-N,50119506,CHEMBL385289,5-hydroxytryptamine receptor 2A,,
232141,COc1cc(cc(C=Nc2nn[nH]n2)c1O)-c1cccs1,"InChI=1S/C13H11N5O2S/c1-20-10-6-8(11-3-2-4-21-11)5-9(12(10)19)7-14-13-15-17-18-16-13/h2-7,19H,1H3,(H,15,16,17,18)",KAYRFYIVEJDGJA-UHFFFAOYSA-N,111410,"US8614253, 38-11",Serine/threonine-protein kinase/endoribonuclease IRE1,Homo sapiens, 157
192196,CCOC(=O)c1c2CCCc2c(=S)sc1N,"InChI=1S/C11H13NO2S2/c1-2-14-10(13)8-6-4-3-5-7(6)11(15)16-9(8)12/h2-5,12H2,1H3",VWOJESZFVONLRW-UHFFFAOYSA-N,48325,"3-amino-1-sulfanylidene-6,7-dihydro-5H-cyclopenta[c]thiopyran-4-carboxylic acid ethyl ester::3-amino-1-thioxo-6,7-dihydro-5H-cyclopenta[c]thiopyran-4-carboxylic acid ethyl ester::MLS000071298::SMR000034348::cid_658981::ethyl 3-amino-1-sulfanylidene-6,7-dihydro-5H-cyclopenta[c]thiopyran-4-carboxylate::ethyl 3-azanyl-1-sulfanylidene-6,7-dihydro-5H-cyclopenta[c]thiopyran-4-carboxylate",Polyadenylate-binding protein 1,Homo sapiens,>66000
51138146,Cn1c(=O)[nH]c2ccc(cc2c1=O)S(=O)(=O)NC1(C)CC1,"InChI=1S/C13H15N3O4S/c1-13(5-6-13)15-21(19,20)8-3-4-10-9(7-8)11(17)16(2)12(18)14-10/h3-4,7,15H,5-6H2,1-2H3,(H,14,18)",YASXIBKHWUEKGC-UHFFFAOYSA-N,370900,"3-Methyl-N-(1-methylcyclopropyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-sulfonamide::US10239843, Example 7",Poly(ADP-ribose) glycohydrolase,,
51211813,COc1c(F)c(F)ccc1-c1csc(n1)N1CCOCC1,"InChI=1S/C14H14F2N2O2S/c1-19-13-9(2-3-10(15)12(13)16)11-8-21-14(17-11)18-4-6-20-7-5-18/h2-3,8H,4-7H2,1H3",UZZZYERDPQSGCX-UHFFFAOYSA-N,50497998,CHEMBL3323484,Androgen receptor,Homo sapiens, 180
50524612,CC1CCCCN1C(=O)C(CCn1cccc1C#N)NS(=O)(=O)c1cc(Cl)c(N)c(Cl)c1,"InChI=1S/C21H25Cl2N5O3S/c1-14-5-2-3-9-28(14)21(29)19(7-10-27-8-4-6-15(27)13-24)26-32(30,31)16-11-17(22)20(25)18(23)12-16/h4,6,8,11-12,14,19,26H,2-3,5,7,9-10,25H2,1H3",WPYNFVJDHQRBAL-UHFFFAOYSA-N,50199001,CHEMBL3927890,C-C chemokine receptor type 10,, 794
50341787,CN1CCc2cc(O)ccc2Cc2ccc(O)cc2CC1,"InChI=1S/C18H21NO2/c1-19-8-6-15-11-17(20)4-2-13(15)10-14-3-5-18(21)12-16(14)7-9-19/h2-5,11-12,20-21H,6-10H2,1H3",SBKJMNCSBLEGCS-UHFFFAOYSA-N,50184439,"3,11-Dihydroxy-7-methyl-5,6,7,8,9,14-hexahydrodibenzo[d,g]azecine::CHEMBL381936",D(1A) dopamine receptor,,
50706596,Nc1nc2ccccc2nc1\N=C\c1ccc(CN2CCCCC2)cc1,"InChI=1S/C21H23N5/c22-20-21(25-19-7-3-2-6-18(19)24-20)23-14-16-8-10-17(11-9-16)15-26-12-4-1-5-13-26/h2-3,6-11,14H,1,4-5,12-13,15H2,(H2,22,24)/b23-14+",OABSCYUVGRKVNB-OEAKJJBVSA-N,50359387,CHEMBL1929413,Acetylcholinesterase,Rattus norvegicus, 748
50059882,CCCCCNC(=O)Nc1c(NS(=O)(=O)C(F)(F)F)cccc1OCCCn1cnc(c1C)-c1ccccc1,"InChI=1S/C26H32F3N5O4S/c1-3-4-8-15-30-25(35)32-24-21(33-39(36,37)26(27,28)29)13-9-14-22(24)38-17-10-16-34-18-31-23(19(34)2)20-11-6-5-7-12-20/h5-7,9,11-14,18,33H,3-4,8,10,15-17H2,1-2H3,(H2,30,32,35)",OKIVIQCORMCPET-UHFFFAOYSA-N,50047594,"C,C,C-Trifluoro-N-[3-[3-(5-methyl-4-phenyl-imidazol-1-yl)-propoxy]-2-(3-pentyl-ureido)-phenyl]-methanesulfonamide::CHEMBL42128",Acyl-CoA:cholesterol acyltransferase,,>10000
881276,CC(C)Nc1nc(Nc2cc(C)nn2)nc2ccn(-c3cnn(c3)C3CCOCC3)c12,"InChI=1S/C21H26N9O/c1-13(2)23-20-19-17(24-21(26-20)25-18-10-14(3)27-28-18)4-7-29(19)16-11-22-30(12-16)15-5-8-31-9-6-15/h4,7,10-13,15H,5-6,8-9H2,1-3H3,(H2,23,24,25,26,28)",OROXGZYEGHKLAT-UHFFFAOYSA-N,434641,"US10562902, Compound 47",Interleukin-1 receptor-associated kinase 4,Homo sapiens, 550
1240221,Clc1cc2NC(=O)COc2cc1NCc1cccc(NC(=O)c2ccccc2Cl)c1,"InChI=1S/C22H17Cl2N3O3/c23-16-7-2-1-6-15(16)22(29)26-14-5-3-4-13(8-14)11-25-18-10-20-19(9-17(18)24)27-21(28)12-30-20/h1-10,25H,11-12H2,(H,26,29)(H,27,28)",MVYTWHFWTDTQSK-UHFFFAOYSA-N,582675,"US11548860, Compound 7::Z1567948782",Aromatase,Homo sapiens,>25000
50165491,S=C(NCC1CCN(CC2COc3ccccc3O2)CC1)Nc1ccccc1,"InChI=1S/C22H27N3O2S/c28-22(24-18-6-2-1-3-7-18)23-14-17-10-12-25(13-11-17)15-19-16-26-20-8-4-5-9-21(20)27-19/h1-9,17,19H,10-16H2,(H2,23,24,28)",RNSJPUZYZKKDCL-UHFFFAOYSA-N,50092441,"1-[1-(2,3-Dihydro-benzo[1,4]dioxin-2-ylmethyl)-piperidin-4-ylmethyl]-3-phenyl-thiourea::CHEMBL332741",D(2) dopamine receptor,Rattus norvegicus, 750
50893683,COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1,"InChI=1S/C20H22N4O3/c1-25-16-6-3-13(4-7-16)12-27-17-8-5-14(10-18(17)26-2)9-15-11-23-20(22)24-19(15)21/h3-8,10-11H,9,12H2,1-2H3,(H4,21,22,23,24)",MYQAUKPBNJWPIE-UHFFFAOYSA-N,32362,"5-[[3-methoxy-4-[(4-methoxyphenyl)methoxy]phenyl]methyl]pyrimidine-2,4-diamine::GW-2580::[2-amino-5-(3-methoxy-4-p-anisyloxy-benzyl)pyrimidin-4-yl]amine::cid_11617559",Cyclin-dependent kinase 8,Homo sapiens,
525281,N#Cc1cc(ccc1OC1CCOCC1)-c1ccnc2[nH]c(cc12)C1CC1,"InChI=1S/C22H21N3O2/c23-13-16-11-15(3-4-21(16)27-17-6-9-26-10-7-17)18-5-8-24-22-19(18)12-20(25-22)14-1-2-14/h3-5,8,11-12,14,17H,1-2,6-7,9-10H2,(H,24,25)",WWRBLGBEFCCCCB-UHFFFAOYSA-N,276864,"US10072001, Example 50::US10259811, Example 50",Serine/threonine-protein kinase TBK1,, 651
1002320,OC(=O)c1ccc2nn3[C@@H]4[C@H](COc3c2c1)N(CC1CC1)[C@]1([C@H]4c2cccc(Cl)c2F)C(=O)Nc2cc(Cl)ccc12,"InChI=1S/C30H23Cl2FN4O4/c31-16-7-8-19-22(11-16)34-29(40)30(19)24(17-2-1-3-20(32)25(17)33)26-23(36(30)12-14-4-5-14)13-41-27-18-10-15(28(38)39)6-9-21(18)35-37(26)27/h1-3,6-11,14,23-24,26H,4-5,12-13H2,(H,34,40)(H,38,39)/t23-,24-,26+,30+/m0/s1",JJCQXIRROLOGAC-HLNVOFQHSA-N,374733,"US10246467, Example I-4::US10246467, Example I-5::US10919913, # I-5",E3 ubiquitin-protein ligase Mdm2,Homo sapiens, 7.00
50961199,COc1ccc(NC(=O)CNS(=O)(=O)c2cccc(c2)C(N)=N)cc1OC,"InChI=1S/C17H20N4O5S/c1-25-14-7-6-12(9-15(14)26-2)21-16(22)10-20-27(23,24)13-5-3-4-11(8-13)17(18)19/h3-9,20H,10H2,1-2H3,(H3,18,19)(H,21,22)",HQZPFXBTOHGJRH-UHFFFAOYSA-N,50394300,CHEMBL2159387,Prothrombin,,
292589,CN(C)S(=O)(=O)c1ccc2NC(=O)\C(=N/Nc3ccccc3Cl)c2c1,"InChI=1S/C16H15ClN4O3S/c1-21(2)25(23,24)10-7-8-13-11(9-10)15(16(22)18-13)20-19-14-6-4-3-5-12(14)17/h3-9,19H,1-2H3,(H,18,20,22)",AVHGMOHTWHNUDL-UHFFFAOYSA-N,152127,"US8987474, HL2-016-1",Tyrosine-protein phosphatase non-receptor type 11,Homo sapiens,>100000
50185659,Oc1ccc(O)c(CNc2ccc(O)c(c2)C(=O)NCCCc2ccccc2)c1,"InChI=1S/C23H24N2O4/c26-19-9-11-21(27)17(13-19)15-25-18-8-10-22(28)20(14-18)23(29)24-12-4-7-16-5-2-1-3-6-16/h1-3,5-6,8-11,13-14,25-28H,4,7,12,15H2,(H,24,29)",NWPOOMNWBCXQHP-UHFFFAOYSA-N,50102422,"5-(2,5-Dihydroxy-benzylamino)-2-hydroxy-N-(3-phenyl-propyl)-benzamide::5-(2,5-dihydroxybenzylamino)-2-hydroxy-N-(3-phenylpropyl)benzamide::CHEMBL341946",Tubulin beta-2B chain,Bos taurus, 5000
51294306,Cc1cc2cn[nH]c2cc1-c1nnc2ccc(cn12)-c1ccoc1,"InChI=1S/C18H13N5O/c1-11-6-14-8-19-20-16(14)7-15(11)18-22-21-17-3-2-12(9-23(17)18)13-4-5-24-10-13/h2-10H,1H3,(H,19,20)",JRQTVMCZPUHAHA-UHFFFAOYSA-N,50527642,CHEMBL4458447,5'-nucleotidase,,>1000000
192095,O=C(CCC1CCCC1)Nc1ccc(cc1)C(=O)NCc1cccnc1,"InChI=1S/C21H25N3O2/c25-20(12-7-16-4-1-2-5-16)24-19-10-8-18(9-11-19)21(26)23-15-17-6-3-13-22-14-17/h3,6,8-11,13-14,16H,1-2,4-5,7,12,15H2,(H,23,26)(H,24,25)",VSQUNIFZLZOAQW-UHFFFAOYSA-N,6508,cid_1150831,Nuclear receptor coactivator 1,Homo sapiens, 3871
193237,Cc1ccc(NC(=O)CCn2c3ccccc3oc2=S)cc1F,"InChI=1S/C17H15FN2O2S/c1-11-6-7-12(10-13(11)18)19-16(21)8-9-20-14-4-2-3-5-15(14)22-17(20)23/h2-7,10H,8-9H2,1H3,(H,19,21)",JPDDLXSLXONEDM-UHFFFAOYSA-N,88785,"MLS001202227::N-(3-fluoranyl-4-methyl-phenyl)-3-(2-sulfanylidene-1,3-benzoxazol-3-yl)propanamide::N-(3-fluoro-4-methyl-phenyl)-3-(2-thioxo-1,3-benzoxazol-3-yl)propionamide::N-(3-fluoro-4-methylphenyl)-3-(2-sulfanylidene-1,3-benzoxazol-3-yl)propanamide::N-(3-fluoro-4-methylphenyl)-3-(2-thioxo-1,3-benzoxazol-3(2H)-yl)propanamide::SMR000564947::cid_5064419",Tyrosine-protein phosphatase non-receptor type 11,Homo sapiens, 3140
50713168,Clc1ccc(cc1)-c1cc2Cc3cc(ccc3-n3ccnc3-c2o1)N1CCNCC1,"InChI=1S/C24H21ClN4O/c25-19-3-1-16(2-4-19)22-15-18-13-17-14-20(28-10-7-26-8-11-28)5-6-21(17)29-12-9-27-24(29)23(18)30-22/h1-6,9,12,14-15,26H,7-8,10-11,13H2",MEYZYVFRRYUEJP-UHFFFAOYSA-N,50362172,CHEMBL1938684,MAP kinase-activated protein kinase 2,Homo sapiens, 7
50697012,CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1,"InChI=1S/C23H28N8OS/c1-15-13-20(29-28-15)25-19-14-21(31-11-9-30(2)10-12-31)27-23(26-19)33-18-7-5-17(6-8-18)24-22(32)16-3-4-16/h5-8,13-14,16H,3-4,9-12H2,1-2H3,(H,24,32)(H2,25,26,27,28,29)",GCIKSSRWRFVXBI-UHFFFAOYSA-N,13534,CHEMBL572878::N-[4-({4-[(3-methyl-1H-pyrazol-5-yl)amino]-6-(4-methylpiperazin-1-yl)pyrimidin-2-yl}sulfanyl)phenyl]cyclopropanecarboxamide::N-[4-[[4-(4-methylpiperazino)-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]thio]phenyl]cyclopropanecarboxamide::VX-680::VX680::cyclopropane carboxylic acid {4-[4-(4-methyl-piperazin-1-yl)-6-(5-methyl-2H-pyrazol-3-ylamino)-pyrimidin-2ylsulphanyl]-phenyl}-amide,Protein kinase C theta type,Homo sapiens,
51312074,Cc1cnc(n1C)[C@]1(CNC(=O)c2cc3cc(Cl)ccc3o2)NC(=O)NC1=O,"InChI=1S/C18H16ClN5O4/c1-9-7-20-15(24(9)2)18(16(26)22-17(27)23-18)8-21-14(25)13-6-10-5-11(19)3-4-12(10)28-13/h3-7H,8H2,1-2H3,(H,21,25)(H2,22,23,26,27)/t18-/m0/s1",SPAODDWHKVLWKW-SFHVURJKSA-N,50532311,CHEMBL4587825,Disintegrin and metalloproteinase domain-containing protein 17,, 8900
217136,COCCNC(=O)C(=C\c1c(nc2c(C)cccn2c1=O)N1CCN(CC1)c1ccc(OC)cc1)\C#N,"InChI=1S/C27H30N6O4/c1-19-5-4-11-33-24(19)30-25(23(27(33)35)17-20(18-28)26(34)29-10-16-36-2)32-14-12-31(13-15-32)21-6-8-22(37-3)9-7-21/h4-9,11,17H,10,12-16H2,1-3H3,(H,29,34)/b20-17+",NYFQURFFDGCBCB-LVZFUZTISA-N,75184,"(E)-2-cyano-3-[4-keto-2-[4-(4-methoxyphenyl)piperazino]-9-methyl-pyrido[1,2-a]pyrimidin-3-yl]-N-(2-methoxyethyl)acrylamide::(E)-2-cyano-N-(2-methoxyethyl)-3-[2-[4-(4-methoxyphenyl)-1-piperazinyl]-9-methyl-4-oxo-3-pyrido[1,2-a]pyrimidinyl]-2-propenamide::(E)-2-cyano-N-(2-methoxyethyl)-3-[2-[4-(4-methoxyphenyl)piperazin-1-yl]-9-methyl-4-oxidanylidene-pyrido[1,2-a]pyrimidin-3-yl]prop-2-enamide::(E)-2-cyano-N-(2-methoxyethyl)-3-[2-[4-(4-methoxyphenyl)piperazin-1-yl]-9-methyl-4-oxopyrido[1,2-a]pyrimidin-3-yl]prop-2-enamide::MLS001213408::SMR000540458::cid_5933865",Kallikrein-7,Homo sapiens,
572951,CC[C@H](N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1)c1nc(no1)C1CC1,"InChI=1S/C28H29Cl2N3O4/c1-3-22(26-31-25(32-37-26)17-7-8-17)33-24(16-9-11-19(29)12-10-16)21(18-5-4-6-20(30)13-18)14-28(2,27(33)36)15-23(34)35/h4-6,9-13,17,21-22,24H,3,7-8,14-15H2,1-2H3,(H,34,35)/t21-,22+,24-,28-/m1/s1",NCSZELYZOAIKBQ-YEPCPMPXSA-N,215138,"US9296736, 89::US9593129, Example 89",E3 ubiquitin-protein ligase Mdm2 [1-188],, 80.0
1254078,CCn1c(c2CC(C)(C)COC(=O)[C@@H]3CCCN(N3)C(=O)[C@H](Cc3cc(O)cc(c3)-c3ccc1c2c3)NC(=O)[C@H](C(C)C)N(C)C(=O)[C@H]1CCN(C1)C(=O)C#CCOC)-c1cccnc1COC,"InChI=1S/C52H65N7O9/c1-9-58-44-17-16-34-27-39(44)40(47(58)38-13-10-19-53-43(38)30-67-8)28-52(4,5)31-68-51(65)41-14-11-20-59(55-41)50(64)42(25-33-23-36(34)26-37(60)24-33)54-48(62)46(32(2)3)56(6)49(63)35-18-21-57(29-35)45(61)15-12-22-66-7/h10,13,16-17,19,23-24,26-27,32,35,41-42,46,55,60H,9,11,14,18,20-22,25,28-31H2,1-8H3,(H,54,62)/t35-,41-,42-,46-/m0/s1",ANWHHLTYINXDLY-FMGRFAOQSA-N,591457,"US11566007, Example A135",GTPase NRas [G12C],, 55.0
124357,Oc1cc2OCOc2cc1CN1CCN(CC1)c1ncccn1,"InChI=1S/C16H18N4O3/c21-13-9-15-14(22-11-23-15)8-12(13)10-19-4-6-20(7-5-19)16-17-2-1-3-18-16/h1-3,8-9,21H,4-7,10-11H2",ARCOXMPSRJYGRO-UHFFFAOYSA-N,66927,"6-[(4-pyrimidin-2-ylpiperazin-1-yl)methyl]-1,3-benzodioxol-5-ol::6-[[4-(2-pyrimidinyl)-1-piperazinyl]methyl]-1,3-benzodioxol-5-ol::6-[[4-(2-pyrimidyl)piperazino]methyl]sesamol::MLS001150220::SMR000688762::cid_7480032",Bcl-2-like protein 11,Homo sapiens,
51276608,COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(NC(=O)c2ccc(OC)c(OC)c2)n1,"InChI=1S/C28H35N7O5/c1-8-26(36)30-19-16-20(23(39-6)17-21(19)35(4)14-13-34(2)3)31-28-29-12-11-25(33-28)32-27(37)18-9-10-22(38-5)24(15-18)40-7/h8-12,15-17H,1,13-14H2,2-7H3,(H,30,36)(H2,29,31,32,33,37)",MUTDHCVPHOKJPT-UHFFFAOYSA-N,50521025,CHEMBL4450061,Epidermal growth factor receptor,Homo sapiens, 187
559628,CN1CCc2cc(ccc2C1)C(=O)Nc1cc2cc(ccc2cn1)-c1cn(C)nn1,"InChI=1S/C23H22N6O/c1-28-8-7-15-9-17(4-6-19(15)13-28)23(30)25-22-11-20-10-16(3-5-18(20)12-24-22)21-14-29(2)27-26-21/h3-6,9-12,14H,7-8,13H2,1-2H3,(H,24,25,30)",LZKASKVJGDNERL-UHFFFAOYSA-N,293555,"US10106527, Compound 256::US10544128, Compound 256::US9951048, Compound 256",Glycogen synthase kinase-3 beta,Homo sapiens,
51294669,O[C@@H]1[C@@H]2C[C@@H]2[C@H]([C@@H]1O)n1cnc2c(NCCc3ccc(O)cc3)nc(nc12)C#Cc1ccccc1,"InChI=1S/C27H25N5O3/c33-18-9-6-17(7-10-18)12-13-28-26-22-27(31-21(30-26)11-8-16-4-2-1-3-5-16)32(15-29-22)23-19-14-20(19)24(34)25(23)35/h1-7,9-10,15,19-20,23-25,33-35H,12-14H2,(H,28,30,31)/t19-,20+,23+,24+,25-/m0/s1",USWJRDNZGKAEGP-IRYUZJHDSA-N,50527836,CHEMBL4459700,Adenosine receptor A3,Mus musculus,
50964528,Fc1ccc(CC(=O)Nc2ccccc2N2CCCC2)cc1F,"InChI=1S/C18H18F2N2O/c19-14-8-7-13(11-15(14)20)12-18(23)21-16-5-1-2-6-17(16)22-9-3-4-10-22/h1-2,5-8,11H,3-4,9-10,12H2,(H,21,23)",VCFABBVOFIVCLH-UHFFFAOYSA-N,50395494,CHEMBL2164063,Potassium voltage-gated channel subfamily KQT member 2,Homo sapiens,
1008380,C[C@@H](Nc1cc(N[C@H](C)C2CC2)nc(n1)-c1cccc(n1)C(F)(F)F)C1CC1,"InChI=1S/C20H24F3N5/c1-11(13-6-7-13)24-17-10-18(25-12(2)14-8-9-14)28-19(27-17)15-4-3-5-16(26-15)20(21,22)23/h3-5,10-14H,6-9H2,1-2H3,(H2,24,25,27,28)/t11-,12-/m1/s1",MEKMADZCSPFPMP-VXGBXAGGSA-N,280255,"US10028961, Compound 414::US10172864, Compound 414::US10946023, Compound 414",Isocitrate dehydrogenase [NADP] cytoplasmic [R132H],, 75
50936157,CS(=O)(=O)Cc1cc(nc(n1)-c1ccccc1)N1CCOCC1,"InChI=1S/C16H19N3O3S/c1-23(20,21)12-14-11-15(19-7-9-22-10-8-19)18-16(17-14)13-5-3-2-4-6-13/h2-6,11H,7-10,12H2,1H3",ATWTWEBSSHJSEC-UHFFFAOYSA-N,50384262,CHEMBL2030440,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",Homo sapiens,>1000000
448496,CN1CC2(CC1=O)CCN(CC2)c1cc(ncn1)-c1n[nH]c2ccc(OC3(C)CC3)cc12,"InChI=1S/C24H28N6O2/c1-23(5-6-23)32-16-3-4-18-17(11-16)22(28-27-18)19-12-20(26-15-25-19)30-9-7-24(8-10-30)13-21(31)29(2)14-24/h3-4,11-12,15H,5-10,13-14H2,1-2H3,(H,27,28)",VATKQTNKZJFJJN-UHFFFAOYSA-N,257193,"US9493440, 37","Leucine-rich repeat serine/threonine-protein kinase 2 [970-2527,G2019S]",, 0.7
678983,OC(CCc1cccc(CNC2CCCC2)c1)CN1CCc2ccccc2C1,"InChI=1S/C25H34N2O/c28-25(19-27-15-14-22-8-1-2-9-23(22)18-27)13-12-20-6-5-7-21(16-20)17-26-24-10-3-4-11-24/h1-2,5-9,16,24-26,28H,3-4,10-15,17-19H2",RIRAPLTXMZUEMQ-UHFFFAOYSA-N,343742,"US9777008, Compound 36",Methylosome protein 50/Protein arginine N-methyltransferase 5,, 25000
215758,Nc1nc2ccc(cc2[nH]1)C(=O)N1CCCC2[C@@H]1Cc1ccccc21,"InChI=1S/C20H20N4O/c21-20-22-16-8-7-13(10-17(16)23-20)19(25)24-9-3-6-15-14-5-2-1-4-12(14)11-18(15)24/h1-2,4-5,7-8,10,15,18H,3,6,9,11H2,(H3,21,22,23)/t15?,18-/m0/s1",CKCPVILKBNAHHT-PKHIMPSTSA-N,99413,"US8497281, 191",11-beta-hydroxysteroid dehydrogenase 1,Homo sapiens, 1322
1163136,Clc1ccc2cc([nH]c2c1)C(=O)N1CC2(C[C@H]1C(=O)N[C@@H](C[C@@H]1CCCNC1=O)C#N)CCCCC2,,,509962,"US11124497, Compound 733 (Isomer 1)::US11312704, Compound 733 Isomer 1::US11472793, Compound 733 (Isomer 1)",Replicase polyprotein 1ab,,<2000
50560232,CC(=O)NC(O)CCOc1ccc(cc1)C(=O)N1CCC(CC1)n1c2ccccc2ccc1=O,"InChI=1S/C26H29N3O5/c1-18(30)27-24(31)14-17-34-22-9-6-20(7-10-22)26(33)28-15-12-21(13-16-28)29-23-5-3-2-4-19(23)8-11-25(29)32/h2-11,21,24,31H,12-17H2,1H3,(H,27,30)",XLAAEQOWWZDYNT-UHFFFAOYSA-N,50212859,CHEMBL46419,Vasopressin V1a/V1b receptor,, 3300
552598,CC1(C)Cc2c(CO1)sc1n(Cc3ccc(Cl)cc3)c(=O)n3ncnc3c21,"InChI=1S/C19H17ClN4O2S/c1-19(2)7-13-14(9-26-19)27-17-15(13)16-21-10-22-24(16)18(25)23(17)8-11-3-5-12(20)6-4-11/h3-6,10H,7-9H2,1-2H3",LDKZURJACNZTAQ-UHFFFAOYSA-N,289595,"6-(4-Chlorobenzyl)-10,10-dimethyl-6,8,10,11-tetrahydro-5H-pyrano[4',3':4,5]thieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-one::US10092575, Example 83::US10376514, Example 83","Dual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B",Homo sapiens,
30753,Ic1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCCNC(=O)c1cccs1,"InChI=1S/C23H26IN7O2S/c24-18-15-27-22(30-20(18)25-9-5-10-26-21(32)19-8-4-13-34-19)28-16-6-3-7-17(14-16)29-23(33)31-11-1-2-12-31/h3-4,6-8,13-15H,1-2,5,9-12H2,(H,26,32)(H,29,33)(H2,25,27,28,30)",VAVXGGRQQJZYBL-UHFFFAOYSA-N,17051,"BX-795::BX-795, 3::N-(3-{[5-iodo-4-({3-[(thiophen-2-ylcarbonyl)amino]propyl}amino)pyrimidin-2-yl]amino}phenyl)pyrrolidine-1-carboxamide::N-{3-[(5-iodo-4-{[3-(thiophen-2-ylformamido)propyl]amino}pyrimidin-2-yl)amino]phenyl}pyrrolidine-1-carboxamide",3-phosphoinositide-dependent protein kinase 1,Homo sapiens, 6
524995,FC(F)c1ccnc(OCc2cn(nn2)-c2ccc(Cl)c(c2)C(F)F)n1,"InChI=1S/C15H10ClF4N5O/c16-11-2-1-9(5-10(11)13(17)18)25-6-8(23-24-25)7-26-15-21-4-3-12(22-15)14(19)20/h1-6,13-14H,7H2",CAGIHHHPMFGUSU-UHFFFAOYSA-N,276688,"2-[[1-[4-Chloro-3-(difluoromethyl)phenyl]triazol-4-yl]methoxy]-4-::US10071988, Example 628::US10233173, Example 628",Retinoic acid receptor RXR-alpha,Homo sapiens, 42.0
50022754,COc1cc(ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12)C(=O)NS(=O)(=O)c1ccccc1C,"InChI=1S/C31H33N3O6S/c1-20-8-4-7-11-29(20)41(37,38)33-30(35)22-13-12-21(28(17-22)39-3)16-23-19-34(2)27-15-14-24(18-26(23)27)32-31(36)40-25-9-5-6-10-25/h4,7-8,11-15,17-19,25H,5-6,9-10,16H2,1-3H3,(H,32,36)(H,33,35)",YEEZWCHGZNKEEK-UHFFFAOYSA-N,50009073,4-(5-cyclopentyloxycarbonylamino-1-methyl-1H-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide::CHEMBL603::ZAFIRLUKAST::cyclopentyl 3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methylindole-5-carbamate::cyclopentyl 3-[2-methoxy-4-(2-methylphenylsulfonylcarbamoyl)benzyl]-1-methyl-1H-indol-5-ylcarbamate,Cytosolic phospholipase A2,Homo sapiens, 85000
1249038,CC[C@@H](COC1CN(C1)C(=O)C#CC(C)(C)N(C)C)C(=O)N[C@H]1Cc2nc(cs2)-c2ccc3n(CC)c(c(CC(C)(C)COC(=O)[C@@H]4CCCN(N4)C1=O)c3c2)-c1cccnc1[C@H](C)OC,"InChI=1S/C50H66N8O7S/c1-11-32(28-64-34-26-56(27-34)43(59)19-20-50(6,7)55(8)9)46(60)53-39-24-42-52-40(29-66-42)33-17-18-41-36(23-33)37(45(57(41)12-2)35-15-13-21-51-44(35)31(3)63-10)25-49(4,5)30-65-48(62)38-16-14-22-58(54-38)47(39)61/h13,15,17-18,21,23,29,31-32,34,38-39,54H,11-12,14,16,22,24-28,30H2,1-10H3,(H,53,60)/t31-,32-,38-,39-/m0/s1",FNEBYYDNJKCLRD-JWZSAVIXSA-N,592025,"US11566007, Example A705",GTPase KRas [G12S],, 5500
588263,C[C@@H](COc1ccc(cc1)[C@H]1N(CC2(F)COC2)[C@H](C)Cc2c1[nH]c1ccccc21)NCCCF,,,306741,"3-fluoro-N- ((S)-1-(4- ((1R,3R)-2-((3- fluorooxetan- 3-yl)methyl)-3- methyl-2,3,4,9- tetrahydro- 1H-pyrido[3,4- b]indol-1- yl)phenoxy) propan-2- yl)propan-1- amine::US10149839, Example 27",Estrogen receptor,, 2.20
992972,C[C@@H]([C@H](NS(=O)(=O)c1ccc(Cl)c2C(O)CCOc12)c1n[nH]c(=O)o1)c1c(F)ccc(Cl)c1C,,,477468,"5-chloro-N-((1S,2R)-2-(3-chloro-6-fluoro-2-methylphenyl)-1-(5-::US10889555, Example 238A",Muscarinic acetylcholine receptor M1/M2,, 110
50462224,CC(C)(C)CCNC1=NC(=Cc2c[nH]c3ncccc23)C(=O)N1,"InChI=1S/C17H21N5O/c1-17(2,3)6-8-19-16-21-13(15(23)22-16)9-11-10-20-14-12(11)5-4-7-18-14/h4-5,7,9-10H,6,8H2,1-3H3,(H,18,20)(H2,19,21,22,23)",QHPPNQGMZBPMAC-UHFFFAOYSA-N,50279335,"CHEMBL484988::Z)-2-[(3,3-Dimethylbutyl)amino]-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-3,5-dihydro-4H-imidazol-4-one",Cell division cycle 7-related protein kinase,Homo sapiens, 24
51053035,Cc1cccc(NC(=O)Nc2ccc(Nc3ncnc4n[nH]cc34)cc2)c1C,"InChI=1S/C20H19N7O/c1-12-4-3-5-17(13(12)2)26-20(28)25-15-8-6-14(7-9-15)24-18-16-10-23-27-19(16)22-11-21-18/h3-11H,1-2H3,(H2,25,26,28)(H2,21,22,23,24,27)",VWCFFXCKCOGDHF-UHFFFAOYSA-N,50429507,CHEMBL2332843,Vascular endothelial growth factor receptor 2,Danio rerio,>100000
50412606,CNC(=O)C1C(C(C(=O)NC)=C(C)C2Sc3ccccc3N=C12)c1ccccc1Cl,"InChI=1S/C23H22ClN3O2S/c1-12-17(22(28)25-2)18(13-8-4-5-9-14(13)24)19(23(29)26-3)20-21(12)30-16-11-7-6-10-15(16)27-20/h4-11,18-19,21H,1-3H3,(H,25,28)(H,26,29)",KTOKZQQZWMYQTB-UHFFFAOYSA-N,50248626,"2-(2-Chlorophenyl)-N,N',4-trimethyl-2,10-dihydro-1H-phenothiazine-1,3-dicarboxamide::CHEMBL518856",Glutathione hydrolase 1 proenzyme,Homo sapiens, 19000
51285192,ONC(=O)[C@@H]1C[C@H](O)CN1C(=O)c1ccc(cc1)C#Cc1ccc(OCCCCCF)cc1,"InChI=1S/C25H27FN2O5/c26-14-2-1-3-15-33-22-12-8-19(9-13-22)5-4-18-6-10-20(11-7-18)25(31)28-17-21(29)16-23(28)24(30)27-32/h6-13,21,23,29,32H,1-3,14-17H2,(H,27,30)/t21-,23-/m0/s1",LXWCLFCLBYYKME-GMAHTHKFSA-N,50523959,CHEMBL4584968,Matrix metalloproteinase-9,Homo sapiens, 108
51267657,CC(C)C[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)c1cnc(C)s1)C(=O)N[C@@H](Cc1ccc(CN)cc1)\C=C\S(C)(=O)=O,"InChI=1S/C32H47N5O5S2/c1-21(2)16-27(30(38)35-26(14-15-44(4,41)42)17-24-10-12-25(19-33)13-11-24)36-31(39)28(18-23-8-6-5-7-9-23)37-32(40)29-20-34-22(3)43-29/h10-15,20-21,23,26-28H,5-9,16-19,33H2,1-4H3,(H,35,38)(H,36,39)(H,37,40)/b15-14+/t26-,27+,28+/m1/s1",DYMSMUGVJHOWOY-WHYQKWHESA-N,50517596,CHEMBL4450505,Proteasome subunit beta type-10,, 420
51304270,CNC(=O)c1cnc(Nc2ccc(C)nn2)cc1Nc1ccccc1S(C)(=O)=O,"InChI=1S/C19H20N6O3S/c1-12-8-9-17(25-24-12)23-18-10-15(13(11-21-18)19(26)20-2)22-14-6-4-5-7-16(14)29(3,27)28/h4-11H,1-3H3,(H,20,26)(H2,21,22,23,25)",JKRWCQHQAJZOHK-UHFFFAOYSA-N,50530388,CHEMBL4453545,Non-receptor tyrosine-protein kinase TYK2/Tyrosine-protein kinase JAK1,Homo sapiens, 320
51226777,Cc1cc(N2CC(CC2=O)C(=O)N\N=C\c2ccc(cc2)[N+]([O-])=O)c(Cl)c(C)c1S(N)(=O)=O,"InChI=1S/C20H20ClN5O6S/c1-11-7-16(18(21)12(2)19(11)33(22,31)32)25-10-14(8-17(25)27)20(28)24-23-9-13-3-5-15(6-4-13)26(29)30/h3-7,9,14H,8,10H2,1-2H3,(H,24,28)(H2,22,31,32)/b23-9+",VNBKZNNTVDGEAL-NUGSKGIGSA-N,50503786,CHEMBL4555622,Carbonic anhydrase 13,,
50519784,NC(=O)c1ccccc1Nc1ccccc1,"InChI=1S/C13H12N2O/c14-13(16)11-8-4-5-9-12(11)15-10-6-2-1-3-7-10/h1-9,15H,(H2,14,16)",JKWQUMKCVDUICQ-UHFFFAOYSA-N,50297159,2-(phenylamino)benzamide::CHEMBL561194,NAD-dependent protein deacetylase sirtuin-2,Homo sapiens, 74000
15091,N#Cc1ccc2C(CCc2c1)=Cc1cnc[nH]1,"InChI=1S/C14H11N3/c15-7-10-1-4-14-11(5-10)2-3-12(14)6-13-8-16-9-17-13/h1,4-6,8-9H,2-3H2,(H,16,17)",FFOSLNTUQPRRRB-UHFFFAOYSA-N,8876,"(1E)-1-(1H-Imidazol-5-ylmethylene)indane-5-carbonitrile::(1E)-1-(1H-imidazol-5-ylmethylidene)-2,3-dihydro-1H-indene-5-carbonitrile::Imidazolylmethyleneindane 5a::Imidazolylmethyleneindane 5b","Cytochrome P450 11B2, mitochondrial",, 35.7
1111953,C[C@H](Nc1cc(F)c(cc1Cl)S(=O)(=O)Nc1nccs1)c1ccc(F)cc1,"InChI=1S/C17H14ClF2N3O2S2/c1-10(11-2-4-12(19)5-3-11)22-15-9-14(20)16(8-13(15)18)27(24,25)23-17-21-6-7-26-17/h2-10,22H,1H3,(H,21,23)/t10-/m0/s1",NNOURUCQGKSLJV-JTQLQIEISA-N,50530559,"CHEMBL4519633::US11174268, Example 48",Sodium channel protein type 1 subunit alpha,, 2604
50298723,COC(=O)c1cccnc1COc1nn2c(nnc2c2C3CCC(CC3)c12)-c1ccccc1,"InChI=1S/C25H23N5O3/c1-32-25(31)18-8-5-13-26-19(18)14-33-24-21-16-11-9-15(10-12-16)20(21)23-28-27-22(30(23)29-24)17-6-3-2-4-7-17/h2-8,13,15-16H,9-12,14H2,1H3",AZIRFKLEFANUIC-UHFFFAOYSA-N,50162257,"CHEMBL359906::methyl 2-[6-phenyl-4,5,7,8-tetraazatetracyclo[9.2.2.02,10.03,7]pentadeca-2(10),3,5,8-tetraen-9-yloxy]nicotinate",GABA-A receptor; alpha-2/beta-3/gamma-2,,
118409,O=C1CCC(=O)N1CNc1ccccn1,"InChI=1S/C10H11N3O2/c14-9-4-5-10(15)13(9)7-12-8-3-1-2-6-11-8/h1-3,6H,4-5,7H2,(H,11,12)",JFSVMQBWCVYVBE-UHFFFAOYSA-N,62588,"1-[(2-pyridinylamino)methyl]pyrrolidine-2,5-dione::1-[(2-pyridylamino)methyl]pyrrolidine-2,5-quinone::1-[(pyridin-2-ylamino)methyl]pyrrolidine-2,5-dione::MLS000039267::SMR000038123::cid_659627",Heat shock factor protein 1,Mus musculus,
50740629,CCCNc1nc(nc2n(cnc12)[C@@H]1O[C@@H]([C@@H](O)[C@H]1O)C(=O)NC)C#Cc1ccc(Cl)s1,"InChI=1S/C20H21ClN6O4S/c1-3-8-23-17-13-18(26-12(25-17)7-5-10-4-6-11(21)32-10)27(9-24-13)20-15(29)14(28)16(31-20)19(30)22-2/h4,6,9,14-16,20,28-29H,3,8H2,1-2H3,(H,22,30)(H,23,25,26)/t14-,15+,16-,20+/m0/s1",VVAIUXGEZUTKDN-KSVNGYGVSA-N,50236779,CHEMBL4086593,Alpha-2C adrenergic receptor,,
971894,CN(C)C1CCN(CC1)c1ccc(Nc2ncc3C(=O)N(CSc3n2)c2c(F)cccc2Cl)cc1Cl,"InChI=1S/C25H25Cl2FN6OS/c1-32(2)16-8-10-33(11-9-16)21-7-6-15(12-19(21)27)30-25-29-13-17-23(31-25)36-14-34(24(17)35)22-18(26)4-3-5-20(22)28/h3-7,12-13,16H,8-11,14H2,1-2H3,(H,29,30,31)",FIQWLNDOUQXDLD-UHFFFAOYSA-N,470220,"US10807994, Compound 1.245::US10807994, Example S-97",Wee1-like protein kinase,Homo sapiens, 297
397299,CC(C)(C)NC(=O)c1c[nH]c2ncc(Nc3cncc(c3)S(C)(=O)=O)nc12,"InChI=1S/C17H20N6O3S/c1-17(2,3)23-16(24)12-8-19-15-14(12)22-13(9-20-15)21-10-5-11(7-18-6-10)27(4,25)26/h5-9H,1-4H3,(H,19,20)(H,21,22)(H,23,24)",FLNUTOVGNFXLNP-UHFFFAOYSA-N,227540,"US9334278, I-29",Tyrosine-protein kinase SYK [360-635],, 227.5
805149,C[C@H](NC(=O)c1nccnc1N)c1nc2cccc(C#C)c2c(=O)n1-c1ccccc1,"InChI=1S/C23H16N6O2/c1-3-15-8-7-11-17-18(15)23(31)29(16-9-5-4-6-10-16)21(28-17)14(2)27-22(30)19-20(24)26-13-12-25-19/h1,4-14H,2H3,(H,27,30)/t14-/m0/s1",XPSKUOGFSDZSBT-AWEZNQCLSA-N,342479,"US10329299, Compound 47::US10675286, Compound 47::US9775844, Compound 47","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform",Homo sapiens, 2000
1259445,CCC(N1C[C@H](CC)N(C[C@H]1CC)c1nc(=O)n(C)c2ccc(nc12)C#N)c1ccc(cc1)C(F)(F)F,"InChI=1S/C27H31F3N6O/c1-5-20-16-36(25-24-23(34(4)26(37)33-25)13-12-19(14-31)32-24)21(6-2)15-35(20)22(7-3)17-8-10-18(11-9-17)27(28,29)30/h8-13,20-22H,5-7,15-16H2,1-4H3/t20-,21+,22?/m1/s1",MVPFPBIHUUHXGU-LKXRKSRJSA-N,594211,"US11584747, Example 5::US11584747, Example 6",Diacylglycerol kinase alpha,, 160
50453360,Cc1ccnc2N(C3CC3)c3ncccc3C(=O)Nc12,"InChI=1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20)",NQDJXKOVJZTUJA-UHFFFAOYSA-N,1434,"11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2 ,3 -e][1,4]diazepin-6-one::2-cyclopropyl-7-methyl-2,4,9,15-tetraazatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3,5,7,12,14-hexaen-10-one::BI-RG-587::CHEMBL57::Nevirapine::Nevirapine (NVP)::US11420959, Example NVP::Viramune",Reverse transcriptase,Human immunodeficiency virus 1, 8800
987348,Cc1c(C(=O)C(=O)NC2(CC(F)(F)C2)c2cnn[nH]2)c2C[C@H]3C[C@H]3n2c1C(=O)Nc1ccc(F)cc1,,,400121,"(1aR,6aR)-5-(2-((3,3-difluoro-1-(1H-1,2,3-triazol-5-yl)cyclobutyl)amino)-2-oxoacetyl)-N-(4-fluorophenyl)-4-methyl-1,1a,6,6a-tetrahydrocyclopropa[b]pyrrolizine-3-carboxamide ::US10328053, Compound 100::US10874640, Compound 100",Capsid protein,,
388503,C(N1CCOCC1)c1nc2ccccc2n1Cc1nnc(o1)-c1ccccc1,"InChI=1S/C21H21N5O2/c1-2-6-16(7-3-1)21-24-23-20(28-21)15-26-18-9-5-4-8-17(18)22-19(26)14-25-10-12-27-13-11-25/h1-9H,10-15H2",YSNDMAHXEPOQLU-UHFFFAOYSA-N,222027,"2-(Morpholinomethyl)-1-((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)-1H-benzimidazole (5f)",Prostaglandin G/H synthase 1,,>1.00e+5
50839584,CCOc1ccccc1CC(N1CCNCC1)c1ccccc1,"InChI=1S/C20H26N2O/c1-2-23-20-11-7-6-10-18(20)16-19(17-8-4-3-5-9-17)22-14-12-21-13-15-22/h3-11,19,21H,2,12-16H2,1H3",CVFBVSUFNWOPLD-UHFFFAOYSA-N,50188045,1-(2-(2-ethoxyphenyl)-1-phenylethyl)piperazine::CHEMBL386224,Sodium-dependent dopamine transporter,Homo sapiens,>4000
513826,C[C@@H](Cn1c(=O)[nH]\c(=N/c2ccc(Oc3noc(C)n3)cc2)n(Cc2ccc(Cl)cc2)c1=O)C(O)=O,,,271799,"US10065941, Compound R-114::US9732060, Compound R-114",P2X purinoceptor 3,Homo sapiens, 39.0
750719,Fc1ccc(cc1)-n1cccc(C(=O)Nc2ccc(Oc3cc(cn4nccc34)N3CCCC3)c(F)c2)c1=O,"InChI=1S/C29H23F2N5O3/c30-19-5-8-21(9-6-19)35-15-3-4-23(29(35)38)28(37)33-20-7-10-26(24(31)16-20)39-27-17-22(34-13-1-2-14-34)18-36-25(27)11-12-32-36/h3-12,15-18H,1-2,13-14H2,(H,33,37)",LEYQWKNHKYHAMT-UHFFFAOYSA-N,375854,"US9914731, Ex. No. 75",Hepatocyte growth factor receptor,Homo sapiens,<10
50665282,Cn1nc(NCC(=O)NC2CN(C2)[C@H]2CC[C@H](CC2)c2cccnc2)c2cc(ccc12)C(F)(F)F,"InChI=1S/C25H29F3N6O/c1-33-22-9-6-18(25(26,27)28)11-21(22)24(32-33)30-13-23(35)31-19-14-34(15-19)20-7-4-16(5-8-20)17-3-2-10-29-12-17/h2-3,6,9-12,16,19-20H,4-5,7-8,13-15H2,1H3,(H,30,32)(H,31,35)/t16-,20+",DPMNRWVBWPCZHV-MOBUCQHHSA-N,50355281,CHEMBL1834789,C-C chemokine receptor type 2,, 11
51415359,OC(=O)C(F)(F)F.NCCCCc1cn(nn1)-c1ccc(-c2nc(c(s2)-c2ccccc2)-c2ccccc2)c(OCCN2CCNC2=O)c1,"InChI=1S/C32H33N7O2S.C2HF3O2/c33-16-8-7-13-25-22-39(37-36-25)26-14-15-27(28(21-26)41-20-19-38-18-17-34-32(38)40)31-35-29(23-9-3-1-4-10-23)30(42-31)24-11-5-2-6-12-24;3-2(4,5)1(6)7/h1-6,9-12,14-15,21-22H,7-8,13,16-20,33H2,(H,34,40);(H,6,7)",RZVHJTRGHNHACL-UHFFFAOYSA-N,50571699,CHEMBL4855840,Trypanothione reductase,,
333521,CC1CN(CC(C)N1)c1cc(ccn1)-c1ccc(cc1)[S+]([O-])(=O)Nc1c(C)nn(C)c1C,"InChI=1S/C23H30N6O2S/c1-15-13-29(14-16(2)25-15)22-12-20(10-11-24-22)19-6-8-21(9-7-19)32(30,31)27-23-17(3)26-28(5)18(23)4/h6-12,15-16,25H,13-14H2,1-5H3,(H-,27,30,31)",YKEDODVDSKYZBX-UHFFFAOYSA-N,184914,"US9156811, DDD87761",Glycylpeptide N-tetradecanoyltransferase 1,Homo sapiens, 40
1124688,NC(=O)c1ccnc(Oc2ccc(c(F)c2)-c2cc(-c3cccc(NC(=O)C=C)c3)c3ncncc3c2)c1,"InChI=1S/C29H20FN5O3/c1-2-26(36)35-21-5-3-4-17(11-21)24-12-19(10-20-15-32-16-34-28(20)24)23-7-6-22(14-25(23)30)38-27-13-18(29(31)37)8-9-33-27/h2-16H,1H2,(H2,31,37)(H,35,36)",RTWHUPNPDSSKOQ-UHFFFAOYSA-N,426738,"2-(4-(8-(3-acrylamidophenyl)quinazolin-6- yl)-3-fluorophenoxy)isonicotinamide::US10544106, Compound C194::US11208388, Example 196",Tyrosine-protein kinase BTK,Homo sapiens,<100.0
50945175,Fc1ccc2cc(CN3[C@@H]4CC[C@@H]3CC(C4)NC(=O)N3CCN(CC3)C(=O)c3c(Cl)cccc3Cl)ccc2c1,"InChI=1S/C30H31Cl2FN4O2/c31-26-2-1-3-27(32)28(26)29(38)35-10-12-36(13-11-35)30(39)34-23-16-24-8-9-25(17-23)37(24)18-19-4-5-21-15-22(33)7-6-20(21)14-19/h1-7,14-15,23-25H,8-13,16-18H2,(H,34,39)/t24-,25-/m1/s1",JKTDSWBPQGRDKI-JWQCQUIFSA-N,50387655,CHEMBL2057757,C-C chemokine receptor type 3,Homo sapiens, 1600
50970806,C[C@@H](OC(=O)Nc1c(nnn1C)-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1,"InChI=1S/C26H24N4O4/c1-17(19-6-4-3-5-7-19)34-26(33)27-25-24(28-29-30(25)2)22-14-12-21(13-15-22)20-10-8-18(9-11-20)16-23(31)32/h3-15,17H,16H2,1-2H3,(H,27,33)(H,31,32)/t17-/m1/s1",CTNSCPPHPORJPG-QGZVFWFLSA-N,50398096,"CHEMBL2182042::US9321738, 3",Lysophosphatidic acid receptor 3,, 21940
239499,COC(C1Cc2cc3cc(OC4CC(OC5CC(O)C(O)C(C)O5)C(O)C(C)O4)c(C)c(O)c3c(O)c2C(=O)C1OC1CC(OC2CC(OC3CC(O)C(OC)C(C)O3)C(O)C(C)O2)C(O)C(C)O1)C(=O)C(O)C(C)O,"InChI=1S/C52H76O24/c1-18-30(72-36-15-31(44(59)21(4)68-36)73-34-13-28(54)43(58)20(3)67-34)12-26-10-25-11-27(51(66-9)49(64)42(57)19(2)53)52(48(63)40(25)47(62)39(26)41(18)56)76-38-17-33(46(61)23(6)70-38)75-37-16-32(45(60)22(5)69-37)74-35-14-29(55)50(65-8)24(7)71-35/h10,12,19-24,27-29,31-38,42-46,50-62H,11,13-17H2,1-9H3",NKGFIFLSQXHQOK-UHFFFAOYSA-N,115153,MLS002703041::SMR001566849::Variamycin::cid_99927,PC4 and SFRS1-interacting protein,Homo sapiens, 3564
1245361,CCCOc1cc(ccc1OC)-c1cccc(n1)C1CCOB(O)C1,"InChI=1S/C19H24BNO4/c1-3-10-24-19-12-14(7-8-18(19)23-2)16-5-4-6-17(21-16)15-9-11-25-20(22)13-15/h4-8,12,15,22H,3,9-11,13H2,1-2H3",JBLWUCDJRDWLFX-UHFFFAOYSA-N,589763,"US11559538, Example 26",Interferon gamma receptor 1,, 3302
370728,Cc1ncc(-c2ccn(C)c(=O)c2)c(OC[C@H]2C[C@@H]2c2ccc3ccccc3n2)n1,"InChI=1S/C24H22N4O2/c1-15-25-13-20(17-9-10-28(2)23(29)12-17)24(26-15)30-14-18-11-19(18)22-8-7-16-5-3-4-6-21(16)27-22/h3-10,12-13,18-19H,11,14H2,1-2H3/t18-,19+/m1/s1",TWRSCHYJESAPBR-MOPGFXCFSA-N,209779,"US9273033, 79","cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A",Homo sapiens,
50215289,OCc1cc2n[nH]c(=O)n2c2cc(ccc12)-c1ccoc1,"InChI=1S/C15H11N3O3/c19-7-11-6-14-16-17-15(20)18(14)13-5-9(1-2-12(11)13)10-3-4-21-8-10/h1-6,8,19H,7H2,(H,17,20)",RZCOQYVZZPPZLS-UHFFFAOYSA-N,50379579,CHEMBL2012883,Serine/threonine-protein kinase Chk1,Homo sapiens, 30
550053,Cc1nc2c(N)cc(nn2c1Nc1ccccc1CN1CCOCC1)N1CCOCC1,"InChI=1S/C22H29N7O2/c1-16-21(25-19-5-3-2-4-17(19)15-27-6-10-30-11-7-27)29-22(24-16)18(23)14-20(26-29)28-8-12-31-13-9-28/h2-5,14,25H,6-13,15,23H2,1H3",FLBVZNMHURJSOP-UHFFFAOYSA-N,288378,"US10087187, Compound 69","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform",Homo sapiens,
50579308,CCCN(CCC)CCCCCCCCOc1ccc(CN(CC)CC)cc1,"InChI=1S/C25H46N2O/c1-5-19-27(20-6-2)21-13-11-9-10-12-14-22-28-25-17-15-24(16-18-25)23-26(7-3)8-4/h15-18H,5-14,19-23H2,1-4H3",FVHPNAPOIIIEBJ-UHFFFAOYSA-N,50319381,"8-(4-((diethylamino)methyl)phenoxy)-N,N-dipropyloctan-1-amine::CHEMBL1086100",Cholinesterase,, 9.1
105491,Cc1cc(C)c2C3C=CCC3C(Nc2c1)C(O)=O,"InChI=1S/C15H17NO2/c1-8-6-9(2)13-10-4-3-5-11(10)14(15(17)18)16-12(13)7-8/h3-4,6-7,10-11,14,16H,5H2,1-2H3,(H,17,18)",OGVRZBLIJMLYFQ-UHFFFAOYSA-N,31727,"7,9-dimethyl-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-4-carboxylic acid::MLS-0111559.0001::cid_3125599",Genome polyprotein,Hepatitis C virus, 3674
50755754,COc1cc(OC)c(F)c(COc2cnc(N[C@@H]3COC[C@@H]3NC(=O)C=C)nc2)c1F,"InChI=1S/C20H22F2N4O5/c1-4-17(27)25-13-9-30-10-14(13)26-20-23-6-11(7-24-20)31-8-12-18(21)15(28-2)5-16(29-3)19(12)22/h4-7,13-14H,1,8-10H2,2-3H3,(H,25,27)(H,23,24,26)/t13-,14+/m0/s1",FPLYXYDSEPGNHS-UONOGXRCSA-N,50240573,CHEMBL4077859,Tyrosine-protein kinase ITK/TSK,Homo sapiens,>10000
668765,COc1nc2ccc(cc2c(Cl)c1OCC(C)(C)O)[C@](O)(c1cnnn1C)c1ccc(C)nc1C,"InChI=1S/C25H28ClN5O4/c1-14-7-9-18(15(2)28-14)25(33,20-12-27-30-31(20)5)16-8-10-19-17(11-16)21(26)22(23(29-19)34-6)35-13-24(3,4)32/h7-12,32-33H,13H2,1-6H3/t25-/m1/s1",AVOZAMVKUBLFIO-RUZDIDTESA-N,339105,"US10201546, Example 50b",Nuclear receptor ROR-gamma,, 1800
234209,CC(CCc1ccc(cc1)C1CN(C1)c1cccc(n1)C(F)(F)F)NC(C)=O,"InChI=1S/C21H24F3N3O/c1-14(25-15(2)28)6-7-16-8-10-17(11-9-16)18-12-27(13-18)20-5-3-4-19(26-20)21(22,23)24/h3-5,8-11,14,18H,6-7,12-13H2,1-2H3,(H,25,28)",ZUUIBDOTBNKIRF-UHFFFAOYSA-N,112927,"US8623860, 2.06",Acetyl-CoA carboxylase 2,Homo sapiens, 1420
51205862,Cc1ccc(cc1)C(=O)Nc1nc(Cl)c2cn(CCc3ccccc3)nc2n1,"InChI=1S/C21H18ClN5O/c1-14-7-9-16(10-8-14)20(28)25-21-23-18(22)17-13-27(26-19(17)24-21)12-11-15-5-3-2-4-6-15/h2-10,13H,11-12H2,1H3,(H,24,25,26,28)",RXHSAYJYEIARQG-UHFFFAOYSA-N,50495598,CHEMBL3114158,Adenosine receptor A2b,Homo sapiens,
202301,OCCN1CCN(CC1)NC(=O)OC1(CC1)[C@H]1CCCC(N1CS(=O)(=O)c1ccc(F)c(F)c1)c1cccc(F)c1,"InChI=1S/C28H35F3N4O5S/c29-21-4-1-3-20(17-21)25-5-2-6-26(35(25)19-41(38,39)22-7-8-23(30)24(31)18-22)28(9-10-28)40-27(37)32-34-13-11-33(12-14-34)15-16-36/h1,3-4,7-8,17-18,25-26,36H,2,5-6,9-16,19H2,(H,32,37)/t25?,26-/m1/s1",ZBBNNLOJSFKHQY-FXDYGKIASA-N,93331,"Carbamate {3,13}, 7",Amyloid-beta precursor protein,Homo sapiens, 9.8
341095,CCCCCCc1ccn(Cc2ccccc2Cl)c(=O)c1,"InChI=1S/C18H22ClNO/c1-2-3-4-5-8-15-11-12-20(18(21)13-15)14-16-9-6-7-10-17(16)19/h6-7,9-13H,2-5,8,14H2,1H3",PJBRBZYHOXOPFM-UHFFFAOYSA-N,190653,PT172,Enoyl-[acyl-carrier-protein] reductase [NADH],, 5.5e+4
1131803,CCCCCCCCCCCCCCCCCCC[C@H](COP(O)(=O)OC[C@H]1O[C@](C#N)([C@H](O)[C@@H]1O)c1ccc2c(N)ncnn12)OCc1ccccc1,"InChI=1S/C40H62N5O8P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21-24-33(50-27-32-22-19-18-20-23-32)28-51-54(48,49)52-29-35-37(46)38(47)40(30-41,53-35)36-26-25-34-39(42)43-31-44-45(34)36/h18-20,22-23,25-26,31,33,35,37-38,46-47H,2-17,21,24,27-29H2,1H3,(H,48,49)(H2,42,43,44)/t33-,35-,37-,38-,40+/m1/s1",JPDQDOUGPMLROY-RTZKIGCUSA-N,534269,"((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl ((R)-2-(benzyloxy)henicosyl) hydrogen phosphate (72)::WO2022081973, Example 72",Fusion glycoprotein F0,,
50973941,CCCCCCCCCCCCCCCC(=O)OC[C@H](CSC[C@H](NC(=O)COCC(=O)NCCCOCCOCCOCCCNC(C)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)OC(=O)CCCCCCCCCCCCCCC,"InChI=1S/C73H136N8O21S/c1-4-6-8-10-12-14-16-18-20-22-24-26-28-34-70(89)101-54-62(102-71(90)35-29-27-25-23-21-19-17-15-13-11-9-7-5-2)59-103-60-64(81-69(88)58-100-57-68(87)77-38-32-42-95-45-49-97-48-44-93-40-30-36-75-61(3)83)73(92)79-52-66(85)80-63(53-82)72(91)78-39-33-43-96-47-51-98-50-46-94-41-31-37-76-67(86)56-99-55-65(74)84/h62-64,82H,4-60H2,1-3H3,(H2,74,84)(H,75,83)(H,76,86)(H,77,87)(H,78,91)(H,79,92)(H,80,85)(H,81,88)/t62-,63-,64+/m1/s1",XWTKNAKNIMXMRA-JJGWWSOQSA-N,50399450,CHEMBL2179403,Toll-like receptor 2,,
50804704,Nc1cnc(-c2ccncc2)n(CC(=O)NC(Cc2ccccc2)C(=O)C(F)(F)C(=O)NCc2ccccc2)c1=O,"InChI=1S/C29H26F2N6O4/c30-29(31,28(41)35-16-20-9-5-2-6-10-20)25(39)23(15-19-7-3-1-4-8-19)36-24(38)18-37-26(21-11-13-33-14-12-21)34-17-22(32)27(37)40/h1-14,17,23H,15-16,18,32H2,(H,35,41)(H,36,38)",CAPFLCVXIMWPQO-UHFFFAOYSA-N,50098885,"4-[2-(5-Amino-6-oxo-2-pyridin-4-yl-6H-pyrimidin-1-yl)-acetylamino]-2,2-difluoro-3-oxo-5-phenyl-pentanoic acid benzylamide::CHEMBL275228",Chymase,Homo sapiens,
50797886,NS(=O)(=O)c1cc(c(NC(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F)cc1Cl)S(N)(=O)=O,"InChI=1S/C15H7ClF17N3O5S2/c16-3-1-4(6(43(35,40)41)2-5(3)42(34,38)39)36-7(37)8(17,18)9(19,20)10(21,22)11(23,24)12(25,26)13(27,28)14(29,30)15(31,32)33/h1-2H,(H,36,37)(H2,34,38,39)(H2,35,40,41)",GEYYELXISHWILS-UHFFFAOYSA-N,50094334,"2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-Heptadecafluoro-nonanoic acid (5-chloro-2,4-disulfamoyl-phenyl)-amide::CHEMBL343047",Carbonic anhydrase 4,Bos taurus,
51210323,CC1CC1c1cc(NC(=O)Nc2ccc(F)c(C)c2)n(CC(F)(F)F)n1,"InChI=1S/C17H18F4N4O/c1-9-6-12(9)14-7-15(25(24-14)8-17(19,20)21)23-16(26)22-11-3-4-13(18)10(2)5-11/h3-5,7,9,12H,6,8H2,1-2H3,(H2,22,23,26)",OZNVAQFXGNOYPW-UHFFFAOYSA-N,50497420,CHEMBL3339148,G protein-activated inward rectifier potassium channel 4,Homo sapiens,
1129052,Fc1ccc2OCCc2c1CNc1ncc(-c2cnccc2Cl)c2nc(cn12)C#N,"InChI=1S/C21H14ClFN6O/c22-17-3-5-25-8-14(17)16-10-27-21(29-11-12(7-24)28-20(16)29)26-9-15-13-4-6-30-19(13)2-1-18(15)23/h1-3,5,8,10-11H,4,6,9H2,(H,26,27)",NJOVETZRLXEYMT-UHFFFAOYSA-N,513748,"US11091495, Example 109::US11220509, Example 109::US11485738, Example 109",Histone-binding protein RBBP4/Histone-lysine N-methyltransferase EZH2/Polycomb protein EED/Polycomb protein SUZ12/Zinc finger protein AEBP2,,<100
445471,Nc1cnc(cn1)-n1c(nc2c(Cl)ccc(Cl)c2c1=O)[C@@H](Nc1nc(N)nc(N)c1Cl)C1CC1,"InChI=1S/C20H17Cl3N10O/c21-8-3-4-9(22)15-12(8)19(34)33(11-6-27-10(24)5-28-11)18(30-15)14(7-1-2-7)29-17-13(23)16(25)31-20(26)32-17/h3-7,14H,1-2H2,(H2,24,27)(H5,25,26,29,31,32)/t14-/m0/s1",TXPPHNQEBCMUGH-AWEZNQCLSA-N,255538,"US9499523, 12","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform",Homo sapiens, 1200
51242899,CCN(CC)Cc1cc2C[C@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc(c2)c1O)cc7)N(C)CCc6cc5OC)c34,"InChI=1S/C42H51N3O6/c1-8-45(9-2)25-30-18-27-20-34-39-29(15-17-44(34)4)23-38(48-6)41(49-7)42(39)51-36-24-32-28(22-35(36)47-5)14-16-43(3)33(32)19-26-10-12-31(13-11-26)50-37(21-27)40(30)46/h10-13,18,21-24,33-34,46H,8-9,14-17,19-20,25H2,1-7H3/t33-,34+/m0/s1",XJBJIWASMVFSOF-SZAHLOSFSA-N,50508728,CHEMBL4590539,Acetylcholinesterase,Homo sapiens, 68000
1118702,C[C@@H]1[C@@H]2CN(C[C@]12NC(=O)C1CC1)c1nc(Nc2cnc(CO)c(Cl)c2)ncc1F,"InChI=1S/C20H22ClFN6O2/c1-10-13-7-28(9-20(10,13)27-18(30)11-2-3-11)17-15(22)6-24-19(26-17)25-12-4-14(21)16(8-29)23-5-12/h4-6,10-11,13,29H,2-3,7-9H2,1H3,(H,27,30)(H,24,25,26)/t10-,13+,20+/m1/s1",AAWJXJTWXOTSRP-FBWDIHGXSA-N,330022,"US10463675, Example 105::US10980815, Ex. No. 105::US11197867, Example 105::US9663526, Example 105",Tyrosine-protein kinase JAK3,Homo sapiens,>10000
51310585,O=c1ccc2cc3ccoc3cc2o1,InChI=1S/C11H6O3/c12-11-2-1-7-5-8-3-4-13-9(8)6-10(7)14-11/h1-6H,ZCCUUQDIBDJBTK-UHFFFAOYSA-N,50331544,"7H-furo[3,2-g]chromen-7-one::CHEMBL164660::Furo[3,2-g]chromen-7-one::psoralen",Amine oxidase [flavin-containing] A,,>20000
744008,CCC[C@H](N)c1cccc(n1)-c1cc(OCC(C)(C)O)c2cnn(-c3cccc(CO)n3)c2c1,"InChI=1S/C26H31N5O3/c1-4-7-20(27)22-10-6-9-21(30-22)17-12-23-19(24(13-17)34-16-26(2,3)33)14-28-31(23)25-11-5-8-18(15-32)29-25/h5-6,8-14,20,32-33H,4,7,15-16,27H2,1-3H3/t20-/m0/s1",WIZGQPJZJHDNIB-FQEVSTJZSA-N,374320,"(S)-1-((6-(6-(1-aminobutyl)pyridin-2-yl)-1-(6-(hydroxymethyl)pyridin-2-yl)-1H-indazol-4-yl)oxy)-2-methylpropan-2-ol::US10246456, Example 471::US10577367, Example 471",Interleukin-1 receptor-associated kinase 4,Homo sapiens,<100.0
51025760,CC(C)Oc1ccc(cc1Cl)-c1nc(no1)-c1cccc2c(CC(O)=O)c[nH]c12,"InChI=1S/C21H18ClN3O4/c1-11(2)28-17-7-6-12(8-16(17)22)21-24-20(25-29-21)15-5-3-4-14-13(9-18(26)27)10-23-19(14)15/h3-8,10-11,23H,9H2,1-2H3,(H,26,27)",HPWRAENLHHTNRS-UHFFFAOYSA-N,50419993,CHEMBL2018317,Sphingosine 1-phosphate receptor 1,Homo sapiens,
955375,Clc1ccc(cc1)-n1c(cc2ccncc12)-c1ccn(C2CC2)c(=O)c1,"InChI=1S/C21H16ClN3O/c22-16-1-3-18(4-2-16)25-19(11-14-7-9-23-13-20(14)25)15-8-10-24(17-5-6-17)21(26)12-15/h1-4,7-13,17H,5-6H2",ANMSOARYIIUEQS-UHFFFAOYSA-N,389967,"4-[1-(4-Chlorophenyl)-1H- pyrrolo[2,3-c]pyridin-2-yl]-1- cyclopropyl-1,2-dihydropyridin- 2-one::US10766897, Compound 138::US9951068, Compound 138",Potassium voltage-gated channel subfamily H member 2,Homo sapiens, 5500
50186858,O=C(N1CCNCC1)c1ccc(\C=C\c2n[nH]c3ccccc23)cc1,"InChI=1S/C20H20N4O/c25-20(24-13-11-21-12-14-24)16-8-5-15(6-9-16)7-10-19-17-3-1-2-4-18(17)22-23-19/h1-10,21H,11-14H2,(H,22,23)/b10-7+",YYLKKYCXAOBSRM-JXMROGBWSA-N,50355496,CHEMBL1908397,Epidermal growth factor receptor,Homo sapiens,
407434,FC(F)(F)c1ccnc(Nc2cc(cc(c2)-c2ccccc2)N2CCOC3(CCCC3)C2)n1,"InChI=1S/C25H25F3N4O/c26-25(27,28)22-8-11-29-23(31-22)30-20-14-19(18-6-2-1-3-7-18)15-21(16-20)32-12-13-33-24(17-32)9-4-5-10-24/h1-3,6-8,11,14-16H,4-5,9-10,12-13,17H2,(H,29,30,31)",KUTJUPCPRCQQJU-UHFFFAOYSA-N,233557,"US9353066, 1.10",Tyrosine-protein kinase SYK,Homo sapiens, 846.2
50005460,NC(=N)c1ccc2[nH]c(Cc3ccccc3)cc2c1,"InChI=1S/C16H15N3/c17-16(18)12-6-7-15-13(9-12)10-14(19-15)8-11-4-2-1-3-5-11/h1-7,9-10,19H,8H2,(H3,17,18)",RSJJRSWDMOGILH-UHFFFAOYSA-N,50287156,2-Benzyl-1H-indole-5-carboxamidine::CHEMBL287401,Prothrombin,, 1400
51426147,COc1cccc(CN2CC(Oc3ccccc23)C(N)=O)c1,"InChI=1S/C17H18N2O3/c1-21-13-6-4-5-12(9-13)10-19-11-16(17(18)20)22-15-8-3-2-7-14(15)19/h2-9,16H,10-11H2,1H3,(H2,18,20)",GCDIOJQICTZTPA-UHFFFAOYSA-N,50576073,CHEMBL4861333,"NAD-dependent protein deacetylase sirtuin-3, mitochondrial",,>60000
315760,NC1=N[C@@](C(F)F)([C@H]2C[C@H]2O1)c1cc(NC(=O)c2cnc(OCC3CCOCC3)cn2)ccc1F,"InChI=1S/C23H24F3N5O4/c24-16-2-1-13(7-14(16)23(21(25)26)15-8-18(15)35-22(27)31-23)30-20(32)17-9-29-19(10-28-17)34-11-12-3-5-33-6-4-12/h1-2,7,9-10,12,15,18,21H,3-6,8,11H2,(H2,27,31)(H,30,32)/t15-,18+,23+/m0/s1",LABLWWZXLRYFFH-TUVUNVSASA-N,171787,"US9085576, 412::US9611261, Example 412",Beta-secretase 1,Homo sapiens, 128.5
51317475,NCc1ccc(cc1)S(N)(=O)=O,"InChI=1S/C7H10N2O2S/c8-5-6-1-3-7(4-2-6)12(9,10)11/h1-4H,5,8H2,(H2,9,10,11)",TYMRLRRVMHJFTF-UHFFFAOYSA-N,10860,"4-(aminomethyl)benzene-1-sulfonamide::CHEMBL419::MAFENIDE::aromatic sulfonamide compound 6::aromatic/heteroaromatic sulfonamide 5::hCA inhibitor, 9",Carbonic anhydrase 2,Homo sapiens,
50475107,CCn1c(-c2ccccc2)c2cc(N)ccc2c2ccc(=[NH2+])cc12,"InChI=1S/C21H19N3/c1-2-24-20-13-16(23)9-11-18(20)17-10-8-15(22)12-19(17)21(24)14-6-4-3-5-7-14/h3-13,23H,2,22H2,1H3/p+1",QTANTQQOYSUMLC-UHFFFAOYSA-O,50105463,"2,7-diamino-10-ethyl-9-phenylphenanthridinium bromide::2,7-diamino-9-phenyl-10-ethylphenanthridinium bromide::3,8-diamino-5-ethyl-6-phenylphenanthridinium bromide::CHEMBL284328::Dromilac::EtBr::Ethidium bromide::Homidium bromide",Telomerase reverse transcriptase,Homo sapiens, 2180
51452540,CCN(Cc1ccccc1)Cc1ccc(NC(=O)Cc2ccc(cc2)S(=O)(=O)CC)cc1,"InChI=1S/C26H30N2O3S/c1-3-28(19-22-8-6-5-7-9-22)20-23-10-14-24(15-11-23)27-26(29)18-21-12-16-25(17-13-21)32(30,31)4-2/h5-17H,3-4,18-20H2,1-2H3,(H,27,29)",IPHBOHDGOHENCO-UHFFFAOYSA-N,50586431,CHEMBL5089839,Nuclear receptor ROR-gamma,,
278956,OC1CCN(C1)c1cc(cc(Nc2nc(NC3CC3)c3ncc(C#N)n3n2)c1Cl)C#N,"InChI=1S/C20H18ClN9O/c21-17-15(5-11(7-22)6-16(17)29-4-3-14(31)10-29)26-20-27-18(25-12-1-2-12)19-24-9-13(8-23)30(19)28-20/h5-6,9,12,14,31H,1-4,10H2,(H2,25,26,27,28)",XMYPWCUEOAYOMV-UHFFFAOYSA-N,142775,"US8940736, 7",Casein kinase II subunit alpha,Homo sapiens, 0.17
50190896,CSc1ccc2c(Cc3ccc(Cl)cc3)ccc(C(C)C(O)=O)c2c1,"InChI=1S/C21H19ClO2S/c1-13(21(23)24)18-9-5-15(11-14-3-6-16(22)7-4-14)19-10-8-17(25-2)12-20(18)19/h3-10,12-13H,11H2,1-2H3,(H,23,24)",BNUPVYGGLHTBCE-UHFFFAOYSA-N,50105285,2-[4-(4-Chloro-benzyl)-7-methylsulfanyl-naphthalen-1-yl]-propionic acid::CHEMBL90603,Prostaglandin G/H synthase 2,Rattus, 4200
50407986,Cc1ccccc1C1CCN(CC1)S(=O)(=O)CC1(CCN(CC1)C(=O)OC1COCC1(C)C)C(=O)NO,"InChI=1S/C26H39N3O7S/c1-19-6-4-5-7-21(19)20-8-12-29(13-9-20)37(33,34)18-26(23(30)27-32)10-14-28(15-11-26)24(31)36-22-16-35-17-25(22,2)3/h4-7,20,22,32H,8-18H2,1-3H3,(H,27,30)",VVHOXHYIVMZQIO-UHFFFAOYSA-N,50229635,"4,4-dimethyl-tetrahydrofuran-3-yl 4-(hydroxycarbamoyl)-4-((4-o-tolylpiperidin-1-ylsulfonyl)methyl)piperidine-1-carboxylate::CHEMBL439405",72 kDa type IV collagenase,, 574
1159381,COc1cc2CCN(C)Cc2cc1Nc1ncc2ccc(cc2n1)-c1ccn2ncnc2c1,"InChI=1S/C25H23N7O/c1-31-7-5-17-11-23(33-2)22(10-20(17)14-31)30-25-26-13-19-4-3-16(9-21(19)29-25)18-6-8-32-24(12-18)27-15-28-32/h3-4,6,8-13,15H,5,7,14H2,1-2H3,(H,26,29,30)",TTXNATGDOHVYQQ-UHFFFAOYSA-N,548620,"WO2022098806, Compound 1-16",Mitogen-activated protein kinase kinase kinase kinase 1,Homo sapiens, 154
50125648,CC1C(O)C(O)C(O)C(CO)N1CC=O,"InChI=1S/C9H17NO5/c1-5-7(13)9(15)8(14)6(4-12)10(5)2-3-11/h3,5-9,12-15H,2,4H2,1H3",TVTBPJSCVHDHKU-UHFFFAOYSA-N,50072685,"(3,4,5-Trihydroxy-2-hydroxymethyl-6-methyl-piperidin-1-yl)-acetaldehyde::CHEMBL114103",Tissue alpha-L-fucosidase,Homo sapiens, 4
51373701,Oc1cc(OC(=O)N(c2ccccc2)c2ccccc2)cc2oc(cc(=O)c12)-c1ccc(OC(=O)N(c2ccccc2)c2ccccc2)cc1,"InChI=1S/C41H28N2O7/c44-35-25-34(49-41(47)43(31-17-9-3-10-18-31)32-19-11-4-12-20-32)26-38-39(35)36(45)27-37(50-38)28-21-23-33(24-22-28)48-40(46)42(29-13-5-1-6-14-29)30-15-7-2-8-16-30/h1-27,44H",FVSVQJANVZBUMV-UHFFFAOYSA-N,50555562,CHEMBL4745591,Carboxylic ester hydrolase,Rattus norvegicus, 37600
164938,CCOC(=O)\C=C1/CN(CCC(C)C)S(=O)(=O)c2ccccc12,"InChI=1S/C17H23NO4S/c1-4-22-17(19)11-14-12-18(10-9-13(2)3)23(20,21)16-8-6-5-7-15(14)16/h5-8,11,13H,4,9-10,12H2,1-3H3/b14-11+",RWVLMNYKQQYZTI-SDNWHVSQSA-N,82989,"(2Z)-2-(2-isoamyl-1,1-diketo-3H-1,2-benzothiazin-4-ylidene)acetic acid ethyl ester::(2Z)-2-[2-(3-methylbutyl)-1,1-dioxo-3H-1,2-benzothiazin-4-ylidene]acetic acid ethyl ester::MLS000879611::SMR000674027::cid_24789301::ethyl (2Z)-2-[2-(3-methylbutyl)-1,1-bis(oxidanylidene)-3H-1,2-benzothiazin-4-ylidene]ethanoate::ethyl (2Z)-2-[2-(3-methylbutyl)-1,1-dioxo-3H-1,2-benzothiazin-4-ylidene]acetate",Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1,Homo sapiens, 45251
379605,O=C(Nc1ccc(cc1)C(=O)NCc1ccc(cc1)N1CCCC1=O)N1Cc2ccccc2C1,"InChI=1S/C27H26N4O3/c32-25-6-3-15-31(25)24-13-7-19(8-14-24)16-28-26(33)20-9-11-23(12-10-20)29-27(34)30-17-21-4-1-2-5-22(21)18-30/h1-2,4-5,7-14H,3,6,15-18H2,(H,28,33)(H,29,34)",IGTRDXBXARJRGG-UHFFFAOYSA-N,216078,"US9302989, 416",Nicotinamide phosphoribosyltransferase,Homo sapiens, 41
50141173,CCc1cccc(CC)c1NC(=O)CN1C[C@@H]([C@H]([C@@H]1c1ccc(CCOC)cc1)C(O)=O)c1ccc2OCOc2c1,"InChI=1S/C33H38N2O6/c1-4-22-7-6-8-23(5-2)31(22)34-29(36)19-35-18-26(25-13-14-27-28(17-25)41-20-40-27)30(33(37)38)32(35)24-11-9-21(10-12-24)15-16-39-3/h6-14,17,26,30,32H,4-5,15-16,18-20H2,1-3H3,(H,34,36)(H,37,38)/t26-,30-,32+/m1/s1",FGUXLHMMTIYRQF-FUKIBTTHSA-N,50080596,"(2R,3R,4S)-4-Benzo[1,3]dioxol-5-yl-1-[(2,6-diethyl-phenylcarbamoyl)-methyl]-2-[4-(2-methoxy-ethyl)-phenyl]-pyrrolidine-3-carboxylic acid::CHEMBL331066",Endothelin receptor type B,Homo sapiens, 3.8
455118,COC(=O)c1ccc(CN2c3ccccc3Sc3ccc(Cl)cc23)cc1,"InChI=1S/C21H16ClNO2S/c1-25-21(24)15-8-6-14(7-9-15)13-23-17-4-2-3-5-19(17)26-20-11-10-16(22)12-18(20)23/h2-12H,13H2,1H3",HIDDWKTVRSKQSL-UHFFFAOYSA-N,65514,"CPZ analog, 8",Proteasome subunit alpha type-6,,
349275,Cc1nc2ccc(Nc3nc(=O)c(cn3Cc3ccc(Cl)cc3)C(=O)NC3CC3)cc2s1,"InChI=1S/C23H20ClN5O2S/c1-13-25-19-9-8-17(10-20(19)32-13)27-23-28-22(31)18(21(30)26-16-6-7-16)12-29(23)11-14-2-4-15(24)5-3-14/h2-5,8-10,12,16H,6-7,11H2,1H3,(H,26,30)(H,27,28,31)",DSTIXJOFQYEFGR-UHFFFAOYSA-N,196387,"US9212130, I-309",P2X purinoceptor 3,Homo sapiens, 61
50218903,CNC(=O)c1nc(cnc1N)-c1ccc(Cl)c(c1)S(=O)(=O)Nc1ccc(Cl)cc1,"InChI=1S/C18H15Cl2N5O3S/c1-22-18(26)16-17(21)23-9-14(24-16)10-2-7-13(20)15(8-10)29(27,28)25-12-5-3-11(19)4-6-12/h2-9,25H,1H3,(H2,21,23)(H,22,26)",KSFQJLSQGFAJRQ-UHFFFAOYSA-N,50393355,CHEMBL2152146,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform",Homo sapiens, 394
719843,Fc1cccc(c1)N([C@H](C(=O)NC1CCC(F)(F)CC1)c1ccccc1Cl)C(=O)[C@@H]1CCC(=O)N1c1cnccn1,"InChI=1S/C29H27ClF3N5O3/c30-22-7-2-1-6-21(22)26(27(40)36-19-10-12-29(32,33)13-11-19)37(20-5-3-4-18(31)16-20)28(41)23-8-9-25(39)38(23)24-17-34-14-15-35-24/h1-7,14-17,19,23,26H,8-13H2,(H,36,40)/t23-,26-/m0/s1",LZIRTPPXKUUODZ-OZXSUGGESA-N,363568,"US10640534, Compound 58::US10689414, Compound 58::US10717764, Compound 58::US11021515, Compound 58::US9850277, Compound 58",Isocitrate dehydrogenase [NADP] cytoplasmic [R132H],,<500
710748,OC(=O)c1ccc(NC(=O)C(CC2CC2)n2cc(Cl)c(cc2=O)-c2cc(Cl)ccc2C#N)cc1,"InChI=1S/C25H19Cl2N3O4/c26-17-6-3-16(12-28)19(10-17)20-11-23(31)30(13-21(20)27)22(9-14-1-2-14)24(32)29-18-7-4-15(5-8-18)25(33)34/h3-8,10-11,13-14,22H,1-2,9H2,(H,29,32)(H,33,34)",APZJTXHPPDAWRM-UHFFFAOYSA-N,246140,"US10183932, Example 47::US9434690, 45::US9434690, 46::US9434690, 47::US9822102, Example 47",Coagulation factor XI,Homo sapiens, 13.0
699949,C[C@@H]1C[C@H](N)CN(C1)c1ccncc1NCc1ccc(F)c(n1)-c1ccccc1F,"InChI=1S/C23H25F2N5/c1-15-10-16(26)14-30(13-15)22-8-9-27-12-21(22)28-11-17-6-7-20(25)23(29-17)18-4-2-3-5-19(18)24/h2-9,12,15-16,28H,10-11,13-14,26H2,1H3/t15-,16+/m1/s1",BGNZFPGHJLJRBF-CVEARBPZSA-N,352092,"4-((3S,5R)-3-Amino-5-methylpiperidin-1-yl)-N-((5-fluoro-6-(2-fluorophenyl)pyridin-2-yl)methyl)pyridin-3-amine::US9802918, Example 23",Serine/threonine-protein kinase pim-3,Homo sapiens,<10
944736,CCC(=O)Nc1ccc(s1)C(=O)Nc1nc2ccccc2n1[C@H]1C[C@]2(C1)CCN(C2)C(=O)C=C,"InChI=1S/C25H27N5O3S/c1-3-20(31)27-21-10-9-19(34-21)23(33)28-24-26-17-7-5-6-8-18(17)30(24)16-13-25(14-16)11-12-29(15-25)22(32)4-2/h4-10,16H,2-3,11-15H2,1H3,(H,27,31)(H,26,28,33)/t16-,25-",IURZLQRYJRVUAA-ODAJSGAPSA-N,458208,"US10752615, Compound 105",Tyrosine-protein kinase ITK/TSK,Homo sapiens, 128
50335041,C[C@@H]1CC[C@H](CN1C(=O)c1ccccc1-n1nccn1)Oc1cc(C)ccn1,"InChI=1S/C21H23N5O2/c1-15-9-10-22-20(13-15)28-17-8-7-16(2)25(14-17)21(27)18-5-3-4-6-19(18)26-23-11-12-24-26/h3-6,9-13,16-17H,7-8,14H2,1-2H3/t16-,17-/m1/s1",WKEQQLYEZQNSSQ-IAGOWNOFSA-N,50084388,CHEMBL3426131,Orexin/Hypocretin receptor type 1,Homo sapiens, 788
547722,CN(c1ncc(F)cc1CNc1nc(cc2[nH]nc(C(N)=O)c12)-c1cc(F)c(O)cc1CC(F)(F)F)S(C)(=O)=O,"InChI=1S/C23H20F5N7O4S/c1-35(40(2,38)39)22-11(3-12(24)9-31-22)8-30-21-18-16(33-34-19(18)20(29)37)6-15(32-21)13-5-14(25)17(36)4-10(13)7-23(26,27)28/h3-6,9,36H,7-8H2,1-2H3,(H2,29,37)(H,30,32)(H,33,34)",WLMZXCCBYNGDFJ-UHFFFAOYSA-N,281471,"US10022376, Example 78",Tyrosine-protein kinase JAK3,Homo sapiens, 89.9
452680,CC(C)(C)c1nc(N2CCC[C@@H]2CO)c2ncn(Cc3nnnn3C3CC3)c2n1,"InChI=1S/C19H27N9O/c1-19(2,3)18-21-16-15(17(22-18)27-8-4-5-13(27)10-29)20-11-26(16)9-14-23-24-25-28(14)12-6-7-12/h11-13,29H,4-10H2,1-3H3/t13-/m1/s1",CMGFGKRDCDOOAA-CYBMUJFWSA-N,259778,"US9505762, 146",Cannabinoid receptor 2,Homo sapiens,
51428658,COc1ccc2CN(CCCCc3cn(CCCC(=O)NCCc4c[nH]c5ccccc45)nn3)CC[C@@]34C=C[C@H](O)C[C@@H]3Oc1c24,,,50577149,CHEMBL4855760,Acetylcholinesterase,Homo sapiens, 120
497265,Nc1ncc2c(cccc2n1)-c1ccc(c(c1-c1nn[nH]n1)S(N)(=O)=O)C(F)(F)F,"InChI=1S/C16H11F3N8O2S/c17-16(18,19)10-5-4-8(7-2-1-3-11-9(7)6-22-15(20)23-11)12(13(10)30(21,28)29)14-24-26-27-25-14/h1-6H,(H2,20,22,23)(H2,21,28,29)(H,24,25,26,27)",MSVOTOYDDFNLRA-UHFFFAOYSA-N,262703,"3-(2-aminoquinazolin-5-yl)-2- (2H-tetrazol-5-yl)-6- (trifluoromethyl)benzenesulfon- amide::US9708336, 556",VIM-1 metallo-beta-lactamase,, 0.122
50552605,C[C@H]1CN(CCCn2c3ccccc3c3ccccc23)C[C@@H](C)N1,"InChI=1S/C21H27N3/c1-16-14-23(15-17(2)22-16)12-7-13-24-20-10-5-3-8-18(20)19-9-4-6-11-21(19)24/h3-6,8-11,16-17,22H,7,12-15H2,1-2H3/t16-,17+",GUDVQJXODNJRIJ-CALCHBBNSA-N,50019742,"9-(3-((3S,5R)-3,5-dimethylpiperazin-1-yl)propyl)-9H-carbazole::9-(3-(3,5-dimethylpiperazin-1-yl)propyl)-9H-carbazole::9-[3-((3R,5R)-3,5-Dimethyl-piperazin-1-yl)-propyl]-9H-carbazole::9-[3-((3R,5S)-3,5-Dimethyl-piperazin-1-yl)-propyl]-9H-carbazole::9-[3-((3S,5R)-3,5-Dimethyl-piperazin-1-yl)-propyl]-9H-carbazole::9-[3-(3,5-Dimethyl-piperazin-1-yl)-propyl]-9H-carbazole::9-[3-(3,5-Dimethyl-piperazin-1-yl)-propyl]-9H-carbazole (Rimcazole) (BW234U)::9-[3-(3,5-Dimethyl-piperazin-1-yl)-propyl]-9H-carbazole(rimcazole)::CHEMBL275707::RIMCAZOLE",Sigma non-opioid intracellular receptor 1,Cavia porcellus,
50236093,CCOc1c(cc(cc1C(C)(C)CC)C(C)(C)CC)C(\C)=C/C=C/C(/C)=C/C(O)=O,"InChI=1S/C27H40O3/c1-10-26(6,7)21-17-22(20(5)15-13-14-19(4)16-24(28)29)25(30-12-3)23(18-21)27(8,9)11-2/h13-18H,10-12H2,1-9H3,(H,28,29)/b14-13+,19-16+,20-15-",XPNYPEOXBQXYDQ-BLWADDNASA-N,50129722,"7-[3,5-Bis-(1,1-dimethyl-propyl)-2-ethoxy-phenyl]-3-methyl-octa-2,4,6-trienoic acid::CHEMBL315986",Retinoic acid receptor RXR-alpha,Homo sapiens, 17
140334,Oc1ccc(\C=C2\SC(=S)N(Cc3ccccc3)C2=O)cc1,"InChI=1S/C17H13NO2S2/c19-14-8-6-12(7-9-14)10-15-16(20)18(17(21)22-15)11-13-4-2-1-3-5-13/h1-10,19H,11H2/b15-10+",QUYCETSYSJOKIN-XNTDXEJSSA-N,69656,"(5E)-3-benzyl-5-(4-hydroxybenzylidene)-2-thioxo-thiazolidin-4-one::(5E)-3-benzyl-5-[(4-hydroxyphenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one::(5E)-5-[(4-hydroxyphenyl)methylidene]-3-(phenylmethyl)-2-sulfanylidene-1,3-thiazolidin-4-one::(5E)-5-[(4-hydroxyphenyl)methylidene]-3-(phenylmethyl)-2-sulfanylidene-4-thiazolidinone::3-Benzyl-5-(4-hydroxy-benzylidene)-2-thioxo-thiazolidin-4-one::MLS001207944::SMR000504792::cid_1912931",Caspase-3,Homo sapiens, 41000
1065509,C[C@H]1COCCN1CCc1nc2c3ccc4OC(F)(F)Oc4c3nc(N)n2n1,"InChI=1S/C17H18F2N6O3/c1-9-8-26-7-6-24(9)5-4-12-21-15-10-2-3-11-14(28-17(18,19)27-11)13(10)22-16(20)25(15)23-12/h2-3,9H,4-8H2,1H3,(H2,20,22)/t9-/m0/s1",RBRWXJDRARDMOH-VIFPVBQESA-N,508575,"2,2-difluoro-8-{2-[(3S)-3- methylmorpholin-4- yl]ethyl}[1,3]dioxolo[4,5- h][1,2,4]triazolo[1,5- c]quinazolin-5-amine::US11046714, Example 43",Adenosine receptor A2a,Homo sapiens,
51122759,CC(C)OC(=O)N1CCC2(CC(CCCOc3ccc(C(=O)N4CCCC4)c(F)c3)C2)CC1,"InChI=1S/C26H37FN2O4/c1-19(2)33-25(31)29-13-9-26(10-14-29)17-20(18-26)6-5-15-32-21-7-8-22(23(27)16-21)24(30)28-11-3-4-12-28/h7-8,16,19-20H,3-6,9-15,17-18H2,1-2H3",BAJCRGLBSKKOHP-UHFFFAOYSA-N,50460305,CHEMBL4227731,Glucose-dependent insulinotropic receptor,,
50706572,Cc1c(cnc2cc(nn12)-c1ccccc1)C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N,"InChI=1S/C25H29N7O2/c1-17-20(14-27-22-12-21(30-32(17)22)18-8-5-4-6-9-18)24(34)28-16-25(2,3)29-15-23(33)31-11-7-10-19(31)13-26/h4-6,8-9,12,14,19,29H,7,10-11,15-16H2,1-3H3,(H,28,34)/t19-/m0/s1",ZWYVWOHOVTWLNH-IBGZPJMESA-N,50359371,CHEMBL1929392,Dipeptidyl peptidase 9,Homo sapiens, 30
51398189,C\C(=N/NC(N)=O)c1nnn(c1C)-c1ccc(cc1)S(N)(=O)=O,"InChI=1S/C12H15N7O3S/c1-7(15-17-12(13)20)11-8(2)19(18-16-11)9-3-5-10(6-4-9)23(14,21)22/h3-6H,1-2H3,(H3,13,17,20)(H2,14,21,22)/b15-7+",AODKDQVAHNORKL-VIZOYTHASA-N,50564913,CHEMBL4795119,Prostaglandin G/H synthase 1,, 5900
50891343,Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1,"InChI=1S/C19H16N4O3/c24-13-4-1-3-12(11-13)17-21-15-14-5-2-6-20-19(14)26-16(15)18(22-17)23-7-9-25-10-8-23/h1-6,11,24H,7-10H2",TUVCWJQQGGETHL-UHFFFAOYSA-N,25045,"3-(4-morpholin-4-ylpyrido[2,3]furo[2,4-b]pyrimidin-2-yl)phenol::3-(4-morpholin-4-ylpyrido[3 ,2 :4,5]furo[3,2-d]pyrimidin-2-yl)phenol::3-(4-morpholinopyrido[2,3]furo[2,4-b]pyrimidin-2-yl)phenol::3-[4-(4-morpholinyl)-2-pyrido[2,3]furo[2,4-b]pyrimidinyl]phenol::3-[6-(morpholin-4-yl)-8-oxa-3,5,10-triazatricyclo[7.4.0.0^{2,7}]trideca-1(9),2,4,6,10,12-hexaen-4-yl]phenol::CHEMBL538346::PI-103::US9637488, PI-103::cid_9884685::mTOR Inhibitor, PI103::pyridofuropyrimidine derivative, 2",Cyclin-dependent kinase 18 [3-474],Homo sapiens,
1151741,COCCN1CCN(C[C@H]2CCC[C@H](C)[C@@H](C)S(=O)(=O)NC(=O)c3ccc4OC[C@]5(CCCc6cc(Cl)ccc56)CN(C[C@@H]5CC[C@@H]25)c4c3)CC1=O,"InChI=1S/C40H55ClN4O6S/c1-27-6-4-7-31(22-43-16-17-44(18-19-50-3)38(46)24-43)34-12-9-32(34)23-45-25-40(15-5-8-29-20-33(41)11-13-35(29)40)26-51-37-14-10-30(21-36(37)45)39(47)42-52(48,49)28(27)2/h10-11,13-14,20-21,27-28,31-32,34H,4-9,12,15-19,22-26H2,1-3H3,(H,42,47)/t27-,28+,31+,32-,34-,40-/m0/s1",GZTJFAOLVBZXHW-HBHGPIKDSA-N,543870,"(1S,3'R,6'S,7'S,11'S,12'R)- 6-chloro-7'-((4-(2- methoxyethyl)-3-oxo-1- piperazinyl)methyl)- 11',12'-dimethyl-3,4- dihydro-2H,15'H- spiro[naphthalene-1,22'- [20]oxa[13]thia[1,14]di- azatetracyclo[14.7.2.0~3, 6~.0~19,24~]pentacosa 16,18,24]trien]-15'-one 13,13'-dioxide AND::US11279712, Example 3::US11279712, Example 7",Bcl-2-like protein 11 [51-76]/Induced myeloid leukemia cell differentiation protein Mcl-1 [171-327],, 0.181
75552,CCCOC(=O)C1=C(C)N=C2CCCC(=O)C2C1c1cccc(OC)c1OC,"InChI=1S/C22H27NO5/c1-5-12-28-22(25)18-13(2)23-15-9-7-10-16(24)20(15)19(18)14-8-6-11-17(26-3)21(14)27-4/h6,8,11,19-20H,5,7,9-10,12H2,1-4H3",LKRMWGKPPHXQBH-UHFFFAOYSA-N,40301,"4-(2,3-dimethoxyphenyl)-2-methyl-5-oxo-4,6,7,8-tetrahydro-1H-quinoline-3-carboxylic acid propyl ester::4-(2,3-dimethoxyphenyl)-5-keto-2-methyl-4,6,7,8-tetrahydro-1H-quinoline-3-carboxylic acid propyl ester::MLS000106913::SMR000111289::cid_2847880::propyl 4-(2,3-dimethoxyphenyl)-2-methyl-5-oxidanylidene-4,6,7,8-tetrahydro-1H-quinoline-3-carboxylate::propyl 4-(2,3-dimethoxyphenyl)-2-methyl-5-oxo-4,6,7,8-tetrahydro-1H-quinoline-3-carboxylate",Ubiquitin carboxyl-terminal hydrolase BAP1,Homo sapiens, 33938.6
50210050,OC(=O)Cn1c2cc(c(cc2[nH]c(=O)c1=O)C(F)(F)F)-n1ccc(CNC(=O)Nc2ccc(cc2)[N+]([O-])=O)c1,"InChI=1S/C23H17F3N6O7/c24-23(25,26)15-7-16-18(31(11-19(33)34)21(36)20(35)29-16)8-17(15)30-6-5-12(10-30)9-27-22(37)28-13-1-3-14(4-2-13)32(38)39/h1-8,10H,9,11H2,(H,29,35)(H,33,34)(H2,27,28,37)",ONWXFZVXNOZZFR-UHFFFAOYSA-N,50116040,"(7-{3-[3-(4-Nitro-phenyl)-ureidomethyl]-pyrrol-1-yl}-2,3-dioxo-6-trifluoromethyl-3,4-dihydro-2H-quinoxalin-1-yl)-acetic acid::CHEMBL13076","Glutamate receptor ionotropic, kainate 3",Homo sapiens,
50855692,CCCNC1=Nc2ccccc2C(C)N1,"InChI=1S/C12H17N3/c1-3-8-13-12-14-9(2)10-6-4-5-7-11(10)15-12/h4-7,9H,3,8H2,1-2H3,(H2,13,14,15)",IOTYITSEKLQPMA-UHFFFAOYSA-N,50371988,CHEMBL270658,5-hydroxytryptamine receptor 5A,,
686539,CCCCS(=O)c1sc2nc(cc(-c3ccc(COC(C)=O)cc3)c2c1N)-c1nccs1,"InChI=1S/C23H23N3O3S3/c1-3-4-11-32(28)23-20(24)19-17(16-7-5-15(6-8-16)13-29-14(2)27)12-18(26-22(19)31-23)21-25-9-10-30-21/h5-10,12H,3-4,11,13,24H2,1-2H3",WABZOOGTSBVUMM-UHFFFAOYSA-N,347440,"US10869871, ID # SW209511::US9789116, SW209511",15-hydroxyprostaglandin dehydrogenase [NAD(+)],Homo sapiens, 2.50
503782,COc1ncc(cn1)-n1nc(C)c2C(=O)N([C@@H](c12)c1ccc(Cl)cc1)c1cc(Cl)c(=O)n(C)c1,"InChI=1S/C23H18Cl2N6O3/c1-12-18-20(31(28-12)16-9-26-23(34-3)27-10-16)19(13-4-6-14(24)7-5-13)30(22(18)33)15-8-17(25)21(32)29(2)11-15/h4-11,19H,1-3H3/t19-/m1/s1",PIPFCKKGOLUZIH-LJQANCHMSA-N,264440,"5-(5-chloro-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-6-(4-chlorophenyl)-2-(2-methoxypyrimidin-5-yl)-3-methyl-5,6-dihydropyrrolo[3,4-c]pyrazol-4(2H)-one::US9714249, 8b",Bromodomain-containing protein 3,, 140
51417587,O=C(Cn1c2ccccc2nc(Cc2ccccc2)c1=O)NNC(=S)Nc1ccccc1,"InChI=1S/C24H21N5O2S/c30-22(27-28-24(32)25-18-11-5-2-6-12-18)16-29-21-14-8-7-13-19(21)26-20(23(29)31)15-17-9-3-1-4-10-17/h1-14H,15-16H2,(H,27,30)(H2,25,28,32)",HSEJNGQSFXATBM-UHFFFAOYSA-N,50572690,CHEMBL4852596,Amine oxidase [flavin-containing] B,, 6.8
50884760,C[C@@H]1CN([C@@H](C)CN1)C(=O)Oc1ccc(Br)cc1,"InChI=1S/C13H17BrN2O2/c1-9-8-16(10(2)7-15-9)13(17)18-12-5-3-11(14)4-6-12/h3-6,9-10,15H,7-8H2,1-2H3/t9-,10+/m1/s1",MIKIVVXHMFOLQJ-ZJUUUORDSA-N,50296736,"(2S,5R)-4-bromophenyl 2,5-dimethylpiperazine-1-carboxylate::CHEMBL561733",Neuronal acetylcholine receptor subunit alpha-7,Rattus norvegicus,
50233346,Cc1ccc(COc2cc(\C=C\C(O)=O)ccc2OC(=O)CCc2c(F)cc(F)cc2F)cc1,"InChI=1S/C26H21F3O5/c1-16-2-4-18(5-3-16)15-33-24-12-17(7-10-25(30)31)6-9-23(24)34-26(32)11-8-20-21(28)13-19(27)14-22(20)29/h2-7,9-10,12-14H,8,11,15H2,1H3,(H,30,31)/b10-7+",VTIXTSZVVVWWJK-JXMROGBWSA-N,50024772,CHEMBL3337713,Aldo-keto reductase family 1 member C3,Homo sapiens, 540
50938701,O[C@@H](Cc1cccc(c1)-c1cc2ccccc2o1)\C=C\[C@H]1CCC(=O)N1CCSc1nc(cs1)C(O)=O,"InChI=1S/C28H26N2O5S2/c31-22(15-18-4-3-6-19(14-18)25-16-20-5-1-2-7-24(20)35-25)10-8-21-9-11-26(32)30(21)12-13-36-28-29-23(17-37-28)27(33)34/h1-8,10,14,16-17,21-22,31H,9,11-13,15H2,(H,33,34)/b10-8+/t21-,22+/m0/s1",PWCLBJYOGZNYIQ-PCBIHFGQSA-N,50385131,CHEMBL2036322,Prostaglandin E2 receptor EP2 subtype,Rattus norvegicus,
50690929,CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C,"InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-",WINHZLLDWRZWRT-ATVHPVEESA-N,4814,"CHEMBL535::N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide::N-[2-(diethylamino)ethyl]-5-{[(3Z)-5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene]methyl}-2,4-dimethyl-1H-pyrrole-3-carboxamide::SU11248::SUNITINIB::SUNITINIB MALATE::US10464902, Sunitinib::US9163010, Sunitinib::US9914707, SU11248",Serine/threonine-protein kinase PAK 4,Homo sapiens,
50593548,CCCCCC1=NN(CC1c1ccccc1)C(=O)NCC1CCCCC1,"InChI=1S/C22H33N3O/c1-2-3-6-15-21-20(19-13-9-5-10-14-19)17-25(24-21)22(26)23-16-18-11-7-4-8-12-18/h5,9-10,13-14,18,20H,2-4,6-8,11-12,15-17H2,1H3,(H,23,26)",WURIOZZNHAKSDX-UHFFFAOYSA-N,50325594,"3-Pentyl-4-phenyl-4,5-dihydro-pyrazole-1-carboxylic acid cyclohexylmet hyl-amide::CHEMBL1224688",Cannabinoid receptor 1,Homo sapiens,
50036375,CN(C)CCc1c[nH]c2ccc(Nc3ncccc3[N+]([O-])=O)cc12,"InChI=1S/C17H19N5O2/c1-21(2)9-7-12-11-19-15-6-5-13(10-14(12)15)20-17-16(22(23)24)4-3-8-18-17/h3-6,8,10-11,19H,7,9H2,1-2H3,(H,18,20)",SZQUYNBBTURBHB-UHFFFAOYSA-N,50039565,CHEMBL314213::[3-(2-Dimethylamino-ethyl)-1H-indol-5-yl]-(3-nitro-pyridin-2-yl)-amine,5-hydroxytryptamine receptor 1D,Rattus, 10
51328752,Nc1ncnc2n(cnc12)[C@H]1[C@H](O)[C@H](O)[C@@H](CCO)C1(F)F,"InChI=1S/C12H15F2N5O3/c13-12(14)5(1-2-20)7(21)8(22)9(12)19-4-18-6-10(15)16-3-17-11(6)19/h3-5,7-9,20-22H,1-2H2,(H2,15,16,17)/t5-,7-,8-,9+/m1/s1",NXDYJYGPWFOQMN-YYNOVJQHSA-N,50537763,CHEMBL4644901,Adenosylhomocysteinase,Homo sapiens, 2030
51178825,CC(NC(=O)c1cncc(n1)N1C[C@@H]2CNC[C@@H]2C1)c1ccccc1,"InChI=1S/C19H23N5O/c1-13(14-5-3-2-4-6-14)22-19(25)17-9-21-10-18(23-17)24-11-15-7-20-8-16(15)12-24/h2-6,9-10,13,15-16,20H,7-8,11-12H2,1H3,(H,22,25)/t13?,15-,16+",PDPCMTBDWRHVEZ-VHRNVKJDSA-N,50484607,CHEMBL1939293,Neuronal acetylcholine receptor subunit alpha-4/beta-2,,
50590044,COc1cc(OC)c(-c2cc(n[nH]2)-c2ccccc2Cl)c(O)c1C1CCN(C)C1CO,"InChI=1S/C23H26ClN3O4/c1-27-9-8-14(18(27)12-28)21-19(30-2)11-20(31-3)22(23(21)29)17-10-16(25-26-17)13-6-4-5-7-15(13)24/h4-7,10-11,14,18,28-29H,8-9,12H2,1-3H3,(H,25,26)",QOSFZNMAGBGKDS-UHFFFAOYSA-N,50324034,"2-[5-(2-Chloro-phenyl)-1H-pyrazol-3-yl]-6-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl)-3,5-dimethoxy-phenol::CHEMBL1214236",Polyphenol oxidase 2,Agaricus bisporus, 29400
796022,Clc1ccc(cc1)-c1nc(CN2CCSCC2)c2ccc(cc2n1)C(=O)NCCCc1ncc[nH]1,"InChI=1S/C26H27ClN6OS/c27-20-6-3-18(4-7-20)25-31-22-16-19(26(34)30-9-1-2-24-28-10-11-29-24)5-8-21(22)23(32-25)17-33-12-14-35-15-13-33/h3-8,10-11,16H,1-2,9,12-15,17H2,(H,28,29)(H,30,34)",KNWPNCVSWGDNEV-UHFFFAOYSA-N,398297,"US10323018, Compound I-26",Nicotinamide phosphoribosyltransferase,Homo sapiens,>100
161538,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12,"InChI=1S/C21H26N2O3/c1-26-21(25)19-15-10-17-20-14(13-4-2-3-5-16(13)22-20)8-9-23(17)11-12(15)6-7-18(19)24/h2-5,12,15,17-19,22,24H,6-11H2,1H3/t12-,15-,17-,18-,19+/m0/s1",BLGXFZZNTVWLAY-SCYLSFHTSA-N,50013515,"(+)-yohimbine::(16alpha,17alpha)-17-hydroxyyohimban-16-carboxylic acid methyl ester::17alpha-hydroxyyohimban-16alpha-carboxylic acid methyl ester::CHEMBL15245::CORYNANTHINE::Johimbin::Quebrachin::RAUWOLSCINE::YOHIMBINE CHLORIDE::Yohimbin::Yohimbine::aphrodine::cid_8969::corynine::methyl 17alpha-hydroxyyohimban-16alpha-carboxylate::quebrachine::yohimbic acid methyl ester",Alpha-2C adrenergic receptor,Rattus,
50477819,CC(C)C[C@H](CC(=O)NO)C(=O)N[C@@H](CC(C)C)c1nc2ccc(cc2[nH]1)C(F)(F)F,"InChI=1S/C21H29F3N4O3/c1-11(2)7-13(9-18(29)28-31)20(30)27-17(8-12(3)4)19-25-15-6-5-14(21(22,23)24)10-16(15)26-19/h5-6,10-13,17,31H,7-9H2,1-4H3,(H,25,26)(H,27,30)(H,28,29)/t13-,17+/m1/s1",QVXRAVFETVTALN-DYVFJYSZSA-N,50287377,(R)-N*4*-Hydroxy-2-isobutyl-N*1*-[(S)-3-methyl-1-(6-trifluoromethyl-1H-benzoimidazol-2-yl)-butyl]-succinamide::CHEMBL289513,Matrilysin,Homo sapiens, 10
1126574,CN(Cc1ccc(cc1)C(O)=O)C(=O)c1c(CCCOc2cc(C)c(Cl)c(C)c2)c2ccc(Cl)c(-c3c(C)nn(C)c3C)c2n1CCN1CCOCC1,"InChI=1S/C41H47Cl2N5O5/c1-25-22-31(23-26(2)37(25)43)53-19-7-8-32-33-13-14-34(42)36(35-27(3)44-46(6)28(35)4)38(33)48(16-15-47-17-20-52-21-18-47)39(32)40(49)45(5)24-29-9-11-30(12-10-29)41(50)51/h9-14,22-23H,7-8,15-21,24H2,1-6H3,(H,50,51)",RWWYFPDGJDQBJC-UHFFFAOYSA-N,429237,"US10533010, Example I-374::US11208415, Example I-374",Induced myeloid leukemia cell differentiation protein Mcl-1,Homo sapiens,
50616349,COC(=O)[C@@H]1C[C@H](OC(=O)[C@@H](N)C(C)C)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](C[C@]21C)c1ccoc1,"InChI=1S/C26H35NO8/c1-13(2)19(27)24(31)34-17-10-16(22(29)32-5)25(3)8-6-15-23(30)35-18(14-7-9-33-12-14)11-26(15,4)21(25)20(17)28/h7,9,12-13,15-19,21H,6,8,10-11,27H2,1-5H3/t15-,16-,17-,18-,19-,21-,25-,26-/m0/s1",BYMGZZQEXWAHIJ-SYCSBVGDSA-N,50334060,"(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-((S)-2-amino-3-methylbutanoyloxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate::CHEMBL1644775",Mu-type opioid receptor,Homo sapiens,
50539764,FC(F)(F)CCOc1ccc(cn1)C(=O)NCc1ccc(Br)cc1OC(F)(F)F,"InChI=1S/C17H13BrF6N2O3/c18-12-3-1-10(13(7-12)29-17(22,23)24)8-26-15(27)11-2-4-14(25-9-11)28-6-5-16(19,20)21/h1-4,7,9H,5-6,8H2,(H,26,27)",VLVJWVWVJRMAMD-UHFFFAOYSA-N,50302462,"CHEMBL566648::N-(4-bromo-2-(trifluoromethoxy)benzyl)-6-(3,3,3-trifluoropropoxy)nicotinamide",Bifunctional epoxide hydrolase 2,, 12
50545597,CCOC(=O)c1c(Cc2ccccc2Cl)[nH]c2c1cc(O)c1ccccc21,"InChI=1S/C22H18ClNO3/c1-2-27-22(26)20-16-12-19(25)14-8-4-5-9-15(14)21(16)24-18(20)11-13-7-3-6-10-17(13)23/h3-10,12,24-25H,2,11H2,1H3",UHAYSTCWGQPHKI-UHFFFAOYSA-N,31123,"5-hydroxy-1H-benzo[g]indole-3-carboxylate, 11b",Prostaglandin E synthase,Homo sapiens, 20500
1174270,CCN1CCC(CC1)c1ccc(Nc2ncc(F)c(n2)-c2cc(F)c3nc4CCC(C)(C)n4c3c2)nc1,"InChI=1S/C28H31F2N7/c1-4-36-11-8-17(9-12-36)18-5-6-23(31-15-18)33-27-32-16-21(30)25(35-27)19-13-20(29)26-22(14-19)37-24(34-26)7-10-28(37,2)3/h5-6,13-17H,4,7-12H2,1-3H3,(H,31,32,33,35)",AKUJQCDZMJSNMC-UHFFFAOYSA-N,448950,"N-(5-(1-Ethylpiperidine-4-yl)pyridin-2-yl)-5-fluoro-4-(5-fluoro-1,1-dimethyl-2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazol-7-yl)pyrimidin-2-amine::US10696678, Example 45::US11351170, Example 4",Cyclin-dependent kinase 5,Homo sapiens, 38.3
395364,Oc1cc(O)c(cc1Cl)-n1c2ccc(cc2[nH]c1=O)N(=O)=O,"InChI=1S/C13H8ClN3O5/c14-7-4-10(12(19)5-11(7)18)16-9-2-1-6(17(21)22)3-8(9)15-13(16)20/h1-5,18-19H,(H,15,20)",LUOBGAJDKGXRFD-UHFFFAOYSA-N,225716,hsp90_9,Heat shock protein HSP 90-beta,Homo sapiens, 46.8
50347615,Clc1ccc(Nc2s[nH]c(=O)c2C(=N)NCC2CCCCC2)c(Cl)c1,"InChI=1S/C17H20Cl2N4OS/c18-11-6-7-13(12(19)8-11)22-17-14(16(24)23-25-17)15(20)21-9-10-4-2-1-3-5-10/h6-8,10,22H,1-5,9H2,(H2,20,21)(H,23,24)",WBCQVYZRFOIYAD-UHFFFAOYSA-N,50187852,"CHEMBL380328::N-(cyclohexylmethyl)-5-(2,4-dichlorophenylamino)-3-hydroxyisothiazole-4-carboxamidine",Dual specificity mitogen-activated protein kinase kinase 1,Homo sapiens, 410
451935,CC[C@H](Nc1ncnc(N)c1-c1ccon1)c1cc2cccc(F)c2c(=O)n1-c1ccccc1,"InChI=1S/C25H21FN6O2/c1-2-18(30-24-22(19-11-12-34-31-19)23(27)28-14-29-24)20-13-15-7-6-10-17(26)21(15)25(33)32(20)16-8-4-3-5-9-16/h3-14,18H,2H2,1H3,(H3,27,28,29,30)/t18-/m0/s1",WUEYKZHWSVGDPM-SFHVURJKSA-N,259455,"US9512114, 19::US9657007, Example 19","Phosphatidylinositol 3-kinase regulatory subunit alpha/4,5-bisphosphate 3-kinase catalytic subunit delta isoform",Homo sapiens, 46
77488,O=C1CCCC(=O)C1=CNCCc1ccccc1,"InChI=1S/C15H17NO2/c17-14-7-4-8-15(18)13(14)11-16-10-9-12-5-2-1-3-6-12/h1-3,5-6,11,16H,4,7-10H2",VLYKGJWLSABHKX-UHFFFAOYSA-N,40920,"2-[(2-phenylethylamino)methylidene]cyclohexane-1,3-dione::2-[(phenethylamino)methylene]cyclohexane-1,3-quinone::MLS000108318::SMR000104278::cid_2248605",Cathepsin G,Homo sapiens,>50000
50132710,NC(=N)NCCC[C@H](NC(=O)[C@@H]1CCN2CC[C@@](N)(Cc3ccccc3)CN12)C(=O)c1nc2ccccc2s1,"InChI=1S/C28H36N8O2S/c29-27(30)32-14-6-10-21(24(37)26-34-20-9-4-5-11-23(20)39-26)33-25(38)22-12-15-35-16-13-28(31,18-36(22)35)17-19-7-2-1-3-8-19/h1-5,7-9,11,21-22H,6,10,12-18,31H2,(H,33,38)(H4,29,30,32)/t21-,22-,28+/m0/s1",WQDOEYAJPUSQCH-RXYILKCJSA-N,50076222,"(1S,7S)-7-Amino-7-benzyl-hexahydro-pyrazolo[1,2-a]pyridazine-1-carboxylic acid [(S)-1-(benzothiazole-2-carbonyl)-4-guanidino-butyl]-amide::CHEMBL282830",Tissue-type plasminogen activator,Homo sapiens, 495
51280024,Nc1nc2ccc(SCc3ccc(cc3)C#N)cc2s1,"InChI=1S/C15H11N3S2/c16-8-10-1-3-11(4-2-10)9-19-12-5-6-13-14(7-12)20-15(17)18-13/h1-7H,9H2,(H2,17,18)",QGVLQSFGSQHYEK-UHFFFAOYSA-N,50522411,CHEMBL4564287,Cytochrome P450 2D6,,<10000
280401,N#Cc1cc(ccc1OC1CCOCC1)-c1ccnc(Nc2cncc(n2)C2=CCCCO2)c1,"InChI=1S/C26H25N5O3/c27-15-20-13-18(4-5-23(20)34-21-7-11-32-12-8-21)19-6-9-29-25(14-19)31-26-17-28-16-22(30-26)24-3-1-2-10-33-24/h3-6,9,13-14,16-17,21H,1-2,7-8,10-12H2,(H,29,30,31)",HIONSSOVORAGDX-UHFFFAOYSA-N,144155,"US8969335, A92",Serine/threonine-protein kinase TBK1,, 850
484592,C[C@@H](Nc1nc(nc2nc(N(C)C(C)c3ccccn3)n(C[C@H]3CC[C@H](C)CC3)c12)-c1noc(=O)[nH]1)C1CCC1,,,223598,"3-(6-{[(1r)-1- cyclobutylethyl]amino}- 7-[(trans-4- methylcyclohexyl) methyl]-8-[methyl(1- pyridin-2- ylethyl)amino]-7h- purin-2-yl)-1,2,4- oxadiazol-5(4h)-one (diastereomer 1)::US9540377, 11.24::US9540377, 11.25",E3 ubiquitin-protein ligase Mdm2 [17-125],, 10.47
1087056,CC(C)c1c([nH]c2ccc(nc12)C1CC2(C1)CN(C2)C(=O)CN(C)C)-c1cn2ncnc2c(C)c1C,"InChI=1S/C28H35N7O/c1-16(2)24-25(20-11-35-27(29-15-30-35)18(4)17(20)3)32-22-8-7-21(31-26(22)24)19-9-28(10-19)13-34(14-28)23(36)12-33(5)6/h7-8,11,15-16,19,32H,9-10,12-14H2,1-6H3",UJWWIWGDMSWBBL-UHFFFAOYSA-N,428591,"US10544143, Example 1027::US10730877, Example 1027::US11053244, Example 1027",Toll-like receptor 7,, 0.600
51337127,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1,"InChI=1S/C21H31N5O2/c27-18-16-21(6-1-2-7-21)17-19(28)26(18)11-4-3-10-24-12-14-25(15-13-24)20-22-8-5-9-23-20/h5,8-9H,1-4,6-7,10-17H2",QWCRAEMEVRGPNT-UHFFFAOYSA-N,50001859,"(buspirone) 8-[4-(4-Pyrimidin-2-yl-piperazin-1-yl)-butyl]-8-aza-spiro[4.5]decane-7,9-dione::8-[4-(4-Pyrimidin-2-yl-piperazin-1-yl)-butyl]-8-aza-spiro[4.5]decane-7,9-dione : (Hydrochloride)::8-[4-(4-Pyrimidin-2-yl-piperazin-1-yl)-butyl]-8-aza-spiro[4.5]decane-7,9-dione; Hydrochloride(Buspirone)::8-[4-(4-pyrimidin-2-yl-piperazin-1-yl)-butyl]-8-aza-spiro[4.5]decane-7,9-dione::BUSPAR::BUSPIRONE::CHEMBL49::US10562853, Compound Buspirone",5-hydroxytryptamine receptor 1A,,
100147,Cc1ccc(NNC2=c3cc(F)ccc3=NC2=O)cc1,"InChI=1S/C15H12FN3O/c1-9-2-5-11(6-3-9)18-19-14-12-8-10(16)4-7-13(12)17-15(14)20/h2-8,18H,1H3,(H,17,19,20)",KHSRKYSSOSUIDA-UHFFFAOYSA-N,52924,5-fluoranyl-3-[2-(4-methylphenyl)hydrazinyl]indol-2-one::5-fluoro-3-[(4-methylphenyl)hydrazo]-2-indolone::5-fluoro-3-[2-(4-methylphenyl)hydrazinyl]indol-2-one::5-fluoro-3-[2-(4-methylphenyl)hydrazono]indolin-2-one::5-fluoro-3-[N'-(p-tolyl)hydrazino]indol-2-one::MLS000850951::SMR000456968::cid_5703533,POsterior Segregation,Caenorhabditis elegans,
844759,CCOc1cc(cn2nc(C)nc12)-c1[nH]c2ccc(cc2c1C(C)C)C1CCNCC1,"InChI=1S/C25H31N5O/c1-5-31-22-13-19(14-30-25(22)27-16(4)29-30)24-23(15(2)3)20-12-18(6-7-21(20)28-24)17-8-10-26-11-9-17/h6-7,12-15,17,26,28H,5,8-11H2,1-4H3",DHKUOSYMTDCYEX-UHFFFAOYSA-N,273354,"US10071079, Example 135::US10478424, Example 135",Toll-like receptor 7,, 3.20
1091177,CCc1ccc(Cl)cc1Nc1nc(=O)c(OC)cn1Cc1ccccc1,"InChI=1S/C20H20ClN3O2/c1-3-15-9-10-16(21)11-17(15)22-20-23-19(25)18(26-2)13-24(20)12-14-7-5-4-6-8-14/h4-11,13H,3,12H2,1-2H3,(H,22,23,25)",MJOOWCIEFZKMSU-UHFFFAOYSA-N,459917,"US10774051, Compound I-0175::US11124486, Compound I-0175",P2X purinoceptor 7,, 55
50145898,NC(=N)c1ccc(COc2ccc3OC(CC(O)=O)CCc3c2)cc1,"InChI=1S/C19H20N2O4/c20-19(21)13-3-1-12(2-4-13)11-24-15-7-8-17-14(9-15)5-6-16(25-17)10-18(22)23/h1-4,7-9,16H,5-6,10-11H2,(H3,20,21)(H,22,23)",CJDNCRHRAFTMLI-UHFFFAOYSA-N,50082926,CHEMBL144408::[6-(4-Carbamimidoyl-benzyloxy)-chroman-2-yl]-acetic acid,Integrin alpha-IIb/beta-3,, 39
50941377,CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCC(c3ccccc3)c3ccccc3)nc(NCCc3ccc(Br)cc3)nc12,"InChI=1S/C34H36BrN7O4/c1-2-36-32(45)29-27(43)28(44)33(46-29)42-20-39-26-30(38-19-25(22-9-5-3-6-10-22)23-11-7-4-8-12-23)40-34(41-31(26)42)37-18-17-21-13-15-24(35)16-14-21/h3-16,20,25,27-29,33,43-44H,2,17-19H2,1H3,(H,36,45)(H2,37,38,40,41)/t27-,28+,29-,33+/m0/s1",XINQUHWFRVILKN-KCIBBDPESA-N,50385951,CHEMBL2042307,Adenosine receptor A2a,Homo sapiens,
51057184,COc1cccc(CNC(=O)N(CCO)c2ccc(cc2)-c2cn[nH]c2)c1,"InChI=1S/C20H22N4O3/c1-27-19-4-2-3-15(11-19)12-21-20(26)24(9-10-25)18-7-5-16(6-8-18)17-13-22-23-14-17/h2-8,11,13-14,25H,9-10,12H2,1H3,(H,21,26)(H,22,23)",NGAVHWOZWVFLIS-UHFFFAOYSA-N,50431153,CHEMBL2332093,Rho-associated protein kinase 2,Homo sapiens, 611
50505539,COc1ccc(CC2N(CC(=O)NC3CCc4ccccc34)CCc3cc(OC)c(OC)cc23)cc1,"InChI=1S/C30H34N2O4/c1-34-23-11-8-20(9-12-23)16-27-25-18-29(36-3)28(35-2)17-22(25)14-15-32(27)19-30(33)31-26-13-10-21-6-4-5-7-24(21)26/h4-9,11-12,17-18,26-27H,10,13-16,19H2,1-3H3,(H,31,33)",KZVKGPJADMQNID-UHFFFAOYSA-N,50292949,"CHEMBL489303::N-(2,3-dihydro-1H-inden-1-yl)-2-(6,7-dimethoxy-1-(4-methoxybenzyl)-3,4-dihydroisoquinolin-2(1H)-yl)acetamide",Orexin/Hypocretin receptor type 1,Homo sapiens, 1182
50768037,COc1cccc2OCC(Cc12)N1CCCC1,"InChI=1S/C14H19NO2/c1-16-13-5-4-6-14-12(13)9-11(10-17-14)15-7-2-3-8-15/h4-6,11H,2-3,7-10H2,1H3",HDUPNKAXLWKEFD-UHFFFAOYSA-N,50036854,1-(5-Methoxy-chroman-3-yl)-pyrrolidine::CHEMBL285010,5-hydroxytryptamine receptor 2A,Bos taurus, 60000
848563,Cc1cccc(c1)-c1cn2c(cnc2c(N)n1)-c1cc(ccc1C)S(=O)(=O)N[C@H]1CC[C@H](O)CC1,"InChI=1S/C26H29N5O3S/c1-16-4-3-5-18(12-16)23-15-31-24(14-28-26(31)25(27)29-23)22-13-21(11-6-17(22)2)35(33,34)30-19-7-9-20(32)10-8-19/h3-6,11-15,19-20,30,32H,7-10H2,1-2H3,(H2,27,29)/t19-,20-",YYFSZDFPUZCXAP-MXVIHJGJSA-N,421016,"3-[8-Amino-6-(3-methylphenyl)imidazo[1,2-a]pyrazin-3-yl]-N- (trans-4-hydroxycyclohexyl)-4-methylbenzenesulfonamide::US10479795, Example 19","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform",Homo sapiens,<500
50534498,CCNC(=O)Nc1ccc(cc1)-c1nc(N2CCOC(C)C2)c2cnn(C3CCN(CC3)C(=O)OC)c2n1,"InChI=1S/C26H34N8O4/c1-4-27-25(35)29-19-7-5-18(6-8-19)22-30-23(33-13-14-38-17(2)16-33)21-15-28-34(24(21)31-22)20-9-11-32(12-10-20)26(36)37-3/h5-8,15,17,20H,4,9-14,16H2,1-3H3,(H2,27,29,35)",UPQRSQYXPGPCQM-UHFFFAOYSA-N,50300090,"CHEMBL576937::methyl 4-(6-(4-(3-ethylureido)phenyl)-4-(2-methylmorpholino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",Homo sapiens, 721
50751628,CC(C)C1(c2c(C)[nH]nc2OC(N)=C1C#N)c1cc(cc(c1)-c1ccc(s1)C(F)(F)F)C#N,"InChI=1S/C23H18F3N5OS/c1-11(2)22(16(10-28)20(29)32-21-19(22)12(3)30-31-21)15-7-13(9-27)6-14(8-15)17-4-5-18(33-17)23(24,25)26/h4-8,11H,29H2,1-3H3,(H,30,31)",SPNNSIVYARLBSM-UHFFFAOYSA-N,50239678,CHEMBL4077713,Glycine hydroxymethyltransferase,, 388
50966608,CS(=O)(=O)c1ccccc1C(=O)N1CCC(CC1)c1ccc(cc1C(F)(F)F)C(=O)NC(N)=N,"InChI=1S/C22H23F3N4O4S/c1-34(32,33)18-5-3-2-4-16(18)20(31)29-10-8-13(9-11-29)15-7-6-14(19(30)28-21(26)27)12-17(15)22(23,24)25/h2-7,12-13H,8-11H2,1H3,(H4,26,27,28,30)",TXBXIEFGFYGJHN-UHFFFAOYSA-N,50396448,CHEMBL2170634,Sodium/hydrogen exchanger 1,Homo sapiens, 269
718611,CO[C@@H]([C@H](C)S(=O)(=O)Nc1nnc(-c2ccccn2)n1-c1c(OC)ncnc1OC)c1cnc(C)cn1,"InChI=1S/C22H25N9O5S/c1-13-10-25-16(11-24-13)18(34-3)14(2)37(32,33)30-22-29-28-19(15-8-6-7-9-23-15)31(22)17-20(35-4)26-12-27-21(17)36-5/h6-12,14,18H,1-5H3,(H,29,30)/t14-,18-/m0/s1",CGHLLSRSRRPZCY-KSSFIOAISA-N,270211,"(1R,2S)-N-(4-(4,6-dimethoxy-5-pyrimidinyl)-5-(2-pyridinyl)-4H-1,2,4-triazol-3-yl)-1-methoxy-1-(5-methyl-2-pyrazinyl)-2-propanesulfonamide::US10058550, Example 779.0::US10221162, Example 779.0::US9845310, Example 779.0",Apelin receptor,Homo sapiens,
824778,CCC(C(=O)Nc1ccc(cc1)C(=O)OC[C@H](NC(=O)CN1CCCC1)C(O)=O)n1cc(OC)c(cc1=O)-c1cc(Cl)ccc1C#N,"InChI=1S/C33H34ClN5O8/c1-3-27(39-17-28(46-2)25(15-30(39)41)24-14-22(34)9-6-21(24)16-35)31(42)36-23-10-7-20(8-11-23)33(45)47-19-26(32(43)44)37-29(40)18-38-12-4-5-13-38/h6-11,14-15,17,26-27H,3-5,12-13,18-19H2,1-2H3,(H,36,42)(H,37,40)(H,43,44)/t26-,27?/m0/s1",JBZDNYYESRXQMG-QBHOUYDASA-N,413465,"O-[4-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)-benzoyl]-N-(pyrrolidin-1-ylacetyl)-L-serine (Enantiomerically Pure Diastereomer)::US10414731, Example 5",Coagulation factor XI,Homo sapiens, 60.0
383058,C[C@H]1CN(C[C@@H](C)N1)c1nc(NC2CC2)n2ncc(\C=C3/NC(=O)NC3=O)c2n1,"InChI=1S/C18H23N9O2/c1-9-7-26(8-10(2)20-9)16-23-14-11(5-13-15(28)24-18(29)22-13)6-19-27(14)17(25-16)21-12-3-4-12/h5-6,9-10,12,20H,3-4,7-8H2,1-2H3,(H,21,23,25)(H2,22,24,28,29)/b13-5-/t9-,10+",WIEASERILCJXTG-XNFJCXGQSA-N,219341,"US9303033, O20, Table 37A, Compound 15",Casein kinase II subunit alpha/beta,Homo sapiens,<100
51255232,CN(CC#C)Cc1cc2cc(OCc3ccccc3)ccc2n1C,"InChI=1S/C21H22N2O/c1-4-12-22(2)15-19-13-18-14-20(10-11-21(18)23(19)3)24-16-17-8-6-5-7-9-17/h1,5-11,13-14H,12,15-16H2,2-3H3",YASPBSWTXDWFLF-UHFFFAOYSA-N,50359390,CHEMBL1929418::CHEMBL2022924,Amine oxidase [flavin-containing] A,Rattus norvegicus, 100
1034805,CC(C)(C)NC(=O)CN1Cc2ccc(cc2C1=O)-c1nc(NC2CCOCC2)ncc1Cl,"InChI=1S/C23H28ClN5O3/c1-23(2,3)28-19(30)13-29-12-15-5-4-14(10-17(15)21(29)31)20-18(24)11-25-22(27-20)26-16-6-8-32-9-7-16/h4-5,10-11,16H,6-9,12-13H2,1-3H3,(H,28,30)(H,25,26,27)",ZREYQWDDINYDOY-UHFFFAOYSA-N,50456361,"CHEMBL4215376::US11001575, Example 141",Mitogen-activated protein kinase 1,Homo sapiens, 9.00
119982,COc1cc(\C=C2/COC\C(=C/c3cc(OC)c(OC)c(OC)c3)C2=O)cc(OC)c1OC,"InChI=1S/C25H28O8/c1-27-19-9-15(10-20(28-2)24(19)31-5)7-17-13-33-14-18(23(17)26)8-16-11-21(29-3)25(32-6)22(12-16)30-4/h7-12H,13-14H2,1-6H3/b17-7+,18-8+",WDUOPQZLRWPGTF-ZEELXFFVSA-N,43491,"(3E,5E)-3,5-bis(3,4,5-trimethoxybenzylidene)tetrahydropyran-4-one::(3E,5E)-3,5-bis[(3,4,5-trimethoxyphenyl)methylidene]-4-oxanone::(3E,5E)-3,5-bis[(3,4,5-trimethoxyphenyl)methylidene]oxan-4-one::3,5-di(3,4,5-trimethoxybenzylidene)tetrahydro-2H-pyran-4-one::MLS000860258::SMR000461037::cid_5703458",Heat shock factor protein 1,Mus musculus,
286694,CCC(C)CN1CCN(CC1)c1ccc(Nc2ncc3cc(C(=O)N(C)C)n(C4CCCC4)c3n2)nc1,"InChI=1S/C28H40N8O/c1-5-20(2)19-34-12-14-35(15-13-34)23-10-11-25(29-18-23)31-28-30-17-21-16-24(27(37)33(3)4)36(26(21)32-28)22-8-6-7-9-22/h10-11,16-18,20,22H,5-9,12-15,19H2,1-4H3,(H,29,30,31,32)",WFCLNWRQLIWVHI-UHFFFAOYSA-N,148285,"US8962630, 99",Cyclin-dependent kinase 2,Homo sapiens,>15000
50999571,Cc1ccc2N=C(C(=O)c2c1)c1c(O)[nH]c2ccccc12,"InChI=1S/C17H12N2O2/c1-9-6-7-13-11(8-9)16(20)15(18-13)14-10-4-2-3-5-12(10)19-17(14)21/h2-8,19,21H,1H3",KQGNXKLJTGXPAE-UHFFFAOYSA-N,50148066,"5-Methyl-1H,1'H-[2,3']biindolylidene-3,2'-dione::CHEMBL326919",Cyclin-dependent kinase 5 activator 1,Homo sapiens, 1900
525151,COc1cnc2c(Nc3ccc(F)c(c3)[C@]3(C)CS(=O)(=O)N(C)C(=N)N3)ncnc2c1,"InChI=1S/C19H20FN7O3S/c1-19(9-31(28,29)27(2)18(21)26-19)13-6-11(4-5-14(13)20)25-17-16-15(23-10-24-17)7-12(30-3)8-22-16/h4-8,10H,9H2,1-3H3,(H2,21,26)(H,23,24,25)/t19-/m0/s1",OLNCEEMYACPFFF-IBGZPJMESA-N,276799,"N-{4-fluoro-3-[(5R)-3-imino-2,5-dimethyl-1,1-dioxido-1,2,4-thiadiazinan-5-yl]phenyl}-7-methoxypyrido[3,2-d]pyrimidin-4-amine::US10071998, Example 14",Beta-secretase 2,,
51298684,CN(CC(=O)N(C)C)Cc1ccc2C[C@H](CCc2c1)N(C)C(=O)c1ccc(cc1)-c1ccc(F)cc1,"InChI=1S/C30H34FN3O2/c1-32(2)29(35)20-33(3)19-21-5-6-26-18-28(16-13-25(26)17-21)34(4)30(36)24-9-7-22(8-10-24)23-11-14-27(31)15-12-23/h5-12,14-15,17,28H,13,16,18-20H2,1-4H3/t28-/m0/s1",JWTBNTCDSNQIDW-NDEPHWFRSA-N,50198500,"(S)-N-(6-(((2-(dimethylamino)-2-oxoethyl)(methyl)amino)methyl)-1,2,3,4-tetrahydronaphthalen-2-yl)-4'-fluoro-N-methylbiphenyl-4-carboxamide::CHEMBL214432",Melanin-concentrating hormone receptor 1,Homo sapiens, 24
1041741,OC[C@@H]1CC[C@H](CO1)Nc1ncnc2[nH]cc(C(=O)c3ccc(cc3Cl)C(=O)Nc3cccnc3)c12,,,499933,"3-chloro-4-(4-(((3R,6S)-6- (hydroxymethyl)tetrahydro-2H-pyran-3- yl)amino)-7H-pyrrolo[2,3-d]pyrimidine- 5-carbonyl)-N-(pyridin-3-yl)benzamide::US11020398, Compound I-256",Tyrosine-protein kinase BTK [C481S],, 317
144108,COc1ccc(cc1)C(=O)ON=C(N)c1ccc(Cl)cc1,"InChI=1S/C15H13ClN2O3/c1-20-13-8-4-11(5-9-13)15(19)21-18-14(17)10-2-6-12(16)7-3-10/h2-9H,1H3,(H2,17,18)",JCODIOPPRDUNST-UHFFFAOYSA-N,78384,4-chloro-N&#39;-[(4-methoxybenzoyl)oxy]benzenecarboximidamide::4-methoxybenzoic acid [(Z)-[amino-(4-chlorophenyl)methylene]amino] ester::4-methoxybenzoic acid [(Z)-[amino-(4-chlorophenyl)methylidene]amino] ester::MLS001196046::SMR000558654::[(Z)-[amino-(4-chlorophenyl)methylidene]amino] 4-methoxybenzoate::[(Z)-[azanyl-(4-chlorophenyl)methylidene]amino] 4-methoxybenzoate::cid_12515961,Mitochondrial import inner membrane translocase subunit TIM10,Saccharomyces cerevisiae (strain ATCC 204508 / S288c), 13300
50612784,COc1ccc(CC(=O)Nc2cccc(c2)C(=O)C(=O)c2ccccn2)cc1,"InChI=1S/C22H18N2O4/c1-28-18-10-8-15(9-11-18)13-20(25)24-17-6-4-5-16(14-17)21(26)22(27)19-7-2-3-12-23-19/h2-12,14H,13H2,1H3,(H,24,25)",BAOHDGHDGBREJU-UHFFFAOYSA-N,50332636,2-(4-methoxyphenyl)-N-(3-(2-oxo-2-(pyridin-2-yl)acetyl)phenyl)acetamide::CHEMBL1630815,Cholinesterase,Homo sapiens,
1082245,CC(C)c1ccc(cc1)-c1nc2ncccn2c1CN1CC2CCC1CN2C(=O)c1cccc(OC(F)F)n1,"InChI=1S/C29H30F2N6O2/c1-18(2)19-7-9-20(10-8-19)26-24(36-14-4-13-32-29(36)34-26)17-35-15-22-12-11-21(35)16-37(22)27(38)23-5-3-6-25(33-23)39-28(30)31/h3-10,13-14,18,21-22,28H,11-12,15-17H2,1-2H3",PMDZYSBRJCKJBX-UHFFFAOYSA-N,515577,"US11098063, Example 75::US11098063, Example 76",Potassium channel subfamily K member 9,Homo sapiens, 56.0
304847,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2OCOc2cc1-c1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)c(C)n1CCN(C)C,"InChI=1S/C40H40N4O5/c1-26-20-28-10-8-9-11-29(28)24-43(26)39(46)35-23-38-37(48-25-49-38)22-34(35)36-21-33(27(2)42(36)19-18-41(3)4)40(47)44(30-12-6-5-7-13-30)31-14-16-32(45)17-15-31/h5-17,21-23,26,45H,18-20,24-25H2,1-4H3/t26-/m1/s1",KADNHVXFTHHVMI-AREMUKBSSA-N,161549,"US9108983, Example 98",Apoptosis regulator Bcl-2,, 7.6
51016650,Cc1ncoc1-c1nnc(SCCCN2CC3CC3(C2)c2cccc(c2)S(F)(F)(F)(F)F)n1C,"InChI=1S/C21H24F5N5OS2/c1-14-18(32-13-27-14)19-28-29-20(30(19)2)33-8-4-7-31-11-16-10-21(16,12-31)15-5-3-6-17(9-15)34(22,23,24,25)26/h3,5-6,9,13,16H,4,7-8,10-12H2,1-2H3",WHOZDXFLKLSAJU-UHFFFAOYSA-N,50322854,CHEMBL1210614,Potassium voltage-gated channel subfamily H member 2,Homo sapiens, 1995.26
51438070,[O-][N+](=O)c1ccc(o1)C(=O)Nc1ccc(NS(=O)(=O)c2cccc(c2)C(F)(F)F)cc1,"InChI=1S/C18H12F3N3O6S/c19-18(20,21)11-2-1-3-14(10-11)31(28,29)23-13-6-4-12(5-7-13)22-17(25)15-8-9-16(30-15)24(26)27/h1-10,23H,(H,22,25)",GWNFURCPOFWHQG-UHFFFAOYSA-N,50580914,CHEMBL5072845,Urea transporter 1,Rattus norvegicus, 1660
50608876,CN(C)[C@@H]1CC[C@@H](C1)c1c[nH]c2ccc(cc12)C#N,"InChI=1S/C16H19N3/c1-19(2)13-5-4-12(8-13)15-10-18-16-6-3-11(9-17)7-14(15)16/h3,6-7,10,12-13,18H,4-5,8H2,1-2H3/t12-,13+/m0/s1",CMJSIPQFDNXSOL-QWHCGFSZSA-N,50330813,"3-[(1S,3R)-3-Dimethylaminocyclopentyl]-1H-indole-5-carbonitrile::CHEMBL1275709",D(1A) dopamine receptor,, 7200
51438743,Cc1nc(NCc2ccsc2)c2c(c[nH]c2n1)-c1ccnc(N)c1,"InChI=1S/C17H16N6S/c1-10-22-16(20-7-11-3-5-24-9-11)15-13(8-21-17(15)23-10)12-2-4-19-14(18)6-12/h2-6,8-9H,7H2,1H3,(H2,18,19)(H2,20,21,22,23)",KRWCFCQJKXIENS-UHFFFAOYSA-N,50581240,CHEMBL5083159,Dual specificity tyrosine-phosphorylation-regulated kinase 1B,, 1.000000
51103748,C[C@@H](O)[C@H](N)C(=O)Nc1nc(C)c(s1)-c1cnc(Cl)c(NS(=O)(=O)c2ccccc2)c1,"InChI=1S/C19H20ClN5O4S2/c1-10-16(30-19(23-10)24-18(27)15(21)11(2)26)12-8-14(17(20)22-9-12)25-31(28,29)13-6-4-3-5-7-13/h3-9,11,15,25-26H,21H2,1-2H3,(H,23,24,27)/t11-,15+/m1/s1",GMFGIAAVYFVKEH-ABAIWWIYSA-N,50449971,CHEMBL4168101,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",Homo sapiens, 28
337790,COC(=O)c1ccc(cc1)-c1cc(Nc2cccc(n2)N2CCCC2C)c2nccn2n1,"InChI=1S/C24H24N6O2/c1-16-5-4-13-29(16)22-7-3-6-21(27-22)26-20-15-19(28-30-14-12-25-23(20)30)17-8-10-18(11-9-17)24(31)32-2/h3,6-12,14-16H,4-5,13H2,1-2H3,(H,26,27)",GHRHSDCPMOVNPC-UHFFFAOYSA-N,188132,"US9169259, I-14",Tyrosine-protein kinase SYK [360-635],, 368.85
170538,C1CN=C(N1)C1COc2ccccc2O1,"InChI=1S/C11H12N2O2/c1-2-4-9-8(3-1)14-7-10(15-9)11-12-5-6-13-11/h1-4,10H,5-7H2,(H,12,13)",HPMRFMKYPGXPEP-UHFFFAOYSA-N,50019848,"2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole::4,5-dihydro-2-(2,3-dihydro-1,4-benzodioxin-2-yl)-1H-imidazole::CHEMBL10316::Idazoxan::US8633208, Idazoxan",5-hydroxytryptamine receptor 7,Rattus norvegicus,
50626058,Cc1ccc2cc([nH]c2c1)-c1n[nH]c2ccc(NC3CCN(Cc4ccccc4)C3)cc12,"InChI=1S/C27H27N5/c1-18-7-8-20-14-26(29-25(20)13-18)27-23-15-21(9-10-24(23)30-31-27)28-22-11-12-32(17-22)16-19-5-3-2-4-6-19/h2-10,13-15,22,28-29H,11-12,16-17H2,1H3,(H,30,31)",HKMBVPDIYWYWMK-UHFFFAOYSA-N,50338112,CHEMBL1684655::N-(1-benzylpyrrolidin-3-yl)-3-(6-methyl-1H-indol-2-yl)-1H-indazol-5-amine,Tyrosine-protein kinase ITK/TSK,Homo sapiens, 30
50532154,CCN(CC)C(=O)[C@H]1CN[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34,"InChI=1S/C19H23N3O/c1-3-22(4-2)19(23)13-8-15-14-6-5-7-16-18(14)12(10-20-16)9-17(15)21-11-13/h5-8,10,13,17,20-21H,3-4,9,11H2,1-2H3/t13-,17-/m1/s1",SUXLVXOMPKZBOV-CXAGYDPISA-N,50299166,"(6aR,9R)-N,N-diethyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide::4,6,6a,7,8,9-Hexahydro-indolo[4,3-fg]quinoline-9-carboxylic acid diethylamide::CHEMBL21343",D(1A) dopamine receptor,,>10000
50234844,CC(=O)O[C@@H]1NC(=O)[C@H]1NC(=O)C1CCCN1C(=O)OCc1ccccc1,"InChI=1S/C18H21N3O6/c1-11(22)27-17-14(16(24)20-17)19-15(23)13-8-5-9-21(13)18(25)26-10-12-6-3-2-4-7-12/h2-4,6-7,13-14,17H,5,8-10H2,1H3,(H,19,23)(H,20,24)/t13?,14-,17+/m1/s1",VRSUHJFYRRJBQO-ROFXEPAZSA-N,50129078,"2-((2S,3S)-2-Acetoxy-4-oxo-azetidin-3-ylcarbamoyl)-pyrrolidine-1-carboxylic acid benzyl ester::CHEMBL411932",Procathepsin L,Homo sapiens,
595507,CN(C)C(=O)c1ccc2CN(C(=O)c2c1)c1cccc(n1)-c1nncn1C1CC1,"InChI=1S/C21H20N6O2/c1-25(2)20(28)13-6-7-14-11-26(21(29)16(14)10-13)18-5-3-4-17(23-18)19-24-22-12-27(19)15-8-9-15/h3-7,10,12,15H,8-9,11H2,1-2H3",SADRMVXUFCEHJG-UHFFFAOYSA-N,307682,"2-(6-(4-cyclopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-N,N-dimethyl-3-oxoisoindoline-5-carboxamide ::US10150755, Compound 2::US10150755, Compound 74",Mitogen-activated protein kinase kinase kinase 5,,
50127496,C([C@@H]1ON=C2[C@H]1CNc1ccccc21)N1CCN(Cc2ccc3ccccc3c2)CC1,"InChI=1S/C26H28N4O/c1-2-6-21-15-19(9-10-20(21)5-1)17-29-11-13-30(14-12-29)18-25-23-16-27-24-8-4-3-7-22(24)26(23)28-31-25/h1-10,15,23,25,27H,11-14,16-18H2/t23-,25-/m0/s1",WUSIUKLVFNJEHL-ZCYQVOJMSA-N,50024303,CHEMBL2112984,Sodium-dependent serotonin transporter,Homo sapiens,
50002134,CCN(CCC1CCc2ccccc12)S(=O)(=O)c1ccc(C)cc1,"InChI=1S/C20H25NO2S/c1-3-21(24(22,23)19-12-8-16(2)9-13-19)15-14-18-11-10-17-6-4-5-7-20(17)18/h4-9,12-13,18H,3,10-11,14-15H2,1-2H3",IFWQLDANAGMQRQ-UHFFFAOYSA-N,50001355,CHEMBL126194::N-Ethyl-N-(2-indan-1-yl-ethyl)-4-methyl-benzenesulfonamide,Oxytocin receptor,Rattus,>10000
50023077,CC(C)O[C@@H]1[C@@H]2N(C1=O)C(C(=O)OC(C)(C)C)=C(COC(C)=O)CS2(=O)=O,"InChI=1S/C17H25NO8S/c1-9(2)25-13-14(20)18-12(16(21)26-17(4,5)6)11(7-24-10(3)19)8-27(22,23)15(13)18/h9,13,15H,7-8H2,1-6H3/t13-,15+/m0/s1",RBLBVIUSEMGREF-DZGCQCFKSA-N,50015868,"3-Acetoxymethyl-7-isopropoxy-5,5,8-trioxo-5lambda*6*-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid tert-butyl ester::CHEMBL84442",Neutrophil elastase,Homo sapiens, 30000
50694867,COC(=O)c1cccnc1N[C@@H]1CC[C@@H](C)N(C1)C(=O)c1ccccc1-n1nccn1,"InChI=1S/C22H24N6O3/c1-15-9-10-16(26-20-18(22(30)31-2)7-5-11-23-20)14-27(15)21(29)17-6-3-4-8-19(17)28-24-12-13-25-28/h3-8,11-13,15-16H,9-10,14H2,1-2H3,(H,23,26)/t15-,16-/m1/s1",XJPXAOVFVWBQMW-HZPDHXFCSA-N,50233292,CHEMBL4062167,Orexin/Hypocretin receptor type 1,Homo sapiens, 69
1171988,Cn1cc(Nc2ncc(C(N)=O)c(Nc3ccccc3CC3CC3)n2)cn1,"InChI=1S/C19H21N7O/c1-26-11-14(9-22-26)23-19-21-10-15(17(20)27)18(25-19)24-16-5-3-2-4-13(16)8-12-6-7-12/h2-5,9-12H,6-8H2,1H3,(H2,20,27)(H2,21,23,24,25)",YIPOLFUZADBGMV-UHFFFAOYSA-N,555520,"US11344549, Example 196",Tyrosine-protein kinase JAK3,Homo sapiens, 1.36
249449,CC(C)CN(Cc1cc(Cl)c2OCCCOc2c1)C(=O)[C@H](C)CNCc1cccc(O)c1,"InChI=1S/C25H33ClN2O4/c1-17(2)15-28(16-20-11-22(26)24-23(12-20)31-8-5-9-32-24)25(30)18(3)13-27-14-19-6-4-7-21(29)10-19/h4,6-7,10-12,17-18,27,29H,5,8-9,13-16H2,1-3H3/t18-/m1/s1",HCMJCMYVOXIEMD-GOSISDBHSA-N,121324,"US8722896, (-)-(2R)-2-Methyl-3-((3- hydroxy)benzylamino)-N-(9- chloro-3,3-difluoro-3,4-dihydro- 2H-1,5-benzodioxepin-7- ylmethyl)-N- isobutylpropanamide",Prokineticin receptor 2,,
50425048,C[C@@H]1Cc2c([nH]c3ccccc23)[C@H](N1CCC(O)=O)c1ccc(Cl)cc1,"InChI=1S/C21H21ClN2O2/c1-13-12-17-16-4-2-3-5-18(16)23-20(17)21(24(13)11-10-19(25)26)14-6-8-15(22)9-7-14/h2-9,13,21,23H,10-12H2,1H3,(H,25,26)/t13-,21-/m1/s1",BGWIRVUOHABHMB-LRTDBIEQSA-N,50125083,CHEMBL3622995,Estrogen receptor,, 776
51346852,Clc1ccc(cc1)C(=O)CSc1nccc(Nc2ccc(cc2)S(=O)(=O)Nc2ccccn2)n1,"InChI=1S/C23H18ClN5O3S2/c24-17-6-4-16(5-7-17)20(30)15-33-23-26-14-12-22(28-23)27-18-8-10-19(11-9-18)34(31,32)29-21-3-1-2-13-25-21/h1-14H,15H2,(H,25,29)(H,26,27,28)",GAGFQORKDCBVQR-UHFFFAOYSA-N,50544896,CHEMBL4632763,Carbonic anhydrase 9,Homo sapiens,
745080,Cc1ncc(F)cc1C1CCCN1c1ccn2ncc(C(=O)N3CC(O)C3)c2n1,"InChI=1S/C20H21FN6O2/c1-12-15(7-13(21)8-22-12)17-3-2-5-26(17)18-4-6-27-19(24-18)16(9-23-27)20(29)25-10-14(28)11-25/h4,6-9,14,17,28H,2-3,5,10-11H2,1H3",DIVNKYZMVMAVDL-UHFFFAOYSA-N,127819,"US10251889, Example 192::US10758542, Example 192::US8791123, 192::US9782415, Example 192::US9796724, Example 192",High affinity nerve growth factor receptor,,>1000
51154170,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(c1ccc(F)cc1)c1cccc(F)c1,"InChI=1S/C21H23F2NO/c1-24-18-9-10-19(24)13-20(12-18)25-21(14-5-7-16(22)8-6-14)15-3-2-4-17(23)11-15/h2-8,11,18-21H,9-10,12-13H2,1H3/t18-,19+,20+,21?",MIJCRUAXIVIMFX-LUQWZTMUSA-N,50472978,CHEMBL3084906,Sodium-dependent dopamine transporter,Rattus norvegicus,
706787,Nc1cc(Cc2c(F)cccc2F)c2nn[nH]c2n1,"InChI=1S/C12H9F2N5/c13-8-2-1-3-9(14)7(8)4-6-5-10(15)16-12-11(6)17-19-18-12/h1-3,5H,4H2,(H3,15,16,17,18,19)",QEWIOOMOXLQDHR-UHFFFAOYSA-N,357661,"7-(2,6- difluorobenzyl)- 3H-[1,2,3] triazolo[4,5- b]pyridin-5- amine::US10214527, Example 33",Myeloperoxidase,Homo sapiens, 55
793956,COCCN(C)c1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cn1,"InChI=1S/C22H24FN7O2/c1-4-20(31)26-15-6-5-7-16(12-15)27-21-18(23)14-25-22(29-21)28-17-8-9-19(24-13-17)30(2)10-11-32-3/h4-9,12-14H,1,10-11H2,2-3H3,(H,26,31)(H2,25,27,28,29)",NFSNTHIPBLRXCV-UHFFFAOYSA-N,397163,"US10596172, Compound I-77::US10828300, Compound I-77::US11351168, Compound I-77::US9987276, Compound I-77",Epidermal growth factor receptor,Homo sapiens, 55
680681,C[C@@H](C[C@H]1CN(c2cc(NC(=O)OC(C)(C)C(F)(F)F)ccc2O1)S(=O)(=O)c1cccc(OC(F)(F)F)c1)C(O)=O,"InChI=1S/C24H24F6N2O8S/c1-13(20(33)34)9-16-12-32(41(36,37)17-6-4-5-15(11-17)39-24(28,29)30)18-10-14(7-8-19(18)38-16)31-21(35)40-22(2,3)23(25,26)27/h4-8,10-11,13,16H,9,12H2,1-3H3,(H,31,35)(H,33,34)/t13-,16-/m0/s1",UQHQELLNHSZXAX-BBRMVZONSA-N,344548,"(S or R)-2-methyl-3-((S)-6- ((((1,1,1-trifluoro-2- methylpropan-2- yl)oxy)carbonyl)amino)-4- ((3- (trifluoromethoxy)phenyl) sulfonyl)-3,4-dihydro-2H- benzo[b][1,4]oxazin-2- yl)propanoic acid::US9783511, 6CR",Nuclear receptor ROR-gamma,, 12.9
50490933,NS(=O)(=O)c1cccc(c1)C(=O)Cn1cnc2ccccc12,"InChI=1S/C15H13N3O3S/c16-22(20,21)12-5-3-4-11(8-12)15(19)9-18-10-17-13-6-1-2-7-14(13)18/h1-8,10H,9H2,(H2,16,20,21)",XGDKZWDANQETLY-UHFFFAOYSA-N,50163864,"3-(1H-benzimidazol-1-ylacetyl)benzenesulfonamide (3a)::CHEMBL3799296::carbonic anhydrase (CA) inhibitors, benzenesulphonamide ligand, 3",Carbonic anhydrase 9,Homo sapiens,
77547,Oc1c(cnc2ccc(cc12)S(=O)(=O)N1CCC2(CC1)OCCO2)C(=O)N1CCOCC1,"InChI=1S/C21H25N3O7S/c25-19-16-13-15(32(27,28)24-5-3-21(4-6-24)30-11-12-31-21)1-2-18(16)22-14-17(19)20(26)23-7-9-29-10-8-23/h1-2,13-14H,3-12H2,(H,22,25)",NKHLOWKQRUQANL-UHFFFAOYSA-N,41461,"6-(1,4-dioxa-8-azaspiro[4.5]dec-8-ylsulfonyl)-3-(morpholin-4-ylcarbonyl)quinolin-4(1H)-one::6-(1,4-dioxa-8-azaspiro[4.5]decan-8-ylsulfonyl)-3-(morpholine-4-carbonyl)-1H-quinolin-4-one::6-(1,4-dioxa-8-azaspiro[4.5]decan-8-ylsulfonyl)-3-(morpholine-4-carbonyl)-4-quinolone::6-(1,4-dioxa-8-azaspiro[4.5]decan-8-ylsulfonyl)-3-[4-morpholinyl(oxo)methyl]-1H-quinolin-4-one::6-(1,4-dioxa-8-azaspiro[4.5]decan-8-ylsulfonyl)-3-morpholin-4-ylcarbonyl-1H-quinolin-4-one::MLS000046892::SMR000032903::cid_3245646",Ephrin type-B receptor 4,Homo sapiens,>79400
314383,CNC(=O)c1ccc(cc1)-c1cccc2C(N(CCc12)C(=O)\C=C\c1c(F)c(Cl)ccc1-n1cnnn1)C(=O)NCc1nccn1C,"InChI=1S/C33H29ClFN9O3/c1-36-32(46)21-8-6-20(7-9-21)22-4-3-5-24-23(22)14-16-43(31(24)33(47)38-18-28-37-15-17-42(28)2)29(45)13-10-25-27(44-19-39-40-41-44)12-11-26(34)30(25)35/h3-13,15,17,19,31H,14,16,18H2,1-2H3,(H,36,46)(H,38,47)/b13-10+",AHJFGHVZVOCIKJ-JLHYYAGUSA-N,170425,"US9079929, 66",Coagulation factor XI,Homo sapiens,
50361234,Oc1ccccc1CC(=O)Nc1nc(cs1)-c1ccncc1,"InChI=1S/C16H13N3O2S/c20-14-4-2-1-3-12(14)9-15(21)19-16-18-13(10-22-16)11-5-7-17-8-6-11/h1-8,10,20H,9H2,(H,18,19,21)",WBWCAXAHOIVEKO-UHFFFAOYSA-N,50097352,CHEMBL3581122,Rho-associated protein kinase 1,Homo sapiens,
50408144,CC(C)(C)c1cc(NC(=O)c2c(Cl)cc(NCc3cccs3)cc2Cl)ccc1O,"InChI=1S/C22H22Cl2N2O2S/c1-22(2,3)16-9-13(6-7-19(16)27)26-21(28)20-17(23)10-14(11-18(20)24)25-12-15-5-4-8-29-15/h4-11,25,27H,12H2,1-3H3,(H,26,28)",OBUFJAWWNIOLLM-UHFFFAOYSA-N,50118084,CHEMBL3613429,Bile acid receptor,Homo sapiens, 8600
125493,CC(C)(C)c1[nH]nc2-c3ccccc3C(=O)c12,"InChI=1S/C14H14N2O/c1-14(2,3)13-10-11(15-16-13)8-6-4-5-7-9(8)12(10)17/h4-7H,1-3H3,(H,15,16)",WMDLBUILMXLFQA-UHFFFAOYSA-N,67629,"3-tert-butyl-3aH-indeno[1,2-c]pyrazol-4-one::MLS000737966::SMR000528110::cid_223899",Serine/threonine-protein kinase 33,Homo sapiens,
1044615,FC1(F)CC(C1)NC(=O)[C@@H](N(C(=O)[C@@H]1CCC(=O)N1c1nccc(n1)C#N)c1cccc(c1)C#N)c1ccccc1Cl,"InChI=1S/C29H22ClF2N7O3/c30-22-7-2-1-6-21(22)25(26(41)36-19-13-29(31,32)14-19)38(20-5-3-4-17(12-20)15-33)27(42)23-8-9-24(40)39(23)28-35-11-10-18(16-34)37-28/h1-7,10-12,19,23,25H,8-9,13-14H2,(H,36,41)/t23-,25-/m0/s1",QHTMVLYGBIEEHT-ZCYQVOJMSA-N,363680,"US10640534, Compound 167::US10689414, Compound 167::US10717764, Compound 167::US11021515, Compound 167::US9850277, Compound 167",Isocitrate dehydrogenase [NADP] cytoplasmic [R132C],,<100
848776,Cc1ccc(cc1-c1cnc2c(N)ncnn12)S(=O)(=O)NC1CC(CO)(CO)C1,"InChI=1S/C18H22N6O4S/c1-11-2-3-13(29(27,28)23-12-5-18(6-12,8-25)9-26)4-14(11)15-7-20-17-16(19)21-10-22-24(15)17/h2-4,7,10,12,23,25-26H,5-6,8-9H2,1H3,(H2,19,21,22)",CZNBFXFXVDJMFN-UHFFFAOYSA-N,421091,"3-(4-aminoimidazo[2,1-f][1,2,4]triazin-7-yl)-N-[3,3- bis(hydroxymethyl)cyclobutyl]-4- methylbenzenesulfonamide::US10479795, Example 126","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform",Homo sapiens,<100
51347914,Fc1cc(ccc1N1CCN(Cc2ccc(COc3cccc4C(=O)N(Cc34)C3CCC(=O)NC3=O)cc2)CC1)C#N,"InChI=1S/C32H30FN5O4/c33-26-16-23(17-34)8-9-27(26)37-14-12-36(13-15-37)18-21-4-6-22(7-5-21)20-42-29-3-1-2-24-25(29)19-38(32(24)41)28-10-11-30(39)35-31(28)40/h1-9,16,28H,10-15,18-20H2,(H,35,39,40)",YTINZZFBHWSAGL-UHFFFAOYSA-N,50545276,CHEMBL4637801,Alpha-1A/Alpha-1B/Alpha-1D adrenergic receptor,, 980
50720173,CCc1nc2nc(C)cc(Nc3ccc(cc3)S(F)(F)(F)(F)F)n2n1,"InChI=1S/C14H14F5N5S/c1-3-12-22-14-20-9(2)8-13(24(14)23-12)21-10-4-6-11(7-5-10)25(15,16,17,18)19/h4-8,21H,3H2,1-2H3",CEZYGDRWJZTHFD-UHFFFAOYSA-N,50365243,"CHEMBL1956265::US9238653, Table 5, Compound 50","Dihydroorotate dehydrogenase (quinone), mitochondrial",Homo sapiens,>100000
573548,Nc1ncnc2ccc(cc12)-c1cccc(NC(=O)C2CCOC2)c1,"InChI=1S/C19H18N4O2/c20-18-16-9-13(4-5-17(16)21-11-22-18)12-2-1-3-15(8-12)23-19(24)14-6-7-25-10-14/h1-5,8-9,11,14H,6-7,10H2,(H,23,24)(H2,20,21,22)",KHFNAIPDJZBARS-UHFFFAOYSA-N,299422,"N-[3-(4-amino- quinazolin-6-yl) phenyl]tetra- hydrofuran-3- carboxamide::US9592235, Example 215::US9855269, Compound 62",Mitogen-activated protein kinase kinase kinase kinase 4,Homo sapiens, 438
1201528,O=C(Nc1ccc2cnccc2c1)[C@@H]1CC1c1ccc(cc1)S(=O)(=O)Nc1cccnc1,"InChI=1S/C24H20N4O3S/c29-24(27-19-6-3-18-14-26-11-9-17(18)12-19)23-13-22(23)16-4-7-21(8-5-16)32(30,31)28-20-2-1-10-25-15-20/h1-12,14-15,22-23,28H,13H2,(H,27,29)/t22?,23-/m1/s1",USXYFWZRBRCQLR-OZAIVSQSSA-N,569252,"US11427563, Compound 119",Tyrosine-protein kinase JAK1,Homo sapiens, 55.0
50768099,O=C1N(CCCCN2CCN(CC2)c2ncccn2)S(=O)(=O)c2ccccc12,"InChI=1S/C19H23N5O3S/c25-18-16-6-1-2-7-17(16)28(26,27)24(18)11-4-3-10-22-12-14-23(15-13-22)19-20-8-5-9-21-19/h1-2,5-9H,3-4,10-15H2",TZJUVVIWVWFLCD-UHFFFAOYSA-N,50005127,"1,1-Dioxo-2-[4-(4-pyrimidin-2-yl-piperazin-1-yl)-butyl]-1,2-dihydro-1lambda*6*-benzo[d]isothiazol-3-one::1,1-Dioxo-2-[4-(4-pyrimidin-2-yl-piperazin-1-yl)-butyl]-1,2-dihydro-1lambda*6*-benzo[d]isothiazol-3-one (Ipsapirone)::1,1-Dioxo-2-[4-(4-pyrimidin-2-yl-piperazin-1-yl)-butyl]-1,2-dihydro-1lambda*6*-benzo[d]isothiazol-3-one(Ipsapirone)::CHEMBL8412::IPSAPIRONE",5-hydroxytryptamine receptor 2A,Bos taurus, 7500
500728,Fc1cc(ccc1C[C@H](NC(=O)[C@H]1N[C@@H]2CC[C@H]1C2)C#N)-c1cnn(C[C@H]2CCCO2)c1,"InChI=1S/C24H28FN5O2/c25-22-10-15(18-12-27-30(13-18)14-21-2-1-7-32-21)3-4-16(22)8-20(11-26)29-24(31)23-17-5-6-19(9-17)28-23/h3-4,10,12-13,17,19-21,23,28H,1-2,5-9,14H2,(H,29,31)/t17-,19+,20-,21+,23-/m0/s1",HMZMPMLDAMDPBI-YMBXHIRXSA-N,150586,"US10238633, Example 260::US8987249, 260::US9713606, 260",Cathepsin K,Homo sapiens, 3900
51102490,CNC(=S)NCCC(=O)Nc1ccc(OCc2cccc(NC(=O)CSc3nc(C)cc(C)n3)c2)cc1,"InChI=1S/C26H30N6O3S2/c1-17-13-18(2)30-26(29-17)37-16-24(34)32-21-6-4-5-19(14-21)15-35-22-9-7-20(8-10-22)31-23(33)11-12-28-25(36)27-3/h4-10,13-14H,11-12,15-16H2,1-3H3,(H,31,33)(H,32,34)(H2,27,28,36)",MBMSTXZGVOXVMR-UHFFFAOYSA-N,50449716,CHEMBL4169477,NAD-dependent protein deacetylase sirtuin-2,Homo sapiens, 11749
51052577,CCCCNC(=O)\C=C\c1c(OC)cc(OC)cc1\C=C\c1ccc(OC)cc1,"InChI=1S/C24H29NO4/c1-5-6-15-25-24(26)14-13-22-19(16-21(28-3)17-23(22)29-4)10-7-18-8-11-20(27-2)12-9-18/h7-14,16-17H,5-6,15H2,1-4H3,(H,25,26)/b10-7+,14-13+",AZRQUVUEZZPGNQ-CDITWBNYSA-N,50429262,CHEMBL2334141,Prostaglandin G/H synthase 1,,>50000
50027910,Nc1ccc(cc1)S(=O)(=O)n1c2ccccc2c2ccccc12,"InChI=1S/C18H14N2O2S.ClH/c19-13-9-11-14(12-10-13)23(21,22)20-17-7-3-1-5-15(17)16-6-2-4-8-18(16)20;/h1-12H,19H2;1H",HJMQBMQZABZUFX-UHFFFAOYSA-N,50452059,CHEMBL2113365,5-hydroxytryptamine receptor 6,Homo sapiens,
50558476,NN(CC(=O)N1CSC[C@H]1C#N)C1CCN(CC(=O)Nc2ccc(Cl)cn2)CC1,"InChI=1S/C18H24ClN7O2S/c19-13-1-2-16(22-8-13)23-17(27)9-24-5-3-14(4-6-24)26(21)10-18(28)25-12-29-11-15(25)7-20/h1-2,8,14-15H,3-6,9-12,21H2,(H,22,23,27)/t15-/m1/s1",DFFXGYZKYOSQOB-OAHLLOKOSA-N,50310584,"CHEMBL1078049::N-(5-Chloro-pyridin-2-yl)-2-(4-{N-[2-((R)-4-cyano-thiazolidin-3-yl)-2-oxo-ethyl]-hydrazino}-piperidin-1-yl)-acetamide, trifluoroacetate",Dipeptidyl peptidase 2,Homo sapiens,>10000
400560,NC(=O)c1cn(nc1Nc1ccc(F)cc1)C1(CC#N)CCC(CC1)N1CC(F)C1,"InChI=1S/C21H24F2N6O/c22-14-1-3-16(4-2-14)26-20-18(19(25)30)13-29(27-20)21(9-10-24)7-5-17(6-8-21)28-11-15(23)12-28/h1-4,13,15,17H,5-9,11-12H2,(H2,25,30)(H,26,27)",CGYZIGRPAAEHSP-UHFFFAOYSA-N,229467,"US9328099, 40-100",Tyrosine-protein kinase JAK1,Homo sapiens, 18
50539958,CN(C)c1nc(N[C@@H]2CC[C@@H](CC2)NC(=O)c2ccc(F)c(F)c2)ncc1C,"InChI=1S/C20H25F2N5O/c1-12-11-23-20(26-18(12)27(2)3)25-15-7-5-14(6-8-15)24-19(28)13-4-9-16(21)17(22)10-13/h4,9-11,14-15H,5-8H2,1-3H3,(H,24,28)(H,23,25,26)/t14-,15+",RUWDCXXLJIBDAO-GASCZTMLSA-N,50302559,"CHEMBL578049::N-(cis-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-3,4-difluorobenzamide",Melanin-concentrating hormone receptor 1,Homo sapiens, 2
50101814,Fc1ccc(SCCCN2CCN(CC2)c2ncccn2)cc1,"InChI=1S/C17H21FN4S/c18-15-3-5-16(6-4-15)23-14-2-9-21-10-12-22(13-11-21)17-19-7-1-8-20-17/h1,3-8H,2,9-14H2",WRSUPAJSUHYUKP-UHFFFAOYSA-N,50362861,CHEMBL1940416,D(1B) dopamine receptor,,
51017751,COc1ccccc1N1CCN(C[C@@H]2CO[C@@](CN3CCCC3=O)(O2)c2ccccc2)CC1,"InChI=1S/C26H33N3O4/c1-31-24-11-6-5-10-23(24)28-16-14-27(15-17-28)18-22-19-32-26(33-22,21-8-3-2-4-9-21)20-29-13-7-12-25(29)30/h2-6,8-11,22H,7,12-20H2,1H3/t22-,26+/m1/s1",AOZOBKDTJZCKJE-GJZUVCINSA-N,50416778,CHEMBL1242445,Alpha-1D adrenergic receptor,Homo sapiens,
51434337,Fc1ccc2c(NCCc3cnc(NC(=O)Nc4cccc(Cl)c4)s3)ncnc2c1,"InChI=1S/C20H16ClFN6OS/c21-12-2-1-3-14(8-12)27-19(29)28-20-24-10-15(30-20)6-7-23-18-16-5-4-13(22)9-17(16)25-11-26-18/h1-5,8-11H,6-7H2,(H,23,25,26)(H2,24,27,28,29)",LPQVMJBOZXWART-UHFFFAOYSA-N,50579464,CHEMBL4867079,Aurora kinase A,, 9.0
50040783,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(c1ccccc1)c1ccc(O)cc1,"InChI=1S/C21H25NO2/c1-22-17-9-10-18(22)14-20(13-17)24-21(15-5-3-2-4-6-15)16-7-11-19(23)12-8-16/h2-8,11-12,17-18,20-21,23H,9-10,13-14H2,1H3/t17-,18+,20+,21?",TVHYKAAFLUFNOM-QHGOKARQSA-N,50453899,CHEMBL3084872,Sodium-dependent dopamine transporter,Rattus norvegicus,
723034,Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cc(cnc2N)B(O)O)c1,"InChI=1S/C19H18BFN4O3/c1-11-2-7-16(21)17(8-11)25-19(26)24-14-5-3-12(4-6-14)15-9-13(20(27)28)10-23-18(15)22/h2-10,27-28H,1H3,(H2,22,23)(H2,24,25,26)",HENUTJSTZJVGEK-UHFFFAOYSA-N,365356,"US10633373, Example 61::US10669265, Example 61::US9868726, Example 61::[6-amino-5-(4-{[(2-fluoro-5- methylphenyl)carbamoyl]amino} phenyl)pyridin-3-yl]boronic acid",Vascular endothelial growth factor receptor 2,Homo sapiens, 58.0
51038121,CCOc1nc2n(C)c(=O)n(C)c(=O)c2n1CCCC(=O)N\N=C\c1ccc(O)cc1O,"InChI=1S/C20H24N6O6/c1-4-32-19-22-17-16(18(30)25(3)20(31)24(17)2)26(19)9-5-6-15(29)23-21-11-12-7-8-13(27)10-14(12)28/h7-8,10-11,27-28H,4-6,9H2,1-3H3,(H,23,29)/b21-11+",GXJAVEGDFNMTRO-SRZZPIQSSA-N,50457966,CHEMBL4214256,"cAMP-specific 3',5'-cyclic phosphodiesterase 4B",, 16200
816505,COc1cccc(CNC(=O)c2cn(Cc3ccc(Cn4ccccc4=O)cc3)c(n2)C(F)(F)F)c1F,"InChI=1S/C26H22F4N4O3/c1-37-21-6-4-5-19(23(21)27)13-31-24(36)20-16-34(25(32-20)26(28,29)30)15-18-10-8-17(9-11-18)14-33-12-3-2-7-22(33)35/h2-12,16H,13-15H2,1H3,(H,31,36)",UZZGYTADFHNIGM-UHFFFAOYSA-N,408803," N-[(2-fluoro-3-methoxyphenyl)methyl]-1-({4-[(2-oxopyrldin-1- yl)methyl]phenyl}methyl)-2-(trifluoromethyl)imidazole-4-carboxamide ::US10364238, Example 124::US11001578, Example 124::US11084809, Example 124::US11198691, Example 124",Plasma kallikrein,, 191
50091530,O=C(N[C@@H](Cc1ccc(cc1)-c1ccc(cc1)C#N)C#N)[C@@H]1CCCCN1,"InChI=1S/C22H22N4O/c23-14-17-6-10-19(11-7-17)18-8-4-16(5-9-18)13-20(15-24)26-22(27)21-3-1-2-12-25-21/h4-11,20-21,25H,1-3,12-13H2,(H,26,27)/t20-,21-/m0/s1",NWEHEPXTNMPJSH-SFTDATJTSA-N,50011505,CHEMBL3261919,Procathepsin L,Homo sapiens,<10000
75071,OC12OC3=C(C(=O)CCC3)C1(O)C(=O)c1ccccc21,"InChI=1S/C15H12O5/c16-10-6-3-7-11-12(10)14(18)13(17)8-4-1-2-5-9(8)15(14,19)20-11/h1-2,4-5,18-19H,3,6-7H2",RQRSZYHVVUHFRF-UHFFFAOYSA-N,39886,"4b,9b-bis(oxidanyl)-7,8-dihydro-6H-indeno[1,2-b][1]benzofuran-9,10-dione::4b,9b-dihydroxy-7,8-dihydro-6H-indeno[1,2-b][1]benzofuran-9,10-dione::4b,9b-dihydroxy-7,8-dihydro-6H-indeno[1,2-b]benzofuran-9,10-dione::4b,9b-dihydroxy-7,8-dihydro-6H-indeno[1,2-b]benzofuran-9,10-quinone::MLS000104338::SMR000054273::cid_2834991",14-3-3 protein gamma,Homo sapiens,>50000
732189,CC(CF)n1nc(C(=O)Nc2cc(C)[nH]n2)c2c(N)ncnc12,,,370365,"US10233189, Example 46",Proto-oncogene tyrosine-protein kinase receptor Ret,Homo sapiens, 0.480
1139992,CCNc1cc2n(nc(N3CCC(CC3)OC)c2cn1)C1CC[C@@H](CC1)Oc1nccc(c1F)C(F)(F)F,"InChI=1S/C26H32F4N6O2/c1-3-31-22-14-21-19(15-33-22)24(35-12-9-17(37-2)10-13-35)34-36(21)16-4-6-18(7-5-16)38-25-23(27)20(8-11-32-25)26(28,29)30/h8,11,14-18H,3-7,9-10,12-13H2,1-2H3,(H,31,33)/t16?,18-",QCPHNMYIFNRURV-NREYKIJXSA-N,537508,"N-ethyl-1-((1s,4s)-4((3- fluoro-4- (trifluoromethyl)pyridin-2- yl)oxy)cyclohexyl)-3-(4- methoxypiperidin-1-yl)-1H- pyrazolo[4,3-c]pyridin-6- amine::US11247990, Example 333",Tyrosine-protein kinase receptor UFO,,<20
50912298,C[C@@H]1CC[C@@]2(CC[C@]3(C(O)=O)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O[C@H]6O[C@@H](C)[C@H](O)[C@@H](O)[C@H]6O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O,"InChI=1S/C36H56O9/c1-18-10-15-35(30(40)41)16-17-36(31(42)43)21(25(35)19(18)2)8-9-23-33(6)13-12-24(32(4,5)22(33)11-14-34(23,36)7)45-29-28(39)27(38)26(37)20(3)44-29/h8,18-20,22-29,37-39H,9-17H2,1-7H3,(H,40,41)(H,42,43)/t18-,19+,20+,22+,23-,24+,25+,26+,27-,28-,29-,33+,34-,35+,36-/m1/s1",PUOQHFWXBKTHST-OOYHRPKBSA-N,50317553,3-O-alpha-L-rhamnopyranosyl quinovic acid::CHEMBL1095351,DNA topoisomerase 1,,>250000
285474,NC(=O)c1cn(nc1Nc1ccc(C=O)cc1)[C@H]1CCCC[C@@H]1C#N,"InChI=1S/C18H19N5O2/c19-9-13-3-1-2-4-16(13)23-10-15(17(20)25)18(22-23)21-14-7-5-12(11-24)6-8-14/h5-8,10-11,13,16H,1-4H2,(H2,20,25)(H,21,22)/t13-,16+/m1/s1",NWJUZMPZIJLOTD-CJNGLKHVSA-N,147544,"US8962608, 17-25",Tyrosine-protein kinase JAK2,Homo sapiens, 3
50353754,COc1ccc(CN2CCc3sc(\C=C4/[C@H]5SC=C(N5C4=O)C([O-])=O)cc3C2)cc1,"InChI=1S/C22H20N2O4S2/c1-28-15-4-2-13(3-5-15)10-23-7-6-19-14(11-23)8-16(30-19)9-17-20(25)24-18(22(26)27)12-29-21(17)24/h2-5,8-9,12,21H,6-7,10-11H2,1H3,(H,26,27)/p-1/b17-9-/t21-/m1/s1",ZKKACLLQVNCVQU-VYBYYTRPSA-M,50191381,"(5R,6Z)-6-{[5-(4-methoxybenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)]methylene}-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid sodium salt::CHEMBL378041",Metallo-beta-lactamase type 2,, 78
618602,O=S(=O)(NCc1cccs1)c1ccc(Oc2cccc(c2)N2CCNCC2)s1,"InChI=1S/C19H21N3O3S3/c23-28(24,21-14-17-5-2-12-26-17)19-7-6-18(27-19)25-16-4-1-3-15(13-16)22-10-8-20-9-11-22/h1-7,12-13,20-21H,8-11,14H2",FMVUDOLLRSTNLT-UHFFFAOYSA-N,316402,"US9617239, BRITE-355014",Beta-glucuronidase,, 600
51092887,O=C1NC(=O)C(=C1Nc1ccccc1OCCn1ccnc1)c1c[nH]c2ccccc12,"InChI=1S/C23H19N5O3/c29-22-20(16-13-25-17-6-2-1-5-15(16)17)21(23(30)27-22)26-18-7-3-4-8-19(18)31-12-11-28-10-9-24-14-28/h1-10,13-14,25H,11-12H2,(H2,26,27,29,30)",QLNVMVUPVQLKAN-UHFFFAOYSA-N,50447874,CHEMBL3114770,Tyrosine-protein kinase JAK1,Homo sapiens,>10000
471691,CCCCCCCCCCCc1cc(-c2nnc(o2)C2(CC2)C(N)=N)c(OC)cc1OC,"InChI=1S/C25H38N4O3/c1-4-5-6-7-8-9-10-11-12-13-18-16-19(21(31-3)17-20(18)30-2)22-28-29-24(32-22)25(14-15-25)23(26)27/h16-17H,4-15H2,1-3H3,(H3,26,27)",LEPWJBLDUPIZLD-UHFFFAOYSA-N,174055,"US9688668, 22",Sphingosine kinase 1,,
1086187,CC(C)c1c([nH]c2ccc(nc12)N1C[C@@H](C)NC[C@@H]1C)-c1cn2ncnc2c(C)c1C,,,428301,"6-(5-((2S,5R)-2,5-dimethylpiperazin-1-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-2-yl)-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine::US10544143, Example 737::US10730877, Example 737::US11053244, Example 737",Toll-like receptor 8,, 0.550
389037,Cc1ncc(\C=C\c2ccc(CN3CCCC3)c(O)c2)c(CO)c1O,"InChI=1S/C20H24N2O3/c1-14-20(25)18(13-23)16(11-21-14)6-4-15-5-7-17(19(24)10-15)12-22-8-2-3-9-22/h4-7,10-11,23-25H,2-3,8-9,12-13H2,1H3/b6-4+",AGEBYRHPUNYMRC-GQCTYLIASA-N,222335,(E)-5-(3-hydroxy-4-(pyrrolidin-1-ylmethyl)styryl)-4-(hydroxymethyl)-2-methylpyridin-3-ol (7c),Amine oxidase [flavin-containing] B,, 24260
50029426,CC[N+](C)(CC)CCc1ccccn1,"InChI=1S/C12H21N2/c1-4-14(3,5-2)11-9-12-8-6-7-10-13-12/h6-8,10H,4-5,9,11H2,1-3H3/q+1",WZXGSKIGSSEPSE-UHFFFAOYSA-N,50405152,CHEMBL15822,Acetylcholinesterase,Rattus norvegicus,>1000000
80478,Cc1cc(C(=O)Oc2ccccc2C(O)=O)c(C)o1,"InChI=1S/C14H12O5/c1-8-7-11(9(2)18-8)14(17)19-12-6-4-3-5-10(12)13(15)16/h3-7H,1-2H3,(H,15,16)",BMKCLZOCRZROOA-UHFFFAOYSA-N,43246,"2-(2,5-dimethyl-3-furoyl)oxybenzoic acid::2-(2,5-dimethylfuran-3-carbonyl)oxybenzoic acid::2-(2,5-dimethylfuran-3-yl)carbonyloxybenzoic acid::2-[(2,5-dimethyl-3-furanyl)-oxomethoxy]benzoic acid::2-[(2,5-dimethyl-3-furoyl)oxy]benzoic acid::MLS000062122::SMR000070396::cid_877366",Ras-related C3 botulinum toxin substrate 1,Mus musculus,
640144,COc1ccc(cc1OC)[C@H](Cc1c(Cl)c[n+]([O-])cc1Cl)OC(=O)c1ccc(CNC(C(=O)OCC2C[C@@H]3CC[C@H](C2)N3C)c2ccccc2)s1,"InChI=1S/C38H41Cl2N3O7S/c1-42-26-10-11-27(42)16-23(15-26)22-49-38(45)36(24-7-5-4-6-8-24)41-19-28-12-14-35(51-28)37(44)50-33(18-29-30(39)20-43(46)21-31(29)40)25-9-13-32(47-2)34(17-25)48-3/h4-9,12-14,17,20-21,23,26-27,33,36,41H,10-11,15-16,18-19,22H2,1-3H3/t23?,26-,27+,33-,36?/m0/s1",UPRGGDBDNPOLLO-UBKCESNYSA-N,325710,"US9636336, Example 114::[(1S)-2-(3,5-dichloro-1-oxido-pyridin-1-ium-4-yl)-1-(3,4-dimethoxyphenyl)ethyl]5-[[[2-[[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]methoxy]-2-oxo-1-phenyl-ethyl]amino]methyl]thiophene-2-carboxylate",Muscarinic acetylcholine receptor M3,Homo sapiens, 55
354447,OC[C@@H](NC(=O)Nc1nc(cs1)-c1ccncc1)c1ccccc1,"InChI=1S/C17H16N4O2S/c22-10-14(12-4-2-1-3-5-12)19-16(23)21-17-20-15(11-24-17)13-6-8-18-9-7-13/h1-9,11,14,22H,10H2,(H2,19,20,21,23)/t14-/m1/s1",OQORIVHBMBWOAH-CQSZACIVSA-N,199292,"US9221808, 1at",Rho-associated protein kinase 1,Homo sapiens, 30
50986271,COc1cc(ccc1-n1cnc(C)c1)-c1noc2C(CCCc12)NCC(F)(F)F,"InChI=1S/C20H21F3N4O2/c1-12-9-27(11-25-12)16-7-6-13(8-17(16)28-2)18-14-4-3-5-15(19(14)29-26-18)24-10-20(21,22)23/h6-9,11,15,24H,3-5,10H2,1-2H3",NWEFVYYZGXWFDP-UHFFFAOYSA-N,50279136,CHEMBL4160518,Presenilin-1,, 460
50805535,CC[C@@H](C)[C@H]1NC(=O)[C@@H](NC(=O)CCSSC[C@@H](NC(=O)[C@@H](CC(N)=O)NC(=O)[C@@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@@H]1C(=O)N[C@@H](CCCNC(=O)c1ccc2C(=O)OC3(c2c1)c1ccc(O)cc1Oc1cc(O)ccc31)C(=O)NCN)c1ccc(O)cc1,"InChI=1S/C61H72N12O17S2/c1-3-30(2)50-57(85)68-41(18-19-47(63)77)54(82)69-42(27-48(64)78)55(83)70-43(28-92-91-23-20-49(79)71-51(58(86)72-50)31-8-11-33(74)12-9-31)59(87)73-22-5-7-44(73)56(84)67-40(53(81)66-29-62)6-4-21-65-52(80)32-10-15-36-39(24-32)61(90-60(36)88)37-16-13-34(75)25-45(37)89-46-26-35(76)14-17-38(46)61/h8-17,24-26,30,40-44,50-51,74-76H,3-7,18-23,27-29,62H2,1-2H3,(H2,63,77)(H2,64,78)(H,65,80)(H,66,81)(H,67,84)(H,68,85)(H,69,82)(H,70,83)(H,71,79)(H,72,86)/t30-,40+,41-,42-,43-,44-,50-,51+/m1/s1",JOVDCZXVGAWIKQ-TUIVOMIJSA-N,50370110,CHEMBL1790721,Oxytocin receptor,,
50764709,CCCN(CC1CC1)[C@@H]1CCc2ccc3[nH]c(cc3c2C1)C(N)=O,"InChI=1S/C20H27N3O/c1-2-9-23(12-13-3-4-13)15-7-5-14-6-8-18-17(16(14)10-15)11-19(22-18)20(21)24/h6,8,11,13,15,22H,2-5,7,9-10,12H2,1H3,(H2,21,24)/t15-/m1/s1",YQWYZWBIKZPITE-OAHLLOKOSA-N,50368632,CHEMBL1788192,D(2) dopamine receptor,Homo sapiens,
50657150,Oc1ccc(CC(=O)NN=C2C(=O)Nc3c2cccc3Cl)cc1,"InChI=1S/C16H12ClN3O3/c17-12-3-1-2-11-14(12)18-16(23)15(11)20-19-13(22)8-9-4-6-10(21)7-5-9/h1-7,21H,8H2,(H,19,22)(H,18,20,23)",HNVOBOIYCNVTSG-UHFFFAOYSA-N,50351724,CHEMBL1822586,Hepatocyte growth factor receptor,Homo sapiens, 22
50737557,[NH3+]C(=N)NCCC[C@H](NCc1ccc2ccccc2c1)C(=O)NCc1c[nH]c2ccccc12,"InChI=1S/C26H30N6O/c27-26(28)29-13-5-10-24(30-15-18-11-12-19-6-1-2-7-20(19)14-18)25(33)32-17-21-16-31-23-9-4-3-8-22(21)23/h1-4,6-9,11-12,14,16,24,30-31H,5,10,13,15,17H2,(H,32,33)(H4,27,28,29)/p+1/t24-/m0/s1",PKLUWFADRRIBQE-DEOSSOPVSA-O,50111192,(2S)-5-[(E)-[amino(azaniumyl)methylidene]amino]-N-(1H-indol-3-ylmethyl)-2-[(naphthalen-2-ylmethyl)amino]pentanamide::MK-53::N-Alkylaminoacid derivative,Melanocortin receptor 4,,
50622706,CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1,"InChI=1S/C12H21NO8S/c1-10(2)18-7-5-16-12(6-17-22(13,14)15)9(8(7)19-10)20-11(3,4)21-12/h7-9H,5-6H2,1-4H3,(H2,13,14,15)/t7-,8-,9+,12+/m1/s1",KJADKKWYZYXHBB-XBWDGYHZSA-N,10887,"Sulfamate 7::Topiramate (TPM)::US11535599, Example topiramate::[(1R,2S,6S,9R)-4,4,11,11-tetramethyl-3,5,7,10,12-pentaoxatricyclo[7.3.0.0^{2,6}]dodecan-6-yl]methyl sulfamate",Carbonic anhydrase 1,Homo sapiens,
50911372,C[C@H]1CN(C[C@@H](C)[C@]1(O)c1ccccc1)C(=O)[C@H]1CN(C[C@@H]1c1ccc(F)cc1F)c1cccnn1,"InChI=1S/C28H30F2N4O2/c1-18-14-34(15-19(2)28(18,36)20-7-4-3-5-8-20)27(35)24-17-33(26-9-6-12-31-32-26)16-23(24)22-11-10-21(29)13-25(22)30/h3-13,18-19,23-24,36H,14-17H2,1-2H3/t18-,19+,23-,24+,28-/m1/s1",SPVBIVLOVRDUPG-HCCOPHJMSA-N,50315673,"((3R,4S)-4-(2,4-difluorophenyl)-1-(pyridazin-3-yl)pyrrolidin-3-yl)((3S,4S,5R)-4-hydroxy-3,5-dimethyl-4-phenylpiperidin-1-yl)methanone::CHEMBL1092860",Melanocyte-stimulating hormone receptor,,
50638268,Cc1cc(NC(=O)CS(=O)(=O)c2cn(Cc3ccccc3Cl)c3ccccc23)no1,"InChI=1S/C21H18ClN3O4S/c1-14-10-20(24-29-14)23-21(26)13-30(27,28)19-12-25(18-9-5-3-7-16(18)19)11-15-6-2-4-8-17(15)22/h2-10,12H,11,13H2,1H3,(H,23,24,26)",FPBRFRSODHILCO-UHFFFAOYSA-N,65913,"2-[1-(2-chlorobenzyl)indol-3-yl]sulfonyl-N-(5-methylisoxazol-3-yl)acetamide::2-[1-[(2-chlorophenyl)methyl]indol-3-yl]sulfonyl-N-(5-methyl-1,2-oxazol-3-yl)acetamide::2-[1-[(2-chlorophenyl)methyl]indol-3-yl]sulfonyl-N-(5-methyl-1,2-oxazol-3-yl)ethanamide::2-[[1-[(2-chlorophenyl)methyl]-3-indolyl]sulfonyl]-N-(5-methyl-3-isoxazolyl)acetamide::VU0108370-10::cid_2157678",Muscarinic acetylcholine receptor M5,Homo sapiens,
846983,CC(C)c1c([nH]c2ccc(cc12)C1CCN(CC1)C(=O)CCNCC1CCCO1)-c1cn2ncnc2c(C)c1C,,,274101,"US10071079, Example 887::US10478424, Example 887",Toll-like receptor 8,, 11.6
713057,CN(C1CCN(C)C1)S(=O)(=O)c1ccc(-c2cccc3sc(N)nc23)c(-c2nnn[nH]2)c1S(N)(=O)=O,,,360898,"4-(2-amino-1,3- benzothiazol-4-yl)-N1- methyl-N1-(1- methylpyrrolidin-3-yl)-3- (1H-tetrazol-5-yl)benzene- 1,2-disulfonamide::US10221163, Example 54::US10544130, Example 54",Metallo-beta-lactamase type 2,, 0.190
910156,CC(C)c1c([nH]c2ccc(cc12)C1CCN(CC1)C(=O)C(=O)N1CCN(C)CC1)-c1cc(C)nc(C)c1,"InChI=1S/C30H39N5O2/c1-19(2)27-25-18-23(6-7-26(25)32-28(27)24-16-20(3)31-21(4)17-24)22-8-10-34(11-9-22)29(36)30(37)35-14-12-33(5)13-15-35/h6-7,16-19,22,32H,8-15H2,1-5H3",QNYZDZLPDNNCDF-UHFFFAOYSA-N,444266,"US10660877, Example 856",Toll-like receptor 7,, 2.90
469228,COc1ccc(CNc2nc(nn2C(=O)CCc2ccccc2)-c2ccccn2)cc1,"InChI=1S/C24H23N5O2/c1-31-20-13-10-19(11-14-20)17-26-24-27-23(21-9-5-6-16-25-21)28-29(24)22(30)15-12-18-7-3-2-4-8-18/h2-11,13-14,16H,12,15,17H2,1H3,(H,26,27,28)",KKCIDLBRYQMWGB-UHFFFAOYSA-N,163544,"US9687479, 323 1-(5-[(4-methoxyphenyl)methyl]amino-3-(pyridin-2-yl)-1H-1,2,4-triazol-1-yl)-3-phenylpropan-1-one",Kallikrein-1,, 55000
50021182,CC(C)OC(=O)Cc1ccncc1,"InChI=1S/C10H13NO2/c1-8(2)13-10(12)7-9-3-5-11-6-4-9/h3-6,8H,7H2,1-2H3",UXVBBTZUKVHNGI-UHFFFAOYSA-N,50014463,CHEMBL102510::Pyridin-4-yl-acetic acid isopropyl ester,"Steroid 17-alpha-hydroxylase/17,20 lyase",,>100000
709126,CC(C)(C)OC(=O)Nc1ccc2O[C@@H](CN3C(=O)COC3=O)CN(c2c1)S(=O)(=O)c1cccc(c1)C#N,"InChI=1S/C24H24N4O8S/c1-24(2,3)36-22(30)26-16-7-8-20-19(10-16)28(37(32,33)18-6-4-5-15(9-18)11-25)13-17(35-20)12-27-21(29)14-34-23(27)31/h4-10,17H,12-14H2,1-3H3,(H,26,30)/t17-/m0/s1",IHFDCUPKIHEZLU-KRWDZBQOSA-N,352571,"US10745364, Example 24::US9809561, 24::[(S)-4-(3-cyano-benzenesulfonyl)-2-(2,4-dioxo-oxazolidin-3-ylmethyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl]-carbamic acid tert-butyl ester ",Nuclear receptor ROR-gamma,, 11.6
50730719,CN([C@@H]1[C@H]2CC[C@H](O2)[C@@H]1C(=O)NO)S(=O)(=O)c1ccc(OCc2cc(C)nc3ccccc23)cc1,"InChI=1S/C25H27N3O6S/c1-15-13-16(19-5-3-4-6-20(19)26-15)14-33-17-7-9-18(10-8-17)35(31,32)28(2)24-22-12-11-21(34-22)23(24)25(29)27-30/h3-10,13,21-24,30H,11-12,14H2,1-2H3,(H,27,29)/t21-,22+,23-,24+/m0/s1",WQWVTFKKGIYLJY-UARRHKHWSA-N,50236619,CHEMBL4070236,Disintegrin and metalloproteinase domain-containing protein 17,, 1.1
50297994,Oc1ccc(NC(=O)[C@@H]2CCN(CC(=O)N3CCN(CC3)c3ccc(cc3)-c3ccccc3)C2)cc1Cl,"InChI=1S/C29H31ClN4O3/c30-26-18-24(8-11-27(26)35)31-29(37)23-12-13-32(19-23)20-28(36)34-16-14-33(15-17-34)25-9-6-22(7-10-25)21-4-2-1-3-5-21/h1-11,18,23,35H,12-17,19-20H2,(H,31,37)/t23-/m1/s1",TWFINIJCRDJMKR-HSZRJFAPSA-N,50030888,CHEMBL3356121,Mitogen-activated protein kinase 1,Homo sapiens, 4400
754177,COc1cc(ccc1N1CCN(CC1)C1COC1)-c1cc2c(ncnc2[nH]1)-c1ccc(N2CC[C@@H](O)C2)c(c1)C#N,"InChI=1S/C31H33N7O3/c1-40-29-13-20(2-5-28(29)37-10-8-36(9-11-37)23-17-41-18-23)26-14-25-30(33-19-34-31(25)35-26)21-3-4-27(22(12-21)15-32)38-7-6-24(39)16-38/h2-5,12-14,19,23-24,39H,6-11,16-18H2,1H3,(H,33,34,35)/t24-/m1/s1",PPLYZIXDSCRZFR-XMMPIXPASA-N,276966,"US10072001, Example 142::US10259811, Example 142",Inhibitor of nuclear factor kappa-B kinase subunit epsilon,Homo sapiens, 14.7
50357217,Fc1ccc(cc1)S(=O)(=O)N1CSC[C@@H]1C(=O)NC(Cc1ccccc1)C=O,"InChI=1S/C19H19FN2O4S2/c20-15-6-8-17(9-7-15)28(25,26)22-13-27-12-18(22)19(24)21-16(11-23)10-14-4-2-1-3-5-14/h1-9,11,16,18H,10,12-13H2,(H,21,24)/t16?,18-/m1/s1",ZCMDOQMWCXCTGH-UHUGOGIASA-N,50193495,"(S)-3-(4-fluorophenylsulfonyl)-N-((R,S)-1-oxo-3-phenylpropan-2-yl)thiazolidine-4-carboxamide::CHEMBL378691",Calpain-1 catalytic subunit,Sus scrofa,
50096876,NC(=O)C[C@H](NC(=O)[C@@H]1CCCN1C(=O)OCc1ccc(cc1)-c1ccc(Cl)cc1)C#N,"InChI=1S/C23H23ClN4O4/c24-18-9-7-17(8-10-18)16-5-3-15(4-6-16)14-32-23(31)28-11-1-2-20(28)22(30)27-19(13-25)12-21(26)29/h3-10,19-20H,1-2,11-12,14H2,(H2,26,29)(H,27,30)/t19-,20-/m0/s1",URVHMNONXKIWEU-PMACEKPBSA-N,50015354,CHEMBL3264584,Legumain,, 124
51112482,Cc1nc2ccccc2n1CC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O,"InChI=1S/C16H14ClN3O3S/c1-10-19-13-4-2-3-5-14(13)20(10)9-15(21)11-6-7-12(17)16(8-11)24(18,22)23/h2-8H,9H2,1H3,(H2,18,22,23)",TTXDYSSNPNOXIT-UHFFFAOYSA-N,50329831,"2-Chloro-5-[(2-methyl-1H-benzimidazol-1-yl)acetyl]benzenesulfonamide::CHEMBL1272188::N-alkylated benzimidazole derivative, 4b",Carbonic anhydrase 14,Homo sapiens,
50714811,COc1ccc2c(noc2c1)-n1c2ccc(cc2n(Cc2ccccc2[C@@]2(C)OC(O)=NC2=O)c1=O)C(F)(F)F,"InChI=1S/C27H19F3N4O6/c1-26(23(35)31-24(36)39-26)18-6-4-3-5-14(18)13-33-20-11-15(27(28,29)30)7-10-19(20)34(25(33)37)22-17-9-8-16(38-2)12-21(17)40-32-22/h3-12H,13H2,1-2H3,(H,31,35,36)/t26-/m1/s1",MNOITKPTQNWKLG-AREMUKBSSA-N,50362963,CHEMBL1947138,Peroxisome proliferator-activated receptor delta,,>50000
560215,Cc1c(cccc1-n1c(=O)[nH]c2c(F)cc(F)cc2c1=O)-c1c(Cl)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O,"InChI=1S/C31H23ClF2N4O4/c1-13-16(5-4-6-23(13)38-29(40)19-10-15(33)11-21(34)26(19)37-30(38)41)24-20(32)12-18(28(35)39)27-25(24)17-8-7-14(31(2,3)42)9-22(17)36-27/h4-12,36,42H,1-3H3,(H2,35,39)(H,37,41)",RVWUDEQVQNNWJB-UHFFFAOYSA-N,230088,"US10106559, Example 48::US10435415, Example 48::US9334290, 10::US9850258, Example 48",Tyrosine-protein kinase JAK2,Homo sapiens,>2000
50357544,CC(C)C1N(CCc2c(C)cccc12)C(=O)CNCC1(O)CCCCC1,"InChI=1S/C18H18N6O4S/c1-2-20-17(27)14-12(25)13(26)18(28-14)24-8-21-11-15(19)22-10(23-16(11)24)6-5-9-4-3-7-29-9/h3-4,7-8,12-14,18,25-26H,2H2,1H3,(H,20,27)(H2,19,22,23)/t12-,13+,14+,18?/m1/s1",VKKBMFFFMITCPD-IXSHNIHPSA-N,50095981,CHEMBL3593437,Cytochrome P450 2D6,,<780
665092,Nc1cnc(cn1)-c1ccc(cc1F)-c1ccccc1S(=O)(=O)NC1CC2CCC1C2,"InChI=1S/C23H23FN4O2S/c24-19-11-15(7-8-18(19)21-12-27-23(25)13-26-21)17-3-1-2-4-22(17)31(29,30)28-20-10-14-5-6-16(20)9-14/h1-4,7-8,11-14,16,20,28H,5-6,9-10H2,(H2,25,27)",SWQDGDPDJGPZLZ-UHFFFAOYSA-N,168637,"US9079866, 10::US9745328, Compound 10::US9884878, Compound 10",Flap endonuclease 1,Homo sapiens,
233904,CCOC(=O)[C@H]1[C@@H]2NC(=O)NC1(C)Oc1ccccc21,"InChI=1S/C14H16N2O4/c1-3-19-12(17)10-11-8-6-4-5-7-9(8)20-14(10,2)16-13(18)15-11/h4-7,10-11H,3H2,1-2H3,(H2,15,16,18)/t10-,11-,14?/m1/s1",PRBINTYBUYEJNZ-HRQHSXBYSA-N,112652,"(±)2,6-Methano-4-oxo-3,4,5,6-tetrahydro-2H- [1,3,5]benzoxadiazocines (4d)",Alpha-glucosidase MAL12,Saccharomyces cerevisiae, 1.2243e+5
210226,CC1(C)CC(=O)C(=CNCCc2ccc(O)cc2)C(=O)C1,"InChI=1S/C17H21NO3/c1-17(2)9-15(20)14(16(21)10-17)11-18-8-7-12-3-5-13(19)6-4-12/h3-6,11,18-19H,7-10H2,1-2H3",WFZFBERHRHYSDO-UHFFFAOYSA-N,96585,"2-[[2-(4-hydroxyphenyl)ethylamino]methylene]-5,5-dimethyl-cyclohexane-1,3-quinone::2-[[2-(4-hydroxyphenyl)ethylamino]methylidene]-5,5-dimethyl-cyclohexane-1,3-dione::2-[[2-(4-hydroxyphenyl)ethylamino]methylidene]-5,5-dimethylcyclohexane-1,3-dione::MLS000107078::SMR000111450::cid_2247137",Guanine nucleotide-binding protein subunit alpha-15,,
131880,COCCn1c(SCC(=O)NC2CCCCC2)nc2CCSc2c1=O,"InChI=1S/C17H25N3O3S2/c1-23-9-8-20-16(22)15-13(7-10-24-15)19-17(20)25-11-14(21)18-12-5-3-2-4-6-12/h12H,2-11H2,1H3,(H,18,21)",YUKYRKLCEWPXGZ-UHFFFAOYSA-N,73132,"MLS001237855::N-cyclohexyl-2-[[3-(2-methoxyethyl)-4-oxidanylidene-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl]sulfanyl]ethanamide::N-cyclohexyl-2-[[3-(2-methoxyethyl)-4-oxo-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl]sulfanyl]acetamide::N-cyclohexyl-2-[[3-(2-methoxyethyl)-4-oxo-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl]thio]acetamide::N-cyclohexyl-2-[[4-keto-3-(2-methoxyethyl)-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl]thio]acetamide::SMR000806699::cid_22430904",Heat shock factor protein 1,Mus musculus,
51151789,Cc1cc(nn1CCOc1ccc(C[C@H](Nc2ccccc2C(=O)c2ccccc2)C(O)=O)cc1)-c1ccccc1,"InChI=1S/C34H31N3O4/c1-24-22-31(26-10-4-2-5-11-26)36-37(24)20-21-41-28-18-16-25(17-19-28)23-32(34(39)40)35-30-15-9-8-14-29(30)33(38)27-12-6-3-7-13-27/h2-19,22,32,35H,20-21,23H2,1H3,(H,39,40)/t32-/m0/s1",OBEYMPYDVQYKGH-YTTGMZPUSA-N,50471955,CHEMBL148797,Peroxisome proliferator-activated receptor gamma,Homo sapiens,
50008672,NC(=N)NCCCNC(=O)[C@@H]1CCCCN1C(=O)[C@@H](CC1CCCCC1)NCC(O)=O,"InChI=1S/C21H38N6O4/c22-21(23)25-11-6-10-24-19(30)17-9-4-5-12-27(17)20(31)16(26-14-18(28)29)13-15-7-2-1-3-8-15/h15-17,26H,1-14H2,(H,24,30)(H,28,29)(H4,22,23,25)/t16-,17+/m1/s1",CDPROXZBMHOBTQ-SJORKVTESA-N,50073316,CHEMBL114715::INOGATRAN::{(R)-1-Cyclohexylmethyl-2-[(S)-2-(3-guanidino-propylcarbamoyl)-piperidin-1-yl]-2-oxo-ethylamino}-acetic acid::{1-Cyclohexylmethyl-2-[2-(3-guanidino-propylcarbamoyl)-piperidin-1-yl]-2-oxo-ethylamino}-acetic acid(inogatran)::{[(1R)-2-((2S)-2-{[(3-{[AMINO(IMINO)METHYL]AMINO}PROPYL)AMINO]CARBONYL}PIPERIDINYL)-1-(CYCLOHEXYLMETHYL)-2-OXOETHYL]AMINO}ACETIC ACID,Prothrombin,,
50936052,O=C(Cc1ccncc1)Nc1cccc(CCN2CCN(CC2)c2ccccc2)c1,"InChI=1S/C25H28N4O/c30-25(20-22-9-12-26-13-10-22)27-23-6-4-5-21(19-23)11-14-28-15-17-29(18-16-28)24-7-2-1-3-8-24/h1-10,12-13,19H,11,14-18,20H2,(H,27,30)",ZKFSEJHRACMHEP-UHFFFAOYSA-N,50384191,CHEMBL2029926,D(2) dopamine receptor,Homo sapiens,
50197485,CC(C)(C)c1cc(CC2NC(=O)C(CCCCNC(=O)CNC2=O)NC(=O)C(N)Cc2ccccc2)ccc1O,"InChI=1S/C30H41N5O5/c1-30(2,3)21-15-20(12-13-25(21)36)17-24-28(39)33-18-26(37)32-14-8-7-11-23(29(40)35-24)34-27(38)22(31)16-19-9-5-4-6-10-19/h4-6,9-10,12-13,15,22-24,36H,7-8,11,14,16-18,31H2,1-3H3,(H,32,37)(H,33,39)(H,34,38)(H,35,40)",WQCVKFYFRFRIGI-UHFFFAOYSA-N,50108830,"2-Amino-N-[6-(3-tert-butyl-4-hydroxy-benzyl)-2,5,8-trioxo-1,4,7triaza-cyclotridec-9-yl]-3-phenyl-propionamide::CHEMBL158969",Motilin receptor,, 33
733713,Cc1nnsc1Cn1c(=O)n(C)c2ccc(cc2c1=O)S(=O)(=O)NC1(C)CC1,"InChI=1S/C17H19N5O4S2/c1-10-14(27-20-18-10)9-22-15(23)12-8-11(4-5-13(12)21(3)16(22)24)28(25,26)19-17(2)6-7-17/h4-5,8,19H,6-7,9H2,1-3H3",YAQFWXPTKPAQOO-UHFFFAOYSA-N,371084,"US10239843, Example 191",Poly(ADP-ribose) glycohydrolase,, 877
840203,CCc1ccc(cc1)N(CC(C)C)S(=O)(=O)c1ccc(OCC2CCOCC2)c(c1)S(=O)CC,"InChI=1S/C26H37NO5S2/c1-5-21-7-9-23(10-8-21)27(18-20(3)4)34(29,30)24-11-12-25(26(17-24)33(28)6-2)32-19-22-13-15-31-16-14-22/h7-12,17,20,22H,5-6,13-16,18-19H2,1-4H3",RKEKMGUGGBHNDU-UHFFFAOYSA-N,419158,"US10457637, Compound 22::ethanesulfinyl-N-(4- ethylphenyl)-N-isobutyl- 4-(tetrahydropyran-4- ylmethoxy)benzene- sulfonamide",Interleukin-17A,, 550
51093803,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1nc(c[nH]1)-c1ccc(cc1)-c1ccc(cc1)-c1c[nH]c(n1)[C@@H]1CC2(CN1C(=O)[C@@H](NC(=O)OC)C(C)C)OCCO2,"InChI=1S/C42H52N8O8/c1-24(2)34(47-40(53)55-5)38(51)49-17-7-8-32(49)36-43-21-30(45-36)28-13-9-26(10-14-28)27-11-15-29(16-12-27)31-22-44-37(46-31)33-20-42(57-18-19-58-42)23-50(33)39(52)35(25(3)4)48-41(54)56-6/h9-16,21-22,24-25,32-35H,7-8,17-20,23H2,1-6H3,(H,43,45)(H,44,46)(H,47,53)(H,48,54)/t32-,33-,34-,35-/m0/s1",YMCAVGXTSCNFDE-BBACVFHCSA-N,50448434,CHEMBL3121951,Cytochrome P450 2C19,Homo sapiens,>33000
50714573,CC(=O)Oc1ccccc1C(O)=O,"InChI=1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)",BSYNRYMUTXBXSQ-UHFFFAOYSA-N,22360,2-(acetyloxy)benzoate::2-(acetyloxy)benzoic acid::Acetylsalicylic acid::Aspirin::Endosprin::Polopirin::Zorprin::acetylsalicylate::cid_2244,Prostaglandin G/H synthase 2,Homo sapiens,>400000
50956456,COCCn1cc(C(=O)N[C@@H]2C(C)(C)C3CC[C@]2(C)C3)c(=O)c2ccc(F)cc12,"InChI=1S/C23H29FN2O3/c1-22(2)14-7-8-23(3,12-14)21(22)25-20(28)17-13-26(9-10-29-4)18-11-15(24)5-6-16(18)19(17)27/h5-6,11,13-14,21H,7-10,12H2,1-4H3,(H,25,28)/t14?,21-,23-/m1/s1",YXRXOBOTFASVBH-QLXIDDQXSA-N,50392554,CHEMBL2152806,Cannabinoid receptor 1,Homo sapiens,
691007,COc1cc(CCC(C)(C)N2Cc3cccc(C(=O)NCCN(C)C)c3C2)ccc1O,"InChI=1S/C25H35N3O3/c1-25(2,12-11-18-9-10-22(29)23(15-18)31-5)28-16-19-7-6-8-20(21(19)17-28)24(30)26-13-14-27(3)4/h6-10,15,29H,11-14,16-17H2,1-5H3,(H,26,30)",PGLDFPQDEVYLIU-UHFFFAOYSA-N,349560,"US10207991, Ex. Cpd. No. 78::US10611728, Example Compound 78",Sigma intracellular receptor 2,,
50982184,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO,"InChI=1S/C26H35N5O6/c1-17(30-25(36)21(27)14-19-8-10-20(33)11-9-19)24(35)29-16-23(34)31(2)22(26(37)28-12-13-32)15-18-6-4-3-5-7-18/h3-11,17,21-22,32-33H,12-16,27H2,1-2H3,(H,28,37)(H,29,35)(H,30,36)/t17-,21+,22+/m1/s1",HPZJMUBDEAMBFI-WTNAPCKOSA-N,21015,"(2S)-2-{2-[(2R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]propanamido]-N-methylacetamido}-N-(2-hydroxyethyl)-3-phenylpropanamide::2-Ala-4-MePhe-5-Gly-Enkephalin::CHEMBL38874::D-Ala2-MePhe4-Met(0)5-enkephalin-ol::DAMGO::RX 783006::US11492374, ID 2::[3H]DAMGO::[tyrosyl-3,5-3H(N)]-D-Ala2-Mephe4-glyol5-enkephalin",Mu-type opioid receptor,Homo sapiens,
50831101,C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1,"InChI=1S/C19H35N/c1-3-9-16(10-4-1)19(17-11-5-2-6-12-17)15-18-13-7-8-14-20-18/h16-20H,1-15H2/t18-/m1/s1",CYXKNKQEMFBLER-GOSISDBHSA-N,50260108,CHEMBL4082420,"Carnitine O-palmitoyltransferase 1, muscle isoform",Rattus norvegicus, 32000
931210,C[C@@H]1CN(C2CCc3cc(ccc3C12S(=O)(=O)c1ccc(F)cc1)C(F)(C(F)(F)F)C(F)(F)F)C(=O)[C@H]1CC[C@@H](CC1)C(O)=O,"InChI=1S/C30H29F8NO5S/c1-16-15-39(25(40)17-2-4-18(5-3-17)26(41)42)24-13-6-19-14-20(28(32,29(33,34)35)30(36,37)38)7-12-23(19)27(16,24)45(43,44)22-10-8-21(31)9-11-22/h7-12,14,16-18,24H,2-6,13,15H2,1H3,(H,41,42)/t16-,17-,18-,24?,27?/m1/s1",INLCDNRAIIGCBA-NTUALMSUSA-N,382589,"US10273259, Example 298::US10711020, Example 298",Nuclear receptor ROR-gamma [262-507],, 49.0
50053362,C[C@]1(N)CCCC[C@@H]1c1cnc[nH]1,"InChI=1S/C10H17N3/c1-10(11)5-3-2-4-8(10)9-6-12-7-13-9/h6-8H,2-5,11H2,1H3,(H,12,13)/t8-,10+/m1/s1",QRPSMQORRBAFIK-SCZZXKLOSA-N,50034713,"(1S,2S)-2-(1H-Imidazol-4-yl)-1-methyl-cyclohexylamine::CHEMBL37568",Histamine H3 receptor,Cavia cutleri,
1038014,Cc1c(-c2ccc(Oc3ncccc3C(F)(F)F)c3[nH]ccc23)n(C)c(=O)[nH]c1=O,"InChI=1S/C20H15F3N4O3/c1-10-16(27(2)19(29)26-17(10)28)12-5-6-14(15-11(12)7-9-24-15)30-18-13(20(21,22)23)4-3-8-25-18/h3-9,24H,1-2H3,(H,26,28,29)",ZFJDLEQDDNOMPH-UHFFFAOYSA-N,160930,"US11014909, Example 19::US9107923, 19",D(1A) dopamine receptor,,
50904696,COCCNc1ccn(-c2ccccc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc3cc(OC)ccc23)cn1,"InChI=1S/C30H27N5O5/c1-38-17-15-32-24-13-16-35(20-6-4-3-5-7-20)30(37)28(24)29(36)34-27-11-9-22(19-33-27)40-26-12-14-31-25-18-21(39-2)8-10-23(25)26/h3-14,16,18-19,32H,15,17H2,1-2H3,(H,33,34,36)",AKLARZWWYXICKZ-UHFFFAOYSA-N,50301362,"4-(2-methoxyethylamino)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide::CHEMBL570955",Focal adhesion kinase 1,Homo sapiens,>125000
969583,COc1ccc(cc1)-c1cc2c(ncnn2c1)N1CCN(CC1)c1ncc(Cc2ccccc2)cn1,"InChI=1S/C28H27N7O/c1-36-25-9-7-23(8-10-25)24-16-26-27(31-20-32-35(26)19-24)33-11-13-34(14-12-33)28-29-17-22(18-30-28)15-21-5-3-2-4-6-21/h2-10,16-20H,11-15H2,1H3",MUTDSMFDBHESKX-UHFFFAOYSA-N,469243,"US10807985, Compound 18",Mast/stem cell growth factor receptor Kit [D816V],, 55
1197781,CC(C)Cc1ccccc1[C@@H]1CCCN1C1CC2(C1)CCN(CC2)c1ccc(C(=O)NS(=O)(=O)c2ccc(NCC3CCOCC3)c(c2)[N+]([O-])=O)c(Oc2cnc3[nH]ccc3c2)c1,,,567686,"US11420968, Example F52",Apoptosis regulator Bcl-2,, 1.60
50875493,CN([C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45)C(=O)\C=C\c1cccs1,"InChI=1S/C28H32N2O4S/c1-29(23(32)9-7-19-3-2-14-35-19)20-10-11-28(33)22-15-18-6-8-21(31)25-24(18)27(28,26(20)34-25)12-13-30(22)16-17-4-5-17/h2-3,6-9,14,17,20,22,26,31,33H,4-5,10-13,15-16H2,1H3/b9-7+/t20-,22-,26+,27+,28-/m1/s1",CREYUPGJHVPMCU-NUINQRJCSA-N,50274255,"(2E)-N-[(5R,6R)-17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-yl]-3-(thiophen-2-yl)-N-methylprop-2-enamide::CHEMBL485428",Kappa-type opioid receptor,, 0.1
51017927,NCc1cnc(s1)C1=CCC(CC1)N(CCN1CCCC1)C(=O)Nc1ccc(F)c(Cl)c1,"InChI=1S/C23H29ClFN5OS/c24-20-13-17(5-8-21(20)25)28-23(31)30(12-11-29-9-1-2-10-29)18-6-3-16(4-7-18)22-27-15-19(14-26)32-22/h3,5,8,13,15,18H,1-2,4,6-7,9-12,14,26H2,(H,28,31)",IZZFEMFQNQCCFU-UHFFFAOYSA-N,50215588,1-(4-(5-(aminomethyl)thiazol-2-yl)cyclohex-3-enyl)-3-(3-chloro-4-fluorophenyl)-1-(2-(pyrrolidin-1-yl)ethyl)urea::CHEMBL441886,Melanin-concentrating hormone receptor 1,Homo sapiens,
50016524,CCCCCCCCCCCCCCCCOCC1OCC(COCCCC[n+]2ccsc2)O1,"InChI=1S/C28H52NO4S/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-16-20-31-25-28-32-24-27(33-28)23-30-21-17-15-18-29-19-22-34-26-29/h19,22,26-28H,2-18,20-21,23-25H2,1H3/q+1",DIMHYAQLAIEZKY-UHFFFAOYSA-N,50011098,"CHEMBL14604::Toluene-4-sulfonate3-[4-(2-hexadecyloxymethyl-[1,3]dioxolan-4-ylmethoxy)-butyl]-thiazol-3-ium;Toluene-4-sulfonate",Platelet-activating factor receptor,, 1200
246229,CCOC(=O)N1CCN(CC1)C(=O)[C@H](CCC(O)=O)NC(=O)c1cc(OCC(=O)N2CCCC2c2ccccc2)c2ccccc2n1,"InChI=1S/C34H39N5O8/c1-2-46-34(45)38-19-17-37(18-20-38)33(44)26(14-15-31(41)42)36-32(43)27-21-29(24-11-6-7-12-25(24)35-27)47-22-30(40)39-16-8-13-28(39)23-9-4-3-5-10-23/h3-7,9-12,21,26,28H,2,8,13-20,22H2,1H3,(H,36,43)(H,41,42)/t26-,28?/m0/s1",FAJICISULDPTIS-QODXOHEASA-N,119425,"US8669266, 334",P2Y purinoceptor 12,Homo sapiens, 102
50102137,OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O,"InChI=1S/C6H13NO4/c8-2-3-5(10)6(11)4(9)1-7-3/h3-11H,1-2H2/t3-,4+,5-,6-/m1/s1",LXBIFEVIBLOUGU-JGWLITMVSA-N,18351,"(2R,3R,4R,5S)-2-(Hydroxymethyl)piperidine-3,4,5-triol, 10::(2R,3R,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol::1-Deoxynojirimycin::1-deoxynojirimycin (DNJ)::CHEMBL307429::US9181184, 1::dNM",Beta-glucosidase,Agrobacterium sp. ZY-2006e,
6939,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCn1ccnn1,"InChI=1S/C19H16BrFN6O2/c1-28-17-9-13-16(10-18(17)29-7-6-27-5-4-24-26-27)22-11-23-19(13)25-15-3-2-12(20)8-14(15)21/h2-5,8-11H,6-7H2,1H3,(H,22,23,25)",YBTGTVGEKMZEQX-UHFFFAOYSA-N,4651,"N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[2-(1H-1,2,3-triazol-1-yl)ethoxy]quinazolin-4-amine::ZD4190",Vascular endothelial growth factor receptor 2,Homo sapiens, 30
50695815,CS(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1,"InChI=1S/C21H16FN3OS/c1-27(26)18-8-4-16(5-9-18)21-24-19(14-2-6-17(22)7-3-14)20(25-21)15-10-12-23-13-11-15/h2-13H,1H3,(H,24,25)",CDMGBJANTYXAIV-UHFFFAOYSA-N,13336,4-[4-(4-fluorophenyl)-2-(4-methanesulfinylphenyl)-1H-imidazol-5-yl]pyridine::4-[4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-1H-imidazol-5-yl]pyridine::4-{4-(4-fluorophenyl)-2-[4-(methylsulfinyl)phenyl]-1H-imidazol-5-yl}pyridine::CHEMBL10::SB-203580::SB203580::cid_176155,RAF proto-oncogene serine/threonine-protein kinase,Homo sapiens,
727563,CNC1CCN(C1)c1cc(OC(F)(F)F)ccc1Nc1c(F)cc(cc1F)S(=O)(=O)Nc1cscn1,"InChI=1S/C21H20F5N5O3S2/c1-27-12-4-5-31(9-12)18-6-13(34-21(24,25)26)2-3-17(18)29-20-15(22)7-14(8-16(20)23)36(32,33)30-19-10-35-11-28-19/h2-3,6-8,10-12,27,29-30H,4-5,9H2,1H3",UPXMGRICOKGRIO-UHFFFAOYSA-N,368234,"US10227338, Example 15",Sodium channel protein type 9 subunit alpha,, 369
50925108,COc1ccc(cc1OC)C(C)(C)c1cnc(SCCOCc2ccc(cc2)-c2nnn[nH]2)n1-c1ccc(F)cc1,"InChI=1S/C30H31FN6O3S/c1-30(2,22-9-14-25(38-3)26(17-22)39-4)27-18-32-29(37(27)24-12-10-23(31)11-13-24)41-16-15-40-19-20-5-7-21(8-6-20)28-33-35-36-34-28/h5-14,17-18H,15-16,19H2,1-4H3,(H,33,34,35,36)",MZNVBILGXVMJOQ-UHFFFAOYSA-N,50271987,CHEMBL4126607,G-protein coupled bile acid receptor 1,Homo sapiens,
51314104,CNc1nccc(n1)N1CC[C@@H](C1)NC(=O)Nc1ccc(CN2CCOCC2)c(c1)C(F)(F)F,"InChI=1S/C22H28F3N7O2/c1-26-20-27-6-4-19(30-20)32-7-5-17(14-32)29-21(33)28-16-3-2-15(18(12-16)22(23,24)25)13-31-8-10-34-11-9-31/h2-4,6,12,17H,5,7-11,13-14H2,1H3,(H,26,27,30)(H2,28,29,33)/t17-/m0/s1",LVIYMOOJJGCMCP-KRWDZBQOSA-N,50532616,CHEMBL4532382,Cyclin-C,, 17
1000592,Cc1c(OCCCN2CC(C)(O)C2)cccc1-c1cccc2[C@H](CCc12)Oc1cc(OCc2cncc(c2)C#N)c(CNCC2CCC(=O)N2)cc1Cl,"InChI=1S/C42H46ClN5O5/c1-27-32(6-4-9-37(27)51-15-5-14-48-25-42(2,50)26-48)33-7-3-8-35-34(33)11-12-38(35)53-40-18-39(52-24-29-16-28(19-44)20-45-21-29)30(17-36(40)43)22-46-23-31-10-13-41(49)47-31/h3-4,6-9,16-18,20-21,31,38,46,50H,5,10-15,22-26H2,1-2H3,(H,47,49)/t31?,38-/m0/s1",MYBDAGVHYOVALW-ZENVVIPHSA-N,482373,"US10919852, Compound TABLE 1.72",Programmed cell death protein 1,,<5
50164666,NC(=O)c1cc(nc(c1)-c1ccnc(NC2CCCC2)c1)N1CCNCC1,"InChI=1S/C20H26N6O/c21-20(27)15-11-17(25-19(13-15)26-9-7-22-8-10-26)14-5-6-23-18(12-14)24-16-3-1-2-4-16/h5-6,11-13,16,22H,1-4,7-10H2,(H2,21,27)(H,23,24)",LRYNHRWGDADZKP-UHFFFAOYSA-N,50324329,"2'-Cyclopentylamino-6-piperazin-1-yl[2,4']bipyridinyl-4-carboxylicAcid Amide::CHEMBL1215076",Serine/threonine-protein kinase D1,Homo sapiens, 6
50768352,CC(C)c1cccc(C(C)C)c1NC(=O)NCC(Cc1ccccc1)NCc1ccccc1O,"InChI=1S/C29H37N3O2/c1-20(2)25-14-10-15-26(21(3)4)28(25)32-29(34)31-19-24(17-22-11-6-5-7-12-22)30-18-23-13-8-9-16-27(23)33/h5-16,20-21,24,30,33H,17-19H2,1-4H3,(H2,31,32,34)",FIAQNKRHOLWVFD-UHFFFAOYSA-N,50038559,"1-(2,6-Diisopropyl-phenyl)-3-[2-(2-hydroxy-benzylamino)-3-phenyl-propyl]-urea::CHEMBL54040",Sterol O-acyltransferase 1,Rattus norvegicus, 410
51430814,Nc1cccc(c1)-c1cccnc1,"InChI=1S/C11H10N2/c12-11-5-1-3-9(7-11)10-4-2-6-13-8-10/h1-8H,12H2",YTJQJGKMRLQBJP-UHFFFAOYSA-N,152261,"US8993552, 4H8 Compound 42",Tyrosine-protein kinase receptor UFO,, 363000
51318429,CCc1cccc(N2CCN(CCCCNC(=O)c3cc4ccccc4[nH]3)CC2)c1Cl,"InChI=1S/C25H31ClN4O/c1-2-19-9-7-11-23(24(19)26)30-16-14-29(15-17-30)13-6-5-12-27-25(31)22-18-20-8-3-4-10-21(20)28-22/h3-4,7-11,18,28H,2,5-6,12-17H2,1H3,(H,27,31)",WEMWEQGYQWENGE-UHFFFAOYSA-N,50533609,CHEMBL4544583,D(3) dopamine receptor,,
51013870,CCn1c(=O)n(Cc2ccco2)c2nc(Cc3cccs3)[nH]c2c1=O,"InChI=1S/C17H16N4O3S/c1-2-20-16(22)14-15(19-13(18-14)9-12-6-4-8-25-12)21(17(20)23)10-11-5-3-7-24-11/h3-8H,2,9-10H2,1H3,(H,18,19)",PPBHCKHMCRVBPO-UHFFFAOYSA-N,50415174,CHEMBL595431,Adenosine receptor A1,Rattus norvegicus,
51354103,CC(=O)n1ccc2cc(ccc12)C(=O)N1CCCC(C1)c1ccnc2ncnn12,"InChI=1S/C21H20N6O2/c1-14(28)26-10-7-15-11-16(4-5-18(15)26)20(29)25-9-2-3-17(12-25)19-6-8-22-21-23-13-24-27(19)21/h4-8,10-11,13,17H,2-3,9,12H2,1H3",ACILVPXHSUHXNS-UHFFFAOYSA-N,50547765,CHEMBL4783572,"cGMP-dependent 3',5'-cyclic phosphodiesterase",, 2.1
1198827,CC(C)c1c([nH]c2ccc(cc12)C(=O)N(C)Cc1cccc(N)c1)-c1cc(C)nc(C)c1,"InChI=1S/C27H30N4O/c1-16(2)25-23-14-20(27(32)31(5)15-19-7-6-8-22(28)13-19)9-10-24(23)30-26(25)21-11-17(3)29-18(4)12-21/h6-14,16,30H,15,28H2,1-5H3",YHQIPROWUIBXTC-UHFFFAOYSA-N,568225,"US11420973, Example 103",Toll-like receptor 7,, 54.0
306293,CCN1CCc2c(C1)nc(nc2NCc1ccccc1)-n1c(CN)cc2ccccc12,"InChI=1S/C25H28N6/c1-2-30-13-12-21-22(17-30)28-25(29-24(21)27-16-18-8-4-3-5-9-18)31-20(15-26)14-19-10-6-7-11-23(19)31/h3-11,14H,2,12-13,15-17,26H2,1H3,(H,27,28,29)",ZQPHAGPZGLPAFN-UHFFFAOYSA-N,163153,"US9062026, Table III, Compound 81",Transitional endoplasmic reticulum ATPase,,<2000
51163344,COc1cc(-c2ccccc2)c2[nH]cc(CCNC(C)=O)c2c1,"InChI=1S/C19H20N2O2/c1-13(22)20-9-8-15-12-21-19-17(14-6-4-3-5-7-14)10-16(23-2)11-18(15)19/h3-7,10-12,21H,8-9H2,1-2H3,(H,20,22)",ZTVQTJJYIPYWHJ-UHFFFAOYSA-N,50476616,CHEMBL233311,Melatonin receptor type 1C,Xenopus sp.,
978026,COc1cc(cc(OC)c1Cl)N1CCN(CC1)C(=O)CC[C@H]1NC(=O)NC1=O,"InChI=1S/C18H23ClN4O5/c1-27-13-9-11(10-14(28-2)16(13)19)22-5-7-23(8-6-22)15(24)4-3-12-17(25)21-18(26)20-12/h9-10,12H,3-8H2,1-2H3,(H2,20,21,25,26)/t12-/m1/s1",WLRSTEPNEZIVEB-GFCCVEGCSA-N,471903,"(5R)-5-[3-[4-(4- chloro-3,5- dimethoxy- phenyl) piperazin-1- yl]-3-oxo-propyl] imidazolidine- 2,4-dione::US10829478, Compound 135",ADAMTS5,,>10000
50126862,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13,"InChI=1S/C28H26N4O3/c1-28-26(34-3)17(29-2)12-20(35-28)31-18-10-6-4-8-14(18)22-23-16(13-30-27(23)33)21-15-9-5-7-11-19(15)32(28)25(21)24(22)31/h4-11,17,20,26,29H,12-13H2,1-3H3,(H,30,33)/t17-,20-,26-,28+/m1/s1",HKSZLNNOFSGOKW-FYTWVXJKSA-N,2579,"(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1^{2,6}.0^{7,28}.0^{8,13}.0^{15,19}.0^{20,27}.0^{21,26}]nonacosa-8(13),9,11,14(28),15(19),20(27),21(26),22,24-nonaen-16-one::CHEMBL388978::Staurosporin, 4::Staurosporine::Staurosporine, 8::US9206188, Staurosporine::US9226923, Staurosporine",BMP-2-inducible protein kinase,Homo sapiens,
50526527,CC1Oc2c(C)c(C)c(O)c(C)c2CC1CN1CCN(CC1)c1cc(nc(n1)N1CCCC1)N1CCCC1,"InChI=1S/C30H44N6O2/c1-20-21(2)29-25(22(3)28(20)37)17-24(23(4)38-29)19-33-13-15-35(16-14-33)27-18-26(34-9-5-6-10-34)31-30(32-27)36-11-7-8-12-36/h18,23-24,37H,5-17,19H2,1-4H3",SCUZVSHLJVHGDP-UHFFFAOYSA-N,50200553,CHEMBL3898379,Caspase-1,Homo sapiens,
50770916,OC[C@H]1O[C@@H](SS[C@@H]2O[C@H](CO)[C@H](O)[C@@H]([C@H]2O)n2cc(nn2)-c2ccc(F)c(F)c2)[C@H](O)[C@H]([C@H]1O)n1cc(nn1)-c1ccc(F)c(F)c1,"InChI=1S/C28H28F4N6O8S2/c29-13-3-1-11(5-15(13)31)17-7-37(35-33-17)21-23(41)19(9-39)45-27(25(21)43)47-48-28-26(44)22(24(42)20(10-40)46-28)38-8-18(34-36-38)12-2-4-14(30)16(32)6-12/h1-8,19-28,39-44H,9-10H2/t19-,20-,21+,22+,23+,24+,25-,26-,27+,28+/m1/s1",HTECVDNTYQJQOS-MQFIMZJJSA-N,50247477,CHEMBL4102995,Galectin-3,Homo sapiens,
563922,Cc1ncc(o1)-c1cc(cnc1N)-c1cc(ccc1C)S(=O)(=O)NCC1CCCOC1,"InChI=1S/C22H26N4O4S/c1-14-5-6-18(31(27,28)26-10-16-4-3-7-29-13-16)9-19(14)17-8-20(22(23)25-11-17)21-12-24-15(2)30-21/h5-6,8-9,11-12,16,26H,3-4,7,10,13H2,1-2H3,(H2,23,25)",YUOWESWMDNFZDM-UHFFFAOYSA-N,295236,"3-(6-amino-5-(2- methyloxazol-5- yl)pyridin-3-yl)-4- methyl-N-((tetrahydro- 2H-pyran-3- yl)methyl)benzenesulfon- amide::US10112926, Example 104.8","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform",Homo sapiens, 800
50452986,N#Cc1ccc2cc(OCC3CCNCC3)ccc2c1,"InChI=1S/C17H18N2O/c18-11-14-1-2-16-10-17(4-3-15(16)9-14)20-12-13-5-7-19-8-6-13/h1-4,9-10,13,19H,5-8,12H2",SHJHTXWKDLOBQS-UHFFFAOYSA-N,50278527,6-(piperidin-4-ylmethoxy)-2-naphthonitrile::CHEMBL469552,Sodium-dependent dopamine transporter,Homo sapiens, 6000
349283,CCn1c(=O)cc(Nc2ccc(Oc3ccnc(c3)C(O)=O)cc2)n(Cc2ccc(Cl)cc2)c1=O,"InChI=1S/C25H21ClN4O5/c1-2-29-23(31)14-22(30(25(29)34)15-16-3-5-17(26)6-4-16)28-18-7-9-19(10-8-18)35-20-11-12-27-21(13-20)24(32)33/h3-14,28H,2,15H2,1H3,(H,32,33)",CMHLBSGBYSOXAO-UHFFFAOYSA-N,196395,"US9212130, I-317",P2X purinoceptor 3,Homo sapiens, 3
209715,Oc1ccccc1C(=O)NNC(=O)CSc1nnc(-c2ccccc2)n1Cc1ccccc1,"InChI=1S/C24H21N5O3S/c30-20-14-8-7-13-19(20)23(32)27-25-21(31)16-33-24-28-26-22(18-11-5-2-6-12-18)29(24)15-17-9-3-1-4-10-17/h1-14,30H,15-16H2,(H,25,31)(H,27,32)",SWWKGTCUEFXKBX-UHFFFAOYSA-N,96317,"2-Hydroxy-benzoic acid N&#39;-[2-(4-benzyl-5-phenyl-4H-[1,2,4]triazol-3-ylsulfanyl)-acetyl]-hydrazide::2-hydroxy-N'-[1-oxo-2-[[5-phenyl-4-(phenylmethyl)-1,2,4-triazol-3-yl]thio]ethyl]benzohydrazide::2-oxidanyl-N'-[2-[[5-phenyl-4-(phenylmethyl)-1,2,4-triazol-3-yl]sulfanyl]ethanoyl]benzohydrazide::MLS000553916::N'-[2-[(4-benzyl-5-phenyl-1,2,4-triazol-3-yl)sulfanyl]acetyl]-2-hydroxybenzohydrazide::N'-[2-[(4-benzyl-5-phenyl-1,2,4-triazol-3-yl)thio]acetyl]-2-hydroxy-benzohydrazide::SMR000172137::cid_1136282",Albumin,Bos taurus,>94075
1234088,C[C@H]1COCCN1CCCn1nc(c2CN(CCc12)C(=O)C(N)=O)-c1ccc(Cl)c(c1)C#Cc1ccc(cc1)C(=O)NC[C@@H]1CCCN1,"InChI=1S/C36H42ClN7O4/c1-24-23-48-19-18-42(24)15-3-16-44-32-13-17-43(36(47)34(38)45)22-30(32)33(41-44)28-11-12-31(37)27(20-28)10-7-25-5-8-26(9-6-25)35(46)40-21-29-4-2-14-39-29/h5-6,8-9,11-12,20,24,29,39H,2-4,13-19,21-23H2,1H3,(H2,38,45)(H,40,46)/t24-,29-/m0/s1",UFAVKAUWMZQJQK-OUTSHDOLSA-N,587283,CatS_451,"Cathepsin S [115-331,C139S]",, 30
50672118,CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C,"InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-",WINHZLLDWRZWRT-ATVHPVEESA-N,4814,"CHEMBL535::N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide::N-[2-(diethylamino)ethyl]-5-{[(3Z)-5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene]methyl}-2,4-dimethyl-1H-pyrrole-3-carboxamide::SU11248::SUNITINIB::SUNITINIB MALATE::US10464902, Sunitinib::US9163010, Sunitinib::US9914707, SU11248",Calcium/calmodulin-dependent protein kinase type II subunit delta,,
153560,Nc1c(sc2nc(ccc12)-c1ccc(F)cc1)C(=O)Nc1ccc(F)cc1Cl,"InChI=1S/C20H12ClF2N3OS/c21-14-9-12(23)5-7-16(14)25-19(27)18-17(24)13-6-8-15(26-20(13)28-18)10-1-3-11(22)4-2-10/h1-9H,24H2,(H,25,27)",KKXYGKPDPOWFJD-UHFFFAOYSA-N,81361,"NadD inhibitor 3_23::US8785499, 3_23",Nicotinate-nucleotide adenylyltransferase,Escherichia coli,>2.00e+5
869120,Cn1c(nc(-c2ccc(C#N)c(F)c2)c(-c2ccc(nc2)N2CCCC2)c1=O)N1CCC(N)CC1,"InChI=1S/C26H28FN7O/c1-32-25(35)23(19-6-7-22(30-16-19)33-10-2-3-11-33)24(17-4-5-18(15-28)21(27)14-17)31-26(32)34-12-8-20(29)9-13-34/h4-7,14,16,20H,2-3,8-13,29H2,1H3",OLORNMQBALCRLD-UHFFFAOYSA-N,283277,"4-[2-(4-amino-piperidin-1-yl)-1- methyl-6-oxo-5-(6-pyrrolidin-1- yl-pyridin-3-yl)-1,6-dihydro- pyrimidin-4-yl]-2-fluoro- benzonitrile::US10023543, Example 60::US10207999, Example 60::US10328077, Example 60::US10548896, Example 60::US10849898, Example 60::US10960005, Example 60::US11084793, Example 60::US9573930, Example 60::US9771329, Example 60::US9776974, Example 60",Lysine-specific histone demethylase 1A,Homo sapiens,<100
50840281,CC(C)S(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1,"InChI=1S/C31H30ClFN4O4S/c1-20(2)42(38,39)13-12-34-17-25-8-11-29(41-25)22-6-9-28-26(15-22)31(36-19-35-28)37-24-7-10-30(27(32)16-24)40-18-21-4-3-5-23(33)14-21/h3-11,14-16,19-20,34H,12-13,17-18H2,1-2H3,(H,35,36,37)",IRPQLCLTIKGBTQ-UHFFFAOYSA-N,50189126,CHEMBL214487::N-(4-(3-fluorobenzyloxy)-3-chlorophenyl)-6-(5-((2-(isopropylsulfonyl)ethylamino)methyl)furan-2-yl)quinazolin-4-amine,Epidermal growth factor receptor,Homo sapiens, 18
819179,Cc1cccc(c1)S(=O)(=O)N1CCCc2ncc(NC(=O)c3c(F)cccc3Cl)cc12,"InChI=1S/C22H19ClFN3O3S/c1-14-5-2-6-16(11-14)31(29,30)27-10-4-9-19-20(27)12-15(13-25-19)26-22(28)21-17(23)7-3-8-18(21)24/h2-3,5-8,11-13H,4,9-10H2,1H3,(H,26,28)",TUZJJTZUWMMKRB-UHFFFAOYSA-N,310123,"2-chloro-6-fluoro-N-(5-(m-tolylsulfonyl)-5,6,7,8-tetrahydro-1,5-naphthyridin-3-yl)benzamide ::US10377768, Compound 37::US9657033, Compound 37",Nuclear receptor ROR-gamma,,
50961226,Cc1ccccc1NC(=O)Oc1ccc2N(Cc3ccccc3)CCCc2c1,"InChI=1S/C24H24N2O2/c1-18-8-5-6-12-22(18)25-24(27)28-21-13-14-23-20(16-21)11-7-15-26(23)17-19-9-3-2-4-10-19/h2-6,8-10,12-14,16H,7,11,15,17H2,1H3,(H,25,27)",VZWIJVLZLCGEAM-UHFFFAOYSA-N,50394325,CHEMBL2159415,Acetylcholinesterase,Mus musculus, 14300
991116,CCOc1cc(-c2ccc(nc2)N2CCC(C)(CC2)NC(=O)C2(C)CCC2)c2c(cnn2c1)C#N,"InChI=1S/C27H32N6O2/c1-4-35-21-14-22(24-20(15-28)17-30-33(24)18-21)19-6-7-23(29-16-19)32-12-10-27(3,11-13-32)31-25(34)26(2)8-5-9-26/h6-7,14,16-18H,4-5,8-13H2,1-3H3,(H,31,34)",ODSTXSQKUKHXON-UHFFFAOYSA-N,305526,"N-(1-(5-(3-cyano- 6- ethoxypyrazolo[1, 5-a]pyridin-4- yl)pyridin-2-yl)-4- methylpiperidin-4- yl)-1- methylcyclobutane- 1-carboxamide::US10144734, Example 543::US10172845, Example 543::US10441581, Example 543::US10881652, Example 543",Proto-oncogene tyrosine-protein kinase receptor Ret [V804M],, 91.9
50060714,NC1CCN(CC1)C(=O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC1CCCCC1)[C@@H](O)[C@@H](O)CCc1ccccn1,"InChI=1S/C39H55N7O5/c40-30-16-19-46(20-17-30)36(48)23-29(21-27-9-3-1-4-10-27)38(50)45-34(24-32-25-41-26-43-32)39(51)44-33(22-28-11-5-2-6-12-28)37(49)35(47)15-14-31-13-7-8-18-42-31/h1,3-4,7-10,13,18,25-26,28-30,33-35,37,47,49H,2,5-6,11-12,14-17,19-24,40H2,(H,41,43)(H,44,51)(H,45,50)/t29-,33+,34+,35+,37-/m1/s1",LGVOTNOMAMGKRU-XHRNTERESA-N,50045683,"4-(4-Amino-piperidin-1-yl)-2-benzyl-N-[1-(1-cyclohexylmethyl-2,3-dihydroxy-5-pyridin-2-yl-pentylcarbamoyl)-2-(1H-imidazol-4-yl)-ethyl]-4-oxo-butyramide::CHEMBL94762",Renin,Homo sapiens, 13
471592,CCc1ccc(Cl)cc1-c1c(cc(-c2cc(NC)ncn2)n1C)C(N)=O,"InChI=1S/C19H20ClN5O/c1-4-11-5-6-12(20)7-13(11)18-14(19(21)26)8-16(25(18)3)15-9-17(22-2)24-10-23-15/h5-10H,4H2,1-3H3,(H2,21,26)(H,22,23,24)",BEMRQBQIGSYKSL-UHFFFAOYSA-N,174031,"US9688661, 2-(5-Chloro-2-ethylphenyl)-N-methyl-5-[6-(methylamino)pyrimidin-4-yl]-1H-pyrrole-3-carboxamide (compd 302)",Tyrosine-protein kinase JAK1 [861-1152],, 1.00
55951,Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1,"InChI=1S/C23H27FN4O4/c1-13-20(10-18-17-9-15(24)3-4-19(17)27-22(18)30)26-14(2)21(13)23(31)25-11-16(29)12-28-5-7-32-8-6-28/h3-4,9-10,16,26,29H,5-8,11-12H2,1-2H3,(H,25,31)(H,27,30)/b18-10-/t16-/m0/s1",CTNPALGJUAXMMC-PMFHANACSA-N,31095,"5-[(Z)-(5-fluoranyl-2-oxidanylidene-1H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[(2S)-3-morpholin-4-yl-2-oxidanyl-propyl]-1H-pyrrole-3-carboxamide::5-[(Z)-(5-fluoro-2-keto-indolin-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-morpholino-propyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide::5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide::5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-morpholin-4-ylpropyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide::SU-14813::cid_10138259",ALK tyrosine kinase receptor,Homo sapiens,
50921252,CCc1nc(CC(C)(C)C)c(CN)c(-c2ccc(C)cc2)c1CC(O)=O,"InChI=1S/C22H30N2O2/c1-6-18-16(11-20(25)26)21(15-9-7-14(2)8-10-15)17(13-23)19(24-18)12-22(3,4)5/h7-10H,6,11-13,23H2,1-5H3,(H,25,26)",HQVOROHHYWZJLD-UHFFFAOYSA-N,50336820,"CHEMBL1672127::[5-(Aminomethyl)-6-(2,2-dimethylpropyl)-2-ethyl-4-(4-methylphenyl)pyridin-3-yl]acetic acid hydrate",Dipeptidyl peptidase 8,Homo sapiens,>100000
50555351,C\C(=N/OCCCCO\N=C(\CCC(O)=O)c1ccccc1)c1ccc(C)c(C)c1,"InChI=1S/C24H30N2O4/c1-18-11-12-22(17-19(18)2)20(3)25-29-15-7-8-16-30-26-23(13-14-24(27)28)21-9-5-4-6-10-21/h4-6,9-12,17H,7-8,13-16H2,1-3H3,(H,27,28)/b25-20+,26-23-",AHSPCWCKKHRZAG-WHVOXNPRSA-N,50309069,"2-(3,4-dimethylphenyl)-11-phenyl-4,9-dioxa-3,10-diazatetradeca-2,10-dien-14-oic acid::CHEMBL592236",Peroxisome proliferator-activated receptor gamma,Homo sapiens,
1006033,N[C@H]1CCC[C@H]1NC(=O)c1sc2nccc3n(-c4cc(cnn4)-c4ccccc4)c(=O)[nH]c1c23,,,485513,"N-((1R,2S)-2-Aminocyclopentyl)-4-oxo-5-(5-phenylpyridazin-3- yl)-4,5-dihydro-3H-1-thia-3,5,8-triazaacenaphthylene-2- carboxamide::US10934310, Ex # 349::US11319329, Ex # 349",Tyrosine-protein kinase BTK,Homo sapiens,<1000
51026931,CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O,"InChI=1S/C13H19NO4S/c1-3-9-14(10-4-2)19(17,18)12-7-5-11(6-8-12)13(15)16/h5-8H,3-4,9-10H2,1-2H3,(H,15,16)",DBABZHXKTCFAPX-UHFFFAOYSA-N,50206509,4-Dipropylsulfamoyl-benzoic acid::4-Dipropylsulfamoyl-benzoic acid anion::4-Dipropylsulfamoyl-benzoic acid(probenecid)::Benemid::CHEMBL897::PROBENECID::Probalan,Solute carrier family 22 member 2,Rattus, 1700000
51305851,Cc1cc(Nc2nccc(n2)-c2sc(nc2-c2ccc(F)cc2)C2CCNCC2)ccn1,"InChI=1S/C24H23FN6S/c1-15-14-19(8-12-27-15)29-24-28-13-9-20(30-24)22-21(16-2-4-18(25)5-3-16)31-23(32-22)17-6-10-26-11-7-17/h2-5,8-9,12-14,17,26H,6-7,10-11H2,1H3,(H,27,28,29,30)",ZDESNDWWUUVJLG-UHFFFAOYSA-N,50530637,CHEMBL4591417,Amine oxidase [flavin-containing] A,,>100000
1002176,CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(OCc3ccccn3)cc2)c2c(N)nccn12,"InChI=1S/C26H24N6O2/c1-2-6-22(33)31-15-5-8-21(31)26-30-23(24-25(27)29-14-16-32(24)26)18-9-11-20(12-10-18)34-17-19-7-3-4-13-28-19/h3-4,7,9-14,16,21H,5,8,15,17H2,1H3,(H2,27,29)/t21-/m0/s1",MGXCNOOHUDDZAH-NRFANRHFSA-N,483351,"US10919899, Compound 5",Tyrosine-protein kinase BTK,Homo sapiens, 5500
50430391,CN(CCN1CCCCC1)C(=O)N1CCC2(CC(=O)c3ccccc23)CC1,"InChI=1S/C22H31N3O2/c1-23(15-16-24-11-5-2-6-12-24)21(27)25-13-9-22(10-14-25)17-20(26)18-7-3-4-8-19(18)22/h3-4,7-8H,2,5-6,9-17H2,1H3",PSRPOZWPJIGRFL-UHFFFAOYSA-N,50264067,"CHEMBL521798::N-methyl-3-oxo-N-[2-(piperidin-1-yl)ethyl]-2,3-dihydrospiro[indene-1,4'-piperidine]-1'-carboxamide",Histamine H3 receptor,Homo sapiens, 43
50656130,O=C(NC1CCCCC1)NC12CC3CC(CC(C3)C1)C2,"InChI=1S/C17H28N2O/c20-16(18-15-4-2-1-3-5-15)19-17-9-12-6-13(10-17)8-14(7-12)11-17/h12-15H,1-11H2,(H2,18,19,20)",VESXWSWSGQONHC-UHFFFAOYSA-N,25732,"3-adamantan-1-yl-1-cyclohexylurea::CHEMBL242255::US8815951, 192::Urea-based compound, 13",Epoxide hydrolase B,Mycobacterium tuberculosis, 130
50252419,C[C@@]1(O)C[C@@H](Nc2c(cnn3cccc23)C(N)=O)C(C)(C)C1,"InChI=1S/C16H22N4O2/c1-15(2)9-16(3,22)7-12(15)19-13-10(14(17)21)8-18-20-6-4-5-11(13)20/h4-6,8,12,19,22H,7,9H2,1-3H3,(H2,17,21)/t12-,16-/m1/s1",RMCFFPUQAHGNPG-MLGOLLRUSA-N,50035851,CHEMBL3359917,Tyrosine-protein kinase JAK2,Homo sapiens, 61
51094900,CSC(=O)CCCCc1cnc(o1)C(=O)CCCCCCc1ccccc1,"InChI=1S/C22H29NO3S/c1-27-21(25)16-10-9-14-19-17-23-22(26-19)20(24)15-8-3-2-5-11-18-12-6-4-7-13-18/h4,6-7,12-13,17H,2-3,5,8-11,14-16H2,1H3",XRLYGLZYTDVTOA-UHFFFAOYSA-N,50448901,CHEMBL3125291,Fatty-acid amide hydrolase 1 [30-579],,
909290,CC(C)c1c([nH]c2ccc(cc12)C1CCN(CC1)S(=O)(=O)Cc1ccccc1)-c1ccnc(C)c1,"InChI=1S/C29H33N3O2S/c1-20(2)28-26-18-24(9-10-27(26)31-29(28)25-11-14-30-21(3)17-25)23-12-15-32(16-13-23)35(33,34)19-22-7-5-4-6-8-22/h4-11,14,17-18,20,23,31H,12-13,15-16,19H2,1-3H3",YGCREQMWFNHBHG-UHFFFAOYSA-N,443968,"US10660877, Example 556",Toll-like receptor 8,, 731
940040,O=C(NCC1CC11CCN(CC1)C(=O)C1CC1)c1cc2ccncc2o1,"InChI=1S/C20H23N3O3/c24-18(16-9-14-3-6-21-12-17(14)26-16)22-11-15-10-20(15)4-7-23(8-5-20)19(25)13-1-2-13/h3,6,9,12-13,15H,1-2,4-5,7-8,10-11H2,(H,22,24)",SIHJZOYDDZRTGA-UHFFFAOYSA-N,455536,"N-[[6-(cyclopropanecarbonyl)-6- azaspiro[2.5]octan-2- yl]methyl]furo[2,3-c]pyridine-2- carboxamide::US10730889, Example 130::US11485745, Example 130",Nicotinamide phosphoribosyltransferase,Homo sapiens, 2000
653454,COc1cc2c(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C)c3)ncnc2cc1OCCN1CCC(CO)CC1,"InChI=1S/C31H38N6O6/c1-31(2,3)27-17-28(36-43-27)35-30(39)34-21-6-5-7-22(14-21)42-29-23-15-25(40-4)26(16-24(23)32-19-33-29)41-13-12-37-10-8-20(18-38)9-11-37/h5-7,14-17,19-20,38H,8-13,18H2,1-4H3,(H2,34,35,36,39)",UMVVCSSWBLZQDK-UHFFFAOYSA-N,333495,"1-(5-tert- Butyl- isoxazol-3- yl)-3-(3-{7- [2-(4- hydroxymethyl- piperidin-1-yl)- ethoxy]-6- methoxy- quinazolin-4- yloxy}- phenyl)-urea::US9730937, Example 37",Serine/threonine-protein kinase B-raf [V600E],,
50440196,CC(=O)N1CC[C@@H](NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)c2cc(Cc3ccccc3)ccc12,"InChI=1S/C29H33N3O3/c1-18-13-23(34)14-19(2)24(18)17-26(30)29(35)31-27-11-12-32(20(3)33)28-10-9-22(16-25(27)28)15-21-7-5-4-6-8-21/h4-10,13-14,16,26-27,34H,11-12,15,17,30H2,1-3H3,(H,31,35)/t26-,27+/m0/s1",MLGZKVPTJOZDIX-RRPNLBNLSA-N,50133888,CHEMBL3634247,Kappa-type opioid receptor,Homo sapiens,
50652381,COc1cc(OC2CCNCC2)ccc1Nc1ncc(Cl)c(n1)-c1cnc2ccccn12,"InChI=1S/C23H23ClN6O2/c1-31-20-12-16(32-15-7-9-25-10-8-15)5-6-18(20)28-23-27-13-17(24)22(29-23)19-14-26-21-4-2-3-11-30(19)21/h2-6,11-15,25H,7-10H2,1H3,(H,27,28,29)",DVNORHCAMSIRBE-UHFFFAOYSA-N,50349693,CHEMBL1809050,Insulin-like growth factor 1 receptor,Homo sapiens, 12
449444,COc1c(F)cccc1-c1nnc([nH]1)[C@@H]1CCCN1C(=O)c1cc(C)c(C)cc1-n1nccn1,"InChI=1S/C24H24FN7O2/c1-14-12-17(20(13-15(14)2)32-26-9-10-27-32)24(33)31-11-5-8-19(31)23-28-22(29-30-23)16-6-4-7-18(25)21(16)34-3/h4,6-7,9-10,12-13,19H,5,8,11H2,1-3H3,(H,28,29,30)/t19-/m0/s1",JIXLYZFMWGQCJO-IBGZPJMESA-N,258005,"US9493446, 474",Orexin/Hypocretin receptor type 1,Homo sapiens, 16
50913645,CC1(C)O[C@@H]2CO[C@@]3(CNS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1,"InChI=1S/C12H22N2O7S/c1-10(2)18-7-5-17-12(6-14-22(13,15)16)9(8(7)19-10)20-11(3,4)21-12/h7-9,14H,5-6H2,1-4H3,(H2,13,15,16)/t7-,8-,9+,12+/m1/s1",NQRKKQKMTGLNOZ-XBWDGYHZSA-N,13055,"CHEMBL283695::Compound 8::Topiramate Sulfamide Analogue 8::amino-N-{[(1R,2S,6S,9R)-4,4,11,11-tetramethyl-3,5,7,10,12-pentaoxatricyclo[7.3.0.0^{2,6}]dodecan-6-yl]methyl}sulfonamide",Carbonic anhydrase 3,Homo sapiens,
51345826,Clc1ccc(CCC(=O)C(=O)NCc2ccccc2)cc1,"InChI=1S/C17H16ClNO2/c18-15-9-6-13(7-10-15)8-11-16(20)17(21)19-12-14-4-2-1-3-5-14/h1-7,9-10H,8,11-12H2,(H,19,21)",CWZXUVBWSQHAQX-UHFFFAOYSA-N,50544549,CHEMBL4646350,Phospholipase A and acyltransferase 5,, 251
866086,CC(C)c1c([nH]c2ccc(nc12)C1CCN(CCS(C)(=O)=O)CC1)-c1cn2ncnc2c(C)c1C,"InChI=1S/C26H34N6O2S/c1-16(2)23-24(20-14-32-26(27-15-28-32)18(4)17(20)3)30-22-7-6-21(29-25(22)23)19-8-10-31(11-9-19)12-13-35(5,33)34/h6-7,14-16,19,30H,8-13H2,1-5H3",IQNCZCYIJXDMLB-UHFFFAOYSA-N,428121,"US10544143, Example 556::US10730877, Example 556::US11053244, Example 556",Toll-like receptor 7,, 1.70
50286164,CCC[C@@H]1CSCCC(N)=N1,"InChI=1S/C8H16N2S/c1-2-3-7-6-11-5-4-8(9)10-7/h7H,2-6H2,1H3,(H2,9,10)/t7-/m1/s1",SWOQAUBWIBZBLQ-SSDOTTSWSA-N,50155784,"(R)-3-Propyl-[1,4]thiazepan-(5E)-ylideneamine::CHEMBL186985","Nitric oxide synthase, inducible",Homo sapiens, 1200
533771,FC(F)(F)c1cccc(n1)-c1nc(NC2CCC(F)(F)CC2)nc(Nc2ccnc(c2)-c2ccccc2)n1,"InChI=1S/C26H22F5N7/c27-25(28)12-9-17(10-13-25)33-23-36-22(19-7-4-8-21(35-19)26(29,30)31)37-24(38-23)34-18-11-14-32-20(15-18)16-5-2-1-3-6-16/h1-8,11,14-15,17H,9-10,12-13H2,(H2,32,33,34,36,37,38)",WTQROKONFNCZLX-UHFFFAOYSA-N,280067,"US10028961, Compound 220::US10172864, Compound 220::US10946023, Compound 220",Isocitrate dehydrogenase [NADP] cytoplasmic [R132H],, 75
51222303,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(C)=O)C(=O)N[C@@H](CCCCNC(=O)Cc1ccc(cc1)\N=N\c1ccc(cc1)N(CC)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O,"InChI=1S/C53H80N16O8/c1-6-33(4)46(66-50(76)41(62-34(5)70)14-11-29-60-52(55)56)51(77)64-42(48(74)63-43(15-12-30-61-53(57)58)49(75)65-44(47(54)73)31-35-18-26-40(71)27-19-35)13-9-10-28-59-45(72)32-36-16-20-37(21-17-36)67-68-38-22-24-39(25-23-38)69(7-2)8-3/h16-27,33,41-44,46,71H,6-15,28-32H2,1-5H3,(H2,54,73)(H,59,72)(H,62,70)(H,63,74)(H,64,77)(H,65,75)(H,66,76)(H4,55,56,60)(H4,57,58,61)/b68-67+/t33-,41-,42-,43-,44-,46-/m0/s1",GIVANBDIGIBKKJ-AJWFRBGYSA-N,50502265,CHEMBL4461872,"NAD-dependent protein deacetylase sirtuin-3, mitochondrial",, 180
812942,OC12CCC(CC1)(CC2)Nc1cc(ncc1C(=O)NCCC#N)-c1ccc2cc(cnn12)C#N,"InChI=1S/C25H25N7O2/c26-10-1-11-28-23(33)19-16-29-21(22-3-2-18-12-17(14-27)15-30-32(18)22)13-20(19)31-24-4-7-25(34,8-5-24)9-6-24/h2-3,12-13,15-16,34H,1,4-9,11H2,(H,28,33)(H,29,31)",NJGVATNAKLFMGR-UHFFFAOYSA-N,407410,"N-(2-cyanoethyl)-6-(3- cyanopyrrolo[1,2-b] pyridazin-7-yl)-4- ((4-hydroxybicyclo[2.2.2] octan-1-yl)amino) nicotinamide::US10336762, Compound 352",Tumor necrosis factor,Homo sapiens,
50770069,CC#C[C@@H](CC(O)=O)c1ccc(OCc2ccc3nc(nn3c2)-c2ccc(cc2)C(C)C)cc1,"InChI=1S/C28H27N3O3/c1-4-5-24(16-27(32)33)22-11-13-25(14-12-22)34-18-20-6-15-26-29-28(30-31(26)17-20)23-9-7-21(8-10-23)19(2)3/h6-15,17,19,24H,16,18H2,1-3H3,(H,32,33)/t24-/m0/s1",AUGDZUDMRWARAQ-DEOSSOPVSA-N,50247166,CHEMBL4082711,Melanocortin receptor 4,Rattus norvegicus,
1069400,CCn1ccc2c(ccnc12)-c1ccc(Nc2ccc(cn2)N2CCN(C)CC2)c2C(=O)NCc12,"InChI=1S/C27H29N7O/c1-3-33-11-9-21-20(8-10-28-26(21)33)19-5-6-23(25-22(19)17-30-27(25)35)31-24-7-4-18(16-29-24)34-14-12-32(2)13-15-34/h4-11,16H,3,12-15,17H2,1-2H3,(H,29,31)(H,30,35)",MLVSNERBXCUPKJ-UHFFFAOYSA-N,500391,"4-(1-ethylpyrrolo]2,3- b]pyridin-4- yl)-7-[[5-(4- methylpiperazin- 1-yl)-2-pyridyl]amino] isoindolin-1-one::US11021481, Compound I-49::US11078201, Compound I-49",Mitogen-activated protein kinase kinase kinase kinase 1,Homo sapiens,<100
50451176,FC(F)(F)c1ccccc1-c1ccc(CN2CCO[C@H](C2)c2ccccc2)cc1,"InChI=1S/C24H22F3NO/c25-24(26,27)22-9-5-4-8-21(22)19-12-10-18(11-13-19)16-28-14-15-29-23(17-28)20-6-2-1-3-7-20/h1-13,23H,14-17H2/t23-/m1/s1",JGFCVRSCIFSRKJ-HSZRJFAPSA-N,50257802,(S)-2-phenyl-4-((2'-(trifluoromethyl)biphenyl-4-yl)methyl)morpholine::CHEMBL523039,Cannabinoid receptor 2,Homo sapiens,
205634,[O-][N+](=O)c1ccc(Oc2ccc(C=C3C(=O)NC(=O)N(C3=O)c3ccccc3F)cc2)nc1,"InChI=1S/C22H13FN4O6/c23-17-3-1-2-4-18(17)26-21(29)16(20(28)25-22(26)30)11-13-5-8-15(9-6-13)33-19-10-7-14(12-24-19)27(31)32/h1-12H,(H,25,28,30)",FLKDPUOGWPHJAL-UHFFFAOYSA-N,94589,"(5E)-1-(2-fluorophenyl)-5-[4-[(5-nitro-2-pyridyl)oxy]benzylidene]barbituric acid::(5E)-1-(2-fluorophenyl)-5-[[4-(5-nitropyridin-2-yl)oxyphenyl]methylidene]-1,3-diazinane-2,4,6-trione::(5E)-1-(2-fluorophenyl)-5-[[4-[(5-nitro-2-pyridinyl)oxy]phenyl]methylidene]-1,3-diazinane-2,4,6-trione::1-(2-fluorophenyl)-5-{4-[(5-nitro-2-pyridinyl)oxy]benzylidene}-2,4,6(1H,3H,5H)-pyrimidinetrione::MLS000684650::SMR000268521::cid_5348896",Perilipin-1,Homo sapiens, 2733
556085,Nc1ncnc(NCC2CCN(CC2)C(=O)\C=C\CN2CCCC2)c1-c1ccc(Oc2ccccc2)cc1,"InChI=1S/C30H36N6O2/c31-29-28(24-10-12-26(13-11-24)38-25-7-2-1-3-8-25)30(34-22-33-29)32-21-23-14-19-36(20-15-23)27(37)9-6-18-35-16-4-5-17-35/h1-3,6-13,22-23H,4-5,14-21H2,(H3,31,32,33,34)/b9-6+",MPLQKVHLBRTXIK-RMKNXTFCSA-N,291500,"(E)-1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)piperidin-1-yl)-4-(pyrrolidin-1-yl)but-2-en-1-one ::US10413562, Compound A220::US9580449, Example A220",Tyrosine-protein kinase BTK,Homo sapiens,<1000
667284,Cc1c2COC(=O)c2ccc1C(O)CN1CCC2(CC1)CCN(CC2)c1ncc(cn1)C#N,"InChI=1S/C25H29N5O3/c1-17-19(2-3-20-21(17)16-33-23(20)32)22(31)15-29-8-4-25(5-9-29)6-10-30(11-7-25)24-27-13-18(12-26)14-28-24/h2-3,13-14,22,31H,4-11,15-16H2,1H3",JIPOQUOYXJMGGV-UHFFFAOYSA-N,338580,"US9751881, Example 109",ATP-sensitive inward rectifier potassium channel 1,Homo sapiens, 14.5
428499,CCOc1cc(=O)n(C)cc1-c1cc(NC(=O)Cc2cnc(C)s2)ccc1Oc1ccc(F)cc1F,"InChI=1S/C26H23F2N3O4S/c1-4-34-24-12-26(33)31(3)14-20(24)19-10-17(30-25(32)11-18-13-29-15(2)36-18)6-8-22(19)35-23-7-5-16(27)9-21(23)28/h5-10,12-14H,4,11H2,1-3H3,(H,30,32)",ZGQOAYWWKZFUIU-UHFFFAOYSA-N,245819,"US9428514, 7",Bromodomain-containing protein 4 [57-168],,
50605430,O=S(=O)(Nc1nc(NCCc2ccccc2)nc2CCN(Cc3ccccc3)Cc12)c1ccc2ccccc2c1,"InChI=1S/C32H31N5O2S/c38-40(39,28-16-15-26-13-7-8-14-27(26)21-28)36-31-29-23-37(22-25-11-5-2-6-12-25)20-18-30(29)34-32(35-31)33-19-17-24-9-3-1-4-10-24/h1-16,21H,17-20,22-23H2,(H2,33,34,35,36)",MAEKBOFLYVOEBZ-UHFFFAOYSA-N,50329498,"CHEMBL1271447::N-(6-benzyl-2-(phenethylamino)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)naphthalene-2-sulfonamide",Mitogen-activated protein kinase 14,Homo sapiens, 11000
50104333,Cl.NC(=N)Nc1ccc(cc1)-c1cc(no1)C(=O)Nc1ccccc1Br,"InChI=1S/C17H14BrN5O2.ClH/c18-12-3-1-2-4-13(12)22-16(24)14-9-15(25-23-14)10-5-7-11(8-6-10)21-17(19)20;/h1-9H,(H,22,24)(H4,19,20,21);1H",XRRXARWDWYHNSU-UHFFFAOYSA-N,50018989,CHEMBL3287460,Acrosin,Homo sapiens, 27900
51371756,ON(CCc1nnn2cc(ccc12)C#Cc1ccc(CN2CCOCC2)cc1)C=O,"InChI=1S/C22H23N5O3/c28-17-26(29)10-9-21-22-8-7-20(16-27(22)24-23-21)6-3-18-1-4-19(5-2-18)15-25-11-13-30-14-12-25/h1-2,4-5,7-8,16-17,29H,9-15H2",VTUYDMNEYZYBJO-UHFFFAOYSA-N,50554708,CHEMBL4746493,UDP-3-O-acyl-N-acetylglucosamine deacetylase,, 37
393492,COc1cc(nc(NC(C)C)n1)-c1c[nH]c2ccc(cc12)-c1nnc(N)s1,"InChI=1S/C18H19N7OS/c1-9(2)21-18-22-14(7-15(23-18)26-3)12-8-20-13-5-4-10(6-11(12)13)16-24-25-17(19)27-16/h4-9,20H,1-3H3,(H2,19,25)(H,21,22,23)",CYARIWRQUWGCTF-UHFFFAOYSA-N,224942,"US9321756, 202",Serine/threonine-protein kinase pim-3,Homo sapiens, 11.095
667366,FC(F)(F)c1cccnc1CNC(=O)c1ccc(cc1)C1CC1NCC1CC1,"InChI=1S/C21H22F3N3O/c22-21(23,24)17-2-1-9-25-19(17)12-27-20(28)15-7-5-14(6-8-15)16-10-18(16)26-11-13-3-4-13/h1-2,5-9,13,16,18,26H,3-4,10-12H2,(H,27,28)",DAUWTXFNOLKTAP-UHFFFAOYSA-N,338594,"4-(trans-2- ((cyclopropylmethyl)- amino)cyclopropyl)-N-((3- (trifluoromethyl)pyridin- 2-yl)methyl)benzamide bis(trifluoroacetate)::US9751885, 26",Lysine-specific histone demethylase 1A,Homo sapiens,<100.0
50505537,COc1ccc(CC2N(CC(=O)NC3CCc4ccccc34)CCc3cc(OC)c(OC)cc23)cc1F,"InChI=1S/C30H33FN2O4/c1-35-27-11-8-19(14-24(27)31)15-26-23-17-29(37-3)28(36-2)16-21(23)12-13-33(26)18-30(34)32-25-10-9-20-6-4-5-7-22(20)25/h4-8,11,14,16-17,25-26H,9-10,12-13,15,18H2,1-3H3,(H,32,34)",WRMUZKBAXLSEAP-UHFFFAOYSA-N,50292947,"CHEMBL489284::N-(2,3-dihydro-1H-inden-1-yl)-2-(1-(3-fluoro-4-methoxybenzyl)-6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)acetamide",Orexin/Hypocretin receptor type 1,Homo sapiens, 127
1048482,CCC(CC)n1cc(cn1)-c1nc(cn2nccc12)-c1cnn(c1)C1CN(C1)C(=O)CNC,"InChI=1S/C23H29N9O/c1-4-18(5-2)30-12-17(9-27-30)23-21-6-7-25-32(21)15-20(28-23)16-8-26-31(11-16)19-13-29(14-19)22(33)10-24-3/h6-9,11-12,15,18-19,24H,4-5,10,13-14H2,1-3H3",LNIHJHKFYSROAO-UHFFFAOYSA-N,325525,"2-(methylamino)-1-(3-(4-(4-(1-(pentan-3-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl)-1H-pyrazol-1-yl)azetidin-1-yl)ethanone bis(2,2,2-trifluoroacetate)::US10189845, Example 187::US10730880, Example 187::US11028093, Example 187",Tyrosine-protein kinase JAK1,Homo sapiens, 550
714834,C[C@@H]1Cc2c([nH]c3c(F)cccc23)[C@H](N1CC(F)(F)CO)c1c(F)ccc(OCCNCCCF)c1F,,,361468,"3-((1R,3R)-1- (2,6-difluoro- 3-(2-((3- fluoropropyl) amino)ethoxy) phenyl)-8- fluoro-3- methyl- 1,3,4,9- tetrahydro-2H- pyrido[3,4- b]indol-2-yl)- 2,2- difluoropropan-1- ol::US10221173, Example 60::US10590132, Example 60::US11046689, Example 60",Potassium voltage-gated channel subfamily H member 2,Homo sapiens, 4400
50663994,Fc1ccc(cc1)-c1cn(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12,"InChI=1S/C24H26ClFN4O/c25-18-3-6-21-22(17-1-4-19(26)5-2-17)16-30(23(21)15-18)20-7-10-28(11-8-20)13-14-29-12-9-27-24(29)31/h1-6,15-16,20H,7-14H2,(H,27,31)",IXWMONQJSSRIPH-UHFFFAOYSA-N,50001806,1-(2-{4-[6-Chloro-3-(4-fluoro-phenyl)-indol-1-yl]-piperidin-1-yl}-ethyl)-imidazolidin-2-one::CHEMBL422130,5-hydroxytryptamine receptor 2A/2B/2C,Rattus, 1.9
50946353,COc1ccc(CC[C@@H](OC(=O)[C@@H]2CCCCN2S(=O)(=O)c2cc(Cl)c(NC(C)=O)c(Cl)c2)c2cccc(OCCN3CCOCC3)c2)cc1OC,"InChI=1S/C37H45Cl2N3O9S/c1-25(43)40-36-30(38)23-29(24-31(36)39)52(45,46)42-14-5-4-9-32(42)37(44)51-33(12-10-26-11-13-34(47-2)35(21-26)48-3)27-7-6-8-28(22-27)50-20-17-41-15-18-49-19-16-41/h6-8,11,13,21-24,32-33H,4-5,9-10,12,14-20H2,1-3H3,(H,40,43)/t32-,33+/m0/s1",ZSNBYQQLJAZHBE-JHOUSYSJSA-N,50388267,CHEMBL2058797,Peptidyl-prolyl cis-trans isomerase FKBP4,Homo sapiens, 8300
429039,CN1CCC(CC1)NC(=O)c1ccc(Nc2ncc(F)c(n2)-c2cnc(N3CC[C@H](F)C3)c(c2)C#N)cc1,"InChI=1S/C27H28F2N8O/c1-36-9-7-22(8-10-36)33-26(38)17-2-4-21(5-3-17)34-27-32-15-23(29)24(35-27)19-12-18(13-30)25(31-14-19)37-11-6-20(28)16-37/h2-5,12,14-15,20,22H,6-11,16H2,1H3,(H,33,38)(H,32,34,35)/t20-/m0/s1",CGEGCAFAQJHNHO-FQEVSTJZSA-N,245956,"US9433622, DMX- 28",Serine/threonine-protein kinase TBK1,,<15
289829,Fc1cc(ccc1C[C@H](NC(=O)[C@H]1N[C@@H]2CC[C@H]1C2)C#N)-c1cnn(c1)C(=O)C1CCOCC1,"InChI=1S/C25H28FN5O3/c26-22-11-16(19-13-28-31(14-19)25(33)15-5-7-34-8-6-15)1-2-17(22)9-21(12-27)30-24(32)23-18-3-4-20(10-18)29-23/h1-2,11,13-15,18,20-21,23,29H,3-10H2,(H,30,32)/t18-,20+,21-,23-/m0/s1",UAHSBFZVBPGAMM-SQMWVJLWSA-N,150400,"US10238633, Example 74::US8987249, 74::US9713606, 74",Dipeptidyl peptidase 1,, 11.4
50938011,CC(C)=CCc1cc(\C=C\C(O)=O)ccc1OC(=O)CCc1ccccc1,"InChI=1S/C23H24O4/c1-17(2)8-12-20-16-19(10-14-22(24)25)9-13-21(20)27-23(26)15-11-18-6-4-3-5-7-18/h3-10,13-14,16H,11-12,15H2,1-2H3,(H,24,25)/b14-10+",BJIVLGIZOMJQRT-GXDHUFHOSA-N,50384946,CHEMBL511708,Aldo-keto reductase family 1 member C3,Homo sapiens,
50357349,CCCCCN1C(=O)\C(=C\NC2CCCCC2)C(=O)c2cccc(CC)c12,"InChI=1S/C22H36N6O4/c1-2-3-4-5-6-7-8-9-10-11-12-24-21(31)18-16(29)17(30)22(32-18)28-14-27-15-19(23)25-13-26-20(15)28/h13-14,16-18,22,29-30H,2-12H2,1H3,(H,24,31)(H2,23,25,26)/t16?,17?,18-,22+/m0/s1",VDTPBYBUCBOTNQ-PNXXNBOHSA-N,50095862,CHEMBL3590612,Cannabinoid receptor 1,Homo sapiens,
1214146,Cc1nc2ncc(nc2n1Cc1ccc(cc1)S(C)(=O)=O)-c1cn(C)c(=O)c2[nH]ccc12,"InChI=1S/C22H20N6O3S/c1-13-25-20-21(28(13)11-14-4-6-15(7-5-14)32(3,30)31)26-18(10-24-20)17-12-27(2)22(29)19-16(17)8-9-23-19/h4-10,12,23H,11H2,1-3H3",XJEZWOCYIJYKAQ-UHFFFAOYSA-N,576080,"6-methyl-4-(2-methyl-1-(4- (methylsulfonyl)benzyl)-1H- imidazo[4,5-b]pyrazin-6-yl)- 1H-pyrrolo[2,3-c]pyridin-7(6H)- one::US11466034, Example 33",Bromodomain-containing protein 4 [44-167],,<100
50224906,CNc1nc(C)c(s1)-c1nc(Nc2cccc(c2)N2CCCN(CC2)C(C)=O)ncc1C#N,"InChI=1S/C23H26N8OS/c1-15-21(33-23(25-3)27-15)20-17(13-24)14-26-22(29-20)28-18-6-4-7-19(12-18)31-9-5-8-30(10-11-31)16(2)32/h4,6-7,12,14H,5,8-11H2,1-3H3,(H,25,27)(H,26,28,29)",DZHBFQMOLIUZMP-UHFFFAOYSA-N,50431346,CHEMBL2348651,Cyclin-A1/Cyclin-A2/Cyclin-dependent kinase 2,Homo sapiens,
51112442,CCc1nccn1CC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O,"InChI=1S/C13H14ClN3O3S/c1-2-13-16-5-6-17(13)8-11(18)9-3-4-10(14)12(7-9)21(15,19)20/h3-7H,2,8H2,1H3,(H2,15,19,20)",IMQFUBXBYVBNLS-UHFFFAOYSA-N,50454292,CHEMBL4208414,Carbonic anhydrase 7,Homo sapiens,
1110665,CCCn1c2ccccc2[nH]\c1=N/C(=O)c1ccnc(c1)-c1cnn(C)c1,"InChI=1S/C20H20N6O/c1-3-10-26-18-7-5-4-6-16(18)23-20(26)24-19(27)14-8-9-21-17(11-14)15-12-22-25(2)13-15/h4-9,11-13H,3,10H2,1-2H3,(H,23,24,27)",ICVFAOVNIKFBIS-UHFFFAOYSA-N,525431,"US11174245, # I-014","Epidermal growth factor receptor [695-745,751-1022,T790M,C797S]",, 48.8
50168025,COc1cccc(OCC(O)CNC2CCN(CC2)c2ncnc3scc(-c4ccccc4)c23)c1,"InChI=1S/C27H30N4O3S/c1-33-22-8-5-9-23(14-22)34-16-21(32)15-28-20-10-12-31(13-11-20)26-25-24(19-6-3-2-4-7-19)17-35-27(25)30-18-29-26/h2-9,14,17-18,20-21,28,32H,10-13,15-16H2,1H3",LBELPNBKSBOXOB-UHFFFAOYSA-N,50328333,"1-(3-methoxyphenoxy)-3-(1-(5-phenylthieno[2,3-d]pyrimidin-4-yl)piperidin-4-ylamino)propan-2-ol::CHEMBL1258024",Beta-1 adrenergic receptor,Homo sapiens,
166342,COc1cc2n(Cc3cccc(C)c3)cc3c(nnc3c2cc1OC)-c1ccc(F)cc1,"InChI=1S/C26H22FN3O2/c1-16-5-4-6-17(11-16)14-30-15-21-25(18-7-9-19(27)10-8-18)28-29-26(21)20-12-23(31-2)24(32-3)13-22(20)30/h4-13,15H,14H2,1-3H3",NYTUWWIBPCHWPE-UHFFFAOYSA-N,83213,"3-(4-fluorophenyl)-7,8-dimethoxy-5-(3-methylbenzyl)pyrazolo[4,3-c]quinoline::3-(4-fluorophenyl)-7,8-dimethoxy-5-[(3-methylphenyl)methyl]pyrazolo[4,3-c]quinoline::MLS000530102::SMR000127109::cid_2136917",Endoribonuclease toxin MazF,Escherichia coli str. K-12 substr. MG1655,
51050432,CCc1cc2[C@H]3CNC[C@@H]3N(C)C(=O)c2c(c1)C(F)(F)F,"InChI=1S/C15H17F3N2O/c1-3-8-4-9-10-6-19-7-12(10)20(2)14(21)13(9)11(5-8)15(16,17)18/h4-5,10,12,19H,3,6-7H2,1-2H3/t10-,12+/m1/s1",ZNGNYBWMSPSURG-PWSUYJOCSA-N,50428528,CHEMBL2337488,5-hydroxytryptamine receptor 2B,Homo sapiens,
50983546,CCCN(Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1)c1ncnc2cccc(C(=O)OC)c12,"InChI=1S/C27H25N7O2/c1-3-15-34(26-24-22(27(35)36-2)9-6-10-23(24)28-17-29-26)16-18-11-13-19(14-12-18)20-7-4-5-8-21(20)25-30-32-33-31-25/h4-14,17H,3,15-16H2,1-2H3,(H,30,31,32,33)",QVGZPYIJLHJJOG-UHFFFAOYSA-N,50403199,CHEMBL421865,Type-1 angiotensin II receptor,Oryctolagus cuniculus,
51399500,C[C@@H](Nc1ccc2[nH]nc(\C=C\c3ccccn3)c2c1)c1cc(F)cc(F)c1,,,50565310,CHEMBL4792981,"Muscle, skeletal receptor tyrosine-protein kinase",Homo sapiens,
41611,Cc1cc2C(=O)C(=O)Nc2c(C)c1,"InChI=1S/C10H9NO2/c1-5-3-6(2)8-7(4-5)9(12)10(13)11-8/h3-4H,1-2H3,(H,11,12,13)",HFZSCCJTJGWTDZ-UHFFFAOYSA-N,22828,"5,7-dimethyl-2,3-dihydro-1H-indole-2,3-dione::Isatin-based compound, 48",Cholinesterase,Homo sapiens,
380747,O=C(NCCCc1ccccc1)[C@H]1C[C@@H](C1)NC(=O)N1Cc2ccncc2C1,"InChI=1S/C22H26N4O2/c27-21(24-9-4-7-16-5-2-1-3-6-16)18-11-20(12-18)25-22(28)26-14-17-8-10-23-13-19(17)15-26/h1-3,5-6,8,10,13,18,20H,4,7,9,11-12,14-15H2,(H,24,27)(H,25,28)/t18-,20-",RXFBGPRDTVZPAD-KESTWPANSA-N,217293,"US9302989, 1478",Nicotinamide phosphoribosyltransferase,Homo sapiens, 68.2
94778,CCCCCCn1c(=O)[nH]c2nc3cc(N)ccc3nc2c1=O,"InChI=1S/C16H19N5O2/c1-2-3-4-5-8-21-15(22)13-14(20-16(21)23)19-12-9-10(17)6-7-11(12)18-13/h6-7,9H,2-5,8,17H2,1H3,(H,19,20,23)",NVCLSXSHBDFPLR-UHFFFAOYSA-N,51030,"8-amino-3-hexyl-1H-benzo[g]pteridine-2,4-dione::8-amino-3-hexyl-1H-benzo[g]pteridine-2,4-quinone::8-azanyl-3-hexyl-1H-benzo[g]pteridine-2,4-dione::MLS000590527::SMR000217535::cid_5549699",Glycoprotein 42,Human herpesvirus 4 type 2,840.0
51184262,CCOP(=O)(OCC)Oc1ccc(cc1)[N+]([O-])=O,"InChI=1S/C10H14NO6P/c1-3-15-18(14,16-4-2)17-10-7-5-9(6-8-10)11(12)13/h5-8H,3-4H2,1-2H3",WYMSBXTXOHUIGT-UHFFFAOYSA-N,50240416,"CHEMBL23838::O,O-diethyl O-p-nitrophenyl phosphate::diethyl 4-nitrophenyl phosphate::diethyl p-nitrophenyl phosphate::diethyl paraoxon::ethyl paraoxon::p-nitrophenyl diethyl phosphate::paraoxon::phosphacol::phosphoric acid diethyl 4-nitrophenyl ester",Muscarinic acetylcholine receptor DM1,,
50251249,CC(=O)OC[C@H]1OC(NS(=O)(=O)NO)C=C[C@@H]1OC(C)=O,"InChI=1S/C10H16N2O8S/c1-6(13)18-5-9-8(19-7(2)14)3-4-10(20-9)11-21(16,17)12-15/h3-4,8-12,15H,5H2,1-2H3/t8-,9+,10?/m0/s1",AABRCNRVOVLRHF-QIIDTADFSA-N,50035167,CHEMBL3343177,Carbonic anhydrase 9,Homo sapiens,
248012,NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CCc1ccc(cc1)C#Cc1ccccc1,"InChI=1S/C27H29N3O7/c28-26(36)21(13-16-24(32)33)30-27(37)22(14-17-25(34)35)29-23(31)15-12-20-10-8-19(9-11-20)7-6-18-4-2-1-3-5-18/h1-5,8-11,21-22H,12-17H2,(H2,28,36)(H,29,31)(H,30,37)(H,32,33)(H,34,35)/t21-,22-/m0/s1",AVFCHUYQSZAIFE-VXKWHMMOSA-N,120182,"US8691753, 30",Collagenase 3,Homo sapiens,
250965,NC1=N[C@@H](CCC2(CC2)c2cc(F)cc(Cl)c2)CO1,"InChI=1S/C14H16ClFN2O/c15-10-5-9(6-11(16)7-10)14(3-4-14)2-1-12-8-19-13(17)18-12/h5-7,12H,1-4,8H2,(H2,17,18)/t12-/m0/s1",DJHUCZSPXPVGQO-LBPRGKRZSA-N,122384,"US8729113, 143",Trace amine-associated receptor 1,Mus musculus,
1228657,COc1cc(cc2nc(-c3cc4ccc(nc4n3CC3CC3)-c3ccc(cc3)-c3nnn[nH]3)n(C)c12)C(=O)N1CC2CCC1[C@@H]2N,,,583469,"(1R,4R,7R)-2-{2-[1- (cyclopropylmethyl)-6-[4-(1H-1,2,3,4- tetrazol-5-yl)phenyl]-1H-pyrrolo[2,3- b]pyridin-2-yl}-7-methoxy-1-methyl-1H- 1,3-benzodiazole-5-carbonyl}-2- azabicyclo[2.2.1]heptan-7-amine::US11524959, Compound 361.",Protein-arginine deiminase type-4,Homo sapiens, 79.0
50092901,Cc1oc(cc1COc1ccc(cc1)-c1ccc(OC(F)F)cc1)C(=O)NS(=O)(=O)c1ccccc1,"InChI=1S/C26H21F2NO6S/c1-17-20(15-24(34-17)25(30)29-36(31,32)23-5-3-2-4-6-23)16-33-21-11-7-18(8-12-21)19-9-13-22(14-10-19)35-26(27)28/h2-15,26H,16H2,1H3,(H,29,30)",KQRPAOHVFDJWCE-UHFFFAOYSA-N,50012502,CHEMBL3260457,Prostaglandin E2 receptor EP4 subtype,Homo sapiens,
50201218,CCC(C)c1ccc(cc1)-n1nc(C(=O)NN2CCCCC2)c(C)c1-c1ccc(Cl)cc1,"InChI=1S/C26H31ClN4O/c1-4-18(2)20-10-14-23(15-11-20)31-25(21-8-12-22(27)13-9-21)19(3)24(28-31)26(32)29-30-16-6-5-7-17-30/h8-15,18H,4-7,16-17H2,1-3H3,(H,29,32)",OPMDTRSKQCBHDD-UHFFFAOYSA-N,50110958,1-(4-sec-Butyl-phenyl)-5-(4-chloro-phenyl)-4-methyl-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide::CHEMBL32855,Cannabinoid receptor 1,Rattus norvegicus,
1244439,CC(NC(=O)c1ccc(cc1)-c1ccncc1)c1cccc(OCC(=O)Nc2ccc3CCN(C)Cc3c2)c1,"InChI=1S/C32H32N4O3/c1-22(34-32(38)26-8-6-23(7-9-26)25-12-15-33-16-13-25)27-4-3-5-30(19-27)39-21-31(37)35-29-11-10-24-14-17-36(2)20-28(24)18-29/h3-13,15-16,18-19,22H,14,17,20-21H2,1-2H3,(H,34,38)(H,35,37)",KAMNBOLPNOGCJQ-UHFFFAOYSA-N,456953,"US10738007, Compound ID 16::US11555039, Compound ID 16",Rho-associated protein kinase 2,Homo sapiens, 3.60
642203,Fc1cnc(nc1)-c1ccccc1C(=O)N1C2CCC1C(C2)Nc1ncc(cc1F)C(F)(F)F,"InChI=1S/C23H18F5N5O/c24-13-10-30-20(31-11-13)15-3-1-2-4-16(15)22(34)33-14-5-6-19(33)18(8-14)32-21-17(25)7-12(9-29-21)23(26,27)28/h1-4,7,9-11,14,18-19H,5-6,8H2,(H,29,32)",NTVHKKLBSSTWRJ-UHFFFAOYSA-N,326743,"((1S,2R,4R)-2-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-7-azabicyclo[2.2.1]heptan-7-yl)(2-(5-fluoropyrimidin-2-yl)phenyl)methanone::US9637496, 460",Orexin/Hypocretin receptor type 1,Homo sapiens,
50601794,N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O,"InChI=1S/C11H13NO5/c12-8(10(13)14)9(11(15)16)17-6-7-4-2-1-3-5-7/h1-5,8-9H,6,12H2,(H,13,14)(H,15,16)/t8-,9-/m0/s1",BYOBCYXURWDEDS-IUCAKERBSA-N,50093753,"(2S,3S)-2-Amino-3-benzyloxy-succinic acid::(2S,3S)-2-amino-3-(benzyloxy)succinic acid::(3S)-3-(BENZYLOXY)-L-ASPARTIC ACID::CHEMBL79140::DL-TBOA",Excitatory amino acid transporter 3,Homo sapiens, 7000
1245693,CCCOc1cc(ccc1SC)-c1cncc(c1)C1COB(O)C1,"InChI=1S/C18H22BNO3S/c1-3-6-22-17-8-13(4-5-18(17)24-2)14-7-15(11-20-10-14)16-9-19(21)23-12-16/h4-5,7-8,10-11,16,21H,3,6,9,12H2,1-2H3",KGTGEWWRRVKTSZ-UHFFFAOYSA-N,589858,"US11559538, Example 112::US11559538, Example 113::US11559538, Example 114",Interferon gamma receptor 1,, 8.10
50345433,CO[C@H]1[C@@H](CC=CC1=O)OCc1ccccc1,"InChI=1S/C14H16O3/c1-16-14-12(15)8-5-9-13(14)17-10-11-6-3-2-4-7-11/h2-8,13-14H,9-10H2,1H3/t13-,14-/m1/s1",SXTHGTCBVVQWGY-ZIAGYGMSSA-N,50186508,"(5R,6S)-5-(benzyloxy)-6-methoxycyclohex-2-enone::CHEMBL211945",Gamma-secretase subunit APH-1A/Gamma-secretase subunit APH-1B/Gamma-secretase subunit PEN-2/Nicastrin/Presenilin-1/Presenilin-2,Homo sapiens, 26000
50343177,CC(NC(=O)c1ccccc1NC(=O)c1cc2ccccc2[nH]1)C(O)=O,"InChI=1S/C19H17N3O4/c1-11(19(25)26)20-17(23)13-7-3-5-9-15(13)22-18(24)16-10-12-6-2-4-8-14(12)21-16/h2-11,21H,1H3,(H,20,23)(H,22,24)(H,25,26)",GNVBTLURHXQVAD-UHFFFAOYSA-N,50185259,"2(R,S)-{2-[(1H-indole-2-carbonyl)amino]-benzoylamino}propionic acid::2-(R,S)-{2-[(1H-Indole-2-carbonyl)-amino]-benzoylamino}-propionic acid::CHEMBL380355",Cholecystokinin receptor type A,Homo sapiens, 2800
50517170,CC(C)c1onc(c1COc1ccc2n(ccc2c1)S(=O)(=O)c1cccc(c1)C(O)=O)-c1c(Cl)cccc1Cl,"InChI=1S/C28H22Cl2N2O6S/c1-16(2)27-21(26(31-38-27)25-22(29)7-4-8-23(25)30)15-37-19-9-10-24-17(13-19)11-12-32(24)39(35,36)20-6-3-5-18(14-20)28(33)34/h3-14,16H,15H2,1-2H3,(H,33,34)",FLCYQOXMJYAMLK-UHFFFAOYSA-N,50297955,"3-{[5-({[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)-1H-indol-1-yl]sulfonyl}benzoic acid::CHEMBL549310",Bile acid receptor,Homo sapiens,
50796634,O=c1[nH]c(CN2CCCC2)nc2cc(sc12)-c1cn[nH]c1,"InChI=1S/C14H15N5OS/c20-14-13-10(5-11(21-13)9-6-15-16-7-9)17-12(18-14)8-19-3-1-2-4-19/h5-7H,1-4,8H2,(H,15,16)(H,17,18,20)",OFPLMRKDJFHRSH-UHFFFAOYSA-N,50253762,CHEMBL4098392,Cell division cycle 7-related protein kinase/Protein DBF4 homolog A,Homo sapiens, 4.5
736641,Cc1ccc(NC(=O)c2cccc(c2)C(F)(F)F)cc1-c1cc(nc(n1)N1CCOCC1)N1CCS(=O)(=O)CC1,"InChI=1S/C27H28F3N5O4S/c1-18-5-6-21(31-25(36)19-3-2-4-20(15-19)27(28,29)30)16-22(18)23-17-24(34-9-13-40(37,38)14-10-34)33-26(32-23)35-7-11-39-12-8-35/h2-6,15-17H,7-14H2,1H3,(H,31,36)",CASQHERFADFEPM-UHFFFAOYSA-N,202661,"US10245267, Example 6::US10709712, Example 6::US9242969, 6::US9694016, 6",RAF proto-oncogene serine/threonine-protein kinase,Homo sapiens, 0.400
109995,Oc1ccc(Oc2ccc(Oc3ccc(O)cc3)cc2)cc1,"InChI=1S/C18H14O4/c19-13-1-5-15(6-2-13)21-17-9-11-18(12-10-17)22-16-7-3-14(20)4-8-16/h1-12,19-20H",RLSMYIFSFZLJQZ-UHFFFAOYSA-N,53447,"4,4&#39;-[1,4-phenylenebis(oxy)]diphenol::4-[4-(4-hydroxyphenoxy)phenoxy]phenol::4-[4-(4-oxidanylphenoxy)phenoxy]phenol::MLS001162917::O-acyl oxime isatin derivative, 13::SMR000495822::cid_786365",Streptokinase A,Streptococcus pyogenes M1 GAS,
51413991,COc1ccc(cc1)S(=O)(=O)Nc1ccc(cc1)-c1nc2cc(NS(=O)(=O)c3ccc(OC)cc3)ccc2o1,"InChI=1S/C27H23N3O7S2/c1-35-21-8-12-23(13-9-21)38(31,32)29-19-5-3-18(4-6-19)27-28-25-17-20(7-16-26(25)37-27)30-39(33,34)24-14-10-22(36-2)11-15-24/h3-17,29-30H,1-2H3",GJXVVORHVKJGDK-UHFFFAOYSA-N,50501256,CHEMBL3947198,Co-chaperonin GroES,, 30000
50935492,Cc1nc(no1)-c1ccc(OCc2ccc3ccccc3n2)cc1[C@@]1(C[C@H]2CC[C@H]1C2)c1ccccc1,"InChI=1S/C32H29N3O2/c1-21-33-31(35-37-21)28-16-15-27(36-20-26-14-12-23-7-5-6-10-30(23)34-26)18-29(28)32(24-8-3-2-4-9-24)19-22-11-13-25(32)17-22/h2-10,12,14-16,18,22,25H,11,13,17,19-20H2,1H3/t22-,25-,32-/m0/s1",ZBWWCNSJSMVWRX-PBONVNOTSA-N,50383910,CHEMBL2031651,Arachidonate 5-lipoxygenase-activating protein,Homo sapiens, 1.6
50947443,CCCCCCCCCCCCCCCC(NCc1ccc(OC)cc1)=C1C(=O)OC(CO)C1=O,"InChI=1S/C29H45NO5/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-25(27-28(32)26(22-31)35-29(27)33)30-21-23-17-19-24(34-2)20-18-23/h17-20,26,30-31H,3-16,21-22H2,1-2H3",GCVAIVIHGPRFBK-UHFFFAOYSA-N,50388813,CHEMBL2062708,Tyrosine-protein phosphatase non-receptor type 1,Homo sapiens,>100000
50067979,CNC(=O)[C@H](Cc1ccc2ccccc2c1)N1CCN([C@@H](CCCN=C(N)N)C1=O)C(=O)[C@@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccc(O)cc1)NC(C)=O,"InChI=1S/C42H50N8O6/c1-27(51)47-34(24-29-15-18-33(52)19-16-29)38(53)48-35(25-28-9-4-3-5-10-28)40(55)49-21-22-50(41(56)36(49)13-8-20-46-42(43)44)37(39(54)45-2)26-30-14-17-31-11-6-7-12-32(31)23-30/h3-7,9-12,14-19,23,34-37,52H,8,13,20-22,24-26H2,1-2H3,(H,45,54)(H,47,51)(H,48,53)(H4,43,44,46)/t34-,35+,36-,37-/m0/s1",KYOVLZCJSUXUJI-NBRFXYHLSA-N,50189010,(S)-2-[(S)-4-{(R)-2-[(S)-2-acetylamino-3-(4-hydroxy-phenyl)-propionylamino]-3-phenyl-propionyl}-3-(3-guanidino-propyl)-2-oxo-piperazin-1-yl]-N-methyl-3-naphthalen-2-yl-propionamide::CHEMBL379054,Melanocortin receptor 3,,
1143536,CS(=O)(=O)N1CC(CC#N)(C1)n1ncc(n1)-c1cc(cc2ncccc12)-c1ccc(F)cc1O,"InChI=1S/C23H19FN6O3S/c1-34(32,33)29-13-23(14-29,6-7-25)30-27-12-21(28-30)19-9-15(10-20-18(19)3-2-8-26-20)17-5-4-16(24)11-22(17)31/h2-5,8-12,31H,6,13-14H2,1H3",ZXLVTBHGXPJNKX-UHFFFAOYSA-N,539095,"US11254668, Example 441",Tyrosine-protein kinase JAK3,Homo sapiens,>10000
50837113,Cn1cc2c(n1)nc(NC(=O)Nc1ccco1)n1nc(nc21)-c1ccco1,"InChI=1S/C16H12N8O3/c1-23-8-9-12(21-23)19-15(20-16(25)17-11-5-3-7-27-11)24-14(9)18-13(22-24)10-4-2-6-26-10/h2-8H,1H3,(H2,17,19,20,21,25)",JFYMKBXIBSTVJQ-UHFFFAOYSA-N,50183524,"5-[[(2-furyl)amino]carbonyl]amino-8-methyl-2-(2-furyl)-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine::CHEMBL382665",Adenosine receptor A2b,Homo sapiens,>1000
50409086,O=C(Nc1ccc(cc1)S(=O)(=O)Nc1nccs1)C(c1ccccc1)c1ccccc1,"InChI=1S/C23H19N3O3S2/c27-22(21(17-7-3-1-4-8-17)18-9-5-2-6-10-18)25-19-11-13-20(14-12-19)31(28,29)26-23-24-15-16-30-23/h1-16,21H,(H,24,26)(H,25,27)",URSQNPPONHUJDL-UHFFFAOYSA-N,50118516,CHEMBL3617053,Sodium channel protein type 4 subunit alpha,,>10000
286989,C[C@H](NC(C)=O)c1ccc(O[C@@H]2CCN(C2)c2ncnc(OCC3CC(F)(F)C3)c2F)cc1,"InChI=1S/C23H27F3N4O3/c1-14(29-15(2)31)17-3-5-18(6-4-17)33-19-7-8-30(11-19)21-20(24)22(28-13-27-21)32-12-16-9-23(25,26)10-16/h3-6,13-14,16,19H,7-12H2,1-2H3,(H,29,31)/t14-,19+/m0/s1",MBUYZMOFZNFSTD-IFXJQAMLSA-N,148619,"US8962641, 7.43",Acetyl-CoA carboxylase 2,Homo sapiens, 452
50018841,COc1ccc(cc1)[P@](=O)(OCC(F)(F)F)N1Cc2ccccc2C[C@@H]1C(=O)NO,"InChI=1S/C19H20F3N2O5P/c1-28-15-6-8-16(9-7-15)30(27,29-12-19(20,21)22)24-11-14-5-3-2-4-13(14)10-17(24)18(25)23-26/h2-9,17,26H,10-12H2,1H3,(H,23,25)/t17-,30+/m1/s1",DZWVTHAIOWIVNT-ZQHDKMAOSA-N,50291704,"(3-Hydroxycarbamoyl-3,4-dihydro-1H-isoquinolin-2-yl)-(4-methoxy-phenyl)-phosphinic acid 2,2,2-trifluoro-ethyl ester::(R)-((R)-3-Hydroxycarbamoyl-3,4-dihydro-1H-isoquinolin-2-yl)-(4-methoxy-phenyl)-phosphinic acid 2,2,2-trifluoro-ethyl ester::CHEMBL347440",Matrix metalloproteinase-9,Homo sapiens,
50767272,Clc1ccc(COc2ccc(cc2)-c2nn(CCC#N)c(=O)o2)cc1,"InChI=1S/C18H14ClN3O3/c19-15-6-2-13(3-7-15)12-24-16-8-4-14(5-9-16)17-21-22(11-1-10-20)18(23)25-17/h2-9H,1,11-12H2",YPXVVHAGDCBOAE-UHFFFAOYSA-N,50047028,"3-{5-[4-(4-Chloro-benzyloxy)-phenyl]-2-oxo-[1,3,4]oxadiazol-3-yl}-propionitrile::CHEMBL16569",Amine oxidase [flavin-containing] A,Rattus norvegicus, 3300
1006251,COc1cc(Nc2cc(Oc3ccc(NC(=O)Nc4cc(cc(NS(C)(=O)=O)c4OC)C(C)(C)C)c4ccccc34)ccn2)ccc1C(=O)NCCC1CCN(C)CC1,"InChI=1S/C44H53N7O7S/c1-44(2,3)29-24-36(41(57-6)37(25-29)50-59(7,54)55)49-43(53)48-35-14-15-38(33-11-9-8-10-32(33)35)58-31-17-21-45-40(27-31)47-30-12-13-34(39(26-30)56-5)42(52)46-20-16-28-18-22-51(4)23-19-28/h8-15,17,21,24-28,50H,16,18-20,22-23H2,1-7H3,(H,45,47)(H,46,52)(H2,48,49,53)",FSRFRWLXYSIGBM-UHFFFAOYSA-N,298392,"4-[[4-[[4-[[5-tert-Butyl-3-(methanesulfonamido)-2-methoxy-phenyl]carbamoylamino]-1-naphthyl]oxy]-2-pyridyl]amino]-2-methoxy-N-[2-(1-methyl-4-piperidyl)ethyl]benzamide::US10125100, Example 14::US10392346, Example 14::US10941115, Example 14::US9751837, Example 14",Proto-oncogene tyrosine-protein kinase Src,, 19.0
50501219,CN(C)C(=O)Oc1ccc2c(c1)oc(=O)n(Cc1cccc(NS(=O)(=O)NCc3ccccc3)c1F)c2=O,"InChI=1S/C25H23FN4O7S/c1-29(2)24(32)36-18-11-12-19-21(13-18)37-25(33)30(23(19)31)15-17-9-6-10-20(22(17)26)28-38(34,35)27-14-16-7-4-3-5-8-16/h3-13,27-28H,14-15H2,1-2H3",KIWHVDKXYWSISW-UHFFFAOYSA-N,50179529,CHEMBL3814639,Serine/threonine-protein kinase B-raf,Homo sapiens, 1490
51111422,CCCN(CCC)[C@@H]1C=C(C[C@H](N)[C@H]1NC(C)=O)C(O)=O,"InChI=1S/C15H27N3O3/c1-4-6-18(7-5-2)13-9-11(15(20)21)8-12(16)14(13)17-10(3)19/h9,12-14H,4-8,16H2,1-3H3,(H,17,19)(H,20,21)/t12-,13+,14+/m0/s1",MUAKAPZVYKVOTQ-BFHYXJOUSA-N,5232,"(3R,4R,5S)-5-amino-3-(dipropylamino)-4-acetamidocyclohex-1-ene-1-carboxylic acid::C3-Aza Carbocyclic Analogue 3h",Sialidase,Clostridium perfringens, 12
702620,Cc1nc(cc(=O)[nH]1)C(=O)NC1(CCC1)c1ccc(OC(F)(F)F)cc1,"InChI=1S/C17H16F3N3O3/c1-10-21-13(9-14(24)22-10)15(25)23-16(7-2-8-16)11-3-5-12(6-4-11)26-17(18,19)20/h3-6,9H,2,7-8H2,1H3,(H,23,25)(H,21,22,24)",NVNFAHGLGFPVGM-UHFFFAOYSA-N,355178,"2-methyl-6-oxo-N-{1-[4- (trifluoromethyl)phenyl]cyclobutyl}- 1,6-dihydropyrimidine-4-carboxamide::US9815796, Example 269",Phosphodiesterase,,
51235445,COC(=O)N1CCN(CC1)[C@H]1CC[C@@H](CC1)Nc1nc(Nc2cnn(C)c2)nc2ccc(CC#N)nc12,"InChI=1S/C25H32N10O2/c1-33-16-19(15-27-33)30-24-31-21-8-5-18(9-10-26)28-22(21)23(32-24)29-17-3-6-20(7-4-17)34-11-13-35(14-12-34)25(36)37-2/h5,8,15-17,20H,3-4,6-7,9,11-14H2,1-2H3,(H2,29,30,31,32)/t17-,20-",RPGMSHCJIWHISY-IRJFHVNHSA-N,50505743,CHEMBL4582624,Cyclin-dependent kinase 7,Homo sapiens, 17000
363829,CNC(C)C(=O)Nc1cc(cc(NC(=O)c2ccc(Cl)cn2)n1)-c1cccc2cncc(C)c12,"InChI=1S/C25H23ClN6O2/c1-14-11-28-12-16-5-4-6-19(23(14)16)17-9-21(31-24(33)15(2)27-3)30-22(10-17)32-25(34)20-8-7-18(26)13-29-20/h4-13,15,27H,1-3H3,(H2,30,31,32,33,34)",SOZXCUHRCMBRSI-UHFFFAOYSA-N,205407,"US9249151, 53",Baculoviral IAP repeat-containing protein 3 [256-363],sequence, 1
50941658,CC(C)[C@H](NC(=O)c1cc(no1)-c1ccc(NC(=O)Nc2ccccc2C(F)(F)F)cc1)C(O)=O,"InChI=1S/C23H21F3N4O5/c1-12(2)19(21(32)33)29-20(31)18-11-17(30-35-18)13-7-9-14(10-8-13)27-22(34)28-16-6-4-3-5-15(16)23(24,25)26/h3-12,19H,1-2H3,(H,29,31)(H,32,33)(H2,27,28,34)/t19-/m0/s1",QRCCVAUNRPNVIE-IBGZPJMESA-N,50386137,CHEMBL2042339,Chondroitin sulfate N-acetylgalactosaminyltransferase 1,Homo sapiens, 54000
710425,CO[C@H]1C[C@@H](CN(C1)c1ncc(F)cn1)S(=O)(=O)Nc1nnc(-c2cccnc2)n1-c1c(OC)ncnc1OC,"InChI=1S/C23H25FN10O5S/c1-37-16-7-17(12-33(11-16)22-26-9-15(24)10-27-22)40(35,36)32-23-31-30-19(14-5-4-6-25-8-14)34(23)18-20(38-2)28-13-29-21(18)39-3/h4-6,8-10,13,16-17H,7,11-12H2,1-3H3,(H,31,32)/t16-,17-/m0/s1",PAUDZYVLSKBWGA-IRXDYDNUSA-N,360474,"(3S,5S)-N-(4-(4,6-dimethoxy-5-pyrimidinyl)-5-(3-pyridinyl)-4H-1,2,4-triazol-3-yl)-::US10221162, Example 812.0",Apelin receptor,Homo sapiens,
50944942,CC(C)(C)NS(=O)(=O)c1cncc(c1)-c1ccc2nc(N)nn2c1,"InChI=1S/C15H18N6O2S/c1-15(2,3)20-24(22,23)12-6-11(7-17-8-12)10-4-5-13-18-14(16)19-21(13)9-10/h4-9,20H,1-3H3,(H2,16,19)",YKJGGEMOMSRCDT-UHFFFAOYSA-N,50387529,CHEMBL2059909,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform",Homo sapiens, 200
50615958,CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12,"InChI=1S/C12H16N6O4/c1-2-14-11(21)8-6(19)7(20)12(22-8)18-4-17-5-9(13)15-3-16-10(5)18/h3-4,6-8,12,19-20H,2H2,1H3,(H,14,21)(H2,13,15,16)/t6-,7+,8-,12+/m0/s1",JADDQZYHOWSFJD-FLNNQWSLSA-N,21220,"(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-N-ethyl-3,4-dihydroxyoxolane-2-carboxamide::Adenosine analog, 3::Adenosine, N6-Ethyl-carboxamido::Adenosine-5-(N-ethylcarboxamide)::CHEMBL464859::N-Ethylcarboxamidoadenosine::NECA",Adenosine receptor A2a/A2b,Rattus norvegicus,
50896968,Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl,"InChI=1S/C24H25ClFN5O3/c1-2-23(32)30-21-13-17-20(14-22(21)34-9-3-6-31-7-10-33-11-8-31)27-15-28-24(17)29-16-4-5-19(26)18(25)12-16/h2,4-5,12-15H,1,3,6-11H2,(H,30,32)(H,27,28,29)",OMZCMEYTWSXEPZ-UHFFFAOYSA-N,4779,"CHEMBL31965::CHEMBL545315::CI-1033::Canertinib::N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide::PD0183805::US10507209, Compound CI-1033::US9730934, CI-1033::cid_156414",BMP-2-inducible protein kinase,Homo sapiens,
194857,CCN(CC)CCn1c2ccccc2c2cnc(N)c(C#N)c12,"InChI=1S/C18H21N5/c1-3-22(4-2)9-10-23-16-8-6-5-7-13(16)15-12-21-18(20)14(11-19)17(15)23/h5-8,12H,3-4,9-10H2,1-2H3,(H2,20,21)",YEVMYZBKILWGFV-UHFFFAOYSA-N,89185,"3-Amino-5-(2-diethylamino-ethyl)-5H-pyrido[4,3-b]indole-4-carbonitrile::3-amino-5-[2-(diethylamino)ethyl]-4-pyrido[4,3-b]indolecarbonitrile::3-amino-5-[2-(diethylamino)ethyl]pyrid[4,3-b]indole-4-carbonitrile::3-amino-5-[2-(diethylamino)ethyl]pyrido[4,3-b]indole-4-carbonitrile::3-azanyl-5-[2-(diethylamino)ethyl]pyrido[4,3-b]indole-4-carbonitrile::MLS000554093::SMR000146410::US10252984, Table 2.28::cid_946898",DNA (cytosine-5)-methyltransferase 1,,>99000
50866404,OC1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C#N)CC1,"InChI=1S/C21H23N3OS/c22-15-16-6-7-21-19(14-16)24(18-4-1-2-5-20(18)26-21)11-3-10-23-12-8-17(25)9-13-23/h1-2,4-7,14,17,25H,3,8-13H2",LUALIOATIOESLM-UHFFFAOYSA-N,50346422,10-(3-(4-hydroxypiperidin-1-yl)propyl)-10H-phenothiazine-2-carbonitrile::CHEMBL251940::PROPERICIAZINE::periciazine,Androgen receptor,Rattus norvegicus,
302132,Cc1cn(CCCn2c(=S)[nH]c3sc(cc3c2=O)-c2ccccc2)cn1,"InChI=1S/C19H18N4OS2/c1-13-11-22(12-20-13)8-5-9-23-18(24)15-10-16(14-6-3-2-4-7-14)26-17(15)21-19(23)25/h2-4,6-7,10-12H,5,8-9H2,1H3,(H,21,25)",SUEZJTASQILVKW-UHFFFAOYSA-N,159367,"US9034907, 20",Glutaminyl-peptide cyclotransferase,Homo sapiens, 5580
50258808,O=C(CCC(=O)n1sc2ccccc2c1=O)c1cccs1,"InChI=1S/C15H11NO3S2/c17-11(13-6-3-9-20-13)7-8-14(18)16-15(19)10-4-1-2-5-12(10)21-16/h1-6,9H,7-8H2",IRZYVIBRQPMBSG-UHFFFAOYSA-N,50040334,CHEMBL3360059,Caspase-3,Homo sapiens, 235
803958,CCN(CCN(C)c1cccc(n1)C(C)(C)O)C(=O)c1ccccc1-n1cccn1,"InChI=1S/C23H29N5O2/c1-5-27(17-16-26(4)21-13-8-12-20(25-21)23(2,3)30)22(29)18-10-6-7-11-19(18)28-15-9-14-24-28/h6-15,30H,5,16-17H2,1-4H3",VJOHXQPFIPDCJH-UHFFFAOYSA-N,402150,"N-ethyl-N-(2-((6-(2- hydroxypropan-2-yl)pyridin-2- yl)(methyl)amino)ethyl)-2-(1H- pyrazol-1-yl)benzamide::US10011595, I-10",Orexin receptor type 2,Homo sapiens, 93.3
50432545,CC#CCOc1ccc(cc1)S(=O)(=O)CC1(CCN(CC1)S(=O)(=O)C(C)C)C(=O)NO,"InChI=1S/C20H28N2O7S2/c1-4-5-14-29-17-6-8-18(9-7-17)30(25,26)15-20(19(23)21-24)10-12-22(13-11-20)31(27,28)16(2)3/h6-9,16,24H,10-15H2,1-3H3,(H,21,23)",CEVLUPQNDFOYSI-UHFFFAOYSA-N,23500,"4-({[4-(but-2-yn-1-yloxy)benzene]sulfonyl}methyl)-N-hydroxy-1-(propane-2-sulfonyl)piperidine-4-carboxamide::CHEMBL209970::beta-sulfonyl hydroxamate analogue, 4",Interstitial collagenase,, 8780
352961,N#C\C(=C/N1CCC(CC1)c1nnn2cnc3[nH]ccc3c12)c1ccccc1,"InChI=1S/C21H19N7/c22-12-17(15-4-2-1-3-5-15)13-27-10-7-16(8-11-27)19-20-18-6-9-23-21(18)24-14-28(20)26-25-19/h1-6,9,13-14,16,23H,7-8,10-11H2/b17-13+",VOPVUEZBFPSDIH-GHRIWEEISA-N,198433,"US9216999, 230::US9556187, Example 230",Tyrosine-protein kinase JAK3,Homo sapiens,>1000
50205911,O[C@@H](CNCCc1ccc(OC2Cc3ccccc3C2)cc1)c1ccc(O)c(NC=O)c1,"InChI=1S/C26H28N2O4/c29-17-28-24-15-21(7-10-25(24)30)26(31)16-27-12-11-18-5-8-22(9-6-18)32-23-13-19-3-1-2-4-20(19)14-23/h1-10,15,17,23,26-27,30-31H,11-14,16H2,(H,28,29)/t26-/m0/s1",CTLPMPPAPOCJQW-SANMLTNESA-N,50151717,CHEMBL184538::N-[2-Hydroxy-5-(1-hydroxy-2-{2-[4-(indan-2-yloxy)-phenyl]-ethylamino}-ethyl)-phenyl]-formamide,Beta-2 adrenergic receptor,Homo sapiens,
51382822,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13,"InChI=1S/C28H26N4O3/c1-28-26(34-3)17(29-2)12-20(35-28)31-18-10-6-4-8-14(18)22-23-16(13-30-27(23)33)21-15-9-5-7-11-19(15)32(28)25(21)24(22)31/h4-11,17,20,26,29H,12-13H2,1-3H3,(H,30,33)/t17-,20-,26-,28+/m1/s1",HKSZLNNOFSGOKW-FYTWVXJKSA-N,2579,"(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1^{2,6}.0^{7,28}.0^{8,13}.0^{15,19}.0^{20,27}.0^{21,26}]nonacosa-8(13),9,11,14(28),15(19),20(27),21(26),22,24-nonaen-16-one::CHEMBL388978::Staurosporin, 4::Staurosporine::Staurosporine, 8::US9206188, Staurosporine::US9226923, Staurosporine",Inhibitor of nuclear factor kappa-B kinase subunit beta,Homo sapiens, 2.1
51214907,Cc1noc(n1)[C@H]1C[C@@H]1C(=O)NCc1ccc(-c2cccc(OC(F)(F)F)c2)c2CCN(Cc12)C(=O)NC(C)(C)C,"InChI=1S/C29H32F3N5O4/c1-16-34-26(41-36-16)23-13-22(23)25(38)33-14-18-8-9-20(17-6-5-7-19(12-17)40-29(30,31)32)21-10-11-37(15-24(18)21)27(39)35-28(2,3)4/h5-9,12,22-23H,10-11,13-15H2,1-4H3,(H,33,38)(H,35,39)/t22-,23-/m0/s1",XKDFZZUFCHOVRN-GOTSBHOMSA-N,50499290,CHEMBL3734797,Diacylglycerol O-acyltransferase 1,Mus musculus,>10000
50991526,CSCC[C@H]1NC(=O)[C@H](CC(C)C)N2C=CC(NC(=O)[C@H](Cc3ccccc3)N(C)C(=O)C(Cc3c[nH]c4ccccc34)NC(=O)C(CCC(N)=O)NC1=O)C2=O,"InChI=1S/C41H52N8O7S/c1-24(2)20-34-39(54)45-30(17-19-57-4)37(52)44-29(14-15-35(42)50)36(51)47-32(22-26-23-43-28-13-9-8-12-27(26)28)40(55)48(3)33(21-25-10-6-5-7-11-25)38(53)46-31-16-18-49(34)41(31)56/h5-13,16,18,23-24,29-34,43H,14-15,17,19-22H2,1-4H3,(H2,42,50)(H,44,52)(H,45,54)(H,46,53)(H,47,51)/t29?,30-,31?,32?,33+,34+/m1/s1",BSLJSMNNFQAERZ-UUQHSHPSSA-N,50406739,CHEMBL266884,Substance-P receptor,Cavia cutleri,
733202,CN1C(=N)N[C@@]2(C)[C@H](CCCc3ccc(NC(=O)c4cnc(C)cn4)cc23)S1(=O)=O,"InChI=1S/C20H24N6O3S/c1-12-10-23-16(11-22-12)18(27)24-14-8-7-13-5-4-6-17-20(2,15(13)9-14)25-19(21)26(3)30(17,28)29/h7-11,17H,4-6H2,1-3H3,(H2,21,25)(H,24,27)/t17-,20+/m0/s1",WVGQBKGRCZGLLS-FXAWDEMLSA-N,370648,"US10238743, Example 24",Beta-secretase 2,,
50619585,CO\C(O)=C1\C(C(C(=O)OCC(C)C)=C(C)N=C1C)c1ccccc1C(F)(F)F,"InChI=1S/C21H24F3NO4/c1-11(2)10-29-20(27)17-13(4)25-12(3)16(19(26)28-5)18(17)14-8-6-7-9-15(14)21(22,23)24/h6-9,11,18,26H,10H2,1-5H3/b19-16+",DCZKYOPFILCJIP-KNTRCKAVSA-N,50227256,CHEMBL103806,Voltage-dependent L-type calcium channel subunit alpha-1C/alpha-1D/alpha-1F/alpha-1S,Homo sapiens, 0.027000
379476,CCCNC(=O)c1ccc(NC(=O)N2Cc3ccc(Br)cc3C2)cc1,"InChI=1S/C19H20BrN3O2/c1-2-9-21-18(24)13-4-7-17(8-5-13)22-19(25)23-11-14-3-6-16(20)10-15(14)12-23/h3-8,10H,2,9,11-12H2,1H3,(H,21,24)(H,22,25)",BCAUBLUVWFUWHK-UHFFFAOYSA-N,216072,"US9302989, 284",Nicotinamide phosphoribosyltransferase,Homo sapiens, 33.3
51028466,C[C@@H]1CN(CCN1C(=O)OC(C)(C)C)c1ncc(OCc2ccc(cc2)S(C)(=O)=O)cn1,"InChI=1S/C22H30N4O5S/c1-16-14-25(10-11-26(16)21(27)31-22(2,3)4)20-23-12-18(13-24-20)30-15-17-6-8-19(9-7-17)32(5,28)29/h6-9,12-13,16H,10-11,14-15H2,1-5H3/t16-/m1/s1",XEKZYGCNVPYPIU-MRXNPFEDSA-N,50420862,CHEMBL2086661,Glucose-dependent insulinotropic receptor,Mus musculus,
266472,Cc1onc(c1COc1ccc(cn1)C(=O)NCC1(O)CC1)-c1ccccc1,"InChI=1S/C21H21N3O4/c1-14-17(19(24-28-14)15-5-3-2-4-6-15)12-27-18-8-7-16(11-22-18)20(25)23-13-21(26)9-10-21/h2-8,11,26H,9-10,12-13H2,1H3,(H,23,25)",DERLWJKVSFUZRZ-UHFFFAOYSA-N,133505,"US8846719, 194",Gamma-aminobutyric acid receptor subunit alpha-5,Homo sapiens,
50390590,CNC(=O)c1cc(CNc2ncsc2C(=O)Nc2ccc3OC(F)(F)C(F)(F)Oc3c2)ccn1,"InChI=1S/C20H15F4N5O4S/c1-25-17(30)12-6-10(4-5-26-12)8-27-16-15(34-9-28-16)18(31)29-11-2-3-13-14(7-11)33-20(23,24)19(21,22)32-13/h2-7,9,27H,8H2,1H3,(H,25,30)(H,29,31)",BAFNQSRMVYVKQR-UHFFFAOYSA-N,50215787,"4-((5-((2,2,3,3-tetrafluoro-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)carbamoyl)thiazol-4-ylamino)methyl)-N-methylpicolinamide::CHEMBL247434",Mast/stem cell growth factor receptor Kit,, 12
584414,COc1cc(cc2nnn(C)c12)C(CC(O)=O)c1ccc(C)c(CN2C[C@H](C)Oc3ccccc3S2(=O)=O)c1,"InChI=1S/C28H30N4O6S/c1-17-9-10-19(22(14-27(33)34)20-12-23-28(25(13-20)37-4)31(3)30-29-23)11-21(17)16-32-15-18(2)38-24-7-5-6-8-26(24)39(32,35)36/h5-13,18,22H,14-16H2,1-4H3,(H,33,34)/t18-,22?/m0/s1",ZDNGJXBUEQNFBQ-HXBUSHRASA-N,304728,"3-(7-methoxy-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(4-methyl-3-(((S)-4-methyl-1,1-dioxido-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepin-2-yl)methyl)phenyl)propanoic acid::US10144731, Example 14",Nuclear factor erythroid 2-related factor 2,,
794633,Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(Oc2ccnc(Nc3ccc(O)cc3O)n2)c2ccccc12)C(C)(C)C,"InChI=1S/C35H33N7O4/c1-21-9-11-22(12-10-21)42-31(20-30(41-42)35(2,3)4)39-34(45)38-26-15-16-29(25-8-6-5-7-24(25)26)46-32-17-18-36-33(40-32)37-27-14-13-23(43)19-28(27)44/h5-20,43-44H,1-4H3,(H,36,37,40)(H2,38,39,45)",NSYKHTWNGWUTST-UHFFFAOYSA-N,330290,"1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)- 3-(4-((2-((2,4-dihydroxyphenyl)amino) pyrimidin-4-yl)oxy)naphthalen-1-yl)urea::US10238658, Example 32::US10813932, Example 32::US9724347, Example 32::US9993478, Example 32",Glycogen synthase kinase-3 alpha,Homo sapiens,>1620
51158554,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@@H](O)[C@@H]2O,"InChI=1S/C18H24O3/c1-18-7-6-13-12-5-3-11(19)8-10(12)2-4-14(13)15(18)9-16(20)17(18)21/h3,5,8,13-17,19-21H,2,4,6-7,9H2,1H3/t13-,14-,15+,16-,17+,18+/m1/s1",PROQIPRRNZUXQM-ZXXIGWHRSA-N,50410506,ESTRIOL,Corticosteroid-binding globulin,,
50676280,OC(=O)CCCc1ccc(cc1)N(CCCl)CCCl,"InChI=1S/C14H19Cl2NO2/c15-8-10-17(11-9-16)13-6-4-12(5-7-13)2-1-3-14(18)19/h4-7H,1-3,8-11H2,(H,18,19)",JCKYGMPEJWAADB-UHFFFAOYSA-N,50003677,"4-(p-bis(beta-chloroethyl)aminophenyl)butyric acid::4-[p-[bis(2-chloroethyl)amino]phenyl]butyric acid::4-{4-[bis(2-chloroethyl)amino]phenyl}butanoic acid::Ambochlorin::CHEMBL515::CHLORAMBUCIL::Leukeran::N,N-di-2-chloroethyl-gamma-p-aminophenylbutyric acid::chloraminophen::gamma-[p-di(2-chloroethyl)aminophenyl]butyric acid::phenylbutyric acid nitrogen mustard",Carbonic anhydrase 1,Homo sapiens,
544968,O=C(Nc1ccc2occ(CN3CCOCC3)c2c1)c1cnn(Cc2ccccc2)c1,"InChI=1S/C24H24N4O3/c29-24(19-13-25-28(16-19)14-18-4-2-1-3-5-18)26-21-6-7-23-22(12-21)20(17-31-23)15-27-8-10-30-11-9-27/h1-7,12-13,16-17H,8-11,14-15H2,(H,26,29)",FCEFQRNGVCNQCP-UHFFFAOYSA-N,286081,"1-benzyl-N-(3-(morpholinomethyl)benzofuran-5-yl)-1H-pyrazole-4-carboxamide::US10081632, Compound 8::US10758530, Compound 8::US9771366, Compound 8",Ribosomal protein S6 kinase alpha-3,Homo sapiens,>10000
51018978,OC(=O)C1CN(C1)C1CC[C@@]2(C1)Cc1ccccc1Cc1ccccc21,"InChI=1S/C23H25NO2/c25-22(26)19-14-24(15-19)20-9-10-23(13-20)12-18-7-2-1-5-16(18)11-17-6-3-4-8-21(17)23/h1-8,19-20H,9-15H2,(H,25,26)/t20?,23-/m0/s1",CXDSZAINFKAKPN-AKRCKQFNSA-N,50330751,"1-((1S)-5',11'-Dihydrospiro[cyclopentane-1,10'-dibenzo[a,d]-cyclohepten]-3-yl)-3-azetidinecarboxylic Acid::CHEMBL1276948",Histamine H1 receptor,Homo sapiens,
51194165,CCCCCn1cc(C(=O)NC2CCCCC2)c(=O)n2nc(C)cc12,"InChI=1S/C19H28N4O2/c1-3-4-8-11-22-13-16(18(24)20-15-9-6-5-7-10-15)19(25)23-17(22)12-14(2)21-23/h12-13,15H,3-11H2,1-2H3,(H,20,24)",WQNAMSABBJVDIJ-UHFFFAOYSA-N,50491589,CHEMBL2381802,Cannabinoid receptor 2,Homo sapiens,
50649941,N#Cc1cccc(c1)C1(Cc2ccccc2)c2ccccc2-c2nccn12,"InChI=1S/C24H17N3/c25-17-19-9-6-10-20(15-19)24(16-18-7-2-1-3-8-18)22-12-5-4-11-21(22)23-26-13-14-27(23)24/h1-15H,16H2",BXTNFBLUOIHDMG-UHFFFAOYSA-N,50348598,CHEMBL1801323,Neuropeptide S receptor,Homo sapiens, 3166
50546554,CCN(CCCc1c[nH]c2ccc(F)cc12)C1COc2c(F)cc3CCNC(=O)c3c2C1,"InChI=1S/C25H27F2N3O2/c1-2-30(9-3-4-16-13-29-22-6-5-17(26)11-19(16)22)18-12-20-23-15(7-8-28-25(23)31)10-21(27)24(20)32-14-18/h5-6,10-11,13,18,29H,2-4,7-9,12,14H2,1H3,(H,28,31)",BNXCKNFYLODKCG-UHFFFAOYSA-N,50305091,"(+/-)-9-(ethyl(3-(5-fluoro-1H-indol-3-yl)propyl)amino)-6-fluoro-2,3,4,8,9,10-hexahydro-1H-pyrano[2,3-h]isoquinolin-1-one::CHEMBL595055",5-hydroxytryptamine receptor 1A,,
466877,Cc1noc(n1)-c1cc2cc(C)ccc2nc1N1CCC(CC1)NC1CCCC1,"InChI=1S/C23H29N5O/c1-15-7-8-21-17(13-15)14-20(23-24-16(2)27-29-23)22(26-21)28-11-9-19(10-12-28)25-18-5-3-4-6-18/h7-8,13-14,18-19,25H,3-6,9-12H2,1-2H3",KEJMUYFPRIVJCI-UHFFFAOYSA-N,156591,"US10118915, Compound 369::US9682966, 369",Kappa-type opioid receptor,Homo sapiens, 2.00
50368823,CN(CCN(C)Cc1coc2cc(C)c(C)cc2c1=O)Cc1cn(-c2cccc(c2)C(F)(F)F)c2ccccc12,"InChI=1S/C32H32F3N3O2/c1-21-14-28-30(15-22(21)2)40-20-24(31(28)39)18-37(4)13-12-36(3)17-23-19-38(29-11-6-5-10-27(23)29)26-9-7-8-25(16-26)32(33,34)35/h5-11,14-16,19-20H,12-13,17-18H2,1-4H3",JZNXLPPJRFFECJ-UHFFFAOYSA-N,50373071,CHEMBL255489,Tumor necrosis factor,Homo sapiens, 20300
51240104,OC(=O)CNC(=O)c1c(O)c2cc(OC(F)(F)F)cc3OC(Cn(c23)c1=O)c1ccc(cc1)C#N,"InChI=1S/C22H14F3N3O7/c23-22(24,25)35-12-5-13-18-14(6-12)34-15(11-3-1-10(7-26)2-4-11)9-28(18)21(33)17(19(13)31)20(32)27-8-16(29)30/h1-6,15,31H,8-9H2,(H,27,32)(H,29,30)",WKLDLAIFXJRTMG-UHFFFAOYSA-N,50507415,CHEMBL4451025,Egl nine homolog 1,Homo sapiens, 2.0
802249,CC(C)C[C@H](N)[C@](O)(Cc1cc(CC2CCCC2)c(C)cn1)C(O)=O,"InChI=1S/C20H32N2O3/c1-13(2)8-18(21)20(25,19(23)24)11-17-10-16(14(3)12-22-17)9-15-6-4-5-7-15/h10,12-13,15,18,25H,4-9,11,21H2,1-3H3,(H,23,24)/t18-,20+/m0/s1",DHAVNCIMFSRZRO-AZUAARDMSA-N,401391,"US10005762, Example 71",Leucyl-cystinyl aminopeptidase,Homo sapiens, 3.90
50533018,CC[C@@H]1[C@H]2CCC[C@@H]3[C@@H]2[C@@H](CCN3CCOC)CC1=O,"InChI=1S/C17H29NO2/c1-3-13-14-5-4-6-15-17(14)12(11-16(13)19)7-8-18(15)9-10-20-2/h12-15,17H,3-11H2,1-2H3/t12-,13+,14+,15+,17+/m0/s1",GHUMNUGGNLJZGQ-ZAPJKBGESA-N,50204297,CHEMBL3918389,Kappa-type opioid receptor,Homo sapiens,
1237235,CC(=O)N1CCC(CC1)c1cnc(CN2CCN(C[C@H](O)CN3CCc4ccccc4C3)C2=O)cn1,"InChI=1S/C27H36N6O3/c1-20(34)31-10-7-22(8-11-31)26-15-28-24(14-29-26)17-32-12-13-33(27(32)36)19-25(35)18-30-9-6-21-4-2-3-5-23(21)16-30/h2-5,14-15,22,25,35H,6-13,16-19H2,1H3/t25-/m1/s1",WFHWZMJBMBDFTD-RUZDIDTESA-N,588412,"US11542275, Compound 34",Protein arginine N-methyltransferase 5,, 47.0
719038,CCOC(=O)c1cccc(Sc2c(C)n(CC(=O)N3CCC4(CC(C4)C#N)CC3)c3c(F)c(Cl)ccc23)c1,"InChI=1S/C29H29ClFN3O3S/c1-3-37-28(36)20-5-4-6-21(13-20)38-27-18(2)34(26-22(27)7-8-23(30)25(26)31)17-24(35)33-11-9-29(10-12-33)14-19(15-29)16-32/h4-8,13,19H,3,9-12,14-15,17H2,1-2H3",MDOBOSVCJJDXEO-UHFFFAOYSA-N,362952,"3-((6-Chloro-1-(2-(2-cyano-7-azaspiro[3.5]nonan-7-yl)-2-oxoethyl)-7-fluoro-2-methyl-1H-indol-3-yl)thio)benzoic acid ::US9850203, Compound 1-19",Ectonucleotide pyrophosphatase/phosphodiesterase family member 2,,<500
1166239,CC(C)[C@@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@H](Cc1ccc(cc1)-c1ccccc1)C(N)=O)n1nnc(C)c1C,"InChI=1S/C29H36N6O4/c1-17(2)26(35-19(4)18(3)32-33-35)29(39)34-16-23(36)15-25(34)28(38)31-24(27(30)37)14-20-10-12-22(13-11-20)21-8-6-5-7-9-21/h5-13,17,23-26,36H,14-16H2,1-4H3,(H2,30,37)(H,31,38)/t23-,24-,25+,26+/m1/s1",VXLQQFJLYAIHIX-XPGKHFPBSA-N,552722,"(2S,4R)-N-((R)-3-([l,l'-biphenyl]-4-yl)-l-amino-l-oxopropan-2-yl)-l-((S)-2-(4,5-dimethyl-lH-l,2,3-triazol-l-yl)-3-methylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide (Compound 40)::WO2022103411, Compound 40::WO2022103411, Example S37",von Hippel-Lindau disease tumor suppressor,, 1660
51121183,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](CO)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H]2CSSC[C@H](NC(=O)CN)C(=O)N[C@@H](CSSC[C@H](NC1=O)C(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N2,"InChI=1S/C58H92N18O17S5/c1-8-28(4)44-56(91)70-36(45(60)80)22-95-97-25-39-52(87)68-34(20-77)49(84)67-33(17-31-19-61-26-62-31)57(92)75-14-9-11-40(75)53(88)73-43(27(2)3)55(90)72-38(24-98-96-23-37(51(86)71-39)65-42(79)18-59)50(85)64-29(5)46(81)63-30(6)47(82)66-32(13-16-94-7)48(83)69-35(21-78)58(93)76-15-10-12-41(76)54(89)74-44/h19,26-30,32-41,43-44,77-78H,8-18,20-25,59H2,1-7H3,(H2,60,80)(H,61,62)(H,63,81)(H,64,85)(H,65,79)(H,66,82)(H,67,84)(H,68,87)(H,69,83)(H,70,91)(H,71,86)(H,72,90)(H,73,88)(H,74,89)/t28-,29-,30-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,43-,44-/m0/s1",MDBOMZXVBCMPLL-JXBBXVLESA-N,50459659,CHEMBL4214003,Neuronal acetylcholine receptor subunit alpha-3/alpha-6/beta-4,Rattus norvegicus, 178
51276227,NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(cc2)\N=C2/C(=O)N(Cc3ccc(cc3)C#N)c3ccc(Cl)cc23)cc1,"InChI=1S/C29H21ClN6O4S/c30-20-5-14-26-25(15-20)27(28(37)36(26)17-19-3-1-18(16-31)2-4-19)33-21-6-8-22(9-7-21)34-29(38)35-23-10-12-24(13-11-23)41(32,39)40/h1-15H,17H2,(H2,32,39,40)(H2,34,35,38)/b33-27-",KRFLJZFSJJPYKF-KGGMANCPSA-N,50520836,CHEMBL4574077,Carbonic anhydrase 12,Homo sapiens,
1161712,Cc1ccc(cc1-c1cnc(N)c(n1)-c1ccncn1)S(=O)(=O)NC12CC(CO)(C1)C2,"InChI=1S/C21H22N6O3S/c1-13-2-3-14(31(29,30)27-21-8-20(9-21,10-21)11-28)6-15(13)17-7-24-19(22)18(26-17)16-4-5-23-12-25-16/h2-7,12,27-28H,8-11H2,1H3,(H2,22,24)",SJJQHVSOVDIVNY-UHFFFAOYSA-N,550140,"3-(5-Amino-6-(pyrimidin-4-yl)pyrazin- 2-yl)-N-(3- (hydroxymethyl)bicyclo[1.1.1]pentan-1- yl)-4-(methyl-d3)benzenesulfonamide trifluoroacetate salt::US11306079, Example 81","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform",Homo sapiens,<100
590772,CCCCNc1ncc(C(=O)NCc2ccc(nc2)-c2ccccc2OC)c(N[C@H]2CC[C@H](O)CC2)n1,"InChI=1S/C28H36N6O3/c1-3-4-15-29-28-32-18-23(26(34-28)33-20-10-12-21(35)13-11-20)27(36)31-17-19-9-14-24(30-16-19)22-7-5-6-8-25(22)37-2/h5-9,14,16,18,20-21,35H,3-4,10-13,15,17H2,1-2H3,(H,31,36)(H2,29,32,33,34)/t20-,21-",MDBQDUFVZUXGHO-MEMLXQNLSA-N,308156,"US9649309, Compound UNC4255A",Tyrosine-protein kinase receptor TYRO3,Homo sapiens, 336
89943,CCc1cccc(CC)c1N(COC)C(=O)Cn1nnc2ccccc12,"InChI=1S/C20H24N4O2/c1-4-15-9-8-10-16(5-2)20(15)23(14-26-3)19(25)13-24-18-12-7-6-11-17(18)21-22-24/h6-12H,4-5,13-14H2,1-3H3",QSLFSSDBXDHYLA-UHFFFAOYSA-N,47839,"2-(1-benzotriazolyl)-N-(2,6-diethylphenyl)-N-(methoxymethyl)acetamide::2-(benzotriazol-1-yl)-N-(2,6-diethylphenyl)-N-(methoxymethyl)acetamide::2-(benzotriazol-1-yl)-N-(2,6-diethylphenyl)-N-(methoxymethyl)ethanamide::MLS000077552::SMR000037737::cid_661510",3C-like protease,Infectious bronchitis virus, 40505
1025539,CO[C@H](C(=O)Nc1nnc(N[C@@H]2CCN(C2)c2cccnn2)s1)c1cc(OC)cc(OC)c1,"InChI=1S/C21H25N7O4S/c1-30-15-9-13(10-16(11-15)31-2)18(32-3)19(29)24-21-27-26-20(33-21)23-14-6-8-28(12-14)17-5-4-7-22-25-17/h4-5,7,9-11,14,18H,6,8,12H2,1-3H3,(H,23,26)(H,24,27,29)/t14-,18+/m1/s1",MCWGAWNVXRUZFM-KDOFPFPSSA-N,416686,"(2S)-2-(3,5-Dimethoxyphenyl)-2-methoxy-N-[5-[[(3R)-1-pyridazin-3-ylpyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2-yl]acetamide and (2R)-2-(3,5-Dimethoxyphenyl)-2-methoxy-N-[5-[[(3R)-1-pyridazin-3-ylpyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2-yl]acetamide::US10323028, Example 21(a)::US10981904, Example 44","Glutaminase kidney isoform, mitochondrial [63-669]",, 48.2
50404084,CSC[C@H]1CN(Cc2c[nH]c3c(N)ncnc23)C[C@@H]1O,"InChI=1S/C13H19N5OS/c1-20-6-9-4-18(5-10(9)19)3-8-2-15-12-11(8)16-7-17-13(12)14/h2,7,9-10,15,19H,3-6H2,1H3,(H2,14,16,17)/t9-,10+/m1/s1",NTHMDFGHOCNNOE-ZJUUUORDSA-N,22113,"(3R,4S)-1-({4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl}methyl)-4-[(methylsulfanyl)methyl]pyrrolidin-3-ol::(3R,4S)-1-[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]-4-[(methylsulfanyl)methyl]pyrrolidin-3-ol::(3R,4S)-1-[(9-Deazaadenin-9-yl)methyl]-3-hydroxy-4-methylthiomethylpyrrolidine, 7::DADMe-ImmA-Me::MT-DADMe-ImmA",S-methyl-5'-thioadenosine phosphorylase,Homo sapiens,
51375881,COc1cccc2nc(Nc3cccc(NC(=O)c4cc(cc(c4)C(F)(F)F)-n4cnc(C)c4)c3)ccc12,"InChI=1S/C28H22F3N5O2/c1-17-15-36(16-32-17)22-12-18(11-19(13-22)28(29,30)31)27(37)34-21-6-3-5-20(14-21)33-26-10-9-23-24(35-26)7-4-8-25(23)38-2/h3-16H,1-2H3,(H,33,35)(H,34,37)",ICTHETAEMVJBRJ-UHFFFAOYSA-N,50556319,CHEMBL4800457,RAF proto-oncogene serine/threonine-protein kinase,Homo sapiens, 414
50403357,CC[C@H](C)[C@@H]1NC(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](Cc4cnc[nH]4)NC(=O)[C@H](CCCCN)NC3=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N2)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)O)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CCCNC(N)=N,"InChI=1S/C169H274N54O47S7/c1-14-84(5)126-159(263)207-112(70-125(234)235)150(254)221-131(91(12)230)163(267)219-127(85(6)15-2)164(268)223-63-34-47-122(223)158(262)201-98(40-22-26-55-170)136(240)191-86(7)132(236)193-102(44-31-60-186-167(178)179)141(245)212-120-80-275-274-78-118-155(259)198-103(45-32-61-187-168(180)181)137(241)195-101(43-25-29-58-173)144(248)220-130(90(11)229)162(266)215-116(135(239)189-72-124(233)217-128(88(9)227)161(265)216-121(165(269)270)81-277-276-79-119(156(260)218-126)214-153(257)113(73-224)208-134(238)97(174)39-30-59-185-166(176)177)76-272-273-77-117(211-142(246)105(52-53-123(175)232)199-146(250)108(66-92-35-18-16-19-36-92)202-133(237)87(8)192-160(264)129(89(10)228)222-157(120)261)154(258)197-100(42-24-28-57-172)139(243)206-111(69-95-71-184-82-190-95)149(253)210-114(74-225)151(255)200-106(54-64-271-13)143(247)194-99(41-23-27-56-171)138(242)204-110(68-94-48-50-96(231)51-49-94)147(251)196-104(46-33-62-188-169(182)183)140(244)203-107(65-83(3)4)145(249)209-115(75-226)152(256)205-109(148(252)213-118)67-93-37-20-17-21-38-93/h16-21,35-38,48-51,71,82-91,97-122,126-131,224-231H,14-15,22-34,39-47,52-70,72-81,170-174H2,1-13H3,(H2,175,232)(H,184,190)(H,189,239)(H,191,240)(H,192,264)(H,193,236)(H,194,247)(H,195,241)(H,196,251)(H,197,258)(H,198,259)(H,199,250)(H,200,255)(H,201,262)(H,202,237)(H,203,244)(H,204,242)(H,205,256)(H,206,243)(H,207,263)(H,208,238)(H,209,249)(H,210,253)(H,211,246)(H,212,245)(H,213,252)(H,214,257)(H,215,266)(H,216,265)(H,217,233)(H,218,260)(H,219,267)(H,220,248)(H,221,254)(H,222,261)(H,234,235)(H,269,270)(H4,176,177,185)(H4,178,179,186)(H4,180,181,187)(H4,182,183,188)/t84-,85-,86-,87-,88+,89+,90+,91+,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,126-,127-,128-,129-,130-,131-/m0/s1",HXWRRTCVHCEFEO-KSIGKOHTSA-N,50115500,CHEMBL3608999,Potassium voltage-gated channel subfamily A member 1,, 308
50138640,NC(N)=NCCC[C@@H]1C[C@@H](CN1C(=O)[C@@H](Cc1ccccc1)NC(=O)C1CCCCN1)OCc1ccc2ccccc2c1,"InChI=1S/C34H44N6O3/c35-34(36)38-18-8-13-28-21-29(43-23-25-15-16-26-11-4-5-12-27(26)19-25)22-40(28)33(42)31(20-24-9-2-1-3-10-24)39-32(41)30-14-6-7-17-37-30/h1-5,9-12,15-16,19,28-31,37H,6-8,13-14,17-18,20-23H2,(H,39,41)(H4,35,36,38)/t28-,29+,30?,31-/m1/s1",AIBOPTDBFGOAQA-VHBSPPJTSA-N,50191562,"(S)-N-((R)-1-((2R,4S)-2-(3-guanidinopropyl)-4-(naphthalen-2-ylmethoxy)pyrrolidin-1-yl)-1-oxo-3-phenylpropan-2-yl)piperidine-2-carboxamide::CHEMBL210009",Melanocortin receptor 3,,
50403069,CC[C@H](C)[C@@H]1NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](Cc4cnc[nH]4)NC(=O)[C@H](CCCCN)NC3=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N2)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]2CCCN2C1=O)[C@@H](C)O)[C@@H](C)O)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)O,"InChI=1S/C169H275N55O48S7/c1-11-85(4)127-164(270)224-63-32-46-123(224)159(265)202-100(41-21-26-57-173)140(246)210-114(74-226)151(257)196-104(45-31-62-189-169(183)184)141(247)214-121-81-277-276-79-119-156(262)199-102(43-29-60-187-167(179)180)135(241)194-101(42-22-27-58-174)144(250)221-130(89(8)231)162(268)217-117(134(240)190-72-125(235)219-128(87(6)229)161(267)218-122(165(271)272)82-279-278-80-120(216-154(260)113(73-225)209-133(239)96(175)37-28-59-186-166(177)178)157(263)198-99(40-20-25-56-172)138(244)208-112(70-126(236)237)150(256)222-131(90(9)232)163(269)220-127)77-274-275-78-118(213-142(248)105(51-52-124(176)234)200-146(252)108(66-91-33-14-12-15-34-91)203-132(238)86(5)192-160(266)129(88(7)230)223-158(121)264)155(261)197-98(39-19-24-55-171)137(243)207-111(69-94-71-185-83-191-94)149(255)212-115(75-227)152(258)201-106(53-64-273-10)143(249)193-97(38-18-23-54-170)136(242)205-110(68-93-47-49-95(233)50-48-93)147(253)195-103(44-30-61-188-168(181)182)139(245)204-107(65-84(2)3)145(251)211-116(76-228)153(259)206-109(148(254)215-119)67-92-35-16-13-17-36-92/h12-17,33-36,47-50,71,83-90,96-123,127-131,225-233H,11,18-32,37-46,51-70,72-82,170-175H2,1-10H3,(H2,176,234)(H,185,191)(H,190,240)(H,192,266)(H,193,249)(H,194,241)(H,195,253)(H,196,257)(H,197,261)(H,198,263)(H,199,262)(H,200,252)(H,201,258)(H,202,265)(H,203,238)(H,204,245)(H,205,242)(H,206,259)(H,207,243)(H,208,244)(H,209,239)(H,210,246)(H,211,251)(H,212,255)(H,213,248)(H,214,247)(H,215,254)(H,216,260)(H,217,268)(H,218,267)(H,219,235)(H,220,269)(H,221,250)(H,222,256)(H,223,264)(H,236,237)(H,271,272)(H4,177,178,186)(H4,179,180,187)(H4,181,182,188)(H4,183,184,189)/t85-,86-,87+,88+,89+,90+,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,127-,128-,129-,130-,131-/m0/s1",PBQAFRYWKSMSLJ-ZUFWYUKVSA-N,50115816,CHEMBL3609063,Potassium voltage-gated channel subfamily A member 3,Homo sapiens, 153
50981418,CCCCNC(=O)[C@H](C[C@H](O)[C@H](CC1CCCCC1)NC(=O)[C@H](CCCC)N1CCN([C@H](Cc2ccccc2)C1=O)C(=O)N1CCN(C)CC1)C(C)C,"InChI=1S/C42H70N6O5/c1-6-8-20-36(40(51)44-35(28-32-16-12-10-13-17-32)38(49)30-34(31(3)4)39(50)43-21-9-7-2)47-26-27-48(42(53)46-24-22-45(5)23-25-46)37(41(47)52)29-33-18-14-11-15-19-33/h11,14-15,18-19,31-32,34-38,49H,6-10,12-13,16-17,20-30H2,1-5H3,(H,43,50)(H,44,51)/t34-,35+,36+,37-,38+/m1/s1",NGCGSAFHWCZMPV-LDVAZLSXSA-N,50402348,CHEMBL2206678,Candidapepsin-2,Candida albicans,
50474696,Cc1cc(-c2ccc(C=c3c(=C)[nH]n(-c4ccc(cc4)C(O)=O)c3=O)o2)c(cc1C)[N+]([O-])=O,"InChI=1S/C24H19N3O6/c1-13-10-20(21(27(31)32)11-14(13)2)22-9-8-18(33-22)12-19-15(3)25-26(23(19)28)17-6-4-16(5-7-17)24(29)30/h4-12,25H,3H2,1-2H3,(H,29,30)",QZBUMRNGAHPCMI-UHFFFAOYSA-N,50346552,CHEMBL1797936,Histone acetyltransferase p300,Homo sapiens,
965824,C[C@H]1CN(Cc2cnc(n12)[C@@](C)(O)C(F)(F)F)C(=O)c1c(Cl)c(nn1C)-c1ccc(cc1)C#N,"InChI=1S/C22H20ClF3N6O2/c1-12-10-31(11-15-9-28-20(32(12)15)21(2,34)22(24,25)26)19(33)18-16(23)17(29-30(18)3)14-6-4-13(8-27)5-7-14/h4-7,9,12,34H,10-11H2,1-3H3/t12-,21+/m0/s1",BNSMNQFWANUEIK-LAJNKCICSA-N,467050,"US10800784, Example 40","[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial",, 6.00
50643327,O[C@@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]([C@@H]1O)n1ccc(=O)[nH]c1=O,"InChI=1S/C9H15N2O15P3/c12-5-1-2-11(9(15)10-5)8-7(14)6(13)4(24-8)3-23-28(19,20)26-29(21,22)25-27(16,17)18/h1-2,4,6-8,13-14H,3H2,(H,19,20)(H,21,22)(H,10,12,15)(H2,16,17,18)/t4-,6-,7-,8-/m1/s1",PGAVKCOVUIYSFO-XVFCMESISA-N,50118213,5'-UTP::CHEMBL336296::H4utp::UTP::uridine 5'-(tetrahydrogen triphosphate)::uridine 5'-triphosphoric acid,P2Y purinoceptor 4,Homo sapiens,
664548,FC(F)(F)c1cc(Cl)ccc1-c1cnc2nc(COc3ccccn3)cn2c1,"InChI=1S/C19H12ClF3N4O/c20-13-4-5-15(16(7-13)19(21,22)23)12-8-25-18-26-14(10-27(18)9-12)11-28-17-3-1-2-6-24-17/h1-10H,11H2",PYPFACQYDOQFRM-UHFFFAOYSA-N,292290,"US10100057, Example 145::US11046702, Example 145::US9745310, Example 145",Metabotropic glutamate receptor 5,Homo sapiens,
1102689,CN1c2ccccc2C(=O)N(C)c2cnc(Nc3ccc(cc3C)S(N)(=O)=O)nc12,"InChI=1S/C20H20N6O3S/c1-12-10-13(30(21,28)29)8-9-15(12)23-20-22-11-17-18(24-20)25(2)16-7-5-4-6-14(16)19(27)26(17)3/h4-11H,1-3H3,(H2,21,28,29)(H,22,23,24)",ACQZFXBAXXIVCX-UHFFFAOYSA-N,50193025,"CHEMBL3932938::US11155556, No. 18",Aurora kinase A,Homo sapiens, 4850
50797996,NS(=O)(=O)c1ccc(COS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F)cc1,"InChI=1S/C15H8F17NO5S2/c16-8(17,10(20,21)12(24,25)14(28,29)30)9(18,19)11(22,23)13(26,27)15(31,32)40(36,37)38-5-6-1-3-7(4-2-6)39(33,34)35/h1-4H,5H2,(H2,33,34,35)",SXRDAZRGQNDIGS-UHFFFAOYSA-N,50094416,"1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-Heptadecafluoro-octane-1-sulfonic acid 4-sulfamoyl-benzyl ester::CHEMBL342390",Carbonic anhydrase 2,Homo sapiens,
51317316,CC(C)c1c(C)[nH]c2c(cnn2c1=O)C#N,"InChI=1S/C11H12N4O/c1-6(2)9-7(3)14-10-8(4-12)5-13-15(10)11(9)16/h5-6,14H,1-3H3",UHVUUCAAVHIPKM-UHFFFAOYSA-N,191596,"6-isopropyl-5-methyl-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-3-carbonitrile (N8)",Lysine-specific demethylase 5A,Homo sapiens, 24
1116257,COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1nccc(C)c1F,"InChI=1S/C26H26FN5O3/c1-18-10-11-28-22(25(18)27)13-29-26(34)21-16-32(30-23(21)17-35-2)15-20-8-6-19(7-9-20)14-31-12-4-3-5-24(31)33/h3-12,16H,13-15,17H2,1-2H3,(H,29,34)",KORWPMHMESLCMI-UHFFFAOYSA-N,528097,"N-[(3-fluoro-4-methylpyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide::US11180484, Example 28",Kallikrein-1,,>40000
50688357,OC(=O)c1ccc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2F)cc1,"InChI=1S/C25H15ClF2N4O2/c26-15-6-9-17-18(10-15)23(21-19(27)2-1-3-20(21)28)29-11-14-12-30-25(32-22(14)17)31-16-7-4-13(5-8-16)24(33)34/h1-10,12H,11H2,(H,33,34)(H,30,31,32)",HHFBDROWDBDFBR-UHFFFAOYSA-N,31093,"4-[[7-[2,6-bis(fluoranyl)phenyl]-9-chloranyl-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid::4-[[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid::CHEMBL259084::MLN-8054::cid_11712649",MAP kinase-interacting serine/threonine-protein kinase 2,Homo sapiens,
51234882,C[C@H]1SC(N)=N[C@@](C)([C@H]1F)c1cc(NC(=O)c2cnc(OCF)cn2)ccc1F,"InChI=1S/C18H18F3N5O2S/c1-9-15(21)18(2,26-17(22)29-9)11-5-10(3-4-12(11)20)25-16(27)13-6-24-14(7-23-13)28-8-19/h3-7,9,15H,8H2,1-2H3,(H2,22,26)(H,25,27)/t9-,15+,18-/m1/s1",JWJQXZNLFNMIHE-AHRODOEDSA-N,50505569,CHEMBL4557670,Beta-secretase 1,Homo sapiens, 5.0
51041178,O=C(CCCCCCC(=O)N1CCCN(CC1)C1(C(=O)NC(=O)NC1=O)c1ccc(Oc2ccccc2)cc1)N1CCCN(CC1)C1(C(=O)NC(=O)NC1=O)c1ccc(Oc2ccccc2)cc1,"InChI=1S/C50H54N8O10/c59-41(55-27-11-29-57(33-31-55)49(43(61)51-47(65)52-44(49)62)35-19-23-39(24-20-35)67-37-13-5-3-6-14-37)17-9-1-2-10-18-42(60)56-28-12-30-58(34-32-56)50(45(63)53-48(66)54-46(50)64)36-21-25-40(26-22-36)68-38-15-7-4-8-16-38/h3-8,13-16,19-26H,1-2,9-12,17-18,27-34H2,(H2,51,52,61,62,65)(H2,53,54,63,64,66)",WDDBBBHPBMFFCX-UHFFFAOYSA-N,50424983,CHEMBL2311778,Neutrophil collagenase,Homo sapiens, 88
1103179,CN1C(=O)Cc2cc(ccc12)-c1cncc(c1)-c1ccc(=O)n(c1)C1CC1,"InChI=1S/C22H19N3O2/c1-24-20-6-2-14(8-16(20)10-22(24)27)17-9-18(12-23-11-17)15-3-7-21(26)25(13-15)19-4-5-19/h2-3,6-9,11-13,19H,4-5,10H2,1H3",JNHOSPJQAAEXMO-UHFFFAOYSA-N,522102,"US11160797, Example 10",Activin receptor type-1 [172-499],, 410
50325388,Oc1ccccc1Cc1ccc(O)c(Cc2c(O)c(Cc3cc(Cc4ccccc4O)ccc3O)c3O[C@@H](CC(=O)c3c2O)c2ccccc2)c1,"InChI=1S/C43H36O8/c44-34-12-6-4-10-28(34)18-25-14-16-36(46)30(20-25)22-32-41(49)33(23-31-21-26(15-17-37(31)47)19-29-11-5-7-13-35(29)45)43-40(42(32)50)38(48)24-39(51-43)27-8-2-1-3-9-27/h1-17,20-21,39,44-47,49-50H,18-19,22-24H2/t39-/m0/s1",KEKCCRCHJCRAMG-KDXMTYKHSA-N,50079361,CHEMBL3416824,Cell division protein FtsZ,, 8300
642243,CCOC(=O)C1(CC1CCCN(C(=O)OC(C)(C)C)C(=O)OC(C)(C)C)c1cn(cn1)-c1ccccc1Cl,"InChI=1S/C28H38ClN3O6/c1-8-36-23(33)28(22-17-31(18-30-22)21-14-10-9-13-20(21)29)16-19(28)12-11-15-32(24(34)37-26(2,3)4)25(35)38-27(5,6)7/h9-10,13-14,17-19H,8,11-12,15-16H2,1-7H3",DJUGKLDQGDPBHX-UHFFFAOYSA-N,326355,"(1R*,2S*)-2-(3-Aminopropyl)-1-[1-(2-chlorophenyl)-1H-imidazol-4-yl]cyclopropanecarboxylic acid hydrochloride::US9662310, Example 20",Carboxypeptidase B2,Homo sapiens, 140
50231613,COc1cc(COc2ccc3c(NCCN([C@H](CCCCN)C(=O)NO)S3(=O)=O)c2)cc(OC)c1,"InChI=1S/C23H32N4O7S/c1-32-18-11-16(12-19(13-18)33-2)15-34-17-6-7-22-20(14-17)25-9-10-27(35(22,30)31)21(23(28)26-29)5-3-4-8-24/h6-7,11-14,21,25,29H,3-5,8-10,15,24H2,1-2H3,(H,26,28)/t21-/m1/s1",TXFHRXOVMCSUEC-OAQYLSRUSA-N,50127474,"6-Amino-2-[7-(3,5-dimethoxy-benzyloxy)-1,1-dioxo-1,3,4,5-tetrahydro-1lambda*6*-benzo[f][1,2,5]thiadiazepin-2-yl]-hexanoic acid hydroxyamide::CHEMBL51557",Disintegrin and metalloproteinase domain-containing protein 17,,
882842,CNc1cc(Nc2cccn(-c3ccc(C)nc3)c2=O)nc2c(cnn12)C(=O)N[C@H]1CCC[C@@H](C1)OC,"InChI=1S/C26H30N8O3/c1-16-9-10-18(14-28-16)33-11-5-8-21(26(33)36)31-22-13-23(27-2)34-24(32-22)20(15-29-34)25(35)30-17-6-4-7-19(12-17)37-3/h5,8-11,13-15,17,19,27H,4,6-7,12H2,1-3H3,(H,30,35)(H,31,32)/t17-,19-/m0/s1",YMOALRHBPFPIGQ-HKUYNNGSSA-N,424684,"US10508120, Compound I-1188::US10508120, Compound I-1289::US10577373, Compound I-1289::US11046698, Compound I-1289",Non-receptor tyrosine-protein kinase TYK2 [556-888],,
641092,CN(C(=O)\C=C\CN1CCOCC1)c1cccc(c1)-n1c2ncnc(N)c2n(-c2ccc(Oc3ccccc3)cc2)c1=O,"InChI=1S/C32H31N7O4/c1-36(28(40)11-6-16-37-17-19-42-20-18-37)24-7-5-8-25(21-24)39-31-29(30(33)34-22-35-31)38(32(39)41)23-12-14-27(15-13-23)43-26-9-3-2-4-10-26/h2-15,21-22H,16-20H2,1H3,(H2,33,34,35)/b11-6+",HTPUPJRNEVSXMS-IZZDOVSWSA-N,326246,"(E)-N-(3-(6-amino-8-oxo-7-(4-phenoxyphenyl)-7H-purin-9(8H)-yl)phenyl)-N-methyl-4-morpholinobut-2-enamide ::US9637487, Compound 51",Tyrosine-protein kinase BTK,Homo sapiens,<100
538280,CC[C@@H](NC(=O)c1cc(C(=O)NCC(C)(C)C)n2CCOCc12)c1ccccc1,"InChI=1S/C23H31N3O3/c1-5-18(16-9-7-6-8-10-16)25-21(27)17-13-19(22(28)24-15-23(2,3)4)26-11-12-29-14-20(17)26/h6-10,13,18H,5,11-12,14-15H2,1-4H3,(H,24,28)(H,25,27)/t18-/m1/s1",WDMAWULCCSIVDZ-GOSISDBHSA-N,218432,"US9284333, 16go::US9884860, Example 16go",Potassium channel subfamily K member 3,, 900
50717443,OC(=O)Cn1nnc(n1)-c1cc(OCCCOc2cc(F)ccc2Br)no1,"InChI=1S/C15H13BrFN5O5/c16-10-3-2-9(17)6-11(10)25-4-1-5-26-13-7-12(27-20-13)15-18-21-22(19-15)8-14(23)24/h2-3,6-7H,1,4-5,8H2,(H,23,24)",PDACCUWRIROUSQ-UHFFFAOYSA-N,50364036,CHEMBL1950546,Acyl-CoA (8-3)-desaturase,Homo sapiens,>20000
50401957,OC[C@@H](N1CCCn2cc(cc2C1=O)-c1ccnc(NC2CCOCC2)n1)c1ccccc1,"InChI=1S/C25H29N5O3/c31-17-23(18-5-2-1-3-6-18)30-12-4-11-29-16-19(15-22(29)24(30)32)21-7-10-26-25(28-21)27-20-8-13-33-14-9-20/h1-3,5-7,10,15-16,20,23,31H,4,8-9,11-14,17H2,(H,26,27,28)/t23-/m1/s1",QGLYANQKQKONGT-HSZRJFAPSA-N,50115397,CHEMBL3608462,Mitogen-activated protein kinase 1,Homo sapiens, 0.033000
50270550,CCCCc1c(C)n(oc1=O)C(=O)N1CCC(C)CC1,"InChI=1S/C15H24N2O3/c1-4-5-6-13-12(3)17(20-14(13)18)15(19)16-9-7-11(2)8-10-16/h11H,4-10H2,1-3H3",RZMSVANUOWXIML-UHFFFAOYSA-N,50147299,4-Butyl-3-methyl-2-(4-methyl-piperidine-1-carbonyl)-2H-isoxazol-5-one::4-butyl-3-methyl-2-(4-methylpiperidine-1-carbonyl)isoxazol-5(2H)-one::CHEMBL322794,Hormone-sensitive lipase,Homo sapiens, 10
50753015,CC(C)CCNC(=O)[C@@H](NC(=O)[C@@H](CC(=O)[C@@H](N)CC(C)C)Cc1ccccc1)C(C)C,"InChI=1S/C26H43N3O3/c1-17(2)12-13-28-26(32)24(19(5)6)29-25(31)21(15-20-10-8-7-9-11-20)16-23(30)22(27)14-18(3)4/h7-11,17-19,21-22,24H,12-16,27H2,1-6H3,(H,28,32)(H,29,31)/t21-,22+,24+/m1/s1",QZUXJQWIIVGFJI-GPXNEJASSA-N,50017472,5-Amino-2-benzyl-7-methyl-4-oxo-octanoic acid [2-methyl-1-(3-methyl-butylcarbamoyl)-propyl]-amide::CHEMBL284714,Leucyl-cystinyl aminopeptidase,Rattus norvegicus,>500000
50904138,NS(=O)(=O)Cc1noc2ccccc12,"InChI=1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12)",UBQNRHZMVUUOMG-UHFFFAOYSA-N,10888,"1,2-benzoxazol-3-ylmethanesulfonamide::CHEMBL750::SPR_2::US10172837, Zonisamide::Zonisamide::Zonisamide (ZNA)::Zonisamide (ZNS)::Zonisamide, 1::Zonisamide, ZNS","Carbonic anhydrase 5A, mitochondrial",Homo sapiens,
476095,Clc1cc(Nc2cc(NC(=O)C3CC3)ncn2)c(=O)n2c1C(=O)NC21CCCC1,"InChI=1S/C19H19ClN6O3/c20-11-7-12(18(29)26-15(11)17(28)25-19(26)5-1-2-6-19)23-13-8-14(22-9-21-13)24-16(27)10-3-4-10/h7-10H,1-6H2,(H,25,28)(H2,21,22,23,24,27)",QGCZTCRYEXQLPN-UHFFFAOYSA-N,168207,"US9669031, 38 N-[6-[(8-chloro-1,5-dioxo-spiro[2H-imidazo[1,5-a]pyridine-3,1&#8242;-cyclopentane]-6-yl)amino]pyrimidin-4-yl]cyclopropanecarboxamide (Cpd. No. 38)",MAP kinase-interacting serine/threonine-protein kinase 2,Homo sapiens,<10.00
51050282,NS(=O)(=O)c1cccc(c1)-n1nc(CO)cc1-c1ccc2ccccc2c1,"InChI=1S/C20H17N3O3S/c21-27(25,26)19-7-3-6-18(12-19)23-20(11-17(13-24)22-23)16-9-8-14-4-1-2-5-15(14)10-16/h1-12,24H,13H2,(H2,21,25,26)",AUOCTKBTMUGTFR-UHFFFAOYSA-N,50428501,CHEMBL2336617,Carbonic anhydrase 2,Homo sapiens,
50923485,CC(C)(C)c1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1,"InChI=1S/C24H29N3O2/c1-24(2,3)23-20(19-6-4-5-7-21(19)26-23)14-15-25-16-18-10-8-17(9-11-18)12-13-22(28)27-29/h4-13,25-26,29H,14-16H2,1-3H3,(H,27,28)/b13-12+",OBWNLXZLIGARLU-OUKQBFOZSA-N,50350820,CHEMBL1819260,Histone deacetylase 1,Homo sapiens, 2
51154105,CCCCNc1nc(N)c2ncn(C3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1,"InChI=1S/C14H22N6O4/c1-2-3-4-16-14-18-11(15)8-12(19-14)20(6-17-8)13-10(23)9(22)7(5-21)24-13/h6-7,9-10,13,21-23H,2-5H2,1H3,(H3,15,16,18,19)/t7-,9-,10-,13?/m1/s1",LJWLPFCQLKDNTR-RJNFYWFKSA-N,50472932,CHEMBL610670,Phosphoglycerate kinase 1,, 1500000
50764602,OC(=O)CCCc1cc2cc(ccc2n1S(=O)(=O)c1cccc(Cl)c1)C(F)(F)F,"InChI=1S/C19H15ClF3NO4S/c20-14-3-1-5-16(11-14)29(27,28)24-15(4-2-6-18(25)26)10-12-9-13(19(21,22)23)7-8-17(12)24/h1,3,5,7-11H,2,4,6H2,(H,25,26)",XNTWWHKKRVWSRT-UHFFFAOYSA-N,50244325,CHEMBL4067479,Peroxisome proliferator-activated receptor alpha,,
1032958,CC(C)(C)NC(=O)C(N(Cc1ccccc1Cl)C(=O)C=C)c1cncc2ccccc12,"InChI=1S/C25H26ClN3O2/c1-5-22(30)29(16-18-11-7-9-13-21(18)26)23(24(31)28-25(2,3)4)20-15-27-14-17-10-6-8-12-19(17)20/h5-15,23H,1,16H2,2-4H3,(H,28,31)",ZEBJZJBLIFBLIX-UHFFFAOYSA-N,496397,NIR-WEI-f9286bb6-4,Replicase polyprotein 1ab,, 99500
1079934,CC(C)[C@H](N)C(=O)N1Cc2ccc(F)cc2[C@H]1B(O)O,"InChI=1S/C13H18BFN2O3/c1-7(2)11(16)13(18)17-6-8-3-4-9(15)5-10(8)12(17)14(19)20/h3-5,7,11-12,19-20H,6,16H2,1-2H3/t11-,12-/m0/s1",FCIDEQNVBVMFSV-RYUDHWBXSA-N,514541,"US11096924, DASH-inhibitors 5321",Dipeptidyl peptidase 4,Homo sapiens, 20270000
51676,CNCCNC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1c(C)nc2c(N)ncnc12,"InChI=1S/C14H23N7O3/c1-7-20-9-12(15)18-6-19-13(9)21(7)14-11(23)10(22)8(24-14)5-17-4-3-16-2/h6,8,10-11,14,16-17,22-23H,3-5H2,1-2H3,(H2,15,18,19)/t8-,10-,11-,14-/m1/s1",WOZXSUBFHZHWHJ-IDTAVKCVSA-N,28447,"(2R,3R,4S,5R)-2-(6-amino-8-methyl-9H-purin-9-yl)-5-({[2-(methylamino)ethyl]amino}methyl)oxolane-3,4-diol::AdoMet substrate analogue, 19d",S-adenosylmethionine decarboxylase proenzyme,Homo sapiens,
50155430,COC(=O)c1ccc2ccccc2c1CCCn1cnc2C(O)CNC=Nc12,"InChI=1S/C21H22N4O3/c1-28-21(27)17-9-8-14-5-2-3-6-15(14)16(17)7-4-10-25-13-24-19-18(26)11-22-12-23-20(19)25/h2-3,5-6,8-9,12-13,18,26H,4,7,10-11H2,1H3,(H,22,23)",MIKPTUCVJMIOKY-UHFFFAOYSA-N,50087358,"1-[3-(8-Hydroxy-7,8-dihydro-6H-imidazo[4,5-d][1,3]diazepin-3-yl)-propyl]-naphthalene-2-carboxylic acid methyl ester (1.0H2O)::CHEMBL37181",Adenosine deaminase,Bos taurus,
50194303,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,"InChI=1S/C30H29ClN6O3/c1-4-39-28-16-25-23(15-26(28)36-29(38)9-7-13-37(2)3)30(20(17-32)18-34-25)35-21-10-11-27(24(31)14-21)40-19-22-8-5-6-12-33-22/h5-12,14-16,18H,4,13,19H2,1-3H3,(H,34,35)(H,36,38)/b9-7+",JWNPDZNEKVCWMY-VQHVLOKHSA-N,50161957,"4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(pyridin-2-ylmethoxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide::CHEMBL180022::HKI-272::N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide::N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)butanamide::NERATINIB::US10822334, Compound Neratinib",Serine/threonine-protein kinase 17A,Homo sapiens,
51005166,Cc1ccc2c(cccc2n1)-c1nnc(SCCCN2CCc3cc4nc(oc4cc3CC2)C(C)(F)F)n1C,"InChI=1S/C29H30F2N6OS/c1-18-8-9-21-22(6-4-7-23(21)32-18)26-34-35-28(36(26)3)39-15-5-12-37-13-10-19-16-24-25(17-20(19)11-14-37)38-27(33-24)29(2,30)31/h4,6-9,16-17H,5,10-15H2,1-3H3",MMAVGOXTOMTHGO-UHFFFAOYSA-N,50411696,CHEMBL256473,D(3) dopamine receptor,,
547568,CNC(=O)c1n[nH]c2cc(nc(NCc3ccccc3N(C)S(=O)(=O)c3cccnc3)c12)-c1cc(F)c(O)cc1CC(F)(F)F,"InChI=1S/C29H25F4N7O4S/c1-34-28(42)26-25-22(38-39-26)12-21(19-11-20(30)24(41)10-17(19)13-29(31,32)33)37-27(25)36-14-16-6-3-4-8-23(16)40(2)45(43,44)18-7-5-9-35-15-18/h3-12,15,41H,13-14H2,1-2H3,(H,34,42)(H,36,37)(H,38,39)",BBQPXRWWGFVMOX-UHFFFAOYSA-N,281433,"6-[5-fluoro-4-hydroxy-2-(2,2,2-trifluoroeth-yl)phenyl]-N-methyl-4-({2-[methyl(pyridin-3-ylsulfonyl)amino]-benzyl}amino)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide::US10022376, Example 68",Tyrosine-protein kinase JAK1,Homo sapiens, 14.2
899064,COCCN1C[C@@H](NC(=O)Nc2c(C)c(nn2-c2ccccc2)-c2cnc3nn(cc3c2)C(F)F)[C@@H](O1)c1ccnc(F)c1,"InChI=1S/C29H28F3N9O3/c1-17-24(19-12-20-15-40(28(31)32)38-26(20)34-14-19)37-41(21-6-4-3-5-7-21)27(17)36-29(42)35-22-16-39(10-11-43-2)44-25(22)18-8-9-33-23(30)13-18/h3-9,12-15,22,25,28H,10-11,16H2,1-2H3,(H2,35,36,42)/t22-,25+/m1/s1",CFQGSDAMSGALLU-RDGATRHJSA-N,441377,"US10640495, Example I-331",High affinity nerve growth factor receptor,,<100
50265748,CCS(=O)(=O)c1ccc(CC(=O)Nc2ccc(c(Oc3ccccc3)c2)-c2ccccc2)cc1,"InChI=1S/C28H25NO4S/c1-2-34(31,32)25-16-13-21(14-17-25)19-28(30)29-23-15-18-26(22-9-5-3-6-10-22)27(20-23)33-24-11-7-4-8-12-24/h3-18,20H,2,19H2,1H3,(H,29,30)",JXWFLWDGAISEOG-UHFFFAOYSA-N,50044242,CHEMBL3314040,Nuclear receptor ROR-gamma,,
149616,Cc1cc(C)cc(c1)-n1c(O)cc(Sc2nnnn2-c2ccccc2)c1O,"InChI=1S/C19H17N5O2S/c1-12-8-13(2)10-15(9-12)23-17(25)11-16(18(23)26)27-19-20-21-22-24(19)14-6-4-3-5-7-14/h3-11,25-26H,1-2H3",XRBPTHIBDCAODP-UHFFFAOYSA-N,51326,"1-(3,5-dimethylphenyl)-3-(1-phenyltetrazol-5-yl)sulfanylpyrrolidine-2,5-dione::1-(3,5-dimethylphenyl)-3-[(1-phenyl-1,2,3,4-tetrazol-5-yl)sulfanyl]pyrrolidine-2,5-dione::1-(3,5-dimethylphenyl)-3-[(1-phenyl-1H-tetrazol-5-yl)thio]-2,5-pyrrolidinedione::1-(3,5-dimethylphenyl)-3-[(1-phenyl-5-tetrazolyl)thio]pyrrolidine-2,5-dione::1-(3,5-dimethylphenyl)-3-[(1-phenyltetrazol-5-yl)thio]pyrrolidine-2,5-quinone::MLS000576813::SMR000198093::cid_2936558",Beta-galactosidase,Escherichia coli,>66600
1050391,CN(C)c1ccc(nc1)[C@@H](NC(=O)c1ccc(Cl)c(Cl)c1)c1ccccc1,"InChI=1S/C21H19Cl2N3O/c1-26(2)16-9-11-19(24-13-16)20(14-6-4-3-5-7-14)25-21(27)15-8-10-17(22)18(23)12-15/h3-13,20H,1-2H3,(H,25,27)/t20-/m0/s1",KWXVNLHPBOREHH-FQEVSTJZSA-N,399204,"US10323029, Generic formula 52397 IB::US11034691, CYM generic formula 52397 IB",Sphingosine 1-phosphate receptor 2,Homo sapiens, 30800
1180314,CC(=C)C#Cc1ccc2OC[C@H](NC(=O)c3n[nH]c(Cc4ccccc4)n3)C(=O)Nc2c1,"InChI=1S/C24H21N5O3/c1-15(2)8-9-17-10-11-20-18(12-17)25-23(30)19(14-32-20)26-24(31)22-27-21(28-29-22)13-16-6-4-3-5-7-16/h3-7,10-12,19H,1,13-14H2,2H3,(H,25,30)(H,26,31)(H,27,28,29)/t19-/m0/s1",AZYKXMRRNCAORK-IBGZPJMESA-N,554435,"US11332451, Compound I-93::US11370764, Compound I-93::US11377428, Compound I-93",Receptor-interacting serine/threonine-protein kinase 1,, 64.1
51303458,OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21,"InChI=1S/C19H12ClN3O2/c20-12-2-1-3-13(9-12)22-18-15-6-7-21-10-16(15)14-5-4-11(19(24)25)8-17(14)23-18/h1-10H,(H,22,23)(H,24,25)",MUOKSQABCJCOPU-UHFFFAOYSA-N,50335638,"5-(3-Chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid::5-[(3-chlorophenyl)amino]benzo[c][2,6]naphthyridine-8-carboxylic acid::CHEMBL1230165::US9062043, Table 13, Compound 17::US9062043, Table 20b, Compound 12",Dual specificity protein kinase CLK2,Homo sapiens, 4.0
986864,Nc1ncnc2n(nc(CCc3ccccc3)c12)[C@@H]1O[C@H](COS(N)(=O)=O)[C@@H](O)[C@H]1O,"InChI=1S/C18H22N6O6S/c19-16-13-11(7-6-10-4-2-1-3-5-10)23-24(17(13)22-9-21-16)18-15(26)14(25)12(30-18)8-29-31(20,27)28/h1-5,9,12,14-15,18,25-26H,6-8H2,(H2,19,21,22)(H2,20,27,28)/t12-,14-,15-,18-/m1/s1",WEYQHDMGURKOGT-SCFUHWHPSA-N,475953,"US10865208, Compound I-12::{(2R,3S,4R,5R)-5-[4-amino-3-(2-phenylethyl)-1H-pyrazolo[3,4-d]pyrimidin-1- yl]-3,4-dihydroxytetrahydrofuran-2-yl}methyl sulfamate",Ubiquitin-like modifier-activating enzyme ATG7,Homo sapiens, 300
50426138,COc1ccc(cc1)-n1c(CCN(C(C)=O)C(C)=O)nc2ccc(Cl)cc2c1=O,"InChI=1S/C21H20ClN3O4/c1-13(26)24(14(2)27)11-10-20-23-19-9-4-15(22)12-18(19)21(28)25(20)16-5-7-17(29-3)8-6-16/h4-9,12H,10-11H2,1-3H3",RHVYQKLXLYKYHP-UHFFFAOYSA-N,50125990,CHEMBL3627809,"cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A",Homo sapiens,
1006907,Cn1cc(-c2cc(OS(N)=O)ccc2OCC2CC2)c2ccccc2c1=O,"InChI=1S/C20H20N2O4S/c1-22-11-18(15-4-2-3-5-16(15)20(22)23)17-10-14(26-27(21)24)8-9-19(17)25-12-13-6-7-13/h2-5,8-11,13H,6-7,12,21H2,1H3",OZYJWMPTVPBDNQ-UHFFFAOYSA-N,486013,"US10941160, Example 214::[4-(cyclopropylmethoxy)-3-(2-methyl-1- oxoisoquinolin-4-yl)phenyl]sulfamate",Bromodomain-containing protein 4,,<500
50349262,Cc1cccc(C)c1Nc1ccc(cc1S(=O)(=O)NC(=O)NC(C)(C)C)[N+]([O-])=O,"InChI=1S/C19H24N4O5S/c1-12-7-6-8-13(2)17(12)20-15-10-9-14(23(25)26)11-16(15)29(27,28)22-18(24)21-19(3,4)5/h6-11,20H,1-5H3,(H2,21,22,24)",NHHSZFFUNUCPFW-UHFFFAOYSA-N,50188608,"CHEMBL209306::N-tert-butyl-N'-[2-(2,6-dimethylphenylamino)-5-nitrobenzenesulfonyl]urea",Thromboxane A2 receptor,, 90
458059,COc1nnc(cc1N1CCOCC1)-c1cc(NC(=O)c2cnnc(c2)C(F)(F)F)ccc1C,"InChI=1S/C22H21F3N6O3/c1-13-3-4-15(27-20(32)14-9-19(22(23,24)25)29-26-12-14)10-16(13)17-11-18(21(33-2)30-28-17)31-5-7-34-8-6-31/h3-4,9-12H,5-8H2,1-2H3,(H,27,32)",UFSSCDAODYJAIS-UHFFFAOYSA-N,81286,"US10245267, Example 554::US10709712, Example 554::US9694016, 551::US9694016, 554",Serine/threonine-protein kinase B-raf [V600E],, 1.20
50441108,CC(CCOC(=O)NCCCc1ccccc1)N(C)C,"InChI=1S/C16H26N2O2/c1-14(18(2)3)11-13-20-16(19)17-12-7-10-15-8-5-4-6-9-15/h4-6,8-9,14H,7,10-13H2,1-3H3,(H,17,19)",CLNHOZKBDJOIQN-UHFFFAOYSA-N,50254543,3-(dimethylamino)butyl 3-phenylpropylcarbamate::CHEMBL448084,Neuronal acetylcholine receptor subunit alpha-3,Homo sapiens,
50287404,COc1cc(cc(OC)c1OC)C(=O)Nc1ccc(cc1N)-c1cc(F)cc(F)c1,"InChI=1S/C22H20F2N2O4/c1-28-19-9-14(10-20(29-2)21(19)30-3)22(27)26-18-5-4-12(8-17(18)25)13-6-15(23)11-16(24)7-13/h4-11H,25H2,1-3H3,(H,26,27)",NNUDZSBFWBBRKN-UHFFFAOYSA-N,50056311,CHEMBL3317935,Multidrug resistance-associated protein 1,, 15800
51106957,Cc1cc(C)c2cc(ccc2n1)C(=O)NC1CN(C1)c1cc(Cl)nc(Cl)c1,"InChI=1S/C20H18Cl2N4O/c1-11-5-12(2)23-17-4-3-13(6-16(11)17)20(27)24-14-9-26(10-14)15-7-18(21)25-19(22)8-15/h3-8,14H,9-10H2,1-2H3,(H,24,27)",RVJSGPVQCUHCBT-UHFFFAOYSA-N,50451548,CHEMBL4210986,Muscarinic acetylcholine receptor M4,Rattus,
50823226,CC[C@@H](CO)Nc1ccc2ncc(-c3ccnc(SC)n3)n2n1,"InChI=1S/C15H18N6OS/c1-3-10(9-22)18-13-4-5-14-17-8-12(21(14)20-13)11-6-7-16-15(19-11)23-2/h4-8,10,22H,3,9H2,1-2H3,(H,18,20)/t10-/m0/s1",HHTIJHCFCZBRNC-JTQLQIEISA-N,50259474,CHEMBL4092047,Dual specificity protein kinase CLK4,Mus musculus, 310
66154,CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C,"InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-",WINHZLLDWRZWRT-ATVHPVEESA-N,4814,"CHEMBL535::N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide::N-[2-(diethylamino)ethyl]-5-{[(3Z)-5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene]methyl}-2,4-dimethyl-1H-pyrrole-3-carboxamide::SU11248::SUNITINIB::SUNITINIB MALATE::US10464902, Sunitinib::US9163010, Sunitinib::US9914707, SU11248",Cyclin-dependent kinase 17,Homo sapiens,
621041,O=C1NCCOCCOc2cc(ccn2)-c2csc(n2)C(=O)Nc2cn(nc12)C1CCOCC1,"InChI=1S/C22H24N6O5S/c29-20-19-16(12-28(27-19)15-2-6-31-7-3-15)25-21(30)22-26-17(13-34-22)14-1-4-23-18(11-14)33-10-9-32-8-5-24-20/h1,4,11-13,15H,2-3,5-10H2,(H,24,29)(H,25,30)",HTFJTAOBXRINCN-UHFFFAOYSA-N,317438,"US9617282, Example 214",Interleukin-1 receptor-associated kinase 4,Homo sapiens,<1000
50103383,CCCCCCC#Cc1nc(N)c2nc(-n3nccn3)n(CC#C)c2n1,"InChI=1S/C18H20N8/c1-3-5-6-7-8-9-10-14-22-16(19)15-17(23-14)25(13-4-2)18(24-15)26-20-11-12-21-26/h2,11-12H,3,5-8,13H2,1H3,(H2,19,22,23)",RWMNMAZHKGFWDE-UHFFFAOYSA-N,50018693,CHEMBL3291306,Adenosine receptor A2a,Rattus norvegicus, 1.9
669345,COc1nc2ccc(cc2c(Cl)c1CC(F)(F)F)[C@@](O)(c1cncn1C)c1ccc(nc1)C(F)(F)F,"InChI=1S/C23H17ClF6N4O2/c1-34-11-31-10-18(34)22(35,13-4-6-17(32-9-13)23(28,29)30)12-3-5-16-14(7-12)19(24)15(8-21(25,26)27)20(33-16)36-2/h3-7,9-11,35H,8H2,1-2H3/t22-/m0/s1",MZKDWGXAUSBJMM-QFIPXVFZSA-N,339394,"US10201546, Example 240b",Nuclear receptor ROR-gamma,, 320
837896,OC[C@@H](NC(=O)CN1Cc2ccc(cc2C1=O)-c1nc(NC2CCOCC2)ncc1Cl)c1ccc(nc1)C1CC1,"InChI=1S/C29H31ClN6O4/c30-23-13-32-29(33-21-7-9-40-10-8-21)35-27(23)18-3-4-20-14-36(28(39)22(20)11-18)15-26(38)34-25(16-37)19-5-6-24(31-12-19)17-1-2-17/h3-6,11-13,17,21,25,37H,1-2,7-10,14-16H2,(H,34,38)(H,32,33,35)/t25-/m1/s1",RUXQYFQGPHXGRP-RUZDIDTESA-N,418026,"2-(6-{5-chloro-2-[(oxan-4- yl)amino]pyrimidin-4-yl}-1-oxo-2,3- dihydro-1H-isoindol-2-yl)-N-[(1S)-1-(6- cyclopropylpyridin-3-yl)-2- hydroxyethyl]acetamide::US10457669, Example 716::US11001575, Example 716",Mitogen-activated protein kinase 1,Homo sapiens, 3.00
909155,CC(C)c1c([nH]c2ccc(cc12)C1CCN(CC1)C(=O)CNC[C@@H](O)CO)-c1ccnc(C)c1,,,443923,"US10660877, Example 511",Toll-like receptor 8,, 31.3
50618124,CC1=C(CC(C#N)C(=O)N1)c1ccc(cc1)-n1ccnc1,"InChI=1S/C16H14N4O/c1-11-15(8-13(9-17)16(21)19-11)12-2-4-14(5-3-12)20-7-6-18-10-20/h2-7,10,13H,8H2,1H3,(H,19,21)",UEMLUAWBMUYPGO-UHFFFAOYSA-N,50018627,"5-(4-Imidazol-1-yl-phenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydro-pyridine-3-carbonitrile::CHEMBL61692","Dual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A/1B/1C",Homo sapiens, 130000
894343,CN(C1CCN(C)CC1)C(=O)Nc1cc2cc(cc(F)c2cn1)-c1cnc(C)o1,"InChI=1S/C21H24FN5O2/c1-13-23-12-19(29-13)15-8-14-10-20(24-11-17(14)18(22)9-15)25-21(28)27(3)16-4-6-26(2)7-5-16/h8-12,16H,4-7H2,1-3H3,(H,24,25,28)",OWGGPIQEZFVSHY-UHFFFAOYSA-N,439291,"US10604514, Compound 229",Dual specificity tyrosine-phosphorylation-regulated kinase 1A,Homo sapiens,
50431228,NC(=S)N\N=C(/c1ccc(O)cc1)c1cccc(c1)C(=O)c1ccc(O)cc1,"InChI=1S/C21H17N3O3S/c22-21(28)24-23-19(13-4-8-17(25)9-5-13)15-2-1-3-16(12-15)20(27)14-6-10-18(26)11-7-14/h1-12,25-26H,(H3,22,24,28)/b23-19+",GLTPIHKHHQYXFH-FCDQGJHFSA-N,50128816,CHEMBL3629198,Procathepsin L,Homo sapiens, 341
50310508,CONC(=O)c1cc(Nc2ncnn3cc(-c4nnc(CC(F)(F)F)o4)c(C(C)C)c23)c(F)cc1F,"InChI=1S/C21H18F5N7O3/c1-9(2)16-11(20-31-30-15(36-20)6-21(24,25)26)7-33-17(16)18(27-8-28-33)29-14-4-10(19(34)32-35-3)12(22)5-13(14)23/h4-5,7-9H,6H2,1-3H3,(H,32,34)(H,27,28,29)",KNCMFVBGBJGBGI-UHFFFAOYSA-N,50168395,"2,4-Difluoro-5-{5-isopropyl-6-[5-(2,2,2-trifluoro-ethyl)-[1,3,4]oxadiazol-2-yl]-pyrrolo[2,1-f][1,2,4]triazin-4-ylamino}-N-methoxy-benzamide::CHEMBL194872",Vascular endothelial growth factor receptor 2,Homo sapiens, 29
1190345,CSc1nc(Nc2ccc(CN3CCN(C)CC3)cc2)nc2[nH]cc(-c3ccc(cc3)S(=O)(=O)N(C)C)c12,"InChI=1S/C27H33N7O2S2/c1-32(2)38(35,36)22-11-7-20(8-12-22)23-17-28-25-24(23)26(37-4)31-27(30-25)29-21-9-5-19(6-10-21)18-34-15-13-33(3)14-16-34/h5-12,17H,13-16,18H2,1-4H3,(H2,28,29,30,31)",LQBDZMZNBNPGIB-UHFFFAOYSA-N,563360,"N,N-dimethyl-4-(2-((4- ((4-methylpiperazin-1- yl)methyl)phenyl)amino)- 4-(methylthio)-7H- pyrrolo[2,3- d]pyrimidin-5- yl)benzenesulfonamide::US11407757, Cpd 23",Tyrosine-protein kinase receptor UFO,, 250
600250,CC(=O)c1ccc2n(CCCCN3CCN(CC3)c3ccc(F)cc3[N+]([O-])=O)c(=O)oc2c1,"InChI=1S/C23H25FN4O5/c1-16(29)17-4-6-20-22(14-17)33-23(30)27(20)9-3-2-8-25-10-12-26(13-11-25)19-7-5-18(24)15-21(19)28(31)32/h4-7,14-15H,2-3,8-13H2,1H3",AWYWOBZBICTPAQ-UHFFFAOYSA-N,312204,"US9604926, Compound CM-592::US9724435, Compound CM592",Sigma intracellular receptor 2,,
150740,Fc1ccccc1NC(=O)c1ccc(CSc2ncccn2)cc1,"InChI=1S/C18H14FN3OS/c19-15-4-1-2-5-16(15)22-17(23)14-8-6-13(7-9-14)12-24-18-20-10-3-11-21-18/h1-11H,12H2,(H,22,23)",XDAKTQYHPQWKEF-UHFFFAOYSA-N,80459,MLS000624963::N-(2-fluorophenyl)-4-(pyrimidin-2-ylsulfanylmethyl)benzamide::N-(2-fluorophenyl)-4-[(2-pyrimidinylthio)methyl]benzamide::N-(2-fluorophenyl)-4-[(2-pyrimidylthio)methyl]benzamide::SMR000293728::cid_977424,DNA dC->dU-editing enzyme APOBEC-3G,Homo sapiens, 9710
50249308,CN1CCC[C@@H]1COCCCc1cc(Cl)c(c(Cl)c1)S(=O)(=O)N(C(F)F)c1c(C)nn(C)c1C,"InChI=1S/C22H30Cl2F2N4O3S/c1-14-20(15(2)29(4)27-14)30(22(25)26)34(31,32)21-18(23)11-16(12-19(21)24)7-6-10-33-13-17-8-5-9-28(17)3/h11-12,17,22H,5-10,13H2,1-4H3/t17-/m1/s1",YOVVEEOQRUQRLN-QGZVFWFLSA-N,50033622,CHEMBL3358125,Glycylpeptide N-tetradecanoyltransferase 1,Homo sapiens, 45
37588,Cc1onc(c1COc1ccc(cn1)C(=O)NC1CC1)-c1ccc(Cl)cn1,"InChI=1S/C19H17ClN4O3/c1-11-15(18(24-27-11)16-6-3-13(20)9-21-16)10-26-17-7-2-12(8-22-17)19(25)23-14-4-5-14/h2-3,6-9,14H,4-5,10H2,1H3,(H,23,25)",ARBLJOFSCMJCAL-UHFFFAOYSA-N,10521,"US8846719, 303",Gamma-aminobutyric acid receptor subunit alpha-5,Homo sapiens,
360022,COc1cc(OC)c(C2CCC(=O)N2Cc2ccc(OC(F)(F)F)cc2)c(OC)c1,"InChI=1S/C21H22F3NO5/c1-27-15-10-17(28-2)20(18(11-15)29-3)16-8-9-19(26)25(16)12-13-4-6-14(7-5-13)30-21(22,23)24/h4-7,10-11,16H,8-9,12H2,1-3H3",GNLURNURWXRIRN-UHFFFAOYSA-N,202961,"US9242970, 108",Orexin/Hypocretin receptor type 1,Homo sapiens, 1930
725726,CCN(C)C(=O)C1Cc2[nH]c(c(Nc3ccccc3)c2C(=O)C1)-c1ccncc1,,,367327,"(6RS)&#151;N-Ethyl-N-methyl-4-oxo-3-(phenylamino)-2-(pyridin-4-yl)-4,5,6,7-tetrahydro-1H-indol-6-carboxamide::US10227299, Example 18",Mitotic checkpoint serine/threonine-protein kinase BUB1,Homo sapiens, 8.00
406122,COCCNCCn1cc(NC(=O)c2cnn3cccnc23)c(n1)-c1cc(Cl)ccc1OC(F)F,"InChI=1S/C22H22ClF2N7O3/c1-34-10-7-26-6-9-31-13-17(29-21(33)16-12-28-32-8-2-5-27-20(16)32)19(30-31)15-11-14(23)3-4-18(15)35-22(24)25/h2-5,8,11-13,22,26H,6-7,9-10H2,1H3,(H,29,33)",BSRJNKQEXXOLAI-UHFFFAOYSA-N,232748,"US9346815, 294::US9604984, Example 294",Tyrosine-protein kinase JAK2,Homo sapiens,
190721,CN1CN(c2ccccc2)C2(CCN(CCNC(=O)c3ccc4ccccc4c3)CC2)C1=O,"InChI=1S/C27H30N4O2/c1-29-20-31(24-9-3-2-4-10-24)27(26(29)33)13-16-30(17-14-27)18-15-28-25(32)23-12-11-21-7-5-6-8-22(21)19-23/h2-12,19H,13-18,20H2,1H3,(H,28,32)",MEUUAOBDTAVZNS-UHFFFAOYSA-N,87162,"N-[2-(3-methyl-4-oxidanylidene-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl]naphthalene-2-carboxamide::N-[2-(3-methyl-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl]-2-naphthalenecarboxamide::N-[2-(3-methyl-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl]naphthalene-2-carboxamide::N-[2-(4-keto-3-methyl-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl]-2-naphthamide::VU0404363-1::cid_53469965",Phospholipase D1,Homo sapiens, 2800
577278,CC(C)[C@@H]1NC(=O)[C@H](Cc2cccs2)NC(=O)[C@H](Cc2ccc(Cl)cc2)NC(=O)CCCSC[C@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)CCCNC(N)=N,"InChI=1S/C43H62ClN11O9S2/c1-24(2)36-41(63)52-31(21-34(45)57)38(60)53-32(42(64)55-16-4-9-33(55)40(62)49-27(22-56)7-3-15-48-43(46)47)23-65-17-6-10-35(58)50-29(19-25-11-13-26(44)14-12-25)37(59)51-30(39(61)54-36)20-28-8-5-18-66-28/h5,8,11-14,18,24,27,29-33,36,56H,3-4,6-7,9-10,15-17,19-23H2,1-2H3,(H2,45,57)(H,49,62)(H,50,58)(H,51,59)(H,52,63)(H,53,60)(H,54,61)(H4,46,47,48)/t27-,29+,30+,31+,32+,33+,36+/m1/s1",TXAGRBCBFPPBPX-HTRMGZLOSA-N,301690,"US10131692, Compound 22",Vasopressin V1b receptor,,
51440592,CCCCn1c(=O)n(CCCNC(=O)c2ccc(cc2)S(F)(=O)=O)c2[nH]c(nc2c1=O)C12CCC(CC1)(CC2)C(=O)NCCCCCCCCN=[N+]=[N-],"InChI=1S/C36H50FN9O6S/c1-2-3-24-46-31(48)28-29(45(34(46)50)25-10-22-39-30(47)26-11-13-27(14-12-26)53(37,51)52)43-32(42-28)35-15-18-36(19-16-35,20-17-35)33(49)40-21-8-6-4-5-7-9-23-41-44-38/h11-14H,2-10,15-25H2,1H3,(H,39,47)(H,40,49)(H,42,43)",HTAAFDMUMXKSNA-UHFFFAOYSA-N,50581959,CHEMBL5076192,Adenosine receptor A1,Homo sapiens,
51233531,CC(C)(O)c1ccc(cc1)-c1nc2c(F)ccc(F)c2c(=O)[nH]1,"InChI=1S/C17H14F2N2O2/c1-17(2,23)10-5-3-9(4-6-10)15-20-14-12(19)8-7-11(18)13(14)16(22)21-15/h3-8,23H,1-2H3,(H,20,21,22)",ZEQVKZNUMQSOLV-UHFFFAOYSA-N,50505330,CHEMBL4454894,Poly [ADP-ribose] polymerase tankyrase-2,, 40
653239,COc1cc(OC)c(Cl)c(NC(=O)N(Cc2cc(C)no2)c2cc(Nc3ccccc3NC(=O)C=C)ncn2)c1Cl,"InChI=1S/C27H25Cl2N7O5/c1-5-23(37)33-18-9-7-6-8-17(18)32-21-12-22(31-14-30-21)36(13-16-10-15(2)35-41-16)27(38)34-26-24(28)19(39-3)11-20(40-4)25(26)29/h5-12,14H,1,13H2,2-4H3,(H,33,37)(H,34,38)(H,30,31,32)",AMYAAZXUYDZFKS-UHFFFAOYSA-N,249418,"US10537571, Compound 136::US10912774, Compound 136::US9434697, 136::US9730931, Compound 136",Fibroblast growth factor receptor 1,Homo sapiens, 112
50410836,Cc1cc(cc2[nH]c(nc12)-c1c(NCCc2ncn(C)c2Cl)cc[nH]c1=O)N1CCOCC1,"InChI=1S/C23H26ClN7O2/c1-14-11-15(31-7-9-33-10-8-31)12-18-20(14)29-22(28-18)19-16(3-6-26-23(19)32)25-5-4-17-21(24)30(2)13-27-17/h3,6,11-13H,4-5,7-10H2,1-2H3,(H,28,29)(H2,25,26,32)",GLISBSFAODYFPL-UHFFFAOYSA-N,50234509,4-(2-(5-chloro-1-methyl-1H-imidazol-4-yl)ethylamino)-3-(4-methyl-6-morpholino-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one::CHEMBL256072,Insulin-like growth factor 1 receptor,Homo sapiens, 38
50184566,Cc1cc(Cl)c(O)c(c1)-c1cc2cc(ccc2[nH]1)C(N)=N,"InChI=1S/C16H14ClN3O/c1-8-4-11(15(21)12(17)5-8)14-7-10-6-9(16(18)19)2-3-13(10)20-14/h2-7,20-21H,1H3,(H3,18,19)",DJPZZIPELMVWNS-UHFFFAOYSA-N,50101876,2-(3-Chloro-2-hydroxy-5-methyl-phenyl)-1H-indole-5-carboxamidine::CHEMBL54018,Prothrombin,,
202162,CNC(=O)[C@@H](NC(=O)[C@H](OCc1ccccc1C(=O)N1CCc2ccccc12)[C@H](O)[C@@H](O)[C@@H](OCc1ccccc1C(=O)N1CCc2ccccc12)C(=O)N[C@@H](C(C)C)C(=O)NC)C(C)C,"InChI=1S/C50H60N6O10/c1-29(2)39(45(59)51-5)53-47(61)43(65-27-33-17-7-11-19-35(33)49(63)55-25-23-31-15-9-13-21-37(31)55)41(57)42(58)44(48(62)54-40(30(3)4)46(60)52-6)66-28-34-18-8-12-20-36(34)50(64)56-26-24-32-16-10-14-22-38(32)56/h7-22,29-30,39-44,57-58H,23-28H2,1-6H3,(H,51,59)(H,52,60)(H,53,61)(H,54,62)/t39-,40-,41+,42+,43+,44+/m0/s1",QEPSCLPHRZEKFR-LVFDAWRISA-N,93239,"HIV-1 Protease Inhibitor, 6j",HIV-1 protease,Human immunodeficiency virus,
51136131,O(c1ccc(cc1)-c1cccc2nccn12)c1nccc2occc12,InChI=1S/C20H13N3O2/c1-2-17(23-12-11-21-19(23)3-1)14-4-6-15(7-5-14)25-20-16-9-13-24-18(16)8-10-22-20/h1-13H,LXWUHUKLUZUIPE-UHFFFAOYSA-N,50465938,CHEMBL4294009,D(1A) dopamine receptor,,
178723,COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34,"InChI=1S/C38H42N2O6/c1-39-15-13-25-20-32(42-4)34-22-28(25)29(39)17-23-7-10-27(11-8-23)45-33-19-24(9-12-31(33)41-3)18-30-36-26(14-16-40(30)2)21-35(43-5)37(44-6)38(36)46-34/h7-12,19-22,29-30H,13-18H2,1-6H3/t29-,30+/m0/s1",WVTKBKWTSCPRNU-XZWHSSHBSA-N,85444,"CHEMBL506025::Isotetrandrine (R,S)::Pheanthine (R,R)",Trypanothione reductase,Crithidia fasciculata, 2.35e+5
50805516,Cc1c(F)c(Oc2cccc(N)c2)nc(Oc2cccc(c2)C(N)=N)c1F,"InChI=1S/C19H16F2N4O2/c1-10-15(20)18(26-13-6-2-4-11(8-13)17(23)24)25-19(16(10)21)27-14-7-3-5-12(22)9-14/h2-9H,22H2,1H3,(H3,23,24)",OGLUIQADIHCVKD-UHFFFAOYSA-N,50113902,"3-[6-(3-Amino-phenoxy)-3,5-difluoro-4-methyl-pyridin-2-yloxy]-benzamidine::CHEMBL83648",Serine protease 1,Homo sapiens,
609911,COc1ccc(COc2ccc(Cn3cnc4cc(ccc34)-c3cnn(c3)C3CCNCC3)cc2OC)cn1,"InChI=1S/C30H32N6O3/c1-37-29-13-21(3-7-28(29)39-19-22-4-8-30(38-2)32-15-22)17-35-20-33-26-14-23(5-6-27(26)35)24-16-34-36(18-24)25-9-11-31-12-10-25/h3-8,13-16,18,20,25,31H,9-12,17,19H2,1-2H3",OZFHIGAKHHLPEF-UHFFFAOYSA-N,164891,"US10166239, Ex. 3-5::US11406644, Example 3-5::US9067914, Ex. 3-5",Macrophage colony-stimulating factor 1 receptor,, 2.00
223942,CC(c1ccc(F)c(F)c1)n1cccc(C(=O)NCC#Cc2ccc3nccc(OCCCN(C)C)c3c2)c1=O,"InChI=1S/C31H30F2N4O3/c1-21(23-10-11-26(32)27(33)20-23)37-17-5-8-24(31(37)39)30(38)35-14-4-7-22-9-12-28-25(19-22)29(13-15-34-28)40-18-6-16-36(2)3/h5,8-13,15,17,19-21H,6,14,16,18H2,1-3H3,(H,35,38)",BWRVOGBJZDIKDC-UHFFFAOYSA-N,105357,"US8575203, I-124",3-phosphoinositide-dependent protein kinase 1,Homo sapiens, 2
51086277,NC(=N)c1ccccc1,"InChI=1S/C7H8N2/c8-7(9)6-4-2-1-3-5-6/h1-5H,(H3,8,9)",PXXJHWLDUBFPOL-UHFFFAOYSA-N,50038002,Benzamidine (Protonated)::CHEMBL20936::CHEMBL537204::benzamidine,Suppressor of tumorigenicity 14 protein,Homo sapiens,
837334,CC1N(CCc2ccccc12)C(=O)CN1Cc2ccc(cc2C1=O)-c1nc(NC2CCOCC2)ncc1Cl,"InChI=1S/C29H30ClN5O3/c1-18-23-5-3-2-4-19(23)8-11-35(18)26(36)17-34-16-21-7-6-20(14-24(21)28(34)37)27-25(30)15-31-29(33-27)32-22-9-12-38-13-10-22/h2-7,14-15,18,22H,8-13,16-17H2,1H3,(H,31,32,33)",ZCESIBKZWOSTKC-UHFFFAOYSA-N,417462,"6-{5-chloro-2-](oxan-4- yl)amino]pyrimidin-4- yl}-2-[2-(1-methyl- 1,2,3,4- tetrahydroisoquinolin- 2-y1)-2-oxoethyl]-2,3- dihydro-1H-isoindol-1- one::US10457669, Example 74::US11001575, Example 74",Mitogen-activated protein kinase 1,Homo sapiens, 6.50
50277521,COc1ccccc1C(=O)Nc1cccc(NC(=O)c2ccccc2C(C)C)c1,"InChI=1S/C24H24N2O3/c1-16(2)19-11-4-5-12-20(19)23(27)25-17-9-8-10-18(15-17)26-24(28)21-13-6-7-14-22(21)29-3/h4-16H,1-3H3,(H,25,27)(H,26,28)",BYJDHIBPQCZZKQ-UHFFFAOYSA-N,50050544,CHEMBL3187764,Potassium channel subfamily K member 3,, 7.0
50147012,COCC[C@H]1CN(CCN1Cc1cnc[nH]1)C(=O)c1cccc2ccccc12,"InChI=1S/C22H26N4O2/c1-28-12-9-19-15-26(11-10-25(19)14-18-13-23-16-24-18)22(27)21-8-4-6-17-5-2-3-7-20(17)21/h2-8,13,16,19H,9-12,14-15H2,1H3,(H,23,24)/t19-/m0/s1",ZESVWFCJDOBZAV-IBGZPJMESA-N,50083430,CHEMBL148816::[(S)-4-(3H-Imidazol-4-ylmethyl)-3-(2-methoxy-ethyl)-piperazin-1-yl]-naphthalen-1-yl-methanone,Dimer of Protein farnesyltransferase subunit beta,Homo sapiens, 1300
339731,CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H]4CCN(CC(F)F)C4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1,"InChI=1S/C45H49ClF2N8O6S/c1-45(2)14-11-31(38(24-45)29-3-5-32(46)6-4-29)26-53-17-19-55(20-18-53)34-7-9-37(41(22-34)62-35-21-30-12-15-49-43(30)50-25-35)44(57)52-63(60,61)36-8-10-39(40(23-36)56(58)59)51-33-13-16-54(27-33)28-42(47)48/h3-10,12,15,21-23,25,33,42,51H,11,13-14,16-20,24,26-28H2,1-2H3,(H,49,50)(H,52,57)/t33-/m0/s1",VGCOANRSVUOVOT-XIFFEERXSA-N,189620,"US10213433, Compound 182::US11369599, Compound 182::US9174982, 182",Apoptosis regulator Bcl-2,,
1143805,Cn1ccc2cc(cnc12)-n1nc(cc1-c1ccc(cc1)C#N)C(=O)N1CCC[C@@H](N)C1,"InChI=1S/C24H23N7O/c1-29-10-8-18-11-20(14-27-23(18)29)31-22(17-6-4-16(13-25)5-7-17)12-21(28-31)24(32)30-9-2-3-19(26)15-30/h4-8,10-12,14,19H,2-3,9,15,26H2,1H3/t19-/m1/s1",FPMASXVYCVXMOY-LJQANCHMSA-N,539211,"(R)-4-(3-(3-aminopiperidine-1-carbonyl)- 1-(1-methyl-1H-pyrrolo[2,3-b]pyridine-5- yl)-1H-pyrazole-5-yl)benzonitrile::US11254676, Example 93",Lysine-specific histone demethylase 1A,Homo sapiens, 376
50170792,CC(=O)N[C@@H]1[C@@H](O)[C@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@@H](CO)O[C@@H]1OCCCCCCCCCCCCS,"InChI=1S/C26H49NO11S/c1-16(30)27-19-21(32)24(38-26-23(34)22(33)20(31)17(14-28)36-26)18(15-29)37-25(19)35-12-10-8-6-4-2-3-5-7-9-11-13-39/h17-26,28-29,31-34,39H,2-15H2,1H3,(H,27,30)/t17-,18-,19-,20+,21-,22+,23-,24-,25+,26+/m1/s1",IRUGNGIDNXATAJ-AGTZLAJMSA-N,50336203,12-Mercaptododecyl-beta-D-galactopyranosyl-(1->4)-2-acetamido-2-deoxy-alpha-D-glucopyranoside::CHEMBL1669631,Galectin-4,Homo sapiens,
51170384,Fc1cc(NC(=O)Nc2ccc(Cl)c(c2)C(F)(F)F)ccc1Oc1ccnc2[nH]c(=O)[nH]c12,"InChI=1S/C20H12ClF4N5O3/c21-12-3-1-9(7-11(12)20(23,24)25)27-18(31)28-10-2-4-14(13(22)8-10)33-15-5-6-26-17-16(15)29-19(32)30-17/h1-8H,(H2,27,28,31)(H2,26,29,30,32)",NVJVWUDGYDGZIX-UHFFFAOYSA-N,50480104,CHEMBL498024,Serine/threonine-protein kinase B-raf,Homo sapiens, 47
50326898,COc1ccccc1Oc1ccc(Nc2c(cnn3cc(NC(=O)NCCN4CCOCC4)c(C)c23)C#N)cc1,"InChI=1S/C29H31N7O4/c1-20-24(34-29(37)31-11-12-35-13-15-39-16-14-35)19-36-28(20)27(21(17-30)18-32-36)33-22-7-9-23(10-8-22)40-26-6-4-3-5-25(26)38-2/h3-10,18-19,33H,11-16H2,1-2H3,(H2,31,34,37)",ZVVMZLPTOJNISN-UHFFFAOYSA-N,50176559,"1-(3-cyano-4-(4-(2-methoxyphenoxy)phenylamino)-5-methylH-pyrrolo[1,2-b]pyridazin-6-yl)-3-(2-morpholinoethyl)urea::CHEMBL202356",Dual specificity mitogen-activated protein kinase kinase 1,Homo sapiens, 24
50832222,CCCCCCCCCCCCCCC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(N)=O,"InChI=1S/C47H69N11O5/c1-2-3-4-5-6-7-8-9-10-11-12-16-25-42(59)55-41(29-35-31-51-32-54-35)46(63)58-40(27-33-20-14-13-15-21-33)45(62)56-38(24-19-26-52-47(49)50)44(61)57-39(43(48)60)28-34-30-53-37-23-18-17-22-36(34)37/h13-15,17-18,20-23,30-32,38-41,53H,2-12,16,19,24-29H2,1H3,(H2,48,60)(H,51,54)(H,55,59)(H,56,62)(H,57,61)(H,58,63)(H4,49,50,52)/t38-,39-,40+,41-/m0/s1",ZCYDDEYLARALIR-SHOCBOQASA-N,50166134,CHEMBL193151::Pentadecanoic acid [(S)-1-((R)-1-{(S)-1-[(S)-1-carbamoyl-2-(1H-indol-3-yl)-ethylcarbamoyl]-4-guanidino-butylcarbamoyl}-2-phenyl-ethylcarbamoyl)-2-(3H-imidazol-4-yl)-ethyl]-amide,Melanocortin receptor 5,,
50079852,OP(O)(=O)C(Nc1ccc(Cl)c(Cl)c1)P(O)(O)=O,"InChI=1S/C7H9Cl2NO6P2/c8-5-2-1-4(3-6(5)9)10-7(17(11,12)13)18(14,15)16/h1-3,7,10H,(H2,11,12,13)(H2,14,15,16)",ADHSWFUIIRWNHD-UHFFFAOYSA-N,50442512,CHEMBL2440433,Carbonic anhydrase 2,Homo sapiens,>10000
51021612,CN(C)CCCn1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O,"InChI=1S/C20H22ClN3O/c1-23(2)12-5-13-24-20(25)18-7-4-3-6-17(18)19(22-24)14-15-8-10-16(21)11-9-15/h3-4,6-11H,5,12-14H2,1-2H3",SAKVKDBLCRHLAV-UHFFFAOYSA-N,50418286,CHEMBL1767135,Histamine H1 receptor,Homo sapiens,
723870,OC1(CCN(CC1)c1cccn2nc(Nc3ccc(cc3)C(=O)NCCCN3CCOCC3)nc12)c1ccc(Cl)cc1,"InChI=1S/C31H36ClN7O3/c32-25-8-6-24(7-9-25)31(41)12-17-38(18-13-31)27-3-1-16-39-28(27)35-30(36-39)34-26-10-4-23(5-11-26)29(40)33-14-2-15-37-19-21-42-22-20-37/h1,3-11,16,41H,2,12-15,17-22H2,(H,33,40)(H,34,36)",QXHBPLCOJXRBRV-UHFFFAOYSA-N,366505,"4-[[8-[4-(4- chlorophenyl)-4- hydroxy-1-piperidyl]- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-(3- morpholinopropyl) benzamide::US9873709, Example 1-98",Tyrosine-protein kinase JAK1,Homo sapiens,
341041,Fc1ccc2nc([nH]c2c1)-c1ccc(cc1)[C@@H]1CNCCO1,,,190609,"US9181230, 15",Trace amine-associated receptor 1,Rattus norvegicus,
50985450,CC[C@H](C)[C@H](CC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(N)=O)C(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(C)=O)[C@@H](C)CC,"InChI=1S/C48H86N12O12/c1-10-27(6)34(56-48(72)42(29(8)12-3)59-45(69)31(16-13-14-20-49)54-47(71)36-17-15-21-60(36)30(9)62)23-39(65)53-32(18-19-37(50)63)44(68)57-35(25-61)46(70)55-33(26(4)5)22-38(64)52-24-40(66)58-41(43(51)67)28(7)11-2/h26-29,31-36,41-42,61H,10-25,49H2,1-9H3,(H2,50,63)(H2,51,67)(H,52,64)(H,53,65)(H,54,71)(H,55,70)(H,56,72)(H,57,68)(H,58,66)(H,59,69)/t27-,28-,29-,31-,32-,33-,34-,35-,36-,41-,42-/m0/s1",HXWNPNBOIIOVHS-WQSPITHDSA-N,50278348,CHEMBL4161548,Trypanothione reductase,,>75000
50539719,CCc1cc2c(nc(NCCCO)nc2s1)N1CCN(CC1)C(=O)c1ccc(cc1)-c1ccccc1,"InChI=1S/C28H31N5O2S/c1-2-23-19-24-25(30-28(29-13-6-18-34)31-26(24)36-23)32-14-16-33(17-15-32)27(35)22-11-9-21(10-12-22)20-7-4-3-5-8-20/h3-5,7-12,19,34H,2,6,13-18H2,1H3,(H,29,30,31)",ODBHJHKECUFQQM-UHFFFAOYSA-N,50302450,"CHEMBL585317::biphenyl-4-yl(4-(6-ethyl-2-(3-hydroxypropylamino)thieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)methanone",P2Y purinoceptor 12,Homo sapiens,
51265413,Cc1nc(sc1C(=O)NC1CCCc2ccccc12)-c1ccccc1,"InChI=1S/C21H20N2OS/c1-14-19(25-21(22-14)16-9-3-2-4-10-16)20(24)23-18-13-7-11-15-8-5-6-12-17(15)18/h2-6,8-10,12,18H,7,11,13H2,1H3,(H,23,24)",IBDVKPRUZGKSPR-UHFFFAOYSA-N,50516783,CHEMBL4446746,Cannabinoid receptor 2,Homo sapiens,
50110344,CCOC(=O)CC1CCCN1C(=O)C(=O)c1c[nH]c2c(C)cccc12,"InChI=1S/C19H22N2O4/c1-3-25-16(22)10-13-7-5-9-21(13)19(24)18(23)15-11-20-17-12(2)6-4-8-14(15)17/h4,6,8,11,13,20H,3,5,7,9-10H2,1-2H3",GAGMZQZBWNYDQU-UHFFFAOYSA-N,50089763,CHEMBL29277::{1-[2-(7-Methyl-1H-indol-3-yl)-2-oxo-acetyl]-pyrrolidin-2-yl}-acetic acid ethyl ester,GABA-A receptor; alpha-2/beta-3/gamma-2,,
50442426,Cc1cc(C)c2nc(cc(C(=O)Nc3ccc4ccccc4c3)c2c1)-c1ccccn1,"InChI=1S/C27H21N3O/c1-17-13-18(2)26-22(14-17)23(16-25(30-26)24-9-5-6-12-28-24)27(31)29-21-11-10-19-7-3-4-8-20(19)15-21/h3-16H,1-2H3,(H,29,31)",FSSBBJDSNDJSNN-UHFFFAOYSA-N,50273787,"6,8-Dimethyl-N-(naphthalen-2-yl)-2-(pyridin-2-yl)quinoline-4-carboxamide::CHEMBL514090",Cytochrome P450 2C9,Homo sapiens,
51275748,CCC(=O)N1CCC(C1)n1cc(-c2cc3cc(C)cc(OC)c3s2)c2c(N)ncnc12,"InChI=1S/C23H25N5O2S/c1-4-19(29)27-6-5-15(10-27)28-11-16(20-22(24)25-12-26-23(20)28)18-9-14-7-13(2)8-17(30-3)21(14)31-18/h7-9,11-12,15H,4-6,10H2,1-3H3,(H2,24,25,26)",DOWBTQHWXGZIER-UHFFFAOYSA-N,50520624,CHEMBL4552123,Fibroblast growth factor receptor 4,, 55
50766322,COc1cccc(NC(=O)NC2N=C(c3ccccc3)c3ccccc3N(CCN(C)C)C2=O)c1,"InChI=1S/C27H29N5O3/c1-31(2)16-17-32-23-15-8-7-14-22(23)24(19-10-5-4-6-11-19)29-25(26(32)33)30-27(34)28-20-12-9-13-21(18-20)35-3/h4-15,18,25H,16-17H2,1-3H3,(H2,28,30,34)",HJQWPSHCCQIVGY-UHFFFAOYSA-N,50043540,"1-[1-(2-Dimethylamino-ethyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-3-(3-methoxy-phenyl)-urea::CHEMBL137714",Gastrin/cholecystokinin type B receptor,Homo sapiens, 192
51056020,CC1CCCCN1S(=O)(=O)c1cccc(c1)N1CCCC1=O,"InChI=1S/C16H22N2O3S/c1-13-6-2-3-11-18(13)22(20,21)15-8-4-7-14(12-15)17-10-5-9-16(17)19/h4,7-8,12-13H,2-3,5-6,9-11H2,1H3",FCKFTJUSWBCXQG-UHFFFAOYSA-N,50430707,CHEMBL2333915,Aldo-keto reductase family 1 member C3,Homo sapiens,>30000
1000465,FC(F)(F)c1cc2-c3n[nH]c4ccnc(N(Cc2cn1)C1CCOCC1)c34,"InChI=1S/C18H16F3N5O/c19-18(20,21)14-7-12-10(8-23-14)9-26(11-2-5-27-6-3-11)17-15-13(1-4-22-17)24-25-16(12)15/h1,4,7-8,11H,2-3,5-6,9H2,(H,24,25)",YATFNRRBIGOWSE-UHFFFAOYSA-N,482284,"US10918645, Example 89",Leucine-rich repeat serine/threonine-protein kinase 2 [G2019S],, 49.0
241620,Nc1ccn2ncc(C(=O)Nc3ccnn3-c3cc(Cl)ccc3Cl)c2n1,"InChI=1S/C16H11Cl2N7O/c17-9-1-2-11(18)12(7-9)25-14(3-5-20-25)23-16(26)10-8-21-24-6-4-13(19)22-15(10)24/h1-8H,(H2,19,22)(H,23,26)",MLUHNCCVOONEHK-UHFFFAOYSA-N,116316,"US8637526, 277",Tyrosine-protein kinase JAK1,Homo sapiens,
1144049,FC(F)(F)c1ccc(CNC(=O)c2nc(NCc3ccc(nc3)C(F)(F)F)nc3ccsc23)cn1,"InChI=1S/C21H14F6N6OS/c22-20(23,24)14-3-1-11(7-28-14)9-30-18(34)16-17-13(5-6-35-17)32-19(33-16)31-10-12-2-4-15(29-8-12)21(25,26)27/h1-8H,9-10H2,(H,30,34)(H,31,32,33)",QSDATZIAQZECEW-UHFFFAOYSA-N,539289,"US11254686, Compound Z72",Adenosine receptor A2b,Homo sapiens,>500
929685,COc1nc(cnc1CNC[C@@H]1CCC(=O)N1)-c1cccc(c1Cl)-c1cccc(c1Cl)-c1cnc(CN[C@@H]2CCO[C@@H]2C)c(OC)n1,"InChI=1S/C34H37Cl2N7O4/c1-19-25(12-13-47-19)38-18-29-34(46-3)43-27(17-40-29)24-9-5-7-22(32(24)36)21-6-4-8-23(31(21)35)26-16-39-28(33(42-26)45-2)15-37-14-20-10-11-30(44)41-20/h4-9,16-17,19-20,25,37-38H,10-15,18H2,1-3H3,(H,41,44)/t19-,20+,25-/m1/s1",INDRTFZGPWXFIZ-OHUGHZGNSA-N,452156,"US10710986, Example 295",Programmed cell death 1 ligand 1 [19-238]/protein 1 [25-167],, 0.414
503058,CCN(CC)CCOc1ccc(Nc2cc3[nH]c(=O)c(cc3cn2)-c2ccccc2)nc1,"InChI=1S/C25H27N5O2/c1-3-30(4-2)12-13-32-20-10-11-23(27-17-20)29-24-15-22-19(16-26-24)14-21(25(31)28-22)18-8-6-5-7-9-18/h5-11,14-17H,3-4,12-13H2,1-2H3,(H,28,31)(H,26,27,29)",HGDBRPWKZKQYJJ-UHFFFAOYSA-N,264293,"US9714247, 14",Tyrosine-protein kinase Lyn,Homo sapiens, 550
579019,CC1CC1NC(=O)c1nc2cccnn2c1-c1ccc(Cl)cc1,"InChI=1S/C17H15ClN4O/c1-10-9-13(10)20-17(23)15-16(11-4-6-12(18)7-5-11)22-14(21-15)3-2-8-19-22/h2-8,10,13H,9H2,1H3,(H,20,23)",VSOPHYORBVNBMU-UHFFFAOYSA-N,285557,"3-(4-chlorophenyl)-N-(2-methylcyclopropyl)imidazo[1,2-b]pyridazine-2-carboxamide::US10077269, Example 30::US10669279, Example 30::US9598421, Example 30","cAMP-specific 3',5'-cyclic phosphodiesterase 4A",Homo sapiens, 11.6
51363149,CCOC(=O)c1c(N)n(cc1-c1ccc(Cl)cc1)-c1ccc(cc1)S(N)(=O)=O,"InChI=1S/C19H18ClN3O4S/c1-2-27-19(24)17-16(12-3-5-13(20)6-4-12)11-23(18(17)21)14-7-9-15(10-8-14)28(22,25)26/h3-11H,2,21H2,1H3,(H2,22,25,26)",IYCYGSLYRLCMMV-UHFFFAOYSA-N,50550958,CHEMBL4761716,Carbonic anhydrase 12,Homo sapiens,
235152,Cc1cc(COc2ccc(cc2)S(=O)(=O)NC[C@H](N2CCN(CC2)C(=O)OCc2ccccc2)C(=O)NO)c2ccccc2n1,"InChI=1S/C32H35N5O7S/c1-23-19-25(28-9-5-6-10-29(28)34-23)22-43-26-11-13-27(14-12-26)45(41,42)33-20-30(31(38)35-40)36-15-17-37(18-16-36)32(39)44-21-24-7-3-2-4-8-24/h2-14,19,30,33,40H,15-18,20-22H2,1H3,(H,35,38)/t30-/m0/s1",WYQFYOPMZXRDFX-PMERELPUSA-N,113582,"US8633196, 10::US9365529, 10",Disintegrin and metalloproteinase domain-containing protein 17,, 47
485306,COC1(CCOCC1C)c1nc2nc(nc(-c3cncc(Cl)c3)c2n1C[C@H]1CC[C@H](C)CC1)-c1noc(=O)[nH]1,,,227681,"1,5-anhydro-3-c-[6-(5- chloropyridin-3-yl)-7- [(trans-4- methylcyclohexyl)methyl]- 2-(5-oxo-4,5-dihydro- 1,2,4-oxadiazol-3-yl)-7h- purin-8-yl]-2,4-dideoxy-2- methyl-3-o- methylpentitol (racemic diastereomer 1)::US9540377, 23.96::US9540377, 23.97",E3 ubiquitin-protein ligase Mdm2 [17-125],, 11.29
648691,CCCOC[C@H]1C[C@H](CN1S(=O)(=O)c1ccc(OC(C)C)cc1)n1nc(CC(O)=O)c2ccc(F)cc12,"InChI=1S/C26H32FN3O6S/c1-4-11-35-16-20-13-19(30-25-12-18(27)5-10-23(25)24(28-30)14-26(31)32)15-29(20)37(33,34)22-8-6-21(7-9-22)36-17(2)3/h5-10,12,17,19-20H,4,11,13-16H2,1-3H3,(H,31,32)/t19-,20-/m1/s1",UBOVDKUXLFTWGU-WOJBJXKFSA-N,330755,"US9725442, Compound I-327",Prostaglandin D2 receptor 2,Homo sapiens,
50030904,CC(C)NCC(O)COc1ccc(COCC2CC2)cc1,"InChI=1S/C17H27NO3/c1-13(2)18-9-16(19)12-21-17-7-5-15(6-8-17)11-20-10-14-3-4-14/h5-8,13-14,16,18-19H,3-4,9-12H2,1-2H3",UOKWVICUCYNXFO-UHFFFAOYSA-N,50405536,CHEMBL6939,Beta-1 adrenergic receptor,Cavia cutleri,
50376894,CC(C)(N)c1ccc(cc1)-c1nc(Nc2ccc(CCN3CCOCC3)cc2)ncc1Cl,"InChI=1S/C25H30ClN5O/c1-25(2,27)20-7-5-19(6-8-20)23-22(26)17-28-24(30-23)29-21-9-3-18(4-10-21)11-12-31-13-15-32-16-14-31/h3-10,17H,11-16,27H2,1-2H3,(H,28,29,30)",CJSSYVIHFXDFFC-UHFFFAOYSA-N,50206280,4-(4-(2-aminopropan-2-yl)phenyl)-5-chloro-N-(4-(2-morpholinoethyl)phenyl)pyrimidin-2-amine::4-ARYL-2-PHENYLAMINO PYRIMIDINE::CHEMBL233209,Vascular endothelial growth factor receptor 2,Homo sapiens, 148
50132477,NC(=N)N1CCC[C@H](NC(=O)Cn2ccc(CCc3ccccc3)c(NS(=O)(=O)CC(F)(F)F)c2=O)C1O,"InChI=1S/C23H29F3N6O5S/c24-23(25,26)14-38(36,37)30-19-16(9-8-15-5-2-1-3-6-15)10-12-31(21(19)35)13-18(33)29-17-7-4-11-32(20(17)34)22(27)28/h1-3,5-6,10,12,17,20,30,34H,4,7-9,11,13-14H2,(H3,27,28)(H,29,33)/t17-,20?/m0/s1",QZQQGWLVAUEZSU-DIMJTDRSSA-N,50076071,"1N-[1-amino(imino)methyl-6-hydroxy-(5S)-tetrahydro-5-pyridinyl]-2-[2-oxo-4-phenethyl-3-(2,2,2-trifluoroethylsulfonamido)-1,2-dihydro-1-pyridinyl]acetamide::CHEMBL414832",Serine protease 1,Homo sapiens, 1220
50026617,CCCCCCCCCCC[C@H]1CC[C@@H](O1)[C@H]1CC[C@H](CCCCCCCCCCCCCC2=C[C@H](C)OC2=O)O1,"InChI=1S/C37H66O4/c1-3-4-5-6-7-11-15-18-21-24-33-26-28-35(40-33)36-29-27-34(41-36)25-22-19-16-13-10-8-9-12-14-17-20-23-32-30-31(2)39-37(32)38/h30-31,33-36H,3-29H2,1-2H3/t31-,33-,34-,35+,36+/m0/s1",TUPBNDUHNNWPOG-KYBSVACCSA-N,50139594,"(S)-5-Methyl-3-[13-((2R,5S,1'S,3'R)-5'-undecyl-octahydro-[2,2']bifuranyl-5-yl)-tridecyl]-5H-furan-2-one::CHEMBL352106","Acyl carrier protein,/NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial",Bos taurus, 85
50704276,CCCc1ccc(NC(=O)c2nc(oc2C(F)(F)F)-c2ccccc2)cc1,"InChI=1S/C20H17F3N2O2/c1-2-6-13-9-11-15(12-10-13)24-18(26)16-17(20(21,22)23)27-19(25-16)14-7-4-3-5-8-14/h3-5,7-12H,2,6H2,1H3,(H,24,26)",XQWRBQYKGZEHQW-UHFFFAOYSA-N,50358326,CHEMBL1922589,Diacylglycerol O-acyltransferase 1,, 13900
50631452,COCCN(c1ccnc(Nc2cc(cc(c2)N2CCOCC2)N2CCOCC2)n1)c1cc(CO)ccc1C,"InChI=1S/C29H38N6O4/c1-22-3-4-23(21-36)17-27(22)35(11-12-37-2)28-5-6-30-29(32-28)31-24-18-25(33-7-13-38-14-8-33)20-26(19-24)34-9-15-39-16-10-34/h3-6,17-20,36H,7-16,21H2,1-2H3,(H,30,31,32)",HVLNVFOAUCUYQK-UHFFFAOYSA-N,50340552,"(3-((2-(3,5-dimorpholinophenylamino)pyrimidin-4-yl)(2-methoxyethyl)amino)-4-methylphenyl)methanol::CHEMBL1762549",Fibroblast growth factor receptor 1,Homo sapiens, 720
50683046,COc1cc2C\C(=C/C3CCCCN3Cc3ccccc3)C(=O)c2cc1OC,"InChI=1S/C24H27NO3/c1-27-22-14-18-12-19(24(26)21(18)15-23(22)28-2)13-20-10-6-7-11-25(20)16-17-8-4-3-5-9-17/h3-5,8-9,13-15,20H,6-7,10-12,16H2,1-2H3/b19-13+",DFKLKRLIFOPVEY-CPNJWEJPSA-N,50231984,CHEMBL4060269,Acetylcholinesterase,Electrophorus electricus, 750
51413417,COc1ccc(OC)c(\C=C2\N=C(N(C2=O)c2ccc(cc2)S(N)(=O)=O)c2ccccc2)c1,"InChI=1S/C24H21N3O5S/c1-31-19-10-13-22(32-2)17(14-19)15-21-24(28)27(23(26-21)16-6-4-3-5-7-16)18-8-11-20(12-9-18)33(25,29)30/h3-15H,1-2H3,(H2,25,29,30)/b21-15+",MTCFRUCNMWCOMS-RCCKNPSSSA-N,50570991,CHEMBL4878381,Carbonic anhydrase 1,Homo sapiens,
50964901,CCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1,"InChI=1S/C18H18Br2N6O4S/c1-2-25-31(27,28)26-16-15(12-3-5-13(19)6-4-12)17(24-11-23-16)29-7-8-30-18-21-9-14(20)10-22-18/h3-6,9-11,25H,2,7-8H2,1H3,(H,23,24,26)",PIJUSICWAKBTEZ-UHFFFAOYSA-N,50395627,CHEMBL2165338,Endothelin receptor type B,Homo sapiens, 830
50889115,CC(C)(C)OC(=O)N1CC[C@@H](C1)C(=O)Nc1cc(Cn2c3ccccc3c(=O)[nH]c2=O)cnc1Cl,"InChI=1S/C24H26ClN5O5/c1-24(2,3)35-23(34)29-9-8-15(13-29)20(31)27-17-10-14(11-26-19(17)25)12-30-18-7-5-4-6-16(18)21(32)28-22(30)33/h4-7,10-11,15H,8-9,12-13H2,1-3H3,(H,27,31)(H,28,32,33)/t15-/m0/s1",MDURPWFKFWBOHZ-HNNXBMFYSA-N,50268286,CHEMBL4068890,Poly [ADP-ribose] polymerase 2,, 12
50610176,COc1cc(O)cc(O)c1C(=O)\C=C\c1ccccc1,"InChI=1S/C16H14O4/c1-20-15-10-12(17)9-14(19)16(15)13(18)8-7-11-5-3-2-4-6-11/h2-10,17,19H,1H3/b8-7+",NYSZJNUIVUBQMM-BQYQJAHWSA-N,50185446,"(E)-1-(2,4-dihydroxy-6-methoxyphenyl)-3-phenylprop-2-en-1-one::CHEMBL378104::cardamomin::cardamonin",Potassium voltage-gated channel subfamily A member 3,Homo sapiens, 2
206541,CCOC(=O)c1sc2ncc(cc2c1C)C(=O)c1cc(C)ccc1O,"InChI=1S/C19H17NO4S/c1-4-24-19(23)17-11(3)13-8-12(9-20-18(13)25-17)16(22)14-7-10(2)5-6-15(14)21/h5-9,21H,4H2,1-3H3",MCGMWSDVUGDVNL-UHFFFAOYSA-N,94940,"5-(2-hydroxy-5-methyl-benzoyl)-3-methyl-thieno[2,3-b]pyridine-2-carboxylic acid ethyl ester::5-[(2-hydroxy-5-methylphenyl)-oxomethyl]-3-methyl-2-thieno[2,3-b]pyridinecarboxylic acid ethyl ester::MLS000393048::SMR000248151::cid_2098056::ethyl 3-methyl-5-(5-methyl-2-oxidanyl-phenyl)carbonyl-thieno[2,3-b]pyridine-2-carboxylate::ethyl 5-(2-hydroxy-5-methylbenzoyl)-3-methylthieno[2,3-b]pyridine-2-carboxylate",Low molecular weight phosphotyrosine protein phosphatase,,>80000
1139195,Cn1cc(cn1)-c1nn(C2CC[C@@H](CC2)Oc2ccc(=O)n(C)n2)c2cc(Nc3ccccc3F)ncc12,"InChI=1S/C27H27FN8O2/c1-34-16-17(14-30-34)27-20-15-29-24(31-22-6-4-3-5-21(22)28)13-23(20)36(33-27)18-7-9-19(10-8-18)38-25-11-12-26(37)35(2)32-25/h3-6,11-16,18-19H,7-10H2,1-2H3,(H,29,31)/t18?,19-",RLFHUVUKZFFZBK-HSNGWXBGSA-N,537242,"6-(((1s,4s)-4-(6-((2- fluorophenyl)amino)-3- (1-methyl-1H-pyrazol-4- yl)-1H-pyrazolo[4,3- c]pyridin-1- yl)cyclohexyl)oxy)-2- methylpyridazin-3(2H)- one::US11247990, Example 67",Tyrosine-protein kinase Mer,Homo sapiens, 110
51059502,CCN1CCC[C@](COCc2cc(cc(c2)C(F)(F)F)C(F)(F)F)(CC1)c1ccccc1,"InChI=1S/C24H27F6NO/c1-2-31-11-6-9-22(10-12-31,19-7-4-3-5-8-19)17-32-16-18-13-20(23(25,26)27)15-21(14-18)24(28,29)30/h3-5,7-8,13-15H,2,6,9-12,16-17H2,1H3/t22-/m1/s1",BKZACLJXDQEZGG-JOCHJYFZSA-N,50432296,CHEMBL2347857,Sodium-dependent serotonin transporter,Homo sapiens,>1000
136919,Cc1ccc(cc1)-n1ncc(Cl)c(Oc2ccccc2)c1=O,"InChI=1S/C17H13ClN2O2/c1-12-7-9-13(10-8-12)20-17(21)16(15(18)11-19-20)22-14-5-3-2-4-6-14/h2-11H,1H3",MNUUQMMVABGDGH-UHFFFAOYSA-N,75872,5-chloranyl-2-(4-methylphenyl)-4-phenoxy-pyridazin-3-one::5-chloro-2-(4-methylphenyl)-4-phenoxy-3-pyridazinone::5-chloro-2-(4-methylphenyl)-4-phenoxypyridazin-3-one::5-chloro-4-phenoxy-2-(p-tolyl)pyridazin-3-one::SR-02000000337::SR-02000000337-1::cid_45382325,Neuropeptides B/W receptor type 1,Homo sapiens, 18200
50594748,O=C1CN([C@@H]2CCN(CCc3cnccn3)C2)C(=O)[C@H]2Cc3c([nH]c4ccccc34)[C@H](N12)c1ccc2OCOc2c1,"InChI=1S/C31H30N6O4/c38-28-17-36(21-8-12-35(16-21)11-7-20-15-32-9-10-33-20)31(39)25-14-23-22-3-1-2-4-24(22)34-29(23)30(37(25)28)19-5-6-26-27(13-19)41-18-40-26/h1-6,9-10,13,15,21,25,30,34H,7-8,11-12,14,16-18H2/t21-,25-,30-/m1/s1",RBDTXUKCFPFLRR-WIISGGPLSA-N,50126464,"(6R,12aR)-6-Benzo[1,3]dioxol-5-yl-2-[(R)-1-(2-pyrazin-2-yl-ethyl)-pyrrolidin-3-yl]-2,3,6,7,12,12a-hexahydro-pyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione::CHEMBL33121",O43924/P16499/P18545/P35913/P51160/Q13956,, 358
50451431,COc1ccc(cc1)-c1nc2ccc(NCc3cccc(c3)C(F)(F)F)nc2n(CCC(N)=O)c1=O,"InChI=1S/C25H22F3N5O3/c1-36-18-7-5-16(6-8-18)22-24(35)33(12-11-20(29)34)23-19(31-22)9-10-21(32-23)30-14-15-3-2-4-17(13-15)25(26,27)28/h2-10,13H,11-12,14H2,1H3,(H2,29,34)(H,30,32)",XWKNIHACUXAXDU-UHFFFAOYSA-N,50257758,"3-(2-(4-methoxyphenyl)-3-oxo-6-(3-(trifluoromethyl)benzylamino)pyrido[2,3-b]pyrazin-4(3H)-yl)propanamide::CHEMBL521993",Acyl-CoA 6-desaturase,Rattus norvegicus,>30
50330851,CC(C)Cn1cc(C#N)c2cc(ccc12)S(=O)(=O)c1ccc(NC(=O)[C@@H]2CCCN2)cc1,"InChI=1S/C24H26N4O3S/c1-16(2)14-28-15-17(13-25)21-12-20(9-10-23(21)28)32(30,31)19-7-5-18(6-8-19)27-24(29)22-4-3-11-26-22/h5-10,12,15-16,22,26H,3-4,11,14H2,1-2H3,(H,27,29)/t22-/m0/s1",VTMZMKMCPQYOPV-QFIPXVFZSA-N,50082125,CHEMBL3421735,"6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2",,>100000
50368478,CCCC(=O)c1cnn(c1C)-c1ccc(NC(=O)c2cn(CC(=O)N3CCN(C)CC3)c3cc(Br)c(C)cc23)cc1,"InChI=1S/C31H35BrN6O3/c1-5-6-29(39)25-17-33-38(21(25)3)23-9-7-22(8-10-23)34-31(41)26-18-37(28-16-27(32)20(2)15-24(26)28)19-30(40)36-13-11-35(4)12-14-36/h7-10,15-18H,5-6,11-14,19H2,1-4H3,(H,34,41)",DRMWSFRPKMHIEH-UHFFFAOYSA-N,50055854,CHEMBL3325795,P2Y purinoceptor 12,Rattus norvegicus, 1700
1231699,FC(F)Oc1cc(ccc1Cl)-c1cnc2cnn(Cc3cncc(Cl)c3)c2c1,"InChI=1S/C19H12Cl2F2N4O/c20-14-3-11(6-24-8-14)10-27-17-4-13(7-25-16(17)9-26-27)12-1-2-15(21)18(5-12)28-19(22)23/h1-9,19H,10H2",IEXPJYJGSZBRQC-UHFFFAOYSA-N,585628,"6-[4-Chloro-3-(difluoromethoxy)phenyl]-1-[(5-chloro-3- pyridyl)methyl]pyrazolo[4,3-b]pyridine::US11530210, Example 243","Glutamate receptor ionotropic, NMDA 1/2B",Homo sapiens, 146
51258610,C[C@H]1CN(CCN1c1nc(=O)n(-c2c(ncnc2C2CC2)C2CC2)c2nc(c(Cl)cc12)-c1c(O)cccc1F)C(=O)C=C,"InChI=1S/C31H29ClFN7O3/c1-3-23(42)38-11-12-39(16(2)14-38)29-19-13-20(32)27(24-21(33)5-4-6-22(24)41)36-30(19)40(31(43)37-29)28-25(17-7-8-17)34-15-35-26(28)18-9-10-18/h3-6,13,15-18,41H,1,7-12,14H2,2H3/t16-/m0/s1",ZSWUOKQZXOXZJL-INIZCTEOSA-N,50514370,CHEMBL4588277,GTPase KRas,Homo sapiens, 34
50806890,COC(=O)[C@@H]1C2CC[C@H](C[C@@H]1c1ccccc1)N2C,"InChI=1S/C16H21NO2/c1-17-12-8-9-14(17)15(16(18)19-2)13(10-12)11-6-4-3-5-7-11/h3-7,12-15H,8-10H2,1-2H3/t12-,13-,14?,15+/m1/s1",OMBOXYLBBHNWHL-VOFREWHGSA-N,50366564,CHEMBL1790051::CHEMBL83729::WIN-35065-2,Sodium-dependent serotonin transporter,Rattus norvegicus,
280433,CC(C)(C)c1cc(Nc2cc(ccn2)-c2ccc(OC3CCOCC3)c(c2)C#N)n[nH]1,"InChI=1S/C24H27N5O2/c1-24(2,3)21-14-23(29-28-21)27-22-13-17(6-9-26-22)16-4-5-20(18(12-16)15-25)31-19-7-10-30-11-8-19/h4-6,9,12-14,19H,7-8,10-11H2,1-3H3,(H2,26,27,28,29)",NOCFKKXWSSCWRO-UHFFFAOYSA-N,144187,"US8969335, A10",Inhibitor of nuclear factor kappa-B kinase subunit epsilon,Homo sapiens, 43
51335754,CC1(C)O[C@@H]2CN(CCCCCCn3cc(CNc4ccc(cc4)S(N)(=O)=O)nn3)[C@H]([C@@H](O)[C@@H]2O1)[C@@H]1[C@H](O)[C@H]2CO[C@@H](O2)[C@H]1O,"InChI=1S/C29H44N6O9S/c1-29(2)43-20-15-34(23(26(38)27(20)44-29)22-24(36)21-16-41-28(42-21)25(22)37)11-5-3-4-6-12-35-14-18(32-33-35)13-31-17-7-9-19(10-8-17)45(30,39)40/h7-10,14,20-28,31,36-38H,3-6,11-13,15-16H2,1-2H3,(H2,30,39,40)/t20-,21?,22-,23+,24-,25+,26-,27-,28?/m1/s1",MWZLBQWPJOSIAH-MAEDULGDSA-N,50540617,CHEMBL4649348,Carbonic anhydrase 4,Homo sapiens,
671272,Nc1nccn2c(nc(-c3ccc(cc3)C(=O)Nc3ccccn3)c12)C1CCCCCN1C(=O)C=C,"InChI=1S/C27H27N7O2/c1-2-22(35)33-16-7-3-4-8-20(33)26-32-23(24-25(28)30-15-17-34(24)26)18-10-12-19(13-11-18)27(36)31-21-9-5-6-14-29-21/h2,5-6,9-15,17,20H,1,3-4,7-8,16H2,(H2,28,30)(H,29,31,36)",WCSLENALJUQVRH-UHFFFAOYSA-N,340148,"US10239883, Example 37::US10934296, Example 37::US9758524, Example 37",Tyrosine-protein kinase Lyn,Homo sapiens,
1181460,FC(F)(F)Oc1cccc(CNC(=O)c2cn(CCCCn3cc(NC(=O)CN4CCC(F)(F)C4)nn3)nn2)c1,"InChI=1S/C23H26F5N9O3/c24-22(25)6-9-35(15-22)14-20(38)30-19-13-37(34-32-19)8-2-1-7-36-12-18(31-33-36)21(39)29-11-16-4-3-5-17(10-16)40-23(26,27)28/h3-5,10,12-13H,1-2,6-9,11,14-15H2,(H,29,39)(H,30,38)",PZOPJFRAXAAGGM-UHFFFAOYSA-N,404987,"1-(4-{4-[2-(3,3-difluoropyrrolidin-1- yl)acetamido]-1H-1,2,3-triazol-1- yl}butyl)-N-{[3- (trifluoromethoxy)phenyl]methyl}- 1H-1,2,3-triazole-4-carboxamide::US10344025, Example 331::US11370786, Example 331","Glutaminase kidney isoform, mitochondrial",Homo sapiens,<100
736929,C[C@H](Oc1ncc(cc1N1CCOCC1)-c1cc(NC(=O)c2cccc(c2)C(F)(F)F)ccc1C)C#N,"InChI=1S/C27H25F3N4O3/c1-17-6-7-22(33-25(35)19-4-3-5-21(12-19)27(28,29)30)14-23(17)20-13-24(34-8-10-36-11-9-34)26(32-16-20)37-18(2)15-31/h3-7,12-14,16,18H,8-11H2,1-2H3,(H,33,35)/t18-/m0/s1",VXMIFMXPRCRODA-SFHVURJKSA-N,202805,"US10245267, Example 152::US10709712, Example 152::US9242969, 152::US9694016, 152",RAF proto-oncogene serine/threonine-protein kinase,Homo sapiens, 0.500
50171635,Cc1cc2c(CC(O)=O)c(C)n(Cc3ccc(cc3Cl)S(C)(=O)=O)c2s1,"InChI=1S/C18H18ClNO4S2/c1-10-6-15-14(8-17(21)22)11(2)20(18(15)25-10)9-12-4-5-13(7-16(12)19)26(3,23)24/h4-7H,8-9H2,1-3H3,(H,21,22)",RTSWBUWMSOJCEL-UHFFFAOYSA-N,50338163,"2-(6-(2-chloro-4-(methylsulfonyl)benzyl)-2,5-dimethyl-6H-thieno[2,3-b]pyrrol-4-yl)acetic acid::CHEMBL1684732",Prostaglandin D2 receptor 2,Homo sapiens, 330
50195678,COC(=O)c1cccc(c1)-c1ccc(NCc2cccc(S)c2)cc1-c1ccccc1,"InChI=1S/C27H23NO2S/c1-30-27(29)22-11-6-10-21(16-22)25-14-13-23(17-26(25)20-8-3-2-4-9-20)28-18-19-7-5-12-24(31)15-19/h2-17,28,31H,18H2,1H3",BTHZULPQBZZWQC-UHFFFAOYSA-N,50108071,"4'-(3-Mercapto-benzylamino)-[1,1';2',1'']terphenyl-3-carboxylic acid methyl ester 33(FTI-2314)::CHEMBL293110",Geranylgeranyl transferase type-1 subunit beta/Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha,,>10000
50639814,CN(CCC(F)CN1CCN(CC1)c1cccc(Cl)c1Cl)Cc1ccc-2c(Cc3ccccc-23)c1,"InChI=1S/C29H32Cl2FN3/c1-33(19-21-9-10-26-23(17-21)18-22-5-2-3-6-25(22)26)12-11-24(32)20-34-13-15-35(16-14-34)28-8-4-7-27(30)29(28)31/h2-10,17,24H,11-16,18-20H2,1H3",KROSHEKWTTXFGB-UHFFFAOYSA-N,50343809,"CHEMBL1773087::N-((9H-Fluoren-2-yl)methyl)-4-(4-(2,3-dichlorophenyl)-piperazin-1-yl)-3-fluoro-N-methylbutan-1-amine",D(2) dopamine receptor,Homo sapiens,
738224,Cc1ccc(NC(=O)c2ccnc(c2)C(C)(C)C#N)cc1-c1nc2CCS(=O)(=O)c2c(n1)N1CCOCC1,"InChI=1S/C27H28N6O4S/c1-17-4-5-19(30-26(34)18-6-8-29-22(14-18)27(2,3)16-28)15-20(17)24-31-21-7-13-38(35,36)23(21)25(32-24)33-9-11-37-12-10-33/h4-6,8,14-15H,7,9-13H2,1-3H3,(H,30,34)",QKINODCXLKEKAE-UHFFFAOYSA-N,87825,"US10245267, Example 855::US10709712, Example 855::US9694016, 855",Serine/threonine-protein kinase B-raf [V600E],, 2.30
50230228,Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl,"InChI=1S/C24H25ClFN5O3/c1-2-23(32)30-21-13-17-20(14-22(21)34-9-3-6-31-7-10-33-11-8-31)27-15-28-24(17)29-16-4-5-19(26)18(25)12-16/h2,4-5,12-15H,1,3,6-11H2,(H,30,32)(H,27,28,29)",OMZCMEYTWSXEPZ-UHFFFAOYSA-N,4779,"CHEMBL31965::CHEMBL545315::CI-1033::Canertinib::N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide::PD0183805::US10507209, Compound CI-1033::US9730934, CI-1033::cid_156414",Tyrosine-protein kinase ABL1,Homo sapiens,
50787566,CCN1CCc2c(sc3ccccc23)C(C1)c1ccc(Cl)c(Cl)c1,"InChI=1S/C20H19Cl2NS/c1-2-23-10-9-15-14-5-3-4-6-19(14)24-20(15)16(12-23)13-7-8-17(21)18(22)11-13/h3-8,11,16H,2,9-10,12H2,1H3",UUABPOTWOAIFHX-UHFFFAOYSA-N,50067810,"9-(3,4-Dichloro-phenyl)-7-ethyl-6,7,8,9-tetrahydro-5H-10-thia-7-aza-benzo[a]azulene::CHEMBL336437",Sodium-dependent serotonin transporter,Rattus norvegicus, 1200
50164403,CCCC[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(C)(C)SSC(C)(C)[C@H](NC(=O)[C@@H]2CCCN2C1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCc1cc(cc(c1)C(F)(F)F)C(F)(F)F,"InChI=1S/C72H90F6N12O11S2/c1-8-9-20-51-67(100)89-28-15-23-56(89)65(98)88-59(70(6,7)103-102-69(4,5)58(87-60(93)49(79)33-42-24-26-47(91)27-25-42)66(99)82-39-57(92)83-53(63(96)84-51)34-41-17-11-10-12-18-41)68(101)90-29-16-22-55(90)64(97)86-52(30-40(2)3)62(95)85-54(35-44-38-80-50-21-14-13-19-48(44)50)61(94)81-37-43-31-45(71(73,74)75)36-46(32-43)72(76,77)78/h10-14,17-19,21,24-27,31-32,36,38,40,49,51-56,58-59,80,91H,8-9,15-16,20,22-23,28-30,33-35,37,39,79H2,1-7H3,(H,81,94)(H,82,99)(H,83,92)(H,84,96)(H,85,95)(H,86,97)(H,87,93)(H,88,98)/t49-,51-,52-,53-,54-,55-,56-,58+,59+/m0/s1",DKZNWZVQLFXZER-JHOFKJSISA-N,50323866,"(S)-1-((3R,8R,14S,17S,22aS)-8-((S)-2-amino-3-(4-hydroxyphenyl)propanamido)-14-benzyl-17-butyl-4,4,7,7-tetramethyl-1,9,12,15,18-pentaoxoicosahydropyrrolo[2,1-g][1,2,5,8,11,14,17]dithiapentaazacycloicosine-3-carbonyl)-N-((S)-1-((S)-1-(3,5-bis(trifluoromethyl)benzylamino)-3-(1H-indol-3-yl)-1-oxopropan-2-ylamino)-4-methyl-1-oxopentan-2-yl)pyrrolidine-2-carboxamide::CHEMBL1214027",Substance-K receptor,, 105
405812,FC(F)Oc1ccc(Cl)cc1-c1nn(Cc2cn(nn2)C2CCNCC2)cc1NC(=O)c1cnn2cccnc12,"InChI=1S/C25H23ClF2N10O2/c26-15-2-3-21(40-25(27)28)18(10-15)22-20(32-24(39)19-11-31-37-9-1-6-30-23(19)37)14-36(34-22)12-16-13-38(35-33-16)17-4-7-29-8-5-17/h1-3,6,9-11,13-14,17,25,29H,4-5,7-8,12H2,(H,32,39)",CIMUAWWNMUPXLY-UHFFFAOYSA-N,232906,"US9346815, 452::US9604984, Example 452",Tyrosine-protein kinase JAK1,Homo sapiens,
50302511,CN(C)C(=O)Oc1ccc2c(C)c(Cc3cccc(c3)N(C)S(=O)(=O)CCCNCCCCCC(=O)N3CCN(CC3)c3nc(nc(n3)-n3c(nc4ccccc34)C(F)F)N3CCOCC3)c(=O)oc2c1,"InChI=1S/C49H59F2N11O8S/c1-33-37-18-17-36(69-49(65)57(2)3)32-41(37)70-45(64)38(33)31-34-12-10-13-35(30-34)58(4)71(66,67)29-11-20-52-19-9-5-6-16-42(63)59-21-23-60(24-22-59)46-54-47(61-25-27-68-28-26-61)56-48(55-46)62-40-15-8-7-14-39(40)53-44(62)43(50)51/h7-8,10,12-15,17-18,30,32,43,52H,5-6,9,11,16,19-29,31H2,1-4H3",KYJAPJCTKKWSCJ-UHFFFAOYSA-N,50066136,CHEMBL3400291,Dual specificity mitogen-activated protein kinase kinase 1,Homo sapiens, 473
68016,CCN(C(=O)C1CCCCC1)c1nnc(s1)-c1cccnc1,"InChI=1S/C16H20N4OS/c1-2-20(15(21)12-7-4-3-5-8-12)16-19-18-14(22-16)13-9-6-10-17-11-13/h6,9-12H,2-5,7-8H2,1H3",YDVDNNQOLPJCPA-UHFFFAOYSA-N,36848,"Cyclohexanecarboxylic acid ethyl-(5-pyridin-3-yl-[1,3,4]thiadiazol-2-yl)-amide::MLS000069062::N-ethyl-N-(5-pyridin-3-yl-1,3,4-thiadiazol-2-yl)cyclohexanecarboxamide;hydrochloride::N-ethyl-N-[5-(3-pyridinyl)-1,3,4-thiadiazol-2-yl]cyclohexanecarboxamide;hydrochloride::N-ethyl-N-[5-(3-pyridyl)-1,3,4-thiadiazol-2-yl]cyclohexanecarboxamide;hydrochloride::SMR000005347::cid_6603155",Sphingosine 1-phosphate receptor 1,Homo sapiens,
702766,COc1ccc(cc1)[C@@H](C)NC(=O)c1cc(=O)[nH]c(n1)-c1ccccc1,,,355256,"N-[(1R)-1-(4-methoxyphenyl)ethyl]- 6-oxo-2-phenyl-1,6- dihydropyrimidine-4-carboxamide::US9815796, Example 347",Phosphodiesterase,,
178817,CC(C)c1cccc(C(C)C)c1NC(=O)N[C@@](C)(Cc1c[nH]c2ccccc12)C(=O)NCC1(CCCCC1)c1ccccn1,"InChI=1S/C37H47N5O2/c1-25(2)28-15-13-16-29(26(3)4)33(28)41-35(44)42-36(5,22-27-23-39-31-17-8-7-14-30(27)31)34(43)40-24-37(19-10-6-11-20-37)32-18-9-12-21-38-32/h7-9,12-18,21,23,25-26,39H,6,10-11,19-20,22,24H2,1-5H3,(H,40,43)(H2,41,42,44)/t36-/m0/s1",RVCSRPVACXMJEL-BHVANESWSA-N,50071754,"(S)-2-[3-(2,6-Diisopropyl-phenyl)-ureido]-3-(1H-indol-3-yl)-2-methyl-N-(1-pyridin-2-yl-cyclohexylmethyl)-propionamide::CHEMBL86828::NMB::Xenopus NMB",Bombesin receptor subtype-3,Homo sapiens,
50180522,COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl,"InChI=1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31)",UBPYILGKFZZVDX-UHFFFAOYSA-N,4552,"4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile::4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile::BOSUTINIB::CHEMBL288441::SKI-606",Mast/stem cell growth factor receptor Kit,,
1082615,OCCn1cc(cn1)-c1cnc(Nc2cc(Cl)cc(Cl)c2)nc1NC1CCN(CC1)C(=O)C(F)(F)F,"InChI=1S/C22H22Cl2F3N7O2/c23-14-7-15(24)9-17(8-14)31-21-28-11-18(13-10-29-34(12-13)5-6-35)19(32-21)30-16-1-3-33(4-2-16)20(36)22(25,26)27/h7-12,16,35H,1-6H2,(H2,28,30,31,32)",QXDWUUOURQLHJK-UHFFFAOYSA-N,515792,"US11053225, Compound 71",Tyrosine-protein kinase Mer,Homo sapiens, 1100
50610102,CC(C)S(=O)(=O)N[C@H]1CN(C)C[C@@H]1c1ccc(cc1)-c1cccc(c1)C(C)=O,"InChI=1S/C22H28N2O3S/c1-15(2)28(26,27)23-22-14-24(4)13-21(22)18-10-8-17(9-11-18)20-7-5-6-19(12-20)16(3)25/h5-12,15,21-23H,13-14H2,1-4H3/t21-,22+/m1/s1",XASZFPDUJYFCOJ-YADHBBJMSA-N,50331376,"CHEMBL1290504::N-((3R,4R)-4-(3'-acetylbiphenyl-4-yl)-1-methylpyrrolidin-3-yl)propane-2-sulfonamide",Potassium voltage-gated channel subfamily H member 2,Homo sapiens, 7900
50492248,CCCN(C)[C@@H]1Cc2cccc3[nH]c(=O)n(C1)c23,"InChI=1S/C14H19N3O/c1-3-7-16(2)11-8-10-5-4-6-12-13(10)17(9-11)14(18)15-12/h4-6,11H,3,7-9H2,1-2H3,(H,15,18)/t11-/m1/s1",SLXIGTACOFFTMI-LLVKDONJSA-N,50164879,CHEMBL3797740,D(3) dopamine receptor,,
51402942,Cc1ccc(CCNC(=O)Cn2nnc3ccccc3c2=O)cc1,"InChI=1S/C18H18N4O2/c1-13-6-8-14(9-7-13)10-11-19-17(23)12-22-18(24)15-4-2-3-5-16(15)20-21-22/h2-9H,10-12H2,1H3,(H,19,23)",RHLQOJVKJGYHQZ-UHFFFAOYSA-N,263507,"US10561662, Example 76::US11173161, EX 76::US9556130, test 76::n-(4-methylphenethyl)-2-(4-oxobenzo[d][1,2,3]triazin-3(4h)-yl)acetamide",Probable G-protein coupled receptor 139,,
1165214,Oc1c2C(=O)N3CN([C@H](c4cccc(F)c4)c4cc(F)ccc4OC\C=C/C3)n2ccc1=O,"InChI=1S/C24H19F2N3O4/c25-16-5-3-4-15(12-16)21-18-13-17(26)6-7-20(18)33-11-2-1-9-27-14-29(21)28-10-8-19(30)23(31)22(28)24(27)32/h1-8,10,12-13,21,31H,9,11,14H2/b2-1-/t21-/m1/s1",BZMHTNVRXBWZDW-MLBSJROLSA-N,552099,"US11312727, Compound 25A",Polymerase basic protein 2,, 318
556609,CN(C)C(=O)c1ccc(cn1)-c1cnc(NCc2c3CCOc3ccc2F)n2cnnc12,"InChI=1S/C22H20FN7O2/c1-29(2)21(31)18-5-3-13(9-24-18)15-10-25-22(30-12-27-28-20(15)30)26-11-16-14-7-8-32-19(14)6-4-17(16)23/h3-6,9-10,12H,7-8,11H2,1-2H3,(H,25,26)",KBJMHUHSYLAULW-UHFFFAOYSA-N,291825,"5-(5-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)-[1,2,4]triazolo[4,3-c]pyrimidin-8-yl)-N,N-dimethylpicolinamide::US11207325, Example 140::US9580437, Example 140",Histone-lysine N-methyltransferase EZH2/Polycomb protein EED/Polycomb protein SUZ12,, 55.1
50863570,CCc1cccc2n(CC(=O)c3ccc(Cl)cc3)c(=N)n(CCCN(C)C(=O)Cc3ccccc3)c12,"InChI=1S/C29H31ClN4O2/c1-3-22-11-7-12-25-28(22)33(18-8-17-32(2)27(36)19-21-9-5-4-6-10-21)29(31)34(25)20-26(35)23-13-15-24(30)16-14-23/h4-7,9-16,31H,3,8,17-20H2,1-2H3",NORQBQYXNZJWEB-UHFFFAOYSA-N,50375125,CHEMBL256891,C-X-C chemokine receptor type 3,Mus musculus, 1800
50144737,ONC(=O)C1Cc2ccccc2CN1S(=O)(=O)c1ccc(cc1)N1CCOCC1,"InChI=1S/C20H23N3O5S/c24-20(21-25)19-13-15-3-1-2-4-16(15)14-23(19)29(26,27)18-7-5-17(6-8-18)22-9-11-28-12-10-22/h1-8,19,25H,9-14H2,(H,21,24)",MSWCSYXARJOPRA-UHFFFAOYSA-N,50082444,"2-(4-Morpholin-4-yl-benzenesulfonyl)-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid hydroxyamide::CHEMBL141098",Neutrophil collagenase,Homo sapiens, 100
51224791,C(c1ccccc1)n1nnc2ccccc12,"InChI=1S/C13H11N3/c1-2-6-11(7-3-1)10-16-13-9-5-4-8-12(13)14-15-16/h1-9H,10H2",OQVSPZZIBWDHOF-UHFFFAOYSA-N,50234596,CHEMBL1884989,Metabotropic glutamate receptor 2,,
50407726,Cc1nc(sc1C(=O)NCc1ccc(OC(C)(C)C(=O)NS(=O)(=O)C(F)(F)F)cc1)-c1ccc(cc1)C(F)(F)F,"InChI=1S/C24H21F6N3O5S2/c1-13-18(39-20(32-13)15-6-8-16(9-7-15)23(25,26)27)19(34)31-12-14-4-10-17(11-5-14)38-22(2,3)21(35)33-40(36,37)24(28,29)30/h4-11H,12H2,1-3H3,(H,31,34)(H,33,35)",HAFHLUVWUDJABJ-UHFFFAOYSA-N,50229211,CHEMBL254743::N-(4-(2-methyl-1-oxo-1-(trifluoromethylsulfonamido)propan-2-yloxy)benzyl)-4-methyl-2-(4-(trifluoromethyl)phenyl)thiazole-5-carboxamide,Peroxisome proliferator-activated receptor alpha,Mus musculus,
28008,CC1CC(=O)NN=C1c1ccc(NC2=C(Cc3ccccc3)C(=O)CCC2)cc1Cl,"InChI=1S/C24H24ClN3O2/c1-15-12-23(30)27-28-24(15)18-11-10-17(14-20(18)25)26-21-8-5-9-22(29)19(21)13-16-6-3-2-4-7-16/h2-4,6-7,10-11,14-15,26H,5,8-9,12-13H2,1H3,(H,27,30)",MPIGBQZXCYUSDC-UHFFFAOYSA-N,15320,"6-{4-[(2-benzyl-3-oxocyclohex-1-en-1-yl)amino]-2-chlorophenyl}-5-methyl-2,3,4,5-tetrahydropyridazin-3-one::dihydropyridazinone 14n","cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B [387-1112]",Homo sapiens, 4.8
19867,CC(C)c1cnn2c(Nc3ccc(cc3)S(=O)(=O)N(C)C)cc(NC3CCCC(N)C3)nc12,"InChI=1S/C23H33N7O2S/c1-15(2)20-14-25-30-22(27-17-8-10-19(11-9-17)33(31,32)29(3)4)13-21(28-23(20)30)26-18-7-5-6-16(24)12-18/h8-11,13-16,18,27H,5-7,12,24H2,1-4H3,(H,26,28)",GOXWKSGPJSRKKD-UHFFFAOYSA-N,11436,"4-({5-[(3-aminocyclohexyl)amino]-3-(propan-2-yl)pyrazolo[1,5-a]pyrimidin-7-yl}amino)-N,N-dimethylbenzene-1-sulfonamide::pyrazolo[1,5-a]pyrimidine 9i",Cyclin-A2/Cyclin-dependent kinase 2,Homo sapiens, 2100
94493,OCCCc1nc2N=C(CC(c3cccs3)n2n1)c1ccccc1,"InChI=1S/C18H18N4OS/c23-10-4-9-17-20-18-19-14(13-6-2-1-3-7-13)12-15(22(18)21-17)16-8-5-11-24-16/h1-3,5-8,11,15,23H,4,9-10,12H2",SZMMMUXRCCSIQJ-UHFFFAOYSA-N,34190,"3-(5-phenyl-7-thiophen-2-yl-1,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-1-propanol::3-(5-phenyl-7-thiophen-2-yl-1,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)propan-1-ol::3-[5-phenyl-7-(2-thienyl)-1,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]propan-1-ol::MLS000103362::SMR000018755::cid_5310167",Glycoprotein 42,Human herpesvirus 4 type 2,2080.0
51297541,C[C@@H]1C[C@@H]2O[C@@]3(C[C@@]4(C)C(C=C[C@H]5[C@@]6(C)CCC(=O)C(C)(C)[C@@H]6CC[C@]45C)=C13)O[C@H]2C(C)(C)O,"InChI=1S/C30H44O4/c1-17-15-19-24(26(4,5)32)34-30(33-19)16-29(8)18(23(17)30)9-10-21-27(6)13-12-22(31)25(2,3)20(27)11-14-28(21,29)7/h9-10,17,19-21,24,32H,11-16H2,1-8H3/t17-,19+,20+,21+,24-,27+,28+,29+,30+/m1/s1",ZUYNEWCDFCSDNK-ZQCSCMBKSA-N,50528869,CHEMBL4437194,Bile acid receptor,Homo sapiens,
50336257,CCO[C@@H](CC(O)=O)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1,"InChI=1S/C18H18Cl2O4/c1-2-23-17(10-18(21)22)13-4-6-14(7-5-13)24-11-12-3-8-15(19)16(20)9-12/h3-9,17H,2,10-11H2,1H3,(H,21,22)/t17-/m0/s1",PMWAAQCQJWJKES-KRWDZBQOSA-N,50085593,CHEMBL3427703,Free fatty acid receptor 1,,
50468786,C[N+](C)(C)CCC[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O,"InChI=1S/C32H49N9O5/c1-41(2,3)18-8-12-25(28(34)43)38-31(46)27(20-21-9-5-4-6-10-21)40-30(45)26(11-7-17-37-32(35)36)39-29(44)24(33)19-22-13-15-23(42)16-14-22/h4-6,9-10,13-16,24-27H,7-8,11-12,17-20,33H2,1-3H3,(H9-,34,35,36,37,38,39,40,42,43,44,45,46)/p+1/t24-,25-,26+,27-/m0/s1",UYFVABWFCNUFPW-NFGXINMFSA-O,50283039,CHEMBL424228::[(S)-4-((S)-2-{(R)-2-[(S)-2-Amino-3-(4-hydroxy-phenyl)-propionylamino]-5-guanidino-pentanoylamino}-3-phenyl-propionylamino)-4-carbamoyl-butyl]-trimethyl-ammonium,Mu-type opioid receptor,Rattus norvegicus,
686838,COc1cc(Nc2cc(Oc3ccc(NC(=O)Nc4cc(cc(NS(C)(=O)=O)c4OC)C(C)(C)C)c4ccccc34)ccn2)cc(OCCOCCOCCO)c1,"InChI=1S/C41H49N5O10S/c1-41(2,3)27-21-35(39(52-5)36(22-27)46-57(6,49)50)45-40(48)44-34-11-12-37(33-10-8-7-9-32(33)34)56-29-13-14-42-38(26-29)43-28-23-30(51-4)25-31(24-28)55-20-19-54-18-17-53-16-15-47/h7-14,21-26,46-47H,15-20H2,1-6H3,(H,42,43)(H2,44,45,48)",DBKIZDKUZBXXRO-UHFFFAOYSA-N,256595,"US10435361, Example 84(e)::US9481648, 84(e)::US9790174, Example 84(e)",Glycogen synthase kinase-3 alpha,Homo sapiens, 4468
51438412,C[C@]1(CCSC(N)=N1)c1cc(c(F)cc1F)-c1cncnc1,"InChI=1S/C15H14F2N4S/c1-15(2-3-22-14(18)21-15)11-4-10(12(16)5-13(11)17)9-6-19-8-20-7-9/h4-8H,2-3H2,1H3,(H2,18,21)/t15-/m0/s1",MJQMRGWYPNIERM-HNNXBMFYSA-N,50012632,CHEMBL2333941,Beta-secretase 1,Homo sapiens, 239
952441,COc1nc(ccc1CNC[C@@H]1CCC(=O)N1)-c1cccc(c1C)-c1cccc2[C@H](CCc12)Oc1nc(OC)c(CN2CC3(CCC2CC3)C(O)=O)cc1Cl,"InChI=1S/C43H48ClN5O6/c1-25-30(6-4-7-31(25)36-13-10-26(39(47-36)53-2)21-45-22-28-11-15-38(50)46-28)32-8-5-9-34-33(32)12-14-37(34)55-41-35(44)20-27(40(48-41)54-3)23-49-24-43(42(51)52)18-16-29(49)17-19-43/h4-10,13,20,28-29,37,45H,11-12,14-19,21-24H2,1-3H3,(H,46,50)(H,51,52)/t28-,29?,37-,43?/m0/s1",YQAGELOZDWJFKK-FNKPFDAOSA-N,461610,"US10774071, Example B-77",Programmed cell death 1 ligand 1 [19-238]/protein 1 [25-167],, 0.064
51397366,Clc1ccccc1NC(=O)Nc1ccc(cc1)-c1c(sc(N2CCOCC2)c1C#N)-c1nc[nH]n1,"InChI=1S/C24H20ClN7O2S/c25-18-3-1-2-4-19(18)30-24(33)29-16-7-5-15(6-8-16)20-17(13-26)23(32-9-11-34-12-10-32)35-21(20)22-27-14-28-31-22/h1-8,14H,9-12H2,(H,27,28,31)(H2,29,30,33)",OHHJTGRTQJGKLY-UHFFFAOYSA-N,50564520,CHEMBL4796569,"Phosphatidylinositol 3-kinase regulatory subunit alpha/4,5-bisphosphate 3-kinase catalytic subunit beta isoform",Homo sapiens,
50540203,CCCCCOC(=O)N1CCN(CC1)C(=O)[C@H](CCC(O)=O)NC(=O)c1cc(nc(n1)-c1ccccc1)N1CCC(CN(CC)CC)CC1,"InChI=1S/C36H53N7O6/c1-4-7-11-24-49-36(48)43-22-20-42(21-23-43)35(47)29(14-15-32(44)45)38-34(46)30-25-31(39-33(37-30)28-12-9-8-10-13-28)41-18-16-27(17-19-41)26-40(5-2)6-3/h8-10,12-13,25,27,29H,4-7,11,14-24,26H2,1-3H3,(H,38,46)(H,44,45)/t29-/m0/s1",FROMLTZQUDUXPE-LJAQVGFWSA-N,50302723,(4S)-4-[(6-{4-[(diethylamino)methyl]piperidin-1-yl}-2-phenylpyrimidin-4-yl)formamido]-5-oxo-5-{4-[(pentyloxy)carbonyl]piperazin-1-yl}pentanoic acid::CHEMBL565974,P2Y purinoceptor 12,Homo sapiens, 860
51106452,COc1cc(ccc1Nc1ncc(Cl)c(Oc2ccccc2NC(=O)\C=C\CN(C)C)n1)N1CCN(C)CC1,"InChI=1S/C28H34ClN7O3/c1-34(2)13-7-10-26(37)31-22-8-5-6-9-24(22)39-27-21(29)19-30-28(33-27)32-23-12-11-20(18-25(23)38-4)36-16-14-35(3)15-17-36/h5-12,18-19H,13-17H2,1-4H3,(H,31,37)(H,30,32,33)/b10-7+",PBUXJOZGADIDJZ-JXMROGBWSA-N,50451290,CHEMBL4202780,Tyrosine-protein kinase ABL1,Mus musculus, 8120
51319701,Cc1ccc(cc1)-c1cc2ncccc2c2cc(nn12)C(=O)NN1CCCCC1,"InChI=1S/C23H23N5O/c1-16-7-9-17(10-8-16)21-14-19-18(6-5-11-24-19)22-15-20(25-28(21)22)23(29)26-27-12-3-2-4-13-27/h5-11,14-15H,2-4,12-13H2,1H3,(H,26,29)",ZZQVHRUCXYZQFZ-UHFFFAOYSA-N,50534084,CHEMBL4467772,Cannabinoid receptor 1,Homo sapiens,
51348516,Oc1ccc2C[C@H]3N(CC[C@@]45[C@@H](Oc1c24)c1[nH]c2ccccc2c1C[C@@]35O)C(=O)Cc1ccccc1,,,50545479,CHEMBL4638693,Delta-type opioid receptor,Homo sapiens,
50558708,N[C@@H](Cc1cccs1)C(=O)N[C@@]1(C[C@@H]1c1ccccc1)C#N,"InChI=1S/C17H17N3OS/c18-11-17(10-14(17)12-5-2-1-3-6-12)20-16(21)15(19)9-13-7-4-8-22-13/h1-8,14-15H,9-10,19H2,(H,20,21)/t14-,15+,17+/m1/s1",FUYOZZGSCQXNCB-VYDXJSESSA-N,50310690,"CHEMBL1078411::Cis-(S)-2-amino-N-((1R,2R)-1-cyano-2-phenylcyclopropyl)-3-(thiophen-2-yl)propanamide",Cathepsin B,Homo sapiens,>50000
1205723,COc1nc(Nc2cc(ncn2)-c2ccc(O[C@H]3CCN(C[C@H]3F)C(=O)OC(C)(C)C)c(c2)C#N)ccc1N1CCN(C)CC1,"InChI=1S/C32H39FN8O4/c1-32(2,3)45-31(42)41-11-10-27(23(33)19-41)44-26-8-6-21(16-22(26)18-34)24-17-29(36-20-35-24)37-28-9-7-25(30(38-28)43-5)40-14-12-39(4)13-15-40/h6-9,16-17,20,23,27H,10-15,19H2,1-5H3,(H,35,36,37,38)/t23-,27+/m1/s1",NKLLXDBYVMYKMP-KCWPFWIISA-N,570853,"US11440899, Example 57",Serine/threonine-protein kinase TBK1,,<100
1021382,NC(=O)c1ccc(cc1NC1CCC(O)CC1)-n1cccc1Cc1ccncc1,"InChI=1S/C23H26N4O2/c24-23(29)21-8-5-19(15-22(21)26-17-3-6-20(28)7-4-17)27-13-1-2-18(27)14-16-9-11-25-12-10-16/h1-2,5,8-13,15,17,20,26,28H,3-4,6-7,14H2,(H2,24,29)",QJNYTGIMTPSRNS-UHFFFAOYSA-N,210966,"2-(((1r,4r)-4-hydroxycyclohexyl)amino)-4-(2-(pyridin-4-ylmethyl)-1H-pyrrol-1-yl)benzamide (8q)::US10975030, Compound 8q",Heat shock protein HSP 90-alpha,Homo sapiens,
575602,FC(F)(F)Oc1ccc(cc1NC(=O)CN1CCOCC1)C(=O)Nc1ccc(cn1)-c1ccccc1,"InChI=1S/C25H23F3N4O4/c26-25(27,28)36-21-8-6-18(14-20(21)30-23(33)16-32-10-12-35-13-11-32)24(34)31-22-9-7-19(15-29-22)17-4-2-1-3-5-17/h1-9,14-15H,10-13,16H2,(H,30,33)(H,29,31,34)",OEZXPVZTYHPRBN-UHFFFAOYSA-N,300561,"3-[(morpholin-4-ylacetyl)amino]-N-(5-phenylpyridin-2-yl)-4-(trifluoromethoxy)benzamide::US10130633, Example 131",Protein Wnt-3a,Homo sapiens, 13000
50311266,Cc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(cc12)-c1ccc(c(F)c1)-c1ccccc1Cl,"InChI=1S/C33H28Cl2FNO2/c1-20-27-16-22(23-10-14-26(29(36)17-23)25-6-4-5-7-28(25)35)11-15-30(27)37(19-21-8-12-24(34)13-9-21)31(20)18-33(2,3)32(38)39/h4-17H,18-19H2,1-3H3,(H,38,39)",VHOPZWJNKYEBDX-UHFFFAOYSA-N,50168776,"3-(5-(2'-chloro-2-fluorobiphenyl-4-yl)-1-(4-chlorobenzyl)-3-methyl-1H-indol-2-yl)-2,2-dimethylpropanoic acid::3-[1-(4-Chloro-benzyl)-5-(2'-chloro-2-fluoro-biphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethyl-propionic acid::CHEMBL180617",Prostaglandin E synthase 2,, 4
1059154,Cn1cc2cccc([C@H](Nc3cc(C#N)c4ncc(C#N)c(NCC(C)(C)C)c4c3)C3=CN(NN3)C3(CC3)C(F)(F)F)c2n1,"InChI=1S/C31H31F3N10/c1-29(2,3)17-38-26-20(13-36)14-37-25-19(12-35)10-21(11-23(25)26)39-28(22-7-5-6-18-15-43(4)41-27(18)22)24-16-44(42-40-24)30(8-9-30)31(32,33)34/h5-7,10-11,14-16,28,39-40,42H,8-9,17H2,1-4H3,(H,37,38)/t28-/m0/s1",MQCAUZCMKYPSNH-NDEPHWFRSA-N,505924,"(S)-6-(((2-methyl-2H-indazol-7-yl)(1-(1- (trifluoromethyl)cyclopropyl)-1H-1,2,3- triazol-4-yl)methyl)amino)-4- (neopentylamino)quinoline-3,8-dicarbonitrile::US11066414, Compound 573",Epidermal growth factor receptor,Homo sapiens, 66.0
50362708,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N[C@H]3CCCO3)nc(nc12)-n1cc(cn1)C(=O)NCc1ccc(F)cc1,"InChI=1S/C25H27FN8O6/c26-15-5-3-13(4-6-15)8-27-23(38)14-9-29-34(10-14)25-31-21(30-17-2-1-7-39-17)18-22(32-25)33(12-28-18)24-20(37)19(36)16(11-35)40-24/h3-6,9-10,12,16-17,19-20,24,35-37H,1-2,7-8,11H2,(H,27,38)(H,30,31,32)/t16-,17-,19-,20-,24-/m1/s1",PLHMVORQBRPVOS-BNCYDMKUSA-N,50196573,"CHEMBL234779::N-(4-fluorobenzyl)-1-(9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-6-((R)-tetrahydrofuran-2-ylamino)-9H-purin-2-yl)-1H-pyrazole-4-carboxamide",Adenosine receptor A3,Homo sapiens,
50795825,CCCN1CCO[C@H]2[C@H]1CSc1ccc(O)cc21,"InChI=1S/C14H19NO2S/c1-2-5-15-6-7-17-14-11-8-10(16)3-4-13(11)18-9-12(14)15/h3-4,8,12,14,16H,2,5-7,9H2,1H3/t12-,14-/m1/s1",OMQYELRKBALQJF-TZMCWYRMSA-N,50090828,"(-)-1-Propyl-2,3,10,10a-tetrahydro-1H,4aH-4-oxa-9-thia-1-aza-phenanthren-6-ol::CHEMBL98305",D(3) dopamine receptor,,
50213446,O[C@@H](CNCCc1ccc(NC(=O)Cc2nc3ccccc3o2)cc1)c1cccnc1,"InChI=1S/C24H24N4O3/c29-21(18-4-3-12-25-15-18)16-26-13-11-17-7-9-19(10-8-17)27-23(30)14-24-28-20-5-1-2-6-22(20)31-24/h1-10,12,15,21,26,29H,11,13-14,16H2,(H,27,30)/t21-/m0/s1",XYCBBUPJVQZGNT-NRFANRHFSA-N,50313931,(R)-2-(benzo[d]oxazol-2-yl)-N-(4-(2-(2-hydroxy-2-(pyridin-3-yl)ethylamino)ethyl)phenyl)acetamide::CHEMBL1089725,Beta-2 adrenergic receptor,Homo sapiens, 1100
51119386,COCC1=C[C@](C)(N=C(N)O1)c1cc(NC(=O)c2ccc(cn2)C#N)ccc1F,"InChI=1S/C20H18FN5O3/c1-20(8-14(11-28-2)29-19(23)26-20)15-7-13(4-5-16(15)21)25-18(27)17-6-3-12(9-22)10-24-17/h3-8,10H,11H2,1-2H3,(H2,23,26)(H,25,27)/t20-/m0/s1",PBAGMXJDUUVRJA-FQEVSTJZSA-N,50457590,CHEMBL4217881,Beta-secretase 1,Homo sapiens, 74
50926400,Cc1nn(c2CC(C)(C)CC(=O)c12)-c1ccc2c(N)ncnc2c1,"InChI=1S/C18H19N5O/c1-10-16-14(7-18(2,3)8-15(16)24)23(22-10)11-4-5-12-13(6-11)20-9-21-17(12)19/h4-6,9H,7-8H2,1-3H3,(H2,19,20,21)",KXPMFHBHSVJEJF-UHFFFAOYSA-N,50379852,CHEMBL2011844,Heat shock protein HSP 90-beta,Homo sapiens, 5813
50078934,O=C1N(CC#CCN2CCN(CC2)c2nsc3ccccc23)C(=O)c2ccccc12,"InChI=1S/C23H20N4O2S/c28-22-17-7-1-2-8-18(17)23(29)27(22)12-6-5-11-25-13-15-26(16-14-25)21-19-9-3-4-10-20(19)30-24-21/h1-4,7-10H,11-16H2",LFDFDERYUSRWCV-UHFFFAOYSA-N,50048808,"2-[4-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-but-2-ynyl]-isoindole-1,3-dione::CHEMBL43513",5-hydroxytryptamine receptor 1A,Rattus norvegicus, 420
489026,COc1cccc(c1)C(O)CN1C[C@@H]2C[C@@H](C[C@@H]2C1)c1ccccc1,"InChI=1S/C22H27NO2/c1-25-21-9-5-8-17(12-21)22(24)15-23-13-19-10-18(11-20(19)14-23)16-6-3-2-4-7-16/h2-9,12,18-20,22,24H,10-11,13-15H2,1H3/t18-,19-,20+,22?",ZUEIFROVSPJZID-APLYNWFVSA-N,235316,"US10052306, 117::rac-1-(3- methoxyphenyl)-2-{5- phenyl- octahydrocyclopenta[c] pyrrol-2-yl}ethan-1-ol","Glutamate receptor ionotropic, NMDA 2B",Homo sapiens, 10000
386570,CC(C)NS(=O)(=O)c1ccc(OC\C(CN)=C/F)cc1,"InChI=1S/C13H19FN2O3S/c1-10(2)16-20(17,18)13-5-3-12(4-6-13)19-9-11(7-14)8-15/h3-7,10,16H,8-9,15H2,1-2H3/b11-7-",PBHHQZSGADNWMY-XFFZJAGNSA-N,220882,"US9302986, 33",Amine oxidase [flavin-containing] B,,>10000
72209,[O-]\[N+](=C/c1ccncc1)c1ccccc1,InChI=1S/C12H10N2O/c15-14(12-4-2-1-3-5-12)10-11-6-8-13-9-7-11/h1-10H/b14-10-,LJAZWXXSTFVHRG-UVTDQMKNSA-N,35380,MLS000096457::N-phenyl-1-(4-pyridyl)methanimine oxide::N-phenyl-1-pyridin-4-yl-methanimine oxide::N-phenyl-1-pyridin-4-ylmethanimine oxide::SMR000062185::cid_768563,M-phase inducer phosphatase 2,Homo sapiens, 28778
980668,CCc1noc(n1)-c1nnc2C(C)N(CCn12)C(=O)c1ccc(F)cc1,"InChI=1S/C17H17FN6O2/c1-3-13-19-16(26-22-13)15-21-20-14-10(2)23(8-9-24(14)15)17(25)11-4-6-12(18)7-5-11/h4-7,10H,3,8-9H2,1-2H3",AWKTWOOCLJMRQH-UHFFFAOYSA-N,242774,"US10030025, Compound 40::US10836768, Cpd no 40::US9422299, 40::US9987274, Compound 40",Substance-K receptor,Homo sapiens,
817718,Clc1cccc(c1)-c1cnc2ccn(CC(=O)N3CCC3)c2c1,"InChI=1S/C18H16ClN3O/c19-15-4-1-3-13(9-15)14-10-17-16(20-11-14)5-8-22(17)12-18(23)21-6-2-7-21/h1,3-5,8-11H,2,6-7,12H2",LZIYKUJNFOMIHT-UHFFFAOYSA-N,409597,"1-(Azetidin-1-yl)-2-[6-(3-chlorophenyl)pyrrolo[3,2-b]pyridin-1-::US10377753, Example 463","Glutamate receptor ionotropic, NMDA 2B",Homo sapiens, 100
984572,CC(=O)c1cn(CC(=O)N(CC(=O)NCc2cccc(Cl)c2F)C2CC2)c2ccc(NS(C)(=O)=O)cc12,"InChI=1S/C25H26ClFN4O5S/c1-15(32)20-12-30(22-9-6-17(10-19(20)22)29-37(2,35)36)14-24(34)31(18-7-8-18)13-23(33)28-11-16-4-3-5-21(26)25(16)27/h3-6,9-10,12,18,29H,7-8,11,13-14H2,1-2H3,(H,28,33)",IEQCBPCNLIJZFE-UHFFFAOYSA-N,474709,"US10849883, Compound 133c",Complement factor D,,<1000
1151439,CNc1cc(Nc2ncc3ccn(-c4cccc(NS(=O)(=O)C(C)(C)C)c4)c3n2)ccc1N1CCN(C)CC1,"InChI=1S/C28H36N8O2S/c1-28(2,3)39(37,38)33-22-7-6-8-23(17-22)36-12-11-20-19-30-27(32-26(20)36)31-21-9-10-25(24(18-21)29-4)35-15-13-34(5)14-16-35/h6-12,17-19,29,33H,13-16H2,1-5H3,(H,30,31,32)",SXFOBTSUQUOQBX-UHFFFAOYSA-N,543694,"US11279703, TABLE 6.283",Tyrosine-protein kinase JAK2,Homo sapiens, 22.0
50795729,Cc1ccc2c(N)cc(nc2n1)-c1ccccc1,"InChI=1S/C15H13N3/c1-10-7-8-12-13(16)9-14(18-15(12)17-10)11-5-3-2-4-6-11/h2-9H,1H3,(H2,16,17,18)",ZUQJILBTGSLROV-UHFFFAOYSA-N,50090708,"7-Methyl-2-phenyl-[1,8]naphthyridin-4-ylamine::7-methyl-2-phenyl-1,8-naphthyridin-4-amine::CHEMBL97337",Adenosine receptor A2a,Homo sapiens,
919461,OC(=O)[C@H](CCN1CC(CCc2ccc3CCCNc3n2)C1)NC(=O)[C@H]1CCN(C1)c1ccccn1,"InChI=1S/C27H36N6O3/c34-26(21-10-15-33(18-21)24-5-1-2-12-28-24)31-23(27(35)36)11-14-32-16-19(17-32)6-8-22-9-7-20-4-3-13-29-25(20)30-22/h1-2,5,7,9,12,19,21,23H,3-4,6,8,10-11,13-18H2,(H,29,30)(H,31,34)(H,35,36)/t21-,23-/m0/s1",YPRUMNIQLMEZFC-GMAHTHKFSA-N,448906,"US10696672, Compound 138",Integrin alpha-V/beta-6,Homo sapiens, 625
50331283,NNc1nc2ccccc2nc1Cc1ccccc1,"InChI=1S/C15H14N4/c16-19-15-14(10-11-6-2-1-3-7-11)17-12-8-4-5-9-13(12)18-15/h1-9H,10,16H2,(H,18,19)",VVXTVQMXZGMAAH-UHFFFAOYSA-N,50179015,1-(3-benzylquinoxalin-2-yl)hydrazine::CHEMBL379678,Amine oxidase [flavin-containing] B,Rattus norvegicus, 840000
51264285,COc1ccc(cn1)-n1c(CC#N)nnc1N1C[C@@H]2C[C@@]2(C1)c1ccc(F)cc1Cl,"InChI=1S/C21H18ClFN6O/c1-30-19-5-3-15(10-25-19)29-18(6-7-24)26-27-20(29)28-11-13-9-21(13,12-28)16-4-2-14(23)8-17(16)22/h2-5,8,10,13H,6,9,11-12H2,1H3/t13-,21-/m0/s1",DDPIHYVFODKELW-ZSEKCTLFSA-N,50516424,CHEMBL4575160,Vasopressin V1a receptor,, 769
355799,CCOc1ccc(CC(=O)CNN([C@@H](Cc2ccccc2)C(=O)NCc2ccc(CN)c(Cl)c2)C(=O)CC)cc1,"InChI=1S/C31H37ClN4O4/c1-3-30(38)36(35-21-26(37)16-23-11-14-27(15-12-23)40-4-2)29(18-22-8-6-5-7-9-22)31(39)34-20-24-10-13-25(19-33)28(32)17-24/h5-15,17,29,35H,3-4,16,18-21,33H2,1-2H3,(H,34,39)/t29-/m0/s1",SBMXVJAAZJABGK-LJAQVGFWSA-N,200032,"US9234000, 23",Plasma kallikrein,, 31
51408603,Clc1ccc2CC(CCN3CCN(CC3)c3ccccn3)Cc2c1,"InChI=1S/C20H24ClN3/c21-19-5-4-17-13-16(14-18(17)15-19)6-8-23-9-11-24(12-10-23)20-3-1-2-7-22-20/h1-5,7,15-16H,6,8-14H2",HVROSOVHMGPEMN-UHFFFAOYSA-N,50568916,CHEMBL4866058,5-hydroxytryptamine receptor 7,Homo sapiens,
51059313,Cc1ccc(cc1)S(=O)(=O)Nc1ccc2C(=O)N(CCOc3cccc(O)c3)C(=O)c2c1,"InChI=1S/C23H20N2O6S/c1-15-5-8-19(9-6-15)32(29,30)24-16-7-10-20-21(13-16)23(28)25(22(20)27)11-12-31-18-4-2-3-17(26)14-18/h2-10,13-14,24,26H,11-12H2,1H3",CFHJQDAGMYKZRK-UHFFFAOYSA-N,50432215,CHEMBL2347150,Lysosomal alpha-glucosidase,Rattus norvegicus, 55600
412509,CC(C)[C@@H]1C[C@H]2[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O,"InChI=1S/C23H31NO2/c1-14(2)18-11-20-21-9-16-5-6-17(25)10-19(16)23(20,12-22(18)26)7-8-24(21)13-15-3-4-15/h5-6,10,14-15,18,20-21,25H,3-4,7-9,11-13H2,1-2H3/t18-,20-,21+,23+/m0/s1",JIYAXHKPIXIXDQ-VXPBHUBDSA-N,236866,"US9388162, 73",Kappa-type opioid receptor,Homo sapiens,
977889,CC1(CCC(=O)N2CCN(CC2)c2ccc(OC(F)(F)F)cc2)NC(=O)NC1=O,"InChI=1S/C18H21F3N4O4/c1-17(15(27)22-16(28)23-17)7-6-14(26)25-10-8-24(9-11-25)12-2-4-13(5-3-12)29-18(19,20)21/h2-5H,6-11H2,1H3,(H2,22,23,27,28)",ARBBXRIMFUIHSQ-UHFFFAOYSA-N,471722,"5-methyl-5-[3- oxo-3-[4-[4- (trifluoromethoxy) phenyl]piperazin- 1-yl]propyl] imidazolidine- 2,4-dione::US10829478, Compound 3",A disintegrin and metalloproteinase with thrombospondin motifs 4,Homo sapiens,>10000
619570,CC[C@@H]1CN(CCN1c1cnc2[nH]cc(C(=O)NC(C)C)c2n1)C(=O)C=C,,,316824,"2-[(2R)-4-acryloyl-2-ethylpiperazin-1-yl]-N-(propan-2-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxamide::US11111242, Example 321::US9617258, Example 321",Tyrosine-protein kinase JAK3,Homo sapiens, 144
918809,CN(CCCO)Cc1cc(nc(n1)C(F)(F)F)C(=O)N1CCC(CC1)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12,"InChI=1S/C30H34F3N11O2/c1-41(9-2-12-45)16-21-13-24(40-28(39-21)30(31,32)33)27(46)42-10-4-22(5-11-42)43-17-29(18-43,6-7-34)44-15-20(14-38-44)25-23-3-8-35-26(23)37-19-36-25/h3,8,13-15,19,22,45H,2,4-6,9-12,16-18H2,1H3,(H,35,36,37)",YIIGWJSOXWUCMP-UHFFFAOYSA-N,400629,"US10695337, Example 385::US11285140, Example 385::US9999619, Example 385::{1-(1-{[6-{[(3-hydroxypropyl)(methyl)amino]methyl}-2-(trifluoromethyl)pyrimidin-4-yl]carbonyl}piperidin-4-yl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile",Tyrosine-protein kinase JAK1 [837-1142],,<5.00
377373,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](C[C@]21C)c1ccoc1,"InChI=1S/C23H28O8/c1-12(24)30-16-9-15(20(26)28-4)22(2)7-5-14-21(27)31-17(13-6-8-29-11-13)10-23(14,3)19(22)18(16)25/h6,8,11,14-17,19H,5,7,9-10H2,1-4H3/t14-,15-,16-,17-,19-,22-,23-/m0/s1",OBSYBRPAKCASQB-AGQYDFLVSA-N,50159165,"(2S,4aR,6aR,7R,9S,10aS,10bR)-9-(acetyloxy)-2-(furan-3-yl)dodecahydro-6a,10b-dimethyl-4,10-dioxo-2H-naphtho-[2,1-c]pyran-7-carboxylic acid methyl ester::(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-(acetylthio)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-dodecahydro-1H-benzo[f]isochromene-7-carboxylate::(2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-dodecahydro-1H-benzo[f]isochromene-7-carboxylate::(3S,4aR,4bS,6S,8R,8aR,10aR)-6-Acetoxy-3-furan-3-yl-4a,8a-dimethyl-1,5-dioxo-dodecahydro-2-oxa-phenanthrene-8-carboxylic acid methyl ester::2S,4aR,6a(R,7R,9S,10aS,10bR)-9-(acetyloxy)-2-(furan-3-yl)dodecahydro-6a,10b-dimethyl-4,10-dioxo-2H-naphtho[2,1-c]pyran-7-carboxylic acid methyl ester::CHEMBL445332::Salvinorin A::Salvonorin A::salvinorin-A",Kappa-type opioid receptor [H291F],,
137695,COc1ccc(cc1)-c1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)Nc2onc(C)c2C)c2ccccc2n1,"InChI=1S/C28H24N4O5S/c1-17-18(2)31-37-28(17)32-38(34,35)22-14-10-20(11-15-22)29-27(33)24-16-26(19-8-12-21(36-3)13-9-19)30-25-7-5-4-6-23(24)25/h4-16,32H,1-3H3,(H,29,33)",UDIKDAMDJUXXDX-UHFFFAOYSA-N,76088,"MLS-0295640.0001::N-[4-[(3,4-dimethyl-1,2-oxazol-5-yl)sulfamoyl]phenyl]-2-(4-methoxyphenyl)quinoline-4-carboxamide::N-[4-[(3,4-dimethyl-5-isoxazolyl)sulfamoyl]phenyl]-2-(4-methoxyphenyl)-4-quinolinecarboxamide::N-[4-[(3,4-dimethylisoxazol-5-yl)sulfamoyl]phenyl]-2-(4-methoxyphenyl)cinchoninamide::cid_2333197",G-protein coupled receptor 55,Homo sapiens, 18200
51152153,CC(=O)NCC1CCCc2c1c1ccccc1n2C,"InChI=1S/C16H20N2O/c1-11(19)17-10-12-6-5-9-15-16(12)13-7-3-4-8-14(13)18(15)2/h3-4,7-8,12H,5-6,9-10H2,1-2H3,(H,17,19)",FXGOVZAZDXYZHV-UHFFFAOYSA-N,50472154,CHEMBL127827,Melatonin receptor type 1C,,
1073449,Fc1ccc2[nH]c(cc2c1)C(=O)On1nnc2ccccc12,"InChI=1S/C15H9FN4O2/c16-10-5-6-11-9(7-10)8-13(17-11)15(21)22-20-14-4-2-1-3-12(14)18-19-20/h1-8,17H",PAEPADFRKKOUIH-UHFFFAOYSA-N,59244,"Benzotriazole ester, 10::acs.jmedchem.1c00409_ST.11",Replicase polyprotein 1ab,Human SARS coronavirus,
578339,NC(=O)CN1CCC[C@H]1c1nc2ccccc2n1[C@@H]1C[C@@H]2CCC[C@H](C1)N2[C@H]1C[C@@H]2C[C@H](C1)CCCC2,"InChI=1S/C31H45N5O/c32-30(37)20-34-14-6-13-29(34)31-33-27-11-3-4-12-28(27)36(31)26-18-23-9-5-10-24(19-26)35(23)25-16-21-7-1-2-8-22(15-21)17-25/h3-4,11-12,21-26,29H,1-2,5-10,13-20H2,(H2,32,37)/t21-,22+,23-,24+,25-,26+,29-/m0/s1",WGMLKJXEFMLZMR-FDYHHLSLSA-N,172388,"US9090618, H36b(i)::US9598411, Ref. No. H36b(i)",Delta-type opioid receptor,Homo sapiens,
50714554,Cc1coc-2c1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc-21,"InChI=1S/C19H18O3/c1-10-9-22-18-12-6-7-13-11(5-4-8-19(13,2)3)15(12)17(21)16(20)14(10)18/h6-7,9H,4-5,8H2,1-3H3",HYXITZLLTYIPOF-UHFFFAOYSA-N,83922,"1,6,6-trimethyl-8,9-dihydro-7H-naphtho[1,2-g][1]benzofuran-10,11-dione::1,6,6-trimethyl-8,9-dihydro-7H-naphtho[1,2-g]benzofuran-10,11-dione::1,6,6-trimethyl-8,9-dihydro-7H-naphtho[1,2-g]benzofuran-10,11-quinone::MLS001048863::SMR000387068::acs.jmedchem.1c00409_ST.743::cid_164676::med.21724, Compound 173",Aldo-keto reductase family 1 member B1,Rattus norvegicus, 1140
191476,Clc1cccc(NC(=O)CC2SCCNC2=O)c1,"InChI=1S/C12H13ClN2O2S/c13-8-2-1-3-9(6-8)15-11(16)7-10-12(17)14-4-5-18-10/h1-3,6,10H,4-5,7H2,(H,14,17)(H,15,16)",NOVSTNSQVOXPFL-UHFFFAOYSA-N,87390,MLS000042591::N-(3-chlorophenyl)-2-(3-ketothiomorpholin-2-yl)acetamide::N-(3-chlorophenyl)-2-(3-oxidanylidenethiomorpholin-2-yl)ethanamide::N-(3-chlorophenyl)-2-(3-oxo-2-thiomorpholinyl)acetamide::N-(3-chlorophenyl)-2-(3-oxothiomorpholin-2-yl)acetamide::SMR000047743::cid_666338,Tyrosine-protein kinase ABL1,Homo sapiens, 20779
50575096,CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3SCCc3n2)c1,"InChI=1S/C33H37NO3S2/c1-32(2,37)27-9-4-3-7-24(27)11-14-29(39-22-33(17-18-33)21-31(35)36)25-8-5-6-23(20-25)10-12-26-13-15-30-28(34-26)16-19-38-30/h3-10,12-13,15,20,29,37H,11,14,16-19,21-22H2,1-2H3,(H,35,36)/b12-10+/t29-/m1/s1",KIUKUOYAZCSXNU-KSGUIJNZSA-N,50069370,"(1-{(R)-1-{3-[(E)-2-(2,3-Dihydro-thieno[3,2-b]pyridin-5-yl)-vinyl]-phenyl}-3-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-propylsulfanylmethyl}-cyclopropyl)-acetic acid::CHEMBL140058",Cysteinyl leukotriene receptor 1/2,Homo sapiens, 4.8
35087,COc1ccc(NCCNC(=O)[C@H](CC2CCCCC2)NC(=O)c2ccc(o2)-c2cccc(c2)C(F)(F)F)cc1,"InChI=1S/C30H34F3N3O4/c1-39-24-12-10-23(11-13-24)34-16-17-35-28(37)25(18-20-6-3-2-4-7-20)36-29(38)27-15-14-26(40-27)21-8-5-9-22(19-21)30(31,32)33/h5,8-15,19-20,25,34H,2-4,6-7,16-18H2,1H3,(H,35,37)(H,36,38)/t25-/m0/s1",NZOFHAVIEGVENV-VWLOTQADSA-N,19582,"(2S)-3-cyclohexyl-N-{2-[(4-methoxyphenyl)amino]ethyl}-2-({5-[3-(trifluoromethyl)phenyl]furan-2-yl}formamido)propanamide::arylaminoethyl amide, 20",Procathepsin L,Homo sapiens,
50499428,Cl.COc1ccccc1CCN1CCC(CCc2ccccc2)CC1,"InChI=1S/C22H29NO.ClH/c1-24-22-10-6-5-9-21(22)15-18-23-16-13-20(14-17-23)12-11-19-7-3-2-4-8-19;/h2-10,20H,11-18H2,1H3;1H",UXVNZNMGKOEYFF-UHFFFAOYSA-N,50175675,CHEMBL3808752,Synaptic vesicular amine transporter,,
771983,COC(=O)N1CCC[C@H](NS(C)(=O)=O)[C@@H]1CO[C@H]1CC[C@H](CC1)c1cccc(OC(F)(F)F)c1,"InChI=1S/C22H31F3N2O6S/c1-31-21(28)27-12-4-7-19(26-34(2,29)30)20(27)14-32-17-10-8-15(9-11-17)16-5-3-6-18(13-16)33-22(23,24)25/h3,5-6,13,15,17,19-20,26H,4,7-12,14H2,1-2H3/t15-,17+,19-,20-/m0/s1",FFALFBUYRHALAB-RKOGWWSCSA-N,386853,"US10287305, Example 298::US10508083, Example 298::US11292766, Example 298::methyl cis-3- ((methylsulfonyl)amino)-2-(((cis-4- (3-(trifluoromethoxy)phenyl)- cyclohexyl)oxy)methyl)piperidine-1- carboxylate",Orexin receptor type 2,Homo sapiens,
51283359,C[C@]12CC[C@H]3[C@@H](C[C@H](CC=C)C4=CCCC[C@]34C)[C@@H]1CCC2=O,"InChI=1S/C22H32O/c1-4-7-15-14-16-18-9-10-20(23)22(18,3)13-11-19(16)21(2)12-6-5-8-17(15)21/h4,8,15-16,18-19H,1,5-7,9-14H2,2-3H3/t15-,16-,18-,19-,21-,22-/m0/s1",JZFCNWOGDZOWOU-AHFNSMAVSA-N,50523400,CHEMBL4520056,Aromatase,Homo sapiens, 210
791095,COCc1nc(no1)-c1cc(OCC2CC2)c(cn1)C1CC1,"InChI=1S/C16H19N3O3/c1-20-9-15-18-16(19-22-15)13-6-14(21-8-10-2-3-10)12(7-17-13)11-4-5-11/h6-7,10-11H,2-5,8-9H2,1H3",QVIXNVNASKMGFT-UHFFFAOYSA-N,395813,"3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-5-(methoxymethyl)-1,2,4-oxadiazole::US10308659, Example 12",Cannabinoid receptor 2,Homo sapiens,
1146436,OC(=O)CCC1CCc2cc(ccc2O1)-c1cccnc1OC1CCC1,"InChI=1S/C21H23NO4/c23-20(24)11-9-17-8-6-15-13-14(7-10-19(15)25-17)18-5-2-12-22-21(18)26-16-3-1-4-16/h2,5,7,10,12-13,16-17H,1,3-4,6,8-9,11H2,(H,23,24)",GSCRGXIKILNDPJ-UHFFFAOYSA-N,540346,"US11261186, Example 277",Free fatty acid receptor 4,Homo sapiens,
50477544,CN1c2ccccc2C(=NC(NC(=O)Nc2cccc(C)c2)C1=O)c1cccc(OCC(=O)NCCC(=O)NCCCOc2cccc(CN3CCCCC3)c2)c1,"InChI=1S/C44H51N7O6/c1-31-12-8-15-34(26-31)47-44(55)49-42-43(54)50(2)38-19-5-4-18-37(38)41(48-42)33-14-10-17-36(28-33)57-30-40(53)46-22-20-39(52)45-21-11-25-56-35-16-9-13-32(27-35)29-51-23-6-3-7-24-51/h4-5,8-10,12-19,26-28,42H,3,6-7,11,20-25,29-30H2,1-2H3,(H,45,52)(H,46,53)(H2,47,49,55)",HTOJUIVQXWRKOG-UHFFFAOYSA-N,50287242,"3-(2-{3-[1-Methyl-2-oxo-3-(3-m-tolyl-ureido)-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-phenoxy}-acetylamino)-N-[3-(3-piperidin-1-ylmethyl-phenoxy)-propyl]-propionamide::CHEMBL282646",Gastrin/cholecystokinin type B receptor,Mus musculus, 760
50875344,CN(C)c1ccc(\C=C\c2cc3ccccc3o2)cc1,"InChI=1S/C18H17NO/c1-19(2)16-10-7-14(8-11-16)9-12-17-13-15-5-3-4-6-18(15)20-17/h3-13H,1-2H3/b12-9+",XLEXDXOZTVTOAH-FMIVXFBMSA-N,50263827,"4-(2-(benzofuran-2-yl)vinyl)-N,N-dimethylbenzenamine::CHEMBL492216",Amyloid-beta precursor protein,Homo sapiens, 2300
51401819,CCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N1CCC[C@H]1C(=O)N[C@H](Cc1cccc(c1)-c1ccccc1)C(O)=O,,,50566285,CHEMBL4879061,Apelin receptor,Homo sapiens,
737885,C[C@@H]1COCCN1c1cc(nn(C)c1=O)-c1cc(NC(=O)c2ccnc(c2)C(C)(C)F)ccc1C,"InChI=1S/C26H30FN5O3/c1-16-6-7-19(29-24(33)18-8-9-28-23(12-18)26(3,4)27)13-20(16)21-14-22(25(34)31(5)30-21)32-10-11-35-15-17(32)2/h6-9,12-14,17H,10-11,15H2,1-5H3,(H,29,33)/t17-/m1/s1",CPJKUNGRXXQWFE-QGZVFWFLSA-N,86398,"US10245267, Example 673::US10709712, Example 673::US9694016, 673",RAF proto-oncogene serine/threonine-protein kinase,Homo sapiens, 2.70
1168349,NCCCCC(NC(=O)c1ccc(F)nc1)C(=O)COc1ccon1,"InChI=1S/C16H19FN4O4/c17-14-5-4-11(9-19-14)16(23)20-12(3-1-2-7-18)13(22)10-24-15-6-8-25-21-15/h4-6,8-9,12H,1-3,7,10,18H2,(H,20,23)",BQOGBOZVNFTTKQ-UHFFFAOYSA-N,553834,"US11325884, Compound 55a",Cathepsin L2,Homo sapiens,>10000
50713115,CC(=O)N[C@@H](Cc1ccccc1)C(=O)Nc1ccc(cc1)C(=O)NS(=O)(=O)c1ccc(NCCSc2ccccc2)c(c1)[N+]([O-])=O,"InChI=1S/C32H31N5O7S2/c1-22(38)34-29(20-23-8-4-2-5-9-23)32(40)35-25-14-12-24(13-15-25)31(39)36-46(43,44)27-16-17-28(30(21-27)37(41)42)33-18-19-45-26-10-6-3-7-11-26/h2-17,21,29,33H,18-20H2,1H3,(H,34,38)(H,35,40)(H,36,39)/t29-/m0/s1",FYLZETVUGWJRIK-LJAQVGFWSA-N,50362146,CHEMBL1940665,Bcl-2-like protein 1,Homo sapiens,
927552,Cc1ccc(NC(=O)c2cccc(c2)C(F)F)cc1-c1cc(N2CCOCC2)c2nccn2c1,"InChI=1S/C26H24F2N4O2/c1-17-5-6-21(30-26(33)19-4-2-3-18(13-19)24(27)28)15-22(17)20-14-23(31-9-11-34-12-10-31)25-29-7-8-32(25)16-20/h2-8,13-16,24H,9-12H2,1H3,(H,30,33)",DPTXNTRRZXCRJM-UHFFFAOYSA-N,87818,"US10245267, Example 848::US10709712, Example 848::US9694016, 848",RAF proto-oncogene serine/threonine-protein kinase,Homo sapiens, 0.100
804469,CN1C(=N)N[C@]2(CCC[C@H]2S1(=O)=O)c1cc(NC(=O)c2cnc(C)cn2)ccc1F,"InChI=1S/C19H21FN6O3S/c1-11-9-23-15(10-22-11)17(27)24-12-5-6-14(20)13(8-12)19-7-3-4-16(19)30(28,29)26(2)18(21)25-19/h5-6,8-10,16H,3-4,7H2,1-2H3,(H2,21,25)(H,24,27)/t16-,19-/m1/s1",TZNJQQFHTFHSBF-VQIMIIECSA-N,50271174,CHEMBL4126480,Beta-secretase 2,,
50558724,OC\C=C1/O[C@@H]2CC(=O)N2[C@H]1C(O)=O,"InChI=1S/C8H9NO5/c10-2-1-4-7(8(12)13)9-5(11)3-6(9)14-4/h1,6-7,10H,2-3H2,(H,12,13)/b4-1-/t6-,7-/m1/s1",HZZVJAQRINQKSD-PBFISZAISA-N,50021959,"CHEMBL777::MM 14151::US9120808, Clavulanic acid potassium salt::antibiotic MM 14151::clavulanic acid",Metallo-beta-lactamase type 2,, 251
83497,Brc1ccc(NCc2cc(=O)n3ccsc3n2)cc1,"InChI=1S/C13H10BrN3OS/c14-9-1-3-10(4-2-9)15-8-11-7-12(18)17-5-6-19-13(17)16-11/h1-7,15H,8H2",RCKHQWYVODHOIN-UHFFFAOYSA-N,45204,"7-[(4-bromoanilino)methyl]-5-thiazolo[3,2-a]pyrimidinone::7-[(4-bromoanilino)methyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one::7-[(4-bromoanilino)methyl]thiazolo[3,2-a]pyrimidin-5-one::7-[[(4-bromophenyl)amino]methyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one::MLS000335421::SMR000250125::cid_2492524",Multidrug resistance-associated protein 1,,
50063652,CC[C@H](C)[C@H](NC(=O)[C@H]1CCCN1C[C@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](C(C)C)C(=O)OC,"InChI=1S/C42H68N8O11/c1-9-25(6)36(41(59)48-35(24(4)5)42(60)61-8)49-40(58)32-16-13-17-50(32)21-33(53)28(19-27-14-11-10-12-15-27)45-38(56)30(20-34(43)54)47-37(55)29(18-23(2)3)46-39(57)31(22-51)44-26(7)52/h10-12,14-15,23-25,28-33,35-36,51,53H,9,13,16-22H2,1-8H3,(H2,43,54)(H,44,52)(H,45,56)(H,46,57)(H,47,55)(H,48,59)(H,49,58)/t25-,28-,29-,30-,31-,32+,33-,35-,36-/m0/s1",MJOXWVYKMFPFPL-CFAAZYDSSA-N,50000751,CHEMBL300050,Gag-Pol polyprotein [489-587],Human immunodeficiency virus 1,
51103333,FC(F)(F)c1cccc(NC(=O)c2ccccc2NC(=O)C2CCCCCC2)c1,"InChI=1S/C22H23F3N2O2/c23-22(24,25)16-10-7-11-17(14-16)26-21(29)18-12-5-6-13-19(18)27-20(28)15-8-3-1-2-4-9-15/h5-7,10-15H,1-4,8-9H2,(H,26,29)(H,27,28)",IIWZJZLNNDCNKN-UHFFFAOYSA-N,50449878,CHEMBL3719257,Relaxin receptor 1,Homo sapiens,
994180,CC(=O)NCC#Cc1ccc(OCc2nnc(SC3CCCC=C3)n2-c2cccnc2)cc1C,"InChI=1S/C26H27N5O2S/c1-19-16-23(13-12-21(19)8-6-15-28-20(2)32)33-18-25-29-30-26(34-24-10-4-3-5-11-24)31(25)22-9-7-14-27-17-22/h4,7,9-10,12-14,16-17,24H,3,5,11,15,18H2,1-2H3,(H,28,32)",TXNDEOARBDGWNO-UHFFFAOYSA-N,478230,"US10894782, No 83",Transitional endoplasmic reticulum ATPase,, 46.0
50278190,CC1=CC(=O)N(Cc2c(F)cccc2F)S(=O)(=O)O1,"InChI=1S/C11H9F2NO4S/c1-7-5-11(15)14(19(16,17)18-7)6-8-9(12)3-2-4-10(8)13/h2-5H,6H2,1H3",BPKVXAKFVAFVAU-UHFFFAOYSA-N,50050782,CHEMBL3322453,Carbonic anhydrase 9,Homo sapiens,
51136288,CC(=O)N[C@@H]1[C@@H](O)C=C(O[C@H]1[C@H](O)[C@H](O)CNC(=O)c1ccc(N)cc1)C(O)=O,"InChI=1S/C18H23N3O8/c1-8(22)21-14-11(23)6-13(18(27)28)29-16(14)15(25)12(24)7-20-17(26)9-2-4-10(19)5-3-9/h2-6,11-12,14-16,23-25H,7,19H2,1H3,(H,20,26)(H,21,22)(H,27,28)/t11-,12+,14+,15+,16+/m0/s1",UZCSUOHIFZYFTP-OVJXPFRRSA-N,50465959,CHEMBL4287431,Sialidase-1,Homo sapiens, 29000
690085,CN(C)C1CCCN(C1)C(=O)c1ccc(cc1)-c1cccc2nc(NC(=O)C3CC3)nn12,"InChI=1S/C24H28N6O2/c1-28(2)19-5-4-14-29(15-19)23(32)18-12-8-16(9-13-18)20-6-3-7-21-25-24(27-30(20)21)26-22(31)17-10-11-17/h3,6-9,12-13,17,19H,4-5,10-11,14-15H2,1-2H3,(H,26,27,31)",XITHZEACRCHNAV-UHFFFAOYSA-N,349135,"Cyclopropanecarboxylic acid {5-[4-(3-dimethylamino- piperidine-1-carbonyl)- phenyl]-[1,2,4]triazolo[1,5- a]pyridin-2-yl}-amide::US10206907, Compound 269",Tyrosine-protein kinase JAK2 [808-1132],,>1000
50551730,Cn1nc(C(N)=O)c2CCc3cnc(NCc4ccc(cc4)S(C)(=O)=O)nc3-c12,"InChI=1S/C19H20N6O3S/c1-25-17-14(16(24-25)18(20)26)8-5-12-10-22-19(23-15(12)17)21-9-11-3-6-13(7-4-11)29(2,27)28/h3-4,6-7,10H,5,8-9H2,1-2H3,(H2,20,26)(H,21,22,23)",RBAODIAUJYQMMC-UHFFFAOYSA-N,50307540,"1-Methyl-8-{[4-(methylsulfonyl)benzyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide::CHEMBL598987",Aurora kinase A,Homo sapiens, 890
51162049,CC[C@H]1OC(O)=C2[C@@H](C3=C(COCC3=O)N=C12)c1ccc(F)c(Br)c1,"InChI=1S/C18H15BrFNO4/c1-2-13-17-16(18(23)25-13)14(8-3-4-10(20)9(19)5-8)15-11(21-17)6-24-7-12(15)22/h3-5,13-14,23H,2,6-7H2,1H3/t13-,14-/m1/s1",UTHUTBNOTJCXJO-ZIAGYGMSSA-N,50475982,CHEMBL215375,ATP-binding cassette sub-family C member 9/ATP-sensitive inward rectifier potassium channel 11,,
467275,CC(C)(Cc1nc2cc(OCc3ccc4ccccc4n3)ccc2n1Cc1ccccc1Br)C(O)=O,"InChI=1S/C29H26BrN3O3/c1-29(2,28(34)35)16-27-32-25-15-22(36-18-21-12-11-19-7-4-6-10-24(19)31-21)13-14-26(25)33(27)17-20-8-3-5-9-23(20)30/h3-15H,16-18H2,1-2H3,(H,34,35)",CTKFJQUTIYCJCC-UHFFFAOYSA-N,165000,"US9067917, 33::US9682971, 33",Arachidonate 5-lipoxygenase-activating protein,Homo sapiens,
51101787,Cc1cnc(C)c2nc(nn12)-c1ccc2nc([nH]c2c1)-c1ncccc1F,"InChI=1S/C40H66N12O4/c41-51-49-33-17-19-35(37(53)31-33)39(55)47-29-15-27-45-25-13-7-5-11-23-43-21-9-3-1-2-4-10-22-44-24-12-6-8-14-26-46-28-16-30-48-40(56)36-20-18-34(50-52-42)32-38(36)54/h17-20,31-32,43-46,53-54H,1-16,21-30H2,(H,47,55)(H,48,56)",MUVXQSMBGIYDEY-UHFFFAOYSA-N,50422428,CHEMBL4173656,"cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A",Homo sapiens, 69
51412904,C\C(=N/NC(=O)c1ccc(C)c(F)c1)c1ccc(cc1)C(=O)Nc1cc(ccn1)N1CCOCC1,"InChI=1S/C26H26FN5O3/c1-17-3-4-21(15-23(17)27)26(34)31-30-18(2)19-5-7-20(8-6-19)25(33)29-24-16-22(9-10-28-24)32-11-13-35-14-12-32/h3-10,15-16H,11-14H2,1-2H3,(H,31,34)(H,28,29,33)/b30-18+",FSLZHWYVXKKRCN-UXHLAJHPSA-N,50570767,CHEMBL4852194,Serine/threonine-protein kinase mTOR,Homo sapiens, 3830
51330946,ONC(=O)c1ccc(NC(=O)C2(CCCCC2)c2ccc(cc2)-c2cn[nH]c2)cc1,"InChI=1S/C23H24N4O3/c28-21(27-30)17-6-10-20(11-7-17)26-22(29)23(12-2-1-3-13-23)19-8-4-16(5-9-19)18-14-24-25-15-18/h4-11,14-15,30H,1-3,12-13H2,(H,24,25)(H,26,29)(H,27,28)",CWMHAEARRTUTJU-UHFFFAOYSA-N,50538657,CHEMBL4639966,Histone deacetylase 2,Homo sapiens, 10.0
227564,Oc1ccccc1CNNC(=O)c1ccccc1O,"InChI=1S/C14H14N2O3/c17-12-7-3-1-5-10(12)9-15-16-14(19)11-6-2-4-8-13(11)18/h1-8,15,17-18H,9H2,(H,16,19)",SJSJXRMQLWUZCN-UHFFFAOYSA-N,50056898,2-Hydroxy-benzoic acid N'-(2-hydroxy-benzyl)-hydrazide::2-hydroxy-N&#39;-[(2- hydroxyphenyl)methyl]benzohydrazide (Compound 4)::CHEMBL433983,Gag-Pol polyprotein [1148-1435],Human immunodeficiency virus 1, 7e+2
50555375,NCCO.CC(=O)Nc1cccc2ccc(CCc3c([nH]c(=O)[nH]c3=O)C(O)=O)cc12,"InChI=1S/C19H17N3O5/c1-10(23)20-15-4-2-3-12-7-5-11(9-14(12)15)6-8-13-16(18(25)26)21-19(27)22-17(13)24/h2-5,7,9H,6,8H2,1H3,(H,20,23)(H,25,26)(H2,21,22,24,27)",FDHKZJZWEILTCM-UHFFFAOYSA-N,50212055,CHEMBL3971851,"Dihydroorotate dehydrogenase (quinone), mitochondrial",Homo sapiens, 3960
873177,CC(C)C(=O)N1CCC11CCN(CC1)c1ccc(cn1)-c1cc(OCCN2CCOCC2)cn2ncc(C#N)c12,"InChI=1S/C30H37N7O3/c1-22(2)29(38)36-10-7-30(36)5-8-35(9-6-30)27-4-3-23(19-32-27)26-17-25(21-37-28(26)24(18-31)20-33-37)40-16-13-34-11-14-39-15-12-34/h3-4,17,19-22H,5-16H2,1-2H3",YZSQXGWVBAFQIZ-UHFFFAOYSA-N,296799,"US10112942, Example 534::US10137124, Example 534::US10172851, Example 534::US10555944, Example 534::US10953005, Example 534","Proto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M]",, 625
51167756,CN(C)c1ccc(cc1)-c1cn(CCCCCC(=O)NO)nn1,"InChI=1S/C16H23N5O2/c1-20(2)14-9-7-13(8-10-14)15-12-21(19-17-15)11-5-3-4-6-16(22)18-23/h7-10,12,23H,3-6,11H2,1-2H3,(H,18,22)",ZOMJMENPBZNACI-UHFFFAOYSA-N,50478819,6-(4-Anilyl)Triazolylhexahydroxamic Acid::CHEMBL478115,Histone deacetylase 1/2/3/4/5/6/7/8/9/11/Polyamine deacetylase HDAC10,Homo sapiens, 4.3
314587,COC1CCN(Cc2cc(Cl)c(F)c(CNC(=O)[C@@H]3C[C@@H](F)CN3C(=O)Nc3cn(C(N)=O)c4ccccc34)c2)CC1,"InChI=1S/C29H33ClF2N6O4/c1-42-20-6-8-36(9-7-20)14-17-10-18(26(32)22(30)11-17)13-34-27(39)25-12-19(31)15-38(25)29(41)35-23-16-37(28(33)40)24-5-3-2-4-21(23)24/h2-5,10-11,16,19-20,25H,6-9,12-15H2,1H3,(H2,33,40)(H,34,39)(H,35,41)/t19-,25+/m1/s1",KNLSASNHWQZNFN-CLOONOSVSA-N,170595,"US9085555, 20",Complement factor D,, 1126
50757062,CC[C@H](C)[C@H](NC(=O)C[C@H](O)[C@H](CC1CCCCC1)NC(=O)CCNC(=O)[C@@H](Cc1ccccc1)NC(=O)CC(C)(C)N)C(=O)NCc1cnc(C)nc1N,"InChI=1S/C40H63N9O6/c1-6-25(2)36(39(55)45-24-29-23-44-26(3)46-37(29)41)49-34(52)21-32(50)30(19-27-13-9-7-10-14-27)47-33(51)17-18-43-38(54)31(20-28-15-11-8-12-16-28)48-35(53)22-40(4,5)42/h8,11-12,15-16,23,25,27,30-32,36,50H,6-7,9-10,13-14,17-22,24,42H2,1-5H3,(H,43,54)(H,45,55)(H,47,51)(H,48,53)(H,49,52)(H2,41,44,46)/t25-,30-,31+,32-,36-/m0/s1",FNYXLVDAMGHCMH-RGXDSYRCSA-N,50368156,CHEMBL1203096,Cathepsin D,Bos taurus,>10000
50156011,CC[S@@](=O)c1ccc(cc1)-c1coc2ccc(cc12)-c1ccc(C)o1,"InChI=1S/C21H18O3S/c1-3-25(22)17-8-5-15(6-9-17)19-13-23-21-11-7-16(12-18(19)21)20-10-4-14(2)24-20/h4-13H,3H2,1-2H3/t25-/m1/s1",NCGGCRHITOMNJS-RUZDIDTESA-N,50299082,(R)-3-(4-(ethylsulfinyl)phenyl)-5-(5-methylfuran-2-yl)benzofuran::CHEMBL575882,Glycogen synthase kinase-3 beta,Homo sapiens, 35
50194917,C[N+](C)(C)CCOC(N)=O,"InChI=1S/C6H14N2O2/c1-8(2,3)4-5-10-6(7)9/h4-5H2,1-3H3,(H-,7,9)/p+1",VPJXQGSRWJZDOB-UHFFFAOYSA-O,50004656,"(2-Carbamoyloxy-ethyl)-trimethyl-ammonium::(2-Carbamoyloxyethyl)trimethylammonium chloride::(2-Hydroxyethyl)trimethyl ammonium chloride carbamate::(2-Hydroxyethyl)trimethylammonium chloride carbamate::(carbachol)(2-Carbamoyloxy-ethyl)-trimethyl-ammonium::2-((Aminocarbonyl)oxy)-N,N,N-trimethylethanaminium chloride::2-((Aminocarbonyl)oxy)-N,N,N-trimethylethanaminum chloride::2-(carbamoyloxy)-N,N,N-trimethylethanaminium::2-(carbamoyloxy)-N,N,N-trimethylethanaminium chloride::CARBACHOL::CARBASTAT::CHEMBL14::Carbachol chloride::Carbamylcholine::Choline carbamate chloride::Choline chloride, carbamate::Choline chlorine carbamate::Karbachol::Karbamoylcholin chlorid::MIOSTAT",Muscarinic acetylcholine receptor M5,Homo sapiens,
1027263,CO[C@H]1\C=C\C[C@H](C)C[S@@](=O)(NC(=O)NCC2CC2)=NC(=O)c2ccc3OC[C@]4(CCCc5cc(Cl)ccc45)CN(C[C@@H]4CC[C@@H]14)c3c2,"InChI=1S/C37H47ClN4O5S/c1-24-5-3-7-33(46-2)30-13-10-28(30)20-42-22-37(16-4-6-26-17-29(38)12-14-31(26)37)23-47-34-15-11-27(18-32(34)42)35(43)40-48(45,21-24)41-36(44)39-19-25-8-9-25/h3,7,11-12,14-15,17-18,24-25,28,30,33H,4-6,8-10,13,16,19-23H2,1-2H3,(H2,39,40,41,43,44,45)/b7-3+/t24-,28-,30+,33-,37-,48-/m0/s1",XFTSOVRWSKEBQZ-HTTWKPIMSA-N,493637,"US10988451, Example 107",Induced myeloid leukemia cell differentiation protein Mcl-1 [171-327],, 0.100
51120076,CC(C)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](C)N)C(=O)N[C@@H](Cc2ccc(cc2)C#Cc2ccccc2)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N1)C(O)=O,"InChI=1S/C57H68N10O10S2/c1-33(2)49(57(76)77)67-56(75)48-32-79-78-31-47(65-50(69)34(3)59)55(74)63-44(27-37-20-18-36(19-21-37)17-16-35-11-5-4-6-12-35)52(71)64-46(29-39-30-60-42-14-8-7-13-41(39)42)54(73)61-43(15-9-10-26-58)51(70)62-45(53(72)66-48)28-38-22-24-40(68)25-23-38/h4-8,11-14,18-25,30,33-34,43-49,60,68H,9-10,15,26-29,31-32,58-59H2,1-3H3,(H,61,73)(H,62,70)(H,63,74)(H,64,71)(H,65,69)(H,66,72)(H,67,75)(H,76,77)/t34-,43+,44+,45+,46+,47+,48+,49+/m1/s1",LWPABDJNWSXGPM-CNZATWHVSA-N,50459264,CHEMBL4216988,Urotensin-2 receptor,Rattus,
51397910,COc1ccc(cc1)-c1ccccc1N1CCN(C[C@@H](O)COc2ccc(Cl)cc2F)CC1,"InChI=1S/C26H28ClFN2O3/c1-32-22-9-6-19(7-10-22)23-4-2-3-5-25(23)30-14-12-29(13-15-30)17-21(31)18-33-26-11-8-20(27)16-24(26)28/h2-11,16,21,31H,12-15,17-18H2,1H3/t21-/m1/s1",GBOWFMPWIDDQAH-OAQYLSRUSA-N,50564771,CHEMBL4788259,5-hydroxytryptamine receptor 7,Homo sapiens,
50606474,COc1cccc(NC(=O)Nc2cccn(Cc3c(F)cccc3Cl)c2=O)c1,"InChI=1S/C20H17ClFN3O3/c1-28-14-6-2-5-13(11-14)23-20(27)24-18-9-4-10-25(19(18)26)12-15-16(21)7-3-8-17(15)22/h2-11H,12H2,1H3,(H2,23,24,27)",VTQGIZQKCPGUNG-UHFFFAOYSA-N,50329821,"1-(1-(2-chloro-6-fluorobenzyl)-2-oxo-1,2-dihydropyridin-3-yl)-3-(3-methoxyphenyl)urea::CHEMBL1272135",Cytochrome P450 2C19,Homo sapiens, 4500
542266,Cn1cc(cn1)-c1cc(-c2ccc(nc2)N2CCN(Cc3ccccc3)CC2)c2c(Cl)cnn2c1,"InChI=1S/C27H26ClN7/c1-32-18-23(15-30-32)22-13-24(27-25(28)16-31-35(27)19-22)21-7-8-26(29-14-21)34-11-9-33(10-12-34)17-20-5-3-2-4-6-20/h2-8,13-16,18-19H,9-12,17H2,1H3",YMVWCMCJINTMFL-UHFFFAOYSA-N,284614,"US10023570, Example 647::US10174027, Example 647",Proto-oncogene tyrosine-protein kinase receptor Ret [658-1114],, 34.4
50552298,CC(C)(C)c1cc(NC(=O)Nc2cccc(Oc3cccc4[nH]c(=O)[nH]c34)c2)n(n1)-c1ccccc1,"InChI=1S/C27H26N6O3/c1-27(2,3)22-16-23(33(32-22)18-10-5-4-6-11-18)30-25(34)28-17-9-7-12-19(15-17)36-21-14-8-13-20-24(21)31-26(35)29-20/h4-16H,1-3H3,(H2,28,30,34)(H2,29,31,35)",YLQMVIRZBOJBCV-UHFFFAOYSA-N,50307878,"1-(3-Tert-butyl-1-phenyl-1H-pyrazol-5-yl)-3-(3-(2-oxo-2,3-dihydro-1Himidazo[4,5-b]pyridin-7-yloxy)phenyl)urea::CHEMBL597592",Mitogen-activated protein kinase 12,Homo sapiens, 1810
20346,C[C@H]([C@H]([NH3+])C(=O)N1CC[C@H](F)C1)c1ccc(cc1)-c1cccc(c1)C(O)=O,"InChI=1S/C21H23FN2O3/c1-13(19(23)20(25)24-10-9-18(22)12-24)14-5-7-15(8-6-14)16-3-2-4-17(11-16)21(26)27/h2-8,11,13,18-19H,9-10,12,23H2,1H3,(H,26,27)/p+1/t13-,18-,19-/m0/s1",QOHCKNSBKXAMAV-AGRHKRQWSA-O,11500,"(2S,3S)-3-[4-(3-carboxyphenyl)phenyl]-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-aminium; 2,2,2-trifluoroacetate::3-(S)-fluoropyrrolidide 20",Dipeptidyl peptidase 2,Homo sapiens, 9200
50344132,NCCC[C@@H]1N=C(c2[nH]c(cc2N(CCc2ccc(O)cc2)C1=O)C(O)=O)c1ccc2ccccc2c1,,,50089669,CHEMBL3577302,Urotensin-2 receptor,Rattus,
1132080,Nc1nc2cc(ccn2n1)-c1ccc(Cl)c(C(=O)NCC[C@H](O)c2ccc(F)cc2)c1F,"InChI=1S/C22H18ClF2N5O2/c23-16-6-5-15(13-8-10-30-18(11-13)28-22(26)29-30)20(25)19(16)21(32)27-9-7-17(31)12-1-3-14(24)4-2-12/h1-6,8,10-11,17,31H,7,9H2,(H2,26,29)(H,27,32)/t17-/m0/s1",HKDBKENBVSIISE-KRWDZBQOSA-N,534353,"WO2022086828, Example 80",Mixed lineage kinase domain-like protein,, 9.00
50358734,Cc1cc2c(cnc(NC3CCNCC3)c2[nH]c1=O)-c1cncc(NS(C)(=O)=O)c1,"InChI=1S/C22H16N4O6S/c27-18(25-33(31,32)13-6-2-1-3-7-13)9-12-5-4-8-14-15(12)10-17-19(14)24-21(28)20-23-16(22(29)30)11-26(17)20/h1-8,11H,9-10H2,(H,24,28)(H,25,27)(H,29,30)",JRLLESZXDXKGDL-UHFFFAOYSA-N,50096281,CHEMBL3585460,Bromodomain-containing protein 4,, 794
51308972,Oc1ccc2ccccc2c1Cc1c([nH]c(=S)[nH]c1=O)-c1ccccc1,"InChI=1S/C21H16N2O2S/c24-18-11-10-13-6-4-5-9-15(13)16(18)12-17-19(14-7-2-1-3-8-14)22-21(26)23-20(17)25/h1-11,24H,12H2,(H2,22,23,25,26)",RVNSQVIUFZVNAU-UHFFFAOYSA-N,29040,cambinol,NAD-dependent protein deacetylase sirtuin-2,Homo sapiens, 49900
50524473,Oc1ccc(\C=C2/SC(=O)NC2=O)cc1Br,"InChI=1S/C10H6BrNO3S/c11-6-3-5(1-2-7(6)13)4-8-9(14)12-10(15)16-8/h1-4,13H,(H,12,14,15)/b8-4-",BQYDIAPNPDEQHK-YWEYNIOJSA-N,50198774,CHEMBL3927255,CDGSH iron-sulfur domain-containing protein 1,Homo sapiens,
147298,Cc1ccc(cc1)C1(CC1C(=O)Nc1ccc(cc1O)[N+]([O-])=O)c1ccc(C)cc1,"InChI=1S/C24H22N2O4/c1-15-3-7-17(8-4-15)24(18-9-5-16(2)6-10-18)14-20(24)23(28)25-21-12-11-19(26(29)30)13-22(21)27/h3-13,20,27H,14H2,1-2H3,(H,25,28)",PSPYSXQQDKBXKX-UHFFFAOYSA-N,66392,"2,2-bis(4-methylphenyl)-N-(4-nitro-2-oxidanyl-phenyl)cyclopropane-1-carboxamide::MLS000579026::N-(2-hydroxy-4-nitro-phenyl)-2,2-bis(p-tolyl)cyclopropanecarboxamide::N-(2-hydroxy-4-nitrophenyl)-2,2-bis(4-methylphenyl)-1-cyclopropanecarboxamide::N-(2-hydroxy-4-nitrophenyl)-2,2-bis(4-methylphenyl)cyclopropane-1-carboxamide::N-(2-hydroxy-4-nitrophenyl)-2,2-bis(4-methylphenyl)cyclopropanecarboxamide::SMR000186615::cid_3375236",DNA damage-inducible transcript 3 protein,Mus musculus,>10000
57826,COc1ccc(cc1)-c1nc(CS(=O)CC(=O)NCc2ccccn2)c(C)o1,"InChI=1S/C20H21N3O4S/c1-14-18(23-20(27-14)15-6-8-17(26-2)9-7-15)12-28(25)13-19(24)22-11-16-5-3-4-10-21-16/h3-10H,11-13H2,1-2H3,(H,22,24)",CVBYCSIAIVHEFX-UHFFFAOYSA-N,32120,"2-[[2-(4-methoxyphenyl)-5-methyl-1,3-oxazol-4-yl]methylsulfinyl]-N-(pyridin-2-ylmethyl)acetamide::2-[[2-(4-methoxyphenyl)-5-methyl-1,3-oxazol-4-yl]methylsulfinyl]-N-(pyridin-2-ylmethyl)ethanamide::2-[[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]methylsulfinyl]-N-(2-pyridinylmethyl)acetamide::2-[[2-(4-methoxyphenyl)-5-methyl-oxazol-4-yl]methylsulfinyl]-N-(2-pyridylmethyl)acetamide::MLS000117623::SMR000094571::cid_5308158",Heat shock protein HSP 90-alpha,Homo sapiens, 19271.2
339860,CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCCCN(C4CC4)C4CCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1,"InChI=1S/C49H57ClN8O6S/c1-49(2)19-17-35(43(30-49)33-7-9-36(50)10-8-33)32-55-23-25-56(26-24-55)39-13-15-42(46(28-39)64-40-27-34-18-21-52-47(34)53-31-40)48(59)54-65(62,63)41-14-16-44(45(29-41)58(60)61)51-20-4-22-57(38-11-12-38)37-5-3-6-37/h7-10,13-16,18,21,27-29,31,37-38,51H,3-6,11-12,17,19-20,22-26,30,32H2,1-2H3,(H,52,53)(H,54,59)",VOSHORWBODTEPW-UHFFFAOYSA-N,189750,"US10213433, Compound 320::US11369599, Compound 320::US9174982, 320",Apoptosis regulator Bcl-2,,
1034389,Cn1cnc(n1)-c1ccc(OC\C(CN)=C/F)cc1,"InChI=1S/C13H15FN4O/c1-18-9-16-13(17-18)11-2-4-12(5-3-11)19-8-10(6-14)7-15/h2-6,9H,7-8,15H2,1H3/b10-6-",HFUDEGFAPDPSIS-POHAHGRESA-N,497158,"US11001563, Compound WX025",Membrane primary amine oxidase,Homo sapiens, 0.900
50853617,C[C@H](Cc1ccccc1)N(C)CC#C,"InChI=1S/C13H17N/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13/h1,5-9,12H,10-11H2,2-3H3/t12-/m1/s1",MEZLKOACVSPNER-GFCCVEGCSA-N,15579,"CHEMBL972::DEPRENYL::L-Deprenyl::N-methyl-N-[(2R)-1-phenylpropan-2-yl]prop-2-yn-1-amine::SLG::Selegiline::US8633208, Deprenyl::US9469653, Selegiline::methyl[(2R)-1-phenylpropan-2-yl]prop-2-yn-1-ylamine",Amine oxidase [flavin-containing] A,, 1200
51093133,CCCc1c(Cc2ccc(cc2)-c2ccccc2C(O)=O)c2ccc(cc2n1C)C(=O)NC(CC)c1ccccc1,"InChI=1S/C36H36N2O3/c1-4-11-33-31(22-24-16-18-25(19-17-24)28-14-9-10-15-30(28)36(40)41)29-21-20-27(23-34(29)38(33)3)35(39)37-32(5-2)26-12-7-6-8-13-26/h6-10,12-21,23,32H,4-5,11,22H2,1-3H3,(H,37,39)(H,40,41)",KEDCDYJNIWOZOY-UHFFFAOYSA-N,50448033,CHEMBL3115237,Peroxisome proliferator-activated receptor alpha,Mus musculus,
50989890,Cn1cc(\C=C2/CC(CO)(COC(=O)C3CCCCC3)OC2=O)c2ccccc12,"InChI=1S/C23H27NO5/c1-24-13-18(19-9-5-6-10-20(19)24)11-17-12-23(14-25,29-22(17)27)15-28-21(26)16-7-3-2-4-8-16/h5-6,9-11,13,16,25H,2-4,7-8,12,14-15H2,1H3/b17-11+",DPQYCBYVJBHECV-GZTJUZNOSA-N,50280745,CHEMBL4163809,Protein kinase C epsilon type,Homo sapiens,
504192,CCCCN(C)C(=O)CSc1ccc(O)c(O)c1,"InChI=1S/C13H19NO3S/c1-3-4-7-14(2)13(17)9-18-10-5-6-11(15)12(16)8-10/h5-6,8,15-16H,3-4,7,9H2,1-2H3",YTMVNAFVZGNMEQ-UHFFFAOYSA-N,264649,"US9718760, C200",Plasminogen activator inhibitor 1/Urokinase-type plasminogen activator,Homo sapiens, 58370
580490,C[C@@H]1C[C@@H](CC(C)(C)C1)n1c(Nc2ccc(OC(F)(F)F)cc2)nc2cc(ccc12)-c1nnc(C)o1,"InChI=1S/C26H28F3N5O2/c1-15-11-19(14-25(3,4)13-15)34-22-10-5-17(23-33-32-16(2)35-23)12-21(22)31-24(34)30-18-6-8-20(9-7-18)36-26(27,28)29/h5-10,12,15,19H,11,13-14H2,1-4H3,(H,30,31)/t15-,19+/m1/s1",WJELXOOQYUBURM-BEFAXECRSA-N,303122,"(+/-) 5-(5-methyl-1,3,4-oxadiazol-2-yl)-N-[4-(trifluoromethoxy)phenyl]-1-[(cis)-3,3,5-trimethylcyclohexyl]-1H-benzimidazol-2-amine::US10137110, Example 2-31",Isocitrate dehydrogenase [NADP] cytoplasmic [R132H],, 390
491381,Cc1ncsc1-c1nnc2[C@H]3CC[C@@H](Cn12)N3C(=O)c1cccc(c1Cl)C(F)(F)F,"InChI=1S/C19H15ClF3N5OS/c1-9-15(30-8-24-9)17-26-25-16-13-6-5-10(7-27(16)17)28(13)18(29)11-3-2-4-12(14(11)20)19(21,22)23/h2-4,8,10,13H,5-7H2,1H3/t10-,13+/m0/s1",UTJIXYNAGLZGIN-GXFFZTMASA-N,174828,"US10053462, 59::US9102686, 59::US9540388, 59",P2X purinoceptor 7,, 100
50222604,Oc1ccc(CCNCCNC(=O)CCOCCc2ccccc2)c2sc(=O)[nH]c12,"InChI=1S/C22H27N3O4S/c26-18-7-6-17(21-20(18)25-22(28)30-21)8-11-23-12-13-24-19(27)10-15-29-14-9-16-4-2-1-3-5-16/h1-7,23,26H,8-15H2,(H,24,27)(H,25,28)",CMOORUPKABTWGD-UHFFFAOYSA-N,50418830,CHEMBL111775,Beta-2 adrenergic receptor,Homo sapiens,
50719806,O[C@H]1CN(CCc2ccccc2)[C@H]2CCC[C@@]1(C2)c1cccc(O)c1,"InChI=1S/C22H27NO2/c24-20-10-4-8-18(14-20)22-12-5-9-19(15-22)23(16-21(22)25)13-11-17-6-2-1-3-7-17/h1-4,6-8,10,14,19,21,24-25H,5,9,11-13,15-16H2/t19-,21-,22+/m0/s1",RYGOAYGVHBVXQE-ILWGZMRPSA-N,50365109,CHEMBL1951701,Mu-type opioid receptor,Homo sapiens,
51031837,CN(C)CCc1c[nH]c2ccc(CN3CCNS3(=O)=O)cc12,"InChI=1S/C15H22N4O2S/c1-18(2)7-5-13-10-16-15-4-3-12(9-14(13)15)11-19-8-6-17-22(19,20)21/h3-4,9-10,16-17H,5-8,11H2,1-2H3",UWHVVRIUSATDPT-UHFFFAOYSA-N,50422028,CHEMBL102548,5-hydroxytryptamine receptor 1D,Sus scrofa, 100
13556,COc1ccccc1-c1ccc(C[C@H](NC[C@H](O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)c2ccccn2)C(C)C)C(N)=O)cc1,"InChI=1S/C37H43N5O5/c1-24(2)34(42-36(45)29-14-9-10-20-39-29)37(46)41-30(21-25-11-5-4-6-12-25)32(43)23-40-31(35(38)44)22-26-16-18-27(19-17-26)28-13-7-8-15-33(28)47-3/h4-20,24,30-32,34,40,43H,21-23H2,1-3H3,(H2,38,44)(H,41,46)(H,42,45)/t30-,31-,32-,34-/m0/s1",KNBUMBGSBPCJDJ-SUGCFTRWSA-N,8029,"(2S)-N-[(2S,3S)-4-{[(1S)-1-carbamoyl-2-[4-(2-methoxyphenyl)phenyl]ethyl]amino}-3-hydroxy-1-phenylbutan-2-yl]-3-methyl-2-(pyridin-2-ylformamido)butanamide::(2S,5S,6R)-3-Aza-5-hydroxy-2-[p-(o-methoxyphenyl)-benzyl]-7-phenyl-6-[(picolyl-L-valinyl)amino]heptanoyl Amide::hydroxyethylamine-based inhibitor 16d",Cathepsin D,Homo sapiens,
452888,NC(=O)C(=C\c1ccc(cc1)-c1ncnc2[nH]cnc12)\C#N,"InChI=1S/C15H10N6O/c16-6-11(14(17)22)5-9-1-3-10(4-2-9)12-13-15(20-7-18-12)21-8-19-13/h1-5,7-8H,(H2,17,22)(H,18,19,20,21)/b11-5+",BRZWHXQQGAAXPX-VZUCSPMQSA-N,259810,"US9505766, 10",Ribosomal protein S6 kinase alpha-3 [399-740],, 5000
50304779,COc1cc(Sc2nc3c(N)ncnc3n2CCCC#C)c(Cl)c(OC)c1OC,"InChI=1S/C19H20ClN5O3S/c1-5-6-7-8-25-18-14(17(21)22-10-23-18)24-19(25)29-12-9-11(26-2)15(27-3)16(28-4)13(12)20/h1,9-10H,6-8H2,2-4H3,(H2,21,22,23)",FJDWNDYYMRLXGQ-UHFFFAOYSA-N,50165293,"8-(2-Chloro-3,4,5-trimethoxy-phenylsulfanyl)-9-pent-4-ynyl-9H-purin-6-ylamine::CHEMBL192647",Heat shock protein HSP 90-alpha,Mus musculus,
253986,Cc1cnc2ccccc2c1N1CC(C)(C)c2ccc(cc12)N1CCOCC1,"InChI=1S/C24H27N3O/c1-17-15-25-21-7-5-4-6-19(21)23(17)27-16-24(2,3)20-9-8-18(14-22(20)27)26-10-12-28-13-11-26/h4-9,14-15H,10-13,16H2,1-3H3",TWZVRQMWEHTIFK-UHFFFAOYSA-N,124715,"US8765940, 4-(3,3-dimethyl-6-(4-morpholinyl)-2,3-dihydro-1H-indol-1-yl)-3-methylquinoline","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",Homo sapiens,
343554,CCC(=O)NC1CCCc2c1cncc2-c1ccc(Cl)c(F)c1,"InChI=1S/C18H18ClFN2O/c1-2-18(23)22-17-5-3-4-12-13(9-21-10-14(12)17)11-6-7-15(19)16(20)8-11/h6-10,17H,2-5H2,1H3,(H,22,23)",BTXHAHICPWSTRI-UHFFFAOYSA-N,191903,"US9187429, 36::US9187429, 37::US9187429, 38","Cytochrome P450 11B1, mitochondrial",Homo sapiens,
83651,COc1ccc(C)cc1NC(=O)CSc1nnc(COc2ccc(Cl)cc2)n1Cc1ccco1,"InChI=1S/C24H23ClN4O4S/c1-16-5-10-21(31-2)20(12-16)26-23(30)15-34-24-28-27-22(29(24)13-19-4-3-11-32-19)14-33-18-8-6-17(25)7-9-18/h3-12H,13-15H2,1-2H3,(H,26,30)",WDMJXGQJRZEAAS-UHFFFAOYSA-N,45337,"2-[[5-[(4-chloranylphenoxy)methyl]-4-(furan-2-ylmethyl)-1,2,4-triazol-3-yl]sulfanyl]-N-(2-methoxy-5-methyl-phenyl)ethanamide::2-[[5-[(4-chlorophenoxy)methyl]-4-(2-furanylmethyl)-1,2,4-triazol-3-yl]thio]-N-(2-methoxy-5-methylphenyl)acetamide::2-[[5-[(4-chlorophenoxy)methyl]-4-(2-furfuryl)-1,2,4-triazol-3-yl]thio]-N-(2-methoxy-5-methyl-phenyl)acetamide::2-[[5-[(4-chlorophenoxy)methyl]-4-(furan-2-ylmethyl)-1,2,4-triazol-3-yl]sulfanyl]-N-(2-methoxy-5-methylphenyl)acetamide::MLS000083335::SMR000047797::cid_666557",Coagulation factor XII,,>50000
50209569,NC(=N)c1cc2[nH]c(nc2cc1F)-c1cccc(OCC2CCCNC2)c1O,"InChI=1S/C20H22FN5O2/c21-14-8-16-15(7-13(14)19(22)23)25-20(26-16)12-4-1-5-17(18(12)27)28-10-11-3-2-6-24-9-11/h1,4-5,7-8,11,24,27H,2-3,6,9-10H2,(H3,22,23)(H,25,26)",TYKNBRGVFCIVAT-UHFFFAOYSA-N,50115854,6-Fluoro-2-[2-hydroxy-3-(piperidin-3-ylmethoxy)-phenyl]-1H-benzoimidazole-5-carboxamidine::CHEMBL303978,Tissue-type plasminogen activator,Homo sapiens,
1051326,O\C(=N/C(=N)c1ccccc1)C(NC(=O)C(c1ccccc1)c1ccccc1)c1ccc(Cl)cc1,"InChI=1S/C29H24ClN3O2/c30-24-18-16-22(17-19-24)26(29(35)33-27(31)23-14-8-3-9-15-23)32-28(34)25(20-10-4-1-5-11-20)21-12-6-2-7-13-21/h1-19,25-26H,(H,32,34)(H2,31,33,35)",LPJGPSDFCQDVPZ-UHFFFAOYSA-N,399548,"US10323029, Generic formula 52515 IB::US11034691, CYM generic formula 52515 IB",Sphingosine 1-phosphate receptor 1,Homo sapiens,>50000
785524,Cc1cc(ccn1)-c1n[nH]c2cc3NC(=O)N(Cc3cc12)[C@@H]1CCCN(Cc2ccc(F)cc2F)C1,,,318240,"US10301317, Example 196::US9624228, Example 196",Mitogen-activated protein kinase 1,Homo sapiens,<50
50485089,Nc1ncnc2n(cc(-c3cccc(OC[C@H]4CCCCO4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1,"InChI=1S/C26H33N5O2/c27-25-24-23(19-5-3-7-21(13-19)33-16-22-6-1-2-10-32-22)15-31(26(24)29-17-28-25)20-11-18(12-20)14-30-8-4-9-30/h3,5,7,13,15,17-18,20,22H,1-2,4,6,8-12,14,16H2,(H2,27,28,29)/t18-,20+,22-/m1/s1",UTHVKVUADCCITP-KAGYGMCKSA-N,50157894,CHEMBL3786383,Insulin-like growth factor 1 receptor,Homo sapiens, 80
50280054,COC(Cn1ccnc1)c1ccc(Cl)cc1Cl,"InChI=1S/C12H12Cl2N2O/c1-17-12(7-16-5-4-15-8-16)10-3-2-9(13)6-11(10)14/h2-6,8,12H,7H2,1H3",BIKDBWRSTMWPIQ-UHFFFAOYSA-N,50051820,CHEMBL3318358,"Indoleamine 2,3-dioxygenase 1",Homo sapiens, 140000
1202260,CN(C)C1CCN(CC1)c1ccc(c(F)c1)-n1cc(nc1C)-c1nc(NC2CCN(CC2)S(C)(=O)=O)ncc1C(F)(F)F,"InChI=1S/C28H36F4N8O2S/c1-18-34-24(17-40(18)25-6-5-21(15-23(25)29)38-11-9-20(10-12-38)37(2)3)26-22(28(30,31)32)16-33-27(36-26)35-19-7-13-39(14-8-19)43(4,41)42/h5-6,15-17,19-20H,7-14H2,1-4H3,(H,33,35,36)",CZAWLHLSKKJDHX-UHFFFAOYSA-N,569456,"US11427567, Example 101",Cyclin-dependent kinase 2/G1/S-specific cyclin-E1,Homo sapiens,<50
50335523,CC(C)(C)CNC(=O)NCCCCN1CCN(CC1)c1cc(nc(n1)C(C)(C)C)C(F)(F)F,"InChI=1S/C23H39F3N6O/c1-21(2,3)16-28-20(33)27-9-7-8-10-31-11-13-32(14-12-31)18-15-17(23(24,25)26)29-19(30-18)22(4,5)6/h15H,7-14,16H2,1-6H3,(H2,27,28,33)",PCPMHRDGGJEPAZ-UHFFFAOYSA-N,50181163,1-(4-(4-(2-tert-butyl-6-(trifluoromethyl)pyrimidin-4-yl)piperazin-1-yl)butyl)-3-neopentylurea::CHEMBL381514,D(2) dopamine receptor,Homo sapiens,
1212356,O=C1NCCN1c1ccc2CCN(Cc2c1)c1ncc(Cc2ccc(cc2)-n2cccn2)s1,"InChI=1S/C25H24N6OS/c32-24-26-10-13-30(24)22-7-4-19-8-12-29(17-20(19)15-22)25-27-16-23(33-25)14-18-2-5-21(6-3-18)31-11-1-9-28-31/h1-7,9,11,15-16H,8,10,12-14,17H2,(H,26,32)",HEBUQULKVNFTNE-UHFFFAOYSA-N,575080,"US11459321, Example 25",Transmembrane anterior posterior transformation protein 1 homolog,, 911
1050957,Cc1cc(Br)cnc1[C@@H](Nc1nc2ccc(Cl)cc2o1)c1ccc(Cl)c(F)c1,"InChI=1S/C20H13BrCl2FN3O/c1-10-6-12(21)9-25-18(10)19(11-2-4-14(23)15(24)7-11)27-20-26-16-5-3-13(22)8-17(16)28-20/h2-9,19H,1H3,(H,26,27)/t19-/m0/s1",YILYDYRSTBZITD-IBGZPJMESA-N,399439,"US10323029, Generic formula 52770::US11034691, CYM generic formula 52770",Sphingosine 1-phosphate receptor 3,Homo sapiens, 40.0
90988,Cc1ccc(cc1)S(=O)(=O)Cc1ccc(o1)C(O)=O,"InChI=1S/C13H12O5S/c1-9-2-5-11(6-3-9)19(16,17)8-10-4-7-12(18-10)13(14)15/h2-7H,8H2,1H3,(H,14,15)",VNPAVLDSIONFMU-UHFFFAOYSA-N,40211,5-(tosylmethyl)-2-furoic acid::5-[(4-methylphenyl)sulfonylmethyl]-2-furancarboxylic acid::5-[(4-methylphenyl)sulfonylmethyl]furan-2-carboxylic acid::MLS000521988::SMR000132396::cid_9551108,Estrogen receptor beta,, 5221.62
987262,Cc1c(C(=O)C(=O)NC2(CC(F)(F)C2)C(=O)N2CC3(C2)CS(=O)(=O)C3)c2CCCn2c1C(=O)Nc1ccc(F)c(Cl)c1,"InChI=1S/C27H26ClF3N4O6S/c1-14-19(18-3-2-6-35(18)20(14)22(37)32-15-4-5-17(29)16(28)7-15)21(36)23(38)33-26(8-27(30,31)9-26)24(39)34-10-25(11-34)12-42(40,41)13-25/h4-5,7H,2-3,6,8-13H2,1H3,(H,32,37)(H,33,38)",QNLAZNSUEDHRSC-UHFFFAOYSA-N,400034,"N-(3-chloro-4-fluorophenyl)-7-(2-((1-(2,2-dioxido-2-thia-6-azaspiro[3.3]heptane-6-carbonyl)-3,3-difluorocyclobutyl)amino)-2-oxoacetyl)-6-methyl-2,3-dihydro-1H-pyrrolizine-5-carboxamide ::US10328053, Compound 13::US10874640, Compound 13",Capsid protein,,
50627792,COC(=O)CCC(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)C(F)(F)F,"InChI=1S/C22H33F3N4O7/c1-11(2)17(18(32)22(23,24)25)28-20(34)14-7-6-10-29(14)21(35)13(4)27-19(33)12(3)26-15(30)8-9-16(31)36-5/h11-14,17H,6-10H2,1-5H3,(H,26,30)(H,27,33)(H,28,34)/t12-,13-,14-,17-/m0/s1",GLEKDCYUGXACTA-WSMBLCCSSA-N,50014730,"CHEMBL130271::N-(1-{1-Methyl-2-oxo-2-[2-(3,3,3-trifluoro-1-isopropyl-2-oxo-propylcarbamoyl)-pyrrolidin-1-yl]-ethylcarbamoyl}-ethyl)-succinamic acid methyl ester",Neutrophil elastase,Homo sapiens,
1061278,COC(=O)CN1CCc2c(Cl)c(OCc3cccc(c3C)-c3cccc(OCCCN4CC[C@@H](O)C4)c3C)cc(OCc3cncc(c3)C(=O)OC)c2C1,"InChI=1S/C42H48ClN3O8/c1-27-30(8-5-9-33(27)34-10-6-11-37(28(34)2)52-17-7-14-45-15-12-32(47)22-45)26-54-39-19-38(53-25-29-18-31(21-44-20-29)42(49)51-4)36-23-46(24-40(48)50-3)16-13-35(36)41(39)43/h5-6,8-11,18-21,32,47H,7,12-17,22-26H2,1-4H3/t32-/m1/s1",XLABBPDKUWKHOE-JGCGQSQUSA-N,507129,"US11046675, Example 1008","Programmed cell death protein 1 [25-167,N33K], Immunoglobulin heavy constant gamma 1 [99-330,C104S,C109S,C112S,L118I,P121S]/Programmed cell death 1 ligand 1 [18-239,H172E]",,>10000
51203354,CC(=O)COc1cc(=O)oc2cc(OCc3cccc(Cl)c3)ccc12,"InChI=1S/C19H15ClO5/c1-12(21)10-24-17-9-19(22)25-18-8-15(5-6-16(17)18)23-11-13-3-2-4-14(20)7-13/h2-9H,10-11H2,1H3",SZFIHKIRINEKEA-UHFFFAOYSA-N,50038054,CHEMBL3091489,Amine oxidase [flavin-containing] B,Rattus norvegicus, 27
50129433,C(CC1CCCCC1)C#CC1CC1c1cnc[nH]1,"InChI=1S/C16H22N2/c1-2-6-13(7-3-1)8-4-5-9-14-10-15(14)16-11-17-12-18-16/h11-15H,1-4,6-8,10H2,(H,17,18)",RIUKBQARIDWZSC-UHFFFAOYSA-N,50074624,4-[2-(4-Cyclohexyl-but-1-ynyl)-cyclopropyl]-1H-imidazole::CHEMBL353905,Histamine H3 receptor,Rattus norvegicus,
99706,Cc1cc(\C=C(\C#N)c2nc3ccccc3[nH]2)c(C)n1-c1cc(cc(c1)C(O)=O)C(O)=O,"InChI=1S/C24H18N4O4/c1-13-7-15(8-18(12-25)22-26-20-5-3-4-6-21(20)27-22)14(2)28(13)19-10-16(23(29)30)9-17(11-19)24(31)32/h3-11H,1-2H3,(H,26,27)(H,29,30)(H,31,32)/b18-8-",CTKZTWNBAHUHSD-LSCVHKIXSA-N,51145,"5-[3-[(Z)-2-(1H-benzimidazol-2-yl)-2-cyano-ethenyl]-2,5-dimethyl-pyrrol-1-yl]benzene-1,3-dicarboxylic acid::5-[3-[(Z)-2-(1H-benzimidazol-2-yl)-2-cyano-vinyl]-2,5-dimethyl-pyrrol-1-yl]isophthalic acid::5-[3-[(Z)-2-(1H-benzimidazol-2-yl)-2-cyanoethenyl]-2,5-dimethyl-1-pyrrolyl]benzene-1,3-dicarboxylic acid::5-[3-[(Z)-2-(1H-benzimidazol-2-yl)-2-cyanoethenyl]-2,5-dimethylpyrrol-1-yl]benzene-1,3-dicarboxylic acid::MLS000716063::SMR000277580::cid_5769138",POsterior Segregation,Caenorhabditis elegans,
1190825,Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ncc(CCc2ccncc2)s1)C1(C)CSC1,"InChI=1S/C25H26N6OS2/c1-17-3-6-19(7-4-17)31-22(13-21(30-31)25(2)15-33-16-25)28-23(32)29-24-27-14-20(34-24)8-5-18-9-11-26-12-10-18/h3-4,6-7,9-14H,5,8,15-16H2,1-2H3,(H2,27,28,29,32)",RWOYZWNBURNFTF-UHFFFAOYSA-N,563597,"1-[5-(3-Methyl-thietan-3-yl)-2-p- tolyl-2H-pyrazol-3-yl]-3-[5-(2- pyridin-4-yl-ethyl)-thiazol-2-yl]- urea::US11407771, Compound 273",Mitogen-activated protein kinase 13,Homo sapiens,<250
50936632,OC1CC[C@@H](CNC(=O)c2cccc3cccnc23)N(C1)C(=O)c1ccccc1-c1ccccc1,"InChI=1S/C29H27N3O3/c33-23-16-15-22(18-31-28(34)26-14-6-10-21-11-7-17-30-27(21)26)32(19-23)29(35)25-13-5-4-12-24(25)20-8-2-1-3-9-20/h1-14,17,22-23,33H,15-16,18-19H2,(H,31,34)/t22-,23?/m0/s1",HLZFNXPRACQSDC-NQCNTLBGSA-N,50384436,CHEMBL2031500,Orexin receptor type 2,Homo sapiens, 13
51123225,Oc1ccc(cc1C(=O)NCC#N)[N+]([O-])=O,"InChI=1S/C9H7N3O4/c10-3-4-11-9(14)7-5-6(12(15)16)1-2-8(7)13/h1-2,5,13H,4H2,(H,11,14)",OSGFHGICFOQNGB-UHFFFAOYSA-N,50460486,CHEMBL4228513,Cathepsin B,Homo sapiens,
50122601,CCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(C)C)C(=O)NCC(=O)N[C@@H](CCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(N)=O,"InChI=1S/C75H104N20O15/c1-4-5-22-52(90-73(110)63(43(2)3)95-64(101)51(77)36-46-26-29-50(96)30-27-46)65(102)86-42-61(98)87-55(31-32-76)69(106)92-57(38-45-18-10-7-11-19-45)70(107)88-54(24-15-34-84-75(81)82)68(105)93-58(39-47-25-28-48-20-12-13-21-49(48)35-47)71(108)94-59(40-62(99)100)72(109)89-53(23-14-33-83-74(79)80)67(104)91-56(66(103)85-41-60(78)97)37-44-16-8-6-9-17-44/h6-13,16-21,25-30,35,43,51-59,63,96H,4-5,14-15,22-24,31-34,36-42,76-77H2,1-3H3,(H2,78,97)(H,85,103)(H,86,102)(H,87,98)(H,88,107)(H,89,109)(H,90,110)(H,91,104)(H,92,106)(H,93,105)(H,94,108)(H,95,101)(H,99,100)(H4,79,80,83)(H4,81,82,84)/t51-,52-,53-,54-,55-,56-,57?,58?,59-,63-/m0/s1",LJKCKOVLKSSRAB-JBVSWJPQSA-N,50134943,CHEMBL2370966::H-Tyr-Val-Nle-Gly-Aib-Phe-Arg-D-Nal(2')-Asp-Arg-Phe-Gly-NH2,Melanocortin receptor 4,,
50697103,Cc1c(CC(O)=O)c2cccnc2n1Cc1ccc(cc1C(F)(F)F)S(C)(=O)=O,"InChI=1S/C19H17F3N2O4S/c1-11-15(9-17(25)26)14-4-3-7-23-18(14)24(11)10-12-5-6-13(29(2,27)28)8-16(12)19(20,21)22/h3-8H,9-10H2,1-2H3,(H,25,26)",GFPPXZDRVCSVNR-UHFFFAOYSA-N,50233520,Fevipiprant::NVP-QAW039::QAW039,Prostaglandin D2 receptor 2,Homo sapiens, 3.1
293367,O=C(NCC#N)OCc1ccccc1,"InChI=1S/C10H10N2O2/c11-6-7-12-10(13)14-8-9-4-2-1-3-5-9/h1-5H,7-8H2,(H,12,13)",DVUXKEFDAGQPQU-UHFFFAOYSA-N,152724,2477,Papain,Carica papaya, 7.7e+4
194795,CC(=O)c1ccc2[nH]c3c(CCCC3=O)c2c1,"InChI=1S/C14H13NO2/c1-8(16)9-5-6-12-11(7-9)10-3-2-4-13(17)14(10)15-12/h5-7,15H,2-4H2,1H3",SAVUIJLZGYGDSF-UHFFFAOYSA-N,89124,"6-acetyl-2,3,4,9-tetrahydrocarbazol-1-one::6-ethanoyl-2,3,4,9-tetrahydrocarbazol-1-one::MLS-0463403.0001::cid_708520",Mitochondrial import inner membrane translocase subunit TIM10,Saccharomyces cerevisiae (strain ATCC 204508 / S288c), 79350
199466,COc1cccc(c1)-n1nnnc1SCC(=O)Nc1c(C)cc(C)cc1C,"InChI=1S/C19H21N5O2S/c1-12-8-13(2)18(14(3)9-12)20-17(25)11-27-19-21-22-23-24(19)15-6-5-7-16(10-15)26-4/h5-10H,11H2,1-4H3,(H,20,25)",MKUKVBGQSYPOND-UHFFFAOYSA-N,91816,CS81,Cyclin-A2/Cyclin-dependent kinase 2,Homo sapiens,
994237,COc1cc(ccn1)-c1ccc2nc(Nc3cc(CN4CCN(CC4)C(=O)CC(F)(F)F)ccn3)[nH]c2c1,"InChI=1S/C26H26F3N7O2/c1-38-23-14-19(5-7-31-23)18-2-3-20-21(13-18)33-25(32-20)34-22-12-17(4-6-30-22)16-35-8-10-36(11-9-35)24(37)15-26(27,28)29/h2-7,12-14H,8-11,15-16H2,1H3,(H2,30,32,33,34)",WIKKZRKBGSMRPL-UHFFFAOYSA-N,478286,"3,3,3-trifluoro-1-{4-[(2-{[6-(2-methoxypyridin-4-yl)-1H-benzimidazol-2-yl]amino}pyridin-4-yl)methyl]piperazin-1-yl}propan-1-one::US10894784, Example 02.03",Serine/threonine-protein kinase TBK1,, 36.8
51118036,Cn1cc(cn1)-c1ccc(=O)n(CCOc2ccnc3cc(ccc23)-c2ccc(s2)C(=O)Nc2ccccc2N)n1,"InChI=1S/C30H25N7O3S/c1-36-18-20(17-33-36)23-8-11-29(38)37(35-23)14-15-40-26-12-13-32-25-16-19(6-7-21(25)26)27-9-10-28(41-27)30(39)34-24-5-3-2-4-22(24)31/h2-13,16-18H,14-15,31H2,1H3,(H,34,39)",GIGLKJOCNUGOJM-UHFFFAOYSA-N,50457080,CHEMBL4209189,Histone deacetylase 1,Homo sapiens, 467
812631,CC(C)(O)[C@H](F)CNC(=O)c1cnc(cc1N[C@H]1CCOC1)-c1ccc2cc(cnn12)C#N,"InChI=1S/C23H25FN6O3/c1-23(2,32)21(24)12-27-22(31)17-11-26-19(8-18(17)29-15-5-6-33-13-15)20-4-3-16-7-14(9-25)10-28-30(16)20/h3-4,7-8,10-11,15,21,32H,5-6,12-13H2,1-2H3,(H,26,29)(H,27,31)/t15-,21+/m0/s1",MXRMKAMXRQHYPE-YCRPNKLZSA-N,407254,"6-(3-cyanopyrrolo[1,2-b] pyridazin-7-yl)-N- ((R)-2-fluoro- 3-hydroxy-3- methylbutyl)-4-(((S)- tetrahydrofuran-3- yl)amino)nicotinamide::US10336762, Compound 195",Interleukin-1 receptor-associated kinase 4,Homo sapiens,<1.000
36075,Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O,"InChI=1S/C15H10O5/c16-9-3-1-8(2-4-9)11-7-20-13-6-10(17)5-12(18)14(13)15(11)19/h1-7,16-18H",TZBJGXHYKVUXJN-UHFFFAOYSA-N,19459,"5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one::CHEMBL44::Genistein::Genistein, 8::Genisteol::Prunetol::US8552057, 2::cid_5280961",Estrogen receptor,, 1973
50508779,Clc1ccc(OC(C2CCNCC2)c2cccnc2)c(Cl)c1,"InChI=1S/C17H18Cl2N2O/c18-14-3-4-16(15(19)10-14)22-17(12-5-8-20-9-6-12)13-2-1-7-21-11-13/h1-4,7,10-12,17,20H,5-6,8-9H2",VKEVCZGXCJOVET-UHFFFAOYSA-N,50294274,"CHEMBL540978::rac-3-((2,4-dichlorophenoxy)(piperidin-4-yl)methyl)pyridine",Sodium-dependent noradrenaline transporter,Homo sapiens,>400
51035869,O=C(N1CCC2(CCN(Cc3cccc(Oc4ccccc4)c3)CC2)CC1)c1ccncn1,"InChI=1S/C27H30N4O2/c32-26(25-9-14-28-21-29-25)31-17-12-27(13-18-31)10-15-30(16-11-27)20-22-5-4-8-24(19-22)33-23-6-2-1-3-7-23/h1-9,14,19,21H,10-13,15-18,20H2",GDZWYFZOGVMUEB-UHFFFAOYSA-N,50414968,CHEMBL410885,C-C chemokine receptor type 8,Homo sapiens, 28
50941801,CCc1cc(F)c2ccccc2c1CNC(=O)c1c2OC3=CC(=O)C(C(C)=O)C(=O)[C@@]3(C)c2c(O)cc1OC,"InChI=1S/C30H26FNO7/c1-5-15-10-19(31)17-9-7-6-8-16(17)18(15)13-32-29(37)25-22(38-4)11-21(35)26-27(25)39-23-12-20(34)24(14(2)33)28(36)30(23,26)3/h6-12,24,35H,5,13H2,1-4H3,(H,32,37)/t24?,30-/m1/s1",UZSWJCGMMXLNGV-BXFARTRRSA-N,50386199,CHEMBL2042814,Peroxisome proliferator-activated receptor gamma,Homo sapiens,
50915040,Cc1ncccc1Oc1ccc(NC(=O)N2CCc3cc(F)c(Cl)cc23)cn1,"InChI=1S/C20H16ClFN4O2/c1-12-18(3-2-7-23-12)28-19-5-4-14(11-24-19)25-20(27)26-8-6-13-9-16(22)15(21)10-17(13)26/h2-5,7,9-11H,6,8H2,1H3,(H,25,27)",GHWRYTXWRJFGJW-UHFFFAOYSA-N,50321889,"6-Chloro-5-fluoro-2,3-dihydro-indole-1-carboxylic acid [6-(2-methyl-pyridin-3-yloxy)-pyridin-3-yl]-amide::6-chloro-5-fluoro-N-(6-(2-methylpyridin-3-yloxy)pyridin-3-yl)indoline-1-carboxamide::CHEMBL299530",5-hydroxytryptamine receptor 2C,Homo sapiens,
50665463,C[C@H](Cc1ccccc1)N(C)CC#C,"InChI=1S/C13H17N/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13/h1,5-9,12H,10-11H2,2-3H3/t12-/m1/s1",MEZLKOACVSPNER-GFCCVEGCSA-N,15579,"CHEMBL972::DEPRENYL::L-Deprenyl::N-methyl-N-[(2R)-1-phenylpropan-2-yl]prop-2-yn-1-amine::SLG::Selegiline::US8633208, Deprenyl::US9469653, Selegiline::methyl[(2R)-1-phenylpropan-2-yl]prop-2-yn-1-ylamine",Amine oxidase [flavin-containing] B,, 19.6
50529029,COc1ccc2C[C@@H]3N(C)CCc4c(OC)c(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34,"InChI=1S/C39H44N2O7/c1-40-16-14-25-21-32(43-4)34-22-28(25)29(40)18-23-8-11-26(12-9-23)47-33-20-24(10-13-31(33)42-3)19-30-35-27(15-17-41(30)2)36(44-5)38(45-6)39(46-7)37(35)48-34/h8-13,20-22,29-30H,14-19H2,1-7H3/t29-,30-/m0/s1",FUZMQNZACIFDBL-KYJUHHDHSA-N,50201796,CHEBI:5677::Hernandezine,ATP-dependent translocase ABCB1,, 188
1132024,Cc1ccc(-c2ccn3nc(N)nc3c2)c(F)c1C(=O)NCC[C@H](O)c1ccc(cc1)C(F)(F)F,"InChI=1S/C24H21F4N5O2/c1-13-2-7-17(15-9-11-33-19(12-15)31-23(29)32-33)21(25)20(13)22(35)30-10-8-18(34)14-3-5-16(6-4-14)24(26,27)28/h2-7,9,11-12,18,34H,8,10H2,1H3,(H2,29,32)(H,30,35)/t18-/m0/s1",NKNSMRWBHMCQTM-SFHVURJKSA-N,534330,"WO2022086828, Example 57","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform",Homo sapiens,>15000
50411298,CC(=O)Nc1nnc(s1)S(N)(=O)=O,"InChI=1S/C4H6N4O3S2/c1-2(9)6-3-7-8-4(12-3)13(5,10)11/h1H3,(H2,5,10,11)(H,6,7,9)",BZKPWHYZMXOIDC-UHFFFAOYSA-N,10880,"AZA::AZA2::AZM acetazolamide::Acerazolamide, AAZ::Acetazolamide::Acetazolamide (AAZ)::Acetazolamide (AZA)::Acetazolamide (AZM)::Acetazolamide, 5::Acetazolamide, AAZ::Acetazolamide, AZA::Acetazolamide, AZM::CHEMBL20::N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)acetamide::Sulfonamide, 1::US10172837, Acetazolamide::US11278534, Example acetazolamide::US11535599, Example acetazolamide::sulfonamide 1",Carbonic anhydrase 2,Homo sapiens, 36
1053253,Cc1cc(cnn1)-c1nc2ccc(cc2n1C1CC1)C(F)(F)F,"InChI=1S/C16H13F3N4/c1-9-6-10(8-20-22-9)15-21-13-5-2-11(16(17,18)19)7-14(13)23(15)12-3-4-12/h2,5-8,12H,3-4H2,1H3",VHQGEXYNHFIELM-UHFFFAOYSA-N,287712,"US10085984, Example 90::US11040034, Ex. No. 90","Cytochrome P450 11B1, mitochondrial",Homo sapiens,>10000
929124,Nc1ncc(cc1C(=O)NC12CCC(O)(CC1)CC2)-c1ccc(cc1)[C@]12C[C@H]1CN(C2)C1CCC(F)(F)CC1,"InChI=1S/C31H38F2N4O2/c32-31(33)7-5-24(6-8-31)37-18-23-16-30(23,19-37)22-3-1-20(2-4-22)21-15-25(26(34)35-17-21)27(38)36-28-9-12-29(39,13-10-28)14-11-28/h1-4,15,17,23-24,39H,5-14,16,18-19H2,(H2,34,35)(H,36,38)/t23-,28?,29?,30+/m0/s1",RQXROVVCXFAAOM-GXLPGVSKSA-N,451803,"US10710980, Example 35::US10947218, Example 35",Serine/threonine-protein kinase receptor R3 [166-493],, 283
50526638,CCOc1ccc2cc(cnc2c1)-c1nn(C2CCCCCC2)c(N)c1C(N)=O,"InChI=1S/C22H27N5O2/c1-2-29-17-10-9-14-11-15(13-25-18(14)12-17)20-19(22(24)28)21(23)27(26-20)16-7-5-3-4-6-8-16/h9-13,16H,2-8,23H2,1H3,(H2,24,28)",CMVANALWKBATOM-UHFFFAOYSA-N,50148641,"CHEMBL3770649::US9518026, Example 49::US9956214, Compound 1604",Calmodulin-domain protein kinase 1,, 6.0
50152510,Nc1ncnc2n(C3CCCC3)c(nc12)-c1ccc(o1)P(O)(O)=O,"InChI=1S/C14H16N5O4P/c15-12-11-14(17-7-16-12)19(8-3-1-2-4-8)13(18-11)9-5-6-10(23-9)24(20,21)22/h5-8H,1-4H2,(H2,15,16,17)(H2,20,21,22)",HZMMJXCAXGJFAK-UHFFFAOYSA-N,50277562,CHEMBL519477::[5-(6-Amino-9-cyclopentyl-9H-purin-8-yl)-furan-2-yl]-phosphonic Acid,"Fructose-1,6-bisphosphatase 1",, 2000
966615,Cc1cc(OC(F)(F)F)ccc1-n1c2ccnc3sc(C(=O)N[C@@H]4CCCN(C4)C(=O)C=C)c([nH]c1=O)c23,,,467844,"(R)-N-(1-Acryloylpiperidin-3-yl)-5-(*S)-(2-methyl-4- (trifluoromethoxy)phenyl)-4-oxo-4,5-dihydro-3H-1-thia-3,5,8- triazaacenaphthylene-2-carboxamide;::US10800792, Example 505",Tyrosine-protein kinase BTK,Homo sapiens, 15.8
50890738,CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C,"InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-",WINHZLLDWRZWRT-ATVHPVEESA-N,4814,"CHEMBL535::N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide::N-[2-(diethylamino)ethyl]-5-{[(3Z)-5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene]methyl}-2,4-dimethyl-1H-pyrrole-3-carboxamide::SU11248::SUNITINIB::SUNITINIB MALATE::US10464902, Sunitinib::US9163010, Sunitinib::US9914707, SU11248",Mitogen-activated protein kinase 10,Homo sapiens,
1045282,CCN(C)c1ncccc1-c1cc(NCc2ccc(OC)cc2)c2n(nc(C)c2n1)C(C)C,"InChI=1S/C26H32N6O/c1-7-31(5)26-21(9-8-14-27-26)22-15-23(28-16-19-10-12-20(33-6)13-11-19)25-24(29-22)18(4)30-32(25)17(2)3/h8-15,17H,7,16H2,1-6H3,(H,28,29)",YNHQWVLFISTQIU-UHFFFAOYSA-N,279167,"5-(2-(ethyl(methyl)amino)pyridin-3-yl)-1-isopropyl-N-(4-methoxybenzyl)-3-methyl-1H-pyrazolo[4,3-b]pyridin-7-amine::US10034861, Example 198::US10512632, Example 198::US10766893, Example S198::US10806718, Example 198::US11026923, Example 198::US11491140, Example 198","Dual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A",, 1100
652997,O[C@@H]1CS[C@H]([C@@H]1O)c1nnc2c(NC3CC3c3cccc(Cl)c3)nccn12,"InChI=1S/C18H18ClN5O2S/c19-10-3-1-2-9(6-10)11-7-12(11)21-16-18-23-22-17(24(18)5-4-20-16)15-14(26)13(25)8-27-15/h1-6,11-15,25-26H,7-8H2,(H,20,21)/t11?,12?,13-,14-,15-/m1/s1",RSTPSSHAQTWCQQ-CLACGNGHSA-N,333276,"(2S,3R,4S)-2-(8-((2-(3-chlorophenyl)cyclopropyl)amino)-[1,2,4]triazolo[4,3-a]pyrazin-3-yl)tetrahydrothiophene-3,4-diol::US10196396, Compound 71",Adenosine receptor A3,Homo sapiens, 5500
50725588,CCCN(C)C(=O)[C@@H]1OC(=C[C@H](N=C(N)N)[C@H]1NC(C)=O)C(O)=O,"InChI=1S/C14H23N5O5/c1-4-5-19(3)12(21)11-10(17-7(2)20)8(18-14(15)16)6-9(24-11)13(22)23/h6,8,10-11H,4-5H2,1-3H3,(H,17,20)(H,22,23)(H4,15,16,18)/t8-,10+,11+/m0/s1",QPJWMZVTNXFTKV-JMJZKYOTSA-N,4933,"(2R,3R,4S)-4-carbamimidamido-3-acetamido-2-[methyl(propyl)carbamoyl]-3,4-dihydro-2H-pyran-6-carboxylic acid::carboxamide deriv. 5f",Neuraminidase,Influenza B virus (strain B/Lee/1940), 4500
50126361,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13,"InChI=1S/C28H26N4O3/c1-28-26(34-3)17(29-2)12-20(35-28)31-18-10-6-4-8-14(18)22-23-16(13-30-27(23)33)21-15-9-5-7-11-19(15)32(28)25(21)24(22)31/h4-11,17,20,26,29H,12-13H2,1-3H3,(H,30,33)/t17-,20-,26-,28+/m1/s1",HKSZLNNOFSGOKW-FYTWVXJKSA-N,2579,"(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1^{2,6}.0^{7,28}.0^{8,13}.0^{15,19}.0^{20,27}.0^{21,26}]nonacosa-8(13),9,11,14(28),15(19),20(27),21(26),22,24-nonaen-16-one::CHEMBL388978::Staurosporin, 4::Staurosporine::Staurosporine, 8::US9206188, Staurosporine::US9226923, Staurosporine",Tyrosine-protein kinase Lck,,
50240199,Cc1c(oc2c(cccc2c1=O)C(=O)NCCCN1CCN(CC1)c1ccccc1OCc1no[n+]([O-])c1C#N)-c1ccccc1,"InChI=1S/C34H32N6O6/c1-23-31(41)25-11-7-12-26(33(25)45-32(23)24-9-3-2-4-10-24)34(42)36-15-8-16-38-17-19-39(20-18-38)28-13-5-6-14-30(28)44-22-27-29(21-35)40(43)46-37-27/h2-7,9-14H,8,15-20,22H2,1H3,(H,36,42)",QINUQIXOUYBPRY-UHFFFAOYSA-N,50131890,3-Methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylic acid (3-{4-[2-(4-cyano-5-oxy-furazan-3-ylmethoxy)-phenyl]-piperazin-1-yl}-propyl)-amide::CHEMBL125989,Alpha-1B adrenergic receptor,,
909176,CNCC(=O)N1CCC(CC1)c1ccc2[nH]c(c(C(C)C)c2c1)-c1cc(ncc1F)C1CC1,"InChI=1S/C27H33FN4O/c1-16(2)26-21-12-19(17-8-10-32(11-9-17)25(33)15-29-3)6-7-23(21)31-27(26)20-13-24(18-4-5-18)30-14-22(20)28/h6-7,12-14,16-18,29,31H,4-5,8-11,15H2,1-3H3",DBTJDELMJUCPMM-UHFFFAOYSA-N,443930,"1-(4-(2-(2-cyclopropyl-5-fluoropyridin-4-yl)-3-isopropyl-1H-indol-5-yl)piperidin-1-yl)-2-(methylamino)ethan-1-one::US10660877, Example 518",Toll-like receptor 8,, 257
51138344,ClC(Cl)C(=O)NCCCCCCCCNC(=O)C(Cl)Cl,"InChI=1S/C12H20Cl4N2O2/c13-9(14)11(19)17-7-5-3-1-2-4-6-8-18-12(20)10(15)16/h9-10H,1-8H2,(H,17,19)(H,18,20)",FAOMZVDZARKPFJ-UHFFFAOYSA-N,50459608,CHEBI:90441::CHEMBL3276621,"Aldehyde dehydrogenase, mitochondrial",Homo sapiens, 229
50119208,CC(C)c1c(Sc2cc(C)cc(C)c2)n(COCCO)c(=O)[nH]c1=O,"InChI=1S/C18H24N2O4S/c1-11(2)15-16(22)19-18(23)20(10-24-6-5-21)17(15)25-14-8-12(3)7-13(4)9-14/h7-9,11,21H,5-6,10H2,1-4H3,(H,19,22,23)",DLDYWYXMJCSMIQ-UHFFFAOYSA-N,50008329,"6-(3,5-Dimethyl-phenylsulfanyl)-1-(2-hydroxy-ethoxymethyl)-5-isopropyl-1H-pyrimidine-2,4-dione::CHEMBL276108",Reverse transcriptase/RNaseH,Human immunodeficiency virus 1,
1080721,COc1cccnc1-c1nc2c(ccnc2[nH]1)-c1ccc(CNC(=O)c2nc(no2)C(C)(C)C)c(F)c1,"InChI=1S/C26H24FN7O3/c1-26(2,3)25-33-24(37-34-25)23(35)30-13-15-8-7-14(12-17(15)27)16-9-11-29-21-19(16)31-22(32-21)20-18(36-4)6-5-10-28-20/h5-12H,13H2,1-4H3,(H,30,35)(H,29,31,32)",FVWGGTBTBWDWMP-UHFFFAOYSA-N,514922,"US11098041, Example 152",Tyrosine-protein kinase BTK [328-659],,<100
51227020,Cc1cc(C)n(NC(=O)C2CN(C(=O)C2)c2cc(C)c(c(C)c2Cl)S(N)(=O)=O)n1,"InChI=1S/C18H22ClN5O4S/c1-9-5-14(16(19)12(4)17(9)29(20,27)28)23-8-13(7-15(23)25)18(26)22-24-11(3)6-10(2)21-24/h5-6,13H,7-8H2,1-4H3,(H,22,26)(H2,20,27,28)",SQIXPRUJAUUIMS-UHFFFAOYSA-N,50503793,CHEMBL4461481,"Carbonic anhydrase 5B, mitochondrial",Homo sapiens,
50807384,C[C@H]1C[C@@H](C)N1C(=O)[C@H]1CN(C)C2Cc3c[nH]c4cccc(C2=C1)c34,"InChI=1S/C21H25N3O/c1-12-7-13(2)24(12)21(25)15-8-17-16-5-4-6-18-20(16)14(10-22-18)9-19(17)23(3)11-15/h4-6,8,10,12-13,15,19,22H,7,9,11H2,1-3H3/t12-,13+,15-,19?/m1/s1",DUKNIHFTDAXJON-MUIJYRPGSA-N,50118576,"(2,4-Dimethyl-azetidin-1-yl)-(7-methyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinolin-9-yl)-methanone::CHEMBL137781",D(3) dopamine receptor,,
50083922,N[C@@H]1CCN(C1)c1cc(Cc2ccccc2)nc(N)n1,"InChI=1S/C15H19N5/c16-12-6-7-20(10-12)14-9-13(18-15(17)19-14)8-11-4-2-1-3-5-11/h1-5,9,12H,6-8,10,16H2,(H2,17,18,19)/t12-/m1/s1",RHWLGGMQMOADRO-GFCCVEGCSA-N,50006763,CHEMBL3236573,Histamine H4 receptor,Homo sapiens,
51263250,COc1ccc2nc(C)cc(N\N=C\c3c[nH]cn3)c2c1,"InChI=1S/C15H15N5O/c1-10-5-15(20-18-8-11-7-16-9-17-11)13-6-12(21-2)3-4-14(13)19-10/h3-9H,1-2H3,(H,16,17)(H,19,20)/b18-8+",WCZXPOPEPIBDAW-QGMBQPNBSA-N,50515986,CHEMBL4553527,Ribosyldihydronicotinamide dehydrogenase [quinone],Homo sapiens, 71
1260551,Nc1ccc(Cn2c3ccsc3c(C(O)=O)c(O)c2=O)cn1,"InChI=1S/C14H11N3O4S/c15-9-2-1-7(5-16-9)6-17-8-3-4-22-12(8)10(14(20)21)11(18)13(17)19/h1-5,18H,6H2,(H2,15,16)(H,20,21)",OCHPBURMQKWPQC-UHFFFAOYSA-N,594808,"US11584755, Example 97",Flap endonuclease 1,Homo sapiens,<200
51454096,C[C@]1(CO[C@](C)(C(N)=N1)C(F)(F)F)c1cc(NC(=O)c2ccc(Br)cn2)ccc1F,"InChI=1S/C19H17BrF4N4O2/c1-17(9-30-18(2,16(25)28-17)19(22,23)24)12-7-11(4-5-13(12)21)27-15(29)14-6-3-10(20)8-26-14/h3-8H,9H2,1-2H3,(H2,25,28)(H,27,29)/t17-,18+/m0/s1",XXUKTXRJOFQHLP-ZWKOTPCHSA-N,134356,"US8846658, 68",Cathepsin D,Homo sapiens,>250000
50931742,O=C(CNC(=O)c1cccc(c1)-c1ccccc1)N1CCC[C@H]1C#N,"InChI=1S/C20H19N3O2/c21-13-18-10-5-11-23(18)19(24)14-22-20(25)17-9-4-8-16(12-17)15-6-2-1-3-7-15/h1-4,6-9,12,18H,5,10-11,14H2,(H,22,25)/t18-/m0/s1",FJWRWAFBWCAAQZ-SFHVURJKSA-N,50382267,CHEMBL2022513,Dipeptidyl peptidase 4,Homo sapiens,>100000
367978,CNC(=O)c1c(oc2cc(N(CCF)S(C)(=O)=O)c(cc12)-c1ncc2OCn3c(cc4ccccc34)-c2n1)-c1ccc(F)cc1,"InChI=1S/C32H25F2N5O5S/c1-35-32(40)28-22-14-21(31-36-16-27-29(37-31)25-13-19-5-3-4-6-23(19)38(25)17-43-27)24(39(12-11-33)45(2,41)42)15-26(22)44-30(28)18-7-9-20(34)10-8-18/h3-10,13-16H,11-12,17H2,1-2H3,(H,35,40)",QXKQSRLAWZMQRS-UHFFFAOYSA-N,208251,"US9265773, 196",Genome polyprotein,, 3.6
50115016,COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(C)cc4)cc3)c2cc1OC,"InChI=1S/C25H23N3O4/c1-16-4-6-17(7-5-16)27-25(29)28-18-8-10-19(11-9-18)32-22-12-13-26-21-15-24(31-3)23(30-2)14-20(21)22/h4-15H,1-3H3,(H2,27,28,29)",ARFSBNIXMVQEPO-UHFFFAOYSA-N,50162155,"1-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-phenyl]-3-p-tolyl-urea::CHEMBL362634",Vascular endothelial growth factor receptor 2,Homo sapiens, 0.500000
665717,NCCOc1ccccc1-c1ccc(c(F)c1)-c1cnc(N)nc1,"InChI=1S/C18H17FN4O/c19-16-9-12(15-3-1-2-4-17(15)24-8-7-20)5-6-14(16)13-10-22-18(21)23-11-13/h1-6,9-11H,7-8,20H2,(H2,21,22,23)",OQWJVUUYTZZQAD-UHFFFAOYSA-N,169238,"US9079866, 641::US9745328, Compound 641::US9884878, Compound 641",Flap endonuclease 1,Homo sapiens,
51413669,Cn1cc(cn1)-c1nc2c(ccnc2[nH]1)-c1ccc(CN2CCc3cc(ccc3C2=O)C(C)(C)C)c(F)c1,"InChI=1S/C30H29FN6O/c1-30(2,3)22-7-8-24-19(13-22)10-12-37(29(24)38)17-20-6-5-18(14-25(20)31)23-9-11-32-28-26(23)34-27(35-28)21-15-33-36(4)16-21/h5-9,11,13-16H,10,12,17H2,1-4H3,(H,32,34,35)",BWKFJQXCFVEGAL-UHFFFAOYSA-N,514875,"US11098041, Example 100","1,3-beta-glucan synthase component GSC2",Saccharomyces cerevisiae, 2600
50846054,CCCCCCc1ccc(OCCCCCCCCCCC(=O)NCc2ccc(OC)c(O)c2)cc1O,"InChI=1S/C31H47NO5/c1-3-4-5-12-15-26-18-19-27(23-28(26)33)37-21-14-11-9-7-6-8-10-13-16-31(35)32-24-25-17-20-30(36-2)29(34)22-25/h17-20,22-23,33-34H,3-16,21,24H2,1-2H3,(H,32,35)",KHABPDQLPRMQRS-UHFFFAOYSA-N,50215226,11-(4-hexyl-3-hydroxy-phenoxy)-undecanoic acid(3-methoxy-4-hydroxy-phenyl)-amide::CHEMBL229816,Fatty-acid amide hydrolase 1 [30-579],,>50000
914150,C(Nc1ccc2ncc(-c3cc4ccccc4o3)n2n1)c1ccncc1,"InChI=1S/C20H15N5O/c1-2-4-17-15(3-1)11-18(26-17)16-13-23-20-6-5-19(24-25(16)20)22-12-14-7-9-21-10-8-14/h1-11,13H,12H2,(H,22,24)",AJBOLFIHFBPBBR-UHFFFAOYSA-N,214650,"US10688093, Compound 229_0237_0073::US9284319, R8::US9730929, Example R8::US9783543, R8",Tyrosine-protein kinase Fyn,, 6450
1030972,Cc1cc(Cc2ccc(cc2C)C(=O)NCC(=O)N2[C@@H](CC[C@@H]2C(F)(F)F)c2cccc(F)c2)c(=O)[nH]n1,,,495076,"US10995084, Ex. No. 3A-13",Calcitonin gene-related peptide type 1 receptor,,
50854420,COCCOc1ccnc2[nH]cc(-c3ccnc(N)n3)c12,"InChI=1S/C14H15N5O2/c1-20-6-7-21-11-3-5-16-13-12(11)9(8-18-13)10-2-4-17-14(15)19-10/h2-5,8H,6-7H2,1H3,(H,16,18)(H2,15,17,19)",NFOHQNIARGGZFN-UHFFFAOYSA-N,50371398,MERIOLIN 7,Dual specificity tyrosine-phosphorylation-regulated kinase 1A,Rattus,>10000
334778,Cc1ccc2c(Nc3ccc(F)c(Cl)c3)nccc2c1NC(=O)c1csc2c(N)ncnc12,"InChI=1S/C23H16ClFN6OS/c1-11-2-4-14-13(6-7-27-22(14)30-12-3-5-17(25)16(24)8-12)18(11)31-23(32)15-9-33-20-19(15)28-10-29-21(20)26/h2-10H,1H3,(H,27,30)(H,31,32)(H2,26,28,29)",GNDBDDNLWIOKDN-UHFFFAOYSA-N,185590,"US9156852, 105::USRE47451, Example 105",Epithelial discoidin domain-containing receptor 1,Homo sapiens, 71
50263347,C(CCCCCCC[n+]1ccccc1)CCCCCC[n+]1ccccc1,"InChI=1S/C24H38N2/c1(3-5-7-9-13-19-25-21-15-11-16-22-25)2-4-6-8-10-14-20-26-23-17-12-18-24-26/h11-12,15-18,21-24H,1-10,13-14,19-20H2/q+2",BAROVFANZMEZJO-UHFFFAOYSA-N,50143293,1-[6-(pyridinium-1-yl)tetradecyl]pyridinium; Dibromide::CHEMBL54580,Neuronal acetylcholine receptor subunit alpha-4/beta-2,,
50563717,COc1ccccc1-c1ccc(cc1)C(=O)N1CCN([C@@H](C)C1)C(=O)c1ccc2cc[nH]c2c1,"InChI=1S/C28H27N3O3/c1-19-18-30(15-16-31(19)28(33)23-12-9-21-13-14-29-25(21)17-23)27(32)22-10-7-20(8-11-22)24-5-3-4-6-26(24)34-2/h3-14,17,19,29H,15-16,18H2,1-2H3/t19-/m0/s1",WGTCBXOFOSMWEQ-IBGZPJMESA-N,50312777,(S)-(4-(1H-indole-6-carbonyl)-3-methylpiperazin-1-yl)(2'-methoxybiphenyl-4-yl)methanone::CHEMBL1081212,Alpha-2A adrenergic receptor,,
1049614,FC(F)(F)c1cnc(N2CCC(CC2)C(=O)NCCC2CCN(Cc3ccccc3)CC2)c(Cl)c1,"InChI=1S/C26H32ClF3N4O/c27-23-16-22(26(28,29)30)17-32-24(23)34-14-9-21(10-15-34)25(35)31-11-6-19-7-12-33(13-8-19)18-20-4-2-1-3-5-20/h1-5,16-17,19,21H,6-15,18H2,(H,31,35)",UCDAGGLRRYYIRU-UHFFFAOYSA-N,503052,"N-[2-(1-benzylpiperidin-4-yl)ethyl]-1-[3-chloro-5 (trifluoromethyl)pyridin-2-yl]piperidine-4-carboxamide::US11033539, Cpd. No. 9-63",Muscarinic acetylcholine receptor M2,,
50618650,C1C[C@H]2N(C1)C[C@@H](c1ccccc1)c1ccccc21,"InChI=1S/C18H19N/c1-2-7-14(8-3-1)17-13-19-12-6-11-18(19)16-10-5-4-9-15(16)17/h1-5,7-10,17-18H,6,11-13H2/t17-,18+/m0/s1",KJHWRRVSXANANB-ZWKOTPCHSA-N,50021874,"6-Phenyl-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;C4H4O4::6-Phenyl-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;HBr::6-Phenyl-1,2,3,5,6,10b-hexahydro-pyrrolo[2,1-a]isoquinoline;HCl::CHEMBL35184",Alpha-1A/Alpha-1B/Alpha-1D adrenergic receptor,,
51377150,NS(=O)(=O)c1ccc(NS(=O)(=O)CCNC(=O)Nc2cccc3ccccc23)cc1,"InChI=1S/C19H20N4O5S2/c20-30(27,28)16-10-8-15(9-11-16)23-29(25,26)13-12-21-19(24)22-18-7-3-5-14-4-1-2-6-17(14)18/h1-11,23H,12-13H2,(H2,20,27,28)(H2,21,22,24)",KRFNOZSITCGEBH-UHFFFAOYSA-N,50556855,CHEMBL4744521,Carbonic anhydrase 2,Homo sapiens,
51207946,[O-][S+](CC(=O)NCCCc1ccccc1)C(c1ccc(Br)cc1)c1ccc(Br)cc1,"InChI=1S/C24H23Br2NO2S/c25-21-12-8-19(9-13-21)24(20-10-14-22(26)15-11-20)30(29)17-23(28)27-16-4-7-18-5-2-1-3-6-18/h1-3,5-6,8-15,24H,4,7,16-17H2,(H,27,28)",UZGMDRDNGDSQDH-UHFFFAOYSA-N,50496380,CHEMBL3126729,Sodium-dependent dopamine transporter,Rattus norvegicus,
984462,CC(C)CCN(CC(=O)NCc1cccc(Cl)c1F)C(=O)Cn1nc(C(N)=O)c2ccccc12,"InChI=1S/C24H27ClFN5O3/c1-15(2)10-11-30(13-20(32)28-12-16-6-5-8-18(25)22(16)26)21(33)14-31-19-9-4-3-7-17(19)23(29-31)24(27)34/h3-9,15H,10-14H2,1-2H3,(H2,27,34)(H,28,32)",JQTIWPIWTOFISS-UHFFFAOYSA-N,474600,"US10849883, Compound 29b",Complement factor D,, 5500
257606,Nc1ncnn2c(cc(C(=O)NC3CCOCC3)c12)-c1ccncc1,"InChI=1S/C17H18N6O2/c18-16-15-13(17(24)22-12-3-7-25-8-4-12)9-14(23(15)21-10-20-16)11-1-5-19-6-2-11/h1-2,5-6,9-10,12H,3-4,7-8H2,(H,22,24)(H2,18,20,21)",PRPDTJCUQLMLCF-UHFFFAOYSA-N,127323,"US8791257, 51",Casein kinase II subunit alpha,Homo sapiens, 170
50877250,Cc1sc2nc(N)[nH]c(=O)c2c1Sc1ccc(cc1)C(=O)N(CCC(O)=O)C(O)=O,"InChI=1S/C18H16N4O6S2/c1-8-13(12-14(25)20-17(19)21-15(12)29-8)30-10-4-2-9(3-5-10)16(26)22(18(27)28)7-6-11(23)24/h2-5H,6-7H2,1H3,(H,23,24)(H,27,28)(H3,19,20,21,25)",JOQXWQAZSGUWDV-UHFFFAOYSA-N,50252968,"CHEMBL522363::N-{4-[(2-Amino-6-methyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-5-yl)sulfanyl]benzoyl}-L-glutamic acid",Dihydrofolate reductase,Homo sapiens, 20
214534,CNC[C@H]1CC[C@@H](CC1)c1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)nccn12,"InChI=1S/C26H29N5O/c1-28-17-18-7-9-20(10-8-18)26-30-23(24-25(27)29-15-16-31(24)26)19-11-13-22(14-12-19)32-21-5-3-2-4-6-21/h2-6,11-16,18,20,28H,7-10,17H2,1H3,(H2,27,29)/t18-,20-",WEUOUAXOJODGNO-KESTWPANSA-N,98424,"US8481733, 236",Activated CDC42 kinase 1,Homo sapiens, 153.6
180683,Cc1cc(cc(C)[n+]1-c1ccc(cc1)S(=O)(=O)Nc1nnc(s1)S(N)(=O)=O)-c1ccccc1,"InChI=1S/C21H20N5O4S3/c1-14-12-17(16-6-4-3-5-7-16)13-15(2)26(14)18-8-10-19(11-9-18)33(29,30)25-20-23-24-21(31-20)32(22,27)28/h3-13H,1-2H3,(H,23,25)(H2,22,27,28)/q+1",UQVQBJWQKAPUBT-UHFFFAOYSA-N,14722,"1-N-[5-Sulfamoyl-1,3,4-thiadiazol-2-yl-(aminosulfonyl-4-phenyl)]-2,6-dimethyl-4-phenylpyridinium perchlorate::2,6-dimethyl-4-phenyl-1-{4-[(5-sulfamoyl-1,3,4-thiadiazol-2-yl)sulfamoyl]phenyl}-1-pyridin-1-ylium perchlorate::Sulfonamide, 8::pyridinium-containing sulfonamide analog 14e",Carbonic anhydrase 1,Homo sapiens,
50304736,COc1ccccc1-c1ccc(o1)C(=O)NC(N)=N,"InChI=1S/C13H13N3O3/c1-18-9-5-3-2-4-8(9)10-6-7-11(19-10)12(17)16-13(14)15/h2-7H,1H3,(H4,14,15,16,17)",YYDRXURXUXPSGT-UHFFFAOYSA-N,50165252,CHEMBL370954::N-[5-(2-Methoxy-phenyl)-furan-2-carbonyl]-guanidine,Sodium/hydrogen exchanger 1,Homo sapiens, 2300
50106086,CC(C)C[C@H](CC(=O)NO)C(=O)N[C@H](Cc1ccc(cc1)-c1ccccc1)C(=O)N[C@@H](C)c1ccccc1,"InChI=1S/C31H37N3O4/c1-21(2)18-27(20-29(35)34-38)30(36)33-28(31(37)32-22(3)24-10-6-4-7-11-24)19-23-14-16-26(17-15-23)25-12-8-5-9-13-25/h4-17,21-22,27-28,38H,18-20H2,1-3H3,(H,32,37)(H,33,36)(H,34,35)/t22-,27+,28+/m0/s1",OUMHWPMKRPJGKY-XDAJTCOGSA-N,50062334,(R)-N*1*-[(R)-2-Biphenyl-4-yl-1-((S)-1-phenyl-ethylcarbamoyl)-ethyl]-N*4*-hydroxy-2-isobutyl-succinamide::CHEMBL70406,Neutrophil collagenase,Homo sapiens,
381149,COc1cc(F)cc(c1)-c1ccc(OC)c(c1)-n1c2ccc(cc2ccc1=O)S(=O)(=O)Nc1ccon1,"InChI=1S/C26H20FN3O6S/c1-34-20-12-18(11-19(27)15-20)16-3-7-24(35-2)23(14-16)30-22-6-5-21(13-17(22)4-8-26(30)31)37(32,33)29-25-9-10-36-28-25/h3-15H,1-2H3,(H,28,29)",JONDZQGZGUYDIC-UHFFFAOYSA-N,217578,"US9212182, 838::US9212182, 853",Sodium channel protein type 9 subunit alpha,, 60
982192,CC(C)(C)n1nc(-c2cc3c(Cl)cccc3[nH]2)c2c(N)ncnc12,"InChI=1S/C17H17ClN6/c1-17(2,3)24-16-13(15(19)20-8-21-16)14(23-24)12-7-9-10(18)5-4-6-11(9)22-12/h4-8,22H,1-3H3,(H2,19,20,21)",MDIXZDPYCMPWJS-UHFFFAOYSA-N,473732,"1-tert-Butyl-3-(4-chloro-1H-indol-2- yl)pyrazolo[3,4-d]pyrimidin-4-amine::US10844067, Example 75",Proto-oncogene tyrosine-protein kinase receptor Ret,Homo sapiens, 157
762748,Cc1nn(CCN2CCOCC2)c2ncc(C(=O)Nc3ccc(cc3)C(F)(F)F)c(Cl)c12,"InChI=1S/C21H21ClF3N5O2/c1-13-17-18(22)16(20(31)27-15-4-2-14(3-5-15)21(23,24)25)12-26-19(17)30(28-13)7-6-29-8-10-32-11-9-29/h2-5,12H,6-11H2,1H3,(H,27,31)",UUCXYXNYCZCHNA-UHFFFAOYSA-N,381510,"4-Chloro-3-methyl-1-(2-morpholin- 4-yl-ethyl)-1H-pyrazolo[3,4- b]pyridine-5-carboxylic acid (4- trifluoromethyl-phenyl)-amide::US10272074, Example 344",Glucocorticoid receptor,,<50
50926743,OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(cc1)C(=O)Nc1nnc(CCCc2ccc(F)cc2)s1,"InChI=1S/C26H28FN3O3S/c27-22-14-6-17(7-15-22)2-1-3-23-29-30-26(34-23)28-25(33)21-12-10-20(11-13-21)19-8-4-18(5-9-19)16-24(31)32/h6-7,10-15,18-19H,1-5,8-9,16H2,(H,31,32)(H,28,30,33)/t18-,19-",RHDSRTWMNQPWDV-WGSAOQKQSA-N,50380051,CHEMBL2012620,Diacylglycerol O-acyltransferase 1,, 181
50580726,CN1C[C@@H]2C[C@H]1CN2c1ccc(nn1)-c1ccc2[nH]c(C)cc2c1,"InChI=1S/C19H21N5/c1-12-7-14-8-13(3-4-17(14)20-12)18-5-6-19(22-21-18)24-11-15-9-16(24)10-23(15)2/h3-8,15-16,20H,9-11H2,1-2H3/t15-,16-/m0/s1",PVRYQEGJMHZJRA-HOTGVXAUSA-N,50319944,"2-methyl-5-(6-((1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)pyridazin-3-yl)-1H-indole::CHEMBL1083616",Neuronal acetylcholine receptor subunit alpha-7,Rattus norvegicus,
129155,CCCN(CCC)Cc1c(nnn1-c1nonc1N)C(=O)NN=Cc1ccc(C)o1,"InChI=1S/C18H25N9O3/c1-4-8-26(9-5-2)11-14-15(21-25-27(14)17-16(19)23-30-24-17)18(28)22-20-10-13-7-6-12(3)29-13/h6-7,10H,4-5,8-9,11H2,1-3H3,(H2,19,23)(H,22,28)",HSNZVBSSKJPNIM-UHFFFAOYSA-N,70052,"1-(4-amino-1,2,5-oxadiazol-3-yl)-5-[(dipropylamino)methyl]-N-[(5-methyl-2-furanyl)methylideneamino]-4-triazolecarboxamide::1-(4-amino-1,2,5-oxadiazol-3-yl)-5-[(dipropylamino)methyl]-N-[(5-methylfuran-2-yl)methylideneamino]triazole-4-carboxamide::1-(4-aminofurazan-3-yl)-5-[(dipropylamino)methyl]-N-[(5-methyl-2-furyl)methyleneamino]triazole-4-carboxamide::1-(4-azanyl-1,2,5-oxadiazol-3-yl)-5-[(dipropylamino)methyl]-N-[(5-methylfuran-2-yl)methylideneamino]-1,2,3-triazole-4-carboxamide::MLS000923821::SMR000620322::cid_4103935",Glycogen synthase kinase-3 beta,Homo sapiens,
50153873,CS(=O)(=O)c1ccc(NNC(=O)c2ccccc2)cc1,"InChI=1S/C14H14N2O3S/c1-20(18,19)13-9-7-12(8-10-13)15-16-14(17)11-5-3-2-4-6-11/h2-10,15H,1H3,(H,16,17)",JIBWASVUXGNHRK-UHFFFAOYSA-N,50086475,Benzoic acid N'-(4-methanesulfonyl-phenyl)-hydrazide::CHEMBL155436,Prostaglandin G/H synthase 2,Homo sapiens,>10000
50905962,CCOc1cccc(c1)-c1nc(SCC(=O)Nc2nc(cs2)-c2cc(Cl)c(N)c(Cl)c2)[nH]c(=O)c1C#N,"InChI=1S/C24H18Cl2N6O3S2/c1-2-35-14-5-3-4-12(6-14)21-15(9-27)22(34)32-24(31-21)37-11-19(33)30-23-29-18(10-36-23)13-7-16(25)20(28)17(26)8-13/h3-8,10H,2,11,28H2,1H3,(H,29,30,33)(H,31,32,34)",RIMCGTVMTSKNSJ-UHFFFAOYSA-N,50270758,CHEMBL4127486,Beta-secretase 1,Homo sapiens, 13500
51341567,CCn1sc(=O)n(CCc2ccccc2)c1=O,"InChI=1S/C12H14N2O2S/c1-2-14-11(15)13(12(16)17-14)9-8-10-6-4-3-5-7-10/h3-7H,2,8-9H2,1H3",HYCIUMWKUONOEF-UHFFFAOYSA-N,50542899,CHEMBL4642643,Sortase family protein,Staphylococcus aureus,>50000
50288360,COC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)CCCOc1ccc2ccc(OCCCC(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CCC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)cc2c1)C(C)C)C(C)C,"InChI=1S/C59H87N7O14/c1-34(2)29-45(53(60)71)63-54(72)44(25-26-50(70)80-59(9,10)11)62-55(73)47(31-38-17-21-41(67)22-18-38)61-48(68)15-13-27-78-42-23-19-39-20-24-43(33-40(39)32-42)79-28-14-16-49(69)65-51(36(5)6)57(75)64-46(30-35(3)4)56(74)66-52(37(7)8)58(76)77-12/h17-24,32-37,44-47,51-52,67H,13-16,25-31H2,1-12H3,(H2,60,71)(H,61,68)(H,62,73)(H,63,72)(H,64,75)(H,65,69)(H,66,74)/t44-,45-,46-,47-,51-,52-/m0/s1",NQASSMBJMQUNQZ-JHIQSVMBSA-N,50156901,(S)-tert-butyl 5-((S)-1-amino-4-methyl-1-oxopentan-2-ylamino)-4-((S)-3-(4-hydroxyphenyl)-2-(4-(7-(4-((S)-1-((S)-1-((S)-1-methoxy-3-methyl-1-oxobutan-2-ylamino)-4-methyl-1-oxopentan-2-ylamino)-3-methyl-1-oxobutan-2-ylamino)-4-oxobutoxy)naphthalen-2-yloxy)b::CHEMBL375250,Gag-Pol polyprotein [489-587],Human immunodeficiency virus 1, 1100
51252668,C(Oc1nn2c(nnc2c2ccccc12)-c1ccccc1)c1ccccn1,"InChI=1S/C21H15N5O/c1-2-8-15(9-3-1)19-23-24-20-17-11-4-5-12-18(17)21(25-26(19)20)27-14-16-10-6-7-13-22-16/h1-13H,14H2",QZDWWRKBDPYMIP-UHFFFAOYSA-N,50143115,"3-Phenyl-6-(pyridin-2-ylmethoxy)-[1,2,4]triazolo[3,4-a]phthalazine::CHEMBL299611",Gamma-aminobutyric acid receptor subunit alpha-1/beta-3/gamma-2,Homo sapiens,
51181585,C[C@H](NC(=O)c1ccc(nc1)N1C2CCC1CC(C2)NC(=O)c1ccc(C(N)=O)c(Nc2ccccc2)c1)c1ccc(cc1)N1CCN(C)CC1,"InChI=1S/C40H46N8O3/c1-26(27-8-12-32(13-9-27)47-20-18-46(2)19-21-47)43-40(51)29-11-17-37(42-25-29)48-33-14-15-34(48)24-31(23-33)45-39(50)28-10-16-35(38(41)49)36(22-28)44-30-6-4-3-5-7-30/h3-13,16-17,22,25-26,31,33-34,44H,14-15,18-21,23-24H2,1-2H3,(H2,41,49)(H,43,51)(H,45,50)/t26-,31?,33?,34?/m0/s1",LURJVPQLVIVOBJ-WPYKHMBLSA-N,50486061,CHEMBL2204521,Heat shock protein HSP 90-alpha/90-beta,Homo sapiens, 260
51424731,Cc1sc(cc1[C@@H]1NCCc2ccc(Cl)cc12)C(=O)c1cncnc1N[C@H]1C[C@H](O)[C@@H](COS(N)(=O)=O)C1,"InChI=1S/C25H28ClN5O5S2/c1-13-18(23-19-7-16(26)3-2-14(19)4-5-29-23)9-22(37-13)24(33)20-10-28-12-30-25(20)31-17-6-15(21(32)8-17)11-36-38(27,34)35/h2-3,7,9-10,12,15,17,21,23,29,32H,4-6,8,11H2,1H3,(H2,27,34,35)(H,28,30,31)/t15-,17-,21+,23+/m1/s1",LXRZVMYMQHNYJB-UNXOBOICSA-N,462958,"US10780090, Compound I-263a::US10780090, Compound I-263b::[(1R,2S,4R)-4-{[5-({4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methyl-2- thienyl}carbonyl)pyrimidin-4-yl]amino}-2-hydroxycyclopentyl]methyl sulfamate",SUMO-activating enzyme subunit 1/2,, 15
50799330,CN1C(=O)N(C[C@@H]([C@@H](CC2CCCC2)C(=O)N2CCCCC2)C(=O)NO)C(=O)C1(C)C,"InChI=1S/C22H36N4O5/c1-22(2)20(29)26(21(30)24(22)3)14-17(18(27)23-31)16(13-15-9-5-6-10-15)19(28)25-11-7-4-8-12-25/h15-17,31H,4-14H2,1-3H3,(H,23,27)/t16-,17+/m1/s1",GFUITADOEPNRML-SJORKVTESA-N,30344,Cipemastat::Trocade,Neutrophil collagenase,Homo sapiens,
38554,Cc1ccc2c(cn(CC3CCOCC3)c2c1)C(=O)C1C(C)(C)C1(C)C,"InChI=1S/C23H31NO2/c1-15-6-7-17-18(20(25)21-22(2,3)23(21,4)5)14-24(19(17)12-15)13-16-8-10-26-11-9-16/h6-7,12,14,16,21H,8-11,13H2,1-5H3",ACYBOEVFMUHYEK-UHFFFAOYSA-N,21291,"6-methyl-1-(oxan-4-ylmethyl)-3-[(2,2,3,3-tetramethylcyclopropyl)carbonyl]-1H-indole::Tetrahydropyranyl-methyl analogue, 12",Cannabinoid receptor 2,Homo sapiens,
510823,COc1cccc(OC)c1-n1c(NS(=O)(=O)[C@@H](C)[C@H](O)c2ncc(F)cn2)nnc1-c1cncc(C)c1,"InChI=1S/C23H24FN7O5S/c1-13-8-15(10-25-9-13)22-28-29-23(31(22)19-17(35-3)6-5-7-18(19)36-4)30-37(33,34)14(2)20(32)21-26-11-16(24)12-27-21/h5-12,14,20,32H,1-4H3,(H,29,30)/t14-,20-/m0/s1",GBNJSEGQAULKEB-XOBRGWDASA-N,269611,"(1S,2R)-N-(4-(2,6-dimethoxyphenyl)-5-(5-methyl-3-pyridinyl)-4H-1,2,4-triazol-3-yl)-1-(5-fluoro-2-pyrimidinyl)-1-hydroxy-2-propanesulfonamide, (1R,2S)-N-(4-(2,6-dimethoxyphenyl)-5-(5-methyl-3-pyridinyl)-4H-1,2,4-triazol-3-yl)-1-(5-fluoro-2-pyrimidinyl)-1-hydroxy-2-propanesulfonamide::US10058550, Example 125.0::US10058550, Example 126.0::US10221162, Example 126.0::US9845310, Example 126.0",Apelin receptor,Homo sapiens,
50971685,CC(C(=O)NCc1ccc(nc1N1CCC(C)(C)CC1)C(F)(F)F)c1ccc(NS(C)(=O)=O)c(F)c1,"InChI=1S/C24H30F4N4O3S/c1-15(16-5-7-19(18(25)13-16)31-36(4,34)35)22(33)29-14-17-6-8-20(24(26,27)28)30-21(17)32-11-9-23(2,3)10-12-32/h5-8,13,15,31H,9-12,14H2,1-4H3,(H,29,33)",ZQDWMWXWVXDPCQ-UHFFFAOYSA-N,50398491,CHEMBL2177432,Transient receptor potential cation channel subfamily V member 1,Homo sapiens, 8
